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Reproductive Genetics/Prenatal Genetics
P01.001A
Copy number variation proﬁle in the placental and
parental genomes of recurrent pregnancy loss families
L. Kasak1, K. Rull1,2,3, S. Sõber1, M. Laan1,4
1Institute of Molecular and Cell Biology, University of
Tartu, Tartu, Estonia, 2Department of Obstetrics and
Gynaecology, University of Tartu, Tartu, Estonia,
3Women’s Clinic of Tartu University Hospital, Tartu,
Estonia, 4Institute of Biomedicine and Translational
Medicine, University of Tartu, Tartu, Estonia
Introduction:We have previously shown an extensive load
of somatic copy number variations (CNVs) in the human
placental genome with the highest fraction detected in
normal term pregnancies1. Our parallel study on recurrent
pregnancy loss (RPL) identiﬁed that the proﬁle of parental
CNVs may be critical for a viable pregnancy2. Hereby, we
hypothesized that insufﬁcient promotion of CNVs may
impair placental development and lead to RPL.
Materials and Methods: We analysed placental and
parental CNV proﬁles of idiopathic RPL trios (mother-
father-placenta) and duos (mother-placenta). CNV detection
pipeline included genome-wide genotyping and CNV call-
ing using three alternative algorithms.
Results: Consistent with the hypothesis, the placental
genomes of RPL cases exhibited 2-fold less CNVs compared
to uncomplicated 1st trimester pregnancies3. This difference
mainly arose from lower number of duplications. Overall, 1st
trimester control placentas shared only 5.3% of identiﬁed
CNV regions with RPL cases, whereas the respective fraction
with term placentas was 35.1%. Interestingly, genes with
higher overall expression were prone to deletions. Addition-
ally, large pericentromeric and subtelomeric CNVs in parental
genomes emerged as a risk factor for RPL.
Conclusions: Early placental development may need a
burst of somatic genomic rearrangements to guarantee
active proliferation, migration and invasion of trophoblasts.
1Kasak, L et al. Sci. Rep. 2015
2Nagirnaja, L, Palta P, Kasak L et al. Hum. Mutat. 2014
3Kasak et al. 2017 submitted
This work was supported by European Union through the
European Regional Development Fund (project HAPPY
PREGNANCY, 3.2.0701.12-0047); Estonian Science
Foundation Grant (ETF9030); Institutional Research Grant
(IUT34-12).
L. Kasak: None. K. Rull: None. S. Sõber: None. M.
Laan: None.
P01.002B
Validation and application of a novel integrated genetic
screening method to a cohort of 1,112 men with idio-
pathic azoospermia or severe oligozoospermia
M. S. Oud1, L. Ramos2, M. K. O'Bryan3, R. I.
McLachlan4, Ö. Okutman5, S. Viville5, P. F. de Vries1, D.
F. C. M. Smeets1, D. Lugtenberg1, J. Y. Hehir-Kwa1, M.
van de Vorst1, L. E. L. M. Vissers1, A. Hoischen1, A. M.
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Meijerink2, K. Fleischer2, J. A. Veltman1,6,7, M. J.
Noordam7
1Department of Human Genetics, Donders Institute for
Brain, Cognition and Behaviour, Radboudumc, Nijmegen,
Netherlands, 2Department of Gynaecology and Obstetrics,
Radboudumc, Nijmegen, Netherlands, 3The Development
and Stem Cells Program of Monash Biomedicine Discovery
Institute and the Department of Anatomy and Develop-
mental Biology, Monash University, Melbourne, Australia,
4Hudson Institute of Medical Research, Monash University,
Melbourne, Australia, 5Laboratory of Genetic Diagnostics,
UF3472-Genetics of Infertility, University Hospital Stras-
bourg, Strasbourg, France, 6Institute of Genetic Medicine,
Newcastle University, Newcastle, United Kingdom,
7Department of Genetics and Cell Biology, Maastricht
UMC+, Maastricht, Netherlands
Infertility affects 10–15% of all couples and about half of
the cases can be assigned to male factors. Microdeletions of
the Y chromosome (YCMs) and Klinefelter syndrome (47,
XXY) are common causes of severe oligozoospermia
(reduced sperm count) and azoospermia (no sperm in eja-
culate), but the majority of cases remain idiopathic. Here we
describe a single molecule Molecular Inversion Probes
(smMIP) assay, to screen infertile men for variation in
known and candidate disease genes.
We designed a set of 4,525 smMIPs targeting the coding
regions of causal (n= 6) and candidate (n= 101) male
infertility genes. After validation, we screened 1,112 idio-
pathic infertile men who presented with azoospermia or
severe oligozoospermia at the outpatient clinics of the
Radboudumc and Monash Universities. Next to 5 patients
with YCMs and 5 with chromosomal anomalies (47,XXY,
47,XYY and 46,XX male), we identiﬁed 159 patients with
rare point mutations or Copy Number Variations (CNVs)
affecting known infertility genes (AURKC, CFTR, DDX3Y,
DPY19L2, SYCP3, TEX11). A genetic diagnosis that may
explain the infertility was made in 18 patients (1.6%).
Evaluation of variants in 101 candidate genes is ongoing
and may increase diagnostic yield.
In conclusion, we developed a ﬂexible and scalable
method to reliably detect point mutations, CNVs and sex
chromosomal anomalies causing male infertility. The assay
consolidates the detection of different types of genetic
variation while increasing the diagnostic yield and detection
precision at the same or lower price compared to currently
used methods and helps to deﬁne more genetic infertility
causes to inform doctors and patients.
M.S. Oud: None. L. Ramos: None. M.K. O'Bryan:
None. R.I. McLachlan: None. Ö. Okutman: None. S.
Viville: None. P.F. de Vries: None. D.F.C.M. Smeets:
None. D. Lugtenberg: None. J.Y. Hehir-Kwa: None. M.
van de Vorst: None. L.E.L.M. Vissers: None. A. Hoi-
schen: None. A.M. Meijerink: None. K. Fleischer: None.
J.A. Veltman: None. M.J. Noordam: None.
P01.003C
FOG2/ZFPM2 is a noval disease gene for primary
ovarian insufﬁciency
D. Baetens1, N. De Vriese1, N. Reynaert2, A. Bachelot3, P.
Touraine3, J. Dulon3, P. De Sutter1, F. De Zegher2, M.
Cools1, E. De Baere1
1Ghent Univerity, Ghent, Belgium, 2University Hospitals
Leuven, Leuven, Belgium, 3Université Pierre et Marie
Curie, Paris, France
Background: Premature ovarian insufﬁciency (POI) is a
major cause of female infertility. The genetic causes of POI
remain mainly unknown. We hypothesized that Friend of
GATA 2 (FOG2/ZFPM2) haploinsufﬁciency could con-
tribute to POI pathogenesis, based on the identiﬁcation of a
heterozygous FOG2 deletion in a child with an isolated 46,
XY disorder of sex development (DSD) and in his 25-years
old mother with low serum anti-Müllerian hormone (AMH)
levels, suggestive of a decreased ovarian reserve. This
hypothesis is supported by the role of FOG2 in mouse
ovarian development.
Methods: Targeted next-generation sequencing of
FOG2 was conducted in 31 Belgian and 357 French POI
cases. Copy number analysis of FOG2 was performed with
array-CGH followed by qPCR. Functional validation of the
identiﬁed FOG2 variants was performed by luciferase
assays in HEK293T cells.
Results: A heterozygous FOG2 deletion was found in a
child with isolated 46,XY DSD and in his mother with
putative POI risk. Subsequently, seven novel, likely
pathogenic FOG2 variants were found in a heterozygous
state in a large POI cohort (7/388, 1.8%), ﬁve of which are
missense variants, one in-frame duplication and one fra-
meshift. Luciferase assays showed signiﬁcantly lowered
transcriptional activation of the mutated FOG2/GATA4
complex for several of the identiﬁed variants.
Conclusion: We demonstrate that FOG2 haploinsufﬁ-
ciency can lead to POI, supporting a role of FOG2 in human
ovarian maintenance and contributing to the molecular
pathogenesis of POI. Finally, we expand the phenotypic
spectrum of FOG2 mutations, thus far associated with cardiac
anomalies, congenital diaphragmatic hernia and 46,XY DSD.
D. Baetens: None. N. De Vriese: None. N. Reynaert:
None. A. Bachelot: None. P. Touraine: None. J. Dulon:
None. P. De Sutter: None. F. De Zegher: None.M. Cools:
None. E. De Baere: None.
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P01.004D
Detection of de novo structural chromosomal rearran-
gements with nucleotide level resolution for assessment
of their clinical outcome in prenatal diagnosis
I. Carvalho1, J. Freixo1, M. Marques2, M. Cardoso2, J.
Fino2, C. Alves2, B. Marques2, M. Talkowski3,4,5, H.
Correia6, C. Morton4,5,7,8, D. Dezso2
1Serviço de Genética, Centro Hospitalar de Lisboa Central,
Lisbon, Portugal, 2Department of Human Genetics,
National Health Institute Doutor Ricardo Jorge, Lisbon,
Portugal, 3Center for Human Genetic Research, Depart-
ments of Neurology, Pathology and Psychiatry, Massachu-
setts General Hospital, Boston, MA, United States,
4Harvard Medical School, Boston, MA, United States,
5Broad Institute of MIT and Harvard, Cambridge, MA,
United States, 6Departmet of Human Genetics, National
Health Institute Doutor Ricardo Jorge, Lisbon, Portugal,
7Departments of Obstetrics and Gynecology, and of
Pathology, Brigham and Women’s Hospital, Boston, MA,
United States, 8University of Manchester, Manchester
Academic Health Science Center, Manchester, United
Kingdom
Recognition of de novo (dn) balanced chromosomal aber-
rations (BCAs) leading potentially to congenital anomalies
constitutes a huge challenge in prenatal diagnosis (PND).
Therefore, cytogenetic and cytogenomic approaches,
including CMA have to be complemented by methods
allowing identiﬁcation of breakpoints at nucleotide resolu-
tion within the actionable time frame of a prenatal diag-
nosis. Concomitantly with the conventional PND protocol,
we apply large-insert whole-genome sequencing for iden-
tiﬁcation of dnBCA breakpoints in two prenatal samples.
The ﬁrst fetus, referred for PND because of increased risk,
is a female with a t(16;17)(q24;q21.3)dn. Sequencing
identiﬁed the 16q24 and 17q21.3 breakpoints within IVS3
of ANKRD11 and IVS1 of WNT3, respectively. Hap-
loinsufﬁciency of ANKRD11 causes dominant KBG syn-
drome (OMIM #148050), whereas of WNT3 results in
recessive tetraamelia syndrome (OMIM #165330).
Although the translocation results in fusion genes no evi-
dence of chimeric transcripts was found. The second fetus,
referred for PND due to maternal anxiety, is a male with a t
(2;19)(p13.3;q13.11)dn. The 2p13.3 breakpoint is localized
within IVS1 of ATP6V1B1 whereas that of 19q13.11 is
proximal to CEP89. ATP6V1B1 causes a recessive form of
renal tubular acidosis with progressive sensorineural deaf-
ness (OMIM #192132). Clinical features of the newborns
corroborate the predicted outcome in the light of chromatin
topological association domains (TADs); KBG syndrome in
the ﬁrst case and a normal phenotype in the second case.
Although prediction of the phenotypic outcomes highlights
the gaps in our current knowledge, this approach allows
improved genetic counselling. Therefore, we recommend
inclusion of this approach into current PND care. Research
grant: FCT HMSP-ICT/0016/2013.
I. Carvalho: None. J. Freixo: None. M. Marques:
None. M. Cardoso: None. J. Fino: None. C. Alves: None.
B. Marques: None. M. Talkowski: None. H. Correia:
None. C. Morton: None. D. Dezso: None.
P01.005A
Large population cohorts reveal unrecognized adult
traits of the 16p11.2 CNV syndromes
K. Mannik1,2, M. Lepamets2, S. Martin-Brevet3, T. Laisk-
Podar4, The 16p11.2 European Consortium, The Simons
VIP Consortium, A. Metspalu2, C. M. Lindgren5,6,7, S.
Jacquemont8, B. Draganski9, R. Mägi2, A. Reymond1
1Center for Integrative Genomics, University of Lausanne,
Lausanne, Switzerland, 2Estonian Genome Center, Uni-
versity of Tartu, Tartu, Estonia, 3Service de Génétique
Médicale, Centre Hospitalier Universitaire Vaudois, Uni-
versity of Lausanne, Lausanne, Switzerland, 4Women’s
Clinic, Institute of Clinical Medicine, University of Tartu,
Tartu, Estonia, 5Program in Medical and Population
Genetics, Broad Institute, Cambridge, MA, United States,
6Wellcome Trust Centre for Human Genetics, Nufﬁeld
Department of Medicine, University of Oxford, Oxford,
United Kingdom, 7Li Ka Shing Centre for Health Informa-
tion and Discovery, The Big Data Institute, University of
Oxford, Oxford, United Kingdom, 8CHU Sainte-Justine
Research Centre, Montreal, QC, Canada, 9LREN, Départe-
ment des neurosciences cliniques, Centre Hospitalier
Universitaire Vaudois, University of Lausanne, Lausanne,
Switzerland
Disorders caused by rare CNVs are a common health pro-
blem, but their phenotype associations have almost exclu-
sively been investigated in clinically ascertained (often
pediatric) patients.
The 16p11.2 600kb BP4-BP5 rearrangements have a
population prevalence of about 1 in 1,000. Akin to other
rare CNVs, they have so far been studied mostly in cohorts
pre-selected for developmental disorders and thus adult data
are lacking. To overcome such ascertainment bias, we have
combined data from the pan-European and the Simons VIP
cohort of 16p11.2 families (584 individuals) with the UK
Biobank and the Estonian Genome Center general popula-
tion cohorts (>160,000 individuals). This "disease agnostic"
approach has identiﬁed a signiﬁcant association between
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16p11.2 dosage alterations and reproductive health. In
female UK Biobank participants, 16p11.2 CNVs are asso-
ciated in a dosage-dependent manner with age of menarche:
compared to controls signiﬁcant decrease in deletion (Δ=
−1.33 years, p= 2.4 × 10−4) and increase in duplication
carriers (Δ=+1.42 years; p= 8.9 × 10−4). The variance
between the three groups remained signiﬁcant even after
correction for BMI (p= 1.3 × 10−7). We replicated these
associations using the geographically distinct 16p11.2
cohorts. Importantly, in the investigated cohorts both female
and male 16p11.2 CNV carriers have signiﬁcantly increased
prevalence of reproductive tract disorders. This is further
paralleled by 16p11.2 dosage dependent alterations in the
hypothalamus in mouse models and humans' brain imaging
studies. Despite numerous previous studies on the 16p11.2
CNVs, the link with the reproductive axis remained over-
looked, illustrating that identiﬁcation of traits associated
with rare variants in unselected populations provides valu-
able and unbiased insight into disease etiologies.
K. Mannik: None. M. Lepamets: None. S. Martin-
Brevet: None. T. Laisk-Podar: None. A. Metspalu: None.
C.M. Lindgren: None. S. Jacquemont: None. B. Dra-
ganski: None. R. Mägi: None. A. Reymond: None.
P01.006B
Analytical Validation of a SNP-Based Noninvasive Pre-
natal Test to Detect the 22q11.2 Microdeletion
A. Norvez, A. Ryan, A. Kalyan, V. Vijayan, Z. Demko
Natera, Inc., San Carlos, CA, United States
Background: Non-invasive prenatal testing (NIPT) for
aneuploidy using cell-free DNA in maternal plasma has
been widely adopted. Recently, NIPT coverage has
expanded to detect subchromosomal anomalies including
the 22q11.2 microdeletion. Validation of a SNP-based
NIPT for detection of 22q11.2 deletions showed high sen-
sitivity (97.8%) and speciﬁcity (99.75%) (Wapner, 2015;
Gross 2016). Here, we validated an updated version of this
test in a larger cohort of pregnancy plasma samples.
Materials and Methods: Blood samples were obtained
from pregnant women at participating hospitals and contract
research organizations. Ten positive control samples and
390 negative control samples were analyzed using an
updated SNP-based NIPT for the 22q11.2 microdeletion.
Samples were ampliﬁed and sequenced using pooled primer
sets that included 1,351 SNPs spanning a 2.91Mb section of
the 22q11.2 region. A risk score was assigned to all samples
as previously described. The algorithm’s conﬁdence
threshold was raised to 0.95 and all “high-risk” samples
were reﬂexively sequenced at high depth of read (6 × 106
reads/sample). The sensitivity and speciﬁcity of the assay
were measured. Results: Sensitivity of the assay was 90%
(9/10), and speciﬁcity of the assay was 99.74% (389/390),
with a corresponding false positive-rate of 0.26%. Con-
clusions: This validation of the updated SNP-based assay in
a cohort of pregnancy-plasma samples demonstrates that it
detects the 22q11.2 microdeletion with high sensitivity and
speciﬁcity. Given the beneﬁts of early intervention in
patients with the 22q11.2 deletion and the high incidence of
the condition, this SNP-based methodology provides a
valuable addition to current population-wide prenatal
screening approaches.
A. Norvez: E. Ownership Interest (stock, stock options,
patent or other intellectual property); Modest; Natera, Inc.
A. Ryan: E. Ownership Interest (stock, stock options,
patent or other intellectual property); Modest; Natera, Inc.
A. Kalyan: E. Ownership Interest (stock, stock options,
patent or other intellectual property); Modest; Natera, Inc.
V. Vijayan: E. Ownership Interest (stock, stock options,
patent or other intellectual property); Modest; Natera, Inc.
Z. Demko: E. Ownership Interest (stock, stock options,
patent or other intellectual property); Modest; Natera, Inc..
P01.007C
Non-invasive prenatal testing (NIPT) for 22q11.2 dele-
tion syndrome using a targeted microarray-based cell-
free (cfDNA) test
M. Schmid, E. Wang, P. Bogard, J. Zahn, C. Hacker, R.
Stokowski, S. Wang, K. White, A. Sparks
Ariosa Diagnostics Inc., Roche Sequencing Solutions Inc.,
San Jose, CA, United States
Objective: To determine the analytical performance of a
targeted microarray based cfDNA test (Harmony Prenatal
Test®) for the identiﬁcation of pregnancies at increased risk
for a 22q11.2 deletion.
Methods: 1736 plasma samples were studied. 122 sam-
ples had a 22q11.2 deletion ranging in size from 1.96 to
3.25 Mb. These included simulated pregnancy samples and
maternal plasma from pregnancies with a fetal 22q11.2
deletion. The simulated samples were created with plasma
from individuals with 22q11.2 deletions titrated with
plasma from unaffected, non-pregnant women to simulate
fetal fractions ranging from 4% to 33%. 1614 samples were
from women with presumed unaffected pregnancies in
which the maternal and fetal 22q11.2 deletion status was
unknown. Cell-free DNA analysis using Digital ANalysis of
Selected Regions (DANSRTM) was performed as previously
described with additional assays for assessment of fetal
22q11.2 deletions within a 3.0 Mb region. DANSR
116
products were quantiﬁed on custom microarrays and the
probability of a deletion being present was determined
using the FORTETM algorithm.
Results: Of the 122 samples with a 22q11.2 deletion, 92
were determined to have a high probability of a deletion
(sensitivity: 75.4%; 95% CI: 67.1–82.2%). No evidence of a
deletion was observed in 1606 of the 1614 samples from
presumed unaffected pregnancies (speciﬁcity: 99.5%; 95%
CI: 99.0–99.7%).
Conclusions: Targeted cell-free DNA testing using
microarray quantitation is able to identify pregnancies at
increased risk for 22q11.2 deletions of 3.0 Mb and smaller
while maintaining a low false positive rate.
M. Schmid: A. Employment (full or part-time); Sig-
niﬁcant; Ariosa Diagnostics Inc., Roche Sequencing Solu-
tions Inc. E. Wang: A. Employment (full or part-time);
Signiﬁcant; Ariosa Diagnostics Inc., Roche Sequencing
Solutions Inc. P. Bogard: A. Employment (full or part-
time); Signiﬁcant; Ariosa Diagnostics Inc., Roche Sequen-
cing Solutions Inc. J. Zahn: A. Employment (full or part-
time); Signiﬁcant; Ariosa Diagnostics Inc., Roche Sequen-
cing Solutions Inc. C. Hacker: A. Employment (full or
part-time); Signiﬁcant; Ariosa Diagnostics Inc., Roche
Sequencing Solutions Inc. R. Stokowski: A. Employment
(full or part-time); Signiﬁcant; Ariosa Diagnostics Inc.,
Roche Sequencing Solutions Inc. S. Wang: A. Employment
(full or part-time); Signiﬁcant; Ariosa Diagnostics Inc.,
Roche Sequencing Solutions Inc. K. White: A. Employ-
ment (full or part-time); Signiﬁcant; Ariosa Diagnostics
Inc., Roche Sequencing Solutions Inc. A. Sparks: A.
Employment (full or part-time); Signiﬁcant; Ariosa Diag-
nostics Inc., Roche Sequencing Solutions Inc..
P01.008D
False 46,XX sex reversal in infertile male patient
V. B. Chernykh1,2, Z. G. Markova1, Y. O. Kozlova1, N. V.
Shilova1, O. P. Ryzhkova1, A. V. Polyakov1, V. Y.
Tabakov1, L. F. Kurilo1
1Research Centre for Medical Genetics, Moscow, Russian
Federation, 2Pirogov Russian National Research Medical
University, Moscow, Russian Federation
We report on the clinical case of false 46,XX-sex reversal.
A proband is 24 years-old man referred to genetic evalua-
tion because of infertility and non-obstructive azoospermia.
Previously, proband’s chromosome analysis on cultivated
peripheral lymphocytes showed non-mosaic 46,XX kar-
yotype, and a diagnosis ‘46,XX testicular DSD (46,XX
male syndrome)’ was suspected. However, the detailed
questioning revealed that the patient was subjected to
allogeneic transplantation of haematopoietic stem cells from
his health sister. Allo-HSCT was performed because of
aplastic anemia, which the patient developed at 7 years old.
After that procedure, he developed chronic Graft-versus-
host disease; therefore, the patient received continuous
immune-suppression therapy. Because of the transplanta-
tion, genetic evaluation was needed to carry out on non-
haematopoietic cell lines. Repeated cytogenetic and FISH
analysis with X and Y centromeric DNA (CEPX, CEPY)
probes were performed on cultivated skin ﬁbroblasts. SRY,
ZFX/ZFY loci and the Y chromosome microdeletions of
AZFa,b,c regions were analyzed by multiplex PCR on
genomic DNA extracted from buccal smears. The patient
was found to be SRY positive and to have non-mosaic 46,
XY karyotype in non-haematopoietic cells. Results of
interphase FISH analysis: nuc ish (DXZ1,DYZ3) × 1[300].
No Y chromosome microdeletion was detected. Combined
genetic examination allowed to reject ‘46,XX testicular
DSD’ diagnosis. Possible male infertility in the patient was
due to long-term immune-suppression therapy.The pre-
sented case demonstrates the need for detailed collection of
anamnestic information and factors that may affect results
of genetic research, including transplantation and blood
transfusion, and the successful use of combined genetic
analysis in mosaics and chimeras.
V.B. Chernykh: None. Z.G. Markova: None. Y.O.
Kozlova: None. N.V. Shilova: None. O.P. Ryzhkova:
None. A.V. Polyakov: None. V.Y. Tabakov: None. L.F.
Kurilo: None.
P01.009A
Comparison of variants of uncertain signiﬁcance
(VOUS) using different array CGH resolution
platforms-implication in prenatal diagnosis
E. Oikonomidou1, G. Efstathiou1, C. Malamaki1, E.
Darmani1, A. Arampatzi1, A. Zavlanos2, S. Vittas1
1Eurogenetica M.S.A, Thessaloniki, Greece, 221st Depart-
ment of Obstetrics and Gynecology, A.U.TH., “Papageor-
giou” G. Hospital, Thessaloniki, Greece
Introduction: Over the past few years, aCGH application
in prenatal diagnosis has contributed signiﬁcantly in chro-
mosomal microdeletions/microduplications detection.
However, the implementation of aCGH also gave rise to the
detection of variants of uncertain signiﬁcance (VOUS). The
present study is a comparative investigation of low and
high-resolution aCGH application in prenatal diagnosis in
terms of VOUS ﬁndings.
Materials and Methods: 2646 prenatal cases were
referred to our center during the period 2012–2016. 2325
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cases were analyzed using low-resolution aCGH (1Mb
backbone resolution-Cytochip Focus Constitutional, Blue-
gnome), and 321 using high-resolution aCGH (500kb
backbone resolution-SurePrint G3 ISCA V2, CGH 8 × 60k,
Agilent Technologies).
Results: Out of 2325 cases analyzed by low-resolution
aCGH, 58 cases resulted in a known chromosomal imbal-
ance (2.5%) and 45 cases showed a VOUS (1.9%).
Accordingly, out of 321 cases analyzed with high-resolution
aCGH, 13 cases resulted in a known chromosomal imbal-
ance (4.1%) and 32 cases showed a VOUS (10.0%). Par-
ental origin of each VOUS was tested where possible (53/77
cases) and in the majority of cases the variant was inherited
from one of the two parents (46/53 cases - 86.8%).
Conclusions: Application of high resolution aCGH in
prenatal diagnosis led to the detection of more pathogenic
aberrations in comparison to low-resolution aCGH (2.5% to
4.0%), increasing the diagnostic yield. However, VOUS
detection frequency was signiﬁcantly elevated (1.9% to
10.0%), making genetic counseling more complex and
increasing anxiety of the future parents. The present study
indicates that the implementation of high resolution aCGH
in prenatal diagnosis should be thoroughly evaluated.
E. Oikonomidou: None. G. Efstathiou: None. C.
Malamaki: None. E. Darmani: None. A. Arampatzi:
None. A. Zavlanos: None. S. Vittas: None.
P01.010B
A novel mutation causes Non Obstructive Azoospermia
in infertile men
M. Arafat1,2, I. Har-Vardi3, A. Harlev3, E. Levitas3,4, A.
Zeadna3, M. Abofoul-Azab1,2,4, V. Dyomin5, V. Shefﬁeld6,
E. Lunenfeld3,4, M. Huleihel1,2,4, R. Parvari1,2
1The shraga segal Department of Microbiology,Immunol-
ogy & Genetics, Faculty of Health Sciences, Ben-Gurion
University of the Negev, Beer-Sheva, Israel, 2The National
Institute for Biotechnology in the Negev, Ben-Gurion
University of the Negev, Beer-Sheva, Israel, 3Fertility and
IVF Unit, Department of Obstetrics and Gynecology,
Soroka University Medical Center, Faculty of Health
Sciences, Ben Gurion University of the Negev, Beer-Sheva,
Israel, 4The Center of Advanced Research and Education in
Reproduction (CARER), Faculty of Health Sciences, Ben-
Gurion University of the Negev, Beer-Sheva, Israel, 5Insti-
tute of Pathology, Soroka University Medical Center, Beer-
Sheva, Israel, 6Department of Pediatrics, Division of
Medical Genetics, University of Iowa, Iowa, IA, United
States
Introduction: Infertility is deﬁned as a failure of concep-
tion after 12 months of having unprotected intercourse, and
male infertility accounts for 30–55% of infertile couples.
Azoospermia, is diagnosed when sperm is completely
absent in the ejaculate even after centrifugation.
Materials and Methods: Genotyping was done on four
azoospermic individuals of a consanguineous Bedouin
family and their parents. Exome sequencing was performed
on the DNA of one patient.
Results: Assuming homozygosity of a recessive founder
mutation as the likely cause of the disorder, we have gen-
otyped 4 patients and their parents. We identiﬁed 5 shared
homozygous regions larger than 2 cM, encompassing a total
of 13.8Mbp on the autosomal chromosomes. In these
regions only one homozygous variant with allele fre-
quencies of less than 1% in the public databases (ExAc
browser, 1000 Genomes and dbSNP) was identiﬁed. This
variant segregated as expected in the family, with a calcu-
lated Lod score of 3.42. The variation was not present in
620 Bedouin controls.
The variation is a frameshift mutation in a gene encoding
a protein demonstrated to be essential for silencing of Line-
1 retrotransposon in the male germline. Using a commercial
antibody to the N-terminus of the encoded protein, immu-
noﬂuorescent studies demonstrated it is produced in
patients' testes, especially in spermatogonial cells (mainly in
the cytoplasm) and in spermatocysts/round spermatids
(mainly in the nucleus).
Conclusions: The identiﬁcation of the mutation causing
azoospermia enables accurate diagnosis in the enlarged
family and demonstrates the importance of repressing ret-
rotransposon activation in the male germline in human.
M. Arafat: None. I. Har-Vardi: None. A. Harlev:
None. E. Levitas: None. A. Zeadna: None. M. Abofoul-
Azab: None. V. Dyomin: None. V. Shefﬁeld: None. E.
Lunenfeld: None. M. Huleihel: None. R. Parvari: None.
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Using molecular karyotypes of blastocoel ﬂuid to obtain
data about the origin of aneuploidies in human pre-
implantation embryo development
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1Department of Cytology and Genetics, National Research
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Introduction: Due to cell elimination during preimplanta-
tion development, the DNA from some cells enters into
cavity of blastocyst. Analysis of the blastocoel ﬂuid
apparently provides additional information about aneu-
ploidy that presented in the embryo cells. Therefore, we can
more conﬁdently suggest the origin of aneuploidies.
Materials and Methods: Fifteen human blastocysts of
good quality were analyzed on the day 5th of embryonic
development. All embryos were obtained in treatment
cycles of IVF, underwent blastocoel collection and separa-
tion into inner cell mass and trophectoderm cells under
informed consent. Microarray-based comparative genomic
hybridization was used to analyze molecular karyotypes of
all trio samples.
Results: A total of 77 aneuploidies were detected in 11
from 15 embryos. Six embryos (40%) had a chromosomal
mosaicism with the presence of 2 or more different aneu-
ploidies. Four detected aneuploidies (5.2%) had apparently
a meiotic origin, as they were observed in both inner cell
mass and trophectoderm of the same embryo. Probably,
sixteen aneuploidies (20.8%) had a mitotic origin because
they were presented by reciprocal aneuploidies in inner cell
mass and trophectoderm or in trophectoderm cells and
blastocoel ﬂuid. Most of the identiﬁed aneuploidies (74%)
were conﬁned by only one tissue type.
Conclusions: Our results suggest that majority of chro-
mosomal abnormalities have mitotic origin during early
stages of preimplantation development. They provide also
evidence for underestimation of chromosomal mosaicism in
human blastocysts.
This study was supported by the Russian Foundation for
Basic Research (no. 15-04-08265), and the Mendeleev Fund
Program of Tomsk State University in 2016.
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Recessive Complex Brachydactyly, Symphalangism,
Zygodactyly and Male Infertility - not a Novel Syn-
drome but Caused by Linked Mutations in BMPR1B
and PDHA2, a New Male Infertility Gene
Y. Yildirim1, T. Ouriachi2, U. Woehlbier3, W. Ouahioune2,
M. Balkan4, S. Malik5, A. Tolun1
1Bogazici University, İstanbul, Turkey, 2University Hospital
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Chile, 4Dicle University, Diyarbakir, Turkey, 5Quaid-i-
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Introduction:We present a consanguineous family with six
sibs afﬂicted with complex brachydactyly, symphalangism
and zygodactyly plus infertility in males due to azoospermia
or sperm immotility/death, which we hypothesized as a new
syndrome. BMPR1B is known to be responsible for domi-
nant brachydactyly type A1 and type A2 and recessive
acromesomelic chondrodysplasia. Animal models indicate
that many genes are involved in mammalian spermatogen-
esis. One such gene is exclusively testis-speciﬁc PDHA2,
encoding the mitochondrial matrix enzyme PDHA2
expressed during spermatogenesis.
Materials and Methods: Candidate disease loci were
found by homozygosity mapping using SNP data from four
affected and three unaffected members of the family.
Exome sequencing was applied to ﬁnd rare/novel variants at
the loci.
Results: We mapped the disease locus and identiﬁed
novel homozygous missense variant c.640C > T (p.
(Arg214Cys)) in BMPR1B in patients. We also detected
homozygous c.679A > G (p.(Met227Val)) in PDHA2 in
infertile brothers. Structural protein modelling, protein
sequence conservation and in silico analysis indicate that
both variants are damaging.
Conclusion: The complex brachydactyly afﬂicting the
family is the ﬁrst recessive brachydactyly reported to date.
PDHA2 is a novel candidate gene for male infertility. The
disease afﬂicting the family is a unique example of two
linked variants, approximately 711 Kbp apart, in different
genes that together manifest as a seemingly novel syn-
drome. Hence, we conclude that exome sequencing and not
candidate gene approach should be employed in disease
gene hunt, deﬁning new diseases and genetic testing.
Grants: TÜBİTAK grant 114Z829, Boğaziçi University
Research Fund 10860 and FONDECYT no. 1150743.
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MPS-based carrier screening: search deeper, not wider
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Pavlov3, T. Simakova3, J. Vnuchkova3, M. Glushkova3, A.
Bragin3
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Rapid development of Massive Parallel Sequencing (MPS)
technologies opens wide possibilities for reproduction
medicine such as carrier screening for monogenic disorders.
While available MPS-based panels tend to expand including
more and more inheritable conditions one may raise a
concern regarding clinical proportion of such an expansion.
Addition of extremely rare conditions, those of multi-
factorial inheritance, reduced penetrance or mild phenotype
worsen technical performance of the test and complicates
genetic counseling. Wider scope means decreased coverage
depth leading to potential inaccuracy in residual risk
assessment for severe genetic condition with childhood-
onset. Expanded carrier screening sacriﬁces quality (clinical
value) of the test for quantity (number of condition
screened). We established a distinct approach to MPS car-
rier test for gamete donors and couples. NextGen21 genetic
test includes 21 genes associated with frequent, severe
genetic conditions. Target regions of the assay were selec-
ted by combining functional regions of the genes (CDSs,
splicing sites and UTRs) and the hotspots (i.e. clinically
signiﬁcant variants). Test was veriﬁed by human DNA
standards from NIST and the 1000 Genomes Project. CFTR
and PAH regions were additionally veriﬁed by Sanger
sequencing. The assay was applied to 42 gamete donors and
29 patients. Carriers of X-linked and autosomal-dominant
conditions with late-onset were excluded from donor pro-
gramme. 14 pathogenic variants (1096 unique overall) were
detected. Rare pathogenic variants found in genes CFTR,
PAH and GBA proves tagline “search deeper, not wider”
credible in terms of residual risk assessment, therefore,
clinical proportion of test overall.
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Expanded carrier screening for recessive disorders:
review of the characteristics of current internet-based
offers
D. Chokoshvili, D. F. Vears, P. Borry
University of Leuven, Leuven, Belgium
Carrier screening allows identiﬁcation of healthy pro-
spective parents who are at risk of conceiving a child
affected with a monogenic recessive disorder. Recently,
expanded carrier screening (ECS), which can identify car-
riers of a large number of recessive disorders in the general
population, has grown in popularity and is now widely
accessible, primarily through commercial companies. We
performed a review of internet-based ECS offers in January
2017 to investigate the characteristics of ECS tests currently
available, such as the number and nature of conditions
screened. We excluded ethnicity-based carrier screening
initiatives, research-centered ECS pilot programs, and offers
where test characteristics, such as the lists of included
genes/disorders were unavailable. We identiﬁed ﬁfteen
providers of ECS tests: 12 commercial companies, two
medical hospitals and one academic medical center. The
majority (12) of the providers were based in the USA, with
the remaining three located in the Netherlands, Spain, and
South Korea. We observed drastic differences in the char-
acteristics of ECS tests, with the number of conditions
ranging from 41 to 1700. Only three conditions (Cystic
ﬁbrosis, Maple syrup urine disease 1b, and Niemann-Pick
disease) were screened for by all providers. Where the same
disease gene was analyzed by multiple providers, sub-
stantial differences existed in the mutations included and/or
variant interpretation methodologies. Given the importance
of carrier screening results in reproductive decision-making,
the observed heterogeneity across ECS panels is concern-
ing. Efforts should be made to ensure that clear and concrete
clinical criteria are in place to help inform the development
of ECS panels.
D. Chokoshvili: None. D.F. Vears: None. P. Borry:
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Introduction: Ethnicity-based carrier testing for single
gene conditions is the current standard of prenatal care.
Technological advances have allowed for rapid expanded
carrier testing for hundreds of genetic mutations across a
signiﬁcant number of conditions, improving detection of at
risk carrier couples in non-targeted ethnic groups.
Methods: A retrospective review of over 30,000 carrier
test results was performed to identify positive carriers of 23
conditions included in ACOG/ACMG recommendations.
Ethnicity was self-reported. For each condition and ethni-
city, expected numbers of positive carriers were calculated
and compared to observed rates. A Chi-square analysis was
performed to calculate statistical signiﬁcance (p ≤ .01).
Results: When evaluating for Ashkenazi Jewish dis-
eases, a higher than expected number of patients who
identify as Caucasian screened positive for Tay-Sachs dis-
ease (46 individuals observed as carriers vs 21.7 expected)
and Fanconi anemia type C (15 individuals observed as
carriers vs 1.4 expected). Patients who identiﬁed as His-
panic screened positive for CF and SMA more often than
expected as well. All of these observations were statistically
signiﬁcant. A select data set is represented in Table 1.
Conclusion: Testing patients with an expanded pan-
ethnic panel will identify more carriers of conditions that
would be missed by current ethnicity-based conventions.
Expanded carrier testing will identify more carriers, allow-
ing for more complete risk assessments and consideration of
planning options.
Table 1: * indicates p ≤0.01
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CarrierTest - the expanded preconception carrier
screening
F. Lhota, F. Zembol, M. Koudova, M. Bittoova, D.
Stejskal
Gennet, Clinic of genetics and reproductive medicine,
Prague, Czech Republic
In recent years clinical genetic testing has moved from
gene-by-gene direct analysis of distinct monogenic heredi-
tary disorders to more complex approaches using high
throughput methods, such as next-generation sequencing
(NGS). This approach can be used for testing of carrier
status of signiﬁcant autosomal recessive diseases by pre-
conception expanded carrier screening in couples without a
positive family history.We have developed a NGS
amplicon-based panel testing 874 key mutations of 81 genes
which can inﬂuence reproductive health of prospective
parents or can cause inherited diseases at offspring. Car-
rierTest targets (i) mutations of 72 genes causing serious
recessive diseases at offspring of healthy carriers (genetic
compatibility test); (ii) low penetrant mutations primarily
associated with health conditions of prospective parents and
inﬂuenced by external factors; (iii) mutations associated
with blood hypercoagulability which can inﬂuence inferti-
lity treatment and pregnancy; (iv) inherited ovarian
response to standard gonadotrophin stimulation.CarrierTest
uses locally assembled bioinformatic pipeline and database
implemented into laboratory information system. To replace
MLPA and fragmentation analysis methods we developed
coverage analysis-based CNV detection of frequent large
deletions of SMN1 and CFTR genes. A software tool
developed for this application generates semi-automatically
Cystic ﬁbrosis Spinal muscular atrophy Fragile X Fanconi anemia, type C Tay-Sachs disease
Expected
positives
Observed
positives
Expected
positives
Observed
positives
Expected
positiλves
Observed
positives
Expected
positives
Observed
positives
Expected
positives
Observed
positives
African
American
58.3 57 46.5 48 16.7 16 0.5 0 8.5 2
Ashkenazi
Jewish
15.67 7 8.1 3 1.46 1 4.1 4 11.3 14
Asian 9.75 4 28.6 28 6.28 4 0.2 0 3.2 1
Caucasian 420 483 297.9 230* 42.35 55 1.4 15* 21.7 46*
Hispanic 123 204* 65.7 133* 32.39 21 1 2 16.7 5
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result report. The report contains comparative analysis of
detected variants for evaluation of residual risk and pre-
conception compatibility of couple for consideration of
preimplantation or prenatal diagnostics.
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Non-syndromic congenital hydrocephalus is aetiologically
diverse and while a genetic cause is often suspected, it often
cannot be conﬁrmed. The most common genetic cause is the
L1CAM-related X-linked hydrocephalus and that explains
only 5%-10% of all male cases. This underlines a current
limitation in our understanding of the genetic burden of
non-syndromic congenital hydrocephalus, especially for
those cases with likely autosomal recessive inheritance.
Additionally, the prognosis for most cases of severe con-
genital hydrocephalus is poor, with a majority of surviving
infants displaying signiﬁcant intellectual impairment despite
surgical intervention. It is for this reason that couples with
an antenatal diagnosis of severe hydrocephalus are given
the option, and may opt, for termination of the pregnancy.
We present two families with CCDC88C-related autosomal
recessive congenital hydrocephalus with children who had
severe, antenatally diagnosed hydrocephalus. Those indi-
viduals who were shunted within the ﬁrst few weeks of life,
who did not require multiple surgical revisions, and who
had a more distal truncating mutation of the CCDC88C
gene met their early childhood developmental milestones in
most cases. This suggests that children with CCDC88C-
related autosomal recessive hydrocephalus can have normal
developmental outcomes. We recommend CCDC88C
analysis in cases of severe non-syndromic congenital
hydrocephalus, especially when aqueduct stenosis with or
without a medial diverticulum is seen, in order to aid
prognosis discussion.
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Introduction: Although noninvasive prenatal testing
(NIPT) has been well studied for its efﬁcacy in detecting
common trisomies, there is a lack of clinical evaluation of
its performance in detecting extra chromosome abnormal-
ities. Herein in this study, we aimed to evaluate the per-
formance and incremental yield of NIPT in detecting sex
chromosomal aneuploidy, chromosome copy number var-
iants, and other incidental ﬁndings.
Materials and Methods: We performed genome-wide
NIPT in 15633 consecutive pregnancies prospectively col-
lected in our center. In each case chromosomal abnormality
was analyzed in all 23 pairs of chromosome. NIPT results
were accordingly reported and counseled depending on the
presence of other chromosome abnormalities. NIPT results
were validated by invasive diagnosis of positive results and
phenotypic follow-up of negative results.
Results: NIPT identiﬁed a total of 191 cases (1.2%) of
chromosomal abnormality including 101 common trisomies
(T21/T18/T13) and 90 extra abnormalities. By reporting
extra abnormalities, NIPT increased the detection yield
from 0.5% to 0.76% (p= 0.0086), and had the overall
sensitivity of 97.14% (95%CI 91.27%–99.26%), speciﬁcity
of 99.63% (95%CI 99.51%–99.72%), and PPV of 66.67
(95%CI 58.53%–73.93%). There was no signiﬁcant reduc-
tion of the sensitivity and PPV by reporting extra chromo-
some abnormality, although speciﬁcity dropped
signiﬁcantly (p= 0.0001). Nonetheless, comparing with
conventional biochemical screening, NIPT still had 60
times higher true positive rate and a small number of false
positive results.
Conclusions: NIPT can detect extra chromosome
abnormalities with high sensitivity and speciﬁcity. It may
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offer clinical beneﬁts due to incremental yield and out-
performed efﬁcacy than conventional biochemical
screening.
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Introduction: The aim of this study was to quantify cell-
free fetal DNA (cffDNA) with SRY gene and the fetal epi-
genetic marker RASSF1A, in maternal plasma samples of
pregnant women in the ﬁrst trimester of gestation. The
objective was to evaluate the potential of the universal
marker RASSF1A for quantiﬁcation of fetal DNA indepen-
dently of the fetal sex.
Materials and Methods: From 102 maternal plasma
samples collected between 8–12 weeks of gestation, there
were 62 male pregnancies and 40 female pregnancies.
Maternal plasma DNA was extracted, digested with
methylation-sensitive restriction enzyme BstUI, and the
fetal speciﬁc DNA was quantiﬁed by the QX200 Droplet
Digital PCR (ddPCR™, Bio-Rad) system.
Results: The results observed by ddPCR revealed that; a)
in male pregnancies, the median fetal fraction for SRY gene
was 7.8% and for hypermethylated RASSF1A gene it was
2.9%. b) In female pregnancies, there was no ampliﬁcation
for the SRY gene in any sample, and the median fetal
fraction observed for RASSF1A gene was 2.7%.
Conclusions: Digital PCR technology has shown a high
sensitivity in the detection and quantiﬁcation of cffDNA in
the ﬁrst trimester of gestation, since all plasma samples has
been well characterized. However, the universal epigenetic
marker RASSF1A has shown an underestimation of fetal
fraction compared to SRY gene in male pregnancies during
this early period of gestation, suggesting that RASSF1A
could be a good marker for detection of fetal DNA inde-
pendently of fetal sex, but not the most accurate method of
quantiﬁcation in the ﬁrst trimester of gestation.
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Introduction: Chromosomal microarray (CMA) is gradu-
ally replacing standard karyotyping for all prenatal indica-
tions. Chromosomal mosaicism is detected in less than 1%
of cultured chorionic villus samples (CVS) by karyotyping.
The frequency of CMA-detected chromosomal mosaicism
in uncultured prenatal samples is not known. The aim of
this study was to evaluate the detection of chromosomal
mosaicism in uncultured CVS and amniotic ﬂuid (AF)
samples using CMA. Materials and Methods: All patients
undergoing invasive prenatal testing by CMA were inclu-
ded in the study. CMA was carried out on a total of 2377
uncultured samples: 906 AF and 1471 CVS. Results:
Chromosomal mosaicism was detected in 53 cases (2.2%,
CI: 1.7–2.9), of which 41 were detected in CVS (2.8%, CI:
2.1–3.8), and 12 in AF (1.3%, CI: 0.8–2.3). In 13 cases
(25%) we detected sex chromosome mosaicism (45,X/46,
XX (n= 5), 45,X/46,XY (n= 6), 47,XXY/46,XY (n= 2)),
in 22 cases (42%) mosaicism for autosomal chromosomes
(4 common and 18 other), and in 17 cases (33%) mosaicism
for a copy number variation. Conclusion: This study
demonstrates that CMA as a ﬁrst-line test is able to identify
chromosomal mosaicism. CMA on uncultured prenatal
sampels may be more likely detect mosaicism for unba-
lanced chromosomal abnormalities than traditional cytoge-
netic techniques.
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A single pelvic kidney is observed in up to 1:600 preg-
nancies. In some countries this ﬁnding mandates a routine
amniocentesis for chromosomal microarray analysis testing.
The objective of our study was to examine the risk for
chromosomal aberrations among fetuses with apparently
isolated pelvic kidney. Data from all chromosomal micro-
array analysis reported to the Ministry of Health between
January 2013 and September 2016 were retrospectively
obtained from a computerized database. Only pregnancies
with sonographic diagnosis of isolated pelvic kidney and
documentation of chromosomal microarray analysis result
were included. Risk estimation was performed based on
comparison the rate of abnormal observed CMA ﬁnding to
the general population risk, based on systematic review
encompassing 9272 cases of chromosomal microarray
analysis for fetuses with normal ultrasound. Of 114 preg-
nancies with isolated pelvic kidney, two cases of known
microduplication syndromes were demonstrated (absolute
risk 1.75%, 95% conﬁdence interval (CI) 0.2–6.2%). Both
of the duplications were inherited from healthy mothers. In
addition, six variants of unknown signiﬁcance were detec-
ted (5.3%, 95% CI 1.96–11.1%). Calculation of the effect
estimate for pathogenic chromosomal microarray analysis
ﬁndings yielded a relative risk of 1.73 (95%CI 0.43–6.89)
compared to control population (p= 0.44) Our study is the
ﬁrst report describing the rate of chromosomal anomalies in
fetuses with isolated pelvic kidney. Its results question the
routine recommendation for chromosomal microarray ana-
lysis analysis in such cases. Prospective well-adjusted stu-
dies are still needed to guide the optimal management of
pregnancies with isolated pelvic kidney.
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Introduction: Congenital structural anomalies in man is
one of the contributing factors of male infertility and one of
these is called as Congenital Bilateral Absence of the Vas
Deferens (CBAVD). According to the literature, 75–85 %
of the patients with CBAVD carry at least one pathogenic
CFTR mutation. Till date, there is no evidence showing an
association of a nuclear gene associated with CBAVD.
However, based on our published data, only 15,90% of
Turkish CBAVD cases carry CFTR mutations. Therefore,
we have decided to identify the candidate genomic regions
that can cause CBAVD by using copy number variation
(CNV) analysis.
Methods: Unrelated 19 CBAVD cases (wild genotype
for CFTR) were included in the study. Genomic DNA was
extracted from peripheral blood. Whole genome CNV
analysis was performed with Affymetrix Cytoscan HD and
Agilent ISCA 8 × 60K array-CGH platforms; analysed with
the related softwares.
Results:We found 11 higly pathogenic microdeletion (in
25.5% of the cases) and microduplication (in 41% of the
cases) regions in nine of the cases. Deletion in 14q11.2del is
detected in three of the cases. Based on the literature, no
known genes were localized in this shared deleted region
(299 kb). However, Defender Against Cell Death 1 (DAD1)
nuclear gene deletion which has also localized in 14q11.2
was detected in two of the cases.
Conclusion: In the light of these data, DAD1 can be a
potential candidate gene and 14q11.2 can be a potential
chromosomal region for CBAVD cases.
This research was supported by grant from TUBITAK
(#115S171)
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Background: Hypertension prevalence is increasing, also
in pregnant women. The most used antihypertensives dur-
ing pregnancy are beta-blockers.
Objective: To investigate whether ﬁrst trimester use of
beta-blockers increases the risk of speciﬁc congenital
anomalies in offspring.
Methods: A population-based case-malformed control
study was conducted in 117,166 registrations of congenital
anomalies from 17 EUROmediCAT registries. We tested
associations previously reported in literature (signals) and
performed an exploratory analysis to identify new signals.
Odds ratios (ORs) of exposure to any beta-blocker or to a
beta-blocker subgroup were calculated for each signal
anomaly compared to two control groups (chromosomal
anomalies and non-chromosomal, non-signal anomalies).
The exploratory analyses were performed for each non-
signal anomaly compared to all other non-signal anomalies.
Results: Cleft palate (CP, OR 10.0; 95% CI 1.9–52.2)
and cleft lip with or without cleft palate (CL/P, OR 5.7;
95% CI 1.1–30.7) had signiﬁcant increased odds of expo-
sure to non-selective beta-blockers compared to chromo-
somal controls. The other literature signals (neural tube
defects, congenital heart defects, hypospadias) were not
conﬁrmed. The exploratory analysis revealed that multi-
cystic kidney disease (MCKD, OR 4.0; 95% CI 1.4–11.4)
had signiﬁcant increased odds of exposure to combined
alpha- and beta-blockers.
Conclusion: Our study investigating ﬁrst trimester use of
beta-blockers conﬁrmed the association between non-
selective beta-blockers and CP and CL/P and found a
possible new signal for MCKD and combined alpha- and
beta-blockers, including labetalol. We did not ﬁnd an
increased risk for selective beta-blockers.
The EUROmediCAT project was supported by the Eur-
opean Union under the Seventh Framework Programme
(HEALTH-F5-2011-260598).
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De novo copy number variants and parental age
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It has long been known that older parents are at increased
risk of having children with genetic disorders, however
most of this relates to a maternal age effect on non-
disjunction. Recent studies suggest advancing paternal age
increases the risk of de novo single nucleotide mutations.
The aim of our study was to investigate whether increased
parental age is associated with an increased risk for de novo
copy number variation (CNV) formation in offspring, since
previous studies have yielded conﬂicting results. We
investigated CNV calls from 2323 individuals referred to
Signature Genomic Laboratories for clinical microarray-
based comparative genomic hybridization. Overall 17%
(388, 127 cases and 261 controls) were prenatal and 83%
(1935, 664 cases and 1271 controls) were postnatal. The de
novo CNV data was further split into de novo CNVs bound
by low copy repeats (LCRs) and de novo CNVs not bound
by LCRs. Despite our large sample size, we did not ﬁnd any
association between de novo CNV occurrence and paternal
age in both of pre-natal (p= 0.6795) and postnatal (p=
0.1741) cohorts. We found advancing maternal age was
associated with an increased de novo CNV occurrence in
our postnatal cohort (p= 0.0126). Furthermore, maternal
age was associated with higher rate of de novo CNVs that
are bound by LCRs (p= 0.0026) and simple CNVs not
bound by LCRs (p= 0.0305) but not complex
rearrangements.
N. Foyouzi: None. I. Wadhawan: None. Y. Hai: None.
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Introduction: The clinical noninvasive prenatal testing
(NIPT) is mainly focused on detecting whole-chromosome
aneuploidies using low-coverage whole genome sequen-
cing. However, various subchromosomal copy number
variants such as microdeletions and microduplications
(MD) are relatively common but challenging to identify.
Recent articles show that these abnormalities can be
sometimes detected based on few factors (sufﬁcient fetal
fraction, MD length, and coverage), but a statistical eva-
luation of these algorithms is missing.
Materials and Methods: We have developed a software
that can identify and visualize small subchromosomal
aberrations using low-coverage sequencing without prior
knowledge of their location. It is based on published work
and ﬁne tuned for selected MDs. Training was performed
on 790 samples with more than 7M reads.
Results: We have performed a study on pooled samples
with 20M reads and the sensitivity is more than 95% when
the fetal fraction is at least 10% and MD length is at least
3Mb. This is conﬁrmed by real examples, where we have
detected 1Mb, 2.6Mb, and 2.9Mb deletions with fetal
fractions 12.5% and 17.5%, but not with 7.5%.
Conclusions: The algorithm for identifying MDs can be
applied in clinical NIPT when fetal fraction and MD length
is sufﬁcient. The fetal fraction seems to be the most
important factor - samples with 5% fetal fraction show very
poor accuracy even for large MD, while small MD can be
identiﬁed when the fetal fraction is high. The coverage does
not appear to have such impact on detection accuracy when
we carried out read count downsampling.
M. Kucharík: None. J. Budiš: None. M. Hýblová:
None. G. Minárik: None. T. Szemes: None.
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Prenatal diagnosis of corpus callosum dysgenesis in 104
fetuses
E. Marchionni1,2, A. Giancotti1, L. Manganaro1, A.
Pizzuti1,2, A. Ferraris2, A. Antonelli1, S. Bernardo1
1Sapienza University of Rome, Rome, Italy, 2IRCCS Casa
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Introduction: Corpus callosum dysgenesis (CCD) is a
spectrum of midline congenital anomalies, present in many
monogenic syndromes. The aim of the work was the char-
acterization of isolated and non-isolated forms of CCD and
the identiﬁcation of early predictors of associated anoma-
lies, improving prenatal counseling.
Materials and Methods: We retrospectively analyzed
104 fetuses with CCD undergoing fetal magnetic resonance
imaging (MRI) after ultrasonographic suspicion of CNS
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anomalies. Intra and extra-cranial malformations were
evaluated. Standard karyotype was obtained in 38 cases and
molecular cytogenetics in 16. In 3 cases, in-depth analysis
was performed by next-generation sequencing (NGS).
Results: At MRI, CCD was deﬁned as isolated in 26.9%,
the rest being associated to other abnormalities. In the group
with additional ﬁndings, cortical dysplasia was the most
frequently associated feature (P= 0.008), with a more fre-
quent occurrence in complete agenesis (70%). Mesial
frontal lobes were more often involved than other cortical
regions (P= 0.006). Multivariate analysis conﬁrmed the
association between complete agenesis and cortical dys-
plasia (odds ratio= 7.29, 95% conﬁdence interval 1.51–
35.21). Genetic tests evidenced six fetuses with abnormal
karyotype and three with cytogenomic defects. By NGS a
Walker-Warburg syndrome, a channelopathy and a tubuli-
nopathy were detected. In one isolated CCD case a de novo
microdeletion was identiﬁed.
Conclusions: CCD is often complicated by intra and
extra-cranial ﬁndings (cortical dysplasias being the most
prevalent) signiﬁcantly affecting postnatal prognosis.
Cytogenetic analysis should always be performed in any
CCD and, when imaging reveals a syndromic pattern, pre-
natal sequencing by NGS should be considered.
E. Marchionni: None. A. Giancotti: None. L. Man-
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in consanguineous couple - a severe phenotypic expres-
sion of Joubert syndrome
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Introduction: We describe a consanguineous, Indian cou-
ple with ﬁve gestations and hereof four fetuses with occi-
pital encephalocele.
Materials and Methods: Exome sequencing was per-
formed on both parents to identify variants, which the
parents had in common and variants which in compound
heterozygous form could cause encephalocele. Only for-
malin ﬁxated fetal tissue, inappropriate for exome sequen-
cing, was available. Subsequently, Sanger sequencing of
two identiﬁed variants in CSPP1 and DHCR7 were
conducted on two fetuses and on the couple’s son. Tissue
from the ﬁrst two fetuses was not available because the
terminations had occurred in India. Histopathologic exam-
ination of two fetuses was performed.
Results: Both parents were heterozygous for two var-
iants: 1) CSPP1 c.766C > T, p.(Gln256*). CSPP1 is asso-
ciated with Joubert syndrome 21 (JBTS21). The variant is
suspected to be pathogenic in homozygous form, but has
not previously been described. 2) DHCR7 c.1091C > T, p.
(Thr364Met). DHCR7 is associated with Smith-Lemli-Opitz
syndrome (SLOS). The variant has previously only been
described in heterozygous form. It is uncertain if the variant
in homozygote form will cause SLOS. The results of the
Sanger sequencing and the histopathology are shown in
table 1.
Conclusions: Based on the sequencing results it is likely
that the recurring encephaloceles can be explained by the
variant in CSPP1. Thus, we have identiﬁed a new patho-
genic variant in CSPP1 causing a severe and consistent
presentation of JBTS21.
Individual Father
I.I
Mother
I.II
Genotype CSPP1:+ /-
DHCR7:+ /-
CSPP1:+ /-
DHCR7:+ /-
Individual Fetus
II.I
Fetus
II.II
Son
II.III
Fetus
II.IV
Fetus
II.V
Genotype Unknown Karyotype 46,XY CSPP1:+ /-
DHCR7:
+ /+
CSPP1: +/+
DHCR7:+ /-
CSPP1: +/+
DHCR7:+ /+
Phenotype Prenatal
ultrasonography:
Occipital
encephalocele
and
microphthalmia
Histopathology:
Occipital
encephalocele,
microphthalmia,
bilateral cleft lip
and cleft palate,
and female
external genitalia
1½ years
old. Healthy
according to
the parents.
Phenotypic
examination
is planned
Prenatal
ultrasonography:
Occipital
encephalocele
Histopathology:
Occipital
encephalocele,
bilateral cleft
lip and cleft
palate, and
abdominal wall
defect
Table 1. CSPP1, CSPP1 c.766C>T, p.(Gln256*);
DHCR7, DHCR7 c.1091C>T, p.(Thr364Met).
S. Markholt: None. N.Q. Hansen: None. R. Chris-
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Molecular investigation of Cystic Fibrosis: methodolo-
gical approaches and diagnostic evaluation
E. Darmani, V. Papanikolaou, S. Dubos, E.
Oikonomidou, S. Vittas, M. Papadakis
Eurogenetica M.S.A, Thessaloniki, Greece
Introduction: Cystic ﬁbrosis (CF) is the second most
common autosomal recessive genetic disease in Greek
population. The present study shows the comparative results
of 1742 cases that were referred to our center and analyzed
by DGGE and NGS methodology for CFTR mutations.
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Materials and Methods: A total of 1742 cases were
analyzed using 3 different approaches: two protocols that
identify 75% (505 samples) and 85% (525 samples) of the
Greek known mutations by DGGE and a protocol that
covers 96–98% (712 samples) of the known mutations in
the Greek population by NGS technology (ION Ampliseq
™).
Results: CF-causing mutations frequencies identiﬁed by
DGGE were 1.6% (8/505) for the 75% protocol and 5.3%
(28/525) for the 85% protocol, while by using the NGS
methodology 6.5% (46/712) of the samples were found to
carry at least one CF-causing mutation. Frequencies of
CFTR-Related Disease mutations were 0.8%, 5.9% and
9.6% for 75%, 85% and 96–98% methodologies respec-
tively. Finally, mutations that were classiﬁed as variants of
uncertain signiﬁcance (VOUS) were detected in 0.8%, 1.5%
and 7.6% of the samples depending on the method used
(DGGE 75%, DGGE 85% and NGS 96–98% respectively).
Conclusions: The results indicate the analytical and
diagnostic efﬁcacy of the NGS methodology. The dis-
crepancy between the detected and the expected frequency
(4%) of CF-causing, CFTR-RD and VOUS mutations, can
only be partially explained by the referral indication for the
majority of the samples analyzed (infertility, IVF units).
E. Darmani: None. V. Papanikolaou: None. S. Dubos:
None. E. Oikonomidou: None. S. Vittas: None. M.
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Introduction: The objective was to evaluate the perfor-
mance of noninvasive prenatal testing (NIPT) as a con-
tingent screening model as part of a Danish public
combined ﬁrst trimester screening (cFTS) program (93%
participation). In our clinical setting NIPT has primarily
been offered to women in the intermediate-risk group
(1:700 - 1:300 for trisomy 21) and secondly as an alter-
native to invasive testing for high-risk (>1:300).
Materials and Methods: The cohort includes con-
secutive on-going singleton pregnancies with intermediate
or high-risk of fetal aneuploidy after cFTS that underwent
NIPT from January 2015 to December 2016 in Central
Denmark Region. Genome-wide massive parallel sequen-
cing and Veriseq NIPT analysis software were used.
Results: 98% of the women were provided with a deﬁ-
nite NIPT screening result within two weeks (Table 1).
In the high-risk group (n= 242) the sensitivity for tris-
omy 21 and 18 were 100% and speciﬁcity 99.6% and 100%
Noninvasive prenatal
testing results, n= 810
Normal results for
chromosomes 21, 18, 13
and sex, n= 783 (96.7 %)
High risk of
trisomy 21,
n= 6 (0.7 %)
High risk of
trisomy 18,
n= 3 (0.4
%)
High
risk og
trisomy
13, n=
0
High risk of sex
chromosome
aberration, n= 5 (0.6
%)
Inconclusive results and
failed tests, n= 13* (1.6 %)
High-risk (>1:300 of
trisomy 21) after
combined ﬁrst trimester
screening, n= 242 (29.9
%)
230 (95.0 %) 4 (1.7 %)
(conﬁrmed,
n= 3; not
conﬁrmed, n
= 1)
3 (1.2 %)
(conﬁrmed,
n= 3)
2 (XYY, no follow-
up and monosomy
X, conﬁrmed)
3 (1.2 %) (failed tests)
Intermediate-risk
(1:700 - 1:300) after
combined ﬁrst trimester
screening, n= 568 (70.1
%)
553 (97.4 %) (false
negative trisomy 21, n=
1, postnatal blood sample,
46,XX,rob(21;21)(q10;
q10))
2 (0.4 %)
(conﬁrmed,
n= 2)
3 (monosomy X, one
not conﬁrmed and
one no follow-up
and XXY,
conﬁrmed)
5 (0.9 %) (failed tests), 5 (0.9
%) (inconclusive results)
*n= 8, repeated NIPT with
normal results; n= 3,
invasive diagnostics with
normal results; n= 2, no
follow-up
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respectively. Two conﬁrmed trisomy 21 cases and one false
negative trisomy 21 (46,XX,rob(21q;21q)) were found in
the intermediate-risk group (n= 568). Four follow-up
invasive procedures were carried out in the intermediate
risk group.
Conclusions: NIPT may be used as a valuable screening
tool to increase the detection rate of fetal trisomy 21 in
intermediate-risk pregnancies after cFTS. It is paramount,
however, that women should be informed that it is limited
to few syndromes and it is not a diagnostic test.
Table 1. NIPT results and follow-up.
I.C.B. Lund: None. E.M. Vestergaard: None. D.
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Introduction: We present the results from the ﬁrst 15 fetus
to which clinical exome (13) or whole exome sequencing
(2) was offered in two prenatal diagnosis centers.
Methods: After diagnosis of sonographic abnormality
and medical termination of pregnancy (13), or foetal death
with multiple anomalies conﬁrmed at autopsy (2), a pre-
deﬁned panel of 4813 genes (13) or a trio whole exome
sequencing (WES) (2) were performed, following a pre-
vious extensive evaluation.
Results: A deﬁnitive diagnosis was achieved in eight
cases: primary microcephaly-5 ; minicore myopathy;
microcephaly, seizures, and developmental delay; hydro-
cephalus due to aqueductal stenosis; fetal akinesia defor-
mation sequence; Meckel syndrome type 1; lissencephaly-1;
Tosti syndrome; and a likely diagnosis of Fanconi anemia.
Only one of those precise diagnoses was previously sus-
pected in the sonogram.
Discussion: The very high diagnostic yield achieved
likely derives from cohort ascertainment: recurrence was
present at ﬁve of the nine families and very severe, but
viable, phenotype, in other two. In the families without a
diagnosis, the phenotype was always associated with intra-
uterine lethality, suggesting a causative gene that has not yet
been described. The information was highly relevant; in
four families the diagnosis was established during a preg-
nancy and recurrence could be excluded. At the moment,
our proposal is to restrain the use of clinical exome or WES
to cases with recurrence or high severity and only if col-
laboration with a medical geneticist is assured. In a short
future, the use of these tests will increase and become part
of the initial diagnostic approach.
J. Sá: None. F. Melo: None. A. Tarelho: None. M.
Branco: None. J. Pereira: None. E. Galhano: None. S.
Sousa: None. J. Saraiva: None. C. Lourenço: None. J.
Castro: None. F. Valente: None. F. Ramos: None. L.
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Systematic design and comparison of expanded carrier
screening panels
K. A. Beauchamp, G. A. Lazarin, H. Kang, K. Wong, E. A.
Evans, J. D. Goldberg, I. S. Haque, D. Muzzey
Counsyl, South San Francisco, CA, United States
Introduction: Growth in expanded carrier screening (ECS)
raises questions about design and evaluation of such panels.
Design principles might improve detection of at-risk cou-
ples and facilitate objective comparisons of panels.
Materials and Methods: Guided by medical-society
statements, we propose a method for the selection of genes
and assays that aims to maximize the aggregate and per-
disease sensitivity and speciﬁcity for Mendelian disorders
considered serious by a systematic classiﬁcation scheme.
We evaluated this method retrospectively using results from
474,644 de-identiﬁed carrier screens. We then constructed
several idealized panels to highlight strengths and limita-
tions of different ECS methodologies.
Results: A panel of 94 diseases, properly assayed, is
expected to detect 183 affected conceptuses per 100,000 US
births, based on published frequency data. A screen's sen-
sitivity is greatly impacted by two factors: (1) the metho-
dology used (e.g., full-exon sequencing ﬁnds up to 48 more
affected fetuses per 100,000 than targeted genotyping with
an optimal 50 variant panel), and (2) the detection rate of
the screen for diseases with high prevalence and complex
molecular genetics (e.g., fragile X syndrome, spinal
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muscular atrophy, 21-hydroxylase deﬁciency, and alpha-
thalassemia account for 54 affected fetuses per 100,000).
Conclusion: The described approaches allow principled,
quantitative evaluation of which diseases and methodolo-
gies are appropriate for pan-ethnic expanded carrier
screening.
K.A. Beauchamp: A. Employment (full or part-time);
Signiﬁcant; Counsyl. E. Ownership Interest (stock, stock
options, patent or other intellectual property); Signiﬁcant;
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options, patent or other intellectual property); Signiﬁcant;
Counsyl. E.A. Evans: A. Employment (full or part-time);
Signiﬁcant; Counsyl. E. Ownership Interest (stock, stock
options, patent or other intellectual property); Signiﬁcant;
Counsyl. J.D. Goldberg: A. Employment (full or part-
time); Signiﬁcant; Counsyl. E. Ownership Interest (stock,
stock options, patent or other intellectual property); Sig-
niﬁcant; Counsyl. I.S. Haque: A. Employment (full or part-
time); Signiﬁcant; Counsyl, Freenome. E. Ownership
Interest (stock, stock options, patent or other intellectual
property); Signiﬁcant; Counsyl, Freenome. D. Muzzey: A.
Employment (full or part-time); Signiﬁcant; Counsyl. E.
Ownership Interest (stock, stock options, patent or other
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Expanded carrier panels and the rate of identifying
individuals who are heterozygous for disease-causing
variants in more than one gene
J. DaRe, C. Terhaar, C. Holland; rogenity, Inc., Ann
Arbor, MI, United States
Introduction: Expanded carrier testing for inherited genetic
disorders is not yet broadly recommended; however, many
patients and clinicians choose this option for greater
reproductive risk assessment. Through utilization of large
panels, patients may learn that they are heterozygous for
multiple autosomal recessive or X-linked recessive
conditions.
Materials and Methods: We performed a retrospective
analysis of carrier tests performed on more than 11,000
patients through the clinical laboratory at Progenity, Inc.
We examined the number of patients found to be hetero-
zygous for more than one condition when tested using either
the Preparent Global (200+ disorder) or Global Plus (220+
disorder) panels.
Results: A total of 722 (6.1%) patients were found to be
carriers for more than one disease. This included 619
(5.2%) patients who carried 2 diseases; 89 (0.75%) patients
who carried 3 diseases; 12 (0.1%) patients who carried 4
diseases; as well as one each of patients carrying 5 or 6
diseases. Patients were found to be carriers of a total of 129
different diseases, of which 37 (28.7%) were found in more
than 10 patients.
Conclusions: Expanded panels allows for testing carrier
status of many conditions at one time, thus providing more
information than single gene or ethnicity-based testing.
With larger panels, patients may discover positive carrier
status for more than one condition. Pre-test counseling and
informed consent should include a discussion of this pos-
sibility. Understanding the likelihood of this outcome sets
appropriate expectations for patients and ordering
Providers.
J. DaRe: A. Employment (full or part-time); Signiﬁcant;
Progenity, Inc. C. Terhaar: A. Employment (full or part-
time); Signiﬁcant; Progenity, Inc. C. Holland: A.
Employment (full or part-time); Signiﬁcant; Progenity, Inc.
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Couple-based expanded preconception carrier screening
(ECS) offered by the general practitioner: what is the
uptake and who participates?
J. Schuurmans1,2, A. V. Ranchor3, A. M. Lucassen2, E.
Birnie1, I. M. van Langen1, M. Plantinga1
1Department of Genetics, University Medical Center
Groningen, University of Groningen, Groningen, Nether-
lands, 2Clinical Ethics and Law, Faculty of Medicine,
University of Southampton, Southampton, United Kingdom,
3Department of Health Psychology, University Medical
Center Groningen, University of Groningen, Groningen,
Netherlands
Introduction: The University Medical Center Groningen
developed a couple-based preconception ECS test covering
50 serious autosomal recessive conditions simultaneously.
As part of an implementation study, we investigated uptake,
feasibility and psychological impact of this test-offer in
general practice. This study describes uptake.
Materials and Methods: GPs from nine participating
practices invited 4295 female patients aged 18–40 to par-
ticipate in a survey study. Inclusion criteria were: having a
male partner, planning to have (more) children and not
being pregnant. All couples were offered a (free) ECS test,
which required attending pre-test counselling by their GP.
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Knowledge, attitude and socio-demographic characteristics
between female test-acceptors and test-decliners were
compared using Fisher’s exact tests for ordinal and T-tests
for continuous variables.
Results: 847/4295 (20%) women responded to the
invitation. 324/847 (38%) fulﬁlled the inclusion criteria.
Reasons for non-participation included personal medical
circumstances, religious beliefs, wrong timing and over-
medicalization of pregnancy. 181/324 (56%) participated in
the study. 127/181 (70%) attended pre-test counselling and
115/127 (91%) had couple-testing. 89% of test-acceptors
and 79% of test-decliners showed sufﬁcient knowledge (≥
3/5 correct answers). Test-acceptors differed signiﬁcantly
from test-decliners in attitude towards ECS (more positive),
timing of pregnancy (less soon) and relationship satisfaction
(higher). No signiﬁcant differences were found in (sufﬁ-
cient) knowledge, age, religion or educational level.
Conclusions: Our study demonstrates an interest in
couple-based ECS among couples from the general popu-
lation based on actual participation. Most couples who
attended pre-test counselling had couple testing. As a next
step to further explain uptake, multivariate analysis will be
conducted.
J. Schuurmans: None. A.V. Ranchor: None. A.M.
Lucassen: None. E. Birnie: None. I.M. van Langen:
None. M. Plantinga: None.
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Mendeliome sequencing as a prenatal diagnostic inves-
tigation after detecting fetal anomalies during ultra-
sound screening
K. Muru1, S. Pajusalu1,2, K. Ridnõi2,3, H. Roomere1, R.
Zordania4, E. Kurvinen4, M. Sitska1, T. Reimand1,2,5
1Department of Clinical Genetics, United Laboratories,
Tartu University Hospital, Tartu, Estonia, 2Department of
Clinical Genetics, Institute of Clinical Medicine, University
of Tartu, Tartu, Estonia, 3Women’s Clinic, East-Tallinn
Central Hospital, Tallinn, Estonia, 4Department of Clinical
Genetics, United Laboratories, Tartu University Hospital,
Tallinn, Estonia, 5Department of Biomedicine, Institute of
Biomedicine and Translational Medicine, University of
Tartu, Tartu, Estonia
Introduction: Fetal anomalies are detected in about 3% of
pregnancies during routine ultrasound (US) screening.
Certain congenital anomalies have been associated with
chromosomal aneuploidies, while other ﬁndings may indi-
cate monogenic disorders.The aim of our study was to
evaluate the efﬁcacy of using large next generation
sequencing (NGS) panel in diagnostic settings in fetuses
with prenatally diagnosed anomalies.
Material and Methods: Our study sample consisted of
prenatal cases in whom TrueSight One (TSO, Illumina)
panel covering 4813 genes was sequenced between July
2015 and December 2016 (18 months).
Results: During this period 17 fetuses were investigated
with TSO panel. A certain genetic etiology was conﬁrmed
in two cases. First, de novo heterozygous mutation in TP63
gene was detected causing split-hand/foot malformation.
Second, compound heterozygous mutations were identiﬁed
in DYNC2H1 conﬁrming the diagnosis of short-rib thoracic
dysplasia. In two additional cases possibly pathogenic
mutations were detected - 1) paternally inherited hetero-
zygous COL1A1 mutation and 2) heterozygous PTH1R
mutation (not inherited from mother, paternal carrier status
unknown). Both fetuses had shortening of long bones dur-
ing second trimester US screening.
Conclusions: In our study cohort of 17 fetuses with US
anomaly, NGS facilitated a deﬁnite diagnosis in two cases
(2/17); while in another two possible pathogenic mutations
were detected (2/17). Thus NGS is a feasible method for
detect genetic etiology of fetal anomalies. At the same time
ethical questions remain regarding reporting variants of
unclear clinical signiﬁcance. This work was supported by
the Estonian Research Counsel grant PUT355.
K. Muru: None. S. Pajusalu: None. K. Ridnõi: None.
H. Roomere: None. R. Zordania: None. E. Kurvinen:
None. M. Sitska: None. T. Reimand: None.
P01.036D
Applying a fetal-fraction based risk score (FFBR) to
SNP-based NIPT with no results due to low fetal
fraction
T. McKanna, S. Krinshpun, S. Kareht, A. Ryan, K. Martin
Natera, Inc., San Carlos, CA, United States
Background: Fetal fraction (FF) is inﬂuenced by gesta-
tional age, maternal weight, and other factors. There is a
relationship between low FF and an increased risk of
aneuploidy, prompting a recommendation by professional
societies that women who receive ‘no results’ from NIPT be
offered invasive testing. However, not all women with low
FF are truly at risk of aneuploidy.
Objective: To determine the relative risk for FF-related
aneuploidies—trisomy 13, trisomy 18, and digynic triploidy
—in cases that received ‘no results’ due to low FF using an
FFBR model that adjusts for maternal weight and gesta-
tional age
Abstracts from the 50th European Society of Human Genetics Conference:. . . 131
Methods: Clinical follow-up was collected on 1352
patients who received ‘no results’ due to low FF on NIPT.
The FFBR score, computed by comparing the observed FF
with three models (‘normal’, ‘trisomy 13 or 18’, ‘digynic
triploidy’), identiﬁes cases with lower-than-expected FF,
corrected for gestational age and maternal weight. When
FFBR is <1%, the total aneuploidy rate is consistent with
prior risk. High FFBR scores indicate a >1% risk of FF-
related aneuploidy.
Results: Women with high FFBR scores had >10-fold
increased risk of FF-related aneuploidy than women with
low FFBR scores (4.8% vs. 0.4%) and a 6-fold higher
incidence of pregnancy loss or aneuploidy (17.2% vs.
2.9%). Trisomy 21 risk was consistent with a priori risk in
both FFBR groups.
Conclusions: We have validated the FFBR model for
women who received ‘no results’ on NIPT due to low FF.
The FFBR score may provide clinicians with additional
information on patients’ relative risk for aneuploidy.
T. McKanna: E. Ownership Interest (stock, stock
options, patent or other intellectual property); Modest;
Natera, Inc. S. Krinshpun: E. Ownership Interest (stock,
stock options, patent or other intellectual property); Modest;
Natera, Inc. S. Kareht: E. Ownership Interest (stock, stock
options, patent or other intellectual property); Modest;
Natera, Inc. A. Ryan: E. Ownership Interest (stock, stock
options, patent or other intellectual property); Modest;
Natera, Inc. K. Martin: E. Ownership Interest (stock, stock
options, patent or other intellectual property); Modest;
Natera, Inc..
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FMR1 epigenetic control can explain variable response
of women ovarian reserve to clinical stimulation
protocol
B. Youness1, J. Dietrich2, T. Strowitzki2, P. Vogt1, J.
Rehnitz1
1University Womens´ hospital, Reproduction Genetics Unit;
Department of Gynecological Endocrinology & Fertility
Disorders, Heidelberg, Germany, 2University Womens´
hospital, Department of Gynecological Endocrinology &
Endocrinology & Fertility Disorders, Heidelberg, Germany
Introduction: FMR1 (Fragile-X-Mental-Retardation-1-
gene) expression is supposed to be functional during folli-
culogenesis. An ampliﬁcation of CGG-triplet-numbers
within its promoter from normal around 30 up to 54–200
(called premutation: PM) is associated with an elevated risk
(~20%) of premature-ovarian-insufﬁciency/failure probably
due to increased FMR1-expression-level. Recently, ﬁrst
epigenetic-elements called FREE1 and FREE2 (Fragile-X-
Epigenetic Element-1/2), were described, assumed to con-
trol FMR1-expression in leukocytes of PM-carriers and
suggested a general epigenetic FMR1-expression-control.
Granulosa cells are the putative target cells of FMR1-
function during human folliculogenesis.
Materials and Methods: Primary granulosa cells of
women undergoing IVF-/ICSI-procedure were collected
and analyzed for quantitative-FMR1-mRNA-expression.
Due to different response to controlled ovarian stimulation
(COS) patients were subdivided into three groups (normal-,
poor-, and high-responder). The promoter-CpG-
methylation-proﬁle in patients´ granulosa cells and leuko-
cytes were analyzed after bisulﬁte-treatment of genomic
DNA and sequence-analysis using sets of speciﬁc primers
along the FMR1-promoter including intron1.
Results: FREE1 and FREE2 were present with variable
patterns of CpG methylation in women granulosa cells as
predescribed in leukocytes. Additionally, a third variable
methylated epigenetic element distal FREE2 within intron1
was detected and named FREE3 in accordance. Speciﬁc
CpG-methylation-pattern within FREE3 as well as the
FMR1-expression-level was depending on ovarian response
in granulosa cells and persisted in leukocytes.
Conclusion: The variable CpG methylation pattern of
FREE3 is dependent on ovarian response to COS. Since this
pattern persist in leukocytes, FREE3-CpG pattern analysis
in women leukocytes prior to COS may serve as a non-
invasive prognostic-tool to predict ovarian response and
help to improve risk-adjusted personal protocols. DFG-
founded- study RE3647/1-1
B. Youness: None. J. Dietrich: None. T. Strowitzki:
None. P. Vogt: None. J. Rehnitz: B. Research Grant
(principal investigator, collaborator or consultant and
pending grants as well as grants already received); Sig-
niﬁcant; DFG-founded- study RE3647/1-1.
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High conﬁdence preimplantation genetic diagnosis of
fragile X syndrome - direct detection of the FMR1 CGG
repeat expansion mutation combined with linked multi-
marker haplotype analysis
I. Rajan-Babu1, M. Lian2,3, F. S. H. Cheah2,3, M. Chen1,
A. S. C. Tan1,3, E. B. Prasath4, S. F. Loh4, S. S. Chong1,2,3
1National University of Singapore, Singapore, Singapore,
2National University Hospital, Singapore, Singapore,
3National University Health System, Singapore, Singapore,
4Thomson Fertility Centre, Singapore, Singapore
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Introduction: Fragile X syndrome (FXS) is caused by
hyperexpansion of a CGG repeat within, and subsequent
inactivation of, the FMR1 gene. Trans-generational FXS
transmission can be avoided using preimplantation genetic
diagnosis (PGD). We describe a robust PGD strategy that
can be applied to virtually any couple at risk of transmitting
this disorder.
Materials and Methods: This novel strategy utilizes
whole-genome ampliﬁcation, followed by triplet-primed
PCR (TP-PCR) for robust detection of the expanded FMR1
allele when present. Diagnostic conﬁdence is further
increased through parallel haplotype analysis of 13 highly
polymorphic microsatellite markers located within 1 Mb on
either side of the FMR1 CGG repeat, together with the
AMELX/Y dimorphism for gender identiﬁcation. The assay
was optimized and validated on single lymphoblasts iso-
lated from fragile X reference cell lines, and applied to a
simulated PGD case and a clinical IVF-PGD case.
Results: In the simulated PGD case, deﬁnitive diagnosis
of the expected results was achieved for all “embryos”. In
the clinical IVF-PGD case, an on-going clinical pregnancy
was achieved after transfer of an expansion-negative
blastocyst.
Conclusions: FMR1 TP-PCR reliably detects presence
of expansion mutations and obviates reliance on informative
normal alleles for determining disease status in female
embryos. Together with multi-marker haplotyping and
gender determination, misdiagnosis and diagnostic ambi-
guity due to allele drop-out is minimized, and couple-
speciﬁc assay customization can be avoided.
I. Rajan-Babu: None. M. Lian: None. F.S.H. Cheah:
None. M. Chen: None. A.S.C. Tan: None. E.B. Prasath:
None. S.F. Loh: None. S.S. Chong: B. Research Grant
(principal investigator, collaborator or consultant and
pending grants as well as grants already received); Sig-
niﬁcant; National University Health System. E. Ownership
Interest (stock, stock options, patent or other intellectual
property); Modest; National University of Singapore.
P01.039C
Haplotyping single cells by using extended family
members: an expanding option for PGD
J. Ding, E. Dimitriadou, A. Destouni, C. Melotte, J.
Vermeesch
Laboratory for Cytogenetics and Genome research,
Department of Human Genetics, KU Leuven, Leuven,
Belgium
Genome-wide haplotyping of preimplantation embryos is
being implemented as a generic approach for genetic
diagnosis of inherited mutations. Previously we have
developed an algorithm that allows concomitant haplotyp-
ing and copy number proﬁling of the embryo. To enable the
phasing of the genotypes into haplotypes, genotyping direct
family members of the prospective parent carrying the
mutation is a requirement. Currently, the algorithm uses
either (1) both parents of the affected prospective parent or
(2) an affected or unaffected child of the affected couple.
However, such parental genotypes are not always accessible
and/or there are no offspring yet. At present, such couples
cannot enter the genome-wide haplotyping-based PGD
program.
Some families have access to genotypes of affected or
unaffected brothers, sisters or other family members. Since
the gene mutation is embedded in a local haplotype, it is
possible to deduce the affected haplotype. We now expan-
ded our algorithms by ﬁrstly determining identity by status
regions (IBS), subsequently deducing the haplotype based
on the shared allele between the parents and their extended
family members, which can be either healthy or affected,
and ﬁnally embedding this information in the genome-wide
haplotype.
Twelve extended families have been analyzed. The
consistency of the results as well as possible challenges will
be discussed.
J. Ding: None. E. Dimitriadou: None. A. Destouni:
None. C. Melotte: None. J. Vermeesch: None.
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Identiﬁaction and homology modeling of novel placental
hemoglobin subunit alpha (HBA) isoform
A. Lipka1, M. Majewska2, L. Paukszto3, J. P. Jastrzebski3,
M. Gowkielewicz1, E. Lepiarczyk2, M. K. Majewski2, M.
Jozwik1
1Department of Gynecology and Obstetrics, Faculty of
Medical Sciences, University of Warmia and Mazury in
Olsztyn, Olsztyn, Poland, Olsztyn, Poland, 2Department of
Human Physiology, Faculty of Medical Sciences, University
of Warmia and Mazury in Olsztyn, Olsztyn, Poland,
Olsztyn, Poland, 3Department of Plant Physiology, Genet-
ics and Biotechnology, Faculty of Biology and Biotechnol-
ogy, University of Warmia and Mazury in Olsztyn, Olsztyn-
Kortowo, Poland, Olsztyn, Poland
Introduction: RNA-seq, based on the next generation
sequencing (NGS) technology, has recently been shown to
have advantages in both sensitivity and cost. One of the
primary aims of RNA-seq is to compare the gene expression
levels in various tissues, and to identify alternative splicing
events, and SNVs. Recent studies using massively parallel
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sequencing techniques have begun to expand the knowl-
edge of the placental transcriptional landscape, in various
eutherians, e.g. humans, elephants, rats, pigs and beavers.
The placenta is essential for sustaining the growth of the
fetus during gestation, and defects in its functioning result
in embryonic/fetal growth restriction or even embryonic and
fetal mortality. It forms the interface between the maternal
and fetal circulation, facilitating metabolic and gas
exchange as well as fetal waste disposal.
Materials and Methods: The aim of our study was
identiﬁcation and homology modeling of novel placental
isoforms. RNA-seq was utilized to identify global expres-
sion pattern in the placentas (N= 4) from women in single
and twin pregnancies.
Results: During analyses, 228 044 transcripts were
reconstructed and 6497 highly covered splice junctions
unannotated in the human genome were identiﬁed and 30
were conﬁrmed as novel. Among them, hemoglobin subunit
alpha (HBA) was chosen to broaden analysis, including
homology modeling using I-TASSER.
Conclusions: Examination of speciﬁc placental isoforms
crucial for placental development and function can help in
understanding and identifying the mechanisms underlying
both normal and pathological pregnancies. Detailing the
placental transcriptome could provide a valuable resource
for genomic studies related to placental disease. *Supported
by UWM (WNM#25.610.001-300)
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Role of HIF1a gene expression in physiological and
uncompleted pregnancies
D. Valieva1, E. Yupatov2, E. Soldatova2, L. Maltseva2, O.
Kravtsova1
1Kazan Federal University, Kazan, Russian Federation,
2Kazan State Medical Academy, Kazan, Russian Federation
Introduction: Almost all physiological pregnancies are
complicated with uterus varicose veins that in some cases
can lead to miscarriage, but genetic background of
uncompleted pregnancy is still unclear. Several studies
suggest that tissue hypoxia induced by indigenous and
environmental factors can lead to spontaneous abortion and
insufﬁcient carriage. So the aim of this study was to eval-
uate the expression of transcription factor HIF1A gene that
plays a fundamental role in the physiological response to
hypoxia in normal and uncomplicated pregnancies.
Materials and Methods: Gene expression analysis was
carried out on venous blood samples from 29 women with
uncompleted pregnancy (UP) (I-II trimester) and 79 phy-
siologically pregnant women (PP) collected during 22–24th,
32–34th weeks of pregnancy, separately in primapara and
multigravidas. The relative gene expression level (RQ)
evaluated by the 2deltaCt method and statistical signiﬁcance
was determined by Student t-test (p = 0.05).
Results:We observed that the expression level of HIF1A
gene dramatically increases in III trimester of PP women
(RQ=9.78, p=0.006) that can marked the hypoxia initiation
in late stages of gestation. Controversially, in PP multi-
gravidas in III trimester the activity of HIF1A gene mildly
decreases (RQ=0.25, p=0.044) that can be explained by
faster reactivity to hypoxia. In UP women we also observed
decreasing gene expression activity (RQ=0.44, p=0.528)
however it wasn’t statistically signiﬁcant.
Conclusions: Our results indicate a better adaptation of
vascular endothelium during the ﬁrst pregnancy, pre-
sumably due to changes in venous hemodynamics in com-
parison with each subsequent pregnancy, especially in
women with uncompleted pregnancy.
D. Valieva: None. E. Yupatov: None. E. Soldatova:
None. L. Maltseva: None. O. Kravtsova: None.
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Ovum donation - a legal parenthesis to the only option
for recurrent molar pregnancies
S. Eraslan1, E. Yucel1, B. Ozcan2, H. Kayserili3
1Koc University Hospital, Istanbul, Turkey, 2Memorial
Atasehir Hospital, Istanbul, Turkey, 3Koc University School
of Medicine, Istanbul, Turkey
Introduction: Gestational trophoblastic disease (GTD)
comprises partial/complete hydatidiform mole (HM), inva-
sive mole, gestational choriocarcinoma, placental-site tro-
phoblastic tumor and epithelioid trophoblastic tumor, all
originating from the abnormal hyper-proliferation of tro-
phoblastic cells. HM, being the most common of GTDs,
may recur in independent pregnancies, suggesting a genetic
predisposition. Incidence of HM varies amongst popula-
tions, 1/600 in western countries and higher rates are
observed for recurrent HMs in middle/far east countries.
Familial recurrent HM is an autosomal recessive condition,
with NLRP7 and KHDC3L reported mutation frequencies of
48–80% and 10–14%, respectively. Women with a history
of two or more molar pregnancies should be evaluated by
genetic testing. We report the molecular ﬁndings of a con-
sanguineous couple who had four HM pregnancies.
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Materials and Methods: NLRP7 and KHDC3L genes
were analysed by Sanger sequencing.
Results: The prospect mother was found homozygous
for NLRP7 IVS7 ds+1 G>A mutation, along with two
heterozygous variations in KHDC3L. Pedigree analysis
showed that her parents were ﬁrst cousins and her sister also
had two HM pregnancies.
Conclusions: The molecular ﬁndings conﬁrmed HM
diagnosis. The couple previously had been offered IVF and
PGD which resulted with non-viable embryos. Non-
directive genetic counseling should adevert all reproduc-
tive options, including ovum donation which might be the
only option for this couple to have healthy off-spring.
However, assisted reproductive regulations restrict ovum
and sperm donation in Turkey like in many other middle-
east countries. The legal issues not only complicate the
clinical practice, but renders the solution based relationship
between the geneticist and the patient.
S. Eraslan: None. E. Yucel: None. B. Ozcan: None. H.
Kayserili: None.
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Next Generation Sequencing improves diagnosis for
fetal hydrops
J. M. Fletcher, K. Brion, M. Gurner, S. Chin, T. Pyragius,
S. Stark
SA Pathology, Women's and Children's Hospital, North
Adelaide, Australia
Introduction: Classical biochemical testing for pregnancies
affected by non-immune fetal hydrops has been replaced in
our laboratory by a custom next generation sequencing
(NGS) panel.
Method: Enzyme activities of ﬁbroblasts cultured from
amniocytes or skin were determined for 19 lysosomal
enzymes known to be associated with non-immune hydrops
and PMM2. Filipin staining and/or cholesterol esteriﬁcation
studies were performed for Niemann-Pick disease type C
testing. Free sialic acid was measured for sialic acid storage
disorder testing. A custom NGS panel (Illumina Trusight
One) was designed to cover 52 genes associated with fetal
hydrops.
Results: Classical testing of 114 samples referred from
Australasian, Paciﬁc basin and Middle Eastern centres
between 1991–2013 resulted in a diagnosis rate of 11%.
The commonest identiﬁed cause was MPS VII (6), with 2
cases of CDG1a and single cases of Gaucher disease,
Galactosialidosis, Sialidosis and Niemann Pick C. Next
generation testing of 16 samples since 2015 has resulted in
3 Noonan syndrome and one Gaucher diagnosis, a rate of
25%.
Discussion: Prior to the introduction of NGS, testing was
restricted to recurrent fetal hydrops because of the com-
plexity and expense of testing. Each of the biochemical
diagnoses made was associated with a 1 in 4 recurrence risk.
The commonest NGS cause of fetal hydrops, Noonan syn-
drome, usually represents new mutations, with a sig-
niﬁcantly reduced recurrence risk.
Conclusion: NGS testing has a higher diagnosis rate for
fetal hydrops than classical testing, with a signiﬁcant impact
on recurrence risk as well as being both quicker and less
expensive.
J.M. Fletcher: None. K. Brion: None. M. Gurner:
None. S. Chin: None. T. Pyragius: None. S. Stark: None.
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Gene expression signatures in patients with severely
impaired spermatogenesis - whole gene expression study
& meta-analysis
A. Hodic1, A. Maver1, B. Zorn2, D. Petrovič3, B. Peterlin1
1Clinical Institute of Medical Genetics, University Medical
Centre Ljubljana, Ljubljana, Slovenia, 2Andrology Unit,
Reproductive Unit, Department of Obstetrics and Gynecol-
ogy, University Medical Centre Ljubljana, Ljubljana,
Slovenia, 3Institute of Histology and Embryology, Faculty
of Medicine, University of Ljubljana, Ljubljana, Slovenia
Introduction: A large proportion of male infertile patients
are having a defect in spermatogenesis of which the
underlying causes remain unknown. The main objective of
this study was to identify genes that play a role in the
etiology of idiopathic male infertility using experimental
data derived from genetic transcriptomic studies.
Material and Methods: We performed whole gene
expression analysis in 20 testis samples of patients with
severely impaired and normal spermatogenesis and meta-
analysis of gene expression data from three additional
transcriptomic studies. The main inclusion criteria for stu-
dies were availability of raw datasets at either GEO or
ArrayExpress repositories, common reference design
approach towards measuring differential expression in the
microarray experiment and interrogation of the same tissue
samples and comparable disease states as in our experiment.
Results: Using whole gene expression testis proﬁles
from 100 patents and 37 controls, we obtained oweral
number of 3545 unique elements attaining p values below
0.01 (1283 down-regulated and 2262 up-regulated) with
changed expression in infertile men. Of these, 30 down-
regulated and 5 up-regulated genes were common between
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all studies. Majority of the down-regulated differentially
expressed genes were related with regulation and comple-
tion of germ cell maturation, whereas up-regulated genes
were related to pathways associated with oxidation-reduc-
tion, response to organic substance, steroid biosynthetic
process, response to wounding and regulation of apoptosis.
Conclusion: Integrated transcriptome analyses provides
new insight into the pathogenesis of male infertility. This
study was supported by grant P3-0326 from the Slovenian
Research Agency.
A. Hodic: None. A. Maver: None. B. Zorn: None. D.
Petrovič: None. B. Peterlin: None.
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Stable estimated live birth prevalence of Down syn-
drome in the Netherlands, 2000–2013
S. Tamminga1,2, M. D. de Groot-van Mooren3, M. E.
Weijerman4,5, D. Oepkes6, M. C. Cornel1,2
1Department of Clinical Genetics, VU University Medical
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3Department of Pediatrics, VU University Medical Center,
Amsterdam, Netherlands, 4Down Center, location West,
Amsterdam, Netherlands, 5Department of Pediatrics,
Alrijne hospital, Leiderdorp, Netherlands, 6Department of
Obstetrics, Leiden University Medical Center, Leiden,
Netherlands
With the introduction of a prenatal screening programme
the live birth prevalence of Down syndrome (DS) may have
changed. The Netherlands lack reliable national data
regarding the livebirth prevalence of DS and relevant trends
since 2007, when information on the First-trimester Com-
bined screening Test was introduced for all pregnant
women. Meanwhile the next stage of prenatal screening is
arriving with non-invasive prenatal testing. The aim of this
study is to analyse trends in factors that inﬂuence livebirth
prevalence and to estimate the prevalence of DS in live-
births for the period of 2000–2013.
Two empirical datasets were used: data on (1) livebirths
according to maternal age, and (2) prenatal testing and
termination of pregnancy subsequent diagnosis of DS. This
data is combined in a model that uses maternal age-speciﬁc
risk on DS and correction factors for natural fetal loss.
The mean maternal age has slightly increased since 2000
from 30.2 years (sd= 4.6 years) to 30.5 years (sd= 4.8
years) in 2013. The annual number of invasive tests per-
formed decreased (from 12 047 to 5 500). In the women
undergoing invasive testing, DS was diagnosed more often
(1.6% in 2000 vs. 4.8% in 2013). However the proportion
of induced abortions after conﬁrmation of diagnosis has
decreased. This resulted in a stable DS livebirth prevalence
of 13.7 per 10 000 livebirths. Because of a decline of the
total number of livebirths in The Netherlands the absolute
number of livebirths with DS decreased from 284 to 244 per
year.
S. Tamminga: None. M.D. de Groot-van Mooren:
None. M.E. Weijerman: None. D. Oepkes: None. M.C.
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Is there any relationship between NRG1 gene duplica-
tion and cardiac ﬁndings in two fetuses with inv dup del
(8p) syndrome ?
A. Sezer1, M. Bayram2, G. Kayhan1, A. Unal1, H.
Ozdemir2, D. Karcaaltincaba2, M. Yirmibes Karaoguz1
1Medical Genetics Department, Gazi University Hospital,
Ankara, Turkey, 2Obstetrics and Gynecology Department,
Gazi University Hospital, Ankara, Turkey
Introduction: 8p inverted duplication deletion syndrome is
a rare disorder often clinically manifests as intellectual
disability, central nervous system abnormalities, congenital
heart defects and dysmorphic features. To date there is a
little knowledge about the clinical presentation and the
submicroscopic chromosomal changes in prenatal period.
Here we report two prenatally detected fetuses with this
condition.
Clinical reports: The ﬁrst fetus referred for increased
nuchal translucency was later found to have cerebellar
vermis agenesis, a solitary interhemispheric cyst and ven-
tricular septal defect (VSD).The second fetus had VSD and
discordance between right and left heart ventricles.
Results: Conventional cytogenetic, ﬂuorescence in situ
hybridization (FISH) and array-CGH (Agilent, ISCA
8×60K) analyzes revealed an inverted duplication deletion
at chromosome 8p in both fetuses. Each of them have a
deletion bigger than 6.5 Mb distal to the 8p23 (8p23.1-pter)
region followed by an intermediate intact segment, and an
inverted duplicated (approximately 30 Mb) proximal seg-
ment (8p23.1-p11.1).
Discussion: Gata-Binding Protein 4 (GATA4) has been
implicated as the gene responsible for the heart defects
associated with 8p23.1 deletions so far. Discordant with this
ﬁnding GATA4 gene region was intact, and Neuregulin 1
(NRG1) gene, related with the trabeculation of the heart
ventricle, was duplicated in both fetuses. We suggest that
the overexpression of NRG1 gene could be responsible for
the discordance between right and left ventricles and VSD.
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More clinical reports and functional studies are necessary to
clarify this hypothesis.
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Isodicentric chromosome 18 in the foetus and jumping
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of Medicine, Charles University and University Hospital
Motol, Prague, Czech Republic
We present one case of the foetus with idic(18) and con-
ﬁned placental mosaicism of various aberrations of chro-
mosome 18, suspected jumping translocations. Jumping
translocations are rare chromosomal events in which a
donor chromosome segment is translocated to various
recipient chromosome sites (mainly observed in haemato-
logical malignancies).
Chorionic villi sampling was indicated due to increased
nuchal translucency and absent nasal bone. Array CGH was
applied to uncultured material and detected 2,5Mb terminal
deletion of 18p, mosaic duplication of the rest of chromo-
some 18 and mosaic 2p duplication. Cultured chorionic villi
interphase FISH showed 18p deletion in all cells together
with mosaicism of one to three 18q copies; karyotyping
revealed six different cell lines: normal karyotype and ﬁve
various aberrations of chromosome 18. Further ultrasound
examination found choroid plexus cysts, atypical position of
lower limbs, shortened upper limbs, suspected brain
anomaly, cleft palate and heart defect. Amniocentesis was
performed with karyotype 46,XX,idic(18)(p11.32). Inter-
phase FISH again detected mosaic status of 18q in culti-
vated amniocytes. After termination of pregnancy foetal
tissue DNA was examined by array CGH and its proﬁle
(18p terminal deletion and duplication of the rest of chro-
mosome 18) conﬁrmed idic(18) in all cells.
Phenotype of patients with idic(18) is similar to trisomy
18. Features of partial monosomy 18p are probably less
speciﬁc and are covered by partial trisomy of the rest of
chromosome 18. We suppose, jumping translocations
including aberrant chromosome 18 may have occured in
trophoblast during embryogenesis in contrast to the forming
of idic(18) in embryoblast.
Support: NF-CZ11-PDP-3-003-2014, IP00064203
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Beneﬁt of comprehensive genetic evaluation of stillbirths
R. Michaelson-Cohen, P. Schwed, O. Lobel, Bar Meir, S.
Koka, R. Segal
Shaare Zedek Medical Center, Hebrew University, Jerusa-
lem Israel, Jerusalem, Israel
Background: Autopsy is important for evaluation of still-
birth (≥20weeks), but rates are declining due to religious/
cultural belief, and conception that no useful information is
obtained. We offered an alternative protocol of testing to
determine cause of death for those rejecting autopsy, to
reduce stillbirth-recurrence in subsequent pregnancies.
Objective: To quantify utility of placental-pathology,
CT and karyotyping in identifying stillbirth-cause. STUDY
DESIGN: Cohort of all 217 stillbirths from 1/2011–5/2014
at a tertiary-care-center. Records were reviewed in stepwise
manner: clinical history and laboratory results, then pla-
cental pathologic evaluation, CT, and ﬁnally karyotyping.
At each step, probable cause of death was determined.
Results: Clinical and basic laboratory information
identiﬁed cause of death in 26/217(12%). Placental patho-
logic examination added probable cause in 48/119(40%,
22% of total). 46/137(34%) had CT ﬁndings, however most
were result rather than cause of stillbirth. 201/217(93%)
underwent karyotyping, 128 yielded results, 13/128(10%,
6% of total) had aneuploidy. 12% of couples consented to
autopsy, which conﬁrmed same etiology. Adding kar-
yotyping resulted in identifying cause of death in 40% in
total. Had comprehensive analysis been successful in all
cases, yield would reach 62%, not far from ~70% yield
reported in studies including autopsy. CT wasn't beneﬁcial.
Conclusion: Adding placental pathological examination
and karyotyping, beyond clinical and basic laboratory
information, raises yield of ﬁnding cause to 62%. CMA and
MRI are expected to further improve this yield. Compre-
hensive evaluation of stillbirths should be implemented,
even in populations declining autopsy. It is necessary that
healthcare professionals convey the value of comprehensive
approach to parents.
R. Michaelson-Cohen: None. P. Schwed: None. O.
Lobel: None. O. Lobel Bar Meir: None. S. Koka: None.
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Expression of Human Leucine-Rich Repeats and WD
Repeat Domain Containing 1 (LRWD1) by methylation
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1National University of Tainan, Tainan, Taiwan, 2Depart-
ment of Biological Sciences and Technology, National
University of Tainan, Tainan, Taiwan, 3Sharjah Institute for
Medical Research and College of Pharmacy, University of
Sharjah, Sharjah, United Arab Emirates, 4Department of
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Introduction: LRWD1 (Leucine-rich repeats and WD
repeat domain containing 1) is highly expressed in the
testes, but down-regulated in the testicular tissues of
patients with severe spermatogenic defects, yet its tran-
scriptional regulation remains unclear. CpG islands are
located between positions −253 to+ 5 nucleotides
upstream from the LRWD1 transcription start site by CpG
Plot analysis in EMBOSS.
Materials and Methods: The quantitative methylation-
speciﬁc PCR and immunostaining were applied to study the
effect of methylation for the transcription effect for LRWD1.
To investigate the effect of methylation for LRWD1
expression, we used the 5-Fluoro-2′-deoxyuridine as an
inducer and 5-Aza-2′-deoxycytidine as an inhibitor for
DNA methylation.
Results: In the quantitative methylation-speciﬁc PCR
and immunostaining showed that the inhibitor by 5-Aza-
2quantitative of DNA methylation increased the LRWD1
expression. Otherwise, the inducer of 5-Fluoro-2, the
inducer for DNA methylation decreased the LRWD1
expression in NT2D1 cells.
Conclusion: The methylation pattern of the promoter is
an important factor for transcription and expression of
LRWD1 in the testicular cell under drug or environmental
effect. We suggest that LRWD1 may be as epigenetic
marker to detect the environmental pollution in future.
Acknowledgments:This study was supported by grants from
National Science Council (NSC 102-2314-B-024 -001) and
Ministry of Science and Technology (MOST 103-2314-B-
024 -002, 104-2314-B-024 -002 -MY2) of Taiwan. We
thanks PD Dr. Michael Rehli kindly provided the pCpGL-
vector or derivatives.
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Introduction: LRWD1(Leucine-Rich repeats and WD
repeat domain containing 1)is highly expressed in the testes
and down-regulated in the testicular tissues of the patients
with severe spermatogenic defects. LRWD1 expressed in the
centrosome of sperm and involved in microtubule growth.
In the Bioinformatics prediction for miR-320, there are
binding sites in the LRWD1 3′UTR by miRnada software
and high expression at reproduction tissue by miRnaMap
software.
Materials and Methods: There is a potential binding
site for MiR-320 on the 3′UTR of the LRWD1 transcript by
the microRNA analyzing tools. We made LRWD1-3′UTR
fused to a luciferase reporter vector to construct pMIR-
LRWD1-3′UTR. Hydrogen peroxide (H2O2) or Sodium
nitroprusside dehydrate (SNP) treatment to NT2D1 cell, and
then to assay LRWD1 expression by western blot and real-
time PCR.
Results: The LRWD1 3′UTR was constructed to the
pMIR plasmid and conﬁrmed that miR-320 increased
LRWD1 expression by Dual-Luciferase Reporter Assay.
LRWD1 expression increased by transfected miR-320 mimic
in NT2D1 cells. The expression of miR-320 and LRWD1
was increased by H2O2 or SNP treatment in TaqMan real
time-PCR assay. Transfection mimic of miR-320 enhanced
cell growth.
Conclusion: The results help to understand the functions
and roles of the miR-320 in post-transcriptional regulation
of LRWD1 and may apply for further diagnosis and treat-
ment of spermatogenic defect and male infertility diseases.
Acknowledgments:This study was supported by grants from
National Science Council (NSC 102-2314-B-024 -001) and
Ministry of Science and Technology (MOST 103-2314-B-
024 -002, 104-2314-B-024 -002 -MY2) of Taiwan.
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Advances of genetics in andrology and potential impli-
cations towards improved diagnostics and patient
management
M. Laan1, M. Grigorova1, A. Punab1, L. Kasak1, M.
Punab1,2
1University of Tartu, Tartu, Estonia, 2Andrology Center,
Tartu University Hospital, Tartu, Estonia
Introduction: Although genetic factors are among the
generally acknowledged causes for impaired male repro-
ductive health and infertility, current genetic testing in
andrology clinics is limited, including cytogenetics, Y-chr.
microdeletions and CTFR mutations. Notably, 60% of men
with impaired sperm counts remain idiopathic (Punab et al
2017 Hum Reprod 32:18-31). Studies of our clinical-basic
research team have aimed to uncover clinically important
genetic factors shaping male reproductive physiology and
fertility potential.
Materials and Methods: All patients have been recrui-
ted at the Andrology Center, Tartu University Hospital. We
have applied complimentary approach combining analysis
of candidate genes encoding reproductive hormones (FSH,
LH, testosterone, SHBG), and genome-wide methods
(CNVs, Exome-Seq) aiming to discover novel loci impli-
cated in male infertility.
Results: We have discovered and/or validated a number
of genetic variants modulating male reproductive hormone
levels and consequently, testicular and seminal parameters.
Combination of these variants in consort deserves attention
as a potential pharmacogenetic panel in choosing alternative
management options for andrology patients. Candidate gene
and exome sequencing of idiopathic infertility cases have
both proved as suitable tools to detect rare patient-speciﬁc
mutations. Genome-wide analysis of structural variants
revealed an overall altered autosomal CNV proﬁle as a
considerable risk factor to male infertility, and revealed
novel genomic hotspots and CNVs as potential causes of
impaired spermatogenesis.
Conclusions: Uncovering genetic contribution to
impaired male reproductive health paves the way to
improved diagnostics and management in andrology clinics.
This work was supported by grants from SA Archimedes
(HAPPY PREGNANCY, 3.2.0701.12-0047) and Estonian
Research Council (IUT34-12, PUT181).
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Introduction: Approximately one out of every seven cou-
ples are infertile worldwide and male factor infertility
accounts for 30–50% of the infertility cases. Previous stu-
dies from our lab have shown that about 8.5% Indian men
are infertile due to Y chromosome microdeletions. Further,
analysis of a few autosomal genes and mitochondrial gen-
ome accounted for additional 21% of the genetic factors
responsible for infertility among Indian men. However,
etiology of large proportion (71%) of infertile men still
remained unknown. Therefore, we have performed exome
sequencing to identify novel autosomal genetic causes of
male infertility.
Materials and methods: Exome sequencing was per-
formed in 44 idiopathic infertile men using Illumina Hiseq-
2000 platform with 100X coverage. Using various bioin-
formatic tools, we have identiﬁed 60 novel and rare variants
from 58 genes. Subsequent replication study (using
Sequenom MassARRAY iPLEX platform) on 1344 samples
has identiﬁed 12 variants (12 genes), which are strongly
associated with male infertility. Further, we have genotyped
28 additional damaging variants from the above 12 genes in
960 case-controls. CETN1 is one among the potential can-
didates identiﬁed; hence variants of this gene were char-
acterized using biophysical and cell biology approaches.
Results: We have identiﬁed a total of 24 novel, rare,
nonsense and missense variants from 12 genes that showed
high expression in testis. Of which, rs61734344 (CETN1)
showed highly signiﬁcant association with male infertility
(p=1.658e−35). Functional studies have shown that
rs61734344 alters calcium binding afﬁnity, thermodynamic
properties, surface hydrophobicity and disrupts spindle
formation during cell division; suggesting its role in
infertility.
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Abstracts from the 50th European Society of Human Genetics Conference:. . . 139
P01.054B
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tamination on prenatal molecular testing
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Introduction: Prenatal molecular genetic testing is avail-
able for many severe monogenic diseases. These assays
mostly use amniotic ﬂuid or chorionic villus samples, that
are obtained by invasive techniques. Maternal cell con-
tamination (MCC) in fetal samples is considered as a pre-
analytical risk for prenatal molecular analysis and may lead
to false genotyping. It is recommended to determine the
used diagnostic tests’ sensitivity to MCC.
Materials and Methods: Sensitivity of three different
diagnostic methods to MCC: Sanger sequencing, multiplex
ligation-dependent probe ampliﬁcation (MLPA) and a next-
generation sequencing methodology (NGS) was tested. The
experiments were performed by mixing a wild type DNA
sample (’fetal’) with a heterozygote DNA sample (’mater-
nal’) simulating different levels (1, 5, 10, 20, 30 and 40%)
of MCC.
Results: The limit of detection of the mutant allele by
Sanger sequencing was 10% (20% MCC), above this level
the fetal genotype may be obscured. In the case of MLPA,
up to 30% MCC had no effect on genotyping result. Fourty
percent MCC resulted in a maximum of 30% reduction in
relative peak height of relevant probes leading to diagnostic
uncertainty. The NGS method could detect 0.5% maternal
allele. Accurate quantiﬁcation in the range of 0.5–20% did
not lead to false genotyping.
Conclusions: Our results show that the level of MCC
affecting the results of diagnostic tests is highly dependent
on the applied method. These results can be interpreted
correctly only in conjunction with simultaneously deter-
mined MCC level.
This study was supported by the Ministry of National
Economy, Hungary (GINOP-2.3.2-15-2016-00039).
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Infertility, which affects 10–15% of all couples, is attributed
to a male (co-)factor in around 50%. Male infertility is
mostly caused by spermatogenetic failure, clinically noted
as oligo- or azoospermia. However, the reasons for the
decreased sperm production remain largely unclear.
Genome-wide analyses for imbalances have been performed
on infertile patients with idiopathic oligozoospermia and
Sertoli-cell-only syndrome (SCOS) (Tüttelmann et al.,
2011). Here we describe the analysis of 26 patients with
meiotic arrest (MA) by array CGH using the 400k Array Set
(Agilent). We compared the array CGH results with the
results of 100 normozoospermic men. All patients and
controls were selected retrospectively. The mean number of
Copy Number Variants (CNVs) and the amount of DNA
gain/loss were comparable between both groups (patients
and controls). As previously seen in patients with SCOS,
sex-chromosomal CNVs were also overrepresented in
patients with MA. We selected 32 patient-speciﬁc, gene
containing CNVs, which were not seen in normozoos-
permic men or not displayed as common variants in the
Database of Genomic Variants (DGV) for further char-
acterisation. One of these CNVs was found inside the sperm
speciﬁc CATSPERB gene (OMIM 611169). Like the other
proteins of the CATSPER ion channel subunits (CAT-
SPER1-4 and CATSPERG) CATSPERB is localized to the
principal piece of the sperm tail and the channel complex is
required for sperm cell hyperactivation and male fertility. In
conclusion, by studying CNVs in patients with MA we
provide a number of candidate genes possibly causing or
being risk factors for the men’s spermatogenic failure.
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mTOR pathway in the rat ovary
Y. Behram Kandemir1, C. Aydin Acar2, G. Gorgisen3
1Akdeniz University, Faculty of Medicine, Department of
Anatomy, Antalya, Turkey, 2Mehmet Akif Ersoy University,
Bucak School of Health, Department of Nursing, Burdur,
Turkey, 3Yuzuncu Yil University, Faculty of Medicine,
Department of Medical Biology, Van, Turkey
140
Introduction: Mammalian Target of Rapamycin (mTOR)
signaling pathway has important roles in the regulation of
puberty onset, gonadotropin secretion, follicular develop-
ment and ovulation. Melatonin (N-acetyl-5-methoxy-
tryptamine) is a lipophilic hormone has multiple functions
in regulating the fertility. Recent studies have shown that
melatonin affected the number or maturation of follicles in
the ovary. The aim of this study was to investigate the
effects of melatonin on mTOR expression and quantity of
follicle in rat ovary.
Materials and Methods: In the present study a total of
45 female rats were randomly divided into three groups:
Group 1; Control (C), Group 2:Vehicle (V) and Group 3;
Melatonin (M). Melatonin was administered intraper-
itoneally at a dose of 50 mg/kg/day for 30 days in Mela-
tonin group. The effects of Melatonin on expression of
mTOR and downstream components were determined by
Western Blot and Reverse Transcriptase PCR analysis.
Results: Upon Western Blot and RT-PCR evaluations,
we detected higher expression and activation of mTOR,
P70S6K, PKCalpha, PCNA and higher number of pri-
mordial follicles in melatonin group compared with V and
C group. In addition to this results, melatonin decreased
oxidative stress markers, such as MDA, on the contrary,
levels of antioxidative markers, such as CAT and GPx, were
increased by melatonin in rat ovary.
Conclusion: This study indicated that melatonin may
have a signiﬁcant protective effect on primordial follicles
and increase the expression of mTOR and downstream
components in rat ovary. Melatonin treatment may have a
beneﬁcial effect on fertility.
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Microﬂuidics- FISH is a novel technique introduced to
prenatal diagnosis in which a microchip device is used,
consisting of glass coated with nanostructured titanium
dioxide and polymeric pad with microchannels. This
approach allows to combine different steps of FISH into
integral process, shortening and economizing the procedure.
The aim of this study was to evaluate Microﬂuidics-
FISH diagnostic effectiveness, turnaround time and cost in
comparison to FISH as well indicate conditions in which
Microﬂuidics- FISH might be a method of preference.
52 samples of amniotic ﬂuid were drawn from pregnant
women due to common indications, the most frequent being
increased risk of chromosomal aberration (78%). Con-
currently, trisomy 21, 13, 18 and sex chromosomes aneu-
ploidy have been assessed on uncultured amniotic cells by
FISH and Microﬂuidics- FISH method.
All aberrations that have been detected showed 100%
accordance rate for both techniques. The mean turnaround
time was two times shorter for Microﬂuidics- FISH. Also
the cost of single Microﬂuidics- FISH assay comprised half
of FISH cost due to reduced (even 13 fold) consumption of
costly reagents.
Microﬂuidics- FISH proved to be reliable, cost-effective
and rapid testing method of common aneuploidies.
The targeted group of Microﬂuidics- FISH test seems to
be patients, in which amniocentesis was performed between
15–19 week of gestation (higher quality of amniocytes)
from a smaller volume of sample, due to very speciﬁc
indications, increased risk of aneuploidy being the main
one.
This research was partially supported by Pomeranian
Medical University (Young Scientist subsidy No.158-110/
14).
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Objective: To assess the distribution of the parental origin
of the retained X chromosome in monosomy X, either in
miscarriages or in ongoing pregnancies.
Method: The parental origin of the X chromosome was
determined in monosomy X pregnancies, either
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miscarriages or ongoing pregnancies. Microsatellite marker
patterns were compared between maternal and fetal samples
by Quantitative Fluorescence Polymerase Chain Reaction
(QF-PCR). Distributions of maternally and paternally
derived X chromosome were assessed in miscarriages and
in ongoing pregnancies using two tailed Fisher exact test.
Results: Forty monosomy X pregnancies were included
in the study, 26 miscarried at 5–16 weeks, and 14 ongoing
pregnancies diagnosed at 11–20 weeks. The retained X
chromosome was maternally derived in 67% of the cases. In
miscarriages, maternal and paternal X chromosome were
retained in a similar proportion (54% (95%CI: 35–73%)
vs.46%, (95%CI: 27–65%), while in ongoing pregnancies
the maternal proportion was 13 times higher [93% (95%CI:
79–100%) vs. 7%, (95%CI: 0–20%)].
Conclusions: The retained X chromosome in individuals
with monosomy X should theoretically be maternally-
derived in 2/3 of the cases. Our study signals a signiﬁcantly
higher early miscarriage rate in pregnancies with a retained
paternally-derived X chromosome. This may explain the
observation that in 75%-90% of individuals with monos-
omy X retain the maternal X chromosome.
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Genetics Service, University Hospital Southampton NHS
Foundation Trust, Southampton, United Kingdom, 5Pae-
diatric Radiology, University Hospital Southampton NHS
Foundation Trust, Southampton, United Kingdom, 6Aca-
demic Unit of Human Development and Health, Faculty of
Medicine, University of Southampton, Southampton, United
Kingdom
Introduction: We report the case of a male patient with
Larsen syndrome found to be mosaic for a novel point
mutation in FLNB. Quantiﬁcation of the mutation was
performed in four different tissues including sperm in order
to provide accurate advice on transmission risk to future
offspring.
Materials and Methods: Original identiﬁcation of the
mutation was performed by dideoxy-sequencing of DNA
extracted from buccal cells and dermal ﬁbroblasts. To
obtain accurate mutation quantiﬁcation, deep next genera-
tion sequencing (NGS) was performed on DNA extracted
from peripheral blood, ﬁbroblasts, saliva and sperm
samples.
Results: A low-level mosaic FLNB c.698A>G, p.
(Tyr233Cys) mutation was initially identiﬁed in buccal and
ﬁbroblast DNA. This substitution is located within the
second calponin homology domain (CHD2) of the ﬁlamin B
protein, a known hotspot region for Larsen mutations, and
has not been reported previously. NGS allowed accurate
quantiﬁcation of mosaic levels and showed that the muta-
tion was detectable in all four patient samples tested, at
levels ranging from 10.24%±0.26% in saliva, 9.79%
±0.52% in ﬁbroblasts, 9.47%±0.13% in blood and 7.08%
±0.11% in sperm (mutation present in ~20% of diploid
somatic cells, 7% of haploid sperm).
Conclusions: This report illustrates the clinical utility of
performing targeted NGS analysis on multiple somatic tis-
sues and sperm from males affected by a mosaic condition
in order to accurately quantify gonadal mosaicism and
provide evidence-based advice on their transmission risk to
future offspring.
Grant references: National Institute for Health Research
(NIHR) Oxford Biomedical Research Centre Programme,
Wellcome Trust (Award 102731), WIMM Strategic Alli-
ance (G0902418, MC_UU_12025).
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The accumulation of vitriﬁed oocytes is a valid strategy
to increase the number of euploid available embryos for
transfer after Preimplantation Genetic Testing
s. chamayou
Unità di medicina della riproduzione - istituto HERA,
sant'agata li battiati, Italy
Purpose: In a preimplantation genetic diagnosis for aneu-
ploidy (PGD-A) program, the more embryos available for
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biopsy, consequently increases the chances of obtaining
euploid embryos to transfer. The aim was to increase the
number of viable euploid blastocysts in patients undergoing
PGD-A using fresh oocytes together with previously accu-
mulated vitriﬁed oocytes.
Methods: 69 patients with normal ovarian reserve
underwent PGD-A for repeated implantation failure or
recurrent pregnancy loss indication. After several cycles of
ovarian stimulation, 591 accumulated vitriﬁed oocytes and
463 fresh oocytes were micro-injected with the same part-
ner's semen sample. PGD-A was completed on 134 blas-
tocysts from vitriﬁed/warmed oocytes and 130 blastocysts
from fresh oocytes.
Results: A mean of 9.6% euploid blastocyst per micro-
injected vitriﬁed/warmed oocytes and 11.4% euploid blas-
tocyst per micro-injected fresh oocyte were obtained
(p˃0.05). The euploidy and aneuploidy rates were compar-
able in blastocysts obtained from micro-injected vitriﬁed/
warmed oocytes and fresh oocytes (42.5% versus 40.8%
and 57.5% versus 59.2%, p˃0.05). Implantation rates of
euploid blastocysts were comparable between the two
sources of oocytes (56.0% from vitriﬁed/warmed oocytes
versus 60.9% from fresh oocytes, p˃0.05).
Conclusions: Oocyte vitriﬁcation and warming do not
generate aneuploidy in blastocysts. The number of viable
euploid embryos for transfer can be increased by using
accumulated vitriﬁed oocytes together with fresh oocytes in
ICSI.
S. chamayou: None.
P01.061A
Characteristics of no calls from non-invasive prenatal
testing (NIPT) performed at Hvidovre Hospitals NIPT
Center, Denmark
L. Ambye1, T. S. Hartwig2, L. Werge1, M. K. Weiergang1,
A. M. Høgh1, F. S. Jørgensen2, S. Sørensen1
1Department of Clinical Biochemistry, Copenhagen Uni-
versity Hospital Hvidovre, Hvidovre, Denmark, 2Fetal
Medicine Unit, Department of Gynecology and Obstetrics,
Copenhagen University Hospital Hvidovre, Hvidovre,
Denmark
Introduction: Main reasons for no-call results of NIPT are
low fetal-fraction (FF) and technical reasons. Information
on why the result cannot be reported is important, as it
affects how to continue.
Materials and Methods: We performed a validation of
our set-up and evaluated technical, maternal and fetal
characteristics of no-call cases. NIPT analyses were per-
formed on circulating cell-free DNA and Massive Parallel
Sequencing on a HiSeq1500. Bioinformatics were per-
formed in samples > 8 mio-reads using a pipeline for fetal
fraction (SeqFF) and aneuploidy (WISECONDOR).
Results: Among 205 selected cases (incl. 73 aneuploidy
cases), 13 lead to no-call results (6%). In four cases the
reason was technical and in nine cases FF was below cut-off
<0.02. In the group of no-calls caused by low FF two cases
had a maternal BMI>40, four cases had a BMI between 30
and 40, and three cases had a BMI<30. Furthermore, we
found an overrepresentation of aneuploidy cases (T21=2,
T18=4, T13=1, 46XX/XY=2). Two cases of T18 and one
case of T13 had a z-score >3 despite a low FF.
Conclusions: High maternal BMI and fetal aneuploidy
highly inﬂuence the risk of a no-call result. Therefore, labs
performing NIPT in a population with obese women might
have a higher no-call rate. We found an overrepresentation
of aneuploidy cases among no-calls, both T21, T18 and
T13. Only T18 and T13 are described in the literature to
have decreased FF. If we had not included determination of
FF in our set-up, four cases might have been false negative.
L. Ambye: None. T.S. Hartwig: None. L. Werge:
None. M.K. Weiergang: None. A.M. Høgh: None. F.S.
Jørgensen: None. S. Sørensen: None.
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Determination of fetal fraction using Droplet Digital
PCR for Non-Invasive Prenatal Testing (NIPT)
M. Collado1, R. Tena1, M. Calderón1, R. Montaner1, G.
Briz1, P. Ferrer1, D. Diego1, O. Rodríguez2, J. C. Triviño2,
D. Sánchez-Izquierdo1
1Cytogenomics, Sistemas Genómicos S.L., Paterna, Spain,
2Bioinformatics, Sistemas Genómicos S.L., Paterna, Spain
Introduction: With the aim of complementing Prenatal
Non-Invasive Testing (NIPT) based in Next Generation
Sequencing (NGS) for the detection of chromosomal
aneuploidies and fetal sex determination, we developed a
new approach based on digital PCR technique for the
determination of fetal fraction in maternal blood samples.
Materials and Methods: From one hundred pregnant
women (gestational ages from 10 to 19 weeks), one aliquot
of plasma cell free DNA (cfDNA) was selectively digested
for methylated regions while a second one remained undi-
gested. The fetal fraction was established by Droplet Digital
PCR (ddPCR) based on absolute quantiﬁcation of RASSF1A
copies in digested (fetal) and undigested (fetal and mater-
nal) samples. The ratio between both values determined the
fetal fraction. The houseeking gene β-Actin was used as
control for maternal cfDNA complete digestion. Bioinfor-
matics analysis allowed a second assessment of fetal
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fraction in male fetuses, since the analysis is based on the
presence or absence of the chromosome Y, and its quanti-
ﬁcation by the number of total reads normalized respect to
male control samples.
Results: The percentage of circulating cell-free fetal
DNA (cffDNA) in maternal plasma was 3,42% and 31,38%
regardless of gestational age. The correlation coefﬁcient
between the fetal fraction determined by ddPCR and
determined by bioinformatics analysis only for male fetuses
was 0,55.
Conclusions: Digital PCR is an innovative and sensitive
technology compared to real time quantitative PCR as it has
been published recently in the literature. This methodology
is a promising tool to increase the precision of fetal fraction
determination.
M. Collado: None. R. Tena: None. M. Calderón:
None. R. Montaner: None. G. Briz: None. P. Ferrer:
None. D. Diego: None. O. Rodríguez: None. J.C. Triviño:
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Affordable high precision NIPT method implemented in
a fully automated workﬂow
Vanadis team
Vanadis Diagnostics, Sollentuna, Sweden
In several countries, there is an ongoing implementation of
Non Invasive Prenatal Testing (NIPT) for detection of
aneuploidies in high-risk pregnancies. A majority of the
tests are performed using next generation sequencing
technologies that provide both superior speciﬁcity and
sensitivity compared to traditional ﬁrst trimester screening.
However, to enable health care providers to offer all women
a high performance prenatal screening test, the NIPT assay
cost and complexity need to be dramatically reduced. We
present a platform that reduces the cost of the analysis
substantially making the assay available for high throughput
diagnostic laboratories. Our solution, called Vanadis NIPT,
is a fully automated, walk-away solution, from blood
sample to report, which allows one technician to process
over 20,000 samples per year. The Vanadis NIPT technol-
ogy uses DNA probes to speciﬁcally convert chromosomal
targets of interest into DNA circles. These circles are then
clonally expanded into discrete ﬂuorescently labeled DNA
objects, immobilized on a transparent nanopore ﬁlter, and
ﬁnally imaged and counted through the bottom of the well.
By targeting thousands of DNA fragments from each
chromosome, PCR ampliﬁcation can be avoided with
increased assay precision and reduced contamination risks
as a result. We applied the technology to analyze a large set
of clinical samples including trisomy 13, 18 and 21 cases.
By providing a high assay precision, >99% detection rate
was achieved. In conclusion, the Vanadis NIPT platform,
supported by clinical data, is a new solution that holds
promise to provide NIPT to all pregnant women.
Vanadis team: None.
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NIPT for sex chromosome aneuploidy; more harm than
good?
K. Mann1, H. Thomas1, C. Donaghue1, C. Brown1, C.
Mackie Ogilvie2
1Viapath Analytics, Guy’s Hospital, London, United King-
dom, 2Guy's and St Thomas' NHS Foundation Trust,
London, United Kingdom
The reliable performance of NIPT for trisomies 13, 18 and
21 means that it is now available in many European
countries; some providers also offer NIPT for sex chro-
mosome aneuploidy. However, the clinical utility of NIPT
for sex chromosome aneuploidy is debatable - most fetuses
with monosomy X present with ultrasound anomalies
indicating diagnostic testing, and prenatal detection of other
sex chromosome aneuploidies is considered problematic. In
addition, the positive predictive value (PPV) of NIPT for
sex chromosome aneuploidy is reported to be as low as
38%. Within our region, NIPT is self-funded and available
from a number of commercial providers; most referrals are
considered low risk without ultrasound anomalies. Since
January 2014 our centre received, for conﬁrmatory diag-
nostic testing, 188 prenatal samples (117 amniotic ﬂuids
(AF) and 71 chorionic villus samples (CVS)) referred with a
high risk (186) or inconclusive (2) NIPT result. Of these,
169 were conﬁrmed by QF-PCR analysis; 11 cases showing
mosaicism (six AF, ﬁve CVS) were classed as concordant.
In 18 cases, the QF-PCR result showed normal copy
number, discordant with the high risk NIPT result. PPVs
were 97.9% (140/143) for trisomy 21; 90.9% (20/22) for
trisomy 18; 87.5% (7/8) for trisomy 13 and 20% (3/15) for
sex chromosome aneuploidy. Six of seven NIPT results
showing a high risk of monosomy X were false positives.
These data support the suggestion that NIPT for sex chro-
mosome aneuploidy has little clinical utility and results in
unnecessary invasive procedures and increased anxiety for
some couples.
K. Mann: None. H. Thomas: None. C. Donaghue:
None. C. Brown: None. C. Mackie Ogilvie: None.
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A majority of chromosomal imbalances detected by
NIPT are postzygotic in origin and are fetoplacental
mosaics
E. Dimitriadou, N. Brison, K. Van Den Bogaert, C.
Melotte, L. Dehaspe, A. Destouni, H. Peeters, H. van
Esch, T. de Ravel, E. Legius, K. Devriendt, J. R.
Vermeesch
Centre for Human Genetics, University Hospitals Leuven,
Department of Human Genetics, KU Leuven, Leuven 3000,
Belgium
It has been established that cleavage-stage embryos have a
high incidence of chromosomal rearrangements, with most
of them being mosaics consisting of normal and abnormal
cells. The majority of abnormal blastomeres are probably
selected against during further development into the blas-
tocyst stage. Nevertheless a small but signiﬁcant number of
trophectoderm biopsies analyzed by genome-wide aneu-
ploidy detection methods during preimplantation genetic
diagnosis or screening is poised with mosaic chromosomal
imbalances. Within the PGD community there is currently a
debate about the clinical importance of these imbalances
and some authors even suggest that they are clinically
irrelevant. Following 20,000 genome-wide NIPT analyses,
we identiﬁed and reported 6 fetuses with potential clinically
signiﬁcant chromosomal imbalances. Further invasive
follow-up unraveled the presence of complex segmental
anomalies. For all 6 pregnancies we obtained invasive
follow-up via amniocentesis. Additionally, for 5/6 one or
more placental samples have been acquired. In 2 cases, a
discrepancy was observed between the detected placental
and fetal imbalances. Reciprocal and sequential events were
observed in the remaining 4. Such imbalances can only be
the consequence of pre-blastocystic cell lineages harboring
different imbalances, which further evolved following the
separation of the inner cell mass and the trophectoderm
subpopulations. Hence, we demonstrate that (1) most
chromosomal imbalances originate post fertilization, (2)
they can pass the developmental barrier and be present at
different loads in the fetus and/or the placenta, (3) detection
of imbalances in trophectoderm is of clinical importance
and (4) detection of segmental imbalances via NIPT pro-
vides valuable information for pregnancy management.
E. Dimitriadou: None. N. Brison: None. K. Van Den
Bogaert: None. C. Melotte: None. L. Dehaspe: None. A.
Destouni: None. H. Peeters: None. H. van Esch: None. T.
de Ravel: None. E. Legius: None. K. Devriendt: None. J.
R. Vermeesch: E. Ownership Interest (stock, stock options,
patent or other intellectual property); Modest; Cartagenia,
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Non-invasive prenatal diagnosis of single-gene disorders
in maternal plasma: detection of paternally-inherited
mutations using droplet digital PCR
A. gruber, M. Pacault, L. A. El Khattabi, N. Vaucouleur,
L. Orhant, E. Girodon, D. Vidaud, F. Leturcq, C. Costa,
F. Letourneur, O. Anselem, V. Tsatsaris, F. Gofﬁnet, G.
Viot, M. Vidaud, T. Bienvenu, j. Nectoux
Cochin Hospital, paris, France
Background: To limit risks of miscarriages associated with
invasive procedures of current prenatal diagnosis practice,
we propose a standardized protocol for non-invasive pre-
natal diagnosis (NIPD) of single-gene disorders based on
the qualitative detection of paternally-inherited mutations in
maternal blood using droplet digital PCR (ddPCR).
Methods: Four couples at risk of transmitting paternal
NF1 mutations and four couples at risk of transmitting
compound heterozygous mutations of CFTR gene were
included in this study. NIPD was performed between 8 and
15 weeks of gestation, in parallel to conventional invasive
diagnosis. Speciﬁc Taqman probes were designed to detect
the paternal mutation and to control the presence of cell-free
fetal DNA (cffDNA) by ddPCR. Speciﬁcity and sensitivity
of each assay were determined from paternal sample, and
then fetal genotype was inferred from maternal plasma
sample.
Results: Presence or absence of the paternal mutant
allele was correctly determined in all of cases and the
accuracy of the designed protocol was determined 100%.
Conclusions: This protocol is suitable for implementa-
tion in routine clinical practice, with satisfactory accuracy in
detection of paternal mutations in cffDNA, and allows
considering extending the applications of these technologies
in non-invasive prenatal testing of many other monogenic
diseases.
VLM RC20160501598/1/1/172, AFM-Téléthon 19832
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Prospective validation study of utilization of Trisomy
test for noninvasive prenatal testing of common
trisomies
G. Minarik, D. Landlova, R. Lukackova, A. Izsakova, I.
Mojzisikova, M. Sekelska, L. Valentinova, P. Krizan
Medirex, Inc., Bratislava, Slovakia
Noninvasive prenatal testing (NIPT) based on analysis of
circulating DNA of pregnant women is becoming integral
part of prenatal genetics. In last years different laboratories
made NIPT available worldwide.
Aim of our study was prospective validation of Trisomy
test, home-made NIPT test using paired-end low coverage
whole genome sequencing approach and our own bioin-
formatical method for z score calculation.
Between September 2015 and August 2016 altogether
1863 samples of pregnant women were analyzed. In the
sample cohort 21 cases of trisomy 21, 9 cases of trisomy 18
and 3 cases of trisomy 13 were present. Of these all trisomy
21 and trisomy 13 were correctly identiﬁed, in cases with
trisomy 18 eight of nine cases were detected. Overall
detection rate for tested trisomies was 96.97%. Two false
positive cases were recorded, one for trisomy 21 and one for
trisomy 13, therefore speciﬁcity of the test was 99.89%
overall. Noninformative results have been recorded in less
than 4% of samples, of these two thirds have become
informative after second analysis performed from new
blood sample that was taken two to four weeks after the
original one. Higher frequency of samples with low fetal
fraction was detected in pregnant women treated with low
molecular weight heparin or of high body weight, what is in
concordance with previously published data.
Trisomy test based on paired-end low coverage whole
genome sequencing enabled simultaneous fetal fraction
calculation and z score calculation with detection rate and
speciﬁcity comparable with data published in larger studies
and metaanalyses.
G. Minarik: A. Employment (full or part-time); Sig-
niﬁcant; Medirex, Inc. D. Landlova: A. Employment (full
or part-time); Signiﬁcant; Medirex, Inc. R. Lukackova: A.
Employment (full or part-time); Signiﬁcant; Medirex, Inc.
A. Izsakova: A. Employment (full or part-time); Modest;
Medirex, Inc. I. Mojzisikova: A. Employment (full or part-
time); Modest; Medirex, Inc. M. Sekelska: A. Employment
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nova: A. Employment (full or part-time); Signiﬁcant;
Medirex, Inc. P. Krizan: A. Employment (full or part-
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Identiﬁcation of viral DNA from unmapped human
reads in data from NIPT
A. Balá1, I. Gazdaricová2, T. Szemes3
1Faculty of mathematics, physics and informatics, Come-
nius University, Bratislava, Slovakia, 2Faculty of natural
sciences, Comenius University, Bratislava, Slovakia, 3Gen-
eton, Bratislava, Slovakia
Introduction: NIPT analysis based on whole genome
sequencing is one of novel genetic test with wide worldwide
use. It is based on sequencing of DNA isolated on plasma
and followed by mapping of the data to reference human
genome. A signiﬁcant portion of reads remains unmapped
to the reference and it remains unused. The purpose of this
study was to identify if viral DNA can be detected in such
sample data and to attempt to build longer contigs from
such reads.
Materials and methods:We sequenced total DNA from
plasma of pregnant women of two groups. A larger group
had no indication of present viral infection and the second
group contained sample positive for HIV viral infection.
DNA fragments which mapped to the human reference
genome (version hg38) were eliminated. We assigned each
unmapped fragment a taxonomic label using metagenomic
classiﬁer Clark. Taxonomic composition of samples was
compared and visualized using Krona graphs.
Results: We identiﬁed presence of viral sequences in a
small number of samples in both groups of samples. In the
results we present breakdown of the identiﬁed viral data.
Conclusions: Additional information can be extracted
from complex data generated in NIPT tests which were
originally destined to be eliminated by bioinformatic ﬁl-
tering. We show an example of identiﬁed viral sequences
which add value to “junk” data.
A. Balá: A. Employment (full or part-time); Modest;
Geneton. I. Gazdaricová: A. Employment (full or part-
time); Modest; Geneton. T. Szemes: A. Employment (full
or part-time); Signiﬁcant; Geneton.
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The clinical utility of genome-wide non-invasive prenatal
screening
S. Bono, F. Pizzuti, S. Duca, A. Polverari, M. Faieta, S.
Antonucci, M. Baldi, L. Diano, D. Viola, G. Predebon, F.
Spinella, F. Fiorentino
Genoma Group, Rome, Italy
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Introduction Conventional cell-free fetal DNA (cfDNA)-
based NIPT focuses on detection of common aneuploidies,
leaving a gap of ~17% of clinically relevant chromosomal
abnormalities that would go undetected. Genome-wide
NIPT would greatly expand the range of chromosomal
rearrangements detectable, but it could lead to a decrease of
the speciﬁcity and, consequentially, to an increase in
unnecessary invasive testing. In this study, we compared the
performance of the genome-wide NIPT and conventional
cfDNA-based NIPT in a large general population of preg-
nant women, in order to assess the clinical utility of the
genome-wide screening.
Materials and Methods Genome-wide cfDNA analysis
was offered to 12.114 pregnant women undergoing NIPT
for common fetal aneuploidy. Sequencing data were ana-
lyzed using an algorithm optimized to identify aneuploidies
and subchromosomal aberrations.
Results Genome-wide screening allowed detection of 12
(7.4%) potentially viable clinically relevant chromosomal
abnormalities, which would have remained overlooked if
only conventional NIPT had been performed. This resulted
in a statistically signiﬁcant higher sensitivity (100%
vs92.64%,p<0.001) than did standard screening. This was
achieved without sacriﬁcing the speciﬁcity of the test, that
resulted similar to that obtained with standard cfDNA
testing (99.87%vs99.77%,p=0.064).
Conclusion: The clinical utility of expanding NIPT to
cover the entire genome is controversial. It pertains a risk of
overdiagnosis with a higher number of false positives due to
chromosomal rearrangements, which are conﬁned to the
placenta, potentially leading to an increase in unnecessary
invasive testing. The results of this study demonstrate that a
high speciﬁcity may be maintained while extending the
screen to all chromosomal abnormalities.
S. Bono: None. F. Pizzuti: None. S. Duca: None. A.
Polverari: None. M. Faieta: None. S. Antonucci: None.
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Non-invasiveprenatal diagnosis of beta thalassaemia
based on a free fetal DNA Real TimePCR-based
approach
A. Floratos, F. Strikou, L. Ikonomopoulos, M.
Karapanou, C. Chassanidis, A. Balassopoulou, E. Boutou
Laiko Hospital, Athens, Greece
Introduction: Prenatal diagnosis of embryos at risk for
monogenic diseases, like thalassaemias, still presents the
most common method of disease prevention. This approach
is predominantly based on genetic analysis of material of
fetal origin which is mainly obtained through invasive
procedures. Since invasive procedures have a 1–2% prob-
ability of miscarriage, non-invasive prenatal testing (NIPT)
approaches, based on analyzing fetal DNA circulating in the
maternal plasma, were developed. Here, we present the
broaden development of a novel approach for detecting beta
globin gene mutations present in free fetal DNA (ffDNA).
Our method is based on High Resolution Melting (HRM)
combined with quantitative analysis.
Materials and methods: ffDNA is isolated from 2ml
maternal plasma and screened for the presence of β globin
gene parental mutations based on an in-house HRM
developed approach. Previously described SNPs in the
vicinity of β globin gene, for which parents presented dis-
tinct haplotypes, were also determined.
Results: Our hitherto results (27 cases) succeeded in
obtaining the same diagnosis with the preceded analysis of
corresponding chorionic villus sampling. Cases include
male embryos that inherited either the paternal or maternal
mutation and cases where the embryo has inherited both
parental mutations located on the same amplicon (i.e.
CD39/IVS-I-110).
Conclusions: The described approach, after further
evaluation, may allow its application at the diagnostic level
as a primary or secondary method for NIPT in cases where
the embryo is male and has inherited either the paternal or
maternal β globin gene mutation and in certain cases both
parental mutations.
A. Floratos: None. F. Strikou: None. L. Ikonomo-
poulos: None. M. Karapanou: None. C. Chassanidis:
None. A. Balassopoulou: None. E. Boutou: None.
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Novel statistical model for non-invasive prenatal testing
for aneuploidies
F. Ďuri1, J. Budi2,3, M. Hýblová4,3, G. Minárik5, J.
Turňa1,6,4, T. Szeme4,3,6
1Slovak Centre of Scientiﬁc and Technical Information,
Bratislava, Slovakia, 2Faculty of Mathematics, Physics and
Informatics, Comenius University, Bratislava, Slovakia,
3Geneton s.r.o., Bratislava, Slovakia, 4Faculty of Natural
Sciences, Comenius University, Bratislava, Slovakia, 5Med-
irex a.s., Bratislava, Slovakia, 6Comenius University
Science Park, Bratislava, Slovakia
Introduction: Recent studies showed that massively par-
allel DNA sequencing (NGS) of cell-free fetal DNA from
maternal plasma can be used for non-invasive prenatal
aneuploidy testing (NIPT). Especially desired are reliable
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detections of chromosomal aberrations such as Down,
Edwards or Patau syndrome. Most of the current methods in
practice are based on some form of z-score analysis, usually
with an assumption of normality of NGS data. By applying
other probabilistic assumptions on the NGS data we derived
a novel approach to z-score testing with reaches to other
problems as well.
Materials and methods: We applied methods in prob-
ability and statistics to derive a sound mathematical theory
of z-score calculation from the data given by non-normal
distribution.
Results: Our novel method allows calculation of trisomy
z-score, error of this z-score given the genetic variability in
population, fetal fraction estimation with error of this esti-
mation as well as minimal number of reads for our method
to reliably work given some speciﬁed targeted fetal fraction.
We demonstrate on real data from NIPT testing that our
approach allows improved sensitivity and speciﬁcity for
common chromosomal aneuploidies even when ultra-low
read counts are used.
Conclusion: Successful application of trisomy detection
in practice is becoming a reality. By proper understanding
of mathematical background in such tests, we can achieve
higher precision and lower cost of tests.
F. Ďuri: None. J. Budi: A. Employment (full or part-
time); Signiﬁcant; Geneton s.r.o. M. Hýblová: A.
Employment (full or part-time); Modest; Geneton s.r.o. G.
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Non invasive prenatal screening (NIPS) as indication for
prenatal testing
R. Raynova1, I. Bradinova1, S. Andonova1, S. Bichev1, V.
Dimitrova2, M. Tzankova3, A. Savov1
1National Genetic Laboratory, University Hospital of
Obstetrics and Gynecology, Soﬁa, Bulgaria, 2Department
of Fetal Medicine, University Hospital of Obstetrics and
Gynecology, Soﬁa, Bulgaria, 3Maternal Risk Department,
University Hospital of Obstetrics and Gynecology, Soﬁa,
Bulgaria
Non-invasive prenatal screening (NIPS) of cell-free fetal
DNA (cffDNA) for fetal aneuploidy risk assessment is
offered to pregnant women along with, or instead of com-
bined maternal serum screening. It has been validated for
common autosomal trisomies (trisomy 21, 18, 13), sex
chromosome aneuploidies, and a selection of microdeletion
syndromes.
For the past three years 2200 pregnant women with
different indications (increased maternal serum screening
risk, abnormal ultrasound markers and/or advanced mater-
nal age) were referred to our department for prenatal
detection of chromosomal aneuploidies by QF-PCR analy-
sis. Among them 21 were referred for invasive prenatal
diagnosis with a positive result from NIPS: 15 cases - for
trisomy 21, two - for trisomy 18 and three - for sex chro-
mosomal aneuploidies. One case was referred for amnio-
centesis with a positive result from NIPS for both
monosomies 13 and 18.
After invasive procedures - amniocentesis and QF-PCR
analysis, trisomy 21 was conﬁrmed in all but one T21 NIPS
positive cases. The remaining ﬁve NIPS -positive referred
samples were found to be negative for trisomy 18 and sex
chromosomal aneuploidies by use both of QF-PCR and
cytogenetic analysis. Monosomies 13 and 18 were excluded
too in the last case. Conﬁned placental mosaicism was
excluded for all false positive cases, newborns were with
normal karyotype.
NIPS ﬁndings, discordant with the fetal karyotype can be
because of conﬁned placental mosaicism, maternal chro-
mosome abnormalities and other maternal conditions such
as occult malignancy. The lack of further, more sophisti-
cated investigations due mainly to economical reasons
leaves unanswered questions.
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Identiﬁcation and characterization of fetal RNA bio-
markers for the development of NIPT of trisomy 21
S. Kyriakou1,2, C. Loizides1, M. Ioannides1, E. Kypri1,2, G.
Koumbaris1,2, P. C. Patsalis1,2
1NIPD Genetics, Nicosia, Cyprus, 2The Cyprus Institute of
Neurology and Genetics, Nicosia, Cyprus
Currently, non-invasive prenatal testing (NIPT) uses cell
free fetal DNA in maternal plasma as a screening tool for
fetal aneuploidy. However, pregnancies with low fetal
fraction are excluded from the diagnostic screening even
though high sensitivity methodologies and sophisticated
bioinformatics analysis are used. RNA biomarkers can be
advantageous compared to DNA biomarkers in NIPT, due
to their multi-copy characteristic. We aim to identify robust
RNA biomarkers, with the potential to develop a novel test
with high diagnostic accuracy for the NIPT of trisomy 21 in
all pregnancies. We performed whole genome expression
microarrays in four normal and two trisomy 21 fetuses and
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their matching maternal cells. The differentially expressed
genes (DEGs) identiﬁed were conﬁrmed with qPCR and
digital PCR (dPCR) in 60 samples, 30 chorionic villi
samples (CVS) of which 6 were trisomy 21, and 30
maternal cells. Further evaluation of the conﬁrmed DEGs
was performed to assess the maternal background if present.
Additionally, we searched the microarray data to identify
CVS speciﬁc controls with the potential to be used as
normalizers in maternal plasma samples. Expression
microarray data identiﬁed 386 DEGs between normal and
trisomy 21 CVS, of which ﬁve were conﬁrmed as CVS and
trisomy 21 speciﬁc in qPCR. Re-evaluation with dPCR
showed low but consistent expression in all maternal cells
tested for three out of ﬁve DEGs identiﬁed. Additionally,
two genes were identiﬁed and conﬁrmed as CVS speciﬁc
controls. The DEGs identiﬁed are promising biomarkers for
the NIPT of trisomy 21 including low fetal fraction
pregnancies.
S. Kyriakou: A. Employment (full or part-time); Sig-
niﬁcant; NIPD Genetics LTD. C. Loizides: A. Employment
(full or part-time); Signiﬁcant; NIPD Genetics LTD. M.
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Nonclassical adrenal hyperplasia and polycystic ovary
syndrome: evaluation of four cases
H. Ilgin-Ruhi, E. Taşdelen, E. Gokpinar, M. Gokoglu, T.
Tuncali
Ankara University Medical Faculty, Ankara, Turkey
Congenital adrenal hyperplasia is one of the most frequently
seen recessive endocrine disorder. Ninetyﬁve percent of the
patients have mutations in CYP21A2. Non-classical adrenal
hyperplasia (NCAH) is phenotypically the milder form and
usually manifests its self with hyperandrogenism, oligime-
norrhea, amenorrhea, hirsutism, subfertility and in some
cases with male type baldness. Patients may have polycystic
overies. On the other hand, polycystic ovary syndrome
(PCOS) is a extremly heterogenous and complex condition.
Phenotypic ﬁndings of these two disorders may overlap.
There are some PCOS patients that were detected with 21-
hydroxylase deﬁciency and reported to be actually as
NCAH. Here, we present four cases with irregular men-
strual cycles, hypetrichosis, polycyctic ovaries and ele-
veated 17α-hydroxyprogesterone levels that were
investigated for the frequent mutations of CYP21A2. Three
of the patients had the homozygous V281L and one had the
homozygous P30L mutations. The diagnosis or the rule out
of NCAH in hyperandrogenic patients are of great impor-
tance. Being a monogenic condition, in NCAH providing
genetic counselling is crucial both for diagnosis and
reccurence.
Reference
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The presence of cell free fetal DNA in maternal blood
after single fetal reduction of trisomy 21 aneuploidy in a
twin pregnancy
C. C. Hung1, C. W. Huang2, C. W. Yeh2, Y. N. Su1,3
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Performance Computing, Hsinchu, Taiwan, 3Dianthus
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Introduction: Cell-free fetal DNA is present in the mater-
nal plasma and allows non-invasive prenatal testing (NIPT)
for fetal aneuploidy screening. However, the application of
NIPT to twin pregnancies is an additional challenge because
DNA is available for analysis from each fetus. In this study,
we estimate whether cell-free DNA is present after elective
reduction in a twin pregnancy.
Methods: The woman was a 37-year-old who revealed a
twin pregnancy and chose NIPT for prenatal screening of
chromosomal aneuploidies. We used illumina platform and
whole genome sequencing-based NIPT, and analyzed each
chromosome.
Results: The normalized chromosome value (NCV)
value was 8.79 for trisomy 21 and follow-up counseling and
invasive testing was recommended. One fetus was trisomy
21 and another was euploid after karyotyping conﬁrmation
by amniocentesis. The karyotypes were 47,XX,+21 and 46,
XX, respectively. The parents opted for selective termina-
tion of pregnancy. The pregnant woman still accepted NIPT
for tracking the remaining fetus. The NCV values are 17.78,
36.71, 6.24 and 0.80, respectively for 4, 9, 12 and 15 weeks
after selective reduction.
Conclusion: Cell-free fetal DNA is derived mainly from
placenta. In our study, the placenta can continue to shed
cell-free fetal DNA after the reduction a twin pregnancy to a
singleton one and last 12 weeks. Therefore, the discordant
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results for NIPT can therefore be attributed to early fetal
demise.
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Increased nuchal translucency and additional ultra-
sound ﬁndings in Noonan syndrome: when is DNA
testing justiﬁed?
K. E. Stuurman1, T. Rinne2, Dutch prenatal genetics
teams
1Erasmus Medical Centre, Rotterdam, Netherlands, 2Rad-
boud University Medical Centre, Nijmegen, Netherlands
Background: Prenatal features of Noonan syndrome have
been described, but only a few studies have performed
systematic reviews or original research. Increased nuchal
translucency (NT) has been one of the important factors in
detecting Noonan syndrome. This study evaluates ﬁve years
of prenatal Noonan syndrome (NS) testing in the Nether-
lands including the value of testing for NS with isolated
increased NT.
Methods: More than 300 samples that were sent in for
prenatal NS testing in 2011–2016 were collected. During
the ﬁrst years 3–5 NS/RASopathy genes were analyzed, and
later 14 genes. For all mutation-positive samples the refer-
ring physician was asked to provide detailed ultrasound
ﬁndings and postnatal follow up. For ~150 mutation-
negative samples after testing 14 genes the clinical infor-
mation was collected on the requisition form and analyzed
without consulting the referring physician.
Results: In total 43 mutation positive samples were
detected. 26% of these fetuses showed a PTPN11 mutation,
followed by RAF1 mutations (14%) and RIT1 mutations
(9%). SOS1 and HRAS mutations were found in two
fetuses in each gene. SHOC2, BRAF, MAP2K1 mutations
were conﬁrmed in one fetus each. All fetuses showed a
variable degree of involvement of prenatal ﬁndings. Five
fetuses showed only one ultrasound ﬁnding: one with iso-
lated increased NT and four fetuses with cystic hygroma.
Conclusion: Increased NT is rarely seen as an isolated
feature in NS. However, cystic hygroma is an important
sole factor. Overall, fetuses with NS show multiple ultra-
sound ﬁndings and NS should not be tested when increased
NT is isolated.
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Identiﬁcation of de novo genetic targets associated with
natural & accelerated ageing by single-cell whole exome
sequencing
Y. Qian, J. Liao, X. Zeng, L. Chi, C. H. Chung, G. W.
Kong, T. Y. Leung, W. Y. Chan, T. C. Li, T. L. Lee
The Chinese University of Hong Kong, Shatin, Hong Kong
Advanced maternal ageing in women at the age of over 35
is currently a big health concern worldwide. It links to
inferior fertilization rate and higher genetic risks in off-
spring. External factors like hormones and follicular cells
have been reported comprehensively. However, the con-
tribution of genetic alterations in oocyte ageing remains
largely elusive due to limitation on experimental technolo-
gies and the limited amount of sample materials.
In this study, we aimed to identify natural and acceler-
ated ageing-related genetic alternations, including single
nucleotide polymorphism (SNPs) and copy number varia-
tions (CNVs) in mouse oocyte ageing models Four groups
of female mice consisted of a young group (6-weeks-old), a
natural aging group (36-weeks-old), an accelerated aging
group (treated by 4-Vinycyclohexene diepoxide) and a
vehicle group (treated by sesame oil) were mated with an
adult male. The DNA samples derived from single oocytes
and blood samples of females, offspring and males were
subjected to whole exome sequencing. Natural and accel-
erated aging-related de novo variations (DNVs) and asso-
ciated genes were identiﬁed. We found mutation patterns of
DNVs were similar to mutational signatures in women
cancers. Finally, we detected an aberrant CNV region in
natural aging oocytes, where it contained genes involved in
aging diseases and reproduction.
Taken together, our study highlighted the key genetic
targets associated with oocyte aging. The data allows dis-
secting the aging mechanisms of subfertility in women with
advanced maternal age.
This study was supported by Seed Fund, SBS, CUHK
(Ref. No.: 6903807) and Research Council Funding, CUHK
(Ref. No.: C4004-15G).
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The clinical use of determining embryonic ploidy status
in couples undergoing PGD for translocations
150
E. Coonen1, C. van Uum1, J. Engelen1, M. Meijer-
Hoogeveen2, R. van Golde1, J. Derhaag1, A. van
Montfoort1, M. Pieters2, M. Goddijn3, J. Brink-van der
Vlugt4, S. Repping3, C. de Die-Smulders1, S.
Mastenbroek3
1MUMC+, Maastricht, Netherlands, 2UMCU, Utrecht,
Netherlands, 3AMC, Amsterdam, Netherlands, 4UMCG,
Groningen, Netherlands
The use of array technology in preimplantation genetic
diagnosis (PGD) for chromosomal disorders allows for
simultaneous genome-wide ploidy analysis. Whether this
data is useful in selecting embryos for transfer is unknown.
We performed an observational, multicentre study cov-
ering a 3-year period (2014–2016) during which 117 cou-
ples underwent 171 PGD cycles for structural chromosomal
abnormalities in three IVF centres.
Comprehensive chromosome testing was performed on
day 3 single blastomeres by array CGH and only embryos
with a balanced karyotype for the PGD indication were
eligible for transfer. Two of the three centres ranked
embryos for transfer solely based on morphology. The third
centre ranked embryos based on both ploidy status of non-
indication chromosomes and morphology.
In total, 169 embryo transfers were performed (185
embryos). Of these, 37 involved single embryo transfer of a
balanced/aneuploid embryo, leading to three biochemical
pregnancies plus three children born. In the latter, aneu-
ploidy of non-indication chromosomes involved a trisomy
19, a trisomy X and a gain of 17p combined with a loss of
17q. Seven double embryo transfers (DET) were performed
with two balanced/aneuploid embryos, giving rise to three
biochemical pregnancies. Six DETs comprising one
balanced/euploid and one balanced/aneuploid embryo
resulted in one ﬁrst trimester abortion plus two children
born. Compared to balanced/euploid embryos, balanced/
aneuploid embryos had signiﬁcantly lower implantation and
higher miscarriage rates.
Data indicate that in a PGD setting, embryos with an
inferred aneuploidy for non-indication chromosomes have
lower implantation and higher miscarriage rates but are
eligible for transfer and compatible with live birth.
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PGS, PGD and PGD-counselling in Russia: experience
of a reference laboratory
E. Musatova1,2, Y. Sofronova2, R. Bikanov2, E.
Pomerantseva2
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Introduction: Preimplantation genetic screening (PGS) for
chromosomal abnormalities helps to select euploid embryos
for transfer and therefore enhances pregnancy rate in IVF
patients. Preimplantation genetic diagnosis (PGD) for
monogenic disorders allows to prevent birth of affected
child in families with high genetic risk.
Materials and Methods: PGS by aCGH with 24sure kit
or by NGS with Veriseq kit (Illumina). PGD by haplotyping
on ABI3130XL along with restriction analysis.
Results: A total of 3610 embryos were tested for chro-
mosomal abnormalities and 53,7% were found to be aneu-
ploid. Euploidy rate depended on maternal age and ranged
from 59% (<35 years) to 20% (>41 years). Euploidy rate in
oocyte donor cycles was 60%.
Results of PGS by NGS and aCGH were compared and
the only difference was found for mosaicism detection.
Isolated mosaicism was diagnosed in 3% by aCGH and in
12% by NGS.
Analysis for translocations was carried out in 34 IVF
cycles and 126 embryos were analysed, 51 of them euploid.
Out of 75 aneuploid embryos in 15 only anomalies in
chromosomes not involved in translocation were found.
For monogenic PGD, testing systems for 23 different
disorders, Rh and HLA, were developed and veriﬁed on
single cells. Testing systems combined direct mutation
analysis with STR haplotyping. PGD was successfully
implemented in 25 IVF-PGD cycles, with or without PGS
and HLA-matching.
Conclusions: PGS by aCGH and NGS has similar sen-
sitivity for aneuploidy testing, but not for mosaicism. Both
methods are compatible with PGD for monogenic disorders
on the same biopsy specimen.
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Towards optimization of PGD for recurrent t(11;22)
(q23;q11) carrier
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The t(11;22)(q23;q11) is the most frequent reciprocal
translocation in humans. Balanced carriers often have
reproductive problems, such as infertility, recurrent preg-
nancy loss, or the birth of offspring with congenital mal-
formation syndrome called Emanuel syndrome.
Preimplantation genetic diagnosis (PGD) is the useful
solution for such reproductive problems. Since all of the t
(11;22) carriers have the translocation breakpoints within
the small ~500bp regions on 11q23 and 22q11, we can set
up the optimal PGD condition using a sample from a single
typical t(11;22) family. Experiments were performed using
lymphoblastoid cell lines from a patient with Emanuel
syndrome having trisomy of both distal 11q23 and proximal
22q11. Assuming the trophoectoderm biopsy (TE) biopsy,
ﬁve cells were picked up using cell manipulator, and whole
genome ampliﬁcation was performed. For quantitative
analysis of two unbalanced translocation regions on 11q23
and 22q11, we tested oligonucleotide- or BAC-based
microarray as well as next generation sequencing (NGS).
Translocation-speciﬁc PCR was also performed. In general,
NGS detected the unbalanced region better than any of the
microarray platforms, although the sensitivity was not per-
fect at the proximal 22q11 region possibly due to many
segmental duplications. Translocation-speciﬁc PCR worked
without any problems. We conclude that NGS combined
with translocation-speciﬁc PCR is the best way for copy
number analysis of TE biopsied samples from couples of t
(11;22) carrier. (Supported by a grant-in-aid for Scientiﬁc
Research from the MEXT and that from MEWL Japan.)
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First prenatal PIK3CA-related overgrowth spectrum
(PROS) cohort
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Introduction: PIK3CA-related overgrowth spectrum
(PROS) is the umbrella term used to designate phenotypes
caused by PIK3CA postzygotic activating mutations. Even
if prenatal manifestations are described, they rarely lead to
termination of pregnancy, fetal or neonatal death.
Material and methods:We gathered 8 severe fetal cases
suspected of PROS that led to fatal issues. We performed
ultra-deep PIK3CA next-generation targeted sequencing in
several types of fetal tissues, affected or not.
Results: We identiﬁed PIK3CA variants that affect
function for six fetuses (6/8; 75%).
PIK3CA positive fetuses were classiﬁed into two spec-
trums: megalencephaly-capillary malformation (MCAP)
spectrum with cerebral involvement, and congenital lipo-
matous overgrowth, vascular malformation, epidermal
nevus, and scoliosis (CLOVES) spectrum, without cerebral
involvement. All fetal phenotypes were detected during the
second trimester US-scan (table). Autopsies permitted to
precise prenatal data.
The search for mutations in all available tissues permitted
to conﬁrm that mutations are only detectable in affected
tissues.
Conclusion: Most PROS fetuses in our prenatal cohort
had cerebral involvement (4/6; 66.6%), likely due to a
probable bias due to the greater sensitivity of prenatal
screening for brain abnormalities, with a frequency of hot-
spot variants.
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Prenatal fetal phenotypes and pregnancy outcomes
Fetus 1 2 3 4 5 6
Sex F M F M M F
Megalencephaly or
hemimegalencephaly
+ − + − − +
Polymicrogyria − − + − − +
Ventriculomegaly − − + + − −
Dysmorphism + − − + − +
Shortned long bones + − − + − +
Extended
lymphangioma
− + − − + −
Macrosomia + + + + + +
Pregnancy outcomes Terminaison
of pregnancy
Terminaison
of pregnancy
Terminaison
of pregnancy
Terminaison
of pregnancy
Neonatal
death
Death
during
labor
Term of birth/TOP
(WG)
31+0 26+0 27+6 20+5 38+0 30+0
Molecular data
Fetus Phenotype Tissue Affected Protein Variant Allternative allele
count
1 MCAP Lung Yes p.
Phe909Leu
Rare 35%
2 CLOVES Tumor Yes p.
Glu545Lys
Hotspot 10%
2 CLOVES Lung No 0%
2 CLOVES Muscle No 0%
3 MCAP Brain Yes p.
His1047Arg
Hotspot 42%
3 MCAP Brain No 0%
4 MCAP Skin Yes p.
Glu545Lys
Hotspot 5%
4 MCAP Lung No 0%
5 CLOVES Skin Yes p.
His1047Arg
Hotspot 6%
5 CLOVES Liver No 0%
5 CLOVES Skin Yes p.
His1047Arg
Hotspot 24%
6 MCAP Tumor Yes p.Glu110del Rare 19%
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In vitro fertilization has no effect on prevalence of
mosaic copy-number alterations in fetal and placental
lineages
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Chromosomal instability (CIN) is a common phenomenon
in cleavage-stage embryogenesis that leads to a mixture of
euploid and aneuploid cells within the same human embryo
during in vitro fertilization (IVF). However, the rate of CIN
in naturally conceived embryos is largely unknown, because
it is impossible to study human embryos in vivo. Here, we
developed and applied a novel haplarithmisis-based method
to characterize allelic architecture of DNA samples derived
from the placenta and cord blood of the same pregnancy.
Speciﬁcally, we scrutinized genome-wide single nucleotide
polymorphism proﬁles in DNA from the father, mother,
placenta and neonate umbilical cord blood of 55 families
(quartets), of which 26 and 29 quartets were from natural
and IVF pregnancies, respectively. We demonstrate that
CIN is not preserved at later stages of prenatal development,
and that de novo genomic alterations occur at similar rates
in IVF and naturally conceived neonates. The ﬁndings
conﬁrm that IVF treatment has no detrimental effect on the
chromosomal constitution of fetal or placental lineages.
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ciated with severe and early-onset pre-eclampsia
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Introduction: Pre-eclampsia is a vascular pregnancy dis-
order that often involves impaired placental development.
Heme oxygenase-1 (HO-1, encoded by HMOX-1) is a stress
response enzyme crucial for endothelial function and pla-
cental development. Long version of the GTn microsatellite
in the HMOX-1 promoter decreases HO-1 expression, and is
associated with late-onset pre-eclampsia. Our aim was to
study whether the length of fetal repeat is associated with
mother’s pre-eclampsia, and whether maternal serum HO-1
level is altered in pre-eclampsia.
Methods: We genotyped the repeat in the cord blood of
609 pre-eclamptic and 745 non-pre-eclamptic neonates.
Maternal serum HO-1 was measured in the ﬁrst (222 cases/
243 controls) and third (176 cases/53 controls) pregnancy
trimester samples.
Results: The long fetal GTn allele was associated with
pre-eclampsia and early-onset pre-eclampsia, and the long
fetal genotype with pre-eclampsia and severe pre-eclampsia
(additive/dominant models), as well as with early-onset pre-
eclampsia (additive model). Interaction analysis suggested
the maternal and fetal effects to be independent. The ﬁrst or
third trimester maternal serum HO-1 levels were not altered
in pre-eclamptics, but were lower in the carriers of the long
maternal GTn repeat. HO-1 concentration decreased towards
the end of gestation, and also BMI, smoking, age and birth
weight were related to HO-1 level. Experiments are
underway to investigate whether the long fetal repeat
decreases placental HO-1.
Conclusions: The long fetal GTn repeat may increase
mother’s risk of especially severe and early-onset pre-
eclampsia, and the maternal and fetal risk alleles likely
predispose to different disease subtypes.
Grants: AcademyOfFinland, Erkko Foundation, and
others.
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Carrier screening of monogenic hereditary diseases is a
routine practice in at risk families. In Russia, in the absence
of family history, common mutation screening in genes
PAH, CFTR, SMN1 and GJB2 is recommended due to high
prevalence and frequency of carriers. Advances in genomics
made possible to expand traditional preconception screen-
ing to beneﬁt prospective parents. For this reason a diag-
nostic panel including 39 common mutations associated in
the European population with development of more than
20 severe hereditary diseases was designed.
The presence of the mutations was examined in 465
DNA samples including 398 from the patients of IVF
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clinics, 58 from sperm donors and 9 from healthy indivi-
duals. DNA was ampliﬁed in microﬂuidic plates with
TaqMan assays and PCR product detection at the end-point.
Initially, the panel included 48 mutations but 9 mutations
were eliminated during the validation step due to technical
reason or change of clinical status.
As a result mutations c.1521_1523delCTT,
c.1545_1546delTA (CFTR), c.3207C>A (ATP7B),
c.452G>A (DHCR7), c.1903C>T (LAMB3),
c.657_661delACAAA (NBN), c.1062+5G>A (FAH),
c.206C>T (IDUA), c.422G>A (PMM2), c.563A>G (GALT),
c.1423C>T (ADAMTS13) were found in 25 individuals
including a patient with mutations in 2 genes. A homo-
zygous carrier of a mutation in the ATP7B gene was
detected.
Thus, excluding a diagnosed case of hereditary disorder
the carriage of at least one pathological mutation was
identiﬁed in 5.2% of the individuals. The designed diag-
nostic panel can be applied for a carrier screening of severe
hereditary disorders and recommended to prospective par-
ents and donors in the assisted reproduction programs.
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Introduction: Preeclampsia is a multi-systemic disease of
pregnancy and leading cause of maternal and fetal mortality
and morbidity worldwide. The differential expression of
circulating microRNAs were reported in maternal plasma of
pregnant women and they could be stabilized in plasma. In
this regard microRNAs released from placenta to maternal
circulation are potential biomarkers for NIPD. The aim of
this study was to identify expression proﬁles of circulating
miR-1183 and its candidate target genes in maternal plasma.
Materials and Methods: Plasma samples were obtained
at 37–39 weeks of gestation from 31 women who developed
preeclampsia (cases) and 26 women with normotensive
pregnancies (controls). The expression of miR-1183 was
determined using RT-qPCR and comparative Ct method
relative to synthetic C.elegans microRNA (cel-miR-39).
CHURC1 was selected as putative target gene of miR-1183.
Correlation of miR-1183 and CHURC1 expression levels
were analyzed with Pearson’s correlation coefﬁcient (95%
CI). The diagnostic performance of mir-1183 and CHURC1
were assessed by receiver operating characteristic (ROC)
curve analysis.
Results and Conclusions: mir-1183 was signiﬁcantly
overexpressed (p = 0.0068) whereas its target gene
CHURC1 was signiﬁcantly down-regulated (p<0.001) in
maternal plasma of cases compare to controls. Pearson
correlation analysis revealed that mir-1183 expression was
inversely correlated with CHURC1. The area under the
ROC curve (AUC) of miR-1183 and CHURC1 were 0.90
and 0.96 respectively (95%CI) indicated that their expres-
sion can discriminate between cases and controls. These
ﬁndings reveal that circulating CHURC1 can be involved in
preeclampsia pathogenesis and circulating miR-1183 could
contribute to disease pathology functioning through reg-
ulating CHURC1.
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X-linked СNVs in women with idiopathic pregnancy loss
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Introduction: Skewed X-chromosome inactivation is
associated with some human pathology including preg-
nancy loss. According to our data the population frequency
of extremely skewed (threshold >90%) X-chromosome
inactivation in women with miscarriage is 8%. The possible
reasons for the skewed X-chromosome inactivation are
lethal mutations in X-linked genes or aberrations of one of
the X-chromosome.
Material and Methods: In our study, pathogenic CNVs
on X-chromosomes, which may be the cause of skewed X-
chromosome inactivation and pregnancy loss were ana-
lyzed. These CNVs were detected by array CGH using
SurePrint G3 Human CGH+SNP 4×180K Microarray Kit
(Agilent Technologies, USA) in lymphocytes of 5 women
with idiopathic pregnancy loss and extremely skewed X-
chromosome inactivation (>95%).
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Results: One woman had dupXp22.33 (1.7 Mb),
whereas other - delXq24 (239 kb) containing 15 genes
(PLCXD1, GTPBP6, LINC00685, PPP2R3B, SHOX,
CRLF2, CSF2RA, MIR3690, MIR3690-2, IL3RA, SLC25A6,
ASMTL, P2RY8, AKAP17A, ASMT) and 8 genes
(SLC25A43, SLC25A5-AS1, SLC25A5, CXorf56, UBE2A,
NKRF, SEPT6, MIR766), respectively. Products of these
genes are involved in cell proliferation, differentiation and
post-transcriptional regulation of gene expression in multi-
cellular organisms.
Conclusions: An excess or deﬁciency of gene expression
can potentially affect cell cycle arrest and lead to skewed X-
chromosome inactivation in maternal cells, and fetal death.
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Protein A (PAPPA) in human placenta
M. Majewska1, A. Lipka2, L. Paukszto3, J. Jastrzebski3, M.
Gowkielewicz2, M. Jozwik2, A. Bossowska1, M. Majewski1
1Department of Human Physiology, Faculty of Medical
Sciences, University of Warmia and Mazury, Olsztyn,
Poland, 2Department of Gynecology and Obstetrics,
Faculty of Medical Sciences, University of Warmia and
Mazury, Olsztyn, Poland, 3Department of Plant Physiology,
Genetics and Biotechnology, Faculty of Biology and
Biotechnology, University of Warmia and Mazury, Olsztyn,
Poland
Introduction: Human placenta ﬁnely tunes expression of
various genes essential in pregnancy maintenance and
development of the fetus. Any alterations in expression
level of speciﬁc genes and its further processing may
indicate the major molecular mechanisms underlying
pathological pregnancies. Alternative splicing (AS) can
generate various transcripts and hence multiple protein
isoforms from a single gene. Regulation of alternative
splicing events in multi-exon genes not only affects
expression level or protein function, but can also lead to
differences in AS between human individuals. Pregnancy-
associated plasma protein A (PAPPA) is a metalloprotease
belonging to the metzincin superfamily of zinc peptidase.
During pregnancy PAPPA is produced at high levels by the
placenta and circulates as a heterotetrameric complex.
Decreased levels of this complex are associated with
adverse pregnancy outcomes such as IUGR, preterm
delivery, miscarriage, preeclampsia or fetal aneuploidy. The
goal of this study was to identify novel sequence and splice-
junction within PAPPA.
Materials and Methods: NGS was performed to iden-
tify the pattern of PAPPA expression in placentas (N= 4)
from women in single and twin pregnancies. Moreover, in
silico sequence analysis was performed to estimate potential
inﬂuence of AS on structure, function and physicochemical
properties.
Results: Our thorough analyses of placental tran-
scriptome permitted the identiﬁcation of novel alternative
splice junction of PAPPA. In addition we predicted sec-
ondary structure of PAPPA protein.
Conclusions: We can assume that the novel identiﬁed
placental transcripts may contribute to pregnancy course,
but further functional analyses are required to state how
they affect pregnancy outcome.*Supported by UWM
(WNM#25.610.001-300).
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Preimplantation genetic diagnosis (PGD) allows families to
assure their child’s health regarding genetic disorders before
pregnancy and also can prevent medical abortion. this
method, diagnoses perform on blastomers biopsied from 8-
cell stage embryos that are created by in vitro fertilization
method (IVF). PGD combine with HLA typing is a strategy
to select healthy HLA-matched embryos as a potential
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donor for stem cell transplantation of the affected sibling.
Here we present application of molecular PGD to select
healthy HLA-matched embryo as a donor for Recessive
Dystrophic Epidermolysis Bullosa (RDEB). RDEB is a
severe inherited skin disorder which blisters affect the
whole body. A family with a 17 years old affected child
with RDEB was referred to our laboratory. Peripheral blood
samples were collected and genomic DNA was extracted
using salting out method. Mutation detection in COL7A1
gene was carried out using direct sequencing method.
Fragment analysis and haplotype mapping were performed
to track the defective alleles in the family. On day 3 post
fertilization one or two blastomers were removed from each
embryo. Selected mutation (COL7A1:c.6994C>G) was
investigated using direct sequencing and informative STR
markers (17 loci for HLA and 8 for Col7A1) were checked
in the family using nested PCR method. A healthy HLA-
matched embryo was selected and implanted to mother’s
uterus. From 6 blastomeres, only one was suitable for
transfer. Prenatal diagnosis was performed at 16th week of
gestational age which conﬁrmed PGD result. The child was
born and she was healthy according tothe pediatric derma-
tologist examination.
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Introduction: Clinical studies of children born after PGD
in other countries report some concern regarding adverse
perinatal and neonatal outcomes. We collated data on the
congenital malformation rate, misdiagnosis rate, birth
parameters, perinatal mortality and hospital admissions
from a cohort of Dutch children born after PGD.
Materials and Methods: Data on all Dutch PGD preg-
nancies between 1995 and 2014 and corresponding peri-
natal outcome were prospectively collected by
questionnaires ﬁlled out by the couples and from the med-
ical ﬁles of the mothers and the children. A retrospective
analysis of the cohort was performed.
Results: 439 pregnancies in 381 women resulted in 364
live born children. Nine children (2.5%) had major mal-
formations. This percentage is consistent with other PGD
cohorts and comparable to the prevalence reported by the
European Surveillance of Congenital Anomalies (EURO-
CAT). We reported one misdiagnosis resulting in a spon-
taneous abortion of a fetus with an unbalanced chromosome
pattern. Due to twin pregnancies almost 20% of the children
were born premature (<37weeks) and less than 15% had a
low birth weight. The incidence of hospital admissions is in
line with prematurity and low birth weight rate. One child
from a twin, one child from a triplet and one singleton died
at 23, 32 and 37 weeks of gestation respectively.
Conclusions: this ﬁrst report of the children of the Dutch
PGD cohort does not show an increased risk of major
malformations or adverse perinatal outcome, compared to
other PGD cohorts from the literature and naturally con-
ceived children.
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Implementing preimplantation genetic screening: our
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N. Bilbao-Aldaiturriaga, M. Barasoain-Hernandez, A.
Gallastegi-Perez, I. Cela-Dapena, J. Valle-Artetxe, D.
Gonzalez-Abreu, L. Bretaña-García de Andoín, A. Tio-
Castro, I. Davalillo-Bilbao
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Aneuploidy is the major leading cause of age-related
decline in fertility. Indeed, it has been described as the
main reason for failed implantation and development to
term. Preimplantation genetic screening (PGS) provides
chromosomal information of each embryo avoiding aneu-
ploid embryos transfer and increasing implantation rates.
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This technique has been optimized in cleavage-stage
embryo, however it has been shown that biopsies in this
stage impair human embryonic implantation while blas-
tocyst biopsy does not. Moreover, this technique has been
shown to be much more robust, reliable and less harmful for
embryos. For these reasons, our team sifted to blastocyst
biopsies. The aim of this work was to evaluate implantation
rates in cleavage-stage and blastocyst biopsies and conﬁrm
the beneﬁts of blastocyst biopsies. A total of 208 patients
went to PGS from 2013 to 2016. Of these, 183 underwent
cleavage-stage biopsy and 25 experienced blastocyst
biopsy. Array comparative genomic hybridization (aCGH)
was used for cleavage-stage biopsy while next generation
sequencing (NGS) for blastocyst biopsy. Interestingly, from
2015 to 2016 we observed a decrease in evolutionary
pregnancy rate in patients >38 years (53.84% in 42 patients
vs. 32.14% in 49) which is increasing thanks to blastocyst
biopsy. Indeed, we reached almost the same evolutionary
pregnancy rate having half of blastocyst biopsies (20% in
11 patients vs. 32.14% in 49). We also conﬁrmed the cor-
relation between chromosomal alterations observed in
embryos and its morphology. Our results support the suit-
ability of blastocyst biopsy in clinical practice.
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Introduction: The diagnostic value of the prenatal array
testing has been well established in cases of fetal ultrasound
anomalies. Despite substantial case studies are reported in
the literature, some issues remain controversial.
Methods: All examined cases have been select by
gynecologists very experienced in prenatal ultrasound
diagnosis. After excluding karyotype abnormalities, the
samples (CVS or amniotic ﬂuid) have been analyzed with
CytosureTM v2 array 180K. Array results have been sub-
classiﬁed in pathogenic abnormalities (causative, unex-
pected or susceptibility loci) and VOUS.
Results: Overall more than 400 fetuses were analyzed, of
which 300 with malformations well characterized at the US
examination, especially involving the cardiovascular
system. In such cases the additional detection rate of
genomic imbalances (CNVS) not detectable at karyotype
analysis, is about 7.5% (VOUS 2.8%). The remaining
100 samples are from fetuses with NT ≥ 3.5 mm (99centile).
In these cases we are in the presence of a more limited
diagnostic impact, whereas it reaches a DR of about 3.6%,
quite similar to that of VOUS.
Discussion: Accurate US characterization of malforma-
tions appears to highlight as the prenatal array testing is not
useful in the presence of some defects such as muscular
ventricular septal defects or urogenital anomalies, especially
in relation to the potential ﬁnding of VOUS. Our data
suggest also considerable caution in counseling path in the
presence of an increased NT, also for the possible medical-
legal implications for failure detection of a genomic aber-
ration in pregnancies classiﬁed at risk even in the presence
of a normal karyotype.
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Severe ultrasound abnormalities: prenatal whole exome
sequencing to unravel a diagnosis before birth
A. C. J. Gijsbers, D. Smeets, R. Pfundt, E. Kamsteeg, I.
Feenstra, M. Willemsen, I. van der Burgt, E. Sikkel, H. G.
Yntema, K. Neveling, M. Nelen
Radboudumc, Nijmegen, Netherlands
The introduction of whole exome sequencing (WES) in
genome diagnostics has dramatically changed the current
practice in clinical genetics. However, routine application of
WES in a prenatal setting for genetic analysis of fetuses
with multiple congenital abnormalities is not yet widely
accepted. Since a genetic diagnosis can be extremely
helpful for treatment decisions immediately after birth, we
decided to use our rapid WES set-up for late pregnancy
prenatal cases.
We performed a trio analysis using WES for two fetuses
with severe ultrasound abnormalities (>24 weeks) and
parents. After extensive counseling of the parents and get-
ting consent, a report could be issued within two weeks.
Although we were not able to make a diagnosis for these
two fetuses, this study shows the feasibility and utility of
WES in ongoing pregnancies.
Currently, we have introduced a WES workﬂow for
pregnancies >24 weeks, of fetuses with severe ultrasound
abnormalities which are expected being admitted to the
neonatal intensive care unit (NICU). Since in the Nether-
lands termination of pregnancy is not an option in these
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cases, reporting of variants is similar to postnatal cases.
Before extending prenatal WES towards pregnancies
<24 weeks, clear criteria and guidelines are necessary,
mainly on the disclosure of variants of uncertain patho-
genicity and incidental ﬁndings. Here, we will present the
current workﬂow, and discuss options for a possible fra-
mework for earlier pregnancies. It is expected that WES and
ultimately whole genome sequencing will replace current
routine clinical practice (array based technologies), not only
after birth but also during pregnancy.
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Mascarenhas1, A. Jardim1, M. C. Pinto1, C. Pais1, E.
Galhano2, M. Branco2, A. I. Rei2, H. Gonçalves3, J. B.
Melo1,4,5, I. M. Carreira1,4,5
1Laboratório de Citogenética e Genómica, Faculdade de
Medicina da Universidade de Coimbra, Coimbra, Portugal,
2Maternidade Bissaya Barreto, Centro Hospitalar e Uni-
versitário de Coimbra, Coimbra, Portugal, 3Maternidade
Daniel de Matos, Centro Hospitalar e Universitário de
Coimbra, Coimbra, Portugal, 4CIMAGO - Centro de
Investigação em Meio Ambiente, Genética e Oncobiologia,
Coimbra, Portugal, 5CNC-IBILI, Universidade de Coim-
bra, Coimbra, Portugal
A partial deletion of the long arm of the chromosome 13 is
an unusual chromosomal aberration related with a wide
spectrum of clinical phenotypes.
In prenatal a vast number of these chromosomal
abnormalities are diagnosed after the detection of ultra-
sound alterations. In this work we report a set of ﬁve cases
with different deletions diagnosed by different techniques.
Only one pregnancy had an apparently normal ultrasound
and was referred because of advanced maternal age, while
the other four had evident ﬁndings of foetal anomalies and
were, therefore, referred for prenatal diagnosis. All cases,
except the one referred for maternal age, were identiﬁed
and/or characterized by array-CGH 180K. The pregnancy
with an apparently normal ultrasound showed to be a de
novo 13q32.3 to 13qter deletion. Two other cases had
interstitial deletions at 13q34 and 13q31.3. The more distal
one had a high nuchal translucency measurement while the
del(13)(q31.3) had cardiac abnormalities. The most severe
ultrasound anomalies, including brain malformations, were
associated with two de novo large terminal deletions of 40
Mb and 52Mb at 13q22.1 and 13q21.2, respectively. The
literature refers 13q32 deletion as a critical region asso-
ciated with serious congenital malformations, particularly
central nervous system anomalies. Our cases are consistent
with this data. The largest deletions, including 13q32, had
ultrasounds with severe brain disorders, highlighting this
region as critical for central nervous system disorders.
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M. W. Joergensen, N. H. Becher, D. L. Lildballe, I. Vogel
Department of Clinical Genetics, Aarhus University
Hospital, Aarhus, Denmark
Introduction: Costello syndrome (CS) is a rare condition
which arises due to heterozygous germline mutations in
HRAS. In CS, more than 80% of the mutations found,
causes the amino acid changes p.G12S or p.G12A. These
patients have a relatively homogenous phenotype char-
acterized by developmental delay, severe failure to thrive,
cardiac problems, typical coarse facial features and a pre-
disposition to malignancies. A few reports of a very rare but
far more severe and lethal neonatal CS phenotype have been
published. Here, mutations causing amino acid changes p.
G12V, p.G12D or p.G12C have been found. We now add to
this phenotypic description and for the ﬁrst time report two
cases of prenatal CS causing intrauterine death.
Materials and methods: Two separate cases were
diagnosed in our tertiary university hospital clinic.
Although there were several differences, the similarities
were striking: Both presented in ﬁrst trimester with severely
increased nuchal transluceny but a normal chromosomal
microarray. In second trimester polyhydramnios, decreased
foetal movement, macrocephaly, microopthalmus, altered
cardiac axis, and increased abdominal circumference were
found. Despite treatment of polyhydramnios intrauterine
death was diagnosed. Autopsies conﬁrmed the prenatal
ﬁndings and described additional dysmorphic features.
Subsequently trio whole-exome sequencing was performed.
Results: A de novo HRAS mutation was found in the
foetuses p.G12V and p.G12D respectively.
Conclusion: Diagnosing CS prenatally is challenging
and might previously have been missed as a cause of
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intrauterine death. The two cases presented provide further
evidence for recognisable and severe phenotype in CS
caused by p.G12V and p.G12D and expands the phenotypic
description.
M.W. Joergensen: None. N.H. Becher: None. D.L.
Lildballe: None. I. Vogel: None.
P01.096D
Mendeliome and Whole Exome Sequencing in 60 fetuses
with abnormal ultrasound revealed a diagnostic yield of
30%
P. Joset1, J. Wisser2, D. Niedrist1, K. Steindl1, R. Müller†3,
M. Papic1, M. Zweier1, L. Gogoll1, S. Azzarello-Burri1, A.
Baumer1, B. Oneda1, A. Rauch1
1Institute of Medical Genetics, University of Zurich,
Schlieren-Zurich, Switzerland, 2Division of Obstetrics,
University Hospital Zurich, Zurich, Switzerland, 3private
clinic, Winterthur, Switzerland
Only few studies with small numbers about Whole Exome
Sequencing (WES) on prenatal cases with abnormal ultra-
sound ﬁndings are published yet. Since we have success-
fully established NGS on postnatal cases with a diagnostic
yield of almost 50% we performed Mendeliome-sequencing
and WES on a larger cohort of prenatal and aborted cases.
From a total of 60 fetuses with various malformations
pathogenic mutations were found in 18 cases resulting in a
diagnostic yield of 30%. Mutations were found in 17 dif-
ferent genes with NIPBL being the only recurrently mutated
gene (2×). 56% of the diagnoses followed an autosomal
recessive inheritance pattern and 44% were autosomal
dominant with all but one mutations occurring de novo.
Regarding the clinical presentations known from postnatal
syndrome descriptions, some of the phenotypes were
unexpectedly severe. Notably, in one case with suspected
Neu-Laxova-syndrome we found compound heterozygosity
for a deleterious missense mutation in the gene PHGDH and
a CNV deleting 6.8kb of the 3′UTR including part of the
last coding exon. In another case with suspected Meckel
syndrome we found a 28 bp intronic deletion in-trans with a
synonymous substitution affecting splicing in MKS1.
Finally, in 2 cases with multiple severe ultrasound
abnormalities we detected new disease causing candidate
genes. In urgent cases turn-around-time was 2 weeks. We
conclude that an overall diagnostic yield of 30% on prenatal
and aborted samples establishes NGS as a very useful
approach. Moreover, NGS screening in fetuses with severe
pre- and neonatal phenotypes may reveal mutations under-
represented in postnatal observations.
P. Joset: None. J. Wisser: None. D. Niedrist: None. K.
Steindl: None. R. Müller†: None. M. Papic: None. M.
Zweier: None. L. Gogoll: None. S. Azzarello-Burri:
None. A. Baumer: None. B. Oneda: None. A. Rauch:
None.
P01.097A
maternal and neonatal leptin and leptin receptor poly-
morphisms are associated with preterm birth
H. Salem1, T. Rosenfeld2, G. Altarescu3, S. Grisaru-
Granovsky4, R. Birk1
1Department of Nutrition, Health Sciences, Ariel University,
Ariel, Israel, 2Department of Nutrition, Health Sciences,
Ariel University and Genetics Unit and Department of
Obstetrics & Gynecology, Shaare Zedek Medical Center,
Ariel and Jerusalem, Israel, 3Genetics Unit and Department
of Obstetrics & Gynecology, Shaare Zedek Medical Center,,
Jerusalem, Israel, 4Department of Obstetrics & Gynecol-
ogy, Shaare Zedek Medical Center, Jerusalem, Israel
Introduction: Leptin (LEP) and leptin receptor (LEPR) are
suggested to play a role in female reproduction and preg-
nancy. Both LEP and LEPR are synthesized by the pregnant
female and embryo. The link between genetic polymorph-
isms of LEP and LEPR and preterm birth (PTB) is
unknown. We studied maternal and neonatal LEP and
LEPR genetic polymorphisms and the association with
PTB.
Materials and methods: Blood for DNA analysis was
collected from Israeli mothers and from venous umbilical of
their respected idiopathic preterm newborns (24–36 weeks,
n= 102) and control term newborns (>37 weeks, n= 158).
Genotypes of maternal and neonatal LEP (rs7799039) and
LEPR (rs1137101(polymorphisms were analyzed by
restriction fragment length polymorphism analysis.
Genotype-phenotype association was assayed using SPSS
program.
Results: We found a signiﬁcant independent increased
risk of PTB for women and neonates bearing the homo-
zygous AA form of LEP genotype; where women carrying
AA LEP genotype had 2.53 fold ([CI]1.367 - 4.685,
p=0.03) and 2.38 fold ([CI] 1.150–4.915, p=0.019)
increased risk for PTB compared to AG and GG genotypes,
respectively. Neonates carrying the LEP AA genotype had a
signiﬁcant 2.8 fold increased risk for PTB compared to the
AG genotype (CI11.040–7.577, p=0.042). Maternal LEPR
polymorphism was signiﬁcantly associated with severe
PTB; where women carrying the AA and AG genotypes had
a signiﬁcant 4.32 and 4.76 fold increased risk for severe
PTB compared to women carrying the GG genotype
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(CI=1.090–17.112 and 1.332–17.027, respectively
p=0.035).
Conclusion: maternal and neonatal LEP and LEPR
polymorphisms are signiﬁcantly associated with increased
risk for PTB.
H. Salem: None. T. Rosenfeld: None. G. Altarescu:
None. S. Grisaru-Granovsky: None. R. Birk: None.
P01.098B
Single Nucleotide Polymorphism (SNP)-based Products
of Conception (POC) chromosome analysis identiﬁes
molar pregnancy and terminal imbalances to guide
medical management
M. K. Maisenbacher1, K. Merrion1, D. Clark1, L.
Campbell1, K. Howard1, J. Zoladz1, E. Thomas1, M.
Yavari1, K. Hashimoto1, M. Young1, S. Sigurjonsson1, W.
Kutteh2
1Natera, San Carlos, CA, United States, 2Fertility Associ-
ates of Memphis, Memphis, TN, United States
Introduction: Molar pregnancy and chromosome rearran-
gements carry risks for couples, including maternal gesta-
tional trophoblastic disease/neoplasia (GTD), miscarriages,
and chromosomally abnormal offspring. SNP microarray
performed on POC samples identiﬁes these at-risk couples.
Materials and Methods: Retrospective analysis of
26,102 fresh POC samples with parental samples genotyped
using Illumina CytoSNP-12b microarrays with bioinfor-
matics to identify parental origin of abnormalities. Results
of full paternal UPD, paternal triploidy, or one or more
terminal imbalance(s) were identiﬁed. Clinical history and
parental chromosome results were requested with IRB
approval.
Results: 22,452 cases had fetal results: 638 (2.8%) had
paternal triploidy, 72 (0.3%) had full paternal UPD, and 403
(1.8%) had ≥1 terminal segment imbalance(s). Follow-up
was obtained for 221 (31%) molar pregnancy cases and 107
(27%) terminal segment cases. 53 molar pregnancy cases
(24%) were identiﬁed by ultrasound and/or pathology.
Sixty-six (62%) cases at risk of parental chromosome
rearrangement(s) had follow-up studies done; 30 (46%)
reported parental balanced rearrangements.
Conclusions: Genetic testing of POC samples identiﬁes
molar pregnancy, which carries a risk of up to 25% for
maternal GTD, and terminal chromosome imbalances,
which inﬂuence recurrence risk counseling. Without genetic
testing, up to 75% of women at risk for GTD might not be
identiﬁed as at risk. For couples at risk for parental chro-
mosome rearrangement(s), knowing the parental origin of
the fetal ﬁnding prevents unnecessary testing in the other
parent. Expanding pregnancy-loss workups beyond routine
studies to include SNP-based chromosome analysis is use-
ful for medical management.
M.K. Maisenbacher: A. Employment (full or part-
time); Signiﬁcant; Natera. E. Ownership Interest (stock,
stock options, patent or other intellectual property); Modest;
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intellectual property); Modest; Natera. S. Sigurjonsson: A.
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A comprehensive contribution of endothelial dysfunc-
tion genes to recurrent miscarriage susceptibility
E. Trifonova1, T. Gabidulina2, O. Ganzha2, V. Stepanov1
1Research Institute of Medical Genetics, Tomsk, Russian
Federation, 2Siberian State Medical University, Tomsk,
Russian Federation
The roles of genetic polymorphisms in the pathogenesis of
recurrent miscarriage (RM) have been intensively studied.
Complex diseases, including miscarriage are believed to
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have a polygenic basis and gene-gene interactions can play
a signiﬁcant role in the etiology of the disease. This study
was conducted to investigate the association of gene-gene
interaction of endothelial dysfunction genes polymorphisms
and RM. A total of 592 unrelated Russian women com-
prising 253 RM patients and 339 healthy controls were
recruited into the study. Seven functional SNPs were
selected from ACE, MTHFR, SERPINE-1, NOS3, TP53
and VEGF genes based on our previous studies. Two
receptor gene polymorphisms (G634C and C936T VEGF
gene) were signiﬁcantly associated with idiopathic RM (P <
0.001). We found that polymorphism C677T MTHFR gene
is associated with an increased risk of RM (P < 0.04),
whereas polymorphism G894T NOS3 of NOS3 gene
showed an association with a decreased risk of disease (P <
0.02). By Multifactor dimensionality reduction analysis, a
two-locus model (C936T and G634C of VEGF) of gene-
gene interaction was the best for predicting RM risk, and its
maximum testing accuracy was 67.4% and maximum cross-
validation consistency was 10/10. In addition, it was shown
that the interaction of ACE, SERPINE-1 and TP53 genes
has a synergistic effect on the risk of RM. The gene-gene
interaction between MTHFR, NOS3 and VEGF are addi-
tive. Our study was to show that gene-gene interactions of
genes inducing endothelial dysfunction represent important
determinants for the development of RM. This work was
supported by the Russian Foundation for Basic Research.
E. Trifonova: None. T. Gabidulina: None. O. Ganzha:
None. V. Stepanov: None.
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Restrictive dermopathy: novel ZMPSTE24mutation and
clues for prenatal diagnosis
A. Ferraris1, V. Guida2, E. Marchionni1,3, L. Menale1,3, G.
Fatigante4, F. Piceci Sparascio2, A. Giovannetti3, T.
Mazza5, V. Caputo3, A. De Luca2, A. Pizzuti3
1IRCCS Casa Sollievo della Sofferenza - Mendel Institute,
Clinical Genetics Unit, Rome, Italy, 2IRCCS Casa Sollievo
della Sofferenza - Mendel Institute, Molecular Genetics
Unit, Rome, Italy, 3Sapienza University, Department of
Experimental Medicine, Rome, Italy, 4Santo Spirito Hospi-
tal, Obstetrics and Ginecology Unit, Rome, Italy, 5IRCCS
Casa Sollievo della Sofferenza - Mendel Institute, Bioinfor-
matics Unit, Rome, Italy
Introduction: Restrictive dermopathy (RD) is a rare lethal
genodermatosis caused by either heterozygous mutations in
the lamin A/C gene (LMNA) or by biallelic mutations in the
zinc metalloproteinase STE24 gene (ZMPSTE24).
Patients and Methods: In a couple of apparently non
consanguineous parents, two consecutive pregnancies were
complicated by oligohydramnios, premature rupture of
membranes, preterm delivery, and similar foetal abnormal-
ities detected by ultrasonography, including intrauterine
growth restriction, dysmorphisms and reduced foetal
movements. Both male babies shared at birth facial dys-
morphisms, proximal and distal arthrogryposis, and a pro-
geroid appearance suggestive of a laminopathy. The ﬁrst
one was a stillborn at 31 weeks of gestation, while the
second one, born at 28 weeks, died at 8 days. A DNA
sample of the second child and his parents was obtained to
perform genetic tests, including cytogenomic microarray
and next generation sequencing.
Results: A homozygous splicing mutation in the
ZMPSTE24 gene was identiﬁed in the second child. Both
parents were heterozygous carriers. This novel frameshift
mutation, determining exon 7 skipping and introducing a
premature stop codon, is compatible with the severe RD
phenotype observed in both children. Analysis of LMNA
and array-CGH were negative.
Conclusions: While the postnatal RD phenotype can be
fairly recognizable, an extensive description of prenatal
ultrasound ﬁndings is lacking. Comparing data of present
patients with a review of the literature, we suggest that
several foetal anomalies are recurrent in RD and its recog-
nizable combination should help the prenatal diagnosis of
this condition.
A. Ferraris: None. V. Guida: None. E. Marchionni:
None. L. Menale: None. G. Fatigante: None. F. Piceci
Sparascio: None. A. Giovannetti: None. T. Mazza: None.
V. Caputo: None. A. De Luca: None. A. Pizzuti: None.
P01.101A
Transcriptional regulation of Septin12
Y. N. Teng1, J. Y. Tseng1, P. L. Kuo2, C. Y. Wu1, M. S.
Wu1, H. Y. Chen1, M. T. Su2, Y. C. Hou1, C. C. Hsu3
1Department of Biological Sciences and Technology,
National University of Tainan, Tainan, Taiwan, 2Depart-
ment of Obstetrics & Gynecology, National Cheng Kung
University, College of Medicine, Tainan, Taiwan, 3Gradu-
ate Institute of Medical Science, Chang Jung Christian
University, Tainan, Taiwan
Introduction: The human Septin12 was originally identi-
ﬁed by cDNA microarray as one of the genes down-
regulated in the testicular tissues of patients with severe
spermatogenic defects. Some studies showed that Septin12
+/-chimeric mice suffer from severe spermatogenic defects,
including immotile sperm, sperm with a bent tail, round-
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headed sperm, and sperm with acrosomal defects. Those
studies indicated that Septin12 played a critical role in the
process of spermatogenesis. However, the transcriptional
regulation of Septin12 in the spermatogenesis is still
unclear.
Materials and Methods: The core promoter region of
Septin12 was identiﬁed using the luciferase reporter gene
assay. Bioinformatics prediction showed that Septin12 core
promoter region contains binding sites of estrogen receptor
(ER) and androgen receptor (AR). In addition, chromatin
immunoprecipitation analysis conﬁrmed the basal binding
activity of ER and AR to the Septin12 promoter. The
transcription activity and expression of Septin12 was
assayed by reporter assay and real-time PCR under estrogen
or androgen treatment.
Results: Septin12 promoter activity was positively
regulated by estrogen and androgen. Mutation of ER or AR
binding sites decreased the luciferase activity; therefore, the
ER and AR were very important transcription factors for the
Septin12 promoter activity.
Conclusion: Our data suggest that steroid hormones are
important modulators for the transcription and expression of
Septin12 in spermatogenesis. Septin12 could serve to
develop as gene indicator for environmental endocrine
disrupting and steroid hormone. Acknowledgments: This
study was supported by grants from Ministry of Science and
Technology (MOST 103-2314-B-024-001, MOST 104-
2314-B-024-001, MOST 105-2314-B-024-001) of Taiwan.
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Preimplantation genetic testing of monogenic diseases
and aneuploidies using single blastocyst biopsy
approach
L. Volozonoka1,2, D. Perminovs2, L. Korņejeva2, I.
Kempa1, A. Miskova1, O. terna3, V. Fodina2
1Riga Stradins University, Riga, Latvia, 2“IVF Riga”
Reproductive Genetics Clinic, Riga, Latvia, 3Children’s
University Hospital, Riga, Latvia
Introduction: Preimplantation genetic testing (PGT) pro-
tocol development is challenging due to ampliﬁcation fail-
ure, DNA contamination and allele dropout (ADO) risk.
Improvements are achieved through combining direct and
indirect testing, performing whole genome ampliﬁcation
(WGA), excluding aneuploidies for single gene disorder
PGT. The aim of study was to develop robust and afford-
able protocol. We present our experience for families with
autosomal recessive congenital ichthyosis (ALOX12B) and
Huntington disease (HTT).
Materials and methods: WGA for blastocyst single
biopsies were carried out by MDA technology. Gene
adjacent microsatellites were selected using UCSC data-
base, semi-nested PCR primer system was designed for
STR testing. Aneuploidy testing were done by aCGH.
Results: STR haplotyping of family members revealed
14 out of 15 informative markers for ALOX12B-case and
ﬁve out of 13 for HTT-case. All embryos analyzed (seven in
ALOX12B-case and eleven in HTT-case) resulted in suc-
cessful WGA. After STR testing in case of ichthyosis two
embryos had normal genotype, seven were heterozygotes,
three affected, six were mutation-free in HTT-case. ADO
rate was 0.04%. HTT CAG repeat sizing conﬁrmed results
for haplotyped embryos. Single euploid embryo transfers
resulted in clinical pregnancies in both cases.
Conclusions: Single biopsy WGA ensures possibility of
multifactor PGT. Semi-nested testing system minimizes
misdiagnosis risk due to ADO, non-speciﬁc ampliﬁcation or
contamination and can be used without direct mutation
testing. Aneuploidy testing excludes leading PGT failed
implantation cause. These are ﬁrst single gene PGT cases
carried out in Latvia, developed approach can be further
conveniently applied for families seeking alternatives for
prenatal testing.
L. Volozonoka: None. D. Perminovs: None. L. Korņ-
ejeva: None. I. Kempa: None. A. Miskova: None. O.
terna: None. V. Fodina: None.
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Single-cell RNA-seq proﬁling of human preimplantation
8-cell embryos reveals phenotype-dependent expres-
sional patterns
N. Li1, L. Sun2, X. Fang1, Z. Chen2, F. Tian2, Z. Zhou1, Z.
Ou2, X. Peng1, Z. Zhang1, H. Hu1
1Guangzhou Institute of Pediatrics, Guangzhou Women and
Children’s Medical Center, Guangzhou, China, 2Depart-
ment of Reproductive Medicine, Guangzhou Women and
Children’s Medical Center, Guangzhou, China
Assisted reproduction entails standardized preimplantation
embryo grading, which typically assesses an embryo in
terms of fragmentation, symmetry, multi-nucleation,
vacuoles, and zona pellucida. In the era of single-cell –
omics, in-depth work is needed to recapitulate the criteria
by expressional proﬁles of each blastomere.
We apply single-cell RNA sequencing (RNA-seq) tech-
nology in retaining high-quality single-cell transcriptomes
from E3 human preimplantation 8-cell embryos. In sum, 22
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embryos are involved, among which 10 (45.5%), 6 (27.3%),
4 (18.2%), 2 (9.1%) are labeled ‘A’ to ‘D’ by the conven-
tional assessment, respectively. Each blastomere is tran-
scriptional analyzed in a step-wise way of quality control,
alignment, assembly, expression level calculation, annota-
tion in genomic context. We conduct WGCNA and IPA
analyses to classify genes into functional categories.
The transcriptomes from 176 blastomeres are sequenced,
and 174 cells meet with the quality criteria for further
analysis. The 79 grade ‘A’ cells show high correlation with
the published human 8-cell embryo results (Pearson corre-
lation coefﬁcients average 0.92). The intra-embryo corre-
lations between blastomeres are as high as 0.97. Both
results prove high reproducibility of this study. There are 14
functional modules drawn from the expression proﬁles, with
clear enrichment for genes involved in cell division, RNA
processing, and ribosome biogenesis. Intriguingly, low
graded blastomeres present signiﬁcant change in 3 modules.
Especially, 2 genes persistently show biased expression in
blastomeres with high fragmentation, a typical manifesta-
tion of low-quality. Our hitherto results shed light on the
molecular mechanism behind the embryo grading and ren-
der more hints in human early development.
N. Li: None. L. Sun: None. X. Fang: None. Z. Chen:
None. F. Tian: None. Z. Zhou: None. Z. Ou: None. X.
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Whole exome sequencing identiﬁes novel SLC26A2
mutation resulting diastrophic dysplasia
E. G. Okuneva1, D. O. Korostin1, D. Borisevich1, N. A.
Altynnik2, E. V. Sypchenko2
1Genotek Inc, Moscow, Russian Federation, 2Federal state
budgetary education institute of additional professional
education «The Institute of advanced training of Federal
medical-biological Agency, Moscow, Russian Federation
Mutations in the SLC26A2 (DTDST) gene cause rare
autosomal recessive related diseases including achon-
drogenesis, atelosteogenesis, De la Chapelle dysplasia,
diastrophic dysplasia and multiple epiphyseal dysplasia.
These diseases share a number of clinical features, in par-
ticular diastrophic dysplasia (DTD) characterised by short-
limb dwarﬁsm, hearing loss, cleft palate, and normal intel-
ligence. /
The SLC26A2 gene encodes a novel sulfate transporter.
Impaired function of DTDST product would be expected to
lead to undersulfation of proteoglycans in cartilage matrix
and thereby to cause a clinical phenotype such as dia-
strophic dysplasia. Prenatal History: A 29 year old Russian
woman at 19–20 weeks gestation after serial ultrasounds
showed intrauterine shortened tubular bones, abnormal pes
ﬁxing, restricted knee movement, adducted thumbs,
micrognathia. Platsentobiopsiya by an outside institution
reported a normal male karyotype. Previous pregnancy was
aborted in connection with severe skeletal dysplasia.
Аmniocentesis reported a normal female karyotype. Рreg-
nancy was aborted. We performed targeted sequencing of
autopsy tissue using Illumina HiSeq2500, NEBNext pre-
paration protocol, Agilent FocusedExome panel and our
own analytical pipeline. Variant calling and pathogenicity
scoring were done based on ACMG guidelines. We iden-
tiﬁed a compound heterozygous mutation in the SLC26A2
gene on chromosome 5q32. The ﬁrst variant is c.1957T>A
that was previously identiﬁed as a pathogenic. The second
variant is frameshift c.1650delG. This variant is absent from
dbNSFP, Clinvar, OMIM and HGMD pathogenicity data-
bases, and from 1000Genomes project, ExAC and Genotek
frequency databases. Capillary sequencing conﬁrmed
mutations found by NGS in proband. Also both parents
were conﬁrmed to be heterozygous carriers.
E.G. Okuneva: None. D.O. Korostin: None. D. Bor-
isevich: None. N.A. Altynnik: None. E.V. Sypchenko:
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Identiﬁcation of pathogenic single nucleotide variants
(SNVs) associated with heart disease in 290 cases of
stillbirth
E. Sahlin1,2, A. Gréen3, P. Gustavsson1,2, A. Liedén1,2, M.
Nordenskjöld1,2, N. Papadogiannakis1,2, K. Pettersson1,2,
D. Nilsson1,2, J. Jonasson3, E. Iwarsson1,2
1Karolinska Institutet, Stockholm, Sweden, 2Karolinska
University Hospital, Stockholm, Sweden, 3Linköping Uni-
versity, Linköping, Sweden
The incidence of stillbirth in Sweden has essentially
remained constant since the 1980’s, and despite thorough
investigation, many cases remain unexplained. It has been
suggested that a proportion of stillbirth cases is caused by
heart disease, mainly channelopathies. In this study, 79
genes associated with cardiac channelopathies, cardiomyo-
pathies and congenital heart defects (CHD) was analyzed in
290 stillbirth cases. The HaloPlex Target Enrichment Sys-
tem (Agilent Technologies) was utilized to prepare
sequencing libraries which were sequenced on the Illumina
NextSeq platform. We found that 18.6% of the 290 inves-
tigated stillbirth cases had one (n= 47) or two (n= 7)
variants with evidence supporting pathogenicity, i.e. loss-
of-function variants, evidence from functional studies, or
164
previous identiﬁcation of the variants in affected indivi-
duals. The prevalence of the same variants in the Exome
Aggregation Consortium (ExAC) and SweGen was sig-
niﬁcantly lower, 7.24% (p<0.001) and 8.40% (p<0.001),
respectively. Furthermore, we identiﬁed a modest but sig-
niﬁcant difference in the overall proportion of pathogenic
SNVs in relation to the total number of SNVs between the
stillbirth cohort and ExAC, 3.44% vs. 2.35% (p<0.05). Our
results give further support to the hypothesis that cardiac
channelopathies might contribute to stillbirth. Additionally,
our results suggest an increased frequency of pathogenic
variants in genes associated with cardiomyopathies and
CHD in stillbirth compared with the general population.
Screening for pathogenic SNVs in genes associated with
heart disease might be a valuable complement for stillbirth
cases where today’s conventional investigation does not
reveal the underlying cause of fetal demise.
E. Sahlin: None. A. Gréen: None. P. Gustavsson:
None. A. Liedén: None. M. Nordenskjöld: None. N.
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In a prenatal setting we successfully applied targeted
DNA sequencing to detect rare disease causing gene
mutations in two families with strongly increased nuchal
translucency bisides very severe additional fetal
anomalies
P. M. Kroisel1, M. Häusler2, P. Klaritsch2, K. Wagner1
1Institute of Human Genetics, Medical University of Graz,
Graz, Austria, 2Department of Obstetrics and Gynecology,
Medical University of Graz, Graz, Austria
An increased nuchal translucency is frequently observed
during pregnancies. Cytogenetic and molecular genetic
analysis like array CGH following prenatal diagnosis can
just provide an explanation in a proportion of these ﬁndings.
If additional severe fetal anomalies can be found and the
mentioned standard diagnostic tests did not allow sufﬁcient
conclusions a monogenic cause has to be considered. By
using a NextSeq 550 device (Illumina) with a TruSight One
sequencing panel of the same supplier covering more than
4,800 clinically relevant genes we were able to identify in a
seriously affected fetus in a dizygotic twin pregnancy in a
couple of South European origin a fatal skeletal dysplasia
due to the homozygous missense mutation c.1639A>G, p.
Asn547Asp in the LBR gene. Heterozygosity for this
mutation in both parents was conﬁrmed following amnio-
centesis and provided evidence that one twin showed lethal
Greenberg dysplasia. Since parents did not draw any
consequence the risk for the second twin might increase
however it was born healthy ﬁve months later. In another
young healthy Austrian couple who suffered a recurrent
fetal loss in at least two pregnancies associated with com-
parable complex abnormalities we did ﬁnd a homozygous
splice mutation in an important gene essential in blood
metabolism. From this experience we would propose that if
recurrent similar very severe fetal anomalies are recorded in
particular families an effort should be taken early to store
fetal DNA from each pregnancy to allow to apply the
approach mentioned here to potentially provide such cou-
ples with an appropriate prenatal diagnosis.
P.M. Kroisel: None. M. Häusler: None. P. Klaritsch:
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Correlation between Z-score, fetal fraction and
sequencing reads in Non-Invasive Prenatal Testing
M. Balslev-Harder, S. Richter, S. Kjærgaard, P. Johansen
Dept. of Clinical Genetics, University Hospital Copenha-
gen, Copenhagen, Denmark
Introduction: A reliable NIPT result depends on sufﬁcient
amount of fetal DNA and sequencing reads. There has been
a tendency not to report NIPT results from samples with a
fetal fraction below 4%. Such a general cutoff-value will
increase the incidence of test failures compared to study-
speciﬁc cutoff-values. This study examined the combination
of cutoff-values between Z-score, fetal fraction and
sequencing reads in order to deﬁne the optimal study-
speciﬁc cutoff-values and possibly decrease the test failure
rate.
Materials and methods: Whole-genome sequencing
data of plasma-derived DNA from 35 women screen-
positive for trisomy 21 by NIPT was used for analysis. We
computationally simulated 18 fragmented datasets contain-
ing from 5 to 95% of the original data with 5% increments
for each sample. Z-scores and fetal fractions were estimated
using a pipeline based on WISECONDOR and SeqFF
analysis scripts.
Results: The Z-score decreased with increasing frag-
mentation of the original dataset. When our cutoff-values
were met (SeqFF >0.02 and sequencing reads >5million)
we were able to detect the trisomy samples with a Z-score
>4. One sample with a SeqFF of 0.016 (below our cutoff-
value) was only detected with more than 6 million reads
sequenced.
Conclusion: We have shown that our current combina-
tion of cutoff-values (SeqFF >0.02, sequencing reads
>5million and Z-score >4) is appropriate in order to detect
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trisomy 21 pregnancies and lowering of these cutoffs in
order to decrease test failures is not feasible.
Funding sources: None
M. Balslev-Harder: None. S. Richter: None. S.
Kjærgaard: None. P. Johansen: None.
P01.110B
CLIA laboratory experience with over 330,000 samples
of non-invasive prenatal testing (NIPT) using a targeted
microarray-based cell-free (cfDNA) test for fetal trisomy
B. Liedstrand, K. White, R. Steeke, J. Acuna, A. Batey, M.
Schmid
Ariosa Diagnostics Inc., Roche Sequencing Solutions Inc.,
San Jose, CA, United States
Objective To describe the experience with a targeted
microarray-based cfDNA test (Harmony Prenatal Test®) for
fetal trisomy in a large CLIA-certiﬁed laboratory.
Methods Targeted cfDNA analysis using DANSR™ and
FORTE™ with microarray quantitation was used to eval-
uate the probability of trisomy 21, 18, and 13 in the Ariosa
CLIA laboratory (San Jose, CA, USA). The laboratory
performs active follow-up of clinical and diagnostic infor-
mation for patients with high-probability results. In the
present study prospectively collected data on 338,365
reported samples was reviewed.
Results Of the 338,365 samples reported, 1.2% received
a high-probability result for trisomy 21, 18, or 13. In the
entire cohort, mean maternal age was 32.7 years; mean
gestational age was 13.8 weeks. 2.5% of samples were from
twin pregnancies; 6.4% of samples were from IVF preg-
nancies. There were 3,958 high-probability results: 3,102
for trisomy 21, 677 for trisomy 18, and 179 for trisomy 13.
1,612 of these cases were eligible for follow-up. Outcome
information was available for 997 cases. In 655 cases with
diagnostic information, 97.0% of trisomy 21, 85.5% of
trisomy 18, and 34.1% of trisomy 13 cases were conﬁrmed.
342 cases had other outcome information without karyotype
conﬁrmation.
Conclusions This study complements previously pub-
lished validation studies that demonstrated high speciﬁcity
for assessment of fetal aneuploidy using a targeted cfDNA
test with microarray quantitation. High positive predictive
values for trisomy 21 and trisomy 18 were observed. A
lower proportion of conﬁrmed trisomy 13 cases was not
unexpected given the lower prevalence of this condition.
B. Liedstrand: A. Employment (full or part-time); Sig-
niﬁcant; Ariosa Diagnostics Inc., Roche Sequencing Solu-
tions Inc. K. White: A. Employment (full or part-time);
Signiﬁcant; Ariosa Diagnostics Inc., Roche Sequencing
Solutions Inc. R. Steeke: A. Employment (full or part-
time); Signiﬁcant; Ariosa Diagnostics Inc., Roche Sequen-
cing Solutions Inc. J. Acuna: A. Employment (full or part-
time); Signiﬁcant; Ariosa Diagnostics Inc., Roche Sequen-
cing Solutions Inc. A. Batey: A. Employment (full or part-
time); Signiﬁcant; Ariosa Diagnostics Inc., Roche Sequen-
cing Solutions Inc. M. Schmid: A. Employment (full or
part-time); Signiﬁcant; Ariosa Diagnostics Inc., Roche
Sequencing Solutions Inc..
P01.111C
Whole exome sequencing in fetal structural abnormal-
ities: experience of 8 cases
U. Altunoglu1, T. Kalayci1, I. H. Kalelioglu2, H. Kayserili3
1Istanbul University, Medical Faculty of Istanbul, Depart-
ment of Medical Genetics, Istanbul, Turkey, 2Istanbul
University, Medical Faculty of Istanbul, Obstetrics and
Gynecology Department, Istanbul, Turkey, 3Koc University,
Koc University School of Medicine, Medical Genetics
Department, Istanbul, Turkey
Introduction: The underlying cause in fetuses with struc-
tural abnormalities on ultrasonography remains largely
unknown, when pathogenic copy number variations are
ruled out. Lack of a deﬁnitive diagnosis blurs genetic
counseling for most families. Introduction of next genera-
tion techniques to the prenatal setting, improved diagnostic
yield in euploid fetuses with structural abnormalities. Here
we present WES-trio results of eight fetuses with structural
abnormalities, and discuss impacts on genetic counseling.
Materials and Methods: Eight families were consulted
due to fetal structural anomalies in second trimester ultra-
sound, with normal chromosomal array results. DNA was
extracted from cord blood or fetal skin tissue in postmortem
cases. Whole exome sequencing (CentoXome Platinum and
Gold) was performed for fetus and parent trios.
Results: WES was offered all families due to structural
fetal abnormalities ranging from isolated unliateral cleft lip
to micrognathia with microtia. Two families chose to ter-
minate the pregnancy, and have the test performed after the
fetus was examined postmortem. WES revealed CRYBB1
and ASCC1 mutations in these two, ascertaining a diagnosis
of Congenital nuclear cataracts and Spinal muscular atrophy
with congenital fractures. Remaining six had prenatal WES,
revealing mutations in three: BBS10, RIT1, and TCOF1,
providing deﬁnitive diagnoses for Bardet-Biedl, Noonan,
and Treacher-Collins syndromes. 4/6 families who had
prenatal WES made choices based on the WES results.
Conclusions: Due to the small number of inconsecutive
cases included in this study, the high diagnostic yield for
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WES might be misleading. In our experience, WES results
affected the informed choices the families made.
U. Altunoglu: None. T. Kalayci: None. I.H. Kale-
lioglu: None. H. Kayserili: None.
P01.112D
Prenatal measurement of X-inactivation (XCI): cell
culture may have some inﬂuence on the result. A case
report
D. Niedrist1, A. Baumer1, R. Müller Ɨ2, B. Oneda1, A.
Rauch1
1Institute of Medical Genetics, University of Zurich, Zurich,
Switzerland, 2Praxis Dr. R.C. Müller, Winterthur,
Switzerland
X inactivation (XCI) in human occurs early in development
at late blastocyst stage. Structural X chromosomal
abnormalities are usually tolerated in females because of the
preferential inactivation of the abnormal X chromosome.
We report on a case of an unbalanced reciprocal de novo
translocation with partial trisomy 6p and partial monosomy
Xq detected by non-invasive-prenatal testing and conﬁrmed
by chorionic villi sampling (CVS) in a female fetus with
normal ultrasound ﬁndings.
Direct analysis of chorionic villi showed the deletion to
be on the paternal X chromosome and using a methylation-
based test for AR completely skewed XCI (only the
maternal X was active).
Long-term culture of CVS conﬁrmed the chromosomal
aberration, whereas XCI in the cultured cells showed lack of
methylation on both AR-loci. A healthy baby girl was
delivered at term. On cord blood the dup6p and the delXq
were conﬁrmed and the XCI in the new-born girl was
completely skewed (only maternal X active).
DNA methylation is known in the literature to vary
between placenta and the embryo. Peñaherrera et al., 2003,
showed some correlation of XCI between embryonic and
extraembryonic tissues depending on the locus tested.
Our results showed that direct analysis of chorionic villi
correlated with the result of XCI in cord blood, whereas
methylation in cultured CVS cells was completely lacking
on the AR-locus. We suspect cell culture to inﬂuence the
methylation status of AR (hypomethylation) and propose to
only analyze non-cultured cells for XCI using a methylation
based test for AR in prenatal settings.
D. Niedrist: None. A. Baumer: None. R. Müller Ɨ:
None. B. Oneda: None. A. Rauch: None.
P01.113A
The EAA/EMQN external quality control program cri-
tically improves the molecular diagnosis of Y chromo-
some microdeletions
P. Navarro-Costa1, M. Wilke2, L. Hoefsloot3, M. Simoni4,
S. Patton5, F. Tüttelmann6, C. Krausz7
1Gulbenkian Science Institute, Oeiras, Portugal, 2Depart-
ment of Clinical Genetics, Erasmus Medical Center,
Rotterdam, Netherlands, 3Department of Human Genetics.
Radboud University Nijmegen Medical Centre, Nijmegen,
Netherlands, 4Department of Biomedicine, Metabolism and
Neural Sciences. University of Modena and Reggio Emilia,
Modena, Italy, 5European Molecular Genetics Quality
Network (EMQN). St Mary's Hospital, Manchester, United
Kingdom, 6Institute of Human Genetics, University of
Münster, Münster, Germany, 7Andrology Unit - Department
of Experimental and Clinical Biomedical Sciences. Uni-
versity of Florence, Florence, Italy
Introduction: The molecular diagnosis of Y chromosome
microdeletions is a routine genetic test in the workup of
infertile male patients. Owing to its diagnostic and prog-
nostic value, it is crucial that it is performed according to
the highest possible standards. For more than 15 years the
European Academy of Andrology (EAA) and the European
Molecular Genetics Quality Network (EMQN) have been
supporting the improvement of Y chromosome microdele-
tion testing by offering an external quality control program.
Aim: To quantify the impact of external quality control
in the molecular diagnosis of Y chromosome
microdeletions.
Methods: Analysis over a 16-year period of the efﬁ-
ciency of the EAA/EMQN external quality control program
in: i- decreasing genotyping errors; and ii- improving
reporting practice.
Results: The EAA/EMQN external quality control pro-
gram has had a critical impact in reducing diagnostic errors:
at the start of this program the overall diagnostic error rate
was almost 8% and is currently 0.74% of all reported cases.
Furthermore, the program has signiﬁcantly improved
reporting practice: the number of analyses with a full
interpretation score has clearly increased since the start of
the program to the current 68% of all analyses. Never-
theless, there is still room for improvement: several labs
have yet to adopt the best practice multiplex PCR set-up, as
well as to offer the now mandatory deletion extension
analysis.
Conclusion: Participation in the EAA/EMQN external
quality control program has lead to a critical improvement
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in the molecular diagnosis of Y chromosome microdeletions
and is strongly recommended to all labs.
P. Navarro-Costa: None. M. Wilke: None. L. Hoef-
sloot: None. M. Simoni: None. S. Patton: None. F.
Tüttelmann: None. C. Krausz: None.
P01.114B
The role of LRWD1 in the embryonic development of
zebraﬁsh
Y. N. Teng1, Y. C. Hou2, H. Y. Chen1, C. P. Tai1, D. Y.
Tseng1, J. Y. Tseng1, M. S. Wu1
1Department of Biological Sciences and Technology,
National University of Tainan, Tainan, Taiwan., Tainan,
Taiwan, 2Department of Biological Sciences and Technol-
ogy, National University of Tainan, Tainan, Taiwan
Introduction: The human Leucine-rich Repeats and WD
repeat Domain containing 1 (LRWD1) was identiﬁed by
cDNA microarray as one of the down-regulated genes in the
testicular tissues of patients with severe spermatogenic
defects and highly expressed in the testicular tissues.
However, the role of LRWD1 in the embryonic development
is still unclear.
Materials and Methods: In order to understand the role
of LRWD1 in embryonic development, we use zebraﬁsh
(Danio rerio) as an animal model. We analysis the LRWD1
expression in different organs (eyes, brain, heart, liver,
muscle, testis, ovary) and embryogenesis (4, 8, 12, 24, 48,
72 hpf) of zebraﬁsh by Real-Time PCR and immuno-
ﬂuorescence. To investigate the role of LRWD1 in embryo
and germ cells, we used gene knockdown by Morpholino
nucleotide to disrupt the LRWD1 in the embryo of zebraﬁsh.
Results: LRWD1 was in different organs (eyes, brain,
heart, liver, muscle, testis, and ovary), but majorly in the
testis of zebraﬁsh. We found that knockdown LRWD1
caused the tail and spine bending of zebraﬁsh embryo and
early derth.
Conclusion: In addition to the role of LRWD1 in the
reproduction, we suggested that LRWD1 has an indis-
pensable role in the germ cell and embryonic development
for zebraﬁsh. Acknowledgments:This study was supported
by grants from National Science Council (NSC 102-2314-
B-024 -001) and Ministry of Science and Technology
(MOST 103-2314-B-024 -002, 104-2314-B-024 -002
-MY2) of Taiwan.
Y.N. Teng: None. Y.C. Hou: None. H.Y. Chen: None.
C.P. Tai: None. D.Y. Tseng: None. J.Y. Tseng: None. M.
S. Wu: None.
P01.115C
An overlooked phenomenon: female-biased sex ratio
among carriers of Robertsonian translocation in con-
secutive newborns, presumably due to female-speciﬁc
trisomy rescue
N. V. Kovaleva
Academy of Molecular Medicine, St. Petersburg, Russian
Federation
Examination of the sex ratio (SR, male-to-female ratio)
among carriers of Robertsonian translocation (rob) in
newborns in the general population has not previously been
given due attention, probably because of focusing on the
striking female preponderance among fertile carriers
explained by sterility of male carriers. Meta-analysis of
published studies on 68,212 newborns (35,027 males and
33,185 females) showed differences in SR depending on the
type of rearrangements: similar rates of male and female
reciprocal translocations carriers (34 males/33 females, for a
rate of 0.97‰ and 0,99 ‰, correspondingly), but female
preponderance among carriers of rob, regardless of their
parental origin (27M/41F, 0,76 ‰ and 1,24 ‰). Similar
results were obtained in carriers identiﬁed prenatally for
indications other than familial rearrangement. Collectively,
among carriers of rob with known parental origin, there
were 66 males and 97 females (SR=0.68), different from
the ratio of 1.05, p = 0,0023, for carriers of reciprocal
translocations and inversions where a typical slight male
prevalence was found. Female-biased SR was demonstrated
for carriers of the most frequent rob, t(13;14), with 50 males
и 85 females, SR=0,58, but not for carriers of other robs
(28M/27F, SR=1.04). A mechanism of female-speciﬁc
rescue of translocation trisomy resulting in female pre-
ponderance among carriers of balanced translocation, along
with a male preponderance among carriers of unbalanced
translocation, could explain the observed phenomenon.
Both female-biased SR among carriers of balanced 45,der
(13;14),upd(14) with 4M/12F and male-biased SR among
carriers of unbalanced 46,+13,der(13;14) with 16M/2F,
support the proposed hypothesis.
N.V. Kovaleva: None.
P01.116D
Comparative system genetics view of uterine leiomyoma
V. S. Baranov
Ott’s Institute of Obstetrics Gynecology Reproductology, St.
Petersburg, Russian Federation
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The results of comparative system genetics studies of
uterine leyomyoma (LM) - common benign tumor affecting
almost half of all women are reported. Candidate gene
sequencing, methylation and expression proﬁles studies
were applied to paired samples of normal and ﬁbroid tissues
of the same LM patient. Signiﬁcant variations in DNA
methylation and hydroxymethylation in different LM
nodules was shown. Multiple chromosomal rearrangements
mostly partial monosomies of different chromosomes were
registered by array- CGH analysis. A sequencing of exon 2
of MED12 gene demonstrated typical mutations in 59% of
all LM samples. Combined studies of MED12 and AR gene
advocated for independent origin of the most multiply
ﬁbroids in the same uterus . Increased expression of PR
gene and no change in expression of ER gene were also
found. Total DNA methylation in a single LM nodule was
reduced if compared to this one in multiple ﬁbroids whereas
high hydroxymethylation was more common in MED12
positive ﬁbroids. Signiﬁcant (FDR<0.05) expression
decrease of 9 genes with its concomitant increase in 16
genes was shown by comparable expression proﬁles studies
of paired LM and normal myometrium samples. The origin
of LM ﬁbroids from mesenchymal stem cells storage within
endometrium/ myometrium junctional zone of the uterus is
hypothesized. According to our studies personal genetic
background, unique epigenetic landscape as well as detri-
mental (provoking) external factors make principal con-
tribution to the origin, clinical manifestation and
progression of LM. RS F Grant 14-15-00737
V.S. Baranov: None.
P02 Sensory disorders (eye, ear, pain)
P02.01A
Next Generation Sequencing (NGS) followed by in vitro
and in vivo functional studies revealed new genes for
both Hereditary (HHL) and Age Related Hearing Loss
(ARHL)
A. Morgan1, D. Vuckovic1, M. Di Stazio1, M. Alkowari2,
R. Badii3, K. Abdulhadi3, M. La Bianca4, U. Ambrosetti5,
P. Gasparini1,4, G. Girotto1
1University of Trieste, Trieste, Italy, 2Sidra medical
research, Doha, Qatar, 3Hamad Medical Corporation,
Doha, Qatar, 4IRCCS Burlo Garofolo, Trieste, Italy, 5Uni-
versity of Milano U.O.C. Audiologia/Fondazione IRCCS Cà
Granda Ospedale Maggiore Policlinico, Milano, Italy
Introduction: Given the high genetic heterogeneity of
hearing disorders, it is extremely important to look for new
genes involved in HHL and in ARHL, a complex disease
affecting millions of people. To reach this goal 70 HHL-
families and 464 ARHL-patients were screened by NGS
technologies (i.e. Targeted Re-Sequencing and Whole
Exome Sequencing). Genes/alleles identiﬁed were then
functionally analyzed.
M&M: TRS: Panel 1) 113 HHL-genes (4.356-ampli-
cons,~92,6% coverage), Panel 2) 46 ARHL-candidate genes
(1942-amplicons,~96,55% coverage).
WES: 293.903-amplicons,~>99% coverage.
Filtering of NGS data analysis: allele frequency (checked
in public and in our internal databases), pathogenicity pre-
diction and segregation within the HHL families.
In vitro studies: expression vectors containing the wt or
the mutant cDNA sequence, RT-PCR, Western Blot.
In vivo studies: expression studies in mouse/zebraﬁsh
models, KI/KO generation.
Results: Three new HHL-genes and 22 ARHL-candidate
genes have been recently identiﬁed. Table 1 displays the
results of the ﬁrst series of functional studies of the most
promising six genes (prioritized according to literature
updates and type of mutation).
Gene Phenotype Mutation In
vitro
studies
Pathogenicity in vivo
studies
Animal
model
hearing
phenotype
TBL1Y HHL Missense + high NA NA
PLS1 HHL Nonsense NA NA + in
progress
SPATC1L HHL/
ARHL
Missense/
Nonsense
+ high NA NA
SLC9A3R1 ARHL Missense + moderate + yes
SLC44A2 ARHL Missense + moderate + in
progress
SLC28A3 ARHL Nonsense + high + in
progress
Conclusions: This multi-step approach proved to be
extremely powerful for uncovering the molecular mechan-
ism of hearing loss. Updated results will be presented and
discussed.
*Supported by RBSI14AG8P-SIR2014 to GG
A. Morgan: None. D. Vuckovic: None. M. Di Stazio:
None. M. Alkowari: None. R. Badii: None. K. Abdul-
hadi: None. M. La Bianca: None. U. Ambrosetti: None.
P. Gasparini: None. G. Girotto: None.
P02.02B
Congenital hearing impairment as an early sign of mild
phenotype of alpha-mannosidosis : report of ﬁve new
cases
N. Houcinat1, D. Lehalle1, M. O'Grady2, P. Kuentz3, J.
Thevenon1, S. Moutton1, S. Gay4, M. Martin-Delgado5, N.
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Jean1, Y. Duffourd3, C. Thauvin-Robinet1,3, S. Marlin6, L.
Faivre1,7
1Service de génétique CHU Dijon, Dijon, France, 2Depart-
ment of Paediatrics, Midland Regional Hospital,, Mullin-
gar, Co. Westmeath, Ireland, 3Equipe d'Accueil 4271,
Génétique des Anomalies du Développement, Université de
Bourgogne, Dijon, France, Dijon, France, 4Service de
pédiatrie, centre hospitalier de Chalon, Chalon, France,
5Service de pédiatrie, Centre hospitalier de Mâcon, Mâcon,
France, 6Service de génétique, Hôpital Necker-Enfants
Malades, Paris, France, 7Equipe d'Accueil 4271, Génétique
des Anomalies du Développement, Université de Bour-
gogne, Dijon, France
Alpha-mannosidosis (AM) is a very rare (1/500 000)
autosomal recessive lysosomal storage disorder. It is char-
acterized by multi-systemic involvement, with the associa-
tion of intellectual disability, hearing loss, skeletal
anomalies, and coarse facial features. The spectrum is wide,
from very severe and lethal condition to milder phenotype,
usually slowly progressive. AM is caused by deﬁciency of
lysosomal alpha-mannosidase, MAN2B1, that activity can
be measured in the leucocytes to establish the diagnosis.
The molecular conﬁrmation is obtained by the identiﬁcation
of the MAN2B1 mutations. Enzyme replacement therapy is
currently on trial. Here, we report on ﬁve individuals from
four families, aged 3 to 8 years at the diagnosis, referred to a
clinical geneticist for etiologic exploration of syndromic
hearing loss. The deafness was associated with moderate
learning disabilities in three individuals. The sib pair, pre-
sented with atypical clinical presentation and were referred
for exome sequencing after negative genetic workup for the
association of long habitus, intellectual disability and
deafness. The diagnosis has been established by whole-
exome sequencing in three cases including the two sibs.
Whereas systematic screening of urinary oligosaccharides
excretion led to the diagnosis in the two other individuals.
Through these observations, we would like to emphasize
that AM is a probable underdiagnosed rare cause of syn-
dromic hearing loss, whose clinical diagnosis can be chal-
lenging. There is a major input of whole-exome sequencing
to the early diagnosis of these mild phenotypes. Notably,
there is a real beneﬁt for the patients to have an early
diagnosis in term of treatment and management.
N. Houcinat: None. D. Lehalle: None. M. O'Grady:
None. P. Kuentz: None. J. Thevenon: None. S. Moutton:
None. S. Gay: None. M. Martin-Delgado: None. N. Jean:
None. Y. Duffourd: None. C. Thauvin-Robinet: None. S.
Marlin: None. L. Faivre: None.
P02.03C
Genetic characterization of patients with Congenital
Aniridia in Spain
F. Blanco-Kelly1,2, C. Villaverde1,2, L. R. Jacy da Silva3,
M. Palomares4,2, M. Tarilonte1, A. Gimenez1,2, C. Velez1,2,
P. Ramos1, I. Arroyo5, P. Lapunzina4,2, A. Avila-
Fernandez1,2, I. Lorda1,2, M. Trujillo-Tiebas1,2, C.
Ayuso1,2, M. Corton1,2
1Department of Genetics, IIS-Hospital Universitario Fun-
dación Jiménez Díaz, Madrid, Spain, 2Centre for Biome-
dical Network Research on Rare Diseases (CIBERER),
ISCIII, Madrid, Spain, 3Universidad Mogi das Cruzes, Sao
Paulo, Brazil, 4Instituto de Genética Médica y Molecular
(INGEMM), IdiPaz, Hospital Universitario La Paz,
Madrid, Spain, 5Department of Pediatrics. Hospital San
Pedro de Alcántara, Cáceres, Spain
Introduction: Congenital aniridia is a panocular genetic
disease with autosomal dominant inheritance, caused by
PAX6 haploinsufﬁciency. It is characterized by iris hypo-
plasia, and may appear isolated or as part of a syndrome.
Our goal is to deﬁne the mutational spectrum of aniridia in
Spanish population.
Patients & Methods: In 73 families with aniridia,
genetic analysis of PAX6 and 11p13 region was performed
by a combination of techniques, including Sanger and tar-
geted next-generation sequencing, MLPA, FISH, karyotype
and array-based CGH.
Results: 52% of cases presented 33 different mutations
in the PAX6 coding sequence, including 30 loss-of-function
mutations and 3 missense/in-frame deletion variants. Five
well-known PAX6 hotstop mutations were identiﬁed in 2
unrelated families, respectively. 15 of these mutations had
not previously been described. Additionally, 7 families
carried 5 variants of unknown signiﬁcance in non-coding
regions, its potential pathogenicity is currently being
assessed by in vitro and in vivo analysis. In 23% of cases,
11p13-14 genomic rearrangements were identiﬁed: 3 mul-
tiexonic deletions, 4 deletions of PAX6 upstream enhancers,
9 contiguous gene deletion syndromes and one translocation
tr.(6,11). The use of personalized high-resolution array-
CGH allowed specifying the size, breakpoints and involved
genes.
Conclusions: Molecular study of PAX6 has allowed
identifying the cause of Aniridia in 75% of our patients, and
the possible cause in 7 additional families. This study
demonstrates the usefulness of new genomic techniques in
the study of Aniridia, allowing increasing the diagnostic
rate through a more precise analysis of 11p13 and non-
coding PAX6 regions.
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New insights into understanding the genetic basis of
severe bilateral eye anomalies
D. A. Bax1, S. Broadgate1, N. Chassaing2,3, P. Calvas2,3,
R. Holt1, F. Ceroni1, D. Bunyan4, J. Hoffman5, J. Bruty6,
D. McMullan6, Y. Wallis6, M. Grifﬁths5, N. K. Ragge1,5
1Oxford Brookes University, Oxford, United Kingdom,
2Service de Génétique Médicale, Hôpital Purpan, Toulouse,
France, 3UMR 1056 Inserm - Université de Toulouse FRE
3742 CNRS, Toulouse, France, 4Wessex Regional Genetics
Laboratory, Salisbury NHS Foundation Trust, Salisbury,
United Kingdom, 5West Midlands Regional Clinical
Genetics Service and Birmingham Health Partners, Bir-
mingham Women’s Hospital NHS Foundation Trust,
Birmingham, United Kingdom, 6West Midlands Regional
Genetics Laboratory, Birmingham Women’s Hospital,
Birmingham, United Kingdom
Introduction: Anophthalmia and microphthalmia (AM)
syndromes are a genetically heterogeneous group of dis-
orders with overlapping phenotypes reﬂecting the com-
plexity of eye morphogenesis. Here we present our analysis
of a large cohort with severe bilateral AM.
Methods: Detailed phenotyping of probands and parents
was performed with genetic analysis using arrayCGH,
MLPA, targeted and high-throughput sequencing.
Results: SOX2 (18/91) and OTX2 (7/91) were the most
commonly identiﬁed variants; while both are associated
with severe eye and pituitary phenotypes, OTX2 is linked to
milder systemic manifestations and the ocular ﬁndings can
exhibit variable penetrance. FOXE3 (3/91) and VSX2 (3/91)
variants cause ocular phenotypes segregating in both
recessive and dominant fashion, albeit more severe reces-
sively. An X-linked recessive BCOR variant was found in
one male with anophthalmia and atypical normal intelli-
gence. We also identiﬁed variants in genes normally
associated with milder eye phenotypes, GJA8 (cataracts)
and PAX6 (aniridia), in two individuals with severe
microphthalmia. Other genetic diagnoses included
ALDH1A3 (3), TFAP2A (2), BMP7, CHD7, OLFM2,
STRA6 and partial chr13 trisomy (all 1).
Conclusion: We have made genetic diagnoses in 44
families (48%) from our cohort with severe eye anomalies
and will provide detailed descriptions. Although SOX2 and
OTX2 are still the most frequent diagnoses, with increasing
availability of routine testing for these genes, many cases
are being diagnosed and no longer referred for research.
This means our cohort is continually evolving to consist of a
high preponderance of cases where a diagnosis is more
challenging, and highlights the likely existence of new AM
genes.
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ear atresia: is there a role for apoptosis regulating
miRNAs?
E. Aslan1, E. Akbaş2, S. Yilmaz1, A. S. Karaoğlu1, U.
Telli1, S. Yildirim2, H. Güdek3, M. T. Kalcioğlu4, S.
Yilmaz5, I. Akalin5
1Istanbul Medeniyet University, Faculty of Medicine, Phase
III, Istanbul, Turkey, 2Istanbul Medeniyet University,
Faculty of Medicine,Phase II, Istanbul, Turkey, 3Istanbul
Medeniyet University, Faculty of Medicine,Phase IV,
Istanbul, Turkey, 4Istanbul Medeniyet University, Faculty
of Medicine, Department of Otorhinolaryngology, Istanbul,
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Introduction: MicroRNAs (miRNAs) are highly con-
served, small non-coding RNA molecules approximately
21–24 nucleotides in length that control post-transcriptional
gene expression in a wide variety of cellular processes
including proliferation, differentiation, development,
tumorigenesis and apoptosis.
The molecular events underlying ear development
implies numerous regulatory proteins that the role of miR-
NAs have not previously been explored in patients with ear
atresia.
Materials and Methods: We investigated 12 miRNAs,
regulating different pathways such as apoptosis, angiogen-
esis and chondrogenesis. miRNAs were isolated from serum
samples of ear atresia patients (n= 7) and control group (n
= 8) using the miRNeasy Serum/Plasma Kit (Qiagen)
according to manufacturer’s instructions. After com-
plementary DNAs were randomly primed using miScript II
Reverse Transcription (Rt) Kit (Qiagen), miRNA
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expressions were analyzed by real time PCR (RotorGene Q,
Qiagen).
Results: We found apoptosis regulating miRNAs were
signiﬁcantly down regulated in ear atresia patients. Among
them, miR-126 (MIR126), miR-146a, (MIR146), miR-222
(MIR222) and miR-21 (MIR21) were signiﬁcantly 76.2
(p=0.041), 61.8 (p<0.001), 30.5 (p=0.009) and 71.21
(p=0.042) fold decreased compared to controls,
respectively.
Discussion/Conclusions: Signiﬁcant down-regulation
of apoptosis controlling miRNAs in ear atresia patients
could possibly be the cause of abnormal ear develop-
ment. This might be by enhancing intensity of apoptosis
or anticipating the timing of apoptosis during ear
development. Our report is the ﬁrst to provide clues of
relationship between apoptosis regulating miRNAs and
ear atresia/microtia, up to the literature.
Reference: Nishizaki K,(1998) Programmed cell death
in the development of the mouse external auditory canal.
Anat Rec 252:378–382Grant #TSG-2013–333 Research
Fund of Istanbul Medeniyet University
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The lack of LAT2 induces damage in the cytoarchi-
tecture of the inner ear
M. Espino Guarch1, A. M. Celaya2, S. Bodoy3, S. Murillo-
Cuesta2, L. Gonzalez4, E. Prat5, I. Varela-Nieto2, M.
Palacin3, P. Gasparini1, V. Nunes4
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LAT2/CD98hc has a direct role in age-related hearing-loss
(ARHL). Identiﬁcation of rare variants in LAT2 gene
together with amino acid transport loss-of-function in
ARHL patients supports the concept that LAT2 (SLC7A8)
has a role in the auditory system.
A detailed inspection of Lat2 knockout inner ear
(Lat2KO) showed altered stria vascularis with down-
regulation of channel Kir4.1 expression cells and
increased presence of gaps between strial cell-layers. In
addition, a loss of both hair cells in the organ of Corti and
neurons of the spiral ganglion (SGN) were observed.
Alterations in the stria vascularis, SGN and hair cells seem
to be at the basis of the hearing loss phenotype in the
absence of LAT2 although the molecular mechanisms are at
present unknown. Our hypothesis is that LAT2 loss-of-
function might render alterations in the cell content of bulky
neutral amino acids like branched chain amino acids or
glutamine, which affect proteostasis and renewal of cell
structures causing cell stress. Moreover, Lat2KO cochlea
presents signs of unsolved chronic inﬂammation with up-
regulation of IL1b and IL6 mRNA. Currently we are ana-
lyzing oxidative damage in Lat2KO cochlea.
The description of LAT2 as a novel gene involved in
ARHL demonstrates the importance of amino acid home-
ostasis in preserving hearing function and suggests that
genetic screening may enable the identiﬁcation of indivi-
duals susceptible to developing ARHL, allowing for early
treatment or prevention of the disease.
Spanish Founding: FIS PI13/00121-FEDER; SAF2015-
64869-R-FEDER, SAF2014-53979-R-FEDER; CIBERER-
ACCI 2016 and Qatar Foundation: JSREP07-013-3-006.
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Genome wide sequencing (WGS) reveals new insights
into Age Related Hearing Loss (ARHL): cumulative
effects and the role of selection
D. Vuckovic1, M. Mezzavilla2, M. Cocca1, A. Morgan1, M.
Brumat1, P. Gasparini1,2, G. Girotto1
1DMS - University of Trieste, Trieste, Italy, 2Sidra Medical
and Research Centre, Doha, Qatar
Introduction: To unravel the genetic determinants of
ARHL, a highly heterogeneous disease, a WGS study of
cases and controls was conducted.
Materials and Methods: Samples recruitment: a)dis-
covery cohort of 156 subjects and b)independent replication
cohort of 56, both from Italian villages. Samples pheno-
typing: individuals aged more than 50 were deﬁned as cases
or controls based on their hearing thresholds at high fre-
quencies. Linear regression: Total variation load per gene
was compared between cases and controls to detect outlier
genes. Enrichment: Gene Ontology (GO) was analyzed with
PANTHER web-tool. Natural Selection: a PCA-based
method was used to investigate adaptation along the
Europe-EastAsian axis. Expression studies: RT-PCR was
performed in mouse cochlea cDNA.
Results: Two groups of outlier genes were detected: A)
375 more variable in cases and B)371 less variable in cases.
The largest GO enrichment for both groups (fold>5,p<0.05)
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was the “sensory perception of sound”, suggesting cumu-
lative genetic effects involved in ARHL. 141 genes were
replicated in the independent cohort, among which we
identiﬁed 21 genes putatively under selection. After
expression studies in the inner-ear, 20 out of 21 genes were
positively expressed and two of them (CSMD1 and
PTPRD), were previously described as involved in hearing
function [Girotto et al.2011&2014].
Conclusions
We present a novel multistep strategy, providing major
insights into the molecular characterization of complex
diseases such as ARHL and could be applied to other
phenotypes/diseases, where the paucity of samples makes
the GWAS approach not feasible.
Supported by RBSI14AG8P-SIR2014 to GG*.
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A ﬁrst report of copy number variations in CNGB3
implicated in achromatopsia
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Baumann1, E. De Baere2, S. Biskup3, N. Weisschuh1, S.
Kohl1, B. Wissinger1
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Introduction: In hereditary retinal degenerations, up to
50% of cases remain genetically undiagnosed even after
whole exome sequencing analysis. This may be attributed to
as yet unknown disease genes or elusive mutations
including genomic structural variations. Here, we provide a
ﬁrst report on copy number variations (CNVs) in CNGB3,
the major gene for autosomal recessive achromatopsia.
Materials and Methods: We identiﬁed heterozygous
CNVs in 16 of 43 unrelated achromatopsia patients har-
boring a single mutant CNGB3 allele by quantitative real-
time PCR (qRT-PCR) using predesigned TaqMan Copy
Number Assays or custom designed (amplicon-based) qRT-
PCR assays applying the QuantiTect SYBR Green PCR Kit.
A homozygous deletion encompassing 15 exons was iden-
tiﬁed by conventional PCR during routine diagnostics. All
identiﬁed CNVs were validated either by CytoSure arrays or
arrEYE. Breakpoint mapping was performed for all intra-
genic CNVs (14) by long-distance PCR using Phusion
High-Fidelity DNA Polymerase. Segregation analysis was
done in 12/17 cases depending on availability of family
members.
Results: Applying qRT-PCR, we detected heterozygous
CNVs encompassing 1 to 10 consecutive exons in 16
unrelated patients previously shown to carry a second
clearly pathogenic CNGB3 allele. We observed more
patients with duplications (10) than patients with deletions
(6). The largest duplication and all identiﬁed deletions were
unique, while 6 unrelated patients showed an identical
duplication of exon 7. Another duplication encompassing 4
exons was identiﬁed in 3 unrelated cases.
Conclusions: These ﬁndings add to the CNGB3 muta-
tion spectrum and demonstrate the importance of hetero-
zygous CNVs in achromatopsia patients missing a second
clearly pathogenic allele.
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Missense mutation in CEP78 in a family with cone-rod
dystrophy, sensorineural hearing loss, obesity and
subfertility
G. Ascari1, S. Van De Sompele1, L. Derycke2, G.
Holtappels2, O. Krysko2, J. Van Dorpe3, D. Creytens3, T.
Van Laethem1, I. Balikova4,5, J. Gerris6, C. Bachert2, B.
P. Leroy1,4,7, E. De Baere1, F. Coppieters1
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Introduction: Bi-allelic truncating mutations in CEP78
were recently found to cause cone-rod dystrophy (CRD)
with sensorineural hearing loss. Here, we aimed to identify
the causal mutation in a family with CRD and sensorineural
hearing loss, and to explore other ciliary phenotypic
features.
Methods: Whole exome sequencing was performed in 2
affected siblings and segregation analysis was done in 5
additional family members. Skin biopsies and nasal brush
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samples were obtained from both affected individuals and
their parents to study ciliary structure and length.
Results: We identiﬁed a novel missense mutation in
CEP78 in a homozygous state in both affected individuals:
c.449T>C, p.(Leu150Ser). This mutation segregates with
disease in 7 individuals. The affected amino acid is highly
conserved, and the change is predicted to be damaging by
several in silico prediction tools. Phenotyping revealed the
presence of additional features reminiscent to a ciliopathy
such as recurrent airway infections, obesity and subfertility.
Morphology of primary cilia in ﬁbroblasts was evaluated
and induced cilia in patient’s ﬁbroblasts were signiﬁcantly
longer in comparison to control cells. Functional studies are
ongoing on nasal epithelial cells and semen samples to
investigate if this CEP78 mutation affects ciliary structure,
and if it is associated with the ciliary phenotypic features
observed.
Conclusions: In conclusion, we identiﬁed the ﬁrst mis-
sense mutation in CEP78 causing CRD and sensorineural
hearing loss, a recently identiﬁed syndrome distinct from
Usher syndrome. The family studied here displayed addi-
tional features, suggesting a potential involvement of
CEP78 in more complex ciliopathies.
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Genetic analysis of 100 consanguineous families to
identify the molecular cause of mendelian visual
impairment
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K. Gul4, A. A. Khan3, S. A. Paracha5, J. Khan5, S.
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Consanguineous populations have a higher prevalence of
autosomal recessive disorders due to the higher probability
of homozygosity for alleles identical by descent. By
studying the spatial distribution of runs of homozygosity
(ROH) across the genome, we have observed that the
average ROH size of inbred population (215MB) was sig-
niﬁcantly higher than outbred populations (25MB). In order
to decipher the genetic basis of visual impairment, the
current study was designed to identify the known or likely
pathogenic variants in known or novel candidate genes in
consanguineous families with mendelian visual impairment.
By using a strategy that combines exome sequencing and
genotyping, we have analyzed 100 highly consanguineous
families from Pakistan (where consanguinity rate is >60%),
manifesting undiagnosed likely autosomal recessive visual
impairment. We have identiﬁed known or novel likely
pathogenic variants in genes which are already reported to
cause visual impairment in 65% of the families. In 18% of
the cases we have found likely damaging variants in novel
candidate genes. In 17% families, we failed to identify any
causative or candidate variants in the coding regions cov-
ered by exome sequencing.
We conclude that the discovery of novel autosomal
recessive genes for visual impairment can be accelerated by
analyzing large cohorts of consanguineous families. This
has important implication in correct molecular diagnosis,
family planning, and may reduce the incidence of autosomal
recessive disorders in consanguineous couples. Gene dis-
covery of novel candidates is the ﬁrst step in understanding
the molecular pathophysiology of a disease and may con-
tribute to innovative treatment.
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Application of Next Generation Sequencing Upon the
Diagnosis of Deafness
N. T. Trang, P. V. H. Hanh, C. M. Thanh, T. D. Phan, L.
H. Thang
Hanoi Medical university, Ha Noi, Viet Nam
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Introduction: There are 15 000 hearing-impaired children
are born in Vietnam every year. Early detection of common
deafness mutations is a key factor for diagnosing, helping
hearing-loss children to develop their language and aware-
ness normally.
Research’s Objects and Methods: 50 hearing-impaired
and 100 normal children from Viet Nam. Apply technology
of next generation sequencing to detect 100 mutations of 18
deafness genes, namely GJB2, GJB3, SLC26A4, MT-
RNR1, MT-CO1, MT-TL1, MT-TS1, MT-TH, DSPP,
GPR98, DFNA5, TMC1, MYO7A, TECTA, DIABLO,
COCH, MYO15A and PRPS1.
Result: Identify 12 mutations of deafness genes of 11
hearing-impaired patients (account for 22% in total),
including 7 cases of heterozygous mutations of genes GJB2
(c.299-300delAT (3 cases), c.512insAACG); SLC26A4
(c.2168A>G); TMC1 (c.1334G>A and 5 cases of homo-
zygous mutations of genes GJB2 (c.512insAACG, 2 cases),
MT-RNR1 (m.827 A>G, m.961delTinsC); MT-TH
(m.12201T>C); MT-TL1 (m.3243A>G). No mutations
were identiﬁed in the control group.
Conclusion: The incidence of deafness mutations in
hearing-loss group is 22%. Mutations of GJB2 cover the
largest proportion (12%) among 18 genes investigated. In
this review, we describe commonly used genomic tech-
nologies as well as the application of these technologies to
the genetic diagnosis of deafness and to the discovery of
novel genes for syndromic and nonsyndromic deafness.
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to identify genetic markers in painful neuropathies - The
PROPANE study
M. M. Gerrits1, R. Almomani1, M. Marchi2, P. Lindsey1,
M. Sopacua1, J. G. J. Hoeijmakers1, I. S. J. Merkies1, H.
Fadavi3, R. A. Malik3,4, D. Ziegler5, G. Boenhof5, F.
Martinelli-Boneschi6, D. Cazzato2, R. Lombardi2, S. Dib-
Hajj7,8, S. G. Waxman7,8, H. J. M. Smeets1, C. G. Faber1,
C. G. Lauria2
1Maastricht University Medical Center, Maastricht, Nether-
lands, 2IRCCS Foundation “Carlo Besta” Neurological
Institute, Milan, Italy, 3University of Manchester and
Central Manchester NHS Foundation Trust, Manchester,
United Kingdom, 4Weill Cornell Medicibe Qatar, Doha,
Qatar, 5German Diabetes Center, Duesseldorf, Germany,
6San Raffaele Scientiﬁc Institute, Milan, Italy, 7Yale
University School of Medicine, New Haven, CT, United
States, 8Veterans Affairs Medical Center, West Haven, CT,
United States
Introduction: Neuropathic pain is a frequent feature of
peripheral neuropathy causing a signiﬁcant impact on
patients’ quality of life and health care costs. Current
inability to identify high-risk individuals hinders develop-
ment and application of therapies to counteract neuropathic
pain. The purpose of this study is to resolve the genetic
architecture of painful neuropathy by 1) constitution of a
DNA databank of patients with painful and painless diabetic
and idiopathic neuropathy, 2) targeted sequencing of
sodium channel genes expressed in the nociceptive
pathway.
Materials and Methods: DNA was extracted from
peripheral blood of 1258 patients (Idiopathic n= 726,
Diabetic n= 532) recruited in different partner centres.
Targeted sequencing of sodium channel genes has been
performed by Molecular Inversion Probe-Next Generation
Sequencing (MIP-NGS). Variants’ pathogenicity was clas-
siﬁed according to the ACGS practice guidelines.
Results: In a cohort of 859 patients with diabetic (n=
367) and idiopathic neuropathy (n= 492), sequence data of
SCN3A, SCN7A-11A and SCN1B-4B revealed 116 dif-
ferent potentially pathogenic variants in 181 patients
(Idiopathic n= 83/111 patients, Diabetic n= 58/70
patients). Hundred variants were unpublished, and 91 were
speciﬁc for a painful phenotype. Variants with strong evi-
dence for pathogenicity are selected to undergo cell elec-
trophysiology testing. Screening of the ten sodium channel
genes has been extended with 97 candidate genes known to
be involved in neuropathic pain, their interacting partners,
and genes selected by integrative genomics.
Conclusion: MIP-NGS is relatively inexpensive and
ﬂexible technique, allowing a wide genetic characterization
of painful neuropathy patients. This study was funded by
the European Union 7th Framework Programme (grant n°
602273).
M.M. Gerrits: None. R. Almomani: None.M. Marchi:
None. P. Lindsey: None. M. Sopacua: None. J.G.J.
Hoeijmakers: None. I.S.J. Merkies: None. H. Fadavi:
None. R.A. Malik: None. D. Ziegler: None. G. Boenhof:
None. F. Martinelli-Boneschi: None. D. Cazzato: None.
R. Lombardi: None. S. Dib-Hajj: None. S.G. Waxman:
None. H.J.M. Smeets: None. C.G. Faber: None. C.G.
Lauria: None.
P02.13A
Diagnostic exome sequencing in 266 Dutch patients with
visual impairment
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Inherited eye disorders have a large clinical and genetic
heterogeneity, which makes genetic diagnosis cumbersome.
An exome-sequencing approach was developed in which
data analysis was divided into two steps: the vision gene
panel and exome analysis. In the vision gene panel analysis,
variants in genes known to cause inherited eye disorders
were assessed for pathogenicity. If no causative variants
were detected and when the patient consented, the entire
exome data was analyzed. A total of 266 Dutch patients
with different types of inherited eye disorders, including
inherited retinal dystrophies, cataract, developmental eye
disorders and optic atrophy, were investigated. In the vision
gene panel analysis (likely) causative variants were detected
in 49% and in the exome analysis in an additional 2% of the
patients. The highest detection rate of (likely) causative
variants was in patients with inherited retinal dystrophies,
for instance a yield of 63% in patients with retinitis pig-
mentosa. In patients with developmental eye defects, cat-
aract and optic atrophy, the detection rate was 50%, 33%
and 17%, respectively. An exome-sequencing approach
enables a genetic diagnosis in patients with different types
of inherited eye disorders using one test. The exome
approach has the same detection rate as targeted panel
sequencing tests, but offers a number of advantages. For
instance, the vision gene panel can be frequently and easily
updated with additional (novel) eye disorder genes. Deter-
mination of the genetic diagnosis improved the clinical
diagnosis, regarding the assessment of the inheritance pat-
tern as well as future disease perspective.
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CTG18.1 trinucleotide repeat expansion in Polish
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Introduction: Fuchs endothelial corneal dystrophy (FECD)
is the most common, genetically determined degenerative
disease of the cornea. The molecular basis of FECD is
complex and heterogeneous. The latest and the most pre-
disposing genetic factor for the development of FECD is a
trinucleotide repeat expansion CTG18.1, which is located in
the second intron of the TCF4 gene.
Materials and Methods: Clinical evaluation was based
on slit-lamp examination, in vivo confocal microscopy
(IVCM) and anterior segment optical coherence tomo-
graphy (AS-OCT). Genomic DNA was isolated from per-
ipheral blood samples of unrelated FECD patients (n= 236)
and control subjects (n= 58). We genotype the CTG18.1
repeat expansion to determine an association between the
genetic variant and FECD development and to analyse
possible relationships between the different CTG18.1 gen-
otypes and clinical picture of the patients. For this purpose a
combination of methods, i.e. analysis of short tandem
repeats (STR), triplet repeat primed PCR (TP-PCR) and
statistical analysis were performed.
Results: The results showed that the repeat expansion
CTG18.1 is currently the strongest predisposing factor for
the development of FECD in a group of Polish patients
(OR=43,72; CI:13,20-144,83; χ2=80,77; p<0,0001). There
were no statistically signiﬁcant associations between the
CTG18.1 genotype and the best corrected visual acuity
(BCVA), central corneal thickness (CCT) or the density of
the corneal endothelium.
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Conclusions: Our study conﬁrms association of
CTG18.1 repeat expansion with FECD by testing a novel
previously not analysed population. This genetic determi-
nant has an important predictive value and may be bene-
ﬁcial in clinical practice.
Supported by: 1M15/N/2016 and 2WF/W/16
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Molecular diagnosis of hereditary hearing impairment
by high throughput sequencing of targeted exome in
patients from Jordan and North Africa
Z. RIAHI1,2, C. Bonnet1,2, Y. Bouyacoub1,2, A.
Elamraoui3,2, J. Hardelin3,2, C. Ktaiﬁ4, M. Sayeb4, J.
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Bahlouli9, S. Abdi9, M. Makrelouf9, A. Zenati9, M.
Dahmani9, S. Talbi10, F. Ammar Khodja10, H.
Elhachimie11, A. Houmeida11, E. Mohamed Moctar11, M.
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6La Rabta Hospital, Otorhinolaryngology Diseases,, Tunis,
Tunisia, 7Department of Congenital and Hereditary Dis-
eases, Hopital Charles Nicolle, Tunis, Tunisia,
8Département de Recherche Scientiﬁque, Laboratoire de
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Université Saint Joseph, Beyrouth, Lebanon
After the exclusion of the most prevalent mutations, the
identiﬁcation of causal mutations is difﬁcult due to the high
genetic heterogeneity and high cost of the Sanger technique.
We used a targeted exome sequencing strategy (Hear Panel)
to analyze 137 known deafness genes and some candidate
genes in 268 unrelated patients, belonging to families with
at least two affected individuals, originated from Jordan,
Tunisia, Algeria, Morocco, and Mauritania. Molecular
diagnosis was established in 206 patients (77%), with a total
of 194 mutations being identiﬁed in 52 different genes,
among which 140 (72%) had not been previously reported.
This makes Hear Panel a powerful tool to identify rare HI
mutations in populations with high rates of consanguineous
marriages. Six genes were involved in 41% (110/268) of the
patients: MYO15A (26/268), MYO7A (25/268), SLC26A4
(18/268), OTOF (16/268), CDH23 (13/268) and TMC1 (12/
268). Among the 206 diagnosed patients, 178 (86%) carried
biallelic mutations in autosomal recessive deafness (DFNB)
genes (159 patients were homozygote and 19 were com-
pound heterozygote), 27 (13%) carried monoallelic muta-
tions in autosomal dominant deafness (DFNA) genes and
one patient carried a mutation in an X chromosome-linked
deafness (DFNX) gene. In the 36 patients (13%) carrying
biallelic mutations in genes underlying Usher syndrome,
sight impairment was subsequently identiﬁed by ophthal-
mological examination. This establishes the Hear Panel as
an efﬁcient and reliable tool for an early diagnosis of Usher
syndrome before the onset of the sight loss which is of
utmost medical importance as these patients should beneﬁt
from early cochlear implantation
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P02.17A
Genetic background of sensorineural hearing loss in
Slovakia: data from Slovak nation-wide survey
D. Gasperikova1, L. Varga1,2, I. Masindova1, D. Danis1,
M. Skopkova1, Z. Kabatova1, M. Profant2, I. Klimes1
1Diabgene, Biomedical Research Center, SAS, Bratislava,
Slovakia, 2Department of Otorhinolaryngology - Head and
Neck Surgery, Faculty of Medicine and University Hospital,
Bratislava, Slovakia
Introduction: Goal of our study was to perform nationwide
screening for hereditary deafness and elucidate the genetic
background of sensorineural hearing loss (SNHL) in our
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population composed of ~90% Caucasians and ~8% of
Roma ethnicity.
Patients and methods: Between 2010–2016, we col-
lected 1003 DNA samples from 682 families with bilateral
SNHL. Probands were screened for GJB2; negative and
heterozygous subjects were tested for GJB6-D13S1830 and
D13S1854 deletions. Roma patients were further investi-
gated for MARVELD2 gene. Subjects with matrilineal
inheritance of SNHL and diabetes or history of aminogly-
coside treatment were tested for mitochondrial pathogenic
variants m.3243A>G and m.1555A>G. 20 families with
familial nonsyndromic deafness were analysed using whole
exome sequencing (WES).
Results: In case of GJB2, 201 probands carried biallelic
pathogenic variants (29.5%), 50 heterozygous (7.3%) and
431 no pathogenic variant (63.2%). The most frequent
variant was c.35delG in Caucasians and c.71G>A in Roma
population. One subject was compound heterozygote for
GJB2/GJB6-D13S1830. In MARVELD2 gene c.1331
+2T>C pathogenic variant was detected in three families
accounting for 3.5% of SNHL cases in the Roma cohort.
Mitochondrial variant m.3234A>G was detected in four
families and one family carried the m.1555A>G variant.
WES analysis in 20 families identiﬁed causative gene in 11
families (55% of the WES group). These included seven
known genes: COCH, EYA4, MYO6, OTOG, TECTA,
TMC1 and TMPRSS3 with ﬁve novel variants.
Conclusion: We identiﬁed causal genotype in about one
third of unrelated patients with SNHL. As we further
demonstrated, WES may dramatically increase precise
diagnostics of deafness etiology.
Supported: APVV-15-0067, VEGA1/0214/16.
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Expanding the etiological work-up of congenital hearing
loss by targeted resequencing approach
J. J. van den Ende1, A. Boudewyns2, M. Sommen1, N.
Peeters1, W. Wuyts1, G. Van Camp1
1Center of Medical Genetics, Edegem, Belgium, 2Depart-
ment of Otorhinolaryngology Head and Neck Surgery,,
Antwerp University Hospital, University of Antwerp,
Edegem, Belgium
Objective: Infants identiﬁed with congenital hearing loss
through a newborn hearing screening program undergo an
etiological work-up to identify an underlying cause. We
routinely exclude congenital infections and anatomical
abnormalities through magnetic resonance imaging and/or
computerized tomography. Unless clinical ﬁndings or
family history dictate otherwise, until recently, genetic
analysis was limited to a search for mutations in the GJB2
genes (encoding Connexin 26). Based upon current proto-
cols, an etiological diagnosis may be established in about
50% of infants/children with congenital hearing loss
(Declau et al. Pediatrics 2008).
Methods: Targeted next generation sequencing of
known hearing loss causing genes was proposed to 59
children with conﬁrmed bilateral congenital hearing loss of
unknown cause (GJB2 mutations excluded). Two gene
panels (one for non-syndromic hearing loss and one for
syndromic hearing loss) were employed covering more than
100 hearing loss genes.
Results: Informed consent was obtained for 20 children
with bilateral moderate to profound hearing loss. A likely
genetic cause for the hearing loss was found in 11 children
(mutations in Whirlin (DFNB31), Marveld2 (DFNB29),
MYO15A (DFNB3), SOX10 (Waardenburg syndrome type
2E), TRIOBP (DFNB28), Oto-ancorin (DFNB22),
TMPRSS3 (DNFB8/10), MITF (Waardenburg syndrome
type 2A), TMC1 (DFNB7/11), OTOG (DFNB18B), and
GPR98 (USH2C).
Conclusions: Targeted next generation sequencing of
known hearing loss causing genes may expand the diag-
nostic yield of currently available protocols for the etiolo-
gical work-up of congenital hearing loss. The identiﬁcation
of a genetic cause may guide treatment decisions and allow
for genetic counselling.
J.J. van den Ende: None. A. Boudewyns: None. M.
Sommen: None. N. Peeters: None. W. Wuyts: None. G.
Van Camp: None.
P02.19C
Identiﬁcation of candidate pathogenic variants in
patients with hearing loss using extended gene panel
containing 120 disease associated genes
K. Šoltys1, G. Repiská2, T. Kurucová3, G. Minárik2
1Comenius University Science Park, Bratislava, Slovakia,
2Faculty of Medicine Comenius University, Bratislava,
Slovakia, 3Faculty of Natural Sciences, Comenius Uni-
versity in Bratislava, Bratislava, Slovakia
Hearing loss is with incidence higher than 1:1000 one of the
most common hereditary diseases. Routinely GJB2 gene
sequencing is performed as in this gene pathogenic variants
are found the most frequently, with population speciﬁc
predominant mutations like c.35delG in Caucasians or p.
W24* in Gypsies. In cases without GJB2 associated hearing
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loss high level of genetic heterogeneity could be a problem.
Gene panel resequencing bring the possibility to compre-
hensively analyze such patients and could help to solve
previously unsolvable cases. Customized 120 genes con-
taining gene panel was designed to cover the most relevant
genes associated with syndromic as well as nonsyndromic
deafness. Gene resequencing of 32 samples that were
negative for the most common pathogenic variants, as
previously screened for the most common and/or population
speciﬁc mutations of GJB2, GJB6 and MARVELD2 genes,
were analyzed with the designed gene panel. After ﬁltering
and annotation with Ingenuity Variant Analysis altogether
151 variants were identiﬁed to have relevant biological
context. Of these 125 were classiﬁed as variants of
unknown signiﬁcance or likely pathogenic or pathogenic.
Surprisingly also in case of such well studied disease like
hereditary hearing loss only 2 likely pathogenic and 4
pathogenic variants were in this group. These 6 variants
found in USH2A, TECTA, SLC26A4, USH1C and sur-
prisingly also in GJB2 genes. The next 119 identiﬁed var-
iants need more comprehensive research, represented by
detailed literature search and if possible with additional
family members targeted genetic analyses for segregation
analysis. Study was supported by grant VEGA-1/0048/14.
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Next-Generation Sequencing to Decipher the Genetic
Heterogeneity of Deafness in Palestinian Arab Families
A. I. Amal1,2, N. Danial-Farran3,4, Brownstein2, L.
Kamal1, S. Gulsuner5, S. Casadei5, T. Walsh5, S. Allon-
Shalev3,4, M. King5, K. B. Avraham2, M. N. Kanaan1
1Department of Biological Sciences, Bethlehem University,
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Molecular Genetics & Biochemistry, Sackler Faculty of
Medicine, Tel Aviv University, Tel Aviv, Israel, 3Genetics
Institute, Ha'Emek Medical Center, Afula, Israel, 4Rappa-
port Faculty of Medicine, Technion - Israel Institute of
Technology,, Haifa, Israel, 5Department of Medical Genet-
ics and Department of Genome Sciences, University of
Washington, Seattle, WA, United States
Analysis of multiplex families from the Palestinian Arab
provides a rich source for discovery and characterization of
hearing loss (HL) genes. Primary clinical evaluations and
audiological analyses were undertaken for each family, and
GJB2 gene mutations and other common founder alleles
were tested. Families with no such mutations were analyzed
by hybridization and multiplexed sequencing, using our
panel of all known human and mouse hearing loss genes.
SNVs, indels, and CNVs were identiﬁed in exons and
proximal regulatory regions. Mutations were inferred as
damaging only if they co-segregated with deafness in their
families; and were truncating, completely deleted the gene,
or were missense mutations with conﬁrmed functional
effect. Of 85 families evaluated by our panel thus far, 53
families (62%) carried a pathogenic or likely pathogenic
mutation in a known deafness gene. A total of 44 different
mutations, most not previously reported, were identiﬁed in
22 genes and submitted to LOVD and ClinVar. Genes
responsible for non-syndromic HL in 41 families were
CDH23, CLDN14, ESRRB, ADGRV1, GPSM2, LOXHD1,
MYO15A, MYO6, MYO7A, OTOA, OTOG, PCDH15,
PTRH2, TBC1D24, TMC1, TRIOBP and USH1C; genes for
syndromic or other HL phenotypes in 12 families were
OTOF, PAX3, SLC26A4 and USH1G. The 38% of families
with no mutation in any known deafness gene represent a
highly informative resource for identiﬁcation both of addi-
tional HL genes and of distant non-coding regulatory
mutations. We are evaluating these unresolved families with
whole exome and/or whole genome sequencing.
A.I. Amal: None. N. Danial-Farran: None. N. Danial-
Farran Brownstein: None. L. Kamal: None. S. Gulsuner:
None. S. Casadei: None. T. Walsh: None. S. Allon-Sha-
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Siblings with Perralut syndrome and LARS2 mutation
who presented with neurologic abnormalities
R. Kosaki1, R. Horikawa2, K. Kosaki3
1Division of Medical Genetics, National Center for Child
Health and Development Hospital, Setagaya, Tokyo, Japan,
2Division of Endocrinology, National Center for Child
Health and Development Hospital, Setagaya, Tokyo, Japan,
3Center for Medical Genetics, Keio University School of
Medicine, Tokyo, Japan
Perrault syndrome represents a genetically heterogeneous
disorder characterized by sensorineural hearing loss and
ovarian dysgenesis in females. Causative genes include
HARS2, HSD17B4, CLPP, C10orf2, and LARS2 (mito-
chondrial leucyl-tRNA synthetase). Some patients exhibits
neurologic features including learning disability, cerebellar
ataxia, and motor or sensory peripheral neuropathy. No
patients with neurological symptoms have been reported
among 15 patients in 8 families with LARS2 mutations
reported to date. Here we report two female siblings with
biallelic mutation in LARS2, p.Glu 294Lys and p.Thr
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519Met. The proposita developed progressive sensorineural
hearing loss at 18 months and pervasive developmental
disorder at 8 years with cognitive and behavioral problems
included repetitive behavior, insistence on sameness,
attention deﬁcit, chic, and, irritability, and ataxic gait. She
later was diagnosed as having primary amenorrhea with
elevated FSH, LH and decreased estradiol and small uterus
and no detectable ovaries on MRI at the age of 15. The
proposita’s younger sister presented with neonatal sensor-
ineural hearing loss, mild delay in motor and speech
development. She was diagnosed as having primary ame-
norrhea with comparable endocrinologic and radiographic
ﬁndings that were comparable to her sister. Present obser-
vation of PDD in one of the siblings and mild develop-
mental delay in the other sibling with classic symptoms of
Perrault syndrome and LARS2 indicates that patients with
LARS2 mutations are at risk for neuro-behavioral symp-
toms as Perrault syndrome patients with other causative
genes. Variable expressivity between the two siblings could
be ascribed to general tendency of mitochondrial diseases in
which intra-familial variation is common.
R. Kosaki: None. R. Horikawa: None. K. Kosaki:
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Mutation study of 69 genes in 100 Thai patients with
non syndromic hearing loss detected by next generation
sequencing
A. Khongkraparn1, T. Tim-Aroon1, S. Noojarern1, K.
Lertsukprasert2, N. Kasemkosin2, P. Janchompoo3, W.
Narkpoung3, W. Chantratita3, S. Thongpradit4, D.
Wattanasirichaigoon1
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Faculty of Medicine Ramathibodi Hospital, Mahidol
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University, Bangkok, Thailand, 4Research Center, Faculty
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Introduction: Hereditary hearing loss (HHL) is one of the
most common birth defects. One-fourth of HHL is syn-
dromic hearing loss (SHL), in which deafness is accom-
panied by other signs and/or symptoms whereas the
remaining is non-syndromic hearing loss (NSHL). About
80% of NSHL is inherited in autosomal-recessive mode,
almost 20% of NSHL is inherited in autosomal-dominant
pattern, and very small fractions are sex-linked inherited.
The present study attempts to ﬁnd the genetic variants
underlying congenital NSHL in Thai patients.
Materials and methods: A targeted sequencing panel,
using Ion Torrent™ systems, including 69 genes for HHL
were designed and performed in 100 specimens from
unrelated Thai individuals with congenital NSHL, including
11 familial and 89 sporadic index cases. Single-nucleotide
variations (SNVs) and insertions/deletions (INDELs) were
analysed.
Results: We identiﬁed 930 genetic variants (SNVs/
INDELs) in 59 genes studied. We ﬁltered out SNVs/
INDELs with Thai minor allele frequencies >0.03 as well as
synonymous nucleotide substitutions. The overall ﬁltering
process led to 144 to Sanger sequencing validation. Sanger
sequencing were conﬁrmed 21 reported pathogenic, 104
promising variants in 52 patients, and 19 false positive
variants. Usher syndrome associated genes (CDH23,
MYO7A, USH2A) are the most common cause (23.1%) of
Thai apparently NSHL, followed by SLC26A4 (13.5%),
COL11A2 (11.5%), and GJB (9.6%). However, the 104
promising variants require segregation analysis in family
members and further study.
Conclusions: Targeted exome approach for identiﬁca-
tion of causative genes in Thai NSHL population is highly
effective and results in high detection rate at ascend 52%.
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HRC imputations reveal some of the missing heritability
of endophenotypes of glaucoma
E. M. van Leeuwen1,2, P. W. M. Bonnemaijer1,2, A. I.
Iglesias1,2,3, P. Gharahkhani4, C. Hammond5, P. Hysi5, S.
MacGregor4, V. Vitart6, IGGC consortium, A. A. H. J.
Thiadens1,2, C. C. W. Klaver1,2,7, C. M. van Duijn2
1Department of Ophthalmology, Erasmus Medical Center,
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Erasmus Medical Center, Rotterdam, Netherlands,
3Department of Clinical Genetics, Erasmus Medical Center,
Rotterdam, Netherlands, 4QIMR Berghofer Medical
Research Institute, Royal Brisbane Hospital, Brisbane,
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cal Research Council Human Genetics Unit, Institute of
Genetics and Molecular Medicine, University of Edinburgh,
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Introduction: Primary open-angle glaucoma (POAG) is the
main cause of irreversible blindness worldwide. Intraocular
pressure (IOP), central corneal thickness (CCT) and the
morphology of the optic nerve head are important heritable
endophenotypes of the glaucomatous eye. Genome-wide
association studies (GWAS) using the HapMap or 1000
Genomes imputation panels have identiﬁed numerous loci
associated with these traits. The recently developed impu-
tation panel by the Haplotype Reference Consortium (HRC)
allows a better quality of rare variants imputations which
will result in reﬁning causal variants in known loci and
revealing additional loci for IOP, CCT and optic disc
parameters.
Materials and Methods Meta-analysis GWAS results
from 17000 to 31000 European individuals participating in
the IGGC has been carried out using the HRC as a reference
set for imputations. We explored the associations between
all single genetic variants with IOP, CCT and three optic
disc parameters: cup area (CA), disc area (DA), and vertical
cup disc ratio (VCDR).
Results We replicated previous ﬁndings and identiﬁed
13 novel loci (2 with CA and VCDR, 2 with IOP, 3 with
CCT and 6 with CA only). Among the new loci associated
with VCDR and CA is a variant in MEF2C, a gene involved
in synaptic development.
Conclusions The study shows that the HRC panel is a
powerful tool for further enhancing our understanding of
the genetic basis of these traits. The numerous identiﬁed
variants in our study show the genetic complexity of this
disease and increase our knowledge in the pathways leading
to this disease.
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None. A.I. Iglesias: None. P. Gharahkhani: None. C.
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A large multi-ethnic genome-wide association study
identiﬁes novel loci inﬂuencing intraocular pressure and
central corneal thickness
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N. Kvale2, Y. Banda2, C. Schaefer1, N. Risch2,3,1, R.
Melles4, E. Jorgenson1
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Introduction: Intraocular pressure (IOP) and central cor-
neal thickness (CCT) are associated with glaucoma, a
common eye condition which can lead to vision loss.
Family studies indicate that IOP and CCT have a moderate
to strong genetic component, with heritability estimates of
up to 0.67 and 0.95, respectively. Genetic studies have
reported 11 and 29 loci associated with IOP and CCT,
respectively, with one locus associated with both traits. This
suggests that additional loci remain to be discovered and
some of the genetic risk of IOP and CCT might be shared.
Materials and Methods: We ﬁrst conducted a genome-
wide association study (GWAS) of IOP in 76,937 indivi-
duals with 496,897 IOP measurements from four race/eth-
nicity groups (non-Hispanic White, Hispanic/Latino, East
Asian, and African American) in the Genetic Epidemiology
Research in Adult Health and Aging (GERA) cohort. We
then conducted a GWAS of CCT in a GERA subset (N=
17,730) with both IOP and CCT measurements available.
Results: We identiﬁed 51 genome-wide signiﬁcant IOP-
associated loci (P < 5 ×10−8), of which 36 were novel, that
is, not previously-reported to be associated with IOP, CCT,
or glaucoma. We also identiﬁed 23 CCT-associated loci, of
which 8 were novel. Importantly, 11 loci were associated
with both IOP and CCT at a genome-wide level of
signiﬁcance.
Conclusions: Our results conﬁrm that these two traits
partly share a common genetic background. Investigating
genetic variation inﬂuencing IOP and CCT might help
elucidate their role in glaucoma pathophysiology.
Grants: RC2 AG036607 from NIH; Kaiser Permanente
North California Community Beneﬁt
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Whole exome sequencing (WES) identiﬁed COL6A5
variants in familial idiopathic itch
F. Martinelli-Boneschi1, M. Colombi2, M. Castori3, G.
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Merkies8, D. Toniolo9, M. Cocca10, C. Doglioni11, S. G.
Waxman12,13, S. D. Dib-Hajj12,13, M. M. Taiana14, J.
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Introduction: To date, no molecular markers have been
identiﬁed in patients with idiopathic spontaneous chronic
itch (SCI). Here we describe the ﬁrst gene variants identi-
ﬁed in eight patients, all suffering from idiopathic SCI and
neuropathic pain.
Materials and methods: Family1 is 3 generations, 1
member per generation complaining of SCI. Family2 is
diagnosed with JHS/EDS-HT Syndrome, 2 affected mem-
bers referring also daily SCI attacks. In family3 three
affected members are distributed over two generations.
WES was performed on affected and unaffected samples.
Libraries were obtained either by Agilent technologies, run
on 2500Hiseq (Illumina), or by LifeTechnology approach,
run on IonProton platform (LifeTechnologies). Immuno-
ﬂuorescence microscopy, western blotting and null-allele
test were performed on ﬁbroblasts cultures. Skin biopsies
were examined assessing intraepidermal nerve ﬁber density
and protein expression.
Results: We compared the rare genetic variants selected
in the affected samples and found 3 mutations (two in-cis in
family-1; one in family-3) affecting the COL6A5 gene,
encoding a collagen subunit expressed at epidermal level.
WES data were inspected for same variants also in family-2,
recruited in a different project, and the same 2 in-cis
mutations were found to segregate with itch phenotype.
Haploinsufﬁciency were demonstrated by null-allele test on
cDNA from patients’ ﬁbroblasts carrying the nonsense
variant. Immunoﬂuorescence microscopy and Western
blotting revealed disorganization and reduced synthesis of
the speciﬁc collagen ﬁber, immunohistochemistry showed
reduced amount around dermal vessels.
Conclusion: Our ﬁndings revealed that WES on families
with common phenotype could reveal new variants
involved in the individual susceptibility to chronic itch.
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Whole exome sequencing proﬁling indicates inter-tissue
genetic variation in keratoconus patients
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Stawinski6, P. Polakowski7, R. Ploski6, J. P. Szaﬂik7, M.
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Introduction: Evidence linking somatic variants to com-
plex diseases is rising. Keratoconus (KTCN) is a
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multifactorial ocular disease, observed in 1 per 375 indivi-
duals, and its genetic background are not fully understood.
Majority of KTCN molecular studies were performed using
DNA derived from blood. The purpose of this study was to
assess potential inter-tissue genetic variations which may be
involved in KTCN etiology.
Materials and Methods: Corneal tissues as well as
blood samples from ﬁve non-related Polish patients after
KTCN keratoplasty procedure were collected to perform
deep whole exome sequencing (WES) in tissue-blood
sample pairs. DNA samples were prepared into paired-end
libraries and underwent whole exome capture, followed by
deep exome sequencing.
Results: Exome capture discovered somatic variants in
protein-coding regions of each corneal tissue donors. A
number of cornea-speciﬁc variants has differed between
samples and was in range of 6–22, including potential
pathogenic variants in CACHD1 and ZNF467. The most
somatic variation was observed at chr7, including mucins
genes MUC3A and MUC17. No common somatic variant
was observed in the examined samples. Variants in both
blood and matched corneal tissue from the same donor were
also considered. The assessed sample pairs had variants
simultaneously detectable in both tissues, in range of 94–
143, including rare variants in RNF19B and ERICH2.
Conclusions: Somatic variants may represent an addi-
tional component in KTCN etiology. This was the ﬁrst
WES proﬁling of human KTCN corneas.
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Missense mutations substituting Arg51 of Mab21l1
cause a spectrum of murine panocular malformations
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The highly-conserved male abnormal 21 (Mab21)-like
genes are known to regulate eye development. Previously-
reported homozygous Mab21l1-deﬁcient mice have small
eyes with a rudimentary lens (PMID 12642482), whilst
Mab21l2 nulls are embryonic lethal with only a rudimentary
lens and retina (PMID 15385160). Mice heterozygous for
either gene show apparently normal eyes.
We previously identiﬁed heterozygous missense variants
substituting Arg51 of MAB21L2 as a cause of severe eye
malformations with skeletal dysplasia. Homozygous loss-
of-function mutations in MAB21L1 have recently been
reported in a single family with congenital glaucoma and
genital anomalies (PMID 27103078). The crystal structure
of human MAB21L1 was recently determined, with the
protein appearing to pack into a decamer (PMID
27271801). Modelling a mutation of Arg51 was predicted
to disrupt fold stabilisation.
We used CRISPR/Cas9 genome editing to knock-in a p.
Arg51Leu substitution into Mab21l1 resulting in a viable
and fertile heterozygous line on a C57Bl/6 background. The
eyes of adult mice were examined using binocular indirect
ophthalmoscopy, slit lamp and histological examination.
Mab21l1 p.Arg51Leu heterozygotes showed anomalous
optic discs. Homozygous p.Arg51Leu mice showed small
eyes with a spectrum of panocular eye malformations,
including a disorganised anterior segment with abnormal-
ities of the cornea, iris, ciliary body, lens, retina and optic
nerve; the most severely affected eyes had only a rudi-
mentary lens, retina and optic nerve.
In combination with protein structural support of homo-
multimerisation, the heterozygous phenotype in the mice
may be consistent with a mild dominant negative effect of
this mutation, whereas the homozygotes phenocopy null
animals.
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Rare variants with unknown signiﬁcance in candidate
hearing loss genes for Meniere disease in Spain
A. Gallego-Martinez, T. Requena, L. Frejo, A. Estepa, J.
Lopez-Escamez
Centro Pﬁzer-Universidad de Granada-Junta de Andalucía
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Introduction: The genetic architecture in Meniere’s disease
(MD), an inner ear disorder deﬁned by episodic vertigo,
sensorineural hearing loss (SNHL) and tinnitus, is not
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known. We have sequenced a panel of 69 hearing loss
genes to search for rare variants in MD.
Materials and Methods: Nine hundred thirty DNA
samples (890 MD cases and 40 controls) were pooled and
libraries were generated by HaloPlex PCR target enrich-
ment system. Paired-end sequencing of was performed in a
Nextseq500 instrument. BWA and GATK were used for
alignment and quality control. Variant calling was made
through VarScan2. False positives were ﬁltered by similar
strand calling and variants with ≥2 calls in both strands were
examined, prioritized and estimated minor allelic fre-
quencies were compared with public references values in
multiple populations, including Spanish variant server
database.
Results: An enrichment of certain rare variants (18–335
times more frequenctly observed than in gnomAD) was
observed in the DFNB31, GJB2, ESPN, ESRRB, and
MYH14 and RDX genes in our cohort of patients with MD.
Some variants with unknown signiﬁcance showed a higher
MAF compared with Spanish population datasets. Prior-
itizing tools suggest that some of them should be consider
as candidate for MD.
Conclusions: Spanish population has a speciﬁc enrich-
ment of rare variants in some hearing loss genes. The role of
these variants in SNHL and MD remains to be established.
Acknowledgments: Funded by FPS-PI0496–2014 and
2016-Meniere Society, UK.
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Novel GJA8 mutations and CNVs extend the phenotypic
spectrum to include microphthalmia and coloboma
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GJA8 encodes Connexin50 (Cx50), a transmembrane pro-
tein involved in the formation of lens gap junctions. Con-
nexins play a critical role in intercellular communication
and mutations in GJA8 have been linked to congenital and
early onset cataracts in humans and animal models. Inter-
estingly, missense mutations and homozygous deletions of
Gja8 in mice also cause microphthalmia, as well as catar-
acts, suggesting that Gja8 may be involved in ocular growth
in addition to lens development and homeostasis.
To better understand the range of developmental ocular
anomalies associated with GJA8, we screened this gene in a
cohort of patients with severe congenital eye abnormalities,
primarily anophthalmia, microphthalmia and coloboma
(AMC). Four likely pathogenic variants (c.116C>G, p.
(Thr39Arg); c.151G>A, p.(Asp51Asn); c.208T>C, p.
(Phe70Leu); c.290T>G, p.(Val97Gly)) were identiﬁed in
ﬁve families with cataracts, microphthalmia and other
ocular anomalies. These rare or novel mutations were all de
novo or dominantly inherited from an affected parent. Four
rare or novel missense variants of unknown signiﬁcance
were also found in four additional families.
Heterozygous 1q21 deletions involving GJA8 were
identiﬁed in three families with microphthalmia, cataracts
and/or coloboma. Although these structural variants showed
incomplete penetrance, suggesting that modiﬁers may be
important, their identiﬁcation in our cohort supports their
potential contribution to AMC conditions.
The data presented in this study expand the spectrum of
human phenotypes associated with GJA8 variants to include
microphthalmia and coloboma, demonstrating the role of
this gene in early eye development. This highlights the
importance of including GJA8 in the genetic screening of
patients with AMC.
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Anterior segment dysgenesis with microphthalmia,
microcornea, and spontaneously reabsorbed cataract is
associated with a novel mutation in CRYAA
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Introduction: Proband with a sporadic complex ophthalmic
phenotype was initially tested for mutations in PAX6 gene
and 11p13 locus due to congenital iris hypoplasia, micro-
phthalmia, and microcornea and was found to have no
changes. Obscure ophthalmic phenotypes could arise from
clinical and genetic heterogeneity that requires a complex
approach to diagnosis.
Materials and Methods: Affected proband (a 26-year-
old woman) and her healthy relatives underwent detailed
clinical and ophthalmic examination with subsequent
molecular analysis. Whole exome sequencing (WES) was
performed on Illumina NextSeq 500. Sanger sequencing
was used to conﬁrm found changes. The populational study
was performed with PCR-RFLP.
Results: Detailed clinical and ophthalmic examination of
proband revealed microphthalmia, microcornea, anterior
segment dysgenesis, congenital iris hypoplasia, sponta-
neously reabsorbed cataract, complicated glaucoma, fovea
and optic nerve disc hypoplasia, nystagmus and strabismus.
WES analysis identiﬁed heterozygous novel single nucleo-
tide variant (SNV) in CRYAA:c.521A>C leading to C-
terminal extension (CTE) p.*174Serext*41. CRYAA muta-
tions are described in patients with autosomal dominant
congenital cataract type 9 (OMIM #604219). The proband’s
family analysis showed no mutation in healthy members.
The populational study did not ﬁnd this SNV in 210 control
chromosomes of the same ethnic background. Analysis of
closely linked SNP rs112855370 identiﬁed mutation
occurred de novo in the paternal allele.
Conclusions: The in-depth molecular analysis allows
clarifying the diagnosis. Mode of CRYAA damage through
CTE suggests the severity of observed phenotype and
additional defects in ocular development.
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04-00288, 17-04-00475; RSF 17-15-01051.
T.A. Vasilyeva: None. A.A. Voskresenskaya: None. O.
V. Khlebnikova: None. F.A. Konovalov: None. N.A.
Pozdeyeva: None. V.V. Kadyshev: None. R.A. Zinch-
enko: None. A.V. Marakhonov: None.
P02.31C
Identiﬁcation of microRNAs associated with primary
open-angle glaucoma using GWAS data
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Introduction: Genetic polymorphisms in microRNAs
(miRNAs) or miRNA-binding sites (BS) within target genes
are expected to contribute to disease risk. We aimed to
identify miRNAs and target genes that are involved in
glaucoma using data from the largest available GWAS for
glaucoma endophenotypes.
Methods: Polymorphisms in miRNA-encoding sequen-
ces and in miRNA-BS were retrieved from online databases
and their associations were investigated with intraocular
pressure (IOP), cup area, disc area and vertical cup-disc
ratio (VCDR). Target genes for the associated miRNAs
were ranked according to their association with the studied
traits and tested in cell lines by transfection experiments for
regulation by the miRNAs. The most likely functional
miRNA-BS SNPs were prioritized based on various criteria
(e.g. eQTL, miRNA and gene expression, interaction score).
Results: Out of 412 miRNA-SNPs available in IGGC
GWAS data, two SNPs were associated with VCDR and
cup area (signiﬁcant threshold 1.2×10−4). One of the SNPs
is located in the pre-miRNA sequence, and has been shown
to decrease expression of the miRNA. The other is located
in the miRNA-seed region and we showed that the SNP
reduces interaction between the miRNA and its target
CARD10, a gene associated to disc area. Out of 72,052
miRNA-BS SNPs present in IGGC GWAS data, 47 SNPs
(in 21 genes) were signiﬁcantly associated with glaucoma
endophenotypes (p-value<6.9×10−6). These include two
SNPs in CDKN2B, a known glaucoma-associated gene, and
have been experimentally conﬁrmed to disrupt the miRNA-
binding sites.
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Conclusion: Our ﬁndings support the contribution of
miRNAs to the genetic susceptibility to glaucoma.
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During the last 5 years, Massively Parallel Sequencing
(MPS) has deeply modiﬁed routine practices in diagnostic
laboratories. In the ﬁeld of highly genetically heterogeneous
rare diseases, such as non-syndromic hearing loss (NSHL),
MPS has provided the ability to study dozens of genes in a
single assay while only one was analysed just a few years
ago. Since 2015, the Laboratory of Molecular Genetics in
Montpellier University Hospital studies human hearing
impairment with a 70 NSHL genes panel which also
includes 10 Usher syndrome genes. Samples from patients
are referred from all over France. Samples are multiplexed
and 12 samples are sequenced per assay. Considering the
2015-2016 period, we analysed 214 index cases referred for
NSHL. Prior to MPS, we screen for mutations at the
DFNB1 locus (GJB2 gene and GJB6-D13S1830 deletion).
Fifty-ﬁve probands were carriers of a DFNB1 pathogenic
genotype. The remaining 159 probands were analysed using
MPS and 49 of them reported a clear pathogenic genotype
in 24 different genes. Twelve of them carried in addition a
potentially or clearly pathogenic variant in a second gene.
Moreover, several variants, e.g. in ACTG1, TJP2 or in
CDH23, arose de novo. We report here an overall diagnostic
rate of 48% for NSHL in France. We identiﬁed pathogenic
genotypes in several Usher genes, which in some cases
implies critical outcomes for the patient’s follow-up and
outlines the urges to better understand the frontlines
between syndromic and non-syndromic hearing loss. This is
the ﬁrst report of such a large cohort in France.
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First implication of a hypophosphatemia gene in familial
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The ﬁrst etiology of hereditary non-syndromic hearing loss
is the deletion of a Guanine (del35G) in the GJB2 gene,
coding for the Connexin 26 protein. Here we report on a
family with an unusual story of hereditary hearing loss. The
two parents are deaf, as their two daughters, but their son
has normal audition.
Firstly, we performed the molecular analysis of GJB2 in
this nuclear family. The mother was found homozygous for
35delG, her three children were heterozygous, whereas the
father had no GJB2 variant. An enlarged search for GJB2
mutation in the grandparents showed that they were het-
erozygous for 35delG, with a normal hearing function. As
the genotype-phenotype segregation in this family did not
match with the implication of GJB2 35delG, we performed
a New-Generation-Sequencing analysis using a deafness
panel of 146 genes, with no additional informative result.
Finally, an Exome analysis (Integragen) identiﬁed a candi-
date pathogenic variant at the heterozygous state shared by
the deaf father and his two deaf daughters, but absent in the
mother and her son.
This variant concerns SLC9A3R1 gene, that codes for a
Na+/H+ exchanger regulatory factor (NHERF1) expressed
in basal renal cells, and implied in dominant hypopho-
sphatemia with nephrolithiasis (OMIM *604990). Animal
models research proved that this gene is also expressed in
neurons and auditory outer hair cells, with an association
with hearing loss phenotypes.
Our hypothesis is that this gene could be responsible of a
dominant form hearing loss in this family, which has never
been described before in human pathology.
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Introduction: Whole-exome sequencing (WES) represents
a powerful approach to identify genes/mutations responsible
for genetically heterogeneous diseases. We performed WES
on two affected siblings from a consanguineous family with
recessive nonsyndromic hearing loss (NSHL).
Results: Standard WES data analysis for SNVs/indels
excluded point mutations in known NSHL genes and
highlighted a homozygous variant in HCN1 (NM_021072:
c.1250A>G:p.Y417C). The variant segregates with the
phenotype, is absent in ethnically-matched controls and
public databases, and is predicted to be damaging. HCN1
encodes a sodium/potassium channel expressed in spiral-
ganglion neurons and cochlear cells. Moreover, Hcn1
deﬁcient mice show mild auditory deﬁcits. Dominant
mutations in HCN1 were recently associated with early-
infantile epileptic encephalopathy (MIM#615871). Patch-
clamp recordings of HEK293 cells overexpressing the wild-
type or mutant recombinant protein showed a strikingly
decreased current in the presence of the p.Y417C, sug-
gesting a loss-of-function effect. The p.Y417C channel
showed a different current amplitude and kinetics also
compared to the gain-of-function epilepsy-causing p.
D401H mutant. Despite these encouraging results, pointing
to HCN1 as a candidate deafness gene, a re-analysis of
WES data for structural variants, pointed out a 250-kb
homozygous deletion of the OTOA gene, which was con-
ﬁrmed by segregation analysis and PCR.
Conclusions: We characterized a novel loss-of-function
HCN1 variant which is likely functional, although it is
clearly not the primary cause of deafness in our patients. We
are exploring its potential role as phenotype modiﬁer. Our
case report strengthens the importance of performing both
point mutation and structural variant analysis to avoid false
hypes in WES.
Fondazione Cariplo (grant#2013-0825) is acknowledged.
C. Chiereghin: None. F. Mirabella: None. M.
Robusto: None. D. Pozzi: None. P. Primignani: None. L.
Mauri: None. S. Penco: None. M. Patrosso: None. M.
Matteoli: None. S. Duga: None. R. Asselta: None. G.
Soldà: None.
P02.35C
Simultaneous analysis of single nucleotide and struc-
tural variants through NGS using a targeted panel of
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Objectives: Implementation of CNVs detection using a
targeted NGS gene panel for the characterization of ocular
congenital malformations (OCM).
Materials & Methods: A cohort of 88 patients with
OCM was analyzed, including 6 control cases with pre-
viously known pathogenic variants and CNVs. The
remaining 82 uncharacterized patients had variable pheno-
types: 31 with anophtalmia-microphtalmia (A/M), 22 with
coloboma, 17 with optic nerve anomalies and 12 with
anterior segment dysgenesis. A set of 150 genes were
selected and included in a custom gene panel (Haloplex).
SNVs were analyzed following an in-house bioinformatic
pipeline. CNVs identiﬁcation was performed prioritizing
statistically signiﬁcant regions in the read depth. Custom
CGH-arrays (180K, Agilent) are being used for validation
purposes.
Results: A total number of 19 pathogenic SNVs span-
ning 14 different genes and 13 additional VUS were iden-
tiﬁed, validated and segregated in the families. Our speciﬁc
bioinformatic method in combination with the high depth of
coverage (>400×) allowed the detection of the 2 control
cases included in the panel, carrying multi-exon deletions of
PAX6. Additionally, 5 new structural variants were detec-
ted: a duplication of GDF3 and complete deletions of
FOXC1, GJA8, HPS5 and OTX2-SIX6.
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Conclusions: This study allowed the characterization of
24% of the patients (40% of the patients with A/M). Our
results have shown that a NGS panel is a good strategy for
the genetic analysis of OCM patients since it permits the co-
detection of SNVs and CNVs in a single design when a
homogeneous coverage between samples is ensured.
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Introduction: Congenital aniridia is a rare ocular mal-
formation mainly characterized by aplasia or severe
hypoplasia of the iris. Loss of function mutations in PAX6,
the paired box-6 gene essential in eye development, are
involved in >90% of patients with aniridia. We have iden-
tiﬁed seven heterozygous mutations encompassing the
PAX6 DNA binding domain in patients with severe
microphthalmia (reduced eye size) or anophthalmia
(absence of the eye) (MA), developmental delay, micro-
cephaly and/or hypoplasia of the corpus callosum. Subse-
quently, we hypothesized that this atypical phenotype
should be the result of dominant negative mutations. We
thus studied in vitro the functional effects of these mutations
and compared them to the mutations associated with clas-
sical aniridia.
Materials and methods: We performed site-directed
mutagenesis in an expression vector containing the PAX6
coding sequence to create the different mutant clones con-
taining the seven mutations associated with the atypical
phenotype and other three which gave rise to classical
aniridia. Afterwards, we analyzed their transcriptional
activation activity by using the luciferase assay. In addition,
we performed a western blot and a qPCR with the aim of
evaluating the amount of protein and mRNA produced,
respectively.
Results and Conclusions: In this study, we report that
mutations in PAX6 are also involved in MA with a neuro-
logical component. We successfully created all mutated
vectors and optimized the luciferase assay, western blot and
qPCR. Preliminary results showed that luciferase activity
proﬁle might be affected by these two types of mutations,
however, we are currently in the process of conﬁrming this
data.
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Recurrent substitutions in the PAX6 paired domain are
associated with severe microphthalmia, coloboma and
related ocular defects
K. A. Williamson, H. N. Hall, I. M. Hanson, L. J. Owen,
V. van Heyningen, J. A. Marsh, D. R. FitzPatrick
MRC Human Genetics Unit, Institute of Genetics and
Molecular Medicine, University of Edinburgh, Edinburgh,
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Haploinsufﬁciency of PAX6 causes a pan-ocular disease
termed classical aniridia (absent iris associated with foveal
hypoplasia and keratopathy). Missense mutations in PAX6
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have been recognized as a cause of milder or more focal
phenotypes such as partial aniridia, Peters anomaly, isolated
foveal hypoplasia and optic nerve hypoplasia. Here we
show a distinct class of PAX6 missense mutations that are
associated with the structural ocular phenotypes of severe
microphthalmia and coloboma. These recurrent substitu-
tions of speciﬁc residues are primarily in the PAX6 paired
domain alpha helices I and III of the N-terminus subdomain
and helix VI of the C-terminus subdomain: the critical
residues are Arg26, Gly51, Ser54 and Asn124, together
with Arg38 in the linker region between alpha helices I and
II.
In an attempt to understand the molecular mechanisms
underlying these exceptional cases we have used quantita-
tive phenotypic analysis of the differences between >150
individuals with loss-of-function mutations compared to a
matched number with missense variants. This has allowed
us to create rigorous phenotypic classes to inform the
structural modeling of the PAX6 paired domain and the
interpretation of the consequence of substitutions of these
critical residues.
We estimate that this subset of PAX6 missense mutations
account for ~2% of severe eye malformations. It seems
likely that a proportion of these missense mutations result in
a “worse than null” effect via a dominant negative
mechanisim related to altered DNA-protein, or disturbance
of protein-protein, interactions within the bound complex.
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Novel neuro-audiological ﬁndings and further evidence
for TWNK involvement in Perrault syndrome
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Introduction: Hearing loss and ovarian dysfunction are key
features of Perrault syndrome (PRLTS) but the clinical and
pathophysiological features of hearing impairment in
PRLTS individuals have not been addressed. Mutations in
one of ﬁve different genes HSD17B4, HARS2, LARS2,
CLPP or TWNK cause the autosomal recessive disorder but
they are found only in about half of the patients. Materials
and
Methods: We report two siblings with neurological type
of PRLTS. Neuroimaging with volumetric measurements
and objective measures of cochlear hair cell and auditory
nerve function (otoacustic emissions and ABRs) were per-
formed. Whole-exome sequencing was applied to identify
the genetic cause of the disorder. Protein 3D structure
modelling was used to predict the deleterious effects of the
detected variants on protein function.
Results:We found two rare biallelic mutations in TWNK
gene. Mutation c.1196A>G (p.Asn399Ser) recurred for the
ﬁrst time in a patient with PRLTS and the second mutation
c.1802G>A (p.Arg601Gln) was novel for the disorder. In
both patients neuroimaging studies showed diminished
cervical enlargement of the spinal cord and for the ﬁrst time
in PRLTS partial atrophy of the vestibulocochlear nerves
and decreased grey and increased white matter volumes of
the cerebellum. Morphological changes in the auditory
nerves, their desynchronized activity and partial cochlear
dysfunction underlay the complex mechanism of hearing
impairment in the patients.
Conclusions: Our study unveils novel features on the
phenotypic landscape of PRLTS and provides further evi-
dence that the newly identiﬁed for PRLTS TWNK gene is
involved in its pathogenesis. Grants No.: 2011/03/D/NZ5/
05592, 2014/15/B/ST6/05082 and 2013/09/B/NZ2/00121
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Clinical utility of MYOC predictive genetic testing for
primary open-angle glaucoma
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Introduction: MYOC variants are associated with primary
open-angle glaucoma (the most common subtype of glau-
coma) in an autosomal dominant manner with high pene-
trance, and can lead to severe disease if left untreated. Early
interventions can reduce irreversible vision loss due to
glaucoma, emphasising the importance of identifying at-risk
individuals. This study explored the clinical utility of pre-
dictive genetic testing for MYOC.
Material and Methods: MYOC variant carriers were
identiﬁed through the Australian and New Zealand Registry
of Advanced Glaucoma. Individuals were classiﬁed based
on how they retrospectively presented to an ophthalmolo-
gist into Clinical cases (referred by their general practitioner
or optometrist) and Genetic cases (referred following posi-
tive genetic results). Individuals were further classiﬁed
according to the glaucoma severity at the time of their ﬁrst
examination into 4 groups (unaffected, glaucoma suspect,
glaucoma, advanced glaucoma).
Results: 73 MYOC carriers were identiﬁed, comprising
43 Clinical and 30 Genetic cases. At presentation, 83% of
Genetic cases were unaffected and 17% were glaucoma
suspect whereas among Clinical cases, 44% were glaucoma
suspect, 28% had glaucoma and 28% had advanced glau-
coma. Genetic cases were signiﬁcantly younger at pre-
sentation than Clinical cases (40.6 ± 12.5 vs. 47.5 ± 16.7
years, p = 0.018). All clinical parameters related to glau-
coma were worse at presentation among Clinical cases
compared with Genetic cases.
Conclusions: Our ﬁndings show that MYOC predictive
genetic testing leads to early identiﬁcation of at-risk indi-
viduals who can beneﬁt from early interventions to prevent
irreversible blindness. Grants: National Health and Medical
Research Council (APP1023911).
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Introduction: Retinal dystrophy encompasses a range of
diagnoses and modes of inheritance, and more than 250
genes have been associated so far. The molecular diagnostic
strategy has previously depended on the speciﬁc diagnosis
as well as laborious screening of individual genes.
Materials and Methods: We aimed to delineate the
diagnostic outcome and mutation spectrum, by sequencing
124 genes in 602 adult individuals clinically diagnosed with
retinal dystrophy. The individuals had one of the following
diagnoses: autosomal recessive retinitis pigmentosa; auto-
somal dominant retinitis pigmentosa; X-linked retinitis
pigmentosa; Leber’s congenital amaurosis; Usher syn-
drome; Bardet-Biedl syndrome; cone- or cone-rod dystro-
phy; unspeciﬁed macular dystrophy or Stargardt disease;
congenital stationary night blindness or age-related macular
degeneration. All individuals gave written informed consent
for genetic analysis. Variants were interpreted using an in-
house system based on the ACMG 2015 guidelines and
classiﬁed as class 1 (benign), class 2 (likely benign), class 3
(variants of unknown signiﬁcance, VUS), class 4 (likely
pathogenic) or class 5 (pathogenic).
Results: The results from 602 individuals identiﬁed a
likely molecular genetic explanation of their retinal dys-
trophy in 344 (57%) individuals. Variants in nine genes
(ABCA4, EYS, USH2A, BEST1, RHO, RP1, RPGR, CRB1,
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PRPH2) can explain the retinal dystrophy in about half of
the 344 individuals, rendering these as major disease genes.
Conclusion: These ﬁndings conﬁrm that a targeted NGS
panel analysis can provide molecular genetic diagnosis in a
large part of individuals with retinal dystrophies and form
the basis for a rational genetic diagnostic strategy.
Grants: Velux foundation
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CNGA3-associated autosomal recessive achromatopsia
caused by uniparental isodisomy of chromosome 2
S. Kohl, B. Baumann, A. K. Mayer, B. Wissinger
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A single female patient with a clinical diagnosis of achro-
matopsia was referred to our laboratory for genetic research
testing. Achromatopsia is a rare, genetically heterogeneous,
autosomal recessive disorder characterized by color blind-
ness, photophobia, nystagmus, and low visual acuity.
Sanger sequencing revealed an apparent homozygous
missense mutation c.778G>C;p.D260H in CNGA3, pre-
dicted to be disease-causing, and affecting a conserved
amino acid residue in transmembrane domain S3 of the
CNGA3 polypeptide. Segregation analysis proved the father
to be a heterozygous mutation carrier, while the mutation
could not be displayed in the mother. A heterozygous
deletion in the mother explaining the apparent homo-
zygosity of the mutation in the patient was ruled out by
long-distance and qPCR-based copy number analysis of
exon 7. Genotyping of microsatellite markers revealed
homozygosity for all tested markers on chromosome 2 in
the patient for the paternal haplotype, indicative for paternal
uniparental isodisomy (UPD) of chromosome 2.
UPD is a rare phenomenon due to inheritance of both
chromatids of a single chromosome from one parent - here
the paternal chromosome - while the maternal chromosome
is lost. UPD thus can uncover a recessive mutation present
in just one parent, here the missense mutation c.778G>C;p.
D260H in CNGA3 in the father, causing ACHM in the
index patient. It is one of very few examples for this
mechanism observed and described in inherited retinal
dystrophy, and the ﬁrst for achromatopsia. The detection of
UPD highlights the importance of segregation analysis, and
has important implications for counseling and recurrency
risk assessment in this family.
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Introduction: Retinitis Pigmentosa (RP) is a group of
inherited retinal dystrophies (IRD) in which the photo-
receptors and retinal pigment epithelium cells degenerate
leading to progressive visual loss. With a great clinical and
genetic heterogeneity, RP can be inherited in autosomal
dominant (ad), autosomal recessive (ar), or X-linked (xl)
trait. Nevertheless, a major proportion of patients (41% in
Spain) represent simplex cases (sRP) in which the pattern of
inheritance is a priori unknown. Traditionally, sRP patients
have been considered recessive cases; however a precise
inheritance pattern can only be assigned via further diag-
nostic and analytical efforts.
Materials and Methods: We performed a comprehen-
sive genetic study of 106 Spanish patients with sRP using a
high-throughput targeted sequencing panel of 68 IRD-
genes. Sanger sequencing and MLPA was conducted to
validate and to segregate candidate variants in available
family members.
Results: Application of our data analysis pipeline
allowed the identiﬁcation of 96 potential causative muta-
tions in 66 patients (62.26%), of which 37.8% are non-arRP
cases (24.2% adRP and 13.6% xlRP). The most frequent
mutated gene for adRP was PRPF31 and for xlRP, RPGR.
Conclusions: These ﬁndings represent a signiﬁcant
advance in understanding the
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genetic basis of sRP. This study highlights that, although
most families harbour mutations in arRP genes, an unex-
pectedly high proportion of cases harbour mutations in
adRP or xlRP genes which implies consequences for
counselling of patients and families.
Funded by: PI15-01648 (ISCIII and European Union
ERDF/ESF, “Investing in your future”), CIBERER, CTS-
1664 (Government of Andalusia).
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Hereditary sensorineural Non-Syndromic Hearing Loss
(NSHL) is characterized by clinically indistinguishable
phenotypes and genetic heterogeneity, that until recently
have hampered effective early etiological diagnoses.
With the aim of developing advanced diagnostic tools to
investigate the genetic bases of these conditions in a
population of individuals, mainly of pediatric age, we
designed a customized targeted NGS panel of 59 genes,
strongly associated, in Caucasians, with NSHL or syn-
dromes (i.e. Pendred and Usher) with onset as seemingly
isolated deafness.
Ion Torrent PGMTM platform and bioinformatic data
analysis pipeline have been used for the analysis of DNA
samples collected from clinically selected GJB2 negative
patients. Our panel has an average depth coverage of 235X
and a mean of 506 variants/subject.
48 cases have been completed, with a diagnostic yield of
20/48 (42%). We have identiﬁed 18 novel mutations in the
CDH23, MYO7A, COCH, EYA4, PTPRQ, TMPRSS3,
GJB3, SLC17A8, TPRN, OSBPL2, ACTG1, GRHL2,
MYO15A genes. The novel EYA4 mutation, identiﬁed in two
related subjects with post-lingual progressive deafness was
also found to co-segregate in the same family with a new
PAX3 gene mutation in two members with Waardenburg
syndrome phenotype. CDH23 resulted the most frequently
mutated gene in our series (20% positive cases).
The high diagnostic rate demonstrated by the developed
gene panel, is extremely promising for our analysis, which
is currently being extended to other 50 highly selected
cases, and conﬁrms the power of this NGS approach in
combination with appropriate clinical information, to reach
precise etiological diagnoses and provide appropriate
counseling.
F. Cesca: None. E. Bettella: None. R. Polli: None. E.
Leonardi: None. M.C. Aspromonte: None. B. Sicilian:
None. D. Croatto: None. C. Aimoni: None. A. Ferlini:
None. S. Bigoni: None. R. Santarelli: None. A. Murgia:
None.
P02.45A
SLC6A6 taurine transporter: a novel autosomal reces-
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SLC6A6 (OMIM#186854) encodes a known taurine trans-
porter, whose knockout in a reported mouse model is
associated with progressive retinal degeneration at three
months old and very low taurine levels in blood plasma and
other tissues. Taurine plays a key role in retinal develop-
ment, and taurine deﬁciency in rats and cats leads to retinal
degeneration as one of the main pathological features. To
date, SLC6A6 pathogenic variants have not been linked to
any pathology in humans.
Autosomal recessive genetic disorders, including visual
impairment, are more common in consanguineous popula-
tions. By exome analysis and genotyping data within a
consanguineous Pakistani family, with two children suf-
fering from progressive visual loss, we have identiﬁed a
recessively segregating likely pathogenic homozygous
missense variant (NM_003043:c.1196G>T:p.(Gly399Val))
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in the 8th transmembrane domain of SLC6A6. The Gly399
residue is very well conserved down to zebraﬁsh. Interest-
ingly, the fasting blood taurine levels in all tested family
members correspond to the genotypes of the identiﬁed
variant: the two affected children ‘homozygous mutants’
have very low blood taurine levels (6 and 7 μmol/l), while
their parents ‘heterozygous’ have intermediate levels (24
and 34 μmol/l), and an unaffected sibling ‘homozygous
wild-type’ has normal levels (71 μmol/l) (normal values:
37-127 μmol/l). Further studies to characterize the mutation
and to assess its impact on taurine transport, as well as
thorough clinical evaluation of the patients, are currently in
progress.
In summary, SLC6A6 is a promising novel candidate
gene for progressive visual loss in humans and provides a
potential target for nutritional therapeutic intervention.
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Aim: Olfaction plays an important role in daily functioning,
inﬂuencing dietary habits, safety, emotions and overall
well-being, while its’ impairment was implicated in several
neurological diseases. The aim of this study was to inves-
tigate the genetic background of smell recognition.
Materials and methods: 1,966 subjects from two set-
tlements from the Island of Korcula, Croatia, within 10,001
Dalmatians cohort, were involved in the smell recognition
measurement using Snifﬁn' Sticks with 12 scented probes.
Subjects were given four options to choose from for each of
the scent, resulting in the percent of correct responses,
which were used in the HRC imputed GWAS, controlling
for the effects of age, gender, smoking and kinship. Lastly,
a ﬁxed effect meta-analysis was performed, reﬂecting
separate genetic structures of the two sub-sets. Bonferroni
corrected threshold of 2.5E-9 was applied.
Results: Smell recognition was strongly associated with
14 rare intron variants (MAF≤1.3%) involved in various cell
functions, differentiation, structure and chemical sensation.
The most signiﬁcant SNP was rs181890080 (p=2.14E-11,
within STK33 gene) associated with sweet taste signaling.
There were additional 39 SNPs under the signiﬁcance
threshold (p<8.8E-8), and the most relevant gene was
NTN4 responsible for neurite elongation from olfactory
bulb explants.
Conclusion: This study conﬁrms the great complexity of
the genetic basis of smell recognition, having identiﬁed
genes from chemical sensation, but also various other cell
functions that were not previously implied for this trait.
Further reﬁnement of these results in increased sample sizes
is under way.
Funding: Medical Research Council UK, Croatian Sci-
ence Foundation grant 8875.
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Antisense oligonucleotide-based splice correction of two
neighboring deep-intronic ABCA4 mutations causing
Stargardt disease
S. Naessens1, A. Garanto2, M. Bauwens1, R.
Sangermano2, I. Balikova3, B. P. Leroy1,3,4, F. P.
Cremers2, E. De Baere1, R. W. Collin2
1Center for Medical Genetics, Ghent University and Ghent
University Hospital, Ghent, Belgium, 2Department of
Human Genetics and Donders Institute for Brain, Cognition
and Behaviour, Radboud University Medical Center,
Nijmegen, Netherlands, 3Department of Ophthalmology,
Ghent University Hospital and Ghent University, Ghent,
Belgium, 4Division of Ophthalmology, The Children's
Hospital of Philadelphia, Philadelphia, PA, United States
Introduction: Stargardt disease (STGD1) is one of the most
frequent autosomal recessive retinal dystrophies. STGD1
can be caused by over 600 mutations in ABCA4, which
explain 70% of the cases. We and others hypothesize that
the remaining 30% can be largely explained by non-coding
mutations of the ABCA4 locus. Recently, we identiﬁed two
neighboring, deep-intronic mutations in intron 30 of ABCA4
that create a cryptic splice donor site, leading to the inclu-
sion of a 68-bp pseudo-exon.
Materials and methods: We designed 2′-O-methyl
phosphorothioate antisense oligonucleotides (AONs) tar-
geting the cryptic donor site in intron 30. AONs were tested
using minigene assays, by co-transfection of AONs and
minigenes containing exon 30 to 31 of ABCA4 in
HEK293T cells, subsequent RNA-isolation and RT-PCR
analysis. Patients’ ﬁbroblasts were tested for the presence of
the pseudo-exon.
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Results: Both deep-intronic mutations activate a cryptic
donor site, resulting in the use of a nearby strong acceptor
site and the inclusion of a 68-bp pseudo-exon in the ABCA4
mRNA. AONs directed against SC35 motifs in this pseudo-
exon prevent insertion of this exon by blocking the binding
of splicing factors. A nearly full restoration of normal
splicing was observed in a dose-dependent manner. The 68-
bp pseudo-exon was conﬁrmed on patients’ ﬁbroblasts.
Testing of AONs on patients’ ﬁbroblasts is ongoing.
Conclusions: The designed AONs induced skipping of
the aberrant pseudo-exon and resulted in restoration of
normal splicing events of ABCA4 minigenes. Overall, we
demonstrated the efﬁcacy of AON-based splice correction
of two different, neighboring deep-intronic mutations, using
the same AON.
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Next Generation Sequencing of the complete COL2A1
gene and Association Studies in cases of Rhegmatogen-
ous Retinal Detachment
L. K. Towns1, R. Davie2, A. McNinch1,2, A. V. Poulson2, P.
Alexander2, H. Martin2, K. Brugger2, A. J. Richards1,2, M.
P. Snead2
1University of Cambridge, Cambridge, United Kingdom,
2Cambridge University NHS Foundation Trust, Cambridge,
United Kingdom
Retinal detachment (RD) is a serious sight threatening
disorder with approximately 10,000 cases in the UK
annually. Stickler syndrome is the commonest genetic cause
of RD with the type 1 sub-group (mutations in COL2A1) at
particularly high risk but other loci include COL9A1,
COL9A2, COL9A3 and COL11A1. Interestingly, mutations
in COL2A1 have been identiﬁed in dominantly inherited
RD, while the SNP rs1635532 has been found to affect
alternative splicing efﬁciency of exon 2 in COL2A1, pos-
sibly conferring an increased risk of RD. Next generation
sequencing (NGS) was used to identify rare and unique
variants in COL2A1, in a subset of cases with either a giant
retinal tear, bilateral RD or have a family history of RD.
Twenty-seven rare and four unique variants were found,
with six rare variants appearing in three separate samples. A
further 6 cases and 2 controls, from our case/control cohort,
were heterozygous for the variant, c.2356-62 C>T. Ninety-
two SNPs across ﬁve collagen genes (COL2A1, COL9A1,
COL9A2, COL9A3 and COL11A1) were genotyped using
the Sequenom iPLEX assay, including four SNPs in high
linkage disequilibrium with ﬁve rare variants discovered
from NGS. Three SNPs were signiﬁcantly associated with
incidence of RD, rs1635547 (p=0.04747), rs1623332
(p=0.0369) and rs1973953 (p=0.0270). Taqman genotyp-
ing assay conﬁrmed the signiﬁcant associations with
rs1635532 and rs1793953 (p=0.04773 and p=0.02822
respectively). As rs1635532 has previously been found to
affect the alternative splicing efﬁciency of exon 2 in
COL2A1, these results further strengthen its involvement as
a risk factor for RD.
Funded by Cambridge Retinal Research Fund
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Comprehensive study of the STRC gene for the diag-
nosis of autosomal recessive deafness-16 (DFNB16) non-
syndromic hearing loss
R. Muguerza1, J. S. Crettaz1, N. Bastida1, R. Sáez1, L.
Otaolea1, Y. Ramírez1, Z. Martínez2, M. Abrego2
1Genetics Department, Donostia University Hospital, San
Sebastian, Spain, 2Otorhinolaryngology Department,
Donostia University Hospital, San Sebastian, Spain
Introduction: DFNB16, caused by biallelic variants in
STRC, has recently been described as a frequent cause of
non-syndromic hearing loss (NSHL), but the existence of a
pseudogene (pSTRC) with 99.6% coding sequence identity
and the frequency of large deletions in STRC (CNV) make
the study of this gene a challenge. We present a combined
approach for the comprehensive study of STRC.
Materials/methods: 69 NSHL patients negative for the
screening of GJB2/GJB6 and mitochondrial m.1555 and
m.1494 mutations were studied. STRC-speciﬁc digital-
droplet PCR (ddPCR) excluding pseudogene (Mandelker
et al, 2014) was used to detect CNVs. Exome sequencing by
TruSight-One NGS panel (Illumina) was performed to
detect point mutations in STRC and variants were con-
ﬁrmed by Sanger sequencing after a STRC-speciﬁc LR-
PCR (Vona et al, 2015), in order to prevent false-positive
results derived from pseudogene contamination. In addition,
228 normal-hearing individuals where studied to estimate
the general population frequency of STRC deletion carriers.
Results: 4 patients showed homozygous deletion of
STRC and 4 presented heterozygous deletion. From the
latter, 2 presented also a hemizygous single nucleotide
variant, being one pathogenic and the other uncertain but
194
predicted deleterious by bioinformatic tools. Two hetero-
zygous deletion carriers where found in the normal popu-
lation (0.88%).
Conclusions: 5 individuals (7.2%) previously negative
for GJB2/GJB6 and m.1555/m.1494 screening were diag-
nosed using this approach, increasing the diagnostic rate
from 17% to 23%. This data and the frequency of the
deletion carriers in general population underline the con-
venience of including the comprehensive study of STRC in
the screening of NSHL.
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Repair of the prevalent c.2299delG mutation in the
USH2A gene using CRISPR/Cas9 nucleases
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Romero1, T. Jaijo3,1,2, M. D. Sequedo1,2, R. Vazquez-
Manrique1,2, J. M. Millan1,2, E. Aller3,1,2
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Spain, 2CIBER de Enfermedades Raras (CIBERER),
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Introduction: Usher syndrome (USH) is a rare autosomal
recessive disease combining sensorineural hearing loss and
retinitis pigmentosa (RP). Up to 13 genes are associated
with this disorder, although USH2A presents a higher pre-
valence, partially owing to the c.2299delG mutation recur-
rence. Hearing aids or cochlear implants are used by
patients to palliate the hearing impairment. But, up to date,
there are no treatments for RP.
Objetive: To repair the c.2299delG mutation by gene
editing.
Methods: We use the CRISPR/Cas9 system targeting
c.2299delG on ﬁbroblasts from an USH patient carrying the
mutation in homozygosis.
Results: We show successful in vitro mutation repair
when using locus speciﬁc RNA-Cas9 ribonucleoproteins
with subsequent homologous recombination repair induced
by engineered simple strand oligonucleotides (ssODNs)
template supply.
Conclusions: The proven effectiveness of this correction
tool, applied to the c.2299delG pathogenic variant of
USH2A, discloses the CRISPR/Cas9 system future treat-
ment prospects for Usher syndrome. Financial Support:
Fundación Telemaratón “Todos somos raros”. Fondo de
Investigaciones Sanitarias (FIS): proyecto PI13/0068. CFG
is recipient of a fellowship from the FIS:IFI14/00021
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A novel variant in NLRP12 gene in familial Meniere’s
disease suggests NLR mediated inﬂammation in auto-
inﬂammatory inner ear disease
T. Requena1, D. R. Bobbili2, R. Balling2, P. May2, J. A.
Lopez-Escamez1,3
1Genyo, Granada, Spain, 2Luxembourg Centre for Systems
Biomedicine,University of Luxembourg, Luxembourg, Lux-
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tario (CHUGRA), Granada, Spain
Introduction:Meniere’s disease (MD) is a spectrum of rare
disorders characterized by recurrent vertigo attacks, low
frequency sensorineural hearing loss and tinnitus, with a
strong familial aggregation. We have performed whole-
genome sequencing (WGS) analysis in a family with
autosomal dominant MD and autoimmune background.
Materials and Methods: WGS data were processed in a
HiSeqX platform. Scripts developed in house at Lux-
embourg Centre for Systems Biomedicine based in Annovar
were applied to annotate genetic variants with 87 databases,
including allele frequency, protein stability, or regulation
sites. We ﬁltered SNVs by high-quality and MAF &lt 0.001
from 1000 Genomes Project, EVS, ExAC and gnomAD.
We also ﬁltered against a Spanish-database with 790
unrelated individuals to exclude polymorphisms and local
variations. Then we prioritized according different patho-
genic scores including combined scores as CADD, Revel
and FATHMM. All variants were validated by Sanger
sequencing.
Results: After ﬁltering and prioritizing, we have identi-
ﬁed two novel heterozygous variants in the VHL and
NLRP12 genes. Linkage analysis and clinical data dis-
carded VHL as causal gene in this family. We also showed
the expression of NLRP12 in the human inner ear tissue.
Since NLRP12 negatively regulates T cell responses, we
suggest that NLRP12 may cause autoinﬂammatory inner ear
disease in this family.
Conclusion: Our results support that mutations in
NLPR12 may cause autoinﬂammatory inner ear disease in
patients with MD and autoimmune background.
Acknowledgments: Funded by F_69 Action of hearing
grant; DRB and PM were supported by the EU Joint
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17q24.3 Duplication In A Patient Presenting With SRY-
Negative 46,XX Disorders of Sex Development
P. O. Simsek Kiper, A. Ozon, N. Gonc, A. Alikasifoglu, G.
E. Utine, K. Boduroglu, M. Alikasifoglu
Hacettepe University, Ankara, Turkey
Introduction: Disorders of sex development (DSD) are a
group of disorders affecting gonad and/or genitourinary
tract development. The underlying genetic causes of 46,XX
SRY-negative ovotesticular DSDs are poorly understood.
Recently, 46,XX DSD patients with large duplications
upstream of SOX9 have been described. A region located
upstream of SOX9 was assumed to contain gonad speciﬁc
enhancer(s), gain or loss of which results in activation or
inactivation of gonadal SOX9 expression, respectively.
Materials and Methods: We here report on clinical and
molecular ﬁndings of a 19-month-old patient with ambig-
uous genitalia. Karyotype, SRY deletion and array CGH
analyses were performed.
Results: The patient was the product of a non-
consanguineous marriage and was born at term with a
birthweight of 3100 g. Developmental milestones and
growth parameters of the patient were normal. Physical
examination revealed bilaterally palpable gonads in labio-
scrotal folds, a phallus of 4 cm in length, a severe chordee
and a single urogenital sinus opening. The patient was 46,
XX and SRY was negative. Array CGH analysis using
Agilent SurePrint® G3 CGH 8×60K Human Microarray Kit
revealed Arr[hg19]17q24.3(69151003-69970418)X3, a
duplication of 819 kb located upstream of SOX9 on chro-
mosome 17q24.3.
Conclusion: This report adds literature a new case of
SRY-negative 46,XX DSD with a duplication located
upstream of SOX9. Identiﬁcation of new CNVs and deli-
neation of the associated phenotypes in detail will help us
understand better the mechanisms involved in sexual
development and uncover the genetic defects underlying
DSDs.
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Molecular karyotyping in ten patients with isolated
anorectal malformation
P. Ozyavuz Cubuk1,2, E. F. Percin1, G. Kayhan1
1Gazi University Hospital, Medical Genetics Department,
Ankara, Turkey, 2Department of Medical Genetics, Haseki
Resarch and Training Hospital, İstanbul, Turkey
Introduction: Anorectal malformations (ARM) are classi-
ﬁed in the group of multifactorial diseases. Because of the
complexity of the pathological changes, etiology of ARM is
still not clear. In the present study, we aimed to investigate
the molecular cytogenetic factors in ARM etiology.
Materials and Methods: Ten ARM patients with nor-
mal karyotype and not associated with known genetic
syndrome were included in this study. Array-CGH analysis
was performed using the Agilent 60K ISCA Array platform.
Results: Chromosome 22q11.2 deletions were detected
in two patients. One of this patients had anal stenosis, minor
cardiac abnormalities, mild dysmorphic features, and a
small 0.89-Mb deletion. The second patient had anal atresia,
immune deﬁciency, inguinal hernia and 2.7-Mb cryptic
deletion. Overlapping genes in the deletion regions of two
patients are DGCR5, DGCR6 and PRODH. Of the
remaining 8 patients, two had variant of unknown sig-
niﬁcance and six had benign CNVs.
Conclusions: To our knowledge, this region is one of the
smallest interstitial deletion on chromosome 22q11.2 region
which has been published up to now. DGCR5, DGCR6,
PRODH genes may be candidate for one of the etiologic
factors of the ARM. This view is also supported by the
existence of ARM patients with 22q11.2 deletion published
earlier. Especially DGCR6 gene which is a crucial gene for
neural crest cell migration, could be responsible of anal
atresia. We believe that further research on this gene will
clarify this point.
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Sequence variant at 4q25 near PITX2 associates with
appendicitis
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Galesloot2, G. Thorleifsson1, K. K. Aben3, O. B.
Davidsson1, S. Jonsson1, G. A. Arnadottir1, K. F.
Alexandersson1, B. O. Jensson1, G. Walters1, J. K.
Sigurdsson1, S. Sigurdsson1, H. Holm1, D. O. Arnar4, G.
Thorgeirsson1, K. Alexiusdottir4, I. Jonsdottir1, U.
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1deCODE genetics, Reykjavik, Iceland, 2Radboud Univer-
sity Medical Center, Nijmegen, Netherlands, 3Netherlands
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Introduction: Appendicitis is one of the most common
conditions requiring acute surgery and can pose a threat to
the lives of affected individuals.
Materials and methods: We performed a genome-wide
association study of appendicitis in 7,276 Icelandic and
1,139 Dutch cases and large groups of controls.
Results: In a combined analysis of the Icelandic and
Dutch data, we detected a single signal represented by an
intergenic variant rs2129979 [G] close to the gene PITX2
associating with increased risk of appendicitis (OR = 1.15,
P = 1.8×10−11). The association can only be observed in
patients diagnosed in adulthood. The marker is very close
to, but distinct from, a set of markers reported to associate
with atrial ﬁbrillation, which have been linked to PITX2.
Conclusion: PITX2 has been implicated in determination
of right-left symmetry during development. Anomalies in
organ arrangement have been linked to increased prevalence
of gastrointestinal and intra-abdominal complications,
which may explain the effect of rs2129979 on appendicitis
risk.
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Complex genetic analysis approach in selected patients
with congenital anomalies of the kidney and urinary
tract
V. M. Penchev1, A. Boueva2, P. Miteva3, D. Roussinov3,
G. Zlatanova3, S. Marinova3, R. Kaneva1, V. Mitev1, O.
Beltcheva1
1Molecular Medicine Center, Medical University of Soﬁa,
Soﬁa, Bulgaria, 2SBAL Pediatric Diseases "Dr. Lisich-
kova", Varna, Bulgaria, 3SBAL Pediatric Diseases,
Nephrology and Hemodialysis Clinic, and Department of
pediatrics, Medical University of Soﬁa, Soﬁa, Bulgaria
Introduction: Congenital anomalies of the kidney and
urinary tract (CAKUT) are the commonest cause of chronic
kidney disease in children. Defects can be unilateral or
bilateral, and in many cases different anomalies coexist in
onе individual. Some forms are associated with positive
family history which indicates the genetic component in the
pathogenesis. The development of CAKUT is a complex
process where the interactions of many factors are involved.
Materials and methods: In the present study 71 patients
from 56 families were included. All patients were screened
for mutations in HNF1B, PAX2, SALL1, SIX1 and EYA1
genes via Sanger sequencing. MLPA was used for detection
of possible deletions/duplications in HNF1B. Cases, in
which no genetic variants were identiﬁed during the initial
screening were subjected to aCGH and NGS assays in order
to extend the targeting of genetic defects, responsible for the
pathology.
Results: During the initial screen, point mutations in
HNF1B, SALL1 and PAX2, as well as deletion of the entire
HNF1B gene were detected. The higher throughput
approaches (aCGH and NGS) allowed us to identify a low
level mosaic aneuploidy, large deletions as well as oligo-
genic inheritance.
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Conclusions: Application of high throughput techni-
ques, such as aCGH and NGS, could contribute to under-
standing the molecular causes in cases with composite
clinical phenotype. The genetic screening even with
extended genetic panels cannot isolate the molecular
pathology in every CAKUT patient. For those cases an
implementation of exome and transcritptome analysis may
be required.Funding: MU-43/2009, DMU03/73-2011, 18-
D/2014, 17-D/2015; DUNK01-2/2009
V.M. Penchev: None. A. Boueva: None. P. Miteva:
None. D. Roussinov: None. G. Zlatanova: None. S.
Marinova: None. R. Kaneva: None. V. Mitev: None. O.
Beltcheva: None.
P03.06B
NGS-panel consisting of genes with cholestatic potential
identiﬁed pathogenic and predisposing variants in 10 of
33 patients with unexplained cholestatic liver disease
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Introduction: Variants in genes involved in bile transport
and formation may be an important disease-related factor in
cholestatic liver disease. In a clinical setting we examined
this impact by testing a panel of 8 genes (ATP8B1,
ABCB11, ABCB4, JAG1, NOTCH2, ABCC2, ABCG5 and
UGT1A1) known to cause cholestatic disease in patients
with chronic unexplained cholestasis after standard diag-
nostic examination.
Materials and Methods: From 2011-2015 33 patients
with unexplained cholestasis were included. Sequence
variations in the coding regions of the 8 genes and the
promoter region of UGT1A1 were examined by using tar-
geted Next Generation Sequencing of DNA extracted from
whole blood. In close collaboration clinical geneticists and
hepatologists assessed the possible causal relationship of
genetic variants after state-of-the-art clinical genetic work-
up.
Results: Variants considered a major factor or of pre-
disposing importance to the cholestatic condition were
discovered in 10 of 33 cases (30%). To state this association
evaluation of family history was often necessary. In women
with prolonged symptoms after intrahepatic cholestasis
during pregnancy a genetic cause or predisposition was
identiﬁed in 8 of 13 (62%).
Conclusion: The gene panel provided an effective tool to
investigate unexplained cholestatic liver disease and sug-
gests that in at least 30% of the cases genetic variants are
involved in the pathogenesis. Larger cohorts should be
examined in the future to justify genetic testing and the
panel should be expanded. Classical clinical genetic work-
up and hepatological expertise combined are necessary to
interpret results.
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Development of the most comprehensive genetic test
based on next generation sequencing for diagnosis of
congenital hypothyroidism
H. Cangul1, M. Ozel1, N. Genc1, A. D. Kardelen2, F.
Darendeliler1
1Istanbul Medipol University, Istanbul, Turkey, 2Istanbul
University, Istanbul, Turkey
Congenital hypothyroidism (CH) is the most common
neonatal metabolic disorder and, if untreated, results in
severe neuro-developmental impairment and infertility.
Genetic diagnosis not only allows deﬁnite diagnosis of the
disease but also reveals the pathogenic mechanism by
which CH develops. CH is genetically heterogeneous and to
date 11 causative genes have been identiﬁed for the
development of the disease. Next generation sequencing
(NGS) technology enables sequencing of may genes at the
same time in many patients at a reasonable cost. Thus, we
aimed to develop a new method for efﬁcient genetic diag-
nosis of CH based on NGS. To achieve this aim we carried
out following work on DNA samples of 100 CH cases born
especially to consanguineous families: (i) determination of
the known-genetic CH locuses by linkage analysis; (ii)
detection of mutations in patients linked to a known CH
gene by conventional sequencing; (iii) mutation screening
in patients with no linkage by using NGS. By this approach
we were able to detect mutations in 73% of the cases,
doubling the pick-up rate with conventional methods. The
determinations of causative genes and mutations in this
study contributed to the diagnosis and classiﬁcation of CH
and enhanced understanding the thyroid physiology as well
as underlying molecular mechanisms leading to the devel-
opment of CH.
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COPA syndrome in an Icelandic family caused by a
recurrent missense mutation in COPA
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Introduction: Rare missense mutations in the COPA gene
have recently been established as a cause of autoimmune
interstitial lung, joint and kidney disease, also known as
COPA syndrome, under dominant mode of inheritance.
Here we describe an Icelandic family with three affected
individuals over two generations (index, her son and
daughter) with a rare clinical presentation of lung and joint
disease and a histological diagnosis of follicular
bronchiolitis.
Materials and Methods: We performed whole-genome
sequencing of the three affected as well as three unaffected
members of the family, and searched for rare genotypes
associated with disease using 30,067 sequenced Icelanders
as a reference population. We assessed all coding and
splicing variants, prioritizing variants in genes known to
cause interstitial lung disease.
Results: We detected a heterozygous missense mutation,
p.Glu241Lys, in the COPA gene, private to the affected
family members. The mutation occurred de novo in the
mother and was absent from 30,067 Icelandic genomes and
141,353 individuals from the genome Aggregation Data-
base (gnomAD). The mutation occurs within the conserved
and functionally important WD40 domain of the COPA
protein.
Conclusions: This is the second report to present the p.
Glu241Lys mutation in COPA, indicating the recurrent
nature of the mutation. The mutation was reported to co-
segregate with COPA syndrome in a large family from the
USA with ﬁve affected individuals, and classiﬁed as
pathogenic. The two separate occurrences of the p.
Glu241Lys mutation in cases and its absence from a large
sequencing set conﬁrms its role in the pathogenesis of the
COPA syndrome.
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Introduction: Although a striking proportion (25-45%) of
patients with chronic obstructive pulmonary disease
(COPD) are never-smokers, most genetic susceptibility
studies have not investigated this group exclusively. We
therefore performed a Genome-Wide Association Study
(GWAS) on COPD in 5,070 never-smokers of the LifeLines
study and further assessed the identiﬁed genetic variants
using a multi-omics approach.
Methods: COPD was deﬁned as the ratio of Forced
expiratory volume in one second over Forced vital capacity
(FEV1/FEV) <70%. The GWAS was adjusted for sex, age
and height. SNPs with a p-value<10−5 were validated in a
meta-analysis of never-smokers from the Vlagtwedde-
Vlaardingen study and Rotterdam Studies I-III (n=
1,966). Subsequently, we performed quantitative trait loci
(QTL) analyses for expression in lung tissue (cis eQTL, n
= 1,087) and for blood DNA methylation (meQTL, n=
1,561) within the LifeLines study.
Results: Four SNPs were associated with COPD in
never-smokers (p<10−5). Two SNPs were suggestively
replicated: rs7519348 (NFYC, p=0.08) and rs6913003
(FABP7, p=0.07), with the same direction of effect in all
cohorts. Further, rs7519348-A was associated with higher
expression of NFYC-AS1 and a meQTL for 20 CpGs
(12 showed lower methylated). The FABP7 SNP was not an
eQTL in lung tissue, but was associated with lower
methylation of 2 CpGs. NYFC is a transcription factor that
binds promoters of genes previously associated with airway
obstruction, and FABP7 may be involved in abnormal
pulmonary development.
Conclusions: The genes FABP7 and NFYC(-AS1) could
play a role in the pathogenesis of airway obstruction in
never-smokers through epigenetic regulatory mechanisms.
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Cystic ﬁbrosis is one of the commonest monogenic diseases
all over the world. Worldwide the most frequent mutation
causing CF is CFTR p.F508del - deletion of phenylalanine
in the ion channel protein. This deletion results in abnormal
folding and degradation of the protein immediately after its
synthesis. One of the most promising therapeutic approa-
ches for monogenic diseases is gene therapy. CRISPR/Cas9
provides best opportunities to edit mutations directly in the
host genome. We develop CRISPR/Cas9 based correction
of CFTR p.F508del. One of the main drawbacks of genome
editing in vivo is unnecessary editing of the normal allele.
This can be overcome by designing sgRNA targeting
mutated allele only. However, the obligatory PAM
sequence limits choice of target sequences for Cas9/sgRNA
complexes. We performed CFTR editing and compared four
sgRNAs, two different Cas9 enzymes and two cell lines
including CFTR29o- culture homozygous for p.F508del.
We also analyzed possible reasons why sgRNA activity
may depend on cell line and sgRNA sequence. Several
sgRNAs in the region of CFTR p.F508del are active and
induce indels by NHEJ after Cas9 editing, but not the
sgRNA#1 targeting the mutated allele. Different model cells
demonstrate dramatically different editing efﬁcacy. Immune
response which was initially hypothesized to attenuate
activity turned out as unlikely to be responsible. Another
hypothesis why sgRNA#1 may be inefﬁcient include high
AT content and, hence, overall low stability of the
sgRNA#1-DNA interaction. Overall efﬁcacy of CRISPR/
Cas9-induced NHEJ depends greatly on cell type, genome
locus and sgRNA sequence.
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Introduction: Crohn's disease (CD) is usually diagnosed as
uncomplicated form of the disease. Nevertheless, a majority
of patients will progress to complicated stricturing and
penetrating form during their lifetime. The aim of the pre-
sent study was to identify DNA polymorphisms (SNPs)
associated with time of the disease progression using a
comprehensive association study.
Materials and Methods: 111 patients with uncompli-
cated form of the disease at the time of diagnosis were
enrolled in this study and were followed-up for 10 years.
This study was approved by the Regional Ethics Committee
and written informed consent was obtained from all
patients. DNA was extracted from peripheral blood mono-
nuclear cells. Genotyping was performed using a custom
made Illumina iCHIP. Data analysis was performed using
PLINK v1.07 and IBM SPSS Statistics 22.0.
Results: Obtained results have shown that patients with
CC (2 years) or AC (5.1 years) genotype at SNP
rs16857259 near gene CACNA1E progressed to compli-
cated form earlier as compared to patients with genotype
AA (8.8 years) (p=3.82×10−7). Furthermore, suggestive
association with disease progression (p<10−5) was found
for 9 additional SNPs near genes RASGRP1, SULF2, XPO1,
ZBTB44, HLA DOA/BRD2, HLA DRB1/HLA DQA1,
PPARA, PUDP and KIAA1614. Moreover, construction of
genetic risk score (GRS) for associated SNPs with sub-
sequent multiplicative cumulative GRS score for individual
patient conﬁrmed strong correlation with time to progres-
sion (ρ=−0.719; p=2.95×10−18).
Conclusions: Our study found strong association and
correlation between locus on chromosome 1 near gene
CACNA1E with time to progression from uncomplicated to
complicated form of CD in Slovenian patients.
M. Gorenjak: None. K. Repnik: None. C.P. Drobez:
None. I. Ferkolj: None. U. Potocnik: None.
P03.12D
Structure-based prediction of CYP21A2 novel variants
and a survey of gene variations
C. S. Fernandez1, C. D. Bruque1,2, M. Delea1, J. V. Orza1,
L. Simonetti2, M. Taboas3, N. Buzzalino1, L. D. Espeche1,
A. Solari1, V. Luccerini4, A. D. Nadra5, L. Dain1,2,5
1National Center of Medical Genetics, ANLIS, Ministry of
Health, Buenos Aires, Argentina, 2Institute of Biology and
Experimental Medicine, CONICET, Buenos Aires, Argen-
tina, 3Regenerative Medicine Laboratory, Department of
Orthopaedics and Traumatology, J. Fernandez Hospital,
Buenos Aires, Argentina, 4Laboratory of Genetics, Rosario,
Argentina, 5School of Sciences, University of Buenos Aires,
Buenos Aires, Argentina
Congenital adrenal hyperplasia (CAH) due to 21-
hydroxylase deﬁciency accounts for 90-95% of CAH
cases. In this work we performed an extensive survey of
mutations and SNPs modifying the coding sequence of the
CYP21A2 gene. Using bioinformatic tools and two plau-
sible CYP21A2 structures as templates, we initially classi-
ﬁed all known variants (343) according to their putative
functional impacts, which were either reported in the lit-
erature or inferred from structural models. We then per-
formed a detailed analysis on the subset of variants believed
to exclusively impact protein stability. Using the FoldX
software, we initially calculated the free energy difference
between 30 mutants with experimental residual enzymatic
activity (REA) reported and the wild-type counterparts and
plotted against the natural logarithm of the REA. We
obtained a correlation R2=0,79 for the bovine model and
R2=0,60 for the human crystal. We validated our method
by estimating the in silico REA of other 10 mutations with
known experimental activities. A high concordance was
obtained when comparing our predictions with in vitro REA
and/or the patient’s phenotype. The predicted stability and
derived activity of all reported mutations and SNPs lacking
functional assays (n= 108) were assessed. As expected,
most of the SNPs (52/76) showed no biological implica-
tions. Moreover, this approach was applied to evaluate the
putative synergy that could emerge when two mutations
occurred in cis. In addition, we propose a putative patho-
genic effect of ﬁve novel mutations: p.L107Q, p.L122R, p.
R132H, p.P335L and p.H466fs, found in 21-hydroxylase
deﬁcient patients of our cohort.
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Introduction: Androgen insensitivity syndrome (AIS) is an
X-linked recessive condition resulting in a failure of normal
masculinization of the external genitalia in chromosomally
46,XY individuals. This failure of virilization can be either
complete androgen insensitivity syndrome (CAIS) or partial
androgen insensitivity syndrome (PAIS), depending on the
amount of residual receptor function. Mutations in the AR
gene on chromosome Xq12, cause androgen insensitivity
syndrome. In this study, it was aimed to investigate the
mutation spectrum in Turkish patients who had AR muta-
tion analysis with suspected gender development disorder
and AR insensitivity syndrome.
Materials and Methods: The AR gene from the DNA
material isolated from the peripheral blood of patients was
ampliﬁed using appropriate primers and sequenced using
the new generation sequence analysis technique on the Mi-
Seq device.
Results: In this study, molecular analysis results of 383
individuals who underwent AR genetic analysis in Ege
University Medical Genetics Department between 2011-
2016 were evaluated retrospectively. There were 44 muta-
tions in these cases. Of the 44 cases detected in the muta-
tion, 16 were affected and the karyotypes were 46,XY. 28
of them are the 46, XX carrier mothers, carrier relatives or
siblings of the affected cases.
Conclusion: New mutations detected in our studies
between 2011-2016; L57Q, T576I, D691Y, P672R, Q739E,
p.R544KfsX8, c.1745_1747delTCT, F726S, L881V,
R102G, L863F. Different mutations can be detected in AR
gene in Turkish society. In cases with disorder of sex
development, AR should be examined.
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Disorders of sex development (DSDs) refer to a range of
congenital disorders where the chromosomal, gonadal or
anatomical sex is atypical. Genetic testing is key in estab-
lishing diagnosis, allowing for personalised patient man-
agement. Prior to Next Generation Sequencing (NGS),
genetic tests were only available for a few DSD genes,
which required sequential testing. Pinpointing the molecular
cause of a patient’s DSD can signiﬁcantly impact patient
management by informing future needs or altering man-
agement strategies.
Using the TruSight One technology to screen 30 DSD
related genes (listed below), we have demonstrated a 32%
pick-up rate in the ﬁrst 75 patients tested. Pathogenic
mutations in AR, SRD5A2, HSD17B3, NR5A1, AMH,
AMHR2, WT1, LHCGR & MAMLD1 were identiﬁed, some
of which have resulted in changes to patient management.
For example, we reported a girl with an AR mutation who
was subsequently spared surgical intervention and identiﬁed
a WT1 mutation in a baby who was consequently referred
for Wilms tumour screening. This data also highlights some
202
of the challenges around variant interpretation in DSD
diagnostics such as incidental ﬁndings and mosaicism.
46, XY DSD 46, XX DSD
Disorders of
Testicular
Development
Disorders of
Hormone
synthesis or
action
Disorders of
Ovarian
Development
Androgen
Excess
WT1
(11p13)
DHCR7
(11q12-q13)
SRY
(Yp11.3)
HSD3B2
(1p13)
CBX2
(17q25)
LHCGR
(2p21)
SOX9
(17q24)
POR (7q11.2)
NR5A1/SF1
(9q33)
StAR
(8p11.2)
RSPO1
(1p34.3)
CYP11B1
(8q21-q22)
SRY
(YP11.3)
CYP11A1
(15q23-24)
WNT4 (1p35) CYP19A1
(15q21)
SOX9
(17q24-q25)
HSD3B2
(1p13.1)
Glucocorticoid
receptor (5q31)
DHH
(12q13.1)
CYP17A1
(10q24.3)
Table listing
the genes
covered by
our panel.
ARX
(Xp22.13)
POR
(7q11.2)
TSPYL1
(6q22-23)
CYB5A
(18q23)
MAMLD1
(Xq28)
HSD17B3
(9q22)
DMRT1
(9p24.3)
SRD5A2
(2p23)
ATRX
(Xq13.3)
AR (Xq11-
q12)
NR0B1/
DAX1
(Xp21.3)
AMH
(19p13.3-
p13.2)
WNT4
(1p35)
AMHR2
(12q13)
We have demonstrated that an NGS strategy can improve
molecular diagnosis of DSDs, resulting in quicker and
cheaper tests as well as a more accurate prediction of
recurrence risk. For complex multigenic disorders such as
DSD, identifying the molecular cause is crucial for effective
management and counselling.
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Introduction: Familial intrahepatic cholestasis (FIC) refers
to a group of rare autosomal recessive diseases present in
infancy or childhood. Mutations in ATP8B1, ABCB11,
ABCB4 and TJP2 genes are associated respectively to FIC1,
2, 3 and 4 forms. To improve the diagnostics of FIC, we
developed and validated a targeted-NGS to test these genes
simultaneously.
Materials and Methods: We studied 13 FIC1-2, 73
FIC3 and 14 unclassiﬁed patients. The amplicon-based
NGS was developed by Ion Torrent PGM, data analysis was
performed by Variant Caller and predictions were made on
SIFT, PolyPhen-2 and Human Splicing Finder. Validations
were performed by Sanger sequencing.
Results: We identiﬁed 13 likely pathogenic variants, 11
variants of uncertain signiﬁcance and 1 splicing variant: 3 in
ATP8B1, 8 in ABCB11, 10 in ABCB4 and 4 in TJP2 genes.
In ATP8B1 the novel P23L was in compound heterozygosis
with a known mutation. In ABCB11 we identiﬁed the novel
variants Y93S, V597L and S1100Qfs*38 and in ABCB4 the
novel Y403C, L672* and 2925-2A>G. In TJP2, only the
A287V novel variant was detected. 4 among 13 FIC1-2
patients showed defects in ATP8B1 or ABCB11 genes. Only
19 among 73 FIC3 patients had alterations in ABCB4 gene,
while 7 cases showed variants in ABCB11 or TJP2. 39
benign polymorphisms were also detected.
Conclusions: Our analysis yielded a low detection rate
(25%), conﬁrming the great heterogeneity of FIC pheno-
types. Additional genes and/or a non-Mendelian transmis-
sion may contribute to the disease, making up a
predisposing genetic proﬁle.
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Focal segmental glomerulosclerosis (FSGS) is a morpho-
logic pattern of glomerular injury directed at the glomerular
visceral epithelial cell, podocyte, and deﬁned by the pre-
sence of sclerosis involving parts (segmental) or some
(focal) glomeruli, identiﬁed by a renal biopsy. FSGS is
characterized by nephrotic syndrome and it is more frequent
in children and adolescents. About 30-50% of affected
individuals don’t respond to steroid therapy, leading to end-
stage renal disease. So far, our understanding of FSGS
pathogenesis derived only from instrumental studies,
focused to identifying structural alterations of the slit dia-
phragm and the actin cytoskeleton of podocytes, considered
critical to maintaining glomerular function. Up to now,
literature data agree on the genetic heterogeneity of the
FSGS, indicating monogenic disorders (e.g.SRNS) as cru-
cial of this condition.We analyzed the whole-exome
sequencing of 50 individuals diagnosed, by biopsies, for
early onset “primary” FSGS. In more than 50% of cases we
identiﬁed for each sample two or more candidate pathoge-
netic variants not only in podocyte genes, but surprisingly
also in different genes involved in kidney morphogenesis.
Taken together, the pathogenic variants explain the patient's
clinical picture suggesting that digenic/polygenic inheri-
tance, due to variants transmitted in various combination
from each healthy parent, is underlying the renal disorder
that determines the FSGS development. The knowledge of
FSGS molecular basis can contribute to the reﬁnement of
focused clinical management and could be used to counsel
patients and/or parents regarding prognosis.
A. Provenzano: None. S. Landini: None. G. Sansavini:
None. B. Mazzinghi: None. F. Becherucci: None. V.
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Incidence of GANAB in polycystic kidney disease
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UMR1078,Service de Néphrologie, Hémodialyse et Trans-
plantation Rénale, CHU Hôpital de la Cavale Blanche,
Brest, France, BREST, France, 3INSERM UMR1078
Etablissement Français du Sang (EFS) – Bretagne, Brest,
France, BREST, France, 4Service de Néphrologie, Hémo-
dialyse et Transplantation Rénale, CHU Hôpital de la
Cavale Blanche, Brest, France, BREST, France, 5INSERM
UMR1078, BREST, France
Autosomal Dominant Polycystic Kydney Disease(ADPKD)
is a genetically heterogeneous disease with two genes
PKD1 and PKD2 responsible of respectively 75% and 15%
of ADPKD patients .Recently a new gene,GANAB has
been reported to be involved in polycystic diseases(Porath
et al, Am J.Hum Genet 2016) .For many years we have
completely analyzed a large cohort of more than 3000
ADPKD patients and performed a genotype/phenotype
correlations (Audrezet et al, Hum Mut,2012 ;Cornec-Le
Gall et al, J.Am Soc Nephrol, 2013) in this disorder. In
about 10% of our cohort, no mutation were found either in
PKD1 or PKD2.Here we sequenced the coding sequence of
the gene in a large cohort (291 patients) of non PKD1 non
PKD2 mutated patients . Results : We identiﬁed 4 families
with a deleterious mutation in GANAB .The following
mutations were found :c.2723del ;c.39-1G/C ;c.334 C/T ;
c.2176 C/T). A genotype/phenotype correlation was per-
formed and we showed that the patients with a GANAB
mutation display both a renal and a liver polycystic disease .
Most of the time the size of the kidney is not increased and
these patients display a mild form of the disease . Conclu-
sion : GANAB is a new gene associated with an autosomal
dominant transmission of poly cystic kidney and liver dis-
ease .The incidence of the disease is rare with a frequency
of 1.6/1000 of the ADPKD diseases .However the
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molecular diagnosis of GANAB patients is important to
include or not these patients in the future clinical trials .
Mastri: None.M. Audrezet: None. E. Cornec-Le Gall:
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Creation and characterisation of induced pluripotent
stem cells from Hirschsprung disease patients and their
promise for future therapeutic strategies
K. C. MacKenzie1, E. Brosens1, R. W. W. Brouwer1, W. F.
J. van Ijcken1, M. Ghazvini1, J. Gribnau1, C. J. H. M.
Meeussen1, C. E. J. Sloots1, A. S. Brooks1, R. M. H.
Wijnen1, A. J. Burns1,2, R. M. W. Hofstra1,2
1Erasmus University Medical Centre, Rotterdam, Nether-
lands, 2University College London, London, United
Kingdom
Introduction: Hirschsprung disease (HSCR) is a complex
genetic disorder affecting the Enteric Nervous System and
is characterised by a failure of enteric neural crest cells to
fully colonise the developing gut tube. HSCR is currently
treated by removal of the affected aganglionic tissue.
Therefore, current therapies do not alleviate the underlying
cause. This might be overcome by cell therapy, using an
allogenic patient source. However the genetic variants that
prevented normal development would still be present.
HSCR is often the result of multiple genetic disturbances
shifting the balance of a molecular network from normal to
impaired. Correcting one major genetic variant could restore
this balance.
Materials & Methods: Fibroblasts were cultured from
skin biopsies taken at the time of corrective surgery of
HSCR patients. Their DNA was exome screened and
ﬁbroblast lines with deleterious variation in HSCR disease
genes were selected for creation of induced pluripotent stem
cell (iPSC) lines. iPSC lines are established and prolifera-
tion, migration and differentiation to vagal neural crest
lineage were assessed. Ongoing work concerns using
CRISPR-Cas9 to correct the variants and restore impaired
functions.
Results: Patient speciﬁc iPSC lines were induced from
ﬁbroblast samples with deleterious variants in RET, ZEB2,
PHOX2B and GFRA1. Proliferation, migration and differ-
entiation to vagal neural crest lineage were assessed.
Conclusions: Patient speciﬁc iPSC lines have been
established, in order to study the balance of genetic invol-
vement in HSCR. These cells are, to our knowledge, the
ﬁrst HSCR patient-derived iPSC lines containing deleter-
ious variants for HSCR implicated genes.
K.C. MacKenzie: None. E. Brosens: None. R.W.W.
Brouwer: None. W.F.J. van Ijcken: None. M. Ghazvini:
None. J. Gribnau: None. C.J.H.M. Meeussen: None. C.E.
J. Sloots: None. A.S. Brooks: None. R.M.H. Wijnen:
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Introduction: Hirschsprung disease (HSCR) is a develop-
mental neuropathy in which enteric ganglia are absent in the
distal colon. This is the result of either impaired cell
migration, proliferation or differentiation of enteric neural
crest cells (ENCCs) and as a consequence, ENCCs fail to
fully colonize the intestine. HSCR is considered a complex
inherited disorder for which so far ﬁfteen genes and six loci
have been described. However, variants in these genes
explain no more than 20% of the total disease-risk.
Explaining this missing heritability proves difﬁcult. One
possible explanation is that somatic changes, in early
development, contribute to HSCR genetics.
Materials & Methods: The presence of somatic changes
was determined by comparing whole exome sequence
(WES) data, determined in DNA isolated out of blood,
ﬁbroblasts and ﬂow sorted ENCCs of ﬁve patients taken
from intestinal biopsies just proximal to the aganglionic
segment.
Results: We could detect putative deleterious inherited
variation in known disease genes (EDNRB, EDN3, GFRA1,
NRG3) in four out of ﬁve patients. Moreover, several
putative somatic mutations (with a coverage above 30X and
a variant quality above 300) in ENCCs were detected with
WES. Currently, we are conﬁrming these changes with
conventional technologies. Moreover, we are evaluating the
functional consequence of the variations in the known dis-
ease genes.
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Conclusions: Using WES, we could detect putative
somatic mosaicism which might point towards a role for
somatic mutations in HSCR development.
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ritsen: None. R.W.W. Brouwer: None. B.M. de Graaf:
None. W.F.J. van Ijcken: None. C.J.H.M. Meeussen:
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Whole genome sequencing implicates rare variants in
sporadic Hirschsprung disease
C. S. TANG, S. S. Cherny, P. C. Sham, P. P. K. H. Tam,
M. M. Garcia-Barceló
The University of Hong Kong, Hong Kong, Hong Kong
Sporadic Hirschsprung disease (HSCR), representing ~80%
of the HSCR cases, is the most common form of the dis-
order and is believed to be genetically complex. Thus far,
studies of rare mutations have discovered more than 10
genes (e.g. RET, EDNRB and GDNF) associated with the
disease. The major HSCR gene, RET, have both rare coding
mutations and common regulatory variants contributing to
the disease. The differential contributions of these rare and
common, coding and noncoding variants tend to vary with
length of aganglionosis. In view of this, we performed a
high coverage whole genome sequencing (~30×) of 11 trios
of sporadic patients with the rarer subtype (long segment
HSCR; L-HSCR), aiming to identify rare de novo, recessive
and compound heterozygous mutations causal to HSCR.
Our data show that the combined contribution of the de
novo and inherited, both coding and non-coding, variants
contribute to the development of ENS and thereby to
HSCR. The discovery might shed light on pathways rele-
vant to the etiology of HSCR. This work has been sup-
ported by HMRF grant 01121516 to MMGB.
C.S. Tang: None. S.S. Cherny: None. P.C. Sham:
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Genetics of fatty acid proﬁle abnormalities in Inﬂam-
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Introduction: Inﬂammatory bowel diseases (IBD) are
deﬁned by chronic and relapsing inﬂammation of the gas-
trointestinal tract. IBD is thought to arise from inappropriate
immune responses to gut microbes in a genetically sus-
ceptible host. Fatty acid proﬁle abnormalities have been
associated with IBD independent of nutritional status or
disease activity. However, no study so far has attempted to
look for overlap between IBD and fatty acid associated loci
or investigate the genetics of fatty acid proﬁles in IBD.
Materials and methods: Blood samples from 55 con-
trols and 77 IBD patients were fractionated to lymphocyte
and erythrocyte fractions. DNA was isolated from lym-
phocyte fraction. Genotyping was performed using iCHIP, a
custom microarray platform designed for ﬁne mapping of
susceptibility loci in immune-related diseases. Lipids in
erythrocyte fraction were processed and analyzed using gas
chromatography with ﬂame ionization detector to obtain
fatty acid proﬁle data. Genotype and fatty acid proﬁle data
was analyzed using R, PLINK and SPSS software packages.
Results: We identiﬁed 6 loci (near CBS, LRRK2,
FRMPD4, TMCOA5, ZNF767P, ABCA12) signiﬁcantly
associated with fatty acids in IBD. Most signiﬁcant loci is
located near the CBS gene (p = 7.62 × 10−8). Of note, we
also replicated the fatty acid associated FADS locus. Fur-
thermore, we replicated previously observed changes in
fatty acid proﬁles in IBD and inverse correlation between
oleic and arachidonic acid levels.
Conclusions: Our results encourage further investiga-
tions of the genetics of fatty acid proﬁle changes in IBD and
the role of fatty acids in IBD pathogenesis.
G. Jezernik: None. U. Potočnik: None. R. Weesma:
None.
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Mutations in LAMB2 are associated with focal seg-
mental gomerulosclerosis and septo- optic dysplasia
M. M. Tahoun1,2, J. Soo3, M. Dattani1,3, P. Scambler1, A.
Waters1,3
1UCL Great Ormond Street Institute of Child Health,
London, United Kingdom, 2Clinical and Chemical Pathol-
ogy Department, Faculty of Medicine, Alexandria Uni-
versity, Alexandria, Egypt, 3Great Ormond Street Hospital
NHS Foundation Trust, London, United Kingdom
Introduction: Mutations in LAMB2, the gene encoding
laminin-β2, a multidomain protein are associated with
Pierson Syndrome, an autosomal recessive disorder
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characterized by congenital nephrotic syndrome, ocular
abnormalities including microcoria and neurodevelop-
mental delay. Very few patients survive to adolescence,
with only 3 reported to date.
Materials and Methods: We present an 11 years old
male born to a non-consanguineous pedigree, who pre-
sented at 5 years of age with steroid resistant nephrotic
syndrome and focal segmental glomerulosclerosis together
with poor vision, growth hormone deﬁciency and seizures.
MRI of his brain showed a global lack of white matter, a
small anterior pituitary and bilateral hypoplastic optic
nerves. Using whole exome sequencing, we identiﬁed
compound heterozygous missense mutations in LAMB2
[c.737G>A p. Arg246Gln, c.3982G>A p.Gly1328Ser].
Dual immunoﬂuorescent histochemistry revealed reduced
glomerular laminin-β2 expression compared to control
biopsies [time zero renal transplant]. Interestingly, laminin
β2 is expressed during murine anterior pituitary morpho-
genesis and analysis of murine Lamb2 mutant pituitary
morphogenesis is currently underway.
Discussion: Septo-Optic Dysplasia [SOD] is a hetero-
genous condition that is characterized by the presence of
two or more of the following: hypopituitarism with isolated
or combined hormone deﬁciencies, optic nerve hypoplasia
and/or midline brain defects. Our case exhibited both iso-
lated GH deﬁciency and optic nerve hypoplasia and raises
the possibility that mutations in LAMB2 may be associated
with SOD-related phenotypes.
Conclusion: We propose that patients presenting with
genetically undeﬁned SOD should be screened for
albuminuria.
Grants: Egyptian Cultural Affairs and Mission Sector
Ministry of High Education, MRC fellowship award to A
Waters.
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Biallelic variants in methionyl-tRNA synthetase asso-
ciated with anemia, hypothyroidism, cholestasis, and
interstitial lung disease
J. Rips, O. Breuer, R. Tsabari, A. Shaag, S. Revel Vilk, S.
Reif, O. Elpeleg, T. Harel
Hadassah-Hebrew University Medical Center, Jerusalem,
Israel
Aminoacyl-tRNA synthetases (ARSs) are ubiquitously
expressed enzymes responsible for charging tRNA with
cognate amino acids during protein translation. Non-
canonical functions are becoming increasingly recognized,
and include transcription and translation control and extra-
cellular signaling. Mutations in various ARSs, with a pre-
dilection for the catalytic and C-terminal domains, lead to
tissue-speciﬁc disorders. ARSs are mostly speciﬁc to either
the cytoplasm or the mitochondria, with a few being
bifunctional. Monoallelic mutations in cytoplasmic and
bifunctional ARSs have been identiﬁed in axonal Charcot-
Marie-Tooth (CMT2) disease (i.e., AARS, YARS, GARS,
KARS for alanine-, tyrosine-, glycine-, and lysine- ARSs,
respectively). Biallelic mutations in these genes have been
associated with systemic disorders, variably involving the
central nervous system, lung, and liver. We report a 6-
month old male infant of non-consanguineous origin, pre-
senting with successive onset of transfusion-dependent
anemia, hypothyroidism, cholestasis, interstitial lung dis-
ease, and developmental delay. Liver biopsy demonstrated
ﬁbrosis, cholangiolar proliferation, macrovesicular steatosis
and hemosiderosis. Bronchoalveolar lavage showed foamy,
lipid-laden macrophages. Whole exome sequencing (WES)
identiﬁed compound heterozygous variants (p.Y307C and
p.R618C) in MARS, encoding methionyl-tRNA synthetase.
Interestingly, the p.R618C variant, inherited from an unaf-
fected father, was previously reported in a family with
autosomal dominant late-onset CMT2, with functional stu-
dies in yeast supporting pathogenicity. Biallelic MARS
mutations have been reported in a single patient with
remarkable phenotypic overlap to that reported here, as well
as in a cohort with pulmonary alveolar proteinosis. Our
ﬁnding underscores the phenotypic variability associated
with ARS mutations, and implicates modifying genetic or
environmental factors in the onset of monoallelic MARS-
associated CMT2.
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MERTK polymorphism rs4374838 (A/G) inﬂuences the
risck of hepatocellular carcinoma in patients with HCV
cirrhosis through PI3K regulation
S. Grimaudo, R. M. Pipitone, C. Baiamonte, V. Di Marco,
V. Calvaruso, S. Petta, A. Craxì
University of Palermo, Palermo, Italy
Introduction: MERTK is a member of TAM receptor
tyrosine kinases, mainly expressed in M2 macrophages.
GWA studies reported that the rs4374383 (A/G) SNP of
MERTK is associated with the risk of developing liver
ﬁbrosis in patients with hepatitis C virus (HCV) chronic
infection.
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Materials and Methods: Genotyping was performed by
TaqMan genotyping allelic discrimination method. Gene
expression was performed on liver samples by custom RT2
Proﬁler PCR Array (Qiagen).
Results: In a cohort of 349 patients with compensated
HCV cirrhosis treated with Peg-interferon alfa-2b and
ribavirin we found that the homozygosity AA, associated
with protection against ﬁbrosis progression in chronic
hepatitis C, is associated with a higher risk of developing
hepatocellular carcinoma (HCC) in subjects not responding
to treatment.
We evaluate the signaling pathways downstream to
MERTK on liver biopsy from patients (20) with AA and
GG genotypes in absence of HCC. Interestingly, we found
that the AA omozigosity is associated with higher MERTK
expression which leads to up-regulation of
phosphatidylinositol-3-kinase (PI3K) (two folds each). On
the contrary, in AA subjects we found a downregulation of
SOCS3, TRAF3,TRAF6 (2.9, 2.5, 2.2 fold respectively),
involved TLR signaling inhibition TAM receptor mediated.
Conclusion: Since the MERTK is a regulator of tumor-
associated macrophages involved in the modulation of
inﬂammatory responses and in the tumorigenesis, its poly-
morphic status AA could be related to: the direct over-
expression of PI3K, activating proliferation/survival
pathways; the maintenance of inﬂammatory chronic state by
the deﬁciency of the negative feedback usually played by
TAM receptors on TLR signaling.
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Introduction: MODY (maturity onset diabetes of the
young) is a monogenic diabetes mellitus, caused by pan-
creatic beta cell dysfunction. Mutations in the genes
encoding the nuclear transcription factor 1 homeobox A
(HNF1A) and the enzyme glucokinase (GCK) are the most
common causes of MODY. Additionally HNF1B gene is
responsible for 5% of the disease. The aim of this study is to
investigate the mutation spectrum of GCK, HNF1A and
HNF1B genes in MODY patients.
Material and Methods: This study included 152
MODY patients carrying a mutation in one of three MODY
genes; GCK, HNF1A and HNF1. Molecular analysis was
performed using Sanger sequencing or next generation
sequencing. Mutation spectrum of the genes analyzed were
evaluated separately.
Results: Eighty four percent of mutations detected were
in GCK, 13% in HNF1A and 3% in HNF1B genes. Fifty
seven different mutations (40 missense, 8 nonsense, 7 fra-
meshift, 1 inframe deletion, one splice site) in GCK, 15
different mutations (11 missense, 3 frameshift, one 3′ UTR)
in HNF1A and 4 different mutations (2 missense, one fra-
meshift, one indel) in HNF1B were found. Thirty three, 5
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and 2 mutations were detected as novel mutations in GCK,
HNF1A and HNF1B genes, respectively.
Conclusion: Deﬁnition of molecular etiology in MODY
patients is important for giving appropriate genetic coun-
seling and disease management. The most common affected
gene has been found to be GCK gene among the MODY
patients studied. In the genes GCK, HNF1A and HNF1B 40
mutations have been deﬁned for the ﬁrst time in this study.
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Introduction: Congenital deﬁciency of the leptin receptor
is a rare cause of severe early-onset obesity caused by bi-
allelic mutations in LEPR gene. However, it is the most
commonly mutated gene in monogenic obesity from con-
sanguineous families. LEPR encodes leptin receptor and is
involved in the regulation of fat metabolism, energy
homeostasis and varieties of other neuroendocrine functions
including reproduction.
Materials and Methods: Members of an extended
consanguineous family comprising 10 affected individuals
aged 0.2 to 36 years old with severe early-onset obesity
across six interlinked nuclear families were studied. Their
pedigree show an autosomal recessive pattern of inheri-
tance. We employed genome-wide single nucleotide poly-
morphism (SNP) array analysis to map the location of the
causative gene and performed Sanger sequencing of
obesity-associated gene located in the sizeable homozygous
region shared by affected individuals.
Results: The clinical presentation of the condition in the
affected members of the family characterised by extreme
early onset obesity occurring soon after birth, marked
hyperphagia with ravenous hunger, increased susceptibility
to infection, particularly among the females and hirsutism.
Delayed and failure of pubertal development was only
presented in female adults. Unlike females, affected males
started losing weight around puberty at the age of 13–15
years with preserved fertility. Homozygosity mapping and
Sanger sequencing of LEPR located in a single region of
homozygosity revealed a nonsense homozygous mutation
segregated within the family.
Conclusion: Gender discrepancy observed among
member of a same family suggest leptin possibly plays
different roles in male and female reproduction and body
weight regulation.
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Severe acute liver failure with hepatic encephalopathy
due to NBAS mutations signiﬁcantly improved after
total blood exchange transfusion
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ogy, Department of Pediatrics, Faculty of Medicine
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of Pediatrics, Faculty of Medicine Ramathibodi Hospital,
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Introduction: Acute liver failure (ALF) is a severe and life-
threatening condition, which about 50% remains unknown
etiology. Vary prognosis and treatment options has been
reported. Recent publications discovered NBAS mutations
causing recurrent infantile ALF, typically triggered by
fever, with/without extrahepatic phenotypes (eg. short sta-
ture, facial dysmorphism, optic atrophy, and Pelger-Huet
anomaly of granulocyte). Most reported patients with NBAS
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mutations achieve complete recovery, however, some of
their siblings died with severe ALF. Treatment with total
blood exchange transfusion (TBET) has not been reported
in these patients. Here, we described dramatic improvement
after TBET in severe ALF with NBAS mutations.
Materials and methods: Clinical courses were
reviewed. Whole exome sequencing was performed, and
followed by Sanger sequencing in the patient.
Results: A 14-month-old girl presented with drowsiness
after 3 days of fever with rash. We noticed widening
anterior fontanel, frontal bossing, prominent eyes, hepato-
megaly, coma, and pale optic disc. She had pre- and post-
natal growth restriction with delayed bone age. Markedly
elevated liver transminases, coagulopathy, mild hyperbilir-
ubinemia, and hyperammonemia were noted. Metabolic and
infectious investigations were unremarkable. A trial of
TBET with supplemental high caloric intake was provided.
In one day, liver transminases and coagulopathy were sig-
niﬁcantly improved. The patient regained full consciousness
in 2 days, and did not suffer from recurrent ALF till current
age at 3.5 years. Novel compound heterozygous mutations,
c.5752A>C (p.Thr1918Pro) and IVS12+2T>G in NBAS,
were identiﬁed.
Conclusion: We proposed that TBET along with high
caloric intake is an alternative treatment for severe ALF
caused by NBAS mutations.
T. Tim-Aroon: None. S. Noojarean: None. P. Tan-
pawpong: None. C. Lertudomphonwanit: None. S.
Treepongkaruna: None. D. Wattanasirichaigoon: None.
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R. Minardi1,2, C. P. Cristalli1,2, A. Mattiaccio1, M. Pariali1,
O. Baraldi2, I. Capelli2, G. Comai2, C. Graziano3, M.
Seri3, G. La Manna2, V. Mantovani1,3
1Center for Applied Biomedical Research (CRBA),
Bologna, Italy, 2Department of Experimental, Diagnostic
and Specialty Medicine (DIMES), Nephrology Dialysis and
Transplantation Unit, S.Orsola-Malpighi University Hospi-
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Introduction: Nephronophthisis (NPHP) is a rare tubulo-
interstitial autosomal recessive cystic kidney disease and
represents one of the most common genetic causes of end-
stage renal disease in children and adolescents. 15% of
NPHP patients show additional extrarenal manifestations
and are classiﬁed as NPHP-related ciliopathies. Homo-
zygous deletions in the NPHP1 gene account for
approximately 21% of all cases, whereas other 20 causative
genes contribute to less than 3% each.
Materials and Methods: 16 unrelated patients with
NPHP phenotype, including 2 with Senior-Løken syn-
drome, were analyzed in this study. NPHP1 deletions were
investigated using MLPA; the negative-cases for the
homozygous deletion were sequenced by a NGS custom
panel including the most common NPHP-genes and genes
involved in other renal diseases.
Results: Molecular defects were detected in 14 (87%)
patients. Five cases showed the homozygous deletion of the
entire NPHP1; one case presented a deletion of entire
NPHP1 in one allele and a deletion encompassing 12–15
exons region in the conserved one. In three of the four
patients with heterozygous deletions, NGS identiﬁed non-
sense mutations in the conserved allele. A nonsense
homozygous mutation in NPHP5 and a missense hetero-
zygous mutation in UMOD gene were identiﬁed in two
cases. Finally, in one patient a heterozygous deletion of
HNF1B was identiﬁed.
Conclusion: Our study shows a great genetic hetero-
geneity in patients with NPHP-like phenotype and suggests
extending the analysis to additional genes related to other
cystic renal diseases.
R. Minardi: None. C.P. Cristalli: None. A. Mattiaccio:
None. M. Pariali: None. O. Baraldi: None. I. Capelli:
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Human liver transcriptomes reveal tight co-regulation
of cholesterol synthesis pathway and DERL3 as a
potential liver cancer driver
A. Ko1,2, D. Kaminska1, E. Nikkola1, J. Pihlajamäki3,4, P.
Pajukanta1,2,5
1Department of Human Genetics, David Geffen School of
Medicine at UCLA, Los Angeles, CA, United States,
2Molecular Biology Institute at UCLA, Los Angeles, CA,
United States, 3Institute of Public Health and Clinical
Nutrition, University of Eastern Finland, Kuopio, Finland,
4Clinical Nutrition and Obesity Center, Kuopio University
Hospital, Kuopio, Finland, 5Bioinformatics Interdepart-
mental Program, UCLA, Los Angeles, CA, United States
Introduction: Obesity may perturb cholesterol synthesis
and other key liver functions by inducing ectopic fat
deposition to the liver, which can cascade to non-alcoholic
fatty liver disease (NAFLD), non-alcoholic steatohepatitis
(NASH), cirrhosis, and cancer.
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Materials and Methods: To identify genes affecting
NAFLD progression, we RNA-sequenced liver biopsies
from 259 obese bariatric surgery patients. Using 15,670
expressed genes, we performed weighted co-expression
network analysis to identify co-regulated genes critical to
liver’s main functions as well as differential expression
(DE) analysis between healthy and NASH livers (n= 69
and 43) to uncover disease-perturbed genes.
Results: Among the 19 co-expression modules, a 75-
gene module signiﬁcantly correlates with LDL cholesterol
(LDL-C) (adjusted P=1.71×10−6), with enrichment for
cholesterol biosynthesis pathway (FDR=9.68×10−14) and
protein-protein interactions (P<0.00001), implying a tight
co-regulation of cholesterol synthesis at both mRNA and
protein levels. The module encompasses known cholesterol
genes (HMGCR, SREBF2, LDLR and PSCK9) in high
correlation with new candidates for cholesterol regulation
(DERL3, SLC29A2, C14ORF1, and DNHD1). The ﬂanking
(±500kb) variants of the 35 LDL-C associated module
genes (P<6.67×10−4) are highly enriched for LDL-C signal
(P=1.24×10−4), accounting for 2.6% of heritability based
on previous GWAS statistics using LD Score. One new
LDL-C associated gene, DERL3, displays signiﬁcant DE
(adjusted P=0.01) with a 36% reduced expression and
decreased module membership (P=0.037) in NASH versus
healthy, suggesting disrupted co-regulation.
Conclusions: The reduced expression of DERL3, a
tumor suppressor, might contribute to hypercholesterolemia
in NASH and cancer progression from NASH. Overall, the
liver transcriptome reveals tight cholesterol regulation with
perturbations in liver disease.
A. Ko: None. D. Kaminska: None. E. Nikkola: None.
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Introduction: Only a handful of monogenic drivers
underlying childhood obesity have been pinpointed to date.
In particular, copy number variants (CNVs) are known to
contribute to obesity, both syndromic (15q11. deletions,
Prader-Willi syndrome) and non-syndromic (16p11.2 dele-
tions). We have studied the contribution of CNVs in early-
onset obesity and evaluated the expression of candidate
genes in adipose tissue from BMI discordant siblings.
Materials and methods: CNVs were analyzed in 90
obese subjects and 67 normal-weight controls, using a
custom high-density array comparative genomic hybridi-
zation with exon resolution in 1989 genes, including all
known obesity loci and genes implicated in intellectual
disability and ciliopathies. Expression levels of candidate
genes were assessed using microarray analysis of RNA
from adipose tissue.
Results: We identiﬁed 17 (19 %) obese individuals with
rare CNVs, of which three were known syndromic lesions
(22q11.21 duplication, 1q21.1 deletion and 16p11.2 dele-
tion). Only two (3%) controls carried rare CNVs (p<0.001,
Chi-Square test). In ten families where parental DNA was
available, eight CNVs were inherited and seven segregated
with obesity. Expression analysis of 37 candidate loci
showed discordant expression for ten genes (PCM1,
EFEMP1, MAMLD1, ACP6, BAZ2B, SORBS1, KLF15,
MACROD2, ATR, MBD5).
Conclusions: Our data suggest that CNVs contribute
possibly pathogenic alleles to a substantial fraction of
children with early-onset obesity, and pinpoint candidates
for further study. Identiﬁcation of three individuals with
known syndromic lesions that inﬂuence care and follow-up,
highlights the importance of CNV screening in early-onset
obesity.
Grant references: Swedish Society for Medical Research
(SSMF) and Vetenskapsrådet (VR).
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A novel nonsense variant in TJP2 cause divergent phe-
notypes in homozygous siblings
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Introduction: Several distinct forms of “Progressive
Familial Intrahepatic Cholestasis” (PFIC1-PFIC4) have
been described. Variants in TJP2 have recently been con-
nected to autosomal recessive PFIC4. These patients often
require liver transplantation early in life. Known disease-
causing TJP2-variants are predicted to prevent TJP2-protein
expression through premature termination codons inducing
nonsense-mediated mRNA decay (NMD). We describe a
novel nonsense-variant in TJP2 showing divergent pheno-
types in three siblings.
Materials and Methods: The proband is the 7th child of
13 to consanguine parents. Two other siblings with possible
liver affection were also examined. DNA was analysed by
NGS-panel targeting 9 cholestatic liver disease-related
genes (NimbleGen, Illumina MiSeq). Data was analysed
by CLC Biomedical Genomics Workbench (Qiagen). Var-
iants were conﬁrmed by Sanger sequencing.
Results: NGS detected a novel nonsense-variant in TJP2
in a homozygous state in all three siblings (Table 1). Several
common missense-variants in ABCC2 and ABCB11 asso-
ciated with less severe conditions were also detected. The
CNV-analysis was normal. Parental segregation analysis
and histological investigation of TJP2-protein expression in
liver biopsies are pending.
Conclusions: This TJP2-variant is predicted to induce
NMD and subsequent prevention of TJP2-protein expres-
sion. We suspect that it explains cholestasis and liver
ﬁbrosis in the proband. Surprisingly, two siblings with
identical TJP2 genotype only display minor liver affection.
These divergent phenotypes suggest a reduced penetrance
of PFIC4 progression.
Table 1. Genetic and phenotypic description of 3 sib-
lings harbouring a novel nonsense variant in TJP2
Patient
Age
TJP2
[NM_004817.3]
ABCC2
[NM_000392.3]
ABCB11
[NM_003742.2]
Phenotype
Proband
21 years
c.[3334C>T](;)
[3334C>T]
c.[3563T>A](;)
[4544G>A]
c.[1331T>C](;)
[1331T>C]
Icterus as
newborn. Liver
disease since
childhood.
Liver biopsy
shows
cirrhosis, non-
speciﬁc,
maybe caused
by cholestasis.
Candidate for
liver
transplantation.
Table (continued)
Patient
Age
TJP2
[NM_004817.3]
ABCC2
[NM_000392.3]
ABCB11
[NM_003742.2]
Phenotype
Brother
24 years
c.[3334C>T](;)
[3334C>T]
c.[3563T>A](;)
[4544G>A]
c.[1331T>C](;)
[1331T>C]
Icterus as
newborn,
normal liver
biopsy.
Marginally
increased liver
parameters.
Sister
19 years
c.[3334C>T](;)
[3334C>T]
c.[3563T>A](;)
[4544G>A]
c.[1331T>C];
[=]
Icterus as
newborn.
Intrahepatic
cholestasis of
pregnancy
(ICP). Liver
biopsy not
performed yet.
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Complex DNA analysis of polycystic kidney disease
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Seeman3, J. Reiterova4, J. Stekrova1
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Medicine, Charles University and General University
Hospital in Prague, Prague, Czech Republic, 2Institute of
Biochemistry and Experimental Oncology, First Faculty of
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University in Prague and Motol University Hospital in
Prague, Prague, Czech Republic, 43Department of
Nephrology, First Faculty of Medicine, Charles University
in Prague and General University Hospital in Prague,
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Introduction: Polycystic kidney disease is the most fre-
quent hereditary nephropathy. The most severe forms are
caused by mutations of following genes: PKHD1, HNF1β,
PKD1, PKD2. The results of molecular genetic analysis of
58 families with clinically suspected ARPKD are presented.
Materials and methods: The molecular analysis of the
PKHD1 and HNF1 β genes was carried out using next-
generation sequencing method. In patients without 2 causal
mutations of PKHD1 or 1 mutation in HNF1 β, the sub-
sequent MLPA analysis of PKHD1 and HNF1 β was per-
formed. The cohort of probands was divided into 2 groups
on the basis of their fulﬁllment of clinical criteria of
ARPKD (Group A- patients fulﬁlling all criteria, n= 25;
Group B-others, n= 35).
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Results: The detection rate in PKHD1 amounted to 84%
in Group A, and 26% in Group B. Moreover, 8 families
within Group B without mutation in the PKHD1 harbored
mutations in other genes: 5 families had mutations in
HNF1β, 2 families in PKD1 and 1 family in PKD2. The
lowest detection mutation rate was found in fetuses with
renal cysts from terminated pregnancies.
Conclusions: The detection rate of PKHD1 mutations in
children who fulﬁlled all 3 of the clinically diagnostic cri-
teria of ARPKD is high, reaching 84%. Because of the
etiologic heterogeneity of polycystic kidney disease phe-
notype, the complex mutational analysis of several genes is
needed for reliable differential diagnosis, especially in
affected fetuses with cysts.
Supported by the grant project GAUK 1015, PRVOUK-
P25/LF1/2 and IGA MZCR NT 13090-4
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A novel mutation in PROP1 c.109+1G>A identiﬁed by
target gene panel in patients with congenital growth
hormone deﬁciency
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Lerario2, F. A. Correa1, L. R. S. Carvalho1, I. J. P.
Arnhold1
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Background: Congenital GH deﬁciency (GHD) can be
isolated (IGHD) or combined with other pituitary hormone
deﬁciencies (CPHD). The identiﬁcation of mutations has
clinical implications for the treatment of patients and
genetic counseling, yet most of the genetic etiologies
remain currently unknown. Mutations in PROP1 gene are
the most frequently implicated in CPHD associated to
orthotopic posterior pituitary lobe (OPP).
Objective: to screen for mutations in genes associated
with IGHD or CPHD.
Patients and Methods: Forty patients with IGHD (n=
8) or CPHD (n= 32) were studied using target gene
approach. Targeted regions (involving 26 genes associated
with GHD) were captured using Agilent Sure Select tech-
nology. Sequencing was performed with Illumina NextSeq.
Variants were analyzed and classiﬁed as according to
recommendations of ACMG. Copy number analysis for
targeted resequencing method was used to evaluate gains or
losses in the regions of interest.
Results: We identiﬁed 31 rare allelic variants (excluding
synonymous) in 17 of 26 genes associated with GHD in 19
patients. One patient with CPHD and OPP was compound
heterozygous for PROP1 variants: c.[109+1G>A];
[301_302del]. The former a novel mutation in a consensus
splice site location and the latter the already described 2-bp
deletion leading to p.Ser101fs*8 and classiﬁed as patho-
genic. The implications of the remaining variants for the
phenotype are still under analysis.
Conclusion: The target gene panel revealed a novel
mutation in PROP1 in a patient with CPHD further
expanding the list of mutations related to this condition. The
patients with negative results are candidates for whole
exome sequencing.
M. Nakaguma: None. A.A.L. Jorge: None. M.F.A.
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Loss of function mutations in ttc7a cause hereditary
multiple intestinal atresia in patients and disrupt
intestinal lumen in zebraﬁsh
D. Halim, B. M. de Graaf
Erasmus University Medical Centre, Rotterdam,
Netherlands
Introduction: Multiple intestinal atresia (MIA) results in
neonatal intestinal obstruction. MIA is characterized by
multiple intestinal discontinuities throughout the intestine.
Often MIA patients are also immunodeﬁcient. Deleterious
variants in the tetratricopeptide-7A (TTC7A) gene were
identiﬁed. TTC7A encodes a protein with an important role
in iron haemostasis. In vitro studies suggest importance of
TTC7A in regulation of intestinal polarity and cell adhesion.
Materials and methods: Two siblings with MIA and
immunodeﬁciency from a consanguineous family were
studied. Nucleotide sequence of TTC7A was determined by
Sanger sequencing. Human intestinal tissues from both
patients and controls were immunostained and analyzed. A
ttc7a knockout zebraﬁsh model has been generated by
TALEN and characterized. Sections of 5dpf mutant ﬁsh
were stained and analyzed. Fluorescent pellets were fed to a
ttc7a genetically mixed population of ﬁsh for in vivo ana-
lysis of gut function using intravital microscopy.
Results: In both siblings, a homozygous deletion of
13.123 bp from intron 1 to intron 2, including exon 2, was
identiﬁed. Immunostainings revealed abnormal intestinal
lumens and mucosa. Intestinal stenosis was observed in
homozygous mutant ttc7a zebraﬁsh and they present with
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narrowing of the intestinal lumen. They also show a sta-
tistically signiﬁcant slower gastrointestinal transit time.
Conclusion: The homozygous deletion of exon 2 con-
ﬁrms TTC7A to be the disease-causing gene in these
patients diagnosed with hereditary MIA and immunodeﬁ-
ciency. The intestinal phenotype is the result of disturbed
intestinal lumen formation. The homozygous mutant ttc7a
zebraﬁsh closely mimics the human phenotype.
D. Halim: None. B.M. de Graaf: None.
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cing to genotype-phenotype correlation in salt loss
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The Bartter-Gitelman syndromes (BS-GS) are two different
salt loosing tubulopathies. Both diseases are characterized
by inability to reabsorb NaCl in the thick ascending limb
(TAL) of Henle's loop and distal convoluted tubule (DCT).
The main clinical features are common to both diseases
including hyperaldosteronism, hypokalemic metabolic
alkalosis, failure to thrive; hypercalciuria characterizes the
majority of BS, while hypocalciuria and hypomagnesemia
characterizes GS. BS is due to defect in almost 5 genes,
while the SLC12A3 is responsible for GS. We performed
molecular analysis in 25 patients with diagnosis of BS-GS
using a NGS panel in which are included genes associated
and potentially involved in different type of tubulopathies.
Our patients showed mutations in almost all genes asso-
ciated to different type of BS. In one case we found a
homozygous deletion involving both CLCNKA and
CLCNKB genes. Cases already described with digenic form
of BS showed early deafness, while our case did not showed
this features. Moreover among our cases, 5 with BS diag-
nosis, showed mutation in SLC12A3. Our results demon-
strate that this approach can contribute to a correct genetic
diagnosis when it is not always possible a precise dis-
crimination of the clinical phenotypes. Patients with salting
loss tubulophaties are often treated similarly, with little
consideration of individual characteristics that might affect
clinical outcome and therapeutic response. Our study pro-
vides a highly sensitive method for identiﬁcation of variants
in different causative genes associated with a salting loss,
drawing the best way for a tailored medicine.
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Girona3, B. Polo4, I. Sastre5, I. Martínez5, M. Berenguer6,
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Introduction: Wilson’s disease (WD) is an autosomal
recessive disorder caused by mutations in the liver’s copper-
transporter protein ATP7B, which results in an impaired
biliary excretion of copper and its accumulation mostly in
liver and brain. We have performed an in-depth clinical and
molecular characterization of a cohort of WD patients from
the Valencian Region (Eastern Spain), with the purpose of
improving clinical diagnosis and prognosis of these
patients.
Methods: Clinical-diagnosed WD series of 42 index
cases. Differential diagnosis based on routine test for
hepatic dysfunction. Neurological involvement was eval-
uated with the Global Assessment Scale (GAS) for WD.
Genetic analysis of ATP7B included the study of the pro-
moter, coding exons and its ﬂanking intronic regions by
Sanger sequencing, and detection of large deletions and
duplications by multiplex ligation-dependent probe ampli-
ﬁcation (MLPA) analysis. The whole gene, included
introns, is investigated in patients with only one or no
mutations by massive sequencing.
214
Results: Genetic diagnosis was achieved in 24 cases;
only one mutation was detected in 6 cases, and no candidate
mutations were identiﬁed in 12 cases. The most common
mutation in our cohort is p.M645R (21.4% of the alleles).
Studies related to the sequencing of the whole ATP7B are in
progress. Strikingly, apart from hepatic dysfunction, most
of the patients present with neurological signs (tremor,
dystonia and parkinsonism).
Conclusion: The genetic studies performed in our cohort
contribute to improve our knowledge about the genetics and
the clinical picture associated with Wilson’s disease.
Funding: Fundació Per Amor A L’Art.
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Microdeletions in the 11p13 region involving WT1 may
result in genitourinary malformations without WAGR
syndrome
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Introduction: Large deletions affecting the 11p13 chro-
mosomal region have long been known to cause WAGR
syndrome: Wilms’ tumor, aniridia, genitourinary mal-
formations and mental retardation. Recently, some patients
carrying different microdeletions within 11p13 have been
documented in the literature with varying clinical symp-
toms. We hereby report a patient with Phelan-McDermid
syndrome carrying a heterozygous deletion in the 11p13
region in addition to the 22q13 deletion.
Materials and Methods: The patient was diagnosed
with low muscle tone at birth and later developed a classic
form of the Phelan-McDermid syndrome. Additional ﬁnd-
ings at birth included a stricture and dysfunction of the left
ureter. The patient was enrolled in WT1-screening on the
basis of unusual genitourinary ﬁndings, and after a deletion
involving WT1 was detected, copy number analysis of the
region was performed by both qRT-PCR and dPCR.
Results: In addition to the 22q13 deletion, a hetero-
zygous microdeletion was conﬁrmed in the 11p13 region
including WT1 and EIF3M, but not affecting PAX6.
Conclusions: Aniridia is currently thought to be the
main clue to the diagnosis of the 11p13 deletion syndrome,
as it is seen in classic cases of WAGR. However, if we
compare our ﬁndings to similar recent cases reported in the
literature, it seems likely that many 11p13 deletions without
PAX6 involvement are unnoticed. Rather than thinking of
WAGR syndrome as a single entity, we should consider it
as a spectrum of clinical features as different genes may be
affected by each particular deletion.
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P04 Skeletal, connective tissue, ectodermal and skin
disorders
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Hypomelanosis of Ito (HI) is commonly seen as a non-
speciﬁc manifestation of mosaicism. Because of its frequent
association with various extracutaneous anomalies, espe-
cially cerebral involvement, HI is often considered as a
neurocutaneous syndrome. Apart from rare reports of non-
recurrent mosaic chromosomal anomalies, and recent
descriptions of linear hypopigmentation in MTOR-related
hemimegalencephaly, the genetic causes of HI have
remained largely unknown. We studied six unrelated
patients with a previously undescribed mosaic neuroecto-
dermal syndrome combining linear hypopigmentation,
facial, ocular, dental, and acral anomalies, alopecia, and
apparently asymptomatic leukoencephalopathy. We per-
formed whole-exome sequencing (WES) in affected skin
from two parent-case trios, and identiﬁed the same post-
zygotic change of RHOA in both probands. This variant was
also found in two unrelated individuals by targeted ultra-
deep sequencing of RHOA. The ﬁfth proband carries a
different postzygotic variant, detected by trio WES. On the
sixth patient, no changes were detected. RHOA encodes
RhoA, a RAS-related Rho GTPase, which controls mor-
phogenesis, chemotaxis, axonal guidance, and cell cycle
progression. RhoA is a highly conserved protein particu-
larly intolerant to amino acid substitutions, supporting the
idea that RHOA-related mosaic ectodermal dysplasia should
be added to the list of disorders resulting from lethal
mutations surviving only by mosaicism. Transfected NIH
3T3 cells with mutants RhoA plasmid displayerd reduced
cell spreading and decreased stress ﬁber formation, sug-
gesting a dominant-negative effect of both variants. Our
ﬁndings pave the way towards elucidating the etiology of
pigmentary mosaicism and highlight the role of RHOA in
human development and disease.
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Plastin 3 regulates bone development and maintenance
through the NFκB pathway in osteoclasts
J. Milbradt1, S. M. Hosseinibarkooie1, M. Peters1, K.
Hupperich1, V. Grysko1, J. Heilig2, F. Zaucke2,3,4, A.
Niehoff2,5, B. Wirth1
1Institute of Human Genetics, Cologne, Germany, 2Cologne
Center for Musculoskeletal Biomechanics (CCMB),
Cologne, Germany, 3Dr. Rolf Schwiete Research Unit for
Arthritis, Orthopedic University Hospital Friedrichsheim
gGmbH, Frankfurt, Germany, 4Institute for Biochemistry II,
Center for Biochemistry, Cologne, Germany, 5Institute of
Biomechanics and Orthopaedics; German Sport University
Cologne, Cologne, Germany
Introduction: Osteoporosis affects a large proportion of
people, particularly women after menopause. Plastin 3
(PLS3) mutations cause familial osteoporosis and osteo-
porotic fractures in men and an increased risk of fractures in
elderly women. In about 5% of the general population PLS3
is overexpressed, raising the question whether PLS3 over-
expression (OE) can act protective against osteoporosis.
Here we investigated PLS3 OE mice to unravel the impact
on bone structure and remodelling and to identify the
underlying molecular mechanism.
Materials and Methods: Micro-CT and histology were
performed on femora of the animals. Co-
immunoprecipitation and mass spectrometry let to novel
PLS3-interacting partners. Bone resorption assay, immu-
noﬂuorescence staining, WB, Co-IP and qRT-PCR were
performed from primary differentiated osteoclasts.
Results: Femora of PLS3 OE mice showed signiﬁcantly
increased cortical and trabecular thickness compared to
controls. Primary osteoclasts of PLS3 OE compared to WT
mice presented evidently larger and differently shaped
osteoclasts with disrupted podosome formation and severely
decreased resorptive activity. NFκB expression was strik-
ingly upregulated in PLS3 OE osteoclasts. An unbiased
proteomics approach identiﬁed NFκB repressing factor
(NKRF) to interact with PLS3, which we conﬁrmed by an
independent Co-immunoprecipitation assay. We hypothe-
sized that NFκB transcriptional regulation is inhibited
through NKRF and PLS3 interaction, which was supported
by the ﬁnding of downregulated NFATc1, an NFκB
downstream target important for osteoclastic function, as
well as altered NKRF localization in PLS3 OE osteoclasts.
Conclusions: We identiﬁed a novel cellular pathway, by
which PLS3 acts on bone development and remodelling,
which might open new therapeutic possibilities.
Funding: DFG-Wi945/16-1 (BW)
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Retinoic acid catabolizing enzyme CYP26C1 is a genetic
modiﬁer in SHOX deﬁciency
A. Montalbano1, L. Juergensen2, R. Roeth1, B. Weiss1, M.
Fukami3, S. Fricke-Otto4, G. Binder5, T. Ogata6, E.
Decker7, G. Nuernberg8, D. Hassel2, G. Rappold1
1Institute for Human Genetics, Heidelberg University,
Heidelberg, Germany, 2Department of Internal Medicine
III - Cardiology, Heidelberg University, Heidelberg,
Germany, 3Department of Molecular Endocrinology,
National Research Institute for Child Health and Develop-
ment, Tokyo, Japan, 4Children's Hospital Krefeld, Krefeld,
Germany, 5Children's Hospital, University of Tübingen,
Tübingen, Germany, 6Department of Pediatrics, Huma-
matsu University of Medicine,, Humamatsu, Japan, 7Bios-
cientia Center for Human Genetics, Ingelheim, Germany,
8Center for Molecular Medicine, Koeln, Germany
Mutations in the homeobox gene SHOX cause SHOX
deﬁciency, a condition with clinical manifestations ranging
from short stature without dysmorphic signs to severe
mesomelic skeletal dysplasia. In rare cases, individuals with
SHOX deﬁciency are asymptomatic. To elucidate the fac-
tors that modify disease severity/penetrance, we studied a
three‐generation family with SHOX deﬁciency. The variant
p.Phe508Cys of the retinoic acid catabolizing enzyme
CYP26C1 co‐segregated with the SHOX variant p.
Val161Ala in the affected individuals, while the SHOX
mutant alone was present in asymptomatic individuals. Two
further cases with SHOX deﬁciency and damaging
CYP26C1 variants were identiﬁed in a cohort of 68 indi-
viduals with LWD. The identiﬁed CYP26C1 variants
affected its catabolic activity, leading to an increased level
of retinoic acid. High levels of retinoic acid signiﬁcantly
decrease SHOX expression in human primary chondrocytes
and zebraﬁsh embryos. Individual morpholino knockdown
of either gene shortens the pectoral ﬁns, whereas depletion
of both genes leads to a more severe phenotype. Together,
our ﬁndings describe CYP26C1 as the ﬁrst genetic modiﬁer
for SHOX deﬁciency.
A. Montalbano: None. L. Juergensen: None. R.
Roeth: None. B. Weiss: None. M. Fukami: None. S.
Fricke-Otto: None. G. Binder: None. T. Ogata: None. E.
Decker: None. G. Nuernberg: None. D. Hassel: None. G.
Rappold: None.
P04.04D
Chemical modulation of Hedghehog signaling in the
abnormal osteogenic niche of non-syndromic
craniosynostosis
M. Barba1, L. Di Pietro1, C. Bernardini1, L. Massimi2, G.
Tamburrini2, O. Parolini1,3, S. A. Boyadjiev4, W.
Lattanzi1,5
1Institute of Anatomy and Cell Biology, Università
Cattolica del Sacro Cuore, ROMA, Italy, 2Dept. Head
and Neck Surgery, Section of Pediatric Neurosurgery,
Fondazione Policlinico Gemelli, ROMA, Italy, 3Centro di
Ricerca E.Menni, Fondazione Poliambulanza, Brescia,
Italy, 4Section of Genetics, Department of Pediatrics,
University of California Davis, Sacramento, CA, United
States, 5Latium Musculoskeletal Tissue Bank, Rome, Italy
Nonsyndromic craniosynostosis (NCS), is a heterogeneous
congenital anomaly due to premature fusion of one or more
calvarial sutures with largely unknownetiopathogenesis.
Our previous data highlighted the upregulation of the Bar-
det Biedl Syndrome-associated gene 9 (BBS9) expression at
the site of premature suture fusion, along with a dysregu-
lation of the Hedgehog (HH) signaling and aberrant primary
cilium expression.
The aim of this study was to investigate the effect of HH
chemical modulation on the osteogenic commitment of
somatic stem cells residing in the calvarial suture niche.
Cells isolated from fused and unfused sutures of NCS
patients, were cultured either in standard growth or in
osteoinductive media. Subconﬂuent cells were treated either
with the HH modulators cyclopamine (inhibitor) or with
purmorphamine (inducer) at 5μM concentrations in time
course. The expression of BBS9 and bone speciﬁc tran-
scription factor genes (RUNX2, OSX) was assessed by
qPCR. Matrix mineralization was evaluated with Alizar-
inRed staining (AR).
In standard conditions, BBS9 expression was increased in
fused- as compared with unfused-suture derived cells, and
underwent a further increase during osteogenic differentia-
tion. Following treatment with cyclopamine and purmor-
phamine, both osteogenic differentiation rates and the
expression levels of BBS9, RUNX2, and OSX correlated
positively with HH modulation.
These data conﬁrm the involvement of the Hedghehog
pathway in the osteogenic commitment of suture-derived
cells, and provide preliminary hints towards the imple-
mentation of HH chemical modulation through small
molecules, as a potential molecular-targeted approach to
counteract premature suture ossiﬁcation.
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A novel recessive connective tissue disorder is caused by
AEBP1 deﬁciency
P. R. Blackburn1, K. Harris1, J. Jackson1, J. Gass1, M.
Cousin2, N. Boczek2, M. Mitkov1, M. Cappel1, J. Parisi2,
E. Klee2, C. Francomano3, N. McDonnell4, M. Layne5, F.
Alkuraya6, P. Atwal1
1Mayo Clinic Florida, Jacksonville, FL, United States,
2Mayo Clinic, Rochester, MN, United States, 3Greater
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4Veteran's Administration, Eastern Colorado Health Sys-
tem, Denver, CO, United States, 5Boston University School
of Medicine, Boston, MA, United States, 6King Abdulaziz
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Introduction: The AEBP1 gene encodes the aortic
carboxypeptidase-like protein (ACLP) that associates with
collagens in the extracellular matrix and has a number of
roles in development and adult tissue repair. ACLP is
expressed in bone, blood vessels, and skin, and Aebp1−/−
mice have deﬁcient wound repair and have poor ﬁbroblast
proliferation. We recently reported two siblings born with
severe joint and skin laxity, severe osteopenia, and facial
dysmorphisms, who had a homozygous splice site variant
(c.1630+1G>A) in AEBP1. In this study, we describe two
additional families and provide evidence supporting the role
of AEBP1 in disease.
Materials and Methods: Patient 1 is an adult male with
joint laxity, redundant skin, poor wound healing, and
osteopenia. As his phenotype is reminiscent of Ehlers-
Danlos syndrome (EDS), extensive clinical evaluations
were undertaken including a vascular workup that was
normal. Electron microscopy identiﬁed variation in collagen
ﬁbril size and the presence of "collagen ﬂowers,” which are
seen in several variants of EDS. Patient 2 presented with
congenital hip dislocation, bowel rupture, bone degenera-
tion, decreased dermal collagen, and abnormal scarring.
Results: Exome sequencing revealed novel compound
heterozygous variants in AEBP1 (c.1470delC, p.Asn490-
LysfsX6 and c.1743C>A, p.Cys581Ter) in patient 1 and a
homozygous variant (c.1320_1326del, p.Arg440SerfsX3)
in patient 2.
Conclusions: Given the phenotypic overlap of patients
with loss-of-function variants in AEBP1 and concordance
with the phenotypes described in Aebp1−/− mice, we pro-
pose that truncating loss-of-function variants in this gene
are the cause of a novel recessive connective tissue disorder.
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Glutathione S-transferases M1/T1 and P1 polymorph-
isms in patients with alopecia areata
O. Cilingir1, B. Durak Aras1, Z. N. Saracoğlu2, M.
Ozdemir1, K. Haziyeva1, O. Kutlay1, S. Artan1
1Eskisehır Osmangazi University, Faculty of Medicine,
Department of Medical Genetics, Eskisehir, Turkey, 2Eski-
sehır Osmangazi University, Faculty of Medicine, Depart-
ment of Dermatology, Eskisehir, Turkey
Alopecia areata (AA) is a common, recurrent, chronic
autoimmune and inﬂammatory disease resulting from T
cell-induced damage to hair follicules. The disease can
appear in both sexes at any age. Although the aethio-
pathogenesis of AA is unclear, many factors including
genetic predisposition, emotional and environmental stress
are thought to play important roles in its development. Since
antioxidant/ oxidant balance disturbance is a common fea-
ture in autoimmune, emotional and environmental stress,
current evidences support the association between oxidative
stress and AA. Glutathione S-transferases (GSTs) play a
major role in the detoxiﬁcation of various compounds. The
present study was aimed to determine the frequencies of
GSTM1-GSTT1-GSTP1 polymorphisms in 176 patients
with AA and 196 age- and sex- matched healthy controls.
GSTM1 and GSTT1 genotypes were determined by multi-
plex PCR whereas GSTP1 polymorphisms were analyzed
by using PCR-RFLP technique. Genotype frequencies of
the GSTM1, GSTT1 and GSTP1 polymorphisms showed
signiﬁcant differences between AA patients and healthy
controls (Table). In conclusion, our results suggested a
signiﬁcant association between the GSTP1,GSTT1 and/or
GSTM1 null genotypes and AA that is the ﬁrst report
showing the relation with the disease. However, the
potential role of GSTs as markers of susceptibility to AA
needs further studies in larger patient groups. Table. Gen-
otype frequencies and P value of the GSTM1, GSTT1 and
GSTP1 polymorphisms.
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Genotype AA (n= 176) n
(%)
Control(n= 196)
n(%)
P
value
GSTM1 Null
(-)
16(9) 0(0) <0,01
Present (+) 160(91) 196(100)
GSTT1 28(16) 0(0) <0,001
Null (-)
Present (+) 148(84) 196(100)
GSTM1/
GSTT1
112(63,6) 196(100) <0,001
+/+
-/- 10(5,6) 0(0) <0,05
GSTP1 0(0) 30(15) >0,05
Ile/Ile
Ile/Val 98(55,6) 166(84,6) <0,001
Val/Val 34(19) 0(0) <0,001
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Gene panel testing for Alport syndrome reveals inheri-
tance patterns to inform risks and management
V. Dias1, N. Motton1, R. Irwin1, M. Iqbal1, A. Yeung1, C.
Hardy1, F. McDonald1, J. Jarvis2, T. Antoniadi1
1West Midlands Regional Genetics Laboratory - Birming-
ham Womens´s and Children´s Hospital NHS Foundation
Trust, Birmingham, United Kingdom, 2Clinical Genetics
Department - Birmingham Womens´s and Children´s
Hospital NHS Foundation Trust, Birmingham, United
Kingdom
Alport syndrome is a nephropathy, often resulting in end-
stage renal failure; also associated with sensorineural
hearing loss and ocular anomalies. Estimated prevalence is
1:50,000 live births. Approximately 65–80% of cases are X-
linked (COL4A5), 10–15% autosomal recessive (COL4A3,
COL4A4); up to 20% dominant inheritance (COL4A3,
COL4A4), while recently Mencarelli et al. described cases
of digenic inheritance, involving COL4A3 and COL4A4
genes. All three genes encode subunits of type IV collagen,
which is the major structural component of basement
membranes of the kidney, inner ear and eye.
The last 4 years we tested 89 unrelated patients initially
by Sanger sequencing switching to gene panel testing using
Illumina TruSightOne. A genetic diagnosis was achieved in
34 patients (diagnostic yield 38%), while another seven
patients had a variant of uncertain signiﬁcance. A total of 36
pathogenic and likely pathogenic variants identiﬁed, 16
were novel. 28 patients had X-linked disease, four auto-
somal dominant, one autosomal recessive and one patient
had two variants in different genes, COL4A3 and COL4A4,
indicating a possible case of digenic inheritance. 52 follow
up tests were performed across 18 families, including pre-
natal diagnosis. Interesting cases will be presented.
A genetic diagnosis can establish the mode of inheritance
which is important in assessing potential clinical outcome,
allows for improved surveillance and effective treatment
and identiﬁcation of at risk relatives as well as members that
can be live kidney donors. Massively parallel sequencing of
the genes simultaneously enables identiﬁcation of complex
inheritance patterns; these should be considered when
reviewing prognosis and recurrence risks.
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Integration of GWAS data and hair follicle miRNA and
mRNA expression proﬁles yield novel insights into male-
pattern baldness pathobiology
L. M. Hochfeld1,2, A. Keller3, T. Anhalt1,2, N. Fricker1,2,
M. M. Nöthen1,2, S. Heilmann-Heimbach1,2
1Institute of Human Genetics, University of Bonn, Bonn,
Germany, 2Department of Genomics, Life&Brain Center,
University of Bonn, Bonn, Germany, 3Chair for Clinical
Bioinformatics, Saarland University, Saarbrücken,
Germany
Male-pattern baldness (MBP) is characterised by a pro-
gressive loss of androgen-sensitive hair follicle (HF) sub-
populations in the frontal and vertex scalp. HFs in the
occipital scalp remain unaffected.
To gain insights into the underlying pathobiology, we
analysed for a differential micro(mi)RNA and mRNA
expression in HFs from affected (frontal) and unaffected
(occipital) scalp regions and integrated these data with the
results from a large GWAS meta-analysis (N= 22,518) on
MPB. Our analyses revealed differential expression (DE) of
144 miRNAs and 3,230 mRNAs. Of these, only one
miRNA and 49 mRNAs mapped to known MPB risk loci
(P<5×10−8), suggesting that the remaining DE genes may
help to pinpoint novel risk loci and relevant pathways.
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Indeed, DE mRNAs and target genes of DE miRNAs not
only showed an enrichment in previously implicated path-
ways (WNT- and oestrogen-signalling) but also provided
evidence for the involvement of additional pathways such
as mTOR- and ephrin-receptor-signalling in MPB-
aetiology. Moreover, the comparison with suggestive
association ﬁndings (5×10−8<P<10−5) from the meta-
analysis revealed an overlap with DE miRNAs and
mRNAs at nine genomic regions, that had not previously
been implicated in MPB. Among them a locus at 3q22.2
comprising the genes for ephrin-receptor-B1 (EPHB1) and
the prostaglandin-D2-transporter SLCO2A1, which may
contribute to the characteristic hair loss pattern via media-
tion of androgen-sensitivity and hair growth inhibition,
respectively.
In summary, mRNA and miRNA transcriptome proﬁling
and subsequent integration with genetic association data
identiﬁed novel candidate genes (EPHB1,STAT1,DLL1) and
pathways (mTOR-,ephrin-signalling), and highlights nine
novel loci that are likely to contribute to MPB-development.
L.M. Hochfeld: None. A. Keller: None. T. Anhalt:
None. N. Fricker: None. M.M. Nöthen: None. S. Heil-
mann-Heimbach: None.
P04.09A
Arterial tortuosity syndrome: 37 new families and lit-
erature review
A. Beyens1, J. Albuisson2, T. Lepard3, N. Canham4, J.
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Busa31, E. W. Klee29, P. Moceri32, L. Van Laer33, I.
Dewandele1, S. De Schepper1
1Ghent University Hospital, Ghent, Belgium, 2Hôpital
Européen Georges Pompidou, Paris, France, 3University
of Arkansas, Little Rock, AR, United States, 4Northwick
Park Hospital, Harrow, United Kingdom, 5Hôpital Calm-
ette, Lille, France, 6University of Kansas, Kansas, KS,
United States, 7Leuven University Hospital, Leuven,
Belgium, 8John Hopkins University School of Medecine,
Baltimore, MD, United States, 9Charité-Universitätsmedi-
zin Berlin, Berlin, Germany, 10Kanuni Sultan Suleyman
Training and Research Hospital, Istanbul, Turkey, 11Ray-
mond Pointcare Hospital, Garches, France, 12Parc Tauli
University Hospital, Sabadell, Spain, 13Kuwait University,
Kuwait City, Kuwait, 14Arkansas Children's Hospital, Little
Rock, AR, United States, 15Leeds General Inﬁrmary, Leeds,
United Kingdom, 16Clinica Universidad de Navarra,
Pamplona, Spain, 17Hôpital Necker-Enfants Malades,
Paris, France, 18Guy's Hospital, London, United Kingdom,
19Amrita Institute of Medical Sciences and Research
Center, Cochin, India, 20Medical University of Innsbruck,
Innsbruck, Austria, 21Yorkshire Regional Genetics Service,
Leeds, United Kingdom, 22Complejo Hospitalario de
Navarro, Pamplona, Spain, 23Hôpital Femme-Mère-Enfant
Lyon, Lyon, France, 24King Saud University, Riyadh, Saudi
Arabia, 25Hôpital Saint-Jacques, Besançon Cedex, France,
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Introduction: Arterial tortuosity syndrome (ATS,
MIM#208050) is a rare autosomal recessive connective
tissue disorder, characterized by elongation and tortuosity
of the large and middle-sized arteries. ATS is caused by
mutations in SLC2A10. Aim To delineate ATS clinically
and molecularly in 37 newly identiﬁed ATS families (46
individuals) with ultrastructural characterization of skin
biopsies. Results All patients (mean age 11.1, median age 9)
harbor biallellic SLC2A10 mutations of which ten are novel.
Initial manifestations were cardiovascular (aortic coarcta-
tion and cardiac murmurs) in 50%, aspeciﬁc connective
tissue ﬁndings (hernias, stretchy skin) in 25%, pulmonary
manifestations (neonatal respiratory distress, dyspnea) in
15%, and familial segregation in the remaining 10% of
patients. Aggressive aortic root dilatation (ARD) occurred
in four infants without dissection or rupture, ﬁve patients
had slowly progressive ARD. Stenoses, tortuosity and
aneurysm formation occurred widespread, necessitating
extensive imaging of the aorta and renal arteries. Vascular
surgeries and catheterizations are well tolerated. Other
severe but sporadic complications included neonatal intra-
cranial bleeding, ischemic stroke and gastric perforation.
Novel ﬁndings include prenatal manifestations (intra-uterine
growth retardation, prenatally detected aortic tortuosity and
oligohydramnios) and corneal thinning. Transmission
electron microscopy shows a patchy and irregular deposi-
tion of elastin at the periphery of the elastic ﬁbers and
variable diameters of the collagen ﬁber. Conclusion We
conﬁrm a less severe natural history than initially reported,
but respiratory distress, aggressive aneurysm formation and
cerebrovascular accidents occur. In electron microscopy,
skin biopsies show speciﬁc elastic ﬁber and collagen
anomalies discernable from other elastic ﬁber diseases.
Grant Reference BOF01N04516
220
A. Beyens: None. J. Albuisson: None. T. Lepard:
None. N. Canham: None. J. Chopin: None. M. Dasouki:
None. K. Devriendt: None. H. Dietz: None. B. Fischer-
Zirnsak: None. A. Gezdirici: None. F. Giuliano: None.
M. Guitart: None.M. Haider: None. J. Hardin: None. H.
Michael: None. X. Jeunemaitre: None. U. Kornak: None.
M. Landecho: None. S. Lyonnet: None. S. Mohammed:
None. S. Nampoothiri: None. K. Pichler: None. K. Pre-
scott: None. M. Ramos: None. M. Rossi: None. M. Salih:
None. M. Said Ahmed: None. E. Schaefer: None. E.
Steichen-Gersdorf: None. L. Van Malderghem: None. D.
Warner: None. A. De Paepe: None. L. Muino Mosquera:
None. J. De Backer: None. A. Willaert: None. A. Boel:
None. P. Coucke: None. A. Taylor: None. E. Davis:
None. Y. Zarate: None. B. Callewaert: None. S. Temel:
None. M.A. Cousin: None. O. Bostan: None. T. Busa:
None. E.W. Klee: None. P. Moceri: None. L. Van Laer:
None. I. Dewandele: None. S. De Schepper: None.
P04.10B
c.961C>T Sequestosome1 gene mutation, associated to
Paget´s disease of bone, causes a blockade of autophagy
and an activation of NF-kB pathway
R. Usategui-Martin1, I. Calero-Paniagua2, V. Rivero1, J.
Del Pino-Montes2, R. Gonzalez-Sarmiento1
1Unidad de Medicina Molecular. Universidad de Sala-
manca. IBSAL, Salamanca, Spain, 2Servicio de Reumato-
logía. Hospital Universitario de Salamanca. IBSAL,
Salamanca, Spain
Paget´s disease of bone (PDB) is a disorder characterized by
a bone turnover increase in a disorganized way. The strong
tendency to familial aggregation supports the genetic
hypothesis of PDB and the most important known genetic
factor predisposing to the disease is mutation in Sequesto-
some1 (SQSTM1) gene.
We have characterized three PDB patients that carry the
c.961C>T mutation that it is localized in exon 6 of
SQSTM1 gene. It causes the p.R321C mutation, localized
in the LIR domain of p62 protein. LIR domain is crucial in
autophagy process. Our functional analysis showed that p.
R321C mutation caused a blockade in autophagy and
increases the activation of NF-kB pathway. In cells that
over-expressed the p62 321C protein variant we observed
cytoplasm aggregates similar to autophagosomes, which
were unable to fuse with the lysosomes probably due to the
p.R321C a lack of interaction between p62 and LC3 pro-
teins. We have conﬁrmed it by immunoﬂuorescence and
immunoprecipitation assays.
The blockade of autophagy increased the p62 protein
levels that caused IKKα/β phosphorylation and NF-kB
pathway activation. The NF-kB activation induced cell
proliferation. Western blot analysis conﬁrmed IKKα/β
phosphorylation.
We report, for the ﬁrst time, that c.961C>T SQSTM1
gene mutation causes a blockade in autophagy process that
contributes to a higher intracellular expression of p62 pro-
tein, NF-kB pathway activation and an increase of cell
proliferation.
Supported by ISC IIII-FEDER: PI10/00219, PI13/01741,
and GRS FEDER: 185/A/07.
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Precocious prenatal phenotype of BHLHA9 duplication:
a case report
G. Morin, N. Celton, T. Dery, M. Gallet, M. Mathieu-
Dramard, P. Naepels, H. Copin, J. Gondry, G. Jedraszak
University Hospital of Amiens, Amiens, France
Ectrodactyly, also known as split hand-foot malformation
(SHFM), is a rare developmental disorder characterised by
malformations of the distal limbs affecting the central rays
of hands and-or feet. It can occur as an isolated mal-
formation or as part of various complex syndromes. Among
these syndromes, a distinct entity associates SHFM and
long bone deﬁciency (SHFLD). Duplication on chromo-
some 17p13.3 has recently been associated with SHFLD. In
this region, duplication of BHLHA9 has been incriminate in
the physiopathology of limb anomalies. This CNV is not
associated with other organ malformation or developmental
delay. Here, we present a case of ectrodactyly and tibial
agenesia diagnosed in the ﬁrst trimester by two-dimensional
and three-dimensional ultrasonography, leading to the
choice by the patient to make a precocious termination of
pregnancy. Array-Cgh, performed after termination of
pregnancy, found a 157 kb duplication on chromosome
17p13.3. This CNV only includes the BHLHA9 gene. To
our knowledge, this is the earliest diagnosis of BHLHA9
duplication reported to date. Parental analyses proved de
novo character of this CNV. Fetal limb abnormalities are
now being encountered at increasingly earlier gestational
ages due to improvements in image quality of ultrasound in
the ﬁrst trimester. Early identiﬁcation of these types of
malformations without a deﬁnitive diagnosis present a
challenging clinical problematic. In these cases, patients
regularly may opt for earlier termination of pregnancy rather
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than wait for additional information, including chromoso-
mal testing, to help decision-making.
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Identiﬁcation of mutations in the RMRP gene in patients
with Cartilage-Hair Hypoplasia
M. E. S. Gomes1, L. C. B. Paternostro1, D. P. Cavalcanti2,
T. M. Félix3, M. V. Sanseverino3, J. C. Llerena Jr.1, S. M.
C. Gonzalez1
1Instituto Fernandes Figueira/FIOCRUZ, Rio de Janeiro,
Brazil, 2Universidade Estadual de Campinas, Campinas,
Brazil, 3Hospital de Clínicas de Porto Alegre, Porto Alegre,
Brazil
Introduction: Cartilage-Hair Hypoplasia (CHH, #250250),
is an autosomal recessive disease characterized by meta-
physeal and other skeletal abnormalities. Immune deﬁ-
ciency and predisposition for some types of cancer can also
occur. This pathology is caused by mutations in the RMRP
gene, responsible for coding a non-translated RNA, member
of riboproteic RNase MRP complex. RMRP gene is
involved in mitochondrial DNA replication, in pre-5.8S
rRNA processing and in cell cycle progression through
cyclin B2 cleavage. The goal of this study was to identify
mutations in the RMRP gene in patients with CHH clinical
and radiographic suspicion.
Material and Methods: Genomic DNA was extracted
from peripheral blood by salting-out method. Promoter and
transcribed regions of RMRP gene were PCR ampliﬁed,
cloned and sequenced.
Results: In this study, we report twenty-two distinct
alterations including duplication, triplication, insertion and/
or point mutations, among which 11 are new putative
mutations found in a group of 20 different patients. All
genotypes occurred in compound heterozygosity. Patho-
genic mutations were concomitant to polymorphisms
already described in the literature. It is noteworthy that
g.71A>G, the most worldwide frequent described mutation
in CHH patients, was not found in our cohort. In contrast,
more than 50% of our patients presented the g.196C>T
mutation, a frequency not found previously in other
countries.
Conclusions: Molecular results conﬁrm disease etiology
and allow genetic counseling of the families, anticipating
clinical interventions in patients and avoiding serious clin-
ical complications.
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Genetic architecture of early growth phenotypes gives
insights into their link with later obesity
M. De Silva1, S. Sebert2, A. Couto Alves1, U. Sovio3, S.
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Introduction: Early growth in childhood is associated with
adult metabolic health, but the underlying mechanisms are
unclear.
Materials and Methods: We performed genome-wide
meta-analyses and follow-up in up to 22,769 European
children for six early growth phenotypes derived from
longitudinal data: peak height and weight velocities, age
and body mass index (BMI) at adiposity peak (AP
~9 months) and rebound (AR ~5–6 years). We then per-
formed expression quantitative trait loci (eQTLs), pathway
enrichment and genetic correlation analyses for functional
characterization.
Results: We identiﬁed four associated loci (P< 5×10−8):
LEPR/LEPROT with BMI at AP, FTO and TFAP2B with
Age at AR and GNPDA2 with BMI at AR. The common
AR-associated SNPs at FTO, TFAP2B and GNPDA2
represent known BMI-associated variants. The common
variant at LEPR/LEPROT associated with BMI at AP is
independent of the early onset obesity-associated SNPs at
the same locus, and was signiﬁcantly associated with both
LEPR and LEPROT gene expression levels especially in
subcutaneous fat (P<2×10−51). Analysis of the full dis-
covery stage results for Age at AR revealed enrichment for
insulin-like growth factor 1 (IGF-1) signaling and apoli-
poprotein pathways. We also identiﬁed strong positive
genetic correlations between early growth and later adip-
osity traits.
Conclusions: We report the ﬁrst genome-wide associa-
tion study of six childhood growth phenotypes, contributing
to the understanding of genetic inﬂuences on early growth
in humans. Our results suggest mechanistic links between
these phenotypes and increased adiposity in later childhood
and adulthood, highlighting the need to identify modiﬁable
casual factors that determine these early growth phenotypes.
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Implication of syndromic cleft genes in non syndromic
forms : towards translational phenotypes ?
B. Demeer1,2,3, M. Basha2, O. Boute4, M. Mathieu-
Dramard3, L. Van Maldergem5, R. Helaers2, C.
Gbaguidi6, N. Revencu7, B. Bayet8, B. Devauchelle6,1, M.
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7Center for Human Genetics, Cliniques universitaires Saint
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Cleft lip with or without cleft palate (CL/P) and cleft palate
(CP) are the most common craniofacial birth defects with an
approximate incidence of ~1/700. In 30% of cases, clefts are
seen in syndromic forms likely caused by genetic factors.
Non syndromic forms (NS) are believed to be caused by a
combination of genetic and environmental factors. Several
genome-wide association studies have proposed a few loci
in NSCL/P. A few genes have been implicated in both
syndromic and non-syndromic forms of CL/P. Moreover,
there are families with NSCL/P following Mendelian
transmission with low penetrance and variable expressivity.
These two points suggest that a strategy of studying genes
or pathways associated with syndromic forms as the cause
of NS clefts could be productive. To this end we decided to
perform whole exome sequencing on patients with NS cleft,
after having ruled out IRF6 mutations and cytogenetic
anomalies. Patients from 12 families with CP, 10 families
with CL/P, 2 families with velopharyngeal insufﬁciency,
and 6 sporadic CP cases were selected. Several likely cau-
sative variants were identiﬁed in ﬁve families: in GHRL3,
TP63, LRP6 and TBX1. Clinical reassessment conﬁrmed the
isolated occurrence of cleft with variable expressivity in
affected patients, as well as low penetrance, given the
number of unaffected carriers. Our study illustrates the
involvement of genes known to be mutated in syndromic
clefts, in non syndromic CL/P. It raises the question of an
important part of the “missing heritability” of NSCL/P
possibly being explained by modest-to-medium penetrant
variants in such genes
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A novel heterozygous duplication of RUNX2 gene in a
Hungarian family with cleidocranial dysplasia
A. Fekete1, P. Willems2, K. Hadzsiev1, J. Zima1, B.
Melegh1
1University of Pécs, Department of Medical Genetics, Pécs,
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Introduction: Cleidocranial dysplasia (CCD) is an auto-
somal dominant skeletal dysplasia characterized by hypo-
plastic or aplastic clavicles, persistence of wide-open
fontanelles and sutures and tooth anomalies. The prevalence
is estimated 1:1000000. It may be underdiagnosed because
of the extremely wide range of clinical manifestation. CCD
is caused by mutations in the RUNX2 gene which plays an
important role in bone maintenance and ossiﬁcation.
Materials and Methods: We investigated a currently 5
year-old boy with features of CCD. Our proband is the third
child of non-consanguineous Hungarian parents, has had
normal cognitive development and his craniofacial features
included hypertelorism, broad nasal bridge, open anterior
fontanelle, frontal bossing and short stature. Radiological
ﬁndings were: hypoplastic clavicles, spina biﬁda occulta
and lack of coccygeal vertebral segments. Mother, grand-
mother and aunt have the same symptoms in the family.
Results: The molecular genetic test was performed
within the framework of international collaboration at
Gendia. A pathogenic heterozygous duplication of 4
nucleotides RUNX2:c.906_909 dupTTAC was identiﬁed in
exon 7 of the RUNX2 gene. This frameshift causing
duplication results in a premature stop codon which leads to
truncating protein production or diminished mRNA due to
mRNA decay. To the best of our knowledge this variant is
novel not previously described in other individuals.
Conclusions: This case report represents a novel muta-
tion of RUNX2 in the background of classical CCD.
Although the diagnosis is based on clinical signs and on
characteristic radiographic ﬁndings, molecular genetic test-
ing is recommended in order to get appropriate management
and adequate treatment if neccessary.
A. Fekete: None. P. Willems: None. K. Hadzsiev:
None. J. Zima: None. B. Melegh: None.
P04.16D
The ﬁrst report of a severe classical Ehlers-Danlos
syndrome phenotype in two siblings, caused by a
homozygous hypomorphic COL5A1 mutation
D. S. Johnson1, J. M. Bowen1, E. Kinning2, J. Walsh3, B.
E. Wagner4, R. C. Pollitt1, C. Giunta5, B. Steinmann5
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Introduction: Classical Ehlers-Danlos syndrome (cEDS) is
a heritable disorder of connective tissue caused by defects
of type V collagen. Major diagnostic criteria include fragile,
hyperextensible skin with atrophic scars and joint hyper-
mobility. Aortic root dilation and mitral valve prolapse are
reported associations, but tend to be of little clinical sig-
niﬁcance, whereas vascular events have been reported rarely
in cEDS patients.
Methods: Clinical history and examination was per-
formed in ﬁve individuals from a consanguineous family.
Collagen biochemical analysis was done on collagens I, III
and V produced by cultured dermal ﬁbroblasts. Punch
biopsy of non-lesional skin was examined by electron
microscopy (EM) for abnormalities of collagen ﬁbrils.
Mutation analysis was performed by direct sequencing of
COL5A1..
Results: Two siblings had hypermobile joints, hyper-
extensible skin, bruising, atrophic scars and a history of
inferior vena cava dissection at age 7 and mesenteric artery
dissection age 8 respectively. Biochemical analysis sug-
gested deﬁciency of type V collagen. EM showed numerous
collagen cauliﬂowers. Sequencing of COL5A1 detected a
homozygous c.5317_5319del, p.(Glu1773del) mutation. A
half-sibling had hypermobile joints and joint dislocation,
the mother only hypermobile joints, and both had fewer
collagen cauliﬂowers on EM. They were heterozygous for
the familial mutation. A clinically unaffected sibling was
negative for this mutation.
Conclusion: Homozygosity for a hypomorphic mutation
in COL5A1 is associated with a high risk of vessel dissec-
tion. Although heterozygote family members did not meet
the clinical criteria for diagnosis, they have EM ﬁndings
consistent with cEDS. This case widens the known phe-
notypes associated with mutations in COL5A1.
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Phenotypic heterogeneity of craniostenosis syndromes
associated with coronal suture - 14 cases from 9 families
A. Kutkowska-Kaźmierczak1, M. Boczar2, A. Jamsheer3,
A. Sowinska-Seidler3, M. Gos1, P. Własienko1, N.
Bezniakow1, B. Wiśniowiecka-Kowalnik1, K. Czerska4, B.
Nowakowska1, E. Obersztyn1
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3Department of Medical Genetic, Poznan University of
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Center, Warsaw, Poland
Introduction: Craniosynostosis, premature fusion of cra-
nial sutures, results in abnormal shape of head and dys-
morphic facial features. Coronal synostosis is observed in
20–25% of patients with craniosynostosis and related
mainly to TWIST1 and FGFR3 mutations resulting in
Saethre-Chotzen and Muenke syndrome, respectively.
Patients and methods: We present phenotypic mani-
festation in 14 patients with mutations in TWIST1 (9
patients, including 3 familial cases) and FGFR3 (5 patients,
2 familial) genes in comparison to cases from medical lit-
erature. The TWIST1 and FGFR3 genes were analysed
using classic Sanger sequencing technique and chromoso-
mal rearrangements - using array CGH technique (Cyto-
Sure, ISCA 60K v2, OGT, hg18). In single case, clinical
exome was sequenced with TruSight One (Illumina) panel.
Results: In two cases, a 7p21.1 deletion encompassing
TWIST1 gene was identiﬁed and in eight patients known
point mutations in FGFR3 (p.P250R) or TWIST1 (c.G349T,
c.417–438ins21, c.283_285dupAGC). In three families, a
novel mutations p.Ser140Ter, c.177dupG in TWIST1 and p.
Cys613Phe in FGFR3 were found.
Ten patients presented coronal suture synostosis, 5 of
them had cranial surgery. Four patients had wide fontanelles
without synostosis. All patients demonstrated dysmorphic
features, 10 - skin syndactyly of digits 2/3, wide halluces
and 4 - simian creases. Single patients had: congenital heart
defects (2), speech delay (4), mild deafness (2), Arnold-
Chiari malformation type I (1) and lacrimal ducts’s agenesis
(1).
Conclusions: Our results conﬁrm presence of clinical
heterogeneity observed in patients with TWIST1 and
FGFR3 mutations, including familial cases. There were no
signiﬁcant clinical differences depending on gene and type
of mutation.
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A de novo duplication on chromosome 1q22 in a patient
presenting with craniosynostosis and psychomotor
retardation
A. Sowińska-Seidler, E. Olech, M. Socha, A. Jamsheer
Department of Medical Genetics, Poznan University of
Medical Sciences, Poznan, Poland
Craniosynostosis refers to the group of craniofacial mal-
formations characterized by the premature fusion of one or
more cranial sutures. The disorder is clinically and geneti-
cally heterogeneous and occurs in a syndromic form or
more frequently as an isolated trait. The signiﬁcant pro-
portion of cases is caused by genetic factors, however the
molecular origin of 40–70% of craniosynostoses remains
unknown.
Here we report on a sporadic male patient affected by
complex craniosynostosis phenotype (metopic and uni-
lateral lambdoid synostosis), muscular hypotonia, and
severe psychomotor retardation. In order to identify the
genetic cause of the disorder we performed high-resolution
array based comparative genomic hybridization (array-
CGH).
Array-CGH revealed the presence of a previously unre-
ported de novo 1.25 Mb duplication at chromosome 1q22
encompassing a strong candidate gene, LMNA encoding A-
type lamins. Mutations in LMNA cause a wide spectrum of
disorders called laminopathies. Those include diseases of
striated muscles, that could explain muscular hypotonia
observed in our patient. Interestingly, homozygous mis-
sense mutation in LMNA gene is associated with delayed
closure of the cranial sutures, an opposite phenotype to the
craniosynostosis reported in our proband.
We hypothesize that the congenital defects presented in
our patient result from either increased gene dosage of
LMNA or its misexpression caused by the disruption of
LMNA regulatory landscape. The exact pathomechanism
underlying the complex phenotype of the presented patient
is yet to be elucidated.
Funding: This work was supported by a grant from the
Poznan University of Medical Science (502-14-01126186-
08779).
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synostosis in candidate regions on chromosomes 3, 7,
and 20
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Craniosynostosis (CS) is a common congenital malforma-
tion in which one or more of the infant skull sutures
(metopic, coronal, sagittal, or lambdoid) fuse prematurely.
Sagittal non-syndromic craniosynostosis (sNCS) is the most
common type of CS, with an estimated prevalence of 2 per
10,000 live births. We previously performed the ﬁrst
genome-wide association study (GWAS) for sNCS, and
discovered highly signiﬁcant associations to a 120 kb region
located 345kb downstream from BMP2 on 20p12.3 and
within a 167kb region intronic to BBS9 on 7p14.3. Addi-
tionally, analyses of 52 imputed variants in DLG1 on 3q29
were found to be genome-wide signiﬁcant. In the current
study, targeted Next Generation Sequencing (NGS) meth-
ods were used to sequence the regions on 3q29, 7p13.2, and
20p12.3, as well as two additional genes in close proximity
to some of these associated regions (BMP2 and BMPER) in
100 case-parent trios, in order to identify variants in the
coding and noncoding regions responsible for the sNSC
phenotype. Single nucleotide variants and insertions/dele-
tions available from the NGS study were analyzed for de
novo mutations, rare variants in coding regions, and over-
transmission of rare variants in non-coding regions. Can-
didate variants present in more than one trio and predicted
to be damaging to gene function are prioritized for func-
tional studies in zebraﬁsh.
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Bulgaria
Craniosynostosis (CS), the premature fusion of one or more
skull sutures, is a congenital anomaly occurring in 1 of
2,500 newborns. The majority of the patients present with
an isolated nonsyndromic CS (NCS). The aim of this study
is to investigate the genetic and non-genetic factors con-
tributing to the risk of NCS in Bulgarian patients. A total of
39 patients (28 males and 11 females) with different types
of CS were recruited and characterized through standar-
dized clinical, epidemiological and molecular protocols.
Based on clinical evaluation the patients were characterized
as syndromic (9) or NSC (30). Epidemiological ques-
tionnaire was administered to collect data regarding past
medical and family histories, lifestyle and possible envir-
onmental exposures. Patient’s DNA was analyzed by San-
ger sequencing for mutations in targeted “hot spot” regions
of FGFR1 (exon 7), FGFR2 (exons 8 and 10), FGFR3
(exons 6 and 7) and the entire TWIST1 gene. A previously
described pathogenic mutation c.1024T&gtC, p.C342R in
exon 10 of FGFR2 was identiﬁed in a patient with clinical
manifestation of Crouzon syndrome. Chromosomal micro-
array analysis is being considered for the remaining patients
with syndromic CS. A subgroup of patients and their par-
ents was included in a cohort of 415 case-parent trios with
metopic NCS that are currently being analyzed by genome-
wide association study (GWAS) in a search of new genes
and loci, in the frame of the International Craniosynostosis
Consortium. In conclusion, the etiologic deciphering of this
birth defects requires coordinated and complex research
efforts combining clinical, epidemiological, molecular and
modern genomic approaches.
N. Yaneva: None. R. Kaneva: None. E. Simeonov:
None. A. Cuellar: None. K. Georgiev: None. A. Bus-
sarsky: None. M. Penkov: None. S.A. Boyadjiev: None.
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Novel mutation in HOXC13 expand the mutation spec-
trum of pure hair and nail ectodermal dysplasia
A. Humbatova1, R. Marooﬁan2,3, M. T. Romano1, A.
Tafazzoli1, M. Behnam4, N. Nouri5, M. Salehi4,6, S. Wolf1,
P. Kokordelis1, R. C. Betz1
1Institute of Human Genetics, University of Bonn, Bonn,
Germany, 2The RILD Institute, Royal Devon & Exeter NHS
Hospital, Wonford, Exeter, United Kingdom, 3Molecular &
Clinical Sciences Research Institute, St. George's Univer-
sity of London, Cranmer Terrace, London, United King-
dom, 4Medical Genetics Laboratory of Genome, Isfahan,
Iran, Islamic Republic of, 5Labkhand Clinic, School of
Medicine, Isfahan University of Medical Sciences, Isfahan,
Iran, Islamic Republic of, 6Division of Genetics and
Molecular Biology, School of Medicine, Isfahan University
of Medical Sciences, Isfahan, Iran, Islamic Republic of
Ectodermal dysplasias (EDs) are a large group of hetero-
geneous genetic disorders characterized by abnormal
development in ectoderm-derived tissues and organs
including skin, hair, and nails. Among the EDs, pure hair
and nail ectodermal dysplasia (PHNED) is a rare geno-
dermatosis characterized by nail dystrophy and sparse or
absent hair on the scalp.
A family of Iranian origin was enrolled in this study.
Two children from a consanguineous marriage are affected
from PHNED. In addition, the father has alopecia areata
(AA) but does not show any nail dysplasia. The mother is
unaffected. The paternal and maternal grandfathers had nail
dysplasia almost similar to the siblings but did not manifest
any hair loss or AA. Homozygosity mapping and Gene-
distiller analysis were performed to identify candidate
genes.
In total, we identiﬁed 10 homozygous regions with
almost 700 candidate genes. Among these genes were also
KRT85 and HOXC13, already known to be related to the
phenotype of our patients. Sanger sequencing showed a
novel homozygous insertion of 28 bp in exon2 of HOXC13.
We identiﬁed an unknown mutation for PHNED which
expands the spectrum of mutations for PHNED.
The hair loss of the father seems rather be due to a dis-
tinct type of hair loss, namely AA, which is quite common
in the general population. However, the nail dysplasia from
both grandfathers is unclear and cannot be examined any-
more. It still remains unclear if the nail dysplasia in the
grandfathers was due to the same mutation in HOXC13 or is
based on a different mutation.
A. Humbatova: None. R. Marooﬁan: None. M.T.
Romano: None. A. Tafazzoli: None. M. Behnam: None.
N. Nouri: None. M. Salehi: None. S. Wolf: None. P.
Kokordelis: None. R.C. Betz: None.
P04.22B
Vascular Ehlers Danlos syndrome as part of
2q32.2q33.1 microdeletion syndrome
C. Green1, E. Hobson2, J. Radley3, D. Williams3, D.
Johnson1
1Shefﬁeld Clinical Genetics, Shefﬁeld, United Kingdom,
2Yorkshire Regional Genetics Service, Leeds, United King-
dom, 3West Midlands Clinical Genetics Service, Birming-
ham, United Kingdom
Introduction: Interstitial deletions involving 2q32q33
result in clinical features including learning disability,
growth retardation, dysmorphic features, thin and sparse
hair, feeding difﬁculties and cleft or high palate. We present
two patients referred to the Ehlers Danlos Syndrome (EDS)
National Diagnostic Service with 2q microdeletions that
encompass COL3A1 and COL5A2 genes associated with
vascular EDS and classical EDS respectively. Features of
vascular EDS include arterial or hollow organ rupture,
extensive bruising, thin, translucent skin and characteristic
facial features. Major diagnostic criteria for classical EDS
include; joint hypermobility, fragile hyperextensible skin
and poor wound healing.
Material and Methods: Array CGH testing was per-
formed due to developmental delay in these patients by
local genetics services. Upon referral to the EDS National
Diagnostic Service patients were clinically examined for
features of classical and vascular EDS.
Results: These patients both have clinical features con-
sistent with vascular EDS but neither fulﬁlled diagnostic
criteria for classical EDS. Haploinsufﬁcency of COL3A1
has been well described as a disease mechanism whereas
dominant negative effects have been the focus of COL5A2
reports.
Conclusions: These cases highlight the importance of
pre-test genetic counselling to prepare patients for possible
incidental ﬁndings. Early identiﬁcation of vascular EDS has
been shown to lead to improved survival and quality of life
for patients. Referral to specialist services ensures that
patients are informed about the condition and signposted to
appropriate surveillance and management. These cases also
add evidence to the theory that null allele COL5A2 muta-
tions result in no or mild clinical phenotype.
C. Green: None. E. Hobson: None. J. Radley: None.
D. Williams: None. D. Johnson: None.
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New variants in COL5A1 gene among 44 Polish patients
with Ehlers-Danlos syndrome - analysis of nine cases
A. Junkiert-Czarnecka, M. Pilarska-Deltow, O. Haus
Department of Clinical Genetics Collegium Medicum in
Bydgoszcz Nicolaus Copernicus University in Torun,
Bydgoszcz, Poland
Introduction: The Ehlers-Danlos syndrome (EDS) is a
non-inﬂammatory, heritable connective tissue disorder. One
of the subtypes of EDS, classic type (cEDS) is characterized
by hypermobile joints, hyperextensibility of skin and
widened atrophic scars, which are the major criteria of the
Villefranche nosology. cEDS is caused mainly by mutations
in COL5A1, encoding the type V collagen. Material and
methods: The investigated group consisted of 44 patients,
adults and children, from all regions of Poland. Patients
presented clinical symptoms of classic type of Ehlers-
Danlos syndrome, according to Villefranche nosology.
Control group consisted of 100 healthy persons from gen-
eral Polish population. Mutation analysis of selected parts
of COL5A1 gene was performed by Sanger sequencing.
Results and conclusion: In 9 among all tested patients new
mutations were detected, 8 were missense mutations, one
was splice site mutation. They were not described to date in
LOVD, ClinVar and HGMD databases. Pathogenicity of the
mutations was evaluated using SIFT, PolyPhen-2,
AlignGVGD, RNAfolding for missense mutations and
Human Splicing Finder, NetGene2 for splice site mutation.
All used tools indicated pathogenicity of the variants. For
all found mutations control group was also tested. Among
100 healthy individuals variants were not found. Addi-
tionally, in 4 patients (9.09%) previously described altera-
tion c.1588G>A (p.G530S) was detected. In control group
frequency of this variant was assessed as 4%. This inves-
tigation was the ﬁrst one in Poland on such a large scale and
was the ﬁrst one among cEDS patients in Central-East
Europe.
A. Junkiert-Czarnecka: None. M. Pilarska-Deltow:
None. O. Haus: None.
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New splice-site mutation in KRT5 suspected to cause
localized Epidermolysis Bullosa Simplex
L. Graversen1, R. Christensen1, M. Sommerlund2, U. B.
Jensen1
1Department of Clinical Genetics, Aarhus University
Hospital, Aarhus, Denmark, 2Department of Dermatology,
Aarhus University Hospital, Aarhus, Denmark
Background: Epidermolysis Bullosa Simplex (EBS) is
characterized by fragility of the skin resulting in non-
scarring blisters due to minor trauma and is caused mainly
by mutations in the genes, KRT5 and KRT14. The phe-
notypic features of localized EBS are infancy-onset blis-
tering of mainly the hands and feet, but blistering can occur
anywhere if the trauma is signiﬁcant.
Pathogenic variant detection rate in individuals with
biopsy-diagnosed EBS is 75%. The genes are expressed in
keratinocytes. Their protein products, keratin 5 and keratin
14, form heterodimeric molecules that assemble into the
intracellular keratin intermediate ﬁlament network.
Methods and Results:We present a family with biopsy-
diagnosed EBS and autosomal dominant inheritance. The
phenotype is mild. Sequencing analysis of the KRT5 and
KRT14 revealed heterozygosity for a splice variant (c.927
+2T>C) in KRT5 in affected family members. The mutation
has not previously been reported, but is predicted to cause a
splice-variant of keratin 5.
RT-PCR of ﬂanking sequences of the mutation followed
by gel electrophoresis revealed a prolonged RNA transcript.
Sanger sequencing of the cDNA showed that the point
mutation resulted in aberrant splicing leading to incor-
poration of 30 intronic nucleotides into the mRNA tran-
script, which results in incorporation of 10 extra amino
acids into keratin 5.
Conclusion: Our ﬁnding supports the prediction of the
KRT5 c.927+2T>C mutation to be pathogenic. The altera-
tion is located at the terminal end of the coiled coli 1B and
is predicted to affect polymer assembly and consistent with
a dominant negative effect. The phenotype is mild and
localized EBS.
L. Graversen: None. R. Christensen: None. M. Som-
merlund: None. U.B. Jensen: None.
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Combined approach for ﬁnding susceptibility genes for
DISH&Chondrocalcinosis families
A. Couto1,2, B. Parreira1,2, M. Soares1,2, J. Bruges
Armas1,2, M. Brown3
1SEEBMO, Angra do Heroísmo, Portugal, 2Genetics &
Arthritis Research Group, I3S, University of Porto, Porto,
Portugal, 3Translational Genomics Group,, Institute of
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Introduction: Twelve families with early onset of calcium
pyrophosphate dehydrate (CPPD) chondrocalcinosis (CC)
and diffuse idiopathic skeletal hypersostosis (DISH) were
identiﬁed in Terceira Island, the Azores, Portugal.
Material and Methods: After clinical and radiological
characterization, 92 individuals from 12 unrelated families,
were selected for a combined gene-mapping strategy study.
First, a whole genome wide linkage analysis was per-
formed, then an identity-by-descent analysis in 10 indivi-
duals from 5 of the investigated pedigrees.
Results: The maximal LOD score obtained was for an
area of chromosome 16 (D16S1000) with a LOD score of
1.32 (p=0.007). Because this area was not replicated by the
IBD/IBS analysis, it was not further investigated. From the
IBD/IBS analysis, two candidate genes, LEMD3 and
RSPO4, were selected for sequencing analysis. Nine genetic
variants were identiﬁed in the RSPO4 gene. No statistically
signiﬁcant differences in the occurrence of these genetic
variants was observed in DISH/CC phenotype relative to
the controls. However, two regulatory variants
(rs146447064 and rs14915407) are signiﬁcantly more fre-
quent in controls than in DISH/CC patients (p=0.03). Four
variants were identiﬁed in LEMD3; variant rs201930700
was further investigated through segregation analysis. The
10 genetic variants in RSPO4 and in LEMD3 did not seg-
regate within the families studied.
Conclusions: The results of the present study revealed
that two RSPO4 gene regulatory variants, may have a
protective role against the DISH/CC phenotype, possibly by
altering gene expression of the RSPO4 gene. Variant in
LEMD3 is extremely rare and its effect is difﬁcult to
ascertain at this point.
A. Couto: None. B. Parreira: None. M. Soares: None.
J. Bruges Armas: None. M. Brown: None.
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High bone mass due to LRP5 and AMER1 gene defects -
two patients with novel mutations
R. E. Mäkitie1, A. Costantini2, P. Rautiainen3, O.
Mäkitie1,2,4
1Folkhälsan Institute of Genetics and University of Helsinki,
Helsinki, Finland, 2Department of Molecular Medicine and
Surgery and Center for Molecular Medicine, Karolinska
Institutet, Stockholm, Sweden, 3Department of Internal
Medicine, Hospital District of North Karelia, Joensuu,
Finland, 4Children's Hospital, University of Helsinki and
Helsinki University Hospital, Helsinki, Finland
High bone mass (HBM) refers to excessive bone accumu-
lation. Here we describe two patients with novel mutations
in LRP5 or AMER1, leading to increased WNT signaling
and subsequently substantial bone mass and skeletal
complications.
Patient I
A 51-year-old male with severe osteopetrosis (DXA T-
scores+ 7.2 – +10.1). He has undergone several surgeries
for complications of cranial hyperostosis (narrow ear canals,
bilateral jaw exostoses, and mandibular tori). Radiography
showed cranial hyperostosis and long bone cortical thick-
ening. Bone formation marker PINP was elevated. Genetic
studies revealed a novel gain-of-function mutation c.592A
> T (p.N198Y) in LRP5 (LDL Receptor Related Protein 5).
Patient II
A 16-year-old female with osteopathia striata and cranial
sclerosis (OS-CS). She has marked macrocephaly (head
circumference +6 SD), and dysmorphic features (triangular
face, micrognatia, and hypertelorism). Broncoscopy
revealed layngomalasia and subglottic stenosis. Motor
development was delayed and she later developed epilepsy.
Radiography showed severely thick, sclerotic, and long-
itudinally striated long bones. Biochemistry was normal.
Genetic studies identiﬁed a novel de novo X-chromosomal
heterozygous frameshift mutation c.655del (p.
G219Afrs*63) in AMER1 (APC Membrane Recruiting
Protein 1).
Conclusions: WNT signaling is essential to bone health
and defective WNT signaling leads to skeletal disorders.
LRP5 is a co-receptor for WNT-ligands and LRP5 muta-
tions can cause HBM. AMER1 enables degradation of
intracellular β-catenin and thus down-regulates WNT target
gene expression and can cause OS-CS. These two novel
mutations highlight the crucial role and pathogenic effect of
increased WNT signaling in skeletal development.
Grant references: Sigrid Jusélius Foundation, Academy
of Finland, Swedish Research Council, Novo Nordisk
Foundation.
R.E. Mäkitie: None. A. Costantini: None. P. Rautiai-
nen: None. O. Mäkitie: None.
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Holt-Oram syndrome: clinical and molecular insights
C. Vanlerberghe1,2, A. Jourdain2,3, J. Ghoumid1,2, F.
Frenois2, A. Mezel4, G. Vaksmann5, B. Lenne6, B.
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Holt-Oram Syndrome (HOS) is an autosomal dominant
condition characterised by the association of radial and
congenital heart defects (CHD), with or without conduction
disturbances, due to TBX5 mutations. Within syndromic
radial dysplasia, HOS is a challenging diagnosis by its
variability of expression and the large phenotypic overlap
with other conditions, like Okihiro syndrome (SALL4
mutations), TAR syndrome or Fanconi disease.
In this study, 228 patients addressed for suspicion of
HOS between 2002 and 2014, and whose TBX5 gene has
been studied by Sanger sequencing and MLPA, have been
retrospectively reviewed. A TBX5 mutation has been iden-
tiﬁed in 78 patients, forming the largest molecular series
ever described. The patients’ phenotypes were sorted in 2
categories: “typical” (with or without heart defect) or
“uncertain”. 22% of the mutated patients had an “uncertain”
presentation. The genotype-phenotype study highlights the
importance of some critical features in HOS: the bilateral
and asymmetric characteristics of the radial defect, shoulder
or elbow mobility defect and the septal characteristic of the
CHD. Thorax, spinal or lung deformities do not rule out the
HOS hypothesis. Besides, 21 patients presented with
another overlapping condition, including 13 “typical” pre-
sentations. Thirty percent of the typical patients had no
TBX5 or SALL4 mutations.
We propose a molecular workﬂow in HOS and over-
lapping conditions diagnostic approach, based on the results
of an exhaustive clinical examination and systematic com-
plementary evaluations. Finally we discuss the different
strategies that can be adopted to improve the molecular
delineation of the remaining “typical” patients.
C. Vanlerberghe: None. A. Jourdain: None. J.
Ghoumid: None. F. Frenois: None. A. Mezel: None. G.
Vaksmann: None. B. Lenne: None. B. Delobel: None. N.
Porchet: None. V. Cormier-Daire: None. F. Petit: None.
F. Escande: None. S. Manouvrier: None.
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A family sample for primary focal hyperhidrosis
J. Meyer1, P. May2, C. Schick3, K. Gross1
1Department of Neurobehavioral Genetics, Institute of
Psychobiology, University of Trier, Trier, Germany, 2Gen-
ome Analysis Bioinformatics Core, Luxembourg Centre for
Systems Biomedicine (LCSB), University of Luxembourg,
Esch-sur-Alzette, Luxembourg, 3Deutsches Hyperhidrose-
zentrum (DHHZ), Munich, Germany
Introduction: “Sweating” in a narrow sense exists solely in
a few groups of mammals, namely equines and primates.
Hyperhidrosis is a condition characterized by excessive
sweating. Two forms are described, 1, primary hyperhi-
drosis with causation unknown so far, and 2, secondary
hyperhidrosis caused by organic malfunction such as hor-
monal imbalance. Subjects affected by hyperhidrosis may
suffer from psychosocial stress due to ostracism or self-
imposed avoidance of physical contact, and subsequently
experience depressive symptoms, as we have demonstrated
recently. Here, we focus on primary focal hyperhidrosis
(OMIM %114110), which is characterized by excessive
sweating at distinct body regions, for example palms, feet,
or face.
Material and Methods: A total of 15 multiplex families
with 78 affected and 102 non-affected subjects were
recruited. Diagnoses were made by experienced clinicians at
the Deutsches Hyperhidrosezentrum, Munich. DNA sam-
ples await genotyping and Next Generation Sequencing
(NGS) strategies to identify causative mutations.
Results: Preliminary results of our study using micro-
satellite markers to cover previously described candidate
loci (Higashimoto et al., 2006; Chen et al., 2015) point to
conﬁrmation of linkage to chromosomal regions 2q31.1 and
14q11.2 - q13.
Conclusions: Primary focal hyperhidrosis is a geneti-
cally heterogeneous hereditary condition with at least two
chromosomal loci involved, and follows an autosomal-
dominant pattern of inheritance. Linkage studies and NGS
will be performed to identify causative genetic variants.
J. Meyer: None. P. May: None. C. Schick: None. K.
Gross: None.
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A novel EDA gene mutation in two Turkish brothers
with X-linked hypohidrotic ectodermal dysplasia
230
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1İzmir Katip Çelebi University, Ataturk Training and
Research Hospital, İZMİR, Turkey, 2Dr. Behçet Uz
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Introduction: Ectodermal dysplasia is a rare congenital
hereditary disorder characterized by deﬁciency in develop-
ment of structure derived from the ectoderm. The disease
encompasses more than 200 clinically distinct features,
which affect the skin, hair, nails, teeth, sweat glands, and
sebaceous glands. Phenotypes caused by mutations in the
genes EDA, EDAR, or EDARADD have similar clinical
features with different inheritance patterns. Mutations in
EDA gene cause X linked Hypohidrotic Ectodermal Dys-
plasia (HED), which is the most common form of the
ectodermal dysplasia. HED is characterized by the typical
triad that includes hypodontia, hypotrichosis and hypohi-
drosis that can lead to hyperthermia episodes. Affected
males typically exhibit all the typical features of HED, but
heterozygous carriers may show mild to moderate clinical
manifestations. Materials and Methods: Two affected
brothers applied to our clinic with the complaints of HED
with a chief complaint of missing tooth in upper and lower
anterior region. For mutation analysis, the coding region of
EDA of 2 patients was sequenced.
Results: We report two affected siblings with HED with
a novel heterozygous mutation, c.641_668del in the EDA
gene. To our knowledge, the mutation we describe has
never been reported. The mutation was located in exon 4
and consisted of a frame-shift mutation at codon 215, which
gave rise to an abnormal protein with a premature stop
codon after 56 residues. Conclusion: Genetic analyses in
families with HED are useful for checking carrier status, but
they also provide information for genetic counseling and
prenatal diagnosis.
A. Subaşıoğlu: None. F. Hazan: None.
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The COL1A2 SNP rs42524 is associated with adult
Hypophosphatasia in heterozygotes for ALPL mutations
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13Medical Genetics, CHU Angers, Angers, France, 14Rheu-
matology, CHU Strasbourg, Strasbourg, France, 15Rheu-
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Heubner-Centrum für Kinder und Jugendmedizin Allge-
meine Päediatrie Charité, Berlin, Germany, 19Stichting
Klinisch Genetisch Centrum Nijmegen, Nijmegen,
Netherlands
Dominant inheritance of hypophosphatasia (HPP), a rare
skeletal dysplasia, is assumed to be due to the dominant
negative effect (DNE) of missense mutations deriving from
the functional homodimeric structure of TNSALP, the
protein encoded by the ALPL gene. However, there is no
biological argument excluding other causes of dominant
HPP, for instance haploinsufﬁciency. We determined in
silico that 97% of the mutations with an experimentally
proved DNE affected residues of particular domains of
TNSALP (DNE domains), allowing to deﬁne 2 classes of
mutations, class 1 (possible DNE) and class 2 (no DNE).
Then we localized in silico the mutations of 124 patients
with various forms of dominant HPP. Class 2 mutations
were found in 50% of adult patients (26/52) but only 19%
of patients with other forms of dominant HPP, suggesting
that a large subset of adult dominant HPP is due to muta-
tions presumably with no DNE. These patients had a mean
AP level and an age of ﬁrst symptoms slightly higher. We
looked by NGS for coding SNPs that could contribute to
haploinsufﬁciency. We detected in adult HPP patients an
association between class 2 alleles and the GG genotype of
the SNP rs42524 in COL1A2 (χ2 test, p=1.8 10−4). In
conclusion our results suggest that dominant adult HPP may
be due either to DNE or to another mechanism, presumably
haploinsufﬁciency triggered by the GG genotype in
COL1A2 gene, suggesting that this gene is a modiﬁer gene
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of HPP. This result need to be conﬁrmed with a larger
cohort.
A. Taillandier: None. C. Domingues: None. A.
Dufour: None. F. Debiais: None. P. Guggenbuhl: None.
C. Roux: B. Research Grant (principal investigator, colla-
borator or consultant and pending grants as well as grants
already received); Modest; Ultragenyx. D. Speakers
Bureau/Honoraria (speakers bureau, symposia, and expert
witness); Modest; Alexion. C. Cormier: None. B. Cortet:
None. V. Porquet-Bordes: None. F. Coury-Lucas: None.
D. Geneviève: None. J. Chiesa: None. T. Colin: None. E.
Fletcher: None. A. Guichet: None. R. Javier: None. M.
Laroche: None. B. LeHeup: None. C. Lucas: None. G.
Schwabe: None. I. van der Burgt: None. C. Muti: None.
B. Simon-Bouy: None. E. Mornet: D. Speakers Bureau/
Honoraria (speakers bureau, symposia, and expert witness);
Modest; Alexion.
P04.33A
Homozygous p.Arg1014Cys mutation in COL1A1 may
be responsible for a more severe form of infantile cor-
tical hyperostosis (Caffey disease)
A. Kashyap1, A. Szwed2, K. Bernatowicz1, M. Reyes3, H.
Jüppner3, M. Kołban2
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Infantile cortical hyperostosis, or Caffey disease (OMIM
114000) is a disorder characterised by subperiosteal bone
proliferation associated with an inﬂammatory process. Signs
and symptoms appear spontaneously in the ﬁrst months of
life and the course is generally self-limiting. The disease is
caused by a recurrent heterozygous COL1A1 mutation and
is usually transmitted in an autosomal dominant pattern.
Until now, the same heterozygous mutation has been
identiﬁed in several unrelated families. We now present an
11-year old male patient from a family with 10 individuals
diagnosed with Caffey disease. The boy was born with bone
lesions that were already observed in utero during prenatal
ultrasonographic examination. Inﬂammatory process was
severe, but it regressed gradually over several years. At this
point the patient requires orthopaedic surgeries to correct
deformities of lower extremities. The previously described
heterozygous missense mutation c.3040C > T (p.Arg1014-
Cys) in COL1A1 was detected in the affected members of
this family. However, the patient was found to be
homozygous for the mutation. Detailed family history
revealed that homozygosity is most likely due to con-
sanguinity. We assume that the more severe phenotype of
the disease is associated with homozygosity for the mutant
allele. This is most likely the ﬁrst report of a homozygous p.
Arg1014Cys COL1A1 mutation in a patient with Caffey
disease.
A. Kashyap: None. A. Szwed: None. K. Bernatowicz:
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Background: Hyaline ﬁbromatosis syndrome (HFS) is a
recently introduced alternative term for two disorders that
were previously known as juvenile hyaline ﬁbromatosis
(JHF) and infantile systemic hyalinosis (ISH). These two
variants are secondary to mutations in the anthrax toxin
receptor 2 gene (ANTXR2) located on chromosome 4q21.
The main clinical features of both entities include papular
and/or nodular skin lesions, gingival hyperplasia, joint
contractures, and osteolytic bone lesions that appear in the
ﬁrst few years of life, and the syndrome typically progresses
with the appearance of new lesions.
Methods: We describe ﬁve Lebanese patients from one
family, aged between 28 and 58 years, and presenting with
nodular and papular skin lesions, gingival hyperplasia, joint
contractures and bone lesions. Because of the particular
clinical features and the absence of a clinical diagnosis,
Whole Genome Sequencing (WGS) was carried out on
DNA samples from the proband and his parents.
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Results: A mutation in ANTXR2 (p.Gly116Val) that
yielded a diagnosis of HFS was noted. Conclusions: The
main goal of this paper is to add to the knowledge related to
the clinical and radiographic aspects of HFS in adulthood
and to show the importance of Next-Generation Sequencing
(NGS) techniques in resolving such puzzling cases.
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STAT4 gene polymorphism is associated with poly-
articular juvenile idiopathic arthritis in Belarusian
patients
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Goncharova1
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Introduction: Juvenile idiopathic arthritis (JIA) is a mul-
tifactorial disease predominating in pediatric rheumatology,
with varying prevalence among different geographically
distinct populations. As understanding of the disease
mechanisms and genetic predisposition is still insufﬁcient,
the investigation of molecular-genetic basis of the JIA could
shed some light on this problem.
Materials and Methods: A total of 94 patients diag-
nosed with JIA (mean age 8.78±5.21, 66% females), 95
children with articular syndrome (mean age7.90±4.81, 43%
females) and 164 hospital controls with no sign of auto-
immune or inﬂammatory diseases (mean age13.99±2.68,
51% females) were recruited to this study. The JIA patients
were divided into subgroups according to IIAR classiﬁca-
tion criteria. The samples were genotyped for the STAT4
rs7574865 and CTLA4 rs5742909 using PCR-RFLP.
Results: There were no differences between the fre-
quencies of the CTLA4 rs5742909 alleles and genotypes
across all three groups. On the contrary, the minor T allele
of STAT4 rs7574865 was associated with polyarticular JIA
when compared with hospital controls (p=0.03 and p=0.01
for genotypes and alleles accordingly). Besides, TT geno-
type was 8,4 times more frequent in polyarticular JIA
patients (p=0.004; OR=9.96; 95% CI=[1.53–65.00]) and
the frequency of the risk T allele was also 2,3 times higher
(p=0.001; OR=3.37; 95%CI=[1.56–7.28]) when compared
with the group of children with other articular pathology.
Conclusions: STAT4 rs7574865 polymorphism demon-
strated a subtype-related association with JIA owing to
increased frequency of the minor T allele in patients with
polyarticular JIA as compared to both hospital controls and
other articular pathology.
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KCTD15 in a family with frontal lipoma, congenital
heart disease and cutis aplasia of the scalp deﬁnes a
novel syndrome
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The BTB (Broad-complex, Tramtrack and Bric-a-brac)
domain proteins have diverse functions that include potas-
sium channel transport, DNA replication, protein degrada-
tion and transcriptional repression. Heterozygous mutations
in BTB domains within the potassium-channel tetra-
merisation domain-containing proteins (KCTD) were pre-
viously described in scalp-ear-nipple (SEN) syndrome
(KCTD1), characterised by cutis aplasia of the scalp and
anomalies of the external ears, digits/nails, and breasts, and
myoclonus-dystonia (KCTD17). We describe a father and
daughter with a distinct phenotype combining large frontal
lipoma, cardiac defects (tetralogy of Fallot or patent ductus
arteriosus) and cutis aplasia of the scalp. In the father we
identiﬁed, by trio exome sequencing, a de novo hetero-
zygous c.310G > C (p.Asp104His) mutation in KCTD15,
the closest paralogue of KCTD1, that was transmitted to his
affected daughter. We show in vitro that the p.Asp104His
substitution destabilises the pentameric assembly of both
KCTD15 homodimers and KCTD15-KCTD1 heterodimers
by interaction via their BTB domains, indicating a speciﬁc
dominant negative mode of action. Modelling based on the
available KCTD1 structure predicts that this is caused by
disruption of key intermolecular contacts made by the
conserved Asp104 residue within the pentamer. KCTD15
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was previously demonstrated to repress the neural crest
transcription factor AP2, and we are currently investigating
the effects of the mutation using transactivation assays. This
is the ﬁrst report of a mutation identiﬁed in KCTD15,
highlighting the importance of the Asp104 residue in
maintaining the correct structure and function of the protein,
and the critical role played by KCTD15 in tissues of neural
crest and ectodermal origin.
K.A. Miller: None. D. Pinkas: None. J. Bufton: None.
S.R.F. Twigg: None. S.J. McGowan: None. M.J. Parker:
None. D. Johnson: None. A.N. Bullock: None. A.O.M.
Wilkie: None.
P04.37A
Lethal skeletal dysplasias: molecular investigation in a
series of 62 fetus, including a novel phenotype
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Introduction: Around 50 skeletal dysplasias (SD) are lethal
or semi-lethal. The precise diagnosis for this group of SD is
necessary for the correct genetic counseling and conse-
quently for reproductive decisions, including PGD. While
the radiological diagnosis is sufﬁcient for the most frequent
lethal SD (ex: Tanathophoric D, and OI-IIA), usually for the
most rare types the molecular investigation is necessary for
the differential diagnosis. Here we present the results of a
molecular investigation in a cohort of 62 fetus.
Materials and Methods: We used both, the classical
Sanger sequencing (41 cases) and the NGS technology for
the remaining (21 cases). For the NGS we used a custom
panel (TruSeq Custom Amplicon - Illumina) including 39
genes. All mutations found by NGS were conﬁrmed by
Sanger sequencing. We also used WES for studying two
novel phenotypes.
Results: The molecular investigation conﬁrmed the
radiological diagnosis in 54 fetus (87%). The most frequent
diagnosis were: Tanathophoric D (25), collagenopathies
type-2 (8), ciliopathies (7), and Campomelic D (7). The two
fetus with a novel phenotype are still under the exome
analysis. Although these two fetus present a clinical phe-
notype of achondrogenesis (hydrops with severe micro-
melia), the radiological ﬁndings of both fetus are identical
and not related to any known skeletal dysplasia.
Conclusions: The mutation rate detection was very high
(87%), and in all deﬁned cases except one, the molecular
analysis conﬁrmed the radiological diagnosis. Only in one
fetus the radiological evaluation was doubtful (Torrance D).
Grants: FAPESP (98/16006-6; 2015/22145-6); CNPq
(590148/2011-7)
D.P. Cavalcanti: None. T.Y. Kanazawa: None. K.C.
Silveira: None. C. Silveira: None. C.A. Moreno: None.
M.J. Lacarrubba: None. M. Sanseverino: None. L.C.
Bonadia: None.
P04.38B
Identiﬁcation of binding partners of the LPAR6 protein
involved in hypotrichosis simplex
M. T. Romano1, S. M. Pasternack-Ziach1, F. B.
Basmanav1, S. Kittanakom2, A. M. Oprisoreanu3, D.
Angelakis1, N. Ishorst1, A. Linneborn1, P. Kokordelis1, S.
Schoch3, I. Stagljar2, R. C. Betz1
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Introduction: Hypotrichosis simplex (HS) is a genetically
heterogeneous hair loss disorder characterized by pro-
gressive hair loss. Mutations in more than 10 genes have
been identiﬁed for HS, including the LPAR6 gene encoding
for the human lysophosphatidic acid receptor 6 (LPAR6).
This protein belongs to the same signalling network of
lipase H (LIPH), which is also a causative gene for HS.
Considering the importance of this pathway in the deter-
mination of proper hair growth, we speculated that more
genes related to the same pathway could be a cause of HS.
Therefore, our goal was to identify new interactors of
LPAR6.
Materials and methods: Membrane yeast two hybrid
(MYTH) assay and bait dependency test were performed to
spot putative binding partners (BPs) of LPAR6. The results
revealed 72 putative interactors from a skin/hair follicle
library. The interaction was further assessed by pull-down
assay, to discard false positive results and conﬁrm the real
interactions between LPAR6 and the candidate proteins.
Results: Six true BPs have already been conﬁrmed,
including the U11/U12 small nuclear ribonucleoprotein 35
kDa protein (SNRNP35), the 40S ribosomal protein S28
(RPS28), the emopamil-binding protein (EBP), the tran-
scription factor AP-1 (JUN), the lysosomal amino acid
transporter homolog 1 (PQLC2) and the lymphocyte anti-
gen 6 complex locus D (LY6D). Furthermore, many false
positive BPs could be discarded.
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Conclusions: We were able to identify some of the BPs
of LPAR6. Many more putative interactors have been
cloned and await to be studied.
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Diagnostic value of NGS for primary lymphedema in
Slovene patients
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Background: Primary lymphedema is a rare, genetically
diverse disease. Since next generation sequencing (NGS) is
an ideal approach for the diagnosis of such diseases, we
wanted to establish a diagnostic value of NGS in a cohort of
Slovene primary lymphedema patients.
Methods: Index patients of ﬁve unrelated Slovene
families with pedigree typical for primary lymphedema
(lymphedema of upper and/or lower extremities and/or neck
region; autosomal dominant pattern of inheritance) were
sequenced with clinical exome sequencing. We searched for
mutations in coding regions of genes associated with lym-
phedema (HP:0001004). Synonymous variants and variants
with the frequency exceeding 1% in a control population
(esp6500) were not analyzed. The mutations found were
conﬁrmed with Sanger sequencing (in patients and addi-
tionally in at least one of the affected family member(s)).
Results: The female to male ratio of our index cases
were 2/3. Mean age of lymphedema presentation was at
birth, however the oldest patient was 25 years old, when she
ﬁrst got lymphedema symptoms. In 2 patients an already
described, missense mutation causative for primary lym-
phedema, was identiﬁed in the FLT4 gene (c.3489G>A).
Two affected family members of the index cases, one from
each family, were also harboring this mutation. In three
patients, we were not able to identify any mutation asso-
ciated with primary lymphedema.
Conclusions: With clinical exome sequencing, we were
able to identify the genetic cause in 40% of patients in a
cohort of well-deﬁned Slovene primary lymphedema
patients.
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Genotypic and phenotypic evaluation of 40 patients with
marfan syndrome: 7 novel mutations
A. Gezdirici, E. Gulec
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Marfan syndrome is an autosomal dominant genetic con-
dition that affects the connective tissue in many parts of the
body. Cardinal manifestations involve the ocular, skeletal,
and cardiovascular systems. The diagnosis of Marfan syn-
drome relies on deﬁned Ghent criteria, outlined by inter-
national expert opinion to facilitate accurate recognition of
this syndrome and to improve patient management and
counselling. However, it may not be possible to make
deﬁnitive diagnosis according to these criteria in each
patient, thus molecular genetic conﬁrmation is necessary in
such group of patients. Marfan syndrome is caused by
mutation of FBN1. Here we review clinical and genetic
evaluation of 40 patients with marfan syndrome diagnosed
at our center between 2014 and 2017. We identiﬁed muta-
tions that were not previously reported in the literature in 7
of these patients. There are very few studies on the
genotype-phenotype correlation of Marfan syndrome and
no clear genotype-phenotype association has been shown to
date. We have identiﬁed c.5917+5 G>A and c.5917+5
G>C heterozygous mutations of the same locus in two
different patients. And we found that both patients showed a
more severe clinical phenotype than the other patients. We
think that these newly detected mutations we described will
be a positive contribution to the literature.
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Marfan syndrome (MFS) is a connective tissue disorder
with an autosomal dominant inheritance which mainly
affects cardiovascular, skeletal and ocular systems. It dis-
plays considerable inter- and intra-familial clinical varia-
bility, but its environmental are genetic determinants are
still poorly known. The contribution of inherited factors to
this variability has not been quantiﬁed yet, and might be
different for each clinical feature.
In a cohort of 1306 MFS well-phenotyped patients car-
rying FBN1 mutation, we analyzed the distribution of 23
clinical features and found strong correlations between
those interesting the same system, suggesting that they have
common underlying determinants. On the other hand, fea-
tures from different systems appeared to be largely
uncorrelated.
Moreover, classical quantitative models were adapted to
estimate heritability of clinical features in MFS and to
screen the inﬂuence of the major locus FBN1 and the
existence of dominant effects. Most clinical features showed
strong familial aggregation and high heritability. Only
Ectopia lentis showed a signiﬁcant contribution of the
major locus on the phenotypic variance. Among MFS
patients whose transmitting parent had aortic surgery or
dissection, we found that the prevalence of aortic surgery or
dissection is signiﬁcantly higher in the case of maternal
transmission. This phenomenon is a further argument to
support genetic susceptibility for cardiovascular phenotype
in MFS.
Taken together, our results encourage further research to
identify probable genetic modiﬁers.
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Background: Metatropic dysplasia is a skeletal dysplasia
characterized by craniofacial dysmorphia (frontal bossing
and midface hypoplasia), thorax abnormalities (short ribs
and development of severe scoliosis/kyphosis) and short
limbs (metaphyseal abnormalities result in short limbs and
prominent joints) and may present with a tail-like coccygeal
appendage.
It is caused by mutations in the TRPV4-gene. TRPV4 is
implicated in autosomal dominant diseases in two systems -
the skeletal and the peripheral nervous system demonstrat-
ing an extraordinary pleiotropism of TRPV4 mutations.
TRPV4 is expressed in many tissues and is required for
normal development of bone and cartilage.
Material and methods: We present a two years old girl
born with a prominent forehead, short neck, small bell-
shaped thorax, short limbs with prominent joints, long
hands and feet, and a tail-like coccygeal appendage. The
narrow thorax necessitates respiratory support. Spinal ste-
nosis due to columnar deformity has resulted in partial
tetraplegia despite decompression surgery.
The severe phenotype raised suspicion of metatropic
dysplasia and the entire coding region of TRPV4 and
ﬂanking intronic regions were sequenced by direct
sequencing of DNA extracted from a blood sample.
Results: A novel heterozygous missense variant in exon
5 of TRPV4 (c.838G>A, p.Gly280Ser) was detected. The
variant is located in a highly conserved nucleotide and
amino acid position. Software prediction predicts the variant
to be probably damaging. The parents do not carry the
variant in blood.
Conclusion:We believe the c.838G>A variant in TRPV4
is the cause of severe metatropic dysplasia in this patient.
The mutation has not previously been reported.
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Background: Postzygotic BRAF variants result in con-
genital linear syringocystadenoma papilliferum (SCAP) or
phacomatosis pigmentokeratotica (PPK). We previously
identiﬁed a BRAF p.Lys601Asn variant in PPK.
Methods: We performed targeted and whole exome
sequencing (WES) in DNA from affected skin in two
patients with cutaneous mosaicism. Patient 1 had a right-
sided congenital SCAP and aplasia cutis of the scalp and
forehead, a vascular tumour and coloboma of the eyelid, an
epibulbar dermoid and an intracerebral vascular aneurysm
resulting in early stroke, hemiparesia and seizures. Patient 2
had PPK with a right-sided epidermal nevus of the neck and
arm, extensive café-au-lait macules of upper and lower
limbs, with superimposed agminated melanocytic naevi on
her left arm, and an extensive speckled lentiginous naevus
on her left leg.
Results: In both patients, HRAS/KRAS/NRAS targeted
sequencing was negative. Using WES, we identiﬁed in
patient 1 a postzygotic BRAF p.Val600Glu variant in 31%
of reads, already reported in SCAP. In patient 2, BRAF
targeted sequencing identiﬁed a postzygotic BRAF p.
Gly596Arg variant in 3% of reads. Both variants were not
found in blood.
Conclusions: BRAF p.Val600Glu has been reported in
SCAP, possibly associated with ocular coloboma or cere-
bral anaplastic astrocytoma. In addition, our patient had
vascular cerebral involvement. BRAF p.Gly596Arg had not
been reported in mosaic syndromes, but was found in
melanoma, myeloma, colon, and bladder cancer. Both
mutations have never been reported in the germline.
Grant references: Regional Council of Burgundy, Dijon
University Hospital, the Programme Hospitalier de
Recherche Clinique, and the Société Française de
Dermatologie.
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Introduction: Mosaicism has implications for clinical
genetics practice. Depending on which tissues harbor the
variant and to what extent, mosaic individuals may be
affected, display a milder phenotype, or exhibit no signs of
the related genetic disease. The associated risk for offspring
may be as high as 50%.
Materials and Methods: Here we present three cases
identiﬁed on DNA extracted from blood by next-generation
sequencing (NGS) targeted for connective tissue disorders.
Patient #1 (61-year-old man) had a thoracoabdominal aortic
aneurysm. Patient #2 (78-year-old man) presented with
aortic valve insufﬁciency and aortic dilatation (from the root
to the arch). Patient #3 (29-year-old woman), with a family
history of aortic root dilatation, displayed joint hypermo-
bility and reported two preterm deliveries.
Results: Patient #1 carried in 12/286= 4% of the reads a
likely disease-causing ACTA2 variant previously identiﬁed
in his son, who suffered from aortic dissection aged 26.
Sanger sequencing had failed to detect this variant, which
was ﬁltered out by the NGS evaluation pipeline. Patient #2
carried a likely disease-causing mosaic NOTCH1 variant
(10.5% of the reads). Patient #3 carried a mosaic TGFBR1
variant of uncertain clinical signiﬁcance (13.5% of the
reads).
Conclusions: mosaicism should be considered in cases
of inconsistent cosegregation (e.g. affected parent of pro-
band with apparent de novo variant, or healthy parent who
carries the proband’s variant). Moreover, low-level mosai-
cism may be missed by Sanger sequencing and ﬁltered out
during NGS analysis. Finally, one should avoid testing ﬁrst
a potential mosaic individual when assessing a family with
multiple affected members.
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Dermatan 4-O-sulfotransferase-1 (D4ST1) deﬁciency
caused by loss-of-function mutations in CHST14 represents
a clinically recognizable form of Ehlers-Danlos syndrome
(EDS), named as musculocontractural type EDS-CHST14.
It is clinically characterized by multiple congenital mal-
formations (craniofacial features, multiple congenital con-
tractures) and progressive multisystem fragility-related
complications (skin hyperextensibility and fragility, recur-
rent dislocations and progressive talipes or spinal defor-
mities, large subcutaneous hematomas). Pathological and
glycobiological studies on affected skin specimens sug-
gested multisystem fragility to be caused by impaired
assembly of collagen ﬁbrils resulting from loss of dermatan
sulfate in the decorin glycosaminoglycan side chain that
promotes electrostatic binding between collagen ﬁbrils.
Large subcutaneous hematomas are frequent and one of the
most serious complications, typically occurring after minor
traumas, spreading in several hours with severe pain, and
sometimes accompanying hemorrhagic shock. Hypothesiz-
ing that these large subcutaneous hematomas would be
attributable to impaired contraction followed by rupture of
small-sized arteries caused by the structural fragilities, we
performed induced-pluripotent stem cells (iPSCs)-based
pathophysiological studies. After validating undifferentia-
tion status and pluripotency of iPSCs derived from cultured
skin ﬁbroblasts of three patients and healthy subjects, vas-
cular smooth muscle cells (VSMCs) were induced. Sig-
niﬁcantly reduced contraction of VSMCs from affected
iPSCs was observed after stimulation by a muscarinic
agonist or a calcium agonist, compared with VSMCs from
normal iPSCs. Impaired vascular formation was observed
on a Matrigel where affected iPS-derived VSMCs were
transplanted, compared with normal iPS-derived VSMC
transplantation. These results would support the hypothesis,
which also implicates an indispensable role of DS in the
maintenance of arterial structure in humans.
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The nightmare of pediatric orthopedic surgeons: cafe
-au-lait spots
C. M. Popoiu, E. S. Boia, V. L. David, R. E. Iacob, C. M.
Stanciulescu, A. V. Popoiu
niversity of Medicine and Pharmacy V Babes, Timisoara,
Romania
Neuroﬁbromatosis type 1 (NF1) is an autosomal dominant
disorder, manifested with neuroﬁbromas and cafe´-au-lait
spots. NF1 present tibial dysplasia, with anterolateral
bowing of the leg and subsequent fracture and nonunion
(pseudarthrosis). In our study, we present two cases of
congenital pseudarthrosis of tibia (CPT) that suffered mul-
tiple surgeries before the correct diagnosis was completed.
The management of pseudarthrosis of the tibia is one of the
most challenging problems in pediatric orthopedics. The
treatment aims to obtain a long term bone union, to prevent
limb length discrepancies, and to avoid pathological frac-
ture. Surgery is based on: pseudarthrosis resection, biolo-
gical bone bridging of the defect and the correction of
angular deformity. The most common complication is
refracture. Both our cases have been operated for 4,
respective 5 times before obtaining a good result. This is
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why café-au –lait spots should require a multidisciplinary
approach with meticulous clinical examination and genetic
counseling that might lead to an earlier diagnosis of NF1
and CPT.
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High success in the etiology determination of skeletal
dysplasias from a custom NGS panel and identiﬁcation
of a gene related to Beemer-Langer syndrome
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Introduction: The huge breakthroughs driven by next
generation sequencing (NGS) technology, allowed not only
identifying a great number of new genes associated with
skeletal dysplasias (SD) in the last years, but also to fast
reaching a precise diagnosis in the practical clinical. How-
ever, most of the reported results so far have shown a
detection rate of mutation around or less than 50%. Here we
present the results of a cohort of 37 previously and carefully
classiﬁed patients with SD, for which we used the NGS
technology to establish the precise diagnosis.
Materials and Methods: 37 local patients with SD were
analyzed on the MiSeq sequencer using a customized NGS
panel (TruSeq Custom Amplicon - Illumina) with 39 genes
related to SD. Sanger sequencing conﬁrmed all pathogenic
variants.
Results: We identiﬁed a total of 32 different pathogenic
variants (22 novel) in 26 patients giving a detection rate of
70.3%. In 14 lethal SD and 23 non-lethal patients we found
the following detection rates - 78,61% and 60,9%, respec-
tively. One of the identiﬁed mutations (PCYT1A) was only
found by Sanger sequencing of a bad covered region.
Another interesting and novel result was the identiﬁcation
of a cilia-related gene associated with Beemer-Langer
syndrome.
Conclusions: Our results showed a high detection rate
(70,3%) of mutations using NGS; a novel association with a
cilia-related gene and Beemer-Langer syndrome; and we
put in evidence the importance to analyse by Sanger
sequencing the bad covered regions by NGS.
Grants: FAPESP (98/16006-6;2015/22145-6); CNPq
(590148/2011-7)
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Molecular characterization of patients with Neuroﬁ-
bromatosis Type1
M. Tsipi, I. Fylaktou, A. Mitrakos, K. Kosma, S. Kitsiou-
Tzeli, M. Tzetis
National and Kapodistrian University of Athens, Depart-
ment of Medical Genetics, Athens, Greece
Introduction: Neuroﬁbromatosis Type I is one of the most
common autosomal dominant disorders. It is caused by
mutations of the NF1 gene. The aim of the current study is
to identify the genetic causes underlying the disease and
possible phenotype/genotype correlations. Materials and
Methods A protocol based on genomic DNA was estab-
lished in 135 patients fulﬁlling the NHI diagnostic criteria
and in 32 children (<4 years old) strongly suspected of
having NF1. It included multi-step PCR and sequencing of
all exons and adjoining introns. In several cases deletions/
duplications were detected by high resolution aCGH and
MLPA. Novel ﬁndings were evaluated with bioinformatic
tools and family segregation analysis. Results We identiﬁed
the germline mutation in the majority of cases; 87 known
and 66 novel variants in coding and non-coding regions.
We also found three unrelated patients with whole and
partial gene deletion. Partial gene duplication was found in
one patient with B- Acute Lymphoblastic Leukemia. Var-
ious mutations were identiﬁed in 80% of children under the
age of 4 years with only multiple café-au-lait macules
(CALM) as a reason for referral. Different clinical mani-
festations were observed in two brothers with the same
mutation (p.Tyr2264X). Conclusions Reduced penetrance
of speciﬁc mutations suggests the implication of modiﬁer
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genes, epigenetic or environmental factors. Genetic testing
of children with only CALM is recommended in order to
exclude or establish clinical diagnosis. Understanding the
nature of an identiﬁed novel mutation along with in silico
analysis is essential for genetic counseling and clinical
management.
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Next generation sequencing of osteogenesis imperfecta
related genes in Slovene patients
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Introduction: Osteogenesis imeperfecta is characterised by
bone fragility frequently associated with blue/gray dis-
coloration of the sclera and dentinogenesis imperfecta. The
disease is classiﬁed in several types according to the
severity of the bone fragility or genetic aetiology. OI is
genetically heterogeneous disease with dominant mutations
in COL1A1 and COL1A2 being the most common genetic
cause. Molecular genetic testing of OI is important, as it can
prompt the treatment.
Materials and Methods: 15 subjects (3 males, 12
females) aged between 1 month and 18 years were eval-
uated at a tertiary paediatric outpatient clinic due to the bone
fragility and referred to genetic testing with next generation
sequencing (NGS). Fourteen patients had clinically mild OI,
one had clinically severe OI. All had blue sclera and none
had additional hearing loss or dentinogenesis imperfecta.
We performed targeted NGS with TruSightOne Sequencing
Panel on the MiSeq platform (Illumina, USA) followed by
interpretation of variants in the OI associated genes (ALPL,
BMP1, COL1A1, COL1A2, CRTAP, FKBP10, IFITM5,
LEPRE1, LRP5, PLOD2, PPIB, SERPINF1, SERPINH1,
SP7) and subsequent Sanger sequencing conﬁrmation.
Results: Ten different mutations in two genes (COL1A1
and COL1A2) were detected in ten patients (66% success
rate). Among them, two variants, namely COL1A1,
NM_000088.3:c.1853delC (p.Ala618ValfsTer148) and
COL1A1, NM_000088.3:c.740C>T (p.Pro247Leu), were
not previously reported in OI patients.
Conclusion: NGS enables fast and reliable identiﬁcation
of causal mutations in several genes related to OI simulta-
neously. Presented subject group had mutations in genes
commonly associated with OI, where each patients had his
own private mutation.
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Achondroplasia (ACH) is the most common autosomal
dominant non-lethal skeletal dysplasia with an incidence of
1 in 6,500 – 20,000 live births. Non-invasive prenatal
diagnosis (NIPD) of ACH is an ideal application of cell-free
fetal DNA (cffDNA) analysis because in about 99 % it is
caused by a single mutation (G380R) mostly arised de novo
(in approximately 80 % of cases), and there is a correlation
with advanced paternal age.
Methods: cffDNA occurs in maternal plasma in form of
short fragments. By targeting the shorter DNA molecules,
cffDNA was isolated from maternal plasma by the QIAamp
DNA Mini Kit and Clean Circulating DNA Kit. Quality of
the cffDNA isolation was evaluated by automate capillary
electrophoresis on Fragment AnalyzerTM. For conﬁrmation
of cffDNA in a sample, we evaluated three approaches: fetal
gender determination, comparison of SNPs in maternal and
fetal genome, and methylation analysis. In cooperation with
TIBMolBiol, we designed HRM-based LightSNiP assays to
detect the G380R. Real-Time PCR is performed by using
the DyNamo ColorFlash Probe qPCR Kit, Xceed qPCR
Probe 2x Mix No-ROX and SensiFAST™ Probe No-ROX
Kit.
Results: Based on our results, we concluded, that the
cffDNA isolation performed by the evaluated kits does not
differ in cffDNA yield. We concluded that there is no sig-
niﬁcant difference between performances of three Real-
Time PCR master mixes used.
Conclusions: As the NIPD of ACH does not bring any
danger for the mother or the fetus, it can be offered as a
screening test for pregnancies where the father is older.
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A novel frameshift mutation causing NOG-
symphalangism spectrum disorder (NOG-SSD)
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The NOG gene encodes noggin, a negative regulator of
bone morphogenic proteins (BMPs), transcription factors
important for development of nerve tissues, muscles and
bones. Noggin is implicated in morphogenesis and body
patterning, middle ear formation, and apoptosis in digital
and interdigital regions. Heterozygous mutations in NOG
are associated with multiple disorders, such as stapes
ankylosis with broad thumbs and toes (SABTT), proximal
symphalangism 1A, multiple synostoses syndrome, and
carpal-tarsal coalition. Prior to gene identiﬁcation, these
disorders were previously classiﬁed as distinct conditions.
These conditions are now collectively known as NOG-
related symphalangism spectrum disorder (NOG-SSD).
However, genotype-phenotype correlation is unclear.
We review the NOG-SSD literature, and report a 17 year
old male patient with a novel heterozygous truncating
mutation in NOG, c.155dupC, p.(Ile53Tyrfs*3). Our patient
has many symptoms of the NOG-SSD, including a hemi-
cylindrical nose, stapes ankylosis with conductive hearing
loss, hyperopia, fused cervical vertebrae, 5th digit sympha-
langism, and cutaneous syndactyly. In addition, he has 13
ribs and thoracic-type vertebrae, and spina biﬁda occulta,
which to our knowledge, have not been previously reported
in this condition.
Our report provides further expansion of the under-
standing of NOG-SSD. While our patient’s presentation
could be classiﬁed as SABTT, symphalangism is also pre-
sent, which was classically thought to be absent in SABTT.
His features overlap several NOG related conditions, further
supporting that NOG mutations can result in a spectrum of
craniofacial and skeletal manifestations, and that not all
patients ﬁt within previously described discrete phenotypes.
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Bi-allelic loss-of-function mutations in the gene encoding
the natriuretic peptide receptor C (NPR3) result in
enhanced growth and connective tissue abnormalities
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The natriuretic peptide signaling pathway has been impli-
cated in many cellular processes including endochondral
ossiﬁcation and growth. More precisely, different mutations
in the NPR-B receptor and the CNP ligand have been
identiﬁed in patients with either short or tall stature. With
this study we show that the NPR-C receptor is also reg-
ulating bone growth, however by a different mechanism.
Using WES in two affected brothers with tall stature, long
ﬁngers and rapidly growing halluces, we identiﬁed bi-allelic
inactivating mutations in the NPR3 gene, encoding the
NPR-C receptor. Our data indicated that the ﬁrst mutation
(c.442T>C, p.Ser148Pro) hampered proper trafﬁcking of
the mutant protein to the cell membrane and that the second
mutation (c.1524delC, p.Tyr508*) resulted in nonsense
mediated mRNA decay. Biochemical assays in the affected
sibs revealed a reduced clearance of the bio-active
natriuretic peptides by NPR-C and an increase of bone
turnover biomarkers in the serum. The presence of joint
laxity in both sibs and a mild aortic dilatation in the proband
suggests that NPR-C may also be important in connective
tissue homeostasis. The observation of extra epiphyses in
the tubular bones of hands and feet in both patients is
intriguing. This remarkable radiographic ﬁnding was in
retrospect also visible in the family with an activating NPR2
mutation reported by Miura K et al. It suggests that
enhanced growth due to defects in either the NPR2 or NPR3
controlled signaling pathways may be partially mediated
through the creation of extra growth plates in tubular bones.
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Mosaic somatic KRAS gene mutation in Oculo-cerebro-
cutaneous syndrome (OCCS): a seventh patient report
A. De Leener1, A. De Kairelle2, V. Dekeuleneer3, P. De
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Introduction: OCCS is a multisystemic condition with
choristome, epibulbar cyst as ophthalmic involvement;
aplasia cutis congenita, lipomatosis on subcutaneous
regions; intra medullary and cerebral lesions. Fibroma on
jaw during ﬁrst decade and on long bones throughout life
may occur (Moog 2005). Applying whole genome shotgun
sequencing to DNA extracted from femoral ﬁbroma allowed
to select variants in 2 genes. KRAS gene was selected since
found in other tissues and absent in unaffected relatives
(Peacock 2015). These original ﬁndings were conﬁrmed on
4 patients with various degrees of mosaicism as hot spot
mutations on codon 13,19,146 (Boppudi S. 2016).
Expressivity is variable, prognosis factors are not yet
available.
Patient Report: Present patient from birth developed
aplasia cutis on left parieto-occipital region, epibulbar der-
moid kyst of left conjonctiva and a cervical subcutaneous
mass. At the age of 18 months, milestones as behaviour are
normal. Cervical mass ultrasound correlated to lipoma.
Extracted DNA from this lesion, targeted KRAS gene
sequencing identiﬁed presence of the c.38G>A change (p.
Gly13Asp) in 47% of the cells. This mutation is one of the 3
(hotspot) reported so far.
Conclusion: Present patient is the 7th patient with OCCS
identiﬁed carrier of somatic mutation in KRAS gene.
Appropriate genetic counselling is now available. Precise
gain-of-function effect of the missense change in the RAS
pathway to phenotype and indication for mTOR inhibitor
therapy remain to be evaluated.
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Novel and highly accurate method to detect de novo copy
number deletions from targeted resequencing data
identiﬁes potentially causal variant in TRAF3IP3 in an
oral cleft proband
I. Ruczinski1, J. Fu1, R. Scharpf1, A. Scott1, T. Beaty1, E.
Leslie2, M. Marazita2
Johns Hopkins University, Baltimore, MD, United States,
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Copy number variants (CNVs) are deﬁned as gains or losses
of large genomic segments that alter the copy-neutral
diploid state of DNA. CNVs can be major contributors of
genome variability in humans, and frequently underlie the
etiology of disease, including craniofacial disorders. De
novo CNVs delineated in case-parent trios, albeit very rare,
are of particular interest for their potential to have a func-
tional role in the etiology of structural birth defects. We
developed a novel method based on the MinimumDistance
statistic (PMID: 23234608) for delineating de novo copy
number deletions simultaneously across multiple trios from
targeted sequencing data, dramatically lowering the false
positive rate while maintaining high sensitivity. We applied
our method to 1,305 case-parent trios with targeted
sequencing data of 13 regions previously implicated as
possibly causal for orofacial clefts, the most common form
of craniofacial malformations. Across the 6.3Mb of the
genome sequenced here, we detected one de novo deletion
in the gene TRAF3IP3 on chromosome 1q32 (adjacent to
IRF6, a recognized causal gene for Mendelian malformation
syndromes which can include orofacial clefts) in a Cauca-
sian proband with a cleft lip. In addition, we found one rare
inherited deletion and two copy number polymorphic
regions. These calls are further supported by paired end
reads spanning the putative deletions.
I. Ruczinski: None. J. Fu: None. R. Scharpf: None. A.
Scott: None. T. Beaty: None. E. Leslie: None. M. Mar-
azita: None.
P04.56D
Oro-facio-digital syndrome caused by a novel mutation
in DDX59
N. Wasif1,2, N. Kakar3, J. Couthuis4, A. D. Gitler4, J.
Ahmad3, G. Borck1
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of Genetics, Stanford University, Stanford, CA, United
States
Introduction: Oro-facio-digital syndrome type 5 (OFD5,
OMIM: 174300) is characterized by lobulated tongue, cleft
palate and polydactyly; additional features include frontal
bossing and intellectual disability. We have investigated a
Pakistani family with autosomal recessive OFD. Earlier, a
single report of two homozygous mutations of DDX59
(encoding a DEAD-box-containing RNA helicase) has
shown that mutations of this gene are a rare cause of OFD.
Methods and Results: Exome sequencing combined
with Sanger sequencing was used to search for a genetic
cause of OFD. Exome sequencing revealed a missense
variant (c.1430C>T; p.Ser477Leu) in the helicase C termi-
nus domain of DDX59. This variant lies in a 28Mb region
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of homozygosity on chromosome 1. This DDX59 missense
variant is predicted “probably damaging” by Polyphen-2
and “not tolerated” by Sift. Sanger sequencing of 3 affected
and 6 unaffected (3 parents and 3 siblings) family members
revealed that this variant co-segregates in the family with
the OFD phenotype. All three affected members were
showing features of OFD5 including lobulated tongue,
polydactyly and intellectual disability. An additional feature
of absent maxillary lateral incisors was observed in one
affected female.
Conclusion This is the third report of a homozygous
variant of DDX59 causing OFD, strengthening the role of
this RNA helicase family member in the pathogenesis of
OFD5.
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Comprehensive analyses of genome-wide data reveal
novel insights into distinct etiologies of cleft lip with/
without celft palate, and cleft palate only
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Nonsyndromic orofacial clefts are among the most common
human birth defects and can be subdivided into non-
syndromic cleft lip with/without cleft palate (nsCL/P) and
nonsyndromic cleft palate only (nsCPO). We here present
results from two large genome-wide imputation studies on
nsCL/P and nsCPO, respectively. While we identiﬁed four
previously unknown risk loci for nsCL/P (at 2p21, 14q22,
15q24, and 19p13), we did not identify any common risk
variant associated with nsCPO (beyond a previously iden-
tiﬁed missense variant in the GRHL3 gene). Furthermore,
we demonstrate that there is no polygenic component of
nsCL/P detectable that is shared with nsCPO. In total this
suggests that, while common variants are strongly con-
tributing to nsCL/P risk, they do not seem to be involved in
nsCPO. On a systematic level, we show that the association
signals within the nsCL/P imputed dataset are enriched in
functionally-relevant genomic regions that are active in both
human neural crest cells (hNCC) and mouse embryonic
craniofacial tissue. Notably, this enrichment is also detect-
able in hNCC regions that are primed for later activity. Our
data suggest that 30% of the nsCL/P-risk variance can be
attributed to common variants, with 25.5% assigned to the
24 risk loci known to date. Finally, we performed credible
SNP analyses using a Bayesian reﬁnement approach and
identiﬁed two loci (at 2p21 and 17q13) that each harbour
only one likely causative variant. Our study generates novel
insights into both nsCL/P and nsCPO etiology and provides
a systematic framework for research into craniofacial
development and malformation.
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Nonsyndromic cleft palate only - evidence for a limited
contribution of common variants in contrast to non-
syndromic cleft lip +/- palate
N. Ishorst1,2, P. Franceschelli3, S. Mehrem1,2, A.
Böhmer1,2, N. Fricker1,2, P. Mossey4, M. Nöthen1,2, S.
Heilmann-Heimbach1,2, K. Aldhorae5, M. Rubini3, K.
Ludwig1,2, M. Knapp6, E. Mangold1
1Institute of Human Genetics, University of Bonn, Bonn,
Germany, 2Department of Genomics, Life & Brain Center,
University of Bonn, Bonn, Germany, 3Medical Genetic
Unit, Department of Biomedical and Specialty Surgical
Sciences, University of Ferrara, Ferrara, Italy, 4Dental
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5Orthodontic Department, College of Dentistry, Thamar
University, Thamar, Yemen, 6Institute of Medical Biometry
Informatics and Epidemiology, University of Bonn, Bonn,
Germany
Nonsyndromic cleft palate only (nsCPO) is a common
malformation with multifactorial etiology. One genome-
wide signiﬁcant nsCPO locus has been identiﬁed so far. To
discover more risk loci, we increased the marker density of
GWAS data from 550 case-parent trios by genome-wide
imputation, followed by independent replication of sug-
gestive ﬁndings. Eighty-three SNPs at 26 loci showed 5×10
−08<P<1×10−05 in the imputation of (i) 272 European trios
and/or (ii) 550 European and Asian trios. Of these, loci
containing minimally one variant with info-score>0.8, were
chosen for replication in two case/control cohorts from
Central Europe (94 cases,339 controls) and Yemen (38
cases,232 controls), and one European trio cohort (Euro-
Cran study, 224 trios). Genotyping of 25 SNPs (19 loci)
was performed using MALDI-ToF analysis. One SNP
(rs6809420) showed a nominal signiﬁcant association (P=
0.024 in Yemen cohort) to nsCPO in the same direction as
in the imputed GWAS dataset. This locus might harbour
common risk variants with low effect size. Of note, for
nonsyndromic cleft lip with/without cleft palate (nsCL/P),
the other common form of orofacial clefting, 25 risk loci
have been identiﬁed by GWAS so far, with some detected
in samples much smaller than 550 cases. In our dataset none
of the known nsCL/P risk loci showed a P-value<1×10−05,
supporting previous molecular and epidemiological ﬁnd-
ings, that nsCPO is genetically distinct from nsCL/P. Our
ﬁndings indicate that common variants may contribute to
nsCPO, but suggest that the individual effect sizes might be
limited and too small to be detected with current sample
sizes.
N. Ishorst: None. P. Franceschelli: None. S. Mehrem:
None. A. Böhmer: None. N. Fricker: None. P. Mossey:
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Analysis of mRNA proﬁles in extracellular microvesicles
from cultured chondrocytes
R. Pogue, R. J. L. F. Bravo, I. C. C. Cardoso, M. M. Silva,
L. R. Aguiar
Universidade Católica de Brasília, Brasília, Brazil
Chondrocytes are responsible for producing the extra-
cellular matrix of cartilage, a tissue in which inter-cellular
signaling plays an important role in maintenance. Signaling
within cartilage has been studied from the viewpoint of
growth factors, with pathways such as TGF-beta, FGF and
BMP among those characterized. However, intracellular
communication involving extracellular microvesicles
(ECM) has not been extensively studied in cartilage.
Recently, ECM, including exosomes have been shown to be
important in communication between cells, both in normal
processes such as differentiation, in disease pathologies.
The present study aimed to characterize microvesicles iso-
lated from culture media of chondrocytes grown in-vitro,
with a focus in identifying transcripts encapsulated in the
ECM. Microvesicles were collected by ultracentrifugation,
RNA was extracted, and transcripts analyzed by qRT-PCR.
An initial analysis of mRNA and microRNA present in
these microvesicles identiﬁed a set of transcripts associated
with chondrocyte functions. Subsequently, ECM were col-
lected at different time points to study the dynamics of
mRNA encapsulation during culture. We observed variation
in mRNA expression for transcripts Sox9, Wdr5, Fgf3, Ihh,
Acan, Col2a1, Fgfr2, Bmp4 and Col10a1 over 22 days. It
was concluded that the transcripts present in chondrocyte-
derived microvesicles carry factors that participate in the
development and maintenance of cartilaginous tissue,
potentially inﬂuencing chondrogenesis and osteogenesis
through intercellular communication. These data are of
relevance to the study of cartilage development, and may
also be relevant in degenerative diseases such as osteoar-
thritis, due to the potential for microvesicles to be used in
the treatment of lesions, and in-vitro production of
chondrocytes.
R. Pogue: None. R.J.L.F. Bravo: None. I.C.C. Car-
doso: None. M.M. Silva: None. L.R. Aguiar: None.
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Targeted next-generation sequencing in Brazilian indi-
viduals with Osteogenesis Imperfecta
P. A. C. dos Santos1,2, I. P. M. Carneiro2,3, M. A.
Chiabai4, R. E. Pogue4, P. M. Yamagutti2,3, L. C. Castro5,
J. F. Mazzeu6, S. F. Oliveira7, A. C. Acevedo-Poppe2,3
1Health Sciences University of Alagoas, Maceio, Brazil,
2Laboratory of Oral Histopathology, Faculty of Health
Sciences, University of Brasilia, Brasilia, Brazil, 3Oral
Care Center for inherited diseases, University Hospital of
Brasilia, University of Brasilia, Brasilia, Brazil, 4Catholic
University of Brasilia, Brasilia, Brazil, 5Department of
Pediatrics, Faculty of Medicine, University of Brasilia,
Brasilia, Brazil, 6Laboratory of Genetic, Faculty of
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Osteogenesis imperfecta is a clinically and genetically het-
erogeneous group of connective tissue disorders mainly
characterized by bone fragility. The severity in OI varies
widely, ranging from lethal cases to mild bone alterations.
Extra-skeletal ﬁndings such as dentinogenesis imperfecta
(DGI) are also described. OI is considered a collagen-
related disorder and most of the cases (80–90%) are related
to dominant mutations in COL1A1 and COL1A2, the genes
encoding the collagen type 1α chains. In the last decade, at
least 16 other genes, linked to autosomal recessive OI and
one X-linked OI have been reported.
The aim of the present study was to identify mutations in
32 unrelated Brazilian children with moderate or severe OI
referred to the Oral Center for Inherited Diseases, Uni-
versity of Brasilia. For this purpose, a next generation
sequencing panel was designed with 14 known genes
associated with OI and DGI and the analysis was performed
using the Ion AmpliSeq ™ platform.
A total of 18 heterozygous mutations in COL1A1 and
COL1A2 were identiﬁed in this study. Nine previously
reported mutations (7 missense; 1 nonsense; 1 frameshift) in
COL1A1 as well as were identiﬁed total of 9 missense
mutations in COL1A2 including three novel mutations in
COL1A2 (c.1612G>A, c.1657G>T and c.3142G>A). Four
homozygous missense mutations in SERPINF1, P3H1,
CRTAP genes were also identiﬁed in four patients with
history of consanguinity. We did not identiﬁed pathogenic
mutations in 10 patients. This was the ﬁrst study in our
hospital that allowed an accurate molecular diagnosis of OI.
Grant: FAPDF
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FAM46A mutations are responsible for Osteogenesis
imperfecta
M. Doyard1, S. Bacrot1, C. Huber1, M. Di Rocco2, A.
Goldenberg3, P. Brunelle1, C. Michot1, C. Haudry1, M.
Castanet4, J. Leroux5, J. Bonnefont1, A. Munnich1, G.
Baujat1, S. Monnot1, V. Cormier-Daire1
Department of Genetics, INSERM U1163, Université Paris-
Descartes, Institut Imagine, Hôpital Necker-Enfants
Malades, Paris, France, 2Unit of Rare Diseases, Depart-
ment of Pediatrics, Giannina Gaslini Institute, Genova,
Italy, 3Department of Genetics, CHU de Rouen, Rouen,
France, 4Department of Pediatrics, CHU de Rouen, Rouen,
France, 5Department of Pediatric Surgery, CHU de Rouen,
Rouen, France
Stuve-Wiedemann syndrome (SWS) is characterized by
bowing of the lower limb, respiratory distress and hyper-
thermia often responsible for an early death. Survivors
developed progressive scoliosis and spontaneous fractures.
We previously identiﬁed LIFR mutations in SWS. The
absence of LIFR mutations in 5 cases prompted us to per-
form exome sequencing analysis. We identiﬁed, in one case,
a homozygous mutation in FAM46A [p.Ser205Tyrfs*13].
The two parents originated from Italy, were related and
heterozygous for this mutation. The clinical ﬁndings in this
case included bowing of the lower limbs at birth, hyper-
thermia only in the ﬁrst year of age, spontaneous fractures
and abnormal teeth, reminiscent of osteogenesis imperfecta
(OI). We therefore screened OI patients from 25 unrelated
families with no mutations in the OI genes. In one family
(affected brother and sister), we identiﬁed a homozygous
variant in FAM46A [p.His127Arg]. The two parents were
related and heterozygous for the mutation. Clinical mani-
festations included at birth bowing of the lower limb and
blue sclerae and then spontaneous fractures (> 5 at 2 years
of age). FAM46A is a member of the superfamily of
nucleotidyl-transferase fold proteins but its exact function is
unknown. By RT-PCR analysis, we found a speciﬁc
expression in human control osteoblasts. Moreover, a non-
sense mutation in Fam46a has been recently identiﬁed in an
ENU-derived mouse model characterized by short stature,
skull deformities and reduced cortical bone thickness in
long bones. We conclude that FAM46A mutations are
responsible for a form of osteogenesis imperfecta with
bowing of the lower limb.
M. Doyard: None. S. Bacrot: None. C. Huber: None.
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None. C. Michot: None. C. Haudry: None. M. Castanet:
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P04.62B
Genetic transmission of osteogenesis imperfecta type 5
by a healthy mosaic carrier father
E. Steichen-Gersdorf1, K. Maurer2, G. Schweigmann2, S.
Symoens3
1Department of Pediatrics, Innsbruck, Austria, 2Department
of Radiology, Innsbruck, Austria, 3Centre of Medical
Genetics, Gent, Belgium
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Background: OI-V is an autosomal dominant OI, which is
characterized by recurrent fractures, hyperplastic callus
formation and forearm interosseous membrane calciﬁcation.
Less than 5% of patients of OI are diagnosed with OI-V.
The 5'-UTR IFITM5 mutation is a single recurrent hetero-
zygous mutation reported in the majority of patients.
Presenting problem: The 2 years old girl was born at
term, BW 2880g(P25–50), L 48cm (P25–50), OFC 33cm
(P3). Motor developement was delayed, sitting age
15 months, standing without support at 2 years, whereas
cognitive development seemed to be normal. At the age of
7 months the girl complained with pain after bending sitting
at the mothers womb. X-ray revealed a fracture oft he right
femur. A second low impact femur fracture occured at
13 months . Osteogenesis imperfecta (OI) type 1 was
excluded by normal COL1A1/COL1A2 testing.
Fracture healing was noticed to be abnormal with
delayed and hypertrophic callus formation. The child was
treated with Neridronate 1mg every 3 months with good
response. In follow up care a limitation in forearm supina-
tion/pronation was noticed at 1 ½ years. A recurrent
IFITM5 mutation was identiﬁed in the proband c.-14c>T,
5'UTR. The mutation was present and conﬁrmed by NGS in
the mosaik state of about 34% in the healthy father.
Discussion: OI-V caused by the 5'-UTR IFITM5 muta-
tion was conﬁrmed in our patient. There are few reports of
families with autosomal dominant inheritance from an
affected parent. To our best knowledge a transmission from
an unaffected parent was not reported before.
E. Steichen-Gersdorf: None. K. Maurer: None. G.
Schweigmann: None. S. Symoens: None.
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A novel mutation in TCIRG1 gene in a Turkish patient
with malignant autosomal recessive osteopetrosis
G. Kocak1, B. Nur2, E. Mihci2, H. Akkurt1, E.
Manguoglu1
Akdeniz University, Faculty of Medicine, Department of
Medical Biology and Genetics, Antalya, Turkey, 2Akdeniz
University, Faculty of Medicine, Division of Pediatric
Genetics, Antalya, Turkey
Malignant autosomal recessive osteopetrosis is a rare and
severe genetic bone disease characterized by increased bone
density due to failure bone resorption by osteoclasts. About
50% of patients have mutations in the TCIRG1 (T-cell
immune regulator 1) gene that encodes the osteoclast-
speciﬁc a3 subunit of human V-ATPase.
In this report, we present a 5-month-old female infant
born as the second child of the ﬁrst degree cousin marriage.
She was born at term by normal vaginal delivery. Her sister
died at 2 years with an unknown diagnosis, and the second
pregnancy ended with spontaneous abortion. Clinical ﬁnd-
ings include moderately pale appearance, developmental
delay, short stature, frontal bossing, depressed nasal bridge,
hepatosplenomegaly, abdomen distention, hearing loss and
nystagmus. Skeletal survey and limb radiographies showed
calvarial thickening with diffused increase in density of the
bones. X-ray of vertebrae showed sclerosis of vertebra.
Hemoglobin level was 7.7 gr/dl and platelet level was
35.000. Our patient died at nearly 2-years-old with diag-
nosis of osteopetrosis and infection. DNA isolation from
blood sample of the patient and Sanger sequencing analysis
of the all coding exons TCIRG1 gene were performed. A
novel homozygous c.1778_1779delTG mutation
(V595LfsX74) on exon 15 was detected. Analysis of par-
ents’ DNA conﬁrmed heterozygous carrier status for this
mutation in both parents.
According to The Human Gene Mutation Database
TCIRG1 gene mutations include approximately 30% splice-
site mutations, 37% missense/nonsense and 30% deletion/
insertion. To our knowledge, c.1778_1779delTG mutation
has not been reported previously in malignant autosomal
recessive osteopetrosis.
This project is supported by AU BAP TYL-2016-965.
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Unclassiﬁable pattern of hypopigmentation in a patient
with mosaic partial 12p tetrasomy without Pallister-
Killian syndrome
V. Orlando1, V. Alesi1, M. Dentici1, F. Restaldi1, M.
Liambo1, C. Calacci1, R. Capolino1, M. Digilio1, M. El
Hachem2, A. Novelli1, A. Diociaiuti2, B. Dallapiccola1
1Genetics and Rare Diseases Research Division, Bambino
Gesù Children’s Hospital, IRCCS, Rome, Italy, 2Dermatol-
ogy Division, Bambino Gesù Children's Hospital, IRCCS,
Rome, Italy
Pallister-Killian syndrome (PKS-#OMIM601803) is a
multisystem developmental disorder typically due to the
presence of an aneuploidy cell line, consisting of a super-
numerary tetrasomic chromosomal marker (SCM) arisen
from the short arm of chromosome 12 (12p isochromo-
some). The clinical phenotype, which is strictly related to
the percentage and tissue distribution of aneuploid cells, is
characterized by craniofacial dysmorphisms, pigmentary
skin anomalies, limb shortening, congenital heart defects,
diaphragmatic hernia, hypotonia, intellectual disability, and
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epilepsy. We report on a 4 year-old girl harboring a 12p
partial isochromosome, involving the PKS critical region,
affecting about 70% of circulating lymphocytes, urine and
saliva cells and ﬁbroblast from a hyperpigmented skin spot,
and 100% of ﬁbroblasts from a hypopigmented skin spot.
Interestingly, despite the high proportion of affected cells
this patient was not presenting PKS, with a pattern of dis-
seminated pigmentary mosaicism being the sole clinical
manifestation. The present observation suggests that partial
12p SCM can also result in mild phenotypes, and its pre-
valence in the human population could have been under-
estimated. Accurate dermatologic evaluation could be a
major handle for genetic testing.
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Identiﬁcation of genetic modifying factors responsible
for the development of the distinct Papillon-Lefévre
syndrome and Haim-Munk syndrome clinical
phenotypes
A. Sulák1, K. Farkas2, K. Tripolszki1, M. Széll1,2, N.
Nagy1,2,3
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ment of Dermatology and Allergology, University of
Szeged, Szeged, Hungary
Introduction: Papillon-Lefévre syndrome (PLS; OMIM
245000) and Haim-Munk syndrome (HMS; OMIM
245010) are characterized by overlapping clinical symp-
toms including palmoplantar hyperkeratosis and severe
periodontitis. Besides these symptoms, HMS is also fea-
tured by pes planus, arachnodactyly, acroosteolysis and
onychogryphosis. Both PLS and HMS develop as the
consequence of mutations in the cathepsin C (CTSC) gene
and exhibit autosomal recessive inheritance.
Patients and methods: In this study, we have investigated
a Hungarian PLS and a Hungarian HMS patient carrying the
same disease-causing, homozygous, nonsense mutation
(c.748C/T; p.Arg250X). Whole exome sequencing (WES)
of the two patients was performed in order to identify
putative genetic modiﬁer factors responsible for the devel-
opment of the distinct PLS and HMS clinical phenotypes.
Results: The bioinformatic analysis of the WES results
highlighted that the putative genetic modiﬁer factors might
be present in the human leukocyte antigen (HLA) genes.
Rare, putative damaging variants of the HLA-DQA1, HLA-
DQB1, HLA-DRB1 and HLA-DRB5 genes were present
only in the patient with HMS, but not in the PLS patient.
Conclusion: Our results demonstrate that the develop-
ment of the different clinical symptoms in patients carrying
the same disease-causing nonsense mutation (c.748C/T; p.
Arg250X) of the CTSC gene, are the consequence of
genetic modiﬁers present in the HLA-DQA1, HLA-DQB1,
HLA-DRB1 and HLA-DRB5 genes. These results have great
importance, since the elucidation of genetic modiﬁers could
further improve the understanding of genotype-phenotype
correlations and the development of rare diseases.
A. Sulák: None. K. Farkas: None. K. Tripolszki:
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Phacomatosis pigmentokeratotica and precocious pub-
erty associated with HRAS mutation
N. Rajan1, Moss2, Areﬁ1, Splitt1, Redford1, Martin1
1Institute of Genetic Medicine, Newcastle upon Tyne,
United Kingdom, 2Department of Dermatology, Birming-
ham’s Children Hospital, Birmingham, United Kingdom
We report the recurrent co-presentation of precocious pub-
erty (PP) and phacomatosis pigmentokeratotica (PPK) is
associated for the ﬁrst time with mosaic HRAS mutation.
We investigated a 34-year-old male that ﬁrst presented at
the age of 2 years with an extensive epidermal naevus,
multiple melanocytic naevi and the onset of puberty.
Endocrine investigations conﬁrmed central precocious
puberty with adult levels of luteinising hormone and tes-
tosterone. The patient had an extensive Blaschkoid epi-
dermal naevus affecting the face, neck and upper torso.
Clusters of dark naevi were noted on the torso and limbs
within café-au-lait patches. Using next generation sequen-
cing targeting HRAS, KRAS, NRAS and BRAF we demon-
strated the presence of mosaic HRAS mutation in both
clinically affected skin as well as in apparently unaffected
tissues, including blood, saliva and skin. This ﬁnding sup-
ports the view that mosaicism is likely to exist beyond
visible tissues such as birthmarks, and is now demonstrable
with the increased sensitivity of detection offered by next
generation sequencing. It also supports the presence of
mosaic mutation in inaccessible compartments such as the
pituitary gland. Recently a patient with PPK and PP was
reported to carry a mosaic BRAF mutation. Taken together
with our ﬁnding, this strongly implicates Ras-Raf-MEK-
ERK signalling in the development of central precocious
puberty which is important as the mechanisms causing
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central precocious puberty are poorly understood. Further-
more, this pathway is now druggable, and this work may
inﬂuence novel treatment strategies of central precocious
puberty with MEK inhibitors. NR is a Wellcome Inter-
mediate Fellow (WT097163MA).
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Areﬁ: None. N. Rajan Moss Areﬁ Splitt: None. N. Rajan
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Mild manifestations of Proteus syndrome (PS) can be
challenging to diagnose
A. Kuechler1, B. Albrecht1, E. Legius2, K. Devriendt2, T.
de Ravel2, M. Spaepen2, F. Van Calenbergh3, I. Casteels4,
N. C. Bramswig1, H. Lüdecke1,5, T. M. Strom6,7, D.
Wieczorek1,5, M. Zenker8, I. Wieland8
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pital Leuven, Leuven, Belgium, 5Institut für Humangenetik,
Düsseldorf, Germany, 6Institute of Human Genetics,
Helmholtz Zentrum München, Neuherberg, Germany,
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Proteus Syndrome (OMIM176920) is a highly variable
disorder with asymmetric and disproportionate overgrowth,
connective tissue nevi, epidermal nevi, dysregulated adi-
pose tissue, and vascular malformations, caused by a
somatic activating AKT1 mutation.
We report on three unrelated individuals who showed
similar clinical ﬁndings that not fulﬁlled the rigorous clin-
ical criteria for PS (Biesecker, 1999). Beside an asymmetric
hyperostosis of the skull or facial bones, all three had an
ocular dermoid, two individuals developed alveolar hyper-
ostoses and intracranial calcifying meningiomas, only one
individual showed skin changes. All three had normal feet
and no vascular lesions.
Molecular analyses in individual1 performed in blood
revealed normal results for array karyotyping and no rele-
vant variant in whole exome sequencing.
After the working diagnosis PS had been established,
molecular analyses regarding the recurrent AKT1 mutation
(p.Glu17Lys) were performed by Sanger sequencing in
available affected tissue specimen of all three individuals.
This revealed a high level of mosaic state for the AKT1
mutation c.49G>A, (p.Glu17Lys) in affected tissues from
bone and in meningiomas. Re-evaluation of the NGS data
from blood (individual1) conﬁrmed the absence of that
mutation in all reads, and no mutation was detected by
Sanger sequencing in DNA from blood in individuals 2+3.
Thus, a somatic mosaicism leading to a mild Proteus
phenotype could be conﬁrmed as the underlying genetic
cause in all three affected individuals.
In conclusion, mild forms of Proteus syndrome caused
by the recurrent AKT1 mutation in patients with limited
regional involvement may be particularly difﬁcult to diag-
nose and might be underdiagnosed.
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Using Capture Hi-C to identify novel candidate genes in
psoriasis-associated genetic loci
H. F. Ray-Jones, A. J. McGovern, P. Martin, K. Duffus,
S. Eyre, R. B. Warren
University of Manchester, Manchester, United Kingdom
Introduction: Psoriasis is a common, complex autoimmune
condition affecting the skin. Genome-wide association stu-
dies have identiﬁed many psoriasis-associated loci, but most
lead SNPs are non-coding and the target gene remains
unknown. Capture Hi-C (CHi-C) has previously demon-
strated the presence of long-range chromatin interactions
between disease-associated loci and distant gene promoters.
The aim of this work is to apply CHi-C in psoriasis-
associated loci and relevant cell types.
Methods: Duplicate CHi-C libraries were generated from
a CD8+ T cell line (MyLa) and will also be generated from
a keratinocyte cell line (HaCaT) that has been stimulated
with the psoriasis-relevant cytokine IFNγ. RNA capture
baits were designed to target all known psoriasis-associated
loci, deﬁned by a set of SNPs in tight linkage disequilibrium
with the lead SNP. The data was analysed using the HiCUP
and CHiCAGO pipelines to call signiﬁcant interactions.
Results: Interaction data was collected for 64 psoriasis-
associated loci across European and Chinese populations. In
some cases interactions occurred between the psoriasis
association and the nearest gene candidate, for example
NFKBIZ and KLF4. Many other regions demonstrated
complex interactions implicating multiple gene candidates,
for example the SNP set at REL interacted with fragments
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containing the promoters of several distant genes such as
VRK2, USP34 and CCT4.
Conclusions: This is the ﬁrst instance of CHi-C applied
in psoriasis research. As such, this data provides vital clues
towards genes involved in psoriasis pathways that may be
targets for downstream functional analysis and drug
targeting.
Funding: PhD studentship from The Sir Jules Thorn
Charitable Trust
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Introduction: RASopathies are a group of disorders caused
by mutations in genes encoding RAS/MAPK pathway and
share overlapping clinical features like facial dysmorphism,
congenital heart defects, variable degree of intellectual
disability and ectodermal abnormalities. The aim of this
study is to deﬁne clinical and molecular features of Noonan
syndrome and related disorders. Method:33 patients with a
clinical diagnosis of Noonan syndrome and related dis-
orders were enrolled. All exons harboring known mutations
were analyzed for RAS/MAPK pathway genes. 10 patients
whose molecular testing have not been completed yet was
regarded as unknown mutation group (ﬁve of them had
normal results in ﬁrst step analysis). Results:23 hetero-
zygous missense mutations were identiﬁed in 70% of the
patients (seven in PTPN11, ﬁve in SOS1, ﬁve in BRAF,
two in LZTR1, one in RAF1, one in HRAS, one in RIT1,
one in MAP2K2 gene). All patients had typical or sugges-
tive facial dysmorphism. Short stature was observed in 45%
of patients (PTPN11 7/7, SOS1 1/5, BRAF 2/5, LZTR 1/2,
RAF1 1/1, unknown 3/10). The most common cardiac
anomaly was pulmonary valve stenosis, observed in 60%
(PTPN11 5/7, SOS 4/5, BRAF 3/5, LZTR1 2/2, RAF1 1/1,
HRAS 1/1, RIT1 1/1, unknown 3/10) and second most
common was hypertrophic cardiomyopathy observed in
27% (BRAF 2/5, LZTR1 1/2, RIT1 1/1, MAP2K2 1/1,
unknown 4/10). Intellectual disability was in 63% of the
patients (PTPN11 4/7, SOS1 1/5, BRAF 4/5, LZTR1 1/2,
RAF1 1/1, MAP2K2 1/1, unknown 9/10). Conclusion:
Phenotype-genotype correlation allow us to prioritize the
genes to be tested in each patient.
D. Uludag Alkaya: None. G. Yeşil: None. C. Lis-
sewski: None. N. Gunes: None. M. Zenker: None. B.
Tuysuz: None.
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RSPRY1-associated skeletal dysplasia: Spondylo-epi-
metaphyseal dysplasia with cono-brachydactyly and
craniosynostosis
P. O. Simsek-Kiper1, E. Z. Taskiran2, C. Kosukcu2,3, O.
Akgun-Dogan1, G. Yılmaz4, G. E. Utine1, G. Nishimura5,
K. Boduroglu1,2, M. Alikasifoglu1,2
1Hacettepe University Faculty of Medicine Pediatric
Genetics Unit, Ankara, Turkey, 2Hacettepe University
Faculty of Medicine Department of Medical Genetics,
Ankara, Turkey, 3Hacettepe University Graduate School of
Health Sciences Department of Bioinformatics, Ankara,
Turkey, 4Hacettepe University Faculty of Medicine Depart-
ment of Orthopedic Surgery, Ankara, Turkey, 5Tokyo
Metropolitan Children's Medical Center, Tokyo, Japan
Introduction: The number of genetic skeletal disorders has
steadily increased, as application of high-throughput
sequencing technology has expanded. One of new comers
is RSPRY1-associated skeletal dysplasia identiﬁed in four
affected siblings from a consanguineous Saudi family.
Affected individuals manifested with intellectual disability,
facial dysmorphism, short stature, and spondyloepiphyseal
dysplasia (SEMD). However, the skeletal phenotype of
these patients were not delineated in detail. Materials and
Methods: We report on clinical, radiographic and molecular
features of two siblings with this disorder from a con-
sanguineous family. Results: The siblings showed intel-
lectual disability, facial dysmorphism (brachycephaly,
hypertelorism, proptosis, short nose, malar hypoplasia),
short stature, and progressive difﬁculty in walking. The
skeletal hallmarks included; mild spondylar dysplasia, epi-
metaphyseal dysplasia of long bones (ﬂat and irregular
epiphyses, metaphyseal ﬂaring, and mild metaphyseal irre-
gularities) associated with coxa vara and genu valgum,
brachymesophalangy with cone-shaped epiphyses, and
craniosynostosis. Craniosynostosis was overt in the elder
sister who also showed unilateral shortening of the 4th
metatarsal, as were in previously reported patients. Whole
exome sequencing revealed a novel homozygous
[c.377delT] [p.Ile126fs*] mutation in RSPRY1. Conclusion:
RSPRY1-associated skeletal dysplasia shows distinctive
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skeletal phenotype composed of SEMD, cono-brachy-
dactyly, and craniosynostosis, along with typical facial
features and intellectual disability. The triad of the skeletal
changes may be confused with the skeletal alterations in an
other rare skeletal dysplasia termed osteoglophonic dys-
plasia. However, metaphyseal cortical defects in osteoglo-
phonic dysplasia are absent in RSPRY1-associated skeletal
dysplasia. RSPRY1-associated skeletal dysplasia is yet
another type of SEMD, characterized by distinctive clinical
and skeletal ﬁndings.
P.O. Simsek-Kiper: None. E.Z. Taskiran: None. C.
Kosukcu: None. O. Akgun-Dogan: None. G. Yılmaz:
None. G.E. Utine: None. G. Nishimura: None. K. Bod-
uroglu: None. M. Alikasifoglu: None.
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Functional implications of RUNX2 evolutionary sweep
in nonsyndromic craniosynostosis
L. Di Pietro1, M. Barba1, P. Frassanito2, M. Baranzini1,
V. Stumpo1, C. Caricato1, A. Campione1, A. Benitez-
Burraco3, W. Lattanzi1,4
Inst. Anatomy and Cell Biology, Università Cattolica del
Sacro Cuore, Roma, Italy, 2Dept. Head and Neck Surgery,
Section of Pediatric Neurosurgery, Fondazione Policlinico
Gemelli, Roma, Italy, 3Dept. Philology, Universidad de
Huelva, Huelva, Spain, 4Latium Muscoloskeletal Tissue
Bank, Roma, Italy
Introduction: Runt related transcription factor 2 (RUNX2)
encodes a key transcription factor acting downstream of
skeletal developmental pathways. RUNX2 gene dosage
affect skull ossiﬁcation, with opposite trends in cleidocra-
nial dysplasia and craniosynostosis. A previous study
reported signs of positive selection in RUNX2 genomic
sequence in anatomically modern humans (AMH). We
aimed at inferring the functional consequences of such
sequence changes in suture patterning, using nonsyndromic
craniosynostosis (NCS) as a model.
Methods: RUNX2 sequences from extinct hominins
(Neanderthal and Denisova) and AMH genomes were
compared, and their functional consequences were pre-
dicted in silico. The expression of RUNX2 isoforms and of
miRNAs binding to the 3′UTRs of the gene, were then
analyzed in NCS suture tissues and cells.
Results: Sequence changes map within the P1 and P2
promoters and the two alternative 3′-UTRs. Accordingly,
gene expression showed a site-related trend in NCS sutures:
RUNX2 P1-isoforms were upregulated in all but metopic
sites, suggesting a selected contribution of P2 functional
activation in frontal patterning. Changes in the 3′UTRs of
RUNX2 were predicted to affect miRNA binding. Expres-
sion proﬁling showed that miR134, miR3118, miR4728,
miR1249, miR6797, miR4700 and miR8089 are modulated
during the osteogenic differentiation of suture-derived cells,
coherently with transcript expression.
Conclusion: Most evolutionary changes in the RUNX2
locus map within the P2 promoter, which affect early skull
development, and selectively neural crest-derived sites.
Changes at 3′UTR in AMH modiﬁed the epigenetic reg-
ulation of RUNX2, by altering the binding of selected
miRNAs and binding on a selected isoform that lost a
functional domain.
L. Di Pietro: None. M. Barba: None. P. Frassanito:
None. M. Baranzini: None. V. Stumpo: None. C. Car-
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Clinical variability of Sensenbrenner syndrome in Polish
patients with WDR35 mutations
J. Walczak-Sztulpa1, K. Pesz2, N. Wieczorek-Cichecka3,
H. Arts4, A. Wawrocka1, A. Latos-Bielenska1, K.
Chrzanowska5
1Department of Medical Genetics, Poznan University of
Medical Sciences, Poznan, Poland, 2Department of Genet-
ics, Wroclaw Medical University, Wroclaw, Poland,
3Department of Genetics, Polish Mother's Memorial
Hospital - Research Institute, Lodz, Poland, 4Department
of Human Genetics, Radboud University Nijmegen, Nijme-
gen, Netherlands, 5Department of Medical Genetics The
Children's Memorial Health Institute, Warsaw, Poland
Introduction: Sensenbrenner syndrome (Cranioectodermal
dysplasia, CED) is a very rare autosomal recessive and
genetically heterogeneous ciliopathy. CED is characterized
by craniofacial, skeletal and ectodermal abnormalities. The
clinical symptoms include: dolichocephaly, craniosynos-
tosis, brachydactyly, limb shortering, narrow thorax, small
and widely spaced teeth, skin and joint laxity, renal and
liver insuﬁciency. To date ﬁve genes: IFT122, WDR35,
WDR19, IFT43 and IFT52 have been associated with this
disorder. All known genes encode proteins that are part of
the intraﬂagellar transport machinery, which plays an
important role in the assembly of cilia. Methods and results:
Analysis by whole exome sequencing and sequencing of
known genes revealed that compound heterozygosity for a
nonsense (c.1922T>G, p.(Leu641*)) and a missense change
(c.2522A>T, p.(Asp841Val)) in the WDR35 gene is the
most common cause of Sensenbrenner syndrome in Polish
patients. The nonsense mutation p.(Leu641*) has been
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previously reported in two CED patients. The missense p.
(Asp841Val) change is a novel variant and was not listed in
the 1000 Genomes, the NHLBI Exome Variant Server or
the Exome Aggregation Consortium browsers. This change
is predicted to have a damaging effect on IFT121 protein.
These variants have been identiﬁed in three independent
families with Sensenbrenner syndrome. Clinical picture of
CED individuals is variable suggesting that the expressivity
and the severity of patient’s phenotype can be modiﬁed by
genetic and non-genetic factors. Conclusions:
Our results suggest that there is an intrafamilial and inter-
familial clinical variability among the patients with Sen-
senbrenner syndrome and WDR35 mutations. Granted by
Poznan University of Medical Sciences (502-14-01126186-
10642).
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Expanding the spectrum of SHOX regulatory region
alterations in Idiopathic Short Stature patients (ISS)
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G. Stress1, S. Vannelli2, S. Bellone3, F. Prodam3, G.
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Laboratory of Human Genetics, Department of Health
Sciences, University of Eastern Piedmont, Novara, Italy,
2Ospedale Regina Margherita, Turin, Italy, 3Pediatric Unit,
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Mutations and deletions within SHOX (Xp22.33/ Yp11.3)
and its enhancer are reported in 2–15% of children diag-
nosed as ISS. Currently molecular diagnosis for SHOX
deﬁciency is carried out by sequencing the coding regions
of SHOX and MLPA for the identiﬁcation of deletions/
duplications. We screened 469 ISS patients for SHOX
defects. Thirty-four patients (7%) were identiﬁed with
mutations involving SHOX coding region or its enhancers
(3 point mutations and 31 deletions/duplications). In ﬁve
patients we identiﬁed 4 variants c.-55C/T, c.-51G/A, c.-
19G/A, and c.-10delG within the promoter. In a functional
analysis with a dual luciferase assay in U2OS, the variants
c.-51G/A, c.-19G/A and c.-10delG showed 60% (p=
0.00967), 35% (p= 0.02147) and 40% (p= 0.0262) level
of luciferase activity compared to the wild type respectively,
suggesting that mutations in the promoter might alter the
expression of SHOX. In order to identify if there were some
patients remained undiagnosed, thirty-seven patients tested
negative with the standard methods presenting the most
severe phenotype were analysed using a high resolution
custom oligo array-CGH platform. Two small deletions of
12.3 kb (1 patient) and 7 kb (2 patients) downstream SHOX
not reported in the general population were identiﬁed. To
understand if these sequences affect the gene expression, we
are currently performing a functional assay by cloning the
two sequences along with the SHOX promoter in an
expression vector. In conclusion, our ﬁndings suggest that
mutations interfering with SHOX regulation might remain
undisclosed with standard methods and could expand the
spectrum of SHOX alterations associated to Short Stature.
D. Babu: None. I. Fusco: None. A. Fanelli: None. S.
Mellone: None. A. Kozel: None. G. Stress: None. S.
Vannelli: None. S. Bellone: None. F. Prodam: None. G.
Bona: None. M. Giordano: None.
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Comparison of the distribution of duplicated regions
associated with SHOX gene between LWD/ISS patients
and population sample
R. Solc1, K. Hirschfeldova2
1Charles University in Prague, Faculty of Science, Depart-
ment of Anthropology and Human Genetics, Prague, Czech
Republic, 2Charles University in Prague, First Faculty of
Medicine, Institute of Biology and Medical Genetics,
Prague, Czech Republic
Heterozygous deletion or aberration of SHOX gene or one
of its numerous enhancers have been reported to be
responsible for Lėri-Weill dyschondrosteosis (LWD) and
small portion of idiopathic short stature (ISS). Effect of
reciprocal duplications is less distinct. The aim of our study
was to determine and compare distribution of duplicated
SHOX gene associated areas between the LWD/ISS patients
and population sample.
Population sample of 250 unrelated probands was
screened for PAR1 duplication/deletion using the MLPA
method. Duplicated areas frequency distribution was com-
pared to previously reported LWD/ISS cohort of 352
individuals.
There was not a signiﬁcant difference in duplication
frequency between the LWD/ISS cohort and our population
sample. However, there is a single peak (SHOX gene) pat-
tern of duplicated probes frequency distribution in popula-
tion sample in contrast to a pronounced two peak (SHOX
gene; CNE-9 enhancer) distribution pattern for LWD/ISS
cohort.
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We thus propose that only certain duplications of SHOX
gene and related regions are associated with increased risk
of LWD/ISS development.
The study was supported by the Grant Agency of the
Charles University in Prague, project GAUK202615.
R. Solc: None. K. Hirschfeldova: None.
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Sensitive NGS molecular diagnosis using a 49 gene
custom panel for skeletal dysplasia
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Back-ground: Skeletal dysplasia represents an hetero-
geneous group of rare hereditary diseases. The most fre-
quently mutated gene is COL2A1. To extend molecular
diagnosis strategy to a greater number of genes, we
implemented next generation (NGS) sequencing using a 49
genes custom panel. Methods : Agilent SureSelectQXT target
enriched library from 116 patients' genomic DNA was
sequenced using Illumina v2 chemistry on MiSeq or
Nextseq. Fastq ﬁles were aligned and reads were mapped
against the human genome (hg19) with MiSeq Reporter
(v2.2.31) or SeqNext module (v4.0, SeqPilot JSI). Variant
calling was performed through SeqNext. Results: At least
one pathogenic variant was found in 55 of 116 patients
(47,4%). Most (31/55, 56,4%) carried an heterozygous
mutation in one collagen gene (13 COL2A1, 5 COL11A1, 4
COL11A2, 5 COL1A1, 1 COL1A2, 1 COL10A1 and 2
COL9A3). Among 24 patients with mutations in non-
collagen genes (43,6%), 5 displayed homozygous geno-
types: 3 B3GAT3 p.(Gly223Ser) mutation, 1 SLC26A2 p.
(Arg279Trp) and 1 PAPSS2 p.(Thr48Arg). Four patients
displayed compound heterozygous genotypes: 1 SLC26A2,
2 PRG4 and 1 COL11A2. Three patients carried TRPS1
heterozygous mutations: p.(Gln293*), p.(Val793Glyfs*12)
and p.(Arg921*). Finally, new pathogenic variants in
unexpected genes such as in VCAN, COL11A2 and GDF5
were identiﬁed in 3 Czech dysplasia patients. Conclusion:
We show here that our NGS approach, resolved molecular
diagnosis for up to 47% of patients with various skeletal
dysplasia phenotypes. Moreover, this approach not only
revealed new pathogenic mutations in known causative
genes but also in unreported genes.
M. Barat-houari: None. A. Fabre: None. D. Gene-
vieve: None. I. Touitou: None.
P04.76D
Prenatal diagnosis of a de novo TRPV4 associated ske-
letal dysplasia by targeted next generation sequencing
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Liebrecht, S. Minderer, K. P. Gloning, T. Schramm
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We describe the ﬁrst case of prenatal diagnosis of a de novo
TRPV4 associated skeletal dysplasia. Detection of the fetal
mutation was only possible due to application of a NGS
panel including 170 with skeletal dysplasia associated
genes.
Shortening of the long bones with abnormal ﬂared
metaphyseal regions was diagnosed in the 33rd week of the
second pregnancy of a healthy woman. Chromosomal
microarray analysis revealed normal results. A common
heterozygous (hot spot) TRPV4 mutation could be detected
by NGS panel diagnostic within two weeks (c.2396C>T, p.
Pro799Leu). The TRPV4 gene encodes a cation channel
that is thought to be involved in osmotic pressure
regulation.
The woman was counselled regarding the different ske-
letal phenotypes which can be related to this mutation (e.g.
metatropic dysplasia, spondyloepiphyseal dysplasia
Koslowski and Maroteaux type) and other possible pheno-
types associated mit TRPV4 gene mutations (neuromus-
cular diseases). The possibility of postnatal respiratory
problems was adressed as well as postnatal examinations
including MRI to exclude instability of the cervical spine
which has been described in the literature.
The affected boy was born in the 38th week of pregnancy
by cesarean section. No respiratory problems or instablility
of the cervical spine occurred. He had multiple joint con-
tractures, shortened humeri and femora, torticollis and
asymmetric spine with kyphoscoliosis showing an overlap
of skeletal and neuromuscular symptoms related to the
TRPV4 gene mutation.
The application of NGS gene panel diagnostic enabled
prenatal diagnosis of a rare skeletal disorder and made it
possible to give advice for the expected postnatal situation.
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SPARC-related osteogenesis imperfecta with a
myopathy-like presentation
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Heier1, E. Merckoll1, A. Knaus1, T. E. Prescott2, K.
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We report two sisters with healthy consanguineous parents,
normal birth measurements, pes adductus, persistent hypo-
tonia, small joint laxity, delayed motor development and
progressive early thoracolumbar scoliosis. Pathological
fractures started at age two years and loss of primary den-
tition was delayed. Molecular testing did not conﬁrm the
initial suspicion of Ullrich congenital muscular dystrophy.
Multiple fractures and low bone mineral density led to
molecular testing for
osteogenesis imperfecta (OI). Exome sequencing showed
no coverage of exon 4 in SPARC in either girl. Deletion
breakpoints were determined by Sanger sequencing. The
homozygous variant c.121-578_209-94del (NM_003118.3)
present in both children introduces a change in reading
frame likely resulting in nonsense-mediated decay.
Mendoza-Londono et al (1) demonstrated biallelic loss-
of-function mutations in SPARC in two unrelated girls with
severe bone fragility, progressive scoliosis and joint
hyperlaxity. Ullrich muscular dystrophy was initially sus-
pected in one. Subsequently, two siblings with marked joint
laxity, progressive scoliosis and short stature with a
homozygous splice site variant in SPARC were reported (2).
We describe the oldest known individual with SPARC-
related OI and further delineate the phenotype. The
resemblance to a congenital muscle disorder prior to the
onset of fractures is in keeping with evidence that SPARC
(secreted protein acidic and rich in cysteine) interacts with
actin in muscle cells during development and remodeling
(3).
1. Mendoza-Londono R et al., AJHG, 96:979–985, 2015
2. Alazami AM et al., Hum Genet,135:525–540, 2016
3. Jørgensen LH et al., Am J Pathol 187:457–474, 2017
C.F. Rustad: None. Ø.L. Holla: None. H.T. Hilmar-
sen: None. C.A. Heier: None. E. Merckoll: None. A.
Knaus: None. T.E. Prescott: None. K. Tveten: None.
P04.78B
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Spondylocostal Dysostosis (SCD) is a rare disorder char-
acterized by vertebral segmentation defects and malforma-
tions of the ribs. In addition, SCD-patients have some
degree of (kypho)scoliosis, short stature and suffer from
respiratory impairment due to the reduced size of their
thoracic cage. Mutations in DLL3, MESP2, LFNG, HES7,
TBX6 and RIPPLY2 are known to cause different subtypes
of SCD. Here, we present a male neonate with an apparent
severe type of SCD only partly overlapping the previously
described SCD-subtypes. Diagnostic radiological imaging
demonstrated multiple costovertebral abnormalities. The
proband presented with severe costal malformations (miss-
ing, fused, biﬁd, and hypoplastic ribs), vertebral mal-
formations (including intervertebral fusions of the laminae
and irregular ossiﬁcation of the vertebral bodies) and a mild
scoliosis. Other dysmorphic features included: cleft palate
(soft palate), posteriorly rotated ears, short neck, asymmetry
of the thorax, extra nipple, transverse palmar creases, sandal
gap (bilateral), and sacrum acutum. Severe respiratory
insufﬁciency was present from birth. Whole Exome
Sequencing (WES) identiﬁed a homozygous start-loss var-
iant in DMRT2 (NM_006557.6: c.1A>T p.(Met1?)).
Mutations in DMRT2 (OMIM#604935) have not been
described in relation to SCD before. It has been demon-
strated that DMRT2 knock-out mice exhibit severe rib and
vertebral defects overlapping with the radiological pheno-
type of our patient. Therefore, it seems plausible that
mutations in DMRT2 can cause a severe type of SCD
characterized by a striking skeletal phenotype in combina-
tion with extra-skeletal features. This is the ﬁrst report of a
human proband with a severe SCD-like phenotype most
probably caused by a homozygous mutation in DMRT2.
A. Bouman: None. J. Admiraal: None.M. van de Loo:
None. R. R. van Rijn: None. Q. Waisﬁsz: None. R. J.
Oostra: None. I. B. Mathijssen: None.
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The tenascin-X (TNX) deﬁcient type Ehlers-Danlos syn-
drome (EDS) is similar to the classical type of EDS.
Because of the limited awareness among geneticists and the
challenge of the molecular analysis of the TNXB gene, the
TNX-deﬁcient type EDS is probably to be under diagnosed.
We therefore performed an observational, cross-sectional
study. History and physical examination were performed.
Results of serum TNX measurements were collected and
mutation analysis was performed by a combination of next-
generation sequencing (NGS), Sanger sequencing and
multiplex ligation-dependent probe ampliﬁcation (MLPA).
Included were 17 patients of 11 families with autosomal
recessive inheritance and childhood onset. All patients had
hyperextensible skin without atrophic scarring. Hypermo-
bility of the joints was observed in 16 of 17 patients.
Deformities of the hands and feet were observed frequently.
TNX serum level was tested and absent in 11 patients
(seven families). Genetic testing was performed in all
families; 12 different mutations were detected, most of
which are suspected to lead to non-sense mRNA mediated
decay. In short, patients with the TNX-deﬁcient type EDS
typically have generalized joint hypermobility, skin hyper-
extensibility and easy bruising. In contrast to the classical
type, the inheritance pattern is autosomal recessive and
atrophic scarring is absent. Molecular analysis of TNXB in
a diagnostic setting is challenging.
This work was published in Clinical Genetics:
https://www.ncbi.nlm.nih.gov/pubmed/27582382
S. Demirdas: None. E. Dulfer: None. L. Robert: None.
M. Kempers: None. D. van Beek: None. D. Micha: None.
B.G. van Engelen: None. B. Hamel: None. J. Schalkwijk:
None. B. Loeys: None. A. Maugeri: None. N.C. voer-
mans: None.
P04.81A
TNF-alpha gene variants inﬂuence the risk of Spondy-
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Introduction: The group of spondyloarthropathies (SpA)
includes ankylosing spondylitis (AS), psoriatic arthritis
(PsA) and other rheumatic inﬂammatory disorders. A
common genetic feature of spondyloarthropathies is the
association with HLA-B27, but a variable percent of the
patients are HLA-B27-negative. Despite the clinical efﬁ-
cacy of TNF-alpha-inhibitors, the manner in which TNF-
alpha contributes to SpA remains unresolved. Due to TNF-
alpha gene location in the region of HLA loci on chromo-
some 6p21.3, it is difﬁcult to evaluate the contribution of
TNF-alpha gene separate of HLA-B27 marker. The aim of
this study was to analyze three single nucleotide poly-
morphisms (SNPs) of TNF-alpha gene in HLA-B27-
negative SpA patients and controls of Romanian origin.
Materials and methods. After HLA-B27 typing of 266 SpA
patients and 159 controls (B27-SSP low resolution kit
Olerup, Sweden), HLA-B27-negative subjects were selec-
ted. TNF-alpha gene SNPs rs1799724/-857C/T,
rs1800629/-308G/A and rs361525/-238G/A were geno-
typed in 79 SpA patients (27AS/52PsA) and 141 controls
(all HLA-B27-) using TaqMan Allelic Discrimination
Assays (Applied Biosystems, USA). Association tests were
performed with the software package PLINK v 1.9. Results.
Controls and patients were in Hardy-Weinberg equilibrium
for the three SNPs. The frequency of the minor 857*T allele
was signiﬁcantly higher in patients than in controls (32.3%
vs. 18.6%, puncorr.= 0.001, OR 2.09, CI 1.333–3.276). The
carriers of this allele (CT+TT genotypes) were more fre-
quent among patients (53% vs. 32.8%, p= 0.003, OR 2.32).
The haplotype TGG was over-represented in patients
(32.3%) versus controls (18.6%, p= 0.001). Conclusion.
TNF-alpha gene SNP rs1799724 inﬂuences the risk of SpA
in HLA-B27-negative Romanians.
O.M. Popa: None. M. Bojinca: None. V. Bojinca:
None. M.I. Dutescu: None. C. Bara: None. L.O. Popa:
None.
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Follow-up mutational analysis in uncombable hair
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of Neuro- and Sensory Physiology, Göttingen, Germany
Uncombable hair syndrome (UHS), also known as “spun
glass hair syndrome”, or “pili trianguli et canaliculi” is a
rare anomaly of the hair shaft which occurs in early child-
hood and improves with age. UHS is characterized by
frizzy, spangly and often fair hair that is resistant to being
combed ﬂat. Currently, about 100 cases have been reported
worldwide. Recently, we identiﬁed homozygous and/or
compound heterozygous mutations in 11 children in the
three genes PADI3, TGM3, and TCHH, which are all
involved in hair shaft formation. After publishing our novel
data, numerous of people got interested in our study; and we
collected DNA samples from more than 20 families with
UHS. We performed Sanger sequencing on PADI3, TGM3,
and TCHH to identify the underlying mutations. We iden-
tiﬁed the most common mutations c.881C>T;p.Ala294Val
and c.335T>A;p.Leu112His in 10 affected individuals. In
addition, we identiﬁed the novel nonsense mutation
c.545C>T;p.Q169* in two patients. Some individuals did
not carry any mutations in PADI3. Sequencing of the
remaining genes in individuals where no mutations have
been detected are ongoing. According to gnomeAD, the
allele frequency of the most common mutations c.881C>T
and c.335T>A is much more frequent than expected (e.g.
we calculated that in the German population, there should
be around 12.000 UHS cases). We conﬁrmed that most
mutations in patients with UHS can be identiﬁed in PADI3,
however, we speculate that there is also a gene for a
dominant form which is not known yet.
P. Kokordelis: None. F.B. Ü. Basmanav: None. S.
Wolf: None. A. Humbatova: None. M.T. Romano: None.
R.C. Betz: None.
P04.83C
A systematic screening for a monogenic cause in a
cohort of 25 patients with vertebral segmentation defects
S. Salian1, A. Shukla1, S. R. Phadke2, R. Gupta3, S.
Nampoothiri4, R. D. Shenoy5, V. H. Sankar6, K.
Gowrishankar7, D. Joshi8, A. Singh9, K. M. Girisha1
1Kasturba Medical College, Manipal, Udupi, India, 2Sanjay
Gandhi Postgraduate Institute of Medical Sciences, Luck-
now, India, 3Mahatma Gandhi Medical College and
Hospital, Jaipur, India, 4Amrita Institute of Medical
Sciences & Research Centre, Cochin, India, 5K S Hegde
Medical Academy, Mangalore, India, 6Government Medical
College, Thiruvananthapuram, India, 7Kanchi Kamakoti
Childs Trust Hospital, Chennai, India, 8Kailash Cancer
Hospital and Research Centre, Vadodara, India, 9Institute
of Medical Sciences, Varanasi, India
Introduction: During embryogenesis, the process of
somitogenesis is orchestrated by a wide range of genes for
the precise vertebral column development. The disruption
of this process results in either syndromic or non-syndromic
vertebral segmentation defects. In this study, we investi-
gated the genetic basis of syndromic and non-syndromic
vertebral segmentation defects in a cohort of 25 patients.
Materials and methods: We aimed at identifying pathogenic
variants in the genes (DLL3, MESP2, HES7, LFNG, TBX6
and RIPPLY2) known to cause non-syndromic vertebral
segmentation defects by Sanger sequencing. Exome-
sequencing was performed in ﬁve families. Results: We
recruited 22 families with sporadic cases and one family
with three affected members. After clinical and radiological
evaluation, 19 families were categorised as non-syndromic
and four families as syndromic. We performed Sanger
sequencing in 18 sporadic cases with non-syndromic ver-
tebral segmentation defects and detected three novel
pathogenic variants: c.193G>T (p.E65*) in MESP2,
c.661C>T (p.R221*) and c.1069T>G (p.C357G) in DLL3.
Exome sequencing was performed in ﬁve families (four
syndromic and the other familial non-syndromic vertebral
segmentation defects) and identiﬁed ﬁve novel pathogenic
variants: c.314G>A (p.C105Y) in BMPER and c.1243C>T
(p.R415*), c.6407del (p.P2137Rfs*12), c.1204del (p.
V402Wfs*88) and c.1892C>T (p.P631L) in FLNB. Con-
clusions: We identiﬁed a monogenic aetiology in eight
families with vertebral segmentation defects (32%). Further
evaluation is underway. The study has been funded by
Indian Council of Medical Research.
S. Salian: None. A. Shukla: None. S.R. Phadke: None.
R. Gupta: None. S. Nampoothiri: None. R.D. Shenoy:
None. V.H. Sankar: None. K. Gowrishankar: None. D.
Joshi: None. A. Singh: None. K.M. Girisha: None.
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P04.84D
Williams syndrome and hereditary diffuse palmoplantar
keratoderma
B. Nur1, B. Unal2, I. C. Başsorgun2, O. Dicle3, E. Mihci1
Pediatric Genetics Department, Akdeniz University School
of Medicine, Antalya, Turkey, Antalya, Turkey, 2Pathology
Department, Akdeniz University School of Medicine,
Antalya, Turkey, Antalya, Turkey, 3Dermatology and
Venereology Department, Akdeniz University School of
Medicine, Antalya, Turkey, Antalya, Turkey
Introduction: Williams syndrome(WS) is a multi-system
disorder characterized by distinctive facial features, growth
delay, mental retardation with typical neurobehavioral
proﬁle, cardiovascular anomalies, endocrine anomalies,and
hypercalcemia. Dermatologic ﬁndings can include soft skin,
forehead/peri-ocular/peri-oral wrinkling, skin picking, ker-
atosis pilaris, atrophic areas of skin. Dry skin/mild hyper-
keratosis can be present, but palmoplantar keratoderma
(PPK) is not a typical ﬁnding in WS. Our case provides a
very rare example of WS with severe hereditary diffuse
palmoplantar keratoderma.
Case Report: We presented a 4-years-old girl born as the
second child of ﬁrst degree cousin marriage. On her phy-
sical examination; course facies, periorbital fullness, bul-
bous nasal tip, full lips and cheeks, long philtrum, horse
voice, and severe hyperkeratosis on hands and feet detected.
Subaortic ventricular septal defect, mitral valve prolapsus,
and hypothyroidism detected. FISH result was 46.XX, ish
del(7q11.2)(ELN X1)(7q22 X2)ELN deletion compatible
with WS. A skin biopsy from the sole showed hyperpar-
akeratotic stratum corneum, spongiosis, acanthosis, mono-
nuclear inﬂammatory cell inﬁltration around the dermis
veins compatible with palmoplantar keratoderma.
Conclusion: PPK is a heritable or acquired disorder
characterized by abnormal hyperkeratotic thickening of the
palm and sole skin. Hereditary PPK are divided morpho-
logically into four types; diffuse, focal, striate,and punctate.
To our knowledge, this is the ﬁrst report of WS with her-
editary diffusePKK in English literature. We want to draw
attention to the fact that there may be a coincidence between
WS and the developing PKK in this patient, as well as a
ﬁnding that may accompany the WS. Gene studies are
planned to clarify this situation.
B. Nur: None. B. Unal: None. I.C. Başsorgun: None.
O. Dicle: None. E. Mihci: None.
P04.86B
Identiﬁcationof idiopathic scoliosis-associated reg-
ulatory elements
N. Makki, W. Eckalbar, N. Ahituv
University of California San Francisco, San Francisco, CA,
United States
Adolescent idiopathic scoliosis (AIS) affects ~3% of the
population worldwide, yet its genetic basis and tissues of
origin remain largely unknown. Several genome-wide
association studies (GWAS) and functional follow up stu-
dies have implicated nucleotide changes in gene regulatory
sequences such as enhancers as potential drivers of AIS
susceptibility. In addition, various assays using animal
models have suggested that chondrocytes could be an
important cell type for AIS susceptibility. In this study, we
set out to characterize AIS-associated regulatory elements in
chondrocytes by carrying out chromatin immunoprecipita-
tion followed by deep sequencing (ChIP-seq). Chon-
drocytes were isolated from the axial skeleton of newborn
mice (P2-P4) and ChIP-seq was performed using an H3K27
antibody that marks active genomic regions (enhancers and
promoters). Our analysis identiﬁed a catalog of novel
putative chondrocyte speciﬁc enhancers and promoters and
highlights gene regulatory pathways involved in chon-
drogenesis. This catalog provides prime candidate sequen-
ces that can be analyzed for AIS-associated nucleotide
variation. In addition, we plan to use a similar approach for
additional AIS-associated tissues and functionally char-
acterize AIS-associated regulatory elements using trans-
genic enhancer assays and CRISPR/Cas9 genome editing in
mice. Grants: NIH 1P01HD084387-01A1. NM. is sup-
ported by Jane Cofﬁn Childs Postdoctoral Fellowship.
N. Makki: None. W. Eckalbar: None. N. Ahituv:
None.
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P05.01A
Focus on Risk of Familial Abdominal Aortic Aneurysm
in Women
D. F. Majoor-Krakauer, K. M. van de Luijtgaarden, E. V.
Rouwet, S. E. Hoeks, H. J. M. Verhagen
Erasmus University Medical Center, Rotterdam,
Netherlands
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Gender affects the presentation, treatment, and outcomes of
abdominal aortic aneurysm (AAA). Although AAA is less
prevalent in women, at least in the general population,
female AAA patients have poorer prognosis than men.
Gender differences in genetic predisposition for aneurysm
disease remains to be established. Here we investigated
familial risk of aortic aneurysm for women compared to
men. AAA patients were routinely referred to the multi-
disciplinary vascular/genetics outpatient clinic for assess-
ment of family history using detailed questionnaires.
Abdominal aortic aneurysm risk for male and female rela-
tives was calculated separately and stratiﬁed by gender of
the AAA patients. Families of 568 AAA patients were
investigated and 22.5% of the patients had at least one
affected relative. Relatives of female AAA patients had a
higher aneurysm risk than relatives of male patients (9.0 vs.
5.9%, P= .022). Compared to estimated gender speciﬁc
population risks, female relatives had a 2.8-fold and male
relatives a 1.7-fold higher AAA risk. Risk for female and
male relatives of female patients was 5.5- and 2-fold
increased, compared to a 2.4-fold higher risk for female and
1.6-fold higher risk for male relatives of male patients. The
risk for aortic aneurysm in family members of AAA patients
is higher than expected from population risk. The excess
risk is largest for the female relatives of AAA patients and
for the relatives of female AAA patients. These ﬁndings
indicate expanding targeted AAA family screening to
female and male relatives of all AAA patients, particularly
of female AAA patients.
D.F. Majoor-Krakauer: None. K.M. van de Luijt-
gaarden: None. E.V. Rouwet: None. S.E. Hoeks: None.
H.J.M. Verhagen: None.
P05.02B
The effect of adiposity on and cardiovascular risk fac-
tors and bone mineral density: a Mendelian randomi-
zation study
M. Lin1, W. Wu1, T. Wu2, L. S. Chen3, A. Yen3, Y. Lee4, T.
Liu5, H. Chen6
1Institute of Public Health, National Yang-Ming University,
Taipei, Taiwan, 2Department of Public Health, College of
Health Care and Management, Chung Shan Medical
University, Taichung, Taiwan, 3School of Oral Hygiene,
College of Oral Medicine, Taipei Medical University,
Taipei, Taiwan, 4Department of Internal Medicine, College
of Medicine, National Taiwan University, Taipei, Taiwan,
5Lienchiang County Government, Matsu, Taiwan, 6Institute
of Epidemiology and Preventative Medicine, College of
Public Health, National Taiwan University, Taipei, Taiwan
Introduction: The incidence of overweight and obesity
have increased rapidly and has become a major worldwide
health problem. Adiposity constitutes an important risk
factor for type 2 diabetes, dyslipidemia, hypertension,
osteoarthritis, cardiovascular disease and is the major cause
mortality, however, its causes and consequences are often
difﬁcult to determine. The study was aimed to use a Men-
delian randomization design to assess whether adiposity
causally affects known cardiovascular risk factors and bone
mineral density. Methods: A total of 1100 adults were
recruited from the Matsu community-based integrated
health screening project. Three FTO SNPs (rs9939609,
rs9930506, rs14211085) were used as instrument variables
to estimate the causal effect of adiposity on blood pressure,
fasting glucose, lipid levels, and bone marrow density in the
Mendelian randomization analysis using two-stage least
squares instrumental variable regression. Results: We
found that all three SNPs of the FTO gene were sig-
niﬁcantly associated with body-mass index (BMI), and two
SNPs (rs9939609, rs14211085) associated with fat percen-
tage (p<0.05). The results of linear regression showed that
both BMI and fat percentage are signiﬁcantly associated
with blood pressure, fasting glucose, lipid levels (p<0.001),
and bone marrow density (p<0.01). However, Mendelian
randomization analyses did not show that both BMI and fat
percentage, instrumented by the three FTO SNPs, were
associated with any cardiovascular risk factors and bone
mineral density (p > 0.05). Conclusion: Our study could not
replicate previous knowledge of the causal effects of adip-
osity on cardiovascular risk factors and bone marrow den-
sity in our Chinese population. Grant No: MOST 103-2314-
B-010-009 & MOST 105-2314-B-010-017
M. Lin: None. W. Wu: None. T. Wu: None. L.S.
Chen: None. A. Yen: None. Y. Lee: None. T. Liu: None.
H. Chen: None.
P05.03C
Genetic variants in familial abdominal aortic aneurysms
identiﬁed by Whole Genome and Exome sequencing
A. IJpma1,2,3, D. Heijsman1,2, H. Brüggenwirth1,2, I. van
den Boogert1,2, D. Majoor-Krakauer1,2
Erasmus MC, Rotterdam, Netherlands, 2Department of
Clinical Genetics, Rotterdam, Netherlands, 3Department of
Bioinformatics, Rotterdam, Netherlands
Introduction: Abdominal aortic aneurysm (AAA) is a
frequent disorder with a prevalence of 5% in the elderly
population. 20% of AAA patients are familial. In non-
familial AAA predisposition also plays a role since known
cardiovascular risk factors alone do not explain the
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localized weakening of the aortic wall. Our goal is to
identify genes that play a role in the formation of abdominal
aneurysms.
Methods: The study includes approximately 1050 AAA
patients, 350 patients with (fAAA)- and 700 patients
without a family history of AAA (non fAAA). So far we
sequenced the DNA of 470 patients (350 fAAA and 120
non fAAA). Whole genome sequencing (WGS) was per-
formed in 3 families (15 individuals) and whole exome
sequencing (WES) was performed in 365 families with
familial disease.
Prioritization of resulting variants was performed
according to the following gene sets:
1. Genes in diagnostics panel as applied in the Erasmus
MC in thoracic or syndromic aneurysms (n= 25)
2. Genes involved in vascular function or disease (n=
4209)
3. All genes in the genome
Results: We present the detailed workﬂow of the ana-
lysis of the genomics data, including the results so far. In 73
out of 365 families a variant in one of the set 1 genes was
found. Further analysis of the set 2 and 3 genes led to the
identiﬁcation of several candidate genes that show variants
in more than one AAA family and that have not been linked
to AAA before.
Supported by Stichting Lijf en Leven.
A. IJpma: None. D. Heijsman: None. H. Brüggen-
wirth: None. I. van den Boogert: None. D. Majoor-
Krakauer: None.
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Utility of targeted next generation sequencing in a
representative Czech cohort of paediatric and adult
patients with arrhytmogenic cardiomyopathy (AC).
High prevalence of variants in DSP in left ventricular
form of AC
A. Krebsova1, L. Piherova2, P. Norambuena3, J.
Paděrova3, P. Kubus4, M. Kubanek1, J. Kautzner1, J.
Janouek4, S. Kmoch2, M. Macek Sr.3, M. Macek Jr.3
1Institute for Clinical and Experimental Medicine, Prague,
Czech Republic, 2Institute of Inherited Metabolic Disorders,
1st Faculty of Medicine and General Faculty Hospital,
Prague, Czech Republic, 3Department of Biology and
Medical Genetics, 2nd Faculty of Medicine Charles
University and Faculty Hospital Motol, Prague, Czech
Republic, 4Children´s Heart Centre, 2nd Faculty of
Medicine Charles University and Faculty Hospital Motol,
Prague, Czech Republic
Introduction: Arrhytmogenic cardiomyopathy (AC) is
associated with an increased risk of sudden cardiac death.
Patients and Methods: A total of 67 Czech AC cases (7
pediatric) were recruited. All patients/families had under-
gone genetic counselling, including cardiologic examina-
tion in their 1st degree relatives. Targeted NGS, comprising
exonic regions with pathogenic variation (PV, using Tru-
Sight One- Illumina or SeqCap MedExome - Roche) was
performed in 56/67 patients, while 11/67 were analysed by
a custom panel (NimbleGen; Roche).
Results: Family history was positive in 18/67 (27%) of
cases. Likely PV was found in 54/67 (80%) cases: PKP2
(28/67; 28%) and DSP (13/67; 19%). Majority of DSP-
positive cases (11/13) have predominant left ventricular
involvement and underwent catheter ablation (7/13). Var-
iants in DSC2 were found in 4/67 (6%) and in DES, TGFB3,
DSG2 and SCN5A in 2/67 (3% each). Likely PV in
TMEM43, CTNN2, JUP, RYR2 occurred once (1.5% each).
In 13/67 patients (19%) the underlying genetic aetiology
remained unknown (6/13 did not bear any PV, while in 7/13
cases PV were found in genes associated with other types of
hereditary cardiovascular diseases such as KCNE3/TRPM4,
SCN10A/TRDN, TRPM2, TNNT2, FBN1, MYH7, ANK3,
LDB3, FLNC).
Conclusion: The spectrum of PV in our AC patients
corresponds to that observed in other European cohorts.
Patients bearing DSP PV have predominantly left ven-
tricular involvement. Family segregation studies identiﬁed
additional “carriers” of PV, who were enlisted into long-
term cardiologic follow up and discouraged from strenuous
sports activities.
Supported by 00064203, CZ.2.16/3.1.00/24022, NF-
CZ11-PDP-3-003-2014 and MZ 15-27682A.
A. Krebsova: None. L. Piherova: None. P. Nor-
ambuena: None. J. Paděrova: None. P. Kubus: None. M.
Kubanek: None. J. Kautzner: None. J. Janouek: None.
S. Kmoch: None. M. Macek Sr.: None. M. Macek Jr.:
None.
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miRNA proﬁling in a transgenic model of arrhythmo-
genic cardiomyopathy
M. Calore1, A. Lorenzon2, M. Khan1, G. Poloni2, L.
Vitiello2, P. Bonaldo2, P. Braghetta2, A. Rampazzo2, L. J.
de Windt1
Maastricht University, Maastricht, Netherlands, 2Padua
University, Padua, Italy
Arrhythmogenic cardiomyopathy (ACM) is one of the most
common inherited cardiomyopathies, characterized by the
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ﬁbro-fatty replacement in the myocardium. Among the 13
known genes, those encoding for the desmosomal proteins
plakophilin-2 (PKP2), desmoplakin (DSP), and desmoglein-
2 (DSG2) are most commonly mutated. Clinically, ACM
manifests with ventricular arrhythmias, syncope, and sud-
den death and shows wide inter- and intra-familial varia-
bility, which might be determined by epigenetic factors,
such as microRNAs (miRNAs).
AIM: Deﬁning the miRNA signature in a transgenic
mouse model for ACM overexpressing the p.Q558X
mutation in desmoglein-2.
METHODS AND RESULTS: We generated transgenic
mice with cardiac-speciﬁc overexpression of the FLAG-
tagged mutated (Tg-hQ) desmoglein-2, resembling the
features of ACM. In Tg-hQ mice, desmosome density and
length were signiﬁcantly decreased and Wnt/β-catenin sig-
nalling suppressed.
RNA-Seq performed in three Tg-hQ hearts and three
non-transgenic hearts revealed that 24 miRNAs were
deregulated in transgenic animals. MiRWalk and GO ana-
lyses for selected miRNAs suggested that miR-217-5p,
miR-216a-5p, miR-499-5p, and miR-708-5p might be
involved in the regulation of the Wnt/β-catenin signaling.
CONCLUSIONS: We identiﬁed the miRNA signature
in ACM hearts, with miR-708-5p, miR-216a-5p, miR-217-
5p being the most upregulated and miR-499-5p the most
downregulated miRNAs. All of them were predicted to be
involved in the regulation of the Wnt/β-catenin pathway and
might reveal the potential pathophysiology mechanisms of
ACM, as well as be useful as therapeutic targets for the
disease.
Grants: H2020-MSCA-IF-2014; TRANSAC, University
of Padua Strategic Grant CPDA133979/13, Padua, Italy;
Veneto Region Target Research, Venice.
M. Calore: None. A. Lorenzon: None.M. Khan: None.
G. Poloni: None. L. Vitiello: None. P. Bonaldo: None. P.
Braghetta: None. A. Rampazzo: None. L.J. de Windt:
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DNA methylation within microRNA gene MIR10B in
atherosclerosis
A. V. Markov1, I. A. Koroleva1, A. N. Kucher1,2, M. S.
Nazarenko1,3, O. L. Barbarash4, V. P. Puzyrev1,3
1Research Institute of Medical Genetics, Tomsk National
Research Medical Center, Russian Academy of Sciences,
Tomsk, Russian Federation, 2National Research Tomsk
State University, Tomsk, Russian Federation, 3Siberian
State Medical University, Tomsk, Russian Federation,
4Research Institute for Complex Problems of Cardiovas-
cular Diseases, Kemerovo, Russian Federation
DNA methylation and microRNAs are epigenetic mechan-
isms which can act in a tissue-speciﬁc manner, and their
alterations are associated with atherosclerosis. To investi-
gate DNA methylation patterns within microRNA genes we
performed DNA methylation screening of 71 CpG sites in
advanced atherosclerotic lesions of coronary arteries
(CNA), intact internal thoracic arteries (ITA), saphenous
veins (SV) and peripheral blood leukocytes (PBL) of six
patients with coronary atherosclerosis using Human-
Methylation27 BeadChip (Illumina). The results were
validated and extended with DNA from CNA, ITA, SV (n
= 22 each), atherosclerotic plaques of carotid arteries (CTA,
n= 120) and PBL (n= 142) of patients with athero-
sclerosis, and PBL of healthy persons (n= 90) via bisulﬁte
pyrosequencing. We found 50 CpG sites having low
methylation level (< 0.1) and variability (range < 0.1) in all
analyzed samples. Methylation proﬁle of highly variable
CpG sites (within 9 microRNA genes) demonstrated CNA
having similarity with PBL. The most variable CpG sites
were attributed to MIR10B, which was hypomethylated in
atherosclerotic plaques and PBL compared to ITA and SV.
Weak but signiﬁcant positive correlation were shown
between methylation levels in CTA and PBL. Methylation
level within MIR10B promoter was slightly elevated
(p<0.05) both in CTA and PBL of patients compared to
PBL of healthy individuals. Disturbances in methylation of
certain CpG sites were associated with cases of myocardial
infarction, stroke, chronic lower limb ischemia, smoking
etc. Methylation of MIR10B has tissue-speciﬁc pattern,
associated with susceptibility to atherosclerosis, its clinical
manifestations and risk factors. The study was supported by
the Russian Science Foundation (no. 16-15-10150).
A.V. Markov: None. I.A. Koroleva: None. A.N.
Kucher: None. M.S. Nazarenko: None. O.L. Barbarash:
None. V.P. Puzyrev: None.
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Genomic alterations in the recruited macrophages in
human atherosclerotic plaques
A. A. Sleptsov1, M. S. Nazarenko1, N. A. Skryabin1, E. V.
Denisov2, L. A. Tashireva2, I. N. Lebedev1, V. P. Puzyrev1
Research Institute of Medical Genetics, Tomsk National
Research Medical Center, Tomsk, Russian Federation,
2Cancer Research Institute, Tomsk National Research
Medical Center, Tomsk, Russian Federation
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Introduction: It is suggested that somatic genomic altera-
tions may occur in key cells of atherogenesis, for instance,
macrophages, and therefore have been implicated in ather-
osclerotic plaque formation. Thus, our purpose was an
assessment of genomic alterations in macrophages obtained
from atherosclerotic plaque using single-cell microarray
technique. Materials and methods: Using Mouse mono-
clonal Anti-Human CD68 Antibody and Laser capture
microdissection we obtained macrophages (n= 30–40 cells
per sample) from atherosclerotic plaques (IV-V types) from
the coronary arteries (n= 8) with subsequent whole genome
ampliﬁcation (GenomePlex® WGA Kit). The ampliﬁed
DNA samples of macrophages and white blood cells from
the same persons were hybridized on SurePrint G3 Human
CGH 8×60K Microarray (Agilent Technologies). Results:
We found several aneuploidies (4, 7, 12, 14, 15, and 22
chromosomes) in macrophages (≈1 per sample). Compara-
tive analysis of genomic rearrangements in macrophages
demonstrated that certain structural variations were detected
in the similar genomic regions, whereas most of them were
differently dispersed. The most common (50%) structural
variation was located in 9q34.13-q34.2 (arr[hg19] 9q34.13
(9:134337452-135931774)x3) that contains about 20 genes.
Conclusion: Our study indicates that genomic alterations are
diverse in their structure and are widely represented in the
recruited macrophages in atherosclerotic plaques. Further-
more, we identiﬁed common structural variation in 9q34.13
that contains genes potentially relevant to the development
of atherosclerosis. The study was supported by the Russian
Science Foundation (No. 14-15-00305).
A.A. Sleptsov: None. M.S. Nazarenko: None. N.A.
Skryabin: None. E.V. Denisov: None. L.A. Tashireva:
None. I.N. Lebedev: None. V.P. Puzyrev: None.
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A novel missense variant in the gene PLEC increases
risk of atrial ﬁbrillation
R. B. Thorolfsdottir1, G. Sveinbjornsson1, P. Sulem1, D. O.
Arnar2,3, H. Holm1, D. F. Gudbjartsson1,4, K.
Stefansson1,3
1deCODE Genetics/Amgen, Inc., Reykjavik, Iceland,
2Department of Medicine, Landspitali University Hospital,
Reykjavik, Iceland, 3Faculty of Medicine, University of
Iceland, Reykjavik, Iceland, 4School of Engineering and
Natural Sciences, University of Iceland, Reykjavik, Iceland
Introduction: Recently, rare mutations in the sarcomere
genes MYH6 and MYL4 have been linked to risk of atrial
ﬁbrillation (AF). Here, we search for sequence variants that
associate with AF using whole-genome sequence data and
explore their effects on electrocardiogram (ECG)
measurements.
Materials and Methods: We tested for association
between sequence variants and AF among 14,255 Icelandic
cases and 374,393 controls and ECG measures in 289,297
ECGs from 63,000 individuals. Genotype information was
based on whole-genome sequencing of 15,220 individuals,
imputation in 151,678 individuals and calculated genotype
probabilities for untyped relatives.
Results: We discovered a novel missense mutation, p.
Gly3988Ser, in the gene PLEC that associates with
increased risk of AF, minor allele frequency 1.17%, odds
ratio 1.55, P-value 8.0×10−10. PLEC encodes plectin, a
multidomain cytoskeleton linking protein which has a role
in maintaining tissue integrity in the heart. P.Gly3988Ser
signiﬁcantly affects ECG measurements in the absence of
AF. It affects P-wave morphology, lowers the R-amplitude
and prolongs the PR-segment. Other AF associated variants
have variable effects on the conduction system, ranging
from none to extensive.
Conclusions: Through genome-wide analysis we dis-
covered a coding variant in a gene encoding a structural
component of cardiomyocytes that substantially increases
AF risk. The novel mutation in PLEC affects conduction in
both atria and ventricles. The diverse associations of AF
variants with ECG measurements suggests a variable
pathological mechanism behind their respective link to AF.
The discovery implies an important role of structural com-
ponents of cardiomyocytes and cardiac remodelling in the
pathogenesis of AF.
R.B. Thorolfsdottir: A. Employment (full or part-time);
Signiﬁcant; deCODE Genetics/Amgen, Inc. G. Sveinb-
jornsson: A. Employment (full or part-time); Signiﬁcant;
deCODE Genetics/Amgen, Inc. P. Sulem: A. Employment
(full or part-time); Signiﬁcant; deCODE Genetics/Amgen,
Inc.. D.O. Arnar: None. H. Holm: A. Employment (full or
part-time); Signiﬁcant; deCODE Genetics/Amgen, Inc. D.F.
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Candidate gene resequencing in a large BAV/TAA
cohort: SMAD6 as an important contributor
B. L. Loeys1, E. Gillis1, C. Preuss2, A. Kumar1, I. Luyckx1,
E. Cannaerts1, G. van de Beek1, B. Wieschendorf1, M.
Alaerts1, N. Bolar1, G. Vandeweyer1, F. Wünnemann2, R.
A. Gould3, R. Zhurayev4, S. A. Mohamed5, S. Mital6, L.
Mertens6, P. Eriksson7, A. Mc Callion3, L. Van Laer1, J.
M. A. Verhagen8, I. Vandelaar8, M. W. Wessels8, E.
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Albuisson9, G. Andelﬁnger12, H. Dietz3, A. Verstraeten1,
Mibava Leducq Consortium
Antwerp University Hospital/University of Antwerp,
Antwerp, Belgium, 2CHU Saint-Justine, Montreal, QC,
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Baltimore, MD, United States, 4Lviv National Medical
University, Lviv, Ukraine, 5UKSH-Campus, Lübeck, Ger-
many, 6Sick Kids University Hospital, Toronto, ON,
Canada, 7Karolinska Institute, Stockholm, Sweden, 8Eras-
mus Medical Center, Rotterdam, Netherlands, 9Hôpital
Européen Georges Pompidou, Paris, France, 10Institute of
Clinical and Experimental Medicine, Prague, Czech
Republic, 11Radboud University Medical Center, Nijmegen,
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Bicuspid aortic valve (BAV) is the most common con-
genital heart defect. Although most BAV patients remain
asymptomatic, at least 20% develop thoracic aortic aneur-
ysms (TAA). Historically, these BAV-related TAAs were
considered hemodynamic consequences, but multiple lines
of evidence currently suggest that genetic determinants also
contribute to the pathogenesis of BAV and TAA. While
BAV has a high heritability, few genes have been strongly
linked to the BAV phenotype. NOTCH1 is often considered
the sole established human BAV(/TAA) gene, although
several other genes have occasionally been linked to BAV,
including SMAD6 and Nkx2.5. Other candidate genes based
on the presence of BAV in knockout mouse models (eg
GATA5, NOS3) or in syndromic (eg. TGFBR1/2, TGFB2/3)
or non-syndromic (eg. ACTA2) TAA forms have been
suggested. We hypothesized that causal genetic variants in
these genes would be enriched in patients presenting with
both BAV and TAA. We performed targeted resequencing
of 25 candidate genes using Haloplex enrichment in a
strictly deﬁned BAV/TAA cohort (n= 441; at least dia-
meter of 4.0 cm at the sinuses of Valsalva or the ascending
aorta) and in a collection of healthy controls with normal
echocardiographic evaluation (n= 183). After additional
burden analysis against ExAC, the strongest candidate
susceptibility gene was SMAD6, with 2.72% of BAV/TAA
patients harboring causal variants, including two nonsense,
one in-frame deletion and two frameshift mutations. All six
missense mutations were located in the functional MH1 and
MH2 domains. In conclusion, SMAD6 is the ﬁrst gene with
more than 1% contribution to the BAV/TAA phenotype in
humans.
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Mutation load of multiple ion channel gene mutations in
Brugada Syndrome
F. Gualandi1, F. Zaraket2, M. Malagù2, G. Parmeggiani1,
C. Trabanelli1, S. Fini1, D. Xiao3, W. Xiaoming3, F.
Mingyan3, M. Bertini2, R. Ferrari2, A. Ferlini1
1Medical Genetics Unit, Dept. of Medical Science, Uni-
versity of Ferrara, Ferrara, Italy, 2Cardiology Unit,
University Hospital of Ferrara, Ferrara, Italy, 3BGI-
Shenzhen, Shenzhen, China
Introduction: Brugada syndrome (BrS) is a primary
arrhythmic syndrome which accounts for 20% of all sudden
cardiac death cases in individuals with structurally normal
heart. Pathogenic variants associated with BrS have been
identiﬁed in over 20 different genes.
Methods: A new custom NGS panel exploring 66 car-
diac genes was used to search for potential disease-causing
variants in BrS patients.
Results: We identiﬁed in a patient a double hetero-
zygosity for missense mutations in two genes related to BrS.
The c.4501C>G nucleotide substitution in exon 26 of the
SCN5A gene resulted in the amino acid change p.
Leu1501Val. This variant was previously reported in BrS
and in LQTS patients. The second change consists of a
c.2531G>A nucleotide substitution in exon 17 of the
TRPM4 gene that leads to the amino acid change p.
Gly844Asp. This variant is a known pathogenic mutation
and it was reported in various cardiac arrhythmic disorders
including BrS. Parents were heterozygous for each variation
and the family history was negative for major cardiac events
and sudden death, suggesting that single mutation is not
sufﬁcient per se to determine a clinical picture.
Conclusion: Differently from other arrhythmogenic
channelopathies (as long-QT), digenic inheritance has never
been reported in BrS. Our novel ﬁnding highlights the role
of mutation load in this pathology and strongly suggests the
adoption of gene panel to get an accurate genetic diagnosis,
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which is mandatory for risk stratiﬁcation, prevention and
therapy.
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An ABCC9 Mutation in a Family with Severe Brugada
Syndrome and Diabetes
O. A. Louise1, C. James1, Le Quesne Stabej1, H.
Williams1, N. Jani1, A. Gagunashvili1, L. Boukhibar1,
GOSgene1, C. Bachelli1, P. Beales1, P. Winyard2
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Introduction: Brugada syndrome (BrS) is a rare inherited
arrhythmia disorder that disrupts the ﬂow of sodium ions,
increasing the risk of ventricular ﬁbrillation, although most
affected individuals have a structurally normal heart. BrS
contributes up to 12% of cases with Sudden Death Syn-
drome in the general population. It is a heterogeneous dis-
order and several families have been reported with an
autosomal dominant mode of inheritance. Aim: Here we
report an autosomal dominant family consisting of unaf-
fected mother, affected father and two affected sons with
severe BrS. The father and the eldest son, with long QT
syndrome and diabetes, were also heterozygous for a variant
in the sodium channel gene SCN5A. The youngest son was
asymptomatic for BrS until tested; and is negative for the
SCN5A variant. Our objective was to determine the genetic
cause of severe BrS in this family. Materials and Methods:
We performed whole exome sequencing (WES) on the
family with severe BrS. Variants were called with GATK
pipeline and were ﬁltered using an autosomal dominant
inheritance model to identify a causative mutation. Results:
WES analysis successfully identiﬁed a novel missense
mutation (c.3575C>A; p.T1192N) in exon 29 of the ABCC9
gene in all affected individuals. This amino acid residue is
highly conserved amongst species. Conclusion: We have
identiﬁed a novel mutation within the ABCC9 gene pre-
viously associated with BrS and early repolarization syn-
drome. Our ﬁnding provides a new target for molecular
diagnosis and clinical management for BrS cases. Grant:
We are funded by the British Research Council (BRC)
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Relation of cardiac dysfunction to thyroid stimulating
hormone in children with Down syndrome
S. Elsayed1, O. Ibrahim1, H. Salah1, M. Mowafy1, H.
Bolz2
1Ain Shams University, Cairo, Egypt, 2Institute of Human
Genetics, University Hospital of Cologne, Cologne,
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Introduction: Down syndrome (DS) is the most common
chromosomal abnormality and frequently associated with
congenital heart disease. Recently, cardiac dysfunction was
found in these patients even with anatomically normal
hearts. The cause of which is still being investigated. At the
same time, subclinical hypothyroidism (which is particu-
larly common in DS) was suggested to decrease left ven-
tricular diastolic function. The aim of this study was to
evaluate cardiac functions in relation to the thyroid proﬁle
in children with DS.
Patients and methods: 100 consecutive children with DS
were enrolled in this study with age range from 9 months to
264 months. Free T4, TSH levels and thyroid antibodies
(anti-thyroglobulin and anti-peroxidase) were measured.
Tissue Doppler imaging and two-dimensional speckle
tracking echocardiography was used to evaluate cardiac
functions.
Results: Diastolic dysfunction of left ventricle and right
ventricle was found in 59% and 18% of children conse-
quently. There was statistically signiﬁcant difference
between patients with and without left ventricle diastolic
dysfunction regarding TSH level and a signiﬁcant positive
correlation between TSH level and E wave at tricuspid
annulus
Conclusion: Biventricular diastolic dysfunction is a sig-
niﬁcant ﬁnding in children with DS that could be related to
subclinical hypothyroidism. Prospective studies on a larger
number of children and adults is need to conﬁrm or exclude
this hypothesis.
S. Elsayed: None. O. Ibrahim: None. H. Salah: None.
M. Mowafy: None. H. Bolz: None.
262
P05.13A
The ﬁrst genome wide association study in Iran; The
Tehran Cardiometabolic Genetic Study (TCGS)
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Introduction: Cardiometabolic risk factors comprise car-
diovascular diseases and/or diabetes, and need to be eval-
uated in different ﬁelds. Objectives: The primary aim of the
Tehran Cardiometabolic Genetic Study (TCGS) is to create
a comprehensive genome-wide database of at least 16,000
Tehranians, who are participants of the ongoing Tehran
Lipid and Glucose Study (TLGS) cohort. Methods: TCGS
was designed in collaboration with the Research Institute
for Endocrine Sciences and the genetic company deCODE.
Participants had already been followed for over a 20-year
period for major cardiometabolic-related health events
including myocardial infarction, stroke, diabetes mellitus,
hypertension, obesity, hyperlipidemia, and familial
hypercholesterolemia. Results: The TCGS cohort described
here comprises 17,186 (86.3%) of the 19,905 TLGS parti-
cipants who provided a baseline blood sample that was
adequate for plasma and deoxyribonucleic acid analysis.
This study is comprised of 849 individuals and 3109
families with at least one member having genotype infor-
mation. Finally, 5977 males and 7422 females with the total
genotyping rate of 0.9854 were genotyped with
HumanOmniExpress-24-v1-0 bead chips (containing
649,932 single-nucleotide polymorphism loci with an
average mean distance of 4 kilobases). Conclusions:
Investigations conducted within the TCGS will seek to
identify relevant patterns of genetic polymorphisms that
could be related to cardiometabolic risk factors in partici-
pants from Tehran. By linking genome-wide data to the
existing databank of TLGS participants, which includes
comprehensive behavioral, biochemical, and clinical data
on each participant since cohort inception in 1999, the
TCGS will also allow exploration of gene-gene and gene-
environment interactions as they relate to disease status.
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Next generation sequencing in the diagnosis of inherited
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Zanussi1, P. Pucci3, G. Pipitone1, C. Pappone4, S. Sala5,
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Introduction: Inherited cardiac disorders are characterized
by complex genotype and phenotype picture, with many
genes overlapping arrhythmogenic and structural diseases.
The use of next-generation sequencing (NGS) allows to
perform fast sequencing of wide regions. We evaluated and
integrated a NGS panel and set up bioinformatic pipelines
for diagnostic application. Materials and Methods: NGS
analysis of genomic DNA was performed using Illumina
Trusight Cardio, allowing analysis of 174 genes involved in
several cardiac disorders on MiSeq platform. Moreover we
developed a protocol for the enrichment of SCN10A gene,
which has been recently associated to Brugada syndrome
(BrS) and not present in the panel. Results: To validate this
NGS approach we performed two runs including 18 patients
with known genotype. NGS yielded a coverage >20X in
99.4% targeted regions, with 100% sensitivity and ≥94%
speciﬁcity. We then performed analysis of 95 patients with
different cardiac phenotypes. The higher diagnostic yield
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was observed for cardiomyopathies and catecholaminergic
ventricular tachycardia (80–100%), while for BrS and long
QT syndrome we detected a variant in 33–52% patients,
reﬂecting limitations in clinical deﬁnition. 64% identiﬁed
variants were classiﬁed as of unknown signiﬁcance,
requiring further investigation to assign a pathogenetic role.
In addition, 15% patients carried multiple variants, sug-
gesting a more complex inheritance. Conclusions: These
results underline potential and limits of NGS for hetero-
geneous conditions: NGS allows fast and efﬁcient variant
detection to ameliorate clinical management and family
counseling, however it highlights the need of precise clin-
ical deﬁnition and better strategies for the determination of
variant pathogenetic role.
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NGS as a useful strategy in the molecular diagnosis of
heterogeneous cardiomyopathies: a 327 case review
E. Mesa-Rísquez, Medical Genetics Unit, R. Pérez-De la
Fuente, Medical Genetics Unit, D. Cantalapiedra, Medical
Genetics Unit, G. Hernández-Poveda, Medical Genetics
Unit, A. Andújar, Medical Genetics Unit, D. Diego-
Álvarez, Medical Genetics Unit, M. Roca-Cervera,
Medical Genetics Unit, S. Lois, Bioinformatics
Department, G. Legarda, Bioinformatics Department, Á.
Arilla, New Technologies Lab, C. Torres, New
Technologies Lab, L. Cano, Medical Genetics Unit, A.
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Cardiomyopathy represents a heterogeneous group of dis-
orders in which myocardium is structurally and functionally
abnormal. The existence of overlapping signs between
cardiomyopathies requires the simultaneous study of all
known genes currently associated with the disease.
The objectives of this study were: 1. Establishing a
molecular characterization of the studied patients. 2.
Developing a diagnostic algorithm that could improve the
management of these patients.
327 cases were included. Samples were analyzed by
NGS targeted resequencing of a 238-gene panel, using
SureSelect (Agilent) and the HiSeq platform (Illumina).
Bioinformatic analysis was carried out using a state-of-the-
art in-house annotation pipeline.
88 patients of cardiomyopathy were genetically diag-
nosed (27%) (Table 1), whereas the genetic cause of the
pathology was not found in 190 patients who only were
carriers of VUS (58%). On the other hand, 49 patients did
not present any variant (15%).
A rate of 27% positive genetic diagnoses highlights the
effectiveness of NGS for the genetic diagnosis of cardio-
myopathy. Extending the genetic analysis to additional
disease-related genes or genes included in the differential
diagnosis could help to increase this rate and contribute to
patient’s clinical diagnosis disambiguation. Cosegregation
and functional studies could help to re-classify VUS,
achieving a higher diagnostic rate.
Table1. Results from genetic diagnoses, classiﬁed
according to the type of cardiomyopathy (n= 327)
Clinical suspicion Patients
diagnosed
Detected
variant effect
n % NS MS FS SP
Familial cardiomyopathy
(n= 12)
1 8.3% – 1 – –
Hypertrophic
cardiomyopathy
(n= 219)
61 27.9% 4 40 8 12
Dilated cardiomyopathy
(n= 39)
14 35.9% 2 6 4 2
Restrictive cardiomyopathy
(n= 6)
2 33.3% – 1 1 –
Arrhythmogenic right
ventricular dysplasia
(n= 32)
6 18.8% 1 2 2 1
Left ventricular
non-compaction
(n= 18)
4 22.2% – 2 1 1
NS: Nonsense. MS: Missense. FS: Frameshift. SP:
splicing
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cing in clinical genetic diagnostics of cardiomyopathies
Y. J. Vos, P. A. van der Zwaag, L. G. Boven, R. C.
Niessen, Y. M. Hoedemaekers, B. Sikkema-Raddatz, R. J.
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Next generation sequencing (NGS) is successfully applied
to ﬁnd causal mutations and thus conﬁrm the clinical
diagnosis in patients suspected of hereditary cardiomyo-
pathies. In 2012 NGS was introduced in our genome
diagnostics laboratory using an enrichment kit targeting 55
genes associated with cardiomyopathies. We analysed DNA
of 1126 patients with different cardiomyopathy subtypes.
Classiﬁcation of mutations was based on the ACMG
guidelines. Additional haplotype and co-segregation ana-
lyses were performed to further support pathogenicity of
potentially causal mutations. In 23% of the patients the
clinical phenotype was (likely) explained by either a
pathogenic or a likely pathogenic mutation, viz. in 14,4%
(162/1126) of the patients a pathogenic mutation was
identiﬁed, and in 9% (101/1126) one or more likely
pathogenic mutations were identiﬁed. In addition, 52% of
the patients carried at least one variant of unknown clinical
signiﬁcance (VUS), including patients who also carried a
(likely) pathogenic mutation. The identiﬁed likely patho-
genic and pathogenic mutations were found in half of the
genes targeted with our NGS analysis. Yield in the different
cardiomyopathy subtypes varied from 12% in patients with
noncompaction cardiomyopathy to 23% in those with
dilated cardiomyopathy. The contribution of VUSs to the
clinical phenotype remains to be elucidated. To characterize
these variants, data mining and sharing and further genetic
and functional studies are implemented. In conclusion, NGS
provides a genetic diagnosis in a signiﬁcant proportion of
cardiomyopathy cases and additional analyses are needed to
further classify variants of unknown signiﬁcance.
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yield in our 10 years of experience in genetic testing for
cardiomyopathies; data sharing, titin (TTN) mutations
and stricter clinical inclusion criteria
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K. Caliskan2, M. Michels2, A. F. L. Schinkel2, M. W.
Wessels1, D. F. Majoor-Krakauer1, W. F. J. van IJcken3,
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Introduction: Inherited cardiomyopathies are deﬁned by
structural and functional abnormalities of the myocardium,
characterized by extreme genetic and clinical heterogeneity.
In the Erasmus Medical Center genetic testing is offered to
patients with hypertrophic cardiomyopathy (HCM), dilated
cardiomyopathy (DCM) and noncompaction cardiomyo-
pathy (NCCM). Materials and Methods: From 2006 till
2012 we performed Sanger sequencing of eight sarcomere
genes. In the past four years, we applied a targeted next
generation sequencing (NGS) 52 gene panel approach for
~900 patients. For the targeted approach we included the
Titin gene (TTN), encoding the largest known human pro-
tein that plays a central role in sarcomere organization. We
evaluated the diagnostic yield by comparing NGS gene
panels with Sanger sequencing. Results: Sanger sequencing
of eight genes resulted in a pathogenic mutation in 40% of
the HCM patients. Using NGS, the majority of mutations in
HCM were detected in genes, previously tested with Sanger
sequencing. The increase in diagnostic yield from 40% to
50% is mainly achieved by data sharing and by re-
evaluating patients with stricter clinical inclusion criteria.
NGS in DCM and NCCM patients led to a doubling of the
diagnostic yield, from 15% to 30%, mainly explained by
truncating mutations in TTN in exons 259–359, encoding
the A-band of Titin. Conclusions: Targeted NGS has pro-
ven most beneﬁcial for NCCM and DCM patients, resulting
in doubling the diagnostic yield. The increased yield for
HCM patients was mainly achieved by stricter clinical
inclusion criteria together with data sharing, resulting in
reclassiﬁcation of many missense variants.
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Cardiac and genetic features of noncompaction cardio-
myopathy and it’s relation to late outcome: A Dutch
multicenter study of 327 pediatric and adult patients
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du Marchie Sarvaas2, A. P. C. M. Backx3, L. A. Verlooij2,
J. P. van Melle2, M. P. M. Linschoten4, H. Breur4, S. M.
Boekholdt3, L. F. Asselbergs4, R. H. Lekanne dit Deprez3,
J. D. H. Jongbloed2, M. A. van Slegtenhorst1, D. F.
Majoor-Krakauer1
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Noncompaction cardiomyopathy (NCCM) with excessive
trabecularisation of the left ventricle presents as asympto-
matic, with dyspnea, arrhythmias, or sudden death. This
large multicenter study outlined the genetics and cardiac
features of NCCM in adults and children.
Genetic examination allowed to classify 327 Dutch
NCCM patients as 1) genetic, with a mutation in a cardio-
myopathy gene (n= 111, 21 children), 2) probably genetic,
familial cardiomyopathy without a mutation (n= 50, 8
children) and 3) sporadic, without a family history or
mutation (n= 165, 22 children), and record clinical features
and adverse events (i.e. death, heart transplant) in these
groups. Most patients were diagnosed after age 40 years.
The older patients were more likely to be sporadic and
hypertensive. In 35% NCCM was genetic, with 68%
involving MYH7, MYBPC3 or - only in adults- TTN. In
children MYBPC3 defects occurred only as complex geno-
types. Children with sporadic NCCM had better outcome
than the (probably) genetic children. In adults the severity
of NCCM was not linked to genetic status. A reduced LV-
EF was associated with poor outcome in children and adults
(p= 0,033). Genetic adults had more frequently a reduced
right ventricular function. Four patients with a MYH7
mutation had Ebstein’s anomaly. Structural heart defects
were not associated with adverse events.
Mutations in MYH7, MYBPC3 and TTN were the most
common causes for NCCM. Children had more complex
genotypes associated with adverse events. Genetic status
did not affect outcome in adults. Reduced left ventricular
function was the most important predictor for adverse
events in all patients.
J.I. van Waning: None. K. Caliskan: None. Y.M.
Hoedemakers: None. K.Y. van Spaendonck: None. A.F.
Baas: None. M. Dalinghaus: None. G.J. du Marchie
Sarvaas: None. A.P.C.M. Backx: None. L.A. Verlooij:
None. J.P. van Melle: None. M.P.M. Linschoten: None.
H. Breur: None. S.M. Boekholdt: None. L.F. Asselbergs:
None. R.H. Lekanne dit Deprez: None. J.D.H. Jong-
bloed: None.M.A. van Slegtenhorst: None. D.F. Majoor-
Krakauer: None.
P05.19C
Cardiologic family screening for noncompaction cardi-
omyopathy shows variable phenotypes within and
between families
J. I. van Waning, K. Caliskan, M. Michels, A. F. L.
Schinkel, M. A. van Slegtenhorst, R. M. W. Hofstra, D. F.
Majoor-Krakauer
rasmus MC, Rotterdam, Netherlands
Introduction: In 50% of noncompaction cardiomyopathy
(NCCM) there is a genetic cause of familial cardiomyo-
pathy and/or a mutation in a cardiomyopathy gene. We
investigate in a cohort of familial NCCM patients. Pheno-
typical expression of NCCM, or dilated- (DCM) and/or
hypertrophic cardiomyopathy (HCM) in relation to the
genotype. Methods and results: In 61(44%) families 108
relatives with a cardiomyopathy were identiﬁed by cardio-
logic family screening of 152 NCCM index cases; 72
relatives had NCCM, 6 overlapping features of NCCM/
DCM, 17 DCM and 13 HCM. Of the 61 NCCM index
patients 12(20%) also met the diagnostic criteria for DCM.
NGS analysis of cardiomyopathy panel showed mutations
in 42(69%) families. In 23 families (38%) with NCCM
cases without features of DCM or HCM was found, with 15
(65%) mutations including 7 novel mutations, 5 reported
previously in NCCM, 2 reported in DCM, and 1 in NCCM/
DCM. DCM occurred in 30(49%) families of NCCM
patients with 22 mutations: 10 were novel. 4 mutations were
previously associated with in NCCM (18%), 3 with DCM, 5
with DCM/NCCM, In 5 (8%) families, family members
were meeting the diagnostic criteria for HCM, 3 had a
MYBPC3 (2 Dutch HCM founder) mutation. In addition, 2
index cases with NCCM/DCM and relatives with HCM had
MYBPC3 mutations previously linked to HCM. Conclu-
sion: In familial NCCM 45% of the speciﬁc mutations are
novel, 24% speciﬁc for NCCM and an additional 19%
speciﬁc for NCCM with overlapping features of DCM,
suggesting NCCM involves distinct mutations in genes
associated with HCM and DCM.
J.I. van Waning: None. K. Caliskan: None. M.
Michels: None. A.F.L. Schinkel: None. M.A. van Sleg-
tenhorst: None. R.M.W. Hofstra: None. D.F. Majoor-
Krakauer: None.
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P05.20D
A diagnostic odyssey in paediatric dilated cardiomyo-
pathy: WES yields a diagnosis in more than one-third of
patients
J. C. Herkert1, K. Abbott1, M. T. Meems-Veldhuis1, M.
Benjamins1, G. J. du Marchie Sarvaas1, D. Q. C. M.
Barge-Schaapveld2, P. A. van der Zwaag1, Y. J. Vos1, R.
Sinke1, M. P. van den Berg1, I. M. van Langen1, J. D. H.
Jongbloed1
1University Medical Centre Groningen, Groningen, Nether-
lands, 2Leiden University Medical Centre, Leiden,
Netherlands
Introduction: Although NGS-panels targeting dilated car-
diomyopathy (DCM) are quite large (>45 genes), they do
not include genes associated with common neuromuscular,
syndromic, and metabolic causes of paediatric DCM.
Therefore, combined whole exome sequencing (WES) and
SNP-array analysis seems the preferred diagnostic
approach. However, its yield in paediatric DCM has not
been determined.
Materials and methods: We identiﬁed a cohort of 50
patients with onset of DCM <18 years. After excluding 17
patients with a genetic diagnosis that explained their phe-
notype and young age of onset, we performed SNP-array
and trio-WES in 29 probands and four affected siblings. We
used an HPO-based ﬁlter strategy for data analysis. All
patients were carefully phenotyped for extra-cardiac
manifestations.
Results: A genetic diagnosis was made in ten families
(13/33 patients; 39%). Likely pathogenic or pathogenic
heterozygous mutations were identiﬁed in TNNT2, SCN5A,
TTN, MYH7 (6), TPM1, as well as homozygous mutations
in GLB1 (GM1-gangliosidosis) and SPEG (centronuclear
myopathy), and an 1p36.33p36.32 deletion. One child with
syndromic DCM had compound heterozygous mutations in
CEP135 (primary microcephaly). Five patients carried
autosomal recessive disease mutations that did not explain
their phenotypes.
Conclusion: WES and SNP-array yielded diagnoses for
39% of our cohort, with most causal variants located in
well-known cardiomyopathy genes. Variant ﬁltering using
additional HPO-terms in syndromic cases led to one addi-
tional diagnosis, but also to more VUS and incidental
ﬁndings. Our study indicates that analysing a limited
selection of well-known cardiomyopathy genes should be
the preferred ﬁrst diagnostic step during WES of isolated
paediatric cardiomyopathy cases.
J.C. Herkert: None. K. Abbott: None. M.T. Meems-
Veldhuis: None. M. Benjamins: None. G.J. du Marchie
Sarvaas: None. D.Q.C.M. Barge-Schaapveld: None. P.A.
van der Zwaag: None. Y.J. Vos: None. R. Sinke: None.
M.P. van den Berg: None. I.M. van Langen: None. J.D.
H. Jongbloed: None.
P05.21A
High risk variants for cardiovascular diseases in popu-
lation: analysis of Slovenian genomic database
K. Hočevar, A. Maver, A. Hodič, L. Vidmar, B. Peterlin
linical Institute of Medical Genetics, University Medical
Centre Ljubljana, Ljubljana, Slovenia
Introduction: Cardiovascular diseases are one of the lar-
gest public health problems worldwide. Analysis of popu-
lation genomic data can reveal a mutation burden in
cardiovascular diseases and consequently reveal the poten-
tial of genome analysis for precision medicine. The aim of
the present study was to estimate the burden of rare
pathogenic variants in cardiovascular genes in Slovenian
population.
Materials and Methods: We designed a custom list of
136 genes associated with cardiovascular conditions,
including cardiomyopathies, arrhythmias and vasculo-
pathies. Exome sequencing data from 1324 individuals
collected in our institution was de-identiﬁed and aggregate
frequencies of variants in these genes were analysed. We
divided variants into two main categories: (1) known
pathogenic variants (2) rare variants with predicted patho-
logic effects.
Results: Altogether, we detected 47.831 rare variants in
136 cardiac disease-associated genes. Among these, 16
were known pathogenic dominant variants. The prevalence
of known pathogenic variants in our patients was thus
estimated at about 1.2%. We found out that additional
0.98% of patients harbor dominant variants with ClinVar
conﬂicting interpretations of pathogenicity (13 additional
variants). In addition, we identiﬁed 66 (5.0%) rare variants
with theoretically predicted pathogenic effect (6 truncating
and 60 novel predicted pathogenic missense variants).
Conclusion: In the present study, we estimated the bur-
den of known cardiovascular disease associated pathogenic
variants in the general population. Furthermore, we identi-
ﬁed a considerable proportion of novel variants with pre-
dicted pathologic effect, opening further challenges and
opportunities for exploration and individualized prediction
of risk of cardiovascular diseases.
K. Hočevar: None. A. Maver: None. A. Hodič: None.
L. Vidmar: None. B. Peterlin: None.
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P05.22B
Detailed investigation of congenital heart diseases fre-
quency and types with clinical and genetic data in chil-
dren with dysmorphology
M. Elmas1, A. Pektaş2, Z. Söylemez1, M. Solak1
1Afyon Kocatepe University, Medical Faculty, Medical
Genetic department, Afyonkarahisar, Turkey, 2Afyon Koca-
tepe University, Medical Faculty, Pediatric Cardiology
Department, Afyon, Turkey
468 pediatric patients who applied or consulted to the
dysmorphology policlinic were investigated(0–18 years old,
224 girls and 244 boys).Pedigree analyzes of all of the
patients were performed and kinship associations were
identiﬁed.Cardiologic evaluations and echocardiography of
all patients were performed by pediatric cardiologists All
patients had a standard anamnesis form and hospital records
were scanned. Patients were ﬁrst investigated whether there
was any complication detected during the prenatal period
(oligo/polyhydramnios,preeclampsia…etc).Natal period
investigated birth week, type of delivery, birth weight and
birth length. APGAR scores, presence of perinatal asphyxia
were questioned in the postnatal period. In addition, the
stages of motor development, social development and lan-
guage development of the patients were evaluated. Patients
were questioned about the presence of a surgical operation,
seizure, chronic illness.Paternal kinship cases were searched
for family histories. Because consanguineous marriage is
high rate in our region. Autosomal recessive syndromes are
therefore more common. In addition, the presence of indi-
viduals with other congenital heart disease in the family was
questioned. Standard karyotype analyzes of the patients
were performed. We have done FISH and molecular
genetics studies to prove the syndromes that accompany
congenital heart disease to the extent that our center has
possibilities. The resulting data were analyzed statistically
in the SPSS program.As a result, factors such as gender,
intrauterine growth retardation, low APGAR score, low
birth weight, motor, social, language developmental delay,
past surgical operation story, seizure story, chronic disease
story were found to be related to congenital heart disease in
dysmorphology patients.
M. Elmas: None. A. Pektaş: None. Z. Söylemez: None.
M. Solak: None.
P05.23C
Characterisation of the CYP11B2 intron 2 conversion
using MinION Oxford Nanopore sequencing device
C. Maroteau, R. Tavendale, J. M. C. Connell, C. N. A.
Palmer
niversity of Dundee, Dundee, United Kingdom
Introduction: Polymorphisms affecting the synthesis of
aldosterone or its regulation may have effects on blood
pressure. An intron conversion replacing a section of
CYP11B2 intron 2 with the corresponding region of the
94% identical CYP11B1 has been linked to hypertension
risk. However, that polymorphism had never been described
precisely yet. In 2014, Oxford Nanopore released a 3rd
generation sequencer the MinION® device, well suited for
sequencing of complex genomes with large repetitive ele-
ments or high similarities. The aim of this study was to use
this new technology to characterise precisely the conver-
sion. Materials and Methods: Forward and reverse primers
were speciﬁcally designed to amplify CYP11B2 intron 2
region. Amplicons of 100 “wild-type” (WT) and 100 indi-
viduals carrying the intron conversion (CONV) from the
Medical Research Council (MRC) British Genetics of
HyperTension (BRIGHT) Study (http://www.brightstudy.
ac.uk) were sequenced and processed through an in-house
pipeline. Results: With a mean coverage of 460x per
individual we assembled a CONV consensus sequence of
5.5kb that presents 85% identity with CYP11B2 gene
sequence (GenBank: D13752.1). 95% and 97% identity
were found between CONV consensus and respectively
CYP11B1 and CYP11B2 intron 2 sequences. We deﬁned
274bp of CYP11B2 intron 2 (from 7,052bp to 7,326bp)
replaced by 264bp of CYP11B1 corresponding sequence
(from 7,062bp to 7,326bp, GenBank: AH002666.2). Con-
clusion: This study presents a precise characterisation of the
CYP11B2 intron 2 conversion that will lead to the assig-
nation of a tagger SNP and encourages further investigation
of that polymorphism into its role in the physiology of
hypertension.
C. Maroteau: None. R. Tavendale: None. J.M.C.
Connell: None. C.N.A. Palmer: None.
P05.24D
Functional analysis of nexilin in hiPSC-derived
cardiomyocytes
B. Schmidt1, A. Trillhaase1, S. Stölting1, M. Trilck2, J.
Erdmann1, Z. Aherrahrou1
1Institute for Cardiogenetics, Lübeck, Germany, 2Institute
of Neurogenetics, Lübeck, Germany
The protein Nexilin was identiﬁed to be a structural protein
in the Z-disk in the sarcomere of cardiomyocytes. It is
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known to play an important role in sarcomere integrity as it
was shown that loss of Nexilin leads to blurry Z-disks in
zebraﬁsh. Mutations in Nexilin were found to lead to dilated
cardiomyopathy (DCM) in humans, zebraﬁsh and mice. The
underlying pathomechanisms are still unkown. The main
aim of this study is to generate hiPSCs lacking Nexilin and
functionally characterize derived cardiomyocytes to get a
better understanding of the molecular mechanisms leading
to DCM in humans.
In a ﬁrst step of the project we aimed to establish the
protocol of differentiation and characterize cardiomyocytes
derived from human iPSCs. Therefore, modulation of
canonical Wnt signaling is performed, leading to efﬁcient
differentiation of hiPSC to cardiomyocytes. Characteriza-
tion of cells was performed before differentiation at RNA
level using the markers Oct4, Klf4 and Nanog to show
pluripotency of hiPSCs. After differentiation, characteriza-
tion is performed using heart speciﬁc expression markers
such as MYL2, Troponin T, Desmin, GATA4 and HCN4 at
RNA level.
The next step was the generation of Nexilin knockout
iPSCs using the CRISPR/Cas system. The resulted cell lines
will then be differentiated into cardiomyocytes and the same
aforementioned markers will be used for detailed molecular
characterization of Nexn-KO iPSC-derived cardiomyocytes
and compared to controls. Additionally, phenotypic char-
acterization, sarcomere integrity and expression levels of
cardiac transcription factors such as Smad proteins and
Tbx5 will be analysed to understand the function of Nexilin.
B. Schmidt: None. A. Trillhaase: None. S. Stölting:
None. M. Trilck: None. J. Erdmann: None. Z. Aher-
rahrou: None.
P05.25A
Role of CD68 gene expression in atherosclerosis
A. R. Mukhametgalieva1, N. Davlyatshina2, S.
Mayanskaya2, E. Maykova1, O. Kravtsova1
Kazan (Volga Region) Federal University, Kazan, Russian
Federation, 2Kazan State Medical University, Kazan,
Russian Federation
Introduction: Oxidized LDL (oLDL) play a central role in
the progression of atherosclerosis due to their cytotoxic
effects in endothelial vessels. It is assumed that oLDL uti-
lization occurs through the entire group of scavenger
receptors (SR) located on monocytes/macrophages cells
membranes. It’s proposed that SR gene activity may serve
as a sensitive marker for excessive accumulation of foam
cells in the early stages of lipid spots, and as a result of an
atherosclerotic plaque. So, the aim of this study was to
determine the relative gene expression level of scavenger
receptor CD68 in atherosclerotic patients with varying
severity.
Materials and methods: Gene expression analysis was
carried out on venous blood samples from 48 patients with
conﬁrmed multifocal atherosclerosis (IPA), 46 patients with
acute coronary syndrome (ACS), 47 patients with risk fac-
tors (RF) for cardiovascular disease and 16 healthy donors.
The relative gene expression level (RQ) evaluated by the
2deltaCt method and Student t-test (p = 0.05).
Results: In our study patients with chronic IPA char-
acterized with non-signiﬁcantly mild RQ decreased in blood
and increased in carotid atherosclerotic plaques (0.84 and
1.04 respectively), however patients with ACS showed
almost signiﬁcantly 1.82-fold increased RQ (p=0.061). At
the same time, individuals with RF have showed sig-
niﬁcantly low RQ (0.15, p=0.050).
Conclusion: Our results suggest that increasing level of
CD68 in ACS is due to severe acute inﬂammation pro-
cesses, which are not so actual for IPA patients as well as
for FR individuals.
The study was supported by RFBR (project No. 16-34-
00737).
A.R. Mukhametgalieva: None. N. Davlyatshina:
None. S. Mayanskaya: None. E. Maykova: None. O.
Kravtsova: None.
P05.26B
Diagnostic yield of sequencing lipoprotein lipase genes
pathway in patients with severe hypercholesterolemia
N. Marziliano1, C. Reverberi2, S. Uras1, P. Merella1, P.
Berne1, G. Piras1, M. Monne1, R. Asproni1, A. Uras1, N.
Gaibazzi3, A. Fiscella4, D. Fiscella5, M. Gulizia5, G. Casu1
1ASL3 Nuoro-ATS Sardegna, NUORO, Italy, 2Centro
Clinico Gemini, PARMA, Italy, 3AO Universitaria di
Parma, PARMA, Italy, 4Fondazione Floresta Longo,
NUORO, Italy, 5AO Garibaldi, CATANIA, Italy
Background: Elevated concentrations of LDL cholesterol
and lipoproteins are correlated with risk for coronary artery
disease (CAD) and can be caused by a wide range of
genetic, lifestyle, and environmental factors. Gene sequen-
cing allows for the identiﬁcation of causative mutations in
Familial Hypercholesterolemia (FH) and lipoprotein lipase
genes, all belonging to the LPL pathway. Methods: We
sequenced the LDLR, PCSK9, APOB and LPL genes in 88
probands presenting with hypercholesterolemia (LDL cho-
lesterol ≥190 mg/dl), with previous CAD history (N= 67;
76.13%) or without (N= 21; 23.24%). By means of a
custom-based IonAmpliSeq panel, we meant to annotate
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rare (allele frequency <1%) damaging mutations included
loss of function (i.e., nonsense, canonical splice site, and
frameshift) and missense variants annotated as pathogenic
or predicted to be damaging by computer algorithms.
Findings: Across all participants, 41 damaging mutations in
the LDLR, PCSK9, APOB and LPL genes were identiﬁed in
40 probands (one was a carrier of a double heterozygosity).
Compared to non-carriers, heterozygous carriers displayed
higher LDL cholesterol (22% higher, 95%CI 11 - 23; p =
3 ×10−12) and plasma triglycerides (19% higher, 95%CI 12
- 25; p = 3 ×10−12) as well as increased risk for CAD (Odds
Ratio 2.84; 95%CI 1.35 - 2.51; p = 0.0001). Beyond rare
mutations, FH mutation carriers had higher cumulative
exposure to LDL cholesterol than noncarriers. Interpreta-
tion: In our series, about 46.6% carry a damaging mutation
in the LPL pathway genes that are associated with higher
plasma triglycerides as well as increased risk for CAD.
N. Marziliano: None. C. Reverberi: None. S. Uras:
None. P. Merella: None. P. Berne: None. G. Piras: None.
M. Monne: None. R. Asproni: None. A. Uras: None. N.
Gaibazzi: None. A. Fiscella: None. D. Fiscella: None. M.
Gulizia: None. G. Casu: None.
P05.27C
Proactive Identiﬁcation and Genetic Testing for Familial
Hypercholesterolaemia (FH) in Primary Care: Experi-
ences of Patients and General Practitioners
J. A. Tranter, N. Qureshi, J. Kai
niversity of Nottingham, Nottingham, United Kingdom
Introduction
Familial hypercholesterolaemia (FH) is a common
autosomal dominant disorder characterised by elevated
cholesterol. However, around 80% of affected individuals
remain undiagnosed. This study explored the experiences of
GPs and patients participating in an intervention to identify
and test individuals at high risk of FH in primary care.
Methods and materials
Semi-structured audiotaped qualitative interviews with
patients and GPs from six UK family practices. They had
participated in an intervention involving case ﬁnding and
assessment of those at high risk of FH in primary care
(database search of GP records for patients with cholesterol
>7.5mmol/L, with computerised reminders to GPs and
mailed invitation to patients). Experiences of, and attitudes
towards this approach to identiﬁcation, assessment and use
of genetic testing for FH were explored, with descriptive
thematic analysis of data.
Results
A sample of 23 (21.85%) of 95 patients assessed, and all
14 GPs (100%) participated. Patients and practitioners were
generally receptive to proactive identiﬁcation of risk of FH
in primary care, experiencing the approaches used as
acceptable and feasible. Challenges identiﬁed included:
enhancing communication and information for patients; and
accurate family history assessment and decision making on
specialist referral for GPs. Both patients and practitioners
accommodated genetic testing for FH in the general practice
setting without signiﬁcant problems, but shared concerns
about time for effective communication and appropriate
skills for interpretation of test results.
Conclusion
This study suggests the feasibility and acceptability of
proactive identiﬁcation of risk of FH, including genetic
testing, in primary care.
Grant reference: Project 266
J.A. Tranter: None. N. Qureshi: None. J. Kai: None.
P05.28D
Familial Ebstein’s anomaly: whole exome sequencing
identiﬁes novel phenotype associated with FLNA
C. L. Mercer1, G. Andreoeltti2, A. Carroll3, A. P. Salmon3,
I. K. Temple2, S. Ennis2
1Wessex Clinical Genetics Service, University Hospital
Southampton NHS Foundation Trust, Southampton, UK,
Southampton, United Kingdom, 2Human Genetics &
Genomic Medicine, Faculty of Medicine, University of
Southampton, UK, Southampton, United Kingdom, 3Wessex
Cardiac Unit, University Hospital Southampton NHS
Foundation Trust, Southampton, UK, Southampton, United
Kingdom
Mutations in Filamin A are associated with a diverse range
of phenotypes with loss of function mutations typically
causing periventricular nodular heterotopia and missense
mutations associated with a range of skeletal abnormalities
including Fronto-Metaphyseal Dysplasia (FMD), Otopala-
todigital (OPD) and Melnick Needles Syndromes (MNS).
Congenital heart defects have been reported in patients with
skeletal phenotypes but diagnostically bony abnormalities
have been the most striking feature of these conditions. We
report a family in which 7 individuals over 2 generations
had Ebstein’s anomaly of the heart. Presentation in the 3
males in the family was with heart failure in the neonatal
period, which was in one case fatal. The 4 females were all
diagnosed with milder Ebstein’s anomaly, requiring surgery
in 1 case. Affected individuals had camptodactyly, reduced
elbow extension and keloid scarring; males also described
their joints as stiff and had more marked skeletal ﬁndings. A
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molecular genetic diagnosis was made using DNA from two
ﬁrst cousins and whole exome sequencing. Affected family
members were found to share a novel nonsynonymous G>A
highly conserved (Phylop 0.998857) and deleterious (Gerp
5.23) variant in Filamin A on the X chromosome, leading to
the substitution of glycine to arginine at position 1554. The
mutation lies in the 14th ﬁlamin repeat region, mutations in
which have been associated with OPD, FMD and MNS but
not Ebstein’s anomaly. The report of this family both sig-
niﬁcantly extends the phenotype of Filamin A and identiﬁes
this gene as important in the development of right sided
congenital heart disease.
C.L. Mercer: None. G. Andreoeltti: None. A. Carroll:
None. A.P. Salmon: None. I.K. Temple: None. S. Ennis:
None.
P05.29A
A new case of Generalized Arterial Calciﬁcation of
Infancy with compound heterozygous mutations in the
ATP-binding cassette, subfamily C, member 6 gene
R. Celeghin1, K. Ludwig1, E. Lazzarini1, M. Cason1, S.
Rizzo1, P. Balli2, G. Thiene1, C. Basso1, K. Pilichou1
Department of Cardiac, Thoracic and Vascular Sciences,
University of Padua, Padova, Italy, 2--, Rimini, Italy
Introduction: Generalized Arterial Calciﬁcation of Infancy
(GACI) is a rare autosomal-recessive disorder characterized
by calciﬁcation of the internal elastic lamina, ﬁbrotic
myointimal proliferation and subsequent stenosis of large
and medium size arteries. Biallelic inactivating mutations in
ENPP1 have been identiﬁed in most cases, while mutations
in ABCC6 have been identiﬁed in 10% of GACI cases only.
Methods: The 6-years-old proband died suddenly at school.
Past medical history revealed recurrent intestinal angina and
retrosternal pain with normal electrocardiography and
echocardiogram ﬁndings at 2 and 3 years of age. A chronic
ischemic heart disease with post myocardial infarction
aneurysm, associated with widespread arterial calciﬁcation
was identiﬁed at autopsy, leading to the diagnosis of GACI.
Polymerase-chain-reaction products of ENPP1
(NM.006208.2) and ABCC6 (NM.001171.5) were directly
sequenced bidirectionally on a ABI 3500Dx platform and
analysed with LaserGene SeqMan. Results: No mutations
were identiﬁed in ENPP1. Analysis of the ABCC6 gene
identiﬁed two rare variants, both deﬁned as “pathogenic” by
in silico tools: a c.2018 T>C (Leu673Pro) in exon 16,
previously associated with Pseudoxanthoma Elasticum
(PXE), and a c.3836 C>T (Pro1279Leu) in exon 27 (both
inherited from the parents). Conclusions: It is currently a
matter of intense debate whether genetic and phenotypic
overlap between GACI and PXE might reﬂect two ends of
the clinical spectrum of ectopic calciﬁcation rather than two
distinct disorders. Intriguingly, our patient, who had been
symptomatic throughout his whole life, died at the age of 6
years, while affected GACI individuals usually die within
the ﬁrst 6 months of life.
R. Celeghin: None. K. Ludwig: None. E. Lazzarini:
None.M. Cason: None. S. Rizzo: None. P. Balli: None. G.
Thiene: None. C. Basso: None. K. Pilichou: None.
P05.30B
Compound heterozygous GATA5 mutations in a girl
with hydrops fetalis, congenital heart defects and genital
anomalies
M. Hempel1, T. Casar Tena2, T. Diehl1, M. S. Burczyk2, T.
M. Strom3,4, C. Kubisch1, M. Philipp2, D. Lessel1
1University Medical Center Hamburg-Eppendorf, Ham-
burg, Germany, 2Ulm University, Ulm, Germany, 3Helm-
holtz Center Munich, Neuherberg, Germany, 4Technical
University Munich, Munich, Germany
GATA5 belongs to the GATA family of transcription fac-
tors characterized by highly evolutionary conserved zinc-
ﬁnger DNA-binding domains. Mouse models have impli-
cated a role of GATA5 during mammalian embryogenesis,
including proper heart development and gender-speciﬁc
regulation of female genitourinary tract formation. Candi-
date gene studies have associated GATA5 heterozygous
missense alterations with a broad variety of heart diseases.
However, these studies did not include parental testing and
none of these alterations were scrutinized in an in vivo
model. Thus, the clinical relevance of the identiﬁed het-
erozygous alterations remains unclear. Recently, a ﬁrst male
patient bearing biallelic mutations in GATA5 and complex
congenital heart defects (CHD) was described. Here we
report on a girl affected by hydrops fetalis, CHDs, clitor-
omegaly and postnatally increased 17-hydroxyprogesterone
levels. Trio whole-exome sequencing identiﬁed compound
heterozygous missense mutations in GATA5, p.Ser19Trp
and p.Arg202Gln, as the only putative disease-causing
alterations. Notably, extensive clinical follow-up of both
parents and her twin-sister, all heterozygous for a GATA5
mutation, was unremarkable. Extensive functional analyses
revealed that the identiﬁed GATA5 mutations fail to rescue
the cardia biﬁda phenotype in a zebraﬁsh model, mis-
localize to subnuclear foci when transiently transfected in
HEK293 cells and possess less transcriptional activity. In
summary, our ﬁndings show that biallelic GATA5 mutations
are highly penetrant. In addition to heart diseases they can
result in congenital abnormalities of the female
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genitourinary tract, highlighting the gender-speciﬁc effect
of GATA5 in humans. Furthermore, our data suggest low-
penetrance of the heterozygous alterations previously
associated with various heart diseases.
T. Casar Tena: None. T. Diehl: None. M.S. Burczyk:
None. T.M. Strom: None. C. Kubisch: None. M. Philipp:
None. D. Lessel: None.
P05.31C
Genomic variation associated with mortality in Eur-
opean ancestry among individuals with heart failure in
Brazilian population
M. M. S. G. Cardena1, H. C. Santos2, A. R. Horimoto2, A.
J. Mansur2, A. C. Pereira2, M. H. Gouveia3, T. P. Leal3,
M. O. Scliar3, E. M. Tarazona3, C. Fridman1
Departamento de Medicina Legal, Ética Médica e Medicina
Social e do Trabalho, Faculdade de Medicina da
Universidade de São Paulo, São Paulo, Brazil, 2Departa-
mento de Cardiologia, Laboratório de Genética e Cardi-
ologia Molecular, Instituto do Coração, Faculdade de
Medicina da Universidade de São Paulo, São Paulo, Brazil,
3Instituto de Ciências Biológicas, Universidade Federal de
Minas Gerais, Belo Horizonte, Brazil
Introduction: Heart failure (HF) is a relatively common
chronic condition characterized by the inability of the heart
to efﬁciently pump blood. The survival causes signiﬁcant
concern, because after HF is diagnosed, 20% of patients die
within one year. To screen for genetic variants modulating
mortality in patients with HF in Brazilian population, we
used admixture mapping, a technique that scans the gen-
omes of recently admixed populations and searches for
genomic regions in individuals with disease where there is
substantial deviation in one of the parental ancestries
compared with the global genome average.
Materials and Methods: Genomic ancestry was esti-
mated using 182.090 SNPs, three continental reference
populations (European, African and Amerindian) and
PCAdmix software. For admixture analysis, the mortality
was adjusted for age, sex, hypertension and diabetes, using
multivariate linear regression analysis.
Results: Our study included 492 Brazilian patients with
HF. The estimated average of ancestry proportions observed
was 61.8±21.8% European, 24.9±22.3% African and 13.3
±10.6% Amerindian. We performed admixture mapping
and identiﬁed a locus on chromosome 6p22.3 in European
ancestry (P=6.8×10−5) associated with mortality in patients
with HF, where the guanosine monophosphate reductase
gene (GMPR) is mapped.
Conclusions: This study identiﬁed a locus associated
with mortality in European ancestry among individuals with
HF. The ﬁne mapping in this region may be possible to
uncover causative variants that contribute to mortality in
HF.
M.M.S.G. Cardena: B. Research Grant (principal
investigator, collaborator or consultant and pending grants
as well as grants already received); Modest; Fundação de
Amparo à Pesquisa do Estado de São Paulo - FAPESP
(2014/07348-5). C. Other Research Support (supplies,
equipment, receipt of drugs or other in-kind support);
Modest; HCFMUSP (LIM40), Departamento de Medicina
Legal, Ética Médica e Medicina Social e do Trabalho-
FMUSP. H.C. Santos: None. A.R. Horimoto: None. A.J.
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Elucidating the mutation spectrum underlying severe
hypercholesterolemia in Finland
N. Junna, E. Widén, I. Surakka, P. Ripatti, S. Ripatti
FIMM, Helsinki, Finland
Severe hypercholesterolemia is a major risk factor for cor-
onary artery disease (CAD). Patients suffering from familial
inherited forms of severe hypercholesterolemia have a 20-
fold increased CAD-risk. Although CAD may be prevented
by lowering cholesterol levels, less than 20 % of hyperch-
olesterolemia patients are identiﬁed or treated in Finland
and only half of the patients carry hypercholesterolemia-
associated mutations.
Our study aims to unravel the genetic architecture
underlying severe hypercholesterolemia in Finland by
studying individuals with high LDL-cholesterol (>5 mmol/
l) identiﬁed in our ongoing population study GeneRISK,
targeting 10,000 subjects aged 45–64. Hitherto 4,570 study
participants have been recruited. 4.6% had severe
hypercholesterolemia, of which only 3% received lipid-
lowering therapy. 88 cases have been screened for the 5
most common known familial hypercholesterolemia-
associated LDLR-mutations enriched in Finland. Surpris-
ingly, all subjects were mutation negative. Whole-exome
sequencing of 72 subjects didn’t reveal
hypercholesterolemia-causing mutations in the LDLR,
APOB or PCSK9 genes either. Nonetheless, six patients
carried rare potentially pathogenic missense variants in
putative candidate genes MYLIP and SORT1. Polygenic
modeling (genomic risk score (GRS) encompassing 106
SNPs explaining 17% of the LDL-cholesterol variation in
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the population) suggested clustering of polygenic risk in 15
(20,8%) of the sequenced patients (GRS within the top 10%
of population distribution).
In conclusion, hypercholesterolemia-treatment appears
gravely suboptimal and the contribution of known
hypercholesterolemia-mutations may be smaller than pre-
viously anticipated in Southern Finland. We intend to fur-
ther screen up to 200 hypercholesterolemia cases, and to use
in silico and in vitro methods to assess the function of
putative pathogenic variants.
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Multiple gene variants in hypertrophic cardiomyopathy
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Background: Multiple likely pathogenic/pathogenic (LP/P)
variants in hypertrophic cardiomyopathy (HCM) patients
were described 10years ago with a prevalence of 5% and
more severe phenotype suggested. Given increased gene
panel sizes and more stringent variant curation, we sought
to re-examine the signiﬁcance of multiple rare variants.
Methods: We used a retrospective cohort study design
including HCM probands from a specialised HCM centre
from 2002–2016. Research-based genetic testing was per-
formed including 45 cardiac genes. Results: 382 probands
met inclusion criteria. There were 224 (59%) probands with
at least one rare variant (allele frequency ≤0.02%). Variants
were analyzed using varying sized gene panels to represent
comprehensive or targeted testing. Based on a 45-gene
panel, 127 (33%) had a LP/P variant, 139 (36%) had var-
iants of uncertain signiﬁcance (VUS) and 66 (17%) pro-
bands had multiple rare variants. A targeted 8-gene panel
yielded 125 (32%) LP/P variants, 52 (14%) VUS and 14
(4%) probands had multiple rare variants. No proband had 2
LP/P classiﬁed variants. Including affected family members
(total n= 412), cluster-adjusted analyses showed younger
age (OR 0.95, 95%CI 0.92–0.98, p=0.004) and family
history of sudden death (OR 3.5, 95%CI 1.3–9.9, p=0.02)
to be signiﬁcantly more likely in multiple versus single
variant patients when considering an 8-gene panel, but not
larger panels. Those with multiple variants had worse event-
free survival from all cause death, cardiac transplantation
and cardiac arrest (log-rank p=0.008). Conclusions: Mul-
tiple LP/P variants are rare in HCM, but multiple uncertain
variants occur in 4% leading to earlier onset and increased
risk of events.
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Identiﬁcation of disease-causing genetic variants in a
representative cohort of Czech patients with early onset
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Introduction: Hypertrophic cardiomyopathy (HCM) is a
relatively common AD disorder with an estimated popula-
tion frequency of 0.2 %. Since HCM usually manifests later
in life, early-onset HCM is rare and could be caused by
pathogenic variants (PV) different from sarcomere genes.
The aim of our study was to test this hypothesis by iden-
tiﬁcation of PV in early-onset HCM in a representative
cohort of unrelated Czech cases.
Materials and Methods: Nineteen paediatric HCM cases
were subjected to NGS using a targeted panel comprising
174 cardiac conditions-related genes (TruSight Cardio
-Illumina on the MiSeq platform - Illumina). All variants
were validated by Sanger DNA sequencing and ACMG.net
variant classiﬁcation was used.
Results: Pathogenic / likely pathogenic variants were
identiﬁed in 14/19 (73.7 %) cases in MYH7 (7/19, 36.8%),
MYBPC3 (4/19, 21.1%), and CSRP3 (1/19, 5.2%) genes.
One patient is a double-heterozygote for MYBPC3 and
MYH7 (5.2%) PV, while one patient (5.2 %) carries a PV in
the PTPN11 gene.
Conclusions: In paediatric HCM the thick ﬁlament
genes MYBPC3 and MYH7 are most commonly affected,
similarly as in late-onset HCM. High mutation detection
rate corresponds probably to the severe phenotype and early
age of studied cases. We also conﬁrmed the diagnosis of
one patient with Noonan syndrome demonstrating the use-
fulness of broader panels in the diagnosis of cardiac dis-
orders which may be part of other genetic syndromes. The
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identiﬁcation of PV is important for stratiﬁed patient man-
agement and cardiologic follow-up of apparently healthy
PV-positive family members.
Supported by: 00064203, CZ.2.16/3.1.00/24022, 15-
34904A and NF-CZ11-PDP-3-003-2014.
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The variants spectrum and genotype-related histo-
pathological alterations in Chinese hypertrophic
obstructive cardiomyopathy patients
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Introduction: Patients with hypertrophic obstructive car-
diomyopathy (HOCM) have a higher risk of sudden death
than non-obstructive hypertrophic cardiomyopathy (HCM).
A large amount of variants, predominantly in sarcomeric
genes, have been identiﬁed.
Methods and results: A 93-cardiomyopathy-related panel
was used to screen 191 Chinese HOCM patients. The
overall diagnosis rate was 51.3%, including more patho-
genic variants in MYH7 (46.5%) than MYBPC3 (33.8%),
which was similar to previous studies in Chinese population
but distinctive from other ethnic studies around the world.
Using Jian’s method with dbscSNV database, 20 variants
were predicted to affect splicing, and primers were suc-
cessfully designed for 18 of them. With the extracted and
reverse-transcribed RNA from patients’ cardiac tissue, only
6 variants were conﬁrmed to actually cause aberrant RNA
splicing, including all 5 pathogenic MYBPC3 ones and
another likely benign synonymous variant in ANKRD1.
Moreover, histopathological examinations on septal tissues
with haematoxylin and eosin and Masson trichrome staining
revealed characteristic histopathological alterations in
HOCM patients with sarcomeric variants by vacuoles
degeneration, disorganization and whorling of muscle
bundles, irrespective of variants number.
Conclusion: The characteristic spectrum of more MYH7
than MYBPC3 variants was speciﬁc for Chinese HCM
population but not HOCM. Interpreting splice variants
based on in silico tools without validation should be
extremely cautious due to their unexpected low prediction
accuracy. The existence of sarcomeric variant was corre-
lated with distinctive histopathological alterations in
HOCM patients, indicating different pathogenic down-
stream pathways underlying genetic and non-genetic HCM.
This work was supported by Starting Fund for 1000
Youth Talents (No.2013-RSQ02).
Y. Ma: None. H. Cui: None. K. Yin: None. T. Li:
None. T. Li Sun: None. H. Yang: None. B. Han: None. X.
Liu: None. K. Zhao: None.W. Li: None. H. Wang: None.
S. Wang: None. Z. Zhou: None.
P05.36D
Mosaicism in inherited cardiac conditions detected by
targeted NGS analysis
L. Brett1, S. L. Wilkinson1, T. Monk2,1, M. Edwards1, F.
Honti1, T. Homfray3, J. Till3, L. Starling4,3, D. Morris-
Rosendahl5
1Clinical Genetics and Genomics Laboratory, Royal
Brompton and Hareﬁeld NHS Trust, London, United
Kingdom, 2Liverpool Women's NHS Foundation Trust,
Liverpool, United Kingdom, 3Royal Brompton and Hare-
ﬁeld NHS Trust, London, United Kingdom, 4Great Ormond
Street Hospital, London, United Kingdom, 5Clinical
Genetics and Genomics, Royal Brompton and Hareﬁeld
NHS Trust, London, United Kingdom
Molecular genetic analysis of over 500 consecutively
referred patients clinically diagnosed with various inherited
cardiac conditions was undertaken by next generation
sequencing (NGS) of a targeted gene panel comprising 170
genes associated with inherited cardiac conditions. We
detected four families in which either the index patient or a
parent was found to be mosaic for a pathogenic or likely
pathogenic variant.
A male patient, diagnosed with left ventricular hyper-
trophy and no family history, was found to be mosaic for
the pathogenic missense variant c.1387G>A (p.A463T) in
MYH7. Testing of both blood and saliva showed varying
levels of mosaicism. Following an incidental diagnosis of
dilated cardiomyopathy (DCM) in a 12-year old boy, who
was heterozygous for a pathogenic LMNA variant
(c.1622G>A, p.R541H), his father was found to be mosaic
for the same variant, with a much milder phenotype than his
son. Testing of the asymptomatic mothers of two different
patients with catecholaminergic polymorphic ventricular
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tachycardia (CPVT) and pathogenic missense variants in the
RYR2 gene (p.H2486P; p.V4190L), detected the variants as
low-level mosaics. Sanger sequencing failed to detect the
mosaicism.
Detection of mosaicism is important to provide accurate
counselling to families, especially around recurrence risk
for future pregnancies. The higher sensitivity of NGS for
detecting mosaicism is one of its many advantages over
Sanger sequencing as a ﬁrst line diagnostic test and will also
help to elucidate the potentially under-reported prevalence
of mosaicism in cardiac disease.
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Introduction. Left ventricular non-compaction cardio-
myopathy (LVNC) is characterized by two-layer myo-
cardium (compact and “spongy”) and affects mostly left
ventricular apex, lateral wall and ventricular septum.
Although mutations in more than 20 genes have been
detected in patients with LVNC, the effectiveness of the
DNA testing remains unclear and mutation spectrum is
unknown.
Materials and methods. We had observed 44 probands
diagnosed with LVNC. Mutational testing was performed
by NGS (Ion Torrent) sequencing of the panel containing 12
genes, followed by Sanger sequencing of detected variants.
PolyPhen2, SIFT, and MutationTaster were used for in
silico characterization of new missense variants.
Results. Fifteen pathogenic/probably pathogenic variants
were detected in 15 (34%) probands. Most of the variants
were found in the MYH7 and MYBPC3 genes (7 and 6,
respectively). In a single index case the heterozygous
deletion in the DES gene was detected. Mutation p.Q1233*
MYBPC3 was found in 4 probands. Three probands had
carried two genetic variants in different genes. Remarkable
that only 4 variants found in this study were previously
described as mutations. This makes the “signal:noise” (or
“mutation:VUCS”) ratio of 7:10.
Conclusion. Diagnostic yield of simultaneous analysis
of the 12 genes in patients with LVNC was 34%. According
to our data, the “signal:noise” ratio was 0.7:1, showing the
prevalence of VUCS in LVNC-patients despite the fact that
the genes encoding sarcomeric proteins are thoroughly
studied. We assume this may point to particular mutation
spectrum causing LVNC, though additional studies are
necessary. This work was supported by grant RNF № 16-
15-10421
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Long QT syndrome (LQTS), the most often diagnosed
inherited arrhythmic syndrome, is characterized by abnor-
mal prolongation of QT interval associated with a high risk
of life-threatening ventricular arrhythmias and sudden car-
diac death, often in young individuals. The prevalence of
this disease has been shown to be at least 2:2500. Mutations
in 15 genes encoding cardiac ionic channels and related
proteins have been associated with LQTS so far but muta-
tions in only 3 genes (KCNQ1, KCNH2 and SCN5A)
account for 70% of the genetically identiﬁed LQTS. In 30
LQTS families from our database, we found 17 mutations in
KCNQ1 (LQTS type 1) and 8 mutations in KCNH2 (LQTS
type 2). The same KCNQ1 mutation c.926C>T; p.T309I
was present in 6 putatively unrelated families - a rare event
in LQTS where each family is usually characterized by its
own mutation. We hypothesized that the mutation may be
considered as the founder mutation in our region. Haplotype
analysis, performed on probands and family members by
using highly polymorphic microsatellite markers, revealed
of a “founder” effect. We repeated mutational analysis in
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T309I families with a wider set of LQTS-related genes
using Next Generation Sequencing method to identify
possible further genetic variants for a more detailed geno-
type - fenotype analysis. Obtained data allows us to provide
genotype and phenotype guided therapeutic measures to
prevent malignant arrhythmias even in asymptomatic
mutation carriers. This work is sponsored by grant of the
ministry of health of the Czech republic: NV16-30571A.
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Introduction: Long QT syndrome (LQTS) is characterized
by lethal ventricular arrhythmia that might lead to sudden
cardiac death. Although 15 causative genes for LQTS have
been identiﬁed so far, genetic etiology remains unknown in
approximately 40% of LQTS patients. This study aims to
identify undiscovered variants associated with and/or
mutations responsible for LQTS to improve diagnostic
accuracy and prognosis. Methods: We designed a custom
sequencing panel of 100 candidate genes implicated in the
pathophysiology of LQTS including 15 causative genes
based on the previous report by Shigemizu et al. (PLoS
One, 2015). Targeted next-generation sequencing was per-
formed using genomic DNA obtained from peripheral blood
of 552 Japanese LQTS patients. Variants in the exon and
promoter regions were extracted, followed by ﬁltering steps
that excluded synonymous ones and those detected in
public databases. Results: 71 novel rare missense mutations
in the exon regions of 45 genes were identiﬁed in 77
patients. These variants were predicted to be damaging by
both SIFT and PolyPhen-2. We also detected 222 novel
variants in the promoter region of 62 genes in 309 patients.
Bioinformatic analyses predicted afﬁnity change of tran-
scription factors including SMAD3 and GATA4 that are
associated with arrhythmia resulting from these promoter
variations. Conclusion: The present study identiﬁed pre-
viously undiscovered variants in the exon and promoter
regions. These variants may play an important role that
increases susceptibility to arrhythmia. This study was sup-
ported by a grant program (ID:15663808) of the Japan
Agency for Medical Research and Development.
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Introduction: High risk of mortality by cardiovascular
disease(CVD) is a most controversial worldwide subject.
MetS and its components as main risk factors for CVD play
important role. This study aims to estimate heritability and
aggregation of MetS in TCGS participants and to evaluate
linkage association between eight chromosomal regions and
HDL-C in MetS affected families. Methods: All families
were selected based on ATPIII criteria in two steps: 1) 278
families (n= 2080; 396 parents 1116 siblings and 528 other
relatives) with at least two MetS affected in two generation
to analyze Familial Intra Class Correlation(ICC) and herit-
ability of HDL_C, 2) 80 families with at least two MetS
affected and low HDL-C to analyze conditional-logistic
likelihood-ratio based on nonparametric linkage analysis.
To investigate possible genes linked among HDL_C and
MetS, 22 ﬂag single nucleotide polymorphisms were gen-
otyped by Illumina chip-typing. Results: Total populations
were aged 41.29±19.1 years. The heritability of HDL-C
after confounder adjustment was 36% (P=0.032,CI=19.2).
However, ICC showed signiﬁcant correlation among ﬁrst
relatives in ﬁrst selected families group this signiﬁcant
correlation in the second group was limited to mother-son
(r=22%,P=0.0296). Contrasting ASP and DSP showed
higher LOD scores in two regions 6p21.33 (rs2248462
(LOD=13.3), rs28366155(LOD=5.9)) and 11q23.3
(rs17519079(LOD=9.5), rs17120029(LOD=6.7),
rs1942478(LOD=6.4), rs2075294(LOD=4.5)). Conclu-
sion: This study indicates that Tehranian families are
genetically predisposed to low HDL_C level. Also that
6p21.33 and 11q23.3 regions are very likely to contain
genes that control HDL-C level in Tehranian families with
metabolic syndrome. However, for conﬁrming the linkage
results more markers should assess in further studies.
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Introduction: Arrhythmogenic cardiomyopathy (AC) is a
clinically and genetically heterogeneous myocardial dis-
ease. Half of AC patients harbour private desmosomal gene
mutations. Although microRNAs (miRNAs) have been
recently emerged as key regulator molecules in cardiovas-
cular diseases (CVDs), their impact on AC onset and pro-
gression is largely unknown. The aim of the study was to
identify one or more miRNA signatures in genotype-
positive AC-patients with different gene mutations. Meth-
ods: Frozen myocardial tissue of 6 heart transplanted AC
probands: 2 plakophilin-2 (PKP2), 2 desmoplakin (DSP)
and 2 desmoglein-2 (DSG2) mutation carriers, as well as 2
healthy controls underwent miRNAs expression proﬁling.
Analysis of 84 miRNAs was performed by using miScript
microRNA PCR Array kit. Relative quantiﬁcation was
carried out by ΔΔCt method. Results: Among the 84
miRNAs, 23 miRNAs were either over- or under-expressed
in PKP2 probands, 17 in DSP carriers and 12 in DSG2
carriers, when compared to healthy controls. A subsequent
comparison of the miRNA expression proﬁle among
mutation carriers revealed 12 miRNA in common between
PKP2 and DSP carriers whereas DSG2 probands showed a
unique miRNA signature. Conclusions: In our study, the
altered miRNAs expression in AC probands compared to
healthy controls proves their potential role in AC. Further-
more, the shared miRNA expression proﬁle between PKP2
and DSP probands suggests a common pathogenetic path-
way, different from DSG2 mutation carriers as to reﬂect
clinical variability in AC. As for other CVDs, miRNAs
might represent early disease biomarkers for AC.
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The genetic determination of the differentiation between
idiopathic dilated cardiomyopathy and ischemic dilated
cardiomyopathy
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Kocatepe University, Faculty of Medicine, Department of
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Introduction: Dilated cardiomyopathy that causes con-
gestive heart failure and sudden death has have high mor-
tality and morbidity. Mostly dilated cardiomyopathy are
accepted ischemic dilated cardiomyopathy (IsDC) or idio-
pathic dilated cardiomyopathy (IdDC). Although the treat-
ments of both of IsDC and IdDC are similar (as 90%),
coronary revascularization is feasible only for IsDC. There
are several methods to distinguish IsDC and IdDC currently
and some difﬁculties while performing these methods.
Material and Methods: In our study, we investigated
these miRNAs for that IsDC is to distinguish from IdDC,
let-7b, let-7c, miR-1, miR-15, miR-17, miR-19a, miR-19b,
miR-20a, miR-20b, miR-23a, miR-24, miR-27a, miR-28,
miR-30, miR-99b, miR-100, miR-101, miR-103, miR-106a,
miR-125b, miR-126, miR-140, miR-191, miR-195, miR-
199a, miR-214, miR-222, miR-320, miR-342 and miR-378
in IsDC and IdDC to distinguish both of them. The patients
with congestive heart failure having dilated left ventricle
and ejection fraction less than 50% were accepted to the
study. Patients were divided two groups as IsDC (25
patients) and IdDC(25 patients) up to coranary angiography
reports and 10 healthy people accepted as a control group.
Results:We found that miR-24, miR-28, miR-100, miR-
103, miR-125b, miR-214, let-7b and let-7c were over-
expressed and increased more than two fold signiﬁcantly in
both ISDC and IdDC groups when compared with control
groups. Whereas miR-15b and miR-106a were over-
expressed and increased more than two fold signiﬁcantly
only in IsDC group, when compared with IdDC and control
groups.
Conclusions: As a results, only miR-15b and miR-106a
seem to be decisive biomarkers to distinguish IsDC and
IdDC.
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Exome sequencing-based molecular autopsy of
formalin-ﬁxed parafﬁn-embedded tissue in sudden
death
R. D. Bagnall1,2, J. Ingles1,2,3, L. Yeates1,3, S. Berkovic4,
C. Semsarian1,2,3
Centenary Institute, Sydney, Australia, 2Sydney Medical
School, University of Sydney, Sydney, Australia, 3Royal
Prince Alfred Hospital, Sydney, Australia, 4Department of
Medicine, University of Melbourne, Melbourne, Australia
Introduction: Sudden death in the young is a devastating
complication of inherited heart disorders. Finding the pre-
cise cause of death is important, but is often unresolved
after postmortem investigation. The addition of postmortem
genetic testing, i.e. the molecular autopsy, can identify
additional causes of death. We evaluated DNA extracted
from formalin-ﬁxed parafﬁn embedded postmortem tissue
for exome sequencing-based molecular autopsy of sudden
death in the young.
Materials and Methods: We collected clinical and post-
mortem information on patients with sudden death. Exome
sequencing was performed on DNA extracted from ﬁxed
postmortem tissue. Variants relevant to the cause of death
were sought.
Results: Five genetically unresolved patients with sud-
den death were recruited. DNA extracted from ﬁxed post-
mortem tissue was degraded. Exome sequencing achieved
20-fold coverage of at least 82% of coding regions. A three-
fold excess of singleton variants was found in the exome
sequencing data of one patient. We found a pathogenic de-
novo SCN1A frameshift variant in a patient with sudden
unexpected death in epilepsy and a pathogenic LMNA
nonsense variant in a patient with dilated cardiomyopathy.
Conclusion: DNA extracted from ﬁxed postmortem tis-
sue is applicable to exome sequencing-based molecular
autopsy. Fixed postmortem tissues are an untapped resource
for exome-based studies of rare causes of sudden death.
R.D. Bagnall: None. J. Ingles: None. L. Yeates: None.
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Effect of the macrophage migration inhibitory factor
genotype on risk of myocardial infarction is modulated
by other risk factors
R. Attard1, P. Dingli1, C. J. M. Doggen2, K. Cassar1, R.
Farrugia1, S. Bezzina Wettinger1
1University of Malta, Msida, Malta, 2University of Twente,
Enschede, Netherlands
Aim: To investigate the effect of the macrophage migration
inhibitory factor (MIF) genotype on the risk of myocardial
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infarction (MI), alone and in combination with other risk
factor of MI.
Method: A total of 423 cases with a ﬁrst MI and 465
controls from the Maltese Acute Myocardial Infarction
(MAMI) Study were analysed. Data was collected through
an interviewer-led questionnaire and various biochemical
measurements. The MIF G-173C, C656G, and C624T
polymorphisms were genotyped in all participants. Odds
ratios (AdjORs) adjusted for conventional risk factors of MI
were calculated as an estimate of the relative risk of MI.
Results: The allele frequency for the MIF G-173C,
C656G and C624T were 18.0%, 19.1% and 3.7% respec-
tively, amongst population controls. No risk of MI was
associated with these genotypes when analysed individu-
ally. A haplotype analysis was conducted. Different hap-
lotypes alone had no or minimal effect on risk of MI,
however in the presence of smoking and/or HbA1c levels
>6.5% and/or LDL-cholesterol >3.6mmol/L, the MIF
-173GC/656CG/624CC haplotype was associated with a
5.8-fold (95%CI 2.8–12.2) increased risk of MI, relative to
the wildtype haplotype in the absence of risk factors. This
risk was higher than that associated with the risk factors and
wildtype haplotype [AdjOR 4.2 (95%CI 2.2–8.1)]. An
AdjOR of 1.3 (95%CI 0.5–3.6) was observed when the MIF
-173GC/656CG/624CC haplotype was found in the absence
of risk factors.
Conclusion: The MIF -173GC/656CG/624CC haplotype
conveys a strong deleterious effect on the risk of MI only
when found with at least another risk factor of MI.
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A combined analysis of common and rare variants in
miRNA loci reveals miR-659 as a potential gene involved
in myocardial infarction predisposition
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Kathiresan4, S. Duga1,2, R. Asselta1,2
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2Department of Biomedical Sciences, Humanitas Univer-
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BACKGROUND: Coronary artery disease and its main
complication, myocardial infarction (MI), are the major
cause of death worldwide. Genome-wide association studies
(GWAS) and whole-exome sequencing (WES) identiﬁed
~50 loci associated with the disease, which, however,
explain <10% of the heritability. MicroRNAs (miRNAs) are
important regulators of metabolic pathways, nevertheless
their implication in cardiovascular diseases is still poorly
understood. The aim of this project was thus the identiﬁ-
cation of miRNAs potentially implicated in MI suscept-
ibility. METHODS: GWAS and WES data, derived from
an Italian cohort of ~1,600 juvenile MI cases and 1,600
controls, were analyzed to identify miRNA loci potentially
associated with the disease and rare variants directly
affecting the miRNA precursor hairpin. Functional studies
were performed to evaluate the effects of best candidate
variants on miRNA stability and target recognition.
RESULTS: The combined analysis of common and rare
variants evidenced a rare nucleotide substitution located in
the mature miR-659-5p and associated with a protective
effect (p=0.033, OR=0.34). In-vitro experiments revealed
that the variation affects the stability of the hairpin,
decreasing miR-659 expression. Among predicted miR-659
targets, we were able to demonstrate that miR-659 directly
targets the IRS2 gene, a fundamental component of the
insulin signaling pathway. Moreover, the identiﬁed variant
partially releases the IRS2 transcript from the miR-659-5p
regulation. Since decreased expression of IRS2 has been
associated in mice with diabetes, a known MI risk factor,
our results support the functional role of this rare variant,
possibly exerting a protective effect against the develop-
ment of diabetes, and, ultimately, of MI.
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Next Generation Sequencing as a powerful tool in
genetic diagnosis of multiple cardiovascular disorders
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Cardiovascular diseases are the main cause of death
worldwide and constitute a heterogeneous group of dis-
orders that involve heart and blood vessels. Inheritable
thoracic aortic disease (TAAD) and other monogenic car-
diovascular diseases manifest as a separate entity or as a
syndromic form. A NGS 238-gene panel for sequencing and
CNV detection was used to diagnose a cohort of patients
with clinical suspicion of inheritable TAAD. MLPA tech-
nique was performed to conﬁrm the preliminary CNV
results. 122 samples were analyzed using SureSelect-Kit
(Agilent) through HiSeq platform (Illumina). Bioinformatic
analysis was performed using an in-house pipeline for
variant calling and CNV identiﬁcation. Conﬁrmation
through MLPA was carried out following manufacturer’s
instructions (MRC-Holland) in the 19 candidate samples.
The diagnostic algorithm was based on the data ﬁltering for
the variant effect, inheritance pattern, allele frequency and
databases. In 33 patients (27%) pathogenic/probably
pathogenic variants were found: 45.5% missense, 24.2%
frameshift, 24.2% nonsense and 6.1% splicing. The CNV
analysis and later MLPA conﬁrmation revealed a partial
deletion in 1 out of 19 patients. In 35 patients (28.7%) the
variants were classiﬁed as VUS. For the remaining 54
patients (44.3%) no candidate variants were found. The
overall genetic diagnosis ratio was 27.9%. The diagnostic
ratio suggests that the use of both NGS sequencing and
identifying CNVs, could be an effective strategy in the
diagnosis of cardiovascular disorders to determine the genes
involved in these pathologies. Functional and cosegregation
analyses of VUS or/and extension of NGS analysis in
negative patients would help to increase diagnosis ratio.
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Effect of the p.Arg357His mutation of PCSK9 on basal
and postprandial lipoprotein metabolism
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PCSK9 (proprotein convertase subtilysin kexin-like 9) is a
bivalent gene with gain of function (GOF) mutations
responsible of high LDL-cholesterol levels characterizing
Autosomal Dominant Hypercholesterolemia (ADH) and
loss of function (LOF) mutations compatible with hypo-
cholesterolemia. The p.Arg357His-PCSK9 mutant identi-
ﬁed in a French ADH family suggested that it is a GOF
mutation. This study aimed at evaluating the in vivo impact
of this mutation on lipoprotein metabolism.
Two transgenic mice were created: i) Knock-In (KI) for
the p.Arg357His mutant expressed ubiquitously; ii) trans-
genic mice (N) expressing the human p.Arg357His mutant
only in the liver. To mimic the high LDL levels in humans
that is absent in mice, we crossed KI and N mice to the
double transgenic mice expressing human apo B100 and
CETP (BC).
Unexpectedly, KI mice showed a signiﬁcant but small
decrease of total cholesterol (TC) basal level, as well as 3h
after gavage with olive oil, but not under high-fat or high-
sucrose diet. For all mice, basal triglyceride (TG) levels did
not change, while the postprandial TG peak of KI and N
mice was signiﬁcantly lower (as observed in Pcsk9-KO
mice), suggesting a role of PCSK9 in TG metabolism.
Surprisingly, BCKI and BCN males were signiﬁcantly
leaner than BC males, weight of the perigonadal adipose
tissue and percentage of fat mass were signiﬁcantly reduced
in BCKI males, indicating a possible role of PCSK9 in fat
mass regulation.
Identiﬁcation of a role of PCSK9 in fat mass regulation
could open the door to new opportunities for treatments by
PCSK9-antagonists.
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Genome-wide association meta-analysis of coronary
artery disease and periodontitis reveals a novel shared
risk locus
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Strong evidence of associations between the presence of
coronary artery disease (CAD) and the widespread oral
inﬂammatory disease periodontitis (PD) is derived from
randomized clinical trials and shows that the epidemiolo-
gical association between both diseases is independent of
the shared risk factor smoking. Earlier, we gave evidence
that the CAD associations of GWAS-lead SNPs at the genes
ANRIL and PLASMINOGEN are shared with PD, and
showed a rare variant at VAMP3 to be associated with PD
and CAD. To elucidate the genetic basis of PD and CAD
further, we performed a meta-analysis. In the discovery
stage, we used an aggressive periodontitis sample (AgP;
680 cases, 4,130 controls) and the CARDIoGRAMplusC4D
CAD meta-analysis (60,801 cases, 123,504 controls). Two
SNPs at the known CAD loci ADAMTS7 (rs4468572) and
VAMP8 (rs6547621) met pre-assigned selection criteria
(P_AgP<0.05; P_CAD<10-5; P_META<P_CAD,P_PD)
and were replicated in a sample of chronic periodontitis
(3,286 cases, 3,328 controls) and the CARDIo-
GRAMplusC4D replication studies. rs6547621 showed
shared association with CAD and PD (AgP:P=0.007,
OR=1.5[95%CI=1.02–1.29]; CP:P=0.009[OR=1.10, 95%
CI=1.02–1.29]). For this SNP, allele speciﬁc effects on
VAMP8 expression are reported. Interestingly, both
VAMP8 and VAMP3 form complexes with platelet syn-
taxin 4, indicating a shared disease relevant mechanism
involving platelet granule secretion. Our data indicate that
the epidemiological association of CAD and PD cannot be
solely explained by shared environmental risk factors and
thus contribute signiﬁcantly to the current discussion on the
relationship between CAD and PD. We conclude that both
diseases share a molecular pathway involving platelet
function, which increases the susceptibility for both
diseases.
M. Munz: None. H. Dommisch: None. J. Erdmann:
None. A. Schäfer: None.
P05.49A
Selenoprotein gene variants are risk factors for per-
ipheral arterial disease in type 2 diabetes
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Introduction. In this study the role of common genetic
variants in selenoprotein genes (SEPP1 rs3877899, rs7579,
SELS rs34713741 TXNRD1 rs35009941, TXNRD2
rs9605031, GPX4 rs713041) and SOD2 gene (rs4880) and
concentration of selenoprotein P (SeP) and thioredoxin
(Trx) in the development of peripheral arterial disease
(PAD) were assessed. Materials and methods. A group of
450 patients and 522 controls was evaluated. Genotyping
was performed using the TaqMan-based assays. Seleno-
protein P (SeP) and thioredoxin (Trx) levels in plasma were
assessed by ELISA. Results. The SELENOS rs34713741T
allele was associated with PAD (recessive model:
OR=1.58, P=0.031), with stronger effect in type 2 diabetes
(T2DM, OR=2.54). Coexistence of the SEPP1 rs7579A
and GPX4 rs713041T alleles with T2DM was related to
2.49-fold (P<0.0001) and 2.07-fold (P=0.001) increase in
PAD risk, respectively. The interactions between the
SELENOS rs34713741T and SEPP1 rs7579A alleles and
T2DM were observed, that improved the prediction of PAD
in relation to predictions from conventional cardiovascular
risk factors alone. These alleles were also correlated with
more advanced leg ischemia assessed by ankle-brachial
pressure index (allele dose: r = - 0.399, P<0.0001 and r = -
0.205, P=0.048 respectively). The SeP concentration was
decreased in T2DM, while positively correlated with blood
cholesterol levels, especially HDLC. Conclusions. These
results conﬁrmed the protective role of SeP for cardiovas-
cular system and suggested the impact of SELENOS and
SEPP1 variants on PAD risk in T2DM. Supported by the
NSC in Poland under NN403250440 grant, and PUMS
under 502-01-02214335-05962 and 502-14-02214335-
10268 grants.
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Recessive hypoplastic left heart syndrome due to trun-
cating mutation in PKP2
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Background Plakophilin-2 is the primary cardiac plako-
philin, an essential component of desmosomes. Hetero-
zygous mutations in PKP2 encoding plakophilin-2 have
been reported to cause autosomal dominant arrhythmogenic
right ventricular cardiomyopathy (ARVC). ARVC is a
genetically heterogeneous disorder characterized by pro-
gressive ﬁbrofatty replacement of the myocardium, pre-
dominantly affecting the right ventricle. Recently, a
homozygous deletion of the entire PKP2 gene was descri-
bed in two siblings with severe noncompaction cardio-
myopathy of both ventricles.
Method and results We describe prenatally diagnosed
left ventricular hypoplasia in two siblings that died shortly
after birth. Autopsy showed extensive biventricular non-
compaction, septal defects and subendothelial ﬁbroelastosis,
predominantly affecting the small left ventricle. One of the
siblings also had an underdeveloped mitral and aortic valve,
and a hypoplastic aortic arch. Next-generation sequencing
of a panel of 52 cardiomyopathy-related genes was per-
formed in DNA from peripheral blood samples from both
parents. Both were found to carry a heterozygous truncating
mutation c.1211dup in PKP2. This mutation has previously
been described in heterozygous state in ARVC patients.
Sanger sequencing conﬁrmed that this mutation was present
in homozygous state in their two affected daughters.
Immunohistochemical staining showed strongly reduced
expression of desmosomal proteins as well as the gap
junction connexin-43 in the intercalated discs.
Conclusion Our ﬁndings conﬁrm previous observations
that plakophillin-2 is essential for myocardial formation and
that lack of plakophillin-2 gives rise not only to non-
compaction cardiomyopathy, but also to hypoplasia of the
left ventricle and other congenital cardiac defects.
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Application of an LDL-C Genetic Risk Score for diag-
nosis of polygenic hypercholesterolemia in Northern
Irish population: Preliminary trial to evaluate a Randox
6SNP Polygenic Hypercholesterolemia Array
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Introduction: Familial Hypercholesterolemia (FH) is a
common genetic disorder characterised by elevated LDL-C
and early symptoms of coronary heart disease, primarily
caused by a mutation in genes LDLR, APOB or PCSK9.
Despite clinical diagnosis of possible FH, 60% of possible
FH patients are mutation-negative, likely due to an accu-
mulation of common small-effect LDL-C raising alleles.
The effectiveness of the Randox 6SNP Polygenic
Hypercholesterolemia Array to identify polygenic FH was
tested. Materials and Methods: 414 FH cases were selected
for 6SNP genotyping by Sanger sequencing of ﬁve genes
(rs7412, rs429358, rs1367117, rs6544713, rs629301 and
rs6511720) and calculation of the weighted LDL-C genetic
risk score (GRS). Genotyping was performed (10% cases)
using the 6SNP Polygenic Hypercholesterolemia Array and
the Evidence Investigator Analyser. Results: Deﬁnite FH
patients (mutation positive - 196 cases) were shown to have
a mean GRS of 0.705, whereas possible FH patients
(mutation negative - 218 cases) had a mean GRS of 0.777
(p<0.001). Mutation negative patients have 2.3 times the
odds of having a GRS exceeding 0.81 than mutation posi-
tive patients, thus increasing the chance of polygenic
hypercholesterolemia. Accurate genotyping was conﬁrmed
in 100% of cases tested with the 6SNP Polygenic
Hypercholesterolemia Array. Conclusion: The Randox
6SNP Polygenic Hypercholesterolemia Array successfully
genotyped a subset of the Northern Irish possible FH
population. This cost effective method could identify
patients potentially affected with polygenic hypercholes-
terolemia, exclude additional testing for a monogenic cause
and negate inefﬁcient cholesterol based family cascade
screening. This will improve management and treatment of
clinically diagnosed FH patients.
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Patients with pulmonary arterial hypertension asso-
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Pulmonary arterial hypertension (PAH; OMIM #178600,
ORPHA 422) is a rare disease that typically causes the
obstruction of precapillary pulmonary arteries. Much of
what is known about the genetic basis of PAH is related to
BMPR2 gene. However, some other candidate genes have
been advocated. The aim of this study was to analyse
patients with combined mutations in BMPR2, ACVRL1,
ENG and KCNA5 genes and to establish a genotype-
phenotype correlation. We included 57 PAH patients and 50
controls. Using speciﬁc primers, we ampliﬁed and
sequenced the genes. Genotype-phenotype correlation was
performed using SPSS v.19 software. After mutation
screening of BMPR2, ACVRL1, ENG and KCNA5 genes in
our cohort, we identiﬁed pathogenic mutations in 40
patients. We found a high percentage of patients with sev-
eral mutations classiﬁed as pathogenic by in silico analysis.
We found combined mutations in the BMPR2 gene in 25%
of the patients with several mutations included in this study.
In addition, we detected one patient that shows two
pathogenic mutations in ENG gene. We found statistically
signiﬁcant differences, comparing patients with several
mutations and patients with one pathogenic mutation, for
gender (p=0.045), age at diagnosis (p=0.040), PVR
(p=0.030), CI (p=0.042) and no response to therapy
(p=0.011). We show a series of patients with IPAH and
APAH with a high percentage of them being carriers of
more than one pathogenic mutation in several genes. We
wonder whether these additional mutations act as a second
event in the development of the disease, increasing the
penetrance, modifying the patients phenotype.
L. Mauro: None. G. Pousada: None. A. Baloira: None.
D. Valverde: None.
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Design and application of a custom panel of NGS for
Pulmonary Arterial Hypertension: HAP v1.2
P. Arias1,2, J. A. Tenorio1,2, N. Gallego1,2, P. Navas3, C.
Quezada3, Á. Del Pozo1,2, K. Ibañez1,2, J. Silla1,2, J.
Palomino4, N. Ochoa4, I. Hernández4, G. Gordo1,2, I.
Dapía1,2, PAH Consortium, P. Escribano4, P.
Lapunzina1,2
Medical and Molecular Genetics Institute (INGEMM),
Madrid, Spain, 2CIBERER, Centro de Investigación en
Red de Enfermedades Raras, ISCIII, Madrid., Madrid,
Spain, 3Unidad multidisciplinar de Hipertensión Pulmonar,
Servicio de cardiología, Hospital Universitario 12 de
Octubre, Madrid, Madrid, Spain, 4Unidad multidisciplinar
de Hipertensión Pulmonar, Servicio de cardiología,
Hospital Universitario 12 de Octubre, Madrid., Madrid,
Spain
Introduction
Pulmonary Arterial Hypertension (PAH) is an infrequent
cardiac disease characterized by an increase of pulmonary
vascular resistance associated with a high morbidity and
mortality. PAH can be classiﬁed in several groups
depending on the etiology, including idiopathic (IPAH),
hereditary (HPAH) and a more severe form PVOD (Pul-
monary Venooclusive Disease).
Material and methods
We have selected a cohort of 168 patients with IPAH,
HPAH and PVOD from the Spanish REHAP registry,
which includes patients from all over the country. A panel
of 21 genes related to PAH have been designed. A-in-house
script for bioinformatic and variant analysis was performed
and variant validation was done through Sanger sequencing.
Results
After variants ﬁltering, we have found 18,45% (31/168)
patients with pathogenic mutations, 5,8% with variants of
unknown signiﬁcance. Eight% of the samples were rejected
after quality ﬁltering. Additionally, two mutations in two
different genes have been found in one patient from one
family with multiple affected members.
Conclusions
PAH has an extremely wide clinical and molecular
spectrum including penetrance, pattern of expression and
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age of onset. Thus, NGS in combination with a well clinical
characterization seems to be the best approach to study
PAH. Interestingly, in one patient we were able to found
two different mutations in two genes, one of them a non-
sense well known mutation (BMPR2, c.961C>T; p.
Arg321*) and a second hit in a potassium channel. As far as
we know, this is the ﬁrst time that a digenic inheritance has
been found in a patient with PAH.
Grants: FIS-PI15/02012
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Dapía: None. P. Escribano: None. P. Lapunzina: None.
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Study of the contribution of SCN10A mutations to the
Brugada syndrome genetic architecture
M. Alaerts1, A. Nijak1, P. Koopman2, E. Van
Craenenbroeck3, J. Saenen3, B. Loeys1
1Center of Medical Genetics, University of Antwerp and
Antwerp University Hospital, Antwerp (Edegem), Belgium,
2Heart Center Hasselt, Jessa Hospital, Hasselt, Belgium,
3Department of Cardiology, University of Antwerp and
Antwerp University Hospital, Antwerp (Wilrijk), Belgium
The Brugada Syndrome (BrS) is an inherited primary
electrical disorder of the heart characterized by ventricular
arrhythmias and signiﬁcant risk for sudden cardiac death.
Mutations in the SCN5A gene, encoding a voltage-gated
cardiac sodium channel, constitute the major genetic cause
of BrS, accounting for ~20% of all clinically diagnosed
cases. More than 20 other genes have been associated with
BrS, but together only explain an additional ~5% of
patients. Recently SCN10A, encoding another voltage-gated
sodium channel, gained signiﬁcant interest because GWAS
studies associated SCN10A single nucleotide polymorph-
isms with BrS risk, QRS duration and cardiac conduction,
and more recent studies detected rare potentially pathogenic
variants in BrS patients. We screened the coding sequence
of SCN10A in a cohort of 108 SCN5A mutation negative
BrS patients using Sanger sequencing. One patient carried
both a novel and very rare missense mutation, p.Leu309Pro
(absent from ExAC) and p.Lys1247Glu (ExAC MAF =
0.000008). Another patient harboured the rare variant p.
Lys417del (ExAC MAF = 0.0009) and two unrelated
patients presented p.Arg1268Gln (ExAC MAF = 0.001).
All variants altered conserved amino acid residues and were
in silico predicted to be disease causing by Mutationtaster
and SIFT. The p.Arg1268Gln variant was previously shown
to reduce sodium current in vitro.
In conclusion, mutations in SCN10A potentially con-
tribute to 3.7% of BrS patients in our cohort, further high-
lighting the role of SCN10A in BrS causation.
M. Alaerts: None. A. Nijak: None. P. Koopman: None.
E. Van Craenenbroeck: None. J. Saenen: None. B.
Loeys: None.
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The second report of early somatic mosaicism as cause
of life threatening cardiac arrythmias
N. Marziliano, P. Berne, V. Carboni, G. Piras, M. Monne,
R. Asproni, A. Uras, G. Casu
SL3 Nuoro-ATS Sardegna, NUORO, Italy
Background: Brugada syndrome (BrS) was recognized as a
disease responsible for sudden cardiac death, characterized
by a right bundle-branch block with ST segment elevation
in the leads V1 and V2. Extensive research has allowed
better understanding of the genetic background and clinical
management even though controversies still exist being the
sodium channel NaV1.5, encoded by the SCN5A gene,
associated with BrS in only a few proportion of cases.
Somatic mosaicism, is increasingly recognized to play a
causal role in a variety of mendelian diseases included Long
QT syndrome due to SCN5A gene mutations (LQT3). We
investigate the case of a 14-year old girl with clinical
diagnosis of BrS and uncertain genetic causative mutation
of the SCN5A gene. Methods and Findings: Firstly Sanger
Sequencing identiﬁed a heterozygous variant of the SCN5A
gene (NM_000335:c.6010T>C predicting p.Phe2004Leu).
Because of discordant diagnosis with a second testing
laboratory we then applied: 1) high sensitivity NGS with a
cardiac arrhythmias custom-based gene panel on the Ion
PGM platform with a minimum base coverage of
200×(ThermoFisher); 2) microsatellites proﬁling for the
search of mosaicism at circulating leukocytes level and 3) q-
PCR with mutation-speciﬁc TaqMan probes. We conﬁrmed
that the identiﬁed mutation is mosaic in origin, detectable in
2.2–67.8% of sequencing reads in constitutional DNA.
Conclusion: Mosaic SCN5A mutations can cause of Bru-
gada Syndrome in patients with overt phenotype. Sensitivity
provided by classic Sanger sequencing might fail in
detecting such conditions that are rapidly and securely
detected by NGS thus enabling the detection of low-level
mosaic mutations
N. Marziliano: None. P. Berne: None. V. Carboni:
None. G. Piras: None. M. Monne: None. R. Asproni:
None. A. Uras: None. G. Casu: None.
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Sexual dimorphism in SMAD3 mutation carriers:
implications for management derived from a large
family
J. Richer1, H. Al-Amodi2, S. Goobie3, M. W. Chu2, B.
Loeys4
1Children Hospital of Eastern Ontario, Ottawa, ON,
Canada, 2Division of Cardiac Surgery, Western University,
London, ON, Canada, 3Maritime Medical Genetics, IWK
Health Centre, Dalhousie University, Halifax, NS, Canada,
4Center of Medical Genetics, University of Antwerp and
Antwerp University Hospital, Antwerp, Belgium
SMAD3 mutation carriers are at-risk for aortic dissection
and for arterial aneurysms/dissections from brain to pelvis.
Based on prior suggestions in the literature on gender dif-
ferences in thoracic aortic aneurysm/dissection, we inves-
tigated whether there is a sexual dimorphism regarding risk
of vascular events in SMAD3 mutation carriers. In a large
SMAD3 pedigree, we included mutation carrying indivi-
duals who were either (1) >40 years or (2) had aneurysm/
vascular dissection/intervention. We identiﬁed 22 mutation
carriers and categorized them as unaffected or affected. We
subcategorized affected individuals, between (1) aneurysm/
dissection excluding the aortic root/ascending aorta versus
(2) aneurysm/dissection with disease including the aortic
root/ascending aorta (TAAD). In females, we identiﬁed 7 as
unaffected whereas 6 were affected. Of these 6 affected
females, 5 had arterial aneurysms without TAAD. All 9
males were affected. Eight of the males had TAAD and one
had arterial aneurysm without TAAD. In addition, four
other males in the family presented with sudden death and/
or aortic dissection, but were not included because the
precise nature and location of their aneurysm was undocu-
mented. Our ﬁndings are in line with previous human
SMAD3 family observations (VandeLaar et al, JMG, 2012)
and mouse data (van der Pluijm I et al, EBioMedicine,
2016).
In summary, clinicians caring for individuals with a
personal/family history of SMAD3 mutations need to know
that (1) the absolute risk of aneurysms is higher in males
and (2) the risk of vascular events in the presence of a
normal echocardiogram is higher in females.
J. Richer: None. H. Al-Amodi: None. S. Goobie: None.
M.W. Chu: None. B. Loeys: None.
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Should all individuals with Sotos syndrome be screened
for thoracic aortic aneurysms?
J. L. Marcadier1, N. Alvarez2, R. Perrier1
Alberta Children's Hospital, Calgary, AB, Canada, 2Libin
Cardiovascular Institute of Alberta, University of Calgary,
Calgary, AB, Canada
Sotos syndrome is an autosomal dominant overgrowth
disorder caused by mutations in NSD1. Clinical ﬁndings
typically include larger stature, macrocephaly, characteristic
facial features and variable learning disability. Evidence of
mild connective tissue dysfunction has been described in a
minority of affected individuals, and only recently were
four patients reported to have severe connective tissue laxity
and aortic dilatation (Hood et al., 2015). We describe 3
additional patients manifesting enlargement of the thoracic
aorta and milder evidence of connective tissue involvement.
Patient 1 is a 9 year old male with a partial deletion of
NSD1 exon 5 and typical features of Sotos syndrome, along
with mild hypermobility, velvety skin, periumbilical
wrinkling, pes planus, and a 3.2cm aneurysm of the
ascending aorta (Z-score +5.2). Patient 2 came to medical
attention at age 59 with a 6.1cm aortic root aneurysm and
minimal connective tissue involvement. His 26 year old
daughter (Patient 3) was subsequently screened and found
to have a 4cm aortic root (Z-score +3.11), along with
moderately elastic, doughy skin and elbow hyperextensi-
bility. The father-daughter pair are proportionately tall and
macrocephalic, with facial features of Sotos syndrome and a
shared, novel nonsense mutation in NSD1. This report
broadens our understanding of the growing association
between Sotos syndrome and predisposition to aortopathy,
and suggests that routine screening of the thoracic aorta in
affected individuals may be warranted.
J.L. Marcadier: None. N. Alvarez: None. R. Perrier:
None.
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Genetic investigations of sudden unexplained death
victims using targeted capture and next-generation
sequening
S. L. Christiansen1, C. L. Hertz1, L. Ferrero-Miliani1, M.
Dahl2, P. Weeke3, LuCamp, University of Copenhagen, G.
L. Ottesen4, R. Frank-Hansen1, H. Bundgaard5, N.
Morling1
1Section of Forensic Genetics, Department of Forensic
Medicine, University of Copenhagen, Copenhagen, Den-
mark, 2Department of Clinical Biochemistry, Rigshospita-
let, Copenhagen University Hospital, University of
Copenhagen, Copenhagen, Denmark, 3The Department of
Cardiology, Laboratory of Molecular Cardiology,
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versity of Copenhagen, Copenhagen, Denmark, 5The Unit
for Inherited Diseases, The Heart Centre, Rigshospitalet,
Copenhagen University Hospital, University of Copenha-
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Introduction: Sudden cardiac death (SCD) is responsible
for a considerable proportion of natural deaths in young
individuals. Some cases remain unexplained after medico-
legal autopsy, termed sudden unexplained deaths (SUD). A
major proportion of these are suspected to be caused by
inherited cardiac diseases, especially channelopathies.
Sudden death can in some cases be the ﬁrst manifestation of
the disease. It is generally expected that implementation of
genetic investigations in forensic medicine may increase the
diagnostic rate in SUD cases. The purpose of the study was
to explore the utility of genetic testing using next-generation
sequencing (NGS) by investigating the frequency of var-
iants with likely functional effects in 100 genes associated
with cardiac diseases in a cohort of suspected SUD victims.
Methods: Genetic investigation of 61 unrelated, SUD cases
<50 years was performed. Using the Haloplex Target
Enrichment System from Agilent, all coding regions of 100
genes associated with inherited cardiomyopathies and car-
diac channelopathies were sequenced on an Illumina MiSeq
platform. Results: In 34% of the cases, variants with likely
functional effects were identiﬁed. A total of 40% of these
variants were located in genes associated with cardiomyo-
pathies, and 60% of the variants in genes associated with
cardiac channelopathies. Conclusions:We found that broad
genetic screening of SUD victims can increase the diag-
nostic outcome, and that the investigation should comprise
genes involved in both cardiomyopathies and cardiac
channelopathies. These ﬁndings are of importance for
clinical and genetic screening for those left behind.
S.L. Christiansen: None. C.L. Hertz: None. L. Fer-
rero-Miliani: None. M. Dahl: None. P. Weeke: None. G.
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Targeted exome sequencing for mendelian cardiac dis-
orders within the Genome Clinic in Geneva
S. Fokstuen1, M. Guipponi1, E. B. Hammar1, P.
Makrythanasis1, P. Meyer2, M. Beghetti3, N. Sekarski4, E.
Ranza1, M. Lidgren1, F. A. Santoni1, C. Gehrig1, T.
Nouspikel1, S. E. Antonarakis1,5, J. Blouin1
Genetic Medicine, University Hospitals of Geneva, Geneva,
Switzerland, 2Cardiology, University Hospitals of Geneva,
Geneva, Switzerland, 3Pediatric Cardiology, University
Hospitals of Geneva, Geneva, Switzerland, 4Pediatric
Cardiology, University Hospital, Lausanne, Switzerland,
5Department of Genetic Medicine and Development,
University of Geneva Medical School, Geneva, Switzerland
Introduction: Mendelian cardiomyopathies and arrhyth-
mias represent heterogeneous disorders for which current
guidelines recommend molecular analyses to identify a
causative mutation(s) and subsequently provide predictive
testing of relatives at risk. High-throughput sequencing
(HTS) platforms allow to analyse simultaneously large
numbers of cardiac disease genes.
Methods: In order to optimally integrate HTS in our
clinic, we have created at the University Hospitals of
Geneva a multidisciplinary “Genome Clinic Task Force”,
composed of clinical and molecular geneticists, bioinfor-
maticians, bioethicists and a coordinator. This task force
represents also a powerful tool for the diagnosis of cardiac
disorders. We perform whole-exome sequencing (WES)
followed by targeted bioinformatic analysis of a selection of
genes (65 for cardiomyopathies, 47 for arrhythmias).
Results: So far, we have validated the HTS results of 36
different cardiac cases (11 with arrhythmias, 25 with car-
diomyopathies). We found a pathogenic variant in 11
patients with cardiomyopathy (44%) and in 2 patients with
arrhythmia (18%). The highest detection rate (58 %) was
obtained for patients with hypertrophic cardiomyopathy (7/
12). A variant of uncertain clinical signiﬁcance (VUS) was
found in 5 cases with arrhythmia (45 %) and in 3 cases with
cardiomyopathy (12%).
Conclusions : Targeted exome analysis offers an efﬁcient
approach for the fast developing ﬁeld of inherited cardiac
diseases. However, cardio-genetic services face several
challenges implementing this technology, especially variant
interpretation, management of VUS or reduced penetrance.
So far, we disclosed the VUS. To ensure optimal counsel-
ling and management of the concerned families it is
essential to work as a multidisciplinary team.
S. Fokstuen: None. M. Guipponi: None. E. B. Ham-
mar: None. P. Makrythanasis: None. P. Meyer: None.M.
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Integrated copy number and single nucleotide variant
analysis in thoracic aortic aneurysms
J. M. A. Verhagen, H. T. Brüggenwirth, B. H. Eussen, R.
W. W. Brouwer, R. M. van der Helm, T. Brands, W. F. J.
van IJcken, W. G. de Valk, A. de Klein, H. B. Beverloo, A.
M. W. van den Ouweland, M. A. van Slegtenhorst, R. M.
W. Hofstra, J. A. Bekkers, J. W. Roos-Hesselink, M. W.
Wessels, I. M. B. H. van de Laar, E. Brosens
Erasmus University Medical Center, Rotterdam,
Netherlands
Thoracic aortic aneurysm (TAA) is a life-threating condi-
tion. It is usually considered an inherited disorder as
approximately 20% of patients have at least one affected
ﬁrst-degree family member. Mutations in the transforming
growth factor-β signaling pathway and vascular smooth
muscle cell contractility apparatus have emerged as key
players in the pathogenesis of TAA. The clinical variability
might be explained by environmental factors and additional
contributing genetic factors. One of these so-called modi-
ﬁers can be copy number variations (CNVs). Genes affected
by CNVs are good candidates for further research, as these
genes may contain deleterious single nucleotide variants
(SNVs) in other patients. Therefore, we determined the
copy number proﬁle of 167 TAA patients using SNP array
and prioritized the CNVs based on gene content and fre-
quency in control populations. Next, we determined the
frequency of rare SNVs in genes encompassed by these
CNVs in 121 TAA patients using whole exome sequencing
(WES) data. We identiﬁed 71 unique CNVs that were
absent or rare in controls, or that contained known or can-
didate TAA genes. Pathway analysis showed that these
CNVs were enriched for genes involved in ﬁbroblast
growth factor signaling and extracellular matrix organiza-
tion. Screening of our TAA cohort using the CNV-
associated gene panel (n= 289) resulted in the identiﬁca-
tion of 63 putative deleterious SNVs. We are currently
evaluating the presumed consequence of these variants and
their hypothesized relation to TAA formation. In addition,
we are assessing copy number status from WES data using
ExomeDepth and CoNVex. Funded by: Dutch Heart
Foundation (2014T007).
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P06 Metabolic and mitochondrial disorders
P06.01A
MLPA analysis of the HGD gene identiﬁes novel geno-
mic deletions in alkaptonuria
M. Sekelska1, L. Kadasi1,2, A. Zatkova1
Biomedical Research Center, Slovak Academy of Sciences,
Bratislava, Slovakia, 2Department of Molecular Biology,
Faculty of Natural Sciences, Comenius university, Brati-
slava, Slovakia
Alkaptonuria (AKU) is characterised by ochronosis and
ochronotic artropathy due to the accumulation of melanin-
like pigment. This rare autosomal recessive metabolic dis-
order is caused by homozygous or compound heterozygous
mutations of the HGD gene (3q13.33) coding for homo-
gentisate dioxygenase (HGD). Until present, 142 patho-
genic variants have been reported in about 400 AKU
patients worldwide, as summarized in the HGD mutation
database (http://hgddatabase.cvtisr.sk/). In some cases, only
one or no HGD mutation could be identiﬁed by sequencing.
Interestingly, only two larger genomic deletions within the
HGD gene were seen so far: one of exon 2, including short
ﬂanking intronic sequences, and one of an almost entire
intron 2, most likely leading into exon skipping. We
designed MLPA probes for all 14 exons and intron 2 of the
HGD gene and performed MLPA analysis in 22 AKU
patients, in whom only one (14 cases) or no disease-causing
mutation (4 cases) was found, as well as in those with only
silent or intronic variants identiﬁed (4 cases). MLPA
uncovered a heterozygous deletion of exon 13 in four cases
from Italy and a heterozygous deletion of both exons 5 and
6 in one patient from Netherland. Deletion breakpoints of
novel deletions will be deﬁned. MLPA assay successfully
identiﬁes also previously described deletions of exon 2 and
intron 2 of the HGD gene, in homozygous as well as in
heterozygous state. No copy number changes were seen in
remaining 17 cases and a mechanism causing AKU in them
needs to be discovered. (7FP- DevelopAKUre 304985)
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Beta-mannosidosis caused by a homozygous intragenic
inverted duplication in the MANBA gene precisely
characterized by Whole Genome Sequencing
J. Lindgren1, H. Riise Stensland2, M. Falkenberg
Smeland2, M. Blomqvist1, Ø. Nilssen2,3, J. Asin Cayuela1
1Dept Clinical Chemistry, Sahlgrenska University Hospital,
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Introduction: WGS is still not universally used as ﬁrst step
in the genetic investigation of Inborn Errors of Metabolism
(IEM), mainly due to allegedly high economic cost. We
present a case in which early use of WGS would have been
beneﬁcial both in temporal and economic terms.
Patient and methods: 13 year old girl, consanguineous
parents, presenting with recurrent infections, mild intellec-
tual disability, ADHD, behavioural disturbances, sensor-
ineural hearing loss, alacrima and high pain threshold.
Physical examination shows scalp ﬂushing, upslanting,
narrow palpebral ﬁssures, broad nasal tip, thin lips, angio-
keratomas, varicose veins and dilated conjunctival vessels.
Numerous genetic analyses were undertaken over the years.
SNP-array detected six regions of homozygosity, including
one in 4q24, where MANBA gene is located. Present
investigation included exome sequencing panel for lysoso-
mal/peroxisomal diseases, β-mannosidase activity in leu-
kocytes, cDNA analysis of MANBA transcripts and WGS.
Results: Exome sequencing panel showed increased
coverage (+1.73) in exons 8 to 11 of MANBA. Abnormal
distance and orientation of paired reads indicated the pre-
sence of an inverted duplication and the location of one
breakpoint. β-mannosidase analysis showed 3% residual
activity, which conﬁrmed the diagnosis of β-mannosidosis.
cDNA analysis revealed two transcripts lacking exons 8–9
and 8-9-10, respectively. The patient´s mother showed
normal transcript in addition to the two truncated variants.
WGS deﬁned both breakpoints, which were conﬁrmed by
Sanger sequencing.
Conclusion: WGS is superior to exome sequencing in
the identiﬁcation and characterization of Copy Number
Variants. Early use of WGS in the diagnostic ﬂow of IEM
should be considered.
J. Lindgren: None. H. Riise Stensland: None. M.
Falkenberg Smeland: None. M. Blomqvist: None. Ø.
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Improving the diagnosis of cobalamin and related
defects by genomic analysis and functional and struc-
tural assessment of the variants identiﬁed
S. Brasil, F. Leal, A. Vega, P. Rodriguez-Pombo, L. R.
Desviat, M. Ugarte, C. Perez-Cerda, B. Merinero, B. Pérez
entro de Diagnostico de Enfermedades Moleculares,
Centro de Biología Molecular, Madrid, Spain
Detection of cobalamin disorders involves biochemical
analyses after the presentation of symptoms or by newborn
screening. To date the gold standard method includes fur-
ther, time-consuming biochemical and/or cellular analyses
to reduce the number of subsequent gene-by-gene analyses.
This paper reports the accurate and rapid genetic diagnosis
by exome analysis via the massive parallel sequencing of
DNA samples from a cohort of patients with cobalamin and
related defects. The method was ﬁrst validated simulating a
real-world diagnostic scenario. Mendelian segregation,
population frequency and a comprehensive structural and
functional analysis of the variants have been able to identify
disease-causing mutations in 13 genes involved in the
absorption and synthesis of active cofactors of vitamin B12
(23 cases) as well as in the non-cobalamin metabolism-
related genes ACSF3 (four biochemically misdiagnosed
cases) and in SUCLA2 (one case) with an unusual pre-
sentation. Additionally, pathogenic mutations were detected
in two pathway genes in three cases, suggesting a digenic
inheritance. The present ﬁndings suggest that the technol-
ogy used is sufﬁciently sensitive and speciﬁc, and the
results obtained sufﬁciently reproducible, to recommend its
use as second-tier test after the biochemical detection of
cobalamin disorder markers in the ﬁrst days of life. Grants:
PI13/01239, the Fundación Isabel Gemio.
S. Brasil: None. F. Leal: None. A. Vega: None. P.
Rodriguez-Pombo: None. L.R. Desviat: None. M.
Ugarte: None. C. Perez-Cerda: None. B. Merinero:
None. B. Pérez: None.
P06.04D
A DOLK gene-associated Congenital Disorder of Gly-
cosylation should be considered in the presence of ich-
thyosis and dilated cardiomyopathy
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Mayne3, G. O'Regan1, E. Molloy1, L. Bradley1, D. Barton4
1Our Lady's Children's Hospital Crumlin, Dublin, Ireland,
2Galway University Hospital, Galway, Ireland, 3Temple
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4Department of Clinical Genetics, Our Lady’s Children’s
Hospital Crumlin, Dublin, Ireland
A male child of non consanguineous 40 year old Irish
parents was delivered by emergency Caesarean Section at
38+5 weeks, for non-reassuring CTG and decreased fetal
movements. His birth-weight was 2.65kg (2nd-9th centile).
He immediately required cardiopulmonary resuscitation,
ventilation and transfer to the neonatal ICU. He developed
hypotension, hypoglycaemia, cardiac failure, thrombocyto-
penia, coagulopathy, and had one tonic/clonic seizure. He
was stabilised and transferred to a tertiary centre. On
examination, several dysmorphic features, undescended
testes, partial collodion membrane, keratosis, severe ﬁs-
sures, contractures and erythema were noted; suggesting a
unifying diagnosis of congenital ichthyosiform ery-
throderma. An echocardiogram conﬁrmed severe biven-
tricular dilated cardiomyopathy with possible non-
compaction of the right ventriculo-apical region. Investi-
gations included cyto- and molecular genetics (karyotype,
microarray, 10-gene ichthyosis panel) and metabolic
workup. His transferrin isoforms were abnormal, suggesting
a congenital disorder of glycosylation (CDG). Ultimately,
bi-allelic mutations in the DOLK (Dolichol Kinase) gene
provided molecular conﬁrmation of this diagnosis. Despite
maximal therapy, the patient continued to deteriorate and
died on day 2 of life. Few disorders are associated with both
ichthyosis and dilated cardiomyopathy, most of which are
glycosylation disorders. To date, the predominant pheno-
type in patients affected by dolichol kinase deﬁciency has
been dilated cardiomyopathy. Mild ichthyosiform dermatitis
has been noted in some affected individuals, but we believe
this to be the ﬁrst reported case of a severe DOLK-related
ichthyosis. Congenital disorders of glycosylation are rare,
and variable, but should be considered in a child with early
multi-systemic issues, particularly those involving heart,
brain and skin.
T.P. McVeigh: B. Research Grant (principal investi-
gator, collaborator or consultant and pending grants as well
as grants already received); Modest; HRB/HSE NSAFP14/
1. D. O'Donovan: None. M. McDermott: None. P.
Mayne: None. G. O'Regan: None. E. Molloy: None. L.
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The introduction of NGS for the diagnosis of Congenital
Disorders of Glycosylation
E. Souche, L. Keldermans, G. Matthijs, V. Race
ULeuven, Leuven, Belgium
Introduction: Congenital Disorders of Glycosylation
(CDG) are a group of disorders caused by the alteration in
synthesis and structure of protein and lipid glycosylation.
Diagnosis of CDG is challenging because of its clinical and
genetic heterogeneity. Until recently, CDG diagnosis has
been perfomed by Sanger sequencing of one or few genes
tentatively selected based on a combination of biochemical,
cell biological and glycobiological investigations.
Material and Methods:We designed a capture assay for
a panel of 79 genes associated with CDG and other genes
associated to disorders whose phenotype resembles CDG. A
total of 88 CDG cases were captured and Pair-End
sequenced. The reportable range of our NGS assay was
evaluated as well as CDG diagnostic routing.
Results: A genotype was called for more than 97% of
the targeted bases and more than 99% of all coding bases
plus 20 ﬂanking bases of the transcripts used for analysis. A
diagnosis was conﬁrmed in 44 of 88 CDG patients, of
which 27 had been previously tested negative by Sanger
sequencing. Four PMM2-deﬁcient patients were identiﬁed
although a PMM2 enzymatic assay had been performed
prior to NGS.
Conclusions: Our NGS assay allowed a diagnostic yield
of 50% and the genotyping of the coding bases of all CDG
genes, including ALG1 that could not be assayed by
genomic Sanger sequencing due to the abundance of
pseudogenes. Given the prevalence of PMM2-deﬁcient
patients, enzymatic assays are replaced by PMM2 Sanger
sequencing prior to NGS in our new diagnostic routing.
Funding: BELSPO-IAP project IAP P7/43-BeMGI
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Molecular genetic study of children in St. Petersburg,
included in the Federal register of patients with pituitary
dwarﬁsm
O. S. Glotov1,2,3, O. S. Berseneva4, A. S. Glotov1,2,3, M. E.
Turkunova5, E. A. Serebryakova1,2,3, I. V. Polyakova3,2, T.
E. Ivaschenko1, M. A. Fedyakov3, N. Y. Shwed1,2,3, O. V.
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Clinical manifestations of heterogeneity of growth hormone
deﬁciency when deﬁnitive results of hormonal stimulus test
determines the need to search for molecular genetic markers
of the disease to form personalized therapeutic algorithms.
The study of the nature of the genetic changes in a cohort of
patients with congenital hypopituitarism, manifested mul-
tiple anterior pituitary hormone deﬁciency or isolated
growth hormone deﬁciency. Molecular genetic analysis in
patients with congenital hypopituitarism was carried out by
NGS using "Amplisec" technology. All patients with con-
genital hypopituitarism, who are in a special registry of
Saint Petersburg, were included in this study. Differences in
the frequency of detection of mutations in patients with
multiple anterior pituitary hormone deﬁciency and in
patients with isolated growth hormone deﬁciency were
found. The mutation frequency of diagnosis in genes
responsible for congenital hypopituitarism in patients of St.
Petersburg were studied. Mutations in genes associated with
congenital hypopituitarism were identiﬁed in 16.3% of
patients with pituitary dwarﬁsm (16 of 98). The most
commonly diagnosed mutations are changes in gene
PROP1. In carrying out the molecular genetic studies of
patients with congenital hypopituitarism is necessary to
consider the likelihood of the presence of these rare
pathologies such as loss of genes GHSR, ARNT2, BTK.
Currently conducting molecular genetic studies in patients
with congenital hypopituitarism further predicts develop-
ment of the disease and, if necessary, adjust the ongoing
replacement therapy. The study was implemented under the
Alfa-Endo Charity Program and the Russian Science
Foundation grant №14-50-00069
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Diversity of reactions catalyzed by human and nema-
tode cystathionine gamma-lyase
P. Melenovska1, J. Sokolová1, J. Krijt1, R. Vozdek2,1, A.
Hnizda3,1, J. Kraus4, T. Majtan4, V. Kozich1
Institute of Inherited Metabolic Disorders, Charles
University-First Faculty of Medicine and General Hospital
in Prague, Prague, Czech Republic, 2Department of
Physiology, Cardiovascular Research Institute, UCSF
School of Medicine, San Francisco, CA, United States,
3Institute of Organic Chemistry and Biochemistry, Academy
of Sciences of the Czech Republic, Prague, Czech Republic,
4Department of Pediatrics, University of Colorado School
of Medicine, Aurora, CO, United States
Cystathionine gamma-lyase (CGL) is a multifunctional
enzyme that plays a pivotal role in conversion of cysta-
thionine to cysteine and is also known to catalyze produc-
tion of hydrogen sulﬁde. In our study, we used puriﬁed
human CGL and its orthologs CTH-1 and CTH-2 from
model organism C.elegans to analyze the substrate speci-
ﬁcity and to determine kinetic properties of selected reac-
tions using HPLC and LC-MS/MS analysis of aminothiols
and thioethers, respectively. The method of RNA inter-
ference was used to inhibit expression of nematode
enzymes CTH-1 and CTH-2 in vivo. The biochemical
analysis in C. elegans extracts shows that cth-2 knockouts
have elevated cystathionine and decreased cysteine levels
compared to wild-type and cth-1 knockouts. Consistently,
concentration of the glutathione precursor cysteinylglycine
was decreased in cth-2 mutants. These data together with
enzymatic activities indicate transsulfuration role of the
CTH-2. Similarly to human patients with CGL deﬁciency,
inhibition of cth-2 was not associated with a consistent
pathological phenotype.Besides previously deﬁne reactions,
we found that both human and nematode CTH-1 and CTH-
2 are able to catalyze reaction which uses cysteine as the
sulfur donor and homoserine or O-succinylhomoserine to
yield cystathionine. Up to now, this reverse transsulfuration
pathway was described only in bacteria, fungi and plants
but not in humans or nematodes; its physiological role is at
present unknown. Our data conﬁrms C. elegans as a sui-
table model of human CGL deﬁciency which results in
impaired transsulfuration and H2S-producing pathway.This
work was supported by the grant No. 16-30384A from the
Czech Health Research Council.
P. Melenovska: None. J. Sokolová: None. J. Krijt:
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MtDNA meta-analysis reveals both phenotype speciﬁcity
and allele heterogeneity: a model for differential
association
S. Marom, M. Friger, D. Mishmar
Ben Gurion University, Beer Sheva, Israel
Human mtDNA genetic variants have traditionally been
considered markers for ancient population migrations.
However, during the past three decades, these variants have
been associated with altered susceptibility to various phe-
notypes, thus supporting their importance for human health.
Nevertheless, mtDNA disease association has frequently
been supported only in certain populations, due either to
population stratiﬁcation or differential epistatic compensa-
tions among populations. To partially overcome these
obstacles, we performed meta-analysis of the multiple
mtDNA association studies conducted until 2016, encom-
passing 53,975 patients and 63,323 controls. Our ﬁndings
support the association of mtDNA haplogroups and recur-
rent variants with speciﬁc phenotypes such as Parkinson’s
disease, type 2 diabetes, longevity, and breast cancer.
Strikingly, our assessment of mtDNA variants’ involvement
with multiple phenotypes revealed signiﬁcant impact for
Caucasian haplogroups H, J, and K. Therefore, ancient
mtDNA variants could be divided into those that affect
speciﬁc phenotypes, versus others with a general impact on
phenotype combinations. We suggest that the mtDNA could
serve as a model for phenotype speciﬁcity versus allele
heterogeneity.
S. Marom: None. M. Friger: None. D. Mishmar:
None.
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Pitfalls in the diagnosis of Fabry disease: further evi-
dence that p.Asp313Tyr is a non-pathogenic
polymorphism
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Cité University, Paris, France, 7University of Versailles,
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Introduction: Fabry disease (FD, OMIM#301500) is a rare
X-linked inborn error of metabolism caused by mutations in
GLA. Over 700 unique DNA changes have been identiﬁed.
Case presentation: A 50-year-old male was referred to
us with a diagnosis of FD on the basis of familial hyper-
trophic cardiomyopathy (father and three sisters were also
affected) and identiﬁcation of a c.937G>T (p.Asp313Tyr)
change in GLA. Medical history could not document any
symptoms of FD. In particular, there was no acropar-
esthesia, gastrointestinal symptoms, or hypohidrosis. Phy-
sical examination and comprehensive imaging and
laboratory investigations showed absence of neurological or
renal involvement. Enzymatic assay found normal alpha-
galactosidase A activity in leukocytes. On the basis of the
aforementioned ﬁndings and father-to-son transmission of
the cardiomyopathy, NGS sequencing of sarcomeric genes
was performed. A missense mutation, previously associated
with sarcomeric HCM, was found in TNNI3 (p.Arg186Gln).
The diagnosis of FD was ruled out and costly enzyme
replacement therapy was consequently not initiated, but the
proband and his family members beneﬁted from rigorous
cardiac follow-up and genetic counselling.
Discussion: Our case highlights the importance of a
proper knowledge and recognition of variants of unknown
signiﬁcance and non-disease-causing polymorphisms in FD.
The presence of a GLA mutation alone does not constitute a
diagnosis. Hence, expert knowledge of the gene and its
mutations is essential for accurate diagnosis. The initiation
of ERT in a patient misdiagnosed as having FD is wasteful
from a health economic perspective and potentially harmful
because efforts to diagnose the patient’s disease will have
ceased.
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Mitochondrial complex I deﬁciency in patient with
FOXG1 mutation
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Stránecký3, H. Hansíková1, T. Honzík1, P. Martásek1, J.
Zeman1, M. Tesařová1
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Medicine, Charles University and General University
Hospital in Prague, Prague, Czech Republic
Introduction: FOXG1 syndrome presents as a severe
neurodevelopmental multisystemic disease with a complex
and quite multifaceted phenotype, as well as mitochondrial
disorders. In this study, we report on the biochemical and
genetic basis of a severe neurodevelopmental disorder in
two Czech pediatric patients, who both manifest encepha-
lopathy, epilepsy, developmental disability, microcephaly,
dyskinesia, spasticity and failure to thrive.
Materials and Methods: Genetic causes of patients dis-
order were determined with the use of whole exome
sequencing and MLPA assay. Biochemical study of oxi-
dative phosporylation (OXPHOS) was performed in affec-
ted patient tissues.
Results: In both patients, heterozygous mutations were
identiﬁed in the FOXG1 gene. A girl carried large deletion
encompassing exon 1. In a boy, additionally manifesting
lactic acidosis and hearing impairment, novel pathological
variant c.758delA was found. Furthermore, tissue speciﬁc
decrease of the mitochondrial respiratory complex I activity
was detected in his muscle.
Conclusions: Results give an extra supportive evidence
on phenotypic overlap of signs seen in primary mitochon-
drial disorders and features of the FOXG1 syndrome in
humans. Hence, we suppose that disturbances in OXPHOS
system may also play a signiﬁcant role in the etiology of the
FOXG1 syndrome.
This study was supported by grants RVO-VFN64165/
2012, UNCE 204011/2012, Progres Q26/LF1, and AZV15-
28208A.
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L444P :A Founder mutation of GBA gene in patients
affected with Gaucher disease from India
J. J. Sheth1, R. Bhavsar1, M. Mistri1, F. J. Sheth1, A.
Dalal2, S. Phadke3
FRIGE's Institue of Human Genetics, Ahmedabad, India,
2Centre For DNA Finger Printing, Hyderabad, India,
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Introduction: Gaucher disease (GD) is the most common
autosomal recessive inherited lysosomal storage disorder in
India. Present study was to identify the most common dis-
ease causing mutant allele and elucidate the molecular
characterization of novel disease causing mutation in
patients from India. Materials and Methods: Present study
consists of 36 patients in the age of 1 month to 32 years
with hepatosplenomegaly and thrombocytopenia. Six mil-
lilitre peripheral blood was collected from all the patients
for plasma chitotriosidase, conﬁrmative enzyme analysis
and bi-directional Sanger sequencing of coding region
covering exon-intron boundaries of the GBA gene. Novel
mutations were further identiﬁed by insilico analysis using
bioinformatics tools like SIFT, Polyphen2 and Mutation
Taster. Structural study of four novel missense mutant allele
was done using the Phyre2 software. Result and Discussion:
Study has identiﬁed 19 mutation in 33 patients. %). The
most common one was L444P (c.1448T>C) in 23 patients
(63.88%) with 16 homozygous and 7 compound hetero-
zygous mutant allele. Four novel mutations V17G
(c.167T>G)/L444P (c.1448T>C), S97L (c.407C>T)/L444P
(c.1448T>C), G360R (c.1195G>C)/R496C (c.1603C>T),
A448T (c.1459G>A)/A448T (c.1459G>A), and A448T
(c.1459G>A)/S125R (c.492C>G) in 6 (16.66%) patients
were also identiﬁed. Conclusion: L444P is the most com-
mon mutant allele in Indian patients with Gaucher disease.
While novel mutations are mostly affecting protein back-
bone leading to its misfolding. Acknowledgement: Present
study was carried out as a part of National Task Force
Multicentric project on Lysosomal storage disorders with a
grant from Department of Health and Indian Council of
Medical Research (Grant No: GIA/31(ii)/2014-DHR).
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Glucosylsphingosine concentration in the blood of
Gaucher patients reﬂects the severity of GBA mutations
- data from a large global cohort
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Gaucher disease (GD) is an autosomal recessive, rare
genetic disorder characterized by the deposition of gluco-
cerebroside in cells of the macrophage-monocyte system.
Standardized, simple and highly reproducible workﬂows for
the diagnosis are crucial, especially since more than 15
years a highly effective treatment is available. We have
developed and systematically validated a high-throughput
workﬂow for the simple testing of GD patients: beta-
glucocerebrosidase enzymatic activity, glycosylsphingosine
(lyso-Gb1) quantiﬁcation in DBS followed by GBA gene
sequencing from the same blood sample. Here, we report
data from over 1,000 GBA variants in over 640 Gaucher
individuals. Determination of lyso-Gb1 is performed by LC/
MRM-MS. Lyso-Gb1 was investigated in three GBA
cohorts comprising: (A) 133 GBA homozygotes ; (B) 226
GBA compound heterozygotes and (C) 201 Gaucher car-
riers. The lyso-Gb1 levels found Gaucher patients were:
very mild (12 - 25.0 ng/mL), mild (25.1 - 50 ng/mL),
moderate (50.1 - 200 ng/mL) and severe (>200 ng/mL).
Lyso-Gb1 prouved a sensitivity and speciﬁcity of 100%.
The clinical severity of different mutations could be corre-
lated with the lyso-Gb1 in the homozygous cases, e.g.
c.1295G>T have mild lyso-Gb1 values while c.1060G>A
and c.518C>A have extremely high lyso-Gb1 values (>600
ng/mL). The most common mutations were c.1226A>G
(30.1%) and c.1448T>C (24.7 %). While c.1448T>C is a
severe mutation correlating to a massive increase of lyso-
Gb1 up to 1,250 ng/mL. lyso-Gb1 for c.1226A>G can vary
from very mild to moderate. Lyso-Gb1 concentrations in
blood can be used for the easy and early diagnosis of
Gaucher patients and treatment monitoring.
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A family of HHH syndrome with a novel missense
mutation in SLC25A15 gene
U. Abur1, G. Ogur1, C. Dogan1, H. I. Aydin2, E.
Altundag1, S. Ceylaner3
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Introduction:Hyperornithinemia-hyperammonemia-
homocitrullinuria (HHH) syndrome is a rare genetic dis-
order of the urea cycle caused by mutations in the
SLC25A15 gene. It represents a heterogeneous disease with
clinical variability, ranging from a mild form with slight
neurological impairment to a more severe form with coma,
lethargy, hepatic signs and seizures. Only about 50 cases
have been reported. We here report a HHH family with a
novel missense mutation in SLC25A15 gene.
Case presentation: 24 year-old mother with a medical
story of a deceased infant was referred to our genetic center
because of a demand for a new baby. The index case, a
female baby was born at term. Soon after term the baby
died. Metabolic screening showed signs of HHH syndrome:
hyperornithinemia 410 μmol/L (48–211 μmol/L), hyper-
ammonemia 3999μmol/L (18,7–86,9μmol/L) and increased
orotic aciduria. Blood liver enzymes were elevated
(AST;236, ALT;301) and there were parameters of coagu-
lopathy. The DNA of the baby was not available thus DNA
of the parents were sequenced for mutations in the
SCL25A15 gene. Analysis revealed a novel heterozygous
missense mutation in exon 6 (p.D231V;c.692A>T) in each
parent. The family did not accept the prenatal diagnosis and
a male baby with HHH was born from second pregnancy.
He had the same homozygous mutation. A protein-restricted
diet was administered and no life threating complications
(lethargy, coma and hepatic failure) developed.
Discussion/Conclusion:Early identiﬁcation of HHH
syndrome is extremely important, because hepatic failure
can be prevented with treatment. Mutational screening of
the SLC25A15 gene is crucial for an early and accurate
diagnosis of the disease.
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A novel HNF4A pathogenic variant in a case of con-
genital hyperinsulinism with glycogenosis - like
phenotype
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Introduction: Congenital hyperinsulinism (CHI) and gly-
cogen storage disease (glycogenosis) are both causing
hypoglycemia during infancy, but with different additional
clinical features and therapeutic approach.
Patients and Methods: We present a child with an
ambiguous phenotype - hyperinsulinemic hypoglycemia,
physiological 3-OH butyrate, increased triglyceride serum
levels, increased level of glycogen in erythrocytes,
increased liver transaminases, and increased echogenicity
on liver ultrasonography. As both parents of the proband
were referred as healthy, we raised a clinical suspicion on
glycogenosis with recessive inheritance.
Results: The whole exome sequencing revealed no
mutation in genes causing glycogenosis, but a novel het-
erozygous variant LRG_483t1: c.427-1G>A in the HNF4A
gene was identiﬁed. Aberrant splicing resulting in in-frame
deletion c.429_476del, p.(T144_I159del) was conﬁrmed by
sequencing of HNF4A transcripts reverse-transcribed from
whole blood RNA. Haploinsufﬁciency in HNF4A can cause
CHI and results in maturity-onset diabetes mellitus in young
adults. The same variant was found in ﬁve of eight tested
family relatives (one of them already had diabetes, two had
prediabetes). With regard to the results of DNA analysis, the
insulin secretion inhibitor diazoxide was added to the
therapy. Consequently, the frequency and severity of
hypoglycemia in the proband decreased.
Conclusion: We have identiﬁed a novel pathogenic var-
iant in the HNF4A gene in our patient with CHI and
glycogenosis-like phenotype. The proband and her family
members beneﬁted from the genetic testing by WES method
and consequently personalized therapy. Nevertheless, the
HNF4A gene testing may be considered in selected CHI
cases with glycogenosis-like phenotype prior WES analysis.
Supported by: APVV-107-12
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Better identiﬁcation of patients with pediatric hypo-
phosphatasia. Utility of the laboratory screening for
recurrent low levels of alkaline phosphatase adjusted for
gender and age
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Introduction: Hypophosphatasia (HPP) is a rare hereditary
disorder, which is characterized mainly by poor miner-
alization of bone and teeth. It is caused by mutations in the
ALPL gene leading to deﬁciency of the tissue-nonspeciﬁc
isoenzyme of alkaline phosphatase, and accumulation of its
substrates: phosphoethanolamine, pyridoxal-5ʹphosphate
and inorganic pyrophosphate. In Europe the prevalence of
moderate and severe hypophosphatasia is estimated at 1/
6,370 and 1/300,000, respectively.The most severe forms of
hypophosphatasia present an autosomal recessive inheri-
tance, whereas the moderate form can be both recessive and
dominant. Screening for mutations in the ALPL gene allows
diagnosis of approximately 95% of severe cases.Alkaline
phosphatase levels depend on sex and age, mainly due to
bone growth. The Canadian Laboratory Initiative in
Pediatric Reference Intervals (CALIPER) study established
reference lower-threshold levels of the enzyme. Materials
and Methods: We evaluated the utility of screening for
persistent low alkaline phosphatase without ﬂuctuations in
pediatric population, taking into account the reference
values described by the CALIPER study. Sequencing of the
coding exons and intron/exon boundaries of ALPL was
performed in the selected patients. Results: We selected 38
children, of which 25 participated in the study. We found 3
patients with mutation in gene ALPL (12%). Increased
levels of serum pyridoxal-5′ phosphate was detected in all
of them. Conclusions: We observed higher mutation pre-
valence than previously reported. Thus, this study supports
the efﬁcacy of the screening with persistent low levels of
alkaline phosphatase, using reference values obtained by the
CALIPER study, to detect new cases of HPP.
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Zulueta: None. M.J. Ceñal González-Fierro: None. C.
Mercado Díaz: None. M. Olid Velilla: None. N. Torres
Pacho: None. S. Villanueva Curto: None. J. Tenorio
Castaño: None. P. Lapunzina: None. M.T. Darnaude
Ortiz: None.
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Mutational spectrum of CYP24A1 and SLC34A1 genes
in a group of Polish patients with idiopathic infantile
hypercalcemia
P. Halat1, E. Ciara1, A. Janiec2, M. Rydzanićz3, J.
Kosińska3, P. Stawiński3,4, D. Siestrzykowska1, D.
Piekutowska-Abramczuk1, M. Pelc1, D. Jurkiewicz1, B.
Chałupczyńska1, P. Kowalski1, A. Jacoszek3,5, R. Płoski3,
J. B. Książyk2, M. Krajewska-Walasek1, M. Litwin6, E.
Pronicka1,2
1Department of Medical Genetics, The Children's Memorial
Health Institute, Warsaw, Poland, 2Department of Pedia-
trics, Nutrition and Metabolic Diseases, The Children's
Memorial Health Institute, Warsaw, Poland, 3Department
of Medical Genetics, Warsaw Medical University, Warsaw,
Poland, 4Department of Genetics, Institute of Physiology
and Pathology of Hearing, Warsaw, Poland, 5Postgraduate
School of Molecular Medicine, Warsaw, Poland, 6Depart-
ment of Nephrology, The Children's Memorial Health
Institute, Warsaw, Poland
Idiopathic infantile hypercalcemia (IIH) is a mineral meta-
bolism disorder characterized by severe hypercalcemia,
failure to thrive, vomiting, dehydration and nephrocalci-
nosis. Molecular analysis of CYP24A1 and SLC34A1 was
conducted using Sanger sequencing and next-generation
sequencing to identify the molecular basis of the disease in
41 Polish patients. A genetic etiology of IIH was established
in 14 patients. Overall, eleven different pathogenic variants
were identiﬁed. Five known mutations (c.428_430del,
c.443T>C, c.964G>A, c.1186C>T, c.1226T>C) and three
novel variants (c.107del, c.475C>T, c.1157+1G>A) in
CYP24A1 and three known mutations (c.272_292del,
c.464T>C, c.1425_1426del) in SLC34A3 were revealed.
Biallelic occurrence of changes was observed in all patients,
except for one case in which only one mutated allele of
SLC34A1 was found. The novel changes expand the list of
pathogenic mutations in CYP24A1. The study identiﬁed the
most frequent mutation c.1186C>T (p.R396W), which was
found in 50% of CYP24A1 alleles (12/24). Based on this
(and general population) data, the overall carrier frequency
for all mutations in CYP24A1 was calculated as 1.36%.
Thus, the incidence of IIH in the Polish population was
estimated as 1:21,626 births. This indicates that at least
1,500 homozygotes and compound heterozygotes with IIH
risk may be living in the country. Differences in the
mechanism of developing hypercalcemia indicate that its
prevention is different in each of the IIH defects. We sug-
gest that molecular testing for CYP24A1 and SLC34A1
mutations be performed in each case of idiopathic
hypercalcemia/hypercalciuria and high vitamin D levels to
determine the appropriate acute treatment and prevention of
complications. Grants: NSC-2014/15/B/NZ5/03541;CMHI-
180/09.
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P06.17A
Genome-wide association study of infantile hypertrophic
pyloric stenosis identiﬁes four new loci
J. Fadista1, L. Skotte1, F. Geller1, J. Bybjerg-Grauholm1,
S. Gørtz1, H. A. Boyd1, D. M. Hougaard1, M. Melbye1,2,3,
B. Feenstra1
Statens Serum Institut, Copenhagen, Denmark, 2University
of Copenhagen, Copenhagen, Denmark, 3Stanford Uni-
versity, Stanford, CA, United States
Introduction: Infantile hypertrophic pyloric stenosis
(IHPS) is the most common cause of intestinal obstruction
in infancy. IHPS is caused by hypertrophy of the smooth
sphincter muscle that surrounds the pylorus, which connects
the stomach to the duodenum. Materials and Methods: We
performed a genome-wide association study of 1,395
Danish surgery-conﬁrmed cases and 4,438 controls in order
to detect novel loci associated with IHPS. The analysis was
based on 6.6 million variants imputed from the Haplotype
Reference Consortium panel, using logistic regression on
imputed SNP dosages for association testing. Results: In
addition to variants at the known MBNL1, ARHGEF26,
NKX2-5 and APOA1 loci, we found four new loci with
variants reaching genome-wide signiﬁcance (P<5×10-8).
The most strongly associated variant (minor allele fre-
quency; MAF=2%) had an odds ratio (OR) =2.5
(P=5.0×10-14) and is intronic to MTA3, a gene that when
knocked out in mice leads to decreased levels of circulating
LDL cholesterol. The second signal came from a common
variant (MAF=26%, OR=1.3, P=2.7×10-9), which is an
eQTL for SLMAP, a gene with highest expression in
smooth muscle. The third variant (MAF=9%, OR=1.5,
P=4.6×10-9) is an eQTL for PTPDC1, while the fourth
variant (MAF=12%, OR=1.4, P=3.2×10-8) is in a gene
desert at 13q21.31. Using the GCTA method on all geno-
typed SNPs, we estimated the heritability of IHPS to be
52%. Conclusion: Our ﬁndings identify novel genetic
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associations with IHPS, and highlight their putative func-
tional target genes.
Grant support: Danish Medical Research council (DFF
4004-00512; DFF 1331-002440A), Novo Nordisk Foun-
dation, Oak Foundation, Carlsberg Foundation.
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A proper deﬁnition of the target phenotype greatly
improves the identiﬁcation of rare causative mutations:
lessons from the study of 280 suspected HFE hemo-
chromatosis patients treated by phlebotomy
K. UGUEN1,2,3, V. SCOTET1,4, C. KA1,2, I. Gourlaouen4,1,
C. L'HOSTIS5,1, T. CUPPENS1,3, E. GENIN1, C.
FEREC1,3,2, G. LE GAC1,3,2,4
1Inserm UMR1078, Brest, France, 2CHRU de Brest,
Laboratoire de Génétique Moléculaire et d'Histocompati-
bilité, Brest, France, 3Université Bretagne Loire-Université
de Bretagne Occidentale, IBSAM, Brest, France, 4EFS -
Bretagne, Brest, France, 5Association Gaetan Saleun,
Brest, France
Introduction: The best-known and prevalent form of
hemochromatosis (HC) is a an adult-onset autosomal
recessive condition usually associated with the HFE p.
[Cys282Tyr];[Cys282Tyr] genotype. A second genotype, p.
[Cys282Tyr];[His63Asp], is frequently observed. However,
compound heterozygotes patients have a distinct iron
overload phenotype (mild to moderate), usually associated
with the presence of comorbid factors. Rare HFE variants
exist but they are not screened in routine. Materials and
Methods: We selected 35 patients from a cohort of 280 p.
[Cys282Tyr];[=] or p.[Cys282Tyr];[His63Asp] patients
treated by phlebotomy. All these patients presented with
hyperferritinemia and elevated transferrin saturation (≥60%
in males; ≥50% in females), which is a hallmark of hemo-
chromatosis. We excluded patients with secondary causes
of hyperferritinemia: excessive alcohol intake (n= 9),
conﬁrmed metabolic syndrome (n= 134), or both (n= 13).
Next-Generation Sequencing was used to investigate the
ﬁve known hemochromatosis genes (HFE, HFE2, HAMP,
TFR2, SLC40A1). Results: Mutations were only detected
in HFE. The p.Trp155* and c.76+2 T>C mutations, which
cause a truncating protein, were identiﬁed in two p.
[Cys282Tyr];[=] patients. They were not detected in 1460
control chromosomes. The splicing defect of the intronic
mutation was conﬁrmed using the POLR2G minigene
system. A complex allele [His63Asp; Glu168Gln] was
found in trans with the p.[Cys282Tyr] mutation in one
patient. Haplotype inference and cloning experiments con-
ﬁrmed this ﬁnding. The [His63Asp; Glu168Gln] complex
allele is not very rare in our local population (western
extremity of Brittany; MAF: 4/1460). Conclusion: A
complete HFE sequencing is mandatory in p.Cys282Tyr
heterozygous patients with a typical hemochromatosis
phenotype.
K. Uguen: None. V. Scotet: None. C. Ka: None. I.
Gourlaouen: None. C. L'hostis: None. T. Cuppens:
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Identiﬁcation of a human D-lactate dehydrogenase
G. R. Monroe1,2, A. M. van Eerde1,2, F. Tessadori1,2,3, K.
J. Duran1,2, S. M. C. Savelberg1,2, J. C. van Alfen4, S. N.
van der Crabben1, K. D. Lichtenbelt1, J. Gerrits1, M. J.
van Roosmalen1,2, M. van Aalderen1, B. G. Koot5, M.
Oostendorp6, M. Duran7, G. Visser8, T. de Koning9, F.
Calì10, P. Bosco10, M. G. M. de Sain-van der Velden1, N.
V. Knoers1,2, J. Bakkers3,11, N. M. Duif-Verhoeven1,2, G.
van Haaften1,2, J. J. Jans1,2
Department of Genetics, University Medical Center
Utrecht, Utrecht, Netherlands, 2Center for Molecular
Medicine, University Medical Center Utrecht, Utrecht,
Netherlands, 3Hubrecht Institute-KNAW, Utrecht, Nether-
lands, 4Bartiméus, Institute for the Visually Impaired,
Doorn, Netherlands, 5Department of Pediatric Gastroen-
terology and Nutrition, Academic Medical Center, Amster-
dam, Netherlands, 6Department of Clinical Chemistry and
Haematology, University Medical Center Utrecht, Utrecht,
Netherlands, 7Laboratory Genetic Metabolic Diseases,
Academic Medical Center, Amsterdam, Netherlands,
8Department of Pediatric Gastroenterology and Metabolic
Diseases, Utrecht, Netherlands, 9Section of Metabolic
Diseases, Beatrix Children’s Hospital, University Medical
Center Groningen, Utrecht, Netherlands, 10Oasi Institute
for Research on Mental Retardation and Brain Aging
(IRCCS), Troina, Italy, 11Department of Medical Physiol-
ogy, University Medical Center Utrecht, Utrecht,
Netherlands
Introduction: Human knockouts may provide direct insight
into gene function. We identiﬁed two patients homozygous
for loss-of-function variants in LDHD, lactate dehy-
drogenase D. Lactate dehydrogenases catalyze the inter-
conversion of pyruvate and lactate during anaerobic
glycolysis, with L-lactate the form utilized in eukaryotic
metabolism. D-lactate, the stereoisomer, is normally present
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physiologically at much lower levels. D-lactate in the
human body has received recent attention due to D-lactic
acidosis incidence, a complication of short bowel syndrome
following bariatric surgery.
Materials and Methods:
Mass spectrometry performed on two patients identiﬁed
increased urine excretion and elevated plasma concentration
of D-lactate, D-2-hydroxyisovaleric acid and D-2-
hydroxyisocaproic acid. Sanger sequencing was performed
on LDHD, a candidate gene in a region of homozygosity
identiﬁed by SNParray. Functional studies were performed
in the zebraﬁsh model organism using a LDHD knockout
line and patient variant expression. Metabolic levels of D-
lactate were evaluated by mass spectrometry.
Results:
Sanger sequencing identiﬁed two novel, homozygous
LDHD missense variants. LDHD loss-of-function in zeb-
raﬁsh resulted in increased D-lactate concentration.
Expressing human wildtype LDHD rescued D-lactate
metabolism resulting in D-lactate concentration decrease.
In contrast, patient variant LDHD expression was unable to
restore LDHD function and resulted in elevated D-lactate
levels. Together our results conﬁrmed a role of LDHD in D-
lactate metabolism and the loss-of-function effect of our
patient’s variant.
Conclusion:
LDHD has been identiﬁed as a putative metabolizer of
D-lactate but its function had not been shown in vivo. Our
work provides the ﬁrst evidence that LDHD is essential for
D-lactate metabolism in humans.
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Molecular basis of autosomal dominant hypercholes-
terolemia in the Czech Republic
L. Tichy1, J. Pavlouskova2, T. Freiberger3, L. Fajkusova1
1University Hospital Brno, Brno, Czech Republic, 2Masaryk
University, Brno, Czech Republic, 3Centre for Cardiovas-
cular Surgery and Transplantation, Brno, Czech Republic
Introduction: Autosomal dominant hypercholesterolemia
(ADH) is a lipid metabolism disorder characterized by an
elevation in low-density lipoprotein cholesterol and
increased risk for cardiovascular disease. Predominantly,
the clinical phenotype of ADH is caused by mutations in the
LDLR or APOB genes.
Materials and Methods: PCR-RFLP of the APOB
mutation p.(Arg3527Gln); sequencing of the LDLR gene
coding sequence (Sanger sequencing till 2014, actually next
generation sequencing using ADH Master kit (Multiplicom,
Belgium)); MLPA of the LDLR gene. Confocal laser
scanning microscopy was used to analyze the LDLR
expression and binding of the LDL particles to LDLR in
stably transfected Chinese hamster ovary cells. DNA sam-
ples have been collected within the framework of the
MedPed project.
Results: We assessed a spectrum of mutations in 3914
unrelated patients with clinical diagnosis of autosomal
dominant hypercholesterolemia. We have found 432
patients (11.0%) with the APOB gene mutation p.
(Arg3527Gln) and 864 patients (22.1%) with the LDLR
gene mutation. 182 unique allelic variants in LDLR gene
were detected. Using MLPA, 22 different large rearrange-
ments were found. Functional analyses of LDL receptor
protein revealed that the controversial sequence variant p.
(Gly20Arg) is able to reach the cell membrane and to bind
the LDL particle in a similar way as the wt LDLR protein.
Conclusions: The results achieved in the number of
diagnosed patients are comparable with other countries
worldwide. Confocal laser scanning microscopy was
introduced to analyse the LDLR protein expression and
function.
This work was funded by the grants IGA MH CR 16-
29084A and TACR TE02000058.
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Genetic study of Familial Hypercholesterolemia in a
hospital population of Buenos Aires, Argentina
A. Gómez1, G. Giunta2, L. Kaeser1, L. Herman2, A. Costa
Varsi2, P. Morikone1, J. Puente-Prieto3, U. Toscanini1
PRICAI-FUNDACIÓN FAVALORO, Buenos Aires, Argen-
tina, 2Metabolic Unit Service of Favaloro Foundation
University Hospital, Buenos Aires, Argentina, 3LabGe-
netics, Madrid, Spain
Introduction
Familial hypercholesterolemia (FH) is a health problem
that affects a signiﬁcant number of people in Argentina and
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it is one of the factors that determines the early establish-
ment of cardiovascular disease. It is inherited in an auto-
somal dominant manner with 60–80% percent of the
mutations located in the LDLR gene.
Material and Method
The LDLR gene coding regions, adjacent splice sites and
promoter regions were Sanger sequenced in a cohort of 38
unrelated patients with clinical diagnosis of FH and 10
healthy normolipemic controls at the Metabolic Unit Ser-
vice of Favaloro Foundation University Hospital.
Results and Conclusions
In this study we found 24 different pathogenic variants in
the LDLR gene in 23 patients (60,5%), most of them located
in exons 4 and 12. Of these 24 variants, 16 were previously
described and 8 were novel variants (6 located in coding
regions and 2 in the LDLR promotor) predicted to be
pathogenic according to different in silico prediction tools.
Four out of the 7 patients who carry the novel variants
presented subclinical carotid disease, aortic and lower limb
disease; 3 of them required myocardial revascularization
surgery. In addition, 4 of these patients had family history
of hypercholesterolemia.
These results show the importance of the genetic testing
in index cases with the aim of achieving a better adherence
to treatment, re-stratiﬁcation of the risk of early cardiovas-
cular disease onset, and a prompt genetic counseling in a
familial context.
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Functional genomics of stimulated human hepatocytes
revealed long non-coding RNAs involved in liver
inﬂammation
B. Atanasovska1,2, S. S. Rensen3, G. Marsman1, Y. Li2, V.
Kumar2, I. Jonkers2, S. Withoff2, C. Wijmenga2, B. van de
Sluis1, J. Fu1,2
1University of Groningen, University Medical Center
Groningen, Department of Pediatrics, Molecular Genetics,
Groningen, Netherlands, 2University of Groningen, Uni-
versity Medical Center Groningen, Department of Genetics,
Groningen, Netherlands, 3Department of Surgery, Univer-
sity Hospital Maastricht and Nutrition and Toxicology
Research Institute (NUTRIM), University of Maastricht,
Maastricht, Netherlands
Introduction: In recent years functional genomics has
become a powerful tool to understand complex cellular
processes by studying gene transcription, translation,
interactions and epigenetic regulation. This approach often
involves high-throughput methods such as RNA-
sequencing technology, a technique which allows scien-
tists to detect a large proportion of functional RNA mole-
cules known as long non-coding RNAs (lncRNAs). Here,
we aim to investigate the involvement of lncRNAs in non-
alcoholic steatohepatitis (NASH) by combining hepatocyte
and liver transcriptome data.
Materials and Methods: We generated a cellular model to
mimic NASH by stimulating human hepatocytes with free
fatty acids (FFA) to mimic steatosis and tumor necrosis
factor alpha (TNFα) to mimic inﬂammation for 30 min, 3
and 5 hours. Gene expression proﬁles were determined by
performing whole genome RNA-sequencing.
Results: We detected 4373 differentially expressed
genes in all conditions from which 109 were lncRNAs
(FDR<0.1). Pathway analysis showed gene enrichment in
crucial processes including oxidation-reduction, cell pro-
liferation, lipid metabolism (FFA stimulation) and tran-
scriptional and translational initiation, NF-kB signaling and
Wnt signaling (TNF stimulation) as top enriched pathways.
We have selected two lncRNA for functional studies:
lncRNA1 showing 3 fold down-regulation and
lncRNA2 showing 15 fold up-regulation upon TNFα sti-
mulation. The response to inﬂammatory stimuli was in line
with our human data where the lncRNA was negatively
(lncRNA1) or positively (lncRNA2) correlated with NASH
phenotypes.
Conclusion: Using functional genomic approach we
identiﬁed lncRNAs which may be involved in regulation of
liver inﬂammation. This knowledge may offer new avenues
for the development of novel therapeutic strategies.
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Biochemical and genetic data in the largest global Fabry
cohort
S. Shenbakar1, C. Cozma1, S. Schröder1, M. Iurascu1, G.
Oprea1, G. Kramp1, S. Eichler1, J. Lukas2, A. Rolfs2,1
1Centogene AG, Rostock, Germany, 2Albrecht-Kossel-
Institute, University of Rostock, Rostok, Germany
Fabry disease is an X-linked inherited lysosomal storage
disease characterized by a deﬁcient alpha-galactosidase
caused by mutations in GLA gene. Fabry diagnosis is per-
formed in a high-throughput stepwise manner: (a.) males-
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enzymatic activity, lyso-Gb3 quantiﬁcation, followed by
GLA gene sequencing and, (b.) females- GLA gene
sequencing followed by lyso-Gb3. In the development and
validation of the enzymatic assay we observed that alpha-
galactosidase determination in DBS alone is insufﬁcient for
a precise diagnosis of Fabry disease, both in females (ppv
78%) and males (ppv 94.2%) due to multiple variables:
leukocyte count; hematocrit level; sample handling, lyoni-
sation effect in females. To eliminate the differences
between samples several optimizations were introduced:
chemical blank for each sample, a standard curve measured
in the presence of blood extract and the ratio alpha-
galactosidase to another lysosomal enzyme (beta-glucur-
onidase). Lyso-Gb3 was measured using mass spectrometry
(LC/MRM-MS). Mild mutations or late onset patients pre-
sent levels of lyso-Gb3 in normal range (21.59 % of all
Fabry male cases). However, by combining the data from
three different biochemical parameters (Lyso-Gb3, alpha-
galactosidase and ratio alpha-galactosidase / beta-glucur-
onidase) we can simply distinguish between the cohorts of
normal controls, mild (or late onset) Fabry cases and
affected Fabry cases. The biochemical diagnosis was con-
ﬁrmed in all cases by genetic analysis. We report here the
identiﬁcation of over 390 unique GLA genetic variants in
over 3,330 Fabry individuals. From the ca 3,400 allele
sequenced in this study, the most abundant were: c.
937G>T (17.5%); c. 376A>G (20.3%); c. 352C>T (7.2%);
c. 427G>A (5.6%).
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Mutation analysis of LIPA through NGS in a cohort of
731 patients with nonalcoholic hepatic steatosis and
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Introduction Lysosomal Acid Lipase Deﬁciency (LAL-D)
(LIPA, MIM613497) is a rare disease related to two dif-
ferent phenotypes: Wolman disease (WD) and cholesteryl
ester storage disease (CESD). WD is a severe disease that
causes disseminated organ foam cell inﬁltration of liver,
spleen and other organs due to the accumulation of mac-
rophages ﬁlled with cholesterol-esters and triglycerides. The
allele frequency of the most common variant in CESD
(c.894G>A;p.E8SJM) ranged from 0,05% in Asians to
0,17% in Caucasian. The aim of this study was to perform a
molecular analysis of LIPA in a cohort of patients with
nonalcoholic hepatic steatosis (NHS) and familial
hypercholesterolemia (FH), looking for mutations and
changes in LIPA and estimates the allele frequency of the
c.894G>A mutation.
Material y methods Two different NGS panels were
applied in 328 patients with FH and 403 patients with NHS.
Design and capture were carried out with Nimbledesign and
sequencing was done with both NextSeq500 and MiSeq
platforms.
Results We have found a compound heterozygous
mutation in a patient with NHS. Seven additional carriers of
LIPA mutations have been found (ﬁve was the c.894G>A;p.
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E8SJM mutation). Two of these patients with the recurrent
mutation belongs to the NHS group (0,49%) and ﬁve to the
FH group (1,1%).
Conclusions
Allele frequency of LIPA mutations in patients with NHS
and FH are signiﬁcatively higher compared to the general
population. These results suggested that mutations in this
gene could modulate in some way the phenotype in patients
with nonalcoholic hepatic steatosis and familiar
hypercholesterolemia.
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Uyguner2
Istanbul University, Cerrahpasa Medical School, Depart-
ment of Pediatric Genetics, İstanbul, Turkey, 2Istanbul
University, Istanbul Medical School, Department of Med-
ical Genetics, İstanbul, Turkey
Introduction: Mucopolysaccharidosis IVA (MPS IVA) is a
lysosomal storage disease caused by the mutation in the
GALNS gene, encoding galactosamine 6 sulfate sulfatase
enzyme and characterized by progressive skeletal dysplasia
with short stature and severe dysostosis multiplex. We
aimed to investigate clinical and molecular features of the
patients with MPS IVA. Material and Method: 26 clinically
diagnosed and enzymatically conﬁrmed MPS IVA patients
from 19 families were enrolled in this study. All exons and
exon-intron boundries of GALNS gene was studied by
Sanger sequencing method in 18 families. Results: The
median age of patients at diagnosis was 3.0 years (0,1–18,5
years). 23 patients were diagnosed with severe and three
with intermediate form of disease. Initial ﬁnding was ske-
letal deformities. Short stature was apparent by early
childhood in most of the patients; the median of height SDS
at 2, 5, 10 and 15 years of age were -0.6, -3.4, -7.0, -8.1
respectively. Walking was impaired in 7 patients at the
mean age of twelve. Corneal clouding, hearing loss and
heart involvement were detected in 60–70% of the patients.
Molecular analysis revealed ten known mutations (one
deletion, nine missense) and one novel mutation (p.G139D)
in the patients with severe form. Most common mutation
was p.W141R. Known mutations were reported in severe
form of the diseases previously. We determined homo-
zygous known mutation (p.R251Q and p.F346L) in three
patients which were presented as intermediate phenotype.
Conclusion: This study is the ﬁrst large cohort showed
clinical characteristic and mutation spectrum of Turkish
patients with MPSIV.
B. Tuysuz: None. D. Uludag Alkaya: None. G. Tok-
soy: None. N. Gunes: None. Z. Uyguner: None.
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Nucleotide analysis of a gene panel involved in Lysoso-
mal Storage Disease (LSD) in patients with a strong
clinical suspicion
A. Gheldof1,2, S. Seneca1,2, K. Stouffs1,2, G. Martens3, L.
De Meirleir4
1Centre of Medical Genetics, UZBrussel, Brussels, Belgium,
2Neurogenetics Research Group, Reproduction Genetics
and Regenerative Medicine Research Group, Vrije Uni-
versiteit Brussel, Brussels, Belgium, 3VUB Metabolomics
Platform, Vrije Universiteit Brussel, Brussels, Belgium,
4Paediatric Neurology Unit, Department of Paediatrics, UZ
Brussel, Brussels, Belgium
The diagnostic workup in patients clinically suspected of
Lysosomal Storage Diseases (LSD) is often challenging due
to the variability in the clinical phenotype and inconsistent
genotype-phenotype correlations. The standard sequential
workﬂow of a urine screening, followed by enzymatic
testing and a ﬁnal conﬁrmation by iterated Sanger sequen-
cing is time consuming, not widely available and poorly
standardized. To counter these issues, we developed a next
generation sequencing (NGS) gene panel for mutations in
50 LSD-causing genes . Over a period of ten months, we
analysed 80 samples from patients with a strong clinical
suspicion of an LSD. Our panel was able to determine the
molecular cause of the disease in 14 cases (17%), including
diseases such as ceroid lipofuscinosis type 6 and 7, Nie-
mann Pick C, Wolmann disease, MPSI, II and IV (Morquio
B), cystinosis, mannosidosis type I and II and ﬁnally
mucolipidosis type II and III. Most of these patients were
missed by multiple rounds of conventional biochemical
testing. The NGS-based approach was also able to redirect
certain diagnoses: e.g., a patient initially suspected of
galactosialidosis was found to be compound heterozygous
for pathogenic mutations in the GNPTAB gene, causing
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mucolipidosis type II or III. Additionally, we identiﬁed
several patients as carriers of pathogenic mutations in LSD
genes, including GBA. Carriers of GBA mutations have an
increased chance of developing early onset Parkinsonism,
making early genetic counselling possible. In view of these
results, we propose that panel-based NGS should be con-
sidered as ﬁrst-line test in the LSD diagnostic workﬂow.
A. Gheldof: None. S. Seneca: None. K. Stouffs: None.
G. Martens: None. L. De Meirleir: None.
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Mitochondrial DNA sequence context in the penetrance
of mutations: a study across multiple lineages results
with diagnostic signiﬁcance
R. A. Queen1, J. S. Steyn1, P. Lord1, J. L. Elson1,2
Newcatsle University, Newcastle, United Kingdom, 2North-
West University, Potchefstroom, South Africa
Introduction: Mitochondrial DNA (mtDNA) mutations are
an important cause of inherited disease. Diseases caused by
mtDNA mutations exhibit a high degree of clinical het-
erogeneity with a complex genotype-phenotype relation-
ship, with many mutations exhibiting incomplete
penetrance. There is evidence that the spectrum of muta-
tions causing mitochondrial disease might differ between
different mitochondrial lineages (haplogroups) seen in dif-
ferent global populations. This would point to the impor-
tance of sequence context in the expression of mutations.
Methods: To explore this possibility, we looked for muta-
tions, which cause disease in humans, in animals of other
species unaffected by mtDNA disease. Results: The
m.3243A>G mutation on the mt-tRNA-Leu(UUR) being
the most frequently seen mutation in humans. This study
looked for the presence of m.3243A>G in 2784 sequences
from 33 species, as well other mutations reported in asso-
ciation with disease located on mt-tRNA-Leu(UUR). Our
initial report showed a number of disease associated varia-
tions found on mt-tRNA-Leu(UUR) in other chordates, as
the major population variant, with m.3243A>G being seen
in 6 species. In these, we also found a number of mutations
that could be compensatory that is could mask the patho-
genicity associated with this change in humans. In follow-
up work just completed, we can report ﬁnding other
disease-causing mutations in other mt-tRNA’s supporting
our early observations and assertions. Conclusions: This
work has important implications for the discovery and
diagnosis of mtDNA mutations in non-European popula-
tions. It might provide a partial explanation for the con-
ﬂicting results in the literature that examines the role of
mtDNA variants in complex traits.
R.A. Queen: None. J.S. Steyn: None. P. Lord: None. J.
L. Elson: None.
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Challenges in clarifying the at-risk status for malignant
hyperthermia
C. L. Goldsmith, D. A. Dyment, K. M. Boycott
Children's Hospital of Eastern Ontario, Ottawa, ON,
Canada
Malignant hyperthermia susceptibility (MHS) is an auto-
somal dominant disorder of calcium regulation in skeletal
muscle; a molecular cause can be identiﬁed in 70% to 80%
of affected individuals. While failure to recognize an at-risk
patient can have serious consequences, inaccurately label-
ling a patient incurs costs to the health care system. Clar-
ifying at risk status for MHS begins with testing a clearly
affected individual. In a retrospective review of the 52
individuals referred from 2011–2016 for a personal or
family history of MHS, 11 referrals were for affected
individuals. Mutations in the RYR1 gene were found in 4/
11 (36%). The mutation was known for 4/41 of the indi-
viduals referred based on family history. In the remaining
37 cases, the family history was conﬁrmed in 30 but the
affected relative was available to be tested in only 4
families; a mutation was found in 1/4. Our review revealed
that 29% of the 52 referrals received for a personal or family
history of MHS underwent genetic testing; a mutation was
identiﬁed in 33%, a rate signiﬁcantly lower than that
reported in the literature. 87% of individuals with a con-
ﬁrmed family history of a MHS event were unable to
undergo genetic testing; improvements in the sensitivity and
speciﬁcity of MHS testing will allow genetic testing for
individuals where the index case is unavailable.
C.L. Goldsmith: None. D.A. Dyment: None. K.M.
Boycott: None.
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Mendelian randomization approach infers causality
links between gut microbiome and glucose/insulin
metabolism and type 2 diabetes
S. Sanna1, U. Võsa1, A. Vich Vila1,2, M. J. Bonder1, A.
Kurilshikov1, F. Imhann1,2, R. Weersma2, L. Franke1, A.
Mahajan3, N. Van Zuydam3, M. Costa3, M. McCarthy3, A.
Zhernakova1, J. Fu1,4, C. Wijmenga1
University Medical Center Groningen, Department of
Genetics, Groningen, Netherlands, 2University Medical
Abstracts from the 50th European Society of Human Genetics Conference:. . . 301
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Hepatology, Groningen, Netherlands, 3Wellcome Trust
Centre for Human Genetics, Oxford, United Kingdom,
4University Medical Center Groningen, Department of
Pediatrics, Groningen, Netherlands
Accumulating evidence suggests that the gut microbiome
inﬂuences the development of obesity and metabolic dis-
eases. Studies in mice have proposed a causal effect of gut
microbiome on the development of obesity and type 2
diabetes (T2D). Due to the complex host-microbe interac-
tion, we hypothesized that a bi-directional causal effect
exists between gut microbiome, T2D and T2D intermediary
phenotypes. We investigated the effects of impairments in
glucose/insulin metabolism on microbiome in the Life-
LinesDeep population cohort (1123 individuals with meta-
genomics and genomic proﬁles) using a Mendelian
Randomization (MR) approach. We extracted summary
statistics from 12 published genome-wide association stu-
dies on obesity, fasting insulin and glucose, insulin secre-
tion, proinsulin and T2D, and constructed 40 genetic risk
scores (GRS). Of the 410 taxonomies and 782 bacterial
pathways assessed, 67 and 138, respectively, were sig-
niﬁcantly correlated with at least one GRS (FDR <0.1);
evidence for causality was observed only for T2D, insulin
secretion and HOMA-B. In particular, MR approach sug-
gests that high levels of insulin secretion and HOMA-B
cause a reduction in abundance of speciﬁc bacteria from the
Firmicutes phylum, whereas a high load of T2D risk alleles
causes an increased abundance; in mice, the reverse direc-
tional causal link, improved insulin sensitivity upon
reduction of Firmicutes, was observed. Bacterial pathways
associated to GRS of metabolic changes were pre-
dominantly related to biosynthesis of fatty acids, lipids and
vitamins, as well as carbohydrates degradation. Our results
highlight a causal relation of insulin/glucose metabolism in
shaping the microbiome composition and function, bringing
new insights into host-microbe interaction.
S. Sanna: None. U. Võsa: None. A. Vich Vila: None.
M.J. Bonder: None. A. Kurilshikov: None. F. Imhann:
None. R. Weersma: None. L. Franke: None. A. Maha-
jan: None. N. Van Zuydam: None. M. Costa: None. M.
McCarthy: None. A. Zhernakova: None. J. Fu: None. C.
Wijmenga: None.
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Effectiveness of whole exome sequencing in unsolved
patients with a clinical suspicion of a mitochondrial
disease in Estonia
S. Puusepp1,2, K. Reinson1,3, S. Pajusalu1,2, Ü.
Murumets1, R. J. Rodenburg4, K. Õunap1,2
1Department of Clinical Genetics, United Laboratories,
Tartu University Hospital, Tartu, Estonia, 2Department of
Clinical Genetics, Institute of Clinical Medicine, University
of Tartu, Tartu, Estonia, 3Department of Pediatrics,
Institute of Clinical Medicine, University of Tartu, Tartu,
Estonia, 4Radboud Center for Mitochondrial Medicine,
Translational Metabolic Laboratory, Radboud University
Medical Center, Nijmegen, Netherlands
Reaching a genetic diagnosis of mitochondrial diseases is
challenging due to broad phenotypic and genotypic het-
erogeneity. However, there is growing evidence that the use
of whole exome sequencing (WES) in patients with clinical
suspicion of a mitochondrial disease is effective (39–60%
by Wortmann et al 2015, Pronicka et al 2016). We aimed to
study the effectiveness of WES used in Estonia in patients
with an unsolved suspected mitochondrial disease.
A total of 21 cases were selected from patients whose
ﬁbroblast cell cultures have been stored since 2003. We
classiﬁed the cases by Nijmegen mitochondrial disease
scoring (MDS) system (Morava et al 2006) after re-
evaluation of clinical data, and performed WES analysis.
Sanger sequencing was used to conﬁrm the ﬁndings and
analyse familial segregation.
A phenotype-associated mutation was found in 14
patients (67%):
MDS All/
solved
cases
Phenotype-associated mutations
Mitochondrial
function related
genes
Other genes
Deﬁnite
(score 8–
11)
3/3 SLC25A4,
POLG
SMN
Probable
(score 5–
7)
11/8 SPATA5, MT-
ATP6
MYH2, EPG5,
BZRAP1, NKX2-1,
CACNA1A, LMNA
Possible
(score 3–
4)
7/3 NDUFB11 ALS2, ATRX
The diagnostic yield of WES in our cohort was even
higher than previously reported proving a very good
effectiveness. We also provide more evidence that the fea-
tures characteristic for mitochondrial diseases overlap with
other neurological disorders showing the need to use WES
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in clinical genetic practice. This work was supported by
Estonian Science Foundation grant PUT0355.
S. Puusepp: None. K. Reinson: None. S. Pajusalu:
None. Ü. Murumets: None. R.J. Rodenburg: None. K.
Õunap: None.
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A novel approach for investigating mitochondrial DNA
variation in disease
M. Venter1, F. H. van der Westhuizen1, E. van Dyk1, L.
Malan2, E. Erasmus1, I. S. Pienaar3,4, F. Ng5,6, J. L.
Newton5,6, J. L. Elson7,1
Centre for Human Metabolomics, North-West University,
Potchefstroom, South Africa, 2Hypertension in Africa
Research Team (HART), North-West University, Potchefst-
room, South Africa, 3Department of Applied Sciences,
Northumbria University, Newcastle-upon-Tyne, United
Kingdom, 4Centre for Neuroinﬂammation and Neurode-
generation, Imperial College London, London, United
Kingdom, 5Institute of Cellular Medicine & NIHR Biome-
dical Research Centre for Ageing and Chronic Diseases,
Newcastle-upon-Tyne, United Kingdom, 6Newcastle upon
Tyne Hospitals NHS Foundation Trust, Newcastle-upon-
Tyne, United Kingdom, 7Institute of Genetic Medicine,
Newcastle University, Newcastle-upon-Tyne, United
Kingdom
Introduction: As mitochondrial dysfunction has been
implicated in the pathology of several common complex
and late onset diseases, mitochondrial DNA (mtDNA) has
been targeted in the last decade in the search for genetic
markers to better predict disease onset and progression. Just
as genome wide association studies have been utilised to
scour the nuclear genome for disease associated variants, so
too have haplogroup association studies done for mtDNA.
As the limitations of these approaches become more
apparent, the need for new ways to investigate the role of
mtDNA variants in diseases is highlighted. Here we present
a novel approach, the MutPred mutational load hypothesis,
for investigating mtDNA variation in disease. This
approach utilises MutPred pathogenicity scores, to then
obtain a single metric which serves as an estimate of the
likely impact of a person’s non-synonymous mtDNA sub-
stitutions on the functioning of their mtDNA encoded
proteins.
Materials and methods: We applied this novel approach
in two common complex disease cohorts: a bi-ethnic car-
diometabolic disease cohort, and a myalgic encephalo-
myelitis or chronic fatigue syndrome (CFS) cohort with
participants from South Africa and the UK.
Results: While no role was found for non-synonymous
mtDNA variants in hypertension or diabetes, preliminary
results indicate signiﬁcant differences between CFS patients
and control groups.
Conclusions: The MutPred mutational load hypothesis
offers an alternative and well powered approach for inves-
tigation mtDNA variation in disease.
Funders: SA National Research Foundation; SA Medical
Research Council; ROCHE Diagnostics; North-West Uni-
versity, RSA; Metabolic Syndrome Institute, France; and
Action for ME https://www.actionforme.org.uk/.
M. Venter: None. F.H. van der Westhuizen: None. E.
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Mitochondrial dysfunction as a pathobiochemical
mechanism of a wide range of neurodegenerative
disorders
O. Grechanina
Kharkov interregional specialized medical genetic centre,
Kharkiv, Ukraine
Introduction: Mitochondrial dysfunction is the cause of
many pathological disorders that are different their variety
and complexity. Intensive study of the mitochondrial
(mtDNA) polymorphisms made deﬁne it as typical patho-
logical process, for which there is no nosology and etiolo-
gical speciﬁcity. The frequency of mitochondrial
dysfunction in population is 1:3000. Description: Clinical
and genetic characteristics of mtDNA polymorphisms (203
patients) involve disorders of nervous (82.16% of patients),
muscle (43.24%), ophthalmic (62.16%), cardiovascular
(35.14%), skeletal (38.0%) and digestive system (40.54%).
75 patients (36.5%) had characteristic clinical features of
classic mitochondrial syndromes MERRF, MELAS, NARP,
Leigh, Kearns-Sayre, Leber. In 91 patients (45.31%) we
found elements of syntropy, in which each of the "con-
glomerate diseases" retained its speciﬁcity. The more fre-
quent of mtDNA polymorphisms in patient with
neurological symptoms were tRNA polymorphisms-lysine:
8697G/A; 8860G; 8701G/A; 8856G/A; 8860 (CRS);
8251G/A; 8472S/T; 8448T/C; 8994G/A; 8337T/C; 8794S/
T; 8584G/A; 8701A/G and amino acid substitutions tRNA-
lysine (syn, thr/ala, pro/leu, met/val, met/thr, his/tyr, ala/
thr). The causes of encephalopathy were associated with
polymorphisms tRNA-lysine and new mutations (leucine
tRNA) (3624 A/G; 3594S/T, 3705G/A, 3505/G, 3552T/A).
Conclusions: In the process of studying the spectrum of
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rare diseases have been identiﬁed high proportion of mito-
chondrial dysfunction. This makes possible to understand
the pathogenetic mechanisms of the development of clinical
symptoms and to develop pathogenetically substantiated
therapy.
O. Grechanina: None.
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A molecular diagnostic rate of >80% in a 10-year birth
cohort of paediatric patients with mitochondrial disease
A. G. Compton1,2, H. S. Mountford1,2,3, N. J. Lake1,2, S.
Thirukeswaran1,2, R. Ruis1,2, S. E. Calvo4,5,6, V. K.
Mootha4,5,6, J. Christodoulou1,2,7, D. R. Thorburn1,2,7
Murdoch Childrens Research Institute, Melbourne, Austra-
lia, 2Department of Paediatrics, University of Melbourne,
Melbourne, Australia, 3Department of Biological and
Medical Sciences, Oxford Brookes University, Oxford,
United Kingdom, 4Howard Hughes Medical Institute and
Department of Molecular Biology, Massachusetts General
Hospital, Boston, MA, United States, 5Department of
Systems Biology, Harvard Medical School, Boston, MA,
United States, 6Broad Institute of MIT and Harvard,
Cambridge, MA, United States, 7Victorian Clinical Genetics
Services, Royal Children's Hospital, Melbourne, Australia
Mitochondrial oxidative phosphorylation (OXPHOS) dis-
orders are clinically heterogeneous and comprise over 200
different genetic disorders. We previously published a
cohort of 86 children born over a 10-year period (between
Jan 1st 1987 and Dec 31st 1996) with deﬁnite diagnosis of a
mitochondrial OXPHOS disorder and onset of symptoms by
16 years.
These patients were referred to our testing centre for
investigation from the 3 South-Eastern states of Australia
and, when published, were regarded as representing all
children with a deﬁnite diagnosis of OXPHOS disease in
this area and time period. A deﬁnite diagnosis was based on
deﬁned clinical, pathological, enzyme and molecular cri-
teria. This cohort now comprises 105 patients, mainly due
to children who were investigated after the original study.
All but two patients without a molecular diagnosis received
whole exome sequencing with ethics approval to analyse a
‘virtual panel’ of ~2300 genes related to mitochondrial
function. This resulted in a molecular diagnosis in 81.9%
(86 patients) up from 23.3% (20 patients) in 2003. Muta-
tions were identiﬁed in 34 different genes (31 genes known
to cause mitochondrial disease, 2 non-mitochondrial disease
genes with clinical overlap and 1 novel mitochondria-
related gene MRPS34). Fifty-three patients showed an
autosomal recessive inheritance pattern, 6 ×-linked and 27
had mtDNA-related disorders (including 6 patients with
mtDNA deletions). Our study illustrates the increased
ability to obtain molecular diagnoses in well deﬁned
cohorts, especially with the advent of massively parallel
sequencing, and the ever increasing genetic complexity of
mitochondrial disorders. Supported by Australian NHMRC
project grant 1068409.
A.G. Compton: None. H.S. Mountford: None. N.J.
Lake: None. S. Thirukeswaran: None. R. Ruis: None. S.
E. Calvo: None. V.K. Mootha: None. J. Christodoulou:
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Searching for the Maturity Onset Daibetes of the Young
in Turkey by genetic diagnosis
S. Colakoglu1, N. Aydin2, O. F. BAltaci3, M. Sargin4, E.
Berber5, T. Yilmaz6
1MarmaraUniversity, Istanbul, Turkey, 2Turkish Diabetes
Foundation, Istanbul, Turkey, 3Istanbul Technical Univer-
sity, Istanbul, Turkey, 4Istanbul Medeniyet University,
Istanbul, Turkey, 5Istanbul Arel University, Istanbul,
Turkey, 6Istanbul University, Istanbul, Turkey
Introduction: Maturity-Onset Diabetes of the Young
(MODY) is a monogenic insulin secretion defect. MODY2,
associated with GCK mutations, MODY1, MODY3,
MODY5 associated with hepatocyte nuclear factor tran-
scription factors HNF4A, HNF1A, HNF1B mutations are
the most common types. The aim of the study is to screen
HNF1A, GCK, HNF1B, and HNF4A genes of MODY
suspected patients to establish genetic proﬁle of MODY
patients in Turkey.
Materials and Methods: 81 MODY suspected patients
were screened for the HNF1A, GCK, HNF4A, HNF1B gene
mutations by next generation sequencing analysis (NGS).
All patients were ICA/GAD negative. Their average age,
age of diagnosis, weight, BMI, HbA1C, C-peptide is 32.13,
24.83, 63,62 kg, 22.54, 7.4,1.48 ng/ml, respectively.
Results: NGS analysis revealed variations in 11 patients.
Two patients had novel GCK variations, p.R192Q,
c.689delG. One patient had a novel HNF1B variation, p.
His424Arg, two patients had HFN4A p.Tyr139Ile variation.
Seven patients had HNF1A variations p.Val246Leu (novel),
p.Arg263Cys, c.864-c.865InsGC, c.1130InsC, c.1136DelC.
All the patients were heterozygous. One patient had both
HNF4A p.Thr139Ile and HNF1A c.865InsGC variations.
Conclusion: Polyphen2 analysis revealed novel mis-
sense substitutions in GCK, HNF1B and HNF1A as prob-
ably pathogenic variations but HNF4A substitution as a
benign variation although it is a change from polar to
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nonpolar. The MODY frequency in Turkey is found as
13.58 % in diabetic cases with two MODY2, one MODY5
and 7 MODY3 patients. It is also revealed that MODY3 is
the most common form of MODY in Turkey with 7.68%
heterozygous frequency.
This study was supported by TUBITAK grant number
113S217
S. Colakoglu: None. N. Aydin: None. O.F. BAltaci:
None. M. Sargin: None. E. Berber: None. T. Yilmaz:
None.
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A putative hypomorphic recessive variant disrupting the
start-codon of Mitochondrial Pyruvate Carrier 2
(MPC2) in a child with suspected mitochondrial disease
I. S. Pedersen1, A. Ernst1, V. Q. Le1, M. B. Petersen2,3, C.
K. Lautrup2,3
Section of Molecular Diagnostics, Clinical Biochemistry,
Aalborg University Hospital, Aalborg, Denmark, 2Depart-
ment of Clinical Genetics, Aalborg University Hospital,
Aalborg, Denmark, 3Department of Clinical Medicine,
Aalborg University, Aalborg, Denmark
Introduction: The MPC1/MPC2 complex mediates pyr-
uvate transport across the inner membrane of the mito-
chondrion. The genes encoding the mitochondrial pyruvate
carriers were described in 2012 and MPC1 missense
mutations have been identiﬁed in three families with off-
spring exhibiting a devastating defect in mitochondrial
pyruvate oxidation.MPC2 variants have not yet been linked
to human disease, and ubiquitous disruption of Mpc2
expression in mice confers embryonic lethality
Material and methods: A three year old boy presented in
the clinic with developmental delay, hypotonia and lactate
acidosis. The parents are healthy and unrelated and he has
three unaffected brothers. Mitochondrial disease was sus-
pected and exome sequencing was carried out on affected
child, parents and one unaffected brother.
Results: This led to the identiﬁcation of a homozygous
variant disrupting the translational start-site of MPC2
(NM_015415.3:c.3G>A p. (?)) in the affected child. Both
parents are heterozygous carriers of this variant which has
not previously been described. Sanger sequencing con-
ﬁrmed the genotype. None of the three unaffected brothers
carry the variant.
Conclusion: The affected off-spring displays a similar
phenotype to what has been described in patients with
homozygous missense mutations in MPC1. Mice studies
disrupting the start-site of Mpc2 lead to the use of an
alternative start-site and a truncated hypomorphic protein.
We propose that this mechanism is responsible for the
phenotype in the case presented here. Upon conﬁrmation by
functional analysis, this would to our knowledge be the ﬁrst
case identifying a MPC2 variant as the cause of mito-
chondrial disease.
I.S. Pedersen: None. A. Ernst: None. V.Q. Le: None.
M.B. Petersen: None. C.K. Lautrup: None.
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All exons are not created equal
B. S. Andresen, L. L. Christensen
Department of Biochemistry and Molecular Biology,
University of Southern Denmark, Odense, Denmark
We speculated that ACADM exon 5 is vulnerable, and
investigated presumed silent and missense variants identi-
ﬁed in different parts of exon 5 in newborns with MCADD.
Minigene studies revealed that several of the variants cause
exon skipping by abolishing different ESEs. Employing
siRNA/overexpression of splicing regulatory factors (SRFs)
and RNA pull-down, we characterized new ESEs and ESSs
and the binding SRFs. We show that the ESEs and ESSs
need to be in a ﬁnely tuned balance to allow exon 5
inclusion. This balance is not only dependent on steric
competition of SRFs for binding to juxtaposed ESE/ESSs,
as previously demonstrated for the c.362ESE and
c.351ESS. Instead the overall balance between ESEs/ESSs
located throughout the exon needs to be maintained. In line
with this we show that a c.331G>A missense variation
abolishes an ESE to cause complete exon skipping.
Remarkably, the polymorphic c.351A>C, which inactivates
the distant c.351ESS, also makes splicing immune to the
deleterious effect of c.331G>A. Moreover, inactivation of
an ESS at pos. c.325, abolishes the splicing defect of the
distant c.362C>T variant as well as that of the juxtaposed
c.331G>A. We conclude that splicing of weak exons can be
disrupted by several different missense/silent variations.
Moreover, weak exons are critically dependent on the
overall balance between ESE/ESSs located throughout the
exon. It is thus essential to evaluate effects on splicing in the
context of the haplotype.
B.S. Andresen: None. L.L. Christensen: None.
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Discerning the "identical": unexpected mitogenome
diversity behind the most common European mtDNA
control region (D-loop) haplotype
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Introduction: Mitochondrial (mt)DNA is a vital tool in
forensic genetics when nuclear markers do not provide
results or maternal relatedness is investigated. The ~1.1 kbp
non-coding mtDNA control region (CR) displays highly
condensed variation and is therefore routinely typed. In this
restricted range, matching haplotypes do not necessarily
imply that the entire mitogenomes are identical or even
belong to the same phylogenetic lineage. This is especially
true for the most frequent West Eurasian mtDNA CR
haplotype that occurs at a frequency of 3–4% in European
populations and is observed in numerous clades within
haplogroup H (“Helena”) and some relatives. In a seminal
study, we investigated the power of massively parallel
complete mitogenome sequencing in 29 Italian samples
displaying the most common West Eurasian CR haplotype.
This allowed the detection of an unexpected high diversity
with 28 distinct haplotypes clustering into 19 clades of
haplogroup H and raised the power of discrimination from 0
to >99% [1].
Materials and Methods: Here we present novel results
from the ongoing investigation of an expanded pan-Italian
sample of almost 300 individuals carrying the most com-
mon CR haplotype.
Results and Conclusions: Even with the currently
~100 samples examined so far, no saturation is reached.
This study demonstrates the beneﬁt of complete mitogen-
ome sequencing for forensic applications to enforce max-
imum discrimination, highest phylogenetic resolution and
more comprehensive heteroplasmy detection.
[1] Bodner M et al.: Helena, the hidden beauty: Resol-
ving the most common West Eurasian mtDNA control
region haplotype by massively parallel sequencing. FSI:Gen
2015; 15:21.
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next generation sequencing identiﬁes mutations in
GNPTG gene as a cause of familial form of scleroderma-
like disease
s. amasdl1, A. Zrhidri2, J. Lyahyai2, H. Elouardi3, B.
Chkirate3, L. Raymond4, G. Egéa4, M. Taoudi4, S. EL
Mouatassim4, A. Seﬁani1
1Centre de Génomique Humaine, Faculté de Médecine et de
Pharmacie, Université Mohammed V, Département de
Génétique Médicale, Institut National d’Hygiène, rabat,
Morocco, 2Centre de Génomique Humaine, Faculté de
Médecine et de Pharmacie, Université Mohammed V, rabat,
Morocco, 3Département de pédiatrie médicale, Hôpital
d’Enfant, rabat, Morocco, 4Département de Génétique
Moléculaire, Laboratoire Biomnis, Lyon, France
Introduction: Scleroderma is a multisystem disease, char-
acterized by ﬁbrosis of skin and internal organs, immune
dysregulation, and vasculopathy. The etiology of the dis-
ease remains unknown, but it is likely multifactorial.
However, the genetic basis for this condition is deﬁned by
multiple genes that have only modest effect on disease
susceptibility. Material and Methods: Three Moroccan
siblings, born from non-consanguineous Moroccan healthy
parents were referred for genetic evaluation of familial
scleroderma. Whole Exome Sequencing (WES) was per-
formed in the proband and his parents, in addition to Sanger
sequencing that was carried out to conﬁrm the results
obtained by WES. Results: Mutation analysis showed two
compound heterozygous mutations c.196C >T in exon 4
and c.635_636del TT in exon 9 of GNPTG gene. Sanger
sequencing conﬁrmed these mutations in the affected
patient and demonstrated that their parents are heterozygous
carriers. Conclusion: Our ﬁndings expand the mutation
spectrum of the GNPTG gene and extend the knowledge of
the phenotype-genotype correlation of Mucolipidosis Type
III gamma (MLIII gamma). This report also highlights the
diagnostic utility of Next Generation Sequencing (NGS)
particularly when the clinical presentation did not point to
speciﬁc genes. Keywords: Mucolipidosis III gamma;
GNPTG; Whole Exome Sequencing.
S. amasdl: None. A. Zrhidri: None. J. Lyahyai: None.
H. Elouardi: None. B. Chkirate: None. L. Raymond:
None. G. Egéa: None. M. Taoudi: None. S. EL Moua-
tassim: None. A. Seﬁani: None.
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Glycosaminoglycans by tandem mass spectrometry in
dried blood spots as a tool to reduce false positive results
by enzyme analysis
S. Tortorelli, J. M. Lacey, K. Raymond, D. K. Gavrilov, D.
Oglesbee, P. Rinaldo, D. Matern
ayo Clinic, Rochester, MN, United States
MPS-I has already been added to the US Recommended
Uniform (Newborn) Screening Panel, other mucopoly-
saccharidoses (MPSs) will likely follow. Pseudodeﬁciency
is a common issue to several, if not all, MPSs, leading to an
increasing number of false positive results. To improve this
situation, we developed and validated a test to measure
dermatan (DS), heparan (HS), keratan (KS) and chondroitin
sulfate (CS) in dried blood spots (DBS) when low enzy-
matic activities are found by either newborn screening or
diagnostic assays.
DS, HS, KS and CS (data not shown) are extracted from
DBS and enzymatically digested to disaccharides prior to
LC-MS/MS analysis. Run time is 7 minutes/sample.
Newborn DBS (N= 129), pediatric DBS (age > 2 weeks
- 18 years) (N= 97) and adult DBS (N= 125) controls were
analyzed.
DS (nmol/L)
N Median Min Max
MPS-I 7 770.1 242.3 1222.2
MPS-II 6 466.7 297.7 764.7
MPS-III 6 46.5 30.2 83.9
MPS-IVA 4 54.9 31.2 80.9
Controls 97 48.2 19.4 127.2
HS (nmol/L)
N Median Min Max
MPS-I 7 172.1 100.7 230.6
MPS-II 6 260.7 134.5 321.7
MPS-III 6 166.7 115.4 294.1
MPS-IVA 4 59.6 35.7 69.5
Controls 97 41.2 10.1 94.3
KS (nmol/L)
N Median Min Max
MPS-I 7 1900.2 701.8 3858.2
MPS-II 6 1976.8 1495.1 3605.3
MPS-III 6 1254.7 567.5 1899.4
Table (continued)
DS (nmol/L)
N Median Min Max
MPS-IVA 4 2163.9 1880.6 2348.1
Controls 97 948.2 236.9 2466.6
Preliminary data show that our test is a rapid and speciﬁc
method for timely diagnosis and treatment of patients with
MPSs, allowing identiﬁcation of cases with low enzymatic
activity due to pseudodeﬁciency.
S. Tortorelli: None. J.M. Lacey: None. K. Raymond:
None. D.K. Gavrilov: None. D. Oglesbee: None. P.
Rinaldo: None. D. Matern: None.
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Second report of a patient with mutations in FLAD1, a
new gene associated to multiple acyl-CoA dehy-
drogenase deﬁciency
J. Garcia-Villoria1, B. de Azua2, L. Matalonga1, O.
Ugarteburu1, L. Teixidó1, A. Ribes1
1Secc.Errors Congènits del Metabolisme-IBC. Serv.Bioq
Genet Mol. Hospital Clínic,IDIBAPS,CIBERER, Barcelona,
Spain, 2Servicio de Pediatría, Hospital Son Llàtzer,
Mallorca, Spain
Case report: We present a 6 months old female with bilat-
eral cataracts. She developed scoliosis and myopathy at four
years of age. Metabolic investigations showed high excre-
tion of ethylmalonic acid, and high medium- and -long
chain acylcarnitines in plasma. These results were sugges-
tive of multiple acyl-CoA dehydrogenase deﬁciency
(MADD), and palmitate oxidation in ﬁbroblasts conﬁrmed
the suspicion. Consequently, the patient was treated with
riboﬂavin and low fat diet. However, after 3 years of
treatment clinical response was lacking.
Methods: In house designed Haloplex panel (Agilent
technology), containing all seven genes associated with
MADD was used.
Results: The patient was found to be compound het-
erozygous for two new mutations in FLAD1: c.1555-3C>G
and c.797_798delAGinsT.
Discussion: FLAD1 encodes for FADS, that is a protein
implicated in the biosynthesis of ﬂavin adenine dinucleotide
(FAD), which is a redox cofactor involved in several
important reactions in the metabolism. Until now, only a
single article (Olsen et al. Am J Hum Genet, 2016)
recruiting nine patients with mutations in FLAD1 have been
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published. Half of them were shown to have single ami-
noacid changes in the FADS domain and were riboﬂavin-
responsive; our patient was not responsive which can be
explained by the more severe mutations. Clinically, she
presents myopathy, and high ethylmalonic acid excretion,
as most of the published cases, but this is the ﬁrst time that
cataracts are associated with FLAD1 mutations
Conclusion: FLAD1 should be studied in patients with
MADD and high excretion of ethylmalonic acid and cat-
aracts, wether or not they were riboﬂavin-responsive.
J. Garcia-Villoria: None. B. de Azua: None. L.
Matalonga: None. O. Ugarteburu: None. L. Teixidó:
None. A. Ribes: None.
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Neuronal Ceroid-Lipofuscinoses in Portugal: the refer-
ence center casuistry
F. E. D. R. Laranjeira1, C. Caseiro1, I. Ribeiro1,2, E.
Pinto1, S. Rocha1, L. Lacerda1,2
Unidade de Bioquímica Genética, Centro de Genética
Médica Doutor Jacinto Magalhães, Centro Hospitala,
Porto, Portugal, 2Unidade Multidisciplinar de Investigação
Biomédica, Instituto de Ciências Biomédicas Abel Salazar /
Centro Hospitalar do Porto, Porto, Portugal
Introduction
Neuronal Ceroid-Lipofuscinoses (NCLs) is a group of
lysosomal storage disorders. Altogether NCLs are the most
common neurogenetic storage diseases in pediatric age.
NCLs are genetically heterogeneous as thirteen genes are
known to be involved, usually with some correlation with
age of onset, clinical features and course. Symptoms present
in a progressive way and usually include intellectual and
motor deterioration, seizures and visual loss.
Patients and methods
This work includes 43 patients, belonging to 33 families,
with clinical suspicion of NCL with laboratory conﬁrmation
in our center.
For NCL1 and NCL2 testing enzyme activity assays
were used. For the diagnosis of the other types of NCLs,
PCR ampliﬁcation and sequencing were the standard pro-
cedures and NGS was used in some unusual situations.
Results
Patient’s clinical data and laboratory results are
presented.
Fourteen out of the 15 variants present in the NCLs
families were ﬁrst described in Portuguese patients, 12 of
them by our centre.
The most prevalent type of NCLs in Portugal is NCL3
and the “1kb deletion” allele is present in 85% of these 13
families. NCL2 is the disease in 8 families and NCL6 has an
unusual high prevalence, affecting also 8 families and with
the p.I154del variant accounting for 75% of the families
affected by this type of NCL.
Conclusions
These results lead us to modify the diagnostic algorithm
proposed for NCLs as to include the screening for the fre-
quent NCL6 variant in the ﬁrst tier approach, increasing the
diagnostic yield expectancy at this stage for 78%.
F.E.D.R. Laranjeira: None. C. Caseiro: None. I.
Ribeiro: None. E. Pinto: None. S. Rocha: None. L.
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Functional characterization of eight missense variants of
the phenylalanine hydroxylase
M. Pečimonova1, A. Soltysova1,2, D. Kluckova1, F.
Csicsay3, K. Reblova4, L. Skultety3, L. Kadasi1,2
1Department of Molecular Biology, Faculty of Natural
Sciences, Comenius University, Bratislava 4, Slovakia,
2Institute for Clinical and Translational Research, Biome-
dical Research Center, Slovak Academy of Sciences,
Bratislava, Slovakia, 3Institute of Virology, Biomedical
Research Center, Slovak Academy of Sciences, Bratislava,
Slovakia, 4Central European Institute of Technology,
Masaryk University, Brno, Czech Republic
Phenylketonuria (PKU) and hyperphenylalaninemia (HPA)
are a group of genetic disorders predominantly caused by
reduced or absent enzymatic activity of the phenylalanine
hydroxylase (PAH) which is responsible for phenylalanine
metabolism. PAH is active only in its tetrameric form and it
requires 6(R)-L-erytro-5,6,7,8-tetahydrobiopterin (BH4) as
a cofactor, molecular oxygen and iron. To date, 970 variants
have been identiﬁed in the PAH gene but only a small
number of missense mutations has been functionally char-
acterized in vitro to elucidate their impact on the PAH
protein. We used in vitro PAH functional assay to determine
the residual enzymatic activity of eight PAH variants (p.
N167Y, p.T200N, p.D229G, p.G239A, p.V245I, p.F263S,
p.A342P, and p.I406M) previously identiﬁed in Czech HPA
patients. All mutants were expressed in E. coli; also in the
presence of GroEL and GroES bacterial chaperones to
determine whether the formation of tetramers would be
restored. The pathogenic effect on PAH stability was tested
using expression in HepG2 cells, also in the presence of
BH4 precursor sepiapterin which has chaperone-like and
stabilizing effect on PAH protein. Our in vitro PAH func-
tional assay showed that four PAH variants retained residual
enzymatic activity. While p.T200N, p.G239A, p.F263S,
308
and p.A342P variants expressed in HepG2 exerted
increased protein levels when cultivated with sepiapterin,
the protein levels of remaining variants remained unchan-
ged. Our ﬁndings contribute to better understanding of the
function of PAH mutated proteins and optimal PKU treat-
ment using BH4 supplementation. This project was realized
with the ﬁnancial support of grant APVV-0240-12.
M. Pečimonova: None. A. Soltysova: None. D.
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Cognitive outcomes in phenylketonuria: report of a 23
years follow-up of 72 patients diagnosed in the newborn
period
Y. HERENGER1,2, E. Maes3, F. Laurent3, H. Ogier3, M.
Schiff3
CHU de Tours, TOURS, France, 2INSERM U_930,
François Rabelais University, Tours, France, 3Reference
Center for Inherited Disorder of Metabolism, PARIS,
France
Introduction: phenylketonuria is a metabolic genetic dis-
order inherited in a recessive manner, which use to be
efﬁciently treated thanks to appropriate diet in childhood.
Recently, cognitive suboptimal outcome in adults who
underwent a well conduct treatment pointed out the neces-
sity of maintaining diet rules in adulthood.
Materials and Methods: 72 phenylketonuria patients
diagnosed, followed and treated with hypoprotidic diet and
sapropterin supplementation since the newborn period
underwent four neuropsychological evaluations until
adulthood, performed by the same skilled neuropsycholo-
gist. Evolution of cognitive functions are described and
compared between typical and atypical phenylketonuria
patients.
Results: cognitive functions showed a subtle impairment
in performance IQ compared to verbal IQ in phenylk-
etonuria patients irrespectively of the clinical form of the
disease. When compared, atypical and typical phenylk-
etonuria patients displayed signiﬁcant different evolution
and prognosis. Atypical phenylketonuria patient are likely
to keep a good global IQ, verbal IQ and performance IQ
independently of their observance whereas typical phe-
nylketonuria patients presented cognitive function impair-
ment even with a well done treatment.
Conclusions: one genetic disorder but different diseases?
The two groups with very different prognosis highlight the
need for prediction tool which can help to position the
treatment, its goal and the strictness of the follow-up.
Genetic council should also be adapt to the clinical form of
the disease.
Y. Herenger: None. E. Maes: None. F. Laurent: None.
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BH4-response prediction and genotype-phenotype cor-
relations in phenylketonuria patients
P. Gundorova, A. V. Polyakov
Federal State Budgetary Institution «Research Centre for
Medical Genetics», Moscow, Russian Federation
Phenylketonuria (PKU) caused by PAH gene mutations is a
common metabolic disease that leads to mental retardation.
The phenomenon of BH4-sensitive PAH (phenylalanine-
hydrohylase) deﬁciency is conﬁrmed by number of studies.
The severity of PKU correlates with the PAH genotype.
Severe PAH variants provide the reduced PAH activity
<10%. Patients with two severe mutations usually have
moderate or classic PKU and do not respond BH4 therapy.
DNA samples of 165 unrelated PKU patients from Russia
were analyzed for the presence of 25 common PAH gene
mutations using allele-speciﬁc MLPA method. Disease-
causing mutations on 87.6% of chromosomes were identi-
ﬁed. In 126 patients (76.4%) both pathogenic variants were
detected, in 37 patients (22.4%) - only one mutation, in 2
patients no PAH mutations were detected. At least one
mutation was detected in 98.8% of PKU patients, although
only frequent PAH mutations have been studied. Severe
mutations were detected on 72.7% of chromosomes studied,
mild mutations - on 15.2%. Two severe PAH mutations
were identiﬁed in 55.2% of examinees (91 pers.), 95% of
them (86 pers.) have moderate (PA=15–20 mg/dL) or
classic (PA>20mg/dL) PKU. We suppose, that these
patients will not respond BH4-therapy. R408W/R408W
represents 50% of all non-responsive genotypes. In 28.5%
of patients (47 pers.) at least 1 mild mutation was identiﬁed.
Among them 38.3% have mild HPA (PA=2–10 mg/dL),
23.4% mild PKU (PA=10–15mg/dL), 8.5% moderate,
23.4% classic PKU. Severe PKU forms in these cases still
may be responsible to the BH4-therapy. DNA-testing is a
useful tool for the therapy prediction in PKU patients.
P. Gundorova: None. A.V. Polyakov: None.
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Mendeliome massive-parallel sequencing reveals a Pri-
mary CoQ10-deﬁciency in two patients with severe
encephalopathy and lactic acidosis
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Mutations in eight of the at least 13 genes involved in
CoQ10-biosynthesis in mammals have been associated with
Primary Coenzyme Q10-deﬁciency in humans, which is one
of the much-reduced numbers of autosomal-recessive
mitochondrial disorders with effective treatment. Fatal
multisystem disorders or Steroid Resistant Nephrotic Syn-
drome with neurological symptoms are frequently related to
Primary CoQ10-deﬁciencies. Here we described two new
patients with severe encephalopathy and lactic acidosis,
harbouring bi-allelic mutations in COQ2 and PDSS1 genes.
Candidate variants were identiﬁed by massive-parallel
sequencing using TruSightOne panel and bioinformatics
analysis with VariantStudio software. To demonstrate the
pathogenicity of the nucleotide-changes we quantiﬁed
CoQ10 (LC-MS/MS) in patient’s-cells and analysed the
downstream effects of CoQ10-deﬁciency on mitochondrial
function and dynamics. Because CoQ10 is a mobile lipo-
philic electron carrier critical for electron-transfer in the
respiratory chain and an important ROS scavenger for
preserving mitochondrial cristae structure, we have eval-
uated the real-time oxygen consumption rate in intact
ﬁbroblasts, and mitochondrial ultrastructure by electronic
microscopy.
Patient’s cells with COQ2 and PDSS1 mutations dis-
played decreased variable levels of CoQ10 (26% COQ2-
patient and 6% for PDSS1 of control values) which were
apparently related with respiratory activity parameters.
Ultrastructure analysis of mitochondrial morphology
showed an enlargement of COQ2-deﬁcient’s mitochondria
and perturbed cristae morphology for PDSS1-deﬁcient
cells.
Reverse-phenotyping in these patients conﬁrmed the
utility of genomic testing as a ﬁrst option for a prompt
diagnosis of speciﬁc patients with clinical suspicion of
mitochondrial disease, in which a rapid treatment can stop
the progression of the symptoms.
PI12/02078; PI16/00573 MINECO-FEDER. Fundación
Isabel Gemio
I. Bravo-Alonso: None. A. Vega: None. R. Navarrete:
None. P. Ruíz-Sala: None. M. García-Silva: None. A.
Blázquez: None. M. Martín: None. B. Merinero: None.
C. Pérez-Cerdá: None.M. Ugarte: None. B. Pérez: None.
P. Rodríguez-Pombo: None.
P06.48D
Blocking of PCCA pseudoexon inclusion as a tool to
increase PCCA gene expression
M. Dembic1, S. B. Flyvbjerg1, M. Silva1, J. S. Andersen1,
A. Martinez-Pizarro2, L. R. Desviat2
1Department of Biochemistry and Molecular Biology, the
Villum Center for Bioanalytical Sciences, University of
Southern Denmark, Odense M, Denmark, 2Centro de
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Introduction: loss-of-function mutations in the propionyl
CoA carboxylase A (PCCA) gene cause Propionic acidemia
(PA). The intronic mutation c.1285–1416A>G increases
inclusion of a pseudoexon located in intron 14, thereby
targeting the mRNA for nonsense-mediated decay, causing
enzyme deﬁciency. The mutation is located in a splicing
regulatory element (SRE) outside the splice sites. We
investigate the mechanisms of PCCA pseudoexon inclusion
and we assess the effect of splice-shifting oligonucleotides
(SSO) blocking the activating SRE.
Methods: by RNA pull-down we identiﬁed the splicing
regulatory proteins (SRPs) involved in the regulation of the
PCCA pseudoexon. To further deﬁne their roles, analysis of
minigenes and endogenous PCCA was performed in dif-
ferent cell types including patient cells, in knock-down and
SSO transfection experiments.
Results: several members of the hnRNP family of SRPs
inhibit inclusion of the PCCA pseudoexon; however, the
strengthening of a splicing enhancer is the main cause of the
pathogenic missplicing. Treatment with SSOs reduces
inclusion of the pseudoexon, and, interestingly, produces a
signiﬁcant increase of the total levels of PCCA mRNA in
both patient and normal cells.
Conclusions: PA patients could beneﬁt from treatments
that increase the activity of the PCCA enzyme. Blocking the
inclusion of the PCCA pseudoexon with SSOs can strongly
increase the levels of normal mRNA in patient cells with the
activating mutation. Interestingly, PCCA levels were also
signiﬁcantly increased in normal cells indicating that this
310
treatment may also be relevant in patients harbouring mis-
sense mutations with some residual enzyme activity.
Funding: Grant NNF13OC0007939, Novo Nordisk
Foundation.
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Large-scale genetic meta-analysis and correlation ana-
lysis in up to 61,457 Europeans show large genetic
overlap between fasting and random plasma glucose
levels
M. Kaakinen1, L. Jiang1, V. Lagou2, K. S. Gutierrez3, I.
Prokopenko1, MAGIC investigators
Imperial College London, London, United Kingdom, 2VIB
Center for Brain & Disease Research, Leuven, Belgium,
3Erasmus MC, Rotterdam, Netherlands
Introduction: Fasting plasma glucose (FG) and 2-hour
post-prandial plasma glucose (2hGlu) are used as the gold
standard tests for diagnosing type 2 diabetes (T2D). High
non-fasting i.e. random plasma glucose (RG) levels may
also indicate abnormal glucose homeostasis. We sought to
characterise the genetic architecture of RG and its genetic
relationships with other glycaemic traits and T2D.
Materials and Methods: We conducted a ﬁxed-effects
inverse-variance meta-analysis of 15 genome-wide asso-
ciation studies on RG adjusted for age, sex and time since
last meal, when available. We analysed ~2.5M HapMap2-
imputed and CardioMetabochip SNPs in up to 61,457 non-
diabetic Europeans. The LD score regression was used to
evaluate the genetic correlation between RG, FG, 2hGlu,
fasting insulin, glycated hemoglobin (HbA1c), homeostasis
model assessment of beta cell function/ insulin resistance
(HOMA-B/-IR), and T2D.
Results: We identiﬁed four loci associated with RG at
genome-wide signiﬁcance (P<5×10−8): G6PC2 (rs573225,
P=2.4×10−40), GCK (rs6975024, P=4.8×10−30), ADCY5
(rs7613951, P=9.1×10−11), and SLC2A2 (rs16847990,
P=3.6×10−8). These FG and HbA1c established loci var-
iants show directionally consistent effects on RG. We
observed strong (r>0.6) genetic relationships between RG,
FG (r[SE]=0.89[0.13], P=1.03×10−11) and HOMA-IR (r
[SE]=0.61[0.16], P=0.0001), and modest (0.4≤r≤0.6) with
T2D (r[SE]=0.51[0.12], P=1.52×10−5) and HbA1c (r[SE]
=0.40[0.15], P=0.009).
Conclusions: Our meta-analysis on RG has detected FG-
associated variants, and the genetic correlation analysis also
shows large genetic overlap between RG and FG. The
smaller genetic correlation between RG and the other non-
fasting measure HbA1c is likely due to the nature of many
HbA1c loci being erythrocytic.
M. Kaakinen: None. L. Jiang: None. V. Lagou: None.
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A multi exons deletion in the TANGO2 gene region is a
recurrent cause of its functional defect
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Child Neurology, AZ Sint Jan, Bruges, Belgium, 4Paediatric
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Introduction: Rhabdomyolysis and energy deﬁciency is a
clinically and genetically heterogeneous disorder. TANGO2
(transport and Golgi organization 2) encodes a protein with
a putative function in redistribution of Golgi membranes
into the endoplasmic reticulum in Drosophila, while a
mitochondrial localization has been demonstrated in mice.
Mutations in this gene have recently been associated with
rhabdomyolysis, epilepsy, hypothyroidism, metabolic crises
with encephalopathy, and cardiac arrhythmia.Materials and
Methods: Sanger sequencing of the TANGO2 gene was
performed in a 27-year-old woman from Belgian origin. She
presented with seizures and developmental delay in the ﬁrst
years of life. Later she developed hypothyroidism and a
dilated cardiomyopathy. She suffered from two severe
episodes of rhabdomyolysis with cardiac arrhythmias.
Results: Sanger sequencing showed a homozygous multi
exons deletion (exon 3 - 9) of the TANGO2 gene in our
patient. LR-PCR conﬁrmation for the presence of this het-
erozygous allele deletion in both her parents, to validate the
independent segregation of the deletion, is in progress. A
previously reported 34 kb partial gene deletion is suspected.
Conclusions: Sanger sequencing showed a homozygous
deletion encompassing the larger coding part of the
TANGO2 gene in a patient suffering from a complex phe-
notype. TANGO2 deleterious mutations have recently
expanded the genetic compendium as an important cause of
rhabdomyolysis in combination with mitochondrial meta-
bolism energy defects. The multiple exons deletion has been
observed frequently in the small pool of published patients.
It has been suggested that this pathogenic allele variant
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might represent a more common disease allele in European
populations.
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TANGO2 loss of function mutations: an emerging
complex neurometabolic disorder
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University of Turin, Torino, Italy, 2Città della Salute e della
Scienza, Torino, Italy
Introduction: bi-allelic loss of function mutations in
TANGO2 gene have been recently described in patients
with a variable phenotype characterized by acute episodes
of rhabdomyolysis, hypoglycemia, intellectual disability,
hypothyroidism, seizures and cardiac arrhythmias. Today
15 patients have been reported in the literature. Materials
and Methods: we report a family with two novel mutation in
TANGO2 gene co-segregating with the disease. The pro-
band is a male from ﬁrst pregnancy of unrelated, apparently
healthy parents. Family history, pregnancy and neonatal
history were unremarkable. He was diagnosed with devel-
opmental delay at 6 months and with primary hypothyr-
oidism at 12 months. He had 2 acute episodes of
rhabdomyolysis at 13 and 19 months. The second episode
of rhabdomyolysis was complicated with cardiac arrest. We
noticed that the acute crisis were triggered by fasting and
viral infections whereas bacterial infections had no trig-
gering effect. Muscle biopsy showed normal respiratory
chain studies. CGH-array and NGS analysis of the most
common genes associated to HyperCKemia did not identify
clinically relevant variants. Results: exome sequencing
revealed the presence of two mutation in compound het-
erozygosis in TANGO2 gene (maternal p.Arg88* and
paternal p.Glu112fs mutations). Conclusions: we described
two novel pathogenic mutation in TANGO2 gene and a new
patient with TANGO2 associated disease. Our clinical
observation indicate that TANGO2 associated disease is
recognizable on the basis of clinical signs: in this case
psychomotor delay associated with recurrent rhabdomyo-
lysis’ crisis and hypothyroidism. Exome sequencing
allowed a rapid conﬁrmation of the diagnosis preventing
additional invasive diagnostic tests.
D. Carli: None. M. Zoppo: None. F. Ricci: None. F.
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P06.52D
Effect of management of thiamine responsive mega-
loblastic anemia syndrome with sulbutiamine
V. Mikštienė1, J. Songailienė1, J. Byčkova2, G.
Rutkauskienė3, E. Jainskienė4, R. Verkauskienė4, E.
Lesinskas2, A. Utkus1
1Department of Human and Medical Genetics, Faculty of
Medicine,Vilnius University, Vilnius, Lithuania, 2Centre of
Ear, Nose and Throat Diseases, Vilnius University Hospital
Santarikių Clinics, Vilnius, Lithuania, 3Pediatric Oncology
and Haematology unit, Hospital of Lithuanian university of
Health Sciences, Kaunas Clinics, Kaunas, Lithuania,
4Department of Endocrinology, Hospital of Lithuanian
University of Health Science, Kaunas Clinics, Kaunas,
Lithuania
Introduction: thiamine responsive megaloblastic anemia
syndrome (TRMAS) is a rare autosomal recessive metabolic
disorder. Management of TRMAS focuses on lifelong use
of pharmacologic doses of thiamine (Th). High-dose Th
may ameliorate diabetes, anemia and, conjecture, hearing
defect if started from birth or prenatally. TRMAS man-
agement with Th hydrochloride and Benfotiamine, a syn-
thetic Th analog, has been described. Effect of lipophilic
synthetic thiamine derivate, sulbutiamine, effectively
crossing blood-brain barrier and possessing good bioavail-
ability, has never been published. Materials and methods:
we report a 6y old boy clinically and molecularly diagnosed
with TRMAS at the age of 3y. Thiamine 100mg/day was
administered. The condition markedly improved several
days after the initiation of treatment - therapy had positive
effect on anemia and glycaemia, also psychological status
of the child slightly improved. After several months the
patient developed allergic reaction. Moreover, the effect of
thiamine was not sufﬁcient for timely mental development
and psychological balance. After careful consideration
thiamine was replaced with sulbutiamine 100mg/day.
Results: we observed transitory decrease of hemoglobin to
110g/l which resolved within 1st month of treatment. Blood
glycaemia remained stable, with rare elevations due to
stress. Unfortunately, 1 year of treatment with sulbutiamine
did not improve the patient’s mental health: emotional
outbursts, aggressive behavior, speech delay, and inability
to address hygiene tasks remain. Conclusions: our experi-
ence demonstrate that sulbutiamine beneﬁts in maintenance
of blood glycaemia and hematopoiesis in TRMAS patient.
The expected improvement of mental performance was not
attained supposedly due to the late diagnosis or possible
additional underlying condition.
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An RNASEH1 gene variant interacts with HLA tagSNPs
in Colombian families with type 1 diabetes
N. Gomez-Lopera1, D. Sarrazola Yepes1, M. Toro2, M.
Lopera2, J. Alfaro1, N. Pineda-Trujillo1
University of Antioquia, Medellin, Colombia, 2IPS Uni-
versitaria, University of Antioquia, Medellin, Colombia
Introduction:We have recently found association of type 1
diabetes (T1D) with RNASEH1 gene variants. Here we
tested whether RNASEH1 gene variants interact with classic
HLA alleles, in a set of Colombian families with T1D
Methods: We studied 200 familial trios from Medellin-
Colombia, with T1D. Cases were tested for anti-GAD65
and anti-IA2 auto-antibodies in patients sera, using an
ELISA-based kit. DNA was isolated from blood cells by
phenol-chloroform method. RNASEH1 gene variability was
identiﬁed in 96 cases by Sanger sequencing of the coding
region. Forty-ﬁve tagSNPs were then typed by the KASP
method (LGC genomics) in the 200 families. TagSNPs for
classic HLA alleles were identiﬁed for the population where
the sample comes from (CLM) using information available
at www.internationalgenomes.org. Thus, another 45 SNPs
set was tested in both class-I and class-II HLA, using the
same genotyping approach as above. Statistical analyses
included association (TDT) and interaction (M-TDT) tests.
Results: We found that SNP rs7607888 at RNASEH1 gene
associates in a protective manner to develop T1D (P-value=
2e-3). Also, tagSNPs for classic class-I HLA alleles (P-
value= 3.9e-9) as welll as for class-II HLA (P-value= 9.7e-
28) were associated with the disease. Interaction of
rs7607888 with two class-I classic HLA alleles (p-value=
3e-9) and three classic class-II HLA alleles (P-value= 5.3e-
10) in addition to four risk class-II haplotypes (2.47e-8) was
found. Conclusions: Our results show that rs7607888 at
RNASEH1 in the context of certain HLA alleles increases its
contribution to the risk for developing T1D in Colombian
families.
Funding: Colciencias-Grant # 111556933366
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P07
Immunology and hematopoietic system
P07.01A
Application of next generation sequencing in the con-
undrum of primary antibody deﬁciency
H. Abolhassani1, A. Aghamohammadi2, N. Rezaei2, Q.
Pan-Hammarström1, L. Hammarström1
1Division of Clinical Immunology, Department of Labora-
tory Medicine, Karolinska Institutet at Karolinska Uni-
versity Hospital Huddinge, Stockholm, Sweden, 2Research
Center for Immunodeﬁciencies, Pediatrics Center of
Excellence, Children's Medical Center, Tehran University
of Medical Sciences, Tehran, Iran, Islamic Republic of
Introduction: Primary antibody deﬁciency (PAD) is the
most common form of primary immunodeﬁciency, with a
prevalence of about 1 in 600 in the general population. A
correct molecular diagnosis in patients with PAD is crucial
for the appropriate therapeutic management. However, 90%
of patients with late B cell development disorders and 10%
of cases with the defect in early B cell development have no
identiﬁed causative gene mutation. Methods: Clinical and
immunological phenotyping of a cohort of PAD patients
with unknown genetic defects after having been subjected
to the classical targeted sequencing underwent whole-
exome sequencing analysis. Results: Exome sequencing
analysis was performed on 110 PAD probands mostly with
childhood onset (94.5%) born to predominantly con-
sanguineous parents (82.2%). This method and subsequent
multiomics functional assays identiﬁed the disease-causing
variants in 88% of the patients. The ﬁndings of this study
also conﬁrmed 4 new PAD causing genes and also sug-
gested 14 novel candidate-genes. Medical implications of
the deﬁnite genetic diagnosis were reported in 50% of the
patients, including hematopoietic stem cell transplantation,
tertiary preventive screening tests, targeted medication and
prenatal diagnosis. Conclusions: Due to misclassiﬁcation
of the conventional clinical and immunological phenotyp-
ing for targeted sequencing, employing next generation
sequencing as a preliminary step of molecular diagnosis
approach to patients with PAD is essential and could help in
many facets of management and treatment of the patients
and their family members. This study also illustrates the
power of exome sequencing in the identiﬁcation of novel
and candidate genes underlying primary antibody
deﬁciency.
H. Abolhassani: None. A. Aghamohammadi: None. N.
Rezaei: None. Q. Pan-Hammarström: None. L. Ham-
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Natural history and treatment outcome of patients with
adenosine deaminase (ADA) 2 deﬁciency: Twenty years
of the Israeli experience
R. Segel1,2, S. Padeh3,4, O. Goldzweig5,2, M. Gerstein3,4, J.
Barash5, A. Zlotogorski6,2, J. Pres3,4, P. Hashkes1,2, L.
Horev6,2, L. Harel7,4, R. Brik8,9, Y. Butbul Aviel8,9, A.
Rubinow6,2, Y. Naparstek6,2, C. Gur6,2, I. Rosner8,9, A.
Ballbir8,9, P. Navon-Elkan1, Y. Berkun6,2
Shaare Zedek Medical Center, Jerusalem, Israel, 2Hebrew
University School of Medicine, Jerusalem, Israel, 3Sheba
Medical Center Tel Hashomer, Ramat Gan, Israel, 4Tel
Aviv University School of Medicine, Tel Aviv, Israel,
5Kaplan Medical Center, Rechovot, Israel, 6Hadassah
Medical center, Jerusalem, Israel, 7schneider Medical
Center, Petach Tikva, Israel, 8Rambam Medical Center,
Haifa, Israel, 9Faculty of Medicine, Tchnion, Haifa, Israel
We present 30 Israeli patients with PAN-like vasculitis or
leg ulcers and ADA2 deﬁciency, followed for the last 2
decades. 28 were of Georgian -Jewish origin, and 2 of Arab
descent. 2/3 had familial disease. There was no con-
sanguinity, no sex predilection. In most the disease started
before age 10 years, 5 in infancy. The variability and extent
of the clinical spectrum from life threatening, multisystem
vasculitis including strokes to mere livedo reticularis, made
diagnosis difﬁcult.
Before genetic diagnosis could be applied, the hallmark
of the group was “hereditary Georgian-Jewish PAN of
childhood”, encompassing the milder form of “Georgian
Ulcers”. In 2011, the G47R mutation in CECR1, encoding
ADA2, was detected in 20 of the 22 examined patients the
biological role of ADA2 was conﬁrmed. Homozygosity of
the same mutation was detected in all patients, regardless of
the severity of the disease.
Our greatest challenge was treatment of the severely ill.
10 patients (30%) with moderate to severe disease received
anti-TNF agents, with good response. Some patients
homozygous to the G47R mutation in ADA2 had milder
phenotype and received azathiorpine, methotrexate, pre-
dnisone and local treatment only. Four patients died of
severe vasculitis, not receiving biologic treatment.
In summary, we report a long follow-up of the largest
series of ADA2-deﬁciency patients, most homozygous for
the same CECR1 mutation. Clinical manifestations and
severity of ADA2-deﬁciency are variable. Therapy of anti-
TNF agents is effective and warrants genetic screening of
siblings for proper diagnosis, follow-up and timely
treatment.
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The search for missing heritability: combining rare and
common variants to reveal novel disease association
J. Nordin1, A. Mathioudaki1, M. Bianchi1, D. Eriksson2,
L. Hultin-Rosenberg1, Å. Karlsson1, E. Murén1, J.
Dahlqvist1, M. Olsson2, F. Farias3, P. Söderkvist4, J.
Cedergren4, P. Eriksson4, G. Rosengren Pielberg1, K.
Lindblad-Toh1,5, J. R. S. Meadows1
1Science for Life Laboratory, Dept. of Medical Biochem-
istry and Microbiology, Uppsala University, Uppsala,
Sweden, 2Centre for Molecular Medicine, Dept. of Medicine
(Solna), Karolinska Institutet, Stockholm, Sweden,
3McDonnell Genome Institute, Washington University
School of Medicine, St. Louis, MO, United States, 4Dept.
of Clinical and Experimental Medicine, Linköping Uni-
versity, Linköping, Sweden, 5Broad Institute of MIT and
Harvard, Cambridge, MA, United States
Genome-wide association studies (GWAS), utilising com-
mon variants, have implicated more than 40 genes in the
development of ankylosing spondylitis (AS). However, as
with other complex diseases, a large part of the genetic
heritability remains missing. The aim of this study was to
evaluate the effect of rare variants on AS, and so assess their
role in this genetic puzzle.
A targeted NimbleGen array was created to cover 1% of
the human genome; focusing on immunological pathways
including key genes and their regulatory elements. Lever-
aging the expectation of ﬁnding rare disease associated
alleles in a homogenous population, we sequenced 691
Swedish samples (310 cases) to a mean coverage of 35.5 ×.
GATK best practices and additional QC pipeline resulted in
236,014 high quality variants (11% novel) in 4,030 genes.
A multistage approach was taken, with single variant and
aggregate (SKAT) tests performed for all combinations of
minor allele frequencies.
Whilst the majority of association resided within the
MHC, a novel ﬁnding outside this region implicates the IL-
36 pathway in AS. This signiﬁcant signal was not found in
univariate tests, but in aggregate association with rare and
common variants (p = 4.4×10−6). This demonstrated how
even a moderately sized population can identify signals of
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missing heritability if all alleles, not only common, are
evaluated for their role in disease.
Funding: Knut och Alice Wallenbergs Stiftelse, Swedish
Research Council FORMAS
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MAGI2 gene variant association and expression altera-
tions in celiac disease
A. Jauregi-Miguel1, I. Santin2, I. Romero-Garmendia1, K.
Garcia-Etxebarria1, I. Irastorza3, A. Castellanos-Rubio1,
J. Bilbao1
Immunogenetics Research Laboratory, University of the
Basque Country-UPV/EHU and BioCruces Health
Research Institute, Leioa, Spain, 2Endocrinology and
Diabetes Research Group, BioCruces, UPV-EHU, Bara-
kaldo, Spain, 3Pediatric Gastroenterology Unit, Cruces
University Hospital (UPV/EHU), Barakaldo, Spain
In celiac disease (CD), there is a loss of intestinal barrier
function due to structural alterations in the tight junction
(TJ) network, the most apical unions between epithelial
cells. The association of TJ related gene variants points to
an implication of this network in disease susceptibility. In
the current study, we replicated the association of
rs6969266*G (P = 0.0029; OR =1.88 [95%1.24–2.87]),
located in an intron of TJ-related MAGI2 gene and upstream
of RP4-587D13.2 long non-coding RNA (lncRNA). We
found that both, MAGI2 and RP4-587D13.2, are sig-
niﬁcantly downregulated in duodenal biopsies of active and
treated CD patients. Moreover, both genes showed a sig-
niﬁcant coexpression along tissues and in intestinal biop-
sies. However, associated rs6969266 did not seem to
regulate the observed altered expression. To mimic the
situation in the CD gut, we silenced the expression of
MAGI2 in human intestinal C2BBe1 cell line and observed
the alteration of several related TJ genes. Moreover, gliadin
challenge in MAGI2 silenced cells provokes more pro-
nounced gene expression alterations. The nuclear localiza-
tion of RP4-587D13.2 together with its coexpression with
MAGI2 suggests that this lncRNA could be affecting
MAGI2-related pathway. These ﬁndings show that the
associated region is functionally altered in disease and
suggest that RP4-58D13.2 and MAGI2 may be regulating
the celiac disease related TJ alterations.
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Gain-of-function SAMD9L mutations cause a syndrome
with cytopenia, myelodysplastic syndrome, immunode-
ﬁciency and neurological disease
B. Tesi1, J. Davidsson2, M. Voss1, E. Rahikkala3, T.
Holmes4, S. Chiang1, J. Komulainen-Ebrahim3, S.
Gorcenco2, A. Rundberg Nilsson2, T. Ripperger5, H.
Kokkonen3, D. Bryder2, T. Fioretos2, J. Henter1, M.
Möttönen3, R. Niinimäki3, L. Nilsson6, C. Jan Pronk2, A.
Puschmann2, H. Qian1, J. Uusimaa3, J. Moilanen3, U.
Tedgård6, J. Cammenga2, Y. T. Bryceson1
1Karolinska Institutet, Stockholm, Sweden, 2Lund Univer-
sity, Lund, Sweden, 3University of Oulu, Oulu, Finland,
4University of Bergen, Bergen, Norway, 5Hannover Medical
School, Hannover, Germany, 6Skåne University Hospital,
Lund, Sweden
We studied two families with cytopenia, myelodysplastic
syndrome (MDS), immunodeﬁciency, and progressive cer-
ebellar dysfunction. In both families we identiﬁed hetero-
zygous germline missense mutations in SAMD9L, a tumor
suppressor gene located on 7q21. Both mutations, p.
Ile871Thr and p.Arg986Cys, decreased cell proliferation
relative to wild-type protein, suggesting a gain-of-function
effect. Out of ten carriers of either SAMD9L mutation, three
developed MDS with monosomy 7 or del(7q), of which two
in childhood. Interestingly, in MDS-derived DNA, the
mutated SAMD9L allele was located on the deleted chro-
mosome 7. Five carriers, three with spontaneously resolved
cytopenia in infancy, harbored somatic revertant mosaicism
in blood cells in the form of uniparental disomy (UPD) of
7q with loss of the mutated allele or in cis SAMD9L trun-
cating mutations. Clinically, revertant mosaicism was
associated with milder disease, yet neurological manifesta-
tions persisted in three individuals. Examination of DNA
derived from neonatal dried blood spot in one individual
indicated that somatic reversions occurred postnatally in
CD34+ hematopoietic stem cells (HSC). Two carriers also
harbored a rare, in trans germline SAMD9L missense loss-
of-function variant, potentially counteracting the gain-of-
function SAMD9L mutation. Our results demonstrate that
gain-of-function mutations in the tumor suppressor gene
SAMD9L cause cytopenia, immunodeﬁciency, cerebellar
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dysfunction, and predispose to MDS with -7/del(7q). HSC
that eliminate SAMD9L gain-of-function mutations through
-7/del(7q) gain a competitive advantage and expand clon-
ally, simultaneously predisposing to MDS. Hematopoietic
revertant mosaicism through UPD(7q) or in cis SAMD9L
mutations is common in carriers of SAMD9L mutations and
improves hematological manifestations, though leading to
clonal hematopoeisis.
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Generalized pustular psoriasis as an oligogenic disease
and further evidence for signiﬁcant younger age at
manifestation in carriers of IL36RN mutations
U. D. Hüffmeier1, R. Mössner2, P. Gkogkolou3, A.
Körber4, P. Schulz5, J. C. Prinz6, S. Löhr1, K. P. Peters7, S.
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Sticherling12, S. Frey13, S. Uebe1, V. Oji14, H. Sticht15, D.
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Recent research has identiﬁed pustular psoriasis as either
Mendelian traits or major genetic risk factors contrasting
numerous associated SNPs in classical plaque psoriasis.
Autosomal-recessive mutations in IL36RN have been
identiﬁed in ~25–40% of patients with generalized pustular
psoriasis (GPP), a rare, severe pustular psoriatic variant.
Also, heterozygous missense variants in CARD14 and
AP1S3 have been associated to pustular psoriasis and shown
to be functionally relevant.
61 GPP patients were screened for qualitative and
quantitative coding variants in IL36RN, CARD14 and
AP1S3. We identiﬁed two IL36RN mutations in 15 GPP
patients, and single heterozygous mutations in 5 patients.
We did not observe a rare non-coding variant in any carrier
of a single IL36RN mutations by sequencing introns as well
as the IL36RN promotor. Three of the 20 carriers of IL36RN
mutations (15.0%) carried a heterozygous functional variant
in either AP1S3 or CARD14, while only two carriers of
heterozygous CARD14 variants were observed in the group
of non-carriers (4.9%). Also when assuming that a single
IL36RN mutation contributes to disease, our ﬁndings point
to a rather oligogenic than monogenic inheritance in those
GPP patients.
Our genotype-phenotype correlation revealed a strong
association between bi-allelic mutations in IL36RN and
earlier age at manifestation (p=7.4×*10-04).
Overall, our genetic studies suggest a lower impact of
AP1S3 and CARD14 in GPP than of IL36RN. Moreover, its
oligogenic basis might currently be underestimated, as
genetic risk factors apart from the three known genes
remain to be identiﬁed in the majority of GPP patients.
Grants: DFG-CRC1181-A05, DFG-2163/1-1, Laborat.rota-
tion (IZKF)
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Uncovering the etiology of the neglected autoimmune
disease pemphigus foliaceus: the ﬁrst genome-wide
association study
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Malheiros1, A. B. W. Boldt1, B. Sanjabi3, V. Kumar3, E.
Tarazona-Santos2, M. L. Petzl-Erler1
1Universidade Federal do Parana, Curitiba, Brazil, 2Uni-
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Introduction: Pemphigus foliaceus (PF) is an autoimmune
blistering skin disease characterized by autoantibodies
against desmoglein 1. It occurs sporadically all over the
world but is endemic in Brazil and a few other countries,
including Tunisia, Peru and Colombia. In Brazil, PF
represents a local health problem, with the highest incidence
(up to 0.83 cases per 10,000) and prevalence (3.2% in the
Terena population) ever reported for an autoimmune
disease.
Material and Methods: We performed a genome-wide
association study (GWAS) with 235 patients and 5,658
controls, which have been genotyped with an Illumina
platform. After standard quality control procedures,
204,967 single nucleotide polymorphisms (SNP) remained.
We performed logistic regression analysis using principal
components to correct for possible population stratiﬁcation.
Results: As expected on basis of our previous studies,
most of the SNPs that reached genome-wide signiﬁcance
are in the major histocompatibility complex (MHC) class II
region. However, our results spotted new markers in MHC
and non-MHC genes and intergenic regions that were not
seen in previous studies (e.g. an intergenic MHC SNP, OR
= 5.3, p = 2 ×10−18; a NOTCH4 variant, OR = 4.2, p =
4 ×10−7, a long non-coding RNA variant at chromosome 7,
OR = 0.4, p = 10−5).
Conclusion: Our ﬁndings help to dissect the associations
between MHC genotypes and PF susceptibility. In addition,
we identiﬁed new genes and non-coding elements that
might be involved in PF etiology and suggest new pathways
for this complex and poorly understood disease.
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Identiﬁcation of novel surface markers and regulatory
networks governing speciﬁc hematopoietic progenitor
populations
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Boland1,2, J. Deleuze1,2, R. Olaso1,2, S. Ezine3,4, D. Tronik-
Le Roux5,6, C. Battail1,2
Centre National de Génotypage, Institut de Génomique,
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natives, Evry, France, 2Université Paris-Saclay, Paris,
France, 3Institut Necker Enfants Malades, Immunology,
Infectiology and Haematology Department, Inserm U1151,
CNRS UMR 8253, 14 rue Maria Helena Vieira da Silva, CS
61431, Paris, France, 4Université Paris Descartes, Sor-
bonne Paris Cité, Faculté de Médecine Site Necker, 14 rue
Maria Helena Vieira da Silva, CS 61431, Paris, France,
5Commissariat à l’Energie Atomique et aux Energies
Alternatives (CEA), Direction de la Recherche Fondamen-
tale (DRF), Institut des Maladies Emergentes et des
Thérapies Innovantes (IMETI), Service de Recherche en
Hemato-Immunologie (SRHI), Paris, France, 6Universite
Paris Diderot, Sorbonne Paris Cite, IUH, Hôpital Saint-
Louis, UMR_E5, Paris, France
Introduction : Hematopoietic stem cells (HSCs) specify
their lineage fate in non-self-renewing multipotent pro-
genitors (MPPs). MPPs are a compartment deﬁned by three
subsets: MPP2, MPP3 and MPP4. A more restricted pro-
genitor is the common lymphoid progenitor (CLP) which
has lost the ability to produce myeloid cells in vivo. MPP
and CLP are the best candidates to sustain rapidly and
efﬁciently hematopoiesis of differentiated lineages and
compensate for complications of anti-cancer therapies. Our
objective is to identify novel surface marker genes to better
isolate speciﬁc progenitor populations and to reveal gene
networks involved in their regulation.
Materials and methods : We performed whole tran-
scriptome strand-speciﬁc sequencing from three mouse
progenitors: MPP2, MPP3 and CLP. Three biological
replicates, per cell population, were sequenced at high
coverage (2 ×120 millions reads).
Results : We performed differential expression analysis
and identiﬁed, by gene ontology and by unsupervised
classiﬁcation, cell surface genes speciﬁcally co-expressed
per progenitor cell. Correctly classiﬁed reference surface
markers, currently used to purify progenitors, validate our
bioinformatic methodology. Transcriptional regulation of
these markers was further assessed, by searching for co-
expressed transcription factors (TFs) and enriched TF
binding sites in their promoters, to establish regulatory
networks speciﬁc to each progenitor population.
Conclusions : Our transctiptome proﬁling analysis
allowed us to expand the current repertoire of surface
markers for better isolation of hematopoietic progenitor
cells and to determine gene networks involved in their
regulation. Experimental validation of our bioinformatic
results is ongoing.
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HLA genotyping by Next Generation Sequencing in the
clinical laboratory
M. Kuś-Slowińska, K. Huminska, A. Mlodzińska, A.
Brylak, J. Wojciechowicz
DNA Research Center, Poznań, Poland
Introduction: The major histocompatibility complex
(MHC) gene family in humans is termed the human leu-
kocyte antigen (HLA) locus, and is one of the most poly-
morphic loci in human genome. HLA and related genes
play important role in the immune system. A close HLA
match between donor and recipient is critical for the success
of organ transplantation. Design of highly speciﬁc primers
for the most reliable and accurate HLA typing was in major
of our research. Materials and Methods: HLA primers were
designed to identify genes of MHC class I and class II. By
using bioinformatics tools we designed 14 primer pairs
targeting speciﬁc genes: HLA-A, HLA-B, HLA-C, DQA1,
DQB1, DPA1, DPA2, DPB1, DPB2, DRA, DRB1, DRB3,
DRB4, DRB5. Majority of genes were covered as a whole
and all were checked for the speciﬁcity. We compared the
results of standard HLA-typing method, commercially
available HLA-NGS typing kits and our protocol on our
clinical samples. For data analysis we checked commer-
cially available pipelines. Results: The highest HLA reso-
lution was observed in our test. Our newly designed primers
can be used for HLA typing, giving more accurate infor-
mation than using currently available methods. Conclu-
sions: HLA typing using our newly designed primers and
NGS technology generates high-resolution allelic informa-
tion for donor and recipient allowing for the higher level of
HLA allele matching. “Presented work was ﬁnancially
supported by The National Centre for Research and
Development from the Innovative Economy Operational
Programme founds, in the framework of the European
Regional Development Fund.”
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Considerations when using IGH clonality assay by high-
throughput sequencing for minimal residual disease
monitoring of acute lymphoblastic leukemia in the
clinical testing laboratory
I. Jo1, N. Chung2, S. Lee3, J. Park4, W. Jang1, Y. Kim1, M.
Kim1
Department of Laboratory Medicine, Seoul St. Mary's
Hospital, College of Medicine, The Catholic University of
Korea, Seoul, Korea, Republic of, 2Departments of
Pediatrics, Seoul St. Mary's Hospital, College of Medicine,
The Catholic University of Korea, Seoul, Korea, Republic
of, 3Department of Hematology, Catholic Blood and
Marrow Transplantation Center, Seoul St. Mary's Hospital,
College of Medicine, The Catholic University of Korea,
Seoul, Korea, Republic of, 4Department of Laboratory
Medicine, College of Medicine, The Catholic University of
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Introduction : Assessment of minimal residual disease
(MRD) is used for most B-acute lymphoblastic leukemia(B-
ALL) as a powerful prognostic factor which impact on
treatment protocols. Although several tools have been
devised for MRD monitoring, immunoglobulin heavy chain
(IGH) clonality assay using high-throughput sequencing
(HTS) is pending to be applied in clinical testing laboratory.
Before application in clinical settings, we tried to draw up a
practical guideline of MRD monitoring with IGH clonality
assay by HTS.
Materials and Methods : We screened clonal IGH rear-
rangements at diagnosis using both fragment analysis and
HTS using IdentiClone IGH Gene Clonality Assay(InVi-
voScribe Technologies, San Diego, USA) and Lympho-
Track Dx Assay–PGM(InVivoScribe Technologies),
respectively. Longitudinal samples (n= 20) obtained over
the course of therapy were analyzed for the presence of
MRD by IGH HTS as well as morphology, ﬂuorescence
in situ hybridization(FISH) and RT-qPCR of fusion tran-
scripts. LymphoTrack Visualization and Vidjil algorithm
were selected for analysis platform.
Results : Among 22 initial samples, four showed dis-
crepant results between fragment analysis and HTS. Three
patients showed clonality only by HTS and 1 patient did
only by fragment analysis. Median number and size of IGH
clone at diagnosis were 2(0–4) and 33.15%(1.96%-
78.08%), respectively. IGH HTS data were well correlated
with morphology, FISH and RT-qPCR of fusion transcripts.
Furthermore, samples with profound hematogones and
chromosome 14 hyperploidy can be successfully monitored
by the HTS.
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Conclusion : These results demonstrated that IGH clon-
ality assay by HTS is an effective method for MRD mon-
itoring in most of B-ALL as alternatives of IGH RT-qPCR.
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Deciphering Juvenile Idiopathic Arthritis by exome
sequencing: toward a precision medicine and ther-
apeutic targeting
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Objective: Juvenile idiopathic arthritis (JIA) is the main
cause of inﬂammatory rheumatisms in childhood. JIA is a
heterogeneous condition subdivided in seven subgroups and
is thought to be a multifactorial disorder due to combination
of environmental and genetic factors leading to a dereg-
ulation of immunity.
Recently, next-generation sequencing has helped
uncover some of the genes responsible for Mendelian types
of JIA namely LACC1, COPA and STAT3. This discovery
pinpointedt that some JIA could be Mendelian disorders
instead of multifactorial diseases.
Methods: We performed trios exome sequencing in 46
individuals addressed for JIA. Trios were spread into 5 of
the 7 subgroups of JIA. Immuno-monitoring was assessed
using ﬂow cytometry analysis on blood samples from
affected individuals.
Results: We have identiﬁed pathogenic variants in 10.8%
(5/46) of patients and likely pathogenic variations in 13%
(6/46). Identiﬁed pathogenic variations included variants
already reported in previously known genes (CECR1),
novel variants in known genes (SLC29A3). In addition, we
report a novel syndrome with JIA (NAIAD syndrome by
mutations in NLRP1). All patients with pathogenic varia-
tions had, among other anomalies, blockade in B cells
maturation.
Conclusion: Exome sequencing conﬁrms the genetic
heterogeneity of JIA. We also highlight the fact that arthritis
in young patients might be a symptom of Mendelian dis-
eases. In addition, we highlight the power of precision
diagnosis in some patients leading to accurate genetic
counselling and the discovery of new physiopathological
bases of JIA that could lead in a precise therapeutic orien-
tation and a targeted therapy.
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HRM analysis of KLF1 and Aγ/Gγ genes in cases with
elevated fetal haemoglobin in the Greek population
C. Chassanidis1, A. Psychaki2, A. Karamani2, E. Boutou1,
A. Balassopoulou1
Laikon Hospital, Athens, Greece, 2National and Kapodis-
trian University of Athens, Athens, Greece
Introduction: KLF1 is an erythroid transcription factor
acting both as direct activator of β-globin and indirect
repressor of γ-globin gene expression. An increasing num-
ber of KLF1 gene variations have been shown to lead in
elevated expression of Fetal Hemoglobin (HbF), thus con-
sidering KLF1 as a potential therapeutic target for tha-
lassaemia patients.
Materials and Methods: A total of 76 cases a) 35 β-tha-
lassaemia heterozygotes and b) 41 normals presenting high
levels of HbF>3% were studied for KLF1 and Αγ/Gγ gene
mutations, by HRMA followed by direct sequencing where
appropriate. A matched control of 32 normal samples pre-
senting HbF<3% was also analyzed for the above genes and
served for comparison.
Results: i) KLF1: Four already characterized alterations
(-148G>A, c.304T>C, c.544T>C, c.115A>C) were detected
for the ﬁrst time in the Greek population. Although
-148G>A mutation is considered to down-regulate KLF1
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expression and thus increasing HbF, it was identiﬁed in
heterozygosity in three normal samples. Two new alterna-
tions, not yet recorded (-251C>G, c.178 delGGGA/-), were
also identiﬁed. While -251C>G variation is considered as a
SNP, c.178 delGGGA/- is probably altering KLF1 function
as it was detected in a normal sample with HbF 10%. ii) Aγ
two new alterations (-221; insAGCA/-, -176A>Τ) were
detected in normal samples.
Conclusions: KLF1 and Αγ/Gγ genes analysis in Greek
population samples revealed variations that could possibly
contribute in differential HbF expression. For the ﬁrst time,
HRM analysis served as a rapid, cheap and accurate
approach for the screening/scanning for both KLF1 and Αγ/
Gγ genes.
C. Chassanidis: None. A. Psychaki: None. A. Kar-
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Screening of the 19q13 region revealed lncRNA variants
associated with susceptibility to pemphigus foliaceus
T. D. J. Farias, R. C. Almeida, D. G. Augusto, D.
Malheiros, M. Petzl-Erler
Federal University of Paraná (UFPR), Curitiba, Brazil
Pemphigus foliaceus (PF) is a blistering autoimmune skin
disease endemic in Brazil characterized by the detachment
of epidermal cells and the presence of autoantibodies
against desmoglein-1. We have demonstrated strong asso-
ciations of both polymorphisms and differential expression
levels for several genes within the extended leukocyte
receptor complex (LRC) with susceptibility to PF. The
extended LRC genes within the 19q13 genomic region
encode diverse immune-associated molecules. Here we
aimed to search for new genes and single nucleotide poly-
morphisms (SNP) that may contribute to PF susceptibility in
the 19q13 region.
We analyzed 8,669 SNPs genotyped by Illumina plata-
form of 235 patients and 194 controls. After standard
quality control, 2,503 SNPs were used to perform a logistic
regression analysis, using principal components as covar-
iant to correct for possible population stratiﬁcation.
The strongly associated SNP (rs8103298, OR=2.47,
p<10−4) was within a lncRNA (TCONS_l2_00013175).
Two other associated SNPs, rs9304655 and rs453394, are
located at the protein coding region of the genes IGFL2 and
CCDC8 (OR=1.61, OR=0.64, p<10−3). We also per-
formed a haplotype logistic regression. Two haplotypes (i)
the AGAAG haplotype (rs9304655, rs6509255 (IGFL2 gene
upstream variants), rs10439109 (intergenic variant),
rs10412596 (lnc-IGFL2-1), rs2253940 (lnc-IGFL1-1)) and
(ii) the GG haplotype (rs453394, rs878609; CCD8 gene
upstream variants) were associated with PF susceptibility
(OR= 1.78, OR=1.60, p=0.0006). These results are now
being validated in a PF different cohort.
This screening of the 19q13 region showed new genes
and lncRNA variability might inﬂuences PF pathogenesis,
revealing different candidates for further functional studies.
Financial support: CAPES/CNPq/Fundação Araucária
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Comprehensive targeted next-generation sequencing
panel: A rapid diagnostic tool for unraveling primary
immunodeﬁciencies in pediatric patients
A. Aykut1, N. Karaca2, A. Durmaz1, E. Pariltay1, G.
Aksu2, N. Kutukculer2, O. Cogulu1
Department of Medical Genetics, Ege University, Faculty of
Medicine, Izmir, Turkey, 2Department of Pediatric Immu-
nology, Ege University, Faculty of Medicine, Izmir, Turkey
Primary immunodeﬁciency (PID) disorders are a hetero-
geneous group of inherited diseases caused by a variety of
monogenic immune defects. Thus far, mutations in more
than 250 different genes causing PIDs have been described.
Diagnosis can be costly and time consuming because of
genetic and phenotypic heterogeneity of these disorders.
Next Generation Sequencing (NGS) has recently become a
popular tool for gene identiﬁcation and molecular diagnosis
of human diseases. Targeted NGS, in which a selected
number of genes are sequenced, allows rapidly genetic
testing across a large number of diseases in clinical practice.
Here we present the utility of targeted next generation
sequencing (TNGS) of a comprehensive primary immuno-
deﬁciency panel. TNGS workﬂow based on an Ion
AmpliSeq™ Primary Immune Deﬁciency Research Panel
was designed for sequencing 266 PID genes on Ion S5™
Sequencer. Twenty pediatric patients with PIDs were ana-
lyzed and identiﬁed probable disease-causing mutations.
Pathogenic variants were detected in 9 patients in which 6
of them were novel (45%). These variations included
hemizygous mutations in BTK, heterozygous mutations in
CTLA4, PIK3CD and homozygous mutations in CD40LG,
LRBA, PNP, TTC37 and ZAP70. In conclusion, these results
suggested that TNGS approach based on a comprehensive
gene panel allow fast identiﬁcation of PID mutations that
will have further implications for therapeutics.
320
A. Aykut: None. N. Karaca: None. A. Durmaz: None.
E. Pariltay: None. G. Aksu: None. N. Kutukculer: None.
O. Cogulu: None.
P07.16D
A high-performance analysis pipeline to ﬁnd disease-
causing mutations in patients with Primary
Immunodeﬁciencies
L. Opitz1,2, B. Volkmer2, A. Mauracher2, A. Patrigniani1,
S. Vavassori2, J. Pachlopnik Schmid2
1Functional Genomics Center Zurich, Zurich, Switzerland,
2Division of Immunology, University Children's Hospital,
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The emergence of Next Generation Sequencing (NGS) has
greatly modiﬁed the landscape of human genetics especially
with Whole Exome Sequencing (WES) which focuses on
the exonic regions of human genomes. As the protein
coding region of the genome, exomes often harbor disease
causing genetic mutations that can be linked to a phenotype
in Mendelian diseases.
Based on this knowledge we present an ongoing genetic
study and give an overview of results obtained so far. The
designated aim of our project on Immunodeﬁciencies is to
create a workﬂow, initiated by WES results. This should
allow the identiﬁcation of patients with unusual or novel
genetic forms of Primary Immunodeﬁciency diseases (PID)
and is aided by a thorough clinical characterisation.
Patients included in our studies present with symptoms
of immunodeﬁciency or -dysregulation of unknown origin.
High throughput genetics including WES and tran-
scriptomics are initially performed on patients and guide the
choice of functional immunological assays conducted
afterwards. These choices are hinged on the prior data
analysis which involves several steps.
So far, we have included 25 PID patients in our pipeline.
We have found four patients with well-known PIDs, who
were not diagnosed previously due to their unusual clinical
and immunological presentation, three further patients were
found to have mutations associated with recently described
PIDs.
These initial results are very encouraging, yet as there are
very few patients in our cohort with the same disease WES
results can be difﬁcult to interpret this especially if a
mutation has not yet been described yet.
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Genome-wide association analysis of axial involvement
in psoriatic arthritis identiﬁes suggestive evidence for
association to four susceptibility loci in 845 patients of
European origin
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Frankfurt, Germany, 4Arthritis Research UK Centre for
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ster Foundation Trust and University of Manchester,
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Psoriatic arthritis (PsA) is a chronic inﬂammatory joint
disease occurring in ≥30% of patients with psoriasis vul-
garis (PsV). PsA is considered a T-cell mediated disease
with a complex genetic basis. To date, genome-wide asso-
ciation studies (GWAS) identiﬁed 15 susceptibility loci.
Most of these loci overlap with those identiﬁed for PsV and
some of them e.g. with ankylosing spondylitis. To identify
genetic risk factors relevant in axial involvement, we ana-
lyzed genome-wide association data of 845 PsA patients of
European origin for presence (26%) or absence (74%) of
axial involvement. Axial involvement was diagnosed as
sacroiliitis or spondylitis.
None of the loci reached genome-wide signiﬁcance, but
we identiﬁed four with suggestive signiﬁcance character-
ized by ≥5 SNPs with a p-value between 5.0E-05<p<5.0E-
08. Odds ratios were higher than for most PsA susceptibility
factors identiﬁed so far, ranging from 1.70 - 2.16. Two of
the four loci were located in intergenic regions while the
other two were in introns of two genes. One of these genes,
VAV3, has been described to be involved in bone density in
mice and to be expressed in skin and immune cells. We
selected the most signiﬁcantly associated SNP (rs4462178,
p=3.3E-06, OR=1.74) at VAV3 for replication studies of an
independent cohort of 619 German PsA patients, but failed
Abstracts from the 50th European Society of Human Genetics Conference:. . . 321
to identify evidence for association, potentially due to lack
of power. Larger cohorts with detailed phenotypic data will
eventually allow dissecting symptom-speciﬁc disease sub-
groups with diverse genetic etiology.
Supporting grant to AR and UH: BMBF Metarthros
01EC1407A
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Multiple rare variants in immune genes predict common
respiratory infections burden in isolated populations
A. Gelemanović1, A. Relja1, C. Hayward2, I. Kolčić1, O.
Polasek1
1University of Split School of Medicine, Split, Croatia,
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Introduction: Common respiratory infections are causing a
substantial burden of disease, despite numerous infection
control measures. The aim of this study was to elucidate the
role of host genetic in infections susceptibility. Materials
and methods: A follow-up, postal survey was sent to par-
ticipants from the 10,001 Dalmatians cohort, focusing on
the annual frequency of common cold, inﬂuenza and
pneumonia, with 1,082 responses. HRC imputed linear
regression GWAS was adjusted for age, gender, years of
schooling and socioeconomic status. Participants originated
from two different isolated islands, requiring a weighted
ﬁxed effects meta-analysis, with Bonferroni adjusted P-
value of 3.7E-09. Results: We found 45 signiﬁcant hits in
meta-analysis for the life-time risk of pneumonia, majority
of them being rare intron variants. Some of the most
interesting results belong to CXCL1, MARCH1, PAX5, and
RASA3 genes, which were previously implied in inﬂam-
mation and infection response processes. Five other genes
involved in immunity, including IL12RB1 and C5, were
found to be just under the formal signiﬁcance threshold. We
identiﬁed 4 marginally suggestive SNPs for cold and
inﬂuenza frequency, also implied in immunity and infection
response. Conclusions: Despite small sample size, genetic
architecture underlying host susceptibility to common
respiratory infections suggest the role of numerous rare
variants. This result could explain high levels of diversity,
observed in an individual susceptibility risk and infectious
disease outcomes across population. Funding: Medical
Research Council UK, Croatian Science Foundation grants
8875 and 8445, FP7 project PREPARE (602525). We
gratefully acknowledge contribution from the Institute for
Anthropological Research in Zagreb, Croatia.
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High throughput single-cell gene expression analysis of
blood cells from healthy individuals and patients with
rheumatoid arthritis with highly multiplexed
ampliﬁcation
N. Bansal, J. Fan, H. Fan
D Genomics, Menlo Park, CA, United States
Introduction: Bulk RNA studies used to examine gene
expression patterns in patients are limiting due to bulk RNA
masking the contribution from different cell types within a
sample. Recent techniques in high throughput single-cell
RNA sequencing, with the ability to analyze the tran-
scriptomes of thousands of cells simultaneously, are pro-
mising approaches to discern the contribution of these
patterns in speciﬁc cell types. However, the cost of
sequencing the entire transcriptome of every cell limits the
number of biological samples that can be studied, especially
if functionally important genes are expressed at relatively
low levels. To circumvent this issue, we used a targeted
approach to study the digital gene expression of a selected
set of gene markers (454), to study the gene expression
between healthy and Rheumatoid Arthritis (RA) patients.
Materials and Methods: Using the BDTM Resolve
system, we captured and barcoded mRNA transcripts from
~10,000 single-cells from three sets of cryopreserved per-
ipheral blood mononuclear cells from healthy and RA
patients. We then performed targeted multiplex PCR to
amplify the cDNA of the 454 genes, followed by
sequencing.
Results and Conclusions:We found that by focusing on
selected genes, we used a relatively small amount of
sequencing while identifying differences in immune popu-
lations between individuals. Additionally, we observed
activated and distinct monocyte populations in RA patients
as compared to healthy. These results show how high-
resolution single-cell gene expression analysis using tar-
geted ampliﬁcation can be used to routinely examine per-
ipheral blood cells, and may open up the development of
new diagnostic approaches.
N. Bansal: A. Employment (full or part-time); Sig-
niﬁcant; BD Genomics. J. Fan: A. Employment (full or
part-time); Signiﬁcant; BD Genomics. H. Fan: A.
Employment (full or part-time); Signiﬁcant; BD Genomics.
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Slc7a7−/− mouse model develops Lysinuric Protein
Intolerance immune related abnormalities
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Lysinuric protein intolerance (LPI, MIM 222700) is an
inherited aminoaciduria caused by defective cationic amino
acid (CAA) transport mainly, at the basolateral membrane
of epithelial cells in kidney, and also intestine. LPI is caused
by mutations in the SLC7A7 gene, which encodes y+LAT1
transporter. Hallmarks of LPI are intestinal and renal
impairment of CAA that cause a urea cycle dysfunction.
Moreover, major and life threatening complications are
immune-related disorders in which y+LAT1 contribution is
still unknown. Because null Slc7a7 mice are lethal, a ubi-
quitous and tamoxifen-inducible ablation of Slc7a7 in
mouse has been generated. LPI patients treatment, low-
protein diet and citrulline supplementation, is needed to
maintain Slc7a7-/- mice alive. As in humans, mouse CAA
plasma concentration is reduced. This lower availability of
urea cycle substrates, the hyperglutaminemia, hyper-
ammonemia and orotic acid hyperexcretion denotes a urea
cycle dysfunction that could be the cause of brain edema in
Slc7a7-/-. As in humans, hyperferritinemia, hematological
imbalance and clonal expansion defect, are present in the
model. Finally, a live threatening immunity alteration in LPI
patients is pulmonar alveolar proteinosis (PAP). Approxi-
mately 1/3 of Slc7a7-/- develops PAP 90 days after
induction. At the basis of the disease, alveolar macrophages
(AM) play a main role and appear foamy and full of sur-
factant. The loss of y+LAT1 expression in macrophages
could contribute to its malfunction. In summary, the ﬁrst
LPI animal model is an excellent tool to study the unknown
mechanisms of pathophysiology of LPI and improve treat-
ment and health care of patients.
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Objective: Takayasu arteritis (TA) is an inﬂammatory large
vessel vasculitis affecting mainly aorta and its branches.
Inﬂammation in vessels causes thickening of wall, ﬁbrosis,
dilatation and nonspeciﬁc symptoms such as fever, hyper-
tension and arthralgia. It is a rare disorder with unknown
aetiology and the worldwide incidence is 0.4 to 2.6 per
million. We studied a consanguineous family consisting of
two affected and one unaffected sibs and their healthy
parents in order to identify the causative mutation or linked
loci.
Methods: Whole genome single nucleotide polymorph-
ism (SNP) genotyping was performed for ﬁve family
members using Illumina OmniExpress-24 BeadChip tar-
geting ~700,000 SNP markers. Using genotyping data, we
performed multipoint parametric linkage analysis assuming
recessive inheritance and complete penetrance. Also exome
sequencing was performed for index patient to search for a
rare, homozygous deleterious variant in the possibly linking
regions.
Results: Whole genome linkage analysis resulted 25
genomic regions with LOD score above 1.50. Within the
family members, all candidate regions shared homozygosity
by only affected individuals. Causative variant search in
linkage regions identiﬁed seven homozygous candidate
variants in which ﬁve of them were located in 19q13.33.
Candidate non-synonymous variants were found in
ANXA8L, EHBP1L1, MYH14, KCNJ14, SYNGR4, TULP2
and SHANK1 genes.
Conclusion: This is the ﬁrst whole genome linkage
analysis in a TA family with recessive inheritance. Linkage
and following exome sequencing analyses revealed seven
possible variants that may be causative to disease. Further
variant and candidate gene investigations are still in
process.
This study was supported by TÜBİTAK (Grant No
114Z829).
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whole exome sequencing revealed a novel mutation in
TMPRSS6 gene in an iron-refractory iron deﬁciency
anemia patient
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Identiﬁcation of two common types of anemia, beta tha-
lassemia (BT) and iron deﬁciency anemia (IDA) have great
importance to prevent misdiagnosis followed by proper
treatment. BT and IDA are autosomal recessive disorders
characterized by hypochromic microcytic anemia which can
be differentiated by hematological indices. Defects in
TMPRSS6 gene, which encodes a trans-membrane serine
protease protein (Matriptase-2), result in Iron Refractory
Iron deﬁciency anemia (IRIDA). Matriptase-2 regulates
systemic iron homeostasis by down-regulation of the hep-
cidin protein. Here we report an Iraqi kindred with 2
affected siblings in which the 6 years old boy suffered from
severe anemia with high dose of iron supplement. Con-
sidering the high level of hemoglobin A2, the beta globin
gene sequencing was performed and a heterozygote C41–42
mutation was detected which does not justify the severity of
the proband phenotype. We then performed Whole exome
sequencing for proband which revealed a novel homozygote
8 bp deletion (c.1647-1654 delGCAGTGTG) in TMPRSS6
gene. The deletion located in LDLR-class A domain of
Matriptase-2 leads to a premature stop codon at position 11
of the new reading frame (p.Gln550Trp fs*11). In silico
prediction programs (SIFT, polyphen 2, Mutation taster) are
in support of its probable pathogenecity and predicted this
variant as disease causing. The co-segregation analysis
identiﬁed that the parents were both carrier while the gen-
otype of the affected sister was homozygote. Our ﬁndings
indicated that next generation sequencing could be a pro-
mising method for molecular detection in mendelian dis-
orders such as genetic forms of hypochromic deﬁciency in
high prevalence countries.
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Genetic and phenotypic dissection of 1q43q44 micro-
deletion syndrome and neurodevelopmental phenotypes
associated with mutations in ZBTB18 and HNRNPU
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Subtelomeric 1q43q44 microdeletions cause a syndrome
associating intellectual disability, microcephaly, seizures
and anomalies of the corpus callosum. Despite several
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previous studies assessing genotype-phenotype correlations,
the contribution of genes located in this region to the spe-
ciﬁc features of this syndrome remains uncertain. Among
those, three genes, AKT3, HNRNPU and ZBTB18 are highly
expressed in the brain and point mutations in these genes
have been recently identiﬁed in children with neurodeve-
lopmental phenotypes.
In this study, we report the clinical and molecular data
from 17 patients with 1q43q44 microdeletions, four with
ZBTB18 mutations and seven with HNRNPU mutations,
and review additional data from 37 previously published
patients with 1q43q44 microdeletions. We compare clinical
data of patients with 1q43q44 microdeletions with those of
patients with point mutations in HNRNPU and ZBTB18 to
assess the contribution of each gene as well as the possi-
bility of epistasis between genes.
Our study demonstrates that AKT3 haploinsufﬁciency is
the main driver for microcephaly, whereas HNRNPU
alteration mostly drives epilepsy and determines the degree
of intellectual disability. ZBTB18 deletions or mutations are
associated with variable corpus callosum anomalies with an
incomplete penetrance. ZBTB18 may also contribute to
microcephaly and HNRNPU to thin corpus callosum, but
with a lower penetrance. Co-deletion of contiguous genes
has additive effects.
Our results conﬁrm and reﬁne the complex genotype-
phenotype correlations existing in the 1qter microdeletion
syndrome and deﬁne more precisely the neurodevelop-
mental phenotypes associated with genetic alterations of
AKT3, ZBTB18 and HNRNPU in humans.
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Introduction Microduplication of the LCR-a to LCR-d
region on chromosome 22q11.2 is a recurrent copy number
variant (CNV) found in clinical samples with neurodeve-
lopmental disorders. It is also found at lower frequency in
controls, and is often inherited. Case reports of the clinical
features of probands is subject to ascertainment bias, and
there is limited data on the intellectual and psychological
functioning of non-proband adults.
Subjects and Methods We recruited 22 people with this
CNV for psychological assessment. Seven were parents of
probands, and 5 were siblings or cousins. Standardized
psychological assessment measures and questionnaires were
administered, including measures of intellectual (IQ), aca-
demic, adaptive, psychiatric, behavioral and social
functioning.
Results Intellectual and academic skills were within the
average range, with a trend towards slightly lower scores in
probands versus non-probands. In probands, adaptive skills
were within age expectations. Higher rates of attention
deﬁcit (probands only) and anxiety (both groups) were
identiﬁed. The rate of autism spectrum disorder (5% of total
sample), was much lower than previously reported.
Conclusions Intellectual and academic abilities were
intact in probands and non-probands with 22q11.2 dupli-
cation, and symptoms of attention deﬁcit and anxiety were
identiﬁed.
This work was supported by a grant from the Physician
Services Incorporated Foundation.
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Adolescents and adults with 22q11.2 deletion syndrome:
Our experience
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22q11.2 deletion syndrome is the most common micro-
deletion syndrome. This multisystem disorder has age
related presentation needing age related screening. Con-
genital structural malformations of heart (74 %), palate
(69%), renal (32%), immune deﬁciency (70%) endodocri-
nology complications (hypocalcemia, hypothyroidism),
learning difﬁculties and psychiatric issues predominate the
clinical phenotype. Behavioural and psychiatric issues are
seen in 70–90 % . More than 40 % individuals have autistic
spectrum disorder, ADHD or both. Bipolar disorder, schi-
zophrenia and schizoaffective disorders are reported in 10–
30 % of teenagers and adults with 22q. The risk of severe
psychiatric illness is 25 times higher than general popula-
tion in these individuals. We started a specialised 22q
transition clinic in Northern Ireland in April 2016 as there
was no system or arrangement in place to recognise,
anticipate or proactively deal with the issues commonly
associated with this disorder. . There are currently 115
individuals with 22q11.2 deletion on our data base includ-
ing 55 adolescents and adults. The analysis of our patient
cohort showed that the physical issues related to congenital
structural malformations are usually addressed post diag-
nosis in early childhood. However issues related to learning
difﬁculties and psychiatric illnesses evolve with age and are
often under recognised. The main purpose of this clinic was
to address these issues in adolescents and adults. We present
our data describing the clinical phenotype in adolescent and
adult individuals of this cohort. We also present three
interesting cases with unusual central nervous system phe-
notype leading to delayed diagnosis of 22q11.2 deletion
syndrome.
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Riley et al. Am J Med Genet 2015 recently reported an
approximately 1.5 Mb recurrent duplication in 2q11.2 with
variable outcome including a normal carrier mother and 3
patients with mild to moderate developmental delay, short
stature and variable other features. We now observed 9
novel carriers from 6 families including two patients with de
novo duplication. While 8 duplication carriers had low
normal IQ or mild intellectual disability, one patient with de
novo duplication suffered from profound developmental
delay, microcephaly, craniosynostosis, strabism and con-
genital heart defect. Under the suspicion of a second hit in
the latter patient we performed trio exome sequencing
which indeed revealed an additional disease causing muta-
tion in a known ID gene (KAT6A). The symptoms in our
patient not described in the patients with 2q11.2 micro-
duplications can be explained by the de novo KAT6A
mutation. Our observation therefore indicates that the
recurrent duplication 2q11.2 causes mild intellectual deﬁcits
with short stature, gastroesophageal reﬂux with vomiting/
feeding difﬁculties and dysmorphic features as frontal
bossing and other minor facial features, while a more severe
phenotype may be attributed to second hits.
S. Azzarello-Burri: None. P. Joset: None. J. Andrieux:
None. F. Lopes: None. E. Palmer: None. J. Czeschik:
None. B. Demeer: None. F. Duque: None. A. Kuechler:
None. P. Maciel: None. A. Hackenberg: None. B. Oneda:
None. A. Rauch: None.
P08.05A
Evaluation of array comparative genomic hybridisation
for patients with developmental dissabilities or con-
genital anomalies
A. Repáraz-Andrade1, C. Torreira Banzas1, A. Amado
Puentes2, M. Blanco Pérez1, O. Blanco Barca2, M. A.
Andrade Olivié3, J. R. Fernández Lorenzo4
Cytogenetics and Molecular Genetics Unit. Hospital Álvaro
Cunqueiro, Vigo, Spain, 2Neuropediatrics Unit. Hospital
Álvaro Cunqueiro, Vigo, Spain, 3Head of Clinical Labora-
tory Department. Hospital Álvaro Cunqueiro, Vigo, Spain,
326
4Head of Department of Pediatrics. Hospital Álvaro
Cunqueiro, Vigo, Spain
Introduction: Chromosomal microarrays (CMA) are
widely used as ﬁrst-tier test for patients with unexplained
developmental delay/intellectual disability (DD/ID), autism
spectrum disorders (ASD), or multiple congenital anomalies
(MCA).
Objectives: Review the data after the implementation of
an algorithm for array comparative genomic hybridisation
(aCGH) testing in patients with unexplained DD/ID, ASD,
or MCA and assess the diagnostic yield.
Materials and methods: We performed aCGH to 724
patients referred from the neuropediatrics department with
unexplained DD/ID, ASD, or MCA. aCGH was performed
mainly with the Signature Genomics CGX 8×160K arrays
(Perkin Elmer), following ClinGen guidelines (ISCA).
Results were reported following ISCN 2013 recommenda-
tions. If a CMA variant was observed, parental samples
were analyzed. Copy number variations are assigned the
following interpretations: abnormal (well established syn-
dromes, de novo variants and large changes); VOUS (var-
iants of unknown signiﬁcance) and likely benign (not
previously reported but inherited from a healthy parent).
Diagnostic yield was deﬁned as the number of patients with
abnormal variants divided by the total number of patients
tested.
Results. 894 patients and 277 parents were studied. 170
patients (19%) showed an abnormal result, and were clas-
siﬁed as follows: 128 abnormal (14,3%), 30 likely benign
(3,4%) and 12 VOUS (1,3%). The diagnostic yield is
14,3%.
Conclusions. The use of CMA as ﬁrst-tier clinical diag-
nostic test for patients with unexplained DD/ID, ASD, or
MCA has proven to surpass the classical approach with
conventional cytogenetics. Karyotyping is still needed to
address whether the imbalance is due to parental chromo-
somal rearrangements and for genetic counselling purposes.
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Angelman syndrome resulting from UBE3A mutations :
variants update and experience of molecular diagnosis
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Introduction: Angelman syndrome (AS) is a neurodeve-
lopmental disorder caused by absence or inactivation of the
maternally expressed UBE3A gene. The paternal allele of
UBE3A gene is silenced through genomic imprinting in
brain. Different molecular anomalies, involving the UBE3A
gene, were previously described. Genetic counselling
depends on molecular mechanism and parental inheritance.
About 10% patients have loss of function mutations. In this
subgroup, offspring of carrier mothers are at 50% risk of
having AS.
Materials and Methods: Between 1990 and 2015, 548
patients have been referred to our laboratory, for UBE3A
gene analysis. Different approaches, with evolution over
time, were used to screen mutations. Results with instruc-
tions for family study were given back to prescriber by
letters. Parental analysis was always recommended to
determinate de novo or inherited mutation status.
Results: We reported 57 patients with a mutation in
UBE3A gene. The diagnostic rate was 10,4%. Most of
mutations were truncating. We identiﬁed 41 unpublished
mutations with 12 missense variants that were predicted to
be damaging in software. We observed a small number of
polymorphisms. Parental analysis could be performed in
72% cases. Between these cases, mutations were de novo in
59% patients. In maternal inheritance cases (41%), analyses
were extended to family members in 47%. We performed
11 prenatal testing with 3 positive diagnoses.
Conclusions: At the time of NGS, variants updating is
crucial. Because there is no cure, molecular diagnosis, even
if doesn’t change the treatment, is particularly important to
prevent recurrence risk.
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De novo ARX mutations in female patients with agenesis
of the corpus callosum and intellectual disability
Abstracts from the 50th European Society of Human Genetics Conference:. . . 327
M. TAVEIRA1, S. Heide2, C. Mignot2, M. Milh3, A.
Rastetter4, A. Jacquette2, P. Charles2, I. Marey2, S.
Whalen1, B. Keren5, C. Nava5, D. Héron2
APHP - Hôpital Armand-Trousseau, UF de Génétique
Clinique, Paris, France, 2APHP - GH Pitié-Salpêtrière,
Département de génétique, UF de génétique médicale,
Centre de référence des déﬁciences intellectuelles de causes
rares, Paris, France, 3APHM – Hôpital de la Timone,
Service de neuropédiatrie, Marseille, France, 4ICM, UPMC
Inserm UMR S975/CNRS UMR 7225, Paris, France, 5GH
Pitié-Salpêtrière, Département de génétique, UF de géno-
mique du développement, Paris, France
Loss of function mutations in the Aristaless-related (ARX)
gene are typically responsible for brain malformation phe-
notypes in males, including X-linked lissencephaly with
abnormal genitalia (XLAG, also known as LISX2) (MIM#
300215) and Proud Syndrome (MIM# 300004). Within
affected families, carrying females are usually asympto-
matic but few symptomatic females were reported, with
intellectual disability (ID) and/or agenesis of the corpus
callosum (ACC). De novo ARX mutations in affected
females have only been infrequently reported.We describe
here four unrelated female patients with ACC, ID and sei-
zures, related to de novo loss of function mutations in ARX.
All patients presented with intellectual disability, from
moderate to severe. Seizures occurred between 2 months to
3 years of life. Brain MRI showed complete ACC in ¾
patients and partial ACC with absent anterior commissure in
¼ patient. ACC was isolated in ¼ patient whereas other
cerebral or extra-cerebral malformation was associated in ¾
patients (hippocampic hypoplasia (n= 1), bilateral lenti-
cular hypoplasia (n= 1), bilateral optic atrophy (n= 1)).We
report three truncating and one missense mutations, loca-
lized in the homeobox domain of the protein. All mutations
arose de novo. The mutations were identiﬁed by next gen-
eration sequencing (panel of known genes involved in ACC
or epilepsy, or whole exome sequencing).This report con-
ﬁrms the importance of screening ARX and female patients
with ID, seizures and ACC.
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Introduction: We describe 15 yo monozygotic twin girls
with dual molecular diagnoses of Prader-Willi syndrome
(PWS) and Pitt-Hopkins syndrome (PTHS). They were
diagnosed with PWS at nine months of age due to neonatal
hypotonia and feeding difﬁculties. They later developed an
atypical PWS phenotype, including severe intellectual
deﬁciency, lack of ambulation and speech, and absence of
hyperphagia.
Methods: A genetic investigation was carried out using
array-CGH, microsatellite and methylation assays, WES
(whole exome sequencing) and RNA studies.
Results: Genetic studies conﬁrmed the PWS diagnosis
due to the paternal deletion of 15q11-q13 and methylation
of SNRPN promotor. WES revealed a second mutational
event consisting of a novel variant c.145+1G>A affecting a
TCF4 canonical splicing site of exon 3. The unaffected
mother is a mosaic carrier of the TCF4 mutation. RNA
studies conﬁrm that this variant abolishes the donor splicing
site at intron 3 and that an alternative non-canonical splicing
site is utilized; a premature stop codon in exon 4 is pre-
dicted to truncate the protein. Re-evaluation of clinical
symptoms indicate that both variants are likely contributing
to the twins phenotype. The characteristics of PWS are
accentuated in the neonatal period and those of PTHS
predominate from childhood on.
Conclusion: This case illustrates the challenges of
reaching a ﬁnal diagnosis in complex clinical presentations
and highlights the importance of WES in the investigation
of such clinical cases.
Grants: CAPES, CNPq, FAPEMIG, FAPESP, U54
HG006542 National Human Genome Research Institute/
National Heart Lung and Blood Institute to the Baylor
Hopkins Center for Mendelian Genomics.
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Intellectual disability (ID) is a common neurodevelop-
mental disorder, characterized by a high genetic hetero-
geneity, with more than 700 genes involved in monogenic
forms of ID. One of these is AUTS2 for which numerous
intra- and inter-genic deletions have been reported in
patients with a variable global developmental delay and ID,
with or without autism and microcephaly. The severity of
the phenotype seems to correlate to the location of the
deletions and if they affect or not a short isoform transcript
located in the 3′part of the gene, highly expressed in brain
and encoding a nuclear isoform presumably involved in
regulation of gene expression. Even if this evolved between
the two last human genome versions hg19 and hg38, this
short isoform remains still not fully characterized. By using
a targeted and whole exome sequencing strategies we
identiﬁed four novel loss-of-function (LoF) mutations
affecting both isoforms and causing developmental delay,
with or without autistic traits, in a total of 12 individuals
(two de novo and two inherited from affected parents). Our
data enlarged the AUTS2 syndrome phenotype, and showed
that high phenotype variability can be observed among
patients with the same LoF AUTS2 mutation. We carried out
functional studies on available patient’s ﬁbroblasts to
investigate the consequences of these mutations and showed
that short and long transcripts carrying the mutations at least
partially escape to NMD. We also performed transcriptomic
analyses to identify genes commonly dysregulated in
patients and to better characterize the short AUTS2 isoform,
identifying at least two novel exons.
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Cerebrofaciothoracic dysplasia - four new cases further
delineating the phenotypic spectrum with a recurrent
TMCO1 mutation
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Introduction: Cerebrofaciothoracic dysplasia (CFTD;
MIM #213980) is a rare, autosomal recessive, develop-
mental disorder. It is characterised by distinctive craniofa-
cial features, intellectual disability, and skeletal
abnormalities, mostly affecting the ribs and vertebrae.
CFTD is caused by homozygous loss of function mutations
in the TMCO1 gene. Nineteen molecularly conﬁrmed
patients have been reported previously. Here, we present the
phenotypic and genotypic features of a further four patients,
including three brothers from a consanguineous Pakistani
family and an additional unrelated Caucasian patient with
no family history of consanguinity.
Materials and methods: The patients were ascertained via
routine referrals to Clinical Genetics services in the UK.
Exome sequencing was undertaken as part of the Deci-
phering Developmental Disorders study.
Results: All patients had typical craniofacial dys-
morphisms, including brachycephaly (1/4), synophrys (3/4),
highly arched eyebrows (2/4), hypertelorism (1/4), micro-
dontia (2/4), and gingival hyperplasia (1/4). Skeletal fea-
tures included rib abnormalities (2/4), abnormal vertebrae
(1/4), Sprengel deformity (1/4), long hyperextensible ﬁn-
gers (2/4), and talipes equinovarus (3/4). 2/4 patients had an
intention tremor. One patient had atypical café au lait pat-
ches and an anteriorly placed anus, which are novel fea-
tures. All patients had severe learning difﬁculties.
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Interestingly, molecular testing demonstrated all had the
same homozygous c.292_293del (p.Ser98*) TMCO1
mutation (NM_019026.4 transcript), despite one patient
being unrelated.
Conclusion: This report allows further delineation of the
CFTD phenotypic spectrum. Some novel clinical features
are presented. The TMCO1 mutation found is a recurrent
mutation, previously only seen in an isolated Amish
population, revealing a likely mutation hotspot in this gene.
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Whole-Exome Sequencing (WES) is becoming a standard
application for the detection of gene mutations responsible
for human disease, especially SNVs and indels. To date,
most studies of CNVs were diagnosed by array-CGH or
array-SNP with a lower detection limit of about 30kb. The
challenge is now to detect both SNVs and CNVs using an
exome-wide approach with a single test. Several algorithms
have been developed to call CNV from WES data (Exome
CNV, CONTRA, ExomeCopy, ExomeDepth, ConiFer,
XHMM). The XHMM program is optimized for the iden-
tiﬁcation of rare variants in large exome data sets, in par-
ticular exonic CNVs smaller than 30kb. We used XHMM to
screen for exome CNVs in data from 350 patients with
developmental disorders for whom exome sequencing was
performed in a research or diagnostic setting with normal
array-CGH 4×180K Agilent design used in our lab. We
identiﬁed pathogenic CNVs, ranging in size from 685pb to
11kb (all conﬁrmed by qPCR), in ﬁve patients (1.4%).
Among these, four patients showed clinically relevant
deletions in neurodevelopmental disorders (4.5 kb
homozygous deletions of PPT1; 5kb for PIGN; 637pb for
TCF4; 2.2kb homozygous CLCN2 deletion), one patient
had Cohen syndrome (11kb homozygous VPS13b dele-
tions). This study shows that the XHMM program detected
ﬁve CNVs from whole-exome data. This study underlines
the interest of whole-exome sequencing in genetic disorders
to identify SNVs and CNVs especially those smaller than
30kb not detected by array-CGH.
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Clinical spectrum of four patients with Cofﬁn-Siris
syndrome and novel mutations in ARID1B gene
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Cofﬁn-Siris syndrome (CSS) is a multiple malformation /
intellectual developmental disorder (IDD) syndrome caused
by mutations in genes of the BAF complex, ARID1B being
the most frequent (40% of affected individuals). Mutations
in ARID1B also cause non-syndromic IDD, without other
speciﬁc clinical features. It is recognized as one of the most
frequently mutated genes in patients with developmental
disorders caused by de novo dominant mutations.
We reviewed clinical and molecular data of individuals
from our genetics service with a clinical diagnosis of CSS
and a variant in ARID1B. Phenotypic features were com-
pared to CSS and ARID1B-related IDD cohorts reported in
the literature and publicly available databases.
Four female patients were identiﬁed with a clinical
diagnosis of CSS and an ARID1B potentially pathogenic
variant. Clinical features include classical features of CSS,
including IDD, characteristic facial features and hirsutism;
hypoplasia of the ﬁfth digits was a variable feature. All
patients have different putative mutations, including two
truncating and two splice donor variants; the variant
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occurred de novo in three cases; in one case parental sam-
ples were unavailable.
CSS is a clinically recognizable DD syndrome, with
mutations in ARID1B found in approximately 40% of
affected patients reported in the literature. Mutations are
most frequently loss of function, while those affecting
splicing account for approximately 7% of pathogenic and
likely pathogenic variants in ARID1B-related IDD in public
databases. We report 2 novel splice variants, discuss the
broader phenotypic spectrum of ARID1B-related IDD and
provide case reports of how molecular diagnosis affects
parental reproductive decisions.
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Background: Approximately 20–50% developmental delay
(DD)/mental retardation (MR) and 10% of autism spectrum
disorder (ASD) cases can be explained by genetic causes.
Clinical genetic testing is needed for patients with unex-
plained DD/MR/ASD and multiple congenital anomalies.
Herein, the genetic spectrum of Korean patients with
unexplained neurodevelopmental disorders was retro-
spectively analyzed. The diagnostic yield of various genetic
tests was also evaluated in Korean patients with DD/MR/
ASD.
Methods: Retrospective chart and genetic test result
review of MLPA, CMA, and karyotyping testing were
conducted during a 55-month period on patients with
unexplained neurodevelopmental disorders with or without
dysmorphism or seizures. MLPA analysis was used for
screening the 294 patients were included in this study, out
of which 224 patient tested karyotyping. 97 patients referred
for CMA test were included.
Results: A total of 30 pathogenic cases were identiﬁed in
10.2% patients, out of which 20 pathogenic results were
detected by MLPA seven were detected by both MLPA and
CMA. Nine pathogenic results were detected only by CMA.
Pathogenic results were identiﬁed in 93.3% of patients with
DD and/or MR. Microdeletion/microduplication syndrome
was detected in 20 patients using MLPA with a diagnostic
yield of 6.8%, whereas the diagnostic yield of CMA was
16.5%.
Conclusions: The present ﬁndings highlight the clinical
utility of MLPA as a routine diagnostic test for the diag-
nosis of unexplained DD/MR/ASD cases in Korea. MLPA
is recommended as a screening for identifying the genetic
causes of disease in DD/MR/ASD patients.
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Next-generation sequencing allows a diagnostic yield of
24% in monogenic epilepsies
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Epilepsy is a group of neurological disorders affecting 0.7%
of the population. Etiologies are widely heterogeneous,
including monogenic causes. Most of these disorders affect
children, which stresses the need for early molecular diag-
nosis. We developed a 90-gene panel for the diagnosis of
Mendelian epilepsies. Target exon libraries were generated
using SeqCapEZ capture technology (Roche®). Sequencing
was carried out on a Miseq or a NextSeq500 (Illumina®). A
total of 329 DNAs from patients without diagnosis have
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been analyzed. Patients had epileptic encephalopathy (301),
focal epilepsy (10), benign familial neonatal or infantile
epilepsy (5), or other types of epilepsy. We identiﬁed
pathogenic variants in 79 out of 329 patients, including 3
mosaic mutations with a rate between 15 and 20% in blood
and 3 deletion or duplications of whole exons. Pathogenic
variants were de novo in the genes KCNQ2(6), KCNT1(5),
SCN2A(5), SCN8A(4), GNAO1(3), CHD2(3), SYNGAP1(3),
PCDH19(3), ATP1A3(3), FOXG1(2), PRRT2(2), DEPDC5
(2), GRIN2A, GABRB3, SCN1A, STXBP1, SLC6A1, MBD5
; homozygous or compound heterozygous in PIGN(2),
PNPO(2), WWOX(2), PLCB1, ST3GAL3, POLG, SCARB2,
QARS, TBC1D24; and X-linked in CDKL5(4), PIGA(3),
SLC9A6(3), ALG13(2), SLC35A2(2), MECP2 and CASK.
This gene panel increased the diagnostic rate of monogenic
epilepsies to 24%. The identiﬁcation of the disease-causing
mutation(s) will provide accurate genetic counseling and
might have therapeutic consequences in a growing number
of cases. For example, the identiﬁcation of a homozygous
mutation in PNPO in a patient with neonatal drug-resistant
epilepsy led to treatment adaptation (increase and frag-
mentation of Pyridoxal Phosphate doses), which resulted in
satisfactory control of seizures.
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Introduction Clinical and genetic heterogeneity in intellec-
tual disability (ID) represent a major challenge for etiolo-
gical diagnosis. Classically, an etiologic diagnosis was
obtained in ~40% of cases with a combination of targeted
genes or chromosomal analysis and microarrays. Next
Generation Sequencing (NGS) greatly improved the diag-
nosis yield, up to 40% of unresolved cases.
We evaluated successively two NGS strategies as the
last-tier test for patients with ID referred to our genetic unit:
large gene panel and whole exome sequencing (WES).
Materials and Methods:
We performed trio based NGS (proband + parents) using
TruSightOne (TS1) gene panel (including 4813 OMIM
genes) for 263 patients with ID and WES for the next 127
patients. 22 patients were studied with both tools.
Results: Our diagnostic rate was 21% with TS1 and 42%
with WES. 55% of the disease-causing mutations identiﬁed
with WES were found in genes not included in TS1,
because they were too recently described (29/53). Seven
diagnoses with WES were performed in 22 patients without
diagnosis after TS1 studies (32%). Moreover, 9 additional
likely pathogenic variants were found with WES in yet
unpublished genes (ongoing international collaborations).
All diagnoses were validated thanks to a strong collabora-
tion between clinical and biological geneticists.
Conclusion:
NGS is a powerful tool for etiological diagnosis in ID.
WES has a better diagnostic yield than a large panel
because of the rapid advancement of knowledge and the
regular identiﬁcation of new genes of ID. Clinical validation
of the sequenced variants is an indispensable step in the
diagnosis process.
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Diagnostic yield of exome trio analysis to identify the
genetic etiology in 260 undiagnosed cases
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Introduction:Whole exome sequencing (WES) has entered
the medical practice as an effective diagnostic test trans-
forming the molecular diagnosis and clinical management
of undiagnosed genetic diseases. Exome trio analysis is an
effective strategy to identify de novo, hemizygous, homo-
zygous and in compound heterozygous potentially causal
variants of rare genetic disorders.
Materials and Methods: We performed exome sequen-
cing using Ion AmpliSeqTM Exome RDY technology (Life
Technologies) with Ion ProtonTM and Ion S5-XLTM.
Sequencing reads were analysed using Torrent Suite soft-
ware. Trio annotated variants using ION Reporter were
prioritized with an in-house analytical pipeline to identify
causative genetic variants.
Results: We present the analysis of 260 trios referred to
a single institution. Patients were mainly children with
syndromic intellectual disability (57%). The genetic etiol-
ogy was potentially elucidated in 94 probands harboring 56
causal variants and 38 likely causative variants, achieving a
36% molecular diagnostic rate. Among these patients, 57
harbored de novo variants, 7 hemizygous maternally
inherited variants, 7 in compound heterozygous variants, 18
newly homozygous variants and 5 variants inherited from
parents. Patients with syndromic intellectual disability
(42%, 62/149) and speciﬁc neurological disorders (39%, 13/
33) showed higher molecular diagnostics rates than patients
with non-neurologic disorders (29%, 8/27) and non-
syndromic intellectual disability (21%, 11/51).
Conclusions: In our cohort exome trio analysis provide a
diagnostic yield of 36% in patients whom traditional
molecular diagnostics strategies were uninformative. The
implementation of WES as a ﬁrst-tier diagnostic approach
will provide a higher diagnostic yield and a cost-efﬁcient
option particularly in rare syndromic intellectual disabled
patients.
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Familial apparently balanced translocations (ABTs) segre-
gating with discordant phenotypes are extremely challen-
ging for interpretation and counseling due to the scarcity of
publications and lack of routine techniques for quick
investigation. We report a familial ABT shared between a
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proband with intellectual disability (ID) and epilepsy, and
his non-affected mother. All possible mechanisms under-
lying the differential phenotypes were thoroughly investi-
gated using FISH, array-CGH, and whole-genome mate-
pair sequencing; however, no associations were determined.
In the current study, the same family was revisited using
whole-exome sequencing (WES) (patient-unaffected par-
ents trio) in an attempt to identify patient-speciﬁc mutations
underlying phenotypic differences between the two carriers
of the same ABT. WES data analysis was initially focused
on a list of ~700 genes identiﬁed across previous ID-
associated studies.
WES revealed a novel, patient-speciﬁc heterozygous
T>G splice donor mutation in intron 13 of syntaxin-binding
protein 1 (STXBP1) (OMIM-602926), which was also
conﬁrmed by Sanger sequencing. STXBP1 is an autosomal
dominant gene essential for neurotransmitter release
through syntaxin regulation, and STXBP1 disruptions have
been previously reported in ID patients. The STXBP1 splice
donor mutation identiﬁed here is predicted to cause exon
13 skipping thus affecting domain 3a, which together with
domain 1 form the central cavity of STXBP1 protein for
syntaxin binding.
In conclusion, this study supports our previous published
ﬁndings demonstrating that in the majority of familial
ABTs, translocations are unrelated to the phenotype. In the
current familial ABT, an STXBP1 splice donor mutation
might explain the proband’s phenotype; however future
expression studies will further support this.
C. Aristidou: None. A. Theodosiou: None. A. Alex-
androu: None. I. Papaevripidou: None. P. Evangelidou:
None. Z. Kosmaidou-Aravidou: None. C. Sismani: None.
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Paradoxical effect of baclofen in fragile X syndrome
mouse model
S. Zeidler
Erasmus MC, Rotterdam, Netherlands
Introduction: Fragile X syndrome (FXS) is the most
common monogenetic cause of intellectual disability and
autism. Effective disease modifying therapy is lacking.
However, expanding knowledge on the pathophysiology
and involved pathways has opened possibilities for targeted
treatment. FXS is caused by a CGG repeat expansion in the
5′ UTR of the FMR1 gene, resulting in lack of expression of
the FMR1 protein (FMRP). FMRP is a major transporter
and translational regulator of speciﬁc mRNAs at the post-
synaptic compartment in neurons. Absence of FMRP in
FXS leads to an imbalance in excitatory and inhibitory
network functioning, resulting in aberrant synaptic plasti-
city. Evidence from studies in mice demonstrate that the
major inhibitory neurotransmitter system in the brain, the
GABAergic pathway, is reduced in FXS and autism. We
tested the effect of chronic baclofen treatment, a GABAB
agonist, on social behavior in Fmr1 KO mice.
Materials and methods: young adult male Fmr1 KO mice
and WT littermates received baclofen or control drinking
water from weaning. We tested two different doses in two
social behavior paradigms, the automated tube test and the
three chamber sociability test.
Results: Unexpectedly, chronic baclofen treatment
worsened the social behavioral phenotype in the automated
tube test and induced a social behavioral phenotype similar
to FXS in wildtype littermates in both tests. In the highest
dose, hyperactivity was measured.
Conclusion: Altogether, the disappointing results of
recent clinical trials and our current results indicate that
baclofen treatment for FXS should be reconsidered and
further evaluated before its application as targeted therapy.
S. Zeidler: None.
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Glass syndrome caused by a novel mutation in the
SATB2 gene - is there something speciﬁc for cases with
point mutations?
A. Jezela-Stanek1, E. Ciara1, D. Jurkiewicz1, A.
Cieślikowska1, M. Kucharczyk1, P. N. Robinson2, T.
Zemojtel2, M. Krajewska-Walasek1
The Children's Memorial Health Institute, Warsaw, Poland,
2Charité Universitätsmedizin, Berlin, Germany
Introduction: Glass syndrome (OMIM 612313) is a dis-
order caused by heterozygous interstitial aberrations on
chromosome 2q32-q33 or a heterozygous mutation in the
SATB2 gene located within the Glass syndrome chromo-
some region. It is characterized by variable degrees of
psychomotor delay/intellectual disability and craniofacial
dysmorphism (like downslanting palpebral ﬁssures, cleft
palate, crowded teeth, and micrognathia). Other features
may include joint laxity, arachnodactyly, skeletal anomalies
and behavioral problems. Given the variety of mechanisms
leading to alterations of the SATB2 gene, the term “SATB2-
associated syndrome” (SAS) has also been proposed.
Materials and Methods: Targeted next-generation sequen-
cing (NGS) was performed in a 16-year-old girl and her
consanguineous parents of Polish origin. She presented with
intellectual disability (IQ = 35), thin, marfanoid habitus
with arachnodactyly and unrecognizable facial dysmorph-
ism (posteriorly rotated ears, synophrys, long and
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prominent nose, short philtrum, abnormal position/widely
spaced teeth). Results: NGS revealed the presence of a
novel heterozygous mutation in the SATB2 gene c.716del,
p.(Arg239fs) in the proband, not present in either parent.
Conclusions: Mutations in SATB2 are associated with
variation in the severity of developmental defects, including
even Rett-like phenotypes. However, to date only 11 cases
with point mutations have been reported. The aim of the
study is to present another case of Glass syndrome, referred
to our Department at the age of 14 years. In particular, we
want to draw attention to the speciﬁcity of phenotypic
anomalies, which may improve the clinical diagnosis of
Glass/SATB2-associated syndrome. The study was ﬁnanced
by NSC Project Harmonia 4 No. UMO-2013/08/M/NZ5/
00978.
A. Jezela-Stanek: None. E. Ciara: None. D. Jurkie-
wicz: None. A. Cieślikowska: None. M. Kucharczyk:
None. P.N. Robinson: None. T. Zemojtel: None. M.
Krajewska-Walasek: None.
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Characterization of Glycosylphosphatidylinositol Bio-
synthesis Defects on biomarkers, phenotypic data and
automated image analysis
A. Knaus, M. Rodriguez de los Santos, S. Mundlos, P. M.
Krawitz, D. Horn
Medical Genetics and Human Genetics, Berlin, Germany
Glycosylphosphatidylinositol (GPI) biosynthesis defects
(GPIBDs) are a group of phenotypically overlapping syn-
dromes with intellectual disabilities that are caused by
recessive mutations in currently 14 genes of the molecular
pathway. The serum activity of alkaline phosphatase (AP), a
GPI-linked enzyme, has been used to divide GPIBD
patients into Hyperphosphatasia with Mental Retardation
syndrome (HPRMS) and other subtypes, and link these
phenotypic series to certain subsets of genes. However, with
the increasing number of identiﬁed cases we now know that
also AP is a variable feature in GPIBDs. We therefore
studied the discriminatory power of ﬂow cytometry that is
based on multiple GPI-linked substrates. In addition we
evaluated computer-assisted classiﬁcation from FDNA that
is based on all clinical features and as well as on the facial
gestalt of patients with a GPIBD.Results: We found certain
malformations more likely to be associated with particular
gene defects. However, especially at the severe end of the
clinical spectrum of HPMRS, there is a high phenotypic
overlap with another subset of GPIBDs, termed Multiple
Congenital Anomalies Hypotonia Seizures syndrome
(MCAHS). The cell surface reduction of GPI-linked
markers correlates with the severity of the phenotype, but
no gene-speciﬁc proﬁle could be identiﬁed. Interestingly, it
was facial recognition software that achieved the highest
accuracy in clustering GPIBDs. The effectiveness of gestalt
analysis in the correct gene inference in a GPIBD is
remarkable and illustrates how the information contained in
human faces is still pivotal in the delineation of genetic
entities.
A. Knaus: None.M. Rodriguez de los Santos: None. S.
Mundlos: None. P.M. Krawitz: None. D. Horn: None.
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Novel compound heterozygous variants in GPT2 in a
family with microcephaly and intellectual disability
H. Kaymakçalan Çelebiler1, A. Ercan-Sencicek2, C.
Meral3, N. Göç2, F. Toy2, Y. Yarman2, M. Gunel2
İstanbul Bilim University, İstanbul, Turkey, 2Yale Univer-
sity, New Haven, CT, United States, 3Sultan Abdulhamit
Han EAH, İstanbul, Turkey
We here describe an index male patient diagnosed with
microcephaly, intellectual disability (IQ:39), developmental
delay, spastic paraplegia, normal serum biochemical and
metabolic test results that harbors compound heterozygous
missense variants, NM_133443:c.[400C>T] and
NM_133443: [1435G>A], in the glutamic pyruvate transa-
minase (GPT2) gene. Both of these variants, c.400C>T (p.
R134C) and c.1435G>A (p.V479M), resides in the pyr-
idoxal phosphate-dependent aminotransferase domain. The
missense variants affect highly conserved amino acids and
are classiﬁed to be disease-causing by both SIFT and
PolyPhen2. The candidate variants were not found in the
Exome Aggregation Consortium (ExAC) dataset or in
dbSNP. Index patient has an affected sister and 4 affected
paternal aunts who were also diagnosed with microcephaly,
intellectual disability and developmental delay. Affected
sister has a better IQ(63), but has ADHD and seizures.
Index patient’s parents are ﬁrst degree cousins and healthy.
Paternal aunts’ parents are nonconsanguineous and healthy.
Upon Sanger sequencing, we were able to conﬁrm these
mutations in all affected family members and conﬁrmed that
index patient and his affected sister inherited one mutant
allele from each unaffected parent. This was rather an
interesting ﬁnding since autosomal recessive, homozygous
mutation would be a more expected ﬁnding in a con-
sanguineous family. To the best of our knowledge, this is
the fourth family in the literature (Ouyang et al, Celis et al)
with GPT2 mutation and is the ﬁrst family in which a novel
compound heterozygous variant in GPT2 gene was
identiﬁed.
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A recurrent, de novo nonsense mutation in the GRIN2B
gene, comparison of the clinical phenotypes
M. J. V. Hoffer1, E. A. R. Nibbeling1, T. T. Koopmann1, S.
Bollen1, M. E. Y. Laurense-Bik1, I. J. H. van
Minderhout1, J. Knijnenburg1, N. Lamziera1, M.
Verschuren1, I. F. A. Fokkema2, A. van Haeringen1, T. P.
Potjer1, C. A. L. Ruivenkamp1, N. S. den Hollander1
1Dept. of Clinical Genetics, Leiden University Medical
Center, Leiden, Netherlands, 2Dept. of Human Genetics,
Leiden University Medical Center, Leiden, Netherlands
The GRIN2B gene encodes the N-methyl-D-aspartate
(NDMA) receptor that is found at the excitatory synapses
throughout the brain and is implicated in learning and
memory. Mutations in the GRIN2B gene are associated with
autosomal dominant mental retardation 6 and early infantile
epileptic encephalopathy 27.
Patients with intellectual disability and or developmental
delay were referred to our clinic for whole exome sequen-
cing. The exome sequences were analysed with a stringent
post-sequencing annotation pipeline including an intellec-
tual disability/ developmental delay (ID/DD) gene panel of
~711 genes for ﬁltering of the data. Analysis of whole
exomes was only performed when informed consent was
available and gene panel analysis did not reveal a candidate
mutation. In total, 709 index patients, trios or singles, have
been included in this study. Here, we describe three unre-
lated patients with a recurrent de novo nonsense mutation,
p.Arg847*, in the GRIN2B gene. In the same gene, four
other mutations were found, another nonsense, a frameshift,
a missense mutation and a whole gene deletion, each in one
patient. The clinical phenotype of patients carrying the
recurrent mutation and the other mutations are compared
and will be presented.
Overall, the patients with the recurrent mutation in
GRIN2B showed a more severe clinical phenotype with
severe developmental delay, little or no speech, facial
dysmorphology, hypermobility of the joints, and beha-
vioural problems.
M.J.V. Hoffer: None. E.A.R. Nibbeling: None. T.T.
Koopmann: None. S. Bollen: None. M.E.Y. Laurense-
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burg: None. N. Lamziera: None. M. Verschuren: None.
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Phenotypic spectrum of patients with GRIN2B ence-
phalopathy and setup of a database of NMDA-receptor
disorders
K. Platzer, J. R. Lemke
Institute of Human Genetics, University of Leipzig Hospi-
tals and Clinics, Leipzig, Germany
Introduction: N-methyl-D-aspartate receptors (NMDAR)
are ligand-gated cation channels which mediate excitatory
neurotransmission in the brain. NMDAR are obligatory
heterotetramers composed of two Glycine-binding GluN1-
(GRIN1) and usually two Glutamate-binding GluN2-sub-
units (GRIN2A, GRIN2B, GRIN2C and GRIN2D). Het-
erozygous de novo variants in GRIN2B have previously
been reported in patients with intellectual disability (ID),
autism and epilepsy.
Results: Overall, de novo variants in 60 patients were
classiﬁed as pathogenic/likely pathogenic, with 21 patients
having been reported in the literature. Patients presented
with neurodevelopmental disorders (100 %) and a spectrum
of autism (27 %), epilepsy (52 %), dystonic, dyskinetic or
choreatiform movement disorder (10 %), cortical visual
impairment (8 %) and cerebral volume loss (9 %). Six
patients presented with a consistent malformation of cortical
development intermediate between tubulinopathies and
polymicrogyria revealing novel phenotypic consequences of
channelopathies.
Outlook: There are only a few recurrent (likely) patho-
genic variants in GRIN2B, comparable to all other NMDAR
subunits, as most patients constitute single cases. Over time,
the phenotype of patients with (likely) pathogenic variants
in known disease genes tend to be reported more scarcely in
the scientiﬁc literature. Therefore, we are in the process of
setting up a database to enlist patients with variants in any
NMDAR subunit. Data can be submitted online and will be
displayed in the database after review. As all subunits share
signiﬁcant sequence-homology, combining genetic and
phenotypic data of patients from all subunits will hopefully
deepen our understanding of phenotypic consequences and
functional aspects of different segments of the NMDAR.
K. Platzer: None. J.R. Lemke: None.
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HUWE1 mutations cause dominant XLID: a clinical and
genetic study of 22 patients
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de Pathologie et de Génétique, Charleroi, Belgium, 3Alfred
I. duPont Hospital for Children, Wilmington, DE, United
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6Centre Hospitalier Universitaire Dijon, Dijjon, France,
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lands, 8Royal Devon and Exeter Hospital, Exeter, United
Kingdom, 9East Anglian Medical Genetics Service,, Cam-
bridge, United Kingdom, 10Cliniques Universitaires Saint-
Luc, Brussels, Belgium, 11Hospital Universitari i Politècnic
La Fe, Valence, Spain, 12Telemark Hospital, Skien, Norway,
13University Hospitals of Leicester, Leicester, United
Kingdom, 14NTNU, Trondheim, Norway, 15Hôpital Robert
Debré, Paris, France, 16Trondheim University Hospital,
Trondheim, Norway, 17North West Thames Regional
Genetics Centre, London, United Kingdom, 18University
of Oxford, Oxford, United Kingdom, 19Great Ormond Street
Hospital for Children NHS foundation Trust,, London,
United Kingdom, 20MultiCare Health System, Tacoma, WA,
United States, 21University Hospitals Bristol NHS Trust,
Bristol, United Kingdom
Whole-gene duplications and missense mutations in the
HUWE1 gene (NM_031407.6) are a known cause of X-
linked intellectual disability (ID). Increased gene dose
causes non-syndromic mild to moderate ID with speech
delay in affected males. Various missense mutations may
cause syndromic and more severe ID in males with female
sparing, the latter linked to skewed X-inactivation.
Here, we report the largest HUWE1-cohort consisting of
14 females and 8 males, with 16 missense mutations and
one splice site mutation. Nine patients were ascertained
through the DDD-project. HUWE1 variants were interpreted
according to the ACMG 2015 Guidelines. The X-
inactivation pattern was examined, and the current litera-
ture has been reviewed. We highlight common clinical
features consisting of moderate to profound ID, delayed or
absent speech, short stature and facial dysmorphism such as
a broad nose, deep set eyes, epicanthus, short palpebral
ﬁssures, a short philtrum and small hands and feet. We
describe for the ﬁrst time that females can be severely
affected, despite X-inactivation of the mutant X chromo-
some. A notable exception to this are two additional females
with the R110Q mutation in HUWE1, presenting with a
speciﬁc phenotype with mild ID, different facial features,
scoliosis and craniosynostosis, conﬁrming Taylor et al’s
previous report. In these females the X chromosome was
skewed in favour of the mutant transcript.
In summary, HUWE1 missense mutations may cause
syndromic ID in both males and females, and the latter
appears to be more common and more severe than in the
classical X-linked recessive families.
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Attempts to elucidate role of ZBTB11 gene in intellectual
disability
Z. Fattahi1, T. Sheikh2, K. Kahrizi1, R. Harripaul2, F.
Larti1, N. Bazazzadegan1, M. Haddadi3, M. Ansar4, H. H.
Ropers5, J. B. Vincent2, H. Najmabadi1
Genetics Research Centre, University of Social Welfare and
Rehabilitation Sciences, Tehran, Iran, Islamic Republic of,
2Molecular Neuropsychiatry & Development (MiND) Lab,
Campbell Family Mental Health Research Institute, Center
for Addiction and Mental Health, Toronto, ON, Canada,
3Department of Biology, Faculty of Science, University of
Zabol, Zabol, Iran, Islamic Republic of, 4Department of
Biochemistry, Quaid-i-Azam University, Islamabad, Paki-
stan, 5Department of Human Molecular Genetics, Max
Planck Institute for Molecular Genetics, Berlin, Germany
Exploring genes and pathways underlying Intellectual dis-
ability (ID) can clarify the complex puzzle of how cognition
develops. As part of ongoing systematic studies to identify
candidate ID genes, linkage analysis and whole exome
sequencing revealed ZBTB11 in two consanguineous
families. ZBTB11 encodes an understudied transcription
repressor and its zebraﬁsh mutant showed brain and spinal
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cord degeneration with prominent apoptosis of central
nervous system.
To evaluate possible disrupting effects of two missense
variants identiﬁed in ZBTB11, HEK293 cells were trans-
fected with wild-type/mutant ZBTB11-GFP constructs and
protein localization was investigated by confocal ﬂuores-
cence microscopy. To explore target genes and pathways,
ChIP-sequencing was performed on transfected cells. We
also investigated role of ZBTB11-ortholog in Drosophila
brain by targeting RNAi using UAS/Gal4 system.
These variants (p.H729Y, p.H880Q) disrupt canonical
Zn2+-binding residues of C2H2 zinc ﬁnger domains, lead-
ing to possible altered DNA binding. We found abolished
localization for mutants being excluded from the nucleolus
where the wild-type recombinant protein is localized (con-
ﬁrmed by B23/NPM1marker). Although ChIP-sequencing
results did not fulﬁll quality criteria, some relevant targets
can be observed with the help of recent ENCODE data of
HEK293 stably expressing eGFP-ZBTB11 and will be
compared with mutants. The drosophila F1 offspring with
no expression of ZBTB11-ortholog in brain were generated
and subjected to behavioral and structural investigations.
This study provides information on ZBTB11 localization
in nucleolus and clearly shows how these variants disrupt
protein localization and therefore its function. The upcom-
ing results from ChIP-sequencing and Fly models will
elucidate the way it is involved in ID.
Z. Fattahi: None. T. Sheikh: None. K. Kahrizi: None.
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ArrayCGH analysis in patients with intellectual dis-
ability/developmental delay in Turkish Children living
in Trakya Region
H. Gurkan1, I. Görker2, E. Atlı1, E. I. Atlı1, S. Demir
Ulusal1, D. Eker1, H. Tozkır1
1Trakya University, Medical Faculty, Department of
Medical Genetics, Edirne, Turkey, 2Trakya University,
Medical Faculty, Department of Child and Adolescent
Psychiatry, Edirne, Turkey
Introduction: İntellectual Disability is a neurodevelop-
mental disorder identiﬁed at the beginning of the develop-
mental period as the lack of conceptual, social, and practice
areas of both mental and adaptive functions. [1]. The
diagnostic approach to these patients should include clas-
sical karyotyping, Fragile- X analysis, neurological ima-
ging, ﬂourescent in situ hybridization and array based
comparative genomic hybridization (arrayCGH) after taking
a detailed physical examination and medical history [2,3].
The aim of this study is to investigate the copy number
variations (CNVs) by using arrayCGH analysis in patients
who had been found to have normal karyotype and does not
have Fragile-X.Materials and Methods: 45 patients [male:
27 (9.6 years), female: 18 (7.8 years)] were included in the
study who were directed to Genetic Diagnosis Center of
Trakya University Faculty of Medicine between March
2015 and November 2016 with a diagnosis of intellectual
disability/developmental delay Classical karyotyping,
Fragile-X analysis and arrayCGH analysis (Agilent 4×180K
ISCA CGH + SNP) have been applied to all patients. The
pathogenicity of the CNVs found have been assesed by
using the databases. Results: CNVs have been determined
in 14 (9 male; 5 female) out of 45 patients (31.1%). The
disease-related arrayCGH results and clinical characteristics
are shown in Table 1. Conclusions: Our results support the
importance of arrayCGH analysis in detecting submicro-
scopic chromosomal abnormalities in patients with intel-
lectual disability/ developmental delay.
Table 1. Array-CGH results and clinical features of the
15 Turkish patients with pathogenic CNVs
Patient Age Gender arrayCGH
results
Size Inheritance Clinical
features
Classiﬁcation
(ISCA,
UCSC, DGV,
ClinVar and
DECIPHER)
2 9
year
M arr cgh(hg 19)
2q37.2
(236,114,456–
236,512,302)x3
397 kb de novo Intellectual
disability
VOUS
5 1
year
F arr cgh(hg 19)
22q11.21
(18,894,832 -
21,440,514)x1
2546 kb de novo Developmental
delay,
intellectual
disability,
speech delays
Pathogenic
7 1
year
F arr cgh(hg 19)
6q23.3-q27
(138,180,512–
170,906,796)x3
32726
kb
de novo Developmental
delay,
intellectual
disability,
speech delays
Pathogenic
13 13
year
M arr cgh(hg 19)
Xq21.31-q21.32
(91,701,124–
92,238,826)x3
538 kb de novo Intellectual
disability
VOUS
15 8
year
M arr cgh(hg 19)
4q32.3
(167,766,818–
169,176,455)x3
1410 kb de novo Intellectual
disability
VOUS
22 1
year
F arr cgh(hg 19)
1q21.1-q21.2
(146,507,518–
147,824,207)x3
1316 kb de novo Developmental
delay,
Intellectual
disability,
speech delays
Pathogenic
26 17
year
M arr cgh(hg 19)
10q21.3
(68.359.435–
68.486.777)x1
127 kb de novo Mild
Intellectual
disability
VOUS
27 13
year
M arr cgh(hg 19)
2q37.3
(240.057.136–
243.040.276)x1
arr cgh(hg 19)
20q13.32-q13
(56.546.112–
62.908.674)x3
2983
kb6363
kb
de novo Severe
intellectual
disability,
hearing loss
Pathogenic
30 12
year
M arr cgh(hg 19)
16p11.2
(29.656.684–
30.190.568)x1
534 kb de novo Intellectual
disability,
Hyperactivity
Pathogenic
33 F de novo Pathogenic
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Table (continued)
Patient Age Gender arrayCGH
results
Size Inheritance Clinical
features
Classiﬁcation
(ISCA,
UCSC, DGV,
ClinVar and
DECIPHER)
9
year
arr cgh(hg 19)
20q11.21-q12
(29,842,786–
41,548,389)x3
arr cgh(hg 19)
20q13.31
(55,846,129–
56,177,485)x1
11706
kb331
kb
Developmental
delay,
Intellectual
disability
35 15
year
M Chromosome 1
LOH
- de novo Intellectual
disability,
bilateral
cryptorchidism
Pathogenic
38 11
year
M arr cgh(hg 19)
Xp.21.1
(32,791,931–
33,641,487)x3
850 kb de novo Intellectual
disability
VOUS
40 1
year
M arr cgh(hg 19)
15q11.2
(22,698,522–
23,300,287)x1
arr cgh(hg 19)
16q12.1
(48,304,344–
48,549,404)x3
602
kb245
kb
de novo Intellectual
disability
VOUS
41 6
year
F arr cgh(hg 19)
6p23-p22
(14,087,024–
24,834,000)x1
10747
kb
de novo Developmental
delay,
intellectual
disability,
speech delays,
VSD
Pathogenic
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Parent of origin dependent expression of CNTN6 in vitro
in neurons derived from induced pluripotent stem cells
of patient with intellectual disability and 3p26.3 micro-
duplication of paternal origin
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Research Insitute of Medical Genetics, Tomsk National
Research Medical Center, RAS, Tomsk, Russian Federa-
tion, 2National Research Tomsk State University, Tomsk,
Russian Federation, 3Federal Research Center Institute of
Cytology and Genetics, SB RAS, Novosibirsk, Russian
Federation, 4Novosibirsk State University, Novosibirsk,
Russian Federation
Introduction: Understanding the pathogenesis of chromo-
somal diseases is complicated by tissue-speciﬁc effects of
chromosomal imbalances and the size of chromosome
rearrangements, usually involving multiple genes with dif-
ferent functions. These problems can be overcoming using
current technologies of somatic cell reprogramming as well
as high resolution molecular karyotyping, allowing to
identify submicroscopic chromosomal aberrations affecting
a single gene. Here, we report about features of neuronal
in vitro expression of CNTN6, which was recently asso-
ciated with autistic spectrum disorders and intellectual
disability.
Materials and Methods: Neuronal cells were obtained by
NGN2 differentiation of induced pluripotent stem cells
derived from a patient with intellectual disability and
3p26.3 microduplication of paternal origin affecting CNTN6
only (Kashevarova et al., 2014) as well as from healthy
donor with normal karyotype.
Results: For the ﬁrst time, the preferential expression of
maternal allele of CNTN6 was observed both in patients and
donors neuronal cells. It was found also, that expression of
duplicated allele of paternal origin was signiﬁcantly reduced
though the CNTN6 copy number increasing due to chro-
mosomal microduplication.
Conclusions: Obtained results can explain the reported
in literature mode of inheritance of chromosomal rearran-
gements affecting CNTN6 in several generations by parental
origin of CNV. They provide evidence also, that some
identical phenotypes in patients with reciprocal microdele-
tions and microduplications syndromes can be explained by
haploinsufﬁciency in spite of opposite changes in the gene
copy number due to suppression effect of chromosomal
microduplication on the gene expression level.
This study was supported by Russian Science Founda-
tion, grant 14-15-00772.
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zorov: None. A.A. Kashevarova: None. N.A. Skryabin:
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A de novo missense mutation affecting the KCNMA1
gene causes intellectual disability, seizures, facial dys-
morphism and connective tissue disorders
A. Vitobello1,2, G. M. S. Mancini3, S. A. Schrier Vergano4,
M. van Slegtenhorst3, X. Li5, S. Nambot1,2, D. Lehalle1,2,
C. Poe1, Y. Duffourd1,2, E. Tisserant1, J. Rivière6, C.
Thauvin-Robinet1,2, L. Faivre1,2, Q. K. Wang5,7,8,9, J.
Thevenon1,2
1Inserm UMR 1231 GAD team, Genetics of Developmental
disorders, Université de Bourgogne-Franche Comté, Dijon,
France, 2FHU-TRANSLAD, Université de Bourgogne/CHU
Dijon, Dijon, France, 3Department of Clinical Genetics,
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Rotterdam, Netherlands, 4Division of Medical Genetics
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and Metabolism, Children’s Hospital of The King’s
Daughter, Norfolk, VA, United States, 5Key Laboratory of
Molecular Biophysics of the Ministry of Education, College
of Life Science and Technology and Center for Human
Genome Research, Huazhong University of Science and
Technology, Wuhan, China, 6Department of Human
Genetics, McGill University Health Centre, RI-MUHC,
Montreal, QC, Canada, 7Department of Molecular Medi-
cine, Cleveland Clinic Lerner College of Medicine, Cleve-
land, OH, United States, 8The Center for Cardiovascular
Genetics, Department of Molecular Cardiology, NE40,
Lerner Research Institute, Cleveland Clinic, Cleveland,
OH, United States, 9Department of Genetics and Genome
Sciences, Case Western Reserve University School of
Medicine, Cleveland, OH, United States
KCNMA1 gene encodes the pore-forming subunit of a
large-conductance voltage- and Ca2+-activated K+ channel
(BK), which is almost ubiquitously expressed in mamma-
lian tissues. BK channels have been implicated in several
functions including modulation of neurotransmission, con-
trol of smooth muscle tone, epithelial transport and, more
recently, their involvement in the maintenance of
mesenchymal stromal cell population, migration and dif-
ferentiation has been also suggested. Gain-of-function
mutations of KCNMA1 gene have been already asso-
ciated with a human syndrome of coexistent generalized
epilepsy and paroxysmal dyskinesia, yet the impact of loss-
of-function mutations of this channel on human physiology
and development remain poorly characterized.
Using Whole Exome Sequencing analysis, we recently
identiﬁed two unrelated patients carrying the same hetero-
zygous de novo missense mutation and presenting with an
undiagnosed polymalformative association of intellectual
disability, seizures, facial dysmorphism and connective
tissue disorders. This variant affects a conserved nucleotide
resulting in an amino acid substitution (p.Gly375Arg)
associated with high-conﬁdence predicted damaging impact
on the structure and function of Kcnma1 protein. Indeed, p.
Gly375Arg affects the transmembrane segment S6, which
together with P and S5 segments makes up the pore-gate
domain, supporting the hypothesis of its detrimental impact
on K+ conductance. Currently, a collaborative effort is
being deployed in order to model in vitro the outcomes of
such mutation on Kcnma1 function. Furthermore, using a
combination of genotype-ﬁrst strategy coupled with an
international data sharing approach, three further unreported
patients could be identiﬁed, which will contribute to shed
light on the pleiotropic functions of KCNMA1 in human
clinical phenotype.
A. Vitobello: A. Employment (full or part-time); Sig-
niﬁcant; Novartis Institutes for Biomedical Research. G.M.
S. Mancini: None. S.A. Schrier Vergano: None. M. van
Slegtenhorst: None. X. Li: None. S. Nambot: None. D.
Lehalle: None. C. Poe: None. Y. Duffourd: None. E.
Tisserant: None. J. Rivière: None. C. Thauvin-Robinet:
None. L. Faivre: None. Q.K. Wang: None. J. Thevenon:
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Genetics of Neurodevelopmental Disorders [GND]
Consortium - International effort to elucidate the genes
underlying autosomal recessive neurodevelopmental
disorders
R. Abou Jamra1, A. Gregor2, A. de Brouwer3, J.
Gleeson4,2, H. van Bokhoven3
University Medical Center, Leipzig, Germany, 2The Rock-
efeller University, New York, NY, United States, 3Radboud
University Medical Center, Nijmegen, Netherlands, 4Uni-
versity of California San Diego, La Jolla, CA, United States
Autosomal recessive neurodevelopmental disorders (NDD,
including intellectual disability and autism spectrum dis-
orders) are extremely heterogeneous, and more than half of
NDD genes are unknown. Exome in suspected recessive
NDD (i.e. consanguineous parents or more than one affec-
ted sibling) frequently leaves several potential disease-
causing candidate variants. To conﬁrm a candidate gene’s
involvement, typically overlapping cases with variants in
the same gene are necessary. Under a conservative
assumption that there are ~1800 recessive NDD genes with
equally distributed burdens, ~10,000 cases are needed to
identify at least two mutations in 90% of the genes. This
means that deciphering the genetics of NDD can only be
approached via intensive cooperation and data sharing
worldwide. While gene-matching efforts have impacted this
discovery, a phenotype-driven approach that does not
require prior identiﬁcation of candidates would be more
powerful. We have established the GND (Genetics of
Neurodevelopmental Disorders) Consortium to provide a
free portal for sharing exomes with HPO-determined phe-
nomes (www.gnd.academy). Each contributor maintains
exclusive control over his/her data, sharing only candidate
variants that meet pre-speciﬁed criteria. GND will process
data through 3rd party HIPAA-compliant software to match
genotype/phenotype with genome-wide signiﬁcance as well
as incorporate gene-networks to support nominally sig-
niﬁcant genes. GND will return results to groups with
matching genes/phenotypes. More than 3,000 cases are
already included in GND and we aim for 10,000 cases in
2017. We invite all colleagues worldwide to join GND to
elucidate the genetics of neurodevelopmental disorders.
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Mendeliome sequencing increases the diagnostic yield in
patients with unexplained intellectual disability by 30 %
A. Rump1, L. Gieldon1, L. Mackenroth1, A. Kahlert1, J.
Lemke2, K. Hackmann1, A. Krueger1, F. Kuhlee1, F.
Stuebner1, A. Tzschach1, E. Schrock1, N. Di Donato1
1Institut für Klinische Genetik, TU Dresden, Dresden,
Germany, 2Institut für Humangenetik, Universitätsklinikum
Leipzig, Leipzig, Germany
Introduction In the past, array-CGH technology has
boosted the detection rate signiﬁcantly; but up to 50% of
children with developmental delay still remained undiag-
nosed. Since next generation sequencing (NGS) has the
power to improve the diagnostic yield tremendously, we
applied this method to 108 index patients with develop-
mental delay or intellectual disability (ID) and pre-excluded
genomic imbalances.
Method DNA samples of 80 parent-patient trios plus 28
individual patients were analyzed for mutations in 4813
genes, using the TruSight-One gene panel (Illumina). After
sequencing with median target coverage of 80-fold,
sequence variants were called with the CLC Biomedical
Genomics Workbench (Qiagen). All variants with putative
effect on amino acid level (i.e. frameshift, splice site dis-
ruption, missense) and with plausible mode of inheritance
(de novo, recessive, X-linked) were evaluated according to
the ACMG guidelines. The results were discussed in a team
of clinicians and molecular geneticists; relevant variants
were validated by Sanger-sequencing.
Results Using the mendeliome in a diagnostic setting,
we established a diagnosis in 33 of the 108 index patients
(30%). For 12 further patients, we found one or two pos-
sibly causative candidates (11%). Five patients (4.6%)
showed incidental ﬁndings which either made treatment or
surveillance necessary. (e.g. homozygous MUTYH-muta-
tions, SDHA-mutation). Nine patients (8%) have been
identiﬁed to be carriers for a recessive disease (PAH- or
CFTR-mutations).
Conclusion Mendeliome next generation sequencing
signiﬁcantly increases the diagnostic yield in patients with
ID unsolved with array-CGH by at least 30%. However,
variant interpretation remains challenging and calls for
national and international data exchange.
A. Rump: None. L. Gieldon: None. L. Mackenroth:
None. A. Kahlert: None. J. Lemke: None. K. Hackmann:
None. A. Krueger: None. F. Kuhlee: None. F. Stuebner:
None. A. Tzschach: None. E. Schrock: None. N. Di
Donato: None.
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Characterization of genotype and phenotype in 710
patients with developmental delay and intellectual dis-
ability based on chromosome microarray analysis
Y. Fan1, Y. Wu1,2, L. Wang1, J. Ye1, L. Han1, W. Qiu1, H.
Zhang1, L. Liang1, X. Zhang1, X. Liu1, X. Gu1, Y. Yu1
Shanghai Institute for Pediatric Research, Xin Hua
Hospital, Shanghai, China, 2People's Hospital of Shanghai
Pudong New District, Shanghai, China
Introduction: Developmental delay (DD) and intellectual
disability (ID) commonly present with co-occurring condi-
tions like epilepsy. Chromosome microarray analysis
(CMA) has been recommended as a ﬁrst-tier diagnostic test
for DD/ID. Assessing the diagnostic yield of CMA in DD/
ID with different co-occurring condition can offer clinicians
the phenotypic clue of probable pathogenic ﬁnding. This
study aimed to characterize pathogenic copy number var-
iations (pCNVs) in a mixed cohort of DD/ID and identify
phenotypic clues associated with these pCNVs.
Materials and Methods: The study was conducted ret-
rospectively in 710 DD/ID patients with CMA performed.
Clinical data were collected, and the interpretation of CMA
results followed ACMG guidelines.
Results: A total of 247 pCNVs were identiﬁed in 201
patients (28%). A large portion of these pCNVs were copy
number losses, and the size of copy number losses was
generally smaller than gains. Pathogenic CNVs distributed
over all chromosomes, and an enrichment was found in
chr7, 15 and 22. The diagnostic yields were not statistically
different among groups classiﬁed by ID severity (p=0.084,
ﬁsher's exact), while the likelyhood of a pathogenic ﬁnding
increased when congenital heart defects, facial dysmorph-
ism, microcephaly or hypotonia was present in DD/ID
patients (p<0.01, ﬁsher's exact).
Conclusion: Our results suggest varied yields of CMA
among DD/ID patients with different phenotypic
presentation.
Y. Fan: None. Y. Wu: None. L. Wang: None. J. Ye:
None. L. Han: None. W. Qiu: None. H. Zhang: None. L.
Liang: None. X. Zhang: None. X. Liu: None. X. Gu:
None. Y. Yu: None.
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Exome pool-seq: large-scale exome sequencing of pooled
DNA samples in intellectual disability
B. Popp, A. B. Ekici, C. Thiel, J. Hoyer, A. Wiesener, C.
Kraus, A. Reis, C. Zweier
Institute of Human Genetics, Friedrich-Alexander-Univer-
sität Erlangen-Nürnberg, Erlangen, Germany
Introduction: Despite falling costs of high throughput
sequencing and great advances in identiﬁcation and con-
ﬁrmation of novel disease genes, there is a need for gen-
ome-wide, simple, cheap and fast screening technologies in
extremely heterogeneous disorders such as intellectual dis-
ability (ID). Material and Methods: We exome sequenced
96 individuals with sporadic ID in 8 pools of 12 equimolar
concentrated samples each. Variants were called using a
ploidy of 24 and ﬁltered for loss-of-function variants or
likely pathogenic (previously reported, deleterious predic-
tion) missense variants in 923 known ID genes (SysID
database). Additionally, 543 ID candidate and 1,694 hap-
loinsufﬁciency intolerant genes were screened for loss-of-
function variants. Conﬁrmation within the pool and segre-
gation was tested by Sanger sequencing. Results: In known
ID genes we identiﬁed 19 (proven or assumed) de novo,
(likely) pathogenic variants (ACTB, AHDC1, ANKRD11,
ATP6V1B2, CASK, CHD8, GNAS, KCNQ2, KMT2A,
MED12, MED13L, RIT1, SETD5, SIN3A, TCF4, TUBA1A,
WAC, ZBTB18), two pathogenic variants that were inherited
from a symptomatic or healthy parent each (ZMYND11,
IFIH1), two likely pathogenic X-linked variants in boys
(ATRX, MAOA), and a homozygous variant in the recessive
TRAPPC11. Additionally, we identiﬁed 4 de novo variants
in candidate genes. In our cohort this resulted in a high
detection rate of ca. 25%, similar to other screening
approaches, but allowing more ﬂexibility for future data
evaluation. Conclusion: Our high detection rate of at least
25% establishes exome pool-seq as a new screening
approach for large-scale, cost-efﬁcient and ﬂexible
sequencing in highly heterogeneous but well characterized
disorders like ID.
B. Popp: None. A.B. Ekici: None. C. Thiel: None. J.
Hoyer: None. A. Wiesener: None. C. Kraus: None. A.
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PRiSM, a functional genomics screen for relative quick
assessment of neuronal pathogenicity of ND candidate
genes/mutations
G. M. van Woerden, Y. Elgersma
rasmus MC, Rotterdam, Netherlands
Neurodevelopmental disorders (ND) affects 2% of the
population of which the majority has a genetic cause, but in
a considerable amount of cases the gene involved is still
unknown. Next Generation Sequencing (NGS) technology
has made tremendous advancements in gene sequencing
technology, allowing it to become a diagnostic tool to
identify mutations in patients with a neurodevelopmental
disorder. However, in cases when missense mutations are
identiﬁed, the pathogenicity is often unclear.
In our lab we have recently developed a functional
genomics screen (Pipeline for Rapid in vivo and in vitro
Screening of Mutations, PRiSM), to relatively quick assess
the neuronal pathogenicity of ND candidate genes and/or
mutations, without any a priori knowledge about the role of
the gene. Central in the design of PRiSM are the following
features: (1) It is sensitive to pathogenic mutations which
have a dominant effect on down-stream signaling; (2) It
features parallel assays which yield complementary data
and allows scaling; (3) It allows easy implementation of
specialized follow-up measurements (e.g. imaging, elec-
trophysiology). We have started with the assessment of the
pathogenicity of previously published intellectual disability
(ID) candidate mutations on neuronal maturation in vitro
and neuronal migration in vivo. We will show here a brief
overview of the tested mutations and show one example to
illustrate what PRiSM entails.
G.M. van Woerden: None. Y. Elgersma: None.
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Prevalence and origin of chromosomal microduplica-
tions in patients with intellectual disability
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Tomsk, Russian Federation, 2National Research Tomsk
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Introduction: To date, more than 230 microdeletion and 80
microduplication syndromes were revealed in patients with
intellectual disability and developmental delay. Pathogenic
microduplications are founded rarely, probably because of
softer and more variable manifestation of clinical signs or
frequent inheritance from apparently healthy parents.
However, they are more often detected by high-resolution
molecular cytogenetic methods.
Materials and Methods: We examined 140 patients with
autism, intellectual disability and developmental delay in
age from 3 to 18 years by array-CGH (4×44K, 8×60K,
Agilent Technologies). Identiﬁed microduplications were
conﬁrmed and their origin was deﬁned by PCR-RT.
Results: Chromosomal microduplications with patho-
genic or probably pathogenic signiﬁcance were found in 14
patients (10%). Microduplications size ranged from 115 kb
to 32.2 MB. Eleven patients have only one microduplica-
tion: 1q25.1-q25.2, 2p25.3-p25.2, 3p26.3, 5q33.1, 6p22.2,
10q26.3, 12q24.12 (two cases), 14q11.2, 18p11.31,
20q13.12. One patient was a carrier of microtriplication
4q21.21-q21.22 with 1,6 Mb in size. One patient has a
combination of microduplication with microdeletion:
dup2p25.3-p23.3 and del2p25.3; another one has a complex
combination of CNVs: del9p24.3-p24.2, dup9p24.2-p13.3,
trip9p21.1-p13.3, and delXq28. Identiﬁed microduplica-
tions had a de novo origin in 6 patients (46%), whereas in 7
patients (54%) they were inherited from a healthy parent. In
one case the parental DNA samples were not available for
examination.
Conclusions:We determined the prevalence of clinically
signiﬁcant chromosomal microduplications, which are
amount to 10% in patients with intellectual disability, and
conﬁrmed the relatively high rate of their transmissions
from healthy carriers. This study was supported by Russian
Science Foundation, grant 16-15-10229.
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The clinical utility of array-CGH and targeted NGS in
idiopathic intellectual disabilities and developmental
delays: a case report of SCN2A p.Ala263Val variant
M. Wayhelova1,2, J. Oppelt3,4, D. Vesela1, J. Smetana1, F.
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Republic, 3National Centre for Biomolecular Research,
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Republic, 4CEITEC-Central European Institute of Technol-
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Facility Genomics, CEITEC- Central European Institute of
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Introduction: Next-generation sequencing (NGS) techni-
ques have become a powerful tool for the identiﬁcation of
the genetic causes of the heterogeneous conditions such as
intellectual disabilities, multiple congenital anomalies and
autism spectrum disorders.
Material and methods: We present our ﬁrst experience
with targeted NGS approach using commercially available
design SureSelect Inherited Disease (Agilent Technologies)
containing more than 2700 genes known to cause inherited
disorders. We report on a case of 9-year-old boy with a
diagnosis of severe intellectual disability related to early
myoclonic encephalopathy. This patient was examined
according to our investigatory algorithm, from G-banding
karyotype (46,XY) to array-CGH on oligonucleotide DNA
microarrays (Agilent Technologies) followed by con-
ﬁrmative targeted quantitative PCR and FISH.
Results: We detected a de novo copy-number gain of
18q21.23 (539 kb) classiﬁed as probably benign. Conse-
quently this patient was included in our pilot study using
targeted NGS with pre-designed gene panel SureSelect
Inherited disease and Illumina MiSeq. We detected de novo
heterozygous missense genetic variant in SCN2A gene,
resulting in the amino acid residue change from alanine to
valine at position 263 (p.Ala263Val). This variant had been
previously described as deﬁnitely pathogenic in patients
with Otahara syndrome.
Conclusions: This case has proved the usefulness and
effectivity of our molecular diagnostics algorithm enhanced
by NGS approaches leading to higher diagnostic yield of
heterogeneous genetic conditions.
This study was supported by Ministry of Health, Czech
Republic – conceptual development of research organiza-
tion (FNBr, 65269705).
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Next generation sequencing diagnostic yield in intellec-
tual disability
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1Hospital Clinic, Barcelona, Spain, 2CIBERER, Barcelona,
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Introduction: Intellectual disability (ID) is characterized by
signiﬁcant limitations in intellectual functioning and adap-
tative behavior. It is estimated that ID affects approximately
60 million of people worldwide. However, around 60% of
the cases remain without a genetic diagnosis, which can
provide not only information on the etiology of ID but also
allows genetic counseling. Material and Methods: 188
exomes corresponding to 65 families underwent next gen-
eration sequencing (NGS) using different groups of
patients: (i) 8 familial cases with several affected genera-
tions and many affected members; (ii) 15 family nuclei
(healthy parents and siblings); (iii) 27 trios; (iv) 15 index
cases. On the other hand, targeted-resequencing was per-
formed in 100 additional patients with ID. Results: Iden-
tiﬁcation of causative alterations was achieved in 15% of
families’ studied by exome sequencing (10/65) and 1% of
targeted resequencing. Moreover, 6 out of the 10 families’
diagnoses belong to the group of large families with several
affected generations and many affected members, reaching
a diagnostic yield of 75% (6/8) within this group. In addi-
tion, candidate alterations were identiﬁed in 45% of cases.
Conclusion: NGS increases the diagnostic yield in all the
groups studied. However, the best results are obtained in
families with more than one family member affected.
Nevertheless, a good clinical description is essential to both
avoid unnecessary studies and to validate the causality of a
variant. Acknowledgements: ISCIII [(PI12/00879], FEDER
CERCA Programme and AGAUR (2014 SGR603)
CIBERER (ISCIII).
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Update on GeJo-ARID: a cooperation project between
Germany and Jordan for the identiﬁcation of new genes
in autosomal recessive intellectual disability
R. Buchert1, A. Baraghiti2, J. Sommerfeld1, M. Sturm1, P.
A. Koch1, J. Hanselmann1, B. Kootz1, J. Gohlke1, T. B.
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Institute of Medical Genetics and Applied Genomics,
University of Tübingen, Tübingen, Germany, 2Dept. of
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Jordan, 4Ibn Alhytham Hospital, Amman, Jordan, 5Institute
of Human Genetics, University Medical Center Leipzig,
Leipzig, Germany, 6private practice, Amman, Jordan
In a bilateral project between Germany and Jordan, we
examined 40 consanguineous Jordanian families with
intellectual disability (ID) of probably autosomal recessive
inheritance. We conducted whole exome sequencing (WES)
for one affected individual per family and ﬁltered for rare
bi-allelic variants.
With this approach we could identify homozygous
pathogenic variants in the 6 previously established ID-genes
ALDH5A1, DNAJC6, GCDH, GPR56, NT5C2 and WDR62.
In 3 further ID-genes (GMPPB, PGAP2 and PNKP) we
were able to identify likely pathogenic variants.
In a family with one affected individual with severe
intellectual disability and epileptic encephalopathy we
could identify a homozygous truncating mutation in
DENND5A (c.2547delG, p.Lys850Serfs*11) and establish
DENND5A as a new ID-gene.
Although, family pedigrees suggested autosomal reces-
sive ID, we were able to identify autosomal dominant
causes in 3 families: a de novo deletion on chromosome
4q21.22-21.23, a de novo frameshift variant in SHANK2
and a de novo stop variant in TCF4 in two affected siblings,
most likely due to germline mosaicism.
In total, with our approach of WES of affected indivi-
duals with likely autosomal recessive ID, we identiﬁed the
underlying causes of intellectual disability in 13 out of 40
families demonstrating that our approach is viable to iden-
tify causative variants for intellectual disability.
This project is funded through a grant by DAAD.
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Clinical delineation of the phenotype of ﬁve females
carrying heterozygous mutation in KDM5C gene
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X-linked intellectual disability (XLID) is characterized by
extreme genetic heterogeneity with implication of more
than 100 genes on the X chromosome. To date, 28 muta-
tions have been reported in the lysine Speciﬁc Demethylase
5C (KDM5C) gene, which encodes for a histone demethy-
lase. KDM5C appears to be one of the major cause of
moderate to severe XLID in males, and has been associated
with short stature, facial dysmorphism, behavior disorders,
epilepsy and other variable features. For most of these
mutations, female carriers (mothers or sisters) have also
been reported but with poor phenotypic descriptions.
Females present a large phenotypic spectrum, ranging from
unaffected to speciﬁc learning difﬁculties or ID, but never
severe, contrary to males. Here, we present an accurate
study of the clinical and molecular features of ﬁve affected
females carrying unreported heterozygous KDM5C variants
(three missense and two frameshift) detected by whole-
exome sequencing. They all presented with ID, mild
hypertrichosis and endocrine disorders, as well as subtle
common facial dysmorphism. Strikingly, they had a very
particular language disorder, predominant on the expressive
part and contrasting with a correct comprehension for
cognitive age. In conclusion, our ﬁndings extend the num-
ber of KDM5C mutations in affected females, and thus
provide further evidences of its role in ID in females. This
study, conducted thanks to whole-exome sequencing
deployment in ID diagnosis, highlights the increasing
implication in sporadic female cases of genes previously
known to be responsible for XLID in males.
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Background: Kleefsta Syndrome is caused by hap-
loinsufﬁciency of EHMT1, usually caused by deletions at
9q34.3. The phenotype typically includes moderate to
severe intellectual disability. Expressive language in
patients with Kleefsta syndrome is usually most severely
affected, with most patients limited to one to two word
phrases, if they speak. Many adults show regression of
learned language and motor skills. Case reports exist of
occasional patients with milder than expected intellectual
disability, including one child with a small deletion and a
near normal IQ with verbal apraxia.
Case report: We report a case of a 22 year old patient
with a deletion at 9q34.3, including EHMT1, CACNA1B,
and TUBBP5, who has mild intellectual disability and for
whom language is a strength. She speaks three languages
and is able to read, write, spell and type. There have been no
signs of behavioural regression, motor regression or apathy
to this point.
Conclusions: Due to the now widespread use of chro-
mosomal microarray and exome sequencing, traditional
phenotypes for many syndromes are expanding. For
Kleefstra syndrome, this has largely meant an expansion of
the degree of associated intellectual disability to include
more mildly affected patients. While some patients, espe-
cially those with quite small deletions or mutations, have
some preservation of speech function, verbal apraxia has
continued to be a fairly constant feature of the syndrome.
This case further expands the known phenotype to include
patients with strong expressive verbal skills in comparison
with their level of functioning.
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Introduction: Kohlschutter-Tonz syndrome is an auto-
somal recessive disorder characterized by global develop-
mental delay, intractable seizures, and amelogenesis
imperfecta. Majority of cases is caused by homozygous or
compound heterozygous ROGD1 mutations, however,
biallelic SLC13A5 mutations have also been reported
recently.
The ROGDI gene encodes a leucine-zipper protein with
high expression in the human brain and spinal cordMater-
ials and Methods: We here report on clinical and molecular
ﬁndings of a 16-year-old and a 11-year-old two siblings
with Kohlschutter-Tonz syndrome.
Results: The siblings were referred to our center with
seizures and developmental delay at the ages of 22/12 and 29/
12, respectively. Both siblings had normal motor and mental
developmental milestones initially, however, with the onset
of seizures, regression was observed. Physical examination
revealed normal growth with facial features including
hypertelorism, prominent columella, short philtrum, and
yellow teeth. Cranial MRI in the elder sister revealed
asymmetric thickening of the right temporal lobe while in
the younger sister cerebral frontal atrophy was detected.
Seizure control was achieved with levetiracetam and phe-
nobarbital in both. During the clinical follow-up both sib-
lings were diagnosed with Kohlschutter-Tonz syndrome.
DNA sequence analysis revealed homozygous c.201-1G>T
in intron 3 of ROGD1 which is very likely to destroy the
splice acceptor site of exon 4 of ROGD1. Both parents were
heterozygous for the mutation.
Conclusion: Kohlschutter-Tonz syndrome is a rare entity
with an almost consistent phenotype, however, the diag-
nosis may sometimes be overlooked. Co-occurrence of
amelogenesis imperfecta with seizures and developmental
delay should be suggestive of the diagnosis.
P.O. Simsek Kiper: None. G.E. Utine: None. J.
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Introduction: Luscan-Lumish syndrome is an autosomal
dominant hereditary disorder characterized by macro-
cephaly, intellectual disability, speech delay, low socia-
bility, and behavioral problems. Other features include
postnatal overgrowth, obesity, advanced carpal ossiﬁcation,
frequent respiratory infections, developmental delay, and
seizures. Materials and Methods: We present clinical and
genetic characteristics of female patient 3-year old with
Luscan-Lumish syndrome. The girl was born at term fol-
lowing a normal pregnancy. She is the only child of healthy
unrelated parents. Her birth weight was 3740 g, length 57
cm, and OFC 35 cm. Echocardiogram reveals patent ductus
arteriosus. The patient was developmentally delayed and
did not walk until 18 months of age. Speech is absent. By 2-
year old girl appeared trichotillomania. Eruption of sec-
ondary teeth begun by 2,5-year old. Now her height is at the
75th percentile (98 cm), weight is at the 97th percentile (17.3
kg). She has macrocephaly with a head circumference
greater than the 97th percentile (55 cm). A MRI of the brain
at 3-year old revealed ventriculomegaly. An EEG is normal.
A phenotype features include macrocephaly, hypertelorism,
wide nasal bridge, long nose. Behavioral manifestations are
anxiety, obstinacy, impaired communication and limited
eye contact. Results: Exome sequencing detected
c.1102C>T (p.Arg368Ter, NM_014159.6) mutation in
heterozygous state in SETD2 in the proband that was not
present in either parent and was conﬁrmed with dideoxy
sequencing. Conclusions: Our clinical case describes the
phenotype associated with mutation in SETD2 and con-
tributes to the evidence base the role of this gene in intel-
lectual disability.
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Description of MED13L haploinsufﬁciency syndrome in
early adulthood and report of a recurrent missense
mutation
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We previously described the recognizable MED13L hap-
loinsufﬁciency syndrome which has been further char-
acterized after reports of additional patients diagnosed by
genome-wide testing. Here, we present two new patients,
highlighting new aspects of the syndrome. The ﬁrst patient
was a 14-year-old girl with moderate intellectual disability
(ID) and facial features of low set ears, horizontal eyebrows,
upslanting palpebral ﬁssures, midfacial hypoplasia, bulbous
nose, and hypotonic mouth with protruding large tongue.
Her features had led to the primary suspicion of Kleefstra
syndrome at early adulthood but whole exome sequencing
(WES) revealed a de novo frameshift mutation in MED13L.
The second patient was a 6.5-year-old boy who presented
with global developmental delay, absent speech, and some
clumsiness as well as facial features of squared, low set
ears, mild ptosis, ﬂat malar region, and mild broadening of
the nose. WES revealed a deleterious de novo missense
mutation in MED13L, identical to the mutation previously
reported in an ID patient. Notably, our in silico modelling
predicted the missense mutation to decrease the stability of
an alpha-helix and thereby affecting the MED13L second-
ary structure. These ﬁndings, therefore, highlight the
importance of MED13L de novo missense mutations
causing ID and suggest a potential mutational hotspot along
the gene. However, further patients are needed for better
genotype-phenotype correlation among missense mutations.
Considering all the reported patients so far, MED13L hap-
loinsufﬁciency syndrome appears to be a frequent cause of
undiagnosed ID with facial dysmorphism which should be
considered in the differential diagnosis of 22q11.2, 1p36
deletion and Kleefstra syndromes.
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Introduction: MED13L pathogenic variations have been
reported in patients with moderate intellectual disability
(ID), hypotonia, and dysmorphic facial features with or
without congenital heart defects. Here, we report a series of
22 patients with MED13L variations or deletions and
compare data to previously reported cases.
Patients and methods: An international cohort has been
formed with point variations involving MED13L identiﬁed
by next generation sequencing for 18 patients or intragenic
deletions identiﬁed by CGH-array for 4 patients.
Results: We identiﬁed 4 intragenic deletions, 3 non-
sense, 9 frameshift, 2 splice-site and 4 missense variations.
Truncating mutations were distributed along the entire gene.
Missense variations were grouped in exons 15, 16 and 30.
The severity of the MED13L phenotype was similar
between the missense variation group and the truncating
variation group. All patients presented developmental delay
(DD) or mild to severe ID. Speech delay was major with an
extremely poor language. Absence of language was noticed
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in 30% of patients. Neurological evaluation revealed global
hypotonia and ataxia. We observed common facial pre-
sentation with a bulbous nasal tip, depressed nasal bridge
and bulbous nasal bridge, hypotonic open-mouth, deep
philtrum and cupid-bow upper lip, bitemporal narrowing,
and high forehead. Among ten patients who had a cardiac
echography, one had a patent foramen oval.
Conclusions: MED13L patients share a common phe-
notype with moderate to severe DD/ID, speech impairment
and facial dimorphism. The type of mutation does not
appear to interfere with the severity of the phenotype.
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Microcephaly is an abnormally reduced head size and
estimated to affect 1:6250 to 1:8500 live births. It can be
caused by non-genetic factors, but most cases are believed
to have genetic etiologies. However, only a proportion is
usually clariﬁed by routine diagnostic evaluation, while the
majority remain undiagnosed. In this study, we aimed to
identify genetic causes for a cohort of 50 patients with
microcephaly using chromosomal microarray analysis and
trio whole exome sequencing. Until now, 44 patients have
been analyzed. Pathogenic variants were identiﬁed for 4
patients with primary microcephaly affecting genes ASPM,
CDK5RAP2 (2 patients) and CENPJ (9.1%), and for 10
patients with secondary microcephaly (22.7%) affecting
genes CASK, PQBP1, SLC9A6, KMT2A, ERCC6,
TRAPPC9, KARS, PTPN11, TRMT10A and TRIO. While
mutations in CASK, KMT2A, TRIO and PTPN11 were de
novo, those in the other genes were inherited in a recessive
or X-linked pattern. Potentially pathogenic variants in novel
candidate genes, which were predicted to be deleterious and
affect genes with microcephaly-related functions, were
determined for 10 patients (22.7%). To elucidate the cellular
impact of these variants, subsequent molecular biological
analyses will be performed. We expect that the ﬁndings will
help improve disease management and genetic counseling,
and will further expand our knowledge of human brain
development.
This work is funded by E-rare Euromicro Network.
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Phenotypes in siblings with homozygous mutations of
TRAPPC9 and/or MCPH1 support a bifunctional model
of MCPH1
S. Duerinckx1, M. Meuwissen2, C. Perazzolo1, L.
Desmyter1, I. Pirson1, M. Abramowicz1
Université Libre de Bruxelles, Brussels, Belgium, 2Univer-
siteit Antwerpen, Antwerp, Belgium
Autosomal recessive primary microcephaly (MCPH) is a
genetically heterogeneous subgroup of autosomal recessive
intellectual disability (ARID), where the size of the brain is
very small since birth. MCPH1 is an intriguing MCPH-
causing gene, playing a role at the centrosome as well as in
DNA Damage Repair (DDR), and it is not clear which of
these two mechanisms causes MCPH in man. Com-
plementation studies showed that the N-terminal BRCT1
domain was required for centrosomal localization while
BRCT2 and BRCT3 were responsible for DDR. TRAPPC9
is involved in vesicular trafﬁcking, and truncating
TRAPPC9 mutations have been reported in 5 ARID
families.
We here report on a family where two siblings with
MCPH were homozygous for TRAPPC9 (p.L178P) and
MCPH1 (p.R741X) mutations. Brain MRI showed anoma-
lies associated with the TRAPPC9 defect, supporting the
implication of that gene, and this is the ﬁrst report with a
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missense mutation, furthermore with microcephaly of pre-
natal onset. Importantly, an asymptomatic sister with nor-
mal head size was homozygous for the MCPH1 truncating
mutation and did not carry the TRAPPC9 mutation. The
MCPH1 mutation in both affected siblings might, at ﬁrst,
have been considered as causal, and this family illustrates
that the clinical interpretation of genetic variants remains
error-prone. More importantly, our observation in the nor-
mal sister is deﬁnite evidence that the lack of MCPH1
BRCT3 domain does not cause MCPH in man, and supports
a bifunctional model of MCPH1 where the centrosomal
function only is involved in brain volumic development.
Supported by EraNet ERare.
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Introduction: The 2p15p16.1 microdeletion syndrome has
been described in 33 cases (Bagheri et al., 2016). Its core
phenotype includes intellectual disability, microcephaly,
hypotonia, delayed growth, common craniofacial features,
and digital anomalies. Patient cell line and zebraﬁsh studies
identiﬁed three candidate genes XPO1, BCL11A, and REL.
Their knock-down in zebraﬁsh caused microcephaly, dys-
morphic body, hindered growth, small ﬁns and structural
brain abnormalities. It was recently suggested that
2p15p16.1 microduplication causes mirror phenotypes and
macrocephaly in carriers (Loviglio et al., 2016). Our aim
was to test this possibility in a larger number of patients
with the duplication and by overexpression of the 3 can-
didate genes in zebraﬁsh. Methods: Clinical and genomic
information for patients with 2p15p16.1 microduplication
was extracted from DECIPHER. Overexpression of XPO1,
REL and BCL11A in zebraﬁsh embryos was performed by
human RNA injection in 1-cell stage embryos. Head size,
growth and body morphology was examined at 2 days post-
fertilization. Results: Twelve patients were reported in
DECIPHER with 2p15p16.1 duplications and phenotypes
and only 1 had macrocephaly. Patients with microcephaly
were also noted in this cohort ruling out a clear association
of duplication and macrocephaly. Overexpression of XPO1
and REL in zebraﬁsh did not cause phenotypic abnormal-
ities, while BCL11A overexpression caused a hindered body
growth and dysmorphic body trunk, but comparable head
structure and size to controls. Conclusion: Our studies do
not support the existence of mirror phenotypes in cases with
2p15p16.1 duplication. The overexpression of BCL11A,
however, may be associated with body dysmorphology but
not head size anomaly.
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features : A new clinical entity
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Intellectual disability is a neurodevelopmental disorder that
affects 1 to 3% of the population worldwide. If enviro-
mental factors could explain the intellectual disability in
some cases, the remaining majority (up to 60%) has no
identiﬁable cause and about 25 to 50% are thought to have a
genetic cause.
This impairement can be grouped into isolated (non-
syndromic) or syndromic intellectual disability where
patients present with other clinical features in addition to
intellectual impairement. Most known non syndromic
intellectual disability are X-linked, while the number of
autosomal genes related to this disorder is growing rapidly.
However, it is difﬁcult to identify additional subtle clinical
signs and describe a clear phenotype with the scarcity of
similar cases with the same genetic etiology.
We report on the case of 2 moroccan siblings presenting
mild intellectual disability with minimal dysmorphic fea-
tures in which whole exome sequencing analysis revealed
homozygous mutation in the METTL23 gene. Mutations in
this gene have been reported to cause mild intellectual
disability but the association with dysmorphic features
remains controversial.
Hereby, we highlight the similarity of the dysmorphic
traits and the characteristic facial features in patients with
METTL23-related intellectual disability, suggesting a new
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clinical entity associating mild intellectual deﬁciency with
facial dysmorphy for an efﬁcient diagnostic orientation and
a better phenotype-genotype correlation in intellectual dis-
ability disorders.
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Microdeletions of chromosome band 2p25.3 have been
reported in more than 20 patients. Common clinical features
include intellectual disability (ID) /developmental delay,
central obesity and behavioural difﬁculties. MYT1L is
deleted or disrupted in all published patients and thus
became the main candidate gene for these clinical features.
However, only two patients with de novo MYT1L point
mutations have been reported.
Here, we present two novel patients with de novo MYT1L
sequence variants we identiﬁed by trio whole exome
sequencing in a cohort of 311 individuals with ID of
unknown aetiology. Patient 1 carried a nonsense mutation
(c.1531G>T, NM_015025.2; Gly511*) whereas patient 2
carried a direct splice site mutation (c.2769-2A>G).
According to prediction algorithms, both MYT1L variants
are deleterious (patient 1: SIFT score 0, CADD score 42;
patient 2: CADD score 24.6). Additionally, patient 2 carried
a de novo variant in SETD1B that is predicted to be benign
(CADD score 2.5) and a known frequent SNV
(rs749218728, MAF 0.0000323).
A comprehensive clinical characterisation of the two
patients yielded only mild to moderate ID, behavioural
problems and muscular hypotonia as common clinical signs.
Surprisingly, obesity was only present in patient 2. Tall
stature and microcephaly were present in one patient each.
This clinical picture is compared to the published pheno-
types of patients with MYT1L point mutations, with
microdeletions of MYT1L only and with larger 2p25.3
deletions. With the reduced penetrance regarding obesity
shown here, the clinical picture of MYT1L is becoming
more and more unspeciﬁc.
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homeobox gene: A "fault disease model"
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Altucci5, M. Miano1
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Studying molecular convergence in neurodevelopmental
disorders caused by mutations in speciﬁc disease-related
genes permits us to deﬁne druggable molecular pathways.
The purpose of our study is to assess the degree of damage
associated with the ARX-KDM5C and to establish a cor-
relation between similar phenotypes and same cellular
functions. Mutations in ARX, a homeotic transcription fac-
tor, have been found in a spectrum of X-chromosome
phenotypes including cortical malformations, chronic Epi-
lepsy and XLID. About KDM5C, its mutations have been
reported as an important cause of XLID. Its protein is a
histone demethylase acting as transcriptional repressor
during brain development. Here we summarize in vitro and
in vivo functional analysis of two classes of ARX mutations
by studying the impact on the stimulation of KDM5C,
already reported by us as an ARX disease-target gene. We
have proven that PolyAlanine elongations are partial loss-
of-function mutations that impair the activation of KDM5C
transcription; while HD missense mutants are loss-of
function alterations, which abolish the transcriptional
activity attributable to the WT protein. Since H3K4me3 is
the hallmark of open chromatin, ARX-dependent KDM5C
defects could compromise chromatin remodelling. We
propose a “fault disease model” showing that the degree of
spectrum of KDM5C defects correlate with the severity of
the neurophenotypes associated with ARX mutations.
Modelling ARX and KDM5C defects in the identical stem
cell line might allow us to assess the degree of molecular
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convergence caused by altered dosage of these two disease-
related genes and the in vivo validation of potential drugs
that could compensate KDM5C-H3K4me3 deregulation.
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A de novo intragenic deletion in TANC2 in a girl with
clinical features of the Angelman-Rett continuum
E. Bettella1, S. Sartori2, R. Polli1, E. Leonardi1, F. Cesca1,
M. C. Aspromonte1, I. Toldo2, M. Clementi3, A. Murgia1
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Background: Neurodevelopmental disorders are a group of
clinically and etiologically heterogeneous conditions often
characterized by comorbidity of intellectual disability (ID)
and Autism Spectrum Disorders (ADSs). These conditions
show a wide range of overlapping features that may
represent a serious difﬁculty for diagnoses exclusively
based on clinical grounds. Elucidating the etiology offers
insights into the pathogenic mechanisms and allows a better
understanding of the clinical expression of these diseases.
Methods: We report the clinical features of a female subject
affected with severe global developmental delay since early
infancy; the clinical picture evolved into a profound intel-
lectual disability and motor impairment, absent speech and
autistic traits with hand stereotypies, constipation, sleep and
autonomic disturbances and facial dysmorphic features.
Results: an intragenic deletion in the coding sequence of
the TANC2 gene (OMIM *615047) was identiﬁed by Array
CGH. The alteration was conﬁrmed by quantitative PCR
analysis and its limits reﬁned by transcript analysis. Deﬁ-
ciency of the TANC2 protein, a synaptic protein widely
expressed throughout the brain has been found to be
embryonic lethal in mice; a few structural alterations of
TANC2 are listed in genomic databases but speciﬁc phe-
notype correlation have not been reported.
Conclusions: we describe for the ﬁrst time the clinical
phenotype associated with a pathogenic mutation of the
TANC2 gene. Our ﬁndings contribute to deﬁning the
pathogenic role of TANC2 and underline the importance of
considering this gene as possibly involved in otherwise
unexplained neurodevelopmental disorders characterized by
intellectual disability, autistic traits and clinical features of
the Angelman-Rett spectrum.
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19p13 duplications including NFIX cause intellectual
disability, growth retardation and microcephaly: a
reversed Sotos syndrome-2?
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NFIX gene codes for a transcription factor implicated in
neurogenesis and chondrocyte differentiation. Microdele-
tion and loss of function mutations of NFIX are responsible
for the Sotos syndrome-2 (also described as Malan syn-
drome), a syndromic form of intellectual disability asso-
ciated with overgrowth, advanced bone age and
macrocephaly. We report here a cohort of 9 patients with
19p13 microduplications including NFIX. These patients
exhibit variable intellectual disability, short stature with
bone age delay, and microcephaly, which can be described
as a reversed Sotos syndrome-2 phenotype. The opposite
effects of NFIX haploinsufﬁciency and overexpression
could explain these mirror phenotypes associated with
deletions and duplications. There is evidence in the litera-
ture suggesting that NFIX is a negative regulator of endo-
chondral ossiﬁcation, and that tall stature of patients with
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Sotos syndrome-2 could be related to a decrease of this
repression. Conversely, NFIX overexpression in patients
with duplication could lead to increased repression,
explaining the short stature. It is striking that a similar
reversed phenotype has already been described in patients
with duplication encompassing NSD1, the gene which
deletions and loss of function mutations are responsible for
classical Sotos syndrome. Even though the type/contre-type
concept is controversial, this model seems to give a plau-
sible explanation for the pathogenicity of the 19p13 dupli-
cation, and the common phenotype observed in our cohort.
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De novo mutations in NOVA2, a RNA-binding protein,
cause intellectual disability with growth retardation and
epilepsy
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Intellectual disability (ID) is a common neurodevelop-
mental disorder, characterized by a high genetic hetero-
geneity, with more than 700 genes described to be involved
in monogenic forms. We performed a whole exome
sequencing on a patient affected by intellectual disability,
growth retardation, microcephaly, epilepsy, subcortical
atrophy and traits of pyramidal syndrome as main features.
We identiﬁed a de novo loss-of-function (LoF) mutation in
NOVA2, a gene which has never been implicated in ID
before and highly intolerant to LoF variants (from ExAC
data). NOVA2 is a neuron speciﬁc RNA-binding protein
that regulates alternative-splicing events during brain
development. Knockout mice for this gene showed an
overall motor weakness and dysfunction, a failure to thrive
and they died shortly after birth (Saito et al. 2016). Through
data exchange we have been able to identify a second
patient with a de novo LoF mutation in NOVA2 presenting
with similar phenotype. To further conﬁrm the role of
NOVA2 in ID, we have undertaken to knock-down the gene
in zebraﬁsh. In parallel, we are investigating the effect of
NOVA2 silencing on cell proliferation and splicing regula-
tion in human neuronal stem cells, which has never been
reported.
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Clinical delineation of the recurrent de novo c.607C>T
mutation in PACS1
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We have previously described two unrelated boys with a
strikingly similar facial appearance and intellectual dis-
ability in whom an identical de novo mutation in PACS1,
c.607C>T, was detected by exome sequencing (NM_
0180026.2, OMIM 615009) [1]. In vitro and in vivo studies
showed that the mutant protein forms cytoplasmic aggre-
gates with concomitant increased protein stability. Further,
expression studies of mutant PACS1 mRNA in zebraﬁsh
embryos suggest that the mutant zebraﬁsh phenotype is
driven by aberrant speciﬁcation and migration of SOX10-
positive cranial neural crest cells, probably explaining the
craniofacial phenotype in patients. Since this initial report,
we have collected clinical information on 19 individuals
with this identical mutation [2]. Social media (facebook) has
shown its value in collecting additional patients with this
rare genetic disorder. There is a distinctive facial appear-
ance (19/19). Intellectual disability (mild-moderate) was
present in all. Hypotonia is common in infancy (9/19).
Seizures are frequent (12/19) and respond well to antic-
onvulsive medication. Structural malformations are com-
mon, including heart (10/19), brain (12/15), eye (9/19),
kidney (3/19) and cryptorchidism (6/12 males). Feeding
dysfunction is presenting in infancy (6/19). Six individuals
had gastroesophageal reﬂux and ﬁve needed gastrostomy
tube placement. There is persistence of oral motor dys-
function. In summary, this recurrent de novo c.607C>T
mutation in PACS1 gives rise to a clinically recognizable
syndrome. We provide suggestions for clinical work-
up&management. Given the recognizable facial gestalt, we
hope that the present study will facilitate clinical recogni-
tion of further cases.
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Two different additional mutations in TBL1XR1
identiﬁed in patients with Pierpont syndrome, as
opposed ton only recurrent one previousely described
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Introduction: Pierpont syndrome is a rare and sporadic
syndrome, including developmental delay, facial char-
acteristics, and abnormal extremities. Recently, a recurrent
neomutation c.1137A>C; p.Tyr446Cys in TBL1XR1 was
identiﬁed in 6 patients by whole-exome sequencing. A
dominant-negative effect of this mutation is strongly sus-
pected, and patients with TBL1XR1 deletion and other
doesn’t share the same phenotype.
Material and methods: The ﬁrst patient is a 14-year–old
Caucasian boy with severe global developmental delay. He
walked unaided until 3 years old, does not speak, has
autistic features, severe sleep disturbance, facial and extre-
mity features of Pierpont syndrome, and severe postnatal
growth retardation (height at -3SD whereas OFC at
+0.5SD). The second patient is a 24-year-old Caucasian
female who has developmental delay, Arnold Chiari mal-
formation, facial characteristics of Pierpont syndrome and
severe behavioral disorders. Her height is at -1.5 SD.
Whole-exome sequencing was performed for both
patients.
Results: We identiﬁed a heterozygous missense neo-
mutation in TBL1XR1 in each patient different from that
reported in literature, namely c.974 G>A; p. Cys325Tyr for
patient 1 and c.1336T>C; p.Tyr446His for patient 2. The
second mutation is localized in the same nucleotide as the
recurrent mutation. The ﬁrst one is localized in another
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nucleotide but concerns the protein’s same functional and
physical domain. The software PolyPhen-2 predicts patho-
gen mutations.
Discussion: The localization of these mutations and
clinical features of Pierpont syndrome suggest that their
functional consequences are the same as the recurrent
mutation previously described and provides additional data
to understand molecular mechanisms of TBL1XR1
anomalies.
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The long and winding road to the diagnosis of 33
patients with intellectual disability/developmental delay
by target/exome sequencing: the signiﬁcance of re-
evaluation of both phenotypic and genotypic data
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Introduction: It has been demonstrated that diagnosis of
intellectual disability/developmental delay (ID/DD) beneﬁts
from clinical application of target/exome sequencing. The
yield varies from 16%-50%. Materials and Methods: Target/
exome sequencing was performed on 33 ID/DD patients.
Excluded criteria: proband (i)with pathogenic CNVs found
by microarray; (ii)with acquired brain damage; (iii)abnor-
mal metabolic screening. First-round data analysis: SNV/
indel was called by GATK. OMIM data was downloaded in
May 2016. Second-round data analysis: CNV was calcu-
lated by XHMM. OMIM data was updated to January 2017
version. The candidate mutations were returned to the
clinician. If necessary, the patients were invited to the clinic
for a second examination. Results: Molecular diagnosis
was obtained in 20/33 patients(60%). Notably, seven cases
(21%) were solved during re-evaluation of geno-/pheno-
typic phase. Compound heterozygous mutations in UNC80
gene were detected in two sporadic patients. The causal ID
disorder was not added to the OMIM database in the ﬁrst-
round analysis. One patient carry 3.8 kb exonic deletion in
ARID1B gene detected by XHMM. No probe locate in this
region in microarray. Two patients, with KMT2D and ATRX
mutation respectively, only showed ID/DD in their ﬁrst visit
to clinic. A followup evaluation at elder age revealed their
distinct features. Two CREBBP mutations were found in
two patients. They represent a unique entity caused by
defects in exon 30/31 of CREBBP gene. Conclusions: Our
study conﬁrmed the utility of exome sequencing in the
diagnosis of ID/DD. Furthermore, re-evaluation of patients’
phenotype and genotype lead to a 21% improvement of
yield.
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Objectives: Rett syndrome (RTT) is an early-onset neuro-
developmental disorder that almost exclusively affects girls
and is totally disabling. It had been described 3 genes that
cause RTT. However, the etiology of the 15% of these
patients still remains unknown.During the latest years the
NGS has allowed to promote the genetic diagnosis because
of the quickness and affordability of the method. To eval-
uate the usefulness of the NGS in the genetic diagnosis, we
present the genetic study of Rett-like patients using different
techniques based on this technology.
Material and Methods: It has been studied 1659
patients with Rett-like clinical diagnosis as well as it has
been reviewed patients who was previously studied by
Sanger Sequencing in the 3 Rett genes. It has been per-
formed: Custom panel with 17 gens related to Rett-like
clinic through HaloPlex Target Enrichment System, for
Illumina Sequencing; Commercial panel, TruSightOne
Sequencing Panel (Illumina); Whole Exome Sequencing
(WES) in trios with TruSeq Sample Preparation Kit (Illu-
mina). Results: It has been diagnosed genetically 477/1659
patients with a Rett-like suspicion. It has been positive
results in a 30% by Sanger (100% Rett genes), 23% by
custom panel (58% Rett genes), 24% by TSO (25% Rett
genes) and 32% by WES (25% Rett genes).Conclusions:
The genetic study by NGS allows to study a larger number
of genes associated with Rett-like clinic simultaneously,
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providing a genetic study to a wider group of patients.
Finally, the study of the progenitors remains essential for
their characterization as well as functional studies.
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Rett syndrome genes - molecular screening methods
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Introduction: The neurodevelopmental disorder Rett syn-
drome (RTT) was ﬁrst described by Dr. Andreas Rett in
1966. Currently, the diagnosis of both typical and atypical
RTT, is based on the clinical consensus criteria deﬁned in
2010. A molecular ﬁnding is only considered conﬁrmatory
of the clinical diagnosis. Most patients with molecularly
veriﬁed diagnoses have pathogenic variations in either
MECP2, CDKL5 or FOXG1 but an increasing number of
genes associated with RTT like conditions are reported. An
optimal diagnostic strategy for patients with RTT, is
important for both clinicians and families. Materials and
Methods: We have reviewed clinical and molecular data of
all the Danish patients with pathogenic variations in
MECP2, CDKL5 and FOXG1. Results: All 115 patients
with MECP2 variations were molecularly diagnosed with a
single gene analysis. CDKL5 variations were detected using
a single gene analysis only in 4/11 of patients. The
remaining CDKL5 variations and all 4 FOXG1 variations
were identiﬁed by screening techniques. All patients who
fullﬁlled the clinical criteria of typical RTT carried a
MECP2 variation, while patients with CDKL5 and FOXG1
variations had some RTT symptoms, but were not typical.
Conclusion: The survey indicates that large scale screening
methods will greatly increase the discovery of patients with
CDKL5 and FOXG1 variations. In our cohort patients with
CDKL5 and FOXG1 sequence variations do not all ﬁt the
current clinical criteria for atypical RTT. We propose to
expand a RTT spectrum and include both the clinical and
the molecular diagnosis.
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Rett syndrome is a progressive neurodevelopmental dis-
order accounting for a large portion of intellectual disability
(ID) in females. It is most frequently caused by mutations or
deletions in MECP2 gene that codes for the methyl-CPG-
binding protein 2 and is located on Xq28. Here we present
an interesting case of a novel mosaic MECP2 point muta-
tion found in a patient with a typical Rett phenotype.
The patient is a female with autistic features, psycho-
motor delay, speech regression and stereotypic hand
movements, initially referred for copy number screening to
investigate Angelman or Rett syndromes. The results of
MLPA analysis were negative and subsequent Sanger
sequencing of MECP2 gene revealed a mosaic C→T non-
sense mutation at position 139 of exon 3. A second round of
Sanger sequencing with region-speciﬁc primers conﬁrmed
the presence and the mosaic state of the mutation. The same
primers were used to test the biological parents, who were
found negative. Restriction enzyme analysis gave normal
results for both parents and was consistent with a mosaic
mutation in the patient. In order to estimate the level of
mosaicism, Next-Generation Sequencing was performed,
showing approximately 25% abnormal cells.
This is the ﬁrst known female mosaic MECP2 mutation
carrier, who is exhibiting the full spectrum of Rett
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syndrome phenotype. The speciﬁc mutation was not pre-
viously detected in other patients.
Further studies including a buccal swap are currently
ongoing and are expected to provide insights into tissue
speciﬁcity, thereby allowing for a better understanding of
the patient’s phenotype and relevant mechanisms.
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New MEF2C mutations in Rett-like phenotype patients
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Gracía4, J. M. Acedo4, M. A. Martínez5, M. Pineda1, J.
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Objectives: Rett syndrome (RTT) is an early-onset neuro-
developmental disorder that almost exclusively affects girls
and is totally disabling. It had been described 3 genes that
cause RTT: MECP2, CDKL5 and FOXG1. However, the
etiology of the 15% of these patients still remains unknown.
During the latest years the Next Generation Sequencing
(NGS) have allowed to sequence a large number of genes at
the same time. In this way, several genes have been
implicated in RTT typical and variant forms. Here, we
present 4 patients with 3 mutations in MEF2C gene that
related to the MEF2C haploinsufﬁciency syndrome.
Material and Methods: It has been studied 242 patients
with Rett-like clinical diagnosis as well as it has been
reviewed patients, who was previously studied by Sanger
Sequencing in the 3 Rett genes, using the TruSight One
Sequencing Panel (TSO Illumina). Moreover, it has been
performed Sanger sequencing of the found mutations in
patients and their progenitors. Results: Genetic diagnosis
was achieved in 55 of 242 patients (23%). The 60% of these
positive results have mutations in Rett genes (MECP2,
CDKL5 and FOXG1) and the other 40% mutations in Rett-
like genes. We herein present 3 novel mutations and pre-
sume pathogenic in MEF2C gene. Conclusions: The
genetic study by NGS allows studying a larger number of
genes associated with Rett-like clinic, providing a genetic
study to a wider group of patients. MEF2C haploinsufﬁ-
ciency could phenotypically overlaps with RTT, especially
the early onset seizure variant.
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Introduction RSTS is a rare autosomal dominant neuro-
developmental disorder characterized by broad thumbs and
halluces. RSTS is caused by mutations in CREBBP and
EP300 genes in 50–60% and 10% of cases, respectively. To
date, about 230 causative mutations in CREBBP and 76
EP300-patients have been described. Materials and
Methods A total of 72 individuals with the suspected
diagnosis of RSTS were recruited. DNA was obtained from
blood of patients and their parents, when possible. CREBBP
and EP300 MLPA, panel based-NGS of CREBBP and
EP300 genes and Sanger sequencing conﬁrmation were
carried out. Sequence changes were compared to the par-
ents. Results We found CREBBP mutations in 35 patients
(49%), EP300 in 8 (11%), and nothing in 22 (30%). Other
syndromes were conﬁrmed in the rest (10%). Variants
detected were (CREBBP/EP300): large deletions (11/1),
nonsense (12/1), missense (4/1), frameshift (5/4) and spli-
cing (3/1). Relating to phenotype, ID was more severe in
CREBBP patients, as well as the psychomotor, language
delay and the behavioral problems. Typical features such as,
broad thumbs and downslanted palpebral ﬁssures were
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detected equally in both, and angulated thumbs were rare in
EP300-patients. In contrast, the presence of microcephaly
was higher in EP300-patients. Conclusions Phenotypic
spectrum of RSTS patients is wide, although it is usually
less marked in EP300. It is difﬁcult to establish a correlation
genotype-phenotype. The description of more RSTS
patients may contribute to better understand the range of
phenotypes in order to provide clinical pointers that would
improve the detection and diagnosis of these patients.
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Oslo University Hospital, Oslo, Norway, 5Institute of
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Kinesin proteins are critical for various cellular functions
such as intracellular transportation and cell division, and
have been linked to monogenic disorders and cancer. Filges
et al. (2014) previously reported a KIF14-related lethal fetal
ciliopathy phenotype in one single family
(OMIM#616258): The affected fetuses, who were com-
pound heterozygous for two KIF14 frameshift mutations,
had severe IUGR, microcephaly, cerebral and cerebellar
hypoplasia, renal and uterine agenesis/hypoplasia, arthro-
gryposis and dysmorphic facial features. The corresponding
mouse model, laggard (lag), carrying a spontaneous Kif14
splice site mutation, has growth retardation, brain size
reduction, and severe hypomyelination of the central ner-
vous system including optic nerve hypoplasia (Fujikura
et al. 2013). Both the lag/lag and the conditional Kif14
knockout mice die before weaning.
We report here two consanguineous families with
homozygous variants in KIF14 (NM_014875.2): One with
missense c.2522C>T, p.(Ser841Phe), and one with frame-
shift c.246delT, p.(Asn83Ilefs*3), both variants detected by
WES and familial segregation with the phenotype con-
ﬁrmed. The four affected individuals presented with intel-
lectual disability, hypotonia, similar dysmorphic facial
features, proportionate short stature, but had normal birth
weight. The missense mutation siblings have normal head
circumference at age 5y and 13y, respectively. While the
siblings with the frameshift mutation, presently 23y and
30y, have severe microcephaly with prenatal onset, optic
nerve hypoplasia, blindness, and microphthalmia.
Our report demonstrates phenotypic expansion of the
KIF14-linked autosomal recessive Mendelian disease, ran-
ging from a lethal fetal disorder with severe brain growth
restriction and IUGR to a congenital syndrome with
developmental delay/intellectual disability, postnatal short
stature, +/- microcephaly and blindness.
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Analysis of 31-year-old patient with SYNGAP1 gene
defect points to importance of variants in broader splice
regions and reveals developmental trajectory of SYN-
GAP1-associated phenotype
M. Hančárová1, D. Prchalová1, M. Havlovicová1, K.
terbová2, V. Stránecký3, Z. Sedláček1
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We report an adult female patient with severe intellectual
disability, severe speech delay, epilepsy, autistic features,
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aggressiveness, sleep problems, broad-based clumsy gait
and constipation. Whole exome sequencing identiﬁed a de
novo mutation in the SYNGAP1 gene. The variant was
located in the splice donor region of intron 10 and replaced
G by A at position +5 of the splice site. The variant was
predicted in silico and shown experimentally to abolish the
regular splice site and to activate a cryptic donor site within
exon 10, causing frameshift and premature termination.
This observation underscores the importance of considering
not only variants in the canonical splice dinucleotides GT
and AG, but also in broader splice regions. Clinical picture
of the patient corresponded well with the characteristic
SYNGAP1-associated phenotype observed in previously
reported patients. However, our patient was 31 years old
which contrasted with most other published SYNGAP1
cases who were much younger. She had a signiﬁcant growth
delay and microcephaly although both features normalised
later. The cognitive and language performance remained at
the level of a one-year-old child even in adulthood and
showed a slow decline. Myopathic facial features and facial
dysmorphism became more pronounced with age. Although
the gait of the patient was unsteady in childhood, more
severe gait problems developed in her teens. While the
seizures remained well-controlled, her aggressive behaviour
worsened with age and required extensive medication.
These observations contribute to the knowledge of the
developmental trajectory in individuals with SYNGAP1
gene defects. Supported by 00064203, CZ.2.16/3.100/
24022, NF-CZ11-PDP-3-003-2014, LM2015091.
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TARP syndrome - ﬁrst reported adult patient
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Introduction: TARP syndrome is a rare X-linked syndrome
with intellectual disability, Talipes equinovarus, Atrial
septal defect, Pierre Robin sequence, and Persistent left
superior vena cava. Other symptoms include pulmonary
hypoplasia, syndactyly, polydactyly, and hypotonia. TARP
syndrome was ﬁrst described in 1970. In 2010, RBM10 at
Xp11.23 was identiﬁed as the responsible gene. 15 patients
from 6 families have previously been reported. Most
reported patients died in infancy or early childhood. We
present the ﬁrst reported adult with TARP syndrome.
Material and Methods: We report a 27-year-old male
with atrial septal defect, Pierre Robin sequence, severe
intellectual disability, and syndactyly of the second and
third toe. Persistent left superior vena cava and talipes
equinovarus were not reported in this patient. The index
person also had posterior sloping of the forehead, prominent
nasal bridge, long and prominent nose, downturned medial
canthi, esotropia, severe myopia, small hypoplastic teeth,
and severe scoliosis. These features have not previously
been reported in this syndrome.
Results: Sequencing of a diagnostic exome panel con-
taining 749 known intellectual disability genes revealed a
hemizygous mutation in RBM10, NM_005676.4:
c.273_283delinsA. This frameshift mutation has not pre-
viously been reported. The mutation was veriﬁed by Sanger
sequencing and was not found in DNA from the mother of
the index person.
Conclusion: This is the ﬁrst report of an adult with TARP
syndrome. The c.273_283delinsA mutation is the ﬁrst
reported in exon 4 of the RBM10 gene. Exon 4 is skipped in
some isoforms suggesting a possible cause for the milder
phenotype.
Grants: None
A.T. Højland: B. Research Grant (principal investigator,
collaborator or consultant and pending grants as well as
grants already received); Modest; Foundation for the
Advancement of Medical Science. B. Research Grant
(principal investigator, collaborator or consultant and
pending grants as well as grants already received); Sig-
niﬁcant; The Obel Family Foundation, Axel Muusfeldt's
Foundation, Merchant L.F. Foght's Foundation, Doctor
Sofus Carl Emil Friis and wife Olga Friis' Grant, Aase &
Ejnar Danielsen's Foundation. I. Lolas: None. C.K.
Lautrup: D. Speakers Bureau/Honoraria (speakers bureau,
symposia, and expert witness); Modest; Astra Zeneca. H.
Okkels: None. M.B. Petersen: B. Research Grant (princi-
pal investigator, collaborator or consultant and pending
grants as well as grants already received); Signiﬁcant; The
Obel Family Foundation, Axel Muusfeldt's Foundation,
Merchant L.F. Foght's Foundation, Doctor Sofus Carl Emil
Friis and wife Olga Friis' Grant. I.K. Nielsen: B. Research
Grant (principal investigator, collaborator or consultant and
pending grants as well as grants already received); Sig-
niﬁcant; Arvid Nilsson's Foundation.
358
P08.65A
Most severe case of thyroid-alpha-receptor deﬁciency in
a female patient with severe growth and mental retar-
dation, macrocephaly, pubertas tarda and
dysgerminoma
M. Stampfer, S. Beck-Wödl, A. Rieß, O. Rieß, T. Haack
Institute of Medical Genetics and Applied Genomics,
University of Tuebingen, Tuebingen, Germany
We report on a 19-year old female; the second child of non-
consanguineous German parents. She was born at term with
normal measurements but macrocephaly. A meconium
ileus, malrotation and umbilical hernia were present at birth.
A small ASD closed spontaneously. She developed epi-
leptic spasms at 4 months of age and at 8 years of age she
developed atonic seizures with no reoccurrence under
therapy. cMRI showed myelination disorder. She walked at
age 6. A dysgerminoma was detected at age 14 and was
treated with salpingo-ovarectomy and chemotherapy. The
patient has hypothyroidism and is treated with L-Thyroxin.
Her menstruation started with 18 years, she got no pubic
hair yet.She is very small (17 cm < 3. centile), has a dis-
proportionate stature and mild muscular hypotonia. Dys-
morphic features include coarse face, macrocephaly,
macroglossia, hypertelorism, smooth philtrum, thin upper
lip vermillion, wide nasal base and ridge and downslanting
palpebral ﬁssures. She has short, broad thumbs, brachy-
dactyly V and ﬂat feet. She has severe mental retardation
with minimal understanding and developed no expressive
speech. She has a cheerful temper. Exome sequencing was
performed, and led to the identiﬁcation of a previously
unreported deletion in the THRA gene (c.1150del, p.
Arg384Alafs*5). There are several adjacent deletions
known. Segregation analysis in the parents conﬁrmed a de
novo mutation and the diagnosis of Thyroid-alpha-receptor
deﬁciency in the patient. The patient has a more severe
phenotype (in particular mental retardation and dysmorph-
isms) then previously reported cases. It remains unclear
whether the dysgerminoma is part of the disease.
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TRIO variants in individuals with variable intellectual
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The TRIO gene has been recently associated to autosomal
dominant mental retardation (MRD44), characterized by
mild intellectual deﬁcits (ID), distinctive facial features and
digital abnormalities. Mutations in the RhoGEF1 domain
alter GTPase activation and cause a distinct phenotype
including microcephaly, ID, behavioral difﬁculties and
speciﬁc digital features.
We analyzed the 57 TRIO exons with amplicon-based
next-generation sequencing in 76 unrelated individuals with
apparently non-syndromic ID and autism spectrum dis-
orders. On average, 94% of the target regions have a read
depth of at least 20×, with mean depth of coverage of 250x
for each individual.
We identiﬁed eight TRIO rare single nucleotide variants
(SNVs), of which seven are non-synonymous. A SNV
resulting in a stop codon in the RhoGEF1 domain was
identiﬁed in a boy with learning difﬁculties, mild ID, and
subtle dysmorphic features, maternally inherited. A novel
missense variant mapping on the RhoGEF1 domain, was
found de novo in a boy with severe ID, speech failure, and
corpus callosum agenesis, but neither microcephaly nor
autistic features. Other SNVs map to Spectrin repeats or the
C-terminal domain. Three were inherited from an unaf-
fected parent, and predictions of their pathogenicity is dis-
cordant among different computational tools.
Our ﬁndings conﬁrm that truncating TRIO gene muta-
tions are associated to mild phenotypes. However, in con-
trast to previously reported cases, we identiﬁed a missense
mutation in the RhoGEF1 domain associated to a severe
phenotype in absence of microcephaly.
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Study of a Hispanic Wolf-Hirschhorn´s cohort:
genotype-phenotype correlation analysis
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AIM: Wolf-Hirschhorn (WHS) is a poly-malformative
syndrome associated with a delay of growth/development,
epilepsy, and facial dysmorphias resulting from a loss of
genetic material in the short arm of chromosome-4. Our
main goals are to describe social-demographic character-
istics and clinics of an Argentinian-Spaniard cohort of
patients with WHS; to know the prevalence of epilepsy and
its electro-clinical features; to describe the possible exis-
tence of EEG-patterns; to establish a possible genotype-
phenotype relationship.
Patients and methods: A cohort of Argentinian-
Spaniard patients (72) with clinical/genetic diagnosis of
WHS was analyzed by SNP-arrays (cytoSNP850K-Illu-
mina). We matched general epidemiological features, clin-
ical and genetic information for each patient. All this was
under a statistical analysis at different levels.
Results: The sample showed similar clinical manifesta-
tions to other previously described ones; epilepsy affects
90% of patients (it is polymorphic), with the ﬁrst crisis
before the 2 years of life and signiﬁcant predisposition to
develop status (55%). However, 64% of the patients dis-
played an acceptable level of control of crisis. Thus, the
level of psychomotor-development in our cohort seems to
be better than other ones.
Conclusions: Socio-demographic and clinical char-
acteristics of a one of the largest series of WHS patients
characterized by high-resolution arrays were described,
including the degree of psychomotor development and
patients´ level dependency, the possible existence of spe-
ciﬁc EEG-patterns in this syndrome, aspects of epilepsy and
its prevalence. We are establishing for the ﬁrst time, a
relationship between degree of psychomotor-development
and certain variables related to epilepsy, and the size of the
deletion.
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The importance of Array-CGH in the identiﬁcation and
characterization of 4p16.3 microdeletions in patients
with Wolf-Hirschhorn Syndrome: A genotype/pheno-
type correlation attempt
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Wolf-Hirschhorn syndrome (WHS: OMIM 194190) is a
contiguous gene deletion disorder caused by partial deletion
in the region 4p16.3 of the short arm of chromosome 4.
WHS is most often caused by de novo terminal deletions;
although, interstitial deletions, unbalanced translocations
and complex genomic rearrangements are also frequent.
Clinical features of WHS patients include severe growth
delay, short stature and low body weight, intellectual dis-
ability, a typical and distinctive craniofacial appearance
(“Greek warrior helmet proﬁle”) and seizures (or EEG
anomalies). Two critical regions have been proposed: a 165
kb proximal region (WHSCR1) and a second new critical
region (WHSCR2) distal to WHSCR1 including LETM1 (a
candidate gene for seizures) and the 5´ end of WHSC1.
In our cohort of 1500 patients, with ID and ASD, studied
by Agilent 180K oligonucleotide array-CGH, we have
identiﬁed 7 new patients with 4p16.3 deletions and revisited
3 other previously detected by FISH and/or standard cyto-
genetics, redeﬁning the deleted region. All patients exhib-
ited clinical ﬁndings compatible with WHS. In two patients
with 4p16.3 small interstitial deletions of 287Kb and 611Kb
the WHS phenotype was incomplete. Seizures in one
patient, with a deletion not overlapping LETM1 suggest the
idea that this gene alone could not be the cause of seizures
in WHS.
With the implementation of Array-Comparative Geno-
mic Hybridization the diagnostic of WHS patients can now
be better characterized at a molecular level with the estab-
lishment of exact breakpoints, allowing the identiﬁcation of
speciﬁc regions and candidate genes for speciﬁc features
and a better genotype/phenotype correlation.
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Mutations in CoA Synthase cause pontocerebellar
hypoplasia
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Introduction: Pontocerebellar Hypoplasia (PCH) is a het-
erogeneous neurodegenerative disorder with a prenatal
onset. Genes involved in PCH often have a function in
RNA metabolism; defects in mitochondrial function have
also been described. We identiﬁed mutations in the COASY-
gene, encoding Coenzyme A (CoA) synthase, an enzyme
essential in CoA synthesis, in four patients from two
families with prenatal onset microcephaly, PCH and
arthrogryposis.
Methods: Mutations were identiﬁed by whole exome
sequencing. Functional characterization of the mutations
was done by means of RNA analysis, immunoblot and
determination of CoA and acetyl-CoA levels in amniocytes.
Results: In family 1, compound heterozygous mutations
were identiﬁed in COASY: c.1549_1550delAG (p.Ser517-
Profs*61) and c.1486-3C>G. In family 2, all three affected
siblings were homozygous for the c.1486-3C>G mutation.
In both families, the mutations segregated with the pheno-
type. RNA analysis in family 2 showed that the intronic
variant leads to skipping of exon 7 with partial retention of
intron 7, disturbing the reading frame and resulting in a
premature stopcodon. Immunoblot analysis detected no
CoA synthase in ﬁbroblasts of a patient from family 2. In
amniocytes from the patient from family 1, reduced CoA
and acetyl-CoA levels were detected compared to controls.
Conclusions: Partial CoA synthase defects were pre-
viously described as a cause of Neurodegeneration and
Brain Iron Accumulation (NBIA), and here we demonstrate
that loss of function mutations in COASY are associated
with lethal PCH and arthrogryposis. Functional character-
ization conﬁrmed virtually absent CoA synthase protein
levels in ﬁbroblasts and a decrease in CoA and acetyl-CoA
levels in amniocytes.
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Global metabolomic proﬁling unravels metabolite per-
turbations in Rett syndrome
G. Cappuccio1,2, M. Pinelli1,2, M. Alagia1,2, T. Donti3, C.
Bravaccio1, P. Bernardo1, S. H. Elsea3, N. Brunetti-
Pierri1,2
Federico II Univeristy, Naples, Italy, 2Telethon Institute of
Genetics and Medicine, Pozzuoli, Italy, 3Department of
Molecular and Human Genetics, Baylor College of
Medicine, One Baylor Plaza, Houston, TX, United States
Introduction: Rett syndrome is a severe neurodevelop-
mental disorder affecting females with an incidence of 1 in
10,000 caused by loss-of-function mutations in the MECP2
gene encoding the methyl-CpG-binding protein 2. The
pathogenetic mechanisms involved in neurodevelopmental
symptoms and regression of Rett syndrome are not com-
pletely understood. Metabolic alterations are emerging as
important features of Rett syndrome, as loss of function
mutations in squalene epoxidase (SQLE), the rate-limiting
step in cholesterol biosynthesis, were found to ameliorate
symptoms in Mecp2 null mice. Materials and Methods: For
the present study, we performed global metabolome pro-
ﬁling using a semi-quantitative tandem mass spectrometry-
based technique that measures over 700 metabolites on 13
patients with a diagnosis of Rett syndrome conﬁrmed by
MECP2 mutations. Targeted expression and biochemical
analyses were performed on lymphoblast cell lines and
plasma. Results: Metabolomic proﬁling unraveled sig-
niﬁcant biochemical perturbations in nicotinamide-derived
metabolites, sphinganine, and tryptophan-derived mole-
cules, all of which have relevant roles in brain function.
Moreover, we detected higher levels of SQLE and lower
levels lanosterol synthase (LSS), the subsequent step to
SQLE. Interestingly, the expression of both SQLE and LSS
is regulated by HDAC3 which is known to interact with
MECP2. Conclusions: In conclusion, a comprehensive
metabolomic proﬁling of Rett syndrome samples unraveled
perturbations in tryptophan, nicotinamide, and sphingolipid
metabolism. In addition, we conﬁrmed cholesterol bio-
synthesis disruption. Further investigations are required to
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understand the role of such perturbation in the disease
pathogenesis and to investigate whether these metabolites
might be effective disease biomarkers.
G. Cappuccio: None. M. Pinelli: None. M. Alagia:
None. T. Donti: None. C. Bravaccio: None. P. Bernardo:
None. S.H. Elsea: None. N. Brunetti-Pierri: None.
P09.003C
Role of miR-146a in the differentiation and neural
lineage identity determination of human neural stem
cells: relevance for autism spectrum disorders
L. Nguyen1,2, J. Fregeac1,2, C. Bole-Feysot1, P. Nitschke1,
N. Cagnard1, O. Pelle1, L. Colleaux1,2
1INSERM UMR 1163, Imagine Institute, Necker-Enfants
Malades Hospital, Paris, France, 2Paris Descartes -
Sorbonne Paris Cité University, Paris, France
Autism spectrum disorders are a group of neurodevelop-
mental disorders caused by the interaction between genetic,
epigenetic and environmental factors. One of such epige-
netic factors is microRNA (miRNA), which play key roles
in neuronal development and synapse formation. We and
others recently identiﬁed the upregulation of miR-146a as a
common event in various cell types from autistic patients:
olfactory mucosa stem cells, skin ﬁbroblast and lympho-
blastoid cell lines. Here, we showed by Taqman RT-qPCR
that miR-146a is upregulated speciﬁcally in the temporal
lobe of autistic children (age 4–10) and not in adolescents
and adults. To understand its roles in early development, we
generated human H9 neural progenitor stem cells stably
over expressing miR-146a. We demonstrate that, in undif-
ferentiated condition, overexpression of miR-146a has no
effect on the proliferation and apoptotic rate of the cells. By
contrast, in differentiated condition, miR-146a signiﬁcantly
enhances neurite outgrowth and branching and favors dif-
ferentiation into neuronal like TUBIII+ cells. Tran-
scriptomic analyses by RNA-Seq demonstrated that 10% of
the detected transcripts were signiﬁcantly deregulated in
differentiated cells (P<0,05, fold change > 1,5). More
importantly, 16 of 44 detectable markers for different neu-
ronal lineages and layers were affected (DCX, GAD1,
CALB2 and FOXB2 etc), suggesting that miR-146a also
plays a role in neural lineage determination. These results
are consistent with the deregulation of layer formation and
layer-speciﬁc neuronal differentiation observed in brain
cortical samples from autistic patients and give important
clues about the role of miR-146a upregulation in the etiol-
ogy of the disease. Grant references:
16FRM002_9UMF1163, ANR_SAMENTA
0211_EPI_ASD
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Elucidating the spectrum of protein-altering de novo
variants in neurodevelopmental disorders with epilepsy
H. O. Heyne1, the Epilepsy de novo study group, D. Lal2,
J. R. Lemke1
University of Leipzig, Leipzig, Germany, 2Broad Institute of
Harvard and M.I.T., Cambridge, MA, United States
We conducted exome-wide enrichment analyses of protein-
altering de novo variants (DNV) in 7088 published and
unpublished parent-offspring trios of neurodevelopmental
disorders (ND) comprising 2151 patients with epilepsy
(epileptic encephalopathy (EE) or epilepsy comorbid with
developmental delay / autism spectrum disorder / intellec-
tual disability). In patients with ND and epilepsy, we
revealed enrichment in known EE genes, indicating an
overlapping genetic spectrum of EE and ND with epilepsy.
When stratifying the ND cohort for patients with epilepsy,
we identiﬁed signiﬁcant enrichment of DNV in 33 genes,
seven of which with previously limited evidence for disease
association. In the combined cohort of 7088 cases, we
identiﬁed 84 signiﬁcant genes including eleven with pre-
viously no or limited evidence for disease association. We
found that genes involved in synaptic transmission were
more frequently mutated in individuals with epilepsy while
chromatin modiﬁcation was more frequently altered in
individuals without epilepsy. Moreover, we investigated a
potential clinical-diagnostic impact by evaluating 24 com-
mercial and academic sequencing panels designed for ND
with epilepsy. On average 54% of the 33 signiﬁcant epi-
lepsy genes were covered by an individual panel, while
10.5% of the panel genes lacked evidence for disease
association (according to variant-intolerance scores, brain
expression and DNV enrichment). 29.8% of DNV in the
33 signiﬁcant genes were associated with therapeutic con-
sequences with CEBM (Centre for Evidence-Based Medi-
cine) level of evidence of IIb or higher. In summary, we
provide novel insights into the genetic architecture of ND
with epilepsy as well as clinical-diagnostic implications for
this heterogeneous phenotypic spectrum.
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TBCD mutations cause autosomal recessive early
childhood-onset neurodegenerative encephalopathy
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N. Miyake1, T. Chihara2, M. Miura3, H. Shimizu4, A.
Kakita4, N. Matsumoto1
1Yokohama City University Graduate School of Medicine,
Yokohama, Japan, 2Graduate School of Science, Hiroshima
University, Hiroshima, Japan, 3Graduate School of Phar-
maceutical Sciences, The University of Tokyo, Tokyo,
Japan, 4Brain Research Institute, University of Niigata,
Niigata, Japan
Microtubules are essential components of all eukaryotic
cells. They form cylindrical structures composed of rows of
α/β-tubulin heterodimers which are formed with the aid of
tubulin speciﬁc chaperones comprised of ﬁve tubulin fold-
ing co-factors (TBC): TBCA, TBCB, TBCC, TBCD, and
TBCE. Here, we report on four families (two Japanese
families, a Chinese family, and an Israeli family) with
affected siblings showing early onset, progressive diffuse
brain atrophy with regression, postnatal microcephaly,
postnatal growth retardation, muscle weakness/atrophy, and
respiratory failure. Bases on autosomal recessive model, we
identiﬁed biallelic TBCD mutations in eight affected indi-
viduals from the four families by whole exome sequencing.
A total of seven mutations were found: ﬁve missense
mutations, one nonsense, and one splice site mutation
resulting in a frameshift. In vitro experiments revealed the
impaired binding between most mutant TBCD proteins and
ARL2, TBCE, and β-tubulin. The in vivo experiments using
olfactory projection neurons in Drosophila melanogaster
indicated that the TBCD mutations caused loss-of-function.
Furthermore, the autopsied brain from one deceased indi-
vidual showed characteristic neurodegenerative ﬁndings:
cactus and somatic sprouts formation in the residual Pur-
kinje cells in the cerebellum which are also seen in some
diseases associated with mitochondrial impairment. These
ﬁndings might reﬂect structural and metabolic abnormalities
resulting from disrupted mitochondrial transport in neuronal
cells caused by TBCD depletion. Defects of microtubule
formation caused by TBCD mutations may underlie the
pathomechanism of this neurodegenerative encephalopathy.
N. Miyake: None. T. Chihara: None.M. Miura: None.
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Characterizing and quantifying the effect of the recur-
rent copy number variants between BP1-BP2 at chro-
mosome 15q11.2
A. E. Jønch1,2,3, E. Douard4, A. Van Dijck5, F. R. Kooy5,
J. Puechberty6, C. Campbell7, D. Salanville8,9, H. Lefroy10,
D. Genevieve6,11,12, U. Kini10,13, C. Le Caignec14,15, J.
Lespinasse16, A. Skytte17, B. Isidor14, C. Zweier18, J.
Caberg19, C. Brasch-Andersen1, E. Lemyre20, L. B.
Ousager1, S. Jacquemont20
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lier, Montpellier, France, 13The Spires Cleft Centre, John
Radcliffe Hospital, Oxford, United Kingdom, 14CHU
Nantes, Medical Genetics Department, Nantes, France,
15INSERM, UMR1238, Bone sarcoma and remodeling of
calciﬁed tissue, Nantes, France, 16Laboratoire de Génét-
ique Chromosomique, CHU Chambery, Chambery, France,
17Department of Clinical Genetics, Aarhus University
Hospital, Skejby, Aarhus, Denmark, 18Institute of Human
Genetics, Friedrich-Alexander-Universität Erlangen-Nürn-
berg, Erlangen, Germany, 19Department of Human Genet-
ics, University Hospital (CHU) Liège, Liège, Belgium,
20Department of Pediatrics, Sainte Justine Research
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Para ID="Par2430">Introduction: Mild enrichment of the
15q11.2 deletion between breakpoint 1 and 2 has been
reported in neurodevelopmental disorders (OR=2.4),
epilepsy (OR=4.9) and schizophrenia (OR= 1.42). More
than 200 cases have been reported in clinical series leading
some authors to suggest the existence of a microdeletion
syndrome. Our aim was to estimate the contribution of the
15q11.2 deletion and duplication to developmental dis-
orders. Material and Methods: We collected data on 415
deletions and 223 duplication carriers and their non-
carrier relatives. We measured rates of de novo events,
additional genetic changes and symptomatology in carriers
and compared to patients referred for a developmental
disorder using a clinical CGH database. Results: The de
novo rate in 15q11.2 deletion and duplication carriers is
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6.2% (9 of 145; 95% CI: 3.2–11.3) and 2.3% (1 of 44; 95%
CI: 0.4–11.8) respectively. The average frequencies of
additional clinically signiﬁcant CNVs were similar in
carriers of the deletion (55 of 415, 13.3%) and the
duplication (26 of 223,11.7%) respectively. This is equal
to the rate of any clinically signiﬁcant CNVs observed in
probands referred for a CGH array (10.2%). Together with
the low rate of de novo, this suggests a very mild or
negligible contribution of the 15q11.2 deletion and
duplication to the developmental disorders observed in
proband carriers. We are currently investigating weather
the rate of malformations and medical problems is higher in
carriers of the 15q11.2 CNVs than what one would expect
for probands referred for CGH array.
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Improved prediction of genetic predisposition to psy-
chiatric disorders using genomic feature best linear
unbiased prediction models
P. D. Rohde1,2,3, D. Demontis2,3,4, A. D. Børglum2,3,4,
iPSYCH-Broad Consortium, P. Sørensen1
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University, Tjele, Denmark, 2iPSYCH, The Lundbeck
Foundation Initiative for Integrative Psychiatric Research,
Aarhus, Denmark, 3iSEQ, Center for Integrative Sequen-
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Biomedicine, Aarhus University, Aarhus, Denmark
Introduction: Accurate prediction of unobserved pheno-
types from observed genotypes is essential for the success
in predicting disease risk from genotypes. However, the
performance is somewhat limited. Genomic feature best
linear unbiased prediction (GFBLUP) models separate the
total genomic variance into components capturing the var-
iance by a genomic feature (e.g. GO term) and the
remaining genomic variance by differential weighting of the
genetic variants within the two groups. Previously we have
demonstrated (on pigs and fruit ﬂies) increased predictive
ability when the genomic feature is enriched for causal
variants. Here we apply the GFBLUP model to a small
schizophrenia case-control study to test the promise of this
model on psychiatric disorders, and hypothesize that the
performance will be increased when applying the model to a
larger ADHD case-control study if the genomic feature
contains the causal variants.
Materials and Methods: The schizophrenia study con-
sisted of 882 controls and 888 schizophrenia cases geno-
typed for 520,000 SNPs. The ADHD study contained
25,954 controls and 16,663 ADHD cases with 8,4 million
imputed genotypes.
Results: The predictive ability for schizophrenia for the
null model (all SNPs weighted equally) was low (0.07).
Few GO terms did show a tendency of increased predictive
ability; e.g. GO:0008645 had a predictive ability of 0.11
(unadjusted t-test p-value = 7.4×10–5), and explained 9%
of the genomic variance, and 1.5% of the total phenotypic
variance (0.6% for the null model).
Conclusion: The improvement in predictive ability for
schizophrenia was marginal, however, greater improvement
is expected for the larger ADHD data.
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Normal repeat tract of ATXN2 and DMPK genes as
potential modiﬁers of age-at onset in familial amyloid
polyneuropathy
D. Santos1,2, T. Coelho3, M. Alves-Ferreira1,2, J.
Sequeiros1,2,4, D. Mendonça2,5, I. Alonso1,2,4, A. Sousa1,2,
C. Lemos1,2
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Introduction: Familial amyloid polyneuropathy (FAP
ATTRV30M) is a dominant neurological disease, caused
most frequently by a V30M substitution in transthyretin
(TTR) (chr18q12.1) in Portuguese families. Age-at-onset
(AO) varies between 19–82 years, variability also exists
between generations. Unstable oligonucleotide repeats have
been associated with several neurodegenerative diseases.
Our aim was to study the variation of normal repeat length
of 10 such candidate-genes using a family-centred
approach, as possible modiﬁers of AO in Portuguese FAP
364
ATTRV30M families (as shown with other diseases, as
ALS).
Materials and Methods: We analysed 329 patients (128
families). Repeat length (at ATXN1, ATXN2, ATXN3,
ATXN7, HTT, JPH3, ATN1, TBP, DMPK and AR) was
assessed by single and multiplex PCR, using ﬂuorescently-
labeled primers, followed by capillary electrophoresis.
Results were analysed with GeneMapper™ v.4.0 software.
Results: Repeat size at ATXN2 and DMPK was sig-
niﬁcantly associated with AO variation in FAP
ATTRV30M. For ATXN2, the presence of at least one allele
longer than 22 CAGs associated to earlier onset, decreasing
mean AO by 5 years (p=0.002); for DMPK, carrying at
least one allele with longer than 13 CTGs lead to an
increase of 4 years in mean AO (p=0.012). No association
was found for the remaining repeat loci.
Conclusions: Normal repeat length at ATXN2 and
DMPK may modify AO in FAP ATTRV30M, functioning
as a risk or a protective factor. This may be due to their role
in RNA metabolism and as modulators of various cellular
processes, including mitochondrial stress. This may prove
to have implications for genetic counselling.
D. Santos: None. T. Coelho: None. M. Alves-Ferreira:
None. J. Sequeiros: None. D. Mendonça: None. I.
Alonso: None. A. Sousa: None. C. Lemos: None.
P09.010B
Clinical, chromosomal and molecular characterization
of patients with agenesis of the corpus callosum
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Agenesis of the corpus callosum (ACC) is one of the most
frequent brain malformations. Its prevalence is approxi-
mately 0.05–0.7% in general population and 2–3% in
patients with intellectual disability (ID). A genetic origin is
suspected in most cases but the genetic diagnosis is made in
only 30–45% of patients.
To identify genetic causes of ACC, we recruited 183
patients with ACC and ID and 90 patients with ACC but no
ID. All patients were evaluated clinically, cytogenetically
by chromosomal microarray analysis and molecularly by
next generation sequencing (either panel of genes or whole
exome sequencing [WES]).
Among patients with ACC and ID, clinical examination
allowed a diagnosis for 18 patients (yield 10%), whereas
chromosomal imbalances explained the phenotype in 26 of
them (14%). Next, we sequenced 423 genes (associated
with ACC in humans or candidate genes) in 99 patients. We
identiﬁed a pathogenic mutation in 21 patients (21%) in 9
genes. We performed WES in 26 trios and established a
diagnosis in 9 patients (37.5%). Thanks to this combined
approach, we obtained a diagnosis in 40% of patients with
ACC and ID.
In addition, we performed WES in several families with
ACC without ID. This allowed us to report the ﬁrst two
genes responsible for ACC without ID.
Our results show that next generation sequencing
approaches are powerful diagnostic tools for ACC and
conﬁrm the large genetic heterogeneity of this condition.
The identiﬁcation of genes involved in ACC without ID
allows an innovative approach in the prenatal diagnosis of
ACC.
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Modeling early neuropathology in Down syndrome and
APP-associated Alzheimer’s disease using Induced
Pluripotent Stem Cells
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J. Nordlund2, M. Shahsavani3, A. Falk3, N. Dahl1
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Introduction: Early-onset Alzheimer’s disease (AD) may
be caused by rare variants in the gene encoding amyloid
precursor protein (APP) on chromosome 21. Down syn-
drome (DS), owing to trisomy 21 (T21), is associated with a
neuropathology similar to that in AD. Thus, APP is asso-
ciated with early onset dementia through either increased
gene dosage in T21 or through rare structural gene variants
in rare cases of AD. Methods: In search for shared neu-
ropathological mechanisms we established induced plur-
ipotent stem cells (iPSC) from patients with DS and T21 as
well as from AD associated with the APP variant p.V717I.
iPSC were differentiated into neuroepithelial stem cells and
neuronal cells together with WT controls. After four weeks
of differentiation, we generated transcriptomes using whole
RNA-sequencing (Illumina HiSeq). Results: Pathway ana-
lysis of AD derived cells conﬁrmed differentially expressed
genes in pathways for glutamatergic synaptic function and
insulin secretion. Analysis of DS cells revealed dysregula-
tions in extracellular matrix-receptor interaction and pro-
teoglycan pathways. Shared dysregulated pathways in AD
and DS include focal adhesion, previously associated with
Aβ signaling and cell death in AD. We identiﬁed 347 dif-
ferentially expressed transcripts that were shared in neuro-
nal cells derived from AD and DS patients, e.g. the AD
associated genes A2M and CYP26A1. Conclusion: Our data
indicate that several genes previously implicated in the
etiology for AD is also dysregulated in neuronal cells
generated from individuals with DS. Identiﬁcation of shared
pathways and mechanisms in these two disorders may
provide further clues to the neuropathogenesis in early onset
AD.
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Effect of sodium butyrate on some alternative splicing
genes and bace1 isoforms in SH-SY5Y cell line
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Pazarbaşı
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Alzheimer Disease (AD) is caused by many risk factors.
Alternative splicing of BACE1 pre-mRNA affects AD. We
aimed to investigated effect of sodium butyrate (NaB) on
BACE1 isoform such as BACE1/501, BACE1/457 and
BACE1/432 and alternative splicing factors such as hnRNP
H, U2AF35, U2AF65, SRSF1, SRSF2, SRSF5 and SRSF6.
SH-SY5Y cells was treated 1 mM and 5 mM NaB con-
centration, histone deacetylase inhibitor. According to
Mann Whitney U-test, it hasn't been found signiﬁcant dif-
ference between two doses of NaB. (p>0,05) Both 1mM
and 5mM NaB has increased BACE1/501 expression to
control group. While 1mM NaB has decreased expression
of BACE1/457, 5 mM NaB has increased expression of
BACE1/457. 5 mM sodium butyrate has increased expres-
sion of BACE1/432 to control group. Although it wasn’t
obtained statistically signiﬁcant results in expression of
hnRNP H, U1AF35, U2AF65, SRSF1, SRSF2, SRSF5 and
SRSF6 genes, it was observed that U2AF65 gene has a
relative increase in expression of U2AF35 and SRSF6 in 1
mM NaB treatment. Both in 1 mM and 5 mM NaB,
U2AF65 gene has a important decrease In 5 mM NaB, it
was determined relative decrease from %35 to %80 in
average expression proﬁle of SRSF6, SRSF1, SRSF2,
SRSF5 and U2AF65 genes, respectively. It has referred that
contribution of U2AF65 gene in increase of BACE1/457
and BACE1/432 expression is more than the others and
increase of NaB concentration cause U2AF65 gene to bind
G-quadruplex motif in BACE1 exon 3 rather than hnRNP
H. Supported by CUBAP/TSA-2015-5311.
Ü.H. Lüleyap: None. G. Ay: None. G. Cömertpay:
None. D. Alptekin: None. A. Pazarbaşı: None.
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Genomic variants in obesity-related genes are associated
with sporadic amyotrophic lateral sclerosis in Greek
patients
K. Mitropoulos1, E. Merkouri-Papadima2, F. Akcimen3,
A. N. Basak3, A. Loizedda4, S. Orrù4, C. Mizzi2, R.
Drmanac5, T. Katsila2, G. P. Patrinos2
University of Athens School of Medicine, Athens, Greece,
2University of Patras Faculty Health Sciences Department
of Pharmacy, Patras, Greece, 3Bogazici University,
Department of Molecular Biology and Genetics, Istanbul,
Turkey, 4University of Cagliari, Department of Medical
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Amyotrophic lateral sclerosis (ALS) is one of the most
common forms of motor neuron disease. ALS is a neuro-
degenerative disorder that affects the upper and lower motor
neurons in the motor cortex, brain stem, and spinal cord and
leads to death within 3–5 years. Approximately 90% of the
ALS patients suffer from sporadic ALS, having both an
environmental etiology and a strong genetic component.
Today, there is no effective treatment or diagnostic means
for ALS patients. We have performed whole-genome
sequencing of 10 ALS patients and 7 healthy (non-ALS)
individuals of Greek origin (110x sequencing depth).
Extensive data analysis identiﬁed 174 genomic variants that
were present in all 10 ALS patients but none of the 7 non-
ALS ethnically matched controls. Replication of genotyping
in 27 sporadic ALS patients and 50 ethnically matched
control individuals showed that FTO (rs2892469, p=0.005;
rs17217144, p<0.001; rs1861869, p=0.003) and TBC1D1
(rs6850200, p=0.017) genomic variants are positively
associated with the disease phenotype. These variants did
not reach statistical signiﬁcance, when comparing 148 and
124 sporadic ALS patients of Turkish and Italian descent,
respectively, against 74 and 87 ethnically matched controls.
Both proteins are associated with obesity. FTO is a fat mass
and obesity-associated protein. TBC1D1 has been identiﬁed
as a regulator of insulin-dependent glucose transport and
variants in the TBC1D1 gene were linked to obesity. This is
the ﬁrst study that reveals an association between obesity-
related genes and ALS pathobiology, which, however,
should be considered as a pilot study due to the small
sample size.
K. Mitropoulos: None. E. Merkouri-Papadima: None.
F. Akcimen: None. A.N. Basak: None. A. Loizedda:
None. S. Orrù: None. C. Mizzi: None. R. Drmanac: A.
Employment (full or part-time); Modest; Complete Geno-
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Differential expression of several miRNAs and host
genes AATK and DNM2 in leukocytes of sporadic ALS
patients
D. Glavac1, K. Vrabec1, E. Boštjančič1, B. Koritnik2, J.
Zidar2, B. Rogelj3,4, M. Ravnik-Glavač1,5
1Department of Molecular Genetics, Institute of Pathology,
Faculty of Medicine, University of Ljubljana, Ljubljana,
Slovenia, 2Institute of Clinical Neurophysiology, Division of
Neurology, University Medical Centre Ljubljana, Ljubl-
jana, Slovenia, 3Department of Biotechnology, Joef Štefan
Institute, Ljubljana, Slovenia, 4Biomedical Research Insti-
tute, Ljubljana, Slovenia, 5Institute of Biochemistry, Ljubl-
jana, Slovenia
Introduction: Amyotrophic lateral sclerosis (ALS) is a
progressive, fatal neurodegenerative disorder. Multiple
interactions among genetic components, environmental
inﬂuences and epigenetic mechanisms may contribute to
disease development. Materials and Methods: we evaluated
differential expression of ten miRNAs, miR-9, miR-338,
miR-638, miR-663a, miR-124a, miR-143, miR-451a, miR-
132, miR-206 and let-7b and three miRNAs host genes
C1orf61 (miR-9), AATK (miR-338) and DNM2 (miR-638)
in leukocyte samples of 84 patients with ALS and 27
controls. Results: we observed most homogeneous and
differential dysregulation across our patients’ cohort for
miR-206, miR-124a, miR-143-3p, miR-638 and miR-451.
No signiﬁcant differences were observed between ALS
patients with or without C9orf72 expansion. We also
detected signiﬁcant down-regulation of AAKT and DNM2
genes and thus for the ﬁrst time connected them with ALS
cases. Reduced expression of AAKT could be at least partly
explained by observed methylation of its promoter. Con-
clusions: we have detected differential expression of 10
miRNAs involved in ALS pathology in leukocyte samples
of patients with sporadic form of ALS. Seven of these
miRNAs have not been previously investigated in periph-
eral blood leukocytes. We observed most homogeneous and
differential dysregulation across our patients’ cohort for
miR-206, miR-124a, miR-143-3p, miR-638 and miR-451.
Our ﬁnding places these ﬁve miRNAs among miRNAs that
are worth of additional research in leukocytes of larger
cohorts from different populations in order to prove their
potential as ALS disease biomarkers and therapeutic targets.
In addition in most recent studies reported the connection
between AATK and frontotemporal dementia (FTD) and
DNM2 and hereditary spastic paraplegia (HSP).
D. Glavac: None. K. Vrabec: None. E. Botjančič:
None. B. Koritnik: None. J. Zidar: None. B. Rogelj:
None. M. Ravnik-Glavač: None.
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Effects of asenapine and paliperidone on cognition and
locomotion: altered gen expression levels of BDNF and
CREB in the hippocampus of mice
e. gumuslu1, o. mutlu2, g. ulak2, f. akar2, f. erden2
kocaeli university medical genetics department, kocaeli,
Turkey, 2kocaeli university medical pharmacology depart-
ment, kocaeli, Turkey
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Introduction: One of the major symptoms of schizophrenia
is cognitive deﬁcits and may be further aggravated by
antipsychotic treatments. Asenapine and paliperidon two
newer atypical antipsychotics are used frequently in clinics.
This study aimed to investigate the effects of asenapine and
paliperidone on emotional memory and locomotion in naive
mice, using passive avoidance (PA) and open ﬁeld tests.
Brain-derived neurotrophic factor(BDNF) and cyclic ade-
nosine monophosphate (cAMP) response element binding
protein(CREB) regulates cell survival, neurogenesis, neu-
ronal morphology and neuroplasticity. Increased levels of
BDNF are associated with improved learning and memory.
Materials and methods: Mice were treated with asenapine
(0.05, 0.075 mg/kg) and paliperidon (0.25, 0.50 mg/kg) for
15 days and drugs were also administered intraperitoneally
60 min before the tests. Effects of drugs on BDNF and
CREB mRNA levels in the hippocampus of mice were
determined using RT-PCR.
Results: In the PA test, there was no signiﬁcant differ-
ence between the ﬁrst day latency of the animals. Retention
latency signiﬁcantly decreased in asenapine 0.075 mg/kg
(p<0.01) and paliperidon (0.25,0.50 mg/kg) (p<0.01)
groups. In open ﬁeld test, both asenapine (0.075 mg/kg) and
paliperidon (0.5 mg/kg) did not signiﬁcantly alter total
distance moved and speed of the animals (p>0.05). Ase-
napine and paliperidon increased the expression of BDNF
and CREB in the hippocampus of naive mice.
Conclusion: Asenapine and paliperidone disturb memory
when chronically administered while do not alter the loco-
motion of the animals and had slightly enhancing effect on
BDNF expression levels associated with enhanced expres-
sion of CREB.
E. gumuslu: None. O. mutlu: None. G. ulak: None. F.
akar: None. F. erden: None.
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Autosomal recessively ataxia with oculomotor apraxia
type 2 in two Bulgarian patients - case report
A. V. Kirov1, T. Todorov2, T. Chamova3, A. Todorova1,2, I.
Tournev3,4
1Independent Medico-Diagnostic Laboratory Genome Cen-
tre Bulgaria, Soﬁa, Bulgaria, 2Genetic Medico-Diagnostic
Laboratory “Genica”, Soﬁa, Bulgaria, 3Clinic of Nervous
Diseases, UMBAL Aleksandrovska, Department of Neurol-
ogy, Medical University Soﬁa, Soﬁa, Bulgaria, 4Department
for cognitive science and psychology, New Bulgarian
University, Soﬁa, Bulgaria
The autosomal recessively ataxia with oculomotor apraxia,
type 2 (AOA2) is a neurodegenerative disorder
characterized by juvenile or adolescent age of onset, gait
ataxia, cerebellar atrophy, axonal sensorimotor neuropathy,
oculomotor apraxia, and elevated serum AFP levels. It is
caused by pathogenic genetic variants in the senataxin
(SETX) gene.
Here we report two unrelated patients with mutations in
the SETX gene. Both of them have very similar clinical
features of AOA2 and common brain MRI pathological
ﬁndings. Cerebellar atrophy, axonal sensorimotor neuro-
pathy and oculomotor apraxia are presented.
The SETX gene was screened for the pathogenic disease
causing variants by Sanger sequencing and MLPA analysis.
The molecular genetic testing revealed compound het-
erozygous SETX variants in both cases. The ﬁrst patient was
found to be compound heterozygous for novel splice site
pathogenic variant c.6106+1G>T and missense one
c.5825T>C, (p.Ile1942Thr). The second patient was a
compound heterozygous carrier of the same missense var-
iant c.5825T>C and deletion of exon 7: c.719-?_838+?del.
Repetitive genetic elements account for 47.5% of the
entire SETX gene explaining the higher possibility for
deletions/duplications. In the present study we detected one
deletion and 3 point mutations, being more prevalent in our
sample. The missense mutation p.Ile1942Thr was detected
2 times in unrelated patients. It is interesting to mention that
one of the patients is from Turkish Gipsy origin, while the
second one is from Bulgarian origin. This variant could be
common in Balkan region.
A.V. Kirov: None. T. Todorov: None. T. Chamova:
None. A. Todorova: None. I. Tournev: None.
P09.017A
Whole exome sequencing identiﬁes novel candidate
genes involved in Asperger syndrome
K. Poirier1, B. Delobel2, B. Lenne2, J. Nectoux1, F.
Letourneur3, P. Billuart4, T. Bienvenu5
Institut Cochin, Inserm U1016, CNRS (UMR8104), Paris,
France, 2Centre de Génétique Chromosomique GH de
l'Institut Catholique de Lille - Hôpital Saint Vincent de
Paul, Lille, France, 3Inserm, U1016, Institut Cochin, Paris,
France, Cnrs, UMR8104, Paris, France, 4Inserm, U1016,
Institut Cochin, Cnrs, UMR8104, Paris, France, 5Univer-
sité Paris Descartes, Institut Cochin, Inserm U1016, CNRS
(UMR8104), Paris, France
Autism Spectrum Disorders (ASD) are neurodevelopmental
conditions characterized by difﬁculties in communication
and social interaction, alongside unusually repetitive beha-
viours and narrow interests. Asperger Syndrome (AS) is one
subgroup of ASD and differs from classic autism since AS
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patients present with no language or general cognitive
delay. Despite the clear genetic component of ASD and AS,
extreme genetic heterogeneity has made difﬁcult the iden-
tiﬁcation of causative genes. We performed whole-exome
sequencing in nine unrelated individuals (8 males and 1
female) with AS. Variant ﬁltering for functional, damaging
rare variants (MAF<0.1%) was performed. Parallel
sequencing of their parents failed to identify potential de
novo variants in AS probands. However, we found seven
potential variants in X-chromosome genes that were pre-
viously associated with non-syndromic ASD and/or intel-
lectual disability. Potential damaging variants identiﬁed in
these AS male patients were: c.1117C>T (p.R373C) in
UPF3B (12/87660 in ExAC), c.306T>C (p.C1023R) in
FRMPD4 (9/87549 in ExAC), c.5472G>T (p.M1824I) in
HCFC1 (not described in ExAC), c.145A>C (p.N49H) in
Cxorf36/DIA1R (not described in ExAC), c.2270G>A (p.
K757R) in OGT (not described in ExAC), c.1772C>A (p.
T591N) in ZNF182 (not described in ExAC) and
c.4808C>T (p.T1603M) in NHS (5/87571 in ExAC).
Functional analysis of these variants will be carried out to
determine whether these novel variants have a deleterious
effect on protein expression and function. This study
identiﬁed novel candidate genes involved in Asperger
syndrome.
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Phenotype characterization of the SCA28 knockin
mouse model and derived embryonic ﬁbroblasts
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SpinoCerebellar Ataxia type 28 (SCA28, OMIM#610246)
is a rare form of autosomal dominant ataxia, accounting for
~1.5% of the European cases. The causative gene, AFG3L2,
encodes for a mitochondrial protein that assembles into
homo- or hetero-hexamers with paraplegin (SPG7) to
compose the matrix-ATPase Associated with various cel-
lular Activities protease, a large proteolytic complex with
crucial roles in mitochondria. We generated a knockin (KI)
mouse model harboring the p.Met665Arg mutation in
Afg3l2 peptidase domain, reported in patients with early
onset of the disease. Afg3l2KI/KI (KI-ho) were embryonically
lethal, whereas Afg3l2KI/+ mice (KI-hz) were viable and
developed a late-onset ataxia, starting at 18 months of age.
Morphological analysis revealed preserved cytoarchitecture
of cerebellar lobules, with unaltered thickness of the
molecular and granular layers and a conserved number of
Purkinje cells (PC). We evaluated mitochondrial morphol-
ogy and function, studying both homo- and heterozygous
Mouse Embryonic Fibroblasts (MEF). We showed mito-
chondrial dynamics impairment, detected as the complete
loss of long Opa1 isoforms in KI-ho MEF, with a frag-
mented mitochondrial network. A similar imbalance of
Opa1 isoforms was present in cerebellum and brain
homogenates from KI-hz mice. Bioenergetics analysis
revealed a 25% reduction of Complex III activity in KI-ho
(P<0.05), detected by spectrophotometric analysis of the
respiratory chain. KI-ho showed reduced mitochondrial
translation efﬁciency, supporting decreased protein synth-
esis. These results suggest that mutations hitting the pepti-
dase domain negatively impact on m-AAA complex
function, probably acting as hypomorphic on AFG3L2
chaperone function or quality control function. This work is
supported by Italian Telethon Foundation Grant
GGP12217.
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Clinical features and genotype-phenotype correlations
in variant Ataxia-Telangiectasia
K. R. Schon1, N. van Os2, N. Oscroft3, H. Baxendale3, L.
Bottolo4,5, B. van de Warrenburg2, C. Weemaes6, M.
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Background Ataxia-Telangiectasia (A-T) is characterised
by neurological, immune and respiratory complications.
Individuals with residual ATM kinase activity have a milder
form of the disorder, but previously reported cohorts are
small.
Methods Patients were identiﬁed through the UK
Ataxia-Telangiectasia Service and the Nijmegen Medical
Centre, Netherlands and were classiﬁed as having variant
A-T based on genotype (mutations which allow retained
ATM kinase activity, or mutations in the initiator methio-
nine codon).
Results A total of 49 adults from 41 families (19 male/30
female, mean age 40 years, range 20–58) were studied.
Symptom onset was before age ﬁve in 27/49 (55%) patients.
Thirty-seven patients use a wheelchair with median age at
ﬁrst wheelchair use 26.5 years (range 8–51). Conjunctival
telangiectasia were present in 29/46 assessed (63%). Alpha-
fetoprotein levels were raised in 36/39 (92%).
Eleven patients had malignancies (4 breast cancers,
dermatoﬁbrosarcoma protuberans, neuroendocrine tumour,
CML, CLL, ALL, ectopic pituitary tumour and pancreatic
cancer). Four had monoclonal gammopathy of unknown
signiﬁcance. No individuals had severe respiratory or
immunological complications. Seven women from ﬁve
families had offspring.
Individuals with missense mutations producing mutant
protein with retained kinase activity had milder disease
compared to the rest of the cohort, in terms of overall
severity (p= 0.00167), progression (p= 0.00198), A-T
NEST score (p = 0.0492), age at ﬁrst wheelchair use (p=
4.05×10−05) and eye movements (p =0.000414).
Conclusion This is the largest study to date of variant A-
T. It demonstrates a clear genotype-phenotype correlation
and provides new prognostic information for individuals
with variant A-T.
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ATXN3L: may an assumed pseudogene compensate
partial loss-of-function of normal ATXN3 in Machado-
Joseph disease (MJD/SCA3)?
I. P. D. Costa1,2, A. M. Lopes1,2, S. Seixas1,2, J.
Sequeiros1,3,4, A. Amorim1,2,5, S. Martins1,2
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The Machado-Joseph disease (MJD) subfamily of deubi-
quitinases comprises ataxin-3 (ATXN3), ataxin-3 like
(ATXN3L) and Josephin domain-containing proteins 1
(JOSD1) and 2 (JOSD2). Much attention has been given to
ATXN3 after the identiﬁcation of an exonic (CAG)n,
responsible for the autosomal dominant neurodegenerative
MJD when encoding a polyQ tract above 61 glutamines.
The other members of this protease family are poorly
explored; in particular, ATXN3L, remained in the shadow
under the assumption that it would be a non-functional
sequence due to its lack of introns. The partial loss-of-
function mechanism suggested for MJD pathogenesis,
together with the proved deubiquitinating activity of all four
MJD family members led us to hypothesize that they may
exert a neuroprotective role in MJD.
We carried out an analysis of ATXN3L, JOSD1 and
JOSD2 expression patterns in a panel of 23 human tissues
from healthy individuals. The evolutionary conserved
paralogue of ATXN3 - ATXN3L, is transcribed in testis,
placenta and brain. Interestingly, ATXN3L transcription
seems to differ across brain regions, being highly expressed
in the cortex, followed by substantia nigra and residually in
the cerebellum. In contrast, ATXN3, JOSD1 and JOSD2
were found to be ubiquitously expressed. The observation
of distinct ATXN3L expression levels in brain regions dif-
ferently affected by MJD may be relevant for the observed
large clinical variability not explained by the (CAG)n
expansion size. Next, we will attempt to detect ATXN3L
protein in brain extracts of healthy individuals and assess
expression levels of JOSD1 and JOSD2 in patients with
different age-at-onset using blood samples.
I.P.D. Costa: None. A.M. Lopes: None. S. Seixas:
None. J. Sequeiros: None. A. Amorim: None. S. Martins:
None.
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Structural Variation of Chromosomes in Autism Spec-
trum Disorders
K. Łacna1, M. Piechota1, N. Kochalska1, K. Milanowska1,
A. Sowinska-Seidler2, A. Jamsheer1,2, M. Badura-
Stronka1,2, G. Koczyk1,3, D. Popiel1, A. Dawidziuk1, A.
Latos-Bielenska1,2
Centers of Medical Genetics Genesis, Poznan, Poland,
2Department of Medical Genetics, Poznan University of
Medical Sciences, Poznan, Poland, 3Institute of Plant
Genetics, Polish Academy of Sciences, Poznań, Poland
Autism spectrum disorders (ASDs) are characterised by
impaired socialization, reduced communication, and
restricted, repetitive, or stereotyped activities and interests.
The inﬂuence of genetic factors on the severity of the dis-
order is not well characterised - due to the considerable
clinical and genetic heterogeneity of the ASD cases. The
unbalanced copy number variations (CNVs) of chromoso-
mal regions has been identiﬁed in some, but not all, indi-
viduals with autism spectrum disorders. Array comparative
genomic hybridization (aCGH) is a high resolution mole-
cular cytogenetic tool which enables large scale detection
and characterisation of these variants.
The aim of this work was to summarize the positive
results of aCGH tests of patients with clinical symptoms of
ASD.
The presence of CNVs was tested in ADS patients (age
1–31 y.o.) using aCGH method and NimbleGene (2×135k)
or Agilent (SurePrint G3 CGH ISCA v2 8×60K) microarray
kits.
Deletions or duplication were found in 40 ADS cases, in
most chromosome pairs with observed size of the CNVs
affected region ranging from 102kb to 29Mb. Most of the
changes encompassed genes with known pathogenic CNVs,
with few regions containing alterations of unknown sig-
niﬁcance. In 2 cases more than one variation was
uncovered.
Our results have conﬁrmed both the genetic hetero-
geneity of the ASDs patients and the capability of aCGH
microarrays in quickly characterising the underlying varia-
tion of chromosome structure.
The chromosome microarrays are now a ﬁrst-tiered
genetic investigation for many conditions, with scope and
ease of use exceeding conventional cytogenetics or testing
of the individual regions of the genes.
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Interest of searching dysmorphic features in Autism
Spectrum Disorder: Comparison of clinical geneticists
and Face2Gene photos analyses
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Background: Autism Spectrum Disorder (ASD) is deﬁned
according to DSM-5 and ICD-10 criteria as early social
communication impairments and repetitive/restrictive
behaviors or interests. Geneticists have advanced current
knowledge on genetic syndromes associated with ASD.
Clinical genetic examination searching for dysmorphic
features and malformations is a very important step towards
the identiﬁcation of genetic disorders associated with ASD.
Objective and Methods: to compare the etiological genetic
hypotheses stated by clinical geneticists trained in dys-
morphology to the ones resulting from the software pro-
gram Face2Gene based on biometric analyses and
algorithms. Clinical geneticists and Face2Gene analyses
were both performed on the same facial photos of 79 chil-
dren and adolescents with ASD and intellectual disability.
Results: The qualitative variable of "clinical dysmorphy”
observed by the geneticists was signiﬁcantly and
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moderately correlated with the qualitative variable of
"Face2Gene dysmorphy" (Phi coefﬁcient = 0.35, p =
0.0039). The inter-judge agreement represented by the
Cronbach's Alpha coefﬁcient was 0.51. Furthermore, there
was no signiﬁcant correlations between dysmorphism
scores and autism severity ratings based on the ADOS
(current severity), ADI-R past time (period of life from 4 to
5 years old), or ADI-R present time.Conclusion: this study
highlights the need to conduct systematically clinical
genetic examination searching for known genetic disorders
for all individuals with ASD. Biometric analysis software
can provide a helpful additional method, either used after
clinical genetic evaluation to complete the diagnostic
strategy of the geneticist, or used before clinical evaluation
to sensitize the families to the interest of clinical genetic
examination in ASD.
S. Tordjman: None. C. Robert: None. N. Fleischer:
None. C. Baumann: None. L. Burglen: None. D. Cohen:
None. D. Héron: None. N. Pichard: None. A. Verloes:
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Novel PAK3 mutation causing X-linked autism and
mental retardation
Y. Yogev1, G. Meiri2, Y. Perez1, R. Kadir1, O. S. Birk1
Ben-Gurion University of the Negev, Be'er Sheva, Israel,
2Soroka University Medical Center, Be'er Sheva, Israel
A Bedouin Israeli kindred presented with a phenotype of
autism and profound intellectual disability, affecting males
of several generations. Linkage analysis (750K SNP arrays)
of 8 family members identiﬁed two possible disease-
associated loci, on chromosomes 4 and X. Whole exome
sequencing (WES) data of an affected individual were
analyzed and ﬁltered for known benign variants within
these two loci, using our in-house databases along with
open access databases (1000 genomes, NHLBI ESP, ExAC
etc.). Of the variants identiﬁed, only a single variant seg-
regated as expected within the kindred and was not found in
100 ethnically-matched controls: a heterozygous c.212C>G
missense mutation in PAK3 within the Xq23 locus, result-
ing in a p.S71C substitution (LOD score 5.08). In-silico
analysis of the novel variant showed that it is likely to have
a deleterious effect on the mature protein. Mutations in
PAK3 were previously described as causative for X-linked
intellectual disability. Our data implicate this novel PAK3
mutation as the cause for X-linked intellectual disability
with bona-ﬁde autism. This ﬁnding correlates well with the
known function of PAK3 as a key regulator of synapse
formation.
Y. Yogev: None. G. Meiri: None. Y. Perez: None. R.
Kadir: None. O.S. Birk: None.
P09.025A
Ras-like without CAAX 2 (RIT2): a susceptibility gene
for autism spectrum disorder
T. Mohammad, A. Sayad, R. Noroozi
Shahid Beheshti University of Medical Sciences, Tehran,
Iran, Islamic Republic of
Ras-like without CAAX2 (RIT2) which encodes a GTP-
binding protein has recently been reported as a new sus-
ceptibility gene for Autism Spectrum Disorders (ASD) in a
genome-wide association study. Since the gene is suggested
to be involved in the pathogenesis of different neurological
diseases, we investigated the association of two single
nucleotide polymorphisms (SNP) rs16976358 and
rs4130047 of this gene with ASD in Iranian patients. A total
of 1004 individuals, comprising 532 ASD cases and 472
healthy subjects participated in this study. Allele frequency
analyses showed signiﬁcant over-presentation of
rs16976358-C allele in cases versus controls (P<0.0001). In
addition, rs16976358 CC genotype (OR (95% CI) =3.57
(1.72–7.69) and P<0.0001) and rs4130047 CC genotype
(OR (95% CI) =0.64(0.43–0.97) and P= 0.035) were
associated with ASD in recessive inheritance model.
Besides, haplotype analysis demonstrated an association
between the C/T haplotype block (rs16976358/rs4130047)
and ASD (OR (95%CI) = 0.44 (0.31 - 0.62), P<0.0001).
Altogether, our ﬁndings provided additional conﬁrmation
for the RIT2 gene participation in ASD risk and suggested
the rs16976358 variant as a possible genetic risk factor for
this disorder.
T. Mohammad: None. A. Sayad: None. R. Noroozi:
None.
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Trancriptional regulation of the ASD gene Rbfox1
S. Casanovas1,2, S. Schweiger1,2, J. Winter1,2
Institute of Human Genetics, University Medical Centre of
the Johannes Gutenberg, University Mainz, Mainz, Ger-
many, 2Focus Program Translational Neurosciences (FTN)
of the Johannes Gutenberg University, Mainz, Germany
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Autism spectrum disorders (ASD) are neurodevelopmental,
heterogeneous disorders that occur in 1 of 150 children.
Although it is known that ASD have a strong genetic basis
only few causative genes have been identiﬁed.
The RBFOX1 gene encodes an RNA-binding protein that
regulates pre-mRNA splicing events in speciﬁc cell types
including neurons. The RBFOX1 gene, which is located on
chromosome 16p13.2, contains a large noncoding part at the
5'end with at least four alternative promoters driving
expression of alternative RBFOX1 transcript isoforms that
differ in their 5'UTR exons. Rare copy number variants
(CNVs) in the 5' noncoding part of the gene have been
found in patients with several neurodevelopmental disorders
including ASD. The detected CNVs likely interfere with the
transcriptional regulation of speciﬁc RBFOX1 transcript
isoforms. However, as the transcriptional regulation of the
RBFOX1 gene has not been studied so far the pathogenic
potential of these CNVs are still unclear.
In this project, we have been able to demonstrate that the
expression of Rbfox1 in the embryonic and adult brain of
the mouse is mainly driven from two out of the four alter-
native promoter regions which are conserved in humans.
We have further identiﬁed transcription factors that bind to
sequences in either the ﬁrst or the second of these two
promoters and drive Rbfox1 expression in cortical neurons.
At the moment we are carrying out RNAi experiments to
elucidate how the knockdown of speciﬁc transcription fac-
tors inﬂuences expression of all Rbfox1 transcripts as well
as of the speciﬁc Rbfox1 transcript isoforms.
S. Casanovas: None. S. Schweiger: None. J. Winter:
None.
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Resequencing study of ﬁve microRNAs suggests an
involvement of MIR2113 and MIR499 in the develop-
ment of bipolar disorder
A. J. Forstner1,2,3, A. Verhaert2,4, A. Maaser2,4, N.
Fricker2,4, J. Strohmaier5, F. Degenhardt2,4, F. Streit5, S.
Fischer1, S. Herms1,2,4, P. Hoffmann1,2,4, M. Rietschel5, G.
Schratt6, S. Cichon1,2,7, M. M. Nöthen2,4
1Human Genomics Research Group, Department of Bio-
medicine, University of Basel, Basel, Switzerland, 2Institute
of Human Genetics, University of Bonn School of Medicine
& University Hospital Bonn, Bonn, Germany, 3Department
of Psychiatry (UPK), University of Basel, Basel, Switzer-
land, 4Department of Genomics, Life & Brain Center,
University of Bonn, Bonn, Germany, 5Department of
Genetic Epidemiology in Psychiatry, Central Institute of
Mental Health, Medical Faculty Mannheim/University of
Heidelberg, Mannheim, Germany, 6Institute of
Physiological Chemistry, Philipps-University Marburg,
Marburg, Germany, 7Institute of Medical Genetics and
Pathology, University Hospital Basel, Basel, Switzerland
Bipolar disorder (BD) is a severe and highly heritable
neuropsychiatric disorder with a lifetime prevalence of 1%.
Molecular genetic studies have identiﬁed the ﬁrst BD sus-
ceptibility genes. However, the disease pathways remain
largely unknown. Accumulating evidence suggests that
microRNAs, a class of small non-coding RNAs, contribute
to basic mechanisms underlying brain development and
plasticity, suggesting their possible involvement in the
pathogenesis of several psychiatric disorders, including BD.
The most promising candidate microRNAs comprise
MIR499a, MIR708, MIR1908 (Forstner et al., 2015),
MIR137 (Strazisar et al., 2014), and MIR2113 at a genome-
wide signiﬁcant BD locus on chromosome 6 (Mühleisen
et al., 2014).
The aim of the present study was to determine whether
rare variants within these ﬁve candidate microRNAs con-
tribute to the development of BD. For this purpose, we
performed Sanger sequencing of 1,000 BD patients and
1,000 sex-matched healthy controls, all of German origin.
We identiﬁed seven rare variants (minor allele fre-
quency<1%) within the premature microRNAs 2113 and
499a. These include a rare point mutation (rs140486571) in
MIR499a which was detected in nine BD patients and ﬁve
controls (P=0.297). No rare variants were detected in the
premature microRNAs 137, 708 and 1908. Functional
analyses in HEK293 cells indicated that rs140486571
impairs pri-miR-499a processing. The investigation of
rs140486571 in additional samples of BD patients and
controls is currently underway and results will be presented.
Further research is warranted to elucidate the precise
involvement of the implicated microRNAs and their
downstream pathways in BD. AJ.Forstner and A.Verhaert
contributed equally to this work.
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Exome sequencing of multiply affected bipolar disorder
families and follow-up resequencing implicate rare
variants in neuronal genes contributing to disease
etiology
A. Maaser1,2, J. Strohmaier3, K. U. Ludwig1,2, F.
Degenhardt1,2, F. Streit3, L. M. Schenk1,2, A. C. Koller1,2,
S. B. Fischer4, H. Thiele5, P. Nürnberg5, J. Guzmán-
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Flores10, F. J. Cabaleiro Fabeiro11, F. del Río Noriega12,
F. Pérez Pérez13, J. Haro González14, F. Rivas6, F.
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ogy, Department of Neurology, Goethe University Hospital,
Frankfurt am Main, Germany, 9Isar Amper Klinikum
München Ost, kbo, Haar, Germany, 10University Hospital
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Bipolar disorder (BD) is a severe and highly heritable
psychiatric disorder affecting about 1% of the world’s
population. The disease is characterized by recurrent epi-
sodes of mania and depression.
As the cumulative impact of common alleles may only
explain ~38% of the phenotypic variance for BD, rare
variants of high penetrance have been suggested to con-
tribute to BD susceptibility.
In this study, we performed whole-exome sequencing in
226 individuals of 68 large multiplex BD families of Eur-
opean origin. We ﬁltered for rare (minor allele fre-
quency<0.1%), nonsynonymous, potentially functional and
segregating variants.
We identiﬁed 1214 variants implicating 1122 different
genes. Gene enrichment analysis of 294 genes that were
among the 20% most “intolerant” genes showed a sig-
niﬁcant enrichment for 18 pathways (p<0.001) including
neuron projection and cell-adhesion.
For follow up analyses, we prioritized genes that were
either found in at least two unrelated families in the present
study or previously reported in next-generation sequencing
or GWAS studies of BD. In addition, we enclosed genes
that were predominantly driving the signiﬁcant pathways in
the above-mentioned gene enrichment analysis.
The 42 most promising genes are currently being fol-
lowed up by resequencing in larger cohorts of 2500 inde-
pendent BD cases and 2500 controls of European ancestry
using the single molecule molecular inversion probes
technology. The candidate genes include SYNE1, which is a
genome-wide signiﬁcant risk gene for BD.
Our preliminary results suggest that rare and highly
penetrant variants in neuronal and cell-adhesion genes
contribute to BD etiology.
Grant: BMBF IntegraMent.
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Polygenic burden analysis of longitudinal clusters of
psychological features in a cross-diagnostic group of
individuals with severe mental illness
E. C. Schulte1,2, I. Kondofersky3, M. Budde1, K. Adorjan1,
F. Aldinger1, H. Anderson-Schmidt4, T. Andlauer5, K.
Gade4, U. Heilbronner1, J. Kalman1, S. Papiol1, F. J.
Theis3, P. Falkai2, N. S. Mueller3, T. G. Schulze1
1Institute for Psychiatric Phenomics and Genetics, Ludwig
Maximilian Universität München, Munich, Germany,
2Department of Psychiatry, Ludwig Maximilian Universität
München, Munich, Germany, 3Institute of Computational
Biology, Helmholtz Zentrum München, Munich, Germany,
4Department of Psychiatry and Psychotherapy, University
Medical Center, Georg-August University, Göttingen,
Göttingen, Germany, 5Department of Translational Reser-
ach in Psychiatry, Max Planck Institute of Psychiatry,
Munich, Germany
Bipolar disorder (BD), schizophrenia (SZ) and schi-
zoaffective disorder (SZA) are complex genetic disorders
with largely polygenic architecture and severe and over-
lapping psychiatric symptoms. Stratiﬁcation of cases into
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homogeneous subgroups across diagnoses using both psy-
chometric and genetic information could identify indivi-
duals with higher risk for severe illness.
Examined at four time points over 18-months, a subset of
198 participants (46.9±12.4 yrs; 46% female) with DSM-IV
diagnoses of SZ, SZA or BD from an ongoing longitudinal
cohort study (www.kfo241.de) were genotyped on Illumi-
na’s Inﬁnium PsychArray and imputed using the
1000genomes. 67 variables from the Positive and Negative
Syndrome Scale (PANSS), the Inventory of Depressive
Symptoms (IDS) and the Young Mania Rating Scale
(YMRS) entered cluster analyses. Longitudinal trajectories
derived from abstract data dimensions computed by factor
analysis for mixed data (FAMD) were used for clustering.
SZ-polygenic risk scores (PRS) based on the Psychiatric
Genetics Consortium 2 SZ results were tested for cluster
association at 11 thresholds.
Two clusters were identiﬁed in the ﬁrst two dimensions:
(A) individuals with continuously low scores on PANSS
and IDS (70.7%) and (B) individuals with consistently high
scores on PANSS and IDS (29.3%). Clusters differed sig-
niﬁcantly with regard to Global Assessment of Functioning
(higher in (A); FDR-adjusted p-value=2.23×10–10), while
there were no signiﬁcant differences regarding sex, age,
diagnosis, center, age at onset, family history, duration of
illness, or association with the SZ-PRS.
In this preliminary data set, longitudinal clustering
identiﬁed cross-diagnostic homogeneous subgroups. Sur-
prisingly, more severe psychopathological features were not
associated with increased genetic risk burden.
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DNA damage, aneuploidy and chromosome instability in
the Alzheimer’s disease and autism brain
Y. B. Yurov1,2,3, S. G. Vorsanova1,2,3, I. A. Demidova1,2, A.
D. Kolotii1,2, O. A. Smirnova1, T. Liehr4, I. Y. Iourov1,2,5
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cow State University of Psychology and Education,
Moscow, Russian Federation, 4Institute of human genetics,
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Introduction It is consistently noted that brain diseases are
associated with aneuploidy and chromosome instability
(CIN) in the brain. Alzheimer’s disease (AD) and autism
spectrum disorders (ASD) seem to be the most likely dis-
orders to exhibit such an association. Here, we have
attempted to narrow the rates of aneuploidy and CIN in the
AD and ASD brain and to elucidate pathways brain-speciﬁc
CIN. Materials and methods Brain samples of controls (n
= 25) as well as AD (n= 10) and ASD (n= 6) individuals
was studied using multiprobe FISH, quantitative FISH and
interphase chromosome-speciﬁc multicolor banding. Spe-
ciﬁcity of CIN suggested speciﬁc pathway alterations spe-
ciﬁc for this diseases. Results Aneuploidy rate affecting sex
chromosomes in AD was two times higher than in control
(median: 2.8% and 1.3%, respectively, p =0.004). Aneu-
ploidy rate affecting autosomes and sex chromosomes in
ASD was also increased as compared to controls (median:
1.9% and 0.5%, respectively, p =0.002). CIN was observed
in AD and ASD exclusively. Speciﬁcity of CIN suggested
DNA damage response pathway to be altered. Conclusions
Increased aneuploidy and CIN (chromosome rearrange-
ments and breaks) rates result in genomic instability (GIN)
conﬁned to the brain. Paradoxically, these phenomena are
observed in brain cells regardless of their post-mitotic nat-
ure. According to our data, brain-speciﬁc GIN in neu-
ropsychiatric disorders is likely to originate from improper
DNA damage recovery similarly to oncogenic mechanisms.
Supported by the Russian Science Foundation (project #14-
35-00060) (autism studies) and ERA.Net RUS Plus Pro-
gramme (AD studies).
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BRAT1-related myoclonic encephalopathy: a new cause
of congenital stiffness
G. Delplancq1, F. L. Harms2, E. Boucher-Brischoux1, C.
Altuzarra3, K. Kutsche2, L. Van Maldergem1
1Centre de génétique humaine, University of Franche-
Comté, Besançon, France, 2Institute of Human Genetics,
University Medical Center, Hamburg-Eppendorf, Germany,
3Departement of Pediatrics, University of Franche-Comté,
Besançon, France
Introduction: Neonatal myoclonic encephalopathies
represent a diagnostic challenge that have been largely
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circumvented by generalized use of gene panels or whole-
exome sequencing approaches, often replacing an hitherto
complex metabolic work-up. However, there is still room
for ﬁrst line Sanger-sequencing whenever clinical evidence
points to a speciﬁc diagnosis, as illustrated by the history
hereby presented.
Materials and methods: Two males born to Algerian ﬁrst-
cousins died at 6 and 3 weeks after a similar clinical course
of myoclonic pharmaco-resistant seizures and generalized
hypertonia leaving them in ﬂexed position. Tongue myo-
clonic movements were present as well. Brain MRI, EMG,
search for mutations in GLRA1, GLRB, STXBP1, KCNQ2
and SCN8A were negative. Based on the similarity between
this very unusual clinical picture and the usual presentation
of BRAT1-related encephalopathy, BRAT1 sequencing was
undertaken and identiﬁed the homozygous mutation
c.2068G>T in exon 14 in the two index patients, introdu-
cing a premature stop codon [p.(Glu690*)]. Both parents
were heterozygous carriers of the BRAT1 nonsense
mutation.
Conclusion: BRAT1 should be added to the growing list
of genes related to early-onset severe lethal encephalopathy
with epilepsy. Major hypertonia is a paramount feature and
death occurs generally in the ﬁrst weeks of life with severe
deceleration of head circumference growth. Our data con-
ﬁrms the clinical presentation observed in the 12 previously
reported BRAT1 mutation-positive patients.
G. Delplancq: None. F.L. Harms: None. E. Boucher-
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C9ORF72 genetic screening in Serbian patients with
neurodegenerative disorders
A. Marjanovic1, V. Dobricic1, I. Marjanovic1, M.
Brankovic1, M. Jankovic1, G. Mandic1, Z. Stevic1,2, I.
Novakovic1,2, E. Stefanova1,2, V. Kostic1,2
Neurology Clinic, Clinical Center of Serbia, Belgrade,
Serbia, 2School of Medicine, University of Belgrade,
Belgrade, Serbia
Introduction: Recently discovered hexanucleotide repeat
expansions in the non-coding region of C9ORF72 gene
seems to be most common cause of amyotrophic lateral
sclerosis (ALS) and frontotemporal dementia (FTD). This is
the ﬁrst genetic change found to be the link between ALS
and FTD. However, this mutation was found with variable
frequency in other neurodegenerative disorders also. The
size of the GGGGCC hexanucleotide repeats in the
C9ORF72 alleles can range from 2 to more than 4000 and
the precise cut-off for pathogenic repeat size is still under
debate.
Materials and Methods: We have analyzed large cohort
of Serbian patients diagnosed as: ALS (252), FTD (261),
Alzheimer’s disease (AD, 146), and Huntington disease like
syndrome (HD like, 115). The region containing hex-
anucleotide repeats in C9ORF72 was PCR ampliﬁed with
ﬂuorescently labeled primer; fragment analysis was per-
formed on ABI 3500 genetic analyzer. Cut-off size for
repeat expansion was 30 repeats. All apparently normal
homozygous samples were screened for the expansion using
repeat-primed PCR.
Results: C9ORF72 hexanucleotide expansions were
detected in 9 (3,57%) ALS and 5 (1,84%) FTD cases. In
addition, 1 (0,87%) HD like patient showed C9ORF72
expansion and 1 (0,68%) AD patient had borderline repeats
number. All other patients showed normal alleles ranged
from 2–27 repeats.
Conclusion: These are the ﬁrst results of genetic
screening for C9ORF72 expansions in Serbian population.
Our data conﬁrms signiﬁcance of C9ORF72 analysis in
neurodegenerative disorders. In order to improve this test,
we intend to develop Southern blot for the exact estimation
of the expanded repeat size.
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A novel variant in ELF2 gene in cerebellar ataxia,
neuropathy and vestibular areﬂexia syndrome (CAN-
VAS) upregulates ataxin-2 translation in BE(2)-M17
cells
H. Ahmad1,2, T. Requena3, L. Frejo3, M. Cobo4, A.
Gallego-Martinez3, F. Martin4, A. M. Bronstein1, J. A.
Lopez-Escamez3,5
1Division of Brain Sciences, Imperial College, London,
United Kingdom, 2The National Hospital for Neurology and
Neurosurgery, London, United Kingdom, 3Otology &
Neurotology Group CTS495, GENYO, Granada, Spain,
4Gene and Cell Therapy Group, GENYO, Granada, Spain,
5Department of Otolaryngology, Instituto de Investigación
Biosanitaria ibs.Granada, Complejo Hospitalario Univer-
sidad de Granada (CHUGRA), Granada, Spain
Introduction: To identify the gene segregating the cere-
bellar ataxia, neuropathy and vestibular areﬂexia syndrome
(CANVAS) in British kindred and to investigate its patho-
genic effect. Material and Methods: We present a family
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with autosomal dominant CANVAS with incomplete
penetrance and variable expressivity; the proband and his
sister had a complete phenotype and a ﬁrst cousin a partial
syndrome. Exome sequencing was performed in 4 indivi-
duals and functional studies of the candidate mutation were
completed in transduced BE(2)-M17 cells. Results: We
identiﬁed a novel variant in the ELF2 gene at chr4:
g.140058846 C>T, c.10G>A, p.A4T which segregated in
all patients. We also showed that the mutated ELF2 (mt-
ELF2) gene upregulates ATXN2 gene expression and
increases ataxin-2 translation, supporting a pathogenic
effect. Both, western blot and confocal microscopy con-
ﬁrmed increased ataxin-2 in BE(2)-M17 cells transduced
with lentivirus expressing mt-ELF2 (CEE-mt-ELF2), which
was not observed in cells transduced with lentivirus
expressing wt-ELF2 (CEE-wt-ELF2). Moreover, we
observed a signiﬁcant decrease in the number and size of
lipid droplets in the CEE-mt-ELF2-transduced BE(2)-M17
cells, but not in the CEE-wt-ELF2-transduced BE(2)-M17,
a ﬁnding previously observed in neurodegenerative dis-
eases. Conclusions: The transcription factor ELF2, which
interacts with the ETS domain within the 5´-UTR in the
ATXN2 gene could be a repressor of ATXN2 expression.
Furthermore, mt-ELF2 could induce an ATXN2 gain-of-
function involving lipid homeostasis with reduction of lipid
droplets. This novel mechanism conﬁrms that regulation of
ATXN2 gene transcription may be crucial in the patho-
physiology of cerebellar ataxias. Funded by an MRC Grant
MR/J004685/1.
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Next-generation DNA sequencing to identify novel
genetic risk factors underlying cerebral vein thrombosis
M. M. Gorski1, H. G. de Haan2, L. A. Lotta1, I. Mancini1,
P. Bucciarelli1, S. M. Passamonti1, A. Cairo1, E.
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Background: Cerebral vein thrombosis (CVT) is a rare, life-
threatening disease affecting annually 4 adults/million.
Genetic risk factors are deﬁciencies of the natural antic-
oagulant proteins antithrombin, protein C, protein S or
factor V Leiden and prothrombin 20210A mutations. In
20% of patients, the cause of CVT remains unknown.
Aim: To identify novel genetic risk factors underlying
CVT using targeted next-generation DNA sequencing
(NGS).
Methods: We investigated 171 Italian CVT patients and
298 healthy controls. Patients were selected using the fol-
lowing criteria: objective diagnosis of CVT, Caucasian
decent, no active cancer. We performed targeted NGS
analysis of the protein-coding regions of 737 candidate
genes related to hemostasis and inﬂammation, 150 ancestry
informative markers and 28 thrombosis-associated variants.
Results:We obtained 34,357 variants that passed quality
control, of which 4,591 variants were common and low-
frequency with minor allele frequency (MAF) >1% in 618
genes. Single variant association testing using logistic
regression analysis identiﬁed rs8176719 insertion/deletion
(indel) variant in the ABO gene associated with CVT (age
and sex adjusted P=1.37×10−6; OR 2.04; 95% CI 1.53–
2.73; Bonferroni P=0.006). Gene-based association analy-
sis of 13,161 rare variants (MAF ≤1%) using Burden test
revealed a borderline association of variants located in
intron 2 (P=0.02) and introns 15–20 (P=0.01) of the F8
locus with CVT.
Conclusions: Targeted NGS identiﬁed a common indel
variant rs8176719 in the ABO gene as a risk factor for CVT.
Gene-based test of association using Burden test revealed
non-signiﬁcant association of rare intronic variants in the F8
gene with CVT.
M.M. Gorski: None. H.G. de Haan: None. L.A. Lotta:
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A genome-wide association study of common SNPs and
rare coding variants inﬂuencing risk for cluster
headache
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Cluster Headache (CH) is a primary headache, characterized
by unilateral pain with circadian and seasonal rhythmicity.
The etiology of CH is poorly understood, and a complex
genetic predisposition is likely to be involved. Smoking is
the most frequent habit in CH patients, possibly acting as an
environmental trigger; however, its link with CH is unclear.
Previous genetic studies investigated a limited number of
candidate genes, providing no conﬁrmed associations. We
performed a genome-wide association study (GWAS) in a
clinically well-deﬁned cohort of 99 Italian patients with CH
and a control sample of 360 healthy Italian individuals
matched for age and smoking status. We used the Inﬁnium
PsychArray (Illumina), which combines common highly-
informative genome-wide tag SNPs and exonic SNPs.
Single marker case-control association analysis using
common SNPs lead to the identiﬁcation of an interesting
suggestive association (P=9.1×10−6) within the PACAP
receptor gene (ADCYAP1R1). Furthermore, gene-based
association analysis on rare exonic variants in 745 candi-
date genes provided a signiﬁcant evidence of association for
a rare variant of MME (P=2.5×10−5), encoding for nepri-
lysin. Both gene products are known to have a pivotal
function in pain mechanisms, thus making these associa-
tions particularly stimulating. To conﬁrm our initial asso-
ciation results we are currently conducting a replication
study in an independent sample, and ﬁne mapping in the
ADCYAP1R1 locus is ongoing. This study is the ﬁrst
comprehensive association study of common SNPs and rare
exonic variants inﬂuencing risk for CH, which implicates
gene involved in pain processing in CH susceptibility.
C. Cameli: None. E. Bacchelli: None. M. Cainazzo:
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V. A. Stepanov1,2, O. Makeeva1,3, A. Marusin1, A.
Bocharova1, K. Vagaitseva1,2, V. Markova1,3, L.
Minaicheva1, V. Kharkov1,2
Institute for Medical Genetics, Tomsk National Medical
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Cognitive decline with age, including pathological mani-
festations in the form of dementia, is an important social
and medical problem that leads to a signiﬁcant reduction in
the quality of life of the elderly. The aim of the study was to
ﬁnd genetic markers associated with the variability of the
cognitive functions in the elderly in the Russian population.
A random sample of 710 elderly subjects (mean 71.3 years)
was collected from population of Tomsk, Russia. The
cognitive functions were assessed using Montreal Cognitive
Assessment (MoCA). 62 SNPs in 45 genes previously
reported to be associated with cognitive performance and/or
Alzheimers’s disease in multiple GWAS or meta-analysis
studies were genotyped using MALDI-TOF mass spectro-
metry. Parametric (ANOVA) and nonparametric (Kruskal-
Wallis test and the median test) methods were used to
estimate the difference in scores of cognitive tests among
genotypes. 17 markers were detected associated with
MoCA performance test. The strongest effect on cognitive
functions was demonstrated for genetic markers of APOE,
TOMM40, PVRL2 and APOC1 genes, located in the same
locus on chromosome 19q13.32. Highly signiﬁcant asso-
ciations with MoCA were also found for gene markers of
SORL and CSMD1 genes. Analysis of variance indicates
that the proportion of variance in MoCA values, explained
by the variability of genetic markers, is ranged from 0.5% to
1.3% for each of the associated SNP. The largest con-
tribution (8.6%) to cognitive performance variability is
attributable to genetic variation at PVRL-TOMM40-APOE-
APOC1 linked gene cluster. This work was supported by
the Russian Science Foundation (project # 16-14-00020).
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Colpocephaly in Chudley-McCullough syndrome
A. R. E. Potgieser, E. H. Gerkes, E. W. Hoving
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Abstract
Background: The Chudley-McCullough syndrome[1] is
a very rare autosomal recessive disorder characterized by
partial corpus callosum agenesis, colpocephaly with a right-
sided tendency and bilateral severe to profound sensor-
ineural hearing loss. Other abnormalities include cortical
dysplasia, frontal polymicrogyria, cerebellar dysgenesis,
gray matter heterotopy, arachnoid cysts and sometimes
mental retardation [2,3].
Until now, only forty cases have been described in lit-
erature [3]. Mutations in the G-protein signaling modulator
2 gene (GPSM2), which produces the Leu-Gly-Asn repeat-
enriched protein (LGN), were found to be responsible for
the syndrome [4].
Main ﬁndings: we present two adult sisters with asym-
metrical enlarged ventricles who were treated surgically
under the assumption of “hydrocephalus”, yielding no
clinical beneﬁt. They were diagnosed subsequently with the
Chudley-McCullough syndrome. The enlarged ventricles in
this syndrome are secondary to a developmental mal-
formation called colpocephaly, instead of a true hydro-
cephalus caused by a cerebrospinal ﬂuid circulation
disturbance.
Conclusion: The ventriculomegaly in Chudley-
McCullough syndrome is secondary to colpocephaly and
not caused by a true hydrocephalus and thus we recommend
conservative follow-up without cerebrospinal ﬂuid diver-
sion, unless there is evidence of a raised intracranial pres-
sure. We emphasize the importance of determining the right
diagnosis for patients with this rare syndrome, to prevent
unnecessary surgical interventions.
A.R.E. Potgieser: None. E.H. Gerkes: None. E.W.
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Impact of defective protein N-glycosylation on the
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Introduction: Disruption of protein N-glycosylation causes
Congenital Disorders of Glycosylation (CDG), which are
multisystemic disorders with severe neurological symp-
toms. Early-onset cerebellar atrophy and/or hypoplasia are
frequently observed, especially in CDG cases with muta-
tions in the SRD5A3 gene. Materials and Methods: In order
to understand how an N-glycosylation defect could affect
cerebellar development, we developed a cerebellum speciﬁc
Srd5a3 conditional KO mouse. Results: This model reca-
pitulates the human defect with abnormal protein N-
glycosylation and motor coordination impairment. Cere-
bellar development is abnormal at the histological level with
the presence of granule cells ectopia in the molecular layer.
Proteomic proﬁling allowed us to identify a family of
deregulated adhesion N-glycoproteins that are likely to be
responsible of the observed histological defect. Further
work is currently on going to conﬁrm the implication of
those adhesion molecules in the disease and to test for
therapeutic options, in vitro. Conclusions: We have gen-
erated a suitable model for SRD5A3-CDG, whose results
may be extrapolated to other CDG. Second, we have shown
that the cerebellar defect is likely the consequence of an
impaired granule cells development. Investigation of the
biochemical basis of the cerebellar defect suggests that the
misregulation of a limited set of glycoproteins involved in
neural cell adhesion may play a prevalent role in the cere-
bellar defect.
D. Medina-Cano: None. M. Nicouleau: None. C.
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CNV-risk: A database of published association results
examining genetic copy number variants and their effect
on psychiatric illness and cognition
J. H. Thygesen, E. Zartaloudi, A. McQuillin, E. Bramon
Division of Psychiatry, University College London, London,
United Kingdom
Rare genetic copy number variants (CNVs) comprise one of
the most severe risk factors for psychiatric illness. SNP-
microarray technology has helped to establish strong asso-
ciations between speciﬁc CNV loci and psychiatric illness,
cognitive and dysmorphic features. CNVs are highly
pleiotropic, and cause impairment to speciﬁc cognitive
domains (and brain structures) in both affected and healthy
carriers.
The literature describing CNV effects is growing rapidly,
but there is currently no central resource that compiles this
complex knowledge in a manner that facilitates easy com-
bined analysis. Here we present a solution, through the
development of a structured database loaded with CNV
association results from published literature.
We constructed a structured SQLite database schema to
hold information on; loci positions, association results,
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phenotypes, sample size, and inter study relations. The data
source are tables from published articles which are loaded
into the database via a function that integrates overlapping
loci (prompting users with best database match through
position and locus names comparisons). Along with the
database we present a set of interactive graphical visuali-
sations using the R Shiny package to help query CNV
effects.
The database presented here allows researchers to per-
form efﬁcient meta-analysis, cross querying, and annotation
of local datasets. In addition we provide running database
updates along with the tools needed to include additional
data. This resource may be valuable for researchers as well
as clinical geneticists who seek to compare their practice
with the latest published literature. The database and
applications are available for download from https://github.
com/hilge/CNV-risk.
J.H. Thygesen: None. E. Zartaloudi: None. A.
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Michaud5, G. Rouleau3, B. A. Minassian4, G. Bourque3,
P. Cossette2
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Epilepsy will affect nearly 3% of people at some point
during their lifetime. Previous copy number variants
(CNVs) studies of epilepsy have used array-based tech-
nology and were restricted to the detection of large or
exonic events. In contrast, whole-genome sequencing
(WGS) has the potential to more comprehensively proﬁle
CNVs but existing analytic methods suffer from limited
sensitivity and speciﬁcity. To improve on this, we devel-
oped PopSV, an algorithm that uses multiple samples to
control for technical variation and enables the robust
detection of CNVs. Using WGS and PopSV, we performed
a comprehensive characterization of CNVs in 198 epilepsy
samples and 301 controls and found an enrichment of rare
exonic events in patients. Notably, this genome-wide survey
also revealed an enrichment of CNVs in proximal non-
coding elements of previously known epilepsy genes. In
total, coding and non-coding putative pathogenic events
were found in 98 (46.4%) patients. This study was sup-
ported by ﬁnding from Genome Canada, Genome Québec,
Canadian Foundation for Innovation, NSERC and CIHR.
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Severe cognitive impairment and early-onset epilepsy in
six patients with the de novo p.Glu590Lys variant of
CUX2
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Cut homeodomain transcription factor CUX2 plays an
important role in dendrite branching, spine development,
and synapse formation in layer II-III neurons of the cerebral
cortex. Abnormal dendrites and synapses in Cux2(-/-) mice
correlate with reduced synaptic function and defects in
working memory. A de novo CUX2 p.Glu590Lys variant
was reported in two patients involved in large-scale whole-
exome sequencing (WES) studies on intellectual disability
and epileptic encephalopathies. We report on clinical data
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of six patients carrying the de novo p.Glu590Lys variant.
There were 4 males and 2 females. Mean age at inclusion
was 13.6 years [8–21]. Epilepsy occurred in all patients.
Age at onset of seizures ranged from 2 months to 1 year
[mean = 6.6 months]. Seizure types at onset were myo-
clonic seizures, atypical absence with myoclonic compo-
nent, and focal seizures. Seizures were drug-resistant in all
patients but one. EEG initially showed generalized poly-
spikes and waves (4) or multifocal epileptiform discharges
(2). Two patients are seizure-free under treatment whereas
the others still have persistent seizures. Cognitive regression
was noticed in childhood at least for two patients, at 8 and
12 years, respectively. All patients had severe cognitive
impairment and autistic features were present in 4. Two
patients had ataxic gait. Brain MRI only showed minor and
non-speciﬁc anomalies.In conclusion, patients carrying the
p.Glu590Lys variant of CUX2 display a homogeneous
clinical presentation with infantile-onset epilepsy frequently
including myoclonic jerks with polyspikes and waves or
multifocal epileptiform discharges. Patients have severe
cognitive impairment sometimes associated with psycho-
motor regression in childhood.
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reminiscent for a RELN phenotype at brain MRI
M. Wilke, M. van Slegtenhorst, R. Schot, G. Mancini
Department of Clinical Genetics, Rotterdam, Netherlands
The Disabled-1 (DAB1) gene encodes a key regulator of
Reelin signaling, which plays a critical role in the correct
positioning of neurons within the developing brain in mouse
and humans. From animal studies it is known that Reelin
binds to the lipoprotein receptors VLDLR and APOER2 on
the surface of neurons leading to the phosphorylation of
DAB1 which serves as an intracellular adaptor protein
(Huang et al., 2005). In mice, both Reln and Dab1 are
required for the proper layering of neurons in the cortex.
Disruption of murine Dab1 generates a phenotype com-
parable to that of Reelin- deﬁcient mice. Autosomal reces-
sive mutations in Reelin in humans show a similar
phenotype to the murine counterpart. Until now, no disease
associated mutations in DAB1 have been described in man.
Screening of patients with neurodevelopmental disorders
and brain malformations by whole exome sequencing
revealed compound heterozygosity for two splice-site
mutations (c.307-2A>T, p.? and c.67+1G>T, p.?;
NM_021080.3) in the coding region of the DAB1 gene in an
11 year old girl who presented with oral motor difﬁculty,
squint, dysdiadokokinesis, cerebellar ataxia, mild pyramidal
signs, epilepsy well controlled by oxcarbazepine, mood
changes treated with methylphenidate and a 55 TIQ score.
The brain MRI showed mild cortical pachygyria, more
prominent frontally, hypoplasia of cerebellar hemispheres
and more pronounced vermis hypoplasia, enlarged peri-
vascular spaces and lateral ventricles, suggestive of RELN
mutation, which could not be found after Sanger sequen-
cing. We suggest that mutations in DAB1 should be con-
sidered in patients with a RELN-like phenotype at MRI.
M.Wilke: None.M. van Slegtenhorst: None. R. Schot:
None. G. Mancini: None.
P09.044D
Results of a diagnostic NGS gene panel for patients with
dementia
R. M. L. Vervenne - van Spaendonk1, F. van Ruissen2, Y.
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In the Netherlands, diagnostic testing is offered to an
increasing number of patients suffering from dementia. The
identiﬁcation of a causal mutation supports the clinical
diagnosis, especially in patients with dementia of unknown
etiology. Furthermore, when a causal mutation is found,
presymptomatic testing becomes an option for their rela-
tives. During the last decade, our laboratory offered diag-
nostic testing for the 5 most prevalent dementia genes by
Sanger sequencing. Since September 2014, we also offer a
virtual gene panel based on next generation sequencing
(NGS). Our virtual panels consist of whole exome sequence
(WES) data ﬁltered for speciﬁc disease genes. The advan-
tage of virtual panels is that they are ﬂexible and can be
immediately changed when new genes are discovered.
Copy number variations (CNV) analysis on WES data is
possible and will be implemented as well. For dementia we
started with a panel comprising 41 genes that have been
associated with Mendelian inherited dementia at an early
age. Here we present the outcome of the results in the ﬁrst
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180 tested individuals and compare the diagnostic yield of
the NGS gene panel with the Sanger gene panel. Further-
more, we show that the diagnostic result changed the clin-
ical diagnosis in some of these patients.
R.M.L. Vervenne - van Spaendonk: None. F. van
Ruissen: None. Y.A.L. Pijnenburg: None. P. Scheltens:
None. D. van Beek: None. M. Smit: None. P. Cohn:
None. H. Meijers: None. E.A. Sistermans: None. J.M.
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Introduction: Mate choice in human is under the inﬂuence
of a complex interplay of socio-cultural, psychological and
biological factors. Among biological factors, the role of the
MHC has been discussed. A signiﬁcant disassortative
mating signal has been previously found in European
HapMap samples Here, using genome-wide data, we
investigate non-random mating at the MHC in a large
European and Middle Eastern dataset.
Materials and Methods: We analyzed GAIN ADHD
dataset, a trio study for Attention Deﬁcit Hyperactivity
Disorder comprising genotypes for 883 unrelated couples
from 7 European countries and Israel. In order to quantify
relatedness between spouses, we jointly used two measures:
Rousset’s distance and the genetic correlation based on
standardized genotypes. Those were applied ﬁrstly to
genome-wide data and secondly to the MHC.
Results: Our results show that, in most populations
except Spain and the UK, there is a signiﬁcant tendency to
choose a partner more genetically related than if chosen at
random in the population. These patterns may reﬂect socio-
cultural factors inﬂuencing mate choice or may relate to the
sampling strategy. Contrariwise, the MHC region displays
signiﬁcant signature of disassortative mating in the Neth-
erlands, Ireland and the UK.
Conclusion: Our results support that non-random mating
exists at MHC in human populations, a mating strategy
possibly optimizing MHC diversity and immunity in the
offspring. The MHC is associated with many multifactorial
diseases and our ﬁndings highlight the need to better
understand the inﬂuence of such mate choice related ﬁne
scale structures on association studies.
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Dystonia is a genetically heterogeneous disease that causes
involuntary muscle contractions. These contractions result
in repetitive movements or abnormal postures in the
patients. Nowadays, more than 30 genes are known to be
responsible of this pathology; however still there is high
number of patients without a genetic diagnosis. Fifteen
patients with clinical suspicion of dystonia have been stu-
died using the TruSight One Sequencing Panel (Illumina).
This panel contains exonic regions harboring disease-
causing variants in approximately 4,800 clinically relevant
genes. The study was focused in genes previously related to
dystonia and we identiﬁed 7 genetic variants responsible for
the phenotype in 5 patients. In particular, changes have been
identiﬁed in GCH1, PANK2, PARK2, SGCE and THAP1
genes. The variants detected in SGCE and THAP1 genes
had been never previously described. Conﬁrmatory analysis
and familial studies of these variants allowed establishing
pathogenicity of these changes. The application of next
generation sequencing allowed the identiﬁcation of patho-
genic mutations in almost 35% of patients with dystonia.
These results encourage the use of massive sequencing for
the diagnostic of dystonia as well as for other clinical and
genetic rare diseases.
Acknowledgments: Associació lluita contra la distonia a
Catalunya (ALDEC), AGAUR 2014 SG603 (Generalitat de
Catalunya)
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dystonia and myoclonus
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Introduction Following the association of familial dyski-
nesia and facial myokymia (FDFM) with ADCY5 mutations
in 2012, monoallelic ADCY5 mutations have been asso-
ciated with benign hereditary chorea and a mixed hyperki-
netic syndrome of dystonia, chorea, and myoclonus. We
report two siblings with generalized dystonia and myoclo-
nus associated with two novel pathogenic variants of
ADCY5. Material and methods A 27 year old woman and
her 24 year old brother presented for evaluation of a
movement disorder. Both had generalized dystonia and
myoclonus. Due to familial juvenile-onset generalized
dystonia with myoclonus and the previous negative eva-
luations, exome sequencing was pursued. Testing revealed
the presence of a maternally inherited frameshift variant
(c.409_428del20; p.G137Cfs*184) and a paternally inher-
ited missense variant (c.3037C>T; p.R1013C) in ADCY5 in
both siblings. Both variants were interpreted as pathogenic,
the maternally inherited mutation because it results in a
frameshift alteration and the paternally inherited missense
mutation because it is a previously unknown variant, is
evolutionarily conserved across species, and is predicted to
be deleterious by in silico analyses. Conclusions ADCY5
mutations are believed to be inherited in an autosomal
dominant fashion based on observations from the original
FDFM pedigree. Here we report two siblings with a phe-
notype consistent with ADCY5-related dyskinesia and
biallelic pathogenic variants in ADCY5. This family adds to
the growing knowledge about ADCY5-related dyskinesia
by providing an example of how certain pathogenic variants
when inherited in an autosomal recessive manner may
produce a movement disorder phenotype identical to that
produced by autosomal dominant mutations.
M. Barrett: None. E. Williams: None. C. Chambers:
None. R. Dhamija: None.
P09.048D
Pleiotropy of genes involved in early onset epileptic
encephalopathies
E. Bettella1, R. Polli1, F. Cesca1, E. Leonardi1, M.
Aspromonte1, M. Vecchi2, I. Toldo3, C. Boniver2, D.
Baldo4, S. Sartori3, A. Murgia1,5
1Laboratory of Molecular Genetics of Neurodevelopment,
Department of Women’s and Children’s Health, University
of Padova, Padua, Italy, 2Pediatric Neurophysiology Unit,
Department of Women’s and Children’s Health, University
of Padua, Padua, Italy, 3Pediatric Neurology Unit,
Department of Women’s and Children’s Health, University
of Padua, Padua, Italy, 4Clinical Genetics Unit, Hospital of
Treviso, Treviso, Italy, 5Department of Neuroscience,
University of Padova, Padua, Italy
BACKGROUND: Epileptic Encephalopathies (EOEEs) are
a group of clinically heterogeneous neurological disorders
of early infancy, characterized by premature and often drug-
resistant seizures typically resulting in altered neurodeve-
lopment with motor and cognitive deﬁcits. Indeed EOEEs
represent a common clinical outcome in a broad spectrum
of genetically heterogeneous conditions. As single gene
testing is no longer a practical approach, the use of Next
Generation Sequencing should be applied as a routine
molecular diagnostic strategy in patients with early onset
seizures.
MATERIALS and METHODS: We developed a custo-
mized targeted panel containing 31 genes which has been
used for the analysis of 89 well-selected individuals, on Ion
PGM™ Sequencer using Ion Reporter software 5.0.
RESULTS: We have identiﬁed and characterized 18
disease-causing variants that seem to further expand the
phenotypic spectrum of early onset epilepsy genes. We have
detected pathogenic variants in SCN1A, SCN2A, SCN8A,
SCN1B, KCNQ2, FOXG1, PCDH19, ALDH7A1 genes. A
novel ALDH7A1 homozygous mutation c.1256C>T was
detected in a newborn, seventh child of consanguineous
parents who previously lost three children affected with
seemingly different phenotypes.
We found a KCNQ2 and SCN1A variants, both novel and
likely pathogenic, to co-segregate in a subject with an aty-
pical picture of early onset focal drug resistant epilepsy.
CONCLUSIONS: The peculiar phenotypes of indivi-
duals we found to carry pathogenic mutations can con-
tribute to further expanding the genotypic and clinical
spectrum of these disorders. Our ﬁndings highlight the
pleyotropy of early onset epilepsy genes and stress the
importance of integrating clinical and molecular data to
improve genotype-phenotype correlation.
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HYPOPLASTIC ANAEMIA IN AP3B4 RELATED
EPILEPTIC ENCEPHALOPATHY
D. J. Josifova
uy's Hospital, London, United Kingdom
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We report on a patent affected with early infantile epileptic
encephalopathy, EIEE48 [MIM 617276], who also pre-
sented with mutation negative, Diamond-Blackfan anaemia,
and suggest that this is a rare feature of recessive AP3B2
related phenotype.
This patient is one of three affected members from a
consanguineous, Turkish family, harbouring a homozygous
inactivating variant c.445_448delGCTA p.(Ala149fs) in
AP3B2. The neurological phenotype was very similar in all
three patients, and consisted of early onset seizures, pro-
found developmental delay, microcephaly and slowly pro-
gressive, choreoathetoid movement disorder. In addition,
our patient presented with severe congenital anaemia with
bone marrow appearance of Diamond-Blackfan anaemia,
requiring multiple transfusions. Sequencing of 85 genes
associated with Diamond-Blackfan anaemia was normal.
Haematological evaluation of the other affected patients
within this family was normal.
AP3B2 is a subunit of the heterotetrameric, neuronal AP-
3 complex involved in vesicular transport in neurons. The
structurally similar, ubiquitously expressed AP-3, contains
AP3B1 instead. Pearl mice, deﬁcient in ubiquitous AP-3,
manifest abnormal haematopoiesis, but no neurological
signs, while Mocha mice deﬁcient in both, ubiquitous and
neuronal AP-3 exhibit a haematological and neurological
phenotype.
The clinical picture in our patient demonstrates an
overlap between the neuronal and ubiquitous AP-3 deﬁcient
phenotypes. This suggests that neuronal AP-3 may exert
effects beyond the nervous system, or that the mutant
AP3B2 perhaps interfere with the ubiquitous AP-3. Future
reports will help delineate the phenotype and further func-
tional studies clarify the functional relationship between the
ubiquitous and neuronal AP-3.
D.J. Josifova: None.
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A novel CNKSR2 deletion associated to epilepsy-aphasia
spectrum
R. Guerrero-López, B. G. Giráldez, V. Soto-Insuga, I.
Ayuso Jimeno, S. E. López-Pérez, R. Losada del Pozo, M.
Rodrigo-Moreno, G. Iglesias, G. Sánchez-Martín, L.
Ortega-Moreno, J. M. Serratosa
IIS-Fundación Jiménez Díaz and CIBERER, Madrid, Spain
The Epilepsy-aphasia spectrum includes a group of dis-
orders from severe epileptic encephalopathy with con-
tinuous spike-waves during sleep (CSWS) and Landau
Kleffner syndrome to the mild condition of childhood epi-
lepsy with centrotemporal spikes. Recently, a genetic
etiology has been associated with many of these epileptic
disorders. Mutations in the RAS-signaling protein encoded
by CNKSR2 have been found in patients with seizures and
neurodevelopmental deﬁcits, especially those with unex-
plained language problems.
Sanger sequencing of GRIN2A was carried out to exclude
GRIN2A variants before performing Sanger sequencing of
CNKSR2 and a customized array-CGH enriched with
probes targeting CNKSR2, in order to identify alterations in
males patients with CSWS (>50%) and language deﬁcit (n
= 15).
We identiﬁed a novel 10-kb deletion (chrX: 21609392-
21619786) in CNKSR2 in one patient with CSWS and
language deﬁcit. In total, we identiﬁed 5 disease-causing
variants, of which 1 (9%) is in CNKSR2 and 4 (26%) in
GRIN2A.
The molecular diagnosis of CNKSR2 is a guarantee in
patients belonging to these types of epileptic disorders (up
to 9% in our cohort).
Ministerio de Economía y Competitividad (SAF2014-
59594-R)
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The searching for new variants in genes CNTNAP2 and
NRXN1 for patients with epileptic encephalopathies
A. Slavokhotova1, M. Belenikin2,3
Vavilov Institute of General Genetics, Moscow, Russian
Federation, 2Moscow Institute of Physics and Technology
(State University), Dolgoprudny, Russian Federation,
3Gamaleya Research Institute of Epidemiology and Micro-
biology, Moscow, Russian Federation
Background: epilepsies are highly heterogeneous multi-
factorial disease. The only way to identify the causal
mutations is identiﬁcation of all genetic variants associated
with epilepsy. The aims of study: searching the new genetic
variants at CNTNAP2 and NRXN1 genes. Methods:
90 samples: 454 GSJunior (NimbleGen SeqCap target
enrichment, 34 genes, associated with epileptic encephalo-
pathy), 20 samples: Illumina HiSeq (SureSelect, complete
exome sequencing). Informed consents were obtained from
legal representatives of patients according local ethical
approval. Results: Five variants for ﬁve samples was found
at NRXN1 gene: two compound heterozygous missense
mutations (rs56086732 and rs200074974) were found for
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two boys (4 and 6 years old) with preliminary diagnoses
symptomatic focal and cryptogenic epilepsies; one hetero-
zygous missense mutation (rs200646155) was found for girl
11 y/o with preliminary diagnoses GEFS+; one new
undescribed heterozygous missense mutation
(NG_011878.1:g.541548G>C, Asp>His) was found for girl
6 y/o with preliminary diagnoses GEFS+; one new inver-
sions (311b.p. in length) for patient with preliminary diag-
nosis Aicardi-Goutieres syndrome. An interesting new
heterozygous nonsense mutation (2 cases: patient with
symptomatic epilepsy (boy, 2 years old) and health control)
we have found at the end of CNTNAP2`s CDS,
NC_000007.14:g.148415611A>Term, resulting in loss of
the last amino acid residue (-KKEWLI[Opal]>-KKEWL
[Amber]). The authors are grateful to MD Zhylina S.,
Meshcheryakova T, Ananyeva T., Lukyuanova E., and
Ayvazyan S. from Research Center for Children Medical
Care for patients selection. The research was supported by
the Department of Health of Moscow.
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Improving interpretation of the clinical signiﬁcance of
SCN1A variants in patients with Dravet syndrome using
in silico analysis of missense mutations
M. C. Gonsales1, M. A. Montenegro2, P. Preto2, M. M.
Guerreiro2, A. C. Coan2, M. P. Quast3, B. S. Carvalho3, I.
Lopes-Cendes1
1Department of Medical Genetics - University of Campinas,
Campinas, Brazil, 2Department of Neurology - University
of Campinas, Campinas, Brazil, 3Department of Statistics -
University of Campinas, Campinas, Brazil
Introduction: Interpreting the clinical signiﬁcance of
genetic variants can be challenging, particularly for variants
of unknown signiﬁcance such as missense mutations. To
access the rate of success in the classiﬁcation of missense
variants, we assessed algorithms to predict functional
effects of SCN1A missense mutations in patients with
Dravet syndrome (DS) reported in the literature and in our
molecular study. Materials and Methods: We assessed the
use of ten different computer algorithms individually to
predict putative deleterious effects of amino acid changes
resulting from missense mutations in SCN1A in patients
with DS. In addition, we developed a classiﬁer to obtain
more reliable prediction combining the scores of ﬁve pre-
diction algorithms. Furthermore, we evaluated whether
amino acid changes are predominant in speciﬁc protein
regions by performing a permutation test. Results: The
majority (57.5%) of the 353 SCN1A missense variants in
patients with DS are predicted as deleterious by all ten
algorithms individually. Almost all amino acid changes
(92.6%) are considered deleterious by more than half of the
algorithms tested. Our classiﬁer combining multiple pre-
diction scores presented high accuracy (0.8873), sensitivity
(0.8379) and speciﬁcity (0.9191). Moreover, we found a
predominance of amino acid changes in the voltage sensor
segment (S4), the pore forming region (S5-S6) and adjacent
subunit S6 (p<0.05). Conclusion:We were able to correctly
ascertain putative pathogenic effect in the vast majority of
missense mutations in SCN1A found in patients with DS,
thus minimizing the inconvenience of inconclusive reports
in the molecular diagnosis of patients with this severe form
of epilepsy.
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Targeted gene testing on a cohort of 122 epileptic cases
referred to a single institution reveals a high diagnostic
rate on Early Infantile Epileptic Encephalopathy
M. Martinez-Garcia1, C. Rodriguez1, M. Carcajona1, I.
Diez1, R. Sanchez-Alcudia1, M. Peña-Vilabelda1, P.
Maietta1, J. Botet1, N. Sanchez-Bolivar1, A. Santana-
Rodríguez2, A. Santana-Rodríguez2, A. Rodriguez-Valle3,
A. Patiño4, A. Gil-Nagel5, L. Martorell6, M. Gálvez7, S.
Álvarez1
Unidad de secuenciación, NIMGenetics S.L., Madrid,
Spain, 2Hospital Universitario Materno Infantil de Canar-
ias, Las Palmas, Spain, 3Departamento Genética Clínica.
Hospital Universitario Miguel Servet., Zaragoza, Spain,
4Clínica Universidad de Navarra. CIMA., Pamplona,
Spain, 5Hospital Ruber Internacional., Madrid, Spain,
6Hospital Sant Joan de Déu, Barcelona, Spain, 7Labora-
torio de Genética. Gencell Pharma, Bogotá, Colombia
BACKGROUND. Epilepsy is a common clinical and
genetic heterogeneous neurological disorder, with a large
number of cases caused by genetic factors. To understand
the molecular basis of epilepsy, 145 genes associated to
syndromic and non-syndromic epilepsy were analysed on
122 cases. MATERIAL AND METHODS Genomic
libraries were generated using the Ion AmpliSeq Exome
RDY as exome backbone, combined with an AmpliSeq
panel design to improve gene coverage. Sequencing reads
generated on the Ion Proton and Ion S5 platform were
analyzed using Torrent Suite software. Annotated variants
using ION Reporter were prioritized with an in-house
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analytical pipeline. RESULTS Among the 90 patients
referred as Early Infantile Epileptic Encephalopathy (EEIE).
49%were genetically diagnosed. SCN1A, KCNT1 and
SPTAN1 genes, were the most frequently mutated in this
group. On the 32 remaining patients, pathogenic variants
were detected 19% of the cases. ATP1A2 and TPP1 were
the most frequently mutated genes. Out of the 169 identiﬁed
variants, 66 were associated to genes with an autosomal-
dominant inheritance pattern. Variants of uncertain sig-
niﬁcant category were identiﬁed mainly in genes recently
associated to epilepsy as RYR3, GPR98 and FASN.
Recurrent updating of targeted genes, the familial segrega-
tion of identiﬁed variants, and the analyses of other tissues
in cases with mosaicism (as CDKL5) or associated to an
inheritance pattern of cellular interference (as PCDH19)
was essential. CONCLUSIONS Epilepsy panels based on
WES provide a cost effective and comprehensive strategy
that accelerates the identiﬁcation of a deﬁnitive clinical
diagnosis, improving the prognosis accuracy and facilitating
the therapy selection.
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Conﬁrmation of mutations in the PROSC gene as a novel
cause of vitamin B6 dependent epilepsy
B. Plecko1,2, M. Zweier3,2, A. Begemann3,2, D. Mathis4, B.
Schmitt5, P. Striano6, M. Baethmann7, S. Vari6, F.
Beccaria8, F. Zara9, L. M. Crowther1, P. Joset3, H.
Sticht10, S. M. Papuc3,2, A. Rauch3,2
1Division of Child Neurology, University Children’s
Hospital Zurich, Zurich, Switzerland, 2radiz - "Rare
Disease Initiative Zurich, Clinical Research Priority
Program for Rare Diseases University of Zurich", Zurich,
Switzerland, 3Institute of Medical Genetics, University of
Zurich, Schlieren-Zurich, Switzerland, 4Clinical Chemistry,
Univ. Childrens' Hospital Zurich, University of Zurich,
Zurich, Switzerland, 5Division of Child Neurology, Uni-
versity Children’s Hospital Zurich, Schlieren-Zurich, Swit-
zerland, 6Pediatric Neurology and Muscular Diseases Unit,
Department of Neurosciences, Rehabilitation, Ophthalmol-
ogy, Genetics, Maternal and Child Health, University of
Genova, "G. Gaslini" Institute, Genova, Italy, 7Sozial-
pädiatrisches Zentrum, Dritter Orden, München-
Nymphenburg, Germany, 8Child Neuropsychiatry, C. Poma
Hospital, Mantova, Italy, 9IRCCS, "G. Gaslini" Institute,
Genova, Italy, 10Institute of Biochemistry, University of
Erlangen-Nürnberg, Erlangen, Germany
Vitamin B6 dependent epilepsy with neonatal seizure onset
is a heterogeneous clinical entity with defects in two known
genes (ALDH7A1 and PNPO) explaining a major fraction of
cases. Very recently biallelic mutations in PROSC sug-
gested this gene as a novel cause in ﬁve families. The
reported patients with PROSC mutations showed a rather
uniform clinical picture with 6/7 patients presenting with
neonatal seizure onset within 24h and a burst suppression
pattern in 5/7. 4/7 patients had a neonatal head cir-
cumference <10%, cranial imaging was abnormal in 4/7,
and none of the patients had normal cognitive function. PLP
concentrations in plasma and CSF were abnormal in all
patients tested. We now identiﬁed four novel unrelated
patients harbouring a total of six different mutations,
including four novel disease mutations. In contrast to the
previous observation, all four of our patients were normo-
cephalic and had normal cranial imaging, and three had a
favourable intellectual outcome. Vitamin B6 plasma pro-
ﬁling on pyridoxine of our patients with PROSC mutations
is currently ongoing and will delineate if it is speciﬁc for
PROSC mutations. The clinical and electroencephalo-
graphic phenotype in patients with PROSC gene mutations
was indistinguishable from the previously known genes
ALDH7A1 and PNPO. We therefore conﬁrm the PROSC
gene as novel gene for vitamin B6 dependent epilepsy and
will delineate the according plasma vitamin B6 proﬁle.
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Molecular diagnosis of patients with epilepsy and
developmental delay using a customized panel of epi-
lepsy genes
L. Ortega-Moreno, S. E. López-Pérez, B. G. Giráldez, V.
Soto-Insuga, R. Losada-Del Pozo, M. Rodrigo-Moreno, C.
Alarcón-Morcillo, G. Sánchez-Martín, E. Díaz-Gómez, J.
M. Serratosa, R. Guerrero-López, Grupo Español
Genética de las Epilepsias de la Infancia
IS-Fundación Jiménez Díaz, Madrid, Spain
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Pediatric epilepsies are a group of disorders with a broad
phenotypic spectrum that are associated with great genetic
heterogeneity, thus making sequential single-gene testing an
impractical basis for diagnostic strategy. The advent of
next-generation sequencing has increased the success rate of
epilepsy diagnosis, and targeted resequencing using genetic
panels is the a most cost-effective choice. We report the
results found in a group of 87 patients with epilepsy and
developmental delay using targeted exome sequencing
(custom-designed Haloplex panel). Using this gene panel,
we were able to identify disease-causing variants in 17 out
of 87 (19.5%) analyzed patients, all found in known
epilepsy-associated genes (KCNQ2, CDKL5, STXBP1,
SCN1A, PCDH19, POLG, SLC2A1, ARX, ALG13, CHD2,
SYNGAP1, and GRIN1). Twelve of 18 variants arose de
novo and 8 were novel. The highest yield was found in
patients with onset in the ﬁrst years of life, especially in
patients classiﬁed as having early-onset epileptic encepha-
lopathy. Knowledge of the underlying genetic cause pro-
vides essential information on prognosis and can be used to
avoid unnecessary studies, resulting in a greater diagnostic
cost-effectiveness. Ministerio de Economía y Competitivi-
dad (SAF2010-18586 and SAF2013-48960-P).Fundación
Conchita Rábago de Jiménez Díaz
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Impact of a targeted next generation sequencing strat-
egy for the genetic diagnosis of epileptic
encephalopathies
S. Gobin, E. Azouguene, C. Fourrage, S. Hanein, N.
Chemaly, M. Hully, L. Routier, C. Barnerias, N. Bahi-
Buisson, M. Rio, A. Kaminska, I. Desguerre, A. Munnich,
J. Bonnefont, J. Steffann, R. Nabbout, G. Barcia
Necker Hospital, Paris, France
Objective: Epileptic encephalopathies (EE) are clinically
and genetically highly heterogeneous conditions. We
developed a custom targeted next-generation sequencing
(TNGS) strategy for the molecular diagnosis of EE.
Patients: A custom NGS panel targeting 151 genes was
applied to a cohort of 92 patients (51 boys, 41 girls) affected
by EE classiﬁed as known syndromes in 61% and unclas-
siﬁed conditions in 39%. Epileptic seizures started at a
mean age of 9 months (range: birth-7 years). Acquired
pathologies, metabolic diseases and brain malformations
were excluded.
Results: A disease-causing genetic variant was identiﬁed
in 35/92 (38%) of patients and variants of unknown sig-
niﬁcance (VUS) in 7/92 (8%). The groups of migrating
focal seizures of infancy and unclassiﬁed EE had the
highest rate of positive ﬁndings, respectively 70% and 42%.
The most frequently involved genes were KCNQ2, KCNT1
and SCN2A. Mutations in KCNA2, PIGA, ALDH7A1 and
SCN8A were found in “atypical” phenotypes. TNGS
allowed the detection of SCN1A mutation at a low rate
somatic mosaicism (14%) and ofWWOX exonic deletions in
2 patients.
Conclusions: With a diagnostic yield of 38%, TNGS is
an efﬁcient strategy as ﬁrst-step genetic screening of EE.
Our results allowed prenatal diagnosis in 4 families.
Moreover, identifying a genetic diagnosis in patients with
EE can orient treatment management and clinical outcome.
Even if targeted approaches are restricted to a selected
group of genes, interpreting variants generated by TNGS is
challenging. TNGS offers a rapid and relevant selection of
patients available for WES and WGS studies.
1
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The searching for new variants in genes SLC2A1 and
RNASEH2A/B/C for patients with epileptic
encephalopathies
M. Belenikin1,2
Moscow Institute of Physics and Technology (State
University), Dolgoprudny, Russian Federation, 2Gamaleya
Research Institute of Epidemiology and Microbiology,
Moscow, Russian Federation
Background: epilepsies are highly heterogeneous multi-
factorial disease. Identiﬁcation of the causal mutations is
rather difﬁcult task. The aims of study: searching the new
genetic variants at SLC2A1 (GLUT1 deﬁciency syndrome)
and RNASEH2A/B/C genes (AGS4/AGS2/AGS3 types of
Aicardi-Goutieres syndrome (AGS)). Methods: 90 samples:
454 GSJunior (NimbleGen, 34 genes, associated with epi-
leptic encephalopathy), 20 samples: Illumina HiSeq (Sur-
eSelect, WES). Informed consents were obtained from legal
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representatives of patients according local ethical approval.
Results: 6 variants were identiﬁed at SLC2A1 gene for
6 samples: 5 synonymous substitutions (rs146879902,
rs2229682, rs11537641, rs1385129, rs34025424; ClinVar)
and 1 new indel (6 b.p. in length) at position g.36954
(NG_008232.1) (female, 6 y/o, MIM:606777). Among the
100 samples medical geneticist preselected ten patients with
preliminary diagnosis AGS. In RNASEH2A/B/C genes we
found 8 heterozygous missense mutations: RNASEH2A: 5
rs7247284 and 1 rs62619782; RNASEH2B: 2 rs144408326
and rs78705382. Also we identiﬁed 5 heterozygous
synonymous variants (2 at RNASEH2C, 3 at RNASEH2A).
Of particular interest were two cases: compound hetero-
zygous (two missense mutations rs7247284, rs62619782 at
RNASEH2A) was found for boy 5 y/o without spech. For
girl 16 y/o with strong intellectual retardation and speech
disorder were found heterozygous rs78705382 (RNA-
SEH2B) and rs138809301 (GRIN2A) variants. The author is
grateful to MD Ayvazyan S., Ananyeva T., Lukyuanova E.,
Meshcheryakova T, and Zhylina S. from Research Center
for Children Medical Care (Moscow) for patients selection.
The research was supported by the Department of Health of
Moscow.
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Genome-wide association study in essential tremor
identiﬁes three new loci
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Ladwig28,29, N. Dupré30, J. Jankovic23, K. Strauch31,32, M.
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Introduction: Patients with essential tremor (ET) have a
postural and kinetic tremor of the upper extremities and
sometimes of other body parts. Twin and family history
studies indicate a high heritability for ET. However, the
molecular genetic determinants of ET are largely unknown.
Previous GWAS studies suggested associations between
single nucleotide polymorphisms in LINGO1 and SLC1A2
and ET. Replication studies yielded equivocal results.
Materials and Methods: We conducted a two-stage GWAS
of ET. A total of 2,807 ET-patients and 6,441 controls of
European descent were analysed. The Affymetrix Axiom
Genome-wide CEU 1 Array Plate genotyping chip was used
in the discovery stage. The most signiﬁcantly disease
associated genetic markers were genotyped in the replica-
tion stage in an independent case/control sample. We per-
formed expression analysis of the three ET associated genes
in cerebellar cortex tissue of patients and controls and
mined public brain eQTL database Braineac. Results: After
Bonferroni correction, two genetic markers were conﬁrmed
to be associated with ET in the replication stage. The genes
ﬂagged by these markers code for the serine/threonine
kinase STK32B and a transcriptional coactivator
PPARGC1A. Another locus in CTNNA3 met the combined
analysis signiﬁcance threshold. Expression analysis
revealed a signiﬁcant increase in STK32B expression in ET
patients, while no differences were detected for the other
genes. Conclusions: We identiﬁed ET associated single
nucleotide polymorphisms in three loci corresponding to the
genes STK32B, PPARGC1A and CTNNA3. Expression
analysis and public eQTL data provide additional support
for a role of STK32B in ET pathogenesis.
S.H. Müller: None. S.L. Girard: None. F. Hopfner:
None. N.D. Merner: None. C.V. Bourassa: None. D.
Lorenz: None. L.N. Clark: None. L. Tittmann: None. A.
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Neurological phenotype for DST-related disorders
M. Pinelli1, G. Cappuccio1, A. Torella2, M. Alagia1, R.
Auricchio3, A. Staiano3, V. Nigro2, N. Brunetti-Pierri1,
TUDP Consortium
TIGEM & Department of Translational Medicine, Section
of Pediatrics, Federico II University, Naples, Italy, 2TIGEM
& Department of Biochemistry, Biophysics and General
Pathology, Campania University “Luigi Vanvitelli”,
Naples, Italy, 3Department of Translational Medicine,
Section of Pediatrics, Federico II University, Naples, Italy
The gene DST encodes for the large protein BPAG1 that is
involved in the formation of hemidesmosomes. Its alter-
native splicing gives rise to tissue-enriched isoforms for
brain, muscle, and skin. Homozygous DST loss-of-function
mutations cause an autosomal recessive form of epi-
dermolysis bullosa simplex (EBS). We present the case of a
17-years-old girl with pain insensitivity, recurrent skin
blistering, behavioral problems without cognitive impair-
ment. Blisters were localized at the sites of friction and
evolved into ulcers, pigmentary lesions, and atrophic scars.
In addition, she had recurrent headaches, and syncope epi-
sodes, iris heterochromia, cataract, hearing impairment,
syringomyelia, chronic diarrhea, osteopenia with multiple
fractures, osteomyelitis, and growth hormone deﬁciency.
EMG and nerve biopsy showed sensitive and autonomic
peripheral neuropathy. A family-trio whole-exome sequen-
cing unraveled two compound heterozygous variants in the
DST gene with highly-predicted functional impact:
c.806A>G (p.H269R) in exon 29, absent in controls, and
c.3886C>T (p.R1296X) exon 7, 1 allele present in ExAC.
Interestingly, exon 7 is included in the neuronal isoform
whereas exon 29 in all isoforms. Our patient expands the
phenotype of DST-related disorders that are associated with
different phenotypes ranging from isolated skin or periph-
eral nervous system involvement to more complex pheno-
types including a combination of skin and neuronal features,
likely as a consequence of the location of the mutation
relative to the DST isoforms. The identiﬁcation of further
patients with DST mutations might allow to better reﬁne this
genotype-phenotype correlation and to improve clinical
management. Supported by Telethon Italia grant
GSP15001/C.
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Mitogenomic analysis in FXTAS
L. Rodriguez-Revenga1,2, Alvarez-Mora1,2, Madrigal1,2,
Mila1,3
1Hospital Clinic, Barcelona, Spain, 2CIBERER and IDI-
BAPS, Barcelona, Spain, 3CIBERER and IDIBAPS, Bar,
Spain
Introduction: Mitochondria are key regulators of cellular
energy production and are involved in cellular processes
such as cell cycle progression, differentiation and apoptotic
cell death. Mutations in mtDNA accumulate during the
aging process in cells and tissues, causing respiratory chain
dysfunction and theoretically, compromising cellular func-
tion and survival. Some evidence support an association for
somatic mtDNA mutations in the development or progres-
sion of neurodegenerative disease. Fragile X-associated
tremor/ataxia syndrome (FXTAS) is a late-onset neurode-
generative disorder that appears in at least one-third of adult
FMR1 premutation carriers. In an attempt to provide new
data on the role of mtDNA mutations in FXTAS patho-
genesis, we have sequenced mtDNA employing next-
generation sequencing techniques in FXTAS patients.
Material and Methods: mtDNA from 26 unrelated
FMR1 premutation carriers (13 FXTAS and 13 non
FXTAS) were sequenced using the Nextera XT DNA
Sample Preparation kit (Illumina) with a 3000X medium
coverage in a MiSeq platform.
Results: No differences were observed in the total
number of mtDNA on comparing the FXTAs and non
FXTAS group. However, the FXTAS cohort showed a
signiﬁcantly higher number of heteroplasmic variants. An
association was found between these variants and their
localization (within or outside the D-loop) in FXTAs group.
Conclusion: FXTAS patients seem to accumulate a
higher number of heteroplasmic variants in compromised
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regions of the mtDNA, thereby suggesting the potential role
of these variants in the pathogenesis of FXTAS.
Acknowledgements: ISCIII [(PI12/00879], FEDER
CERCA Programme and AGAUR (2014 SGR603)
CIBERER (ISCIII).
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A novel missense variation (Q220R) of GNB4 encoding a
guanine nucleotide-binding protein, beta-4 in a Japanese
neuropathy family
S. Miura1, T. Morikawa2, R. Fujioka3, K. Noda4, K.
Kosaka2, T. Taniwaki1, H. Shibata2
Division of Respirology, Neurology and Rheumatology,
Department of Medicine, Kurume University School,
Kurume, Japan, 2Division of Human Molecular Genetics,
Medical Institute of Bioregulation, Kyushu University,
Fukuoka, Japan, 3Department of Food and Nutrition,
Beppu University Junior College, Beppu, Japan, 4Depart-
ment of Neurology, Fukuoka Saiseikai Futsukaichi Hospi-
tal, Chikushino, Japan
Dominant intermediate Charcot-Marie-Tooth disease F
(CMTDIF) is an autosomal dominant hereditary CMT
caused by variations in the GNB4 gene. We examined two
Japanese familial cases with CMT. Case 1 was a 49-year-
old male. The chief complaint was slowly progressive gait
disturbance and limb dysesthesia which appeared at age 47.
On neurological examination, he showed hyporeﬂexia or
areﬂexia, distal limb muscle weakness, and distal sensory
impairment with lower dominancy. Nerve conduction stu-
dies demonstrated demyelinating sensorimotor neuropathy
with reduced action potentials in the lower limbs. Case 2
was an 80-year-old man, case 1’s father, had no complaint.
On neurological examination, he showed areﬂexia in the
upper and lower limbs. Distal sensory impairment in the
lower limbs was also observed. Nerve conduction studies
revealed mainly axonal change. By the exome analysis, we
identiﬁed a novel heterozygous nonsynonymous variant
(c.659T>C; Q220R) in exon 8 of the GNB4 gene encoding a
guanine nucleotide-binding protein, beta-4 through the
examination of 67 candidate genes known to be responsible
for CMT. By Sanger sequencing, we conﬁrmed that both
patients are heterozygous for the variation. Q220R in GNB4
was predicted to be damaging by Polyphen-2. The SNV is
located in the highly conserved region in GNB4 among
vertebrates. ExAC showed the allele frequency was
0.000008247. This variation was not observed by in-house
Sanger sequencing of 502 Japanese control subjects. We
conclude that the novel variation in GNB4 is the causative
variant for the CMTDIF patient that is the ﬁrst record of the
disease in the Japanese population.
S. Miura: None. T. Morikawa: None. R. Fujioka:
None. K. Noda: None. K. Kosaka: None. T. Taniwaki:
None. H. Shibata: None.
P09.062B
With improving technologies, can we sit on the fence
with Huntington disease alleles?
F. Khawaja1, S. Tobi2, J. P. Warner3, Z. C. Deans1
1UK NEQAS for Molecular Genetics, Royal Inﬁrmary of
Edinburgh, Edinburgh, United Kingdom, 2Genomic Diag-
nostics Laboratory, Manchester Centre for Genomic
Medicine, Manchester, United Kingdom, 3South East of
Scotland Clinical Genetics Service, David Brock Building,
Western General Hospital, Edinburgh, United Kingdom
The UK National External Quality Assessment Service (UK
NEQAS) for Molecular Genetics challenged participants of
the 2016 Huntington disease (HD) external quality assess-
ment (EQA) scheme by distributing a patient sample with
an allele containing 35 repeats (as determined by sourcing
laboratory) i.e. on the normal/reduced penetrance border.
Fourteen of the HD EQA reports submitted included the
size of the triplet repeat allele and a sizing error range. Half
of the participants were deducted marks for failing to state
the possibility that taking into account their quoted sizing
error meant a diagnosis of HD could not be excluded from
the patient.
With advances in modern technology, there has been a
signiﬁcant improvement in the accuracy of triplet repeat
allele sizing amongst laboratories. Seventeen of the eighteen
participants reported identical allele repeat sizes (28 and 35
repeats) and the remaining laboratory was close to the
consensus (28 and 36 repeats). However the implementation
of ISO 15189 has resulted in uncertainty of measurement
being included in clinical reports resulting in the allele size
being portrayed as a range rather than a deﬁned size.
Various testing methods were used for analysis and
although there was consistency in the size of the alleles
reported, the reluctance to commit to a speciﬁc size still
remains, contributing to the deduction of marks in the HD
2016 EQA. The question laboratories must ask themselves
is - with improving technologies, can we sit on the fence
with HD alleles?
F. Khawaja: None. S. Tobi: None. J.P. Warner: None.
Z.C. Deans: None.
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Dissecting the mechanism of action of olesoxime, a
potential therapeutic in the treatment of Huntington’s
disease
S. Kloock1,2, J. Weber1,2, O. Riess1,2, H. Nguyen1,2
Institute of Medical Genetics and Applied Genomics,
University of Tuebingen, Tuebingen, Germany, 2Centre
for Rare Diseases, University of Tuebingen, Tuebingen,
Germany
Introduction Huntington's disease (HD) is a fatal neurode-
generative disorder which is caused by a CAG repeat
expansion in the HTT gene, which encodes the disease
protein huntingtin (htt). An important characteristic of HD
is the proteolytic cleavage of mutant htt and formation of
toxic protein fragments. Different studies showed that cal-
pains, a calcium-activated class of cysteine proteases, are
involved in htt proteolysis. Calcium dyshomeostasis and
mitochondrial dysfunction - further features of HD - may
amplify calpain-mediated mhtt fragmentation as well. This
vicious circle could be interrupted by the cholesterol deri-
vate olesoxime (TRO19622), which binds the mitochondrial
calcium channel VDAC1 and may affect its conductance.
Material and Methods Brain samples of six month old
Hdh-knock-in mice were collected to investigate VDAC1
and IP3 receptor levels in vivo. HEK 293T and PC12 cells
overexpressing wild-type and mutant htt were transfected
with cDNA plasmids or esiRNA to overexpress or knock
down VDAC1 in the HD context. VDAC1 activity was
targeted pharmacologically by the administration of ole-
soxime and itraconazol. All protein samples were analysed
via western blotting.
Results We observed an elevated calpain system activa-
tion and an reduced VDAC1 expression in the striatum of
six-month-old HD mice. Furthermore, we successfully
performed VDAC1 knock-down and overexpression, and
pharmacological treatments in cell culture to analyse their
impact on calpain activity, and htt cleavage and
aggregation.
Conclusion Targeting VDAC1 expression and activity
helps to understand olesoxime’s mode of action and might
by itself represent a promising therapeutic approach for HD.
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Metformin rescues early cognitive symptoms in the
HdhCAG150 mouse model and is therefore a promising
candidate for treatment of HD patients
M. Willam1, K. Radyushkin2, J. Winter1, S. Krauß3, R.
Langston4, O. Monteiro4, C. Chen4, T. Schacht5, A.
Methner5, S. Schweiger1
1Institute for Human Genetics, Mainz, Germany, 2Mouse
Behavior Outcome Unit of the Johannes Gutenberg
University Mainz, Mainz, Germany, 3DZNE, Bonn, Ger-
many, 4Division of Neuroscience, Dundee, United King-
dom, 5Department of Neurology, Mainz, Germany
Huntington‘s disease (HD) is an autosomal dominant neu-
rodegenerative disorder caused by an unstable glutamine
(CAG) trinucleotide repeat expansion within exon 1 of the
Huntingtin gene and leads to cognitive decline and affects
motor abilities. In the prodromal phase patients develop
mood swings, personality changes and subtle cognitive
impairment. Close understanding of clinical signs and
molecular mechanisms behind this early stage of HD is
important for the development of a causal therapy. We have
analysed a knock-in mouse model that carries 150 CAG
repeats and the human exon 1 in the 5′ end of the murine
huntingtin gene. By using a novel object recognition test we
have found a profound deﬁciency of hippocampus depen-
dent long-term memory in heterozygous transgenics. This
phenotype was detected as early as 12 weeks of age. Motor
deﬁcits and intranuclear aggregates are described at much
later stages. We have shown previously that in HD patients,
mediated through mTOR signaling, translation of mRNA
carrying expanded CAG repeats is elevated (Krauss et al.,
2013). We have also seen that the biguanid metformin
antagonizes mTOR signaling in neurons in-vitro and in-
vivo (Kickstein et al., 2010). We show here that metformin,
by interfering with the mTOR kinase and its opposing
phosphatase, PP2A, regulates local protein synthesis in the
brain and suppresses the production of disease making
protein in early HD. Furthermore metformin leads to a
rescue of early cognitive symptoms in the HdhCAG150
animal model. These data suggest that metformin is a pro-
mising candidate for early phase treatment of HD.
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Targeted next generation sequencing in patients with
infantile bilateral striatal necrosis and movement
disorders
L. Martí-Sánchez1, J. Ortigoza-Escobar1, M. Molero-
Luis1, C. Avilés1, H. Baide1, J. Muchart1, M. Rebollo1, E.
Turón-Viñas2, J. Cabrera-López3, Y. Tong-Hong4, M.
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Introduction: Infantile bilateral striatal necrosis (IBSN) is a
heterogeneous histo-pathological condition deﬁned by the
involvement of the neostriata that can be observed in a very
large number of neurological conditions clinically domi-
nated by the presence of movement disorders (MD). MD are
a group of neurological syndromes which affect the ability
to produce and control movement.
Materials and Methods: In a prospective study over the
course of 1 year, we applied targeted next-generation
sequencing (NGS) of 118 genes (76 genes for IBSN and 42
genes for MD), using HaloPlex technology from Agilent
Technologies. In addition, we studied biomarkers of known
causes of IBSN, including blood interferon signature and
free-thiamine and pterins in CSF.
Results: We included 39 patients (26 male, age 1–21
years; mean±SD 8.1±4.3 years). Onset of symptoms was
acute in almost all patients. Interferon signature was altered
in two patients with Aicardi-Goutierès syndrome. Low free-
thiamine and elevated pterins in CSF were detected in two
and three patients, respectively. We established ﬁrm mole-
cular diagnosis in 28% (11/39) of patients, with mutations
in the following genes: RNASEH2B, PDH1A, ADAR,
SLC25A19, NDUFAF6, CACNA1A, FOXG1, SLC39A14,
ATP1A3, TUBBA4 and SGCE, including seven novel
mutations.
Conclusions: Targeted NGS leads to rapid and cost-
effective detection of causative mutations in IBSN and MD.
We have reached a diagnostic rate similar to other labora-
tories. Our study reports new cases of recently described
genes and it brings us closer to the use of personalized
medicine for routine diagnosis.
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PACS1 vs. GNAO1-single or aggregated effect on the
phenotype of a boy with intractable epilepsy and neu-
rological decline
A. Chirita-Emandi1, S. Dumitriu2,1, N. Andreescu1, S.
Farcas1, M. Puiu1
1Center for Genomic Medicine, Genetics Department,
University of Medicine and Pharmacy Victor Babes,
Timisoara, Romania, 2Barnet Enﬁeld and Haringey MHT,
London, United Kingdom
Whole exome sequencing (WES) is effective in identifying
the genetic cause of seizures in patients with early onset
epilepsy, with potential implications for speciﬁc treatment.
Method: A 10 years old male, presents intractable sei-
zures(up to 100/month), since age 2 years,8 months. He has
no dysmorphic features and shows severe regression in
cognitive and motor skills. Normal brain structure. Array
CGH and WES were performed.
Results: Array CGH was normal. WES detected a de
novo heterozygous frameshift variant in the PACS1 gene,
c.778dup p.(His260Profs*2); Chr11(GRCh37):
g.65983707dup; classiﬁed as likely pathogenic. Another
heterozygous variant in the GNAO1 gene, c.389G>A p.
(Arg130Gln); Chr16(GRCh37): g.56362628G>A; was
classiﬁed as VUS.
Discussion: A single de novo missense variant in PACS1
gene has been described by Schuurs-Hoeijmakers et al., as
disease-causing for an autosomal dominant(AD) disorder
characterized by mental retardation, distinct craniofacial
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features, intellectual disability and seizures. GNAO1 gene
pathogenic variants are associated with early infantile epi-
leptic encephalopathy type 17, a severe AD neurologic
disorder characterized by onset of intractable seizures in the
ﬁrst months of life; poor psycho-motor development and
brain abnormalities.
Conclusion: This is an unreported PACS1 variant with
partial overlap of the phenotype described by Schuurs-
Hoeijmakers. The disorders associated with GNAO1 gene
also show considerable phenotype overlap with the patient
and therefore the variant possibly contributes to his overall
presentation. Genetic counseling was done accordingly.
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De novo mutations in C terminal domain of ITPR1 are a
frequent cause of Gillespie syndrome
S. Barresi1, M. L. Dentici1, M. Nardella1, E. Bellacchio1,
P. Alﬁeri1, A. Bruselles2, F. Pantaleoni1, A. Danieli3, G.
Iarossi1, M. Cappa1, E. Bertini1, M. Tartaglia1, G. Zanni1
Bambino Gesù Children's Hospital, Rome, Italy, 2Istituto
Superiore di Sanità, Rome, Italy, 3IRCCS E. Medea,
Conegliano, Italy
ITPR1 encodes inositol 1,4,5 tri-phosphate receptor type 1,
a transmembrane protein localized at the endoplasmic reti-
culum involved in the regulation of intracellular Ca2+
homeostasis and signaling. ITPR1 is highly expressed in the
cerebellum, and inactivating or dominantly acting mutations
in this genes have been identiﬁed to cause spinocerebellar
ataxia and non-progressive congenital ataxia with or with-
out intellectual disability. Recently, mutations of ITPR1
have been associated with Gillespie syndrome, character-
ized by congenital ataxia, mild to moderate intellectual
disability and iris hypoplasia. Exome sequencing and tar-
geted resequencing in two families with sporadic Gillespie
syndrome allowed to identify a novel (p.N2576I) and a
previously reported (p.K2596del) de novo heterozygous
mutations affecting the C-terminal transmembrane domain
of the receptor in both patients. Our study expands the
mutational spectrum of ITPR1 associated with Gillespie
syndrome and indicates that ITPR1 screening should be
implemented in patients with congenital cerebellar ataxia
with or without aniridia.
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Mutations in KIAA0753 cause Joubert syndrome asso-
ciated with growth hormone deﬁciency
J. Stephen1, T. Vilboux2,1, L. Mian1, C. Kuptanon1, C. M.
Sinclair1, D. Yildirimili1, D. M. Maynard1, J. Bryant1, R.
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MD, United States, 6Johns Hopkins University School of
Medicine, Department of Pediatrics and McKusick-Nathans
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Introduction: Joubert syndrome (JS) is a type of ciliopathy
deﬁned based on mid-hindbrain abnormalities that result in
characteristic “molar tooth sign” on brain imaging.
Although over 30 JS genes have been identiﬁed to date,
they do not account for all JS patients suggesting further
genetic heterogeneity. Materials and Methods: We per-
formed whole exome sequencing (WES) of a family with
two affected individuals presented with JS and severe
growth hormone deﬁciency. We used RT-PCR, immuno-
blotting and ﬂuorescence microscopy to further investigate
the pathogenicity of mutations. Results: WES identiﬁed
novel compound heterozygous mutations in KIAA0753
(OFIP), a missense (p.Arg257Gly) and an intronic (c.2359-
1G>C) mutation, in both affected siblings. OFIP, a com-
ponent of OFIP-OFD1-FOR20 complex, is a centrosome
and pericentriolar satellite (PS) protein essential for cilio-
genesis and centriole duplication. p.Arg257Gly is patho-
genic according to prediction tools and c.2359-1G>C alters
normal splicing by activating a cryptic acceptor splice site,
leading to skipping of nine nucleotides that in turn deletes
three amino acids from the coding frame (p.
Lys787_Gln789del). The missense mutation lies in the PS
targeting domain of OFIP which likely disturbs the
recruitment of OFIP complex to the centrosome while in-
frame deletion resides in the highly conserved C-terminal
domain that interacts with OFD1. Analysis of cilia from
cells of patients showed signiﬁcantly lower number of
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ciliated cells (~20–30%) and decrease in cilia length (~15–
20%). Conclusions: Our study highlights two patients with
JS with defective KIAA0753, that affects normal ciliogen-
esis. Funding: This work was supported by the Intramural
Research Program at the NHGRI, NIH, USA
J. Stephen: None. T. Vilboux: None. L. Mian: None.
C. Kuptanon: None. C.M. Sinclair: None. D. Yildirimili:
None. D.M. Maynard: None. J. Bryant: None. R.
Fischer: None. M. Vemulapalli: None. J.C. Mullikin:
None. N. Comparative Sequencing Program: None. M.
Huizing: None. W.A. Gahl: None. M.V. Malicdan: None.
M. Gunay-Aygun: None.
P09.069A
Autosomal dominant Kidd-null blood group with mood
disorders is associated to a zinc-ﬁnger deletion at
ZNF850
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M. Zindel1,2, L. Sans3,6, L. G. Biesecker7, M. G. Fornés8,
N. Nogués9, J. Takahashi10, Y. Tani11, V. Campuzano1,2,3,
M. Á. Rodríguez-Granado4, D. S. Krause5, L. A. Pérez-
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Universitat Pompeu Fabra, Barcelona, Spain, 2Centro de
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Transfusión de la Comunidad de Madrid, Madrid, Spain,
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Background: The Kidd-null blood group, lacking the urea
transporter UT-B1/SLC14A1 in the erythrocyte membrane,
is associated with transfusion risk and urine concentration
defect in humans, and depression-like behavior in mice.
While the autosomal recessive form is due to biallelic
SLC14A1 mutations, the cause of the dominantly inherited
form remained unknown. We identiﬁed six new families
originating from the south of Spain with dominantly
inherited Kidd-null. Methods: Subjects with Kidd-null ery-
throcytes underwent medical and psychological evaluation,
and two probands were tested for urine concentration. We
performed genome-wide linkage analysis, exome
sequencing, mRNA and protein expression analyses in
samples from patients, and functional studies in cell lines.
Results: Most Kidd-null individuals (80.77%) fulﬁlled cri-
teria for mood and/or anxiety disorder, with 7.4-fold
increased suicidal risk (95%CI:2.3–16.7, p=7.9×10−4). The
tested cases presented a reduced ability to concentrate urea
in urine. Kidd-null cells had reduced quantity of glycosy-
lated UT-B1 at the erythrocyte membrane although
SLC14A1 mRNA levels were normal. Linkage analyses
identiﬁed a shared haplotype at 19q13 and exome sequen-
cing identiﬁed a deletion of a single C2H2 zinc ﬁnger-
encoding domain of ZNF850 in Spanish kindreds, absent in
controls. An overlapping deletion was identiﬁed in a Japa-
nese Kidd-null case. Compared to wild-type, mutant
ZNF850 had decreased cytoplasmic location in transfected
HEK293T cells. Conclusions: A predicted zinc-ﬁnger
deletion at ZNF850, prevalent in Southern Spain due to a
founder mutation, leads to UT-B1 dysfunction and underlies
the dominantly inherited Kidd-null blood group. The phe-
notype associates subnormal urine concentrating ability,
mood and/or anxiety disorders, and increased suicidal risk.
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NGS approaches for the molecular diagnosis of leuko-
dystrophies : a french experience
S. Samaan1,2, I. Dorboz2, F. Renaldo-Robin3, K.
Boussaid3, M. Elmaleh4, S. Drunat1,2, D. Rodriguez2,5, O.
Boespﬂug-Tanguy2,3
1Medical Genetics Department, Robert Debre University
Hospital, Paris, France, 2INSERM UMR-S1141, DHU
PROTECT, Paris Diderot University, Robert Debre Uni-
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diatric and metabolic diseases, Robert Debre University
Hospital, Paris, France, 4Department of Radiology, Robert
Debre University Hospital, Paris, France, 5Department of
Neuropeadiatrics, Armand Trousseau University Hospital,
Paris, France
Introduction The confrontation of cerebral MRI patterns
with clinical and neurophysiological data allowed the
classiﬁcation of leukodystrophies (LD), a heterogeneous
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group of neurodegenerative hereditary diseases affecting the
white matter (WM) and its major component, myelin. The
genetic heterogeneity requires high-throughput sequencing
approaches (NGS) to optimize the identiﬁcation of the
causal genes of the largest number of patients.
Materials and Methods Targeted resequencing panel of
45 genes associated with recurrent LD was developed to
study 224 patients adressed for diagnostic purpose. In par-
allel, WES (whole exome sequencing) was performed in an
independent cohort of 100 patients with LD of unknown
etiology.
Results Whereas 56% of cases were diagnosed by WES
analyses, targeted resequencing panel allowed the identiﬁ-
cation of causal mutations in 51/224 patients (23%). In 14
cases (6%), the absence of clinical, MRI data or segregation
studies did not conﬁrm the deleterious caracter of the found
variants. Interstingly, 19% of the mutations identiﬁed by
WES affected 4 genes involved in Aïcardi-Goutiere, HAB-
C and polymerase III linked hypomyelinating syndrome in
addition to PMD. Similar distribution of thoses diseases was
obtened by the targeted resequencing approach suggesting
that their clinical spectrum may have been incomplete.
Conclusion A targeted resequencing approach, studying
the most frequent genes involved in LD, seems to be good
strategy to estabilsh an exaustive molecular diagnosis in,
approximatively, a quarter of cases. WES should be indi-
cated as second step particularly for patients with familial
forms presenting atypical clinical features. Importantly,
clinical spectra of genetic WM abnormalities should be
redeﬁned.
S. Samaan: None. I. Dorboz: None. F. Renaldo-
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Drunat: None. D. Rodriguez: None. O. Boespﬂug-Tan-
guy: None.
P09.071C
LBSL with intellectual disability: Apparent homo-
zygosity due to segmental uniparental disomy at DARS2
locus and misdiagnosis as syrinx of spinal cord
A. Ronan1,2, C. Sorensen3, C. Miteff4, M. van der Knaap5
Hunter Genetics Unit, Newcastle NSW, Australia, 2Univer-
sity of Newcastle, Newcastle NSW, Australia, 3Genetics
Services,, Port Macquarie NSW, Australia, 4Paediatric
Neurology, John Hunter Hospital, Newcastle NSW, Aus-
tralia, 5VU University Medical Centre, Amsterdam,
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Leukoencephalopathy with Brain Stem and Spinal Cord
involvement and Lactate elevation (LBSL) was diagnosed
in a 16 year old Australian girl with severe autism and
intellectual disability but no neurological motor impairment.
Diagnosis was made on review of brain imaging following
identiﬁcation of apparently homozygous DARS2 mutations
on Next Generation Sequencing. MRI was initially reported
as showing patchy demyelination suggestive of Multiple
Sclerosis, with a syrinx of the spinal cord but no brain stem
lesions. The syrinx was correctly identiﬁed as demyelina-
tion of the posterior columns on review. Parental testing
identiﬁed a heterozygous DARS2 mutation in the mother but
the father was not available for testing. A SNP array was
performed looking for possible uniparental disomy to
explain the apparent homozygosity as the parents were
unrelated. This identiﬁed a region of Loss of Heterozygosity
of 5.3Mb at chromosome 1q25 encompassing DARS2.
Intellectual Disability is uncommon in LBSL and identiﬁ-
cation of motor disability was hindered here due to previous
traumatic amputation of one leg and extreme behavioural
problems.
A. Ronan: None. C. Sorensen: None. C. Miteff: None.
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New RNA polymerase III Leukodystrophy
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Boespﬂug-Tanguy1,4
1Inserm U1141, Paris, France, 2Inserm U1212 - Cnrs UMR
5320, Université de Bordeaux, Bordeaux, France, 3Depart-
ment of Medical Genetics, UF Molecular Genetics, Robert
Debré, Paris, France, 4Department of Neuropeadiatric and
metabolic diseases, Robert Debré University Hospital,
Paris, France, 5Department of Radiology, Robert Debré
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RNA polymerase III (POLR3)-related leukodystrophy is an
autosomal recessive hypomyelinating leukodystrophy
characterized by a progressive cerebellar spastic syndrome
with variable age of onset and associated hypo/oligodontia
and hypogonadotropic hypogonadism. This disorder is
caused by mutations in POLR3A, POLR3B and POLR1C.
Here we report two cases of patients with mutation in a gene
coding for another POLR3 subunit. The affected individuals
from consanguineous Algerian parents present with a Peli-
zaeus Merzbacher like disease with a sitting position
acquired with aid (form 1) in one patient and walking with
aid (Form 3) for the other before 24 months of age. A
progressive degradation was observed after 5 years of age
leading to bedridden patients with severe spasticity and
dystonia at respectively 6 and 16 years of age. Despite
gastrostomy, severe growth impairment was observed in
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both cases with hypogonadism in the oldest one and severe
anorexia and hypodontia in the youngest one. Brain MRI
showed a diffuse hypomyelinating leukodystrophy without
cerebellum and subcortical /cortical atrophy at 4 y of age.
Exome sequencing combined to homozygosity mapping
revealed a homozygous mutation. This variant was pre-
dicted to be deleterious, located in a highly conserved
region and not detected in 492 ethnically matched control
chromosomes. In silico structural and functional analysis
predicted that this mutation create conformational changes
in the POLR3 subunit complex. Functional studies in the
patients’ ﬁbroblasts revealed an abnormal expression in
ribosomal RNAs. This study conﬁrm the role of the poly-
merase III in the nervous system and particularly in the
white matter
I. Dorboz: None. K. Boussaid: None. H. Dumay-
Odelot: None. S. Samaan: None. F. Renaldo: None. M.
Elmaleh: None. M. Teichmann: None. O. Boespﬂug-
Tanguy: None.
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Introduction: Malformations of cortical development
(MCD) represent a huge burden to patients and their
families. MCD are diagnosed by (fetal) magnetic resonance
imaging or post-mortem studies. Molecular diagnosis is
signiﬁcantly hampered by the high degree of phenotypic
and genotypic heterogeneity. To optimize diagnosis and
facilitate genetic counselling we have developed a next
generation sequencing gene panel for MCD.
Materials and methods: The panel includes 193 genes
known to be associated with microcephaly, mega-
lencephaly, focal cortical dysplasia, periventricular hetero-
topia, lissencephaly, cobblestone malformation,
polymicrogyria, or vascular brain malformations.
Results: Over a period of 19 months, we have analysed
166 probands with MCD. We were able to ﬁnd a causative
mutation in 29 patients, resulting in a diagnostic yield of
17%. The average coverage is 823x and ~96% of the
regions are covered at least 30×. Most mutations occurred
de novo. The tubulin gene family genes were mutated most
frequently in the cohort of patients with polymicrogyria or
lissencephaly and included mutations in TUBA1A (2),
TUBG1 (2), TUBB3 (2) and TUBA2A (1). The results have
enabled us to further delineate the phenotypic spectrum
associated with mutations in these genes. Mutations in
FLNA (5) accounted for the most frequent cause of peri-
ventricular heterotopia. The remaining mutations occurred
in ARX, ASPM, CASK, COL4A1, DCX, DEPDC5,
DYNC1H1, L1CAM, PTCH1, PTEN, RTTN, TCF4, TREX1
and TSEN54. The mutation in L1CAM was found in a fetal
case.
Conclusion: The implementation of the gene panel in the
MCD diagnostic workﬂow has improved the diagnostic
yield and genetic counselling.
K. Stouffs: None. A. Gheldof: None. S. Seneca: None.
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Effect of variable numbers of tandem 30-base-pair
repeats on promoter activity of the monoamine oxidase
A gene
P. Limprasert, A. Hnoonual, P. Graidist
Faculty of Medicine, Prince of Songkla University,
Songkhla, Thailand
Introduction: Monoamine oxidase A (MAOA) is an
enzyme that degrades neurotransmitters such as serotonin,
dopamine and norepinephrine. The upstream of the pro-
moter region contains a number of polymorphic tandem 30-
base-pair repeats, 2.5, 3.5, 4.5, and 5.5 repeats (2.5R, 3.5R,
4.5R and 5.5R), associated with neuropsychiatric disorders.
Previous controversial reports have suggested that different
repeats have been associated with different promoter
activities (PA) of the MAOA gene. Materials and Methods:
To evaluate the PA of known repeats and a novel 3.3R, we
constructed ﬁve alleles, 2.5R, 3.3R, 3.5R, 4.5R and 5.5R,
and inserted them into the basic pGL3 vectors, and trans-
fected them into two neuroblastoma cell lines (LA-N-5 and
SK-N-SH). We triplicately determined the PAs in each
basic and constructed vector using the luciferase reporter
assay. We used the paired t-test for the statistical compar-
ison of mean PAs between pairs of alleles. Results: Vectors
with 3.3R and 4.5R had approximately 1.5–2.0 higher PAs
than those with 3.5R and 5.5R. The PAs were statistically
signiﬁcantly different among pairs of low and high PA
groups with P-value < 0.05 (i.e. 3.3R vs 3.5R; 4.5R vs
5.5R). Although the vector with 2.5R almost always
showed similar PAs to those with other alleles in both cell
lines, a statistically signiﬁcant difference between vectors
with 2.5R and 5.5R was found only in the SK-N-SH cell
line (P = 0.03). Conclusion: Our study conﬁrms that the
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length of tandem 30-base-pair repeats has an effect on the
promoter activity of the MAOA gene. Grant: Medicine, PSU
P. Limprasert: None. A. Hnoonual: None. P. Graidist:
None.
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patient
R. Cittadella1, E. V. De Marco1, E. Tartara2, G. Piccolo2,
A. Cortese2, I. Ricca2, M. Terzaghi2, P. Benna3, C. A.
Galimberti2
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Council, Cosenza, Italy, 2IRCCS C. Mondino National
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Introduction: McLeod syndrome (MLS) is a rare X-linked
recessive neurodegenerative and multisystemic disease
caused by mutations in the XK gene, that has been identi-
ﬁed at the Xp21 locus. Clinical manifestations, which
include acanthocytosis, chronic anaemia, haemolysis,
hyperCKemia, myopathy, cardiomyopathy, chorea, epi-
lepsy, usually appear after the third or fourth decade of life.
Patient and Methods: We present a 46-year-old male patient
of Italian origin with pharmacoresistant focal epilepsy of
unknown cause of adult onset, associated with persistent
and asymptomatic increase of creatine kinase (CK). The
patient progressively developed mild dyskinetic involuntary
movements, mild obsessive tendencies and axonal neuro-
pathy; acanthocytosis was detected on blood smear, and
immunoserological analyses conﬁrmed the expression of
the Kell antigens supporting the McLeod phenotype. Two
cousins on the maternal side both affected by focal epilepsy
of unknown cause: one showed asymptomatic CK increase
and the other acanthocytosis. Molecular genetic analysis of
the XK gene was performed by sequencing the three exons
and ﬂanking regions. Results: In the proband, molecular
genetic analysis of the three exons of the XK gene detected
a hemizygous 17 base-pair frameshift deletion at exon 1
(c.248_264delGGCCGAGACAACGGCGG). Discussion:
To the best of our knowledge, this variant has not been
previously reported and is not present in public databases.
Epileptic seizures are reported within this syndrome up to
50% of cases, without speciﬁc syndromic features and
usually are not the prominent symptom. This family showed
epilepsy as the main clinical feature, which is not com-
monly described in this disease.
R. Cittadella: None. E.V. De Marco: None. E. Tar-
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Mitochondrial DNA haplogroups are Associated with
psychiatric disease: a nation-wide study of 74,763 Danes
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1Statens Serum Institut, Copenhagen, Denmark, 2University
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Disturbed mitochondrial function has been implicated in
psychiatric disease. All mitochondria contain a small
maternally inherited DNA (mtDNA) of 16.6 kb. Through
evolution and genetic drift the mtDNA sequence has
become ﬁxed into haplogroups (hgs) with a characteristic
population and geographical distribution. Different hgs
exhibit variable functional capacity and have been demon-
strated to be susceptibility factors for various, pre-
dominantly degenerative, diseases. Using dried blood spots
from 50,567 Danish psychiatric patients and 24,196 con-
trols we examined the association between psychiatric dis-
ease and mtDNA haplogroup in the Danish population. Hg
M was associated with affective disorder (n = 17260) with
an OR of 0.47 (cﬁ.95%: 0.39 - 0.58) (p = 1*10−14), ADHD
(n = 13395) with an OR of 0.50 (0.40 - 0.62)(p = 2*10−11).
Among patients belonging to the macro-hg N, patients with
schizophrenia (n = 2589), had a high proportion of hg A (n
= 45), OR: 4.52 (cﬁ.95%: 3.0 - 6.7)(p = 1.2*10−12). In a
mitoGWAS, three mitoSNPs were highly associated with
affective disorder (p-values ranging from 2*10−25 - 2*10
−21), ADHD (p-values: 2*10−11 - 1*10−10), and anorexia
(p-values: 6*10 −8 - 6*10−7) and another mitoSNP with
schizophrenia (p = 2*10−11). In conclusion, psychiatric
disease is a bigenomic disease. Haplogroup A is a risk
factor for schizophrenia and haplogroup M is a protective
factor.
J. Bybjerg-Grauholm: None. C.M. Hagen: None. M.
Bækvad-Hansen: None. C.S. Hansen: None. P.L. Hed-
ley: None. J.K. Kanters: None. J. Nielsen: None. M.
Theisen: None. O. Mors: None. T.M. Werge: None. M.
Nordentoft: None. A. Børglum: None. P.B. Mortensen:
None. D.M. Haugaard: None. M. Christiansen: None.
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Mitochondrial DNA SNPs Associated with schizo-
phrenia exhibit highly variable inter-allelic haplogroup
afﬁliation and nuclear genogeographic afﬁnity: Major
concerns for link to disease
C. M. Hagen1, V. F. Goncalves2, P. L. Hedley1, J. Bybjerg-
Grauholm1, M. Bækvad-Hansen1, C. S. Hansen1, J. K.
Kanters3, J. Nielsen4, O. Mors5, A. B. Demur6, J.
Kennedy2, T. M. Werge6, M. Nordentoft7, A. Børglum5, P.
B. Mortensen5, D. M. Haugaard1, M. Christiansen1
Statens Serum Institut, Copenhagen, Denmark, 2University
of Toronto, Toronto, ON, Canada, 3Univeristy of Copenha-
gen, Copenhagen, Denmark, 4Aalborg University Hospital,
Aalborg, Denmark, 5Aarhus University, Aarhus, Denmark,
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Mitochondria play a signiﬁcant role in human diseases.
However, disease associations with mitochondrial DNA
(mtDNA) SNPs have proven difﬁcult to replicate. A rea-
nalysis of eight previously schizophrenia-associated
mtDNA SNPs, in 23,743 normal Danes and 2,538 schizo-
phrenia patients, revealed marked inter-allelic differences in
haplogroup afﬁliation and nuclear genogeophraphic afﬁnity
(GGA), suggesting population stratiﬁcation. Two SNPs,
m.15043A and m.15218G, were signiﬁcantly (p < 0.05) and
two, m.3197C and m.10398G, borderline signiﬁcantly (p <
0.1) associated with schizophrenia. However, these asso-
ciations disappeared when corrected for haplogroup
afﬁliation. The extensive variation in SNP mtDNA afﬁlia-
tion and GGA should be major concerns when interpreting
historic and designing future mtDNA association studies.
C.M. Hagen: None. V.F. Goncalves: None. P.L.
Hedley: None. J. Bybjerg-Grauholm: None.M. Bækvad-
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explanation for variable phenotypes?
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Netherlands, 4Epilepsy Center Kempenhaeghe, Heeze,
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Introduction: Phenotypes caused by de novo SCN1A
mutations are very variable, ranging from Dravet syndrome
on the severe end of the spectrum, to GEFS+ on the other
end. We investigate whether mosaicism is a major modiﬁer
of de novo SCN1A mutations. Materials and Methods: We
tested 39 patients for mosaicism, from a cohort of 131
patients with de novo, pathogenic SCN1A mutations. Clin-
ical data were collected from medical records and semi-
structured telephone interviews. Next Generation Sequen-
cing with high coverage was performed on DNA from
blood, after capture of SCN1A by single molecule molecular
inversion probes (smMIPs). Only unique reads from single
molecules were counted, using the single-molecule tag to
remove duplicate reads and provide unbiased estimates of
gene copies. The percentages of mutated reads of patho-
genic mutations were used to determine whether mosaicism
was likely, based on an expected binomial distribution and
comparison with heterozygous neutral SNPs. Conﬁrmation
by droplet digital PCR and sequencing of buccal DNA is
pending. Results: In 8 out of 39 patients, mosaicism is
suspected (p-values ranging from 2,89×10−04–5,82×10−36).
Five patients were classiﬁed as “mild”, one as “moderate”
and two as “severe” (25–42%, 25% and 36–40% alternate
allele respectively). Conclusions: Mosaicism is suspected
in 21% of patients in our cohort, and could explain several
mild cases. Conﬁrmational tests and results of the remaining
part of the cohort are needed to make deﬁnite conclusions
about the predictive value of mosaicism in blood.
I.M. De Lange: None. M. Koudijs: None. R. van 't
Slot: None. F. Mulder: None. E.C. Carbo: None. M. van
Kempen: None. B. Gunning: None. L. van Gemert:
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De novo mutations in CBL causing early onset pediatric
moyamoya cerebral angiopathy
E. Tournier-Lasserve1, S. Guey1, L. Grangeon1, F.
Brunelle2, J. Amiel3, S. Lyonnet3, B. Desnous4, C.
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Background and Aims Moyamoya angiopathy (MMA) is
characterized by a progressive stenosis of the terminal part
of the internal carotid arteries and the development of
abnormal collateral deep vessels. Its pathophysiology is
unknown. MMA can be the sole manifestation of the dis-
ease (moyamoya disease) or be associated with various
conditions (moyamoya syndrome) including some Mende-
lian diseases. We aimed to investigate the genetic basis of
moyamoya using a whole exome sequencing (WES)
approach conducted in sporadic cases without any overt
symptom suggestive of a known Mendelian moyamoya
syndrome.
Method WES was performed in four unrelated early-
onset moyamoya sporadic cases and their parents (trios).
Exome data were analyzed under dominant de novo and
recessive hypotheses. A panel of 17 additional early onset
moyamoya sporadic cases was available for mutation
recurrence analysis.
Results We identiﬁed two germline de novo mutations in
CBL in two out of the four trio probands, two females
presenting with an infancy-onset severe MMA. Both
mutations were predicted to alter the ubiquitin ligase
activity of the CBL protein that acts as a negative regulator
of the RAS pathway. These two germline CBL mutations
have previously been described in association with a
developmental Noonan-like syndrome and susceptibility to
Juvenile Myelomonocytic Leukemia (JMML). Notably, the
two mutated girls never developed JMML and presented
only subtle signs of RASopathy that did not lead to evoke
this diagnosis during follow-up.
Conclusion These data suggest that CBL gene screening
should be considered in early-onset moyamoya, even in the
absence of obvious signs of RASopathy.
E. Tournier-Lasserve: None. S. Guey: None. L.
Grangeon: None. F. Brunelle: None. J. Amiel: None. S.
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Rare RNF213 variants located in the RING domain are
associated with moyamoya in Caucasians
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Background and aims Moyamoya angiopathy (MMA) is in
East Asia strongly associated with the RNF213 R4810K
variant. This variant has never been detected in Caucasian
patients. We investigated if rare RNF213 variants are sig-
niﬁcantly associated with Moyamoya in Caucasian patients.
Method 73 European Caucasian MMA patients and 577
controls from the French EXome project were included.
Whole exome sequencing was performed in all subjects. A
principal component analysis was performed with > 16,000
SNP to ensure that patients and controls were ethnically
matched. Association was tested using the ﬁxed threshold
collapsing method. Only functional variants with a minor
allele frequency < 0.01 were considered. The likelihood
ratio (LR) statistics proposed by Ionita-laza et al. was used
to test the presence of a region within RNF213 that would
be signiﬁcantly enriched in rare coding variants
Results We showed a signiﬁcant association between
rare missense RNF213 variants and MMA in Caucasian
patients (OR)=2.23, 95% conﬁdence interval (CI)=[1.18–
4.08], p=0.01). Probands variants had signiﬁcantly higher
pathogenicity scores and preferentially clustered in a c-
terminal hotspot encompassing RNF213 RING domain
(p<10−3).This association was even stronger in childhood-
onset and familial cases (OR=3.76, 95% CI=[1.46–9.29],
p=0.003).
Conclusion We provided signiﬁcant evidence for the role
of rare, non-R4810K, variants in the development of MMA
in Caucasian patients, especially when located in the c-
terminal part of the protein. Elucidation of the functional
consequences of these rare missense variants upon the
binding of RNF213 to its so far unknown substrates would
be of major importance for the understanding of MMA
mechanisms.
S. Guey: None. M. Kraemer: None. D. Hervé: None.
T. Ludwig: None. M. Kossorotoff: None. F. Bergametti:
None. J. Schwitalla: None. S. Choi: None. L. Broseus:
None. E. Génin: None. E. Tournier-Lasserve: None.
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Genotyping of insertionally polymorphic HERV-K loci
in multiple sclerosis patients using targeted next-
generation sequencing
L. Vidmar, A. Maver, B. Peterlin; linical institute of
medical genetics
Univeristy medical centre Ljubljana, Ljubljana, Slovenia
Introduction: Human endogenous retroviral (HERV)
sequences account for 8% of human genome and have been
associated with multiple sclerosis (MS) in the scientiﬁc
literature. The most recently acquired family, HERV-K
(HML-2), includes human speciﬁc proviruses known to be
unﬁxed in the population. The aim of this study was to
assess the presence of selected HERVs with relatively intact
ORFs at 48 polymorphic loci, within a group of MS patients
and controls.
Materials and Methods: DNA from 30 sporadic MS
patients, 40 MS patients from families with recurrent dis-
ease, and 30 controls was extracted from whole blood.
Biotinylated probes were used to target ﬂanking sequences
of putative insertion loci. Enriched libraries were sequenced
on Illumina platform and aligned to hg19 reference genome.
HERV insertions were genotyped by analyzing read-pairs
aligned to insertion breakpoints for LTR sequences of
HERVs using BLAT.
Results: HERV insertion at 19p12d(chr19:22414379)
was predominantly absent in the MS group (Chi-squared
test,p.value 0.01) when compared to controls. Twelve of 48
HERVs were genotyped at both ﬂanks. Amongst them, the
right ﬂank LTR of HERV-K103(10p12.1) was pre-
dominantly absent in MS patients from affected families (p.
value=0.07).
Conclusion: We performed a comprehensive character-
ization of unﬁxed HERV loci in our sample of MS patients.
Since only minimal additional sequencing is needed, the
method employed showcases an interesting extension of the
routinely performed exome sequencing. Despite none of the
results reaching Bonferroni corrected p.values for sig-
niﬁcance, the two mentioned results provide ground for
further exploration.
L. Vidmar: None. A. Maver: None. B. Peterlin: None.
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The burden of rare genetic variants in genes involved in
tumor necrosis factor (TNF) signalling pathway in
multiple sclerosis (MS)
A. M. Peterlin1, A. Maver1, A. Hodzic1, S. Sega2, J.
Drulovic3, I. Novakovic4, T. Pekmezovic3, S. Ristic5, M.
Kapovic5, B. Peterlin1
1Clinical Institute of Medical Genetics, University Medical
Centre Ljubljana, Ljubljana, Slovenia, 2Department of
Neurology, University Medical Centre Ljubljana, Ljubl-
jana, Slovenia, 3Neurology Clinic, CCS, Belgrade, Serbia,
4Institute of Human Genetics, Faculty of Medicine Bel-
grade, Belgrade, Serbia, 5Department of Biology and
Medical Genetics, School of Medicine Rijeka, Rijeka,
Croatia
Introduction: MS is a chronic inﬂammatory disease of
central nervous system with widely studied, however still
poorly understood genetic contribution. Several lines of
evidence imply an important role of TNF pathway in the
pathogenesis of MS including inﬂammatory demyelination
of central nervous system observed in TNF receptor-
associated periodic syndrome (TRAPS) caused by rare
mutations in TNFRSF1A. Therefore, we hypothesized that
an increased mutation burden in genes involved in TNF
signalling pathway may trigger inﬂammation in MS.Mate-
rials and Methods: Nextera Coding Exome enrichment was
used to perform Whole exome sequencing of 35 patients
with familial MS, 43 patients with sporadic MS and 91
population matched controls. Genotypes were called using
GATK toolkit. The selection of variants among 110 genes
involved in TNF signalling pathway (KEGG database) was
narrowed down by evaluation of functional impact of in
silico predictors: Meta-SVM (when described as damaging)
and/or CADD (when N > 20). Results: We identiﬁed 56
rare potentially pathogenic genetic variants in 37 genes. We
detected a statistically signiﬁcant increased burden of rare
genetic variants in sporadic (x2=5.42, p=0.02), but not in
the familial cases of MS (x2=0.13, p=0.72), when com-
pared to controls. Conclusions: We found evidence for an
increased burden of rare genetic variants in genes of the
TNF signalling pathway in sporadic MS patients, which
further supports its pathogenetic role in MS.
A.M. Peterlin: None. A. Maver: None. A. Hodzic:
None. S. Sega: None. J. Drulovic: None. I. Novakovic:
None. T. Pekmezovic: None. S. Ristic: None. M. Kapo-
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Genetic bases of neurodegeneration with brain iron
accumulation
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C. A. Tello Vicente1, A. Darling2, V. Lupo1, A. Sanchez-
Monteagudo1, S. Fernández-Rodríguez1, B. Pérez-
Dueñas2, C. Espinós1
Principe Felipe Research Center, Valencia, Spain, 22.
Department of Pediatric Neurology, Hospital Sant Joan de
Déu. CIBER of rare diseases. (CIBERER), Barcelona,
Spain
Introduction: Neurodegeneration with brain iron accumu-
lation (NBIA) encompass a wide spectrum of rare and
inherited neurologic disorders characterized by progressive
movement disorders and accumulation of iron in brain.
There are 10 genes causing NBIA that resolve 80% of
cases.
Methods: We have investigated a clinical series of 104
index cases. To establish the genetic basis, we have ana-
lyzed the most common genes (PANK2 and PLA2G6) by
Sanger sequencing and Multiplex Ligation-dependent Probe
Ampliﬁcation (MLPA). To analyse all known NBIA genes
and other candidate genes, we have designed a gene panel
with 500 genes involved in movement disorders, based on
SureSelect technologies (Agilent Technologies).
Results: We have achieved the molecular diagnosis for
45 NBIA patients: 31 patients carry mutations in PANK2
and 11 patients in PLA2G6. We have investigated 16
patients by gene panel and no mutations have been detected
in the remaining known NBIA genes. The preliminary
results have revealed that two patients carry homozygote
mutations in EXOSC3 and in one patient, we have detected
homozygote mutations in two genes: DLD and FBXO7.
Conclusions: The analysis of PANK2 and PLA2G6
allows the diagnosis of around 50% NBIA patients.
The data from the gene panel is being ﬁltered and
functional assays are ongoing in order to clarify if the
detected changes are the causative mutations. The designed
gene panel is a cost-effective tool for NBIA and related
disorders, since allows the study of the NBIA genes and
other candidate genes. [Funds: Fundació La Marató TV3,
Fundació per Amor a l’Art.]
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The phenotypic spectrum of rare variants in NBIA
(neurodegeneration brain iron accumulation) associated
genes
M. Molnar1, R. Bencsik1, V. Molnar1, D. Csaban1, Z.
Grosz1, P. Balicza1, A. Lengyel1, A. Gal1, G. Tamas2, P.
Acs3, P. Klivenyi4, B. Kalman5
1Institute of Genomic Medicine and Rare Disorders,
Semmelweis University, Budapest, Hungary, 2Department
of Neurology, Semmelweis University, Budapest, Hungary,
3Department of Neurology, University of Pecs, Pecs,
Hungary, 4Department of Neurology, University of Szeged,
Szeged, Hungary, 53Molecular Pathology, Markusovszky
University Teaching Hospital, Szombathely, Szombathely,
Hungary
Introduction: Neurodegeneration with brain iron accumu-
lation is a disease resulting in movement disorder. Symp-
toms may vary greatly. The factors that inﬂuence disease
severity and clinical phenotype are unknown. Methods: 75
patients with brain iron accumulation, or symptoms char-
acteristic to NBIA, were investigated by targeted Sanger
sequencing, MLPA and/or by Wholes Exome Sequencing.
Sixteen relatives of patients with identiﬁed genetic defects
have been investigated too. Results: In 7 cases C19Orf12
(MPAN), in 6 cases PANK2, in 3 cases PLA2G6, in 3 cases
CP, in one-one family BPAN and FA2H pathogenic muta-
tions were detected. Further 17 rare variants were observed
by WES in NBIA genes. In 8 patients the p.W112X
mutation was present in the C19orf12 gene. Among these
patients one had homozygous, one heterozygous form with
a coexisting mutation of the CP gene. Both had very severe
phenotypes. Among the 6 cases with heterozygous muta-
tion, in 3 iron accumulation in the brain and mild extra-
pyramidal symptoms were present. In 2 patient with
atypical Parkinson syndrome the p.Leu72* mutation and a
rare variant of the C19Orf12 heterozygous mutation was
detected. Family members having the heterozygous p.
Gly69Arg fsTer10 mutation of the MPAN did not have any
clinical symptoms at their 40s. In persons with hetero-
zygous status of the PANK2, CP, BPAN mutations no
clinical signs have been observed. Conclusion: In MPAN
patients a wide variety of clinical symptoms can be seen.
Some mutations and rare variants of the C19Orf12 gene
may predict mild extrapyramidal signs after the 60s. .
M. Molnar: B. Research Grant (principal investigator,
collaborator or consultant and pending grants as well as
grants already received); Modest; National Brain Research
Project. R. Bencsik: None. V. Molnar: None. D. Csaban:
None. Z. Grosz: None. P. Balicza: None. A. Lengyel:
None. A. Gal: None. G. Tamas: None. P. Acs: None. P.
Klivenyi: None. B. Kalman: None.
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Neurodegeneration with brain iron accumulation:
PLA2G6-associated dystonia-parkinsonism: clinical and
animal studies
M. Minkley1, A. Jackson2, D. Smith2, C. Borchers2, E.
Vichinsky3, R. Nashmi1, P. B. Walter1, P. M. MacLeod1
University of Victoria, Victoria, BC, Canada, 2Genome
British Columbia Proteomics Centre, Victoria, BC,
Canada, 3University of California San Francisco Benioff
Children's Hospital Oakland, Oakland, CA, United States
Introduction:Mutations in the phospholipase-A2 group-VI
gene (PLA2G6) have been shown to cause a Parkinson-
dystonia phenotype (PLAN). Previously we reported a 25-
year-old male PLAN patient with a mutation (c.238G>A) in
the PLA2G6 gene; who had abnormal pallidal iron by MRI,
elevated levels of inﬂammation, oxidative stress and an
84% elevation in soluble transferrin receptor (sTfR). This
investigation provides additional information on the PLAN
patient, including antioxidant therapy and characterization
of a mouse model of PLAN.
Methods: Antioxidant therapy consisted of combination
therapy using N-acetylcysteine (1500mg/day) and/or alpha-
lipoate (1200mg/day) for one year. A comparison of iron
trafﬁcking proteins to a haematological proﬁle was per-
formed to examine the impact of altered iron trafﬁcking
proteins. Finally, the symptomatic presentation in a mouse
model (B6.C3-Pla2g6m1J/CxRwb) was used to determine its
eligibility as a model of PLAN.
Results: No adverse events were report during the anti-
oxidant trial. Neither signiﬁcant improvements or further
motor symptoms were observed during therapy. Despite
elevations of sTfR, the haematological proﬁle revealed no
signiﬁcant abnormalities. The mice displayed pronounced
motor deﬁcits by 90 days of age: including resting tremor,
20% reduced velocity and distance covered in an open ﬁeld
movement test and an impaired ability to hang suspended
by a wire hang test.
Conclusions: Similar to PLAN, Pla2g6m1J/CxRwb mice
present with early-onset degenerative motor symptoms due
to a reduced expression of Phospholipase-A2G6 and
represent a potential model to investigate the impact of
inﬂammation and oxidative stress in PLAN and the con-
tribution of changes in systemic iron trafﬁcking to iron
accumulation.
M. Minkley: None. A. Jackson: None. D. Smith: None.
C. Borchers: None. E. Vichinsky: B. Research Grant
(principal investigator, collaborator or consultant and
pending grants as well as grants already received); Sig-
niﬁcant; Apopharma. R. Nashmi: None. P.B. Walter: B.
Research Grant (principal investigator, collaborator or
consultant and pending grants as well as grants already
received); Signiﬁcant; Apopharma. P.M. MacLeod: B.
Research Grant (principal investigator, collaborator or
consultant and pending grants as well as grants already
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A novel NDE1 mutation causing autosomal recessive
primary microcephaly without lissencephaly
S. Alawbathani
University of Cologne, Köln, Germany
Primary microcephaly is a neurodevelopmental disorder
characterized by congenitally small but architecturally
normal brain due to disruption of genes regulating neural
progenitor proliferation. In comparison, lissencephaly is
caused by mutations in genes critical for neuronal
migration.
Here, we report a 9-year-old boy with microcephaly,
severe intellectual disability and seizure. Combining whole-
exome sequencing and linkage analysis identiﬁed a novel
homozygous mutation (c.658C>T; p.Arg220*) in NDE1
gene.
The Nuclear distribution element 1 (NDE1) gene encodes
a protein that is localized at the centrosome and plays an
essential role in mitosis and neuronal migration. NDE1 loss-
of-function mutations have been reported only in a few
cases affected with a wide spectrum of brain malformations
including lissencephaly and hydrancephaly. Interestingly, in
our case report, the patient presented with less severe phe-
notype and brain MRI showed reduce brain volume without
any structural abnormalities (such as lissencephaly). Ndel1
(-/-) mice displayed profound defects in cerebral cortico-
genesis but only modest defects in neuronal migration.
Presumably, NDE1 truncating mutation (p.Arg220*)
leads to the loss of c-terminal domain which is critical for its
centrosomal localization. To conﬁrm this, we overexpressed
the mutant GFP-NDE1, which led to diffuse localization in
the cytoplasm and failure of centrosomal localization,
whereas the immunoreactivity of wild-type protein was
found at centrosome. The analyses of NDE1 in primary
ﬁbroblasts derived from individuals mutated with NDE1
and control are in progress
NDE1 can be considered as one of the overlapping genes
that regulate neural progenitors proliferation and neuronal
migration.
Grant from (CMMC) to A.A.N. and P.N.
S. Alawbathani: None.
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Testing experimental nootropic drug Mitochondrin-2
and Adement on manifestation of SWS/NTE depended
glial neurodegeneration in Drosophila melanogaster
K. Dronska1, N. Matiytsiv1, A. Makarenko2
Ivan Franko national university of Lviv, Lviv, Ukraine,
2Taras Shevchenko National University of Kyiv, Kyiv,
Ukraine
Introduction: The Swiss Cheese (SWS) protein is an
ortholog of NTE in Drosophila melanogaster and shares
39% sequence identify with human Neuropathy target
esterase (NTE). The Drosophila sws mutants are char-
acterized by progressive degeneration of adult nervous
system, glial hyperwrapping and neuronal apoptosis.
Materials and Methods: We created a speciﬁc functional
knockout of sws gene in glial cells. Therapeutic inﬂuence of
experimental preparations Mitohondrin-2 (M-2) and Ade-
ment was assessed on life span, parafﬁn brain sections and
on locomotor activity in “open ﬁeld” (path length, duration
of rest, duration of grooming, number of jumps) experiment
in old ﬂies. We investigated two groups: in ﬁrst group
preparation were delivered to the larvae, and in second
group, preparations were fed to the adult ﬂies. In parafﬁn
brain sections we calculated the total area of vacuoles in
brain using a graphics editor Kompas 13 portable mini.
Results: Our results suggest that M-2 had neuroprotec-
tive effect only if it was delivered to larvae. After treatment
with M2 size of vacuoles reduced by 31% in brain tissue of
old ﬂies with sws functional knockout in glia. Life span
parameters after M-2 treatment became 15% longer.
Nevertheless, we didn’t found any changes in locomotor
activity. In contrast, after Adement treatment in both groups
we observed toxic effect on life span: life expectancy was
signiﬁcantly lower in comparison with ﬂies that did not
receive the drug.
Conclusions: Summarizing obtained data we can con-
clude that in case of glial SWS/NTE-depended pathology in
Drosophila brain Mitochondrin-2 demonstrate a therapeutic
effect.
K. Dronska: None. N. Matiytsiv: None. A. Makar-
enko: None.
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BDNF and FGF-2 growth factors synergistically
enhances the neural stem cell dedifferentiation in vitro
B. S. Tunç, T. Gurbuz, S. Sözer Tokdemir, K. Ateş
İstanbul University, Aziz Sancar İnstitute of Experimental
Medicine, Department of Genetics, İstanbul, Turkey
Introduction: Adult neurogenesis and Neural Stem Cell
(NSC) biology has tremendous potential considering the
treatment modalities in neural related diseases and neural
injuries. In this study, we aimed to determine the effects of
Brain-Derived Neurotrophic Factor (BDNF) and Basic
Fibroblast Growth Factor (FGF-2) proteins individually or
synergistically on the hippocampal originated NSCs.
Materials and Methods: Hippocampal NSCs that were
primarily isolated from rats were utilized in the experi-
ments. NSCs grown in the cell culture medium were treated
either with FGF-2 (0.4μgr/ml) and/or BDNF (1μgr/ml)
during the day1, day3 and day7 of culture. Afterwards, cells
were treated with BrdU and analyzed with ﬂow cytometry.
Doublecortin (DCX), Glial Fibrillary Acidic Protein
(GFAP), Nestin and β-Tubulin-III (Tubb3) genes expres-
sion analysis were performed following RNA isolation and
RT-qPCR. Relative gene expression levels were normalized
to GAPDH.
Results: Astrocyte marker GFAP, was downregulated all
times during the treatment with BDNF and/or FGF-2.
Nestin expression, however, was downregulated in the day1
and upregulated during day3 and day7. Upregulated
expression levels of Tubb3 and DCX were observed in
day1, but downregulated in day3 and day7. BrdU analysis
revealed the cells being quiescent in G0/G1 phase upon
induction and increasing in day3 and day7, respectively.
BDNF induction accumulated the apoptotic cell population
in each time points whereas FGF-2 induction saved the
apoptotic cells.
Conclusions: These observations suggest that BDNF
and FGF-2 induction in the neural cell lineage increases
immature neural de-differentiation from neural cells. Sup-
ported by grants from Istanbul University BAP; Yüksek
Lisans 50267 and BAP THZ-2016-21839
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A comprehensive NGS gene-panel for rapid DNA diag-
nosis of inherited late onset ataxia
C. Verschuuren-Bemelmans, H. H. Lemmink, F.
Vansenne, B. Raddatz, K. Abbott, M. Meems-Veldhuis, A.
Scheper, M. Viel, J. de Vries, B. Kremer, R. Sinke
niversity Medical Centre Groningen, Groningen,
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Aim Our aim was to develop a targeted next generation
sequencing (NGS) gene panel that enables to analyze the
large number of candidate genes in patients with inherited
ataxia at relatively low cost and high speed.
Methods An ataxia-panel of 57 genes involved in spi-
nocerebellar ataxia (SCA) and related ataxia disorders was
developed using the Agilent Sure Select Target Enrich-
ment®. The samples were sequenced using 151 base pair
paired-end reads on an Illumina NextSeq® sequencer and
analyzed using Softgenetics’ NextGENe® and Cartagenia’s
Benchlab NGS® software. Subsequently, for diagnostic
purposes, the targeted ataxia-panel was used to analyze a
total of ﬁfty unrelated patients. A pre-NGS analysis was
offered to test patients for CAG repeat expansions of the
ATXN1 to 3, CACNA1A and ATXN7genes.
Results and conclusion In eleven out of forty-eight
patients, novel (likely) pathogenic gene mutations were
identiﬁed which were all conﬁrmed by Sanger sequencing.
Additionally, mutations were classiﬁed using data from
HGMD, frequencies of variants in the ExAC database and
gene information and clinical data on corresponding gene
variants in OMIM. Sixteen patients were shown to carry
heterozygous variants of unknown clinical signiﬁcance
(VUS) in most cases missense mutations. Cosegregation
analysis of VUS variants was performed in other affected
family members upon availability to elucidate its role in
ataxia. Gene panel analysis adds to ﬁne tuning of the clin-
ical phenotype and expands the genotype-phenotype cor-
relations for ataxia. The use of this gene panel facilitates a
much faster analysis of the large number of currently known
ataxia-genes for mutation analysis.
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Three years molecular diagnosis of hereditary ataxias
with NGS: beneﬁts and challenges
P. Arinto1, A. F. Brandão1, P. Silva1, J. Damásio2, J.
Barros2, I. Alonso1,3, J. Sequeiros1,3,4
1Center for Predictive and Preventive Genetics (CGPP),
IBMC - Institute for Molecular and Cell Biology, i3S -
Instituto de Investigação e Inovação em Saúde, Univ.
Porto, Porto, Portugal, 2Centro Hospitalar do Porto,
Porto, Portugal, 3UnIGENe, IBMC - Institute for Molecular
and Cell Biology, i3S - Instituto de Investigação e Inovação
em Saúde, Univ. Porto, Porto, Portugal, 4Instituto de
Ciências Biomédicas Abel Salazar (ICBAS), Univ. Porto,
Porto, Portugal
Hereditary ataxias are a group of genetic disorders char-
acterized by slowly progressive incoordination of gait, often
associated with poor coordination of hands, speech, and eye
movements, that can be inherited in an autosomal dominant,
autosomal recessive or X-linked pattern. Next-Generation
Sequencing (NGS) allows faster molecular diagnosis, ana-
lysing multiple genes simultaneously, with an excellent
cost-beneﬁt ratio. This is particularly useful for the rarest
and highly heterogeneous forms. A multi-gene panel for
hereditary ataxias was the ﬁrst to be implemented at our
centre, using an Ion torrent PGM platform (32 genes) and,
later on, exome sequencing with an Illumina platform (144
genes). Over the past 3 years, 58 patients (most previously
excluded for repeat-expansions in the more common loci)
were screened for mutations using these panels. A diagnosis
was achieved in 22%, and variants of unknown signiﬁcance
were identiﬁed in 10%. Some of these patients had been
molecularly studied for several years. We identiﬁed disease-
causing variants in genes that are rarely the ﬁrst choice for
testing, such as SYNE1, due its size, or ANO10, due to the
small number of families identiﬁed so far. Several novel
variants have been identiﬁed at our laboratory, classiﬁed
based on clinical and family information, as well as our
bioinformatics predictions and clinical judgement. NGS is
cost-effective, after exclusion of more common repeat-
expansions whenever clinically justiﬁed, and allows the
genetic diagnosis of patients with rarer types of hereditary
ataxia. A great challenge is to conclude about pathogenicity
of the novel and rare variants elicited with this technique.
P. Arinto: None. A.F. Brandão: None. P. Silva: None.
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Genetic variants associated with attenuated niacin ﬂush
response in schizophrenia
S. G. Yang1, W. Lin1, S. Wang1, P. Hsiao1, L. Yeh2, C.
Liu3, C. Liu3, T. Hwang3, M. Hsieh3, Y. Chien3, Y. Lin3, S.
Chandler4, S. Glatt5, N. Laird6, S. Faraone5, M.
Tsuang4,7, H. Hwu1,3,8, W. Chen1,8,9
Institute of Epidemiology and Preventive Medicine,
National Taiwan University, Taipei, Taiwan, 2Department
of Healthcare Administration, College of Health Science,
Asia University, Taichung, Taiwan, 3Department of Psy-
chiatry, College of Medicine and National Taiwan
University Hospital, National Taiwan University, Taipei,
Taiwan, 4Center for Behavioral Genomics, Department of
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Medical Genetics Research Center, SUNY Upstate Medical
University, Syracuse, NY, United States, 6Department of
Biostatistics, Harvard University, Boston, MA, United
States, 7Institute for Genomic Medicine, University of
California San Diego, La Jolla, CA, United States, 8Insti-
tute of Brain and Mind Sciences, College of Medicine,
National Taiwan University, Taipei, Taiwan, 9Genetic
Epidemiology Core Laboratory, Center of Genomic Med-
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Background: Attenuated niacin ﬂush response is con-
sistently found in schizophrenia patients and their non-
psychotic relatives, but its relation to clinical features and
genetic risk factors remain unclear. This study aimed to 1)
examine the association between attenuated niacin ﬂush
response and clinical features in schizophrenia; and 2)
identify the genetic variants related to attenuated niacin
ﬂush response. Methods: A total of 1881 schizophrenia
patients who were interviewed with the Diagnostic Inter-
view for Genetic Studies (DIGS) underwent a niacin skin
patch test rated on a 4-point scale. Part of the sample (n=
858) was genotyped to search for genome-wide genetic
variants. A newly developed polygenic test called the
Adaptive Combination of Bayes Factors was applied to
select SNPs associated with attenuated niacin ﬂush
response. Results: Patients with an attenuated niacin ﬂush
response score that exhibited robust SNP-based heritability
showed lower global functional score (p<0.005), higher
positive symptoms score (p<0.005), and more cognitive
impairment (p<0.05). No single SNP reached genome-wide
signiﬁcance. However, the polygenic test was statistically
signiﬁcant (p=0.015), in which the association signal was
enriched by combining 60 common SNPs each with a
Bayes factor > 85. Conclusions: Attenuated niacin ﬂush
response in schizophrenia is characterized by certain clinical
features and is inﬂuenced by multiple genetic variants with
small effects. Further investigation of biological functions is
warranted. Grant reference: Supported by NIH/NHGRI
grant U54HG003067, NIMH grants R01 MH085521, R01
MH085560, the Gerber Foundation, the Sidney R. Baer, Jr.
Foundation, the Brain and Behavior Research Foundation,
and the Stanley Center for Psychiatric Research.
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Phase 1/2a trial of intrathecal 2-hydroxypropyl-β-
cyclodextrin (VTS-270) for the treatment of Niemann-
Pick Disease, type C1
F. D. Porter1, N. Y. Farhat1, E. Ottinger2, J. C. Mckew2,
L. Weissfeld3, B. N. Machielse4, E. M. Berry-Kravis5, C.
H. Vite6, D. S. Ory1, S. Bianconi1, and the TRND team
1NICHD, National Institutes of Health, Bethesda, MD,
United States, 2NCATS, National Institutes of Health,
Bethesda, MD, United States, 3Statistics, Collaborative,
Washington, DC, United States, 4Vtesse, Inc, Gaithersburg,
MD, United States, 5Rush University Medical School,
Chicago, IL, United States, 6University of Pennsylvania,
Philadelphia, PA, United States
Introduction: Niemann-Pick disease, type C1 (NPC1) is a
lysosomal storage disorder characterized by endolysosomal
storage of unesteriﬁed cholesterol and progressive neuro-
logical impairment. Preclinical studies in mouse and cat
models demonstrated signiﬁcant potential of VTS-270 to
slow neurological progression, decrease cerebellar Purkinje
cell loss and increase survival time.
Methods: Safety and clinical efﬁcacy of monthly intra-
thecal VTS-270 (a speciﬁc formulation of 2-hydroxypropyl-
β-cyclodextrin) were evaluated in an open-label, dose
escalation study. 24-hydroxycholesterol was used as a
pharmacodynamic marker and CSF protein biomarkers
were evaluated. NPC Neurological Severity Scores (NSS)
were used to characterize disease progression. Data are from
12 NPC1 participants treated for 18 months and 2 treated
for 12 months. Comparison of disease progression is rela-
tive to a historical cohort of 21 NPC1 participants of similar
age range.
Results: Biomarker studies were consistent with
improved neuronal cholesterol homeostasis and decreased
neuronal pathology. From a safety perspective, mid- to
high-frequency hearing loss was observed. This was an
expected adverse event based upon preclinical testing. Post
hoc analysis of the total NSS demonstrated signiﬁcant
(p<0.0002) decrease in the rate of disease progression
(1·22 ± 0·34 points/year) in the treated participants com-
pared to the comparison group (2·92 ± 0·27 points/year).
Decreased progression was observed in the NSS sub-
domains of ambulation (p=0·0622), cognition (p=0·0040)
and speech (p=0·0423). Secondary responder analysis
demonstrated decreased or stabilized disease progression in
7/14 treated subjects compared to 1/21 untreated subjects
(p=0.003).
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Conclusions: These data demonstrate the potential efﬁ-
cacy of intrathecal VTS-270 to slow neurological disease
progression in NPC1 patients.
F.D. Porter: C. Other Research Support (supplies,
equipment, receipt of drugs or other in-kind support);
Modest; Johnson & Johnson. F. Consultant/Advisory
Board; Modest; Vtesse, Inc. Other; Signiﬁcant; Vtesse, Inc.
N.Y. Farhat: None. E. Ottinger: F. Consultant/Advisory
Board; Modest; Vtesse, Inc. J.C. Mckew: None. L.
Weissfeld: B. Research Grant (principal investigator, col-
laborator or consultant and pending grants as well as grants
already received); Signiﬁcant; Vtesse, Inc. B.N. Machielse:
A. Employment (full or part-time); Signiﬁcant; Vtesse, Inc.
E.M. Berry-Kravis: B. Research Grant (principal investi-
gator, collaborator or consultant and pending grants as well
as grants already received); Signiﬁcant; Vtesse, Inc. F.
Consultant/Advisory Board; Modest; Vtesse, Inc. C.H.
Vite: None. D.S. Ory: F. Consultant/Advisory Board;
Modest; Vtesse, Inc. S. Bianconi: None.
P09.093A
NPC1 and NPC2 gene analysis in Serbian patients with
Niemann-Pick disease type C
M. Brankovic1, N. Kresojevic1, A. Marjanovic1, I.
Novakovic2, V. Kostic2
Neurology Clinic, Belgrade, Serbia, 2School of Medicine,
University of Belgrade, Belgrade, Serbia
Introduction: Niemann-Pick disease type C (NP-C) is a
lysosomal lipid storage disorder caused by mutations in
either the NPC1 gene (in 95% of cases) or the NPC2 gene.
It is an autosomal recessively inherited disease most com-
monly characterized by hepatosplenomegaly and a severe
progressive neurological dysfunction with the age of onset
ranging from early infancy to adulthood. The large majority
of mutations in NPC1 gene are missens mutations (70%),
while nonsense mutation (E20X) appears relatively frequent
in NPC2 gene.
Materials and methods: This study evaluated 135 Serbian
adult patients with symptoms that meet the NP-C criteria,
and their relatives. Our algorithm for genetic testing
involved analysis of 4 selected (mutation prone) exons of
NPC1 (exons 8, 19, 20 and 21) and than, in negative cases,
sequencing of all ﬁve exons of NPC2 gene. All analyses
were performed on ABI 3500 genetic analyzer.
Results: Genetic testing revealed 13 patients to be either
compound heterozygotes (n= 12) or homozygote (n= 1)
for mutations in NPC1 gene. We identiﬁed 8 missense
mutations, one nonsense mutation, one small deletion, one
large deletion of exons 6 to 9, one intronic mutation in
NPC1 gene, and only one heterozygous 5' donor splice-site
mutation in NPC2 gene, all previously described. Hetero-
zygote mutations were identiﬁed in 22 relatives of patients.
Missense mutations constituted the majority of detected
mutations (~ 85%).
Conclusion: These results signify the importance of
NPC1 sequencing as standard genetic test in NP-C. Our
ﬁndings better characterize NP-C in Serbian population and
facilitate future studies into genotype-phenotype
correlations.
M. Brankovic: None. N. Kresojevic: None. A. Mar-
janovic: None. I. Novakovic: None. V. Kostic: None.
P09.094B
Phenotypic and Molecular Characterization of Cock-
ayne Syndrome; A Spotlight to Mild Cases
G. Yesil1, E. Akyuz1, N. Gunes2, D. Lessel3, C. Kubisch3,
B. Tuysuz2
1Bezmialem Vakif University, Department of Medical
Genetics, İstanbul, Turkey, 2I.U. Cerrahpasa Medical
Faculty, Department of Pediatric Genetics, İstanbul,
Turkey, 3Ulm University Human Genetics Institute, ulm,
Germany
Cockayne syndrome (CS) is a rare disorder characterized by
cachexia, microcephaly, cognitive deﬁcits, cataracts/pig-
mentary retinopathy, deafness, and dysmorphism with deep
sunken eyes. Mutations in ERCC8, ERCC6 and ERCC2 are
the cause. Most of the patients (65%) have mutations in the
ERCC6 gene. Here we report the follow up of 7 patients
with CS. We detected ERCC8 mutation in two and ERCC6
mutation in ﬁve. Of these ﬁve of them were novel. One of
the novel mutations were detected in two unrelated patients.
The patients’ age range was 3–17 excluding the patient who
died from respiratory insufﬁciency at 2 years. Although
ERCC6 mutations were known to be clinically more severe
5 of 3 had mild phenotype. Longest follow up was 12 years.
The patient’s height was improved only 3cm while weight
and OFC remained the same between 5 and 17 year of age.
He had cachectic dwarﬁsm, nystagmus, hypodontia, pectus
excavatus, multiple nevi and anhidrosis on last examina-
tion,. He had aided walking and talk a few words. Poly-
neuropathy, basal ganglion and cerebellum calciﬁcation and
deafness was detected. In contrast to severe cases mild ones
had a better intradermal fat storage and body weight. The
MRI’s revealed isolated nonspeciﬁc white matter changes.
The oldest mild patient was 94/12 years old. Early diagnosis
of CS is crucial in order to prolong life expectancy but also
to avoid extensive tests and substances that aggravate DNA
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breaks. Early genetic counselling with parents concerning
future pregnancies is also beneﬁcial.
G. Yesil: None. E. Akyuz: None. N. Gunes: None. D.
Lessel: None. C. Kubisch: None. B. Tuysuz: None.
P09.095C
Early onset epileptic encephalopathies with suppression-
burst EEG pattern: genetic characterization of a Eur-
opean cohort of 70 patients
M. Milh1,2, F. Riccardi2, P. Cacciagli2,3, C. Lacoste3, C.
Mignon-Ravix2, M. Nagara2, L. VILLARD2,3
Pediatric Neurology - Marseille University Hospital,
Marseille, France, 2Inserm UMR_S 910, Marseille, France,
3Medical Genetics - Marseille University Hospital, Mar-
seille, France
Early-onset epileptic encephalopathies (EOEE) are rare and
severe neurodevelopmental disorders, characterized by
motor seizures occurring before three month of life asso-
ciated with a very abnormal EEG pattern who can be
described as being “suppression-burst” (SB), where bursts
of paroxysmal activity alternate with periods of electric
silence or ﬂattened tracing. There is a strong and hetero-
geneous genetic component to these diseases. We studied
70 patients with a SB EEG pattern, which is the most
characteristic and easily identiﬁable for clinicians. Genetic
explorations were ﬁrst performed in a hospital setting (for
known genetic causes) and secondly, in a research frame-
work. Trio whole exome sequencing analyses were per-
formed for negative cases. We identiﬁed 30 genetic
abnormalities. The diagnostic rate was about 40%. An
overview of the 70 patients highlights the implication of
KCNQ2 and STXBP1, which are the most frequently
mutated genes (20% and 7%, respectively). Other mutations
were identiﬁed in several genes, at a lower frequency:
SCN2A, KCNT1, ARX, GABRB3, GABRG2, ALGT11. The
vast majority of mutations was heterozygote and arose de
novo. Interestingly, no patient had a mutation in SCN8A
gene, which is frequently involved in other EOEE. Deci-
phering molecular basis of EOEE is the ﬁrst step to better
understanding these severely diseases. Progresses in the
ﬁeld of diagnosis, coupled with development of persona-
lized medicine could modify the quality of life of the
patients and their families. This work was supported by
Inserm, Aix Marseille University, Marseille University
Hospital and the JED Foundation.
M. Milh: None. F. Riccardi: None. P. Cacciagli: None.
C. Lacoste: None. C. Mignon-Ravix: None. M. Nagara:
None. L. Villard: None.
P09.096D
Case of assotiation of the Ondine Syndrome, hyperho-
mocysteinemia and mitochondrial deﬁciency - successful
metabolic correction
Y. Grechanina, O. Grechanina, S. Biletska
Kharkov interregional specialized medical genetic center,
Kharkiv, Ukraine
Introduction: Ondine Syndrome is a congenital central
hypoventilation syndrome (CCHS) is a rare disease due to a
severely impaired central autonomic control of breathing
and dysfunction of the autonomous nervous system. The
incidence is estimated to be at 1 of 200 000 livebirths. A
heterozygous mutation of PHOX-2B gene is found in 90%
of the patients. Description: Girl, 3 years, with the coarse
delay of the psycho-speech, motor and physical develop-
ment, seizures, stereotypes, atopic dermatitis. Convulsions
occurred immediately after the birth, there was a depen-
dence on the mechanical ventilation. The Ondine Syndrome
was diagnosed by discovery of the gene PHOX-2B muta-
tion. The metabolic examination revealed a high level of
homocysteine (blood) - 12 mkmol/l ↑. Molecular testing -
MTHFR 677 T/T. Gas chromatography/mass-spectrometry
(urine) - disorder of cycle Krebs metabolites. Lactat (blood)
- 3,2 mmol/l ↑. Amino acids (blood) - methionine ↑. The
treatment included hypomethionine diet, P-5-P, TMG, L-
carnitine, coenzyme Q10, riboﬂavin cropped epileptic sei-
zures and dermatitis. On the background of the therapy
(1 month) seizures are absent, the girl began to speak.
Conclusions: The case demonstrates the syntropy effect,
combination of hard rare monogenic syndrome and meta-
bolic disorders. Correction of associated hyperhomocystei-
nemia and mitochondrial dysfunction were given the
opportunity to improve the quality of life of the child.
Y. Grechanina: None. O. Grechanina: None. S.
Biletska: None.
P09.097A
MRI-targeted screening for mutation in the WDR45
gene reveals NBIA5 case clariﬁcation
T. Todorov1, I. Tournev2,3, A. Todorova1,4, P. Dimova5
Genetic Medico-Diagnostic Laboratory Genica, Soﬁa,
Bulgaria, 2Department of Neurology, Medical University
Soﬁa, Soﬁa, Bulgaria, 3Department of Cognitive Science
and Psychology, New Bulgarian University, Soﬁa, Bul-
garia, 4Department of Medical Chemistry and Biochem-
istry, Medical University Soﬁa, Soﬁa, Bulgaria, 5Epilepsy
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Center, Department of Neurosurgery, University Hospital
“St. Ivan Rilski”, Soﬁa, Bulgaria
Here we report a female patient with peculiar clinical pic-
ture of normal birth history, subsequent psychomotor delay
in early childhood with intellectual disability, followed in
early adulthood by a neurological regression with parkin-
sonism and cognitive decline from the already abnormal
baseline. The performed RI in 2012 and 2015 revealed no
change of the established brain atrophy, low-signal in T2
and FLAIR (ﬂuid-attenuated inversion recovery) areas in
substantia nigra and globus pallidus bilaterally. T1-W
images showed non-homogeneous signal intensity of these
structure changes with low intensity of the center and high
intensity in the periphery. The picture was diagnosed as the
classical “eye-of the-tiger” sign in neurodegeneration with
brain iron accumulation (NBIA) and the diagnosis of Pan-
tothenate kinase-associated neurodegeneration, known as
Hallervorden-Spatz disease has been suspected. NBIA1 is
caused by mutations in the PANK2 gene, but the genetic
testing for mutations in this gene was negative. This
prompted us to reevaluate the MRI (end of 2016). As
described earlier, it was found that on T1-weighted imaging,
the indisputable iron depositions the substantia nigra and
cerebral peduncles have a hyperintense “halo”, which is
very distinctive features for BPAN (Beta-propeller Protein-
Associated Neurodegeneration), which is the only X-linked
dominant NBIA disorder and helped us to guide the targeted
molecular genetic testing of the WDR45 gene. The genetic
analysis revealed a heterozygous pathogenic variant
c.1007_1008delAT, (p.Tyr336CysfsTer4), which conﬁrms
the clinical diagnosis of NBIA5. The variant is known in the
literature. This is an example how neuroimaging can be
applied successfully in guiding the genetic tests.
T. Todorov: None. I. Tournev: None. A. Todorova:
None. P. Dimova: None.
P09.098B
Massive parallel sequencing in an autosomal dominant
Flanders-Belgian family identiﬁed six candidate genes
for Parkinson Disease
S. Smolders1,2, D. Crosiers1,2,3, J. van der Zee1,2, M.
Mattheijssens1,2, K. Peeters1,2, C. Van Broeckhoven1,2
1Neurodegenerative Brain Diseases group, VIB Center for
Molecular Neurology, Antwerp, Belgium, 2Laboratory of
Neurogenetics, Institute Born Bunge, University of
Antwerp, Antwerp, Belgium, 3Department of Neurology,
Antwerp University Hospital, Edegem, Belgium
Introduction: Molecular genetic studies of familial Par-
kinson Disease (PD) have provided important insights into
the underlying molecular pathomechanisms. To date, only
10 % of familial PD can be explained by mutations in the
known genes. We aimed at identifying the genetic defect in
a Flanders-Belgian family segregating autosomal dominant
PD by combining massive parallel sequencing (MPS)
technologies.
Materials and Methods: DNA from three affected rela-
tives was subjected to whole-genome sequencing (WGS).
Shared heterozygous variants were prioritized based on
quality, frequency in public databases and impact. Segre-
gation was evaluated using whole-exome sequencing
(WES) data of two unaffected relatives. We used multiplex
ampliﬁcation resequencing to validate the candidate var-
iants and to screen the Belgian PD patient/control cohorts.
Results: Analysis of the WGS data discovered
approximately 3.95 million variants per individual. Apply-
ing successive prioritization steps resulted in 52 variants
with a high probability of association with PD in the family.
Annotations of these variants, including sequence con-
servation, brain expression and association with other
neurological disorders, identiﬁed six candidate genes:
PSMD7, active in the ubiquitin-proteasome dependent
proteolysis; MDGA1 and HTR1D, involved in synaptic
activity; EGF, implicated in the proliferation and differ-
entiation of neurons; ANK3, associated with multiple neu-
rological disorders; and MYOM3, implicated in
neuromuscular disorders.
Conclusions: Using MPS in a Flanders-Belgian family
identiﬁed potential novel PD genes. Mutation screening of
these genes in Belgian PD patient/control cohorts is needed
to generate further genetic support for an association with
disease, and functional studies to provide insight into the
underlying molecular pathomechanism.
S. Smolders: None. D. Crosiers: None. J. van der Zee:
None. M. Mattheijssens: None. K. Peeters: None. C. Van
Broeckhoven: None.
P09.099C
Construction and testing of cell culture based systems to
monitor alpha-synuclein aggregation
M. Niemeyer, M. Bungeroth, M. Pendziwiat, S. Müller, F.
Hopfner, G. Kuhlenbäumer
Department of Neurology, Kiel University, Kiel, Germany
Introduction: The Alpha-Synuclein Gene (SNCA) and
protein (ASYN) is central in the pathogenesis of Parkinson
disease (PD). ASYN is a small (140 aa) intrinsically dis-
ordered protein with a tendency to aggregate spontaneously.
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Neuronal inclusions containing large amounts of ASYN are
the pathological hallmark of PD. However, it is likely that
oligomeric ASYN intermediates are the neurotoxic form.
The aim of this project is to monitor ASYN aggregation in
cell culture in order to develop a high-throughput drug
screening tool.
Materials and Methods: We modiﬁed a previously pub-
lished system (Outeiro et al. PLoS One (2008)) monitoring
ASYN aggregation based on bimolecular ﬂuorescence
complementation (BFC). We inserted both cistrons of the
system into a single constitutive or tetracycline inducible
expression vector. The cistrons are connected either by a
constitutively cleaved 2A protease site or an internal ribo-
somal entry site (IRES). We used these vectors to construct
stable cell lines (HEK293) and tested the system employing
one aggregation enhancer (MG132) and a putative aggre-
gation inhibitor (Curcumine).
Results: The cell line characterized by inducible
expression and a 2A-site showed the best characteristics in
terms of ﬂuorescence brightness and signal to noise ratio.
Peak differences in signal intensity after substance treatment
were observed after 24h to 36h. MG132 lead to increased
ﬂuorescence while Curcumine diminished ﬂuorescence.
However, both substances were cytotoxic at much lower
concentrations than previously published values. Conclu-
sions: After miniaturization and ﬁxed coupling to cell via-
bility measurements our system should be suitable to screen
for ASYN aggregation inhibitors.
M. Niemeyer: None. M. Bungeroth: None. M. Pend-
ziwiat: None. S. Müller: None. F. Hopfner: None. G.
Kuhlenbäumer: None.
P09.100D
Gene discovery and prioritization in recessive Parkin-
son's disease
V. Drouet1, S. Ben Romdhan1, J. Guégan1, J. Täger2, E.
Lohmann2,3,4, P. Heutink2,3, A. Brice1,5, S. Lesage1
1Inserm U1127, CNRS UMR7225, Sorbonne Universités,
UPMC Univ Paris 06, UMR_S1127, Institut du Cerveau et
de la Moelle épinière, Paris, France, 2German Center for
Neurodegenerative Diseases (DZNE), Otfried-Müller-Str.
23, Tübingen, Germany, 3Hertie Institute for Clinical Brain
Research, University of Tübingen, Tübingen, Germany,
4Behavioral Neurology and Movement Disorders Unit,
Department of Neurology, Istanbul Faculty of Medicine,
Istanbul University, Istanbul, Turkey, 5Assistance Publique
Hôpitaux de Paris, Hôpital de la Salpêtrière, Département
de Génétique et Cytogénétique, Paris, France
Introduction: Parkinson’s disease (PD) is a major public
health problem, affecting 1–2% of persons over 60. Eleven
genes are now conﬁrmed to cause monogenic forms of PD,
but in approximately 50% of the familial and more than
80% of the sporadic cases with early-onset PD, mutations in
these genes are not detected. Thus, a signiﬁcant proportion
of cases remain unexplained genetically. Materials and
methods: The French PDG group and Mediterranean col-
laborations assembled a unique collection of autosomal
recessive PD families, including a large number with known
or suspected consanguinity. We combined whole genome
genotyping and whole exome sequencing in 77 cases and 22
relatives, to identify pathogenic mutations in the regions of
homozygosity. Sanger sequencing was used to validate the
variants and segregation in families, when possible. The
recessive candidate genes will be prioritized using a semi-
automated pipeline studying multiple parameters relevant to
PD pathophysiology (Jansen et al., 2017) in a neuro-
blastoma cell line. Results: We identiﬁed about 70 genes
with potential pathogenic mutations in the regions of
homozygosity of the conﬁrmed consanguineous cases. Lit-
tle or no replication was found in other PD cases, therefore,
functional data to support the pathogenicity of these genes
in PD is required. Functional validation is in progress.
Conclusions: About 70 recessive candidate genes for PD
were identiﬁed. A wide functional screening will be used to
prioritize the genes with the highest overall impact. Further
studies will be carried out to complete the body of proofs
supporting their involvement in PD.
V. Drouet: None. S. Ben Romdhan: None. J. Guégan:
None. J. Täger: None. E. Lohmann: None. P. Heutink:
None. A. Brice: None. S. Lesage: None.
P09.102B
Systematic meta-analyses of small RNA proﬁling studies
identify differentially expressed microRNAs in Parkin-
son’s disease
J. Schulz1, P. Takousis2, I. Wohlers3, I. O. G. Itua2, H.
Binder4, J. P. Ioannidis5, R. Perneczky2,6, L. Bertram3,2,
C. M. Lill1
Institut of Neurogenetics, University of Luebeck, Luebeck,
Germany, 2School of Public Health, Imperial College,
London, United Kingdom, 3Luebeck Interdisciplinary Plat-
form for Genome Analytics, University of Luebeck,
Luebeck, Germany, 4Institute for Medical Biostatistics,
Epidemiology and Informatics, University Medical Center
Mainz, Mainz, Germany, 5Departments of Medicine, Health
Research and Policy, and Statistics, and Meta-Research
Innovation Center at Stanford, Stanford University, Stan-
ford, CA, United States, 6Department of Psychiatry and
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Background: MicroRNA-mediated (dys)regulation of gene
expression has been implicated in many complex traits
including Parkinson’s disease (PD). Numerous publications
have reported a differential expression of speciﬁc micro-
RNAs in PD patients versus unaffected controls. However,
results have been inconclusive. The aim of this study was to
identify microRNAs that show consistent differential
expression across all published small RNA proﬁling studies
in PD.
Methods: We performed a systematic literature search on
microRNA expression studies in PD. Relevant data were
extracted followed by double-checking by an independent
investigator. Data were stratiﬁed for source of tissue, and
overlapping datasets were excluded. Subsequently, we
performed p-value based-meta-analyses across microRNAs
assessed in at least three independent datasets.
Results: Our literature search identiﬁed 32 studies eli-
gible for meta-analysis. We performed 145 meta-analyses
on microRNAs quantiﬁed in blood (n= 11), brain (n=
130), or cerebrospinal ﬂuid samples (n= 4). We identiﬁed
eleven signiﬁcantly (α=3.45×10−4) differentially expressed
microRNAs in blood or brain. The most signiﬁcant ﬁndings
were observed with hsa-miR-15b-5p (p=1.73×10−16), hsa-
miR-181a-5p (p=4.31×10−16) and hsa-miR-29c-3p
(p=2.24×10−12) in blood, and hsa-miR-497-5p
(p=1.13×10−5), hsa-miR-129-2-3p (p=1.25×10−5) and
hsa-miR-132-3p (p=6.37×10−5) in brain. Analyses of
GWAS data did not show signiﬁcant enrichment for asso-
ciation signals in target genes of these microRNAs.
Conclusions: We identiﬁed several microRNAs that
showed highly signiﬁcant and consistent differential
expression in PD in blood and brain tissue. Future studies
may assess the potential of differentially expressed micro-
RNAs in blood as possible biomarkers for PD. Our study
can serve as a model to merge published results of gene
expression studies in other complex diseases.
J. Schulz: None. P. Takousis: None. I. Wohlers: None.
I.O.G. Itua: None. H. Binder: None. J.P. Ioannidis:
None. R. Perneczky: None. L. Bertram: None. C.M. Lill:
None.
P09.103C
Validation of a method for detection of low-level single
nucleotide variant mosaicism in sporadic Parkinson's
disease
M. I. Leija Salazar1, K. Mokretar1, A. Pittman2, D.
Hughes2, M. Athanasopoulou2, H. Morris1, A. Schapira1,
C. Proukakis1
1Dept of Clinical Neurosciences, Institute of Neurology,
University College London, London, United Kingdom,
2Dept of Molecular Neuroscience, Institute of Neurology,
University College London, London, United Kingdom
Neurons are susceptible to develop somatic variations in
their genomes throughout development and life. Although
their pathological role remains undetermined, the mechan-
isms of neurodegeneration could be explained by somatic
mutations occurring in a limited number of cells. We aim to
optimise a robust sequencing method for sensitive detection
of somatic variation in Parkinson’s disease (PD) genes in
sporadic PD samples
Sequencing libraries were prepared by using a Haloplex
HS panel (Agilent) targeting SNCA, GBA and coding exons
of 12 PD genes. Molecular barcodes allow for the removal
of duplicates and generation of consensus sequences to
replicate the original DNA fragments. Six artiﬁcial mosaics,
consisting of dilutions of a brain sample carrying known
variants, were sequenced on a HiSeq 2500. Bioinformatic
analysis was done by Surecall’s de-duplication tool, aligner
and low-level variant caller. LoFreq was used to validate
these results.
After analysing low level variants in artiﬁcial mosaics at
2050x coverage, four false positives were detected at allele
frequency (AF) values under 0.33%. By using our opti-
mised methods, Surecall’s sensitivity for detection of var-
iants at 1% and 0.5% is 92% and 78%. LoFreq showed a
lower sensitivity for 1% and 0.5% variants (88% and 70%).
Deep sequencing of PD samples using a Haloplex HS
allows for sensitive detection of variants at a 0.33% AF
level or higher in PD brain samples. These methods will be
used for the analysis of 50 samples from different brain
regions and other tissues.
Thanks to Michael J Fox Foundation and CONACYT for
awards and fellowships.
M.I. Leija Salazar: None. K. Mokretar: None. A.
Pittman: None. D. Hughes: None. M. Athanasopoulou:
None. H. Morris: None. A. Schapira: None. C. Prouka-
kis: None.
P09.104D
Identiﬁcation of mutations in PARK2 gene in Serbian
patients with Parkinson's disease
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M. Z. Jankovic1, V. Dobricic1, N. Kresojevic1, V.
Markovic1, I. Petrovic1,2, M. Svetel1,2, T. Pekmezovic2, I.
Novakovic2, V. Kostic1,2
Neurology Clinic, Clinical Center of Serbia, Belgrade,
Serbia, 2School of Medicine, University of Belgrade,
Belgrade, Serbia
Introduction: Mutations in the PARK2 (PRKN) gene are
the most common cause of autosomal-recessive (AR)
juvenile parkinsonism and young-onset recessive Parkin-
sonʼs disease (YOPD). More than 100 different variants
have been reported, including point mutations, small indels
and single or multiple exon copy number variations.
Materials and Methods: Mutation screening of PARK2 was
performed in 225 Serbian PD patients (143 males and 82
females) with disease onset before 50 years and/or positive
family history with apparent AR inheritance. All coding
regions and their ﬂanking intronic sequences were ampliﬁed
and directly sequenced by Sanger method. Whole exon
multiplications or deletions were detected using Multiple
Ligation Probe Ampliﬁcation (MLPA) method. Results:
We identiﬁed 12 PD patients with PARK2 mutations
(5.3%). Five patients (2.2%) had biallelic mutations and
seven patients (3.1%) were single mutation carriers. Patients
with compound heterozygous mutations had earlier onset of
the disease compared to non-carriers (p=0.005) or hetero-
zygotes (p=0.001). Other clinical presentations of the dis-
ease in mutation carriers were not different compared to
non-carriers. Conclusion: Estimation of PARK2 mutations
frequency and penetrance in different populations is
important for efﬁcient genetic testing strategy and coun-
seling. In our cohort sequence and dosage variants were
equally represented in patients positive for PARK2 muta-
tions, inducing their ﬁrst symptoms mainly before the age of
30, implying that patients with early, especially juvenile
onset of PD were strong candidates for both dosage and
sequence variants screening in PARK2.
M.Z. Jankovic: None. V. Dobricic: None. N. Kreso-
jevic: None. V. Markovic: None. I. Petrovic: None. M.
Svetel: None. T. Pekmezovic: None. I. Novakovic: None.
V. Kostic: None.
P09.105A
Mutations in DNAJC12, a member of the HSP40/DNAJ
family, cause early-onset parkinsonism
L. Straniero1, I. Guella2, R. Cilia3, V. Rimoldi1,4, L.
Parkkinen5, A. Young2, R. Asselta1,4, J. Follett2, G.
Soldà1,4, E. Saba1, V. Sossi6, J. Stoessl6, K. Nishioka7, N.
Hattori7, A. Rajput8, S. Goldwurm3, M. Farrer2, G.
Pezzoli3, A. Rajput8, S. Duga1,4
1Humanitas University, Rozzano, Italy, 2Centre for Applied
Neurogenetics, University of British Columbia, Vancouver,
BC, Canada, 3Parkinson Institute, ASST “Gaetano Pini-
CTO”, Milano, Italy, 4Humanitas Clinical and Research
Center, Rozzano, Italy, 5Nufﬁeld Department of Clinical
Neurosciences, University of Oxford, Oxford, United King-
dom, 6Parkinson’s Paciﬁc Movement Disorders Centre,
University of British Columbia, Vancouver, BC, Canada,
7Juntendo Medical School, Tokyo, Japan, 8Royal University
Hospital, Saskatoon, SK, Canada
Introduction: Mutations in single genes only explain 30%
of familial Parkinson’s disease (PD). We looked for novel
genes/mutations using whole-exome sequencing (WES) in
selected families showing early-onset (<45ys) recessive PD.
Results: Null homozygous mutations in DNAJC12, a
member of the HSP40/DNAJ family, were identiﬁed in 2
unrelated families: i) a nonsense mutation (c.187A>T, p.
K63X) in a Saskatchewan family (famA); ii) a splicing
mutation (c.79-2A>G, p.S26fs13X) in an Italian family
(famB). Both variants are absent in ethnically-matched
controls and public databases. Proband A had mild non-
progressive parkinsonism from the age of 13 and has since
come to autopsy (at 74). Proband B (onset at 32) has a
similar negligible progression of motor symptoms over
30ys, with mild executive and visuo-spatial dysfunction.
Dopaminergic dysfunction was subtle and non-progressive
in both probands, who had similar sustained symptomatic
beneﬁt on small dose of levodopa and substantial worsening
of symptoms after levodopa discontinuation. Neuropathol-
ogy (famA) revealed no alpha-synuclein pathology and only
some mild age-related Alzheimer’s disease changes. Func-
tional analyses showed that both mutations ablate
DNAJC12 protein expression. Conclusions: Our results
indicate that loss of DNAJC12, a Hsc70 interactor, is a rare
cause of parkinsonism associated with a very slow neuro-
degenerative process. Very recently, biallelic mutations in
DNAJC12 were shown to cause hyperphenylalaninemia
with dystonia and intellectual disability in children. Ana-
lyses are underway in our patients to verify whether they
also show defects in hydroxylase enzymes, which might
explain symptoms and pathology data. We thank Fonda-
zione Cariplo for ﬁnancial support (grant#2015-1017).
L. Straniero: None. I. Guella: None. R. Cilia: None. V.
Rimoldi: None. L. Parkkinen: None. A. Young: None. R.
Asselta: None. J. Follett: None. G. Soldà: None. E. Saba:
None. V. Sossi: None. J. Stoessl: None. K. Nishioka:
None. N. Hattori: None. A. Rajput: None. S. Goldwurm:
None. M. Farrer: None. G. Pezzoli: None. A. Rajput:
None. S. Duga: None.
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P09.106B
Expanding the phenotypic spectrum of FLVCR1
mutations
M. Rio1, C. Gitiaux2, S. Gerber3, V. Cantagrel4, N.
Boddaert5, J. Rozet3
Department of Genetics, Necker Hospital, paris, France,
2Department of Neuropediatry, Necker Hospital, Paris,
France, 3Laboratory of Genetics in Ophthalmology,
Imagine Institute, Paris, France, 4Molecular and patho-
physiological bases of cognitive disorders, Imagine Insti-
tute, Paris, France, 5Department of Pediatric radiology,
Necker Hospital, Paris, France
Posterior column ataxia with retinitis pigmentosa (PCARP)
is an autosomal recessive, childhood onset neurodegenera-
tive disorder characterized by retinitis pigmentosa and
sensory ataxia and ascribed to FLVCR1 mutations. No
cognitive deﬁcits have been reported in the original PCARP
families, but two affected siblings have been reported with
mild mental retardation. We report the clinical character-
ization of two unrelated patients harboring biallelic severe
FLVCR1. Patient 1 was born at term after uneventful
pregnancy, with normal birth parameters. Neonatal hypo-
tonia was noted at birth and he developed epilepsy at age of
3 days. The course was severe, with intractable seizures and
severely delayed psychomotor development. Retinitis pig-
mentosa was diagnosed at 1 year of age. At 8 years, he had
no ocular contact with axial hypotonia and absence of deep
tendon relexes. OFC was 45 cm (-3SD). Brain MRI showed
cerebellar hypoplasia. Electroneuromyography showed a
sensory neuropathy. Patient 2 was born at term after
uneventful pregnancy. During the ﬁrst 4 months of life,
physical and neurological examination was normal. He
presented west syndrome at the age of 5 months. He
developed severe psychomotor delay. He walked at 4 years
and never developed speech. Retinitis pigmentosa and
sensory neuropathy were diagnosed at age of 15 years. At
age 16 years, weigh was 32 kg (-3SD), Height 141 cm
(-4SD), OFC 50 cm (-4 SD). This report expands the phe-
notypic spectrum of FLVCR1 mutations to include west
syndrome, severe psychomotor retardation, intellectual
disability and post-natal microcephaly.
M. Rio: None. C. Gitiaux: None. S. Gerber: None. V.
Cantagrel: None. N. Boddaert: None. J. Rozet: None.
P09.107C
A zebraﬁsh model of pontocerebellar hypoplasia
B. Appelhof, M. A. J. Weterman, F. Baas
Academical Medical centre, Amsterdam, Netherlands
Introduction: Pontocerebellar hypoplasia (PCH) represents
a heterogeneous group of congenital neurodegenerative
diseases. Patients suffer from severe mental and motor
impairments, caused by atrophy of the pons and cerebellum.
So far, ten subtypes (PCH1–10) are described based on
clinical features and/or genetic causes. Most genetic aber-
rations are located in genes with a function in transfer RNA
(tRNA) metabolism pathways, e.g. tRNA Splicing Endo-
nuclease 54 (TSEN54) or Cleavage and Polyadenylation
Factor I Subunit 1 (CLP1). Hitherto, it is unknown if and
how faulty tRNA processing leads to pontine and cerebellar
degeneration. Materials and Methods: To elucidate the
consequences of aberrant tRNA processing, a zebraﬁsh
model with a nonsense mutation in tsen54 was created using
ENU mutagenesis. Survival of homozygous offspring was
assessed and pathologically examined. Results: Tsen54
knockout zebraﬁsh died between 15 days post fertilization
(dpf) and 26dpf. The total body volume increase between
7dpf and 19dpf was dramatically reduced compared to
controls. Brain volumes did not showed to be more severely
affected than other tissue. Conclusions: Here we show that
the knockout of tsen54 in zebraﬁsh results in early dead
between 15dpf and 26dpf. Additionally general hypoplasia,
with no speciﬁc effect on the brain, was seen. This deviates
from ﬁndings in humans carrying TSEN54 mutations were
primarily the pons and cerebellum are affected and no other
tissue outside of the central nervous system. Further
research must show if aberrant amount of tRNA species are
present in the knockout ﬁsh and if these are comparable to
amounts found in PCH patient.
B. Appelhof: None.M.A.J. Weterman: None. F. Baas:
None.
P09.108D
Genetic and phenotypic spectrum of primary familial
brain calciﬁcation in 92 patients from 52 families from
the French PFBC case series and functional assessment
of new XPR1 variants
G. Nicolas1,2,3, U. López-Sánchez4,5,6, A. Richard1,3, C.
Charbonnier1,3, T. Frebourg1,3, D. Campion7,1,3, M.
Sitbon4,5,6, J. Battini4,5,6, D. Hannequin8,3, the French
PFBC study group
Rouen University Hospital, Department of Genetics and
CNR-MAJ, Rouen, France, 2Radboud University Medical
Center, Department of Human Genetics, Nijmegen, Nether-
lands, 3Normandie Univ, UNIROUEN, Inserm U1245,
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Rouen, France, 4Institut de Génétique Moléculaire de
Montpellier, CNRS UMR5535, Montpellier, France, 5Uni-
versité de Montpellier, Laboratory of Excellence Epi-
GenMed, Montpellier, France, 6Laboratory of Excellence
GR-Ex, Paris, France, 7Rouvray Psychiatric Hospital,
Sotteville-lès-Rouen, France, 8Rouen University Hospital,
Department of Genetics, Department of Neurology and
CNR-MAJ, Rouen, France
Introduction: Primary Familial Brain Calciﬁcation (PFBC)
is a rare autosomal dominant calcifying disorder affecting
primarily the basal ganglia, associated with diverse neu-
ropsychiatric expression. Variants in the genes encoding the
inorganic phosphate (Pi) transporters SLC20A2 and XPR1
or the growth factor PDGFB and its main receptor
PDGFRB cause microvessel calciﬁcation through a loss-of-
function mechanism.
Methods: Thanks to nation-wide recruitment and tar-
geted or whole-exome sequencing screening, we report 24
novel families carrying 16 novel and 12 previously reported
rare variants, adding up to a total of 92 patients from 52
families carrying 45 distinct variants. Novel XPR1 variants
were assessed in vitro for Pi export.
Results: Following ACMG-AMP recommendations, 27
variants were classiﬁed as pathogenic, 7 as likely patho-
genic, and 11 of unknown signiﬁcance. Thirty-one families
carried a variant in SLC20A2 (11 novel variants), 11 in
PDGFB (3 novel), 8 in XPR1 (2 novel) and 2 in PDGFRB.
Overall, 75% patients were symptomatic; main symptoms
were psychiatric signs (68.1%), movement disorders
(65.2%) and cognitive impairment (59.4%). Ages of onset
ranged from 6 to 77 years with ﬁrst and last quartiles being
20 and 63 years respectively. Regarding the newly-
identiﬁed gene XPR1, the 2 novel missense variants
showed a defect in transport function as assessed by efﬂux
of radiolabeled Pi. All 10 XPR1 variant carriers were
symptomatic with similar expression compared to the other
groups.
Conclusion: This report is the largest systematic
description of PFBC genes variant carriers and helps
understanding the phenotypic spectrum of this rare disease
with inconstant clinical expression.
G. Nicolas: None. U. López-Sánchez: None. A.
Richard: None. C. Charbonnier: None. T. Frebourg:
None. D. Campion: None. M. Sitbon: E. Ownership
Interest (stock, stock options, patent or other intellectual
property); Modest; Metafora-biosystems. J. Battini: E.
Ownership Interest (stock, stock options, patent or other
intellectual property); Modest; Metafora-biosystems. D.
Hannequin: None.
P09.109A
Autosomal dominant progressive myoclonus dystonia
resulting from a PANK2 mutation
M. C. M. van der Weijden, R. A. Lambrechts, E. A. N.
Nibbeling, J. Groen, T. J. de Koning, O. C. M. Sibon, M.
A. J. Tijssen, D. S. Verbeek
UMCG, University of Groningen, Groningen, Netherlands
Introduction: With the introduction of next generation
sequencing in diagnostics we have to anticipate on the
identiﬁcation of novel gene-disease associations including
apparently dominant mutations in suspected recessive dis-
ease genes or vice versa. Therefore, functional validation of
candidate variants is of utmost importance for clinical
decision-making. Material and Methods: Whole exome
sequencing (WES) was performed in two relatives exhi-
biting autosomal dominant progressive myoclonus dystonia
from a multiplex family followed by bioinformatics analy-
sis. Functional analysis in cell models was used to assess
the pathogenic effects of the dominant candidate variant.
Results: WES identiﬁed a novel heterozygous truncating
variant c.1317delT;p.Arg440Valfs*10 in PANK2. Since
recessive PANK2 mutations cause pantothenate kinase-
associated neurodegeneration (PKAN), PANK2 deletions on
the other allele were excluded. p.
Arg440Valfs*10 segregated with disease and non-
penetrance was observed in 2 relatives. MRI revealed evi-
dent iron accumulation in the patient’s brains, but less
compared to classical PKAN. p.Arg440Valfs*10 led to
aberrant processing of precursor PANK2, instable inter-
mediate (i)PANK2 protein, and disrupted dimerization of
iPANK2 in HEK293T cells like the known recessive p.
Gly521Arg PANK2 mutation. Additionally, increased levels
of the iron exporter, FPN, mRNA were detected in patient
ﬁbroblasts indicative of loss of PANK2 as reported for
PKAN. Conclusion: Our genetic and imaging studies point
to pathogenic effects of p.Arg440Valfs*10 in PANK2.
However, additional functional studies are necessary to
prove that it causes myoclonus dystonia through a
dominant-negative effect. Funding: DSV; Rosalind Franklin
Fellowship, MAFT and TjdK; Actelion pharmaceuticals,
MAFT; Prinses Beatrix Muscle Funds, Merz, Ipsen, Aller-
gan Farmaceutics, and Medtronic, OCMS; NWO VICI
grant (865.10.012).
M.C.M. van der Weijden: None. R.A. Lambrechts:
None. E.A.N. Nibbeling: None. J. Groen: None. T.J. de
Koning: B. Research Grant (principal investigator, colla-
borator or consultant and pending grants as well as grants
already received); Modest; Actelion pharmaceuticals. D.
Speakers Bureau/Honoraria (speakers bureau, symposia,
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and expert witness); Modest; Actelion pharmaceuticals. O.
C.M. Sibon: None. M.A.J. Tijssen: B. Research Grant
(principal investigator, collaborator or consultant and
pending grants as well as grants already received); Modest;
Actelion pharmaceuticals, Merz, Ipsen, Allergan Farm-
aceutics, Medtronic. D. Speakers Bureau/Honoraria
(speakers bureau, symposia, and expert witness); Modest;
Merz. D.S. Verbeek: None.
P09.110B
Post-mortem cerebellar methylome of progressive
supranuclear palsy
J. G. J. van Rooij, M. M. P. J. Verbiest, C. W. Versluijs, A.
G. Uitterlinden, J. C. van Swieten, J. B. J. van Meurs
rasmus Medical Centre, Rotterdam, Netherlands
Introduction; Although Progressive Supranuclear Paly
(PSP) is relatively well described clinically and pathologi-
cally, much is still unknown regarding the underlying
molecular disease mechanisms. We compared genome-wide
DNA methylation in the cerebellum of 4 PSP cases and 4
age and sex-matched controls to investigate the genes and
mechanisms involved in PSP.
Methods; All frozen post-mortem cerebellar tissue was
derived from the Netherlands Brain Bank (NHB). DNA was
isolated and processed from macroscopically dissected tis-
sue, followed by Illumina’s inﬁnium Human Methylation
450K array. After removing poor quality CpGs and DASEN
normalization, methylation values for 434.686 CpGs were
compared between cases and controls using two-tailed t-
tests. Gene set enrichment for the 500 most signiﬁcant
CpGs, based on Illumina’s CpG-Gene annotation, was
performed using WebGestalt.
Results; No CpG reached Bonferroni-corrected sig-
niﬁcance (p<1.2E-7). Two suggestive (p<5E-6) CpGs were
identiﬁed, one in intron 15 of WDR60, the second CpG
upstream of both c19orf44 and CALR3. Gene set enrich-
ment showed involvement of several speciﬁc GO-terms
including anoikis (a form of apoptosis, 5 genes,
adjP=0.0201), regulation of microtubule polymerization (5
genes including MAPT, adjP=0.0201) and neuron projec-
tion morphogenesis (31 genes, adjP=0.0201).
Conclusions; These preliminary results show suggestive
differences in cerebellar methylation in PSP brains.
Although no single CpG reaches genome-wide signiﬁcance,
analysis of the top signals indicates function speciﬁc
enrichment, including validated microtubule-related pro-
cesses and genes previously associated with Tauopathies.
We are currently adding methylation data of additional
cerebellum samples and other affected brain regions and
will replicate these results in an independent cohort.
J.G.J. van Rooij: None. M.M.P.J. Verbiest: None. C.
W. Versluijs: None. A.G. Uitterlinden: None. J.C. van
Swieten: None. J.B.J. van Meurs: None.
P09.111C
Stem cell models for studying the role of epigenetic
machinery in abnormal neurogenesis
N. Kommu, S. Saxena, P. Naik
BITS Pilani - Hyderabad Campus, Jawahar Nagar,
Hyderabad, India
In addition to genetic mutations, the role of epigenetic
abnormalities is widely appreciated in the development of
disorders such as schizophrenia and autism. In support of
this notion, elevated levels of DNMT1 and DNMT3A have
been reported in post-mortem brain samples from patients
with schizophrenia. However, the mechanisms by which
elevated levels of DNMT1 or DNMT3 result in formation
abnormal neurons is not clear. Towards this goal, we
developed a transgenic mouse embryonic stem cell line that
overexpresses DNMT1 and observed that neurons obtained
from the mutant line shows abnormal branching of den-
drites and elevated levels of NMDA receptor activity. To
gain more insights into the abnormal effects of increased
levels of DNMT1, we performed genome-wide methylation
comparisons between wild-type and mutant ES cells to
identify loci undergoing aberrant methylation in the mutant
ES cells. Results of these experiments will be presented.
N. Kommu: None. S. Saxena: None. P. Naik: None.
P09.112D
A new hereditary ataxia disorder with prominent cog-
nitive impairment and 1C2 positive inclusions
L. Donker Kaat1,2, J. G. J. van Rooij1, S. Melhem1, A.
Verkerk1, A. Rozemuller3, J. C. van Swieten1,3
Erasmus Medical Center, Rotterdam, Netherlands, 2Leiden
University Medical Center, Leiden, Netherlands, 3VU
University Medical Center, Amsterdam, Netherlands
Introduction Spinocerebellar ataxias (SCA’s) are a hetero-
geneous group of neurodegenerative disorders characterized
by autosomal dominant cerebellar ataxia together with a
range of other features such as extrapyramidal symptoms
and cognitive impairment. Over 30 genes and loci have
been reported to date with the group of polyglutamine
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expansions as most common genetic cause. In the present
study we report a new Dutch pedigree with late onset ataxia
and prominent cognitive decline. Methods After informed
consent, DNA was obtained from 8 affected and 4 unaf-
fected relatives from one family. Previous genetic testing
excluded mutations in MAPT, PSEN1, PRNP, HTT,
DRPLA, FXTAS, SCA1, SCA2, SCA3, SCA6, SCA7 and
SCA17. We performed whole exome sequencing (WES) on
2 affected and one unaffected individual. During follow-up,
neuropathological examination was performed in three
affected individuals. Results Mean age at onset was 64
years and the clinical symptoms included gait ataxia, dys-
arthria, parkinsonism and prominent cognitive impairment.
Neuroimaging in all affected persons showed cerebellar
and/or generalized atrophy. WES revealed no mutations in
previously reported ataxia genes. Neuropathological exam-
ination showed almost complete loss of Purkinje cells.
Immunohistochemistry with p62 antibody showed few
neuronal intranuclear inclusions in several brain areas,
while more widespread diffuse nuclear staining and cyto-
plasmic inclusions were observed with 1C2 antibody (an
antibody that detects long stretches of glutamine). Conclu-
sions We report a new Dutch SCA pedigree with 1C2
positive inclusions and no known genetic mutation. We are
currently adding haplotype analysis (array-based) and
additional WGS data to identify the underlying genetic
cause.
L. Donker Kaat: None. J.G.J. van Rooij: None. S.
Melhem: None. A. Verkerk: None. A. Rozemuller: None.
J.C. van Swieten: None.
P09.113A
Evaluation of genotype-phenotype relationship of short
NOP56 expansions causing SCA36
B. Quintans1, M. Arias2, M. Garcia-Murias1, Z. Yañez-
Torregroza3, P. Cacheiro1, C. Garcia-Sancho4, M. Garcia-
Antelo4, F. Barros5, M. Pardo6, M. Sobrido1
1Grupo de Neurogenética, Instituto de Investigación
Sanitaria (IDIS); Grupo de Medicina Xenómica,
CIBERER-U711, Santiago de Compostela, Spain, 2Servicio
de Neurología, Complejo Hospitalario Universitario de
Santiago, Santiago de Compostela, Spain, 3Grupo de
Neurogenética, Instituto de Investigación Sanitaria (IDIS);
Universidad Simón Bolivar, Colombia, Santiago de Com-
postela, Spain, 4Servicio de Neurología, Complejo Hospi-
talario Universitario de la Coruña, La Coruña, Spain,
5Fundación Pública Galega de Medicina Xenómica; Grupo
de Medicina Xenómica, CIBERER-U711, Santiago de
Compostela, Spain, 6Servicio de neurología, Hospital
Comarcal de Valdeorras, El Barco de Valdeorras, Spain
Introduction: Spinocerebellar ataxia 36 (SCA36) is an
autosomal dominant ataxia with sensorineural hearing loss
and motor neuron dysfunction, usually starting in the ﬁfth
or sixth decade. The cause is an intronic hexanucleotide
expansion in NOP56, with 4–15 repeat normal alleles and
over 650 repeats, full-penetrant alleles. The pathogenicity of
short expansions is not well documented. Materials and
Methods: 26 patients with full expansions and 3 patients
with short expansions underwent neurologic examination
and SARA scoring for the severity of ataxia. Genotyping
was carried out by standard and repeat-primed PCR on
peripheral blood DNA. Results: A 64 yo man with disease
onset at 55 had an abnormal 35 repeat allele and SARA
score of 9. His 86 yo mother, also with a 35 repeat allele,
reported disease onset around 50. Her current SARA score
was 15. A maternal uncle, with an expanded allele of 49
repeats, had disease onset around 60, and SARA score of 11
at age 70. The age-adjusted SARA score of patients with
short expansions was not signiﬁcantly different from that of
full-expansion patients. The family history did not disclose
cases of non-penetrance. Conclusions: Short NOP56
expansions (at least ≥35 repeats) are pathogenic. There is no
signiﬁcant difference in the clinical impact of short expan-
sion versus fully expanded alleles. However, more cases
with short expansions need to be studied to reach ﬁrm
conclusions on genotype-phenotype relationships, and thus
improve genetic counseling. Penetrance, somatic and
gonadal stability of short expansions require further inves-
tigations. Funding: PI12/00742.
B. Quintans: None. M. Arias: None. M. Garcia-
Murias: None. Z. Yañez-Torregroza: None. P. Cacheiro:
None. C. Garcia-Sancho: None.M. Garcia-Antelo: None.
F. Barros: None. M. Pardo: None. M. Sobrido: None.
P09.114B
A massively parallel reported assay for variants asso-
ciated with schizophrenia and Alzheimer’s disease
D. Avramopoulos, L. Myint, R. Wang, L. Boukas, K.
Hansen, L. Goff
ohns Hopkins University, Baltimore, MD, United States
Genome wide association studies (GWAS) have reported on
numerous loci for complex disorders including schizo-
phrenia (SZ) and Alzheimer’s disease (AD), most located
outside protein coding regions. We hypothesize that some
of these loci act through differential enhancer activity and
test this hypothesis by systematically assaying each locus
using a Massively Parallel Reporter Assay (MPRA). Spe-
ciﬁcally, we investigate all variants in high LD with 71 SZ
and 8 AD loci, for a total of 1083 variants. For each variant
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we designed a 95 bp sequence centered on the variant and
linked it to 5 distinct barcodes, including positive and
negative controls. We generated a plasmid library using
standard protocols, with ﬁnal oligo representation of 80%
(85% of alleles represented by ≥ 3 oligos) and transfected it
3 independent times into K562 cells; this cell line was
chosen because we have observed maximum overlap of
open chromatin with SZ loci (transfection of SK-SY-5Y
human neuroblastoma cells is under way). Following
transfection we extracted RNA and DNA and assayed the
transfection efﬁciency and technical reproducibility. Spe-
ciﬁcally we found that on average, 80% of barcodes were
represented in DNA and 72% in RNA. After summing
counts over barcodes, we compute the correlation of counts
and activity measures (log ratio of RNA over DNA) across
replicates and ﬁnd high mean correlations: 0.999 for DNA,
0.999 for RNA, and 0.749 for log ratios. Signiﬁcant over-
laps with open chromatin marks validate our results. Spe-
ciﬁc results of our assay for SZ and AD will be presented.
D. Avramopoulos: None. L. Myint: None. R. Wang:
None. L. Boukas: None. K. Hansen: None. L. Goff: None.
P09.115C
Genetic association and functional characterization of a
variant in the MCPH1 gene in bipolar disorder and
schizophrenia
m. aleissa, Sally I Sharp, Niamh L O’ Brien, Alessia
Fiorentino, Nicholas J Bass, David Curtis,Andrew
McQuillin
ucl, london, United Kingdom
Abstract
The microcephalin 1 gene (MCPH1) plays an important
role in DNA damage and repair and cell cycle arrest, with
the BRCT1 domain being important for centrosomal loca-
lization throughout the cell cycle. A low frequency MCPH1
variant rs61749465 A>G (p.Asp61Gly) showed evidence
for association with schizophrenia (SCZ). We further
explored this variant in 2,300 bipolar disorder (BPD), 1,930
SCZ subjects and 1,820 normal comparison subjects and
report evidence for association with BPD (P=0.0009).
Notably the variant allele of rs61749465 was absent in the
1,820 comparison subjects tested. rs61749465 is located in
the N-terminal BRCT1 domain of MCPH1 and bioinfor-
matic analysis predicted the Asp61Gly substitution to be
damaging to MCPH1 protein function. A second MCPH1
BRCT1 domain variant (rs199422124 C>G; p.Thr27Arg),
reported to cause autosomal recessive microcephaly, was
also genotyped however the variant was not detected in any
of the subjects tested. We sought to characterize the
functional effects of these variants on MCPH1 function.
Cell viability and cell count assays indicated that the variant
allele of rs199422124 had a larger impact on cell survival
compared to the variant allele of rs61749465, however
neither of the variant alleles signiﬁcantly altered DNA
damage or mRNA stability. Analysis of gene expression
data from RNA sequencing experiments suggested that
rs61749465 expression altered the expression of a number
of genes involved in protein translation and in the Alzhei-
mer's disease pathway. Conﬁrmation of the ﬁndings pre-
sented here could further our understanding of the role of
genetic variants in the risk of developing a psychotic
disorder.
M. aleissa: None.
P09.116D
Genome-wide methylomic analysis of neonatal blood
from Danish monozygotic twins discordant for
schizophrenia
S. Weinsheimer1,2, A. Starnawska3,4,2, C. S. Hansen5,2, A.
Buil1,2, J. Bybjerg-Grauholm2,5, M. Baekvad-Hansen2,5,
D. M. Hougaard2,5, T. Sparsoe1,2, M. Bertalan1,2, P. B.
Mortensen2,6,7, C. B. Pedersen2,6,7, T. M. Werge1,2,8
Institute of Biological Psychiatry, Mental Health Center
Sankt Hans, Roskilde, Denmark, 2iPSYCH, The Lundbeck
Foundation's Initiative for Integrative Psychiatric
Research, Denmark, Copenhagen, Denmark, 3Aarhus
University, Aarhus, Denmark, 4iSEQ, Center for Integrative
Sequencing, Aarhus, Denmark, 5Statens Serum Institute,
Copenhagen, Denmark, 6National Centre for Register-
Based Research, Aarhus University, Aarhus, Denmark,
7Centre for Integrated Register-Based Research, Aarhus
University, Aarhus, Denmark, 8Institute of Clinical
Sciences, Faculty of Medicine and Health Sciences,
University of Copenhagen, Copenhagen, Denmark
Introduction: Emerging evidence implicates altered DNA
methylation in psychiatric disorders including bipolar dis-
order, major depressive disorder and schizophrenia. How-
ever, it is unclear whether the DNA methylation changes
observed to date are causative or reﬂect disease progression
or treatment. The neonatal period is a time of rapid neuro-
development during which alterations in DNA methylation
may contribute to the risk of psychiatric illness. Hence, we
explored whether differences in DNA methylation in blood
at birth were associated with monozygotic twin discordance
for schizophrenia.
Materials and Methods: Neonatal blood samples
obtained from Guthrie cards for sixteen pairs of Danish
monozygotic twins discordant for schizophrenia were used
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for genome-wide proﬁling of DNA methylation with the use
of Inﬁnium HumanMethylation450 BeadChip from Illu-
mina. Differentially methylated positions (DMPs) asso-
ciated with schizophrenia were identiﬁed using linear
regression with sex as a covariate.
Results: The top-ranked schizophrenia-associated DMP
(cg08408303, p=3.4e-06) was located in the 5′UTR of the
C3orf35 gene, a suspected tumor suppressor. Interestingly,
several of the top DMPs map to genes involved in cilia
biology and SHH signaling including TBC1D32, DNAH2,
GPR161, and COLGALT1. In addition, we identiﬁed a
DMP in the TSS200-island of the BORCS5 gene encoding
one of eight subunits of the BORC-1 multisubunit complex,
which regulates lysosome positioning and endosomal traf-
ﬁcking and has known association with risk of
schizophrenia.
Conclusions: Our data indicate that DNA methylation
differences are quantiﬁable in neonatal blood from mono-
zygotic twins discordant for schizophrenia later in life and
suggest that susceptibility to schizophrenia is conferred by
dysregulated neurodevelopmental genes.
S. Weinsheimer: None. A. Starnawska: None. C.S.
Hansen: None. A. Buil: None. J. Bybjerg-Grauholm:
None. M. Baekvad-Hansen: None. D.M. Hougaard:
None. T. Sparsoe: None. M. Bertalan: None. P.B. Mor-
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Large family-based exome sequencing study provides
new insight into schizophrenia
A. C. Koller1,2, J. Strohmaier3, K. U. Ludwig1,2, F. C.
Degenhardt4, M. Wulff1,2, D. Breuer1,2, L. Winkler1,2, F.
Neukirch1,2, A. Maaser1,2, A. Forstner1,5,6, S.
Sivalingam1,2, A. Reif7, A. Ramirez8, W. Maier8, D.
Rujescu9, I. Giegling9, H. Thiele10, P. Nürnberg10, S.
Heilmann-Heimbach1,2, T. Andlauer11, A. Fischer12, G.
Jain12, L. Kaurani12, K. Klockmeier13, K. Worf14, J.
Krumsiek14, D. Wildenauer15, S. Schwab16, M. Rietschel3,
M. M. Nöthen1,2, F. Degenhardt1,2
1Institute of Human Genetics, University of Bonn, Bonn,
Germany, 2Department of Genomics, Life and Brain
Center, Bonn, Germany, 3Department of Genetic Epide-
miology in Psychiatry at the Central Institute of Mental
Health, University Medical Center Mannheim/University of
Heidelberg, Mannheim, Germany, 4Institute of Clinical
Molecular Biology, University of Kiel, Kiel, Germany,
5Division of Medical Genetics and Department of Biome-
dicine, University of Basel, Basel, Switzerland, 6Depart-
ment of Psychiatry (UPK), University of Basel, Basel,
Switzerland, 7Department of Psychiatry
PsychosomaticMedicine and Psychotherapy, University of
Frankfurt, Frankfurt, Germany, 8Department of Psychiatry
and Psychotherapy, University of Bonn, Bonn, Germany,
9Department of Psychiatry Psychotherapy and Psychoso-
matic Medicine, University of Halle, Halle, Germany,
10Cologne Center for Genomics, University of Cologne,
Cologne, Germany, 11Max Planck Institute of Psychiatry,
Munich, Germany, 12Department of Psychiatry and Psy-
chotherapy, University of Göttingen, Göttingen, Germany,
13Max-Delbrück-Center for Molecular Medicine in the
Helmholtz Association Berlin, Berlin, Germany, 14Institute
of Computational Biology, Helmholtz Center Munich,
Munich, Germany, 15University of Western Australia, Perth,
Australia, 16University of Wollongong, Wollongong,
Australia
Schizophrenia (SCZ) is a severe psychiatric disorder with a
prevalence of ~ 1% and a heritability of ~ 65%. Analysing
multiply affected families using whole exome sequencing
(WES) is a very promising approach to identify new SCZ
risk factors as in these families genetic variants with parti-
cularly strong effect might co-segregate with the disorder.
The present study is the worldwide largest SCZ family
study using WES.
We exome sequenced 2–5 affected individuals from 54
families, each. Our analyses focused on rare (allele fre-
quency ≤ 0.1% in the Exome Aggregation Consortium
dataset) variants that were in silico predicted to be patho-
genic (Combined Annotation Dependent Depletion Score ≥
15) and that were shared between all affected individuals in
one family.
Mutations in ~ 800 brain expressed genes were identi-
ﬁed. Based on these data, we have performed protein-
protein-interaction analyses and have built a SCZ network
implicating new genes in the pathogenesis of the disorder
and also providing additional genetic evidence for pre-
viously reported candidate genes; i.e. co-segregating
mutations in DGCR2 (risk locus 22q11.2) and CSMD1
(genome-wide signiﬁcant in worldwide largest genome-
wide association study). To further evaluate the relevance of
the new candidate genes in the pathogenesis of the disorder,
we are currently sequencing these in a large cohort of 5,000
individuals. Our work provides new insight into the genetic
architecture of schizophrenia.
A.C. Koller: None. J. Strohmaier: None. K.U. Lud-
wig: None. F.C. Degenhardt: None. M. Wulff: None. D.
Breuer: None. L. Winkler: None. F. Neukirch: None. A.
Maaser: None. A. Forstner: None. S. Sivalingam: None.
A. Reif: None. A. Ramirez: None. W. Maier: None. D.
Rujescu: None. I. Giegling: None. H. Thiele: None. P.
Nürnberg: None. S. Heilmann-Heimbach: None. T.
Andlauer: None. A. Fischer: None. G. Jain: None. L.
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Effects of ectoine and herbal compound (Rosa canina,
Tanacetum vulgare and Urtica dioica) on behavior and
expression of Alzheimer's disease-related genes in
streptozotocin-rat model of sporadic Alzheimer’s disease
N. Bazazzadegan1, M. Dehghan Shasaltaneh2, K.
Saliminejad3, K. Kamali3, M. Banan1, H. Khorram
Khorshid1
Genetics Research Center, University of Social Welfare and
rehabilitation Sciences, Tehran, Iran, Islamic Republic of,
2Laboratory of Neuro-organic Chemistry, Institute of
Biochemistry and Biophysics (IBB), University of Tehran,
Tehran, Iran, Islamic Republic of, 3Reproductive Biotech-
nology Research Center, Avicenna Research Institute,
ACECR, Tehran, Iran, Islamic Republic of
Possible mechanisms of Alzheimer’s disease such as
inﬂammation and oxidative stresses in the brain motivate
researchers to follow therapies which would be effective, in
the early stages of the disease. Ectoine has been reported
prohibits amyloid formation in vitro. The herbal extract of
R. Canina, T. Vulgare and U. Dioica plant species, has anti-
inﬂammatory and protective effects against oxidative stress.
In this study eight AD-related genes, Daxx, Nfκb, Vegf,
Psen1, Mtap2, Syp, Mapk3 and Tnfα genes were chosen to
investigate the neuroprotective effect of ectoine on gene
expression in the hippocampus of rat model of sporadic AD,
using qPCR in the treated and control groups. The effects
on learning and memory levels were evaluated by Morris
Water Maze (MWM) test. All procedures were accom-
plished for neuroprotective effect of herbal extract on Daxx,
Nfκb and Vegf. Our results showed signiﬁcant down-
regulation of Syp, Mapk3 and Tnfα in ectoine comparing to
the model group. Signiﬁcant up-regulation of Vegf in
ectoine and herbal extract comparing to model group was
indicated as well. In MWM, there was no signiﬁcant change
in swimming distance and time for ﬁnding the hidden
platform in ectoine and herbal-treated comparing to model
group. Furthermore, No signiﬁcant change in ectoine and
herbal-treated comparing to model and related groups in
memory level was seen, but the same change was detected
in the treated comparing to the control group in memory
level. It seems that ectoine and herbal extract may have
signiﬁcant effect on gene expression as same as on clinical
levels.
N. Bazazzadegan: None. M. Dehghan Shasaltaneh:
None. K. Saliminejad: None. K. Kamali: None. M.
Banan: None. H. Khorram Khorshid: None.
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DYT6-associated THAP1 missense mutations affect its
function in regulating genes related to synaptic function
F. Cheng, M. Walter, T. Hentrich, O. Riess, T. Ott, K.
Grundmann-Hauser
Institute of Medical Genetics and Applied Genomics,
Tübingen, Germany
Mutations in THAP1 (THAP domain containing, apoptosis
associated protein 1) were found to be responsible for
DYT6 dystonia. Although more than seventy different
mutations of THAP1 have been identiﬁed in patients with
primary dystonia, the pathogenesis of THAP1 mutations
causing DYT6 dystonia is still largely elusive. THAP1 is a
transcription factor, identifying its target genes might reveal
the pathogenic mechanism of DYT6 / THAP1 dystonia. In
order to identify target genes of THAP1 and to characterize
the pathogenesis of DYT6 dystonia, we performed a
microarray analysis on a neuronal cell model for DYT6
dystonia, which stably overexpress wild-type or mutant
THAP1 (S21T or F81L mutants). Microarray analysis
showed that overexpression of wild-type THAP1 can reg-
ulate expression of genes related to cell growth and pro-
liferation. However, DYT6-associated THAP1 missense
mutations (S21T or F81L) showed dysfunction in regulating
genes related to synaptic function. By using Chromatin
immunoprecipitation (ChIP)-qPCR and luciferase reporter
assay analysis, we found that THAP1 binds to the promoter
region of SYT9 and regulates its activity. Our results indi-
cate that wild-type THAP1 has a function in regulating
genes related to cell growth and proliferation in neuronal
cells, while synaptic functional alteration might be one of
the pathogenic mechanisms of DYT6 dystonia caused by
THAP1 missense mutations.
F. Cheng: None.M. Walter: None. T. Hentrich: None.
O. Riess: None. T. Ott: None. K. Grundmann-Hauser:
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New cases of de novo truncating mutations of TRIM8 in
patients with epileptic encephalopathy, dysmorphic
features and nephrotic syndrome
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M. Assoum1, J. Thevenon1,2,3, V. Darmency4, O.
Devinsky5,6, E. Heinzen7,6, Y. Duffourd1,2,3, C. Thauvin-
Robinet1,2,3, D. Lowenstein8,6, L. Faivre1,2,3
Equipe d’Accueil 4271, Génétique des Anomalies du
Développement, Université de Bourgogne, dijon, France,
2Fédération Hospitalo-Universitaire Médecine Translation-
nelle et Anomalies du Développement (TRANSLAD), Centre
Hospitalier Universitaire Dijon, Dijon, France, 3Centre de
Génétique et Centre de Référence Anomalies du Dével-
oppement et Syndromes Malformatifs de l’Interrégion Est,
Centre Hospitalier Universitaire Dijon, Dijon, France,
4Service de Neurophysiologie Clinique Enfant Pole Neu-
rosciences Hopital d’Enfants CHU DIJON 21079 Dijon
Cedex, dijon, France, 5NYU and Saint Barnabas Epilepsy
Centers, NYU School of Medicine, New york, NY, United
States, 6Epi4K consortium, New york, NY, United States,
7Institute for Genomic Medicine - Columbia University
Medical Center - 701 W 168th Street - Hammer Building
1408 - New York City, NY 10032, New york, NY, United
States, 8Department of Neurology, University of California,
San Francisco, San Francisco, California 94143, USA, San
Francisco, CA, United States
Mutations of the TRIM8 gene coding for a tripartite motif
protein have been reported in a patient with epileptic
encephalopathy by Sakai and colleagues. We present here
two additional patients with TRIM8 mutations: an eight
year old girl with pharmacoresistant epileptic encephalo-
pathy associated with stereotypies and glomerular protei-
nuria, and further clinical details of a patient reported by the
Epi4K consortium. Exome sequencing revealed de novo
truncating mutations of TRIM8 in our patient as well as the
patient from the trio sequenced by the Epi4K consortium.
The de novo mutations were conﬁrmed by Sanger sequen-
cing. Our case presented nephrotic syndrome not reported in
the patient of Sakai and colleagues and the Epi4K con-
sortium case. The clinical presentation of these patients
overlaps with Galloway-Mowat syndrome, but mutations in
the WDR73 gene were absent suggesting a Galloway-
Mowat-like phenotype in our cases. Moreover, Galloway-
Mowat syndrome seems to result in earlier death than in our
cases. These observations suggest that phenotypic varia-
bility is observed in patients with TRIM8 mutations and
genetic testing of TRIM8 should be expanded to patients
with EE associated with dysmorphic features or nephrotic
syndrome.
M. Assoum: None. J. Thevenon: None. V. Darmency:
None. O. Devinsky: None. E. Heinzen: None. Y. Duf-
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Compound heterozygous mutations in UBA5 causing
early-onset epileptic encephalopathy in two sisters in
Iceland
G. A. Arnadottir1, B. O. Jensson1, S. E. Marelsson2, G.
Sulem1, A. Oddsson1, R. P. Kristjansson1, S.
Benonisdottir1, S. A. Gudjonsson1, G. A. Thorisson1, O. T.
Magnusson1, A. Jonasdottir1, A. Jonasdottir1, A.
Sigurdsson1, D. F. Gudbjartsson1,3, U. Thorsteinsdottir1,4,
R. Arngrimsson2, P. Sulem1, K. Stefansson1,4
1deCODE Genetics/Amgen, Inc., Reykjavik, Iceland, 2Land-
spitali University Hospital, Reykjavik, Iceland, 3School of
Engineering and Natural Sciences, University of Iceland,
Reykjavik, Iceland, 4Faculty of Medicine, University of
Iceland, Reykjavik, Iceland
Introduction: Epileptic encephalopathies are a group of
childhood epilepsies characterized by severe seizures or
other paroxysmal eletrical activities that contribute to
impaired cerebral function. The recent, extensive use of
next-generation sequencing has identiﬁed a large number of
genes in epileptic encephalopathies, including UBA5 in
which biallelic mutations were ﬁrst described as pathogenic
in 2016.
Materials and Methods: Two sisters with early-onset
epileptic encephalopathy were whole-genome sequenced
along with their unaffected parents (Icelandic and Amer-
ican). The sisters were born in 2004 and 2006 and ﬁrst
became symptomatic at three months of age when they
developed infantile spasms, which later progressed to
recurrent, treatment-resistant seizures.
Results: We detected a compound heterozygous geno-
type in UBA5 in the affected sisters, a genotype not seen
elsewhere in an Icelandic reference set of 30,067 indivi-
duals. The maternally inherited missense mutation, p.
Ala371Thr, produces a hypomorphic UBA5 allele and has
been reported as pathogenic when in compound hetero-
zygosity with a loss-of-function mutation in UBA5. The
paternally inherited exonic splicing mutation, c.684G>A,
occurs at the last nucleotide of exon 7 of UBA5 and is
predicted to disrupt the splice site with a subsequent loss-of-
function effect. Two unaffected brothers of the sisters (born
in 2002 and 2014) are each heterozygous for only one of the
mutations.
Conclusions: We describe compound heterozygous
mutations in the UBA5 gene in two sisters with early-onset
epileptic encephalopathy. To our knowledge, this is the ﬁrst
description of mutations in UBA5 since the initial discovery
that pathogenic biallelic variants in UBA5 cause early-onset
epileptic encephalopathy.
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Functional characterisation of a variant in the SLC19A1
gene associated with Wernicke-Korskoff syndrome
N. L. O'Brien1, G. Quadri1, A. Thomson1, P. McHugh2, S.
Pope3, D. Curtis4
Molecular Psychiatry Laboratory, Division of Psychiatry,
University College London, London, United Kingdom,
2Huddersﬁeld University, Huddersﬁeld, United Kingdom,
3Neurometabolic Unit, National Hospital for Neurology
and Neurosurgery, Queen Square,, London, United King-
dom, 4UCL Genetics Institute, UCL, Darwin Building,
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Wernicke-Korsakoff syndrome (WKS) is an acute neu-
ropsychiatric disorder characterised by a rapidly progres-
sing Wernicke encephalopathy followed by an irreversible
disorder called Korsakoff’s psychosis. WKS results as a
consequence of low levels of thiamine reaching the brain
and is commonly associated with chronic alcohol abuse due
to malnutrition and liver damage. Whole exome sequencing
was conducted in 30 WKS individuals. We detected 34
truncating mutations in genes predicted to have low intol-
erance to loss of function variants. Amongst these were
genes involved in ciliopathies, “failure to thrive” and with
low BMI. Next we used the WKS exome data as a dis-
covery set to identify variants in genes involved in the
thiamine and folate pathways. Thirty variants had higher
minor allele frequencies in the WKS exome data compared
the European 1000 genomes population and exome variant
server database. Follow up genotyping in a cohort of 112
WKS individuals compared to 439 alcohol dependent sub-
jects with no WKS found nominal association with the
rs1051266 variant in the SLC19A1 gene (p=0.034).
SLC19A1 encodes a folate transporter which also transports
the biologically active forms of thiamine. In vitro assays in
HEK293 cells show a signiﬁcant increase of thiamine
diphosphate (TPP) in the cells with the mutant versus cells
transfected with the wild-type transporter (p=0.023). TPP is
an important component of the Krebs and glucose meta-
bolism cycles and altered TPP levels may have downstream
effects on these cycles and explain why some individuals
who are alcohol dependent develop WKS. Funded by the
Brain Damage Research Trust
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P10 Neuromuscular disorders
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Col6A2 p.G283E: antisense-induced mRNA knockdown
as a possible treatment strategy
S. Kohler1, Z. Aherrahrou1, S. Wrobel1, F. Kaiser2, R.
Kretschmer-Kazemi Far3, G. Szcakiel3, J. Erdmann1
1Institute for Cardiogenetics, Lübeck, Germany, 2Institute
of Human Genetics, Lübeck, Germany, 3Institute of
Molecular Medicine, Lübeck, Germany
Collagen VI myopathies (prevalence of 10/1,000,000)
encompass a broad clinical spectrum from the milder form
Bethlem Myopathy (BM; OMIM: # 158810) to the more
severe Ullrich Congenital Muscular Dystrophy (UCMD,
OMIM: # 254090). Most mutations have a dominant
negative effect, with defects in collagen VI chain secretion
and assembly. It is generally accepted that, reversely, col-
lagen VI haploinsufﬁciency has no pathological con-
sequences. Thus, RNA-targeting approaches aimed at
preferentially inactivating the mutated COL6 messenger
may represent a possible therapeutic strategy.
Exome sequencing revealed a de novo mutation in a
highly conserved region of codon 283 of COL6A2 (p.
G283E) in a patient with an intermediate phenotype. A cell
culture assay with mutant ﬁbroblasts from the patient’s skin
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biopsy was established in order to compare them to wild
type ﬁbroblasts and analyse differences in ECM quality and
quantity. We have identiﬁed a signiﬁcant decrease in col-
lagen VI matrix and non-consistent microﬁbrils from which
we concluded the mutation’s serious impact on ECM.
Speciﬁty of antisense oligo nucleotides (asON) and small
interfering RNA (siRNA) was deﬁned after initial trans-
fection carried out against wild type allele showing a sig-
niﬁcant RNA depletion. Now we aim to transfect with the
mutation-speciﬁc asON and siRNA to examine their beneﬁt
on collagen VI in ECM in the ﬁbroblast assay and perform
quantitative PCR for knockdown validation. These studies
could further establish antisense induced mRNA knock-
down as a possible treatment for collagen VI myopathies.
Dr.-Holger-Müller-Stiftung
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Homozygote ADCY6 mutation causing demyelinating
polyneruopathy
E. Illum, J. Ek, M. Dunø, B. R. Diness
Department of Clinical Genetics, Copenhagen, Denmark
Introduction: CMT is a common yet complex diagnosis to
work up because of the genetic heterogeneity of the disease.
We present a case of two siblings, a boy and a girl, from a
consanguineous family who presented with demyelinating
polyneuropathy phenotypically assessed as CMT. A syn-
dromal CMT form was suspected because of hearing
impairment in one sibling and craniosynostosis in the other.
Materials and Methods: Chromosomal microarray and
metabolic testing were normal. A panel of CMT genes was
without signiﬁcant ﬁndings. We then applied Whole exome
sequencing (WES)
Result: WES revealed a homozygote ADCY6 mutation
c.2975A>G, p. Tyr992Cys in both patients. No other likely
pathogenic variants were detected.
Conclusion. The present report expands the phenotypical
spectrum of ADCY6 related disorder. ADCY6 is gene
encoding a protein, which belong to the adenylate cyclase
family. This protein is responsible for synthesising cAMP,
which has a great variety of functions, and is essential for
correct differentiation of peripheral myelinated axons. In the
current literature, a mutation in ADCY6 is related to AMC,
but these siblings with a homozygote ADCY6 mutation
presented CMT like symptoms along with other symptoms,
not related to CMT. This might be due to the large variety
of the phenotype or due to additional autosomal recessive
disorder. Extensive diagnostic work-up based on the
assumption that the children had CMT did not lead to a
diagnosis whereas the exome approach allowed the clinical
team to identify a likely cause and reevaluatethe clinical
picture.
E. Illum: None. J. Ek: None. M. Dunø: None. B.R.
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Molecular characterization of skeletal muscle of ALS
patients during disease progression: identiﬁcation of
new therapeutic targets
L. Di Pietro1, M. Baranzini1, M. Berardinelli1, M. Barba1,
W. Lattanzi1, M. Monforte2, A. Conte2, G. Logroscino3, F.
Michetti1, E. Ricci2, M. Sabatelli2, C. Bernardini1
1Institute of Anatomy and Cell Biology, Università
Cattolica del Sacro Cuore, Rome, Italy, 2Institute of
Neurology, Fondazione Policlinico Gemelli, Rome, Italy,
3Institute of Orthopedic Clinic, Fondazione Policlinico
Gemelli, Rome, Italy
Introduction: Most of the studies on ALS focused pri-
marily on motor neurons to understand the etiology of the
disease. However, there is evidence suggesting that muscle
dysfunction and neuromuscular junction degeneration occur
long before symptom onset, and may contribute to motor-
neurons' death. Our aim is to unravel the molecular pathway
connecting nerve and muscle in order to identify the
mechanisms that exacerbate the disease.
Methods: Selected genes and miRNAs involved in the
innervation and regeneration pathways were analyzed in
skeletal muscle and in satellite primary cultures derived
from ALS patients and controls. Patients were stratiﬁed
according to disease progression: long (≥4 years without
requiring respiratory support) and rapid (<4 years).
Results: Our data suggested a perturbation in the signals
required for an efﬁcient and complete myogenesis in muscle
biopsies of ALS patients. HDAC4, MYOG, MYOD, PAX7
and PAX3 resulted signiﬁcantly upregulated in patients
compared with controls.
The most interesting results derived from miRNAs
expression analysis: 1) miR206 levels signiﬁcantly
decreased during disease progression; 2) the expression of
selected miRNAs changed signiﬁcantly between the "long"
and "rapid" ALS patients groups. The levels of these
miRNAs also correlated with ﬁber types and muscle
atrophy.
Moreover, our data indicated that ALS satellite cells are
still able to form differentiated myotubes, although this
process is delayed.
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Conclusion: These data may suggest the use of miRNA
mimics in ALS muscles, as a potential therapeutic strategy
to enhance motor performance and slow disease
progression.
This study has been funded by Arisla
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Genetic heterogeneity of amyotrophic lateral sclerosis in
the Hungarian population
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Introduction: Amyotrophic lateral sclerosis (ALS) is a
neurodegenerative disorder associated with degeneration of
upper and lower motor neurons. Affected individuals
usually die of respiratory failure within 3–5 years. Genetic
factors play a key role in all types of ALS, therefore, our
aim was to screen the variation of 7 candidate genes in
Hungarian patients with ALS. Patients and methods: Using
Sanger sequencing, we screened mutations in SOD1, ANG,
TARDBP and UBQLN2 genes in 66 Hungarian patients. A
two-step protocol was followed for the detection of the
repeat expansion in the C9ORF72 gene in all patients.
Genotyping was used to determine whether the individual
carrying the repeat expansion carried the “risk” haplotype.
High-thoughput sequencing was used to screen mutations in
the coding regions of the SETX, FUS and C9ORF72 genes.
Results: We identiﬁed a novel frameshift (p.Lys91Argf-
sTer8) and three recurrent missense mutations (p.Val14Met,
p.Leu144Phe and p.Asp90Ala) in the SOD1 gene. The
novel mutation led to a frameshift with the insertion of 8
novel amino acids and the formation of premature stop
codon. Mutation analysis of the TARDBP gene revealed a
recurrent missense mutation (p.Met311Val). Two known
mutations (p.Met-24Ile; p.Arg33Trp) were detected in the
ANG gene. C9orf72 repeat expansion was identiﬁed in one
patient, who also carried the rs3849942 risk allele. An
additional novel missense mutation (p.Asn264Ser) was
identiﬁed in the SETX gene. Conclusion: Our study adds
novel data to the genetic and phenotypic diversity of ALS
and indicates that complex approaches are needed to
understand the genetic heterogeneity of this disease.
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associated genes by means of targeted NGS analysis
G. Marangi1, S. Lattante1, P. N. Doronzio1, S. Frangella1,
S. Patrizi1, A. Conte2, A. K. Patanella2, M. Zollino1, M.
Sabatelli2
1Institute of Genomic Medicine, Università Cattolica del
Sacro Cuore, Roma, Italy, 2Institute of Neurology, Uni-
versità Cattolica del Sacro Cuore, Roma, Italy
Introduction. Amyotrophic lateral sclerosis (ALS) is a fatal
neurodegenerative disease caused by variants in different
genes in a consistent proportion of both familial and
sporadic cases. The number of ALS-associated genes has
been steadily increasing in recent years. Consequently,
simultaneous screening of multiple genes is likely to be
more efﬁcient than gene-by-gene testing in order to identify
possible causative variants in ALS patients.
Materials and Methods. We designed a custom panel of
32 genes (including 5' and 3' UTRs) and performed targeted
next-generation sequencing in 300 consecutive Italian ALS
patients (both familial and sporadic) and 200 controls.
Results. We evaluated frequencies and relative impact of
different categories of variants, including known pathogenic
variants (found in 10% of cases), novel coding variants
(20%), and variants with MAF < 0.1% (17%). We com-
pared frequencies of both variants in coding regions and in
5′ and 3′ UTRs between patients and controls, thus showing
that patients were enriched for rare variants in previously
neglected genes (i.e.: DCTN1 and EPHA4, among the
others).
Conclusions. Our panel has been proving to be a useful
tool for evaluating and deﬁning the relative contribution of
genes, the effective role of speciﬁc coding variants and the
possible involvement of variants in 5' and 3' UTRs in ALS.
Furthermore, the integration of all genetic data we obtained
allowed us to explore the oligogenic hypothesis in ALS
etiopathogenesis, considering that we found a higher fre-
quency than expected of patients carrying two or more rare
variants in the studied genes.
G. Marangi: None. S. Lattante: None. P.N. Doronzio:
None. S. Frangella: None. S. Patrizi: None. A. Conte:
None. A.K. Patanella: None. M. Zollino: None. M.
Sabatelli: None.
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Big Data in genetic research: the example of titin gene
and titinopathies
M. Savarese1,2,3, M. Johari1, K. Johnson4, A. Torella2,3, A.
Topf4, A. Evilä1, M. Arumilli1, A. Rubegni5, M. Kuhn6, F.
Fattori7, F. Santorelli5, B. Schoser8, V. Straub4, V. Nigro9,
P. Hackman1, B. Udd1,10,11
Folkhälsan Institute of Genetics, Medicum, University of
Helsinki, Helsinki, Finland, 2Dipartimento di Biochimica,
Bioﬁsica e Patologia Generale, Seconda Universita´degli
Studi di Napoli, Naples, Italy, 3Telethon Institute of
Genetics and Medicine, Pozzuoli, Italy, 4The John Walton
Muscular Dystrophy Research Centre, Institute of Genetic
Medicine, Newcastle University, Newcastle upon Tyne,
United Kingdom, 5IRCCS Stella Maris, Pisa, Italy, 6Genet-
ikum, Neu-Ulm, Germany, 7Unit for Neuromuscular and
Neurodegenerative Disorders, Bambino Gesù Children's
Hospital, Rome, Italy, 8Friedrich-Baur-Institut, Neurolo-
gische KlinikLudwig-Maximilians-Universität München,
Munich, Germany, 9Dipartimento di Biochimica, Bioﬁsica
e Patologia Generale, Seconda Universita´degli Studi di
Napoli, Naples, Naples, Italy, 10Neuromuscular Research
Center, Tampere University and University Hospital,
Tampere, Finland, 11Department of Neurology, Vaasa
Central Hospital, Vaasa, Finland
Exome and genome sequencing will soon be adopted as a
ﬁrst-tier test for all the genetically heterogeneous
conditions.
Such extensive screenings will result in the identiﬁcation
of thousands of rare variants which are difﬁcult to interpret
with the current knowledge. Because of its sheer size,
variants in titin gene (TTN) are detected frequently in any
sequencing approach. TTN variants have been described in
so many different clinical conditions that a univocal and
unambiguous interpretation of molecular ﬁndings is almost
impossible, even in monogenic disorders, without access to
additional investigations such as segregation studies, pro-
tein and cDNA assays.
The interpretation of missense variants in TTN, which
represent the vast majority of variants identiﬁed, is the most
signiﬁcant challenge related to NGS investigation. Our data
show that current bioinformatic tools are unable to correctly
predict the effect of most of these missense variants.
We carried out a systematic analysis of rare TTN variants
in our large cohort of patients affected by a skeletal muscle
disorder (over 2,500) as well as in publicly available data-
bases (ExAC, 1000G and LOVD).
We identiﬁed potentially causative missense variants
signiﬁcantly enriched in our cohort. We also identiﬁed
harmless rare variants.
Our work represents a crucial ﬁrst step to prioritise
speciﬁc missense changes for further functional assays.
Considering the increasing role of titin mutations in
skeletal muscle and heart diseases, we strongly encourage a
closer cross-ﬁeld collaboration among all the different
specialists: neurologists, cardiologists, pediatric neurolo-
gists, geneticists, molecular and cell biologists, etc. working
on titin.
M. Savarese: B. Research Grant (principal investigator,
collaborator or consultant and pending grants as well as
grants already received); Signiﬁcant; Orion Oyj. D.
Speakers Bureau/Honoraria (speakers bureau, symposia,
and expert witness); Modest; Genzyme. M. Johari: None.
K. Johnson: None. A. Torella: None. A. Topf: None. A.
Evilä: None. M. Arumilli: None. A. Rubegni: None. M.
Kuhn: None. F. Fattori: None. F. Santorelli: None. B.
Schoser: None. V. Straub: None. V. Nigro: None. P.
Hackman: None. B. Udd: None.
P10.07C
A novel RYR 1 gene mutation in a patient with severe
central core disease
F. E. Percin, G. Kayhan, M. A. Ergun
Medical Genetics Department, Gazi University Hospital,
Ankara, Turkey
Introduction: Central core disease (CCD) is a congenital
myopathy ranging from mild to severe, being relevant to the
age of onset. Findings of the disease are proximal muscle
weakness, motor developmental delay, kyphoscoliosis, joint
contractures and congenital dislocation of the hips. Het-
erozygous or homozygous mutation in the RYR1 gene,
encoding the skeletal muscle ryanodine receptor 1 protein,
causes CCD. Here, we present a CCD patient with a novel
missense mutation in the RYR1 gene.
Clinical report: The patient is a 1-year old baby boy with
hypotonia, feeding difﬁculty, severe kyphoscoliosis, con-
tractures in hands and hip dislocation.
Results: Whole-exome result analysed with in-house
method (SELIM) for variant prioritization revealed de novo
heterozygous missense mutation, NM_000540:exon102:c.
A14758C:p.T4920P, in RYR1 gene.
Discussion: The RyR1 protein is a calcium releasing
channel for the sarcoplasmic reticulum. The mutation
detected at codon 4920 is located in the transmembrane C-
terminal region which is important for the intact RyR1
channel. Musculoskeletal ﬁndings are more prominent in
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patients with C-terminal mutations as in our patient, while
milder in patients with mutation of the other domains. In
literature, a girl with poor fetal movement, hypotonia and
proximal muscle weakness, but no skeletal ﬁndings has
been reported who has threonine-asparagine transformation
at codon 4920 (c.14759C> A). The substitution in this
patient from threonine to asparagine is from polar to polar,
while the alteration in our patient from threonine to proline
resulting in polar to nonpolar. So, this difference in amino
acid change may explain the more severe skeletal ﬁndings
in our patient.
F.E. Percin: None. G. Kayhan: None. M.A. Ergun:
None.
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3´splice site mutations in INF2 cause Charcot Marie
Tooths disease without focal segmental glomerulo-
sclerosis: Implication of differential function of alter-
native splice variants
S. Vaeth1, G. Hoffmann Bruun2, R. Christensen1, M.
Thusholt2, B. S. Andresen2, H. Andersen3, U. Jensen1
Department of Clinical Genetics, Aarhus University
Hospital, Aarhus N, Denmark, 2Department of Biochem-
istry and Molecular Biology and the Villum Center for
Bioanalytical Sciences, University of Southern Denmark,
Odense M, Denmark, 3Department of Neurology, Aarhus
University Hospital, Aarhus N, Denmark
Background Mutations in INF2, encoding inverted formin-
2, cause focal segmental glomerulosclerosis (FSGS) and
Charcot-Marie-Tooth neuropathy (FSGS-CMT). The
reported disease-causing mutations are located in exon 2
and exon 3, thus affecting most known isoforms of INF2.
Alternative mRNA splicing results in at least 3 isoforms of
INF2, but little is known about the function of the indivi-
dual isoforms. Two of the isoforms are long and differ in the
positioning of the translation termination codon due to
alternative splicing of exon 22. The longest isoform con-
tains a prenylation site and is termed INF2-CAAX. The
isoform that excludes exon 22 is termed INF2-non-CAAX.
Results and methods We describe how splicing mutations
in the last intron of INF2 (position INF2 [NM_022489]: c.
*1+1/c.3751+1) result in CMT without the development of
kidney disease. Two families were identiﬁed, each carrying
different splice site mutations in the last intron of INF2 (c.
*1+1G>C /c.3751+1G>C and 1G>C/c.3751+1G>A).
Experiments using minigene constructs conﬁrm that spli-
cing is affected. cDNA analysis from multiple tissues shows
that more than 2 isoforms are expressed in most tissues.
Conclusion Our data suggests that mutations that cause
exon 22 skipping and therefore only affect the long isoform
spare the glomeruli. This indicates that the short splice form
of INF2 is required in the kidneys. Thus, the long isoform
INF2-CAAX that includes exon 22 must be important for
Schwann-cells and causes CMT when mutated. This illus-
trates how mutations that only affect speciﬁc alternative
splice forms can cause restricted phenotypes and thereby
delineate the functional role of protein isoforms.
S. Vaeth: None. G. Hoffmann Bruun: None. R.
Christensen: None. M. Thusholt: None. B.S. Andresen:
None. H. Andersen: None. U. Jensen: None.
P10.09A
Whole exome sequencing reveals a novel missense
mutation in the MARS gene related to a rare Charcot-
Marie-Tooth neuropathy type 2U
L. Sagi-Dain, L. Shemer, G. Larom-Kahn, A. Harari-
Shaham, A. Peleg
Carmel Medical Center, Haifa, Israel
Background: Charcot-Marie-Tooth (CMT) is a hetero-
geneous group of progressive disorders, characterized by
chronic motor and sensory polyneuropathy. This hereditary
disorder is related to numerous genes and varying inheri-
tance patterns. Thus, many patients do not reach a ﬁnal
genetic diagnosis. Patient: We describe a 13-years old girl
presenting with progressive bilateral leg weakness and gait
instability. Extensive laboratory studies and brain Magnetic
Resonance Imaging were normal. Nerve conduction studies
revealed severe lower limb peripheral neuropathy with
prominent demyelinative component. Following pre-
sumptive diagnosis of chronic inﬂammatory demyelinating
polyneuropathy, the patient received treatment with steroids
and intravenous immunoglobulins courses, with no appar-
ent improvement. Results: Whole exome sequencing
revealed a novel heterozygous c.2209C>T (p.Arg737Trp)
mutation in the MARS gene (OMIM 156560). In-silico
prediction programs classiﬁed this mutation as a probable
cause for protein malfunction (3/4 damaging). This gene has
recently been related to CMT type 2U. Allele frequency
data reported this variant in 0.003% of representative
Caucasian population. Family segregation analysis study
revealed that the patient had inherited the variant from her
mother, reported as healthy. Neurologic examination of the
mother demonstrated decreased limb reﬂexes, with
demyelinative and axonal sensory-motor polyneuropathy
revealed by nerve conduction studies. Conclusion: Our
report highlights the importance of next generation
sequencing approach to facilitate the proper molecular
diagnosis of highly heterogeneous neurologic disorders.
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Amongst other numerous beneﬁts, this approach might
prevent unnecessary diagnostic testing and potentially
harmful medical treatment.
L. Sagi-Dain: None. L. Shemer: None. G. Larom-
Kahn: None. A. Harari-Shaham: None. A. Peleg: None.
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Circadian rhythm genes in Duchenne muscular
dystrophy
A. Armaroli1, C. Scotton1, H. Osman1, M. Falzarano1, R.
Rossi1, R. Capogrosso2, A. Cozzoli2, G. Camerino2, E.
Schwartz3, A. De Luca2, A. Ferlini1
Dept. of Medical Science-Medical Genetics Section-
University of Ferrara, Ferrara, Italy, 2Unit of Pharmacol-
ogy, Department of Pharmacy and drug Sciences, Uni-
versity of Bari, Bari, Italy, 3Ariadne Diagnostics LLC,
Rockville, MD, United States
Introduction: Muscular dystrophies are genetic conditions
that cause progressive weakness and loss of muscle mass.
Mutations in structural proteins, such as dystrophin, cause
muscle ﬁbers’ instability with muscle damage.
Circadian rhythm coordinates biological processes
with the 24h cycle; its role in maintaining muscle functions
is known, both in animal models and in humans. Recently,
we disclosed a link between CollagenVI myopathy and
circadian genes.
Methods: To deﬁne the involvement of circadian circuit
in muscle damage, we designed a Fluidic-Card-TaqMan
based assay, including 30 genes related to circadian rhythms
and muscle regeneration. We tested gastrocnemius and
tibialis anterior muscles from unexercised and exercised
mdx mice. We subsequently selected 7 most deregulated
genes and performed expression analysis by Real-time PCR
in 10 DMD patients with different mutations.
Results: We demonstrated the profoundly de-regulation
of circadian genes in mdx mice, both exercised and unex-
ercised. Such deregulation was conﬁrmed in DMD patients
muscle biopsies. Genes mostly deregulated were CSNK1E,
SIRT1, MYOG. In order to explore if the transcript de-
regulation reﬂects on plasma, we designed an ELISA assay
for the profound up-regulated CSNK1E protein and tested
16 DMD and 5 male control plasma samples. The CSNK1E
showed a variable expression proﬁle however, the sample’s
cohort proves to be rather limited and an enlargement of
samples number is needed.
Conclusion: Our preliminary data demonstrate that cir-
cadian genes are affected in both DMD patients and mdx
mice supporting a correlation between circadian circuit and
DMD, open the way to new biomarkers and interesting
therapeutic options.
A. Armaroli: None. C. Scotton: None. H. Osman:
None. M. Falzarano: None. R. Rossi: None. R. Capo-
grosso: None. A. Cozzoli: None. G. Camerino: None. E.
Schwartz: None. A. De Luca: None. A. Ferlini: None.
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CMTsubtypes in a cohort of Italian patients enrolled at
Messina Neuromuscular Center since 1994 to 2016
A. M'Hammed1, A. A.1, S. C.1, G. L.1, R. M1, F. GM2, T.
F2, D. RM1, F. M2, T. A.1, V. G.1, M. A.1
1University of Messina, Messina, Italy, 2University of
Verona, Verona, Italy
INTRODUCTION: The Neuromuscular Diseases of the
University of Messina is a tertiary center for neuromuscular
disorders in South Italy and a Regional Reference Center
for Rare Diseases. We analyzed the percentage of Charcot-
Marie-Tooth (CMT) patients assessed at our Center in the
last twenty years, with the aim to evaluate how many
patients received a genetic diagnosis and the distribution of
the genetic subtypes.
PATIENTS AND METHODS: This was a retrospective
study. We analyzed the clinical records from 523 patients
with anamnestic and/or clinical suspect of CMT seen since
1994 to 2016. The distribution of CMT subtypes and
pathogenic genetic mutations was determined.
RESULTS: 310/523 (59.27%) received a genetic diag-
nosis. The most common subtypes found were CMT1A/
PMP22 duplication (51.6%), HNPP/PMP22 deletion
(16.1%), CMT1B/MPZ mutation (10.6%), CMTX/GJB1
mutation (8.3%), CMT2F/HSP27 mutation (5.1%). Other
mutations included PMP22 point mutation (n.7 pts), MFN2
mutation (n.5 pts), GDAP1 mutation (n.4 pts), BSCL2
mutation (n.3 pts), GARS mutation (n. 2 pts), TRPV4
mutation (n. 2 pts), LITAF mutation (n.1 pt) and NEFL
mutation (n. 1 pt).
CONCLUSION: Our results conﬁrm the heterogeneity of
CMT. The percentage of genetic conﬁrmation is slightly
smaller than the ones previously reported. One explanation
might be that the time period we considered is twenty years,
with a limited number of known genes in the ﬁrst decade.
The subtypes distribution showed a major prevalence of
CMT2F/HSP27 mutation compared to previous reports,
with atypical phenotypic features in some individuals.
A. M'Hammed: None. A. A.: None. S. C.: None. G. L.:
None. R. M: None. F. Gm: None. T. F: None. D. Rm:
None. F. M: None. T. A.: None. V. G.: None. M. A.:
None.
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Custom micro-ﬂuidic exome array to detect transcript
mutations in undiagnosed patients with ColVI
myopathies
H. Osman1,2, R. Rossi2, M. Falzarano2, C. Scotton2, A.
Armaroli2, R. Selvatici2, F. Gualandi2, A. Ferlini2,3
Department of Medical Microbiology, Faculty of Medical
Laboratory Sciences, University of Khartoum, Khartoum,
Sudan, 2UOL (Unita` Operativa Logistica) of Medical
Genetics, University of Ferrara, Ferrara, Italy, 3Neuro-
muscular Unit, Great Ormond Street Hospital, University
College London, London, United Kingdom
Introduction: Collagen VI-related myopathy is a form of
muscular dystrophy caused by mutations in the genes
encoding three different Collagen VI (ColVI) chains α1, α2
and α3. About 40% of Col VI patients are however negative
for ColVI genes mutations. In these cases analysis of ColVI
transcript might be valuable in identifying mutations which
escape routine DNA testing.
We designed and validated a customized micro-ﬂuidic
exome array (FluiColVI) for the analysis of ColVI tran-
scripts to identify mutations missing the DNA diagnosis.
Methods: We designed a custom TaqMan gene expres-
sion assay to proﬁle the entire 115 exons of ColVI genes
covering all the exon-exon junctions of the three ColVI
transcripts α1, α2 and α3. RNAs were extracted from both
muscles biopsies and native/myogenic transformed (MyoD)
urine stem cells (USCs). RNA from patients with a known
mutations was used to validate the FluiColVI method.
Results: FluiColVI identiﬁed the three ColVI transcripts
with the detection of all junction–junction systems in both
muscle and native USCs of controls. The analysis of MyoD-
USCs did not detect any ColVI transcripts, as expected to
be absent in myogenic cells. In the patients, the FluiColVI
conﬁrmed the presence of the mutations in ColVIα1 iden-
tiﬁed at the DNA level.
Conclusion: This study demonstrated that FluiColVI is a
validated diagnostic tool for molecular proﬁling of ColVI
transcripts in skeletal muscles and can be used in
undiangnosed patients. Interestingly, native urine stem cells
represent a noninvasive and cost effective human cell model
to study ColVI transcripts in myopathies.
H. Osman: None. R. Rossi: None. M. Falzarano:
None. C. Scotton: None. A. Armaroli: None. R. Selvatici:
None. F. Gualandi: None. A. Ferlini: None.
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Loss of function mutations in ASCC1 gene cause auto-
somal recessive Congenital muscular atrophy with bone
fractures
R. V. Vazharova1,2, L. Balabanski2, S. Andonova3, I.
Bradinova3, D. Toncheva4,2, A. Savov3
1Soﬁa University "St. Kl. Ohridski", Department of Biology,
Medical genetics and Microbiology, Soﬁa, Bulgaria,
2GARH Malinov, Genomic Laboratory, Soﬁa, Bulgaria,
3UHOG Maichin dom, National genetic laboratory, Med-
ical University Soﬁa, Soﬁa, Bulgaria, 4Medical University
Soﬁa, Department of Medical genetics, Soﬁa, Bulgaria
Introduction: The ASCC1 gene encodes a subunit of the
activating signal cointegrator 1 complex. The ASC-1
complex is a transcriptional coactivator with an important
role in gene transactivation by multiple transcription factors
including NF-kappa-B, SRF and AP1. A missense mutation
in ASCC1 (p.N290S) was associated with Barrett esophagus
and/or esophageal adenocarcinoma in heterozygotes
whereas homozygous loss of function truncating mutation
of the gene was recently reported in two patients with
Congenital muscular atrophy with bone fractures.
Materials and methods: Herein we describe a family of
Roma origin with an affected child who deceased 12 days
after birth with clinical symptoms of the disease. Osteo-
genesis imperfecta was initially suspected based on the
presence of long bone fractures but absent movements
(spontaneous and after stimulation), absent reﬂexes,
respiratory distress syndrome, hepatosplenomegaly, bilat-
eral cryptorchidism and heart insufﬁciency raised revision
of initial diagnosis. NGS using the TruSight One gene panel
(Illumina) was applied to search for pathogenic mutations in
the proband.
Results: A homozygous substitution was found in donor
splice-site of exon 7 of ASCC1 gene - NM_001198799.2:
c.710+1G>A. Results were validated by Sanger sequencing
and segregation analysis in the affected family was per-
formed. Both parents were found to be heterozygous car-
riers of the mutation. The variant is predicted to disrupt
splicing of all gene transcripts and result in loss of function.
Conclusions: Our results support the hypothesis that loss
of function mutations of ASCC1 gene are causative for
Congenital muscular atrophy with bone fractures - a rare
severe form of congenital SMA.
R.V. Vazharova: None. L. Balabanski: None. S.
Andonova: None. I. Bradinova: None. D. Toncheva:
None. A. Savov: None.
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Modeling of a unique desmin mutation in zebraﬁsh by
using genome editing brings new insights into desmin
function
G. Kayman Kürekçi1, C. Koyunlar1, E. Kural1, B. Talim2,
B. Ergin3, S. Ünsal1, N. Puralı3, P. Korkusuz4, S. Erdem
Özdamar5, P. Dinçer1
Department of Medical Biology, Hacettepe University,
Ankara, Turkey, 2Department of Pathology, Hacettepe
University, Ankara, Turkey, 3Department of Biophysics,
Hacettepe University, Ankara, Turkey, 4Department of
Histology and Embryology, Hacettepe University, Ankara,
Turkey, 5Department of Neurology, Hacettepe University,
Ankara, Turkey
Limb-girdle muscular dystrophies (LGMD) are a diverse
group of rare neuromuscular diseases manifesting with
proximal muscle weakness. We previously described an
ultra-rare LGMD phenotype (LGMD2R, MIM 615325)
caused by an unusual desmin mutation predicted to disrupt a
poorly described laminB-binding site and affect mechan-
otransduction in skeletal muscle (1). This phenotype is
unique as no desmin accumulation and cardiomyopathy is
observed unlike other desminopathies. Our aim is to create a
patient-speciﬁc disease model in order to understand
underlying mechanisms of the disease. First we demon-
strated by co-immunoprecipitation and in-situ proximity
ligation assay that desmin interacts directly with laminB
around myonuclei in wild-type zebraﬁsh. Next, we used
genome editing tools in order to create targeted mutations in
zebraﬁsh. By CRISPR/Cas9, we knocked-out desmin
orthologues (desma and desmb) in zebraﬁsh and described
their differential expression proﬁles. Data showed that
desma expression is mainly somitic while desmb is
expressed in gut. However in the absence of desmb, desma
expression is observed both in somites and gut. By TALEN,
we disrupted the laminB-binding domain on desma by
creating an early stop codon. Desmin-laminB interaction
and calcium inﬂux analyses in mutants are ongoing. In
conclusion, modeling of an ultra-rare phenotype in zebraﬁsh
by using genome editing tools provided new insights into
desmin expression and function in zebraﬁsh and will con-
tribute to the understanding of the role of desmin and the
pathophysiology in human.
This study was funded by TUBITAK, Project number
214S174.1. Cetin N. et al., J. Med. Genet. 2013, 50(7):437–
43.
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Chromatin conﬁguration, RNA and protein studies
identiﬁed novel DNA elements that inﬂuence the dys-
trophin transcription dynamics
M. S. Falzarano1, S. Gherardi1,2,3, M. Bovolenta1, C.
Passarelli1,4, D. Erriquez2, C. Scotton1, A. Armaroli1, R.
Rossi1, H. Osman1, M. Mora5, P. Bernasconi5, L. Maggi5,
L. Morandi5, G. Perini2,3, A. Ferlini1,6
1Department of Medical Sciences, Medical Genetics Unit,
Ferrara, Italy, 2Department of Pharmacy and Biotechnol-
ogy, University of Bologna, Bologna, Italy, 3CIRI Health
Sciences & Technologies (HST), Bologna, Italy, 4Paediatric
Hospital Bambino Gesù, Laboratory of Medical Genetics,
Rome, Italy, 5Neuromuscular Disease and Immunology
Unit, Fondazione IRCCS Istituto Neurologico “C. Besta”,
Milano, Italy, 6Dubowitz Neuromuscular Centre, Molecular
Neurosciences Section, Developmental Neuroscience Pro-
gramme, UCL Great Ormond Street Institute of Child
Health, London, United Kingdom
Introduction: Despite of the several reports describing
dystrophin (DMD) gene expression abnormalities, the
DMD transcriptional process remains poorly understood.
We therefore investigated the transcriptional capacity of the
dystrophin locus.
Methods: We designed a DMD locus ChIP-chip array to
identify open chromatin regions, and a Chromosome Con-
formation Capture assay was used for interaction studies.
We selected muscle biopsies from 9 BMD patients in order
to evaluate the different amount of dystrophin and its link to
the novel regulatory regions identiﬁed; dystrophin transcript
and protein were quantiﬁed by FluiDMD card and Western
blot.
Results: We identiﬁed two novel DMD regions which
bind the RNA Pol II, one in intron 52 (DMEi52) and
another one in exon 62 (DMEe62). The DMEi52 contains a
genuine RNA pol II pausing site used during DMD locus
transcription. We also showed that two DMD regions, one
in intron 34 (DMEi34) and one in exon 45 (DMEe45), share
histone marks of open chromatin, but are unrelated to RNA
Pol II activity. The DMEi34 bi-directionally stimulates the
Dp427m promoter transcription. Supporting the DMEi34
transcription enhancing function we found lower dystrophin
RNA and higher protein levels in BMD patients carrying
genomic deletions encompassing the intron 34 compared to
other differently deleted BMDs.
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Conclusion: We identiﬁed the ﬁrst DMD pausing site
which is located in exon 62 and a novel dystrophin muscle
enhancer in intron 34. These ﬁndings have important
repercussions on the understanding of the transcriptional
regulation of the DMD locus, as well as for the designing of
splicing therapies.
M.S. Falzarano: None. S. Gherardi: None. M. Bovo-
lenta: None. C. Passarelli: None. D. Erriquez: None. C.
Scotton: None. A. Armaroli: None. R. Rossi: None. H.
Osman: None. M. Mora: None. P. Bernasconi: None. L.
Maggi: None. L. Morandi: None. G. Perini: None. A.
Ferlini: None.
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Becker muscular dystrophy: a natural gene editing
I. Perez1, M. Sabater1, M. E. Nicolás1, M. C. Martínez2,
M. C. Olmo3, D. López3, C. Gil1, G. Glover2, J. R. Gimeno3
Cardiogenetics laboratoy, Murcia, Spain, 2Centro de
Genética y Bioquímica Clínica, Murcia, Spain, 3Cardiol-
ogy Department, Murcia, Spain
Introduction Duchenne muscular dystrophy (DMD) is
caused by frame-disrupting mutations in DMD gene (DMD;
300377), characterized by progressive muscle weakness and
degeneration. In-frame (IF) dystrophin mutations that do
not disrupt the open reading frame typically cause a clini-
cally milder disorder, Becker muscular dystrophy (BMD).
Methods We have characterized a three generations family
with Hypertrophic cardiomyopathy (HCM). Index case was
diagnosed at ﬁve years old with psychomotor retardation
and HCM (asymptomatic) developing Long QT at twelve.
His father was asymptomatic and his mother had hyper-
trabeculation and Dilated Cardiomyopathy (DCM). The
index case was studied by Next Generation Sequencing and
their relatives by Sanger and MLPA (multiplex ligation-
dependent probe ampliﬁcation). Results Three mutations
were identiﬁed in the index case: p.Arg891Alafs*160, a
HCM causal mutation; p.Thr263Met in KCNJ5 gene which
could be associated to Long QT; and p.Ser2437_-
Ile2554delinsPhe in DMD. His father and three uncles (one
of them affected of HCM) were carried of p.Arg891A-
lafs*160. His mother and grandfather (non affected) were
carried of the other two mutations (p.Thr263Met and p.
Ser2437_Ile2554delinsPhe). The rest of relatives were non-
carriers. Discussion Our results suggest that although two
male patients are carried of mutation in DMD and they had
shorter but partially functional protein than those with
complete gene, they can be diagnosed as BMD or even be
undiagnosed. Conclusion The study of patients with these
kinds of deletions that naturally mimic those that would be
achieved by exon skipping is a way to predict the potential
of AOs in exon skipping therapy for DMD.
I. Perez: None.M. Sabater: None.M.E. Nicolás: None.
M.C. Martínez: None. M.C. Olmo: None. D. López:
None. C. Gil: None. G. Glover: None. J.R. Gimeno:
None.
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32 novel pathogenic sequence variants in 253 DMD/
BMD patients from Turkey
G. Toksoy1, A. Aghayev1, G. Bagirova1, H. Durmuş
Tekçe2, S. Avcı1, U. Altunoğlu1, Y. Parman2, P. Oﬂazer2,
Z. Yapıcı2, H. Kayserili1,3, B. Karaman1, S. Başaran1, O.
Uyguner1
1Dept. of Med. Genet. Istanbul Med. Faculty IU, Istanbul,
Turkey, 2Dept. of Neurology. Istanbul Med. Faculty IU,
Istanbul, Turkey, 3Dept. of Med Genet, School of Medicine,
Koç University, Istanbul, Turkey
Introduction: DMD is the only known gene in dystrophi-
nopathies. Mutations in DMD causes X-linked recessive
distrophinopathies. More than 3300 different mutations
were identiﬁed at present, which is consistent with the
allelic heterogeneity. Materials and Methods: Two hundred
ﬁfty three patients with DMD/BMD clinic were investigated
in this study. Deletion/duplication mutations were screened
by MLPA (P034, P035), mutation negative patients were
further sequenced by next generation sequencing (NGS) on
Ion Torrent-PGM, covering all 79 coding exons and other
23 associated intronic and ﬂanking regions adding up to 148
amplicons covering 28.6 kb region. Results: Deletions were
identiﬁed in 125 (49.4%) and duplications in 23 patients
(9.1%). Sequence analyses in 103 patients revealed different
mutations; 8 splice site, 4 missense, 33 nonsense (including
one mosaic), 13 small deletions, 2 small insertions) in 60
patients (23.7%). 32 of these mutations were novel (53%).
De novo occurrence has been observed in 48.4 % of dele-
tions/duplications and 20.4% of pathogenic sequence var-
iants. Conclusions: Causative mutations were identiﬁed in
82.2% of DMD/BMD patients with this algorithm. Two
single exon deletion in MLPA, presented point mutations at
the probe binding region revealed by sequencing. Patients
with no identiﬁed mutations will be the source for further
screening of intronic regions or whole genome sequencing.
Mutation detection in DMD/BMD is not only important for
genetic counseling and prenatal planning, but also render
the mutation speciﬁc therapeutic drugs in future.
G. Toksoy: None. A. Aghayev: None. G. Bagirova:
None. H. Durmuş Tekçe: None. S. Avcı: None. U. Altu-
noğlu: None. Y. Parman: None. P. Oﬂazer: None. Z.
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A novel point mutation affecting Asn76 of dystrophin
protein leads to dystrophinopathy
K. Koczok1, G. Mero2, E. Ajzner3, G. P. Szabo4, L.
Madar1, E. Gombos1, J. Motyan5, T. Hortobagyi6, I.
Balogh1
Division of Clinical Genetics, University of Debrecen,
Debrecen, Hungary, 2Josa Andras Teaching Hospital,
Nyiregyhaza, Hungary, 3Josa Andras Teaching Hospital,
Nyiregyhaza, Hungary, Debrecen, Hungary, 4Department
of Pediatrics, University of Debrecen, Debrecen, Hungary,
5Department of Biochemistry and Molecular Biology,
University of Debrecen, Debrecen, Hungary, 6Department
of Pathology, University of Debrecen, Debrecen, Hungary
Introduction. Mutations in the DMD gene lead to Duchenne
and Becker muscular dystrophies (DMD/BMD) character-
ized by progressive muscle wasting. Missense mutations are
rare cause of DMD/BMD. Here we report the detection of a
novel missense mutation located in the N-terminal actin
binding domain of dystrophin leading to dystrophinopathy.
Materials and Methods. A six-month old male patient
showed mild generalized muscle weakness, hypotonia and
delayed motor development. Electromyography showed
myopathic features. He had elevated serum creatine kinase.
MLPA analysis was performed. Pyrosequencing was used
for the sequencing the coding region. Dystrophin immu-
nohistochemistry were performed. In silico methods were
used to predict the effect of the mutation on protein struc-
ture and stability.
Results. MLPA assay showed exon 4 deletion. Ampli-
ﬁcation of exon 4 did not conﬁrm the deletion. By
sequencing exon 4 a novel de novo point mutation
(c.227A>T) was detected (p.Asn76Ile). The false positive
MLPA result was explained by the fact that the detected
nucleotide lies directly next to the ligation site. Sequencing
of the whole coding region of the DMD gene proved
c.227A>T to be the sole variant being potentially patho-
genic. Immunohistochemistry results were suggestive of
BMD. The mutation was predicted to be highly destabiliz-
ing on the dystrophin structure.
Conclusions. Our results highlight the importance of the
conﬁrmatory testing of single-exon deletions detected by
MLPA and we describe a novel, destabilizing missense
mutation in the DMD gene leading to dystrophinopathy.
This study was supported by the Hungarian Research
Fund (OTKA K109076) and by the Ministry of National
Economy, Hungary (GINOP-2.3.2-15-2016-00039).
K. Koczok: None. G. Mero: None. E. Ajzner: None. G.
P. Szabo: None. L. Madar: None. E. Gombos: None. J.
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De novo mutation cause compound heterozygosity in
DMD gene, resulting mild phenotype in Duchenne
muscular dystrophy: a case report
K. Arvai1,2, J. Kosa1,2, V. Klujber1, B. Kocsis-Deak2, B.
Tobias1, B. Balla1, A. Kovesdi1, P. Lakatos2
1PentacoreLab Ltd., Budapest, Hungary, 2Semmelweis
University 1st Departmant of Internal Medizine, Budapest,
Hungary
Introduction: Different muscular dystrophies and myo-
pathies can be inherited in an X-linked, autosomal domi-
nant, or autosomal recessive manner. More than 50 genes
have been associated to different forms of muscular dys-
trophy alone, making accurate diagnosis difﬁcult. The
Duchenne and Becker types of muscular dystrophy are two
related conditions that primarily affect skeletal muscles and
cardiac muscle. These forms of muscular dystrophy occur
almost exclusively in males. We are presenting here a case
of a 11 years old girl, with healthy parents and with mild
symptomps.
Materials and Methods: Total genomic DNA was
extracted from the biological sample using a spin column
method. We have targeted all of the coding excons with
exon-intron boundaries of 51 genes using PCR-based
library preparation method. Sequencing reads were map-
ped to the reference genome (hg19) and after variant calling
the variants were classiﬁed based on ExAc, ClinVar and
1000G information.
Results: Gene panel test revealed a coumpound hetero-
zygous state of the DMD gene (c.8421G>A, p.(Trp2807*)
and c.3954T>A, p.(Asp1318Glu). This two mutations has
never been described before, but alterations at this genomic
positions are known disease-causing mutations. The family
analysis revealed that, the father of the patient doesn’t carry
any of this mutations and the mother is a carrier of the
c.3954T>A alteration. The c.8421G>A variation is a de
novo mutation in the patient.
Conclusions:We counclud the mother of our patient is a
carrier of a DMD gene mutation, while the patient is a
„manifesting carrier” at least, with a de novo compound
heterozygous mutation.
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International-DMD (IDMD): a PTC Therapeutics-
supported diagnostic project to widely identify Dystro-
phin mutations by NGS technologies
R. Selvatici, R. Rossi, C. Trabanelli, P. Rimessi, S. Fini, F.
Gualandi, A. Ferlini
University Hospital of Ferrara St. Anna, Ferrara, Italy
Introduction: Extensive molecular diagnosis in genetic
diseases is vital to conﬁrm clinical diagnosis and to enable
genetic counseling and personalized management. Duch-
enne muscular dystrophy (DMD) is a rare genetic neuro-
muscular disease affecting 1/5000 males, due to a variety of
dystrophin gene mutations. The ﬁrst signs and symptoms of
DMD include delayed milestones such as walking and
talking, and enlarged calves. PTC Therapeutics Interna-
tional Ltd. and the University of Ferrara, Italy, have
established a collaboration focused on identifying patients
affected by rare genetic disorders through increased genetic
testing activities, with an initial focus on DMD. Genetic
testing is available to patients throughout European coun-
tries, potentially expanding to other regions.
Methods: Diagnostic settings include MLPA (MRC
Holland) and NGS dystrophin gene sequencing
(Multiplicom).
Results: Currently DNAs from 57 DMD boys were
collected. Patients were from Poland (34), Hungary (10),
Lituania (5), Romania (3), Russia (1) and Bosnia (4).
Among the 30 samples analyzed, 7 deletions, 4 duplica-
tions, 11 small mutations (8 nonsense) were identiﬁed.
Conclusion: The early identiﬁcation of the underlying
genetic mutation is critical to potentially affecting the
course of a disease such as DMD as well as the choice of
treatment and aids in the setup of appropriate and effective
care and follow up as well as eligibility for clinical trials.
Genetic counselling can also be offered to patients and
families with important repercussions on reproductive
choices and lifestyle planning (full details and contacts at
www.ospfe.it/medicalgenetics).
R. Selvatici: None. R. Rossi: None. C. Trabanelli:
None. P. Rimessi: None. S. Fini: None. F. Gualandi:
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Genetic diagnosis of severe fetal akinesia syndrome and
associated abnormalities by means of whole exome
sequencing
T. Reischer, S. Liebmann-Reindl, S. Balendran, B.
Streubel
Medical Uiversity of Vienna, Vienna, Austria
Introduction: The term fetal akinesia represents disorders
within a broad spectrum of diseases leading to reduced or
absent fetal movements. This clinical entity is often
recognized as a sequence of related deformational changes
and includes features like intrauterine growth restriction,
craniofacial anomalies, limb contractures, together with
pregnancy complications such as polyhydramnios. In the
last years, gene discovery was revolutionized by imple-
mentation of NGS technologies, whereas research mainly
focused on postnatally well-deﬁned phenotypes and less on
fetal lethal disorders.
Materials and Methods: We included 15 affected
fetuses in 11 families. Fetal akinesia syndrome was diag-
nosed prenatally by ultrasound and/or MRI. Mainly the
clinical diagnosis was leading to decision of termination of
pregnancy or later to perinatal death. In all cases chromo-
somal aberrations were excluded. Exome sequencing was
performed in the index case of each family.
Results: In 4/11 families, including two consanguineous
families, more than one fetus was affected and an autosomal
recessive disorder was likely. We correlated exome data
with known "33" disease-related genes and found patho-
genic variants of CNTN1-gene and RYR1-gene, respectively
in two cases. In one case exome sequencing was negative,
but a DMPK-gene repeat expansion was identiﬁed. In the
remaining eight cases no previously reported variant was
found.
Conclusions: Fetal akinesia syndrome is a genetically
heterogeneous disorder, following different types of
inheritance. In a minority, a variant in a known disease-
related gene was found. So far, in the majority the under-
lying genetic cause remained unknown, but several new
candidate genes where identiﬁed based on our exome data.
T. Reischer: None. S. Liebmann-Reindl: None. S.
Balendran: None. B. Streubel: None.
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GBE1-related disorders: biallelic pathogenic variation
at one codon resulting in both infantile and adult
phenotypes
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M. Lidgren1, M. Guipponi1,2, F. Santoni1, P.
Makrythanasis1,2, J. Blouin1,2, C. Gehrig1, A. Vannier1, A.
Bottani1, R. Sztajzel3, A. Kohler3, C. M. Korff4, T. Landis5,
J. A. Lobrinus6, S. E. Antonarakis1,2, E. Ranza1
Division of Genetic Medicine, Geneva University Hospitals,
Geneva, Switzerland, 2Department of Genetic Medicine and
Development, University of Geneva, Geneva, Switzerland,
3Department of Neurology, Geneva University Hospitals,
Geneva, Switzerland, 4Pediatric Neurology Unit, Depart-
ment of Child and Adolescent, Geneva University Hospitals,
Geneva, Switzerland, 5Department of Neuroscience, Uni-
versity of Geneva, Geneva, Switzerland, 6Neuropathology
Unit, Department of Clinical Pathology, Geneva University
Hospitals, Geneva, Switzerland
Recessively inherited GBE1 pathogenic variants
(OMIM#607839) have been linked to: (1) Glycogen Sto-
rage Disease IV (GSD4; OMIM#232500), whose clinical
picture includes a variable association of hepatic, cardiac,
neurological and musculoskeletal involvement; (2) an Adult
form of Polyglucosan Body Disease (APBD;
OMIM#263570), presenting as adult-onset progressive
leukoencephalopathy, spastic paraplegia, cognitive impair-
ment and peripheral neuropathy.
Some genotype-phenotype correlations have been sug-
gested: severe forms result from loss-of-function variants
and milder phenotypes from missense mutations. Never-
theless, there is an overlap, since some pathogenic variants
have been described as causing different subtypes of GSD4
or APBD. However, to date, no patient has been reported
presenting with both phenotypes, infantile and adult.
Here, we report a case of a 45 year-old female with
hypotonia and a congenital myopathy, who developed
progressive leukoencephalopathy at age 40 years. Cerebral
MRI showed hyperintense bilateral frontal lobe, occipital
lobe, and periventricular white matter abnormalities on T2
and ﬂuid attenuated inversion recovery (FLAIR) sequences.
There were no cardiac or hepatic manifestations.
Exome sequencing identiﬁed compound heterozygous
missense variants c.785G>A:p.(Arg262His) and c.784C>T:
p.(Arg262Cys) in GBE1; these variants were respectively
classiﬁed as likely pathogenic and pathogenic according to
the latest ACMG guidelines and each inherited from a
different parent. The variant c.784G>A, combined with
another missense variant, has been previously published in a
young girl with congenital myopathy without cardiac or
hepatic involvement.
This case underlines the phenotypic spectrum associated
with GBE1 pathogenic variants.
M. Lidgren: None. M. Guipponi: None. F. Santoni:
None. P. Makrythanasis: None. J. Blouin: None. C.
Gehrig: None. A. Vannier: None. A. Bottani: None. R.
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Novel mutations of the GJB1 gene associated with
Charcot-Marie-Tooth type 1X in Lithuanian cohort
B. Burnyte1,2, I. Kavaliauskiene1,2, A. Molyte1, L.
Ambrozaityte1,2, T. Rancelis1, A. Morkuniene1,2, A.
Matuleviciene1,2, B. Tumiene1,2, V. Kucinskas1,2, A.
Utkus1,2
1Department of Human and Medical Genetics, Faculty of
Medicine, Vilnius University, Vilnius, Lithuania, 2Centre
for Medical Genetics, Vilnius University Hospital Santar-
iskiu Klinikos, Vilnius, Lithuania
BACKGROUND: X-linked Charcot-Marie Tooth disease
(CMT1X) is caused by mutations in the GJB1 gene that
encodes a polypeptide that is arranged in hexameric array
and forms gap junctions.
OBJECTIVE: To estimate the frequency of the GJB1
gene point mutations, insertions and deletions in the
Lithuanian Charcot-Marie-Tooth (CMT) cohort. To exam-
ine the phenotypes of patients with the novel GJB1
mutations.
METHODS: A cohort of 336 CMT Lithuanian subjects
has been screened for mutations in the GJB1 gene by direct
sequencing. Overall, 10 different GJB1 mutations have
been identiﬁed, three of which - novel.
RESULTS: In 14 unrelated probands, three novel GJB1
gene mutations were detected: c.195T>A, c.290A>G and
c.596G>A. Proband P5 had a nonsense mutation c.195T>A
(p.Y65*) which causes a premature stop codon. Probands
P7, P8 and P9 had a missense mutation c.290A>G (p.
H97R) which causes a change of the highly conserved
histidine residue, while proband P13 had a missense
mutation c.596G>A (p.G199D) which causes a change of
the highly conserved glycine residue. These mutations have
been qualiﬁed as a disease causing based on in silico ana-
lysis (PolyPhen-2, SIFT, PROVEAN, SNPs&GO) and were
not detected in the Lithuanian population control group (98
exomes) or in the Exome Aggregation Consortium and
1000 Genomes Project.
CONCLUSION: The c.195T>A, c.290A>G and
c.596G>A mutations are novel mutations of the GJB1 gene
that have not been previously reported. The frequency of all
GJB1 mutations is 4.16% in Lithuanian CMT patients
cohort.
B. Burnyte: None. I. Kavaliauskiene: None. A.
Molyte: None. L. Ambrozaityte: None. T. Rancelis:
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The use of zebraﬁsh in functional genetic study of
Hirschsprung disease
R. K. Chauhan1, B. J. L. Eggen2, A. J. Burns1,3, I. T.
Shepherd4, R. M. W. Hofstra1,3, W. W. Cheng1
ErasmusMC, Rotterdam, Netherlands, 2University of Gro-
ningen, Groningen, Netherlands, 3UCL Institute of Child
Health, London, United Kingdom, 4Emory University,
Atlanta, GA, United States
Introduction: Hirschsprung disease (HSCR) is a congenital
neurocristopathy of the enteric nervous system (ENS) where
enteric ganglia were absent in the distal colon. The inheri-
tance of HSCR range from monogenic inheritance to oli-
gogenic effect of the major gene RET and other modiﬁers.
Besides RET some 20 other genes have been identiﬁed
however, to date, less than 50% HSCR cases have their
disease-causing gene identiﬁed. To discover the unknown
genetic factors of HSCR, researchers focus on studying
patients genome, most lately by whole-exome sequencing.
Candidate genes identiﬁed from these studies are further
assessed by functional genetics to determine their functional
correlation to HSCR etiology. In this abstract we describe
zebraﬁsh as a model for HSCR functional genetics.
Materials and Methods: Morpholino, CRISPR/Cas9 and
mRNA were used to induced gene loss/gain-of-function on
reporter zebraﬁsh where ﬂuorescence proteins were
expressed in differentiated enteric neurons and/or undiffer-
entiated enteric neural crest cells for direct phenotyping.
Transit assay was carried out to evaluate intestinal move-
ment. Heterozygous ret mutant zebraﬁsh was characterized
to determine its potential in studying ret-modiﬁer
interaction.
Results: Loss-of-function of zebraﬁsh ret phenocopied
HSCR in human. Disrupting some of the newly identiﬁed
candidate genes caused similar phenotype, providing func-
tional correlation to the disease. Overexpression of selected
genes on human chromosome 21 revealed possible genetic
link in HSCR-associated Down syndrome. The hetero-
zygous ret mutant displayed mild intestinal hypoganglio-
nosis that will be useful in ret-modiﬁer interaction study.
Conclusions: Zebraﬁsh is a valuable model for HSCR
functional genetic that further our understanding of the
human genetic data.
R.K. Chauhan: None. B.J.L. Eggen: None. A.J.
Burns: None. I.T. Shepherd: None. R.M.W. Hofstra:
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Mutational spectrum of SPG4 (SPAST), SPG3A (ATL1)
genes in Russian patients with hereditary spastic
paraplegia
V. A. Kadnikova1, O. P. Ryzhkova2, G. E. Rudenskaya2, A.
V. Polyakov2
1Federal State Budgetary Institution “Research Centre For
Medical Genetics", Moscow, Russian Federation, 2Federal
State Budgetary Institution “Research Centre For Medical
Genetics, Moscow, Russian Federation
Hereditary spastic paraplegia (HSP) is clinically and
genetically heterogeneous group of neurodegenerative dis-
eases, which characterized by progressive spasticity and
weakness of the lower limbs and mild sensory dysfunction,
due to axonal degeneration in the pyramidal tract.
It is generally accepted, that SPG4 and SPG3A mutations
account for approximately 40% and 10% of all autosomal
dominant HSP, respectively.
We screened DNA from 73 unrelated probands (46
familial, 27 sporadic) with clinical symptoms of SPG. DNA
of 56 (76,7%) probands were sequenced of SPAST gene,
and 20 (27,4%) – of ATL1 gene (some of them have both
incoming diagnosis). Patients without mutations were
examined by MLPA-analysis.
We found 19 SPAST mutations (7 novel), and 8 ATL1
mutations (1 novel) (Table1). There were found 27 (37%)
mutations (74% point mutations; 26% gross deletions/
duplications) in a total 73 patients in both genes, 29,6%
mutations were not described so far. The origin de novo
present in 26%.
Table 1. SPG3A and SPG4 mutations.
Gene Family Exon Mutation
SPAST 2o, 21o 10 c.1291C>T (p.Arg431Term)
43o** 15 c.1663G>T (p.Asp555Asn)
44o 8 c.1107A>G (p.Thr369Thr)*
5** 11 .1391A>G (p.Glu464Gly)*
19 17 c.1750_1751delGAinsT
32 8 c.1139T>C (p.Leu380Pro)
35 10 c.1271delG*
44 1 c.286delG
54 9 c.1245+1G>A (IVS9+1G>A)
73** 9 c.1216A>G (p.Ile406Val)
75 15 c.1684C>T (p.Arg562Term)
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Table (continued)
Gene Family Exon Mutation
53o 3 c.551A>C (p.Asn184Thr)
26o 6–16 del.ex6-16*
33o 1 del.ex1
59o** 10–12 dup.ex10-12
20 10–13 del.ex10-13*
84** 15–16 del.ex15-16*
88 1 dup.ex1*
ATL1 46, 37o 12 c.1243C>T (p.Arg415Trp)
13**, 6o 7 c.715C>T (p.Arg239Cys)
22 8 c.757G>A (p.Val253Ile)
51 12 c.1483C>T (p.Arg495Trp)
70** 8 c.773A>G (p.His258Arg)
42 1–14 del.ex1-14*
*- novel mutation
**- sporadic cases
V.A. Kadnikova: None. O.P. Ryzhkova: None. G.E.
Rudenskaya: None. A.V. Polyakov: None.
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Is the HSPB3 p.Arg7Ser variant really causal? - evi-
dence from three families with different phenotypes
P. Lassuthova1, J. Neupauerová1, A. Mészárosová1, R.
Mazanec2, P. Seeman1
DNA lab, Department of Paediatric Neurology, 2nd Faculty
of Medicine, Charles University in Prague, Prague, Czech
Republic, 2Department of Neurology, 2nd Faculty of
Medicine, Charles University in Prague, Prague, Czech
Republic
Introduction: Mutations in the small heat shock proteins
HSPB1 and HSPB8 cause distal hereditary motor neuro-
pathy (dHMN)1. Kolb et al.2 searched for variants in other
HSBP genes (HSPB2-HSPB10) and found the p.Arg7Ser
variant in the HSPB3 gene in two affected siblings with
autosomal dominant dHMN. They proposed it is pathogenic
and causal for dHMN. We sought to determine the rela-
tionship of HSPB3 variants and dHMN.
Patients and Methods: Two-hundred and ﬁfty patients
were tested by massively parallel sequencing with a gene
panel. Ninety-seven genes (including HSPB3) known to be
associated with inherited peripheral neuropathies were
included.
Results: Variant p.Arg7Ser (NM_006308.2:c.21G>T)
was found in heterozygous state in three families from our
cohort (table 1).
In our population the variant has frequency 0,06%.
Discussion: Each of our families with the p.Arg7Ser
variant has a very different phenotype. Moreover, the var-
iant has a high population frequency (0,05%, 61 alleles in
ExAC), which has been observed in our cohort, as well. No
additional conﬁrmative reports - except for the original
paper by Kolb et al2 - have been published, so far.
However, additional family members need to be tested
for the presence of the variant.
Conclusion: In our three families the variant p.Arg7Ser
is very likely not causal for very different diseases and it is
probably a rare benign variant.
Supported by: AZV 16-30206
1. https://doi.org/10.1002/humu.23189
2. https://doi.org/10.1212/WNL.0b013e3181cef84a
Table 1
Family 1 Family 2 Family 3
Variant p.Arg7Ser p.Arg7Ser p.Arg7Ser
Phenotype dHMN -
distal
hereditary
motor
neuropathy
HSN -
hereditary
sensory
neuropathy
HSP - hereditary
spastic
paraplegia
Onset and
course of
the disease
Onset in
teens;
Axonal
neuropathy
Onset at the
age of 25
years, foot
ulceration
Onset of the
disease from the
age of 10, rapid
worsening
Deep
tendon
reﬂexes
L2-S2 no
response (0)
L2-S2 no
response (0)
L2–4 brisk
response (3+),
L5-S2 clonus (4
+)
Segregation Not available Unaffected
son not a
carrier
Affected
daughter also a
carrier
P. Lassuthova: None. J. Neupauerová: None. A.
Mészárosová: None. R. Mazanec: None. P. Seeman:
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New allelic variant of autosomal recessive hereditary
motor-sensory neuropathy type 2S resulted from
mutation in IGHMBP2 gene
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Ltd.,, Moskva, Russian Federation
Introduction: Hereditary motor and sensory neuropathy
(HMSN, Charcot-Marie-Tooth disease) is a group of
genetically heterogeneous diseases caused by mutations in
more than 80 genes, including the gene IGHMBP2
responsible for the development of HMSN type 2S (OMIM
616155). Until 2014, mutations in IGHMBP2 were asso-
ciated exclusively with distal spinal amyotrophy with neo-
natal respiratory failure (SMARD1, OMIM 604320).
Materials and methods: exome sequencing on Illumina
NextSeq 500 using TruSightOne V1.1 DNA enrichment.
Results: Exome sequencing revealed two mutations in
IGHMBP2 gene in compound heterozygous state: a mis-
sense mutation c.1616S> T (p.Ser539Leu) in exon 11,
described earlier, and deletion / frameshift mutation
c.2601_2602delGA in exon 13, discovered for the ﬁrst time.
These changes were detected in 7-year-old boy who was
suffering, starting in infancy, from pronounced muscular
hypotonia combined with muscle atrophy in distal extre-
mities, deformity of the hands and feet, pronounced ﬁxed
kypho-scoliosis, areﬂexia and sensory disturbances of
polyneurotic type without signs of respiratory disorders and
iris dysfunction. The level of CK activity in the serum was
155 U/L. Electroneuromyography revealed signs of distal
axonal neuropathy. Discussion: the case, similarly to most
patients reported in the literature with HMSN type 2S,
manifested in the ﬁrst year of life with hypotonia in distal
extremities and delayed motor development. Features like
electroneuromyographic data and increased CK, at some
point, can lead diagnostic search in the direction of primary
muscle disease with distal distribution of muscle symptoms.
Features of HMSN 2S clinical manifestation smake its early
diagnosis complex and require differential diagnosis with
SMARD1.
E. Dadali: None. I. Sharkova: None. F. Konovalov:
None.
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Molecular diagnosis of inherited peripheral neuropathies:
gene panel vs. exome sequencing
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Introduction: Inherited peripheral neuropathies (IPNs)
encompass a group of disorders highly heterogeneous,
clinically and genetically. Charcot-Marie-Tooth (CMT)
disease is closely related to distal hereditary motor neuro-
pathy (dHMN) or distal spinal muscular atrophy (DSMA),
and some patients show additional signs associated with
amyotrophic lateral sclerosis (ALS). Targeted gene panel
and exome sequencing are considered to be powerful and
cost-effective tools for diagnosis of these disorders. Mate-
rials and Methods: We have investigated a clinical series of
178 patients diagnosed of motor or sensory-motor periph-
eral neuropathy by exome sequencing or using different
updated versions of a gene panel: Neuro-104, Neuro-111,
and Neuro-119. Each version comprises 104, 111 or 119
IPN genes, respectively, and it shows a high coverage
performance. Both genetic approaches are based on Sur-
eSelect capture technologies (Agilent Technologies).
Results: Exome sequencing has allowed us to identify
causative mutations in 58% of cases. We have identiﬁed
novel genes and novel mutations in known genes, broad-
ening the phenotypical spectrum associated with IPNs.
Gene panel testing has been mostly performed in sporadic
cases, and it has allowed us to identify either disease-
causing or candidate mutations in 40% of cases. In sum,
both strategies have helped us to achieve a more accurate
clinical and genetic reclassiﬁcation of these disorders, an
impossible challenge using conventional sequencing
methods.
Conclusions: Our study expands the clinical phenotype
previously associated to known IPN causing-gene, and
emphasizes that gene panels should be considered as a ﬁrst
diagnosis method for unclariﬁed IPN patients.
Funds: ISCIII (PI12/00453, PI15/00187); Fundació
per Amor a l’Art.
V. Lupo: None. A. Sánchez-Monteagudo: None. M.
Barreiro: None. I. Hinarejos: None. A. Collado: None.
M. García-Romero: None.M.A. Alberti: None. S. Derek:
None. S. Beltrán: None. E. Serra: None. C. Márques-
Infante: None. S. Pascual: None. C. Casasnovas: None.
M. Frasquet: None. T. Sevilla: None. C. Espinós: None.
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Four-hit three event mechanism; investigation of an LZTR1
variant and the possible implications for a woman with
schwannomatosis
A. J. Rotchell1, S. M. Goodman2, B. Castle1, S. Tobi3
1Peninsula Clinical Genetics Service, Exeter, United King-
dom, 2Plymouth University, Plymouth, United Kingdom,
3Manchester Centre for Genomic Medicine, Manchester,
United Kingdom
A woman presented with chronic pain in her lower back and
right leg at 62 years. Magnetic resonance imaging showed
four spinal lesions, of which two were excised and con-
ﬁrmed as schwannomas, giving a diagnosis of schwanno-
matosis but without any known family history. Mutation
analysis of blood revealed a heterozygous missense variant
c.1394C>T p.(Ala465Val) in exon 13 of the leucine-zipper-
like transcription regulator 1 gene (LZTR1) and no variant
in the SMARCB1 gene.
Schwannomatosis is usually sporadic, but 15%-25% are
familial, inherited in an autosomal dominant manner. A
model of schwannomatosis related tumourigenesis
describes a four-hit three event mechanism. We speculate
that in this case the LZTR1 variant is the predisposing
germline mutation, as it lies within a highly conserved
amino acid residue and is considered likely to disrupt the N-
terminal BTB domain of the encoded protein. Investigation
of more than one schwannoma was important to clarify the
disease mechanism and provide evidence of pathogenicity
of the LZTR1 variant if loss of heterozygosity was
demonstrated in multiple specimens. Further analysis of
tumour DNA is underway, testing for somatic NF2 muta-
tions in cis and somatic loss of the other 22q allele in fresh
frozen tissue from the two excised schwannomas.
Challenges of counselling the family are described in the
context of LZTR1, a gene only recently implicated in
schwannomatosis with little data available on penetrance
and a variant currently classiﬁed as of uncertain sig-
niﬁcance. The process of investigation and the possible
consequences are discussed as an illustration of a potential
protocol.
A.J. Rotchell: None. S.M. Goodman: None. B. Castle:
None. S. Tobi: None.
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A recurrent mutation in the MUSK gene associated with a
more severe phenotype of congenital myastenic syndrome?
T. Herget1, K. Steindl1, P. Joset1, T. Schmitt-Mechelke2,
M. L. Giarrana3, A. Rauch1
Institute for medical genetics University of Zürich,
Schlieren, Switzerland, 2Children´s hospital Lucerne,
Lucerne, Switzerland, 3University Children´s Hospital
Zürich, Zürich, Switzerland
In 2004 mutations in the MUSK gene were reported as a
novel cause of a congenital myastenic syndrome. The
clinical course mostly comprised limb girdle (most fre-
quently axial and proximal) and facial weakness, stridor or
vocal cord palsy, respiratory problems and bulbar symp-
toms. In 2015, we reported a severe case from Germany
with prenatal onset and postnatal «dropped head» sign due
to compound heterozygosity for two novel MUSK muta-
tions. We now report on two Turkish siblings with similar
severe clinical course sharing one mutation with the case
from Germany. Both siblings presented amongst others with
congenital diaphragmatic paralysis and tracheomalacia with
consecutive long term ventilation, microcephaly, swallow-
ing difﬁculties and proximal and facial accentuated mus-
cular weakness. The boy additionally showed a rigid spine,
limited abduction of both eyes and had been treated for a
left-sided club foot, right-sided cryptorchism, chronic peri-
cardial effusion and a central nephrocalcinosis.
Exome sequencing revealed the mutations c.496C>T and
c.1779-13A-G in the MUSK gene in both affected children.
The mutations were shown to be compound heterozygous,
as the parents each carried only one mutation.
As the c.496C>T mutation was also present in the severe
case from Germany (Giarrana et al. 2015) with prenatal
onset (e.g. polyhydramnion and contractures at birth) we
hereby suggest it as a recurrent mutation in the MUSK gene
associated with a more severe phenotyp. Additionally, we
report the c.1779-13A-G as a novel mutation in the MUSK
gene.
T. Herget: None. K. Steindl: None. P. Joset: None. T.
Schmitt-Mechelke: None. M.L. Giarrana: None. A.
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Splicing mutations causing unusual early-onset dominant
MYH7-related myopathy
Y. Rogozhina1, A. Filatova2, M. Polyak1, M. Skoblov2,3, E.
Zaklyazminskaya1,4
1Petrovsky Russian Research Center of Surgery, Moscow,
Russian Federation, 2Research Centre for Medical Genet-
ics, Moscow, Russian Federation, 3Moscow Institute of
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Introduction. Dominant mutations in the MYH7 gene cause
allelic series of diseases including various cardiomyopathies
and myopathies usually manifesting in adulthood. Clinical
case. We had under our observation the boy 2 y.o. mani-
fested with predominant axial muscles weaknesses, “drop-
ped head syndrome”, and mild dilatation of the heart
chambers. Parents and older brother (10y.o.) are healthy.
Methods. Clinical investigation was performed by ECG,
EchoCG, neurological examination, and muscular biopsy.
The DNA-diagnostics had included whole exome sequen-
cing with following Sanger resequencing, bioinformatic
analysis, and cascade familial screening. Functional analy-
sis of the variants of interest had included RT-PCR and
expression analysis in HEK293N cell line transfected with 4
plasmids containing fragment of the MYH7 gene from exon
37 to exon 39 (wt, c.5655+5G>C, c.5655G>A, and c.5655
+1G>A). Results. We revealed new de novo mutation
c.5655+5G>C in the MYH7 gene in the 2 y.o proband. In-
frame skipping of the exon 38 in the proband’s mRNA was
conﬁrmed. This variant and two previously published
mutations (c.5655G>A and c.5655+1G>A) also leading to
the 38 exon skipping were studied using expression system.
Surprisingly we had found that wt plasmid expressed two
RNA isoforms: full-length and shortened (skipping of the
38 exon). All mutant plasmids had expressed only shor-
tened isoform. Quantitative difference in expression was
shown for mutant plasmids. Conclusion. We consider the
variant c.5655+5G>C in the MYH7 gene as a pathogenic
mutation causing early-onset myopathy and dilated cardio-
myopathy. All patients with those mutations seem to have
similar phenotype. Acknowledgements.This work was
supported by Russian Science Foundation, grant №16-15-
10421.
Y. Rogozhina: None. A. Filatova: None. M. Polyak:
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Next Generation Sequencing (NGS): a useful approach for
the genetic diagnosis of dystrophies and myopathies
Y. Moreno-Saez, Medical Genetics Unit, A. Romera-
López, Medical Genetics Unit, D. Cantalapiedra, Medical
Genetics Unit, S. Valverde, Medical Genetics Unit, V.
Felipe-Ponce, Medical Genetics Unit, M. Bellón-Robles,
Medical Genetics Unit, G. Marco, Bioinformatics
Department, J. Triviño, Bioinformatics Department, C.
Collado, New Technologies Lab, Y. Roa, New
Technologies Lab, L. Arocas-Castillo, Medical Genetics
Unit, C. Buades-Gomis, Medical Genetics Unit, C. Casañ-
Martínez, Medical Genetics Unit, D. Valero-Hervás,
Medical Genetics Unit, S. Santillán, Medical Genetics
Unit
Sistemas Genómicos, Paterna (Valencia), Spain
Myopathies and muscular dystrophies constitute a a com-
plex and heterogeneous group of more than 50 diseases
characterized by muscle weakness. Diagnosis is mainly
based on medical examination, biochemical and neuro-
physiological assessment and muscle biopsy. However, it
can be challenging due to the presence of overlapping
features among diseases. In this context, genetic testing
through NGS could be a key approach to achieve an
accurate diagnosis of muscle disorders.
We applied a NGS targeted resequencing 74 gene-panel
to a cohort of 87 patients with clinical suspicion of Limb-
girdle dystrophy (26), Duchenne/Becker dystrophy (21),
RYR1-related disorders (10), Ullrich/Bethlem disease (8),
Congenital myopathies and dystrophies (16), Distal myo-
phaties (4) and Emery Dreifuss muscular dystrophy (2).
Samples were analyzed using SureSelect kit (Agilent),
HiSeq (Illumina) platform and an in-house bioinformatic
pipeline. Variant ﬁltering was carried out according to
variant effect, familial pattern of inheritance, allele fre-
quency and information available in databases.
Genetic diagnosis was achieved in 24 out of 87 patients
(27.6%). Nonsense (31%), frameshift (23%), splicing (19%)
or missense variants (27%) were identiﬁed in these patients.
In 27 out 87 of the patients (31%) no candidate variants
were found. Eventually, 4 individuals were heterozygous
carriers of a pathogenic/probably pathogenic variant in
genes associated with autosomal recessive disorders. In 36
patients only VUS were detected (36.8%).
According to the high diagnosis rate, NGS constitute an
effective strategy to study myopathies and muscular
dystrophies.
Functional and cosegregation analysis of VUS or
extension of NGS analysis in negative patients would be
helpful to increase diagnosis rate.
Y. Moreno-Saez: None. A. Romera-López: None. D.
Cantalapiedra: None. S. Valverde: None. V. Felipe-
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A novel mutation in MYBPC1 is associated with myopathy,
tremor, and spinal rigidity
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2Centre Hospitalier Universitaire de Québec, Ville de
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Medicine, Department of Biochemistry and Molecular
Biology, Baltimore, MD, United States, 4Department of
Clinical Genetics, United Laboratories, Tartu University
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Introduction: MYBPC1 encodes the slow skeletal Myosin
Binding Protein-C protein (sMyBP-C), which is expressed
in both slow and fast twitch skeletal muscles. sMyBP-C is a
modular protein that plays structural and regulatory roles
via its dynamic interaction with both actin and myosin
ﬁlaments.
Materials and Methods: Exome sequencing of four
family member samples was performed. The pathogenicity
of variants was evaluated using several in silico prognostic
tools. The NH2-terminal region of sMyBP-C was ampliﬁed
and the mutation was introduced via site-directed muta-
genesis. In vitro binding assays were performed.
Results: We describe a three-generation family with a
skeletal myopathy, accompanied by tremor and spinal
rigidity. Exome sequencing analysis revealed the presence
of a novel missense mutation in the MYBPC1 gene,
c.742G>A p.E248K. The E248K mutation is located in a
highly conserved linker region in the NH2-terminus of the
molecule. Using in vitro binding assays, we demonstrate
that the presence of the E248K mutation results in markedly
increased binding of the NH2-terminus of sMyBP-C to
myosin (~3.5-fold) compared to wild-type protein.
Conclusions: Identiﬁcation of the E248K mutation
expands the range of myopathies caused by alterations in
the MYBPC1 gene. Based on the familial segregation,
absence from the general population, in-silico assessment,
and altered binding properties of the E248K mutation, we
can classify it as pathogenic by ACMG guidelines.
This work was supported by NIH/NIAMS (Training
Program in Muscle Biology, T32 AR007592-17 to J.G.),
the Muscular Dystrophy Association (Research Grant
313579 to A.K.K.) and European Regional Development
Fund (No. 2010/0223/2DP/2.1.1.1.0/10/APIA/VIAA/025 to
B.L.).
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Phenotypic variability of myotonia congenita in Lithuanian
three generation family with heterozygous mutation in
CLCN1 gene
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Introduction: Myotonia congenita (MC) is an inherited
muscle disease due to mutations in the CLCN1 and asso-
ciated with delayed skeletal muscle relaxation after con-
traction, resulting in muscle stiffness. The phenotypic
manifestations can have a broad spectrum even among
patients carrying the same CLCN1 mutation. The two forms
of MC have different patterns of inheritance: Thomsen
disease is inherited in an autosomal dominant pattern and
Becker disease is inherited in an autosomal recessive.
Materials and Methods: Five family members in a three
generation family underwent a detailed clinical analysis,
electromyography (EMG) and genetic analysis (Sanger
sequencing of the CLCN1 gene was performed).
Results: The proband is 12 years old boy complaining of
muscle stiffness and pain at lower limbs, difﬁculties in
initiating walking and writing. EMG revealed burst of
myotonia. Mother and sister of proband were asympto-
matic. Maternal grandmother complained of hand tremors,
difﬁculties in starting speaking and walking. EMG of
mother and maternal grandmother were normal. Hetero-
zygous missense mutation NM_000083.2:c.899G>A was
identiﬁed in exon 8 of the CLCN1 gene for proband, one of
his sisters, mother and maternal grandmother. The in silico
analysis of the identiﬁed variant shows conﬂicting results:
SIFT - 0.02, PolyPhen - 0.853, Mutation Taster - disease
causing, Provean - damaging.
Conclusions: The majority of CLCN1 variants can be
associated with reduced penetrance. Family members het-
erozygous for the same variant may have variable pheno-
types. The genotype phenotype correlation analysis in
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presented family proves the difﬁculties in ascertaining the
deﬁnite diagnosis even based on molecular genetic ﬁndings.
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Introduction: DM1 is the most common form of inherited
muscular dystrophy in adults, with a multisystemic pheno-
type affecting muscle, central nervous system (CNS) and
other tissues. Patients usually present neuropsychological
symptoms such as excessive daytime sleepiness, attention
deﬁcits, intellectual disability and reduced initiative and
apathy. To investigate the role of glia and neuron cells in
the CNS alterations we developed two cellular models of
DM1.
Materials and Methods: DM1 models were created on
MIO-M1 (glia) and SH-SY5Y (neuron) cell lines by using
the Tet-On 3G system. A stable cell line with high induction
levels of trans-activator protein was ﬁrst created. Second
stable cell lines were made with responsive plasmids con-
structions, carrying a fragment of the 3′UTR of DMPK
human gene with 0 and 960 CTG repeats. Models were
validated with TP-PCR, RT-PCR and FISH-IF, and alter-
native splicing and gene expression changes were evaluated
by microarrays.
Results: TP-PCR and capillary electrophoresis identiﬁed
the transgene, expression of the exogenous transcript and
modiﬁcations in the alternative splicing of the MBNL2 gene
were determined by RT-PCR, FISH-IF experiments
revealed nuclear transcript aggregation co-localized with
MBNL proteins. Finally, expression microarrays showed
changes at alternative splicing and gene expression levels in
both cellular models.
Conclusions: These models allow transgene expression
in an inducible manner under identical genetic background
with speciﬁc molecular and cellular markers of DM1. With
these models we will be able to study the speciﬁc
contribution of glial and neuronal cells in the CNS mani-
festations of the disease.
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screening in molecular diagnostics of patients with sus-
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Introduction: Myotonic dystrophies (DM1, CTG expan-
sion in the DMPK gene; DM2, CCTG expansion in the
CNBP gene) are multisystem disorders with prominent
neuromuscular symptomatology. Their proper differential
diagnostics is, however, complicated because of clinical
heterogeneity and symptomatology overlapping other neu-
romuscular disorders. One of those is myotonia congenita, a
nondystrophic myotonia caused by mutations in CLCN1
(chloride voltage-gated channel 1) gene. The aim of our
study was to compare the frequency of pathogenic/likely
pathogenic CLCN1 variants in different groups of patients
initially suspected to have DM1/DM2.
Materials and methods: We performed complex mutation
screening of CLCN1 exons – MLPA and Sanger or mas-
sively parallel sequencing – in four patient groups: 1) 40
patients referred for DM testing but without identiﬁed DM1/
DM2 expansion; 2) 52 patients with identiﬁed DM1
expansion; 3) 55 patients with identiﬁed DM2 expansion; 4)
30 individuals representing the general Slovak population.
Results: Pathogenic/likely pathogenic variants were
identiﬁed in homozygous state in ~8% of patients without
DM1/DM2 expansion, in heterozygous state in > 7% of
DM2 patients, while there were yet not identiﬁed among the
DM1 patients and in the group representing the general
population.
Conclusions: According to our results myotonia con-
genita can be considered for an alternative diagnosis in a
relatively large portion of patients originally suspected to
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have DM but without identiﬁed DM1/DM2 expansion. In
addition CLCN1 variants seem to be common modiﬁers of
DM2 symptomatology that is, however, not typical for
DM1. Consequences of such ﬁndings for genetic counsel-
ling will be presented in our poster. Financial support:
VEGA_2/0115/15.
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Myotonic dystrophy type 1 (DM1; OMIM160900) is the
most common form of inherited adult muscular dystrophy.
It is caused by unstable expansion of the CTG repeat in the
DMPK gene. The incidence of myotonic dystrophy among
Jews from Yemen is 47.3:100,000 as compared to
15.7:100,000 in the general population. Between the years
2011–2015, 29 unrelated families with myotonic dystrophy
were referred to the genetics clinic of the Rabin Medical
Center. Twelve of the families were of Yemenite Jewish
origin. The total percentage of Yemenite Jews in the Israeli
population is roughly 2.5%, whereas they represent about
25% of myotonic dystrophy patients referred to our clinic.
We performed haplotype analysis in these families to look
for evidence of a founder mutation. Analysis of the patients’
haplotypes around the DMPK gene revealed that eight of
the twelve probands shared the same haplotype based on
nine markers . The shared haplotype is located in an 864Kb
region, 100Kb 5' of the DMPK gene and 700Kb 3' of the
gene. Phasing was performed according to the family
members’ haplotypes. The aging of the MD mutation in the
Yemenite population shows it occurred around 160 years
ago.
Our ﬁndings suggest that a high prevalence of myotonic
dystrophy among Yemenite Jews is consistent with a
founder mutation in this population. We recommend a high
degree of suspicion for this disease in Yemenite Jews with
neuromuscular symptoms. This will enable earlier diag-
nosis, better follow-up and on-time preconception coun-
seling as well as prenatal or preimplantation genetic testing.
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DM1 is the most common type of muscular-dystrophy in
adults and is characterized by progressive myopathy,
myotonia, and multiorgan involvement, that is caused by an
unstable CTG repeat expansion in the 3´UTR of DMPK
gene. Oropharyngeal-dysphagia is highly prevalent in DM1
patients and leads to high mortality rate due to pneumonia
and respiratory failure, however there are no reports of this
sign in early stages of disease. Here we present a swal-
lowing evaluation in presymptomatic individuals with
conﬁrmed diagnosis of DM1.
Eleven asymptomatic subjects between 18–74 years old
(mean= 54, SD= 15.62) with conﬁrmed diagnosis of DM1
by TP-PCR and SP-PCR, were subjected to detailed clinical
history. Neuromuscular involvement was scored using
Muscular Impairment Rating Scale (MIRS). Swallowing
assessment was performed by Fiberoptic Endoscopic Eva-
luation of Swallowing (FEES) protocol using different
bolus consistency.
All patients ranging from 50 to 295 CTG repeats per-
ceived themselves as asymptomatic individuals, this con-
dition do not affect their daily activities and quality of life.
MIRS reveals no muscular impairment (MIRS 1). Despite
absence of distal muscles comprise, FEES showed six
patient with decreased sensitivity (54.54%), two with mild
impairment to liquids (18.18%), three mild impairment to
liquids and solid (27.27%), three mild impairment to all
consistencies (27.27%) and two with severe impairment
with alteration of security (18.18%). Signiﬁcant differences
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were found between DM1-patients and a healthy control
group.
For our knowledge, this is the ﬁrst report worldwide in
presymptomatic DM1-subjects. It is important to detect
early clinical manifestations in order to prevent and treat
complications.
L. Márquez-Quiroz: None. A.A. Franco-Guerrero:
None. M.D. Curiel-Leal: None. N.M. Murillo-Melo:
None. N. Leyva-García: None. R.E. Escobar-Cedillo:
None. V.M. Valadez-Jiménez: None. B. Cisneros-Vega:
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Development of a streamlined molecular assay that deter-
mines both allele and expanded repeat size in DMPK for
myotonic dystrophy 1
B. Hall, J. Kemppainen, J. Wisotsky, K. Culp, G. Latham,
E. Bram
Asuragen, Austin, TX, United States
Background: Myotonic dystrophy type 1 (DM1) is an
autosomal dominant disease characterized by > 50 CTG
repeats in the 3′ UTR of DMPK. DM1 testing currently
requires a combination of PCR and Southern blot analysis
because PCR cannot reliably amplify >100 repeats. Here,
we describe results using a novel PCR technology that
permits assessment of normal and expanded alleles in a
single tube.
Materials and Methods: 20 gDNA samples isolated from
presumed healthy whole blood donors (Asuragen) or DM1-
positive cell-line samples with up to 2000 CTG repeats
(Coriell) were acquired. Sample gDNA was ampliﬁed using
prototype PCR reagents (Asuragen). FAM-labeled ampli-
cons were resolved by capillary electrophoresis on a 3500
xL (Thermo Fisher).
Results: CTG-speciﬁc and gene-speciﬁc priming were
optimized with other PCR components in a single reaction
to produce complementary data signatures from repeat-
primed and full-length amplicons. These signatures con-
ﬁrmed the genotypes of normal and expanded alleles
without the need for separate PCR and Southern blot (SB),
resulting in a faster and simpler assay and analysis work-
ﬂow. Prototype PCR reagents could resolve >200 CTG
repeats from 40 ng gDNA and generated repeatable results.
Conclusions: Current methods fail to amplify moderate-
to-large repeat expansions in DM1, and allele drop-outs
may be indistinguishable from frequently-encountered
homozygous samples. We report the ﬁrst single-tube,
long-read PCR technology that can resolve zygosity, iden-
tify expansion to >200 repeats, and ﬂag larger expansions.
This approach signiﬁcantly reduces the need for DM1 SB
analysis, and may also be multiplexed with PCR for DM2-
associated tetranucleotide repeats.
B. Hall: A. Employment (full or part-time); Signiﬁcant;
Asuragen. J. Kemppainen: A. Employment (full or part-
time); Signiﬁcant; Asuragen. J. Wisotsky: A. Employment
(full or part-time); Signiﬁcant; Asuragen. K. Culp: A.
Employment (full or part-time); Signiﬁcant; Asuragen. G.
Latham: A. Employment (full or part-time); Signiﬁcant;
Asuragen. E. Bram: A. Employment (full or part-time);
Signiﬁcant; Asuragen.
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A novel copy number variation detection array for the
diagnostics of neuromuscular disorders
L. Sagath1, V. Lehtokari1, C. Wallgren-Pettersson1, K.
Pelin1,2, K. Kiiski1
The Folkhälsan Institute of Genetics and the Department of
Medical and Clinical Genetics, Medicum, University of
Helsinki, Helsinki, Finland, 2Department of Biosciences,
Division of Genetics, University of Helsinki, Helsinki,
Finland
Introduction: Nemaline myopathy (NM) is caused by
mutations in at least ten different genes, but most commonly
by recessive mutations in the nebulin gene (NEB), a 183
exon gene essential for correct sarcomere structure and
function. NEB harbors a 32kb triplicate region (TRI), in
which eight exons are usually repeated three times (ex 82–
89, 90–97, 98–105).
Materials and Methods: We are currently validating a
new custom-made 4×180k array-CGH design. It includes
the same tiled high-density coverage of the ten known NM
genes as our 8×60k NM-CGH-array, but also covers an 170
additional genes, such as titin (TTN), that have been related
to neuromuscular diseases.
Results: As to date, we have analyzed samples from 259
NM families, and identiﬁed 15 different disease-causing
aberrations in NEB in 31 of these families. The majority of
these pathogenic variations were detected only in one to
three families each. Copy number variants (CNVs) affecting
the TRI region were detected in 16% of the NM families,
and in 5 % of the families the CNV was interpreted to be
pathogenic. Pathogenic CNVs were found in 12 % of all
families analyzed.
Conclusions: The array allows the reliable detection of
CNVs also in regions of segmental duplication, such as the
TRI regions of NEB and TTN. Our novel 4×180k array-
CGH design allows CNV detection of a broader spectrum of
neuromuscular disorders. It can be used for molecular
440
genetic diagnostics, and is available for mutation analysis in
our laboratory.
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Four new pathogenic mutations identiﬁed in SH3TC2 gene
responsible for Charcot-Marie-Tooth disease associated
with deafness and/or scoliosis
A. Lunati1,2, J. Lerat3,2, H. Dzugan1,2, M. Rego1, C.
Magdelaine1,2, E. Bieth4, P. Calvas4, P. Cintas5, B.
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Toutain10, J. Urtizberea11, F. Sturtz1,2, A. Lia1,2
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Médicale, Centre hospitalo-universitaire de Toulouse,
Toulouse, France, 5Service de Neurologie et d'explorations
fonctionnelles, Centre hospitalo-universitaire de Toulouse,
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universitaire de Limoges, Limoges, France, 10Service de
Génétique Médicale, Centre hospitalo-universitaire de
Tours, Tours, France, 11Centre de référence Neuromuscu-
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Introduction: Charcot-Marie-Tooth disease is one of the
most frequent inherited peripheral neuropathies (1/2500).
So far, mutations in more than 80 genes have been identi-
ﬁed causing either the demyelinating form (type 1) or the
axonal form (type 2). Duplication of PMP22 gene is the
most frequent cause of autosomal dominant demyelinating
form. Autosomal recessive demyelinating form is often due
to SH3TC2 gene mutations. Patients suffer then from early
severe neuropathy starting in the ﬁrst decade. Scoliosis and
deafness are often observed.
Material and method: 200 patients suffering from
peripheral neuropathy were screened by multiplex-ligation-
dependant-probe-ampliﬁcation, followed by targeted next-
generation-sequencing using a 92-gene custom panel
designed for the diagnosis of Charcot-Marie-Tooth and
associated neuropathies. Mutations of interest were veriﬁed
by Sanger sequencing.
Results: Diagnosis was positive for 114 patients. As
expected, the most frequent mutation was the PMP22
duplication detected in 30 patients. Deletion of PMP22 was
observed in 18 patients and pathogenic point mutations
were detected in 66 patients. SH3TC2 gene appeared to be
the most frequently mutated with nine patients diagnosed.
Associated with known mutations, four new mutations have
been identiﬁed: two nonsense mutations and two missense
mutations. All these patients presented deafness and/or
scoliosis.
Conclusion: SH3TC2 appears to be an important gene
involved in Charcot-Marie-Tooth disease, often associated
with deafness and /or scoliosis. It is important to pay
attention to these associated symptoms in Charcot-Marie-
Tooth patients in order to guide their diagnosis and to
improve their medical care.
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Functional an biochemical characterization of induced
Pluripotent Stem cells (iPSc) from patients with Neutral
Lipid Storage Disease with Myopathy
D. Tavian1, S. Missaglia1, M. Castagnetta2, D. Degiorgio3,
E. M. Pennisi4, C. Angelini5, P. Dell'era6, C. Mora6, R. A.
Coleman7, D. A. Coviello2
Univeristy, Milan, Italy, 2Galliera Hospital, Genoa, Italy,
3Univeristy, Genoa, Italy, 4S Filippo Hospital, Rome, Italy,
5S Camillo Hospital, Venice, Italy, 6Univeristy, Brescia,
Italy, 7Univeristy, Chapel Hill, NC, United States
Neutral Lipid Storage Disease with Myopathy (NLSDM) is
a very rare disorder characterized by a defect in the
degradation of cytoplasmic triglycerides and accumulation
as lipid droplets (LDs). This lipid dysmetabolism may
determine progressive myopathy, cardiomyopathy, dia-
betes, hepatomegaly, hepatic steatosis, chronic pancreatitis
and short stature. No speciﬁc therapy is currently available.
All patients carry damaging mutations in the PNPLA2 gene,
which codiﬁes for the adipose triglyceride lipase (ATGL),
an enzyme that hydrolyses fatty acids from triacylglycerol.
We have previously reprogrammed dermal ﬁbroblasts from
two patients and healthy subjects into induced pluripotent
stem cells (iPSCs). The iPSCs were tested for pluripotency
evaluating the expression of TRA-1-81, SSEA4 and OCT4
markers, and their differentiation ability into three-germ
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layers by immunoﬂuorescence analysis (β-III tubulin,
ectoderm; SMA, mesoderm; FOXA2, endoderm). Now we
demonstrate that NLSDM-iPSCs present an abnormal
accumulation of triglycerides into LDs, resembling the
hallmark of NLSDM. Indeed, immunoﬂuorescence analysis
shows that NLSDM-iPSCs has 20 times more LDs and
almost 5 larger LDs then control iPSCs. Moreover, the TG
content of NLSDM-iPSCs is signiﬁcant higher than that of
control iPSCs. Oleic acid pulse chase experiments further
conﬁrm that lipase activity is impaired in NLSDM-iPSCs
compared to control cells. These results demonstrate that
iPSCs recapitulate NLSDM speciﬁc-lipid metabolism defect
and can be considered a valid biochemical disease model.
Finally, NLSDM-iPSCs could be differentiated into cardiac
myocytes or myoblasts to screen potential therapeutic
compounds
D. Tavian: None. S. Missaglia: None. M. Castagnetta:
None. D. Degiorgio: None. E.M. Pennisi: None. C.
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Next generation sequencing technologies in the genetic
diagnosis of Congenital Myasthenic Syndrome
A. Töpf1, Y. Azuma1, S. Gorokhova2, E. O'Connor1, A.
Porter1, P. Lorenzoni3, G. McMacken1, H. Alrohaif1, E.
Harris1, J. Müller1, A. Chaouch1, D. Cox1, T.
Evangelista1, D. MacArthur4, O. Magnusson5, S. Nicole6,
A. Roos1, J. Senderek7, M. Bartoli2, A. Abicht8, H.
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Introduction: Congenital myasthenic syndrome (CMS) is a
clinical and genetic heterogeneous condition caused by
defect in the neuromuscular junction and characterised by
fatigable muscle weakness, bulbar and ocular symptoms.
Over 20 disease causative genes have been reported, how-
ever 30% of CMS patients remain genetically undiagnosed,
suggesting that many novel CMS are yet to be identiﬁed.
Materials and Methods: After a hotspot pre-screening
step, we have applied next generation sequencing
techniques, including target panel, whole exome (WES) and
whole genome sequencing (WGS) to investigate a cohort of
clinically diagnosed CMS patients (n= 54; 43 pedigrees).
Results: We have identiﬁed 17 disease causing variants
in known CMS genes in 11 pedigrees. Twelve of these
variants are novel. Thanks to the deep coverage of WGS
and NGS panel data, we were able to detect a homozygous
deletion in COLQ, as well as a large heterozygous intra-
genic deletion in DOK7. Surprisingly, we have also found
variants in genes that had not been anticipated (POLG,
CPL1, CRLF1, SLC2A1 and PTPN11). In addition, two new
CMS genes were identiﬁed, one of them in two independent
families (SCL25A1 and MYO9A, respectively). From the
remaining unsolved cases, three strong candidate and
modiﬁer genes have emerged and functional investigation is
ongoing.
Conclusions: NGS technologies have allowed to
genetically diagnose 19 CMS pedigrees (45%) as well
highlighted new candidate genes and pathways. This is of
extreme value as CMS has effective treatment that depends
on the causative defect, and therefore genetic diagnosis has
a direct impact on patients’ quality of life.
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Two different NGS approaches to address molecular diag-
nosis of Congenital Neuromuscular Diseases
L. Gonzalez-Quereda1, A. Pariente2, L. Alias1, M.
Rodriguez2, M. Baena2, A. Nascimento3, C. Ortez3, J.
Milisenda4, A. Sanchez5, J. Surralles6, P. Gallano1
Genetics Dept. Hospital de la Santa Creu i Sant Pau, U-705
CIBERER, Barcelona, Spain, 2Genetics Dept. Hospital de
la Santa Creu i Sant Pau, Barcelona, Spain, 3Neuropedia-
trics Dept. Hospital Sant Joan de Deu, Barcelona, Spain,
4Neuromuscular Unit, Hospital Clínic, Barcelona, Spain,
5Genetics Dept. Hospital Clínic, Barcelona, Spain, 6Genet-
ics Dept. Hospital de la Santa Creu i Sant Pau, U745
CIBERER, Barcelona, Spain
Introduction Congenital neuromuscular diseases are early
onset muscle disorders encompassing great clinical and
genetic heterogeneity so that reaching and accurate genetic
diagnosis is still a challenge.
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Objectives We aim to evaluate the diagnostic advantage
of different NGS approaches in a cohort of congenital
neuromuscular disorders and to validate an efﬁcient and
cost-effective diagnostic strategy to be incorporated to the
National Health System.
Material and methods Sixty-two gDNA samples from
patients with clinical suspicion of congenital neuromuscular
diseases were analysed by NGS. A custom panel including
118 genes (Nextera Rapid Capture, Illumina) and TruSight
One Panel (Clinical Exome, Illumina) were employed.
Sequencing data were analysed by Variant Studio and DNA
Nexus.
All candidate variants were conﬁrmed by Sanger
sequencing and pathogenicity was analysed by using Ala-
mut Software (Interactive Biosoftwares) and LOVD
database.
Results The genetic cause of the disease was elucidated
in 11/25 samples (44%) by the Clinical Exome and in 28/
48 samples (58%) by the custom panel. Eleven samples
from the second group (custom panel) had previously been
analysed by the Clinical Exome without positive results.
Mutations in RYR1 were the most common cause of
disease in our cohort.
Variants in genes related to Congenital Myasthenic
syndromes were identiﬁed in 8 patients. This was crucial to
choose the appropriate treatment, which depends on the
particular molecular defect.
Conclusions The custom panel design has proved to be a
more useful tool than the clinical exome to provide a
molecular diagnosis of congenital neuromuscular diseases.
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Utility of the X-chromosome exome sequencing for clinical
genetic diagnostics of Duchenne and Becker muscular
dystrophies
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Tanner3, J. Schleutker1,2
1University of Turku, Turku, Finland, 2Turku University
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Introduction: Duchenne and Becker muscle dystrophies
are allelic X-linked recessive disorders affecting 1/3500 and
1/18500 males respectively. Both dystrophinopathies are
caused by mutations in the DMD gene and their clinical
diagnostics relays primarily on MLPA/aCGH and Sanger
sequencing. Sanger sequencing is laborious and expensive
due to large size of DMD. Next generation sequencing
technologies may provide a cost-effective option. The aim
of this study was investigate the utility of a commercial
amplicon based X-chromosome exome panel for sequen-
cing the DMD gene in the clinical diagnostics. Patients and
methods: 50 patients referred for diagnostic Duchenne/
Becker testing with normal MLPA results were selected.
Target enrichment was performed using the ClearSeq kit
(combination of amplicon and hybridization methods) and
libraries were sequenced with Illumina MiSeq. Data align-
ment and variant calling were performed using in-house
pipeline. Detected pathogenic variants were conﬁrmed with
Sanger sequencing. Results: Of the 50 analyzed samples a
pathogenic mutation was detected in 19 samples. All
detected pathogenic variants were truncating or splice site
mutations. Conclusions: As our results indicate amplicon-
based methods may offer advisable following study MLPA
or aCGH being primary study detecting exonic copy num-
ber changes. With this approach it is possible to replace
Sanger sequencing and hence reduce sequencing costs.
However hybridization based methods allow detection of
both SNVs and exact break points of exonic deletions/
duplication. In the future in addition of detecting SNVs
mutation speciﬁc treatments may require precise informa-
tion of break points. Therefore hybridization based methods
may provide a better option.
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A novel GNAO1 mutation in a patient with severe move-
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Introduction: Mutations in the GNAO1 gene have been
recently related to the distinct phenotypes comprising: 1/
early infantile epileptic encephalopaties, and 2/ develop-
mental delay with progressive movement disorders and no
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severe seizures. The latter phenotype reported in 14 cases to
date, seems to predominantly result from two recurrent
substitutions, c.626G>A and c.736G>A. The GNAO1 gene
codes for a speciﬁc subclass of guanine-binding proteins,
Gαo, that acts as important signaling molecules in the
central and peripheral nervous system.
Materials and Methods: Whole-exome sequencing has
been performed in a 7-year old boy born to non-
consanguineous parents of Polish origin. From the third
month of age he presented with progressive axial and limb
hypotonia, dystonic spasms, involuntary movement of
facial muscles and digits, and absent speech. He was able to
sit with support at the age of 4 years. He never stood and
walked independently. Brain MRI, EEG, and EMG exam-
inations showed no abnormalities. Muscle biopsy revealed
selected atrophy of type II ﬁbers.
Results: The novel c.709G>A p.(Glu237Lys) hetero-
zygous GNAO1 variant was identiﬁed in a proband. The
analysis of his parents indicated the substitution occurred de
novo. In silico analyses with 10 prediction algorithms
indicated its pathogenic character.
Conclusions: The novel pathogenic variant has broa-
dened the mutational spectrum related to GNAO1 dys-
function beyond two recurrent mutations.
The study was ﬁnanced by the CMHI projects no. S145/
16, S136/13, S148/16.
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Mutations in PARK2 are the most common cause of auto-
somal recessive Parkinson disease (PD). PARK2 encodes
parkin, an E3 ubiquitin ligase that is able to mediate dif-
ferent types of ubiquitination in several substrates.
Numerous variants located throughout parkin domains have
been shown to be pathogenic for PD. Some of the variants
identiﬁed were shown to impair parkin E3 ubiquitin ligase
activity.
Our group has previously conducted a mutation screen-
ing of PARK2, in order to evaluate 244 unrelated Portu-
guese patients with symptoms of PD. This lead to the
identiﬁcation of 18 disease-causing variants, from which
c.155delA (p.N52MfsX29) was the most common. More-
over we identiﬁed two novel causative variants, including
one indel (c.1072_1073delCTinsA; p.L358RfsX77).
Thereby we aim to functionally characterize parkin
mutants. For that we generated parkin mutant clones in
fusion with EGFP-tag that were transfected in HEK293T
cultured cells. The subcellular localization was accessed by
immunoﬂuorescence and subcellular fractioning. Parkin E3
activity was evaluated by measuring parkin self-
ubiquitination and ubiquitination of DJ1 (a parkin sub-
strate) using co-immunoprecipitation assays in cells co-
transfected with parkin clones and HA-ubiquitin.
Our results showed that parkin mutants have different
subcellular distribution and are aggregation-prone, con-
versely to parkin-WT. Moreover, parkin mutants retain their
ability to self-ubiquitinate, but seem to have altered activity
against DJ1.
In conclusion, we showed that parkin mutants have dif-
ferent biochemical properties and are abnormally localized,
but not all result in a complete loss of enzymatic activity.
Further studies are needed to fully understand the con-
sequences of PD-associated mutations on parkin cellular
functions.
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Mutations in POLG and MPV17 cause a broad spectrum of
mitochondrial disorders
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Introduction: Mitochondrial diseases are genetically and
phenotypically heterogeneous caused by mutations in both
mitochondrial DNA (mtDNA) and nuclear genes. Mutations
in nuclear gene POLG encoding the mtDNA polymerase
gamma required to replicate the mitochondrial genome are
reported to affect mtDNA stability such as accumulation of
point mutations, multiple deletions and depletion of
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mtDNA, and cause progressive mitochondrial disorder.
Materials and Methods: We explored the utility of targeted
next-generation sequencing with a total of 75 nuclear genes
panel and all exons and intron-exon boundaries of the
POLG1 gene was ampliﬁed and sequenced. Results: We
have identiﬁed a homozygous p.R627W mutation in three
patients from two unrelated families as a cause of an
uncommon phenotype with status epilepticus and stroke as
dominant phenotype. In addition patient with compound
heterozygous p.R627W and p.A781T mutations present
with multisystemic clinical presentations. The p.R627W
homozygous mutation not previously documented and we
report here, for the ﬁrst time, the p.A781T mutation in
POLG1 as a cause for recessive mitochondrial disease. The
parents in all family were unaffected carriers with p.R627W
or p.A781T mutations. These mutations were absent in 600
control chromosomes. We also identiﬁed homozygous p.
R41W mutation in the MPV17 gene in four patients. The
majority of POLG and MPV17 mutations show an auto-
somal recessive inheritance. Intriguingly, the p.R627W
mutation causes severe clinical phenotypes and early death
in homozygous condition in contrast to compound hetero-
zygous condition. Conclusion: We conclude that screening
for POLG mutation is very important for diagnosis, proper
medical management and appropriate genetic counseling.
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motor and sensory polyneuropathy with pyramidal signs
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Sade, V. Adir, D. Golan
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Background: Voltage-dependent Ca(2+) channels mediate
the entry of Ca(2+) ions into excitable cells and are also
involved in a variety of Ca(2+)-dependent processes,
including muscle contraction, hormone or neurotransmitter
release and gene expression. Calcium ion channel Alpha -1a
subunit gene (CACNA1A) codes for the Alpha1A subunit
of P/Q type calcium channel Cav2.1 protein. This protein is
expressed mainly in the brain, particularly in the cere-
bellum. Most CNS synapses rely on Cav2.1 and Cav2.2
calcium channels for fast synaptic transmission. Three
allelic autosomal dominant disorders: Spinocerebellar
Ataxia type 6, Episodic Ataxia type 2 and Familial Hemi-
plegic Migraine type 1 have been described with CAC-
NA1A gene mutations. Methods: Whole Exome
Sequencing (WES) Results: We report a pedigree carrying
a rare (0.057% in EXAC database) CACNA1A gene
pathogenic variant (c.5897G>A, p.Arg1966Gln). The
family presented variable combination of pyramidal signs,
peripheral motor and sensory polyneuropathy and cerebellar
atrophy. We speculate that voltage-gated calcium channels
damage in the CNS and peripheral nerves is the etiology for
the familial phenotype. Conclusion: To the best of our
knowledge, variants in CACNA1A gene have not been
previously associated with this phenotype. This report
widens the spectrum of CACNA1A related disorders. We
suggest CACNA1A gene mutations should be included in
the differential diagnosis of patients presenting the combi-
nation of pyramidal signs and peripheral polyneuropathy.
Future population researches can determine the variability
and penetrance of CACNA1A gene variants regarding
“new” neurological conditions.
G. Larom: None. A. Peleg: None. L. Sagi-Dain: None.
A. Harari-Shaham: None. O. Sade: None. V. Adir: None.
D. Golan: None.
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POPDC1 gene mutations screening in laminopathies: pos-
sible role as a modiﬁer
R. Rossi1, C. Scotton1, M. Lorenzo1, A. D'Amico1, G.
Ricci1, L. Vercelli1, S. Benedetti1, E. Bertini1, E. Mercuri1,
C. Rodolico1, T. Mongini1, N. Carboni1, G. Marrosu1, L.
Chico1, L. Santoro1, L. Merlini1, G. Lattanzi1, L.
Morandi1, P. J. R. Barton2, R. Buchan2, R. Walsh2, S. A.
Cook2, H. Milting3, G. Bonne4, T. Brand2, A. Ferlini5,2
University of Ferrara & Italian network for laminopathies,
ferrara, Italy, 2NIHR Cardiovascular Biomedical Research
Unit at Royal Brompton & Hareﬁeld NHS Foundation
Trust, London, United Kingdom, 3Herz- und Diabeteszen-
trum NRW, Erich und Hanna Klessmann-Institut fur̈
Kardiovaskuläre Forschung und Entwicklung, Bad Oeyn-
hausen, Germany, 4Sorbonne Universités, UPMC Univ
Paris 06, INSERM UMRS974, CNRS FRE3617, Center for
Research in Myology, Institut de Myologie, G.H. Pitié
Salpêtrière, Paris Cedex, France, 5University of Ferrara,
ferrara, Italy
Introduction: POPDC1 is the best-studied member of the
Popeye domain-containing gene family. The members of
this family encode transmembrane proteins, which are
abundantly expressed in cardiac and skeletal muscle. The
evolutionary conserved Popeye domain functions as a high-
afﬁnity 3′-5′-cyclic adenosine monophosphate (cAMP)
binding domain. Recently POPDC1 has been identiﬁed as
causative gene in a family affected by Limb-girdle
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Muscular Dystrophy and atrioventricular (AV) block
(OMIM LGMD2X). Methods: In order to evaluate if
POPDC1 may contribute to phenotype variability in other
LGMDs with or without cardiac involvement we screened
by Sanger sequencing 240 patients with different pheno-
types either orphan of known gene mutations or with known
gene mutations.Results: We identiﬁed 9 different hetero-
zygous POPDC1 mutations in 11 patients, 6 of them do also
carry LMNA mutations. Phenotypes vary from classical
LGMD phenotype to pure cardiomyopathy with rhythm
disturbances. Conclusion: We have demonstrated that
POPDC1 mutations do cause rare recessive phenotypes, and
we suggest that POPDC1 gene may also act as disease
modiﬁers. Considering that laminopathies are characterized
by high clinical heterogeneity and by intra- and interfamilial
phenotypic variability, we speculate that POPDC1 may
participate to LMNA phenotype modulation.
R. Rossi: None. C. Scotton: None. M. Lorenzo: None.
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A cryptic amyloidogenic element in the 3'UTR of REEP1
has pathological relevance
A. S. Bock1, S. Günther1, J. Mohr2, L. V. Goldberg1, C.
Klisch3, S. Biskup2, C. Beetz1
1Jena University Hospital, Jena, Germany, 2CeGaT GmbH
und Praxis für Humangenetik, Tübingen, Germany, 3Neu-
rologische Praxis Klisch, Erfurt, Germany
Certain frameshift variants in NEFH result in translation of
part of the gene’s 3′UTR. They have recently been shown to
cause autosomal dominant Charcot-Marie-Tooth disease
type 2 (CMT2) by making the NEFH protein aggregation-
prone. The responsible sequences were termed ‘cryptic
amyloidogenic elements’ (CAEs). Whether CAEs in 3′
UTRs of other genes are of pathological relevance remained
unclear. Applying a gene panel for neuromuscular diseases,
we identiﬁed a REEP1 stop-loss variant in a dominant
CMT2 family. This variant had been identiﬁed upon exome
sequencing of a CMT2 patient in a previous study, but the
authors had favored a heterozygous SETX non-sense variant
as causative. However, truncating SETX variants are
pathogenic only when present homozygously. It therefore
seems more likely that, as in our case, the CMT2 phenotype
results from the REEP1 stop-loss variant. Loss of the
REEP1 stop codon results in translation of the proximal 3′
UTR. In silico analyses suggested that the 55 extra residues
are highly amyloidogenic. Expression of corresponding
constructs revealed cytoplasmic aggregation of the mutant
but not the wild-type REEP1 protein. Likewise, fusion of
the 55 residues to the C-terminus of several reporters trig-
gered aggregation, and co-overexpression experiments
conﬁrmed that the 3'UTR-encoded peptide is both sufﬁcient
and necessary for self-aggregation. Our data conﬁrm the
previous hypothesis of toxic gain-of-function mutations in
REEP1 to primarily affect lower motoneurons while loss-
of-function mutations in this gene result in upper moto-
neuron axonopathy (causing hereditary spastic paraplegia).
More generally, our ﬁndings expand the pathologic rele-
vance of CEAs for peripheral axon degeneration.
A.S. Bock: None. S. Günther: None. J. Mohr: None.
L.V. Goldberg: None. C. Klisch: None. S. Biskup: None.
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Rigid spine myopathy with cardiovascular involvement
A. V. Popoiu, G. Doros, C. Olariu, C. M. Popoiu
University of Medicine and Pharmacy V. Babes, Timisoara,
Romania
Introduction: Rigid spine myopathy or musclar dystrophy
associated with Selenoprotein N1(SEPN1) mutation with is
a rare autosomal recessive disease on gene 1p36. It causes
contracture of the spinal externsors with severe limitation in
the movement of the thoracic cage and whole spine, sco-
liosis, and restrictive respiratory failure. Cardiovascular
involvement is rarely mentioned, mainly cor pulmonare.
Method: A 12 year old girl was admitted in our hospital
with hypercapnic coma (PaCO2 =160 mm Hg) due to
chronic restrictive respiratory failure, narrow thorax,
cachexia (weight= 12 kg), muscular atrophy,
hyperlordosis.
As an infant she presented with axial and proximal
muscle weakness, delayed motor acquisition, by normal
mental development. The feeding difﬁculties started at
3 month of age and remained the main complain despite of
normal gastroenterologic ﬁndings. Progressive limitation of
the spine mobility resulted in hyperlordosis, scoliosis,
thorax deformity, fatigability, respiratory failure.
Echocardiography revealed a severe compression of the
left atrium due to the spine, spearing the mitral valve, as
well as a moderate pulmonary hypertension PSAP= 52 mm
Hg.
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Results: Next-generation-sequencing detected 2 hetero-
zygote mutations in exon 10 and 11 of SEPN1 gene- an
“null-mutation” exon 10 deletion (c.1308delC) and a
“missense” mutation exon 11(c.1397G>A).
After noninvasive BIPAP ventilation was started, a
notable improvement in general status occurred.
Conclusions: Although not frequent, cardiac manifesta-
tions should be screened in rigid spine myopathy.
A.V. Popoiu: None. G. Doros: None. C. Olariu: None.
C.M. Popoiu: None.
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Non coding RNA regulation analyses in the molecular
pathways involved in inﬂammation, senescence, apoptosis
and autophagy during the sarcopenic process functional and
non-functional elderly population
G. Queipo1, J. Rivera1, A. Aco1, Y. Trujillo2, G. Aristi1, M.
Fonseca2
1Hospital General de México Eduardo Liceaga Facultad de
Medicina UNAM, México DF, Mexico, 2Hospital General
de México Eduardo Liceaga, México DF, Mexico
Sarcopenia is one of the most deleterious effects of aging.
The involuntary loss of muscle mass, strength, and mus-
cular function have a major impact on quality of life in the
elderly population. The etiology of the sarcopenia is not
clearly established, although, a multifactorial process that
develops from the fourth decade of life is proposed. The
muscular contractility is a per se and independent factor in
the sarcopenia development not related with the muscle
volume. In order to understand this phenomenon. Our group
found that the genetic proﬁles in muscular tissue showed an
increase in genes involved in apoptosis and inﬂammation in
the group of fragile elderly. Surprisingly, gene expression of
functional elderly was very similar to young sedentary,
while athletes showed expression of genes related to
autophagy. Immunohistochemical analysis showed a
change in the distribution of actin and myosin in fragile
elderly. Our data suggest that in the fragile elderly, the
inﬂammatory and apoptotic process in muscle ﬁber have a
direct impact on the proteins involved in contractility and
muscular functionality, which is clinically reﬂects as lower
volume, muscle strength and performance in this popula-
tion. Here in we present the results of 768 non conding
RNAs (miRNAs) regulation analysis over these molecular
pathway using a QRTPCR array (RT2Proﬁler, Qiagen) in
muscular tissue. Preliminary results showed a speciﬁc group
of miRNAS who has differential expression patterns and
plays a critical role in these molecular pathways depending
the age, the physical activity and the sarcopenic state.
CONACyT Grant number 181798
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Diagnosis rate of DNA fragment analysis for patients with
SMA symptoms
M. Ozdemir1, S. Artan1, C. Yarar2, B. Durak Aras1, K. B.
Carman2, H. Bas1, E. Erzurumluoglu1, O. Cilingir1
Eskisehir Osmangazi University, Faculty of Medicine,
Department of Medical Genetics, Eskisehir, Turkey, 2Eski-
sehir Osmangazi University, Faculty of Medicine, Depart-
ment of Pediatrics, Eskisehir, Turkey
Spinal muscular atrophies (SMAs) are autosomal recessive
neuromuscular disorders characterized by muscle weakness
and atrophy resulting from progressive degeneration of the
motor neurons. SMAs are caused by deletions or intragenic
mutations of SMN1 and increased number of SMN2 copies
usually modify the phenotype. The simplest and most
deﬁnitive diagnostic tests for SMAs are molecular genetics
tests for SMN genes.
We performed molecular genetic analyses of SMN1 and
SMN2 genes on blood samples of 23 patients suspected to
have SMA based on the clinical ﬁndings. We examined 7th
and 8th exons of SMN1 and SMN2 genes by DNA frag-
ment analyses.
Out of the 23 patients we examined, no deletion detected
on two patients (8,7%). Six were homozygous for deletion
of SMN1 (26,1%) and seven were heterozygous for deletion
of one SMN1 allele (30,4%). For SMN2 gene, two patients
were homozygous for deletion (8,7%) and ﬁve were het-
erozygous for deletion of one allele (21,7%). One patient
was heterozygous for deletion of 7th exon of SMN1 allele
and 8th exon SMN2 allele (4,3%).
Only 26,1% of the patients suspected to have SMAs
were able to diagnose with molecular genetic tests we used.
Tests for intrinsic mutations or SMN2 copy numbers may
be required to diagnose some SMA patients in case they
were unnoticed with DNA fragment analysis that we used;
or detailed clinical examinations should be performed
before requesting molecular analyses.
M. Ozdemir: None. S. Artan: None. C. Yarar: None.
B. Durak Aras: None. K.B. Carman: None. H. Bas:
None. E. Erzurumluoglu: None. O. Cilingir: None.
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SMN1 deletions among children with spinal muscular
atrophy in Bosnia and Herzegovina
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M. Hasanhodzic1, A. Mujanovic2, I. Rabotic2, N.
Mustaﬁc1, N. Lojo-Kadric3
1Department of Pediatrics, University Clinical Center
Tuzla, Tuzla, Bosnia and Herzegovina, 2Faculty of
Medicine, University of Tuzla,, Tuzla, Bosnia and Herze-
govina, 3Institute for genetic Engineering and Biotechnol-
ogy, University of Sarajevo, Sarajevo, Bosnia and
Herzegovina
Introduction: Hereditary spinal muscular atrophy (SMA) is
an autosomal recessive disease with a prevalence of 1 in
6,000–10,000 live births. It is the result of homozygous
mutation of the motor neuron 1 (SMN1) gene on Ch5q13,
and characterized by muscle weakness and atrophy. The
purpose of study was to determine the frequency of SMN1
deletions and severity of SMA among Bosnian children.
Material and Methods: Retrospectively study was
performed among patients younger than 18 years from
northeast Bosnia and Herzegovina. The data has been col-
lected from clinical records and molecular genetics tests of
patients with suspicion on SMA.
Results: Our data showed that among 1600 patients, our
19 patients (11 female, 8 male) had clinical records (1,19 %)
on SMA. Seven of them had diagnosis SMA type I, four
SMA type II, and eight SMA type III. Genetics tests con-
ﬁrmed that two patients had muscular dystrophy, and four
had no mutations on SMN1 or DMD gene. Among 13
patients, nine patients had homozygous deletion of SMN1
(69,23 %) and one of SMN2 gene, eight had duplication of
SMN2 gene, eight patients had both, deletion and duplica-
tion of SMN genes. One patient had deletion, and two
patients had duplication of NAIP gene. Three patients with
SMA type 1/2 are died before genetic conﬁrmation.
Conclusion: We present the ﬁrst paper of frequency of
SMN1 deletions in SMA Bosnian children. Anticipating
future gene therapy for SMA, this paper is a starting point
for developing policies and strategies for SMA in Bosnia
and Herzegovina.
M. Hasanhodzic: None. A. Mujanovic: None. I.
Rabotic: None. N. Mustaﬁc: None. N. Lojo-Kadric:
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Percentage of FL-SMN and Δ7-SMN transcripts as bio-
marker of spinal muscular atrophy treatment efﬁcacy
M. A. Maretina1,2, A. A. Egorova1, N. A. Tsyganova2, A.
V. Kiselev1
1D.O. Ott Research Institute of Obstetrics, Gynecology and
Reproductology, Saint-Petersburg, Russian Federation,
2Saint-Petersburg State University, Saint-Petersburg, Rus-
sian Federation.
Introduction: Spinal muscular atrophy (SMA) is a neuro-
muscular disorder caused by mutations within the SMN1
gene. All SMA patients have at least one copy of SMN2
gene - a nearly identical copy of SMN1 - that produces low
amount of full-length SMN (FL-SMN) transcripts. All the
rest transcripts lack exon 7 (Δ7-SMN) and encode non-
functional protein. Correction of SMN2 gene splicing is one
of the principal SMA therapeutic goals. To access the
efﬁciency of fast-developing SMA therapy approaches there
is a need for reliable biomarker whose score differs between
patients, carriers and healthy individuals. Material and
Methods: Detection of FL-SMN and Δ7-SMN transcripts
was carried out by means of RT-PCR. Blood cell RNA
samples from 28 SMA patients, 33 SMA carriers and 15
control individuals were analyzed. SMA patient-derived
ﬁbroblasts were transfected with antisense oligonucleotides
(ASO) aimed at correction of SMN2 exon 7 splicing. The
percentage of exon 7 inclusion was determined using Ima-
geJ software measuring the intensity of each transcript band
in electropherogram. All data were veriﬁed by means of
QF-RT-PCR. Results: Signiﬁcant differences in percentage
of FL-SMN and Δ7-SMN transcripts were found among
three examined groups. Mean percentages of FL-SMN
transcripts in blood cells were following: 16% for SMA
patients, 28% for SMA carriers and 56% for control indi-
viduals. Two-fold increase in exon 7 inclusion was detected
in SMA ﬁbroblasts treated with ASO. Conclusion: FL-SMN
and Δ7-SMN transcripts percentage is potentially useful
biomarker for evaluation of SMA therapy efﬁcacy by cor-
rection of SMN2 splicing
M.A. Maretina: None. A.A. Egorova: None. N.A.
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Progressive SCAR14 with Unclear Speech, Developmental
Delay, Tremor, and Behavioral Problems caused by a
Homozygous Deletion of the SPTBN2 Pleckstrin Homol-
ogy Domain
E. Yildiz Bolukbasi1, M. Afzal2, S. Mumtaz2, N. Ahmad3,
S. Malik2, A. Tolun1
1Bogazici University, Istanbul, Turkey, 2Quaid-i-Azam
University, Islamabad, Pakistan, 3Institute of Biomedical
and Genetic Engineering, Islamabad, Pakistan
Introduction: SCAR14 is autosomal recessive spinocer-
ebellar ataxia caused by mutations in SPTBN2. To date,
only two other SPTBN2 mutations with recessive effect
448
causing SCAR14 that manifest with developmental ataxia
and cognitive impairment, or cerebellar ataxia, mental
retardation and pyramidal signs have been reported. We
report on nine members of a consanguineous Pakistani
kindred with primary presentation of intellectual disability,
developmental delay, limb and gait ataxia, behavioural and
speech problems, and tremor.
Materials and Methods: The disease locus was identiﬁed
by linkage mapping using SNP genotype data of 10 family
members. Whole exome sequencing for one affected subject
was evaluated for rare/novel variants.
Results: We identiﬁed novel homozygous splicing var-
iant c.6375-1G>C in SPTBN2 that encodes beta-III spectrin,
which forms tetramers with alpha-II spectrin, predicted to
lead to the truncation of the encoded protein.
Conclusion: The mutation we identiﬁed would lead to
the deletion of just the pleckstrin homology domain; thus,
the earlier onset and more progressive nature of the disease
in the presented family, as compared to earlier reports, were
unexpected. No other mutation that could possibly explain
the features that were unusual for SCAR14—arched palate,
climacophobia, and behavioural problems—was identiﬁed.
Our ﬁndings expand the recessive SPTBN2 mutation phe-
notype. We also provide a review of SPTBN2 mutation
phenotypes.
(Grants: Boğaziçi University Research Fund 7695 and
URF-QAU (2013–14), Pakistan)
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Wieacker-Wolff syndrome in a tenth family
C. Cabrol1, L. Quevarec2, A. Martin3, S. Reviron4, C.
Guillermet5, J. Piard1, L. Ruaud1, F. Arbez-Gindre6, J.
Melki2, L. Van Maldergem1
Centre de génétique Humaine, CHU, Université de
Franche-Comté, Besançon, France, 2UMR 1169, Inserm,
Université Paris Sud, Le Kremlin-Bicêtre, France, 3Service
de gynécologie - obstétrique, CHU, Université de Franche-
Comté, Besançon, France, 4Service de gynécologie -
obstétrique, CH Jura Sud, Lons-Le-Saunier, France, 5Ser-
vice de pédiatrie 2, CHU, Université de Franche-Comté,
Besançon, France, 6Service d’anatomie pathologique,
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Wieacker-Wolff syndrome (WWS) is a rare X-linked neu-
rodevelopmental disorder, ﬁrst described in 1985 in a
family segregating developmental delay and congenital
contractures in boys. In 2013, Hirata identiﬁed causative
ZC4H2 mutations in ﬁve families. Our patient was detected
prenatally by second trimester ultrasound screening: bilat-
eral club feet and a questionable tethered cord in a male
fetus. The pregnant woman had an unremarkable family
history, herself undergoing surgery in infancy for a right
clubfoot. CS delivery occurred at term with normal growth
parameters, except length at -3SD. However, a severe
hypotonia with limbs hypertonia and respiratory distress
requiring assisted ventilation, bilateral clubfeet and distal
arthrogryposis were observed. Brain MRI was remarkable
for fronto-temporal cortical atrophy. He died at 21 weeks.
The autopsy conﬁrmed the clinical ﬁndings in addition to
auricular septal defect. An exome targeted to 70 genes
known to be associated with arthrogryposis or fetal akinesia
was performed and identiﬁed a ZC4H2 missense mutation
(c.625A>G; p.Lys209Glu) inherited from his mother. This
mutation is predicted to be pathogenic with a high score
(PolyPhen-2 score of 0.94), was not annotated in the
1000Genomes or ExAC Browser databases and was con-
ﬁrmed by Sanger sequencing. A diagnosis of WWS was
made and the females in childbearing age were counselled
accordingly. This is the tenth family described with WWS
mainly characterized by arthrogryposis multiplex congenita
and developmental delay with variable expression in
affected boy. Carrier female can be either asymptomatic or
symptomatic with generally less severe manifestations. Our
family illustrates nicely this “new” X-linked condition.
C. Cabrol: None. L. Quevarec: None. A. Martin:
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P11 Multiple Malformation/anomalies syndromes
P11.001A
Somatic activating PIK3CA mutations cause CLAPO
syndrome
L. Rodriguez Laguna1, K. Ibañez2, J. López-Gutiérrez3, R.
Martín-Arenas4, V. Fernández-Montaño4, E. Vallespín4,
V. Ruiz-Pérez1, Á. del Pozo5, J. Silla5, G. Gordo1, A.
Palencia-Campos6, C. Estañ6, H. González-Pecellin4, R.
Mena4, Gómez del Pozo4, I. Rueda-Arenas4, P.
Lapunzina7, V. Martínez-Glez1
1Vascular Malformations Section, INGEMM-CIBERER-
IdiPaz-Hospital Universitario La Paz, Madrid, Spain,
2Bioinformatics Section, INGEMM-CIBERER-IdiPaz,
Madrid, Spain, 3Section of Plastic and Reconstructive
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Functional Genomics Section, INGEMM-CIBERER-
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Hospital Universitario La Paz, Madrid, Spain, 6IIB,
Instituto de Investigación “Alberto Sols”, UAM, Madrid,
Spain, 7Clinical Genetics Section, INGEMM-CIBERER-
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Introduction: CLAPO syndrome, described so far in 7
patients, is a combined vascular disorder of unknown cause,
characterized by capillary malformation on the lower lip,
lymphatic malformation predominant on the cervicofacial
area, asymmetric face and partial/generalized overgrowth.
Due to the distribution of the affected tissue as well as to its
phenotypic overlap with the PIK3CA-related overgrowth
spectrum (PROS), we studied 13 CLAPO patients under the
hypothesis that it could also be caused by low somatic
mosaic PIK3CA activating mutations.
Materials and Methods: A custom NGS panel and an in-
house bioinformatic pipeline for low mosaics detection
were used to test paired blood/affected tissue samples from
9 CLAPO patients. Candidate variants were validated
according to their degree of mosaicism by Sanger Sequen-
cing (>15%), pyrosequencing (>5%), and/or Droplet Digital
PCR for mosaics as low as >0.1%. Gain of function of
PIK3CA variants not previously described was veriﬁed by
directed mutagenesis, transfection into in HEK293T cells,
and western blot for Akt phosphorylation, its natural target.
Results: Five different low somatic mosaic mutations
(5–16%) in PIK3CA were identiﬁed in affected tissues from
6/9 CLAPO patients. Three of the mutations were pre-
viously described in PROS. The other two showed gain of
function compared to wildtype.
Conclusions: We describe PIK3CA mosaic activating
mutations as the causing mechanism in CLAPO and suggest
including this syndrome into the PROS spectrum. These
ﬁndings will allow a better diagnosis of the syndrome,
which will also beneﬁt from any possible future treatment
targeting the AKT-PI3K-mTOR pathway.
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Biallelic mutations in TBCD, encoding the tubulin folding
cofactor D, perturb microtubule dynamics and cause early-
onset neurodegenerative encephalopathy
M. NICETA1, E. Flex2, S. Cecchetti2, I. Thiffault3, M. G.
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Pfundt8, J. Lepichon10, E. Farrow3, F. Baas11, F.
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Emory University School of Medicine, Atlanta, GA, United
States, 6CINECA, SCAI-SuperComputing Applications and
Innovation Department, Roma, Italy, 7Scuola Normale
Superiore, Pisa, Italy, 8Department of Human Genetics,
Donders Institute for Brain, Cognition and Behaviour,
Radboud University Medical Center, Nijmegen, Nether-
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Microtubules are dynamic cytoskeletal elements coordinat-
ing a variety of neuronal processes, including cell division,
migration, and signal transduction. Mutations in genes
encoding tubulins and microtubule-associated proteins have
been reported to cause neurodevelopmental and neurode-
generative disorders. Growing evidence suggests that
altered microtubule dynamics may also underlie or con-
tribute to neurodegeneration. We report that biallelic
mutations in TBCD, encoding one of the ﬁve co-chaperones
required for assembly and disassembly of the αβ-tubulin
heterodimer, the structural unit of microtubules, cause a
neurodegenerative disease characterized by early-onset
cortical atrophy with microcephaly, developmental delay
and intellectual disability, seizures, and spastic quad-
riplegia. Molecular dynamics simulations predicted sub-
stantial local structural perturbations associated the disease-
causing mutations. Biochemical analyses documented
variably reduced levels of TBCD, indicating relative
instability or insolubility of mutant proteins, and defective
β-tubulin binding in a subset of the tested mutants.
Reduced/defective TBCD function resulted in decreased
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soluble α/β-tubulin levels and accelerated microtubule
polymerization in ﬁbroblasts from affected subjects,
demonstrating an overall shift towards a more rapidly
growing and stable microtubule population. These cells also
displayed an aberrant mitotic spindle with disorganized,
tangle-shaped microtubules and markedly reduced aster
formation, which however did not alter appreciably the rate
of cell proliferation. Our ﬁndings establish that defective
TBCD function underlies a recognizable neurodegenerative
disorder and causes accelerated microtubule polymerization
and enhanced microtubule stability, underscoring a tight
link between aberrant microtubule dynamics and neurode-
generation. M. Niceta and E. Flex equally contributed to
this work.
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Recurrent Cushing syndrome, severe growth retardation
with dysmorphic features and skeletal abnormalities as a
result of de novo microdeletion 17q24.2-q24.3 - a case
report
J. Pilch1, M. A. Kalina2, P. Skiba3, E. Gutmajster4, J. Gil3,
I. Łaczmńska3, A. Januszek-Trzciąkowska2, M. Lisik4, E.
Małecka-Tendera2
1Department of Pediatric Neurology, School of Medicine in
Katowice, Medical University of Silesia,, Katowice, Poland,
2Department of Pediatrics and Pediatric Endocrinology,
School of Medicine in Katowice, Medical University of
Silesia, Katowice, Poland, 3Department of Genetics, Wroc-
law Medical University,, Wroclaw, Poland, 4Department of
Medical Genetics, School of Medicine in Katowice, Medical
University of Silesia, Katowice, Poland
Microaberrations of chromosome 17 are frequently reported
as a cause of birth defects, but microdeletions involving
q24.2-q24.3 are sporadic. Up-to-date only a few cases have
been published, mostly as an isolated Carney complex. In
some of them dysmorphic features were described. We
present an 8-year-old girl who was born from the ﬁrst
pregnancy with oligohydramnios after 42 weeks of
gestation with IUGR and dysmorphic features of Pierre-
Robin sequence. No inborn defect was diagnosed except
from patent foramen ovale. During follow-up severe growth
retardation was observed. On physical evaluation round
face, small mouth, high palate, micro-rethrognathia, chest
asymmetry, diastasis recti, limited pronation and suspicion,
drum-stick ﬁngers were present. Radio-ulnar synostosis was
radiologically conﬁrmed and additionally there were fea-
tures of bone dysplasia. Array-CGH, conﬁrmed by FISH,
revealed de novo 3,4 Mb microdeletion of chromosome
17q24.2-q24.3 containing PRKAR1A, MAP2K6, KCNJ2
genes. Independently, due to polycythemia and growth
delay, endocrinological assessment was performed, with the
suspicion of secondary causes of above complaints. After
careful anamnesis it appeared that recurrent episodes of
growth arrest were accompanied by hyperphagia and weight
gain. Laboratory assays performed in symptomatic periods
revealed disturbed daily rhythm and lack of suppression of
cortisol secretion in the high-dose dexamethasone test. MRI
of adrenal glands repeated in symptomatic and non-
symptomatic periods did not show abnormalities. Head
MRI revealed cortical dysplasia and additionally there was
suspicion of pituitary microadenoma. However, based on
clinical picture and laboratory ﬁndings, the child was qua-
liﬁed for the unilateral adrenalectomy. Phenotype-genotype
correlation will be discussed.
Support: Institutional grant KNW-1-167/N/5/0
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22q11.2 deletion inﬂuences expression levels of hemi-
zygous and normal copy number genes: possible disruption
of cis and trans regulation
A. G. Dantas1, M. L. Santoro1, C. A. Kim2, D. C. Q.
Soares2, V. A. Meloni1, F. T. Bellucco1, N. R. Nunes da
Silva1, S. I. Belangero1, G. G. Carvalheira1, M. I.
Melaragno1
Universidade Federal de São Paulo, São Paulo, Brazil,
2Universidade de São Paulo, São Paulo, Brazil
22q11.2 deletion syndrome (22q11.2DS) results from
hemizygous deletions of chromosome 22, usually ﬂanked
by low copy repeats (LCR), which represent a substrate for
aberrant recombination. The LCR sequences that ﬂank the
22q11.2 deletion region deﬁne the common breakpoints,
being the 3 Mb deletion the most frequent one. Even though
most 22q11.2DS patients presents similar size deletions, the
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phenotype is highly variable among individuals. Presuming
that the phenotype observed is not only caused by the
hemizygous genes, but also by variants outside the deleted
region, we investigated whole-genome gene expression in
peripheral blood from patients with 3 Mb deletion and from
controls, to investigate the expression levels of 22q11.2
genes and to investigate whether 22q11.2 deletion can
inﬂuence the expression of genes in other genomic regions.
We found downregulation in hemizygous genes and in
normal copy number genes ﬂanking the deleted region.
Considering the whole genome expression data, genes from
different chromosomes were found to be both down and
upregulated. These genes differentially expressed were
investigated taking into account the pathways relevant to
the syndrome. Genes located on chromosomes 22, 7 and 11
enriched the pathways that are associated to immune
response, dopamine receptor mediated signaling and adre-
naline and noradrenaline biosynthesis. Based on these data,
we propose that the 22q11.2 deletion is responsible for the
disruption of important interactions between chromatin in
the nucleus, causing an imbalance of gene expression in a
genome wide scale. Financial support: FAPESP, Brazil.
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Investigation of genetic variants in patients with 22q11.2
Deletion Syndrome
K. Ziemkiewicz1, M. S. Hestand2, M. Smyk1, T. B.
Crowley3,4, J. Breckpot2, A. Swillen2, A. Kutkowska-
Kazmierczak1, M. Piotrowicz5, B. Gieruszczak-Białek6, D.
M. McDonald-McGinn3,4, J. R. Vermeesch2, B. A.
Nowakowska1
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The 22q11.2 deletion syndrome is the most common
microdeletion syndrome in humans with an incidence of 1
in 2000 live births. Major clinical characteristics are intel-
lectual disability, congenital heart anomalies,
velopharyngeal abnormalities, characteristic facial appear-
ance, and psychiatric disorders. Most affected individuals
have a hemizygous 3Mb deletion on chromosome 22q11.2,
which includes at least 50 known genes. Highly variable
phenotypic severity is characteristic for the syndrome.
Clinical features are varied and exhibit variable expressivity
even in the patients carrying identical deletions. Potential
genetics mechanisms underlying this variability include:
additional copy number change elsewhere in the genome,
allelic variation of genes within the 22q11.2 region of the
non-deleted chromosome, or modiﬁer genes outside of the
deleted region.
To address copy number change in the genome, besides
deletion of 22q11.2, aCGH analysis was performed on over
50 patients. Next, whole exome sequencing (WES) is being
applied to identify both recessive gene mutation on the
second chromosome and candidate genes that lie outside of
the 22q11.2. Preliminary results from the ﬁrst 29 exomes
identify 290,318 variant positions, of which 74,221 are
protein altering. 53% of these are rare, as deﬁned by < 5%
in 1000 genomes data. Within the 22q11.2 deletion region,
we identiﬁed 33 rare nonsynonymous variant positions and
6 rare frameshift insertion positions spread across 14 dif-
ferent genes. Detailed phenotyping of all tested patients was
performed and correlation between WES results and spe-
ciﬁc phenotypes is ongoing.
This work was granted from National Science Centre
(OPUS NCN 2015/17/B/NZ5/01357 to BN)
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Subtelomeric 2q deletion - evocative features, new signs,
genotype - phenotype correlation
C. Rusu1, M. Gramescu1, E. Gorduza1, M. Panzaru1, E.
Braha1, L. Butnariu1, A. Sireteanu2, R. Popescu1
University of Medicine and Pharmacy, Iasi, Romania,
2Regional Institute of Oncology, Iasi, Romania
2q deletion syndrome is a common subtelomeric rearran-
gement (some cases still unrecognized), deﬁned by typical
dysmorphic face, hand/foot anomalies and intellectual dis-
ability (ID). We present 7 cases to discuss the clinical
features suggestive for this diagnosis, to present new fea-
tures and the genotype-phenotype relationship.
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Case 1: male (24 years), short stature, truncal obesity,
dysmorphic face, short neck, dorsal kyphosis, lowset nip-
ples, small/puffy extremities, hypermobile hands, proximal
4th ﬁnger/toe, moderate ID; normal karyotype; MLPA,
arrayCGH: 2qdel;
Cases 2, 3 (siblings): male (17) and female (13), mild
short stature, truncal obesity, dysmorphic face, short neck,
dorsal kyphosis, lowset nipples, skin with visible small
vessels and hirsutism, normal hands/feet, mild ID, autistic
features, seizures; normal karyotype; MLPA: 2qdel, 9qdup;
Case 4: female (5 years), tall stature, obesity, dysmorphic
face, short neck, dorsal kyphosis, lowset nipples, proximal
4th toe, hypotonia, moderate ID; normal karyotype; MLPA:
2qdel, 15qdup;
Case 5: female (14 years), normal height/weight,
microcephaly, dysmorphic face, proximal 4-5th toe, mild
ID; normal karyotype; MLPA: 2qdel;
Case 6: female (5 years), normal height/weight, dys-
morphic face, wideset nipples, 5th ﬁnger clinodactyly, joint
hypermobility, umbilical/inguinal hernia, VSD, mild ID;
karyotype: 46,XX/46,XX,t(2,9); MLPA: 2qdel;
Case 7: male (4 years), normal height/weight, dys-
morphic face, short neck, deviated hands with ﬂexed ﬁn-
gers, varus equin foot, umbilical hernia, hypospadias,
undescended testes, moderate ID; karyotype: 46,XY,add2;
MLPA: 2qdel.
Features are illustrated and clinical data are correlated
with the size of the deletion.
In conclusion, we present 7 cases of 2q-del to underline
evocative features, illustrate particular features and discuss
genotype-phenotype correlation.
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Familial Williams-Beuren syndrome: case report and
overview
N. Rumiantsava, N. Rumiantsava, O. Khurs, V. Kulak, O.
Gromyko
Republican Medical Center "Mother and Child", Minsk,
Belarus
Williams-Beuren syndrome (WBS, MIM194050) caused by
7q11.23 deletion manifested by recognizable pattern of
multiply abnormalities with heart malformations high fre-
quency. Inherited WBS cases are extremely rare. We pre-
sented WBS maternal transmission (3 relatives in 3
generations, FISH conﬁrmation) and published cases over-
view focused for cardiac abnormalities spectrum. Proposita
(G1,P1 at 38 weeks, BW= 2390g), 2-years-old boy (W=
10,5kg, L= 82cm, OFC= 46cm, <3p.c.) presented bor-
derline growth delay, microcephaly, muscular hypotonia,
typical facial dysmorphisms, nasolacrimalis canals
obstruction, scoliosis, pyeloectasia, hypospadia, inguinal
hernia. Heart: supravalvular aortic stenosis (SVAoS), pul-
monary stenosis (PS), right pulmonary branch hypoplasia,
foramen oval (FO), bicuspid aortic valve (BAoV), mitral
valve prolapse, regurgitation (MVPR). Prenatally detected
moderate extremities shortness was uncommon feature.
Normal motor and speech development. Mother (BW=
1800g at 36 weeks), ﬁrstly was counseled at age 27 years
manifested a similar facial features, gallbladder polyp,
borderline mentality. Heart: BAoV, MVPR, atrial septal
prolapse. Grandmother (52-years-old) showed intellectual
disability, mild dysmorphisms. Heart: mitral, aortic, tricus-
pid valves regurgitation. Reproduction: G1-miscarriege,
G2-WBS, G3-healthy girl. Both woman presented micro-
cephaly (OFC=51cm), muscle weakness, nephroptosis,
hypertensia, normal growth. We analyzed 15 published
families’ data (33 WBS patients): 15 parents, 18 children.
Maternal transmission detected in 11 reports, including one
prenatal case, two families with 2 and 3 affected siblings.
Cardiac abnormalities detected in 12 families (cases without
echocardiography were excluded). Children (11/13 cases)
presented SVAoS/AoS (4/11), SVAoS+ PS (3/11), PS (2/
11), FO (1), MVPR (1). Parents (3/13) showed PS (1),
MVPR (1), mitral valve insufﬁciency (1). Intrafamilial
variability for heart defects, facial dysmorphisms, growth/
mental delay and malformations was found.
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Differential cytogenomic diagnosis in ﬁve patients with
8p23.1 deletion suggesting 22q11.2 deletion syndrome
É. A. Zanardo1, M. M. Montenegro1, D. C. Q. Soares2, M.
S. Grassi2, G. M. Novo-Filho1, F. A. R. Madia1, A. M.
Nascimento1, S. N. Chehimi1, J. G. Damasceno1, R. S.
Honjo2, M. M. Carneiro-Sampaio2, C. A. Kim2, L. D.
Kulikowski1
Laboratório de Citogenômica do Hospital das Clínicas da
Faculdade de Medicina da Universidade de São Paulo, São
Paulo, Brazil, 2Instituto da Criança do Hospital das
Clínicas da Faculdade de Medicina da Universidade de
São Paulo, São Paulo, Brazil
Cytogenomics has become a fast-moving ﬁeld, with
potential to improve the characterization of clinical distin-
guishable phenotypes associated with a common genomic
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region, however, for some cases the establishment of their
correct diagnostic is challenging. We studied ﬁve patients
with initial clinical suspicion of the 22q11.2 deletion syn-
drome using MLPA (multiplex ligation-dependent probe
ampliﬁcation) technique with P064 kit for multiple micro-
deletion syndromes and P250 kit speciﬁc for the DiGeorge
syndrome and others control regions. Unexpected the
molecular analysis revealed the presence of the 8p23.1
deletion involving the genes PPP1R3B, MSRA and GATA4
in all patients. The 22q11.2 and 8p23.1 deletions show
similar clinical signs as cardiac malformations, facial dys-
morphisms and behavioral changes. However the patients
with 8p23.1 deletion may present congenital diaphragmatic
hernia, convulsions, ophthalmic problems, aggressive
behavior with abrupt changes that usually appear in child-
hood, and eczemas. The GATA4 gene is associated to car-
diac abnormalities and the deletion or duplication in this
gene can generate several different cardiac defects with
variable penetrance and expressivity. The MLPA screening
was efﬁcient to accomplish the differential diagnosis, since
it discarded the initial suspicion and also detected the
genomic alteration associated with phenotype, improving
the clinical conduct and allowing the adequate genetic
counseling.
Grants: FAPESP.
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Unraveling the genetic diagnosis in a large cohort of
Adams-Oliver syndrome patients
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Adams-Oliver syndrome (AOS) is a rare developmental
disorder, with an estimated prevalence of one in 225,000
individuals. AOS is typically characterized by aplasia cutis
congenita (ACC) and transverse terminal limb defects.
Additional abnormalities affect the heart, vasculature, eye
and brain. Several genes causing AOS were described over
the past few years. The autosomal dominant form of AOS is
caused by mutations in ARHGAP31, RBPJ, NOTCH1, or
DLL4, while the autosomal recessive form is related or
linked to mutations in DOCK6 or EOGT. Because of the
rarity of this disorder, no reports are available on the dis-
tribution of the frequency of mutations in the currently
known AOS genes in large cohorts. Here, we report on the
molecular diagnostic screening of a cohort of 178 AOS/
ACC patients and families.
The majority of the samples were screened using targeted
next generation resequencing of the six AOS genes. A small
proportion was screened by either whole exome sequencing,
whole genome sequencing or Sanger sequencing. In total,
we identiﬁed 61 mutations, including 20 novel mutations,
providing a molecular cause in 55 of the 178 patients (31%
diagnostic yield). Besides pathogenic mutations, we also
identiﬁed 6 variants of unknown signiﬁcance. NOTCH1
was the major contributor to the phenotype, with mutations
in 11% of the patients, followed by DOCK6 (6%), DLL4
(6%), ARHGAP31 (3%), EOGT (3%) and RBPJ (1%). No
major genotype/phenotype correlations emerged.
In conclusion, the majority of AOS probands remain
unresolved, indicating that additional AOS genes await their
identiﬁcation.
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Fetal akinesia deformation sequence caused by recessive
null mutations of the AGRN gene
I. R. Berry1, H. Lindsay1, C. Sparey2, A. Dobbie3, R.
Charlton1
Leeds Genetics Laboratory, Leeds, United Kingdom, 2Feto-
maternal Medicine, Leeds Teaching Hospitals NHS Trust,
Leeds, United Kingdom, 3Yorkshire Regional Genetics
Service, Leeds, United Kingdom
Fetal akinesia deformation sequence (FADS) is a clinically
and genetically heterogeneous disorder involving reduced
fetal movements, intrauterine growth retardation, and a
range of developmental anomalies including arthryo-
gryposis and skeletal abnormalities. It is usually fatal in
utero. We report a case of a cytogenetically normal fetus
affected with severely reduced fetal movements, pleural and
pericardial effusions, and ﬂexion deformities of the wrists,
hips, knees and elbows apparent on 20-week scan.
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Following termination of pregnancy, reduced muscle bulk
and pterygia were noted on post-mortem examination.
Clinical exome sequencing identiﬁed a homozygous fra-
meshift mutation (LRG_198t1:c.4792_4799del) in the
AGRN gene. AGRN encodes agrin, a synaptic regulator
known to stimulate phosphorylation of MuSK receptors,
thereby facilitating the formation and stabilisation of the
acetylcholine receptor complex at the postsynapse of neu-
romuscular junctions (NMJ). Hypomorphic (largely mis-
sense) mutations in agrin and other NMJ proteins have been
shown to cause a related, milder phenotype, congenital
myasthenic syndrome, however, this is the ﬁrst report of
null mutation in this gene causing FADS. Mutations in
genes encoding other proteins of this complex (DOK7,
MUSK, RAPSN) have been associated with this disorder,
and a knockout mouse model demonstrates an analogous
lethal phenotype showing severe abnormalities of synaptic
differentiation and fetal akinesia.
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Gene discovery by Array- Comparative Genomic
Hybridization
G. Ogur, U. Abur, E. Altundağ, H. Mutlu Albayrak, A.
Sanrı, H. Y. Yalcın, O. S. Akar, H. S. Aymelek, Ç. Dogan
Ondokuz Mayıs University Medical Faculty Department of
Genetics, Samsun, Turkey
INTRODUCTION:Array-ComparativeGenomicHy-
bridization(aCGH) is designed to detect well-characterized
microdeletion/microduplication syndromes, unbalanced
chromosomal-rearrangements. It serves as a powerful
diagnostic tool in chromosomal diseases. Recently the
technique has also been proven to be a method of gene
discovery.Here we report 5 cases of independent Mono-
genicDisorders detected by a-CGH analysis. PATIENTS:
Y.B.E.:A male patient with signs of CysticFibrosis with
additional dysmorphism/mental retardation. CFTR gene
mutation screening by reverse-hybridization and Sanger-
Sequencing failed due to unampliﬁed PCR products. aCGH
revealed 100kb homozygous deletion on chromosome
7q31.2 encompassing theCFTR gene locus.E.T.:A female
patient with clinical signs of CysticFibrosisDisease and
mild-retardation. CFTR gene mutation screening by
reverse-hybridization and SangerSequencing failed due to
unampliﬁed-PCR products. aCGH analysis revealed a 78 kb
homozygousDeletion on chromosome7q31.2 encompassing
the CFTR-gene locus.O.D.:A male patient with Con-
genitalAdrenalHypoplasia, DMD and
GlycerolKinaseDeﬁciency. ArrayCGH analysis revealed a
4.8MB deletion on chromosome Xp21.1-21.2 region
encompassing the Xp21.1DeletionSyndrome gene locus.I.
P.:A 6-month old-male-patient with severe hypotonia.
Follow up impressed ﬁndings of InfantileParkinsonism.
aCGH showed 7 kb homozygous deletion encompassing the
SLC6A3 gene on 5p15.33. DNA-sequencing of SLC6A3
gene was normal except exon-4 which was not ampliﬁed. Z.
V.:A female patient with genital ambiguity and clinical
signs of CongenitalAdrenalHyperplasia(CAH), 21-
hydoxylaseDeﬁciency with additional dysmorphism,
mental-retardation. CYP21A2 gene mutation-screening by
reverse hybridization method failed to amplify PCR pro-
ducts. aCGH revealed a 2.7Mb deletion on chromo-
some6p21.32 encompassing the CYP21A2gene locus.
DISCUSSION:Array-CGH is a powerful disease gene
identiﬁcation strategy. This strategy is most likely to be
successful in patients with a monogenic condition in com-
bination with mental-retardation or in patients with two or
more unrelated genetic conditions.
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Hydrocephalus due to multifocal atresia-forking of the
ependyma is caused by mutations in the MPDZ gene
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Introduction: Congenital hydrocephalus is either syn-
dromic or non-syndromic, and in the latter, no cause is
found in more than half of the patients. In patients with
isolated hydrocephalus, L1CAM mutations represent the
most common aetiology. In the last years, mutations have
been reported in the CCDC88C gene, which cause hydro-
cephalus with mental retardation. A founder mutation has
also been reported in the MPDZ gene in foetuses presenting
massive hydrocephalus, but the neuropathology remained
unknown.
Materials and Methods: We sequenced the MPDZ gene
by targeted NGS sequencing and detailed the neuropatho-
logical data in mutated cases.
Results: We describe here three novel homozygous null
mutations in the MPDZ gene in foetuses whose post-
mortem examination has revealed a homogeneous pheno-
type characterized by multifocal atresia-forking foci along
the aqueduct of Sylvius, the third and fourth ventricles as
well as the central canal of the medulla, with immature cell
accumulation in the vicinity of ependymal lining, probably
detached from the ventricular zone.
Conclusions: MPDZ also named MUPP1 is an essential
component of tight junctions which are expressed from
early brain development in the choroid plexuses and epen-
dyma. Alterations in the formation of tight junctions within
the ependyma very likely account for the lesions observed
and highlight for the ﬁrst time that primary atresia-forking
of the ventricular system is genetically determined in
humans. Therefore, MPDZ sequencing should be performed
when neuropathological examination reveals atresia-forking
of the aqueduct of Sylvius, of the third and fourth ventricles
and of the central canal of the medulla.
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Aymé-Gripp syndrome. Case report and new mutation in
MAF
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Introduction Mutations impairing the GSK3-mediated MAF
phosphorylation cause a syndrome characterized by mental
retardation (MR), cataracts, sensorineural deafness, bra-
chycephaly, ﬂat facial appearance and short stature, also
known as Aymé-Gripp syndrome and delineated by Niceta
et al (2015). We report a patient with phenotype suggestive
of a MAF-related disorder, whose molecular studies showed
a novel mutation in MAF.
Materials and Methods: A 10 years-old boy was eval-
uated for sensorineural hearing loss and dysmorphic fea-
tures. He was the only child of healthy non-consanguineous
parents. Antecedents of bilateral cryptorchidism and ingu-
inal hernia that were surgically repaired. Sensorineural
deafness was detected at 3 years because of speech delay. A
cochlear implantation was performed at 4 years of age. At
examination his weight and height were below 3rd percentile
and his occipito-frontal circumference was over 50th per-
centile. He had a ﬂat midface, hypertelorism, short nasal tip,
small mouth, ﬁne lips, brachycephaly, low-set ears and nail
dystrophy. An autistic spectrum disorder and mild MR was
diagnosed.
Radiological study showed nasal bones hypoplasia.
CGH-Array and sequencing of COL2A1, COL11A1,
COL11A2 (Stickler Syndrome) were negative.
Results: In exon 1 of the MAF gene a novel c.170C > T
transition that predicts a p.Ser57Phe was detected. Both
parents were negative for the mutation. All in silico pre-
dictors indicated this change as probably pathogenic.
Conclusion: We describe a patient with Aymé-Gripp
syndrome (OMIM:601088) due to a novel mutation in
MAF. Our patient showed a clinical phenotype that overlaps
with a patient originally described by Fine and Lubinsky in
1983.
F. Lopez-Grondona: None. S. Boronat: None. I.
Valenzuela: None. A. Cueto-Gonzalez: None. A. Novoa-
Correa: None. T. Vendrell: None. P. Fernandez-Alvarez:
None. M. Borregan-Prats: None. L. Martinez-Ribot:
None. E. Tizzano: None.
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Baraitser-Winter syndrome: two novel mutations of the
ACTB gene
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A. Sandestig1, A. Green1, H. Vogt1, J. Wahlström1, A.
Pepler2, K. Ellnebo1, M. Stefanova1
University Hospital Linköping, Linköping, Sweden,
2Humangenetik Tübingen, Tübingen, Germany
The ACTB gene encodes one of six different actin proteins,
beta (β)-actin. Heterozygous mutations in ACTB have been
identiﬁed in patients with Baraitser-Winter syndrome
(BWS), a recognizable entity, characterized by intellectual
disability, distinctive facial features, bilateral ptosis, ocular
coloboma, short stature, and pachygyria. We have per-
formed exome sequencing analysis on two unrelated
patients, a seven-year-old boy and a four-year-old girl, both
with unclear genetic condition and found two different
novel de-novo missense ACTB mutations, c.208C>G; p.
Pro70Ala and c.511C>T; p.Leu171Phe. Both mutations lay
in a highly conserved site of the ACTB gene and are pos-
sibly involved with subunit interactions near the poly-
merization interface. While the boy presented with a typical
facial appearance, the girl showed facial features difﬁcult to
recognize as a BWS gestalt. Both patients showed mild
intellectual disability and normal growth parameters. The
boy presented shortly after birth with a ventricular septal
defect which closed spontaneously. Brain MRI revealed a
low-grade Chiari 1 malformation. The dysmorphic features
include hypertelorism, epicanthus, prominent nasal bridge,
mild ptosis, anteverted nares, smooth philtrum, thin upper
lip, small ears, broad hands, short ﬁngers, single palmar
crease, multiple café-au-lait spots, low-set nipples and an
overriding scrotum. The girl presented with prenatal extra-
systolia, diagnosed after birth as ventricular arrhythmia as
well as with thrombocytopenia. Additionally, she showed
deeply-set-eyes, mid-face hypoplasia, broad nose, micro-
grathia, isolated cleft palate, dysplastic ears, long slender
ﬁngers, astigmatism, hyperopia, mild grey-matter heteropia
and PVL.The phenotypical spectrum of ACTB mutations is
very broad and may not necessarily be recognized as BWS.
A. Sandestig: None. A. Green: None. H. Vogt: None.
J. Wahlström: None. A. Pepler: C. Other Research Sup-
port (supplies, equipment, receipt of drugs or other in-kind
support); Modest; Humangenetik Tübingen. K. Ellnebo:
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BBS10 frameshift mutation in a turkish girl with bardet
biedl syndrome
M. A. Soylemez, B. B. Geckinli, K. Delil, E. Ates, A.
Turkyılmaz, M. Avsar, G. Girgin, P. Ata, A. Arman, i.
Guney
Marmara University, School of Medicine, Istanbul, Turkey
Introduction: Bardet-Biedl syndrome (BBS) is an auto-
somal recessive disorder characterized by retinitis pigmen-
tosa, rod-cone dystrophy, turuncal obesity, postaxial
polydactyly, cognitive impairment, renal dysfunction and
hypogonadism. BBS is a deﬁned ciliopathy notable for
extensive allelic and genetic heterogeneity and oligogenic
inheritance. The most common mutations are in genes
BBS1, BBS2 and BBS10. Case: Our patient is a 2 year-old
girl born at term with normal physical parameters to con-
sanguineous parents. Postnatally she was hypotonic. In her
physical examination, length was 78 cm (<3P), weight 14
kg (90–97P), and head circumference 47 cm (25P). Her
dysmorphic features were a broad face, narrow forehead,
hypertelorism, narrow palpebral ﬁssures, mild synophrys,
dry rough hair, long eyelashes, broad and depressed nasal
root, broad nasal ridge, long and smooth philtrum, small
mouth, thin upper vermillion, small ears, microdontia, short
neck, atypical palmar crease, turuncal obesity, postaxial
polydactyly of hands and feet and pes valgus. Her eye
examination showed retinal pigment epithelial degenera-
tion. Her pelvic and renal ultrasonography, echocardio-
graphy and cranial MRI were normal. Her high resolution
banded karyotype was normal. Method: BBS1, BBS2 and
BBS10 genes were sequenced via Sanger sequencing.
Results: We found homozygous c.270_271insT (p.
Cys91Leufs*5) mutation in BBS10 in exon 2 resulting in a
highly truncated protein. Her parents are heterozygous for
the same mutation. Conclusions: Our patient has typical
clinical features of BBS. The mutation found is the most
common mutation in the BBS10 gene. We reported our
patient to contribute to genotype-phenotype correlations in
BBS.
M.A. Soylemez: None. B.B. Geckinli: None. K. Delil:
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BCOR mutation a boy with multiple anomalies and large
eyeglobes
P. J. Zwijnenburg, J. M. Weiss, H. J. Meijers-Heijboer, Q.
Waisﬁsz
University medical center, Amsterdam, Netherlands
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A one-month-old boy, second child of non-consanguineous
parents, was admitted because of respiratory insufﬁciency.
He was born term with normal birth weight, length and
OFC. On cardiac ultrasound, a VSD, ASD, PDA, persistent
left vena cava and non-compaction left ventricle were
diagnosed. He suffers from bilateral grade 4–5 vesicour-
eteral reﬂux. The eyespecialist noted high myopia (-15)
with large globes, embryotoxon posterior and nystagmus.
His motor milestones are severely delayed and he does not
speak. From the age of 1 years he has seizures. SNP array,
FISH-analysis (Pallister Kilian syndrome) and analysis of
CHD7, ASXL1 and SETBP1 was normal. WES analysis
revealed a hemizygous variant in the BCOR (BCL-6 cor-
epressor) -gene: NM_001123385.1:c.4741+1G>A p.(?).
This variant is located within the donor splice site of intron
12, most likely resulting in aberrant splicing. His healthy
mother is a carrier and showed 100% skewed X-inactivation
upon analysis. The variant was not present in both maternal
grandparents. We consider this variant in BCOR likely
causative. To our knowledge, this is the ﬁrst report on a
BCOR variant in BCOR in a child without microphtalmia,
but with high myopia and large eyeglobes. The organs
involved in the phenotype in this boy correspond with
oculo-facio-cardio-dental syndrome and Lenz micro-
phtalmia . However, his phenotype is different to the phe-
notype of those two disorders and most described patients
with oculo-facio-cardio-dental syndrome are females with
skewed X-inactivation. This case illustrates a broader phe-
notypic spectrum of oculo-facio-cardio-dental syndrome/
Lenz microphtalmia and that female carriers may be
asymptomatic due to skewed X-inactivation
P.J. Zwijnenburg: None. J.M. Weiss: None. H.J.
Meijers-Heijboer: None. Q. Waisﬁsz: None.
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Beckwith-Wiedemann Syndrome Caused by Non-Mosaic
Uniparental Disomy of the Complete Chromosome 11
L. S. Penney1, E. Aberg2, K. Harrison1, J. Brock1, C.
Fernandez1, J. Frazer1
1Dalhousie University, Halifax, NS, Canada, 2IWK Health
Centre, Halifax, NS, Canada
Beckwith-Wiedemann Syndrome (BWS) is an overgrowth
disorder involving imprinted genes on chromosome
11p15.5. Clinical features are varied and can include mac-
roglossia, somatic overgrowth, abdominal wall defects and
neonatal hypoglycemia. A concern for infants and children
with BWS is the predisposition to develop embryonal
tumors which is estimated at about 7.5%. There are
numerous mechanisms that can result in BWS, including
mosaic paternal uniparental disomy (UPD) of chromosome
11p15.5 which accounts for about 20% of cases. Paternal
UPD involving more than just the short arm of chromosome
11 is very uncommon and non-mosaicism for paternal UPD
11, to our knowledge, has not been reported and is hypo-
thesized to be lethal. Here we present on the prenatal
diagnosis of a female fetus with non-mosaic UPD of the
entirety of chromosome 11. Prenatally there was macro-
glossia and an abdominal circumference and kidneys greater
than the 95th percentile. SNP-based microarray on DNA
from amniocytes and DNA from peripheral blood after birth
identiﬁed non-mosaic paternal UPD spanning the entire
length of chromosome 11. SNP-based array on DNA from
placenta identiﬁed paternal UPD for the entire length of
chromosome 11 in a mosaic state. She was born at 31 weeks
6 days gestation with nephromegaly and hepatomegaly, but
no detectable Wilm’s tumor or hepatoblastoma. Her clinical
course was complicated by respiratory difﬁculties, a bowel
perforation, a patent ductus arteriosis, persistent hypogly-
cemia, and sepsis. At 4.5 months of age, hepatoblastoma
was detected and she died at 7 months due to respiratory
difﬁculties caused by the severe hepatomegaly.
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Cantu syndrome caused by a novel heterozygous ABCC9
mutation: Description of a Malaysian boy with predominant
cardiorespiratory features
W. P. Ong1, H. Y. Leong1, M. A. M. Haniffa1, H. B.
Chew1, G. S. Ch'ng1, L. H. Ngu1, A. Kassim2, N. M.
Zainudin2, L. C. Hung2, K. Duran3, G. van Haaften3, W.
T. Keng1
Department of Genetics, Hospital Kuala Lumpur, Kuala
Lumpur, Malaysia, 2Department of Paediatrics, Institute of
Paediatrics, Hospital Kuala Lumpur, Kuala Lumpur,
Malaysia, 3Department of Medical Genetics, Center for
Molecular Medicine, UMC Utrecht, Netherlands
Introduction: Cantu syndrome, a rare autosomal dominant
disorder characterised by congenital hypertrichosis, dis-
tinctive facies, osteochondrodysplasia, cardiomegaly and
cardiovascular abnormalities, is largely caused by hetero-
zygous mutations in the ABCC9 gene, and rarer in KCNJ8.
Case Report: We present a 3 year-old boy, ﬁrst child of a
consanguineous couple. Born premature at 32weeks, he had
a large PDA, inguinal hernia and undescended testes at
birth. His infantile period was stormy, with frequent severe
respiratory infections and hyperactive airways. Clinically,
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he had relative macrocephaly, hypertrichosis, thick scalp
hair, coarse facies, long eyelashes, ﬂat nasal bridge, full
lips, and also tachypnoea, pectus carinatum, mild hypotonia
and motor delay.
Chest radiographs showed cardiomegaly and broad ribs.
Echocardiogram demonstrated a small PDA, hypertrophy of
both ventricles and biventricular diastolic dysfunction. CT
thorax revealed features of pulmonary hypertension and
bronchiolitis obliterans. His immune screen was normal.
Molecular testing of ABCC9 gene identiﬁed a novel de
novo heterozygous missense Q481H mutation in exon 9.
His clinical course was challenging with very labile
respiratory reserve and prolonged oxygen dependency.
Frequent infections associated with immune dysfunction
have been reported in Cantu syndrome but none so severe
as to result in bronchiolitis obliterans. Another unique fea-
ture is his biventricular diastolic dysfunction as cardiac
function in prior reports has always been normal, thus
potentially expanding the phenotypic spectrum.
Conclusion: We wish to highlight the unique cardior-
espiratory complications and the challenges managing
them. Molecular conﬁrmation directs accurate genetic
counselling and vigilance for other potential complications
like conduction defects, vascular abnormalities, scoliosis
and lymphoedema.
W.P. Ong: None. H.Y. Leong: None.M.A.M. Haniffa:
None. H.B. Chew: None. G.S. Ch'ng: None. L.H. Ngu:
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Cat-Eye Syndrome: Phenotype and Cytogenetic analyses of
a cohort of 44 patients from an international collaborative
study
G. Jedraszak1,2, F. Jobic1, N. Celton1, T. Dery1, M.
Gallet1,2, M. Mathieu-Dramard1, H. Copin1,2, T. Liehr3, G.
Morin1
1University Hospital of Amiens, Amiens, France, 2Univer-
sité de Picardie Jules Verne, Amiens, France, 3Institut für
Humangenetik, Jena, Germany
Cat Eye Syndrome (CES) is a rare genetic disease. It has
been observed that most patients diagnosed with CES carry
a small supernumerary bisatellited marker chromosome
(sSMC), which results in partial tetrasomy of 22p-22q11.21.
Individuals with CES are characterized by three main
clinical features: preauricular pits and/or tags, anal atresia,
and iris coloboma. However, clinical features reveal an
extreme phenotypic variability, including variable con-
genital heart and kidney defects, skeletal abnormalities,
growth delay, associated or not with variable mental
deﬁciency.
This work studies and compares to the literature data 44
patients who carry a cytogenetically proved CES. This is the
largest cohort of CES patients reported to date (excluding
meta-analyses).
On phenotypic level, we conﬁrm the high frequency of
pre-auricular anomalies (84%). But anorectal anomalies
(43%) and iris coloboma (35%) are less frequent than
expected. Furthermore, 35% of patients presented with only
one of the three major sign, and 10% did not present any of
them. Heart defect (46%) and intellectual deﬁciency (46%)
Summary of clinical features of patients with 6q22.1-q22.31 deletions
Patient 1 Patient 2 Patient 3 Patient 4
Age, sex 5 years., male 4 years., male 1 month, female 3 months, female
Developmental
delay
+ + + −
Seizures Only epileptiform activity on
EEG
+ − −
Craniosynostosis − − + +
Brain
malformation
− + − +
Dysmorphic facial
features
+ + + +
Size, Mb 9,8 7,9 13,9 11,9
Molecular
karyotype
arr[hg19] 6q22.1q22.31
(114650304_124411267)x1
arr[hg19] 6q22.1q22.31
(117939083_125843984)x1
arr[hg19] 6q21q22.31
(109428325_123335803)x1
arr[hg19] 6q21q22.31
(113684116_125569047)x1
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are the other most frequent features. Other recurrent
reported anomalies are urogenital anomalies (30%), hor-
monal deﬁciency (31%), and growth delay (19%).
On cytogenetic level we highlighted high prevalence of
mosaic cases (37%). We also highlight the unexpected high
prevalence of parental transmission of sSMC (35%),
whereas only 5 cases have been reported so far. Most often,
the transmitting parent is pauci(a)-symptomatic and carries
the mosaic marker at a very low rate (<10%) making it
difﬁcult to detect without FISH analysis.
These data could signiﬁcantly modify genetic
counseling.
G. Jedraszak: None. F. Jobic: None. N. Celton: None.
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New clinical features in patients with 6q22.1-q22.31
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I. V. Kanivets1, V. G. Solonichenko2, S. S. Zhilina3, O. B.
Kondakova4, G. E. Rudenskaya5, D. V. Pyankov1, F. A.
Konovalov1, S. A. Korostelev1, A. V. Antonets1
Genomed Ltd., Moscow, Russian Federation, 2Filatov Child
clinical hospital, Moscow, Russian Federation, 3Scientiﬁc
and Practical Centre of Specialized Medical Care for
Children, Moscow, Russian Federation, 4Scientiﬁc and
Practical Center for Child psychoneurology, Moscow,
Russian Federation, 5FSBI "Research Centre for Medical
Genetics", Moscow, Russian Federation
Chromosomal microarray analysis (CMA) of 3299 Russian
patients with congenital malformations, developmental
delay and distinctive facial features detected novel patho-
genic copy number variations (CNVs), unclassiﬁed in
OMIM database, in 4,9% cases. Here we describe 4 dele-
tions overlapping 6q22.1-q22.31 region. Size of deletions
varied from 7,9 Mb to 13,9 Mb. The smallest region of
overlap is 5,4 Mb and includes 16 genes. Clinical mani-
festations included developmental delay (3/4) and brain
malformations (2/4). All patients had dysmorphic facial
features. Unlike the previously described patients with
6q22.1-q22.31 deletions, 2 patients had craniosynostosis,
whereas only 1 patient had seizures and another one had
only epileptiform activity on EEG. Deletions of 6q22.1-
q22.31 region were previously associated with variable
clinical features. We suggest that craniosynostosis is a part
of this wide clinical spectrum.
I.V. Kanivets: None. V.G. Solonichenko: None. S.S.
Zhilina: None. O.B. Kondakova: None. G.E.
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Deletion, duplication and ring of chromosome 13 due to
different rearrangements and implication to phenotype
F. T. Bellucco1, R. S. Guilherme1, H. R. de Oliveira-
Júnior1, S. Bragagnolo1, M. A. Ramos1, A. B. Perez1, C.
A. Kim2, E. M. Bertollo3, D. Moretti-Ferreira4, V. A.
Meloni1, M. I. Melaragno1
1Universidade Federal de São Paulo, São Paulo, Brazil,
2Universidade de São Paulo, São Paulo, Brazil, 3Faculdade
de Medicina de São José do Rio Preto, São José do Rio
Preto, Brazil, 4Universidade Estadual de São Paulo,
Botucatu, Brazil
Patients with duplication, deletion, and ring chromosome 13
may present overlap of clinical characteristics making dif-
ﬁcult to delineate a speciﬁc phenotype for each group,
mainly due to the variable size of the deleted segments. We
describe eight patients with different abnormalities invol-
ving chromosome 13 characterized by G-banding kar-
yotype, FISH, and array techniques. Cytogenomic analysis
revealed: three patients with ring chromosome 13, three
patients with interstitial, and one with terminal 13q deletion,
and one with concomitant 13q deletion and duplication.
Array revealed the breakpoints and genomic coordinates in
all cases. FISH with BAC probes revealed a duplicated and
inverted segment in one of the ring chromosomes. All
patients showed neuropsychomotor development delay, but
only one had deletion of the ZIC2 gene (13q32.3), impor-
tant for normal development of the forebrain. Among the
patients who had deletion including 13q32.2-q33.2, a region
associated to Dandy-Walker malformation, only one pre-
sented this feature. The ARHGEF7 gene, which is mapped
in 13q34 and plays a role in the development of human
cerebral cortex, is duplicated in one patient and deleted in
four patients who present microcephaly and neuropsycho-
motor development delay. Our data suggest that the region
responsible for genital abnormalities in male is between
104.2 Mb (13q31.1) and 111.5 Mb (13q34) and includes the
EFNB2 gene. This work shows the relevance of the study of
chromosome rearrangements with similar genome imbal-
ances for a better cytogenetic-phenotype correlation, help-
ing the diagnosis, prognosis, and genetic counseling.
Financial Support: FAPESP, Brazil.
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DOCK6: novel gene involved in ciliopathies
S. Castro-Sánchez1,2, M. Álvarez-Satta1,2, D. Valverde1,2
Department of Biochemistry, Genetics and Immunology,
Faculty of Biology, University of Vigo, Vigo, Spain, 2Rare
Diseases & Pediatric Medicine Group, Instituto de
Investigación Sanitaria Galicia Sur (IISGS), SERGAS-
UVIGO., Vigo, Spain
Introduction: Molecular diagnosis of ciliopathies becomes
complicated due to the high genetic and phenotypic het-
erogeneity associated with these syndromes, it is therefore
necessary to use the variety of genetic techniques currently
available. The objective of this study was to identify the
genetic defect responsible for the pathology of a con-
sanguineous family with BBS-like phenotype, after dis-
carding mutations in predominant BBS genes.
Materials and Methods: We performed whole exome
sequencing (WES) followed by data ﬁltering. Given the
consanguinity of the family, we also carried out homo-
zygosity mapping. Data analysis of both approaches led us
to one candidate gene, which was silenced by siRNA
transfection to perform immunoﬂuorescence assays to
check possible ciliary defects.
Results: Homozygosity mapping revealed several LOH
regions, one of which contained DOCK6 gene. WES data
ﬁltering led us to the homozygous variant c.1289G>A (p.
(Arg430His)), located in the same gene and classiﬁed as
potentially pathogenic by several prediction tools. This
variant, conﬁrmed by Sanger, segregates within the family,
conﬁrming the autosomal recessive inheritance. Given its
possible relation to primary cilium through actin cytoske-
leton, gene expression was suppressed. Immunoﬂuoresence
assays allowed us to conﬁrm F-actin destabilization and,
surprisingly, detect nearly 40–50% of defective primary
cilia.
Conclusions: The combination of WES and homo-
zygosity mapping was useful for the molecular diagnosis of
this family and the identiﬁcation of a novel candidate gene
which seems to be related to defects in primary cilia
structure. Further functional studies will clarify its role in
cilia function.
FPU fellowships: 13/01853 and 12/01442. ISCIII grant:
PI15/00049.
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Extending the phenotype in nephronophtisis-related cilio-
pathies : severe fetal presentation with homozygous ANKS6
mutations
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Saunier4, A. Cazorla2, T. Attié-Bitach3,4,5, F. Guimiot2,6
1Service de génétique, CHU de Rouen, Centre Normand de
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France, 2Department of developmental biology, Institut
National de la Santé et de la Recherche Médicale
(INSERM) UMR1141, Robert Debré university hospital,,
Paris, France, 3Service d’Histologie-Embryolgie-Cytgéné-
tique, Hôpital Necker-Enfants Malades, APHP, Paris,
France, 4Institut National de la Santé et de la Recherche
Médicale (INSERM) UMR 1163, Institut Imagine, Paris,
France, 5Paris Descartes-Sorbonne Paris Cité University,
Institut Imagine, Paris, France, 6Paris Diderot University,
Paris, France
Ciliopathies are a large group of congenital diseases related
to ciliary dysfunction. These are highly heterogeneous in
features and severity with substantial phenotype and geno-
type overlap.
We report here the ﬁrst pregnancy of a young con-
sanguineous couple without peculiar medical history. First
trimester prenatal ultrasound found a small chest, short and
curved femora, hyperechogenic and enlarged kidneys, oli-
gohydramnios, absent corpus callosum and congenital heart
malformation. Pregnancy was terminated at 18+6 WG. At
most-mortem examination, the male fetus had normal size
and body weight, a situs inversus totalis with outﬂow tract
anomaly, large kidneys with interstitial ﬁbrosis and wide-
spread cysts, voluminous and ﬁbrotic pancreas, hepatic
ﬁbrosis and ductal proliferation. Fetal X-ray showed split
lumbar vertebrae and curved long bones.
Fetal DNA was analysed using a ciliary genes targeteted
panel with next-generation-sequencing and allowed to
identify a homozygous frameshift variant in ANKS6 gene.
ANKS6 mutations were ﬁrst described in nephro-
nophthisis cohorts. Almost all nephronophthisis related
genes have already been identiﬁed in syndromic cilio-
pathies, such as Joubert, Sensenbrenner, Jeune or Meckel
syndrome. ANKS6 protein is localized at the basal segment
of the cilia and interacts with NEK8, NPHP3 and INVS. To
date, 18 patients with ANKS6 mutations have already been
described in patients with cystic kidney disease due to
nephronophthisis with variable phenotype and severity.
Patients with loss of function mutations seem to have more
severe phenotype. Here we describe the most severe form of
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ANKS6-related diseases, reﬁning the far end of the spec-
trum by adding brain, skeletal and pancreatic anomalies.
A. Tessier: None. L. Boutaud: None. S. Khung: None.
N. Elkhartouﬁ: None. S. Saunier: None. A. Cazorla:
None. T. Attié-Bitach: None. F. Guimiot: None.
P11.024D
Comprehensive genetic analysis of patients with (non)-
syndromic cleft lip with or without cleft palate
M. J. Koudijs, C. C. Breugem, A. B. Mink van der Molen,
M. J. H. van den Boogaard, J. K. Ploos van Amstel
University Medical Center Utrecht, Utrecht, Netherlands
Non-syndromic cleft lip with or without cleft palate (nsCL/
P) is a common congenital malformation caused by both
genetic- and environmental changes. The underlying
genetic causes of isolated forms of nsCL/P is restricted to a
limited set of genes but primarily by common risk variants,
and is only explaining a fraction of patients with nsCL/P.
On the other hand, CL/P occurs frequently as part of a
syndromic spectrum of congenital abnormalities. Over >200
genes are associated with syndromes for which CL/P is one
of the representations, but comprehensive genetic analysis
of these patients is challenging since incomplete penetrance
and variable expressivity has been described for a sub-
stantial subset of these genes. We performed routine diag-
nostic testing for a set of genes associated with (non-)
syndromic forms of CL/P in a cohort of >40 patients with a
broad spectrum of phenotypes. We identiﬁed (likely)
pathogenic mutations in the LRP4, IRF6, MSX1 and
SMAD4 genes conﬁrming the clinical diagnosis. In 1
family, a paternally inherited SIX3 mutation resulted in a
variable morphological phenotype in two siblings, where
the father did not show apparent abnormalities. Mutations in
SIX3 are associated with autosomal dominant inherited
holoprosencephaly type 2. MRI analysis of the brain did
conﬁrm structural abnormalities in the index patient, sup-
porting the assumption that a mutation in the SIX3 gene is
underlying to the clinical phenotype. These preliminary
results suggest that mutations in genes associated with
syndromic forms of CL/P can be clinically represented as
nsCL/P, underlining the importance of comprehensive
genetic testing.
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van der Molen: None. M.J.H. van den Boogaard: None.
J.K. Ploos van Amstel: None.
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Exome sequencing reveals a recessive mechanism involving
interacting genes in persistent cloaca
M. Garcia-Barcelo1, Hsu1, Yeung1, Wong1, Yu1, Ngo2,
Quang2, So1, Li1, Sham1, Tam1
1The University of Hong Kong, Hong Kong, Hong Kong,
2National Hospital of Pediatrics, Hanoi, Viet Nam
Aim of the study: Persistent Cloaca (PC) is characterized
by the convergence of the rectum, vagina, and urethra into a
single common channel as a result of septational anomalies
during development. PC is rare (1/20,000 live births),
occurs sporadically and exclusively in females. The causes
of this developmental failure are not known, yet there is
strong evidence for a genetic component. The aim of this
study is to investigate the genetic etiology of PC patients.
Methods: Whole exome sequencing was conducted on 21
PC trios following the standard protocol. Main Results:
Two novel and damaging de novo mutations in caudal type
homeobox 2 gene (CDX2) were found in two PC patients.
CDX2 is a transcription factor that deﬁnes urothelial dif-
ferentiation. Different rare damaging mutations in interact-
ing genes relevant for caudal region development such as
laminin, nidogen and integrin were found in several
patients. Similarly, mutations in the gene pair GPRASP1
and LRP2 were recurrently identiﬁed. GPRASP1 and LRP2
directly interact with members of the sonic hedgehog (SHH)
and bone morphogenetic protein (BMP) pathways, which
are essential in the development of the caudal region.
Overall, the mutated genes were over-represented in the
extracellular matrix and basement membrane gene sets
(Gene enrichment test p<4.58×10−10). Conclusion: 1: Our
data supports a strong genetic basis for PC. 2: PC is het-
erogeneous requiring mutations in interacting genes to give
rise to the anomaly : different mutated genes in different
patients. 3: PC is likely to be a recessively inherited dis-
order. Grant acknowledgement: RGC HKU 778213
M. Garcia-Barcelo: None. M. Garcia-Barcelo Hsu:
None. M. Garcia-Barcelo Hsu Yeung: None. M. Garcia-
Barcelo Hsu Yeung Wong: None. M. Garcia-Barcelo
Hsu Yeung Wong Yu: None. M. Garcia-Barcelo Hsu
Yeung Wong Yu Ngo: None. M. Garcia-Barcelo Hsu
Yeung Wong Yu Ngo Quang: None. M. Garcia-Barcelo
Hsu Yeung Wong Yu Ngo Quang So: None. M. Garcia-
Barcelo Hsu Yeung Wong Yu Ngo Quang So Li: None.
M. Garcia-Barcelo Hsu Yeung Wong Yu Ngo Quang So
Li Sham: None. M. Garcia-Barcelo Hsu Yeung Wong
Yu Ngo Quang So Li Sham Tam: None.
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A case of familial Cofﬁn - Lowry syndrome associated with
left ventricular noncompaction cardiomyopathy
D. Avdjieva-Tzavella, H. Kathom, R. Tincheva
Department of Clinical Genetics, University Pediatrics
Hospital, Medical University, Soﬁa, Bulgaria
Introduction: Cofﬁn-Lowry syndrome (CLS) is a rare X-
linked disorder characterised by mental and growth retar-
dation, distinct facial dysmorphism, short and broad hands,
skeletal and cardiac anomalies in men Female carriers are
normal or only mildly affected. CLS is caused by mutations
in the RPS6KA3 gene located at Xp22.2 which encodes
RSK2, a growth-factor-regulated protein kinase.
Materials and Methods: We report a family with CLS
with eight patients in two generations. The patients in this
family, a mother and her seven children - four males and
three females, all except one had severe mental retardation
with the distinct clinical features of CLS: short stature,
prominent forehead, hypertelorism, down-slanting palpebral
ﬁssures, a ﬂat nasal bridge, a wide mouth with full lips,
short hands with stubby, tapering ﬁngers, kyphosis and/or
scoliosis.Two of the male siblings had a left ventricular
noncompaction (LVNC) with a restrictive pattern, as
documented by echocardiography. The oldest sister pre-
sented with a mild facial dysmorphism and a normal
intelligence. Mutation screening was performed on the
RPS6KA3 gene in this family.
Results: All patients tested (the mother and her seven
children) had the same pathogenic mutation in the
RPS6KA3 gene - c.1672C>T (R558X).
Conclusions: This report conﬁrms that some CLS
females may present not only mild clinical features such as
facial and digital dysmorphism and learning difﬁculties, but
can have well noticeable CLS symptoms typical for affected
males. This case underlines that patients with CLS should,
be screened for LVNC cardiomyopathy which is a poten-
tially life threatening condition.
D. Avdjieva-Tzavella: None. H. Kathom: None. R.
Tincheva: None.
P11.027C
Different and atypical presentation of Cohen syndrome in
two sisters
H. Kathom, T. N. Delchev, D. Avdjieva-Tzavella, R.
Tincheva
Medical University-Soﬁa, Soﬁa, Bulgaria
Introduction: Cohen syndrome (CS) is a hereditary con-
dition, consisting of obesity, hypotonia, mental retardation,
characteristic craniofacial dysmorphism and abnormalities
of hands and feet. It is transmitted in an autosomal recessive
pattern, with considerable variability of expression. No
genotype-phenotype correlation has been established. CS is
caused by different mutations in the COH1 gene, located at
8q22-q23. This gene encodes a speciﬁc transmembrane
protein which is involved in vesicle-mediated sorting and
transport within the cells.
Clinical case: We report two sisters who were diagnosed
with CS. The elder sister had mental retardation, obesity,
truncal hypotonia, and some of the distinct features of
Cohen syndrome: hypertelorism, prominent central incisors,
coarse hair and thick eyebrows, long eyelashes, wave-
shaped palpebral ﬁssures, broad nasal tip, smooth or short
philtrum, small and narrow hands and feet, with slim ﬁn-
gers. The younger sister had conical teeth, hypertelorism,
and congenital heart defect. Both sisters had short stature,
dolichocephally without microcephally, kyphosis, and
scoliosis.
Results: Both patients are found to be compound het-
erozygotes carrying one point mutation (c.5086C→T), and
deletion of 5 exons (DelEX46–50).
Conclusions: This report conﬁrms the great variability of
phenotypic expression of Cohen syndrome, and the need for
thorough physical examination of these patients. Con-
sidering the possibility of atypical clinical manifestation, the
Cohen syndrome deserves utmost attention and care.
H. Kathom: None. T.N. Delchev: None. D. Avdjieva-
Tzavella: None. R. Tincheva: None.
P11.028D
Copy number variation spectrum in children with combined
congenital heart defects and renal malformations
A. Zlotina1, T. Pervunina1, E. Grekhov1, I. Kozyrev1, A.
Kostareva1,2
Almazov Federal Medical Research Centre, Saint-Peters-
burg, Russian Federation, 2Institute of Translational
Medicine, ITMO University, Saint-Petersburg, Russian
Federation
Introduction: Combined congenital abnormalities of
cardio-vascular system and renal-urinary tract belong to
severe and relatively rare clinical conditions, the genetic
etiology of which is still poorly characterized. In the present
study we evaluated the impact of copy number variations in
30 children with combined heart and kidney structural
defects without additional severe organ manifestations.
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Materials and methods:Molecular-cytogenetic analysis
was performed using array-based comparative genomic
hybridization (array-CGH) with an Agilent 60K platform.
Results: In 2 out of 30 patients, pathogenic microdele-
tions of the same size (~2.47 Mb) were identiﬁed in 22q11.2
region known as DiGeorge/Velocardiofacial locus. Besides,
a newborn with hypoplastic left heart syndrome, mitral
atresia, ventricle sept defect and congenital megaloureter
harbored a microduplication at 15q26.2 region encom-
passing MCTP2 gene. Given that MCTP2 was recently
identiﬁed as a dosage-sensitive gene essential for proper left
ventricular outﬂow tract development, the revealed dupli-
cation seems to be responsible for at least a cardiac com-
ponent of the patient’s phenotype. We also took notice of
genes NNT, DHFR, ZNF649 and NPHP1 within copy
number gains at 5p12, 5q14.1, 19p13.33 and 2q13 regions.
The genes are shown to widely express in heart and kidney
and play important roles during embryogenesis. To assess
the clinical signiﬁcance of these variants unambiguously,
further comprehensive functional studies are required.
Conclusions: Our ﬁndings support the utility of array-
CGH screening of patients with combined structural cardio-
renal malformations for accurate individual diagnosis,
genetic counseling, and new candidate genes identiﬁcation.
This work was supported by the Government of Russian
Federation, Grant 074-U01.
A. Zlotina: None. T. Pervunina: None. E. Grekhov:
None. I. Kozyrev: None. A. Kostareva: None.
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A new recognizable recessive syndrome with distinct dys-
morphism, lymphedema and sensorineural hearing loss
caused by Carboxypeptidase D mutations
H. Kayserili1, U. Altunoglu2, S. Laupheimer3, C.
Bonnard3, B. Reversade1,3
1Koç University Schol of Medicine, İstanbul, Turkey,
2Istanbul University Faculty of Medicine, İstanbul, Turkey,
3Institute of Medical Biology, A*STAR, Singapore,
Singapore
Lymphedema is the consequence of inefﬁcient uptake and/
or reduced lymph ﬂow, which leads to the accumulation of
high-protein ﬂuid beneath the skin and chronic swelling of
extremities. Approximately 20 genes of VEGFR3 pathway
have been identiﬁed as responsible for related phenotypes.
We report three individuals from two families with a new
recessive syndrome presenting with a recognizable facial
dysmorphism, sensorineural hearing loss and lymphedema
of the lower limbs. The index patient and her affected
second cousin once-removed showed growth retardation of
prenatal onset, prelingual sensorineural hearing loss, short
feet, narrow hands, and distinct facies; dispersed eyebrows,
upslanting palpebral ﬁssures, prominent nasal bridge and
broad ridge, smooth/long philtrum, thin/inverted vermilion
of the upper lip and short neck. Both had mild intellectual
deﬁcit. After 10 years of age, they developed persisting
lower-limb lymphedema.14-year-old female patient from an
unrelated family, presented with similar distinct dysmorphic
features along with short stature, prelingual sensorineural
hearing loss but had no sign of lymphedema. Whole-exome
sequencing in the ﬁrst family revealed three different
pathogenic mutations segregating with the phenotype,
including a protein-null allele, in CPD gene which encodes
for Carboxypeptidase D. Sequencing CPD gene in the
affected of second family, showed a novel homozygous
CPD mutation. CPD is a circulating protease and to date, no
endogenous substrates for CPD have been identiﬁed.
Patient-derived primary cells and zebraﬁsh knockout ani-
mals will enlighten the pathogenesis of this new syndrome
for the identiﬁcation of potential therapeutic options for
lymphedema.
H. Kayserili: None. U. Altunoglu: None. S. Lauphei-
mer: None. C. Bonnard: None. B. Reversade: None.
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A novel variant of GNAI3 gene in a Japanese girl patient
with malformed ears, microstomia, abnormal tempor-
omandibular joint, and mandibular condyle hypoplasia
Y. Kumiko, N. Morimoto, M. Iso, Y. Kuroki, Y. Matsui, K.
Hayashi, H. Ogata, K. Nakabayashi, K. Okamura, K.
Hata, Y. Matsubara, T. Kaname, Initiative on Rare and
Undiagnosed Diseases in Pediatrics (IRUD-P)
National Center for Child Health and Development, Okura,
Setagaya, Japan
Auriculo-condyularsyndrome (ARCND, OMIM #602483)
is a rare craniofacial disorder involving the ﬁrst and second
pharyngeal arches and is characterized by malformed ears
(question mark ears), prominent cheeks, microstomia,
abnormal temporomandibular joint, and mandibular con-
dyle hypoplasia. The GNAI3, EDN1 or PLCB4 gene has
been reported to be responsible for ARCND. We report a
Japanese girl who was clinically diagnosed as Pierre Robin
syndrome. She underwent tracheostomy due to upper air-
way obstruction. In order to make genetic diagnosis, whole
exome sequencing (WES) analysis was performed in the
patient and her parents using Human All Exon V6 kit
(Agilent) and HiSeq 2500 (illumina).
Then, we found a novel de novo variant of the GNAI3
gene (NM_006496) in the patient, which was also
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conﬁrmed by Sanger sequencing. The variant causes an
amino acid change at the GDP/GTP binding site in the
catalytic domain of GNAI3. Another amino acid change at
the same position has been reported in a Caucasian patient
of ARCND. All three prediction program of functional
affects of variations, SIFT, PolyPhen-2 and Mutation taster,
estimated the amino acid change as damaging. The novel
variant found in the patient might be pathogenic for
ARCND.
Grant references; Japan Agency for Medical Research
and Development (AMED)
Y. Kumiko: None. N. Morimoto: None. M. Iso: None.
Y. Kuroki: None. Y. Matsui: None. K. Hayashi: None. H.
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P11.032D
A novel CTNNB1 mutation in a patient with teratoma and
multiple malformations - expansion of the phenotypic
spectrum and possible new gene for Currarino phenotype
M. Mijovic1, A. Miletic1, J. Ruml Stojanovic1, B. Peterlin2,
A. Maver2, N. Borlja1, B. Dimitrijevic1, M. Lukic1, G.
Cuturilo1,3
1University Children's Hospital, Department of Medical
Genetics, Belgrade, Serbia, 2Clinical Institute of Medical
Genetics, University Medical Centre Ljubljana, Ljubljana,
Slovenia, 3Faculty of Medicine, University of Belgrade,
Belgrade, Serbia
Introduction: We present three-year-old girl with a com-
plex phenotype including severe developmental and growth
delay, microcephaly, anal atresia and the massive teratoma
of pelvis, which inﬁltrates sacrum and bladder. The patient
has undergone several surgical interventions and che-
motherapy due to relapse of the teratoma. She also has
facial dysmorphism including gestalt of primary micro-
cephaly and bilateral mild ptosis. Based on this clinical
presentation we suspected Currarino syndrome possibly
caused by (micro)deletion of 7q containing MNX1 gene.
Materials and Methods: We performed chromosomal
microarray (CGH, Agilent Technologies) and the clinical
exome sequencing (Illumina TruSight One) which targeted
genes related to observed clinical presentation.
Results: Unexpectedly, chromosomal microarray
showed normal result. Subsequently, clinical exome
sequencing showed presence of heterozygous pathogenic
nonsense variant in CTNNB1 gene (c.1876G>T, p.
Glu626X). Pathogenic variants in CTNNB1 gene represent a
known cause of CTNNB1-related mental retardation,
autosomal dominant, 19 (OMIM: 615075). Furthermore,
disruption of the beta-catenin (CTNNB1) signaling pathway
has been implicated in the pathogenesis of anorectal
anomalies, possibly explaining the anal atresia in the
patient. Beta-catenin also functions as the gatekeeper in
differentiation and tumorogenesis in embryonic stem cells
and could possibly play a role in development of teratomas.
Conclusion: CTNNB1-associated teratoma has not been
described in humans so far. If associated with anal atresia
and sacrum abnormalities, Currarino syndrome could be
easily suspected. Thus, we propose germline CTNNB1 gene
mutations as a novel cause of human teratomas and Cur-
rarino syndrome phenotypic spectrum, which could be of
interest for clinical geneticists, as well as further research.
M. Mijovic: None. A. Miletic: None. J. Ruml Stoja-
novic: None. B. Peterlin: None. A. Maver: None. N.
Borlja: None. B. Dimitrijevic: None. M. Lukic: None. G.
Cuturilo: None.
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De novo pure 1q42.11qter duplication syndrome: a case
report
M. Gökoglu1, N. Yurur-Kutlay1, T. Özdemir2, Y. Kutbay2,
D. Torun3
Ankara University School of Medicine Department of
Medical Genetics, Ankara, Turkey, 2Department of Medical
Genetics, Izmir Tepecik Education and Research Hospital,
Izmir, Turkey, 3University of Health Sciences Gulhane
Faculty of Medicine Department of Medical Genetics,
Ankara, Turkey
Introduction: 1q42.11qter duplication syndrome is a rare
chromosomal disorder associated with mild mental retar-
dation, neurodevelopmental delay, macrocephaly, cardiac
and urogenital malformations. According to the literature,
most of the cases are related to unbalanced inheritance of
balanced chromosomal rearrangements, particularly trans-
locations derived from parental origins. Here we report a
case of de novo pure 1q42.11qter duplication without par-
ental chromosomal abnormalities. Our report may be help-
ful to better deﬁne the partial 1q duplication syndrome.
Materials and Methods: Metaphases obtained from periph-
eral lymphocyte culture were analyzed after GTG banding.
1p and 1q subtelomeric probes were used for FISH analysis,
DNA microarray analysis was examined using Affymetrix
Cytoscan Optima. Results: Karyotype analysis was repor-
ted as 46,XX,der(1)add(1)(p3?6). FISH analysis revealed
1p and 1q subtelomeric signals consecutively on the 1p
terminal region which was shown as .ishder(1)add(1)(p3?6)
(CEB108/T7+,D1S3738+). Karyotype and FISH analysis
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did not approve any parental origin. On the other hand,
DNA microarray analysis was reported as arr[hg19]
1q42.11q44(224,433,219–249,224,684)x3. As a result, a
pathogenic duplication of 1q42.11q44 region was deter-
mined. Conclusion: Phenotypic features of our patient are
generally consistent with previously reported cases.
Besides, our patient has lateral ventricles enlargement seen
in some cases and arachnoid cyst which is not described
before. Duplication region contains 94 OMIM genes.
According to the literature, some of these genes are
responsible for pathogenesis such as AKT3 is associated
with macrocephaly, TBCE, DISC1, TRAX genes are related
with neurodevelopment, whereas WNT3A,WNT9A are
associated with craniofacial morphogenesis. But, functional
studies are required to verify the relation between these
genes and pathogenesis.
M. Gökoglu: None. N. Yurur-Kutlay: None. T.
Özdemir: None. Y. Kutbay: None. D. Torun: None.
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Duplication of HTR 7 gene in a patient: Is it a possible
cause of autism and congenital cataract ?
G. Kayhan1, D. Torun2, A. Unal1, M. A. Ergun1, F. E.
Percin1
1Medical Genetics Department, Gazi University Hospital,
Ankara, Turkey, 2Medical Genetics Department, Gulhane
Faculty of Medicine, University of Health Sciences, Ankara,
Turkey
Introduction: HTR7 gene, encoding one of the serotonin
receptors, is shown as a candidate region for autistic dis-
order and other some neuropsychiatric diseases. Here, we
present a patient with a HTR7 duplication, in terms of
bringing a new perspective to copy number variations of
this gene.
Clinical report: The patient was an 11-yeard-old boy with
autistic behaviors, bilateral congenital cataract and surgery-
resistant glaucoma developed after cataract operation.
Maternal family history included severe myopia and adult
onset cataract.
Results: Array-CGH (Agilent, 8×60K ISCA) revealed a
453 kb duplication including the HTR7 gene. This CNV
was conﬁrmed in the patient and shown to be present in the
mother using qPCR and qRT-PCR.
Discussion: HTR7 gene is a candidate locus in autism
based on functional studies. Similar duplication of HTR7
gene have been reported in DECIPHER patients with
autistic behavior or other neurological ﬁndings. Recently,
compound heterozygote mutation in HTR7 gene have been
reported in dizygotic twins with autism. So, we consider
that duplication of HTR7 gene may be one of the genetic
causes of autism. Other remarkable ﬁndings in our patient
were bilateral congenital cataract and surgery-resistant
glaucoma. HTR7 gene is expressed in retina, lens, iris and
ciliary body, and 5-HT7 agonists have been shown to
increase intraocular pressure. We suggest that HTR7
duplication may be related to congenital cataract and pre-
disposition to secondary glaucoma. But further knowledge
is needed to clarify these relationships.
G. Kayhan: None. D. Torun: None. A. Unal: None.M.
A. Ergun: None. F.E. Percin: None.
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Dyskeratosis congenita (DC) caused by mutations in PARN
C. Müller-Hofstede1, J. Seggewiss1, J. Horvath1, B.
Burkhardt2, O. Makarova2, B. Fröhlich2, B. Dworniczak1,
C. Rössig2, P. Wieacker1
Institut für Humangenetik, Muenster, Germany, 2Klinik für
Kinder- und Jugendmedizin, Pädiatrische Hämatologie und
Onkologie, Muenster, Germany
We report on a 10 year-old boy with developmental delay,
microcephaly, cerebellar atrophy and hypoplasia of the
corpus callosum. Furthermore he showed short stature,
deep-set eyes, thin eyebrows, sparse, ﬁne hair, dry, trans-
lucent and abnormally pigmented skin, small, dystrophic
nails and carious teeth. Because of bone marrow failure a
transplantation was performed.The telomere length in bone
marrow cells was shortened, but panel diagnostic for 10
dyskeratosis congenita (DC) genes could not identify a
pathogenic mutation. Finally, exome sequencing uncovered
the mutation c.1262+2_1262+3dupTA in the gene PARN.
No unaffected allele was detectable. Mucosal cells were
taken and RNA-analysis revealed a partial skipping of exon
18 of PARN. The mother showed a heterozygous state for
the mutation. A sample of the father was not available, so
that we cannot distinguish true homozygosity from a dele-
tion of the second allele by segregation analysis. Further
investigations (qPCR, RNA of the mother) are in progress.
The protein encoded by PARN (poly(A)-speciﬁc ribonu-
clease), a deadenylase enzyme is involved in the regulation
of mRNA stability. Moreover, it has recently been shown
that PARN is also involved in the regulation of the
expression of different telomere-biology related genes. In
2015, Tummala et al. were the ﬁrst to describe biallelic
PARN-mutations, two of them splice-site mutations as well,
as the cause of severe DC in three families. The ﬁndings in
our patient support the assumption that PARN represents a
new disease-causing gene in patients with a severe DC.
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EAST syndrome - expanding the clinical phenotype of this
recently delineated, rare autosomal recessive multisystemic
disorder caused by mutations in the potassium channel gene
KCNJ10
M. Prapa1, A. Parker2, R. Brown3, K. Carss4, O. Spasic-
Boskovic1, P. Twiss1, K. Brugger1, H. Martin1, S. Abbs1,
L. F. Raymond1, S. Park1
1East Anglian Medical Genetics Service, Cambridge
University Hospital NHS foundations Trust, Cambridge,
United Kingdom, 2Department of Paediatric Neurology,
Cambridge University Hospital NHS foundations Trust,
Cambridge, United Kingdom, 3Department of Paediatrics,
Peterborough City Hospital, Peterborough, United King-
dom, 4SPEED project, NIHR BioResource- Rare Diseases
study, Cambridge, United Kingdom
Biallelic mutations in the KCNJ10 gene were recently
reported to cause a multisystemic disorder characterised by
epilepsy, ataxia, sensorineural deafness, and salt-wasting
renal tubulopathy - EAST syndrome. To date, only a few
clinical reports have been published detailing the pheno-
type. We report 2 unrelated cases of Pakistani origin
expanding on the clinical features of this disorder, including
the ﬁrst reported case of EAST syndrome with structural
renal abnormalities. The ﬁrst case is the ﬁrst child born to
ﬁrst cousin parents after an uneventful pregnancy. He pre-
sented with global developmental delay, sensorineural
hearing loss, marked cerebellar dysfunction, and tonic-
clonic seizures. MRI brain at 1 year showed signs of mild
volume loss. The second case is the 3rd child born to non-
consanguineous parents at 35 weeks by emergency section
following a pregnancy complicated by gestational diabetes,
pre-eclampsia and severe intrauterine growth restriction. He
presented with infantile focal seizures, sensorineural deaf-
ness, failure to thrive, and global developmental delay. He
initially had mild axial hypotonia and then developed
marked ataxia with spastic paraplegia by age 3 years. Brain
MRI at age 8 years showed mild degree of generalised
volume loss with normal cerebellum. Muscle biopsy
showed selective type B ﬁbre atrophy. Renal tubular dys-
function with persistent hypokalaemia was diagnosed. At 14
years he developed heavy haematuria and a renal ultrasound
scan showed very echogenic kidneys containing several
small cysts bilaterally with loss of normal corticomedullary
differentiation. Both cases were found to be homozygous
for a previously reported pathogenic missense variant
c.194G>C (p.Arg65Pro) in KCNJ10.
M. Prapa: None. A. Parker: None. R. Brown: None.
K. Carss: None. O. Spasic-Boskovic: None. P. Twiss:
None. K. Brugger: None. H. Martin: None. S. Abbs:
None. L.F. Raymond: None. S. Park: None.
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The impact of ERCC6 or ERCC8 genes in two turkish
patients with clinical ﬁndings of cockayne syndrome
A. Sanrı1, H. Mutlu Albayrak1, H. Yalcın1, N. Calmels2, A.
Yılmaz1, U. Abur1, G. Ogur1
Ondokuz Mayıs University Medical Faculty Department of
Genetics, Samsun, Turkey, 2Laboratoire de diagnostic
génétique, Strasburg, France
Introduction:Cockayne syndrome (CS) is a rare recessive
disorder characterized by developmental delay, severe
growth failure, photosensitivity, pigmentary retinal degen-
eration and/or cataracts.CS is progressive. There are two
major subtypes: (1) with classical ﬁndings and (2) a severe
form.Type 2 is also referred as cerebrooculofacial-skeletal
[COFS] syndrome because of similar clinical ﬁndings with
CS.Premature aging is the major feature of both types. CS is
linked to mutations in CSB/ERCC6 and CSA/ERCC8
genes. Here we report two cases of CS syndrome and dis-
cuss results of molecular testing. Case 1 and 2:Both patients
were referred because of microcephaly and congenital cat-
aract.They both presented beaked nose, enophthalmia and
contractures at joints.Both were not able to sit without
support, to walk or talk. Clinical ﬁndings were more severe
for case 2. She had early detected, severe contractural joints.
Cranial MRI showed cortical atrophy and dilatated lateral
ventricles.Sequencing with 17 genes, revealed a novel
homozygous nucleotide variation in the ERCC8 (CSA)
gene c.300C>G (exon 4)(p.Tyr100*), in case 1 and a
homozygous nucleotide variation in the ERCC6 (CSB) gene
c.25551T>A (exon 13) (p.Trp851Arg), in case 2. Conclu-
sions:In people with CS, DNA damage is not repaired
normally. Due to DNA errors, cells malfunction and even-
tually die. It is been suspected by researchers that DNA
errors contribute to the several features of CS.There is yet
no genotype-phenptype correlation in CS.It is unclear how
ERCC6 or ERCC8 gene mutations cause all features of this
condition.More cases with molecular testing are needed to
clarify the issue.
A. Sanrı: None. H. Mutlu Albayrak: None. H. Yalcın:
None. N. Calmels: None. A. Yılmaz: None. U. Abur:
None. G. Ogur: None.
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Application of exome sequencing to reverse dysmorphol-
ogy: case report of one patient with pathogenic variant in
HDAC8
M. Migliavacca1, N. Sobreira2, D. Valle2, A. Perez1
1Universidade Federal de São Paulo, São Paulo, Brazil,
2Johns Hopkins University, Baltimore, MD, United States
Introduction: The application of New Generation
Sequencing is enabling the delineation of new syndromes
that have less distinctive clinical features by a process that
can be termed “reverse dysmorphology.” Here, the classical
approach of identifying the phenotype ﬁrst and analyzing
the genotype second is reversed.
The Cornelia de Lange syndrome (CDLS) is a multi-
system malformation syndrome recognized primarily on the
basis of characteristic facial dysmorphism, in association
with mental retardation and, in many cases, upper limb
anomalies. However, there is wide clinical variability in this
disorder, with milder phenotypes that may be difﬁcult to
ascertain on the basis of physical features. Up to now there
are ﬁve different types of CDLS and 19 genes related to
them. Here we describe a patient with multiple dysmorph-
isms and a previous clinical diagnosis of Ohdo Syndrome
that underwent exome sequencing.
Methods: A 6 years old female patient with IUGR,
neonatal seizures, cardiac malformation, horse-shoe kidney,
developmental delay, hypothyroidism and bilateral deafness
had her exome sequenced in the IlluminaTM platform and
analysis performed with acess through the PhenoDb
website.
Results: A rare missense variant was found in exon 4 of
HDAC8 (c.C356T; p.T119M) with a SIFT score of 0 and a
GERP score of 4.89.
Conclusions: This new approach allows the recognition
of common clinical features that were initially too subtle or
too variable to enable a new syndrome to be identiﬁed
solely on clinical grounds. This approach may be particu-
larly valuable for the investigation of disorders with high
locus heterogeneity, like CDLS.
M. Migliavacca: None. N. Sobreira: None. D. Valle:
None. A. Perez: None.
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Familial gastroschisis in Greenland
M. Bugge; niversity of Copenhagen, Copenhagen N,
Denmark
Background. Gastroschisis is an abdominal wall defect
located laterally to a normally closed umbilical ring with
herniation of uncovered organs. The cause of gastroshisis is
unknown. Greenland is the world’s largest island, but 80%
is covered by an ice cap, and it has a small populations of
around 56.000 peoples (2016). We have studied gastro-
schisis in Greenland during the 27 years (1989–2015). We
found 28 cases. The prevalence was 10.7 per 10.000
liveborn-and stillborn infants, the highest described so far.
Material and Methods: We have used two registries to
create extended pedigrees of the 28 infants.1. CPR registry
(Civil Registration System). 2. The Parish registers. Result.
Two families had family occurrence. Family 1. The
ancestor was a man born in Europe in 1779. In Greenland
and had four children with a local woman. One, a boy born
in 1819, had two descendent with gastroschisis, born in
1996 and 2015. Family 2. The ancestor was a man born in
Europe in 1769. He came to Greenland and had seven
children with a local woman. One of their son’s was married
twice. His descendent with the ﬁrst wife had a girl with
gastroschisis born in 1990, and with the second wife three
gastroschisis infants born in 2006, 2007 and 2013 respec-
tively. Conclusion. Six infants out of 28 (21%) born with
gastroschisis in Greenland in the period 1989–2015 belongs
to two families. Familial factors may represent exposure to a
similar environmental factor, a genetic factor, or a combi-
nation of the two.
M. Bugge: None.
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Mutation spectrum of Fanconi anemia associated genes in
eleven patients from Turkey
Z. Uyguner1, G. Toksoy1, D. Uludag Alkaya2, A.
Aghayev1, T. Celkan3, S. Basaran1, B. Tuysuz2
1Dept. Med. Genet, Istanbul Med. Faculty, Ist. Uni.,
Istanbul, Turkey, 2Pediat. Genet, Cerrahpasa Med. Faculty,
Ist. Uni., Istanbul, Turkey, 3Dept. Pediat. Hem. Oncology,
Cerrahpasa Med. Faculty, Ist. Uni., Istanbul, Turkey
Introduction: Fanconi anemia (FA) is phenotypically het-
erogenous, rare multigenic chromosomal instability syn-
drome that predisposes children and adults to life-
threatening bone marrow failure, congenital malformations
and cancer predisposition. Presently, 18 autosomal and one
X linked genes are held responsible from >85% of the
disease. FANCA mutations accommodate the highest share
with 60–70% in genetically heterogeneous pie. Materials
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and Methods: 11 patients, with FA clinic are included into
this investigation. Targeted panel-gene test is designed to
cover all the coding exons and exon-intron boundaries of 17
FA associated genes. Genetic analysis is performed on Ion
Torrent PGM platform by next generation sequencing
(NGS), and detected mutations and/or alterations considered
to be pathogenic are veriﬁed by Sanger. Mutation un-
identiﬁed patients and patients carrying heterozygous
pathogenic variants are further tested by MLPA for dele-
tion/duplication in FANCA, FANCD2, FANCN (PALB2)
and RAD51C genes. Results: four known mutations in ﬁve
alleles (c.[2638C>T];[2638C>T], c.[3492C>T];[3163C>T],
c.3754G>T), and three novel variants in ﬁve alleles (c.
[2938G>C];[2938G>C], c.[3026G>A];[3026G>A],
c.776C>G) in FANCA, and a novel variant in two alleles (c.
[2890G>A];[2890G>A]) in FANCM are identiﬁed. Con-
clusions: Two patients with single heterozygous alteration
and four patients with un-identiﬁed pathogenic variant by
NGS are presently subject to MLPA testing. Comprehen-
sive results will be acknowledged at the poster presentation
upon completion of the algorithmic testing procedures. We
hope to put forward mutation frequencies of FA genes in
our population.
Z. Uyguner: None. G. Toksoy: None. D. Uludag
Alkaya: None. A. Aghayev: None. T. Celkan: None. S.
Basaran: None. B. Tuysuz: None.
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Kromberg5, A. Krause1
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Introduction: Fanconi anemia (FA) is a rare genetic dis-
order of impaired DNA repair resulting in physical and
hematological abnormalities in affected individuals. In
South Africa, individuals with Afrikaner ancestry are at an
increased risk of inheriting disease causing FA mutations,
owing to the three common FANCA founder mutations
present in this population subgroup. Methods: We eval-
uated the physical phenotype of seven patients with
compound heterozygous and homozygous FANCA founder
mutations and one patient with conﬁrmed FANCA com-
plementation analysis using a hospital-ﬁle based review and
a comprehensive clinical examination. We compared the
South African Afrikaner phenotype to other FA cohorts,
including a previously clinically characterized South Afri-
can Black FA cohort. Results: The results indicate a sig-
niﬁcantly earlier age of diagnosis of FA in Afrikaner
patients compared to Black patients (3 years vs. 7 years
8 months), a high frequency of somatic anomalies (with
high average IFAR and PHENOS scores) and higher than
expected incidence of the VACTERL/H phenotype (25%).
Conclusion: Based on our ﬁndings, recommendations for
the care of FA patients with Afrikaner ancestry in South
Africa are made including renal ultrasonography and hear-
ing tests.
C. Feben: None. T. Haw: None. D. Stones: None. C.
Jacobs: None. C. Sutton: None. J. Kromberg: None. A.
Krause: None.
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Screenning Fanconi anemia assosiated genes with next
generation sequencing technology in FA patients
G. Bagirova
Istanbul University, Institute of Health Sciences, Istanbul,
Turkey
Introduction: FA is recessively inherited chromosomal
instability syndrome characterized by bone marrow failure,
congenital malformations and cancer predisposition.
Pathogenic variants of FANCA are attributed to 60–70%,
while BRIP1 is associated in approximately 2% of the FA
patients.
Material and method: Targeted gene panel is design to
cover all the coding exons of 17 FA genes plus ﬂanking
exon-intron regions up to10 bp. Genetic analysis is per-
formed on Ion Torrent PGM platform, and detected muta-
tions and/or alterations considered to be pathogenic are
veriﬁed by Sanger and screened in family for segregation
with inheritance pattern.
Results: 6 out of 14 alleles found to carry mutations.
Two different homozygous mutations (c.894-2A>G and
c.4261-2A>C) in FANCA and one compound heterozygous
[(c.205+5G>T)+(c.761_764delAGCA)]mutations in
BRIP1 gene are identiﬁed, accounting to three DEB positive
patients.
Conclusion & Discussion: 72 different mutations of
BRIP1 gene are known and out of 14 are involved in germ
line bi-allelic FA.c.761_764delAGCA identiﬁed in our
study is novel and attained to be the second deletion that is
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reported in the context of FA, striking the DEAD-2 domain
of the encoding protein that is different than the former
(c.2255_2256delAA), damaging the HELIC domain.
The results of the limited number of individuals tested in
this study, reveals that the DEB positivity assures the
deﬁnitive diagnosis and if the DEB test is ignored, mutation
detection rate is calculated to be 42%, when presently
known FA genes are analyzed, in which that the 28% holds
for FANCA and the 14% holds for BRIP1 associated
mutations.
G. Bagirova: None.
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First Turkish Patient with Feingold Syndrome Type 2 with
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Feingold syndrome type 2 which was ﬁrst described by
Pontual et al. in 2011 is caused by germline heterozygous
deletions of MIR17H (13q31.3). To our knowledge, until
today 11 affected patients has been described. Feingold
syndrome-1 is an autosomal dominant syndrome char-
acterised by short stature, microcephaly, brachymesopha-
langy, brachysyndactyly of the toes, oesophageal and
duodenal atresias and intellectual disability. It is caused by
mutations in or deletions of MYCN (2p24.1). Manifestations
common to both Feingold syndrome-1 and Feingold
syndrome-2 include microcephaly, short stature, and bra-
chymesophalangy; but those with Feingold syndrome-2
lack gastrointestinal atresias. Here we describe the ﬁrst
Turkish patient with micocephaly, short stature, upslanting
palpebral ﬁssures, epicanthal folds, broad nasal bridge
anteverted nostrils, absence of eyebrows-eyelashes, bra-
chydactyly, 5th ﬁnger clinodactyly, hypoplastic nails, single
palmar crease, proximally placed thumps, deafness, patent
foramen ovale, motormental retardation and epilepsy. He
was operated for Hirschsprung's disease in infancy.
Sequence analysis of MYCN was normal. Comparative
genomic hybridisation array testing conﬁrmed a 22.9 Mb
deletion in chromosome region 13q21.33-q.31.33 corre-
sponding to the MIR17HG gene. Herein we present a new
patient with large deletion and additionally. Different from
the other patients Our patient has severe mental retardation
and epilepsy.
F. Hazan: None. B. Ozyilmaz: None. A. Subasıoglu:
None. O. Kirbiyik: None. A. Aykut: None.
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Use of CGH-array in parafﬁn-tissue samples of fetus with
congenital defects
G. Pi1, L. Pedrola2, L. Castillo2, E. Aller2, A. Zuniga2
1Serv. Pediatria. HU La Ribera, Alzira (Valencia), Spain,
2Unidad de Genética. HUP La Fe, Valencia, Spain
Introduction: In fetuses with one or more CD (congenital
defect) and with normal karyotype, the application of CGH-
array, can diagnose chromosomal alterations in an addi-
tional 10–15% of cases. This technique requires little
quantity of DNA and it can be obtained from non-viable
cells, this is important in the study of abortions because the
rate of karyotype failure is very high. Post-mortem study of
fetus with CD is needed to provide relevant information for
diagnosis and reproductive counseling to the family.
Materials and methods: Forty-four fetus were selected for
CGH analysis and classiﬁed according to type of CD. The
best preserved blocks of parafﬁn-tissue were chosen and
processed for genomic DNA (n= 40). The array that has
been selected for the study is the Cytochip Focus Con-
stitutional (Cambridge BlueGnomeTM). In 4 cases, the DNA
could not be used because it was degraded. Results: The
result was normal in 90% of cases (36/40), and pathological
in the remaining 10% (4/40). In 3 cases the chromosomal
alteration is considered causative, with a clear phenotype-
genotype correlation. In one case, the chromosomal altera-
tion is associated with two locus of genetic susceptibility for
neurodevelopmental alteration. In the post-mortem study of
fetuses with CD, the use of new diagnostic techniques, such
as comparative genomic hybridization, allows the detection
of 10% of chromosomal imbalances not diagnosed with
conventional techniques. On the other hand, the exhaustive
study of the phenotype of these patients, it is necessary for
the correct interpretation of the array data.
G. Pi: None. L. Pedrola: None. L. Castillo: None. E.
Aller: None. A. Zuniga: None.
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Identiﬁcation of new genes responsible for syndromic
developmental abnormalities using whole exome
sequencing
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Introduction : Multiple Congenital Anomalies (MCA) are
deﬁned by the association of at least 2 malformations. In
fetuses, the diagnostic rate in MCA is about 30%. From
2014 to 2015, over 12 new Mendelian disease genes were
published per month mainly due to the use of WES, how-
ever about 1600 phenotypes described in OMIM still have
an unknown molecular basis. Since WES has not been fully
evaluated in fetopathology, we aimed to assess the con-
tribution of WES to diagnose and identify new genes
responsible for fetal MCA.
Material and methods : We recruited 100 polymalformed
fetuses from 10 prenatal diagnosis centers in France and
performed WES with the solo strategy. We ﬁrst performed a
targeted analysis of known OMIM disease-causing genes
and then extended the analysis to other genes in the negative
cases.
Results : To date 46 fetal DNA have been sequenced. A
diagnosis has been done in 13 known genes in 15 fetuses
(33%), these diagnosis were aspeciﬁc, atypical or extreme.
3 candidate genes are suspected in 4 fetuses (9%), 2 of them
are from recessive inheritance (one homozygous null var-
iation in a consaguineous family, one compound hetero-
zygous variation in a case of intrafamilial recurrence and
one X-linked variation), 2 variations of unknown sig-
niﬁcance have been identiﬁed in 2 fetuses in recently
described genes.
Conclusion : WES is a powerful tool to diagnose fetal
MCA, to extend our knowledge of the phenotype spectrum
of known disease-causing gene, and to discover new
disease-causing genes with international collaborations
through data-sharing.
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Background Frank-Ter Haar syndrome (FTHS; OMIM
249420) and opsismodysplasia (OPSMD; OMIM 258480)
are two distinct skeletal dysplasias with some overlapping
dysmorphic features. FTHS is a rare, autosomal recessive
condition characterized by multiple skeletal abnormalities,
dismorphic facial features, congenital heart defects and
macrocornea caused by mutations in SH3PXD2B. Opsis-
modysplasia is an uncommon skeletal dysplasia presented
by short stature, characteristic craniofacial abnormalities,
skeletal anomalies and susceptibility to respiratory infec-
tions caused by mutations in the INPPL1 gene. Here, we
describe a case of multiple congenital anomalies with likely
pathogenic homozygous mutations in both SH3PXD2B and
INPPL1 identiﬁed by whole exome sequencing (WES).
Clinical Report 12-day-old baby who was the child of
consanguineous parents was referred to our genetics clinic
because of her facial dysmorphic features including pro-
minent forehead, ﬂat occiput, micrognathia, exophthalmos,
hypertelorism, downslanting palpebral ﬁssures, ﬂat nasal
bridge, nuchal edema and multiple congenital malforma-
tions (pes equinovarus and atrioventricular septal defect).
Chromosome analysis showed normal karyotype. Since her
phenotypic features were consistent with Robinow syn-
drome, ROR2 and WNT5A genes were screened and no
mutation was found. WES was carried out for further
genetic analysis and a homozygous frameshift mutation
(c.969delG; p.G323fs) in SH3PXD2B and a novel homo-
zygous missense mutation (c.G1636A; p.V546I) in INPPL1
were determined. Unfortunately, the patient was deceased
because of recurrent respiratory infections before her radi-
ological examinations were completed. Conclusion The
identiﬁed homozygous variants in this case suggest that
perturbed SH3PXD2B is responsible for dismorphic features
and, heart defect while INPPL1 variants may cause nuchal
edema and recurrent respiratory infections.
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R.A. Gibbs: None. C.M.B. Carvalho: None. J.R. Lupski:
None. Ö.S. Fitöz: None. H.G. Karabulut: None.
P11.047C
Clinical delineation of a subtype of frontonasal dysplasia
with creased nasal dorsum and limb anomalies: report of six
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Introduction: Frontonasal dysplasias (FND) are rare con-
genital malformations of the frontonasal process-derived
structures, characterized by median cleft, nasal anomalies,
hypertelorism, and cranium biﬁdum occultum. Several
entities of syndromic FND have been described, among
which, to date, only the craniofrontonasal syndrome (CFNS,
MIM 304110), ALX-related FND (MIM 136760, 613451,
613456), and acromelic frontonasal dysostosis (AFND,
MIM 603671) have identiﬁed molecular bases. Materials
and methods: We clinically ascertained a cohort of 124
individuals referred for isolated or syndromic FND.
Results: We identiﬁed six individuals (ﬁve males and one
female) with a very similar and easily recognizable phe-
notype. Facial features were remarkable by nasal deformity
with creased dorsum and absent tip, hypertelorism, narrow
palpebral ﬁssures and downturned corners of the mouth. All
had normal psychomotor development. In addition, uni-
lateral transverse upper limb agenesis, brachydactyly and
widely spaced nipples were observed in one individual
each. Interestingly, one patient had an unaffected mono-
zygotic twin. We identiﬁed ﬁve reports in the literature of
cases presenting with the same facial phenotype, associated
with transverse limb agenesis, Poland anomaly and clin-
odactyly. Conclusion: We report six novel sporadic cases
of a speciﬁc FND entity associating recognizable facial
features, limb defects, and normal intelligence. The identi-
ﬁcation of discordant monozygotic twins, as well as the
negativity of the whole exome sequencing approaches in
various FND, supports the hypothesis of a mosaic disorder.
Although previous cases had been reported, this is the ﬁrst
series of patients, allowing delineation of this syndrome and
paving the way toward the identiﬁcation of its molecular
etiology.
D. Lehalle: None. U. Altunoglu: None. A. Bruel: None.
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Introduction: Gillespie Syndrome (GS, OMIM entry:
#206700) is a rare congenital autosomal disorder char-
acterized by partial or complete aniridia, hypotonia, cere-
bellar hypoplasia, ataxia and mild to moderate
developmental delay. GS has recently been associated with
mutations of ITPR1 gene, encoding an intracellular inositol
1,4,5-triphosphate-responsive calcium channel involved in
mediating calcium release from the endoplasmic reticulum.
Materials and methods: WES was performed on the ﬁve
members of an Egyptian family recruited at the Pediatric
Highly Intensive Care Unit of Policlinico Hospital in Milan,
composed of consanguineous healthy parents, two GS-
affected siblings and an unaffected son.
Results: we identiﬁed a novel ITPR1 variant, the
c.278_279+2delACGT, present in both the alleles of the
two GS-affected siblings. Their parents were carriers, whilst
it was absent in the unaffected son. The c.278_279+2del
affects the last two 3′-nucleotides of the exon 5 (AC) and
the two ﬁrst 5′-bases of the respective intron (GT), abol-
ishing the exonic splice donor site. Using functional in-
silico prediction we proposed the likely disease-causing
mechanism of the c.278_279+2del. The analysis revealed
that the presence of this variant may lead to the retention of
the intron 5 in the mature ITPR1 mRNA, with the genera-
tion of a premature STOP codon and the production of a
non-functional protein.
Conclusions: these results corroborate the role of the
homozygous recessive variant c.278_279+2delACGT as
the underlying genetic defect for Gillespie syndrome in this
family, further extending the spectrum of the ITPR1
pathogenetic variants.
Grant references: “Ricerca corrente 2015” from Fonda-
zione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,
Milano.
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HACE1, a previously reported tumour suppressor gene,
encodes a HECT domain– and ankyrin repeat-containing E3
ubiquitin protein ligase that is expressed in the brain and
involved in neuronal and photoreceptor differentiation and
cerebellar development. Two recent publications suggest
that bi-allelic loss-of-function mutations in HACE1 is a
cause of a new autosomal recessive neurodevelopmental
disorder without cancer disposition.
We report a non-consanguineous family originating from
Pakistan with two boys affected with severe global devel-
opmental delay, intellectual disability, hypotonia, bilateral
cryptorchidism, inner retinal dystrophy, strabismus and
morbid obesity with hyperphagia and abnormal thyroid
function. Whole exome sequencing identiﬁed homozygosity
for HACE1 nonsense variants c.805C>T, p.Arg269* in the
two siblings and conﬁrmed their unaffected parents as being
heterozygous.
This variant has previously been reported in one of four
families with HACE1 bi-allelic variants from the UK DDD
study cohort. This report and one other published report of
two other families show that bi-allelic loss-of-function
variants in HACE1 are associated with a severe syndromic
developmental disorder characterised by global develop-
mental delay, intellectual disability, ataxia, hypotonia,
dystonia, spasticity, brain atrophy, hypoplasia of corpus
callosum, epilepsy, hypoplastic genitalia, ocular abnormal-
ities, sensorineural deafness, obesity and skeletal features.
All reported variants are in either the ankryn repeat domain
or in the catalytic HECT domain, predicted to result in a
truncated protein lacking the catalytic HECT domain. Our
seventh family provides further evidence that HACE1 is an
important neurodevelopmental gene with multi-systemic
effects, including metabolic features of morbid obesity and
abnormal thyroid function that merit further future
investigation.
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P11.050B
Novel TP73L variants in two patients with
Ankyloblepharon-Ectodermal Defects-Cleft Lip/Palate
(AEC) Syndrome
E. Tsoutsou1, S. Psoni1, S. Amenta2, P. Willems3, H.
Fryssira1
1Department of Medical Genetics, Medical School,
National and Kapodistrian University of Athens, “Aghia
Sophia” Children’s Hospital, Athens, Greece, 2“MITERA”
Maternity Hospital, Athens, Greece, 3“GENDIA” Genetic-
Diagnostic, Antwerp, Belgium
Introduction: Ankyloblepharon-ectodermal defects-cleft
lip/palate (AEC) syndrome, also known as Hay-Wells
syndrome, is a very rare ectodermal dysplasia autosomal
dominant genetic disorder characterized by Ankylo-
blepharon Filiforme Adnatum (AFA), abnormalities of
ectodermal tissues (skin, hair, nails, teeth and sweat glands)
and cleft lip and/or palate. Mutations in TP73L gene,
member of the p53 family of transcription factors are
responsible for the syndrome.
Materials and Methods: We report two new cases with
AES syndrome. Case 1: A 9-months-old male presented
with previously repaired bilateral ankyloblepharon, lack of
lacrimal ducts, cleft soft palate and ectodermal dysplasia
ﬁndings including onychodystrophy, hypodontia and
sparse, fair hair. Morphological features such as mid-face
hypoplasia, micrognathia and low set ears were obvious.
Psychomotor development was normal. Case 2: Α 14-years-
old boy presented with features of severe ectodermal dys-
plasia such as total alopecia, absent eyebrows and eye-
lashes, dry – eczematoid skin, hypohidrosis, hypodontia and
dysplastic nails. The patient also had lacrimal ducts atresia
and urogenital abnormalities with dysplastic right kidney.
Ankyloblepharon and cleft lip/cleft palate were surgically
repaired during neonatal period and childhood respectively.
Results: In case 1, a novel, de novo, heterozygous
TP73L:C.951C>A missense pathogenic variant in exon 7
was identiﬁed by sequencing. In case 2, a novel, de novo,
heterozygous TP73L:c.1751T>G pathogenic variant was
detected in exon 14 by sequencing.
Conclusion: The identiﬁcation of novel mutations in rare
genetic disorders such as AEC syndrome is crucial and must
be reported because it allows more precise genotype-
phenotype correlation of these conditions. A multi-
disciplinary follow-up of these patients is important.
E. Tsoutsou: None. S. Psoni: None. S. Amenta: None.
P. Willems: None. H. Fryssira: None.
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Extensive skin manifestations in a girl with a severe
´HDAC8-phenotype´
J. Behunova, F. Laccone
Institute of Medical Genetics, Medical University of Vienna,
Vienna, Austria
HDAC8-gene had been implicated in a cohesin-complex
disorder Cornelia de Lange syndrome (CdLS) as the ﬁfth
known gene (CdLS5). It is an X-linked gene and the skewed
inactivation contributes to the great variability of clinical
symptomatology in females. The authors refer on a 4,5 y-
old girl with notable alopecia areata and extensive pig-
mentary mosaicism, which were, apart from the cardinal
features like severe developmental delay (no speech,
walking since 26 mo.), short stature and microcephaly
(-4SD, -4,3SD), heart defect (ASD I, II, AV-canal, MI) and
bilateral hearing loss (40–60%), the most striking clinical
sings. The girl did not really have a typical “CdLS-face”
and the limbs showed no major anomalies. A heterozygous
de novo stop mutation in HDAC8-Gene had been identiﬁed
by WES and conﬁrmed by Sanger sequencing, the X-
inactivation ratio was 30:70. The personality of the child
was very friendly, cooperating. Other anamnestic details
consistent with CdLS(5) involved delayed closing of fon-
tanelles, lacrimal duct obstruction and small birth size. The
areas of alopecia involved a large portion of scalp, the hair
was brittle and the remarkable whorl-streaky lines of skin-
hyperpigmentations covered the trunk, neck and limbs. The
pigmentary mosaicism had been by CdLS5 mentioned just
one time as a minor feature (Kaiser et al, 2014), the areas of
scalp-alopecia not yet and these features are also not in the
Omim clinical-synopsis. Thus it is important to think of a
HDAC8-mutation by girls with mosaic pigment and inte-
gument changes together with variable growth and devel-
opmental delay.
J. Behunova: None. F. Laccone: None.
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A novel homozygous mutation in MMP21 is associated
with heterotaxia & cardiac defects
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L. Aspit1, O. Reish2,3, L. Benyamin2, V. Shefﬁeld4, R.
Parvari1,5
1The Shraga Segal Department of Microbiology,Immunol-
ogy & Genetics, Faculty of Health Sciences, Ben-Gurion
University of the Negev, Beer Sheva, Israel, 2Genetic
Institute, Assaf Aarofeh Medical Center, Zriﬁn, Israel, 3The
Sackler School of Medicine, Tel Aviv University, Tel Aviv,
Israel, 4Department of Pediatrics, Division of Medical
Genetics, University of Iowa, Iowa, IA, United States,
5National Institute of Biotechnology in the Negev, Ben-
Gurion University of the Negev, Beer Sheva, Israel
Introduction: Heterotaxia is a rare congenital autosomal
recessive defect in which the major visceral organs are
distributed abnormally within the chest and abdomen. The
mixed organ orientation found in situs ambiguus often leads
to severe complications mainly of the heart and/or lungs.
We have characterized a consanguineous Bedouin family
from Israel with 2 affected siblings with heterotaxia and
complicated heart defects and detected a novel MMP21
mutation.
Materials and Methods: Genotyping of both patients and
their parents was performed using Affymetrix microarrays
and kinSNP analysis. Regions of homozygosity were
identiﬁed. Exome sequencing was performed on 1 affected
DNA.
Results: Exome sequencing revealed 50 potential var-
iations within the homozygous regions. Following bioin-
formatics predictions, segregation in the family and analysis
of prevalence in the Bedouin population, one candidate
remained - a homozygous variation in the MMP21 gene that
is involved in the breakdown of extracellular matrix for
normal physiological processes, such as embryonic devel-
opment, reproduction, and tissue remodeling. The variation
causes an amino acid change that is predicted to be highly
damaging.
Conclusions: The novel MMP21 mutation presented
here, reinforce the role of this gene that only recently has
been described with association to heterotaxia and is in line
with an ENU-induced mutant mice with LR asymmetry and
major cardiac defects. Further studies are required to verify
whether this gene is a candidate for complicated heart
defects without LR asymmetry.
L. Aspit: None. O. Reish: None. L. Benyamin: None.
V. Shefﬁeld: None. R. Parvari: None.
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HIRA, a candidate gene for the neurodevelopmental phe-
notype of 22q11 deletion syndrome
M. Jeanne1, S. Vonwill1, D. Haye1, N. Chelloug1, M.
Moizard1, N. Ronce1, S. Marouillat2, F. Laumonnier1,2, A.
Toutain1,2
University Hospital of Tours, Tours, France, 2INSERM
U930, François Rabelais University, Tours, France
The 22q11.2 deletion syndrome (22q11DS) is a neurocris-
topathy associated with a wide phenotypic spectrum. Can-
didate genes, located in the 3 Mb typically deleted region
(TDR), such as TBX1, have been proposed to explain part
of the features. However, to date none of them explains the
entire phenotype and the cause of the neurodevelopmental
problems remains speculative. Here we report a 28kb
intragenic deletion in the HIRA (Tuple1) gene, which is
located in the TDR, in a 5-year-old female patient with
features highly suggestive of 22q11DS. To our knowledge
this is the ﬁrst description of an intragenic deletion of the
HIRA gene. This gene is highly expressed in neural crests
and encodes a histone chaperone involved in histone H3.3
deposition in nucleosomes and thereby, plays roles in the
regulation of gene expression. The similarities between the
phenotype of the present case and the classical 22q11.2
deletion syndrome strongly suggest that this gene could be a
candidate for the neurodevelopmental phenotype and the
dysmorphic traits of the 22q11.2 deletion syndrome. To
explore the implication of HIRA in the neurodevelopmental
phenotype of 22q11DS we are performing gene silencing
using shRNA on murine primary neuronal cultures to assess
the impact on neuronal morphology and synaptogenesis.
We are also studying the expression of HIRA in murine
primary neuronal cultures at different times of embryonic
and postnatal development using RT-qPCR and Western-
Blot in order to evaluate the pattern of brain expression. We
will present our ﬁnal results at the ESHG meeting.
M. Jeanne: None. S. Vonwill: None. D. Haye: None. N.
Chelloug: None. M. Moizard: None. N. Ronce: None. S.
Marouillat: None. F. Laumonnier: None. A. Toutain:
None.
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Homozygous deletion in RECQL4 caused by the rare
identical haplotype
Y. Enomoto1, Y. Tsurusaki1, T. Yokoi2, M. Minatogawa2,
M. Umegae2, T. Naruto1, T. Shimokaze3, K. Kurosawa1,2
1Clinical Research Institute, Kanagawa Children's Medical
Center, Yokohama, Japan, 2Division of Medical Genetics,
Kanagawa Children's Medical Center, Yokohama, Japan,
3Department of Pediatrics, Yamagata Saisei Hospital,
Yamagata, Japan
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Introduction: RECQL4 is a responsible gene for three
diseases; Baller-Gerold syndrome, RAPADILINO syn-
drome, and Rothmund-Thomson syndrome. Those are
autosomal recessive diseases.
Materials and Methods: Patient was born as the second
child from healthy and nonconsanguineous parents. She has
short limb, absent radius, absent thumb, clubfoot, scoliosis,
high-arched palate and corpus callosum hypoplasia.
Results: Homozygous deletion in RECQL4 was detected
by whole exome sequence. Deletion size was about 1.5kb.
Homo SNPs were detected in about 1.3Mb region around
the deletion. Therefore, we build the following hypothesis,
homozygous deletion caused segmental isodisomy or
identical haplotype. To test this hypothesis, PCR analysis
using primer pair for region including the deletion per-
formed in parents. Two bands correspond to a normal allele
and a deletion allele were detected in both her father and
mother. This result showed that identical haplotype derived
from parents caused homozygous deletion in RECQL4.
SNP array analysis did not indicate that there was a close
blood relationship between her father and mother. Same
haplotype were not detected in our in-house data consist of
257 samples.
Conclusions: Homozygous deletion in RECQL4 caused
by the rare identical haplotype. Her parents born in a rela-
tively small area. It is possible that the haplotype only
presents in the area and her father is distantly related to
mother.
Y. Enomoto: None. Y. Tsurusaki: None. T. Yokoi:
None. M. Minatogawa: None. M. Umegae: None. T.
Naruto: None. T. Shimokaze: None. K. Kurosawa: None.
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Effects of PAX9 and MSX1 gene variants to hypodontia,
tooth size and the type of congenitally missing teeth
D. Kirac1, F. Eraydın2, T. Avcilar3, K. Ulucan4, F.
Ozdemir2, A. I. Guney3, E. C. Altunok5, E. Keshi3, T.
Isbir1
Yeditepe University, Faculty of Medicine, Department of
Medical Biology, Istanbul, Turkey, 2Yeditepe University,
Faculty of Dentistry, Department of Orthodontics, Istanbul,
Turkey, 3Marmara University, Faculty of Medicine, Depart-
ment of Medical Genetics, Istanbul, Turkey, 4Marmara
University, Faculty of Dentistry, Department of Medical
Biology and Genetics, Istanbul, Turkey, 5Yeditepe Uni-
versity, Faculty of Medicine, Department of Biostatistics,
Istanbul, Turkey
Introducton: Tooth agenesis, affecting up to 20% of human
population, is one of the most common congenital disorder.
The most frequent form of tooth agenesis is known as
hypodontia, which is characterized by the absence of one to
ﬁve permanent teeth excluding third molars. It was con-
sidered that hypodontia is especially related with gene
mutations which play role in tooth formation. Additionally
mutations in PAX9 and/or MSX1 have been identiﬁed as the
defects responsible for missing permanent molars and sec-
ond premolars. In some studies it was also found that PAX9
and MSX1 gene mutations may change tooth size. Therefore
in this study all of these factors were investigated.
Materials and Methods: Thirty one patients and 30
controls were enrolled to the study. Information about tooth
sizes and type of congenitally missing teeth were collected.
MSX1 and PAX9 gene mutations were investigated by direct
sequencing. Results were evaluated statistically.
Results: Twenty two variations were detected in PAX9
in which 18 of them are novel. In addition, 7 variations were
found in MSX1 in which 5 of them are novel and one of
them lead to amino acid change. Statistically signiﬁcant
relations were found between detected variations and tooth
sizes. Any relation between mutations and type of con-
genitally missing teeth were not detected.
Conclusion: Especially new mutations which may cause
hypodontia, effect tooth size and type of congenitally
missing teeth, should be investigated with other researchers
for clarifying the mechanism.
D. Kirac: None. F. Eraydın: None. T. Avcilar: None.
K. Ulucan: None. F. Ozdemir: None. A.I. Guney: None.
E.C. Altunok: None. E. Keshi: None. T. Isbir: None.
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Inverted duplication deletion of 8p : about 3 French cases
S. Baer1,2, L. Mary3, M. Abi Warde2, Y. Alembik1, C.
Antal4,5, M. Beri-Dexheimer6, E. Flori3, V. Laugel2, E.
Schaefer1, C. Depienne3, V. Kremer3, S. Scheidecker3
1Service de Génétique Médicale, Hôpitaux universitaires de
Strasbourg, Strasbourg, France, 2Service de Neuropédia-
trie, Hôpitaux universitaires de Strasbourg, Strasbourg,
France, 3Laboratoire de Cytogénétique, Hôpitaux universi-
taires de Strasbourg, Strasbourg, France, 4Unité Fonction-
nelle de Fœtopathologie, Hôpitaux universitaires de
Strasbourg, Strasbourg, France, 5Faculté de Médecine,
Institut d'Histologie, Strasbourg, France, 6Laboratoire de
Génétique Médicale, Centre Hospitalier Universitaire de
Nancy, Nancy, France
Array-CGH is a technique used for genetic testing of indi-
viduals with unexplained intellectual disability and multiple
congenital anomalies; it offers a diagnostic yield between
15%-20%. Inverted duplication deletion of the short arm of
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chromosome 8 (inv dup del (8p)) is a rare cytogenetic
disorder (less than 1/10.000) characterized by a wide range
of clinical features and cognitive impairment that depend on
the size of the deleted and duplicated regions. The under-
lying mechanism is complex and explains the variability in
the size of the identiﬁed chromosomal abnormalities.
We report here 3 cases with 8p inverted duplication
deletion and various manifestations. The ﬁrst case is a fetus
presenting with antenatal hygroma colli for which array
CGH revealed a 6.8Mb deletion and 31.8Mb duplication of
chromosome 8p. The foetopathologic exam revealed
olfactory bulb agenesis and right ventricular hypertrophy.
The second case was newborn diagnosed with agenesis of
the corpus callosum, microcephaly and feeding difﬁculties.
The array-CGH revealed a deletion of 7.6Mb in 8p23
associated with a 25.8Mb duplication. The third case is a 15
years old male with moderate intellectual disability, lower
limb acrocyanosis, livedo and normal MRI. Array-CGH
identiﬁed a 6.8Mb terminal deletion and a 5.7Mb interstitial
duplication. For each case, we explain cytogenetic
mechanism underlying the origin of these chromosomal
abnormalities.
Our three cases illustrate the large clinical variability
associated with inv dup del (8p) and highlight the correla-
tion between the size of the duplicated region and severity
of the phenotype.
S. Baer: None. L. Mary: None. M. Abi Warde: None.
Y. Alembik: None. C. Antal: None. M. Beri-Dexheimer:
None. E. Flori: None. V. Laugel: None. E. Schaefer:
None. C. Depienne: None. V. Kremer: None. S. Schei-
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Clinical spectrum of Kabuki-like syndrome caused by
HNRNPK haploinsufﬁciency. Case report and literature
review
M. Dentici, S. Barresi, M. Niceta, F. Pantaleoni, S. Pizzi,
B. Dallapiccola, M. Tartaglia, M. Digilio
ambino Gesú Pediatric Hospital, IRCCS, Rome, Italy.,
Rome, Italy
Kabuki syndrome is a genetically heterogeneous disorder
characterized by postnatal growth retardation, skeletal
abnormalities, intellectual disability, facial dysmorphisms
and a variable range of organ malformations. In approxi-
mately 30% of affected individuals, the underlying genetic
defect remains unknown. A small number of inactivating
heterozygous HNRNPK mutations has recently been
reported to be associated with a condition partially over-
lapping or suggestive of Kabuki syndrome. Here, we report
on an 11 year-old girl with a complex phenotype in whom
the diagnosis of KS was suggested but molecular testing for
the known causative disease genes was negative. Whole
exome sequencing identiﬁed a previously undescribed de
novo truncating mutation in HNRNPK as the molecular
defect underlying the trait. Analysis of available records of
patients with HNRNPK haploinsufﬁciency was performed
to delineate the associated clinical phenotype and outline
their distinguishing features in comparison with the KS
clinical spectrum. The clinical proﬁle associated with
inactivating HNRNPK mutations supports the idea that the
associated disorder should be considered as a distinct
nosologic entity clinically related to KS, and that the con-
dition should be considered in differential diagnosis with
KS, in particular in subjects exhibiting brain malformation
(nodular heterotopia), craniosynostosis, and polydactyly.
M. Dentici: None. S. Barresi: None. M. Niceta: None.
F. Pantaleoni: None. S. Pizzi: None. B. Dallapiccola:
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A systematic analysis of missense variants in KMT2D in
Kabuki syndrome and cancer
V. Faundes1,2, G. Malone3, W. G. Newman1,3, S. Banka1,3
1Division of Evolution & Genomic Sciences, School of
Biological Sciences, Faculty of Biology, Medicine and
Health, University of Manchester, Manchester, United
Kingdom, 2Laboratorio de Genética y Enfermedades
Metabólicas, Instituto de Nutrición y Tecnología de los
Alimentos (INTA), Universidad de Chile, Santiago, Chile,
3Manchester Centre for Genomic Medicine, St Mary's
Hospital, Central Manchester University Hospitals NHS
Foundation Trust, Manchester Academic Health Science
Centre (MAHSC), Manchester, United Kingdom
Introduction: KMT2D, a H3K4 methyltransferase, is a
large protein of 5,537 amino acids. Germline loss-of-
function KMT2D mutations cause Kabuki syndrome (KS).
Similar to a number of other developmental genes, somatic
KMT2D mutations are detected in many cancers. Missense
variants (MV) can help understand protein structure and
function, but determining their clinical signiﬁcance can be
challenging. We present a systematic comparison between
KMT2D MV in KS and cancers.
Methods: From various sources, we compiled KMT2D
MV with information regarding their frequencies, evolu-
tionary conservation, thermodynamic properties and
protein-interaction disruption when available.
Results: We identiﬁed 1,535 germline MV in unaffected
controls (Control-MV), 201 in individuals with KS (KS-
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MV) and 584 somatic MVs detected in cancers (Cancers-
MV).
When compared with Control-MV, KS-MV and
Cancers-MV were signiﬁcantly enriched in the PHD3,
PHD4, RING4, FYRC, and SET domains, and for only KS-
MV in the FYRN domain.
Enrichment of only KS-MV was observed in residues
between 4,995–5,090 and between 5,328–5,396; and of
only Cancers-MV between 3,043–3,248. These regions are
not part of any known functional domains.
No signiﬁcant enrichment of either KS-MV or Cancers-
MV was detected in RING1, PHD1, PHD2, PHD5,
SPPPEPEA region, HMG Box, Coiled coils, LXLL motifs
and Post-SET domains.
KS-MV and Cancers-MV affect more conserved
residues.
KS-MV, but not Cancers-MV, increase the folding/
interaction energy of KMT2D.
Conclusions: This analysis will assist in the interpreta-
tion of KMT2D MV in cancer and patients with KS. Iden-
tiﬁcation of regions of the protein with enrichment of
disease MV provides novel insights into functionally
important areas of the protein.
V. Faundes: None. G. Malone: None. W.G. Newman:
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KAT6A Syndrome: The results of an international colla-
borative study of phenotype and genotype
J. S. Kennedy*1,2, V. Arboleda*3, D. Goudie4, E. Blair5, K.
Chandler6, S. Joss7, C. Deshpande8, V. McKay9, A.
Green10,11, R. Armstrong12, M. Lees13, S. Tomkins1, B.
Kamien14, B. Hopper14, T. Yang Tan15,16, P. Yap15,17, Z.
Stark15, N. Okamoto18,19, N. Miyake20, N. Matsumoto20, E.
Macnamara21, J. L. Murphy22, E. McCormick23, D. Li24,
H. Hakonarson23, M. J. Falk23, P. Blackburn25, E.
Klee25,26, D. Babovic-Vuksanovic25,26, S. Schelley27, L.
Hudgins27, S. Kant28, B. Isidor29, B. Cogne29, K.
Bradbury30, M. Williams31, C. Patel32, H. Heussler33, S. F.
Nelson34,35, DDD Study36, R. Newbury-Ecob1,2, *joint ﬁrst
authors
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for Genomic Medicine, Oxford University Hospitals NHS
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Centre for Genomic Medicine, St. Mary’s Hospital, Central
Manchester Foundation NHS Trust, Manchester Academic
Health Science Centre (MAHSC), Manchester, United
Kingdom, 7West of Scotland Genetics Service, Queen
Elizabeth University Hospital, Glasgow, United Kingdom,
8Clinical Genetics 7th ﬂoor, Borough Wing Guy's Hospital
Great Maze Pond, London, United Kingdom, 9Cheshire &
Merseyside Regional Genetics Service, Liverpool Women's
NHS Foundation Trust, liverpool, United Kingdom,
10Department of Clinical Genetics, Our Lady's Children's
Hospital, Crumlin, Dublin, Ireland, Dublin, Ireland,
11School of Medicine and Medical Science, University
College Dublin, Dublin, Ireland, 12East Anglian Medical
Genetics Service, Addenbrooke's Hospital, Cambridge,
United Kingdom, 13Clinical Genetics, Great Ormond Street
Hospital NHS Trust, London, United Kingdom, 14Hunter
Genetics, Newcastle, Australia, 15Victorian Clinical Genet-
ics Services, Murdoch Children’s Research Institute,
Melbourne, Australia, 16Department of Paediatrics, Uni-
versity of Melbourne, Melbourne, Australia, 17Genetic
Health Service New Zealand, Auckland, New Zealand,
18Department of Medical Genetics Osaka M
Through next generation sequencing studies, pathological
germline KAT6A mutations are emerging as a cause of
approximately 1% undiagnosed syndromic intellectual
disability.
We have collected data from 43 cases (25 unpublished)
through international collaboration, the DDD study and the
patient support group established by a parent of an affected
child, more than doubling the number of reported patients
and providing a unique opportunity to review the phenotype
and natural history together with mutation details.
Key features of KAT6A syndrome include a variable
degree of intellectual disability, hypotonia, expressive
speech delay, early feeding difﬁculties, reﬂux, constipation
and craniofacial dysmorphism including a thin tented upper
lip and a widened nasal tip. Newly identiﬁed features
include behavioural difﬁculties and sensory issues that
overlap traits seen in autistic spectrum disorder. We also
report on the high frequency of recurrent infections and
several patients have proven immune or haematological
dysfunction. We expand our knowledge of previously
reported features including the mechanisms of speech delay
and gastrointestinal dysfunction, the prevalence and type of
associated congenital cardiac defects and the high pre-
valence of visual problems including strabismus.
KAT6A encodes an enzyme involved in post transla-
tional protein modiﬁcation via acetylation. It thus regulates
the transcription of many other genes and cellular processes.
Our data suggests that the severity of the phenotype varies
according to the site and type of mutation. The KAT6A
phenotype show striking overlap with the 22q11 Di George
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phenotype and also the phenotypes associated with KAT6B
mutations and other disorders of histone modiﬁcation.
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Novel truncating recessive mutations in KLHL7 gene
causing Bohring-Opitz like syndrome
A. Bruel1,2, S. Bigoni3, J. Kennedy4,5, M. Whiteford6, C.
Buxton7, G. Parmeggiani3, M. Wherlock7, G. Woodward7,
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Garani9, E. Ballardini9, C. Gilissen10, B. van Bon10, R.
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Brunner10, A. Hoischen10, R. Newbury-Ecob4, C.
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Biallelic mutations in KLHL7 gene were recently reported
in four families associated with Crisponi/cold-induced
sweating syndrome type 1-like syndrome (CS/CISS1). CS/
CISS1 characterized by extremities abnormalities, feeding
difﬁculties, inconstant palate defects and respiratory difﬁ-
culties. Here, we report on six cases from four families,
carrying autosomal recessive truncating variations in
KLHL7. None of them had received a clinical diagnosis of
CS/CISS1. They presented with microcephaly (6/6), facial
dysmorphism including prominent eyes (X/6), ﬂammeus
naevus (5/6) and brain abnormalities (6/6). These indivi-
duals presented with ﬁxed contractures and distinctive
posture of elbows and wrist called “BOS posture”, sug-
gestive of a Bohring-Opitz syndrome (BOS). Evolution was
marked by severe feeding problems, seizures and pulmon-
ary infections. BOS is caused by heterozygous mutation in
the ASXL1 gene encoding for chromatin-binding protein.
KLHL7 encodes a BTB-kelch protein implicated in cellular
cycle and protein degradation by ubiquitin-proteasome
pathway. Additionally, KLHL7 may be implicated in the
regulation of gene expression by its interaction with the
Polycomb Repressive Complex 1 (PRC1). PRC1 is a multi-
subunit complex interacting with ASXL1, that is able to
recognize several epigenetic marks and enables the ubi-
quitylation of the lysine 119 of the histone H2A, in order to
block the repressive state of the chromatin and inactivate
gene expression. In conclusion, we expend the clinical
spectrum of KLHL7 autosomal recessive variations,
responsible for CS/CISS1 and a new syndrome with fea-
tures overlapping the BOS.
A. Bruel: None. S. Bigoni: None. J. Kennedy: None.
M. Whiteford: None. C. Buxton: None. G. Parmeggiani:
None. M. Wherlock: None. G. Woodward: None. M.
Greenslade: None.M. Williams: None. J. St-Onge: None.
A. Ferlini: None. G. Garani: None. E. Ballardini: None.
C. Gilissen: None. B. van Bon: None. R. Acuna-Hildago:
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Knobloch syndrome - a rare but distinct phenotype - two
patients with novel mutations in COL18A1 and review of
the literature
I. Hüning1, L. Voges2, B. Neppert3, J. Sperner4, G.
Gillessen-Kaesbach1
Institut für Humangenetik, Lübeck, Germany, 2Department
of Pediatrics and Adolescent Medicine, Göttingen,
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Germany
Knobloch syndrome is an autosomal recessive condition
with mainly ocular manifestations and usually normal
intelligence. Additionally to the severe ocular phenotype an
occipital encephalocele and occipital scalp defects have
been described as a speciﬁc feature. Since the ﬁrst clinical
report in 1971 by Knobloch et al. more than 60 patients with
Knobloch syndrome have been reported. In 1996 the
COL18A1 gene was identiﬁed to cause Knobloch syn-
drome. Yet the clinical diagnosis remains challenging,
especially in patients lacking encephalocele. Due to this, in
the last years mutations in COL18A1 gene were found using
modern sequencing techniques, leading to expanded
knowledge on the phenotype of Knobloch syndrome with
additional neurological features, such as malformations of
the brain cortex and intellectual impairment.
We report on two siblings in a non-consanguineous
German family with typical ocular ﬁndings (myopia magna,
nystagmus, macular hypoplasia, defects of the retinal pig-
ment epithelium, retinal detachment, posterior subscapular
lens opacity) and occipital meningocele in one patient as
well as occipital area of alopecia in the other patient. The
ﬁndings lead to the clinical diagnosis of Knobloch syn-
drome, which was conﬁrmed by Sanger sequencing of the
COL18A1 gene, showing compound heterozygosity for two
novel mutations (a frameshift mutation c.1727_1740dupG-
GAGGGACGGCACC and a splice site mutation c.3618+1
G>T) in the index patient, conﬁrming the clinical diagnosis
of Knobloch syndrome. The parents were shown to be
heterozygous for each COL18A1 mutation.
In addition we review the literature, presenting the clin-
ical and molecular ﬁndings of all 64 patients with Knobloch
syndrome described up to date.
I. Hüning: None. L. Voges: None. B. Neppert: None. J.
Sperner: None. G. Gillessen-Kaesbach: None.
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HOXC4 gene is possibly responsible for Lin-Gettig
syndrome
T. Atik1, E. Isik1, S. Ozen2, B. Akgun1, H. Onay3, O.
Cogulu1, B. Erguner4, S. Savas4, F. Ozkinay1
1Pediatric Genetics Subdivision, Department of Pediatrics,
School of Medicine, Ege University, Izmir, Turkey, 2Pedia-
tric Endocrinology Subdivision, Department of Pediatrics,
School of Medicine, Ege University, Izmir, Turkey,
3Department of Medical Genetics, School of Medicine,
Ege University, Izmir, Turkey, 4Advanced Genomics and
Bioinformatics Research Center (IGBAM), BILGEM, The
Scientiﬁc and Technological Research Council of Turkey
(TUBITAK), Kocaeli, Turkey
Lin-Gettig syndrome, described by Lin and Gettig in 1990,
is a very rare autosomal recessive disease. The syndrome is
characterized by craniosynostosis, severe mental retarda-
tion, absence of corpus callosum, dysmorphic facial fea-
tures, camptodactyly and hypogonadism. The molecular
etiology of the syndrome has not yet been identiﬁed yet. In
this report, we present a patient diagnosed as Lin-Gettig
syndrome via clinical ﬁndings. Molecular genetic studies
have revealed that HOXC4 may be the responsible gene
responsible for this syndrome. Due to motor-mental retar-
dation and abnormal facial features a 15-month-old boy was
referred to our department for genetic conselling and dif-
ferantial diagnosis. On physical examination, his weight,
height and head circumference were measured to be 9.4kg
(10th-25th centile), 74cm (3th-10th centile), 43cm (<3th
centile), respectively. He had microcephaly and trigonoce-
pohaly, proptosis, downslanting palpebral ﬁssures, midface
hypoplasia, depressed nasal bridge, short columella,
micrognatia and low-set dysplastic ears. His genital exam-
ination showed micropenis, biﬁd scrotum and cryptorchid-
ism. Craniosynostosis was diagnosed using 3D
computerized tomography. Brain magnetic resonance ima-
ging (MRI) revealed a Chiari I malformation. Exome
sequencing of the proband showed a homozygous c.
410C>G (p. P137R) mutation in HOXC4 gene. The parents
carried this mutation heterozygously. It has been considered
a mutations in HOXC4 gene is the most probable candidate
responsible for the underlying molecular etiology in the
syndrome. This is the ﬁrst study in the literature deﬁning a
gene considered to be responsible for Lin-Gettig syndrome.
T. Atik: None. E. Isik: None. S. Ozen: None. B.
Akgun: None. H. Onay: None. O. Cogulu: None. B.
Erguner: None. S. Savas: None. F. Ozkinay: None.
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Lissencephaly, osteopenia, and recurrent bone fractures
caused by a novel de novo CUT2 domain mutation of the
SATB2 gene
C. Lam1, C. Law1, E. Yau2, G. Ng2, M. Leung2, N. Fong2
Department of Pathology, The University of Hong Kong,
Hong Kong, China, 2Department of Paediatrics and
Adolescent Medicine, Princess Margaret Hospital, Hong
Kong, China
Introduction: The proband is a 19-month-old Chinese boy
who presented with global developmental delay, epilepsy,
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teeth anomalies and severe osteopenia with recurrent frac-
tures. MRI brain showed pachygyria, lissencephaly, white
matter hypoplasia and partial agenesis of corpus callosum.
Materials and Methods: This case was enrolled in our
Undiagnosed Diseases Program for ending diagnostic
odyssey. We initiated genetic analysis for neurodevelop-
mental impairment using whole-exome sequencing (WES).
Results: WES revealed a novel heterozygous missense
variant in SATB2 gene, NM_001172509.1:c.1555G>A (p.
Glu519Lys) which is predicted to be probably damaging
(PolyPhen-2) and deleterious (SIFT). The mutation was not
detected in the parents. No pathogenic variants were
detected in other neurodevelopmental genes. The history of
recurrent fractures also raises the suspicion of osteogenesis
imperfecta (OI). Through WES, no pathogenic variant in all
known OI-causing genes was found.
Conclusions: This is the ﬁrst report describing SATB2-
associated lissencephaly. The cardinal features of SATB2-
associated syndrome (SAS) include developmental delay/
intellectual disability (ID), craniofacial abnormalities, dys-
morphic features, behaviour problems and palatal/teeth
anomalies. Recently, SATB2-associated bone abnormalities
had been reported and is potentially treatable by osteoclast
inhibitors. SATB2 is a Special AT-rich Binding protein 2
which regulates transcription and remodels chromatin by
binding to speciﬁc genomic matrix. This gene is vital for
craniofacial development and bone regeneration. SATB2
haploinsufﬁciency is now regarded as a common cause for
syndromic ID. SATB2 is highly expressed in cortical neu-
rons which regulates migration of neuronal axons in the
corpus callosum. The p.Glu519Lys, locating in the CUT2
domain, probably interfere the SATB2 mobility and result
to lissencephaly-pachygyria spectrum.
C. Lam: None. C. Law: None. E. Yau: None. G. Ng:
None. M. Leung: None. N. Fong: None.
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Acute treatment decision based on whole exome sequencing
result
F. A. M. Duijkers, A. S. Plomp, R. R. G. Knops, L. A.
Menke, M. Alders
AMC, Amsterdam, Netherlands
Case report A term boy presented with icterus due to a
prenatal intracerebral haemorrhage, cardiac malformation
(VSD, ASD and overriding aorta) and congenital cutaneous
vascular malformations. Besides telecanthus, no major
dysmorphic features were seen. Lymphangioendothelio-
matosis (skin biopsy) and closed lip schizencephaly (MRI-
brain) were identiﬁed. Whole exome sequencing (WES)
was performed. Just before WES results were known, the
patient presented with proptosis due to an intraorbital
venous malformation and several cerebral venous mal-
formations. Treatment with corticosteroids or rapamycin
was considered. Methods WES of the patient, the father and
egg donor was performed. Horizontal coverage was 90.9%
at 30x read depth. Variants identiﬁed in the index ﬁtting a
de novo, autosomal recessive or X-linked inheritance were
analysed. Results A de novo probably pathogenic missense
variant in the TEK-gene was identiﬁed (c.3361G>A; p.
(Glu1121Lys)). Discussion The tyrosine kinase receptor
(TEK) is located in the vascular endothelium and plays an
important role in blood vessel formation and cardiac
development. Patients with activating missense mutations in
this gene have been reported to have cutaneous and mucous
membrane venous malformations. Also ventricular septum
defects have been described in some patients with a germ-
line TEK mutation. Although our patient has different
cutaneous vascular malformations, the TEK mutation is
very probable the cause of his disease. Supported by good
results in mice and patients with somatic TEK mutations,
treatment was started with rapamycin. Six months after
initiation of therapy the cutaneous malformations were
unchanged, but the intracerebral malformations were sig-
niﬁcantly decreased in size.
F.A.M. Duijkers: None. A.S. Plomp: None. R.R.G.
Knops: None. L.A. Menke: None. M. Alders: None.
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Next generation sequencing identiﬁes missense mutations in
EPHB4 causing autosomal dominant generalised lymphatic
dysplasia
S. Martin-Almedina1, G. Brice1, K. Gordon1, S. Lin2, S.
Rockson2, S. Jeffery1, P. Mortimer1, S. Berland3, S.
Mansour1, P. Ostergaard1
St George's University of London, London, United King-
dom, 2Stanford University, Stanford, CA, United States,
3Haukeland University Hospital, Bergen, Norway
Generalised lymphatic dysplasia (GLD) is a rare form of
primary lymphoedema characterised by widespread oedema
including systemic or visceral involvement. The lymphatic
dysfunction often presents prenatally as non-immune
hydrops fetalis. Three autosomal recessive forms of GLD
have been reported previously which suggest high genetic
heterogeneity. The aim of this study was to investigate what
appear to be an autosomal dominant form of GLD.
We studied two multigenerational families with a het-
erogeneous and variable phenotype. Both presented a large
number of in utero and neonatal deaths associated with non-
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immune hydrops fetalis. Whole-exome sequencing (WES)
and Sanger sequencing analysis identiﬁed novel missense
variants in the gene encoding Ephrin receptor B4 (EPHB4),
known to play an important role in lymphangiogenesis. The
two mutations occur at highly conserved residues located in
the tyrosine kinase domain of the EPHB4 protein and are
predicted to compromise protein function. Site-directed
mutagenesis was performed to generate expression con-
structs for the mutant proteins and the phosphorylation
activity was analysed by western blot after transient trans-
fection in HEK293 cells. Mutated proteins showed lack of
phosphorylation compared to wild-type protein indicating
that these novel mutations in the EPHB4 gene inactivate the
tyrosine kinase receptor.
Therefore, mutations in EPHB4 can cause a new form of
GLD with a high mortality. This also suggests not only is
GLD genetically heterogeneous, but it should also be con-
sidered in an autosomal dominant form. This work was
funded by British Heart Foundation (SP/13/5/30288) and
Newlife Foundation for Disabled Children (12-13/01).
S. Martin-Almedina: None. G. Brice: None. K. Gor-
don: None. S. Lin: None. S. Rockson: None. S. Jeffery:
None. P. Mortimer: None. S. Berland: None. S. Man-
sour: None. P. Ostergaard: None.
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Marshall-Smith syndrome in a newborn boy presenting with
respiratory distress and micrognathia
U. Grasshoff1, M. Kehrer1, J. Arand2, S. Müller-
Hagedorn2, M. Zenker3
1Institute of Medical Genetics and Applied Genomics,
Tuebingen, Germany, 2University Hospital, Tuebingen,
Germany, 3Institute of Human Genetics, Magdeburg,
Germany
Introduction: Marshall-Smith syndrome is a very rare
congenital malformation syndrome with less than 100 cases
reported to date. The patients usually show characteristic
facial features, a dysharmonic bone maturation with
advanced bone age, respiratory difﬁculties due to upper
airway obstruction and a moderate to severe developmental
delay. Heterozygous mutations and deletions in the nuclear
factor 1/X gene (NFIX) are the only known cause for
Marshall-Smith syndrome. Case report: We report a new-
born boy with the initial diagnosis of Pierre-Robin
sequence. He was referred to the neonatal intensive care
unit with acute airway obstruction for a treatment with an
orthodontic palate plate (Tuebingen soft palate plate). In
addition to his respiratory problems and micrognathia he
presented with a long face, proptosis and a short nose with
anteverted nares. Hands and feet were large with very long
ﬁngers and toes. A radiograph of a hand showed a very
advanced bone age with a mean of 2 years. The suspected
diagnosis of Marshall-Smith syndrome was supported by a
de novo heterozygous missense variation in the NFIX gene
(c.955G>C). The orthodontic palate plate proved to be a
very satisfactory treatment for the child’s airway obstruc-
tion. Conclusion: Very young patients with milder forms of
Marshall-Smith syndrome might be misdiagnosed as iso-
lated Pierre-Robin sequence because the prevalent clinical
features, airway obstruction and micrognathia, are similar in
both entities.
U. Grasshoff: None. M. Kehrer: None. J. Arand:
None. S. Müller-Hagedorn: None. M. Zenker: None.
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Question mark ear as a clue for loss of MEF2C function in
patients with intellectual deﬁciency
J. Amiel1,2,3, A. Tessier4,1, Z. Demir3, A. Goldenberg4, M.
Oufadem1, N. Voisin1,2, V. Pingault1,2,3, T. Bienvenu5, S.
Lyonnet1,2,6, L. de Pontual1,7, C. Gordon1,2
Laboratory of embryology and genetics of congenital
malformations, Institut National de la Santé et de la
Recherche Médicale (INSERM) UMR 1163, Institut Ima-
gine, Paris, France, 2Paris Descartes-Sorbonne Paris cité
university, Institut Imagine, Paris, France, 3Département de
Génétique, Hôpital Necker-Enfants Malades, Assistance
Publique Hôpitaux de Paris (AP-HP), Paris, France,
4Service de Génétique, CHU de Rouen, Centre Normand
de Génomique Médicale et Médecine Personnalisée, Rouen,
France, 5Laboratoire de biochimie et génétique molécu-
laire, Hôpital Cochin, Paris, France, 6Département de
Génétique, Hôpital Necker-Enfants Malades, Assistance
Publique Hôpitaux de Paris (AP-HP),, Paris, France,
7Service de pédiatrie, Hôpital Jean Verdier, Bondy, France
Auriculocondylar syndrome (ACS, OMIM # 602483 and #
614669) is a rare disorder of the ﬁrst and second pharyngeal
arches (PAs), combining mandibular hypoplasia, condylar
abnormalities and a distinctive anomaly of the pinnae
described as a question mark ear (QME). Isolated QME
(OMIM # 612798) has also been reported. The disease-
causing genes act within the endothelin 1 (EDN1)-endo-
thelin receptor type A (EDNRA) signaling pathway, and
include phospholipase C, beta 4 (PLCB4), guanine
nucleotide binding protein (G protein), alpha inhibiting
activity polypeptide 3 (GNAI3) and endothelin 1 (EDN1).
Here we report 2 patients with a unilateral or bilateral QME,
developmental delay and intellectual deﬁciency. This
combination is highly suggestive of MEF2C loss-of-
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function (deletion encompassing MEF2C in one case and a
frameshift mutation in the other, NM_002397.4, c.146dup,
p.Asn49Lysfs*29). Indeed, on the one hand, heterozygous
deletions encompassing MEF2C or loss-of-function muta-
tions have been identiﬁed in patients presenting congenital
encephalopathy with intellectual disability, severe hypoto-
nia, poor communication and stereotypic hand movements
with or without epilepsy and non-speciﬁc brain anomalies.
On the other hand Mef2c is essential for development of the
craniofacial skeleton in mice and zebraﬁsh and is a tran-
scriptional target of endothelin signaling in neural crest
cells. The penetrance of QME in patients with MEF2C
haploinsufﬁciency can be estimated at 4% (2/54). It is thus a
rare but highly distinctive feature among patients with
severe encephalopathy. Thus, mutations in EDN1, PLCB4,
GNAI3 and MEF2C disrupt the endothelin pathway and
lead to ACS or QME in humans.
J. Amiel: None. A. Tessier: None. Z. Demir: None. A.
Goldenberg: None. M. Oufadem: None. N. Voisin: None.
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Expanding genotype and phenotype of MEIS2-related
neurocristopathy
S. Kupchik1, A. Revah-Politi2, N. Stong2, K. Anyane-
Yeboa2
1Maimonides Medical Center, Brooklyn, NY, United States,
2Columbia University Medical Center, New York, NY,
United States
Loss of function variants in MEIS genes may be linked to
neurocristopathies as MEIS proteins are involved in neural
crest cell development.MEIS2 intragenic gene variants have
been described in individuals with congenital heart defects,
cleft palate, dysmorphic features, autism, developmental
delay, and gastroesophageal reﬂux disorder (GERD). A
similar presentation is seen in 15q14 deletion syndrome, a
multi-gene deletion that includes MEIS2. Fourteen patients
with MEIS2 aberrations from twelve families have been
reported. Aberrations include multi-gene deletions, an
intragenic single exon deletion, an intragenic duplication, an
in-frame deletion and a nonsense variant. We present a
patient with a de novo germline frameshift MEIS2 variant
and previously undescribed clinical features.
Our patient has developmental delays and dysmorphic
features including biﬁd uvula and possible submucosal cleft
palate. Echocardiogram is normal. He had cryptorchidism,
inguinal hernia and meatal stenosis. He also has precocious
adrenarche with a slightly advanced bone age, mild vitamin
D deﬁciency, hyperlipidemia and episodes of GERD. He
developed iris nevus/melanocytosis at 7 years of age.
Trio whole exome sequencing was performed through an
institutional review board approved research study at the
Institute for Genomic Medicine of Columbia University.
A de novo frameshift variant (c.868dupA, p.
Ile290AsnfsTer40) in MEIS2 was identiﬁed in our patient.
To date, frameshift variants in MEIS2 have not been
reported.
The phenotype of individuals with MEIS2 variants has
not been completely delineated. Additional features will be
identiﬁed as more patients are reported. This case expands
both phenotype and range of molecular aberrations for this
rare, recently described neurocristopathy.
S. Kupchik: None. A. Revah-Politi: None. N. Stong:
None. K. Anyane-Yeboa: None.
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ARCN1 haploinsuﬁciency causes a microcephalic dwarﬁsm
due to COPI-mediated transport defects
S. Passemard1,2,3, K. Izumi4,5,6, M. Brett7, E. Nishi6, S.
Drunat1,2, E. Tan8, K. Fujiki5, S. Lebon1,3, B. Cham8, K.
Masuda5, M. Arakawa6, A. Jacquinet9, Y. Yamazumi10, S.
Chen5, A. Verloes2, Y. Katou5, P. Gressens1,3,11, R. Foo12,
E. Tan7, K. Shirahige5,13, V. El Ghouzzi1,3
INSERM U1141-PROTECT, Paris, France, 2AP-HP, Hôpi-
tal Robert Debré, Département de Génétique, Paris,
France, 3Université Paris Diderot Paris 7, Paris, France,
4Division of Human Genetics, The Children’s Hospital of
Philadelphia, Pennsylvania, Philadelphia, PA, United
States, 5Research Center for Epigenetic Disease, Institute
for Molecular and Cellular Biosciences, The University of
Tokyo, Tokyo, Japan, 6Division of Medical Genetics,
Nagano Children’s Hospital, Azumino, Japan, 7KK
Research Centre, KK Women's and Children's Hospital,
Singapore, Singapore, 8Genetics Service, Department of
Paediatrics, KK Women's and Children's Hospital, Singa-
pore, Singapore, 9Département de Génétique, CHU et
Université de Liège, Liège, Belgium, 10Laboratory of
Molecular and Genetic Information, Institute of Molecular
and Cellular Biosciences, University of Tokyo, Tokyo,
Japan, 11Center for Developing Brain, King’s College, St.
Thomas’ Campus, London, London, United Kingdom,
12Genome Institute, Singapore, Singapore, 13CREST, Japan
Science and Technology Agency, Kawaguchi, Japan
We report on 4 patients in 3 independent families with a
newly described autosomal dominant form of microcephalic
dwarﬁsm, associated with micrognatia, shortening of fore-
arms and legs and mild intellectual delay. Exome
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sequencing revealed heterozygous nonsense and frameshift
mutations in ARCN1, leading to gene haploinsufﬁciency.
ARCN1 encodes the subunit delta of the heptameric coat
protein I (COPI), a complex required for retrograde trans-
port of proteins and lipids from the Golgi apparatus to the
endoplasmic reticulum (ER). Down-regulation of the gene
in cell lines or in patient's primary ﬁbroblasts resulted in
overexpression of stress response genes such as ATF4,
DDIT3 and HSPA5, cytosolic accumulation of BiP/GRP78
and reduced secretion of type I collagen, suggesting the
involvement of ER stress response and transport defects in
the pathogenesis of this disorder.
Our ﬁndings demonstrate the importance of COPI-
mediated transport in human development, including ske-
letogenesis and brain growth.
S. Passemard: None. K. Izumi: None. M. Brett: None.
E. Nishi: None. S. Drunat: None. E. Tan: None. K.
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MIRAGE syndrome - a new form of syndromic adrenal
hypoplasia caused by a novel heterozygous activating
mutation p.Leu641Pro in the SAMD9 Gene in mosaic form
D. Ilencikova1, B. Csillag2, M. Meissl3, F. Laccone4, H.
Duba1
1Institute of Medical Genetics, Kepler University Hospital,
Med Campus IV, Linz, Austria, 2Department of Neonatol-
ogy Intensive Care, Kepler University Hospital, Med
Campus IV, Linz, Austria, 3Department of Pediatrics,
Kepler University Hospital, Med Campus IV, Linz, Austria,
4Institute of Medical Genetics, Center of Pathobiochemistry
and Genetics, Medical University, Vienna, Austria
We report a 14 months old Austrian boy with a features of
syndromic adrenal hypoplasia. He was born at 32+0th
pregnancy week per caesarean section because of prenatal
growth retardation and Oligohydramnios. The infant pre-
sented with birth weight of 996 g (-2.25 s.d.) and birth
length 39 cm (-1.44 s.d.), OFC 26 cm (-2.55 s.d.), peno-
scrotal hypospadia and APGAR 6/7/8. He developed
respiratory and catecholamine-dependent circulatory insuf-
ﬁciency. After administration of cortisol it took a turn to
immense clinical improvement. and by ultrasound an
adrenal hypoplasia was diagnosed. Causative genes for
syndromic adrenal hypoplasia as DAX1 and CDKN1C were
without ﬁnding of any germline mutation. At the age of
1 month he presented disturbed myelopoesis with throm-
bocytopenia and anemia. Since birth he was treated for
recurrent infections (more than 16 times) and for the chronic
watery diarrhea with severe wound healing perianal and
chronic ulcers. At the age of 10 month we performed
Exome sequencing and during the analysis we investigated
the ﬁrst information about a novel multisystem disorder
named MIRAGE (Myeolodysplasia, Infection, Restriction
of growth, Adrenal hypoplasia, Genital phenotypes,
Enteropathy) published in May 2016 by Narumi at al.
Considering this we supposed a germline mutation in the
SAMD9 gene. The Exom-analysis revealed a heterozygous
Mutation p.Leu641Pro in mosaic form (22% pathologic cell
line). It has probably evolved postzygotic and arised de
novo as all previously published 11 Corian and Japanese
cases by Narumi et al. We here, to our best knowledge,
present the ﬁrst report about European infant with MIRAGE
Syndrome.
D. Ilencikova: None. B. Csillag: None. M. Meissl:
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The case of double diagnosis - MKRN3-related central
precocious puberty diagnosed after CHD8-related autism
spectrum disorder in a father and his daughter
M. Yakoreva1,2, T. Reimand1,2,3, S. Pajusalu1,2, A. Peet4,5,
K. Õunap1,2
Department of Clinical Genetics, United Laboratories,
Tartu University Hospital, Tartu, Estonia, 2Department of
Clinical Genetics, Institute of Clinical Medicine, University
of Tartu, Tartu, Estonia, 3Department of Biomedicine,
Institute of Biomedicine and Translational Medicine,
University of Tartu, Tartu, Estonia, 4Children’s Clinic,
Tartu University Hospital, Tartu, Estonia, 5Department of
Pediatrics, Institute of Clinical Medicine, University of
Tartu, Tartu, Estonia
Central precocious puberty syndrome (CPP) is a rare con-
dition characterized by premature activation of the
hypothalamic-pituitary-gonadal axis resulting in an early
development of secondary sexual characteristics. Loss-of-
function mutations in the imprinted MKRN3 gene are found
to be the most frequent cause of familial CPP affecting both
girls and boys. Because the maternal allele of MKRN3 gene
is normally silenced, the disease manifests only in the case
of paternal transmission. Here, we present a case of familial
CPP in combination with autosomal dominant CHD8 gene-
related syndrome.
The proband is a girl ﬁrst referred to genetic counselling
at 2.5 years of age due to mild intellectual disability, autistic
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behaviour, epilepsy, macrocephaly, dysmorphic features
and atrial septal defect. Her father and younger brother have
similar developmental problems and macrocephaly. NGS
analysis (TruSight One panel) revealed a heterozygous
mutation c.2423_2424del (p.Arg808Lysfs*12) in the CHD8
gene. Mutation appeared de novo in father and was detected
in the brother.
At the age of 4.5 years, the breast growth started in the
proband. Menarche occurred at 6.5 years. As the precocious
puberty is not typical for CHD8 gene mutations, reanalysis
of NGS data was performed and a heterozygous mutation
c.326G>A (p.Cys109Tyr) in MKRN3 was found. Familial
segregation analysis showed that both proband and her
father inherited the MKRN3 gene mutation from their
fathers. In addition pituitary microadenoma was visualised
in MRI scan.
In conclusion, in the case of atypical symptoms of
genetic disorder, additional genetic testing or data reanalysis
should be performed to test for double diagnosis.
M. Yakoreva: None. T. Reimand: None. S. Pajusalu:
None. A. Peet: None. K. Õunap: None.
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Mosaic tetrasomy 8p associated with mild phenotype
A. Ivankov1, A. Bobinec1, M. Rogac2, I. Sansovic1, I.
Barisić1
1Children's hospital Zagreb, Medical School University of
Zagreb, Zagreb, Croatia, 2Clinical Institute of Medical
Genetics, University Medical Center Ljubljana, Ljubljana,
Slovenia
Introduction: Tetrasomy 8p is a rare chromosomal disorder
generally detected in mosaic form, with 15 cases reported so
far. The phenotype is characterized by agenesis of corpus
callosum (ACC), enlarged cerebral ventricles, congenital
heart defects (CHD), mild facial dysmorphisms, rib and
vertebral abnormalities, and mild to moderate develop-
mental delay. Here we report on a 4.5-year old girl with
mosaic tetrasomy 8p that came to our attention due to mild
facial dysmorphia and failure to thrive.
Results: She had moderate global developmental delay
since birth. She started to walk at 21 months of age and used
few words with meaning at 3.5 years. Failure to thrive due
to feeding difﬁculties was ﬁrst noticed at one year. Clinical
examination showed mild facial dysmorphia (high forehead,
hypoplastic malar region, narrow palpebral ﬁssures, wide
nasal root, high palate, micrognathia), scoliosis and hypo-
tonia. Extensive evaluation including neuroimaging, ultra-
sound examination of heart and kidneys and skeletal X-rays
didn’t show additional anomalies. Cytogenetic analysis
revealed mosaic karyotype: 47,XX,i(8)(p10)[18]/46,XX
[82]. The isochromosome identity was conﬁrmed and fur-
ther characterized by chromosomal microarray.
Conclusion: Most cases of tetrasomy 8p described so far
had at least one congenital anomaly, such as CHD, ACC,
rib and/or vertebral anomalies. Still, 3 patients, including
our patient, showed only minor facial anomalies, hypotonia,
and developmental delay, affecting mainly gross motor
skills, speech and language development. Our patient sup-
ports the observation that mosaic tetrasomy 8p can present
with mild clinical phenotype and highlights the potential of
missing the diagnosis that might be more common than
previously assumed.
A. Ivankov: None. A. Bobinec: None. M. Rogac:
None. I. Sansovic: None. I. Barisić: None.
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Identiﬁcation of a denovo novel missense mutation in ZEB2
gene in a Turkish boy with Mowat Wilson Syndrome
D. Kan Karaer, A. i. Gurler, K. Karaer
Department of Genetic Dr.Ersin Arslan Research and
Training Hospital, Gaziantep, Turkey
Mowat-Wilson syndrome (MWS) is a multiple congenital
anomaly syndrome characterized by moderate or severe
intellectual disability, a characteristic facial appearance,
microcephaly, epilepsy, agenesis or hypoplasia of the cor-
pus callosum, congenital heart defects, Hirschsprung dis-
ease, and urogenital/renal anomalies. It is caused by de
novo heterozygous loss of function mutations including
nonsense mutations, frameshift mutations, and deletions in
ZEB2 at 2q22. A 4 months old boy was referred to genetic
counselling because of congenital anomalies and dys-
morphic features. He was borned to healthy consanguineous
parents. The child had had typical facial ﬁndings; square
shaped face with a prominent but narrow triangular chin,
hypertelorism, deep set but large eyes, broad nasal bridge,
saddle nose, prominent, rounded nasal tip, open mouth, full
or everted lower lip, posteriorly rotated ears, and large
uplifted ear lobes with a central depression. Further, there
was no evidence of dysmorphic ﬁndings in any relative. A
mutation analysis of ZEB2 gene was requested. The results
revealed a previously unpublished sequence variant a mis-
sense c.1660_1664delATAAA in a heterozygous state. As a
consequence of this sequence variation, a reading code shift
occurs that generates stop codon 13 amino acids down-
stream of the deletion, predicting the translation of a trun-
cated protein. Sequencing of ZEB2 gene of both parents was
performed, but the variant was not found, conﬁrming a
denovo event.Thus, clinical data of this family were
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presented by moderate or mild form of the disease. Fuc-
tional studies and more reports are required to understand
for the affect of the mutation and genotype-phenotype
correlation.
D. Kan Karaer: None. A.I. Gurler: None. K. Karaer:
None.
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Mowat-Wilson syndrome in Polish patients
R. Smigiel1, M. Badura-Stronka2, K. Szczałuba3, A.
Jakubiak4, M. Wiśniewska2, E. Obersztyn5, A.
Kutkowska-Kaźmierczak5, T. Chilarska6, J. Pilch7, M.
Kugaudo8, K. Wicher9, A. Jakubiuk-Tomaszuk10, J.
Wierzba11, G. Bugaj2, A. Latos-Bieleńska2, M. Sasiadek4,
M. Krajewska-Walasek12
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New Roman",serif;} Mowat-Wilson syndrome (MWS) is a
rare multisystem congenital disorder. Incidence of MWS is
currently unknown, estimated birth incidence is 50000–
100000. MWS is caused by mutations in gene ZEB2 or
deletions in region 2q22-23. Facial dysmorphy in MWS is
very characteristic and it changes with age. Among con-
genital anomalies most often appears: Hirschsprung disease,
heart defects, brain anomalies, genitourinary system
anomalies and eye abnormalities. Developmental delay is
present, with subsequent intellectual disability. Language
develop tardily, and usually is restricted to few words.
Behavioral phenotype is similar to Angelman syndrome.
We report on clinical and genetic ﬁndings of 18 Polish
patients with diagnosis of MWS. All presented patients
have classical facial phenotype (uplifted ear lobe with
central depression, pointed chin and prognathism in elders),
severe developmental defects, intellectual disability and at
least one congenital anomaly. Language development was
impaired, older patients do not develop expressive lan-
guage. Hirschsprung disease was present in 3 patients (it
suggests that MWS is underdiagnosed in Polish patients
with Hirschsprung disease), 85% patients - heart defect,
55% - brain abnormalities. 45% patients - urogenital or
renal anomalies. All male patients had cryptorchidism and
only two of them had hypospadias. We observe genotype-
phenotype correction between point mutation and exons
deletion of ZEB2 gene and severity of phenotype.
R. Smigiel: None. M. Badura-Stronka: None. K.
Szczałuba: None. A. Jakubiak: None. M. Wiśniewska:
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Smith-Kingsmore Syndrome: four new cases, clinical and
molecular review, and testing recommendations
G. Gordo1,2, J. Tenorio1,2, P. Arias1,2, F. Santos-
Simarro1,2, S. García-Miñaúr1,2, J. Nevado1,2, E.
Vallespín1,2, L. Rodriguez-Laguna1,2, R. Mena1,2, I.
Dapía1,2, M. Palomares1,2, Á. Del Pozo1,2, K. Ibáñez1,2, J.
C. Silla1,2, E. Barroso1,2, V. L. Ruiz-Pérez3,2, V. Martínez-
Glez1,2, P. Lapunzina1,2
INGEMM-Institute of Medical and Molecular Genetics,
IdiPAZ, Hospital Universitario la Paz, Universidad Autón-
oma de Madrid (UAM), Madrid, Spain, 2CIBERER, Centro
de Investigación Biomédica en Red de Enfermedades
Raras, ISCIII, Madrid, Spain, 3IIB, Instituto de Investiga-
ción “Alberto Sols”, UAM, Madrid, Spain
Introduction Smith-Kinsgmore (SKS) is a rare macro-
cephaly/intellectual disability/epilepsy syndrome caused by
mTOR germline mutations. We add four new patients to the
24 previously reported and review the syndrome.
Material and methods Two unrelated patients and two
siblings were assessed and studied by deep coverage NGS
designed to study somatic mosaic syndromes, since they
were originally referred with clinical diagnosis of
Macrocephaly-Capillary Malformation —caused by
somatic mosaic PIK3CA mutations— or Macrocephaly.
Results Major diagnostic criteria for SKS are intellectual
disability (24/26), macrocephaly/megalencephaly or hemi-
megalencephaly (25/28) and seizures (18/23). Nevertheless,
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some less frequent features reported for SKS are also pre-
sent in other PI3K-AKT-mTOR syndromes. In our study,
one patient showed the common mTOR p.Glu1799Lys
variant —present in 13/28 patients—. The variant p.
Phe2202Cys was detected in two siblings, and was not
present in their parents, thus gonadal mosaicism is sus-
pected —described before in other 3 families—. Last
patient showed the p.Cys1483Tyr variant in mosaic (2%
blood, 11% saliva, 32% skin), so it cannot be strictly con-
sidered a case of SKS caused by germline mutations. No
clear genotype-phenotype correlation was found.
Conclusions SKS must be suspected in patients with
intellectual disability, macrocephaly/megalencephaly or
hemimegalencephaly, and seizures. mTOR germline muta-
tions can be detected by Sanger sequencing; however, due
to the great variety of syndromes with highly overlapping
clinical features which comprise the differential diagnosis in
SKS, as well as to the presence of both germ and low
somatic mosaic mutations, we recommend performing deep
coverage NGS for the detection of possible mosaic variants.
Grant: FIS-PI15/01481
G. Gordo: None. J. Tenorio: None. P. Arias: None. F.
Santos-Simarro: None. S. García-Miñaúr: None. J.
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New intragenic rearrangements in non-Finnish MULIBREY
nanism
F. Jobic1, G. Morin1, C. Vincent-Delorme2, E. Cadet1,3, R.
Cabry1,3, N. Celton1, T. Dery1, H. Copin1,3, M. Mathieu-
Dramard1, J. Rochette1,3, G. Jedraszak1,3
1University Hospital of Amiens, Amiens, France, 2Univer-
sity Hospital of Lille, Lille, France, 3Université de Picardie
Jules Verne, Amiens, France
Prenatal growth is a complex dynamic process controlled by
a variety of genetic and environmental factors. Among
genetic syndromes characterized by growth restriction,
MULIBREY nanism represents a rare autosomal recessive
condition presenting with severe pre-and post-natal growth
failure, characteristic dysmorphic features but normal neu-
rological development. The phenotype of MULIBRREY
nanism is variable and overlaps to such as the Silver Russell
syndrome. We report here three patients in two distinct non-
ﬁnnish families who were ﬁrst clinically suspected to have
Silver-Russell syndrome. Molecular analyses did not
conﬁrm a Silver-Russell syndrome. Clinical features in the
three patients led us to also consider the diagnosis of
MULIBREY nanism. Sequencing of the TRIM37 gene
showed the same novel nonsense mutation (c.181 C>T p.
Arg61*) in the three patients in a heterozygous state. We
used a quantitative ﬂuorescent multiplex PCR approach to
explore potential gene rearrangement in TRIM37 which led
to identiﬁcation of a new deletion of exons 15 and 16 in one
isolated patient and of another deletion of exon 9 in two
siblings. Breakpoints of both the deletions were character-
ized and revealed implication of Alu sequences. Given the
high number of Alu sequences, which predisposes to gene
rearrangements, in introns of TRIM37, one should always
consider such genetic mutations in the molecular diagnosis
of MULIBREY nanism. The clinical study conﬁrms the
usefulness of a precocious and careful cardiologic follow up
of the patients, even if they are no sign of heart disease.
F. Jobic: None. G. Morin: None. C. Vincent-Delorme:
None. E. Cadet: None. R. Cabry: None. N. Celton: None.
T. Dery: None. H. Copin: None. M. Mathieu-Dramard:
None. J. Rochette: None. G. Jedraszak: None.
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Familiar case of Myhre syndrome
A. Serrano Antón1, M. Sánchez Soler2,3, M. Ballesta
Martínez2,3, L. Rodríguez Peña2, E. Guillén Navarro4, M.
Segura Puimedon5, B. Rodríguez Santiago5, V. López
González2,3
Sección Genética Médica. Servicio de Pediatría. Hospital
Clínico Universitario Virgen de la Arrixaca (HCUVA),
Murcia, Spain, 2Sección Genética Médica. Servicio de
Pediatría, HCUVA. IMIB-Arrixaca., Murcia, Spain, 3Grupo
Clínico Vinculado al Centro de Investigación Biomédica en
Red de Enfermedades Raras (CIBERER), Instituto de Salud
Carlos III (ISCIII)., Madrid, Spain, 4Consejería de Sanidad,
Murcia, Spain, 5Research and Development Department,
qGenomics Laboratory., Barcelona, Spain
INTRODUCTION. Myhre syndrome (MS) (MIM#139210)
is an autosomal dominant disorder mainly characterized by
dysmorphic facial features, short stature, skeletal anomalies,
muscle pseudohypertrophy, restricted joint mobility, thick
skin and variable intelectual disability. It is often sporadic,
due to gain-of-function mutations in SMAD4. We report on
a new patient with suspected maternal origin.
CLINICAL CASE. 22-year-old boy, born to non con-
sanguineous parents. His mother and sister presented with
short stature, brachydactyly, mild cognitive impairment,
and similar facial phenotype. Uneventful pregnancy, born at
term small to gestational age. His childhood was marked by
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growth and developmental delay. IQ: 48. Associated con-
genital anomalies were right renal agenesis and epigastric
hernia. Clinical phenotype with macrocephaly (2.18 SD),
short stature (-4.6 SD), facial asymmetry, hypertelorism,
prognathism, small ears, broad and short neck. Hoarse
voice. Brachydactyly with slightly progressive ﬁnger and
elbow contractures. Brain MRI, echocardiogram, metabolic
test, arrayCGH, and Fragile-X molecular analysis were
normal. Targeted exome sequencing revealed a c.1498A>G
(p.Ile500Val) mutation at SMAD4, consistent with the
diagnosis of MS. Familiar study is ongoing.
CONCLUSION. We describe the ﬁrst familiar case of
MS. The index patient presents with a classical phenotype
of MS with progressive contractures of ﬁngers as a key
feature for its diagnosis. This uncommon disease should be
bear in mind in the differential diagnosis of patients with
brachydactyly, short stature and macrocephaly. Clinical
suspicion allows earlier diagnosis and proper medical
follow-up to anticipate possible life-threatening complica-
tions such as high blood pressure, pericardial effusion and
recurrent infections.
A. Serrano Antón: None. M. Sánchez Soler: None. M.
Ballesta Martínez: None. L. Rodríguez Peña: None. E.
Guillén Navarro: None. M. Segura Puimedon: None. B.
Rodríguez Santiago: None. V. López González: None.
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Myhre syndrome with novel ﬁndings: bilateral congenital
cortical cataract, bilateral papilledema, accessory nipple and
adenoid hypertrophy
A. Tatar, H. B. Erdem, I. Sahin
Ataturk University, ERZURUM, Turkey
Introduction: Myhre syndrome is a rare autosomal domi-
nant disorder, includes intellectual disability, short stature,
muscular appearance, skeletal abnormalities, decreased joint
mobility, thickened skin, early-onset deafness of mixed
conductive and sensory type and characteristic facial fea-
tures. This syndrome is caused by SMAD4 mutations. Here
we report a 14-year-old boy with multiple features con-
sistent with Myhre syndrome and novel ﬁndings.
Case Report: The 14-year-old boy was referred to our
clinic with mild intellectual disability, short stature, cataract,
hearing loss. He has short strature, characteristic facial
features, adenoid hypertrophy, dry skin, generalized rash,
accessory nipple, joint contractures, brachydactyly and ﬁfth
ﬁnger clinodactyly on both hands. He has also bilateral
congenital cortical cataract, bilateral papilledema and
hypermetropic astigmatism in eye exam. He operated from
right cryptorchidism. He has obsessive-compulsive disorder
and attention deﬁcit hyperactivity disorder. His brain MRI
shows hyperintense plaque on the right cerebral hemi-
sphere. We identiﬁed heterozygosity for an A-to-G transi-
tion at position c.1498, which leads to I500V mutation on
SMAD4 gene. This mutation was described before and was
associated with Myhre syndrome (HGMD: CM110610).
Discussion: Novel clinical ﬁndings in our patient are
accessory nipple, bilateral congenital cortical cataract,
bilateral papilledema and hypernasal speech because of
adenoid hypertrophy. Bilateral cataract was described once
as subcapsular type in Myhre syndrome, and it was not
indicated as congenital or acquired. We suggest that
accessory nipple, bilateral congenital cortical cataract,
bilateral papilledema and hypernasal speech because of
adenoid hypertrophy may evaluate as minor ﬁndings of
Myhre syndrome, in addition to main ﬁndings.
A. Tatar: None. H.B. Erdem: None. I. Sahin: None.
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PTC124 (Ataluren) treatment of nonsense mutations in
BMP4
A. Slavotinek, S. Htun, M. Krall
University of California, San Francisco, San Francisco,
CA, United States
Pharmacological treatments that impact the morphology of
birth defects have not been readily available. Nonsense
suppression therapy (NST) utilizes compounds such as
PTC124 (Ataluren) to induce translational read-through of
stop mutations by promoting the insertion of near cognate
aminoacyl tRNAs that yield functional proteins. We used
PTC124 to determine if we could rescue the phenotypic
defects resulting from stop mutations in BMP4. We gener-
ated p.Arg198* and p.Glu213* mutations in human BMP4
cDNA and obtained bmp4st72/+ zebraﬁsh. After transfection
of 293T/17 cells with wildtype or mutant BMP4 cDNA and
treatment with 0–20μM PTC124, we found a small, non-
signiﬁcant increase in BMP4 expression for both mutations
at 20μM measured with an in-cell ELISA assay. We then
examined the effects of PTC124 treatment on the bmp4st72
nonsense allele in zebraﬁsh. Phenotyping an in-cross of
bmp4st72/+ Danio rerio conﬁrmed the mild to severe tail ﬁn
deformation and cloacal defects previously reported. Doses
of 0–2 μM PTC124 did not affect Mendelian inheritance.
Ventroposterior defects were signiﬁcantly more frequent in
homozygotes compared to other genotypes, consistent with
recessive inheritance of the bmp4st72 allele. For 1μM
PTC124 treatment, there was an increase in homozygous
larvae without phenotypes (non-penetrance), but the dif-
ference was not statistically signiﬁcant. Although the
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increase in non-penetrance suggests rescue by PTC124
could have occurred, non-speciﬁc toxicity was observed,
possibly due to the early timepoint at which treatment was
commenced. We conclude that the utility of PTC124 is
likely to be mutation dependent and that toxicity can occur
at relatively low concentrations in Danio rerio.
A. Slavotinek: F. Consultant/Advisory Board; Modest;
OptumRx. S. Htun: None. M. Krall: None.
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New mutation in NRAS in familial Noonan syndrome
A. Zuñiga1, L. Pedrola1, L. Castillo1, E. Aller1, G. Pi2
1Unidad de Genética. HUP La Fe, Valencia, Spain, 2Serv.
Pediatria. HU La Ribera, Alzira, Spain
Introduction: Noonan syndrome (NS) is a heterogeneous
developmental disorder associated with variable clinical
expression including short stature, congenital heart defect,
unusual pectus deformity and typical facial features, is
caused by activating mutations in genes involved in the
RAS-MAPK signaling pathway. We present a familial case
of a NS patient, her affected brother and father with NRAS
mutation and NS. Materials and Methods: Comprehensive
mutation analysis of NF1, PTPN11, SOS1, CBL, BRAF,
RAF1, SHOC2, MAP2K2, MAP2K1, SPRED1, NRAS,
HRAS and KRAS was performed using targeted next-
generation sequencing. Results: Analysis revealed a
recurrent mutation in NRAS, c.182A>T (p.Gln61Leu) in
the index patient, both father and brother were carriers too.
She was assessed by a clinical geneticist at the age of 3
years due to a peculiar facies in a child with a heart murmur.
Her height and OFC were at the 20th centile and she pre-
sented with a distinctive phenotype suggesting NS: high and
broad forehead, hypertelorism, sparse eyebrows, posteriorly
rotated ears, curly scalp hair, broad chest, and hyperker-
atotic palmar skin. No congenital cardiac anomalies were
found on echocardiography. Her affected father and brother
exhibited anthropometric characteristics similar to the pro-
band, however the boy was discordant for facial features
and had straight hair. Neither of the affected individuals in
this family presented with juvenile myelomonocytic leu-
kemia (JMML). The clinical and genetic heterogeneity
observed in RASopathies is a challenge for genetic testing.
To date, only eight unrelated individuals with NS and three
NS families have been identiﬁed with mutations in NRAS.
A. Zuñiga: None. L. Pedrola: None. L. Castillo: None.
E. Aller: None. G. Pi: None.
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Rapid mutational analysis of RASopathy related genes in
prenatal diagnosis - our ﬁrst experience
M. Matyasova1, A. Michenkova2, I. Grochova2, E.
Svobodova3, A. Souckova3, P. Vlasin2, D. Nikulenkov
Grochova1
1Cytogenetic laboratory Brno, s.r.o., Brno, Czech Republic,
2Center of Prenatal Diagnosis, Brno, Czech Republic,
3Masaryk University Brno, Faculty of Science, Brno, Czech
Republic
Introduction: RASopathies represent a group of syndromes
(e.g. Noonan, Costello, Cardio-Facio-Cutaneous, Legius
and LEOPARD syndrome, neuroﬁbromatosis 1 and 2 etc.)
caused by mutations in genes encoding components of the
signaling RAS/MAPK pathway. While postnatal symptoms
of these conditions are well described, the prenatal features
are more difﬁcult to clearly determine. Reported are pre-
natal cases with indication of suspected RASopathy.
Materials and Methods: Targeted resequencing of
20 selected genes involved in pathogenesis of RASopathies
using HaloPlex HS enrichment system (Agilent) followed
by massive parallel sequencing was performed on 17 pre-
natal cases.
Results: We implemented an approach for molecular
diagnostic of RASopathies with features required in pre-
natal setting, i.e. fast turnaround time, limited input amount
of DNA, few samples per run and high diagnostic yield
(many genes analysed in parallel). In the ﬁrst group of cases
with increased linea nuchea and/or hygroma colli only (7/
17; 41,2%) we did not detect any pathological variant. On
contrary, in the group with severe ultrasound ﬁndings, i.e.
increased linea nuchea, hygroma colli and one or more
additional features (hydrothorax, polyhydramnion, renal
anomalies, cardiac defects, pes equinovarus or polydactyly),
a de novo mutation was detected in 4 cases (4/17; 23,5%).
Diagnostic yield in this group is 40 % (4/10).
Conclusion: In general our ﬁndings correspond to pre-
viously published studies. With our approach the molecular
genetic diagnosis of RASopathies can be performed rapidly
and in cost-effective manner with high diagnostic yield.
This brings a great beneﬁt into genetic counseling and
management of prenatal as well as neonatal period.
M. Matyasova: None. A. Michenkova: None. I. Gro-
chova: None. E. Svobodova: None. A. Souckova: None.
P. Vlasin: None. D. Nikulenkov Grochova: None.
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Noonan Syndrome and portosystemic shunt: a rare
presentation
L. Sagi-Dain, T. Abdalla-Moady, G. Larom-Kahn, A.
Harari-Shaham, A. Peleg
Carmel Medical Center, Haifa, Israel
Background: Noonan syndrome is a common autosomal
dominant disorder, mainly characterized by short stature,
webbed neck, chest deformity, craniofacial dysmorphism
and cardiac abnormalities. However, less typical phenotypic
ﬁndings might entangle the clinical diagnosis. Case report:
We describe a female baby, sixth child to non-
consanguineous parents. Prenatal sonographic examination
demonstrated cystic hygroma, polyhydramnios, right ven-
tricular hypertrophy and suspected portosystemic shunt.
The parents refused invasive prenatal testing. Following
uneventful delivery, imaging testing conﬁrmed the prenatal
ﬁndings. At the age of seven weeks postfeeding hyper-
ammonemia was diagnosed, apparently related to circula-
tory liver bypassing. Postnatal chromosomal microarray
analysis yielded normal results. Several dysmorphic signs
were noted during examination in our genetics clinic at the
age of two months, including hypertelorism, downslanting
palpebral ﬁssures, depressed nasal bridge with upturned
nares, low posteriorly rotated auricles, low posterior hairline
and bilateral transverse line. Results: Sequencing of
selected RAF1 gene exons was performed, due to its sig-
niﬁcant correlation with congenital hypertrophic cardio-
myopathy in patients with Noonan syndrome. This test
revealed a heterozygous c.770C>T heterozygous p.
(Ser257Leu) mutation, previously repeatedly reported as
variant causative for this disorder. Conclusions: Our case
provides valuable information to the scarce literature evi-
dence describing the association between RASopathies and
portosystemic shunts. This ﬁnding suggests that RAF1
mutations should be considered in the differential diagnosis
of fetal vascular anomalies (such as portosystemic shunt),
particularly when accompanied by characteristic features of
Noonan syndrome.
L. Sagi-Dain: None. T. Abdalla-Moady: None. G.
Larom-Kahn: None. A. Harari-Shaham: None. A. Peleg:
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Okamoto syndrome has considerable similarities with Au-
Kline syndrome and caused by HNRNPK mutation
N. Okamoto
Department of Medical Genetics,　Osaka Medical Center
and Research Institute for Maternal and, Osaka, Japan
Au-Kline syndrome (OMIM#616580) is a new syndrome
due to loss-of-function variants in the heterogeneous
nuclear ribonucleoprotein K gene (HNRNPK). It is char-
acterized by intellectual disability, distinctive facial dys-
morphism and skeletal/connective tissue abnormalities. We
report a new patient with a novel HNRNPK mutation. The
4-year-old male was the ﬁrst child of healthy and non-
consanguineous Japanese parents. His birth weight was
3,300 g, length was 48 cm, and head circumference was
33.6 cm, at 35 weeks of gestation. Surgical closure for
omphalocele was carried out after birth. Cleft palate and
bilateral hydronephrosis was noted. He was hypotonic and
his development was delayed. He could not creep or stand
alone. He spoke no meaningful words, with no cognitive or
language perception. He showed severe intellectual dis-
ability. Physical examination revealed dysmorphic features
including hypertelorism, epicanthal folds, low set ears, ﬂat
nasal bridge, high arched palate, macroglossia, and open
mouth. He showed joint hyperextensibility and talipes
equinovarus. Initially, this patient was considered to have
Okamoto syndrome (OMIM604916). Okamoto syndrome is
characterized by severe ID, generalized hypotonia, stenosis
of the ureteropelvic junction with hydronephrosis, cardiac
anomalies and characteristic face. So far, ﬁve patients have
been reported. Okamoto syndrome has considerable simi-
larities with Au-Kline syndrome. A novel splicing variant
(c.1361+1G>A) was found in the patient HNRNPK by
Sanger sequencing. We suggest that Okamoto syndrome
and Au-Kline syndrome is the same syndrome due to
HNRNPK mutation. The present research protocol was
approved by the local institutional board review. Written
informed consent was obtained from the parents.
N. Okamoto: None.
P11.086B
Unveiling the heterogeneous molecular basis of Opitz C
syndrome
R. Urreizti1, H. Franco-Valls1, L. Castilla-Vallmanya1, A.
M. Cueto-González2, E. Tizzano2, J. M. Opitz3, G. Neri4,
D. Grinberg1, S. Balcells1
1Universitat de Barcelona, CIBERER, IBUB, IRSJD,
Barcelona, Spain, 2Department of Clinical and Molecular
Genetics and Rare Diseases Unit, Hospital Vall d'Hebron,
Barcelona, Spain, 3Pediatrics, University of Utah School of
Medicine, Salt Lake City, UT, United States, 4Istituto di
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Medicina Genomica, Università Cattolica Sacro Cuore,
Policlinico A. Gemelli, Rome, Italy
Introduction: Opitz C syndrome (OTCS, MIM #211750) is
an extremely rare genetic disorder characterized by multiple
malformations (e.g. trigonocephaly, congenital heart
defects), contractures, variable intellectual and psychomotor
delay and a high mortality rate. Different patterns of
inheritance and genetic heterogeneity have been suggested.
Material and Methods: We studied a cohort of 13
patients (10 unrelated pedigrees) with clear or tentative
diagnosis of OTCS. Patients and parents were analysed by
means of whole exome sequencing (WES).
Results: We identiﬁed the disease-causing mutation in 8
of the 10 families in 8 different genes sharing demonstrated
roles in development and cancer. Three of them are still in
the ﬁnal validation stage. All these genes were associated
with other diseases with phenotypic similarities to OTCS.
For example,MAGEL2 truncating mutations were shared by
one of our OTCS patients and all patients with Schaaf-Yang
syndrome reported so far.
Conclusions: WES is a very powerful approach to
identify OTCS related mutations, since it was successful in
80% of our cases. Genematcher has been an essential tool to
connect with other researchers who identiﬁed mutations in
the same gene in other patients, a necessary way to solve the
cause of extremely rare diseases in the context of a high
genetic heterogeneity. Our results point to OTCS as a
causally heterogeneous phenotype instead of a speciﬁc
entity.
Grants: Spanish Ministerio de Economía y Competitivi-
dad (SAF2014-56562-R; FECYT, crowdfunding PRE-
CIPITA). Catalan Goverment (2014SGR932).
R. Urreizti: None. H. Franco-Valls: None. L. Castilla-
Vallmanya: None. A.M. Cueto-González: None. E. Tiz-
zano: None. J.M. Opitz: None. G. Neri: None. D. Grin-
berg: None. S. Balcells: None.
P11.087C
Identiﬁcation of a denovo novel missense mutation
inSPECC1L gene in a Turkish boy with Opitz GBBB
Syndrome Type II
K. Karaer, D. Kan Karaer, T. Bahsi
r. Ersin Arslan Training and Research Hospital, Gaziantep,
Turkey
Opitz G/BBB syndrome, is a rare genetic disorder that will
affect physical structures along the midline of the body.
There are two different forms of Optiz G/BBB syndrome:
X-linked (recessive) syndrome (Type I) and dominant
autosomal syndrome (Type II). However, both result in
common physical deformities. Features of the Opitz GBBB
syndrome type II include hypertelorism or telecanthus,
laryngotracheoesophageal cleft; clefts of lip, palate and
uvula; swallowing difﬁculty and hoarse cry; genitourinary
defects, especially hypospadias in males, mental retarda-
tion; developmental delay; and congenital heart defects. It is
caused by a heterozygous mutation in the SPECC1L gene
on chromosome 22q11.23. A 4 months old boy was referred
to genetic counselling because of congenital anomalies and
dysmorphic features. He was borned to healthy non-
consanguineous parents. The child had had typical lar-
yngotracheoesophageal manifestations, swalloving difﬁcul-
ties, hypertelorism, and a broad prominent nasal root and
bridge. Further, there was no evidence of dysplasia,
respiratory abnormality, or hoarse voice in any relative. A
mutation analysis of SPECC1L gene was requested. The
results revealed a previously unpublished sequence variant a
missense c.1382G>A (p.R461Q) in a heterozygous state. In
silico analysis (Mutation Taster, SIFT and PolyPhen) pre-
dicts this mutation as potentially deleterious. Sequencing of
SPECC1L gene of both parents was performed, but the
variant was not found, conﬁrming a denovo event. Thus,
clinical data of this family were presented by moderate or
mild form of the disease. Fuctional studies and more reports
are required to understand for the affect of the mutation and
genotype-phenotype correlation.
K. Karaer: None. D. Kan Karaer: None. T. Bahsi:
None.
P11.088D
New insights in human overgrowth and intellectual
disability
J. A. Tenorio, J. Nevado, P. Arias, P. Barruz, G. Gordo, I.
Dapía, The SOGRI Consortium, P. Lapunzina
INGEMM, Madrid, Spain
Introduction Human overgrowth (OGS) is mainly char-
acterized by an increase of any combination of the fol-
lowing parameters: height, weight and head circumference
above +2sd or 97th-centile of the mean for age, sex and
ethnic group. This overgrowth may be accompanied by
other clinical features, from which intellectual disability
(ID) is one of the most common. Thus, in patients with non-
syndromic OGS+ID we decided to perform CNV analysis
through SNP-microarrays with the aim of identiﬁes new
dosage-altered regions, large rearrangements and LOH.
Material and Methods We have selected a cohort of
patients from the Spanish Overgrowth Syndromes Registry.
The two initial clinical features from which we selected the
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patients were overgrowth and intellectual disability as pre-
sumptive diagnostic.
CytoSNP-850K was applied in 151 patients with OGS
+ID and the results were analyzed with GenomeStudio-
v2011.1.
Results Preliminary results showed a mean of 19-LOH
per patient and 19 possible pathogenic CNV: one translo-
cation, two uniparental disomy (one with low mosaicism
encompassing the whole short arm of chr11), ten deletions
and six duplications that could potentially be related to the
phenotype after the in silico analysis. The CNV size ranged
from 4,326bp to 44Mb.
Conclusions SNP-microarrays is a powerful tool to
study patients with overgrowth and intellectual disability,
due to the high positive rate obtained (approximately
12,5%). Twelve CNVs were not previously reported and
included a cluster of growth-related and ID genes probably
related to the phenotype. Furthermore, SNP-microarrays are
also recommended to study UPD, microdeletions and low-
level mosaicism undetectable with other similar techniques.
Grants: FIS-PI15/01481
J.A. Tenorio: None. J. Nevado: None. P. Arias: None.
P. Barruz: None. G. Gordo: None. I. Dapía: None. P.
Lapunzina: None.
P11.089A
Phenotype expansion for Kosaki Overgrowth Syndrome
K. Kosaki1, M. Minatogawa2, T. Takenouchi3, Y.
Tsurusaki2, F. Iwasaki2, T. Uehara1, C. J. Curry4, K.
Kurosawa2
Center for Medical Genetics, Keio University School of
Medicine, Tokyo, Japan, 2Division of Medical Genetics,
Kanagawa Children’s Medical Center, Kanagawa, Japan,
3Department of Pediatrics, Keio University School of
Medicine, Tokyo, Japan, 4Genetic Medicine, Community
Regional Medical Center, University of California San
Francisco/Fresno, Fresno, CA, United States
Skeletal overgrowth is a characteristic of several genetic
disorders that are linked to speciﬁc molecular signaling
cascades. Recently, we established a novel overgrowth
syndrome (Kosaki overgrowth syndrome, OMIM #616592)
arising from a de novo mutation in PDGFRB, i.e., p.
Pro584Arg. Subsequently, other investigators provided
in vitro molecular evidence that this speciﬁc mutation in the
juxtamembrane domain of PDGFRB causes an overgrowth
phenotype and is the ﬁrst gain-of-function point mutation of
PDGFRB to be reported in humans. Here, we report the
identiﬁcation of a de novo mutation in PDGFRB, p.
Trp566Arg, in two unrelated patients with skeletal
overgrowth, further conﬁrming the existence of PDGFRB-
related overgrowth syndrome arising from mutations in the
juxtamembrane domain of PDGFRB. A review of all four of
these patients with an overgrowth phenotype and PDGFRB
mutations revealed postnatal skeletal overgrowth, premature
aging, cognitive impairment, neurodegeneration, and a
prominent connective tissue component to this complex
phenotype. From a functional standpoint, hypermorphic
mutations in PDGFRB lead to Kosaki overgrowth syn-
drome, infantile myoﬁbromatosis (OMIM #228550), and
Penttinen type premature aging syndrome (OMIM
#601812), whereas hypomorphic mutations lead to idio-
pathic basal ganglia calciﬁcation (OMIM #615007). In
conclusion, a speciﬁc class of mutations in PDGFRB causes
a clinically recognizable syndromic form of skeletal
overgrowth.
K. Kosaki: None. M. Minatogawa: None. T. Take-
nouchi: None. Y. Tsurusaki: None. F. Iwasaki: None. T.
Uehara: None. C.J. Curry: None. K. Kurosawa: None.
P11.090B
Phenotypic overlap of partial trisomy 4q due to a complex
maternal chromosome rearrangement with Cornelia de
Lange Syndrome
U. Siebers-Renelt, Y. Stratis, P. Wieacker, A. Röpke
Institut für Humangenetik, Muenster, Germany
We report on a 5 year old boy, second child to a healthy
non-consanguineous couple. He was born near term.
Length, weight and head circumference at birth were in the
lower normal range. There was postaxial hexadactyly of the
left hand. He showed dysmorphic features with micro-
cephaly (-3,67z), highly arched eyebrows, depressed nasal
bridge, long philtrum and a thin upper lip. No structural
brain abnormalities in MRI. Psychomotor development was
signiﬁcantly retarded especially concerning language. The
clinical picture resembled Cornelia de Lange syndrome.
G-banding showed an unbalanced karyotype with a
derivative chromosome 12 and a marker chromosome in all
metaphases. FISH-analysis clariﬁed that the marker chro-
mosome was formed of chromosome 12 material originat-
ing from an interstitial deletion of the long arm of
chromosome 12. At the site of the deletion, the derivative
chromosome 12 contained an insertion of chromosome 4
material. As shown by array-CGH, there was trisomy of the
chromosomal region 4q24-q28.1 but no visible imbalance
of chromosome 12. Karyotyping of the parents was per-
formed and the healthy mother also exhibited the marker
and the derivative chromosome 12. Additionally, she
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possesses a derivative chromosome 4 with an interstitial
deletion 4q resulting in a balanced situation.
Interestingly, the supernumerary marker was mitotically
and meiotically stable indicating that there should be a
neocentromere. Clinically, our case illustrates, that still a
chromosome analysis should be performed ﬁrst in all syn-
dromic children, even if the phenotype ﬁts with a speciﬁc
genetic diagnosis.
U. Siebers-Renelt: None. Y. Stratis: None. P.
Wieacker: None. A. Röpke: None.
P11.091C
A complex homozygous mutation in ABHD12 responsible
for PHARC syndrome (Polyneuropathy, Hearing loss, cer-
ebellar Ataxia, Retinis pigmentosa and early-onset Cataract)
discovered by NGS
J. Lerat1,2, P. Cintas3, H. Beauvais-Dzugan2,4, C.
Magdelaine2,4, F. Strurtz2,4, A. Lia2,4
Service Oto-Rhino-Laryngologie et Chirurgie Cervico-
Faciale, CHU Dupuytren, Limoges, France, 2EA6309 –
Neuropathies périphériques et maintenance myélinique,
Limoges, France, 3Explorations neurophysiologiques, Cen-
tre SLA, Centre de référence de pathologie neuromuscu-
laire, CHU Toulouse, Toulouse, France, 4Laboratoire de
Biochimie et Génétique Moléculaire, CHU Dupuytren,
Limoges, France
Introduction: PHARC syndrome (MIM612674) is an
autosomal recessive neurodegenerative pathology leading to
demyelinating Polyneuropathy, Hearing loss, cerebellar
Ataxia, Retinis pigmentosa and early-onset Cataract. These
various symptoms can occur at different ages, so that
PHARC syndrome can be a differential diagnosis of
Charcot-Marie-Tooth disease (CMT) associated with deaf-
ness. Only 13 ABHD12 mutations have been reported in 33
patients. We described the 14th mutation and compared our
results to the literature data. Materials and Methods:
Genomic DNA was extracted by standard methods. Next
Generation Sequencing (NGS) strategy was performed by
using a targeted CMT and associated neuropathies 92-gene
panel. Results: A 36-year old male has suffered from
demyelinating sensory and motor polyneuropathy and
ataxia since the age of 15. Bilateral sensorineural deafness
was diagnosed at the age of ﬁve. Bilateral congenital cat-
aracts were operated on at the age of 28. A new large
complex homozygous mutation, with one deletion of seven
base pairs and one insertion of 38 base pairs, was detected
by NGS. In PHARC syndrome, sensorineural deafness
always occurs as the ﬁrst feature in late teens. The oph-
thalmological symptoms are cataracts that occur at a mean
age of 25 yo and then retinis pigmentosa at a mean age of
29. Demyelinating sensory-motor polyneuropathy is the
most variable characteristics, which occurs in the thirties.
Conclusion: We report the ﬁrst large complex homozygous
mutation in PHARC syndrome, which is certainly under-
diagnosed. Therefore, it seems interesting to include
ABHD12 in the panels of the ﬁve symptoms, especially
deafness ones.
J. Lerat: None. P. Cintas: None. H. Beauvais-Dzugan:
None. C. Magdelaine: None. F. Strurtz: None. A. Lia:
None.
P11.092D
Ophthalmological features in a patient with Pierpont
syndrome
J. Porrmann1, S. Weidensee2, N. DiDonato1, A. Kahlert1,
A. Rump1, E. Schröck1, A. Tzschach1
1Technische Universität Dresden Medizinische Fakultät
Carl Gustav Carus Institut für Klinische Genetik, Dresden,
Germany, 2Mitteldeutscher Praxisverbund Humangenetik,
Erfurt, Germany
Pierpont syndrome (OMIM 602342) is a rare disorder
characterized by developmental delay, feeding problems,
facial dysmorphisms, and palmar and plantar fat pads with
deep grooves. In 2016, the mutation c.1337A>G, p.
(Tyr446Cys) in TBL1XR1 (transducin β-like 1 ×-linked
receptor 1) was identiﬁed in six unrelated patients with
Pierpont syndrome.
We report on a 3-year-old boy with clinical signs of
Pierpont syndrome. The patient had hypotrophy at birth and
prolonged jaundice. Subsequently, he developed feeding
problems that required percutaneous endoscopic gastro-
stomy. He was unable to speak or to stand at the age of 3
years. He also had the typical facial characteristics, micro-
cephaly, short stature, and palmar and plantar fat pads.
Ophthalmological examination revealed microphthalmia,
pendular nystagmus, and hypermetropia. Using clinical
exome sequencing, we identiﬁed the de novo mutation
c.1337A>G, p.(Tyr446Cys) in TBL1XR1.
This patient corroborates the assumption that Pierpont
syndrome is exclusively caused by this speciﬁc TBL1XR1
missense mutation, and the ophthalmological features
broaden the phenotypic spectrum of this rare disorder.
J. Porrmann: None. S. Weidensee: None. N. DiDo-
nato: None. A. Kahlert: None. A. Rump: None. E.
Schröck: None. A. Tzschach: None.
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P11.093A
PIK3CA related overgrowth spectrum (PROS): Molecular
diagnosis and phenotype delineation
G. Gordo1,2, L. Rodriguez-Laguna1, F. Santos3, S. Garcia-
Miñaur3, J. Nevado4, E. Vallespin4, A. del Pozo5, K.
Ibañez5, J. C. Silla5, P. Lapunzina2,6, J. C. Lopez-
Gutierrez7, V. Martinez-Glez1,6
Vascular Malformations Section, INGEMM-CIBERER-
IdiPaz-Hospital Universitario La Paz, Madrid, Spain,
2Molecular Endocrinology Section - Overgrowth Syn-
dromes Laboratory, INGEMM-CIBERER-IdiPaz-Hospital
Universitario La Paz, Madrid, Spain, 3Clinical Genetics
Section, INGEMM-CIBERER-IdiPaz-Hospital Universi-
tario La Paz, Madrid, Spain, 4Structural and Functional
Genomics Section, INGEMM-CIBERER-IdiPaz-Hospital
Universitario La Paz, Madrid, Spain, 5Bioinformatics
Section, INGEMM-CIBERER-IdiPaz-Hospital Universi-
tario La Paz, Madrid, Spain, 6Clinical Genetics Section,
INGEMM-CIBERER-IdiPaz-Hospital Universitario La Paz,
Madrid, Spain, Madrid, Spain, 7Section of Plastic and
Reconstructive Surgery, Department of Pediatric Surgery-
IdiPaz-Hospital Universitario La Paz, Madrid, Spain
Introduction: PIK3CA related overgrowth spectrum
(PROS) —MCAP, CLOVES, macrodactyly…— is char-
acterized by segmental overgrowth and vascular anomalies.
It is caused by somatic mutations in PIK3CA. We present
recommendations for molecular testing and review the
phenotype in 63 patients.
Material and methods: A custom deep coverage NGS
panel and a bioinformatic pipeline were designed to test 20
genes related to somatic overgrowth. DNA samples from
blood, saliva and/or affected tissue were studied. Variants
were validated by Sanger (mosaics >20%), pyrosequencing
(between 5–20%) and Droplet Digital PCR (ddPCR, <5%).
Results: We detected 17 different PIK3CA mutations in
13/36 MCAP (1 germline), 10/25 CLOVES and 1/2 mac-
rodactyly. Mutations in “pure” CLOVES/macrodactyly are
only present in affected tissue, as expected. In MCAP,
mosaicism percentage is higher in affected tissue, but low-
mosaic mutations can also be found in saliva and blood. In
addition to PIK3CA, we detected mutations (mosaic and
germline) in two other genes included in the PI3K-AKT-
mTOR pathway in 4 patients referred as MCAP or PROS.
Clinical characteristics are not always consistent and there is
quite phenotypic overlap, making the clinical diagnosis
tricky in some cases.
Conclusions: Combination of NGS and ddPCR allows
detecting mosaics as low as 1%. Testing saliva as ﬁrst
choice avoids unnecessary biopsies in some MCAP cases.
Syndromes within PROS are part of a continuous clinical
spectrum whose manifestations depend on the time/tissue of
the embryonic development in which the mutation arose.
This also predicts the future inclusion of more syndromes
—not yet associated but belonging— to this group.
G. Gordo: None. L. Rodriguez-Laguna: None. F.
Santos: None. S. Garcia-Miñaur: None. J. Nevado:
None. E. Vallespin: None. A. del Pozo: None. K. Ibañez:
None. J.C. Silla: None. P. Lapunzina: None. J.C. Lopez-
Gutierrez: None. V. Martinez-Glez: None.
P11.094B
Pitt-Hopkins syndrome identiﬁed by trio whole-exome
sequencing in a boy with severe intellectual disability,
postnatal microcephaly, myopia, scoliosis and congenital
abnormalities of the elbow joint
J. Schmidt1, G. Gillessen-Kaesbach1, A. Rolfs2, A.
Wartenberg2, I. Hüning1
1Institut für Humangenetik, Lübeck, Germany, 2CENTO-
GENE AG, Rostock, Germany
Pitt-Hopkins syndrome (PTHS, OMIM #610954) is a neu-
rodevelopmental disorder characterized by severe develop-
mental delay, distinctive facial features (including deep-set
eyes, a broad nasal base, widely spaced teeth, a wide mouth
with a tented, upper lip and ﬂeshy ears), postnatal micro-
cephaly, seizures, constipation and breathing anomalies. It
is caused by mutations in the TCF4 gene on 18q21. Here we
report on a six-year-old boy with severe intellectual dis-
ability, postnatal microcephaly, distinctive craniofacial
features, myopia, astigmatism, scoliosis, obstipation and
congenital bilateral radial head subluxation. Genetic testing
including conventional cytogenetic analysis, Microarray-
CGH and Sanger sequencing and MLPA (multiplex
ligation-dependent ampliﬁcation) of COH1 was unremark-
able. Subsequent trio whole-exome sequencing identiﬁed a
de novo heterozygous mutation in TCF4 (c.1459C>T / p.
Arg487*) leading to a premature stop codon that has
already been described in two other patients with PTHS.
Although the patient presented in this report shows clinical
features typical for PTHS we missed to make a speciﬁc
diagnosis. This might be explained by the absence of two
characteristic symptoms such as seizures and abnormal
breathing patterns. Additionally, and so far we know not yet
described as a characteristic feature for PTHS, the patient
showed congenital bilateral radial head subluxation. A ret-
rospective image analysis with face2gene suggested PTHS
as the most likely diagnose. Therefore, this case supports
that computer-assisted facial recognition should be used in
the routine diagnostic workﬂow.
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Rolfs: None. A. Wartenberg: None. I. Hüning: None.
P11.095C
Two pathogenic heterozygous mutations in PNPLA6 but
which is the syndrome?
H. M. Kathom1, D. Avdjieva-Tzavella1, S. Marinova2, I.
Litvinenko3, R. Tincheva1
Department of Clinical Genetics, University Pediatrics
Hospital, Medical University Soﬁa, Soﬁa, Bulgaria,
2Department of Pediatric nephrology and hemodialisis,
University Pediatrics Hospital, Medical University Soﬁa,
Soﬁa, Bulgaria, 3Department of Pediatric Neurology,
University Pediatrics Hospital, Medical University Soﬁa,
Soﬁa, Bulgaria
Introduction: Mutations in PNPLA6 gene results in a wide
spectrum of clinical presentations, mostly involving ataxia,
neuropathy, chorioretinal dystrophy, hypogonadotropic
hypogonadism, hair anomalies, and impaired cognitive
functioning. Sometime features can cluster in speciﬁc syn-
dromes like those of Boucher-Neuhäuser, Gordon-Holmes,
Oliver-McFarlane, Laurence-Moon, and spastic paraplegia
type 39.
Materials and methods: We present a female patient with
pigmentary retinitis and polyneuropathy of sensory-axonal
type, developing between 4th and 6th years of life. At age of
6 y she presented with chronic kidney disease, related to
kidney hypoplasia. MRT at age of 10 y showed mild
atrophy of the cranial part of cerebellar vermis. She presents
no learning disability, no polydactyly, and no obesity till
age of 10 y. In her long medical history many diseases have
been considered in differential diagnosis, and were exclude
by speciﬁc methods. Finally because of vermis anomaly,
retinitis pigmentosa, ataxia, and neuropathy, NGS-analysis
was performed.
Results: NGS of genomic DNA of the patient revealed
two pathogenic heterozygous point mutations within intron
5 (c.199-2A>T) and exon 29 (c.3152G>A) of the PNPLA6
gene, coding neuropathy coding esterase. Both mutations
were subsequently conﬁrmed by conventional DNA capil-
lary sequencing.
Conclusions: This clinical case shows the overlapping
between many different syndromes, caused by mutations in
PNPLA6 gene, as well as the gradual appearance of
symptoms which can mislead to other “closer diagnosis” at
certain moment of patient’s life.
H.M. Kathom: None. D. Avdjieva-Tzavella: None. S.
Marinova: None. I. Litvinenko: None. R. Tincheva:
None.
P11.096D
Compound 16p12.2 microdeletion and hemizygous mis-
sense mutation in POLR3E associated with syndromic
neurodevelopmental impairment and near-fatal cardiac
arrhythmias
R. Tadros1, J. A. E. Kammeraad2, C. R. Lincke2, N. Wolf3,
M. A. van Slegtenhorst2, C. R. Bezzina1, I. M. B. H. van de
Laar2
1Academic Medical Center, Amsterdam, Netherlands,
2Erasmus Medical Center, Rotterdam, Netherlands, 3VU
Medical Center, Amsterdam, Netherlands
Introduction: Microdeletion at 16p12.2 is associated with
developmental delay, sometimes in presence of additional
variants. POLR3E, located at 16p12.2 has been suggested to
be important for phenotypic manifestation but no disease-
causing mutation has yet been reported.
Methods and results: We evaluated a newborn boy with
natal teeth, bilateral club feet, dysphagia, bilateral cerebral
palsy, axial hypotonia and Pierre Robin sequence with
obstructive sleep apnea. During the ﬁrst week of life, car-
diac evaluation for respiratory distress showed a Brugada
syndrome electrocardiogram without structural abnormal-
ities and with recurrent ventricular arrhythmias requiring
extra-corporeal membrane oxygenation. During follow-up,
severe myopia, growth retardation and global develop-
mental delay were noted, with ongoing improvement in
motor functions and communication abilities. Brain mag-
netic resonance imaging at 4 months showed a thin corpus
callosum, cerebral atrophy and slightly delayed myelina-
tion. Array genotyping identiﬁed a 16p12.2 microdeletion
inherited from a healthy mother. Trio whole-exome
sequencing revealed a novel predicted deleterious hemi-
zygous mutation in POLR3E (ENST00000299853;
c.985A>G; p.Ser329Gly), inherited from a healthy father.
Exome aggregation consortium constraint metrics suggest
that POLR3E is intolerant to double loss-of-function.
POLR3E codes for a subunit of the RNA polymerase III
(Pol-III). Dysregulation of other Pol-III genes is involved in
leukodystrophies, sharing some clinical features with the
reported case.
Conclusion: We identiﬁed a hemizygous POLR3E mis-
sense mutation in a patient with the 16p12.2 microdeletion
which may account for a severe multisystem phenotype.
Missense mutations in POLR3E may provide a second hit in
the 16p12.2 microdeletion syndrome. Additional cases are
needed to unequivocally implicate POLR3E to disease.
R. Tadros: None. J.A.E. Kammeraad: None. C.R.
Lincke: None. N. Wolf: None. M.A. van Slegtenhorst:
None. C.R. Bezzina: None. I.M.B.H. van de Laar: None.
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Unravelling proximal 6q deletions with the help of
Facebook
A. Engwerda1, B. Frentz1, P. Bouman2, M. Slofstra1, E.
Adriaanse1, M. A. Swertz1, C. M. A. van Ravenswaaij-
Arts1
University of Groningen, University Medical Centre
Groningen, Department of Genetics, Groningen, Nether-
lands, 2Chromosome 6 Facebook group, Utrecht,
Netherlands
Introduction: Social media are widely used by parents of
children with rare disorders to seek and exchange infor-
mation and are therefore a powerful source for case-ﬁnding.
In the Chromosome 6 Project a successful collaboration
with a Facebook group was realised. Most chromosome 6
aberrations are extremely rare, thus a world-wide collection
of patients is needed to perform genotype-phenotype stu-
dies. Here, we describe the results on proximal 6q deletions.
Materials and methods: Parents of children with a dele-
tion within the region 6q11-q16 were approached via the
private Chromosome 6 Facebook group and asked to
complete an online questionnaire, available in multiple
languages, on the phenotype of their child. Descriptive data
analysis was performed and for speciﬁc features the smal-
lest region of deletion overlap (SRO) was deﬁned.
Results: Data of 16 children from Facebook and 24 lit-
erature cases were used to describe the observed pheno-
types. Most frequently reported features were
hypermobility, hypotonia and developmental delay. In the
more proximal deletions (6q11-q14) an SRO for the com-
bination of club feet, hyperlaxity, delayed motor develop-
ment and umbilical hernia revealed COL12A1 as a
candidate gene for the connective tissue disorder-like phe-
notype. In the more distal deletions (6q14-q16) an SRO for
congenital heart defects revealed the candidate gene
TBX18, which has been shown to be involved in cardiac
development in mice. Further studies are being performed
to conﬁrm the role of TBX18 haploinsufﬁciency in heart
defects.
Conclusions: Our study proved that social media is a
powerful source for case-ﬁnding, resulting in better infor-
mation to counsel families.
A. Engwerda: None. B. Frentz: None. P. Bouman:
None. M. Slofstra: None. E. Adriaanse: None. M.A.
Swertz: None. C.M.A. van Ravenswaaij-Arts: None.
P11.098B
Family case of pure 6p25.2–24.2 duplication
A. Bobinec1, A. Ivankov1, M. Rogac2, Z. Bahtijarevic1, I.
Barisic1
1Children's Hospital Zagreb, Medical School University of
Zagreb, Zagreb, Croatia, 2Clinical Institute of Medical
Genetics, University Medical Center Ljubljana, Ljubljana,
Slovenia
Introduction: Distal 6p trisomy is very rare. Most patients
have variable clinical ﬁndings with duplications that usually
range from 6pter to 6p21–6p25. We report on a family case
with distal interstitial 6p duplication and distinctive phe-
notypic features.
Results: Our proband was born small for gestational age
with dysmorphic features, hypoplastic left kidney, hypos-
padia and uretral stenosis. At present he is 16.5-years old,
tall and obese. His intellectual functioning is normal. His
37-year old mother has similar phenotype, obesity, and is
diagnostically investigated for osteopetrosis. Chromosomal
microarray analysis identiﬁed pure interstitial duplication
6p25.2-p24.2 in both subjects, conﬁrmed by GTG-banding
of chromosomes. Size of the duplicated segment is 8,2 Mb
and it contains 31 OMIM genes. Duplications of similar size
that partially overlap this region have been described in 3
patients so far. One patient has only mild skeletal anomalies
and other two presented with dysmorphia, microcephaly,
ocular, cardiac and renal defects, growth impairment and
developmental delay.
Conclusion: Presented family with interstitial 6p25.2-
p24.2 duplication provides evidence for phenotypic varia-
bility in this region. It is of interest to note that the case
described in the literature as having only mild skeletal
anomalies has inherited the duplication from his mother.
This points to the possibility that familial cases of distal
duplication 6p tend to have mild phenotype. As intellectual
functioning in so far described familial case is normal, there
is possibility that the diagnosis is sometimes missed.
A. Bobinec: None. A. Ivankov: None. M. Rogac:
None. Z. Bahtijarevic: None. I. Barisic: None.
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RLIM is a new candidate gene for congenital diaphragmatic
hernia
M. Kammoun1, P. Brady1, E. Maas2,3, J. Gribnau4, J.
Deprest5, K. Devriendt1, A. Zwijsen2,3, J. R. Vermeesch1
Department of human genetics KU Leuven, leuven,
Belgium, 2VIB Center for the Biology of Disease, leuven,
Belgium, 3Department of human genetics KU Leuven,
Leuven, Belgium, 4Erasmus MC, Department of
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We describe a three generation Belgian family with three
affected males displaying congenital diaphragmatic hernia,
polycystic kidneys and sexual ambiguity. Whole exome
sequencing revealed a new rare and predicted pathogenic
RLIM variant (RLIM:NM_183353:c.G1792A:p.D598N) in
2 second cousins. The clinical phenotype and the variant co-
segregate, with a LOD score of 1.8 for linkage to a shared
region of 24.4 Mb in the X chromosome. No other shared
rare variants are located in this common region. All the
female carriers showed a 100% skewed X inactivation.
RLIM encodes ring zinc ﬁnger protein 12 (RNF12) ubi-
quitin ligase, which is essential for embryonic development
through its involvement in imprinted X-inactivation in
mice, and its function as a co-regulator of LIM home-
odomain transcription factors. In addition, RNF12 has been
shown to regulate TGFbeta and BMP pathways in
embryonic stem cells and in zebraﬁsh. These pathways are
important for diaphragm and kidney development. We
conﬁrmed RLIM expression in diaphragm at the transcrip-
tional and proteic levels. This suggests a possible involve-
ment of this gene in diaphragm genesis. Breeding statistics
of RLIM C57bl/6 knockout female with a wild type male
indicate a perinatal lethality in KO males. The investigation
of the underlying phenotype and the molecular mechanism
of this perinatal death is still ongoing.
M. Kammoun: None. P. Brady: None. E. Maas: None.
J. Gribnau: None. J. Deprest: None. K. Devriendt: None.
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Unraveling clinical and genetic heterogeneity in Robinow
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A. Hoischen4, B. W. M. van Bon4, S. N. Jhangiani5, R. A.
Gibbs5, B. Baylor Hopkins Center for Mendelian
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C. Carvalho3
1Universidade de Brasília (UnB), Brasilia, Brazil, 2Robi-
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Robinow syndrome (RS) is a clinical and genetically het-
erogeneous disorder characterized by mesomelic limb
shortening, genital hypoplasia and distinctive facial fea-
tures. Recessive RS is characterized by severe skeletal
defects and is explained by ROR2 biallelic variants. Auto-
somal dominant RS has been associated with mutations in
WNT5A, DVL1 and DVL3 indicating that noncanonical Wnt
pathway is perturbed in RS. Though some genotype-
phenotype correlations have been proposed the paucity of
patients described so far does not allow any ﬁrm conclu-
sions. Other genes remain to be identiﬁed since several
patients do not have mutations in any of these genes. Since
Robinow-associated genes have deﬁned roles in non-
canonical Wnt pathway, we hypothesized that variants in
other genes within the pathway may underlie the ‘unsolved’
cases. To address this, we recruited 31 unrelated subjects
diagnosed with Robinow or Robinow-like phenotypes.
Preliminary analysis conﬁrmed that DVL1/DVL3 indels
contribute to ~20% of cases. One individual had a WNT5A
variant. Additionally, variants in FZD2 gene which has
been associated with omodysplasia in one case, contributes
to 13% of the DRS cases. Importantly, FZD2 is a relevant
protein partner in the WNT5A interactome, supporting its
role in skeletal development. In summary, our study illu-
minates the molecular causes of this rare Mendelian dis-
order, provides insights relevant to clinical diagnosis and
management, and reveals the contribution of genes from the
same pathway elucidating locus heterogeneity in Robinow
Syndrome. Grant: National Human Genome Research
Institute-National Heart, Lung, and Blood Institute grant
U54 HG006542 to Baylor Hopkins Center for Mendelian
Genomics.
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Clinical utility of next-generation sequencing in the recog-
nition of well-known syndromes with atypical phenotypes
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Introduction: Diagnosis of patients with non-speciﬁc
intellectual disability (ID) presents challenges in daily
clinical practice. In the absence of speciﬁc diagnostic/clin-
ical markers, whole-exome sequencing (WES) is the
method of choice for the detection of gene mutations
responsible for ID.
Material and methods: The study was conducted on a
cohort of 21 families (63 individuals) with a child pre-
senting with sporadic ID (with or without additional minor
physical and neurological/metabolic abnormalities), and
comprised integrated clinical data, WES and the use of
bioinformatics tools like PhenIX2 that utilize Human Phe-
notype Ontology.
Results: Among 21 examined patients, an etiological
diagnosis was made in 8; in 3 of them unexpectedly some
“old” syndromes were detected, such as Rubinstein-Taybi
2, Wiedemann-Steiner, and Cornelia de Lange 2 syndromes.
These patients presented with ID associated with atypical
features not suggestive of a known monogenic syndrome.
Re-evaluation of these patients conﬁrmed that the diagnosis
remained difﬁcult on clinical grounds. In ﬁve others, Glass,
Spastic Paraplegia 50, Bosch-Boonstra-Schaaf Optic Atro-
phy, Cerebral Creatine Deﬁciency 3 and Mental Retardation
31 syndromes were proved.
Conclusions: The introduction of WES led not only to
the description of new syndromes, but also to the recogni-
tion of well-known syndromes with atypical phenotypes.
Our study emphasized that old syndromes can have a
phenotype that is heterogeneous and more variable than
originally thought. The use of WES shows that such
patients may be more readily diagnosed on the basis of
genotype rather than phenotype.
The study was ﬁnanced by NSC Project Harmonia 4 No.
UMO-2013/08/M/NZ5/00978.
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Expansion of the phenotypic spectrum in Rubinstein-Taybi
syndrome associated with novel variants in EP300 and
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Introduction: Rubinstein-Taybi syndrome (RSTS) is a rare
congenital neurodevelopmental disorder. Clinical diagnosis
is complicated by widely varying signs and symptoms.
Mutations in two genes, CREBBP and EP300, have been
identiﬁed in 55%-78% of RSTS individuals.
Methods and Results:We report the clinical and genetic
data of 11 Polish RSTS patients. Causative mutations in 7
patients with a distinct and moderate RSTS phenotype were
identiﬁed. In addition, in four patients with an obvious
RSTS phenotype, no molecular defect was found. Mole-
cular analysis (MLPA, WES) revealed ﬁve different
CREBBP alterations, such as frame-shift (in two cases),
nonsense, missense, and a large deletion, as well as non-
sense and frame-shift mutations in EP300. They were
mostly unreported variants (6/7). Four patients with a
CREBBP mutation presented the classical RSTS phenotype,
including speciﬁc facial dysmorphy, broad thumbs and big
toes, while two patients with an EP300 mutation were
signiﬁcantly less typical (unspeciﬁc facial phenotype,
somewhat broader great toes but normal thumbs and mild
intellectual disability). As a result of such an atypical phe-
notype, in one of them Floating-Harbor syndrome was
initially considered in the differential diagnosis.
Conclusions: Our 63.6% mutation detection rate in
RSTS patients with an either classical or atypical pheno-
type, supports the concept that RSTS is a genetically het-
erogeneous disorder and indicates that RSTS may be caused
by gene/s other than CREBBP or EP300 in up to 36% of
cases. These data conﬁrm the need for expanding the stu-
dies on molecular mechanisms leading to unspeciﬁc RSTS
manifestations.
Supported by projects: CMHI-235/15, NCN-UMO-2013/
08/M/NZ5/00978.
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Segregation pedigree analysis of t(2,13)(p25.1,q33.1) car-
riers and description of the resulting partial trisomy 2p and
monosomy 13q phenotype in progeny
B. Panasiuk1, A. T. Midro1, J. Wierzba2, B. S. Lipska-
Ziętkiewicz3, B. Stasiewicz-Jarocka1, M. Koczkowska3, J.
Limon3
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Introduction: We present the proposal of genetic coun-
selling for carriers of an unique reciprocal chromosome
translocation t(2,13)(p25.1,q33.1). In addition, the pheno-
type spectrum associated with the chromosomal imbalance
in progeny at birth with resulting unbalanced translocation
is provided.
Material and Methods: A combination of several
cytogenetic techniques, including routine karyotype, FISH,
and array CGH [CytoSure ISCA UPD (4×180k), Oxford
Gene Technology] were applied. Probability rate estimation
for different categories of pregnancy outcomes was studied
by direct method of pedigree segregation according to Stene
and Stene-Rutkowski. Phenotype analyzes of three affected
children were performed according to Munchen Dysmor-
phology Database (MDDB) methodology.
Results: The common morphological features observed
in three affected relatives with monosomy 13q33.1→qter
(loss of 13.1Mb) and trisomy 2p25.1→ pter (gain of 7.1Mb)
were: microcephaly, long forehead, ptosis, long nasal
bridge, short philtrum, retrogenia, skeletal malformations
and hypogenitalism. In addition, the affected children pre-
sented muscle hypotonia, bleeding disorders, intellectual
disability, vision problems, speech delay and hyperactivity.
Segregation pedigree analysis of t(2,13)(p25.1,q33.1) car-
riers allowed to estimate the probability rate of having a
child with unbalanced karyotype 13.0±7%, the risk for
miscarriage as 39.1±10.2% and for a stillbirth/neonatal
death as 4.3±4.2%.
Conclusions: The chromosomal imbalance in the form
of monosomy 13q33.1→ qter and trisomy 2p25.1→ pter
does not limit survival of the offspring to term. Chromo-
somal translocation t(2,13)(p25.1,q33.1) carriership is high
risk factor for miscarriages and unbalanced progeny at birth.
Polish Grant - N/ST/ZB/16/001/1106
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A novel familial SIX1 mutation with incomplete penetrance
in Branchio-otic Syndrome
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(* contributed-equally) Introduction: The Branchio-oto-
renal spectrum disorders include branchio-oto-renal (BOR)
and branchio-otic syndromes (BOS). Main clinical features
include otologic, second branchial arch and renal anomalies.
Pathogenic variants in three genes [EYA1(40%), SIX5
(2.5%),SIX1(2%)] have been reported.
Patient report and Methods: A three-year-old girl was
observed to have unilateral cleft lip and palate, anomalies of
the second branchial arch, and a right pre-auricular pit.
Cardiac, renal, ophthalmology and otorhinolaryngology
assessments are normal. She has two paternal cousins with
renal problems from childhood.
Sanger sequencing of SIX1 (NM_005982) identiﬁed a
frameshift mutation. Site directed mutagenesis was used to
generate the identiﬁed mutation and other related constructs.
MEF3 luciferase reporter assays were performed in MCF7
cells after co-transfecting WT or mutant Six1 and its co-
activator Eya2.
Results: A novel heterozygote frameshift variant
[c.561_564delGGAG(p.Arg188fsTer63)] was identiﬁed in
exon 2 of SIX1 gene. Parental studies showed it was
inherited from her healthy father. Although the expression
level of wildtype and mutant Six1 were similar, the ability
of p.Arg188fsTer63 Six1 to activate transcription in a
reporter assay was signiﬁcantly impaired.
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Conclusions: The lack of transcriptional activity of the
identiﬁed Six1 mutant ﬁts well with the observed phenotype
in the patient. However, the lack of phenotype in the father
is intriguing, because most families with BOR spectrum
appear to have 100% penetrance. We speculate that the
father may compensate by overexpressing another Six
family member. Our data also argue that the C-term of Six1
is required for its transcriptional activity, although its spe-
ciﬁc role is still under investigation.
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The mutation spectrum of DHCR7 gene and two novel
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Akdeniz University, Antalya, Turkey, 6Department of
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Introduction: Smith Lemli Opitz syndrome (SLOS) is a
rare autosomal recessive syndrome. It is one of the 46, XY
disorder of sexual development. Molecular defects in
DHCR7 gene are responsible for this syndrome. In this
study, mutation spectrum of the DHCR7 gene in SLOS
patients has been evaluated.Material and Methods: In this
study 13 patients carrying mutations in DHCR7 gene were
evaluated. Molecular analysis was performed using Sanger
sequencing or next generation sequencing. Clinical and
laboratory ﬁndings of all patients were obtained from their
hospital records. Clinical severity scores of patients were
calculated according to Kelley and Hennekam for
phenotype-genotype correlation. Results: In 13 patients 7
different DHCR7 gene mutations (4 missense: p.T93M, p.
R352W, p.Y432C, p.E448K; 2 nonsense: p.W151X, p.
Q259X; and one splice site: IVS7+1) were detected. p.
T93M was the most frequent (57% of all allels) mutation.
Two of the seven mutations (p.Q259X, IVS7+1) deﬁned
for the ﬁrst time in this study. Conclusion: This study
deﬁnes the mutation spectrum and genotype phenotype
correlation of DHCR7 gene in the Turkish SLOS patients.
As seen in other Mediterranean populations, p.T93M
mutation is the most frequent mutation observed in our
patients.
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Absence of major eye malformations further expands the
phenotype of SOX2 deletions
N. Guleray1, G. Urel Demir2, O. Akgun Dogan2, P. O.
Şimsek Kiper2, G. E. Utine2, M. Alikaşifoglu1
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Medical Genetics, Ankara, Turkey, 2Hacettepe University
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Introduction: Syndromic microphthalmia-3 (MCOPS3;
OMIM 206900) is a rare dominant disorder characterized by
anophthalmia or microphthalmia. Iris coloboma and various
extraocular abnormalities such as growth retardation,
developmental delay, central nervous system malforma-
tions, sensorineural deafness, esophageal atresia and genital
abnormalities are also involved in the spectrum. Hetero-
zygous point mutations in SOX2 are responsible from
approximately 20% of MCOPS3 phenotype. Widespread
use of microarray analysis has increased the detection rate
of SOX2 mutations in up to 40% of cases. In this study, we
report on 2 patients with diverse ocular and extraocular
ﬁndings.
Material and Methods: Patients were screened for copy
number variation by Agilent SurePrint G3-CGH 8×60K and
4×180K Human Microarray Kit.
Result: Array CGH analysis revealed de novo hetero-
zygous deletions ranging from 12 Mb (3:180,660,194–
192,709,474) to 33 kb (3:181,418,149–181,451,562) on
chromosome 3q26.33 encompassing the entire SOX2. First
patient with 12 Mb deletion, the largest deletion reported so
far in this region, was a 6 month-old-female. She had iris
coloboma, cleft lip/palate, tracheoesophageal ﬁstula,
500
esophageal and anal atresia, hydrocolpos and pons hypo-
plasia, of which the latter two had not been reported pre-
viously in deletions of this region. Interestingly,
anophthalmia or microphthalmia was not present in this
patient. The second patient with 33 kb deletion demon-
strated anophthalmia, micropenis and cryptorchidism.
Conclusion: This study expands the phenotypic spec-
trum of SOX2 abnormalities and provides evidence that
complete SOX2 deletion might not result in major eye
abnormalities. Thus, SOX2 genetic analysis should be
considered in patients presenting with ocular and/or
extraocular ﬁndings consistent with the phenotype.
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Phenotypic spectrum of SPECC1L mutations encompasses
Teebi hypertelorism syndrome but not Opitz BBBG syn-
drome: report of new families and critical review of the
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Anomalies of midline craniofacial development are
observed in several syndromes that were originally deli-
neated on clinical basis. Opitz BBBG syndrome was asso-
ciated with mutations in MID1, Baraitser-Winter
craniofrontofacial syndrome with mutations in ACTB and
ACTG1, and recently, Teebi syndrome with mutations in
SPECC1L. SPECC1L plays a role in in gap junctions
involved in cell adhesion, in actin cytoskeleton organiza-
tion, microtubule stabilization and spindle organization, and
in cytokinesis. It modulates PI3K-AKT signaling and con-
trols cranial neural crest cells delamination and facial
morphogenesis. SPECC1L mutations were ﬁrst identiﬁed in
patients with oblique facial clefts (OBLFC1; OMIM
600251). Recently, mutations in SPECC1L were reported in
a pedigree reported in 1988 as Opitz syndrome. We report
three further pedigrees with SPECC1L syndrome, including
a 3-generation family and one fetal case. Our patients
conﬁrm that SPECC1L syndrome is clinically similar to
Teebi syndrome. Critical phenotypic analysis of previous
patients published with SPECC1L and MID1 mutations
lead us to consider that SPECC1L syndrome should not be
described as “dominant Opitz syndrome” : hypospadias and
laryngeal anomalies that characterizes Opitz syndrome are
never observed with SPECC1L mutations, whereas bran-
chial anomalies, parietal hernias, uterine anomalies or vas-
cular anomalies characterize SPECC1L mutants.
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Split hand/foot malformation associated with 20p12.1
deletion: a case report
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Introduction: Split hand/foot malformation (SHFM) or
ectrodactyly is a rare congenital disorder affecting limb
development. It is characterized by clinical and genetic
heterogeneity. It is usually inherited as an autosomal
dominant trait with incomplete penetrance. Isolated and
syndromic forms are described. The extent of the mal-
formations associated with SHFM is highly variable and
multiple syndromes with clinical and genetic overlap have
been described.
Material and methods: We report here a 28 year-old
caucasian man born to unrelated parents who presented with
bilateral deep median hand cleft, oligodactyly, right syn-
dactyly and bilateral forearm hypoplasia. Additionally,
sparse hair and extended freckles were noted. Physical and
systemic examination was normal without facial dys-
morphism or intellectual disability.
Results: qPCR analysis of BHLHA9, TP63 Sanger
sequencing and next generation sequencing of more than
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400 genes implicated in bone disorders did not reveal any
signiﬁcant sequence alteration. By contrast, Array-CGH
identiﬁed a 450 kb de novo 20p12.1 microdeletion
encompassing three exons (exon 6 to 8) of MACROD2.
Conclusion: MACROD2 deﬁciency has not been reported
to be associated with limb malformation until now. How-
ever, it is located next to KIF16B, which is involved in
ﬁbroblast growth factor receptor (FGFR) signaling. Addi-
tionally, the deletion encompassed a histone modiﬁcation
H3K27ac mark, which provides a quantitative readout of
promoter and enhancer activity during human limb devel-
opment. Altogether, these relationships suggest that the
CNV is causative in the present case through a positional
effect.
L. Ruaud: None. R. Flöttman: None. F. Escande:
None. L. Van Maldergem: None. S. Mundlos: None. J.
Piard: None.
P11.109A
A case of syndromic split hand/foot malformation type 1
with de novo 7q21.3 deletion
D. Brazdziunaite1, B. Burnyte2,3, B. Aleksiuniene2,3, K.
Grigalioniene2,3, L. Ambrozaityte2,3, V. Norkuniene3, A.
Utkus2,3
Faculty of Medicine, Vilnius University, Vilnius, Lithuania,
2Department of Human and Medical Genetics, Faculty of
Medicine, Vilnius University, Vilnius, Lithuania, 3Centre
for Medical Genetics, Vilnius University Hospital Santar-
iskiu Klinikos, Vilnius, Lithuania
Background: Split hand/foot malformation (SHFM) is a
nonsyndromic or syndromic congenital malformation of
limb development. A locus in chromosomal region 7q21.3
associated with SHFM is referred to as SHFM1. Case: A 4-
year-old patient was monitored since birth because of
multiple dysmorphic features and complaints about devel-
opment delay. A boy is born from the 2nd pregnancy and
delivery (polyhydramnios) via C-section, Apgar score 10/
10. Phenotype of the newborn: craniofacial dysmorphism,
left hand ectrodactyly, syndactyly of I-II, III-IV toes in right
foot, bilateral cryptorchidism. Later, mild bilateral con-
ductive hearing loss, severe astigmatism, hypermetropia,
unclear hyponasal speech, recurrent respiratory tract infec-
tions were observed. He was diagnosed with language and
psychomotor developmental delay. 7q21.3 deletion, 985 kb
in size (arr[GRCh37] 7q21.3 (96222790_97207764)x1) was
identiﬁed by SNP-array analysis. De novo origin of the
deletion was conﬁrmed for the patient by RT-PCR as both
parents are not the carriers of the deletion. On recent
assessment at 4 years of age, his psychomotor development
shows no signiﬁcant improvement, he has social interaction
difﬁculties and food related obsessions. Conclusions:
Phenotype and chromosomal rearrangement of presented
patient conﬁrm the role of known candidate genes that
underlie the pathogenesis of this disorder. The impact of
SHFM1, DLX5 and DLX6 genes is known to have a func-
tion in SHFM1. This has been previously described in cases
with 7q21.3 deletion. Our results support the idea that
imbalances in some genomic regions are associated with
variable phenotypes. Further investigation of genetic and
environmental modiﬁers may explain variable expressivity.
D. Brazdziunaite: None. B. Burnyte: None. B. Alek-
siuniene: None. K. Grigalioniene: None. L. Ambrozai-
tyte: None. V. Norkuniene: None. A. Utkus: None.
P11.110B
A family with 17p13.3 duplication encompassing BHLHA9
gene in four generations and with reduced penetrance in
females
L. Roht1, K. Simenson1, O. ilina1,2, K. Kuuse1, P. Ilisson1,
M. Sitska1, K. Õunap1,3
1Department of Clinical Genetics, United Laboratories,
Tartu University Hospital, Tartu, Estonia, 2Department of
Biotechnology, Institute of Molecular and Cell Biology,
University of Tartu, Tartu, Estonia, 3Department of Clinical
Genetics, Institute of Clinical Medicine, University of Tartu,
Tartu, Estonia
Introduction: Duplications in the 17p13.3 chromosome
region encompassing BHLHA9 gene have been associated
with split hand/foot malformation with or without tibia
hemimelia. It is shown by Klopocki et al (2012) that this
duplication serves as a susceptibility factor for a highly
variable phenotype with reduced penetrance, particularly in
females.
Materials and methods: We are presenting a family
with a duplication of BHLHA9 gene in four generations.
There are four affected males with split hand/foot mal-
formation, tibia hemimelia and/or syndactyly. Index patient
is a 10-month-old boy with bilateral ectrodactyly. All carrier
females were healthy and four of them were investigated. At
ﬁrst, all individuals were investigated with chromosomal
microarray analysis (CMA). For some, additional MLPA
analysis of BHLHA9 gene was performed to conﬁrm the
ﬁnding.
Results: CMA of the index patient showed two small
sequential duplications in the region 17p13.3. The ﬁrst one,
~70-kb in size, included BHLHA9 gene, but the meaning of
the second one, ~95.5-kb in size, remained unclear.
Unfortunately, the ﬁrst pathogenic duplication of BHLHA9
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gene was not visible on CMA in other investigated affected
male and unaffected carrier females. Therefore, additional
MLPA analysis was done to three individuals, revealing a
heterozygous duplication encompassing the entire gene.
Conclusions: We present an additional family with a
duplication of BHLHA9 gene and non-Mendelian inheri-
tance of split hand/foot malformation characterized by a
high degree of non-penetrance with sex bias. The identiﬁ-
cation of small copy number variations can sometimes be
challenging on CMA due to low coverage in some regions.
L. Roht: None. K. Simenson: None. O. ilina: None. K.
Kuuse: None. P. Ilisson: None. M. Sitska: None. K.
Õunap: None.
P11.111C
STIL compound heterozygous mutations cause micro-
cephaly via centriolar lengthening
H. Van Esch1, F. Cristofoli1, B. De Keersmaecker2, L. De
Catte2, J. R. Vermeesch1
Center for Human Genetics, Leuven, Belgium, 2Department
of Obstetrics and Gynecology, UZ Leuven, Leuven, Belgium
STIL (SCL/TAL1 interrupting locus) is a core component
of the centriole duplication process. STIL mutations have
been associated to both Autosomal Recessive Primary
Microcephaly (MCPH) and holoprosencephaly (HPE). In
this report, we describe a family with multiple miscarriages
and two terminations of pregnancy due to marked fetal
microcephaly, delayed cortical gyriﬁcation and dysgenesis
of corpus callosum. Whole exome sequencing allowed to
identify novel compound heterozygous mutations in STIL.
M-phase synchronized amniocytes from both affected
fetuses did not display an aberrant number of centrioles, as
shown previously for either STIL-depleted or over-
expressing cells. However, we observed a signiﬁcant elon-
gation of at least one centriole for each duplicated centro-
some. Since the mutations found in the affected fetuses lie
respectively in the CPAP/CENPJ and the PLK4 interacting
domains of STIL, we suggest that centriole elongation
represents a novel mechanism causing MCPH and
embryonic lethality in humans.
This work was supported by grants from the KUL PFV/
10/016 SymBioSys to JRV and GOA/12/015 to JRV and
HVE, and Belgian Science Policy Ofﬁce Interuniversity
Attraction Poles (BELSPO-IAP) program through the pro-
ject IAP P7/43-BeMGI.
H. Van Esch: None. F. Cristofoli: None. B. De
Keersmaecker: None. L. De Catte: None. J.R. Ver-
meesch: None.
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A study of minor splicing defects associated with
RNU4ATAC pathogenic variants
A. Besson1, A. Cologne1,2, C. Benoît-Pilven1,2, A. Putoux1,
C. Benetollo1, R. W. Padgett3, A. Leutenegger4, V.
Lacroix2, S. Mazoyer1, P. Edery1
1UMR CNRS Inserm, Neuroscience Research Centre of
Lyon, Lyon, France, 2UMR CNRS, Laboratoire de Biomé-
trie et Biologie Évolutive, Lyon, France, 3Waksman
Institute, Rutgers University, Piscataway, NJ, United States,
4UMR Inserm, Genetic variability and human diseases,
Paris, France
- Introduction: We and others have shown that biallelic
variants of RNU4ATAC, a gene transcribed into the U4atac
small nuclear RNA component of the minor (U12) spli-
ceosome, cause Taybi-Linder syndrome (TALS, OMIM
#210710). TALS is a rare autosomal recessive disorder
characterised by dwarﬁsm, severe microcephaly, brain
malformations and other developmental defects. Minor
splicing uses a specialised machinery composed of U4atac
and 4 other snRNAs, along with multiple proteins, and
concerns ~800 U12-type introns harbouring speciﬁc spli-
cing recognition sequences. Minor splicing may play a
regulatory role on gene expression and is evolutionarily
conserved. Recently, another rare disorder, Roifman Syn-
drome (RFMN, OMIM #616651), characterised by growth
retardation, intellectual disability and antibody deﬁciency,
was also associated with compound heterozygous
RNU4ATAC variants, with one variant located in the TALS
region and the other located elsewhere in RNU4ATAC. Our
goal is to assess splicing efﬁciencies of RNU4ATAC var-
iants in a cellular model and to characterize minor intron
splicing and gene expression defects at the transcriptomic
level.
- Materials and Methods: We engineered a cellular model
aiming at assessing the pathogenicity, i.e. the splicing efﬁ-
ciency, of RNU4ATAC variants. We also analysed and
compared transcriptomes of cells derived from patients with
biallelic RNU4ATAC pathogenic variants.
- Results: U12-type intron splicing efﬁciency depends
on the tested RNU4ATAC alleles and correlates with TALS
disease severity. Preliminary transcriptomic studies show
generalised U12-intron splicing defects in patients’ cells.
A. Besson: None. A. Cologne: None. C. Benoît-Pilven:
None. A. Putoux: None. C. Benetollo: None. R.W. Pad-
gett: None. A. Leutenegger: None. V. Lacroix: None. S.
Mazoyer: None. P. Edery: None.
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P11.114B
A novel mutation of TBL1XR1 in individual with Pierpont
syndrome
M. Minatogawa
Kanagawa Children Medical Center, Yokohama, Japan
Background: Exome sequencing is an effective diagnostic
strategy to identify genetic causes of multiple congenital
anomalies and intellectual disabilities (ID). We report on a
Japanese girl with ID, facial dysmorphism, and multiple
congenital anomalies associated with a novel mutation in
TBL1XR1. Case Report: The proposita was a 9-year-old
female. She presented with progressive postnatal growth
failure, developmental delay. On closer examination, noth-
ing was to be found and G-Banded karyotype showed a
normal female karyotype 46,XX. At the age of 5 years, she
was referred to our hospital to determine the existence of the
underlying disease. At the age of 7 years, she complained of
precocious puberty. In the course of the examination, brain
magnetic resonance imaging revealed Arnold Chiari mal-
formation. At the age of 8 years, she underwent surgery for
a Chiari malformation. Methods: Written informed consent
was obtained from the parents. A clinical whole exome
sequencing was performed by using MiSeq (Illumina Inc.
USA) with TruSight One sequencing panel (Illumina Inc.
USA). The detected variants were conﬁrmed by sanger
sequences. Results: Array comparative genomic hybridi-
zation analysis had a normal result. De novo heterozygous
nucleotide substitution for the missense mutation in exon14:
c.A1339C:p.S447R in TBL1XR1 was identiﬁed. Conclu-
sion: Up to now, several different phenotypes caused by the
pathogenic variants of TBL1XR1 have been reported. While
the recurrent and unique variants of TBL1XR1represent each
unique phenotype, it has not been known well about the
mutation speciﬁc mechanism. To reveal the phenotypes
associated with TBL1XR1 mutations required further func-
tional analysis.
M. Minatogawa: None.
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2 new cases of Temple syndrome caused by isolated
hypomethylation of the 14q32 imprinted DLK1/MEG3
region
M. Sánchez Soler1, V. López-González2, M. Ballesta-
Martínez2, A. Serran-Antón1, L. Rodríguez-Peña1, G.
Glóver-López3, M. Martínez-Romero3, I. López-Expósito3,
E. Guilllén-Navarro4
1Medical Genetics Section, H. Clinic Universitary V.
Arrixaca, El Palmar, Spain, 2Medical Genetics Section,
H. Clinic Universitary V. Arrixaca, IMIB-Arrixaca.
CIBERER. ISCIII Madrid, El Palmar, Spain, 3Centro de
Bioquímica y Genética Clínica. HCUV, IMIB-Arrixaca, El
Palmar, Spain, 4Consejería de Sanidad, IMIB-Arrixaca.
CIBERER. ISCIII. Madrid, El Palmar, Spain
Introduction Temple syndrome is a genetic condition
caused by altered imprinted genes expression at chromo-
some 14q32 (maternal UPD 14, paternal deletion within the
locus or loss of methylation (LOM) at DLK1/MEG3).
Although the clinical manifestations are variable, pre-
postnatal growth retardation, poor feeding, hypotonia,
variable motor delay, premature puberty and obesity char-
acterize it. To date only 10 patients have been described
caused by isolated LOM.
Material and Methods We describe 2 cases diagnosed
in the last 7 months. They were born to healthy and non-
consanguineous parents and one was conceived by assisted
reproductive techniques. Prenatal data: one intrauterin
growth retardation; the other increased nuchal translucency
and hypoplastic nasal bone with normal karyotype 46,XY.
Both presented feeding problems (1 gastrostomy), hypoto-
nia, neurodevelopmental delay, big low-set posteriorly
rotated ears, almond eyes, small hands, ﬁfth clinodactyly
and triangular face. Other features (1): hypoplastic nasal
alae, short stature, relative macrocephaly, facial asymmetry,
truncal obesity and high-pitched voice. Molecular studies:
arrayCGH, MS-PCR 11p15, UPD 7, Prader-Willi. S: nor-
mal. MS-PCR 14q32: LOM at DKL1/MEG3, biparental
chromosome 14 origin.
Conclusions These 2 new patients diagnosed since MS-
PCR 14q32 is available in our centre suggest that this dis-
order may be under-diagnosed.
The fact that one child was conceived by ART (third case
described) supports the ART- imprinting disorders
association.
Both patients presented with hypotonia, feeding pro-
blems, ﬁfth cliniodactily and triangular face, and other
manifestation as relative macrocephaly, facial asymetry,
obesity; features also present in Silver-Russell and Prader-
Willi patients, so it should be included in their differential
diagnosis.
M. Sánchez Soler: None. V. López-González: None.
M. Ballesta-Martínez: None. A. Serran-Antón: None. L.
Rodríguez-Peña: None. G. Glóver-López: None. M.
Martínez-Romero: None. I. López-Expósito: None. E.
Guilllén-Navarro: None.
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Analysis of the sequence of Cereblon gene in people with
Thalidomide Embryopathy shows its coding region being
highly conserved
T. W. Kowalski1,2,3, J. A. Gomes1,2,3, M. Furtado1,3, B. D.
Rengel1,3, L. R. Fraga1,2, L. Schuler-Faccini1,2,3, F. S. L.
Vianna1,2,3
Universidade Federal do Rio Grande do Sul, Porto Alegre,
Brazil, 2Instituto Nacional de Genética Médica Populacio-
nal, Porto Alegre, Brazil, 3Hospital de Clínicas de Porto
Alegre, Porto Alegre, Brazil
Introduction: Cereblon protein was proposed as a primary
target of thalidomide teratogenicity. Here, we sequenced
CRBN whole gene in Brazilians with thalidomide embryo-
pathy (TE) to identify variants of susceptibility that may
help to elucidate Cereblon’s role in thalidomide teratogen-
esis. Materials and Methods: Thirty-six Brazilians with TE
participated of this exploratory study. Cereblon whole
coding, untranslated regions, and 50bp of adjacent introns
were sequenced through next-generation sequencing.
Functional prediction of the variants was performed in
silico, evaluating microRNA, transcription factors (TFs),
and splicing sites. Results: Forty-one variants were identi-
ﬁed; thirty-nine previously described. Only two alterations
were exonic (exons 4 and 6), both synonymous. Twenty-
three variants occurred in 3′UTR, sixteen in the region
shared with TRNT1 gene. rs551497808 (3′UTR),
rs199995326 (Intron 9) and rs6793531 (Intron 8) were
present in two individuals, despite their low frequency in
genomic databases (<0.001). Four polymorphisms identi-
ﬁed alter TFs Ikaros and Aiolos binding sites (important in
thalidomide therapy); three other variants modify alignment
sequence of three mature miRNAs identiﬁed in human
embryonic stem cells. Results regarding splicing sites
alterations were controversial and will be further evaluated.
Conclusions: TE individuals do not present coding variants
in CRBN that could drastically alter the protein structure;
hence, we did not evidence a high impact alteration in
CRBN that could be determinant for TE development. Our
approach identiﬁed variants in regulatory regions that could
help to a better understanding of genetic susceptibility to
TE. These results must be further evaluated and may help to
elucidate Cereblon’s role in TE. Grant: INAGEMP
T.W. Kowalski: None. J.A. Gomes: None. M. Fur-
tado: None. B.D. Rengel: None. L.R. Fraga: None. L.
Schuler-Faccini: None. F.S.L. Vianna: None.
P11.117A
Search for the mutation causing the ThoracoAbdominal
Syndrome (TAS) an x-linked dominant disorder
P. Majdalani, R. Parvari
Ben-Gurion University of the Negev, Beer Sheva, Israel
Introduction: The Thoracoabdominal Syndrome (TAS) is a
very rare congenital X-linked dominant disorder presented
only in one Jewish North African family. The features of the
syndrome are ventral herniae (midline abdominal wall
defect), antero-lateral diaphragmatic herniae (manifested
almost exclusively in affected males), hypoplastic lung, and
associated cardiac anomalies.
The aim of this study is to identify and characterize the
mutation causing TAS.
Materials and Methods: The initial search for the muta-
tion causing the syndrome was done by linkage analysis on
the X chromosome using 27 individuals of the TAS family.
Genome sequencing of two of the family members was
performed on the identiﬁed TAS interval on chromosome
X.
Results: The TAS interval was localized to Chr:Xq27.1
in an interval of 1.06 Mb. Three genes and two miRNA are
encoded in the interval. No mutation causing variants were
identiﬁed in these sequences. Large deletions, insertions and
translocations were negated by the sequence. Therefore,
further search for indel variants in the non-coding DNA was
pursued. Variations presenting in more than 1 person in the
population databases and in Short Tandem Repeats (STR)
regions were excluded, leaving 4 variations that are further
characterized for the possibility of causing the TAS
phenotype.
Conclusion: Further analysis using the Chromosome
Conformation Capture-on-Chip (4C-seq) technology will be
held on the mutation causing variant for determining long-
range chromatin interactions and the gene that may be
affected.
P. Majdalani: None. R. Parvari: None.
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Solving the diagnostic enigma of Toriello-Carey syndrome
A. Yeung1,2, M. Hunter2, M. Salaria2, C. Graziano3, E.
Sherr4, N. Sobreira5, S. Vergano6, J. X. Chong7, H.
Toriello8, J. Carey9, M. Bamshad7
Victorian Clinical Genetics Services, Murdoch Children's
Research Institute, Parkville, Australia, 2Monash Genetics,
Monash Health, Clayton, Australia, 3Medical Genetics
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Unit, Policlinico S. Orsola-Malpighi, Bologna, Italy, 4Insti-
tute of Human Genetics, University of California San
Francisco, San Franciso, CA, United States, 5McKusick-
Nathans Institute of Genetic Medicine, John Hopkins
University School of Medicine, Baltimore, MD, United
States, 6Division of Medical Genetics and Metabolism,
Childrens Hospital of The King's Daughters, Norfolk, VA,
United States, 7Department of Pediatrics, University of
Washington, Seattle, WA, United States, 8Medical Genetics,
Spectrum Health Hospital, Michigan State University,
Grand Rapids, MI, United States, 9Department of Pediatric
Genetics, University of Utah School of Medicine, Salt Lake
City, UT, United States
Introduction: Toriello-Carey syndrome (TCS) is char-
acterised by a combination of corpus callosal agenesis,
Pierre-Robin sequence (PRS), facial dysmorphism, intel-
lectual disability and other anomalies. Since the ﬁrst case
was described in 1988, over 50 patients have been reported
yet a single molecular mechanism underlying these diag-
noses has remained elusive.
Materials and Methods: Exome sequencing was per-
formed on ten families with a diagnosis of Toriello-Carey
syndrome following clinical geneticist consultation. Photo-
graphs and clinical features of patients were compared to
determine whether there was uniformity of dysmorphic
features and congenital anomalies.
Results: Of the ten kindreds tested, ﬁve had de novo
variants identiﬁed in genes linked to other Mendelian dis-
orders. These included variants in BAF-complex disorder
genes, SMARCA4 and SMARCE1; as well as variants in
KAT6B, THOC2 and TUBA1A. In the remaining ﬁve
“negative” families, no novel candidate genes were identi-
ﬁed. Comparison of patient data and photographs revealed
considerable heterogeneity in facial dysmorphism, although
almost all exhibited the features of PRS, corpus callosal
agenesis, intellectual disability and cardiac septal defect.
Conclusion: This study suggests that many character-
istics of TCS, rather than being a distinctive phenotype with
a unifying molecular cause, may in fact fall in the spectrum
of other recognised syndromes. This shift in perspective is
likely to impact future diagnostic approaches and recurrence
risk counselling for patients with this constellation of fea-
tures. The possibility remains that there is a true TCS
phenotype and a future direction may be to better delineate
the facial dysmorphology to separate this from the mix.
A. Yeung: None. M. Hunter: None. M. Salaria: None.
C. Graziano: None. E. Sherr: None. N. Sobreira: None.
S. Vergano: None. J.X. Chong: None. H. Toriello: None.
J. Carey: None. M. Bamshad: None.
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Clinical and molecular ﬁndings of seven Turkish non-
photosensitive trichothiodystrophy patients with two novel
mutations in MPLKIP
T. Kalayci1, U. Altunoglu1, B. Karaman1, Z. Uyguner1, H.
Kayserili2
1Istanbul University, Istanbul Medical Faculty, Medical
Genetics Department, Istanbul, Turkey, 2Koc University,
Koc Medical Faculty, Medical Genetics Department,
Istanbul, Turkey
Introduction: Trichothiodystrophy (TTD) is a rare, auto-
somal recessive disease, recognizable by sulphur-deﬁcient
brittle hair with typical tiger-tail pattern on polarizing
microscopy. TTD patients also display variable neuroecto-
dermal features including cogntitive deﬁcit, ichthyosis,
photosensitivity, ocular ﬁndings, infections, and decreased
fertility. Approximately half of TTD patients exhibit pho-
tosensitivity. Non-photosensitive TTD (TTDN) is caused by
mutations in MPLKIP and GTF2E2. An X-linked form was
described in a family with two male affecteds with
RNF113A mutations. We here present the clinical and
molecular ﬁndings of seven patients from ﬁve unrelated
families with non-photosensitive TTD, including two novel
mutations in MPLKIP. Materials and Methods: Sanger
sequencing of MPLKIP was performed in seven clinically
diagnosed TTDN patients from ﬁve unrelated families,
consulted in the Medical Genetics Department of Istanbul
Medical Faculty between 2008–2016. Their clinical and
molecular ﬁndings were reviewed. Results: All our patients
had characteristics of TTDN including the tiger-tail hair
pattern, dysmorphic ﬁndings, cognitive deﬁcit or develop-
mental delay, short stature, ichthyosis and hypogonadism.
Notably, four patients displayed hipo/anhydrosis and tem-
perature intolerance, indicative for ectodermal involvement,
one had hypoplasia of corpus callosum, and one had a
single central incisor. Previously reported c.505dupA (p.
T169Nfs*75) was detected in one patient, novel c.85G>T
(p.G29X) in three families, and novel frameshift c.61delT
(p.W21Gfs*132) in one family. Conclusion: This study
adds to the clinical and mutational spectrum of TTDN, with
two novel mutations, the previously unreported ﬁnding of
single central incisor, and conﬁrmation of callosal
abnormalities as a ﬁnding of TTDN.
T. Kalayci: None. U. Altunoglu: None. B. Karaman:
None. Z. Uyguner: None. H. Kayserili: None.
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A 3-year-old girl with 46,XX,upd(14)mat/47,XX,+14
mosaicism
K. Ushijima1,2, S. Yatsuga2, A. Nakamura1, Y. Koga2, M.
Fukami1, M. Kagami1
Department of Molecular Endocrinology, National Center
for Child Health and Development, Tokyo, Japan, 2Depart-
ment of Pediatrics and Child Health, Kurume University
School of Medicine, Fukuoka, Japan
Introduction: Chromosome 14 contains a cluster of
imprinted genes at 14q32.2. Consistent with this, Temple
syndrome caused by maternal uniparental disomy of chro-
mosome 14 (upd(14)mat) presents discernable clinical fea-
tures such as pre- and postnatal growth failure, and
hypotonia. Although clinical phenotype of mosaic trisomy
14 is varied, pre- and postnatal growth failure has been
frequently reported. Furthermore, a combination of com-
plete trisomy 14 mosaicism and upd(14)mat is rarely
reported.
Subject: A 3-year-old girl, born small for gestational
age, was referred to our hospital due to severe growth
failure (height: -5.1 SD, weight: -3.3 SD), failure to thrive,
hypotonia and developmental delay together with deafness.
Methods and Results: Plasma hormone levels and
growth hormone provocation test showed a normal range.
To clarify the genetic cause of this patient, we ﬁrst per-
formed comparative genomic hybridization and SNP array
analysis, and detected a copy number change of chromo-
some 14. Fluorescence in situ hybridization analysis in
blood showed a mosaic trisomy 14 in 46.8% of cells. To
detect the origin of extra chromosome 14, we performed
methylation analysis and identiﬁed the mild hypomethy-
lated MEG3-DMR at the 14q32.2 imprinted region. Then,
we performed microsatellites analysis for chromosome 14,
and compared the peak area under the curve between
maternal inherited allele and paternal inherited allele.
Finally, we conﬁrmed that this patient had 46,XX,upd(14)
mat/47,XX,+14 mosaicism.
Conclusions: We report the third case of complete tris-
omy 14 mosaicism with upd(14)mat. Severe short stature in
this case may be caused by synergic effect of trisomy 14
mosaicism and upd(14)mat.
K. Ushijima: None. S. Yatsuga: None. A. Nakamura:
None. Y. Koga: None. M. Fukami: None. M. Kagami:
None.
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Partial trisomy 15q21.2-q26.3 and partial deletion Xp22.33-
p11.4 3p in a female patient with amenorrhea and normal
intelligence
M. Rivera-Vega1, L. Gonzalez-Huerta1, J. Valdes-
Miranda1, A. Perez-Cabrera1, S. Cuevas-Covarrubias2
1Genetica, Hospital General de Mexico, Mexico DF,
Mexico, 2Genetica, Facultad de Medicina, Hospital Gen-
eral de Mexico, Universidad Nacional Autonoma de
Mexico, Mexico DF, Mexico
Duplications that affect the distal part of chromosome 15
(dup15q24-q26) have variable phenotypes and are char-
acterized by developmental delay, palpebral ptosis and short
stature. However, duplications in the more telomeric part of
chromosome 15 (15q26.3) have been associated with an
overgrowth syndrome characterized by large size and renal
abnormalities in 45% of cases (polycystic or renal agenesis,
hydronephrosis, vesicourethral reﬂux). Cases with over-
lapping duplications reported range from generalized
developmental delay to cardiac involvement. Partial dele-
tions of the short arm of the X chromosome in female
patients present clinical heterogeneity; typical physical
abnormalities are often mild or absent. In all cases there is a
short stature. In the present study we describe a female
patient with amenorrhea and normal intelligence and a gain
of 49,93 Mb in 15q21.2-q26.3 and loss of 40,05 Mb in
Xq22.33-p11.4. Patient attends to physician due to ame-
norrhea, mammary gland tanner 1, hypergonadotropic
hypogonadism, absence of right gonad and hypoplasia of
left gonad. No other clinical manifestations were found. The
patient's phenotype may be a consequence of the interaction
between the effects of both alterations, this may vary with
respect to the phenotype described for each of the rearran-
gements when presented in an isolated way. There is a case
described in the DECIPHER database which presents very
similar rearrangements and whose reported phenotype is
global developmental delay, conversely to our case that
presented normal intelligence. This data enriches the spec-
trum of clinical manifestations in Partial trisomy 15q21.2-
q26.3 and partial deletion Xp22.33-p11.4 3p.
M. Rivera-Vega: None. L. Gonzalez-Huerta: None. J.
Valdes-Miranda: None. A. Perez-Cabrera: None. S.
Cuevas-Covarrubias: None.
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Trisomy 4q22.3-q35.2 in a patient with additional material
in 16q24 due to a de novo chromosomal rearrangement
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Miranda1, A. Perez-Cabrera1, S. Cuevas-Covarrubias2
Genetica, Hospital General de Mexico, Mexico DF, Mexico,
2Genetica, Facultad de Medicina, Hospital General de
Mexico, Universidad Nacional Autonoma de Mexico,
Mexico DF, Mexico
4q duplication syndrome is characterized by developmental
delay, medium to severe intellectual disability, growth
retardation, microcephaly, facial dimorphism (wide and
prominent nasal bridge, low implantation of ears, palpebral
ﬁssures sloping downward, epicantic fold and hypertelor-
ism) and digital anomalies (thumb hypoplastic and clin-
odactyly of the 5th ﬁnger). Less frequently, cardiac
malformations, renal, unilateral or bilateral cryptorchidism,
umbilical hernia, and epilepsy may occur. Occasionally,
choanal atresia, preaxial polydactyly and neonatal coleos-
tasis are present. Because duplication of the proximal ﬁrst
third of chromosome 4q is infrequent and the clinical effect
is mild, the phenotype described for 4q duplication syn-
drome seems to be associated with more distal region,
speciﬁcally to the 4q33-q34 region. It has been postulated
that the genes contained in this region may affect as fol-
lows: whereas GLRA3 and GMP6A could be related to
developmental delay motor and language and with intel-
lectual disability, HAND2 would be associated with cra-
niofacial and digital anomalies in these patients.
Interestingly, we describe a patient with a duplication of
94.1MB in chromosome 4q22.3–4q35.2 product of a de
novo chromosomal rearrangement of chromosome 16q.
L. Gonzalez-Huerta: None. M. Rivera-Vega: None. J.
Valdes-Miranda: None. A. Perez-Cabrera: None. S.
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Identiﬁcation of TTC21A as a novel cilia gene for Joubert
syndrome by whole exome sequencing
C. LAM, C. LAW
Department of Pathology, The University of Hong Kong,
Hong Kong, China
Introduction: The proband is a Chinese girl who presented
with hypotonia and central apnoea at birth. She had no
dysmorphic feature. Serial MRI and CT brain studies
showed features of Dandy Walker variant, severe hydro-
cephalus, agenesis of corpus callosum, pontocerebellar
hypoplasia and absent cerebellar vermis. Her brother was
similarly affected and succumbed at 1 year.
Materials and Methods: This case was enrolled in our
undiagnosed diseases program for ending diagnostic odys-
sey. Given the clinical features, we initiated genetic analysis
for Joubert syndrome (JS). To-date, there are >30 disease-
causing genes for JS. Instead of a “gene-after-gene”
approach, whole-exome sequencing (WES) was applied to
streamline the genetic analysis.
Results: WES revealed a novel heterozygous splice site
variant in TTC21A gene, NM_145755.2:c.27+2T>G and a
missense pathogenic variant, c.3676C>T (p.Arg1226Cys).
In silico prediction of the splice site variants suggested a
damaging effect on the donor splice site of exon 1. The
variant c.3676C>T is a rare variant with allele frequency of
0.0001373 (total population) and 0.0002746 (East Asian) in
the ExAC database, and is predicted to be probably dama-
ging (PolyPhen-2) and deleterious (SIFT). No pathogenic
variants were detected in other known JS-causing genes.
Conclusions: The diagnosis of JS in this case is chal-
lenging because the MRI hallmark, “Molar-tooth sign” was
absent secondary to the severe Dandy Walker malforma-
tion. TTC21A encodes for tetratricopeptide repeat domain-
containing protein 21A. It is a novel cilia gene for JS and is
widely expressed in nervous system, which probably
interacted with TTC21B, a known disease-gene for JS in
fetal development.
C. Lam: None. C. Law: None.
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Genotype-phenotype correlation in Czech patients with
tuberous sclerosis complex
H. Filipova, R. Vrtel, R. Vodicka, M. Prochazka
Institut of Medical Genetics University Hospital, Olomouc,
Czech Republic
Introduction: Tuberous sclerosis complex is an autosomal
dominant disorder manifested by benign tumors in many
tissues and organs (skin, brain, kidney, heart etc.). Patho-
genic mutations are in TSC1 and TSC2 gene. This study is
focused on analysis of TSC genes in selected group of
patients and subsequent genotype/phenotype correlation.
Materials and Methods: Using MLPA, Sanger or NGS on
Ion Torrent platform we analyzed TSC genes in 118
patients (99 probands and 19 cases of disabled family
members of some probands).
Results: In group of 99 probands were found 75 muta-
tions in TSC2 and 24 mutations in TSC1 gene. TSC2
mutations were associated with more severe phenotypes
than TSC1 mutations. No statistically signiﬁcant correlation
was observed between different types of mutations and
speciﬁc phenotypes in a group of TSC2 patients. In group of
508
TSC1 patients there were almost exclusively only protein-
truncating mutations. We also revealed signiﬁcant correla-
tions between hypomelanotic spots ﬁndings and incidence
of cortical tuber, the facial skin angioﬁbromas involvement
and ﬁnding of renal angiomyolipomas, between hamartoma
of the retina and heart rhabdomyoma or between epilepsy
and mental retardation in the group of patients with TSC2
mutations. Conversely, in individuals with TSC1 mutations
have been rarely observed angiomyolipomas and multiple
renal cysts, head ﬁbrous plaques and retinal hamartomas.
Conclusions: In our cohort the variability of clinical
expression among patients was substantial, even within
families or between unrelated individuals with the same
mutation. In total 27 revealed mutations has not been
described in LOVD TSC1/TSC2.
H. Filipova: None. R. Vrtel: None. R. Vodicka: None.
M. Prochazka: None.
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Phenotypic and molecular characterization of partial 2q
trisomy and partial 9p monosomy resulting from a maternal
balanced translocation. A case report
N. Bastida1, J. Crettaz1, R. Muguerza1, I. Martí2, O.
Martinez-Mugica2, Y. Ramirez1, L. Otaolea1, R. Sáez1
1Genetics Deparment, Donostia University Hospital, San
Sebastian, Spain, 2Neurology Department, Donostia Uni-
versity Hospital, San Sebastian, Spain
We report a female infant presenting with several congenital
malformations at birth. The baby was born to a 33-year-old
G2P0A1 mother at full-term (41+1) by eutocic delivery.
All the follow-up ultrasound scans were normal. Her birth
weight was 3340 g (PC 49) with a length of 50 cm (PC 52)
and a head circumference of 33.5 cm (PC 37). Her Apgar
score was 3/5.
Our patient presented with development delay. Facial
dysmorphisms included round face, progressive micro-
cephaly, hypertelorism, alternating exotropia, low-set ears,
long ﬂat philtrum, thin lips and thick neck with redundant
skin. Echocardiogram showed an interventricular commu-
nication. Vesicoureteral reﬂux, trombopenia and nomal
external female genitalia were present.
The CytoScan array 750K revealed 2q-duplication and
9p-deletion, 2q36.3q37.3(229,586,529–242,782,258)x3,
9p24.3p24.1(208,454–6,211,500)x1. Duplicated region on
chromosome 2 was 13196kbp including 91 OMIM genes
whereas deleted region on chromosome 9 was 6003kbp
including 27 OMIM genes. Maternal karyotype showed a
balanced translocation between chromosomes 2 and 9,[46,
XX,t(2;9)(q36.3;p24.1)].
Ocular problems were described in 9p-deletion similar
cases. Psychomotor, cardiac and renal issues were attribu-
table to both changes. Trygonocephaly, nystagmus, sex
reversal, respiratory, swallowing and otitis problems, for
9p-deletion and limb-ﬁnger alterations for 2q-duplication
were not observed.
The clinic of duplication-deletion syndromes due to
inherited translocations is complicated to integrate in a
unique syndrome. The phenotype is resulted from two
overlapped variants and it is difﬁcult to ﬁnd each change
described separately. It depends on the chromosomes
involved, the size and genes implicated. It is helpful to
characterize and share with the scientiﬁc society each case.
N. Bastida: None. J. Crettaz: None. R. Muguerza:
None. I. Martí: None. O. Martinez-Mugica: None. Y.
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Rhombencephalosynapsis in a Fetus with WAGR Syn-
drome: Extending the Spectrum of Associated Central
Nervous System Anomalies
K. Ludwig1, B. Paradiso1, M. Fedrigo1, D. Danieli2, A.
Zilio3, A. Angelini4
Department of Cardiac, Thoracic and Vascular Sciences,
Padua, Italy, 2Department of Pathology, San Bortolo
Hospital, Vicenza, Italy, 3Medicina Trasfusionale - Genet-
ica e Biologia Molecolare, Vicenza, Italy, 4Department of
Cardiac, Thoracic and Vascular Sciences, University of
Padua, Padua, Italy
WAGR syndrome (Wilms tumour - Aniridia - Genitour-
inary anomalies - Intellectual disability mental retardation)
is a rare genetic disorder caused by cytogenetically visible
deletions of 11p13 or cryptic deletions of the PAX6 and
WT1 genes. In up to one third of patients additional neu-
rological anomalies (either functional or malformative) can
be identiﬁed, including hypertonia or hypotonia, epilepsy,
enlarged ventricles, corpus callosum agenesis, and micro-
cephaly. Here we report the case of a fetus at 21+5 GW
with a 11p13 deletion and rhombencephalosynapsis, a rare
malformation not previously reported in the WAGR syn-
drome. Prenatal invasive analysis by array-CGH on DNA
from amniocentesis, performed after the ultrasonographic
detection of hypoplasia of the corpus callosum, the cere-
bellar vermis and a query Dandy Walker Variant, revealed
the following deletion: arr[GRCh37] 11p14.1p13
(30,000,728×2, 30,034,712–35,323,086×1, 35,380,819×2)
dn. Parents opted for termination of pregnancy at 21 + 5
GW. Autopsy revealed hypoplasia of the iris, a small right
sided postero-lateral diaphragmatic hernia, testicular
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dysgenesis and a complex malformation of the central
nervous system, characterized by partial agenesis of the
corpus callosum and the cerebellar vermis, temporal poly-
microgyria and a partial rhombencephalosynapsis (RS). RS
is a rare malformation of the cerebellum, only around 50
cases have been reported to date, characterised by the
association of total or partial agenesis of the vermis and
fusion of the cerebellar hemispheres. Numerous additional
malformations - cerebral and non - have been reported and
syndromic associations have been observed in some cases.
RS however, has never been reported in cases of WAGR
syndrome.
K. Ludwig: None. B. Paradiso: None. M. Fedrigo:
None. D. Danieli: None. A. Zilio: None. A. Angelini:
None.
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WDR26 haploinsufﬁciency causes a recognizable syndrome
of intellectual disability, seizures, abnormal gait, and dis-
tinctive facial features
M. A. Deardorff1, C. M. Skraban1, C. F. Wells2, P.
Markose3, M. T. Cho4, A. I. Nesbitt3, P. Y. B. Au5, A.
Begtrup4, L. M. Bird6, K. Cao3, E. H. Denenberg3, G.
Douglas4, K. M. Gibson3, K. Grand3, A. Goldenberg7, A.
M. Innes5, J. Juusola4, E. Kinning8, D. M. Markie2, M. M.
Owens9, K. Payne10, R. Person4, A. Stocco11, C. L. S.
Turner9, N. E. Verbeek12, L. E. Walsh10, P. G. Wheeler13,
A. B. Wilkens3, E. Zonneveld-Huijsson12, The DDD Study,
S. P. Robertson2, A. Santani3, K. L. I. van Gassen12
1University of Pennsylvania, Philadelphia, PA, United
States, 2Dunedin School of Medicine, University of Otago,
Dunedin, New Zealand, 3Children's Hospital of Philadel-
phia, Philadelphia, PA, United States, 4GeneDx, Gaithers-
burg, MD, United States, 5Alberta Children's Research
Institute, Cumming School of Medicine, University of
Calgary, Calgary, AB, Canada, 6University of California
San Diego, Rady Children's Hospital, San Diego, CA,
United States, 7CHU de Rouen, Centre Normand de
Génomique Médicale et Médecine Personnalisée, Rouen,
France, 8Queen Elizabeth Hospitals, Glasgow, Scotland,
United Kingdom, 9Royal Devon and Exeter Hospital,
Exeter, United Kingdom, 10Riley Hospital for Children,
Indiana University Health Physicians, Indianapolis, IN,
United States, 11INTEGRIS Baptist Child Neurology Clinic,
Oklahoma City, OK, United States, 12University Medical
Center Utrecht, Utrecht, Netherlands, 13Arnold Palmer
Hospital, Orlando, FL, United States
Introduction: Using exome sequencing, we have identiﬁed
de novo heterozygous loss of functionWDR26 gene variants
in individuals with intellectual disability. The purpose of
this work was to fully characterize the clinical spectrum,
speciﬁc features and molecular pathology that result from
pathogenic WDR26 variants. Materials and Methods: We
utilized a network of collaborators and GeneMatcher to
identify individuals with WDR26 variants, carefully asses-
sed clinical information and correlated ﬁndings with cellular
and molecular data. Results: We identiﬁed eleven indivi-
duals with de novo pathogenic variants in WDR26. Eight
carry loss-of-function mutations and three harbor missense
substitutions. All have intellectual disability with delayed
speech, a history of seizures and abnormal gaits. Common
facial features include a prominent maxilla, widely spaced
teeth, and a broad nasal tip that together comprise a
recognizable facial phenotype. These features are consistent
with those seen with heterozygous chromosome 1q41q42
microdeletions, suggesting that haploinsufﬁciency of
WDR26 contributes to the pathology. To support this,
WDR26 loss-of-function single nucleotide variants lead to
nonsense-mediated decay with subsequent reduction of
RNA expression and protein levels. Finally, structural
modeling of missense mutations also supports hap-
loinsufﬁciency as a mechanism of pathogenicity by dis-
rupting conserved domains of the protein.Conclusions:
Haploinsufﬁciency of WDR26 causes an emerging clinical
syndrome of intellectual disability, seizures, and distinctive
facial features.
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Intragenic deletion of WDR63 results in a dominant nega-
tive ciliopathy disorder
510
W. Hofmeister1,2, D. Kurtoglo1,2, M. Pettersson1,2, M.
Armenio1,2, J. Eisfeldt1,2,3, N. Papadogiannakis4, P.
Gustavsson1,5, A. Lindstrand1,2,5
Department of Molecular Medicine and Surgery, Karo-
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Dysfunctional cilia result in a heterogenous group of human
disorders termed ciliopathies. Using a customized CGH
array and pair-end WGS sequencing we identiﬁed a rare
intragenic heterozygous in-frame WDR63 deletion in a fetal
case with occipital encephalocele and inconsistent brain
lobulation. No other pathogenic CNVs or rare SNVs were
identiﬁed. The deletion spans exons 14–17, interrupting the
3rd and 4th WD repeat domains. RT-PCR showed expres-
sion of this deleted variant, conﬁrmed by Western blot
analysis. Functional studies in zebraﬁsh using over-
expression of WDR63 RNA encoding the deleted variant
resulted in abnormal development (46%, n= 255, P<0.001)
compared to overexpression of wild-type RNA (3%, n=
177). In some embryos, a sac like protrusion of the brain
was identiﬁed (5%, P<0.01). These ﬁndings were further
conﬁrmed by CRISPR/Cas9 mediated mosaic somatic
deletions in zebraﬁsh. Two sets of sgRNAs targeted at
intron regions ﬂanking orthologous exons were designed.
As the individual sgRNAs only targeted intron sequences,
injection of a set of sgRNAs was required to cause the
deletion. Injection of these two different sgRNA pairs
resulted in an increase of abnormal embryos with mal-
formations (41%, n= 161, p<0.01 and 62%, n= 224,
p<0.01 respectively) compared to injection of single
sgRNAs (2–7%, pooled n= 227). Embryos presented with
phenotypes similar to RNA overexpression experiments,
including sac-like brain protrusions (7% and 9%, p<0.01)
not observed in control embryos. We predict the in-frame
WDR63 deletion to result in a dominant negative protein
contributing towards encephalocele formation. These are
the ﬁrst ﬁndings supporting a role for WDR63 in a
ciliopathy-like disorder.
W. Hofmeister: None. D. Kurtoglo: None. M. Pet-
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KMT2A mutation is a major gene inintellectual disability
E. Schaefer1, S. Baer1,2, A. Afenjar3, T. Smol4, B. Gérard2,
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Montpellier-Nimes, Université Montpellier 1, Inserm
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France, 12Service de Génétique Médicale, CHU Robert
Debré, AP-HP, Paris, France, 13Département de Génét-
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14UF de génomique du développement, Centre de Génét-
ique Moléculaire et Chromosomique, CHU La Pitié
Salpêtrière, Paris, France, 15Service de Génétique Médi-
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tre de Génétique Humaine, CHU Besançon, Besançon,
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Intellectual disability (ID) is a common neurodevelop-
mental disorder characterized by an extreme genetic het-
erogeneity with more than 500 genes implicated in
mendelian forms. Wiedemann-Steiner syndrome (WSS)
(MIM 605130) is a rare syndromic condition associating ID
with hypertrichosis cubiti, short stature and a characteristic
facial appearance. Since the identiﬁcation of the causative
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gene KMT2A in 2012, 25 patients with a mutation and a
phenotypic description were reported.
We report herein 32 French individuals with a KMT2A
mutation identiﬁed by targeted gene sequencing or new
generation sequencing. We identiﬁed 25 new mutations (11
frameshift, 7 missense, 7 nonsense and 1 splice mutations)
and 2 already reported ones. We describe the ﬁrst autosomal
dominant transmission (a mother and her son affected) and
the ﬁrst mosaïcism with two affected children and a non-
affected father (mutation found with a rate of 1% in the
blood).
We observed a wide clinical spectrum in severity of ID
(mild to severe), facial appearance (typical or not) and in
associated malformations (bone malformations, cerebral,
renal, cardiac and ophthalmologic anomalies). We com-
pared our results to the literature: our ﬁndings are close to
those reported except for hypertrichosis, only found in 69%,
and growth retardation, found in about 50%, whereas these
symptoms were reported as almost constant. We make the
hypothesis that KMT2A is a major gene of ID as the clinical
spectrum is wide and the gene was identiﬁed recently.
Recent publications reporting several KMT2A mutations in
large cohorts of patients with neurodevelopmental troubles
strengthen this hypothesis.
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Characterization, by array-CGH and whole-exome sequen-
cing, of 6 patients with Williams-Beuren syndrome and
Autism Spectrum Disorder
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Williams-Beuren Syndrome (WBS), caused by 7q11.23
microdeletion, is characterized by multiple congenital
abnormalities, intellectual disability (ID) and a typical
behavioral proﬁle (“overfriendliness”, excessive talkative-
ness), which is generally considered as the polar opposite
phenotype to Autism Spectrum Disorder (ASD). Never-
theless, the prevalence of ASD has been reported to be
signiﬁcantly higher (12%) in WBS than in general popu-
lation (1%): this study aims at characterizing the basis of the
ASD observed in a subset of WBS patients.
We performed array-CGH and whole-exome sequencing
(WES) in 6 patients with WBS and ASD (diagnosed by
ADOS/ADI-R) to evaluate the possible presence of l)
unusually-large 7q11.23 deletions; II) a coexistent patho-
genic CNV; III) a point mutation in a gene localized in the
non-deleted 7q11.23 allele; IV) a mutation in genes causing
ID/ASD localized in other chromosomal regions.
Array-CGH conﬁrmed the presence of classical 7q11.23
microdeletions in all patients and did not show any other
pathogenic CNVs. WES found no recurrent SNVs either in
genes located in the non-deleted 7q11.23 allele or in a panel
of 450 genes causing ID/ASD.
Further studies are currently ongoing to evaluate: I) the
possible presence of a rare inherited or de novo variant in
the 6 WBS/ASD patients II) the functional dysregulation in
disease-relevant pathways using Induced Pluripotent Stem
Cells obtained from skin ﬁbroblasts from 3 among the 6
patients.
This study may provide new insights into the WBS
phenotypic variability of social communication, possibly
ranging from excessive talkativeness and “overfriendliness”
to absence of verbal language and social deﬁcit.
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P11.131C
A double cryptic chromosome imbalance as a cause of
phenotype variability in Wolf-Hirschhorn syndrome
A. Hovhannisyan1,2, A. Baghoyan1, N. Kostandyan1, S.
Midyan1
1Center of Medical Genetics and Primary Health Care,
Yerevan, Armenia, 2National Bureau of Expertises, NAS,
Yerevan, Armenia
We report on a 5-year boy with extreme short stature,
underweight, microcephaly, psychomotor development
delay, triangular-shaped face with pointed chin, low anterior
and posterior hairline, massive nose depressed inside, long
philtrum, mild hypospadias and low muscle tone. The child
has always been growing steadily and speaks syllables only.
Cytogenetic testing revealed normal male karyotype. Per-
formed CGH testing revealed genomic deletion of 4p16.3
(4,2Mb) and genomic duplication of 8p23.1–8p23.3
(7,3Mb): arr4p16.3(85743.3–3770271)x1,8p23.3-p23.1
(194617–6873437)x3. FISH analysis conﬁrmed the ﬁndings
of Wolf-Hischhorn (WHS) syndrome in our patient. To
date, only three recurrent constitutional non-Robertsonian
translocations have been described in humans. Transloca-
tion (4;8) is the third by prevalence along with t(11;22) and
t(8;22). Several literature reports point to a great variability
of the WHS phenotype that is dependent on the genomic
defect (terminal versus interstitial deletions; pure deletions
versus unbalanced translocations; size of the deletion),
consisting in the association of severe growth delay, intel-
lectual disability, peculiar facial dysmorphisms and sei-
zures. The deleted and duplicated regions include multiple
genes, containing WHSC1, WHSC2, and LETM. The latter
reported as an excellent candidate gene also for seizures
although our patient doesn’t perform epilepsy. features. On
the other hand trisomic part of 8p may be responsible for the
clinical variability in our patient. While the interpretation of
terminal duplication of 8p23 is difﬁcult as no overlapping
terminal duplications in literature exist. Duplications of this
region has already been reported as a possible benign
variant.
A. Hovhannisyan: None. A. Baghoyan: None. N.
Kostandyan: None. S. Midyan: None.
P12 Cancer genetics
P12.001A
Integrative approach and eQTL analysis identify breast
cancer risk genetic variants affecting microRNA binding
sites
R. C. Almeida, V. S. Chagas, M. L. Petzl-Erler, M. A. A.
Castro; ederal University of Paraná, Curitiba, Brazil
Genome-wide association studies (GWAS) found ~ 80 risk
loci associated to breast cancer (BC). Approximately 90%
of single nucleotide polymorphisms (SNP) associated to
complex diseases are in non-coding regions of the human
genome, including target sequences of microRNAs (miR-
NAs). MiRNAs act by imperfect base-paring to 3'
untranslated regions (3'- UTR) of target messenger RNAs
(mRNA), leading to translation repression, mRNA degra-
dation or both. SNPs located at the 3'UTR of miRNA tar-
gets called miRSNPs may reduce effectiveness or abolish
miRNA-mediated repression.
Here we used a naïve Bayes classiﬁer approach to inte-
grate results from three tools (Polymirts, miRSNP and
miRSNPscore), which use different methods to predict for
miRSNPs. Further, we integrated miRSNPs predictions
with summary statistics from breast cancer GWAS data. In
addition, to prioritize miRSNPs, miRNAs and targets genes,
we performed a tumour-speciﬁc eQTL analysis (~
2,000 samples from METABRIC), and a Pearson correla-
tion analysis in 847 BC samples (mRNA-seq and small
RNA-seq from TCGA).
We found 338,894 candidate miRSNPs (score > 0.7). Of
those, 43 were associated to BC (P < 5 ×10−8) and predicted
to affect interaction of 160 miRNAs with 20 target genes.
By using a tumour-speciﬁc eQTL analysis we could prior-
itize 5 miRSNPs with cis-eQTL effect (FDR < 0.05).
Additionally, correlation analysis conﬁrmed predictions of
18 miRNAs with their 17 targets (P < 0.05).
Our integrative approach revealed new insights into
miRNAs and BC associated target genes. Thus, it helped to
prioritize BC noncoding risk SNPs that might be involved
in the causal mechanisms.
Funding: CNPq
R.C. Almeida: None. V.S. Chagas: None. M.L. Petzl-
Erler: None. M.A.A. Castro: None.
P12.003C
Landscape of pathogenic variations in a panel of 34 genes in
5131 HBOC families and cancer risk estimation
L. Castéra1,2, V. Harter1,3, S. Krieger1,2,4, N. Goardon1,2,
A. Ricou1, A. Rousselin1,2, G. Paimparay1,2, A. Legros1, O.
Bruet1, C. Quesnelle1, F. Domin1, C. San1, B. Brault1,2, R.
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Fouillet1, C. Abadie5, O. Béra6, P. Berthet7, French
Exome Project consortium, T. Frebourg2,8, D. Vaur1,2
1Laboratory of Cancer Biology and Genetics, Comprehen-
sive Cancer Center François Baclesse, Caen, France,
2Inserm U1245, Normandy Centre for Genomic and
Personalized Medicine, Rouen, France, 3Northwest Data
Center (CTD-CNO), Comprehensive Cancer Center Fran-
çois Baclesse, Caen, France, 4Caen University, Caen,
France, 5Department of Genetics, Comprehensive Cancer
Center Eugène Marquis, Rennes, France, 6Department of
Genetics, CHU, Fort de France, France, 7Department of
Genetics, Comprehensive Cancer Center François
Baclesse, Caen, France, 8Department of Genetics, Uni-
versity Hospital, Rouen, France
The integration of gene panels in the diagnostic of heredi-
tary breast and ovarian cancer (HBOC) requires a careful
evaluation of the risk associated with the genetic variations
detected in each gene. We analyzed by NGS 34 genes in a
series of 5131 index cases suspected to present HBOC.
Only variations strongly suspected to be pathogenic were
considered. Patients were excluded if one variant genomic
position did not reach 20x of coverage. We used as control
data sets, ExAC and 574 individuals from the French
Exome Project (FREX). We controlled stratiﬁcation bias
using correspondence analysis of 1000Genome data and
FREX genotypes to exclude non-European patients. The
probability than an individual from ExAC carries a patho-
genic variation was simulated and compared to the esti-
mated frequency in the HBOC population.
The incidence of pathogenic variations in BRCA2,
BRCA1, CHEK2, ATM, PALB2, RAD51C, TP53, and
BRIP1 was 3.9%, 3.7%, 1.1%, 1.0%, 0.9%, 0.5%, 0.5%,
0.5%, respectively. Odds-ratio (OR) conferred by variations
within BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATM,
BRIP1, CHEK2 and MSH6 were 13.48[10.22–17.58], 8.07
[6.39–10.08], 8.21[4.9–13.02], 4.40[2.46–7.22], 5.23[1.44–
13.04], 3.20[2.14–4.55], 2.49[1.41–3.97], 1.67[1.18–2.28]
and 2.50[1.12–4.63], respectively. Variations within
RAD51C, RAD51D, and BRIP1 were predominantly asso-
ciated with ovarian cancer (OR: 14.17[5.24–28.49], 11.85
[1.09–40.27] and 3.76[0.75–9.36]). PALB2 variations were
associated with bilateral breast cancer (OR 16.17[5.48–
34.10]).
The OR evaluated in this large series validates the inte-
gration, besides BRCA1 and BRCA2, of PALB2, RAD51C,
RAD51D in the molecular diagnostic of HBOC and the
lower values observed for the other genes suggests that they
are involved in an oligogenic determinism.
L. Castéra: None. V. Harter: None. S. Krieger: None.
N. Goardon: None. A. Ricou: None. A. Rousselin: None.
G. Paimparay: None. A. Legros: None. O. Bruet: None.
C. Quesnelle: None. F. Domin: None. C. San: None. B.
Brault: None. R. Fouillet: None. C. Abadie: None. O.
Béra: None. P. Berthet: None. T. Frebourg: None. D.
Vaur: None.
P12.004D
Impact Of Genome Variation On Functional CRISPR
Screens And Mapping Variant Data To Disease Biology
A. Ajetunmobi, L. Brody, N. Humphryes-Kirilov
Desktop Genetics Limited, London, United Kingdom
The wealth of data output from next-generation sequencing
(NGS) technologies have led to tremendous progress in the
study of human genetic variation and its contribution to
human disease. Several consortia have been developed to
map human genetic variation, producing genome-wide
association studies and rare variant analyses in the context
of common and rare diseases. However, many of these
variant databases lack information on the function of these
variants and their contribution to the pathophysiology of
human diseases. Without elucidating the functional con-
tribution of these mutations to cellular activity, these studies
yield little beneﬁt to human health. Clearly, investigation of
the molecular and cellular activity of genetic variation is
increasingly important for understanding the mechanistic
function of the human genome. At Desktop Genetics, we
have developed a CRISPR design platform accounting for
genomic variants including single nucleotide polymorph-
isms, small insertions/deletions, translocations and copy
number variants. Using NGS data and our optimized
CRISPR design rules, we demonstrate a bespoke metho-
dology for in vitro functional assays in cultured human cells
of a deﬁned genotype. We show how model-speciﬁc gen-
omes in conjunction with customizable guide RNAs can be
used to precisely target genomic sites of interest to induce
loss-of-function mutations and validate predicted variant
function. This may provide a unique approach for down-
stream variant interpretation and interrogation of their role
in the pathogenesis of rare and common genetic diseases.
A. Ajetunmobi: None. L. Brody: None. N. Hum-
phryes-Kirilov: None.
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High resolution Chromosomal Microarray Analysis (CMA)
as a tool for the genetic proﬁling of children with B-cell
Acute Lymphoblastic Leukemia (B-ALL)
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A. K. Mitrakos, A. Kattamis, K. Katsibardi, E. Kanavakis,
S. Kitsiou - Tzeli, M. Tzetis
National and Kapodistrian University of Athens, Athens,
Greece
Advances in the genetic proﬁling of patients with ALL
continue to transform diagnosis, prognosis and treatment,
by constantly adding to our knowledge on the biology of the
disease and improving clinical management with the means
for better risk stratiﬁcation and novel therapeutic approa-
ches. With most leukemia patients harboring acquired clo-
nal chromosomal aberrations, we here aim to investigate the
potential beneﬁts of high resolution CMA in B-ALL
patients.
The study material consisted of bone marrow samples
obtained at diagnosis from 27 children (median age 5 years
old) with B-cell ALL, that were analyzed with the high-
resolution genome-wide G3 CGH+SNP 2×400K micro-
array platform (Agilent Technologies), with a median CGH
probe spacing of 4.6kb (Refseq genes). Karyotype and
FISH analysis for the most common translocations were
also performed for all patients.
Overall, clinically relevant CNVs were detected in 22/27
cases (81,4%). The CMA revealed 8 cases with hyperdi-
ploidy, 1 case with hypodiploidy and 13 cases with com-
plex karyotypes. The gene most frequently involved in
aberrations was ETV6. The most notable small size CNVs
were a 87kb deletion encompassing IKZF1, a 9 kb dupli-
cation involving NF1 and a 28kb deletion involving PAX5
gene. Genomic regions that harbored hematopoiesis
(RUNX1) and cell-cycle regulation (CDKN2A/2B) genes, as
well as oncogenes and tumor suppressor genes were also
affected.
In conclusion, higher resolution CMA is able to detect
small CNVs with clinical consequences in a signiﬁcant
number of ALL cases while also proving to be a robust tool
for the identiﬁcation of gross chromosomal imbalances.
A.K. Mitrakos: None. A. Kattamis: None. K. Katsi-
bardi: None. E. Kanavakis: None. S. Kitsiou - Tzeli:
None. M. Tzetis: None.
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ETV6 and NOTCH1 germline variants in adult acute lym-
phoblastic leukemia - a case report
R. Norvilas1,2, V. Dirse1,3, E. Gineikiene1, R. Marcinkute1,
L. Griskevicius1,3
Hematology, Oncology and Transfusion Medicine Center,
Vilnius University Hospital Santariskiu Klinikos, Vilnius,
Lithuania, 2State Research Institute Centre for Innovative
Medicine, Vilnius, Lithuania, 3Department of Internal,
Family Medcine and Oncology, Faculty of Medicine,
Vilnius University, Vilnius, Lithuania
INTRODUCTION: Inherited mutations of ETV6 have
recently been associated with susceptibility to acute lym-
phoblastic leukemia (ALL). In particular, germline ETV6
gene variants were reported in a relation with thrombocy-
topenia and predisposition to childhood ALL (Moriyama
et al., 2015), although little is known about ETV6 variant
status in adult ALL. Also there are no studies about the role
of NOTCH1 germline variants in adult ALL. CASE
REPORT: A 19-year old Caucasian male was diagnosed
with bifenotypic leukemia (T/myeloid). He was born in a
family of non consanguineous healthy parents and has two
elder siblings. No family history of cancer or thrombocy-
topenia was identiﬁed. At diagnosis, next generation
sequencing (NGS) analysis was performed on patient‘s
bone marrow using TruSight Myeloid sequencing panel
(Illumina Inc., CA). Two ETV6 gene variants c.216G>A (p.
W72Ter) and c.304delT (p. R103AfsTer19) and one
NOTCH1 gene variant c.7130C>T (p.P2377L) were detec-
ted. qPCR assay was designed to conﬁrm these variants in
leukemic and non-leukemic DNA. Data analysis conﬁrmed
ETV6W72Ter and NOTCH1 P2377L mutations as germline
variants, whereas ETV6 R103AfsTer19 - as somatic muta-
tion. The proband’s both mother and father had ETV6
W72Ter and NOTCH1 P2377L germline variants, respec-
tively. Notably, one of the proband‘s siblings had ETV6
W72Ter and the other - NOTCH1 P2377L germline variant.
Our ﬁndings suggest that the inheritance of both ETV6 and
NOTCH1 germline variants and the acquisition of an
additional somatic ETV6 mutation may have contributed to
the malignant trasformation to ALL.
R. Norvilas: None. V. Dirse: None. E. Gineikiene:
None. R. Marcinkute: None. L. Griskevicius: None.
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New DNA methylation markers in pediatric acute myeloid
leukemia
V. V. Rudenko1, S. A. Kazakova2, A. S. Tanas1, A. V.
Popa3, V. S. Nemirovchenko3, D. V. Zaletaev2, V. V.
Strelnikov1
1Research Centre for Medical Genetics, Moscow, Russian
Federation, 2I.M. Sechenov First Moscow State Medical
University, Moscow, Russian Federation, 3N.N. Blokhin
Russian Research Center for Oncology, Moscow, Russian
Federation
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Violation of the distribution of methylation markers is the
process of carcinogenesis and it can play a signiﬁcant role
in the initiation and progression of neoplastic degeneration
of the genome. We aimed to establish diagnostic markers
based on DNA methylation for acute myeloid leukemia
(AML) in children, to be used for detection of AML sub-
types having different sensitivity to therapeutic regimens.
We used 107 samples of the bone marrow from 39
children with AML to determine DNA methylation of 6
genes that we previously identiﬁed as abnormally methy-
lated in AML. DNA samples were analyzed by multiplex
methylation-sensitive polymerase chain reaction before
treatment and at different stages of treatment.
We demonstrate that epigenetic therapy with decitabine
before the course of chemotherapy reduces DNA methyla-
tion notably.
Gene Group I (n
= 10) before
treatment/
after
decitabine
(% of
samples with
methylation)
p Group II (n
= 29) before
treatment/
after AIE/
after AIE and
decitabine
(% of
samples with
methylation)
p
CLDN7 30/30 1 20.7/80/66.7 <0.0001
SOX8 50/10 0.1409 51.7/0/0 <0.0001
EGFLAM 20/10 1 10.4/20/13.3 0.4487
THEM176A/
176B
60/30 0.3698 62/68/53.3 0.7772
CXCL14 90/80 1 96.6/100/100 1
GSG1L 10/0 1 10.4/8/0 1
There are an increase of CLDN7 methylation frequency
and a decrease of SOX8 methylation frequency signiﬁcantly
in group II. After chemotherapy treatment there is increase
in the methylation frequency of 4 (CLDN7, EGFLAM,
THEM176A/176B, CXCL14), and a decrease in 2 genes,
indicating clonal evolution of tumors (SOX8, GSG1L).
Chemotherapy causes destabilization of the methylation
proﬁle, frequency of methylation begins to decline, though
not pronounced, with the introduction of decitabine after
AIE. Our new 6-gene panel is useful to estimate the pro-
gression of malignant cells, as blast cells after chemother-
apy, considered morphologically normal, exhibit abnormal
methylation proﬁle of tumor cells.
V.V. Rudenko: None. S.A. Kazakova: None. A.S.
Tanas: None. A.V. Popa: None. V.S. Nemirovchenko:
None. D.V. Zaletaev: None. V.V. Strelnikov: None.
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A rare familial APC deletion in a Tunisian family revealed
in a 18-month-old boy with paravertabral Gardner ﬁbroma
N. B. Abdelmoula1, S. Aloulou1, N. Gouia Moalla1, R.
Louati1, F. Turki1, W. Ben Romdhane1, J. Jabeur1, J.
Elleuch1, S. Mrabet1, H. Ben Ameur1, M. Ben Aziza1, W.
Smaoui1, M. Mhiri1, M. Ben Dhaou2, T. Rebai2, R.
Mhiri2, M. Jallouli2, M. Buisine3
UR17ES36 Genomics of signalopathies in the Service of
Medicine, Medical University, Sfax, Tunisia, 2UR12ES15,
Medical University, Sfax, Tunisia, 3Molecular of Genetics,
University Hospital, Lille, France
We report the case of an 18-month-old boy who underwent
resection of a left thoracic paravertabral deep ﬁbromatous
tumor contracting intimate adhesions to the paravertebral
muscles. Histological evaluation revealed a benign Gardner
ﬁbroma. The family history revealed the presence of a deep-
seated dorsal soft tissue tumour in his 7-year-old brother.
His father as well as his uncle present bone masse at a same
localization which is the left mandible angle. The ortho-
pantamograph revealed a well-deﬁned mass that was con-
sistent with an osteoma (for both the boy’s father and
uncle). Molecular investigation of all members of this
Tunisian non consanguineous family was conducted, using
genomic DNA and bidirectional sequencing of the APC
gene. Molecular analysis showed heterozygous exon 15
deletion of the APC gene: c.4652_4655delAAGA (p.
Lys1551Argfs) in the patient, his brother, his father and his
uncle. This pathogenic 4 pb deletion leading to a truncated
APC protein, is a rare variant which was already described
in association with FAP. However, no details are given
about the patients and their families (https://www.ncbi.nlm.
nih.gov/clinvar/17533765/). Gardner ﬁbromas and osteo-
mas were the only clinical features of this germline APC
variant and this unrecognized FAP. Our family is under
surveillance to detect adenomatous polyps and prevent
colorectal cancer. Somatic variants of CTNNB1 and APC
genes will be investigated to identify biallelic inactivation
of Wnt components/regulators, in a possible recurring or
newly diagnosed soft-tissue tumours to prevent desmoids
and to adopt prophylactic and therapeutic measures.
N.B. Abdelmoula: None. S. Aloulou: None. N. Gouia
Moalla: None. R. Louati: None. F. Turki: None. W. Ben
Romdhane: None. J. Jabeur: None. J. Elleuch: None. S.
Mrabet: None. H. Ben Ameur: None. M. Ben Aziza:
None. W. Smaoui: None. M. Mhiri: None. M. Ben
Dhaou: None. T. Rebai: None. R. Mhiri: None. M. Jal-
louli: None. M. Buisine: None.
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‘Sinapic acid induces apoptosis in LNCaP human prostate
cancer cell line’
C. Eroglu, E. Kurar, E. Avci, H. Vural
Department of Medical Biology, Meram Faculty of
Medicine, Necmettin Erbakan University, KONYA, Turkey
Introduction: The results of experimental studies have
shown that natural compounds can have been antic-
arcinogenic effect. Sinapic acid is one of the natural com-
pounds and found in various vegetables and fruit species.
Prostate cancer is quite often seen in industrialized countries
and the second causing of cancer related death in men. The
aim of the study was to investigate the apoptotic effect of
sinapic acid, in the LNCaP human prostate cancer cells.
Materials and Methods: Cytotoxic effect of sinapic acid was
determined by using XTT assay. Total RNA isolation of
control and dose groups (IC50 dose of sinapic acid) was
conducted using TRIzol Reagent. Relative mRNA expres-
sion levels of important genes in apoptosis including
CASP3, CASP7, CASP8, CASP9, BAX, BCL2, FAS and
CYCS were quantiﬁed in control and dose groups using
qPCR. Results: IC50 dose of sinapic acid was detected as 1
mM for 72h in LNCaP cells. According to qPCR results,
signiﬁcant increases in the expressions of CASP3, CASP7,
BAX and CYCS genes were determined as 3.93, 4.92, 8.54
and 2.71 folds respectively, compared with the control
group cells. Conclusions: Sinapic acid can affect apoptosis
by regulating the expression of CASP3, CASP7, BAX and
CYCS genes in LNCaP cells. Further studies are required to
demonstrate the molecular mechanism of apoptotic effect of
sinapic acid in prostate cancer. Financially supported by N.
E.U. Scientiﬁc Research Projects (BAP #151218023).
C. Eroglu: None. E. Kurar: None. E. Avci: None. H.
Vural: None.
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Using whole exome sequencing to explore germline varia-
tion in BRCA1/BRCA2/PALB2 negative contralateral
breast cancers from the Women's Environmental Cancer
and Radiation Epidemiology (WECARE) study
A. Larionov1, E. Fewings1, J. Redman1, M. Goldgraben1,
J. Hadﬁeld2, WECARE, P. Concannon3, J. Bernstein4, D.
Conti5, M. Tischkowitz1
University of Cambridge, Cambridge, United Kingdom,
2Cancer Research UK Cambridge Institute, Cambridge,
United Kingdom, 3University of Florida, Gainesville, FL,
United States, 4Memorial Sloan-Kettering Cancer Center,
New York, NY, United States, 5University of Southern
California, Los Angeles, CA, United States
Background: BRCA1/2-negative asynchronous con-
tralateral breast cancer (CBC) is associated with familial
history, suggesting a heritable component in CBC beyond
the BRCA1/2 mutations. However, no datasets have yet
been generated to study germline variants associated with
BRCA1/2-negative CBC.
Methods: DNA extracted from blood was obtained from
256 CBC and 256 matched unilateral breast cancer (UBC)
patients of European ancestry enrolled in the WECARE
study. Women with BRCA1, BRCA2 or PALB2 mutations
were excluded. Whole exome sequencing (WES) was per-
formed using Illumina library preparation and sequencing
technologies. VCF ﬁles were generated following GATK
Best Practices workﬂow. Rare variants were aggregated per
gene and statistical associations were assessed using SKAT
R package. Trends in crude allelic frequencies (AFs) were
evaluated by comparing AFs in CBC, UBC and non-Finish
European cases from 1-thousand genomes project.
Results: 235 CBC and 245 UBC were successfully
sequenced to ~60x average depth on targets. Focused ana-
lysis in established breast cancer genes suggested that ATM
and CHEK2 showed crude AFs trends consistent with CBC
association. Small sample and effect sizes precluded exome-
wide detection of candidate genes that would pass multiple
testing-correction in SKAT analysis. However, combination
of SKAT analysis, the crude AFs assessments and manual
prioritising by biological functions allowed for the selection
of candidate genes, which could be used for further geno-
typing in a larger cohort or for experimental validation.
Conclusion: The study reports a new WES dataset for
the identiﬁcation of candidate genes potentially associated
with asynchronous contralateral breast cancer.
A. Larionov: None. E. Fewings: None. J. Redman:
None. M. Goldgraben: None. J. Hadﬁeld: None. P.
Concannon: None. J. Bernstein: None. D. Conti: None.
M. Tischkowitz: None.
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Mutations of ATR in male breast cancer predisposition
M. Chevarin1, N. Bourgon1, D. Alcantara2, M. Colonge-
Rame3, C. Populaire3, A. Baurand1,4, C. Jacquot1,5, G.
Bertolone1,4, Y. Duffourd1, T. Jouan6, P. Jonveaux7, Y.
Bignon8, I. Coupier9, F. Cornelis10, C. Cordier11, M.
Mozelle-Nivois12, J. Rivière1,13, P. Kuentz6, J. Skrzypski4,
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1Centre de Génétique, CHU Dijon, Dijon, France, 2Human
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Centre Georges-François Leclerc, Dijon, France, 5Unité
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ment, Dijon, France, 7Laboratoire de Génétique Médicale,
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d'Oncologie Moléculaire, Centre Jean Perrin, Clermont-
Ferrand, France, 9Unité d'Oncogénétique, ICM Val
d'Aurel, Montpellier, France, 10Univ. Bordeaux, IMB,
UMR 5251, Talence, France, 11UF6948 oncogénétique :
évaluation familiale et suivi, pôle d'hématologie et
oncologie, CHRU de Strasbourg, Strasbourg, France,
12Service de génétique, CHU-Reims, HMB, Reims, France,
13FHU Translad, CHU Dijon, Dijon, France, 14Plateforme
de transfert en biologie des cancer, Centre Georges-
François Leclerc, Dijon, France
Introduction: Male Breast Cancer (MBC) is a rare disorder
representing less than 1% of all breast cancers. BRCA1 and
2 mutations are not found in all high risk families with at
least one male breast cancer, and the involvement of other
predisposing genes are likely.
Methods: To identify new predisposing genes for breast
cancer, we used an “extreme phenotype” strategy, by per-
forming whole exome sequencing in 3 families with several
MBCs and negative diagnostic panel screening. A replica-
tion cohort of 161 patients, including MBC cases and
families with high breast cancer risk, was constituted in
order to sequence the full coding sequences of candidate
genes.
Results: We identiﬁed a truncating mutation in exon 32
of ATR (p.Leu1808*) in one proband. This mutation was
not described in public databases. ATR is implicated in cell
cycle regulation and DNA repair. Functional validation
revealed a decrease of ATR expression and phosphorylation
of CHEK1 in cells exposed to hydroxyurea. No truncated
transcript neither loss of heterozygosity were detected in the
tumour. Within the replication cohort, we identiﬁed a sec-
ond patient with a mutation in the splice-acceptor site of the
last exon of ATR (c.7762-2A>C), and 7 missense and near-
splice VUS.
Conclusion: Including these two novel truncating ATR
mutations, 8 constitutional loss-of-function mutations have
been described in the literature in high-risk families. Our
results converge towards a model in which more moderate
replicative stress due to the haploinsufﬁciency of ATR
allows the survival of the cells but generates sufﬁcient
genomic instability to induce cancerous transformation.
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A novel gross deletion involving PTEN and BMPR1A genes
produces a syndromic case of colorectal cancer
J. López Montiel1, E. Salas Sarduy2, J. M. Lezana
Rosales1, S. Juárez Peñalva3, J. Torres González1, C.
Palma Milla1, I. Idoyaga2, S. M. Carmona Tamajón1, C.
Palma Milla1, L. D. Andrés Garrido1, C. Sánchez
Linares1, J. López Siles1
M.G.C. Genetaq, Málaga, Spain, 2Laboratorio de Biología
y Patología Molecular, Buenos Aires, Argentina, 3Unidad
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Introduction: We present a 4 year old patient with sus-
pected of having Bannayan-Riley-Ruvalcaba syndrome.
She has severe anemia, juvenile polyposis, mild cardiome-
galy, lipoma and Hypoalbuminemia.
Materials and Methods: A next-generation sequencing
(NGS) panel containing 15 genes related to colorectal
cancer (CRC) was carried out. TruSight One kit (Illumina)
was used with a HiSeq4000 sequencer. Alignment of
sequences against hg19 genome followed by GATK variant
calling and ExomeDepth as Copy Number Variants (CNVs)
predictor was performed. Conﬁrmation of CNVs was done
by using Multiplex Ligation-dependent Probe Ampliﬁcation
(MLPA) test (P-225-D2 kit).
Results: No relevant variants were found after variant
calling. Nevertheless, ExomeDepth predicted a high con-
ﬁdence deletion in heterozygous state (Bonferroni Score:
73,1 for PTEN and 60,8 for BMPR1A) involving minimal
coordinates [chr10:88635766-91007415] and maximum
[chr10:88492744-91192810]. This deletion includes PTEN,
BMPR1A, KLLN and FAS genes, among others. This
alteration was further conﬁrmed by MLPA test. Smaller
deletions inside this region have been described in DECI-
PHER database associated with genotypes including
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polyposis, lipomas, macrocephaly, and intellectual and
behavioral ﬁndings.
Conclusions: In cases of syndromic forms of CRC, with
others abnormalities, several genes can be involved, pro-
ducing higher number of clinical ﬁndings, such as in this
patient, where a gross deletion is affecting PTEN and
BMPR1A genes. When a negative result is found in a point
mutations analysis, a CNVs test should always be per-
formed. Gross deletions can be detected by in silico pre-
dictors using NGS data, however, any result should be
conﬁrmed by other alternative methodology as NGS isn’t
the gold standard.
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BAP1 germline mutations in Finnish uveal melanoma
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Täll1, S. Markkinen2, A. Lehesjoki2, T. T. Kivelä1
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Introduction: Germline pathogenic variants of the BRCA-
1 associated protein-1 (BAP1) gene predispose to uveal
melanoma and several other cancers. Testing for germline
BAP1 mutations should be performed if typical BAP1
cancer predisposition syndrome tumors have been diag-
nosed in the family. We report the frequency of germline
pathogenic variants of BAP1 in consecutive Finnish uveal
melanoma patients.
Methods: In Finland, uveal melanomas are treated cen-
trally in the Ocular Oncology Service, Helsinki University
Hospital. We collected clinical data and genomic DNA
from 284 of 417 consecutive patients diagnosed from Jan-
uary 2010 to June 2016. The exons and exon-intron junc-
tions of BAP1 were sequenced.
Results: We found two pathogenic germline variants, a
T-insertion in exon 14 in three patients and donor splice site
mutation in a highly conserved region immediately after
exon 2 in 2 patients. The families of these patients also had
typical BAP1-related cancers (cutaneous melanoma, meso-
thelioma, and renal cell carcinoma). The mutations were not
found in 61,486 controls from the ExAC (http://exac.broa
dinstitute.org). The overall frequency of BAP1 pathogenic
variants was 1.8% (5/284; 95% conﬁdence interval, 0.6–
4.0).
Conclusions: The frequency of BAP1 germline patho-
genic variants in consecutive Finnish patients with uveal
melanoma who come from a high-risk region for the
development of this cancer is comparable with reports from
other populations.
Grant references: The Mary and Georg C. Ehrnrooth
Foundation; the Sigrid Jusélius Foundation; the Eye and
Tissue Bank Foundation; the Folkhälsan Research Foun-
dation; the Finnish Ophthalmological Society; theEvald and
Hilda Nissi Foundation; and the Paulo Foundation.
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Follow-up of a CFTR association with Barrett's esophagus
and esophageal adenocarcinoma
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Esophageal adenocarcinoma (EA) represents one of the
most rapidly increasing cancer types in high-income coun-
tries. Barrett’s esophagus (BE) is a premalignant precursor
of EA. In a recent GWAS meta-analysis (6.167 BE patients,
4.112 AE patients, 17.159 controls) we identiﬁed 14
genome-wide signiﬁcant risk loci. The strongest associated
signal was observed for an intronic variant in the CFTR
gene. CFTR encodes a chloride channel protein and is
mutated in patients with cystic ﬁbrosis (CF). Interestingly,
CF patients show increased incidence of gastroesophageal
reﬂux (GERD), a major risk factor for BE and AE. In view
of the phenotypic overlap for GERD and CF, and for GERD
and both BE and AE, a common pathophysiological
mechanism triggered by CFTR seems plausible. In order to
test this hypothesis, we analyzed the association of the most
common CF mutation ΔF508 in a European case-control
cohort (1.037 BE patients, 1.609 AE patients and 941
controls) using a single-marker genotyping assay. We could
not observe a signiﬁcant association. This might be (i) due
to insufﬁcient sample power or (ii) due to the fact, that not
ΔF508 but other genetic variants at the locus might explain
the underlying pathological mechanism. Fine-mapping of
all genetic variation at the CFTR locus and functional
analysis are needed to elucidate the interference of the
CFTR locus with BE and AE pathomechanism. A recent
functional study indicated CFTR as a tumor suppressor gene
in murine and human intestinal cancer, providing further
evidence for CFTR as a true disease gene for BE and AE.
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Genomic analysis of sporadic basal-cell carcinoma by
comparative genomic hybridization (CGH): PTCH1 altera-
tions and beyond
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Introduction: Basal-cell carcinoma (BCC) is the most
common malignant tumour in Caucasian population. Sev-
eral tumour suppressor genes and proto-oncogenes are
implicated in the pathogenesis of BCC, being PTCH1 the
most important of them with mutations in 48–83% of all
sporadic BCCs. New techniques such as comparative
genomic hybridization (CGH) facilitate the analysis of the
tumour genome, but, to date, only two reports have ana-
lysed sporadic BCCs. The main aim of this work was to
identify genomic and chromosomal imbalances of sporadic
BCC. Our secondary goal was to ﬁnd punctual mutations in
the PTCH1 gene.
Materials and methods: 13 BCC samples were obtained
by surgery and subsequently histologically analysed. Tumor
DNA was studied by CGH and PTCH1 gene by PCR and
Sanger sequencing.
Results: Aneuploidies were found in 10 tumours (77%),
with simultaneous alterations in two o more chromosomes
in 9/10. Most frequent trisomies were +22, +15, +17 y
+20 and the most common monosomie was -4. Partial
chromosome gains and losses were also characterized,
being the most usual -9q22.33 y -9q33. The 9q22.32 region,
where PTCH1 is placed, was lost in 7 cases (53,85%).
Gains in the SHH and SMO locus were detected. Punctual
mutations in PTCH1 gene were found in 10 (76,9%)
tumours. Six of these mutations are ﬁrstly described in this
work.
Conclusions: Our data conﬁrm the importance of
PTCH1 as well as chromosomic imbalances in the patho-
genesis of sporadic BCCs. However, further analysis of
these regions must be carried out.
E. Bueno Martínez: None. I. Palacios Álvarez: None.
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Evaluation of BAT40, NR-24 and D17S250 MSI Markers
in Tumor and Tumor Marginal Samples of Sporadic Col-
orectal Cancer
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Background: Microsatellites, also known as Short Tandem
Repeats (STRs), are small repeating stretches of DNA
scattered throughout the entire genome and account for
approximately 3% of the human genome. Due to their
repeated structure, microsatellites are prone to high muta-
tion rate. Microsatellite instability in tumor DNA is deﬁned
as the presence of alternate sized repetitive DNA sequences
that are not present in the corresponding germ-line DNA.
Microsatellite instability (MSI) is a molecular phenotype
due to a defective DNA mismatch repair system. The pre-
sence of MSI is found in sporadic colon, gastric, endo-
metrial and the majority of other cancers. Determination of
MSI status in colorectal cancer has prognostic and ther-
apeutic implications. As well, MSI can be used diag-
nostically for tumor detection and classiﬁcation.
Material and methods: In this study we investigated
tumoral and tumor marginal DNA of 50 sporadic CRC
patients who have not received chemotherapy. Two
mononucleotide markers (BAT40 and NR-24) and one
dinucleotide marker (D17S250) were used as a triplex PCR
panel to evaluate microsatellite instability status.
Results: Our primary ﬁndings showed that MSI was
detected in almost 25% of samples. Instability was observed
in the tumoral DNA compared to the normal DNA samples.
Moreover, our primary results showed that the instability
frequency of NR-24 marker was more than others and also
the frequency of instability in BAT40 and D17S250 were
almost similar.
Conclusion: Instability of NR-24 can be a promising
potential marker for determination of MSI status in patients
with sporadic colorectal cancer comparing to other inves-
tigated markers.
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Introduction: In this study, we examine the effects of
bemiparin on apoptosis and cell cycle related gene expres-
sion, viability, colony formation and migration/invasion of
the cultured MIA PaCa2 pancreatic and HepG2 hepatocel-
lular cancer cells. Materials and Methods: IC50 dose of
bemiparin in MIA PaCa2 and HepG2 cells were performed
by using XTT assay. Total RNA was isolated by using
Trizol Reagent. Effects of the bemiparin on apoptosis and
cell cycle related genes were determined via RT-PCR. Cell
invasion, colony formation and cell migration status were
detected by matrigel-chamber, colony formation assay and
wound-healing assay. “RT2 Proﬁles PCR Array Data Ana-
lysis” through “Student t-test” was used for statistical ana-
lysis. Results: IC50 dose of bemiparin was found to be 200
IU/mL in the MIA PaCa2 and 50 IU/mL in the HepG2 cell
lines on 48th hours. In HepG2, CCND1 expression was
reduced and p53, caspase-3, p21, caspase-8 expressions
were increased in the dose group cells when compared with
the control group cells. In MIA PaCa2 dose group, CCND1,
CDK4 and CDK6 expressions were reduced and p53
expression was increased. Cell invasion and migration was
signiﬁcantly inhibited and colony formation was sig-
niﬁcantly decreased through bemiparin treatment in both
cell lines. Conclusions: In present study, bemiparin inhibits
cell proliferation by inducing cell cycle arrest, apoptosis and
also decreases invasion, migration and colony formation in
HepG2 and MIA PaCa2 cells. Bemiparin may be a novel
agent for treatment of hepatocellular and pancreatic cancers
as a single agent or in combination with other agents.
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Birt-Hogg-Dubé syndrome as a cause of childhood
pneumothorax
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Introduction: Birt-Hogg-Dubé syndrome (BHD) is a rare
autosomal dominant cancer predisposition syndrome caused
by heterozygous variants in the FLCN gene. Phenotypically
it is characterized by ﬁbrofolliculomas, spontaneous pneu-
mothoraces and renal cell carcinoma. We present a case of
BHD in which pediatric pneumothorax led to the diagnosis.
Case presentation: A fourteen-year old otherwise healthy
boy was admitted to hospital due to sudden onset of
unprovoked chest pain. Chest X-ray was normal, but
echocardiography was with remarkably poor visualization
and this caused suspicion of free air in mediastinum. A
second chest X-ray conﬁrmed pneumomediastinum. Several
relatives had suffered from spontaneous pneumothoraces,
including the patient’s father, paternal uncle, paternal
grandmother and a brother of the grandmother. A clinical
geneticist was consulted and the diagnosis BHD proposed.
Genetic testing showed that the patient is a heterozygous
carrier of the pathogenic variant FLCN, c.1062+2T>G. Age
range of ﬁrst pneumothorax in the family was 14–73 years.
Two relatives had skin lesions consistent with ﬁbrofollicu-
lomas. None had renal cell carcinoma.
Conclusion: Diagnosis of BHD in this case of pediatric
pneumothorax has enabled predictive genetic testing in the
family and renal cancer surveillance for mutation carriers.
In the literature there are only few previous reports of BHD
and pediatric pneumothorax. Based on the present case and
our experience from an additional 106 BHD cases, we
hypothesize that pediatric pneumothorax in BHD may be
more frequent than previously assumed. Along with this
case results from our cohort study will be presented.
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Regulation of immune checkpoint genes revealed by a
bladder cancer data from The Cancer Genome Atlas
(TCGA) - bioinformatical analysis followed by an experi-
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1Cancer Research Centre, Sheba Medical Centre Hospital,
Tel Hashomer, 52621 Ramat Gan, Israel, Ramat Gan,
Israel, 2Sackler Faculty of Medicine, Tel Aviv University,
6997801 Tel Aviv, Israel, Tel Aviv, Israel, 3University of
Cambridge, School of Clinical Medicine, The Old Schools,
Trinity Ln, Cambridge CB2 1TN, UK, Cambridge, United
Kingdom, 4National Institute on Minority Health and
Health Disparities, University of Maryland, Maryland,
MD, United States, 5Department of Orthopedics, Sheba
Medical Centre Hospital, Tel Hashomer, 52621 Ramat
Gan, Israel, Ramat Gan, Israel
Introduction: The complex immunological synapse
between T lymphocytes and cancer or antigen presenting
cells (C/APCs) contains both co-inhibitory and co-
stimulatory checkpoint proteins, modulating the signal
transmitted to T lymphocytes. Despite the antineoplastic
activity of immune checkpoint inhibitors in many malig-
nancies, the majority of bladder cancer patients do not
respond. Since of the function of miR-15/16 miRNAs
family were shown to target PD-L1 in ovarian cancer, in
bladder cancer it remains unknown. Our aim was to study
the associations between these miRNAs and checkpoint
mRNAs in bladder cancer. Materials and methods: Bioin-
formatic analyses of the expression of 15 mRNAs and 8
miRNAs from 403 bladder cancer samples from the TCGA
database were performed. Statistical analysis: Spearman rho
correlation method. Results: Among mRNAs of 15
checkpoint genes known to be expressed on the C/APC, the
expression of six was positively correlated to any of the
other ﬁve mRNAs. These mRNAs encode 3 co-stimulatory
proteins (CD86, TNFSF4, TNFSF9) and 3 co-inhibitory
proteins (PD-L1, PD-L2 LGALS9). The expression of mir-
1 2 3 4 5 6 7 8 9 10 11 12
A ACTA2-AS1 ADAMTS9-AS2 AFAP1-AS1 AIRN BANCR BCAR4 BLACAT1 CAHM CBR3-AS1 CCAT1 CCAT2 CDKN2B-AS1
B CRNDE DGCR5 DLEU2 DLX6-AS1 EMX2OS FTX GACAT1 GAS5 GAS6-AS1 GNAS-AS1 H19 HAND2-AS1
C HEIH HIF1A-AS2 HNF1A-AS1 HOTAIR HOTAIRM1 HOTTIP HOXA11-AS HOXA-AS2 HULC IPW UniSp4 CP JADRR
D KCNQ1OT1 KRASP1 LINC00152 LINC00261 LINC00312 LINC00538 LINC00887 LINC00963 LINC01233 LINC01234 LISNCT5 LUCAT1
E MALAT1 MEG3 MIR155HG MIR17HG MIR31HG MIR7-3HG MRPL23-AS1 NAMA NBR2 NEAT1 NRON PANDAR
F PCA3 PCAT1 PCGEM1 POU5F1P5 PRNCR1 PTCSC1 PTCSC3 PTENP1 PVT1 RMRP RMST RPS6KA2-AS1
G SNHG16 SPRY4-IT1 SUMO1P3 TERC TRERNA1 TSIX TUG1 TUSC7 UCA1 WT1-AS XIST ZFAS1
H ACTB B2M RPLPO RN7SK SNORA73A HGDC RTC RTC RTC PPC PPC PPC
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15b was negatively correlated with 3 of these mRNAs:
CD86, TNFSF4 and PD-L2. Conclusions: A joint tran-
scriptional regulation of a several co-stimulatory and co-
inhibitory mRNAs on the C/APC side of the synapse in
bladder cancer was suggested, in line with the 'tidal wave'
hypothesis of immune checkpoint regulation, where co-
stimulation and co-inhibition occur simultaneously. mir-15b
might negatively regulate expression of checkpoint genes,
and this is now experimentally studied in our lab. Our
results may point to novel methods to enhance the immu-
nogenicity of bladder cancer.
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Clinical usefulness of non coding RNA markers in bladder
cancer
E. M. Borkowska, M. Traczyk-Borszynska, Z.
Jablonowski, T. Konecki, P. Kutwin, M. Sosnowski, M.
Borowiec
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Introduction & Objectives Bladder cancer (BC) is the
fourth commonest male malignancy and one of the most
expensive human cancers to manage. Long noncoding RNA
(lncRNA) could play a role in urothelial carcinogenesis. We
analysed expression of 84 most relevant to tumorigenesis
lncRNAs discovered to date in patients with various cancer
as well as associated with cancer-related miRNA predicted
with bioinformatics.
Material & Methods We examined tissue samples from
patients with urothelial cancer histopathologically con-
ﬁrmed T2G3 and normal urothelium (as a control). The
cDNA was used on the real-time Human Cancer Pathway
ﬁnder RT² Proﬁler PCR Array (QIAGEN) in combination
with RT² SYBR® Green qPCR Mastermix . CT values were
exported to an Excel ﬁle to create a table of CT values
which was then uploaded on to the data analysis web portal
at http://www.qiagen.com/geneglobe. Fig. 1 RT2 lncRNA
PCR Array (96-well format); Human Cancer Pathway
Finder (Qiqgen).
Results We found signiﬁcantly altered expression of
many lncRNAs: PPC, ACTA2-AS1, LINC00887,
CCAT2, GACAT1, ADAMTS9-AS2, PVT1, LSINCT5,
RPLP0, RPS6KA2-AS2, MRPL23-AS1, CDKN2B-AS1,
AFAP1-AS1, EMX2OS, LINC01234, HNF1A-AS1.
Some of them were already described as characteristic for
BC while others have so far been detected only in different
types of tumors.
Conclusions We have identiﬁed a group of new
lncRNAs potentially related to the development or pro-
gression of BC.
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Methylation and clinicopathological markers for predicting
progression of non-muscle invasive bladder cancer
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Most patients with non-muscle invasive bladder cancer
(NMIBC) experience recurrences and up to 25% - pro-
gression to muscle-invasive disease. The risk of progression
is estimated by several clinicopathological parameters
which lack high objectivity and reproducibility. Therefore,
the development of novel prognostic biomarkers is of par-
ticular importance. The aim of our study was to determine
the prognostic value of TBX4, SOX1, HOXA9, and ISL1
abnormal methylation with regard to progression in a pro-
spective cohort of 258 NMIBC patients. Quantitative
methylation analysis was performed using Ms-SNuPE.
We found statistically signiﬁcant association of higher
methylation levels with lamina propria invasion (TBX4,
SOX1, ISL1 genes), high-grade (TBX4, SOX1 genes), and
large tumor size (SOX1, ISL1 genes). However, only the
high ratio of TBX4 methylation (≥ 44.5%) was signiﬁcantly
linked to disease progression, being able to discriminate
between progressors and non-progressors with 92.3% sen-
sitivity, 58.3% speciﬁcity, and 0.76 AUC (р=0.002). The
multivariate Cox regression analysis, after adjusting for
clinical parameters, conﬁrmed an independent effect of high
TBX4 methylation on NMIBC progression (HR 13.1; 95%
CI 1.7–101.8; р=0.014). Using logistic regression, we built
a prediction model, comprising TBX4 methylation marker,
tumor grade, tumor size, and previous recurrence episodes,
which resulted in improved speciﬁcity of 72.2%, sensitivity
of 92.3% and AUC of 0.87 (p<0.001) for tumor progres-
sion. The data obtained demonstrate that the combination of
TBX4 methylation and clinicopathological markers is highly
informative for the selection of patients with more aggres-
sive disease course who are recommended early cystect-
omy. The work was ﬁnancially supported by the BRFFR
(Agreement M15-046).
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P12.022B
Gene expression and relapse of superﬁcial cell carcinoma.
A microarray analysis
J. Mares1, M. Klabanova2, J. Duskova3, A. Horinek3, M.
Babjuk1
2nd Faculty of Medicine, Prague, Czech Republic, 2Diana
Lucina, Prague, Czech Republic, 31st Faculty of Medicine,
Prague, Czech Republic
Treatment of bladder superﬁcial tumours is dependent on
the risk of recurrence and it is therefore clinically important
to identify bladder cancer with high risk of intravesical
recurrence after transurethral bladder tumour resection. For
the improvement of recurrence prognosis we applied gene
expression microarray analysis to two groups of superﬁcial
bladder tumours (with no or late relapse during the period of
two years versus early relapse ones). Data from microarray
containing 29,019 targets (Applied Biosystems) were sub-
jected to a panel of statistical analyses to identify bladder
cancer recurrence-associated gene expression changes.
After validation 33 genes manifested signiﬁcant differences
between both groups. The signiﬁcant expression was
observed in the group of patients without recurrence by 30
genes of which the highest differences were detected by
NINJ1, GNE, ANXA1, TNFSF15, WDR34, ARHGEF4,
PRICKLE1, PSAT41, RNASE1, TM4SF1, TSPAN1,
PLOD2 and WDR72. These genes code for proteins
involved in signal transduction, vascular remodeling and
vascular endothelial growth inhibition, mainly. Specially,
PRICKLE1 and TNFSF15 were described to be linked with
WNT/beta-catenin signaling and angiogenesis regulation
and MTOR pathway. Loci of genes with signiﬁcant changes
of gene expression were located on characterisric chromo-
somes for bladder cancer: 9q, 17q, 2q and 16p. On the basis
of this ﬁndings we documented a number of expression
changes among which some seem to form clinically useful
relapse markers of superﬁcial bladder tumours. Research
was supported by MSM21620808 and Diana Lucina.
J. Mares: None. M. Klabanova: None. J. Duskova:
None. A. Horinek: None. M. Babjuk: None.
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Alterations in TIMP-2 and MMP-9 expression levels in
urinary bladder cancer
N. Ersoy Tunalı1, O. Tiryakioğlu2, S. Pençe3, E. Özbek4,
H. Tunalı5
1Istanbul Medeniyet University, Department of Molecular
Biology and Genetics, Istanbul, Turkey, 2Istanbul Univer-
sity Institute of Experimental Medicine, Department of
Molecular Medicine, Istanbul, Turkey, 3Istanbul University
Institute of Experimental Medicine, Istanbul, Turkey,
4Okmeydani Training and Research Hospital, Department
of Urology, Istanbul, Turkey, 5Istanbul University, Cerrah-
paşa School of Medicine, Department of Physiology,
Istanbul, Turkey
Introduction: Tumor invasion and metastasis are the most
decisive factors in the diagnosis and prognosis of bladder
cancer. Genes regulating extracellular matrix play sig-
niﬁcant roles in invasion and metastasis of bladder tumors.
Therefore the aim of this study was to investigate the
deregulation of TIMP-2 and MMP-9 genes in association
with bladder tumor invasion and metastasis.
Materials and Methods: 50 bladder tumors and 50 paired
cancer free tissues were collected for RNA isolation. Fol-
lowing isolation and cDNAsynthesis, RT-PCR with gene
speciﬁc primers was used to determine mRNA expression
levels. Signiﬁcant alterations in expression levels were
determined by Student's t test.
Results: MMP-9 and TIMP-2 were signiﬁcantly upre-
gulated in tumors compared to cancer free tissue. Sig-
niﬁcant upregulation was also observed for MMP-9 in
invasive and metastatic tumors (Table 1).
Conclusions: According to our results TIMP-2 and
MMP-9 expressions are signiﬁcantly upregulated in asso-
ciation with cellular events during tumorigenesis, invasion
and metastasis. Upregulation of MMP-9 gene, which is
known to enhance tumor invasion and metastasis, results in
the signiﬁcant yet insufﬁcient upregulation of TIMP-2 to
counter the effects of MMP-9. This imbalance between the
expression levels of MMP-9 and TIMP-2 may reﬂect the
invasiness and metastatic potential of bladder tumors.
MMP-9 and TIMP-2 expressions in bladder tissue
Gene Comparison Fc 95%CI p
MMP-
9
Tumor vs Cancer Free
Tissue
7.078 3.08.-
11.07
0.026
TIMP-
2
2.434 1.21-
3.66
0.038
MMP-
9
Invasive vs Non-
invasiveTumor
3.0951 1.50-
4.69
0.037
TIMP-
2
2.3729 1.10-
3.64
0.071
MMP-
9
Metastatic vs Non-
Metastatic Tumor
4.0935 3.51-
4.68
0.000
TIMP-
2
1.9453 1.79–
2.11
0.000
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Next-Generation Sequencing-based genomic proﬁling of
brain metastases of primary ovarian cancer
S. Balendran
Medical University of Vienna, Vienna, Austria
Introduction: Ovarian cancer represents the most common
gynecologic malignancy and has the highest mortality of all
female reproductive cancers whereas brain metastases (BM)
from ovarian carcinoma are uncommon. In this study, we
evaluated the mutational proﬁle of ovarian cancer metas-
tases through Next-Generation Sequencing (NGS) with the
aim of identifying potential clinically actionable genetic
alterations with options for small molecule targeted therapy.
Methods: Library preparation was conducted using Illu-
mina TruSight Rapid Capture kit in combination with a
cancer speciﬁc enrichment kit covering 94 genes. BRCA-
mutations were conﬁrmed by using TruSeq Custom
Amplicon Low Input Kit in combination with a custom-
designed BRCA gene panel.
Results: In our cohort all 8 sequenced BM samples
exhibited a multitude of variant alterations, each with
unique molecular proﬁles. The 37 identiﬁed variants were
distributed over 22 cancer-related genes. In total, 7 out of
8 samples revealed either a BRCA1 or a BRCA2 pathogenic
mutation. Furthermore, all 8 BM samples showed mutations
in at least one DNA repair gene.
Conclusions: Our NGS study of BM of ovarian carci-
noma revealed a signiﬁcant number of BRCA-mutations
beside TP53, ATM and CHEK2 mutations. These ﬁndings
strongly suggest the implication of BRCA and DNA repair
malfunction in ovarian cancer metastasizing to the brain.
Based on these ﬁndings, pharmacological PARP inhibition
could be one potential targeted therapeutic for brain meta-
static ovarian cancer patients.
Funding: This work was supported by the Austrian Sci-
ence Fund (FWF) P26011 (L.K.) and FWF-P 29251-B28
(L.K.) and the European Training Network MSCA-ITN-
2015-ETN ALKATRAS No 675712 (L.K.).
S. Balendran: None.
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MCG-International: Increasing global availability of BRCA
testing for cancer patients
A. Turnbull1, A. George1,2, N. Rahman1,2
1Institute of Cancer Research, London, Sutton, United
Kingdom, 2Cancer Genetics Unit, Royal Marsden NHS
Foundation Trust, London, United Kingdom
BRCA testing can provide useful clinical management
information for patients with ovarian and/or breast cancer
and their relatives. NGS has made BRCA testing fast and
affordable, but access remains limited in many countries.
Through the Mainstreaming Cancer Genetics (MCG) pro-
gramme we developed and validated a rapid, robust, cost-
effective testing pathway in which genetic testing is
undertaken by the cancer team with cascade testing to
relatives performed by genetics. The MCG pathway offers a
means of increasing global availability of BRCA testing,
which we are hoping to foster through a new initiative,
MCG-International.
As a ﬁrst step we performed a review of current testing
activity using a non-systematic search of open-access data
sources: Google, Google Scholar, PubMed, GeneTests,
Orphanet, Genetic Testing Registry (NCBI). We used
search terms to determine BRCA testing availability,
resource availability and research activity. Terms were
applied to each country in turn.
Eleven countries are introducing mainstream BRCA
testing. Thirty countries reported interest in increasing
access to BRCA testing with some supporting infra-
structure. Barriers reported in these latter countries were
similar to those we had to overcome, including lack of
knowledge and conﬁdence amongst healthcare profes-
sionals and patients, insufﬁcient laboratory resources and
inadequate ﬁnancing.
These data suggest there is demand for increased BRCA
testing access. The practical, efﬁcient MCG pathway may
have global utility in this regard. MCG-International aims to
foster this through direct support of countries wishing to
implement mainstream testing and through sharing experi-
ences and best practice. Please contact mcg@icr.ac.uk if
interested in participating. Funder, Wellcome:098518/Z/12/
Z
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Delivering fast, affordable, high-throughput BRCA gene
testing
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A. George1, A. Strydom2, S. Seal2, S. Mahamdallie2, E. J.
Ramsay2, I. M. Uddin2, H. Wylie2, A. Elliott2, E. Ruark2,
Z. Kemp1, N. Rahman2
Royal Marsden NHS Foundation Trust, London, United
Kingdom, 2Institute of Cancer Research, London, London,
United Kingdom
BRCA1 and BRCA2 (BRCA) gene testing is one the most
commonly requested tests in clinical genetics. The results
are used to personalise management in cancer patients and
to determine cancer risk and cancer surveillance manage-
ment in unaffected patients. Delivering fast, affordable,
high-throughput BRCA gene testing is therefore a key
objective in genetic medicine. TGLclinical laboratory, a
medical laboratory accredited to ISO15189, delivers germ-
line BRCA testing to cancer and genetic services, using the
TruSight Cancer Panel (Illumina). We run 96 samples every
week, ~one-third are clinical BRCA test requests. We call
both small mutations and exon deletion/duplications from
NGS data, using the SALSA software package, verifying
pathogenic and rare variants by Sanger and MLPA
respectively. We have reported 2,504 BRCA tests. The
overall mutation detection rate in 2,369 individuals with
cancer was 10%. All ovarian cancer (OC) patients are eli-
gible for testing (12% had mutations). Patients with BC<40
years, BC+ OC, bilateral BC <60 years, triple-negative BC,
male BC or for whom testing would alter management are
eligible (9.5% had mutations). Unaffected individuals with
a strong family history of BC/OC cancer are eligible for
testing, but the mutation detection rate was only 2% (3/
135). Our VUS rate is 0.1% using an integrated inter-
pretation pipeline that leverages gene and variant-speciﬁc
information. Median turnaround is 18 days and cost is £355
These data show that, fast, clear, affordable, large-scale,
high-throughput BRCA testing is achievable and suggests
that services with limited resources should prioritise testing
in affected individuals to maximise mutation detection.
Funder, NIHR-RM/ICR-BRC
A. George: None. A. Strydom: None. S. Seal: None. S.
Mahamdallie: None. E.J. Ramsay: None. I.M. Uddin:
None. H. Wylie: None. A. Elliott: None. E. Ruark: None.
Z. Kemp: None. N. Rahman: None.
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Spectrum of BRCA1 and BRCA2 mutations in Romanian
patients with ovarian cancer
G. Cardos1, A. Curtis2, J. Lisgo2, A. Silmon2, G. Bucur1,
C. Nitipir3, D. Roman4, C. Floares5, M. Zeleniuc1,6, P.
Apostol1
1Personal Genetics, Bucharest, Romania, 2NewGene Ltd,
International Centre for Life, Newcastle upon Tyne, United
Kingdom, 3Elias University Clinical Hospital, Bucharest,
Romania, 4County Clinical Hospital, Tirgu-Mures, Roma-
nia, 5The Oncology Institute "Prof. Dr. Ion Chiricuta",
Cluj-Napoca, Romania, 6Discipline of Medical Genetics,
University of Medicine and Pharmacy “Carol Davila”,
Bucharest, Romania
Ovarian cancer (OC) represents the ﬁfth cause of cancer
deaths among malignancies in European women. Mutations
in the BRCA1 and BRCA2 genes play an important role in
OC pathogenesis and confer more sensitivity to platinum
agents than wild-type BRCA-OC.
The aim of our study was to identify and characterize the
spectrum of germline sequence mutations in the BRCA1/2
genes in order to provide knowledge of the OC pathogen-
esis in Romanian patients and to contribute in guiding
decision-making on their treatment strategies.
Therefore, the complete coding sequences of BRCA1/2
genes were analyzed by Next Generation Sequencing and
Multiplex Ligation-dependent Probe Ampliﬁcation in 153
Romanian unrelated OC patients, aged between 25–80
years.
We identiﬁed pathogenic mutations in the BRCA1/2
genes in 47 (30.72%) OC patients, including 37 (24.18%) in
BRCA1 and 10 (6.54%) in BRCA2. The BRCA1/2 mutation
spectrum identiﬁed was diverse: 12 frameshifts, 3 mis-
senses, 6 nonsenses, 2 splicing variants and 1 exon deletion.
Additionally, 6 VUS (variants with unknown signiﬁcance)
(3.92%) were detected, 2 in BRCA1 and 4 in BRCA2.
The most prevalent mutations were: c.5266dupC p.
(Gln1756Profs*74) identiﬁed in 14 (9.15%) patients,
c.4035delA p.(Glu1346Lysfs*20) in 5 (3.26%) patients and
c.3607C>T p.(Arg1203*) in 4 patients (2.62%) in BRCA1
gene, therefore could be considered founder mutations for
Romanian population.
Our study provided valuable molecular information
about the spectrum of BRCA1/2 mutations involved in OC
pathogenesis in Romanian patients, contributing both to
optimization of therapeutic management of these patients
and providing accurate genetic counselling for OC patients
and their families.
G. Cardos: None. A. Curtis: None. J. Lisgo: None. A.
Silmon: None. G. Bucur: None. C. Nitipir: None. D.
Roman: None. C. Floares: None. M. Zeleniuc: None. P.
Apostol: None.
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A signiﬁcant percentage of BRCA carriers have coinherited
pathogenic mutations in intermediate risk BC genes
M. Jakimovska1, K. Kubelka2, A. Arsovski3, M.
Karagjozov2, L. Ivkovski4, S. Banev5, S. Smickova6, D.
Plaseska-Karanﬁlska1
Research Centre for Genetic Engineering and Biotechnol-
ogy, Skopje, Macedonia, The Former Yugoslav Republic of,
2Acibadem Sistina Hospital, Skopje, Macedonia, The
Former Yugoslav Republic of, 3Re-Medika Hospital,
Skopje, Macedonia, The Former Yugoslav Republic of,
4PZU Histolab, Skopje, Macedonia, The Former Yugoslav
Republic of, 5PZU Biopsija, Skopje, Macedonia, The
Former Yugoslav Republic of, 6Institute for Radiology
and Oncology, Faculty of Medicine, University “Ss Kiril
and Metodij”, Skopje, Macedonia, The Former Yugoslav
Republic of
Although multigene panel testing are increasingly used to
evaluate patients with a suspected genetic predisposition to
breast cancer (BC), most of the published studies using
cancer panels are performed on BRCA negative patients.
Thus, there are limited data on the coinheritance of BRCA
mutations and mutations in other high/intermediate risk BC
genes.
With an aim to determine the frequency of multiple
heterozygotes of high/intermediate BC genes we have
sequenced 94 cancer associated genes in 43 BRCA carriers
(15 BRCA1 and 28 BRCA2) using Illumina TruSight
Cancer kit on a MiSeq platform.
We identiﬁed a high percentage of BRCA carriers
(16.3%; 7/43) with pathogenic mutations in ATM, CHEK2,
FANCM and RAD51D genes (double heterozygotes). The
following double heterozygote genotypes were identiﬁed:
BRCA1:c.[4356delA];ATM:c.[67C>T], BRCA2:c.
[3186_3189delTCAG];ATM:c.[3864delA], BRCA1:c.
[181T>G];CHEK2:c.[573+1G>A], BRCA2:c.[8168A>G];
CHEK2:c.[599T>C], BRCA2:c.[7879A>T];FANCM:c.
[1972C>T], BRCA2:c.[775A>T];FANCM:c.[2953delG]
and BRCA1:c.[3700_3704delGTAAA];RAD51D:c.
[958C>T].
Double heterozygotes were younger (42+8,4 years) in
comparison to simple BRCA carriers (49+12,2 years). ER,
PR and HER2 receptor status was available for 37 of the 43
BRCA carriers. The majority of double heterozygotes had
ER+/PR+ breast tumors (85.7%; 6/7) compared to 50%
(15/30) of the simple BRCA carriers. Only one double
heterozygote (14.3%; 1/7) was triple negative compared to
15 simple BRCA carriers (50%; 15/30).
In conclusion, BRCA carriers often have coinherited
pathogenic mutation in intermediate risk BC genes; they
have earlier onset of the disease and most commonly pre-
sent with ER+/PR+ breast cancer. The identiﬁcation of
double heterozygotes is important for the patients, but has
implication also for the families.
M. Jakimovska: None. K. Kubelka: None. A.
Arsovski: None. M. Karagjozov: None. L. Ivkovski:
None. S. Banev: None. S. Smickova: None. D. Plaseska-
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A next generation sequencing study to detect large rear-
rangements in BRCA1/2 with high sensitivity in blood and
FFPE samples
C. Scafe1, G. Nistala2, G. Bee3, N. Garg1, M.
Manivannan1, A. Broomer3, H. Hamidi2, V. Mittal2, P.
Williams2, D. Brinza1, F. Hyland1, J. Bishop3, S. Sadis2, J.
Sherlock1
1Thermo Fisher Scientiﬁc, San Francisco, CA, United
States, 2Thermo Fisher Scientiﬁc, Ann Arbor, MI, United
States, 3Thermo Fisher Scientiﬁc, Carlsbad, CA, United
States
Introduction: Identifying germline and somatic mutations
in BRCA1 and BRCA2 genes is important to support
translational cancer research as these genes are implicated in
inherited risk and response to certain therapies. Although
small variants (SNV and INDEL) in these genes are com-
monly detected, large rearrangements (LRs) such as exon
level copy number variations are difﬁcult to detect using
traditional sequencing approaches and often require addi-
tional tests such as multiplex ligation dependent probe
ampliﬁcation (MLPA).
Methods: A total of 219 samples were screened for exon
level copy number variations using the Oncomine BRCA
Research NGS Assay and MLPA. The NGS assay covers
100% of all exons of BRCA1/2 with 263 amplicons (tar-
geted regions). A comprehensive bioinformatics algorithm
was developed to detect both small variants and exon level
copy number variations in BRCA1/2.
Results: LRs were detected at high sensitivity from 219
blood and FFPE research samples, even in the absence of
control sample(s). Of the 23 samples that were positive for
LRs using MLPA, 22 (95.7%) were also detected by the
NGS based assay. A range of LRs were detected including
heterozygous whole gene deletions, single and multiple
exon heterozygous deletions, single and multiple exon
duplications, and homozygous multiple exon deletion.
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Conclusions: An NGS assay with a comprehensive data
analysis approach was developed that is capable of detect-
ing both small mutations and LRs simultaneously in FFPE
samples with high sensitivity and is an important advance in
BRCA1/2 translational research.
For research use only. Not for use in diagnostic
procedures.
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Risk of primary and contralateral breast cancer in BRCA1/2
mutation carriers previously affected with ovarian cancer
B. A. M. Heemskerk-Gerritsen, M. J. Hooning, H. C. van
Doorn, M. Collée, L. B. Koppert, A. Jager, A. M. W. van
den Ouweland, HEBON Netherlands, C. Seynaeve, M.
Kriege
Erasmus MC Cancer Institute, Rotterdam, Netherlands
Aim: To evaluate primary and contralateral breast cancer
(PBC and CBC) risks in female BRCA1 and BRCA2
mutation carriers with and without ovarian cancer (OC).
Methods: We selected 1457 BRCA1 (219 with previous
OC) and 976 BRCA2 mutation carriers (78 with OC) at risk
of PBC, and 976 BRCA1 (94 with OC) and 551 BRCA2
mutation carriers (30 with OC) at risk of CBC. We used the
Fine and Gray regression model.
Results: PBC was diagnosed in 10 (5%) BRCA1
mutation carriers with OC and in 192 (16%) without OC.
For BRCA2 mutation carriers, PBC was diagnosed in 6
(8%) OC patients and in 97 (11%) women without OC. OC
diagnosis was associated with a signiﬁcantly lower PBC
risk in BRCA1 mutation carriers (HR, 0.22; 95% CI, 0.11–
0.42) and with a non-signiﬁcantly lower risk in BRCA2
mutation carriers. CBC was diagnosed in 6 (6%) BRCA1
mutation carriers with PBC/OC and in 114 (13%) PBC
patients without OC. For BRCA2 mutation carriers, CBC
was diagnosed in 3 (10%) PBC/OC patients and in 43 (8%)
PBC patients without OC. In BRCA1 mutation carriers, OC
diagnosis was associated with a lower CBC risk (HR, 0.39;
95% CI, 0.17–0.89). For BRCA2 mutation carriers the HR
was 1.42.
Conclusion: BRCA1 mutation carriers with previous OC
have lower risks of PBC and CBC than BRCA1 mutation
carriers without OC, which was not observed in BRCA2
mutation carriers. Our data suggest that the current pre-
vention strategies regarding surveillance and mastectomy
might be reconsidered for BRCA1-associated OC patients.
B.A.M. Heemskerk-Gerritsen: None. M.J. Hooning:
None. H.C. van Doorn: None. M. Collée: None. L.B.
Koppert: None. A. Jager: None. A.M.W. van den
Ouweland: None. C. Seynaeve: None. M. Kriege: None.
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BRCA testing in ovarian tumors initiated by a pathologist: a
pre-screen for germline testing and therapy choice
I. E. Fakkert1, A. R. Mensenkamp1, E. M. Leter2, J. A. de
Hullu3, R. W. Willems4, G. H. Woldringh1, M. Simons4,
M. C. Jongmans1,5, C. M. Kets1, J. Bulten4, M. J.
Ligtenberg1,4, N. Hoogerbrugge1
1Department of Human Genetics, Radboud university
medical center, Nijmegen, Netherlands, 2Department of
Clinical Genetics, Maastricht University Medical Center,
Maastricht, Netherlands, 3Department of Obstetrics and
Gynecology, Radboud university medical center, Nijmegen,
Netherlands, 4Department of Pathology, Radboud univer-
sity medical center, Nijmegen, Netherlands, 5Department of
Medical Genetics, University Medical Center Utrecht,
Utrecht, Netherlands
Introduction: Dutch guidelines recommend germline
BRCA testing in all epithelial ovarian cancer (EOC)
528
patients. Approximately 20% of them have tumor DNA
BRCA mutations of which 75% germline and 25% somatic.
Both may beneﬁt from PARP inhibitor therapy.
We aimed to implement Ovarian tumor DNA BRCA
testing by a PAthologist (OPA) in all newly diagnosed
EOC patients, as a pre-screen for germline BRCA testing
and to enable timely genotype-based therapeutic choices.
Materials and methods: Pathologists were invited to
submit Formalin Fixed Parafﬁn Embedded (FFPE) samples
of newly diagnosed EOCs for tumor DNA BRCA testing by
single molecule Molecular Inversion Probe (smMIP)-based
targeted next generation sequencing of BRCA1/2 and Mul-
tiplex Ligation-dependent Probe Ampliﬁcation (MLPA) of
BRCA1. Outcomes were communicated to patients by their
gynecologist, who referred patients with tumor DNA BRCA
mutations for genetic counseling and germline BRCA ana-
lysis. OPA uptake is evaluated with data from PALGA
(Dutch Pathology Registry) and patients and physicians
experiences with questionnaires.
Results: From October 2015 to January 2017 OPA was
initiated in 199 women. In 195 women with a median age of
65 years (range 21–87), OPA was feasible and 32 tumor
DNA BRCA mutations were identiﬁed (16%). Median
turnaround time was 14 days (8–29). Germline testing
revealed 11 BRCA mutations in 18 women (61%) with a
tumor DNA BRCA mutation.
Conclusion: OPA provides a feasible pre-screen for
genetic testing and PARP inhibitor therapy shortly after
EOC diagnosis. If evaluation by patients and physicians is
positive, international implementation can be considered.
AstraZeneca supported this study ﬁnancially.
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A recurrent intragenic BRCA1 deletion in the Slovene
population could be associated with a high ovarian cancer
risk
A. Blatnik, M. Krajc, V. Stegel, P. Škerl, S. Novaković
Institute of Oncology, Ljubljana, Slovenia
Introduction: There are several published studies on
genotype-phenotype correlations in BRCA-positive families
but the data on cancer risks associated with different
mutations is currently insufﬁcient to enable individual risk
assessment. We present a study of women carrying a
deletion of exons 4–9 in BRCA1, a recurrent genomic
rearrangement in the Slovene hereditary breast and ovarian
cancer population.
Materials and Methods: A retrospective analysis of a
cohort of 382 BRCA-positive probands with breast or/and
ovarian cancer (from 382 different families) tested at our
institution was performed to determine the frequency of the
BRCA1 exons 4–9 deletion. Families of deletion carriers
were subsequently analyzed to determine the number of
breast and ovarian cancer patients. Proven, obligatory and
probable carriers were included in our study.
Results: BRCA1 exons 4–9 deletion was seen in 3.4%
(13/382) of our BRCA-positive probands. The deletion was
somewhat more common in patients with ovarian cancer
than those with breast cancer but the difference was not
statistically signiﬁcant (4.7% vs ~2%; p = 0.17). 42 carriers
of the deletion were identiﬁed in the 13 families studied. Of
those, 40.5% were diagnosed with breast cancer, 38% with
ovarian cancer and 9.5% with both breast and ovarian
cancer; 12% were without cancer. Interestingly, a pair of
monozygotic twins developed ovarian cancer aged 48 and
55.
Conclusions: The high number of ovarian cancer
patients in families with the deletion of exons 4–9 in the
BRCA1 gene implies that the deletion could be associated
with a particularly high risk of developing this disease.
A. Blatnik: None. M. Krajc: None. V. Stegel: None. P.
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BRCA1 p.His1673del is a pathogenic mutation associated
with a predominant ovarian cancer phenotype
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Martelli4, R. Casadio4, E. Capizzi5, D. Santini5, S.
Miccoli1, V. Medici2, R. Danesi3, I. Marchi2, V. Zampiga3,
M. Fiorentino5, S. Ferrari1, D. Turchetti1
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Bologna, Italy, 5UO Anatomia Patologica, Azienda
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Background
Unclassiﬁed BRCA1/2 variants pose serious problems
for counseling and managing patients. Aim of this study
was to investigate the signiﬁcance of the unclassiﬁed
BRCA1 variant p.His1673del, which has been detected in
multiple families from the Emilia-Romagna region of Italy.
Methods
The study involved 14 families carrying the BRCA1 p.
His1673del variant, including 20 breast and 23 ovarian
cancer cases. The multifactorial likelihood method by
Goldgar was used to estimate the probability of the variant
being causative; among the factors analyzed, LOH was
further investigated in ovarian carcinomas through micro-
satellite analysis, CGH-array and FISH. Moreover, in silico
modeling was performed to predict the impact of the dele-
tion on BRCA1 functions.
Results
The multi-likelihood ratio was 2,263,474.04:1 in favor of
causality, exceeding the cutoff of 1,000:1 adopted to
establish that a variant is pathogenic. The breast to ovarian
cancer ratio was 0.87:1, and four out of 14 families dis-
played site-speciﬁc ovarian cancer. All probands shared the
same uncommon haplotype at the BRCA1 locus, con-
sistently with a common ancestor. All six ovarian carcino-
mas and two out of four breast carcinomas available showed
LOH at BRCA1 locus, which in three out of four ovarian
carcinomas analyzed by FISH was associated with dupli-
cation of chromosome 17 containing the variant. In silico
modeling suggests that His1673-lacking BRCA1 protein
may have a decreased binding capability towards BARD1
and other related proteins.
Conclusions
BRCA1 p.His1673del should be regarded as a likely
pathogenic mutation conferring a high ovarian cancer risk,
probably through impairing BRCA1-BARD1 interaction.
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One in four women with high-grade serous ovarian cancer
carries a loss-of-function BRCA1 & BRCA2 germline allele
F. Fostira1, M. S. Papamentzelopoulou1, E. Saloustros2,
P. Apostolou1, V. Mollaki1, A. Vagena1, K. Tsakiri3, I.
Athanasiadis4, E. Timotheadou5, G. Lypas6, Z. Saridaki7,
I. Boukovinas8, G. Aravantinos9, M. Liontos10, C.
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Introduction: High-grade serous ovarian cancer (HGSOC)
patients carrying loss-of-function (LoF) in homologous
recombination (HR) genes, and especially in BRCA1 &
BRCA2, have improved overall survival and better ther-
apeutic response, exempliﬁed by the increased sensitivity to
poly (ADP-ribose) polymerase inhibitors.
Methods: All patients diagnosed with HGSOC from July
2014 and thereafter, unselected for age at diagnosis or
family history, were sequenced by Trusight cancer panel.
All diagnoses were conﬁrmed by histopathology reports,
while detailed pedigrees were constructed. As a ﬁrst step,
BRCA1 & BRCA2 germline mutations were evaluated,
while analysis for mutations in other HR genes is under
way.
Results: In total, 23.7% (64/270) of the 270 patients
(mean age at diagnosis 57±11 years) carried LoF BRCA1 &
BRCA2 mutations; 17.4% BRCA1 and 6.3% BRCA2 (mean
age at diagnosis 52±9 years). Approximately 10% (6/64) of
the mutation carriers had a previous personal history of
breast cancer, while in one case ovarian preceded breast
cancer diagnosis. Family history of breast and ovarian was
seen in 56% (36/64) of the cases. Paternal ancestry, limited
family structure, large number of male family relatives and
prophylactic hystero-oophorectomy can explain the lack of
family history in 20/28 cases with no apparent family
history.
Discussion: Our results further support the recommen-
dation to test all patients with HGSOC and have implica-
tions for treatment and prevention for them and their
families. HGSOC diagnosis itself can be thought as a pre-
dictor for HR deﬁciency, as highlighted by the high fre-
quency of germline BRCA1 & BRCA2 mutations.
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Linking uterine serous carcinoma to BRCA1/2-associated
cancer syndrome: a meta-analysis and case report
C. J. VAN ASPEREN1, M. M. de Jonge2, A. A.
Mooyaart2, M. P. G. Vreeswijk3, C. D. de Kroon4, T. van
Wezel2, V. T. Smit2, O. M. Dekkers5, T. Bosse2
1Department of Clinical Genetics, Leiden, Netherlands,
2Department of Pathology, Leiden, Netherlands, 3Depart-
ment of Human Genetics, Leiden, Netherlands, 4Depart-
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Epidemiology, Leiden, Netherlands
Backgroud: Uterine serous carcinoma (USC) shows greater
morphological, clinical and molecular similarities to high-
grade ovarian tubal serous carcinoma than to other types of
endometrial cancer. As high-grade ovarian tubal serous
carcinoma is known to be associated with BRCA1/2
pathogenic germline mutations (PMs), we aimed to explore
whether USC is also a constituent of hereditary breast and
ovarian cancer syndrome. Methods: Pubmed, EMBASE and
Web of Science were searched in July 2016 for articles
assessing the association between USC and germline
BRCA1/2-PMs. Pooled analysis and comparisons were
performed using a random effects logistic model, stratifying
for ethnicity (Ashkenazi versus non-Ashkenazi). In addi-
tion, tumour tissue from an USC case with a hereditary
BRCA1-PM was analysed for loss of heterozygosity at the
BRCA1 locus and was functionally analysed for homo-
logous recombination proﬁciency. Results: The search
yielded 1893 citations, 10 studies were included describing
345 USC patients. For Ashkenazi Jews, the pooled odds
ratio of having a germline BRCA1/2-PM was increased in
USC patients compared with the general Ashkenazi popu-
lation: odds ratio 5.4 (95%conﬁdence interval: 2.2–13.1). In
the patient with USC, we identiﬁed the known germline
BRCA1-PM in the tumour DNA. Furthermore, we showed
both loss of heterozygosity of the wild-type allele and a
deﬁciency of homologous recombination. Conclusion: This
study suggests that USC may be an overlooked component
of BRCA1/2-associated hereditary breast and ovarian can-
cer syndrome. Screening for germline BRCA1/2-PMs
should be considered in patients diagnosed with USC,
especially in cases with a positive ﬁrst-degree family history
for breast and/or ovarian cancer.
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NGS-based BRCA1, BRCA2, and PALB2 mutation testing
in Iranian population with breast cancer
E. Ebrahimi1, K. Zendehdel1, E. Sellars2, R. Ghiasvand3,
I. Harirchi1, R. Shirkoohi1,4, M. R. Akbari5,6,7
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Khomeini Hospital Complex, Tehran, Iran, Islamic Repub-
lic of, 5- Women’s College Research Institute, Women's
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Background: Hereditary Breast Cancer (HBC) is a well-
characterized syndrome. The cause of this syndrome has
been mainly attributed to the mutations in the BRCA1,
BRCA2 and PALB2 genes. In this study, we aimed to esti-
mate the prevalence of these gene mutations in Iranian
breast cancer patients. Materials and Methods: Next Gen-
eration Sequencing (NGS) was conducted on 424 breast
cancer patients comprising 2 groups. The ﬁrst group con-
sisted of 281 patients who were selected due to presenting
the HBC features including age at onset of under 40 years,
positive family history of breast/ovarian cancer, male breast
cancer or multiple primary tumors in the same individual.
The second group was included 143 patients without the
aforementioned criteria. Results: Overall, 33 pathogenic
mutations were found. This was 13 BRCA1, 14 BRCA2 and
1 PALB2 in 281 selected patients and 4 BRCA2 and 1
PALB2 in 143 patients without the inclusion criteria for
genetic testing. All mutations were singleton. Only 1 out of
96 patients with only an early onset of breast cancer, 2 out
of 10 patients with multiple primary breast cancers and 25
out of 172 patients with family history of breast/ovarian
cancer were diagnosed as the pathogenic mutation carriers.
No pathogenic mutation was found in male breast cancer
patients. Conclusion: Our results indicated that BRCA1/2
mutations are common among Iranians with breast cancer
who reported positive for family history of Breast/Ovarian
cancer. Screening of the early onset breast cancer patients
for BRCA1/2 mutations may not be cost-effective among
Iranian population.
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Thorough second hit analysis in breast and ovarian cancers
from BRCA1/2 germline mutation carriers reveals different
mechanisms in both tumor entities
M. Van Heetvelde1,2, M. Van Bockstal3,2, T. Lepez4, S.
Lefever1,2, L. Pieters5, K. Lambein3, M. Praet3, I. Van Den
Berghe6, F. Coppieters1, J. Vandesompele1,2, N. Van
Roy1,2, D. Deforce4,2, A. Vral5,2, B. Poppe1,2, K. Leeneer1,2,
J. Van Dorpe3,2, K. B. M. Claes1,2
1Center for Medical Genetics, Ghent University Hospital,
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Objective: To paint a detailed picture of somatic BRCA1/2
alterations in breast and ovarian cancers from patients with
a germline mutation at these loci. LOH (loss of hetero-
zygosity) is accepted as the general mechanism, however,
little is known about the prevalence of other somatic events.
Tumor material and Methods: We included 56 breast (36
BRCA1; 20 BRCA2) and 16 high grade serous epithelial
ovarian (9 BRCA1; 7 BRCA2) carcinomas. The complete
coding region of BRCA1/2 was analysed in DNA extracted
from tumor and blood using next generation sequencing.
Exon-spanning deletions/duplications were investigated
using MLPA. MS-MLPA was applied to unravel the
BRCA1/2 methylation status.
Results & conclusions: 23/36(64%) BRCA1-breast
tumors were triple negative, compared to 3/20(15%)
BRCA2-breast tumors. Differences in somatic changes were
established in breast versus ovarian cancers: loss of the wild
type allele was observed in 15/16(94%) ovarian but in only
31/56(55%) breast tumors. Surprisingly, loss of the mutant
allele was found in 7 breast cancers. Therefore, genetic
counseling of VUS in BRCA1/2, should not rely on LOH
analysis in breast tumors. In several breast tumors somatic
truncating point mutations were detected (also in the gene
without the germline mutation); this was not observed in the
ovarian cancers. Methylation of the BRCA1/2 promoters
was not established. MLPA suggests complete or partial
gene deletions in the majority of the samples. The complex
second hit mutation spectrum in the breast cancers could
potentially help explain why PARP inhibitor treatment is
less successful in BRCA1/2-associated breast tumors com-
pared to ovarian tumors.
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Transcript analysis redeﬁnes the pathogenicity of BRCA1/2
VUS and reveals the limitations of in silico prediction tools
A. M. Pinto1,2, M. Colombo3, S. Amitrano1, E. Gelli1, V.
Imperatore1, M. Baldassarri1,2, C. Lo Rizzo2, E.
Tagliaﬁco4, L. Cortesi5, M. A. Mencarelli2, A. Renieri1,2,
P. Radice3, F. Ariani1,2
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University of Siena, Policlinico ‘Santa Maria alle Scotte’,
Siena, Italy, 2Medical Genetics, Azienda Ospedaliera
Universitaria Senese, Siena, Italy, 3Unit of “Molecular
bases of genetic risk and genetic testing”, Department of
Preventive and Predictive Medicine”, Fondazione IRCCS
Istituto Nazionale dei Tumori, Milano, Italy, 4Center for
Genome Research, University of Modena and Reggio
Emilia, Modena, Italy; Department of Medical and Surgical
Sciences, University of Modena and Reggio Emilia,
Modena, Italy, 5Department of Oncology and Haematology,
Azienda Ospedaliero-Universitaria Policlinico, University
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BRCA1 and BRCA2 genes are involved in hereditary pre-
disposition to the development of breast and ovarian cancer
with high penetrance. The detection of BRCA pathogenic
variants allows offering appropriate cancer-risk manage-
ment and has now considerable clinical impact, guiding the
surgical and pharmacological approach. In this context, a
major drawback is represented by the identiﬁcation of
variants of uncertain signiﬁcance (VUS), accounting for a
relevant fraction of alterations. Many intronic/exonic VUS
potentially affect mRNA splicing and transcript analysis is
an essential step for the deﬁnition of pathogenicity. Here,
we assessed the impact on splicing of 17 BRCA variants
whose biological and clinical effects were unknown until
now. Nine variants were demonstrated to impact on the
normal splicing process and aberrant transcripts were
characterized. Different types of abnormal splicing event
were observed, namely exon skipping, intron retention,
usage of “de novo” and cryptic splice sites. As a
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consequence, transcripts with premature stop codons or in-
frame loss of functionally important residues were gener-
ated. A possible “leaky” effect was investigated, allowing
the classiﬁcation into classes 3 or 4/5, according to the
current guidelines of the ENIGMA consortium. Impor-
tantly, this study also highlights that in silico tools are
limited in the prediction of aberrant isoforms. Experimental
analysis revealed that these predictions would have led to
erroneous conclusions in 55% of cases. In conclusion, this
study allowed re-deﬁning the pathogenicity of BRCA var-
iants of uncertain signiﬁcance and underlines the need of
more accurate in silico programs, especially for unmasking
the usage of alternative or pseudo-splice sites.
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BRCA2 mis-splicing: exons 17 and 18 regulation
E. Fraile-Bethencourt1, B. Díaz-Gomez1, Valenzuela-
Palomo1, A. Acedo2, D. Sanz-San José3, E. Goina4, E.
Buratti4, E. Velasco1
1Instituto de Biología y Genética Molecular (CSIC/UVa),
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Mutation screening of BRCA2 identiﬁes a large fraction of
variants of uncertain clinical signiﬁcance (VUS). Our goal
was to investigate the impact of reported variants of
BRCA2 exons 17 and 18 on splicing to assess their role in
hereditary breast cancer and to identify critical regulatory
elements that may constitute hotspots for spliceogenic
variants.
A splicing reporter minigene with BRCA2 exons 14 to-
20 (MGBR2_ex14–20) was constructed in the pSAD vec-
tor. Fifty-two candidate variants were selected with splicing
prediction programs, introduced in MGBR2_ex14–20 by
site-directed mutagenesis and assayed in MCF-7 cells.
Functional mapping by microdeletions revealed essential
sequences for exon recognition on the 3′ end of exon 17 and
the 5′ end of exon 18. Thirty out of the 52 selected variants
induced anomalous splicing in minigene assays with >16
different aberrant transcripts, where exon skipping was the
most common event. According to the biological indicators
of pathogenicity, 18 variants could be classiﬁed as disease-
causing, accounting for 28.6% of all pathogenic variants of
exons 17–18 at the BRCA Share database. Aberrant
splicing is especially prevalent in BRCA2 exons 17 and 18
due to the presence of active ESEs, which are recognized by
splicing factor as SC35 and Tra2β that play an important
role in exon recognition. Splicing functional assays with
minigenes are a valuable strategy for the interpretation of
VUS of any disease-gene.
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Experience of a genetic diagnostic laboratory with a panel
of 18 genes involved in gynecologic cancer
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Leon, A. Moya, I. Maeso, L. Izquierdo, J. Lopez García-
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Introduction. Breast cancer is the most commonly diag-
nosed cancer among women worldwide. In Spain, 500.000
and 65.000 new breast and ovary cancer cases are diag-
nosed per year. A 5–10% of these are thought to be her-
editary. The objective of this work has been to conduct a
retrospective analysis of our experience with an NGS panel
containing 18 genes involved in gynecologic cancer.
Materials and Methods. Cohort of 194 patients from
Europe (the majority), Latin America and Middle East.
Samples were sequenced on a Illumina platform using
TruSight Cancer kit (Illumina). 18 genes were analyzed:
ATM-BRCA1-BRCA2-BRIP1-CDH1-CHEK2-EPCAM-
MLH1-MSH2-MSH6-NBN-PALB2-PMS2-PTEN-RAD51C-
RAD51D-STK11-TP53. MLPA was carried out for BRCA1,
BRCA2 and 3′ end of EPCAM. Pathogenic (P) and likely
patogenic (LP) mutations are conﬁrmed by sanger sequen-
cing. Variant classiﬁcation is carried out following ACMG
guidelines.
Results. A total of 88 variants were identiﬁed, including
P (7,2%), LP (2,1%) and variants of unknown signiﬁcance
(VUS) (28,9%). In 122 patients (62,4%), no variants (P, LP
or VUS) were identiﬁed.
Conclusions. P, LP and VUS percentages are similar to
the ones described by Susswein (1) (9% P + LP; 20,4% to
39,7% VUS, depending on the origin). We have observed
that VUS are more frequent in (a) genes that have been
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more recently described and therefore less studied, and in
(b) non-caucasian populations. These results highlight the
importance of cosegregation studies and taking part in
public databases, with the purpose of decreasing VUS
percentage n these kind of studies.
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The 30 kb deletion in the APOBEC3 cluster decreases
APOBEC3A and APOBEC3B expression and creates tran-
scriptionally active hybrid gene but does not associate with
breast cancer in European population
K. Klonowska1, W. Kluzniak2, B. Rusak2, K. Czubak1, M.
Wojciechowska1, M. Ratajska3, N. Krawczynska3, A.
Podolak3, D. Vasilevska4, J. Limon3, C. Cybulski2, J.
Lubinski2, P. Kozlowski1
1Department of Molecular Genetics, Institute of Bioorganic
Chemistry, Polish Academy of Sciences, Poznan, Poland,
2Department of Genetics and Pathology, International
Hereditary Cancer Center, Pomeranian Medical Univer-
sity, Szczecin, Poland, 3Department of Biology and
Genetics, Medical University of Gdansk, Gdansk, Poland,
4Department of Gynecology, Centre of Obstetrics and
Gynecology, Vilnius University Hospital Santariskiu Klini-
kos, Vilnius, Lithuania
Introduction: A common CNV in the APOBEC3 cluster
(APOBEC3B deletion) was reported to be associated with
breast cancer. Our aim was to assess the inﬂuence of
APOBEC3B deletion on the expression of affected genes
and to analyze its association with breast cancer in Eur-
opean population.
Materials and Methods: We analyzed structure of APO-
BEC3B deletion with three distinct approaches: Sanger
sequencing, and designed by ourselves MLPA and A3B+
PCR assay. Then, we exploited publically available
expression data and our own qPCR/ddPCR results for the
analysis of a relation between APOBEC3B deletion and
mRNA levels of APOBEC3B, APOBEC3A and hybrid
APOBEC3A/APOBEC3B. Additionally, we performed a
large-scale association study in three different cohorts (in
total 2972 cases and 3682 controls) using A3B+ PCR
assay.
Results: We elucidated the structure of APOBEC3B
deletion with nucleotide resolution and conﬁrmed it with
three different tests. This knowledge allowed us to conﬁrm
the presence of transcriptionally active hybrid gene
(APOBEC3A/APOBEC3B; APOBEC3A with 3′UTR of
APOBEC3B) and design tests for separate analysis of
expression of three highly homologous transcripts: APO-
BEC3A, APOBEC3B and APOBEC3A/APOBEC3B. The
analysis showed that APOBEC3B deletion negatively cor-
relates with expression of APOBEC3A and APOBEC3B,
and positively correlates with expression of APOBEC3A/
APOBEC3B. We observed no association between APO-
BEC3B deletion and breast/ovarian cancer.
Conclusions: We provided a direct evidence that APO-
BEC3A/APOBEC3B hybrid gene is transcriptionally active
and conﬁrmed association of APOBEC3B deletion with the
expression of affected genes. Our large case-control study
does not conﬁrm association of APOBEC3B deletion with
breast cancer.
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Transcriptome wide analysis of natural antisense transcripts
shows potential role in breast cancer
S. Wenric, S. El Guendi, B. Charloteaux, L. Karim, B.
Hennuy, W. Bezzaoui, M. Boukerroucha, J. Caberg, C.
Fasquelle, V. Jossa, G. Jerusalem, C. Josse, V. Bours
University of Liege, Liege, Belgium
Introduction: In developed countries, breast cancer is the
most frequent cancer type in females, accounting for
approximately one third of all cancers. It is a complex
disease, characterized by genomic instability.
We investigated the potential role of natural antisense
transcripts in the oncogenic process of breast cancer.
Materials and Methods: Both tumor and normal breast
tissue from 25 female breast cancer patients have been
analyzed by transcriptome-wide strand-speciﬁc paired-end
RNA sequencing.
Differential expression analysis of the antisense tran-
scripts, differential correlation analysis between the anti-
sense transcripts and their paired protein coding genes, and
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read counts ratios variation analysis between the antisense
transcripts and their paired protein coding genes have been
performed.
These three methods yielded candidate antisenses lists
for which the association with survival of the corresponding
protein coding gene has been tested on an independent
cohort of 1060 breast cancer patients from the TCGA.
Results: All three lists showed a higher amount of genes
signiﬁcantly associated with survival than a list of randomly
selected protein coding genes of the same size.
Conclusions: The signiﬁcant difference in terms of
association with survival might be indicative of an onco-
genic role of the antisense transcripts that have been
selected through the three aforementioned methods.
Funding: This work has been funded by the Belgian
FNRS (National Fund for Scientiﬁc Research) PDR
T.0133.13
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Downregulation of Caspase 8 in sporadic human breast
tumours in Iranian patients
M. Aghababazadeh1, N. Dorraki1, F. Afzal Javan2, A.
Fattahi3, M. Gharib4, A. Pasdar1,5,2
1Department of Medical Genetics, Faculty of Medicine,
Mashhad University of Medical Sciences, Mashhad, Iran,
Islamic Republic of, 2Department of Modern Sciences and
Technologies, Faculty of Medicine, Mashhad University of
Medical Sciences, Mashhad, Iran, Islamic Republic of,
33Endoscopic and Minimally Invasive Surgery Research
Center, Faculty of Medicine, Mashhad University of
Medical Sciences, Mashhad, Iran, Islamic Republic of,
4Department of Pathology, Faculty of Medicine, Mashhad
University of Medical Sciences, Mashhad, Iran, Islamic
Republic of, 5Division of Applied Medicine, Medical
School, University of Aberdeen, Aberdeen, United Kingdom
Purpose: It is now well known that evading from apoptosis,
as a cancer hallmark, can lead to tumour initiation, pro-
gression and metastasis. As a result of GWA studies, an
initiator protease in this pathway, CASP8, has been found to
be an important gene regarding to breast cancer suscept-
ibility. It's expression alterations have been reported in
breast cancer cell lines. Given that in previous studies
expression analysis of this gene had only been done in
breast cancer cell lines, in this study we aimed to evaluate
the expression of CASP8 in breast cancer tissues versus
adjacent normal tissues, using real-time quantitative
method. Method: Caspase 8 mRNA expression was quan-
tiﬁed using comparative RT-qPCR in 27 fresh frozen breast
tumours and 27 adjacent normal tissues. Moreover, rela-
tionship between the expression changes of CASP8 in
tumour tissue and various clinical and pathological features
were evaluated in an Iranian population. Results: The
present study showed that CASP8 expression was sig-
niﬁcantly (p = 0.024) reduced in tumour tissues compared
to neighbouring normal tissues. CASP8 expression was
signiﬁcantly correlated with the status of hormone receptors
(ER and PR). Conclusion: To the best of our knowledge,
this study is the ﬁrst report on reduced expression of CASP8
in breast cancer versus adjacent normal tissues. Our data
support previous results obtained from cell lines, therefore
highlights the seminal role of the induction of CASP8
expression, as a novel therapeutic approach, in order to
sensitize tumour cells to apoptotic stimuli.
Grant Number: 940936 Mashhad University of Medical
Sciences, Mashhad, Iran
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Beyond CHEK2 in breast cancer: Search for additional
moderately penetrant risk gene variants by analyzing the
oligogenic disease course in CHEK2 mutation carriers
E. Pohl1, J. Borde1, J. Hauke1, S. Schmidt1, K. Weber-
Lassalle1, C. Ernst1, D. Niederacher2, N. Arnold3, H.
Hellebrand4, A. Meindl4, A. Gehrig5, G. Schmidt6, V.
Dutrannoy7, K. Kast8, E. Hahnen1, R. Schmutzler1
Center for Familial Breast and Ovarian Cancer and Center
for Integrated Oncology (CIO), Medical Faculty, University
of Cologne and University Hospital Cologne, Cologne,
Germany, 2Department of Gynaecology and Obstetrics,
University Hospital Düsseldorf, Heinrich-Heine University,
Düsseldorf, Germany, 3Institute of Clinical Molecular
Biology/Department of Gynaecology and Obstetrics, Uni-
versity Hospital of Schleswig-Holstein, Campus Kiel,
Christian-Albrechts University Kiel, Kiel, Germany,
4Department of Gynaecology and Obstetrics, Division of
Tumor Genetics, Klinikum rechts der Isar, Technische
Universität München, Munich, Germany, 5Centre of
Familial Breast and Ovarian Cancer, Institute of Human
Genetics, University Würzburg, Würzburg, Germany,
6Institute of Human Genetics, Hannover Medical School,
Hannover, Germany, 7Institute of Human Genetics, Campus
Virchow Klinikum, Charite Berlin, Berlin, Germany,
Abstracts from the 50th European Society of Human Genetics Conference:. . . 535
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Hospital Carl Gustav Carus, Technical University Dresden,
Dresden, Germany
In one third, breast cancer (BC) shows a familial aggrega-
tion suggesting a genetic predisposition. Besides BRCA1/2,
CHEK2 displays a relevant risk gene which controls DNA
repair. Although a multiplicative nature of risk effects by
additional variants has been suggested, additional risk genes
in CHEK2 mutation carriers have not been well studied so
far. Here we focused on 168 BRCA1/2 negative BC cases
(average age at onset: 46) from 151 families which are
either heterozygous for CHEK2 founder mutation
c.1100delC or delExon9/10. Using targeted NGS, we were
able to identify a total of 10 patients (10/168;6%) carrying a
deleterious mutation in addition to the known heterozygous
CHEK2 mutation. Deleterious autosomal dominant variants
were identiﬁed in ATM (p.I1581Nfs*5, c.496+5G>A),
CHEK2 (2x p.R117G), FANCM (p.Q156*), MLH1 (p.
N64S), PMS2 (p.D414Rfs*44, c.250+3_250+6del), and in
the autosomal recessive cancer predisposition genes
MUTYH (p.G396D) and XPC (p.C670*). Our results sup-
port the assumption that the increased cancer risk for
CHEK2 mutation carriers with a positive cancer family
history is at least partially explainable by an oligogenic
disease course. Preliminary data suggest an association of
the presence of additional deleterious mutations and an
earlier age of onset in CHEK2 mutation carriers. Further
data analysis is mandatory to validate these ﬁndings. In
addition to the 48 analyzed genes, a total of 318 polygenic
risk score (PRS) variants are currently under examination.
In summary, we could conﬁrm panel diagnostics as a
powerful tool to improve individual risk prediction and
clinical care of CHEK2 mutation carriers. Supported by
German Cancer Aid (#110837).
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Chromosomal alterations in patients with breast cancer
O. Demirhan, N. Tanriverdi, A. Pazarbasi, D.
Suleymanova
Cukurova University, Faculty of Medicine, Department of
Medical Biology, Adana, Turkey
Today, breast cancer (BC) is the most commonly occurring
cancer among women. The aim of the present study was to
describe the types and frequencies of CAs in BC patients.
Fifty-one patients were analysed as part of an ongoing study
of the cytogenetics of BC. Cytogenetic analysis of blood
samples was conducted by Giemsa-banding in patients with
BC. The karyotype results were normal in 68.6% of 51
patients; however, CAs were detected in 31.4% of all
patients. In total, 27.5% of patients exhibited structural
aberrations (translocations, deletions, inversions, duplica-
tions and fragilities) and 3.9% exhibited numerical aberra-
tions. Speciﬁcally, the deletions and fragilities among
structural aberrations were the most common karyotypes
(7.8% each) among the patients. Deletions included del
(7p11), del(7q32), del(9p32), del(11q23) and del(11q15).
Inversions were present in 3.9% of all patients, and included
inv(21)(q11;q21) and inv(11)(p15;q12). Translocations
were detected in one patient (2%) and the frequency of
other CAs, different to those types already mentioned, was
5.9%. Regarding numerical CAs, two patients had aneu-
ploidies. This study demonstrated that genetic instability
existed in 31.4% of BC patients, and emphasizes the
importance of combined cytogenetic analysis for the diag-
nosis of BC. The 7p11, 7q32, 9p32, 11p15, 11q12, 11q23,
21q11, 21q21, 15p11 and 17q23 regions are becoming a
model for understanding chromosomal regions in BC.
Therefore, the presence of 11q and 7q deletions in breast
tumors may suggest that it plays an important role in the
development of BC. If so, different chromosome anomalies
might have different pathogenetic and prognostic
signiﬁcance.
O. Demirhan: None. N. Tanriverdi: None. A. Pazar-
basi: None. D. Suleymanova: None.
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NGS-based detection of copy number variations in heredi-
tary breast- and ovarian cancer germline diagnostics
B. Blümcke, K. Keupp, M. Larsen, A. Baasner, A. Waha,
B. Versmold, J. Driesen, L. Bülow, C. Ernst, B.
Wappenschmidt, E. Hahnen, R. Schmutzler
Center of Molecular Gynaeco-Oncology, Department of
Gynaecology and Obstetrics, University Hospital, Cologne,
Germany
A cohort of 3,032 consecutive index cases with breast and/
or ovarian cancer (BC/OC) was analysed by next generation
sequencing (NGS) covering 34 cancer risk genes/candidate
genes (TruRisk® gene panel, Agilent SureSelect). Sequen-
cing was performed on Illumina NextSeq/MiSeq devices.
For bio-informatic analyses of sequencing date, we
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employed the Sophia Genetics DDM pipeline. All index
cases fulﬁll the criteria of the German Consortium for
Breast- and Ovarian cancer (GC-HBOC) for germline test-
ing. According to the Sophia Genetics pipeline, 77 CNVs
(46 deletions, 31 duplications) were observed in 74 inde-
pendent cases (2.4%). Of those, a total of 33 patients carry
heterozygous CNVs in BRCA1 (n= 22), BRCA2 (n= 4) or
CHEK2 (n= 7). CNVs in further established cancer pre-
disposition genes were observed in another 15 index
patients (5 × ATM, 3×PMS2, 2×RAD51C, 2×BRIP1,
1×TP53, 1×FANCM, 1×NBN). No CNVs were detected in
MLH1, MSH2, MSH6, RAD51D, PALB2, CDH1, NBN,
PTEN, STK11 and XRCC2. Among the candidate genes
investigated in this study, CNVs were frequently observed
in BARD1 (4×), MRE11A (8×), and ERCC2 (12×). At the
time point of the data collection, 40/77 CNVs have been
conﬁrmed by either MLPA or aCGH. In summary, bio-
informatic analyses of NGS gene panel data robustly detects
CNVs. However, it remains to be determined whether
sensitivity/speciﬁcity meets diagnostic criteria.
B. Blümcke: None. K. Keupp: None. M. Larsen:
None. A. Baasner: None. A. Waha: None. B. Versmold:
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Identiﬁcation of potential driver or disease associated
genomic variants as part of multiomic research in patients
with breast cancer
G. Repiska1, K. Soltys2, M. Mego3, Z. Cierna4, M.
Chovanec3, L. Krasnicanova5, G. Minarik5
1Comenius University in Bratislava, Faculty of Medicine,
Institute of Physiology, Bratislava, Slovakia, 2Comenius
University in Bratislava Science Park, Bratislava, Slovakia,
3Comenius University in Bratislava, Faculty of Medicine
and National Cancer Institute, 2nd Department of Oncol-
ogy, Bratislava, Slovakia, 4Comenius University in Brati-
slava, Faculty of Medicine, Institute of Pathological
Anatomy, Bratislava, Slovakia, 5Comenius University in
Bratislava, Faculty of Natural Sciences, Department of
Molecular Biology, Bratislava, Slovakia
Breast cancer is the most common cancer in women
worldwide. Its genetic basis is comprehensively studied and
results from genetic and genomic studies showed potential
to be utilized in identiﬁcation of novel biomarkers valuable
in disease diagnostics, prognostics and therapy.
In our study 50 DNA samples isolated from tumor tissue
of patients with primary breast cancer were analyzed with
custom gene panel containing 56 genes that have been
found to be causaly involved in breast cancer promotion,
progression or having therapy decision value. Study was
performed on samples that were clinically well deﬁned as
were previously or simultaneously analyzed for circulating
tumor cells (CTC) and RNA expression.
After ﬁltering of identiﬁed variants with Ingenuity Var-
iant Analysis using Cancer driver variants ﬁlter totaly 363
variants remained to be potential candidates. Of these 51
were found to be listed in COSMIC database simulta-
neously 21 of these were classiﬁed as likely pathogenic or
pathogenic although the list of likely pathogenic and
pathogenic genomic variants contained 31 variants. Most
frequently mutated gene in the patient group was found to
be TP53 with 10 likely pathogenic or pathogenic variants,
second most mutated gene was found to be PIK3CA with 6
and third most mutated gene was found to be BRCA2 gene
with 3 such variants.
Integration of data from performed gene panel rese-
quencing with clinical records, CTC status and RNA
expression will be performed with ambition ﬁnd novel
disease speciﬁc associations and potentially novel disease
biomarkers.
Study was supported by grant APVV VV-14-0327.
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Antidiabetic exendin-4 activates apoptotic pathway and
inhibits growth of breast cancer cells
G. Yaylalı1, Y. Dodurga2, M. Seçme2, L. Elmas2
Department of Endocrinology and Metabolic Diseases,
School of Medicine, Pamukkale University, Denizli, Turkey,
2Department of Medical Biology, School of Medicine,
Pamukkale University, Denizli, Turkey
Introduction: Exendin-4 is a GLP-1 analog used for the
treatment of type 2 diabetes mellitus in its synthetic form.
As women with diabetes have higher breast cancer inci-
dence and mortality, we examined the effect of the incretin
drug exendin-4 on breast cancer cells. The aim of the study
is to investigate anticancer mechanism of exendin-4 in
MCF-7 breast cancer cells. Materials and Methods: Cyto-
toxic effects of exendin-4 were determined by XTT assay.
mRNA expressions were evaluated by Real-time PCR.
Effects of exendin-4 on cell invasion, colony formation, and
cell migration were detected by Matrigel chamber, colony
formation assay, and wound-healing assay, respectively.
Results: IC50 dose of exendin-4 in MCF-7 cells were
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detected as 5 μM at 48th hour. According to results, cas-
pase-9, Akt, and MMP2 expression was reduced in dose
group cells, compared with the control group cells. p53,
caspase-3, caspase-8, caspase-10, BID, DR4, DR5, FADD,
TRADD, PARP, PTEN, PUMA, NOXA, APAF, TIMP1, and
TIMP2 expression was increased in dose group cells,
compared with the control group cells. Conclusions: To
conclude, it is thought that exendin-4 demonstrates antic-
arcinogenesis activity by effecting apoptosis, invasion,
migration, and colony formation in MCF-7 cells. Exendin-4
may be a therapeutic agent for treatment of breast cancer as
single or in combination with other agents. More detailed
researches are required to deﬁne the pathways of GLP-1
effect on breast cancer cells. Because the molecular biology
of breast cancer involves a complex network of inter-
connected signaling pathways that have role in cell growth,
survival, and cell invasion.
G. Yaylalı: None. Y. Dodurga: None.M. Seçme: None.
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Rapid genetic counselling in the primary diagnostic workup
for young women with breast cancer as a basis for informed
treatment decisions: a prospective cohort study
T. Terkelsen1, H. Rønning2, A. Skytte1
1Department of Clinical Genetics, Aarhus University
Hospital, Aarhus, Denmark, 2Plastic and Breast Surgery,
Aarhus University Hospital, Aarhus, Denmark
Introduction: BRCA screening results and familial risk
assessment may guide women with breast cancer in their
choice between different risk management strategies. Rapid
genetic counselling was introduced in the primary diag-
nostic workup for women diagnosed with breast cancer
before 50 years of age in Central Region Denmark (2013).
The purpose was to avoid adjuvant radiation therapy if
women chose prophylactic mastectomy after genetic
counselling.
Methods: Clinical details recorded for all women inclu-
ded age at diagnosis, pathology, BRCA screening results,
and familial risk assessment. Known BRCA carriers were
excluded. Data on contralateral prophylactic mastectomy
were obtained from a central pathology database. The
women consented to anonymous use of their data for
research purposes.
Results: 133 women with breast cancer accepted genetic
counselling (median age, 36; range, 21–49). We detected 12
BRCA-1 (9.0 %) and 3 BRCA-2 mutations (2.3 %). 41
women (33 %) had triple-negative breast cancer (ER-/
HER2-). 10 women (24 %) with triple-negative breast
cancer had detectable BRCA mutations vs. 5 women (6.1
%) with non-triple-negative breast cancer. Women with
unilateral cancer who chose contralateral prophylactic
mastectomy included 13 women (93 %) with BRCA
mutations, 8 women (67 %) with high-risk pedigrees but no
detectable BRCA mutation, and 18 women (23 %) with
moderate or low-risk pedigrees.
Conclusion: The prevalence of contralateral prophylactic
mastectomy in young women with breast cancer reﬂected
their familial risk assessment. Most BRCA mutations were
found in women with triple-negative breast cancer. Genetic
counselling in the primary diagnostic workup provides a
basis for informed treatment decisions.
T. Terkelsen: None. H. Rønning: None. A. Skytte:
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Major challenge of breast cancer molecular genetics: From
association studies to causation and function
Y. Hamdi1, M. Ben Rekaya1, M. Boujemaa1, N. Mighri1,
L. Chouchane2, S. Abdelhak1, H. Boussen3
Institut Pasteur of Tunis, Tunis, Tunisia, 2Weill Cornell
Medical College-Qatar, Doha, Qatar, 3Service d'oncologie
médicale Hôpital Abderrahmen Mami, Ariana, Tunisia
A family history of breast cancer (BC) has long been
thought to indicate the presence of inherited genetic events
that predispose to this disease. Actually, the major challenge
of BC molecular genetics is to identify causal variants.
Because of important differences in genetic patterns
between ethnicities, association studies and haplotype ana-
lysis in different populations can help to overcome this
challenge. Our present genome-wide-scanning was applied
with Affymetrix-Genome-Wide-Human-SNP-Array-6.0 in
order to determine allelic frequencies of the known BC
associated variants in 135Tunisians representing the
general-population. We constructed and phased haplotypes
carried by the studied Tunisian-population. Moreover, we
assessed the biological effect of the putative functional
variants by conducting eQTL-assays. We also compared BC
associated-loci between different HapMap-populations by
comparing LD-blocks and by conducting Principle-
Component-Analysis. Our haplotype analysis showed that
the Tunisian-population is more predisposed to the fol-
lowing at risk loci: 2p24, 4q21, 6q25, 9q31, 10q26, 11q13,
14q32. Four polymorphisms speciﬁc to the Tunisian
population have also been identiﬁed including one on the
ESR1-gene. Furthermore, we characterized a BRCA1-var-
iant that can be considered as a causal polymorphism. In
addition, we conducted Whole-Exome-Sequencing in 11BC
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patients. Our results showed a family speciﬁc BC genetic
predisposition in a non-BRCA family, and a second Tuni-
sian family with bi-allelic mutations on the BRCA2 gene, a
phenomenon rarely observed in BC families. Therefore,
combining association and functional analysis, it is now
possible to reﬁne the BC genetic component in Tunisia
which will provide a better clinical management of patients.
Funding Agency: Qatar National research FoundationGrant
ID: NPRP 08-083-3-031
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Familial breast cancer with hereditary mutation in MMR
genes: does it exist?
D. Feret, A. Lombard, P. Hilbert, K. Dahan
Institut de pathologie et de génétique, Gosselies, Belgium
The use of multi-gene panels in the diagnostic of hereditary
cancers has become a standard in cancer genetics. These
panels usually include 15–30 cancer susceptibility genes
responsible for speciﬁc hereditary cancer syndromes.
However with the use of these panels we observed the
emergence of variations in unexpected genes regarding the
clinical pictures.
In this study we reviewed the clinical data and pedigrees
of women diagnosed with breast cancer and carrying
mutations in DNA mismatch repair genes (MMR) involved
in Lynch syndrome (MLH1, MSH2, MSH6 and PMS2).
Among 1200 patients tested between March 2016 and
December 2016 using a multi-gene panel 736 women with
new breast cancer diagnoses were included. Of those
women 49 were found to carry mutations in MMR genes
with two of them carrying more than one single mutation.
This represents 47 missense substitutions of unknown sig-
niﬁcance (MLH1: 8; MSH2: 9; MSH6: 16; PMS2: 14) and
4 clearly pathogenic mutations (MLH1: 1; MSH2: 1;
MSH6: 2).
Clinical histories were then correlated with the presence
of Lynch syndrome-related risk. Amsterdam I and II criteria
were absent in almost all families whereas few patients
entered Bethesda guidelines (6/49). By contrast strong
family histories of breast cancer were reported for 32/49
patients.
These data pointed to the detection of mutations without
regard to family histories of cancer in women with breast
cancer diagnoses. For women with strong family histories
of breast cancer, genetic counselling remains complex
especially about the risk assessment for cancer sites being
part of the Lynch syndrome spectrum.
D. Feret: None. A. Lombard: None. P. Hilbert: None.
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The identiﬁcation of microRNA and genes connected with
metastasis among brеаst cancer patients
K. Grishina1, Muzaffarova1, Pospekhova1, Khaylenko2,
Karpukhin1
Research Centre for Medical Genetics, Moscow, Russian
Federation, 2Blokhin Russian Cancer Research Centre,
Moscow, Russian Federation
There were investigated of 16 microRNA quantitative
expression levels in a sample of breast cancer tumors in
relation to the normal breast tissue. All patients of the
sample were not subject to radiation, neither to che-
motherapy. Three clusters of gene co-expression were
identiﬁed. One of the clusters was enriched by patients with
metastases. The accumulation of patients with metastases in
the cluster relative to other clusters was near of statistical
signiﬁcance (p = 0,07, OR = 5). The differential expression
and signiﬁcant association with metastasis was revealed for
MIR34A, MIR125B1, MIR222 and MIR21. In the study of
75 gene expression on the same sample the association of
genes ZEB2, PLAUR, MMP9, CSF1R, FN1 with metas-
tases was identiﬁed. In analyzes of all genes and micro-
RNAs the expression relationship 9 new negative
correlations were found, but not among the metastasis-
associated genes and miRNAs. The analysis of inter-
connection of associated with metastasis miRs and genes by
MirOB database found the principal possibility of their
combining in the network through intermediaries, but on the
basis of known data on breast cancer a single network has
not been received. Analysis of GO processes showed that
these genes and microRNA integrates participation in the
migration and tumor progression. The genes are also
involved in the invasion, metastasis and in EMT processes,
the microRNAs in the process of MAPK pathway regula-
tion that stimulate of metastasis. Finally, we identiﬁed
associated with metastasis miRNAs and the genes, which
are functionally involved in different processes of
metastasis.
K. Grishina: None. K. Grishina Muzaffarova: None.
K. Grishina Muzaffarova Pospekhova: None. K. Grish-
ina Muzaffarova Pospekhova Khaylenko: None. K.
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Strategies to predict treatment response & select therapies in
metastatic breast cancer patients using a next generation
sequencing multi-gene panel
A. Toss1, L. Cortesi1, L. Artuso2, E. Tenedini2, S. Parenti2,
I. Bernardis2, G. Ficarra3, F. Piacentini2, M. Federico2,
E. Tagliaﬁco2
1Department of Oncology and Haematology, Azienda
Ospedaliero-Universitaria Policlinico di Modena, Modena,
Italy, 2Center for Genome Research, University of Modena
and Reggio Emilia, Modena, Italy, 3Department of
Pathology,Azienda Ospedaliero-Universitaria Policlinico
di Modena, Modena, Italy
Introduction: In the last decade, an increasing number of
molecularly targeted drugs have been developed for the
treatment of metastatic breast cancer (BC). The ability to
perform multi-gene testing for a range of recurrent mole-
cular alterations may provide an opportunity to clarify the
mechanisms of treatment response, to ﬁnd the strategies to
overcome treatment resistance and thus, to identify patients
who may be candidates for matched targeted therapies. The
aim of our research is to ﬁnd prognostic and predictive
molecular biomarkers for the management of BC.
Materials and Methods: We used an NGS panel of 25
genes involved in the pathways of resistance to endocrine
and targeted treatments, to test the mutational status of 7
primary BCs and matched metastatic sites using a custom
Ampliseq® panel and the Ion Torrent PGM sequencer.
Results: Ten different genes (PTEN, PIK3CA, mTOR,
ERBB2, ERBB3, MET, INPP4B, MAP2K1, CDK6, KRAS)
in 6 patients showed possible damaging variants. In 4
patients the mutational status of primary and secondary
tumors were identical, and the variants found in primary
tumors were able to explain the subsequent treatment
resistance. In 1 patient, the metastatic site presented 3 new
variants, which could explain the progression of the disease.
In 2 patients, some of the mutations expressed by the pri-
mary tumor were disappeared in the metastases.
Conclusion: In 5 patients the mutational status of primary
tumor predicted treatment resistance and thus relapse; while
in 3 patients the mutational status of metastatic site could
have guided differently subsequent treatment choices.
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Association of MUTYH with familial breast and ovarian
cancer
M. Larsen1, J. Blümcke1, B. Blümcke1, C. Ernst1, K.
Keupp1, L. Bülow1, J. Altmüller2, H. Thiele2, P.
Nürnberg2, E. Hahnen1, R. Schmutzler1
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The MUTYH gene as a caretaker of the genome is asso-
ciated with hereditary cancer. It is a component of a base
excision repair (BER) system that protects DNA from
oxidative damage. Biallelic mutations in this gene are
known to be associated with hereditary colorectal cancer.
In the past different cohorts have been tested for an
association of MUTYH and breast cancer with controversial
results. Here we present the largest case-control-study of
German patients concerning this association. In this study,
we screened a cohort of 2.051 healthy German controls and
3.324 patients with a family history of breast cancer (BC)
and/or ovarian cancer (OC) for pathogenic variants in the
MUTYH gene. All patients fulﬁll the inclusion criteria of the
German Consortium for Hereditary Breast- and Ovarian
Cancer (GC-HBOC) for germline testing. Samples were
screened via NGS (TruRisk® gene panel, Agilent
SureSelect).
We have detected 53 index cases carrying ten different
variants in MUTYH that were previously described patho-
genic for colorectal cancer. In the cohort of healthy controls
28 individuals were detected to carry a pathogenic MUTYH
variant. No biallelic pathogenic MUTYH mutations were
identiﬁed. (Odds ratio 1.17; 95% CI, 0.72–1.91; P = 0.50).
To the time of data-cut our results do not support an asso-
ciation of heterozygous MUTYH mutations with breast and
ovarian cancer. In order to get more precise evidence further
investigations need to be done.
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Next-generation sequencing in familial breast cancer
patients from Lebanon
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Health Sciences Center (HSC), Kuwait University, kuwait,
Kuwait, 5Dasman Diabetes Institute, Dasman, Kuwait,
6Kuwait Medical Genetics Center, Maternity Hospital,
Kuwait, Kuwait, 7Department of Computing Sciences and
Engineering, Kuwait University, Kuwait, Kuwait, 8Health
Sciences Center, Kuwait University, Faculty of Medicine,
Department of Pathology, Kuwait, Kuwait, 9Institut Jerome
Lejeune, Paris, France
Background: Familial breast cancer (BC) represents 5 to
10% of all BC cases. Mutations in two high susceptibility
BRCA1 and BRCA2 genes explain 16–40% of familial BC,
while other high, moderate and low susceptibility genes
explain up to 20% more of BC families. The Lebanese
reported prevalence of BRCA1 and BRCA2 deleterious
mutations (5.6% and 12.5%) were lower than those reported
in the literature.
Methods: In the presented study, 45 Lebanese patients
with a reported family history of BC were tested using
Whole Exome Sequencing (WES) technique followed by
Sanger sequencing validation.
Results: Nineteen pathogenic mutations were identiﬁed
in this study. These 19 mutations were found in 13 different
genes such as: ABCC12, APC, ATM, BRCA1, BRCA2,
CDH1, ERCC6, MSH2, POLH, PRF1, SLX4, STK11 and
TP53.
Conclusions: In this ﬁrst application of WES on BC in
Lebanon, we detected six BRCA1 and BRCA2 deleterious
mutations in seven patients, with a total prevalence of
15.5%, a ﬁgure that is lower than those reported in the
Western literature. The p.C44F mutation in the BRCA1 gene
appeared twice in this study, suggesting a founder effect.
Importantly, the overall mutation prevalence was equal to
40%, justifying the urgent need to deploy WES for the
identiﬁcation of genetic variants responsible for familial BC
in the Lebanese population.
N. Jalkh: None. E. Chouery: None. Z. Haidar: None.
C. Khater: None. D. Atallah: None. A. Hamad: None.M.
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Population-based testing for hereditary breast and ovarian
cancer predisposing mutations in the Australian community
I. G. Campbell1, S. Rowley1, A. H. Trainer1,2, M. Young3,
Lifepool1, L. Devereux1, P. A. James1,2
Peter MacCallum Cancer Centre, Melbourne, Australia,
2Parkville Familial Cancer Centre, Melbourne, Australia,
3Garvan Institute, Sydney, Australia
Germline mutations in hereditary breast and ovarian cancer
(HBOC) genes such as BRCA1 and BRCA2 confer a high
lifetime risk of these cancers but importantly these risks are
not irreversible. Identiﬁcation of asymptomatic carriers
could signiﬁcantly reduce the incidence of these diseases.
The current model of familial cancer practice involves
ascertaining high-risk individuals based on family history
but >50% of mutation carriers may not have a family his-
tory of cancer. Momentum toward genetic testing of the
asymptomatic population is growing but it remains unclear
what is the true frequency of actionable mutations in the
general western population and the extent to which the
public would accept such testing, particularly for those
individuals identiﬁed with an actionable mutation in the
absence of an overt family history.
We sequenced the coding regions of 20 hereditary breast
and ovarian cancer (HBOC) genes in 5,500 cancer-free
Australian women from the lifepool study (www.lifepool.
org). The data was ﬁltered to identify all clinically
“actionable” mutations.
Thirty-nine women were identiﬁed with actionable
mutations in BRCA1 (5 mutations), BRCA2 (18 mutations),
PALB2 (14 mutations) or ATM (4 mutations). To date 24/
24 women notiﬁed of an actionable mutation subsequently
accepted an invitation to attend a Familial Cancer Centre
and proceeded to formal clinical genetic testing and risk
mitigation. In addition, 15 women had pathogenic muta-
tions in potentially actionable genes BRIP1, RAD51C and
RAD51D.
Our data directly demonstrates a population carrier fre-
quency of ~1% for pathogenic mutations HBOC genes and
that such testing is well accepted by the screened
population.
I.G. Campbell: None. S. Rowley: None. A.H. Trainer:
None. M. Young: None. M. Young Lifepool: None. L.
Devereux: None. P.A. James: None.
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Next-generation sequencing via TruRisk® genepanel reveal
high mutation prevalence in additional risk genes in Ger-
man BRCA1/2-negative breast and ovarian cancer families
K. Keupp1, C. Ernst1, B. Blümcke1, B. Versmold1, A.
Waha1, J. Driesen1, A. Baasner1, M. Larsen1, L. Bülow1,
S. Kröber1, J. Altmüller2, H. Thiele2, P. Nürnberg2, B.
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Wappenschmidt1, G. Neidhardt1, K. Rhiem1, R.
Schmutzler1, E. Hahnen1, J. Hauke1
1Center for Hereditary Breast and Ovarian Cancer,
Cologne, Germany, 2Cologne Center for Genomics
(CCG), Cologne, Germany
Within the framework of the German Consortium for Her-
editary Breast and Ovarian Cancer (GC-HBOC) 24% of the
analyzed familial breast cancer (BC) and/or ovarian cancer
(OC) cases are due to pathogenic mutations in BRCA1/2.
However, the mutation prevalence of non-BRCA1/2 genes
associated with familial BC/OC is largely unknown. Here,
we present NGS data generated using the GC-HBOC-
designed TruRisk® gene panel. In this study our cohort of
2515 BRCA1/2 and CHEK2 c.1100delC negative index
cases collected was analyzed which comprises consecutive
patients from BC families and BC/OC families complying
the inclusion criteria of the GC-HBOC. By focusing on 22
BC/OC associated genes, we identiﬁed 115 different dele-
terious variants in 191 unrelated mutation carriers derived
from 2515 BC and BC/OC families (7.6%). Interestingly,
we identiﬁed a high prevalence of ATM mutation carriers (n
= 42, 1.7%) in the familial cases. Additionally mutations in
PALB2 (n= 25), CHEK2 (n= 18), BARD1 (n= 10), BRIP1
(n= 10), RAD51C (n= 9), NBN (n= 8) and TP53 (n= 7)
were frequently observed and we conﬁrmed FANCM (n=
19) as a novel BC predisposing gene. No mutations in
MRE11A, PTEN, and STK11 were identiﬁed in our collec-
tive. Due to the unexpectedly high mutation prevalence in
familial cases, our study highlights the importance of these
genes to be included in BC/OC routine diagnostics. In
contrast we found low occurrence or absence of mutations
for a subset of our gene selection which requires further
investigation to optimize the gene panel for diagnostic
purposes. Nevertheless this approach conﬁrms the TruRisk®
gene panel as a reliable tool for this comprehensive
analysis.
K. Keupp: None. C. Ernst: None. B. Blümcke: None.
B. Versmold: None. A. Waha: None. J. Driesen: None. A.
Baasner: None. M. Larsen: None. L. Bülow: None. S.
Kröber: None. J. Altmüller: None. H. Thiele: None. P.
Nürnberg: None. B. Wappenschmidt: None. G. Neid-
hardt: None. K. Rhiem: None. R. Schmutzler: None. E.
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Routing: A response to the saturation of cancer genetic
clinical sessions
G. Collet1, N. Parodi1, K. Cassinari1, F. Cohen2, C.
Gasnier2, Z. Neviere2,1, A. Brahimi1, F. Lecoquierre1, J.
Thery1, I. Tennevet1, P. Berthet2, E. Lacaze3, T. Frebourg1
Department of Genetics, Rouen University Hospital,
Normandy Centre for Genomic and Personalized Medicine,
Rouen, France, 2Department of Genetics, Comprehensive
Cancer Centre François Baclesse, Normandy Centre for
Genomic and Personalized Medicine, Caen, France,
3Department of Genetics, Le Havre Hospital, Normandy
Centre for Genomic and Personalized Medicine, Le Havre,
France
Introduction: Cancer genetic sessions reach a saturation
point, especially since the development of PARP inhibitors,
which requires ensuring fast tracks in order to identify
BRCA1 and BRCA2 mutation carriers.
Materials and Methods: A new triage procedure has been
set up within our Centre for Genomic and Personalized
Medicine, covering a population in Normandy of 3.3 M ha:
D0, a phone-based appointment (PBA) is ﬁxed within
7 days; D7, trained genetic counsellors or medical residents
call the proband for a 20 min PBA, collecting personal and
family medical history through a structured questionnaire,
in order to establish a pre-genetic session medical ﬁle; D10,
routing: Pre-genetic session medical ﬁles are analyzed by a
senior cancer geneticist with 3 possible conclusions: (i)
priority face to face genetic session with a medical geneti-
cist (immediate therapeutic impact); (ii) face to face genetic
session with a genetic counsellor, or (iii) no clinical session
needed (lack of personal or familial indication and/or sub-
stitution by a more appropriate index case).
Results: Since 2015 August, in the context of breast and
ovarian cancers, 1039 PBA were performed, 38% of PBA
did not lead to face to face genetic sessions, the median
delay for a cancer genetic session was maintained to
12 weeks and all genetic sessions with therapeutic impact
could efﬁciently be ensured within 4 weeks.
Conclusion: This routing procedure allows to suppress
up to 1/3 of unjustiﬁed sessions, to prioritize genetic ses-
sions according to therapeutic impacts, satisﬁes the patients,
and optimizes collaborations between genetic counsellors
and medical geneticists.
G. Collet: None. N. Parodi: None. K. Cassinari: None.
F. Cohen: None. C. Gasnier: None. Z. Neviere: None. A.
Brahimi: None. F. Lecoquierre: None. J. Thery: None. I.
Tennevet: None. P. Berthet: None. E. Lacaze: None. T.
Frebourg: None.
P12.060D
High resolution of breast tumor heterogeneity enabled with
massively parallel single cell transcriptomics
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E. Walczak1, G. Holdgate1, C. Chang1, R. Acob1, N.
Bansal1, G. Lam1, S. Weaver1, J. Fan1, A. Wang2, C.
Lomas2, S. Ghanekar2, R. Blaesius3, C. Egelston4, P. P.
Lee4, H. C. Fan1
1BD Genomics, Menlo Park, CA, United States, 2BD Life
Sciences, San Jose, CA, United States, 3BD Technologies,
Research Triangle Park, NC, United States, 4City of Hope,
Department of Immuno-Oncology, Duarte, CA, United
States
Introduction: Cellular diversity within breast tumors shape
complex cell to cell interactions that drive the tumoral life
cycle from initiation to metastasis. Understanding intratu-
moral heterogeneity is the gateway for discerning key
mechanisms of breast cancer evolution and has direct
implications for patient prognosis and therapeutic
treatments.
Materials and Methods: To assess cellular hetero-
geneity among breast cancer specimens, we utilized BDTM
Resolve to capture the transcriptomes of 62081 single cells
from 3 primary breast tumors and 3 lymph node metastases.
We employed two strategies for RNA-sequencing library
preparation: whole transcriptome ampliﬁcation (WTA) and
targeted library preparation using multiplex PCR with a
gene panel consisting of more than 400 genes. While the
WTA approach allowed unbiased exploration of gene sig-
natures, the targeted approach provided a focused evalua-
tion of genes known to be correlated with prognosis and
breast cancer subtypes, as well as markers for the plethora
of cell types found within tumoral microenvironments.
Results and Conclusions: Both whole transcriptome
and targeted RNA-sequencing revealed diverse cellular
composition in a patient- and sample-dependent manner.
We observed distinct sets of cancer-associated ﬁbroblasts,
endothelial cells, tumor inﬁltrating immune cells, and dis-
parate subpopulations of breast cancer cells. Direct com-
parison of primary and metastatic breast cancer cells derived
from a single patient revealed divergent gene signatures that
may inform the evolutionary processes of a primary tumor
to a metastasis. These data highlight the power single cell
RNA-sequencing to discern heterogeneity in tumor sam-
ples, with implications for both basic cancer research and
translational medicine.
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Evaluation of breast cancer susceptibility loci in Singapore
Chinese women
C. H. T. Chan1, P. Munusamy1, S. Loke1, G. Koh1, A.
Prawira1, H. Law2, C. Yoon2, C. Wong3, W. Yong4, R. C.
H. Ng5, K. Ong4, P. Madhukumar4, C. Oey4, G. Ho4, P.
Tan6, M. Tan5,7, P. Ang5,8, Y. Yap5, A. S. G. Lee1,9,10
Division of Medical Sciences, Humphrey Oei Institute of
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3Department of General Surgery, Singapore General
Hospital, Singapore, Singapore, 4Department of Surgical
Oncology, National Cancer Centre, Singapore, Singapore,
5Department of Medical Oncology, National Cancer
Centre, Singapore, Singapore, 6Department of Pathology,
Singapore General Hospital, Singapore, Singapore, 7Insti-
tute of Bioengineering and Nanotechnology, Singapore,
Singapore, 8Oncocare Cancer Centre, Gleneagles Medical
Centre, Singapore, Singapore, 9Department of Physiology,
Yong Loo Lin School of Medicine, National University of
Singapore, Singapore, Singapore, 10Ofﬁce of Clinical &
Academic Faculty Affairs, Duke-NUS Graduate Medical
School, Singapore, Singapore
Aim: Genome-wide association studies (GWAS) have
identiﬁed common single-nucleotide polymorphisms
(SNPs) associated with breast cancer (BC) risk. However,
these studies have focused predominantly on Caucasian
populations, and the relevance of these SNPs in Asian
populations are less known.
Methods: We studied 48 SNPs in 1,233 BC patients and
1,189 healthy controls, which comprised of women of
Chinese ancestry accrued at the National Cancer Centre
Singapore and KK Women’s and Children’s Hospital,
Singapore. Genotyping was carried out on Fluidigm’s
192.24 microﬂuidics dynamic arrays using TaqMan® SNP
Genotyping Assays. Logistic regression analysis was car-
ried out using R SNPassoc package.
Results:Via an additive model, four SNPs rs4784227
(OR=1.37,95%CI=1.21–1.55;P=7.95×10−5), rs3757318
(OR=1.34,95%CI=1.18–1.52;P=3.41×10−6), rs12662670
(OR=1.37,95%CI=1.21–1.55;P=2.80×10−7) and
rs11155804 (OR=1.31,95%CI=1.16–1.47;P=7.87×10−6),
were found to be signiﬁcantly associated with increased BC
risk at adjusted P value of <1.16 ×10−3 after Bonferroni
correction. Rs3757318, rs12662670 and rs11155804 are
located on 6q25.1. Rs4784227 is within TOX3, a gene
expressed speciﬁcally in ER-positive and PR-positive BC
cases. In our study, rs4784227 was found to be signiﬁcantly
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associated with only ER-positive (OR=1.35,95%CI=1.17–
1.56;P=2.76×10−5) and PR-positive (OR=1.4,95%
CI=1.21–1.62;P=7.77×10−6) BC cases. An additional
SNP, rs7297051, was associated with decreased BC risk in
cases with a family history of BC (OR=0.68,95%CI=0.54–
0.85;P=4.50×10−4).
Conclusion:Four of the 48 SNPs were found to be
associated with increased BC risk, with higher ORs in
Singaporean Chinese compared to Caucasians. This ﬁnding
reiterates the notion that variants identiﬁed from GWAS in
Caucasians might not always be relevant to other popula-
tions. This work was supported by grants from the National
Medical Research Council of Singapore.
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Analysis of genomic alterations in tumours from breast
cancer in women below 40 years old
A. Pascual Rodríguez1,2, E. Lumbreras González1,2, E.
Bueno Martinez3,2, L. Corchete Sánchez4,2, E. M. Sanchez
Tapia1,2, M. Delgado Pérez1,2, J. L. García Hernández1,2,
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manca, Spain, 3Departamento de Medicina, Facultad de
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Introduction: Breast cancer in young women (BCYW) is
considered a distinct entity characterized by poorer prog-
nosis, more aggressive tumor phenotypes, high germline
mutation rates in BRCA1/2 genes and some differences in
risk factors, being familial history the most important.
Identiﬁcation of copy number alteration (CNA) on BCYW
may provide key genes playing causal roles in breast
oncogenesis and potential therapeutic targets.
Materials and methods: 58 FFPE tumour from BC in
women below 40 years were analyze for CNA with Affy-
metrix® SNP Arrays and BRCA1/2 mutation status was
previously studied in DNA from peripheral blood. Thus
allowed us to differentiate 3 groups: BRCA mutation car-
riers (n= 12) and non-carriers; this one divided in two
groups: with and without familial history of breast cancer
(FBC+,n= 20; FBC- n= 26). GISTIC software let us
analyzed common genes and altered regions. CTLPScanner
tool were used to detect chromothripsis like patterns
(CTLPs).
Results: Genomic instability was higher in BRCA+
tumours and speciﬁc altered regions were found statistically
signiﬁcant in each group (Table) These frequent alterations
had not been reported in other publication before. CTLPs
were conﬁrmed in 17% (n= 10) of all cases and chromo-
some 17 (ERBB2, CDK12) was the most altered. The FBC
+ group was the most affected by chromothripsis (n= 5).
Group Gains (%) and genes
involved*
Loss (%) and genes
involved*
BRCA
+
6p25(83%), NOQ2 18q23 (83%),
GALR1
5q35 (100%),
GNB2L1
FBC- 8p11 (61%), FGFR1 4q31 (54%), TLR2,
SFRP2
FBC+ 12q14(57%), CDK4 –
*statiscally signiﬁcant difference between groups
Conclusion: This analysis provides new insights and
differences between these subgroups and it is the ﬁrst time
chromothripsis is reported in BCYW.
A. Pascual Rodríguez: None. E. Lumbreras González:
None. E. Bueno Martinez: None. L. Corchete Sánchez:
None. E.M. Sanchez Tapia: None. M. Delgado Pérez:
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Rising of the c-Myc oncogen expression might be corre-
lated with poor prognosis in CML
H. Galehdari
Genetics, Ahwaz, Iran, Islamic Republic of
Recent studies show cancer development and progression
largely is related to non-coding genes beside well known
coding genes. Long non-coding RNAs (lncRNAs) are
important players in the complex world of gene expression
regulation. Many lncRNAs regulate the expression and
stability of main transcription factors in cells. The c-Myc is
one of the transcription factors playing a major role in
hematopoiesis. Increased expression or aberrant activation
of c-Myc plays an important role in leukemia. It has been
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proposed that PVT-1 lncRNAs regulates c-Myc gene
transcription.
In the present study we aimed to investigate the
expression of PVT1 & MYC in APL and CML peripheral
blood mononuclear cells. To this end peripheral blood
samples were collected from 73 pathologically conﬁrmed
CML patients and 17 pathologically conﬁrmed APL
patients. Correlation of the BCR/ABL translocation and the
expressions of c-MYC and PVT-1 has been analyzed.
At result we found that in our enrolled patients including;
36 cases negative for BCR/ABL, 37 samples positive-BCR/
ABL. The expression of the MYC increased signiﬁcantly in
positive-BCR/ABL samples in comparison to the patients
being negative for BCR/ABL (about~20 fold, p<0.05).
In conclusion, c-MYC expression increases under BCR/
ABL possibly independently from PVT1 expression. Our
result shed light on possible impact of c-MYC and PVT-1
on leukemia characterization. These preliminary data need
additional investigation to explain somewhat about the
clinical use of c-MYC and PVT1 expression in leukemia
characterization and therapy processes.
H. Galehdari: None.
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Two novel CHEK2 large genomic rearrangements are
associated with breast cancer predisposition
P. Apostolou1, V. Mollaki1, F. Fostira1, A. Delimitsou1, M.
Vlassi2, P. Kollia3, G. Fountzilas4, I. Konstantopoulou1, D.
Yannoukakos1
1Molecular Diagnostics Laboratory, NCSR Demokritos,
Athens, Greece, 2Institute of Biosciences and Applications,
NCSR Demokritos, Athens, Greece, 3National and Kapo-
distrian University of Athens, Athens, Greece, 4Aristotle
University of Thessaloniki, School of Medicine, Thessalo-
niki, Greece
Introduction: CHEK2 damaging alleles are associated with
increased risk of breast cancer, with their type and fre-
quency being variable among populations. CHEK2 large
genomic rearrangements (LGRs) are very rare and up to
date two have been described, namely a Czech founder
5.6kb deletion and an Italian 23kb duplication. The aim of
the present study is to elucidate the role of CHEK2 LGRs in
Greek breast cancer patients.
Materials and Methods: Analysis for the two CHEK2
LGRs was performed in 2355 breast cancer patients and
1580 controls using a customized PCR.
Results: Two novel LGRs were identiﬁed, namely a
~5.8Kb and a ~7.5kb deletion removing exons 2–3 and
exon 6 of the gene, respectively. The exact breakpoints of
mutations were deﬁned and further analyzed by a custom
PCR. The deletion of exons 2–3 (p.E107_K197fsX0) was
rare, detected in only 0.09% (1/1020) of breast cancer cases,
while the deletion of exon 6 (p.D308fsX0) was detected in
0.22% (5/2355) of patients and none of the 1580 control
subjects. Haplotype analysis of p.D308fsX0, the more fre-
quent LGR, showed that it is a Greek founder mutation with
carriers sharing a common haplotype of 1850kb. Although
the reading frame is retained, the p.D308fsX0 deletion
impairs CHEK2 function, as shown by in silico analysis, a
CHEK2-yeast functional assay and structure-prediction
models.
Conclusions: The present study reports the association
of rare genomic events with breast cancer susceptibility,
which are rarely reported presumably due to incomplete
analyses.
P. Apostolou: None. V. Mollaki: None. F. Fostira:
None. A. Delimitsou: None. M. Vlassi: None. P. Kollia:
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Utility of panel testing in hereditary cancer: a laboratory
perspective
H. A. Lindsay1, R. Robinson1, N. Camm1, R. Brown1, L.
Mavrogiannis1, S. Shepherd1, C. Watson2, J. Adlard3, J.
Mahon1, N. Dey1, R. Charlton1
Leeds Genetics Laboratory, Leeds, United Kingdom,
2Translational Genomics, Leeds, United Kingdom, 3York-
shire Regional Genetics Service, Leeds, United Kingdom
We have developed a fully customisable 155 gene heredi-
tary cancer panel enabling rapid, cost-effective analysis,
ideal for investigation of patients with complex personal
and/or family histories. To maximise test sensitivity, gene
dosage changes and several pathogenic variants falling
outside the normal scope of standard commercial kits are
also detected e.g. EPCAM deletions, a recurrent MSH2
inversion and BRCA2 Alu insertion, and several deep
intronic and promoter mutations. Results for over 2200
patients indicate an overall diagnostic yield of 16%, repre-
senting 359 likely pathogenic or pathogenic variants
detected in 51 genes, and including patients with mutations
in more than one cancer predisposition gene. Dosage
anomalies account for >10% of clinically actionable ﬁnd-
ings. Review and classiﬁcation of detected variants repre-
sents a signiﬁcant component of service workloads.
Detection of variants of uncertain signiﬁcance (VOUS),
which have no immediate clinical utility, is particularly
pertinent for recently characterised cancer predisposition
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genes e.g. POLE, POLD1, and for genes with low-mid
penetrance e.g. CHEK2, ATM. However, through regular
review of available evidence, patients will hopefully beneﬁt
from these ﬁndings in the future as more genotype-
phenotype data is collated worldwide. In our cohort,
VOUS were reported in only 13% patients overall. This is
in part explained by users typically adopting a phenotype-
focused subset of genes, which tends to result in greater
diagnostic yields e.g. 25% and 19% yield in pheochromo-
cytoma and melanoma sub-panels respectively. However,
the use of extended panel testing still attains a diagnostic
yield of 12% (VOUS rate 17%) and indicates a valid clin-
ical approach.
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Analysis of mismatch repair genes (MMR) in Greek
families with suspected Lynch Syndrome detects a sig-
niﬁcant proportion of MSH2 large genomic rearrangements
A. Vagena, P. Apostolou, D. Yannoukakos, I.
Konstantopoulou, F. Fostira
Molecular Diagnostics Laboratory, NCSR Demokritos,
Athens, Greece
Introduction: Lynch syndrome accounts for about 3%-5%
of all colorectal cancer (CRC) cases and is caused by
germline mutations in the MMR genes, MLH1, MSH2,
MSH6 and PMS2. Most of these loss-of-function (LoF)
alleles are single nucleotide substitutions or small inser-
tions/deletions, with large genomic rearrangements (LGRs)
being detected with variable frequency among different
populations. We aimed to clarify the mutation spectra along
with the prevalence of LGRs in the MMR genes in Greek
CRC patients.
Materials and Methods: Probands from 168 unrelated
families fulﬁlling the Revised Bethesda criteria were
sequenced by Sanger or Next Generation Sequencing, fol-
lowed by MLPA in MMR genes.
Results: The prevalence of MMR LoF mutations was
20.8% (35/168). Point mutations or small insertions/dele-
tions were detected in 17.8% (30/168), while LGRs were
detected in 3% of the cases. Mutations in MLH1 and MSH2
were predominantly identiﬁed, (18.5%), with LGRs in
MSH2 alone (involving deletions of exons 1–6, 1–7, 9–10
and 7–16) seen in 2.4% of the patients tested. CRC was the
most frequent cancer diagnosis (mean age at diagnosis
41.2y, range: 21 – 64 years) among thirty-ﬁve probands
found to carry a mutation. Targeted mutation testing was
uptaken from 46 relatives, with 27 of them testing positive
for the family mutation. Furthermore, 5 out of these 27
carriers were diagnosed with cancer.
Conclusion: Overall, 20.8% of the patients fulﬁlling the
Revised Bethesda criteria carried LoF MMR mutations,
with MSH2 LGRs representing a signiﬁcant proportion,
indicating that such phenomena are possibly frequent in
patients of Greek descent.
A. Vagena: None. P. Apostolou: None. D. Yannou-
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Performance of a 94-gene panel for cancer predisposition
on Greek breast and ovarian cancer patients fulﬁlling the
NCCN criteria for genetic testing
F. FOSTIRA, I. Konstantopoulou, M. S.
Papamentzelopoulou, D. Kalfakakou, A. Vagena, P.
Apostolou, I. Konstanta, A. Delimitsou, I. S. Vlachos, D.
Yannoukakos
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Introduction: NGS technologies, especially in the form of
gene panels, have surely entered the clinical practice for
cancer patient management. Among high-risk breast and/or
ovarian cancer patients of Greek descent, although ﬁve
BRCA1 alleles with founder effect dominate the mutation
spectra, additional susceptibility alleles in a number of
genes are deﬁnitely present.
Materials and Methods: In total, 555 breast and 104
ovarian cancer patients fulﬁlling NCCN genetic testing
criteria have been analyzed by Trusight Cancer panel tar-
geting 94 genes associated with cancer predisposition, in
order to identify loss-of-function (LoF) mutations.
Results: LoF mutations have been identiﬁed in 22% and
26% of the breast and ovarian cancer group respectively, in
27 genes involved in DNA repair. Of these, 87% and 89%
lie in genes with known or suspected associations with
breast and/or ovarian cancer predisposition, predominantly
BRCA1 and BRCA2 (62%; 74%). Mutations in CHEK2,
PALB2 and ATM were more frequent in the breast cancer
series and RAD51C in the ovarian cancer series. Of note is
the remaining 12% of LoF alleles in non-associated genes to
date, which can be either regarded as incidental ﬁndings,
while putative causality for breast/ovarian cancer cannot be
excluded.
Conclusions: Among a high-risk group of breast and
ovarian cancer patients of Greek descent, where there are
strong founder effects, the mutational spectrum is highly
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heterogeneous with respect to both loci and alleles. This
approach can shed light on associations with the post-
BRCA genes and will provide connections of phenotypes
with mutations in additional DNA repair genes.
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Introduction: According to WHO, lung cancer is the most
common cause of cancer deaths worldwide. Cancer burden
can be reduced by early detection and response-adjusted
treatment. It can be achieved by analysis of cell-free DNA
(cfDNA) from blood samples. This minimally invasive
method can capture the whole tumour heterogeneity in
almost real-time setting. Materials and Methods: Our cohort
comprises of 106 lung adenocarcinoma patients who have
donated pre-therapy cfDNA plasma samples. FFPE tumour
samples were available for 70% of subjects. We have set up
an amplicon-based multiplex next-generation sequencing
(NGS) workﬂow for 9 lung adenocarcinoma-related genes.
To verify our results, FFPE analysis results by certiﬁed
diagnostic laboratories was initially used. In the later ana-
lysis, NGS of FFPE samples served as an internal control
for cfDNA. Results: Our results showed that cfDNA NGS
can detect ~1% mutant allele content. The overall con-
cordance between diagnostic laboratory and cfDNA NGS
results was 89%. FFPE analysis provided higher detection
sensitivity, whereas cfDNA analysis has higher speciﬁcity.
We found a resistance mutation in cfDNA of a patient with
previous history of long-term EGFR-TKI therapy whose
treatment should be changed to third generation EGFR TKI-
s. Perspectives: Our further aim is to collect longitudinal
samples and perform a larger screen of drug susceptibility
and resistance mutations in our study cohort, involving
detection of copy number variations and DNA methylation
changes. We believe that regular cfDNA analysis should
become a clinical routine in various cancers. This research
was supported by the EU project 2014–2020.4.01.15–0012
and PUT736 personal grant.
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Introduction: The main cause of breast cancer death is
metastasis to vitally organs such as lungs, liver, brain,
lymph nodes, and bones.According to recent research, cf-
DNA can cause horizontal gene transfer as name is “Gen-
ometastasis Hypothesis” (1).cf-DNA originated from tumor
and healthy cells and present in blood (2).In this study,we
used MDA-MB-231 (breast cancer cells) and hFOB1.19
(osteoblast cells) for co-culture;so that we aimed to create
in vitro metastasis model. Subsequently, whether p53 exon
8 horizontal gene transfers has occurred and affects the
transfers or not viability of osteoblast cells evaluated in the
study.
Materials and Methods: MDA-MB-231 cells were co-
cultured with hFOB1.19 cells for 72 hours.DNA’s were
isolated from cells and cf-DNA isolated from medium and
p53 exon 8 mutant sequence analyzed by PCR.Viability
was evaluated Tripan Blue assay.
Results:We determined that hFOB1.19 cells mutant p53
exon 8 horizontal gene transfection occurred at the end of
72 hours later.hFOB1.19 cells viability were increased in
co-culture system (p<0,05).
Conclusions: In this study,MDA-MB-231 cells co-
cultured with hFOB1.19 cells.We evaluated for the ﬁrst
time “Genometastasis Hypothesis” in vitro systems and
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concluded that mutant p53 exon 8 horizontal gene transfer
to hFOB1.19 from MDA-MB-231 was occurred.
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Introduction: T-ALL represents 15% of newly diagnosed
children with ALL and is regarded as a high-risk disease. It
is a clinically and genetically heterogeneous malignancy
which showed a normal karyotype of bone marrow cells in
approximately half of the cases. The aim of the study was to
determine a frequency of recurrent cryptic chromosomal
aberrations and to correlate the ﬁndings with the course of
the disease.
Materials and Methods: Karyotypes of all patients were
analyzed at the time of diagnosis by G-banding and FISH
methods in order to detect the most frequent known chro-
mosomal changes, i.e. rearrangements of TCR loci (TRA,
TRB, TRG) and TLX3 gene, deletion of CDKN2A and
ampliﬁcation of ABL.
Results: 64 children with T-ALL were examined (19
girls, 45 boys, median age 8,25 years). Chromosomal
aberrations were detected by conventional cytogenetics in
50% of patients, versus 86% found by molecular cytoge-
netic methods. Rearrangements of TCR loci were found in
17 children: 11×TRA and 6×TRB. Deletion of CDKN2A was
proved in 35 patients: 19x homozygous and 16x hetero-
zygous. TLX3 gene rearrangement was established in 15
patients. 48 patients are living in the ﬁrst/second complete
remission and sixteen children died. In this cohort, rear-
rangements of TCR loci were associated with favorable
prognosis.
Conclusion: Using molecular cytogenetic methods
cryptic recurrent aberrations were proved in vaste majority
of children. However, additional studies of larger cohort of
patients are needed to determine their prognostic impact and
to understand implications in T-cell oncogenesis.
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Introduction: Studying familial childhood acute lympho-
blastic leukemia (ALL) provides a unique opportunity to
understand the genetics underlying ALL. Rare germline
pathogenic variants in the ETV6 gene have previously been
reported in families with thrombocytopenia and predis-
position to hematological malignancies, especially ALL. In
addition, overrepresentation of high hyperdiploid (HeH)
ALL and higher age at onset compared to common HeH
ALL was observed in a cohort of childhood ALL cases with
ETV6 germline pathogenic variants.
Materials and Methods: We studied a family with two
cases of childhood ALL in 2nd degree relatives. All family
members were analyzed by karyotyping. Whole genome
sequencing (WGS) was performed on one healthy carrier.
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Samples from leukemia diagnosis were run on SNP array.
Fusion transcripts were Sanger sequenced.
Results: Karyotyping identiﬁed t(12;14) in seven family
members. Two carriers developed ALL at age 9 and 12
years respectively. SNP-arrays showed leukemias were
HeH. WGS conﬁrmed the t(12;14)(p13.2;q23.1) which,
according to transcript sequencing, creates two transcribed
fusion genes. However, transcript sequences (ETV6ex1/
RTN1ex2; RTN1ex1/ETV6ex2-4) suggest translation of
functional fusion protein is unlikely.
Conclusion: Here we report a unique family with pre-
disposition to ALL carrying a t(12;14)(p13.2;q23.1)
affecting ETV6. Our ﬁnding further supports leukemia
susceptibility in patients carrying germline mutations in
ETV6. In line with previous reports leukemias were HeH
and had higher age at onset, however, no thrombocytopenia
was observed. Further, in contrast to previous cases where
germline pathogenic variants in ETV6 create mutant ETV6
protein, this translocation causes a heterozygous loss of
ETV6.
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Introduction: Chromothripsis represents one-off event
causing extensive chromosomal rearrangements. In cancer it
is frequently associated with a wt-TP53 gene loss and
consequently with adverse disease course. However, func-
tional consequences of the chromosomal shattering have not
been studied extensively yet. Therefore, we performed
characterization of chromothripsis in chronic lymphocytic
leukemia (CLL), as a model disease, with aim to understand
its impact on gene expression and cellular processes.
Materials and methods: Chromothripsis was screened
among TP53-mutant CLL cases using CytoScanHD arrays
(Affymetrix). Transcriptome analysis was performed using
TruSeq Stranded Total RNA Library Prep Kit on HiSeq
2000-1T (Illumina) and in parallel using Human Tran-
scriptome Arrays 2.0 (Affymetrix). Obtained data were
analyzed with in-house biostatistic and bioinformatic
pipelines.
Results: Among 72 CLL samples analyzed using cyto-
genetic arrays, chromothripsis was identiﬁed in 16 of them
(22%), affecting recurrently chromosomes 6 (5 cases), 8, 9
and 13 (3 cases each). Ten cases with chromothripsis were
subjected to the transcriptome analysis. Upregulation of
several cellular pathways (i.e. focal adhesion, PI3K-Akt-
mTOR signaling, apoptotic signaling, actin cytoskeleton
regulation and others) was observed. Although median of
49 breakpoints (range 24–74) was detected per case, they
mostly did not lead to formation of expressed fusion genes.
Only in 5/10 cases, aberrant expression of 1–3 fusion
transcripts was noted.
Conclusion: Chromothripsis affects approximately one
ﬁfth of CLL cases with wt-TP53 inactivation and is asso-
ciated with altered regulation of cellular pathways. How-
ever, de novo fusion transcripts are expressed only to a
limited extent.
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Genome-wide association studies (GWAS) are an important
way of identifying germline polymorphisms that are asso-
ciated with a speciﬁc trait or disease. However, character-
izing the functional effects of disease-associated variants is
challenging since many are located in intergenic regions of
the genome. We have established a methodological frame-
work to study the functional effects of disease-associated
polymorphisms by examining their effect on disease-
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speciﬁc transcriptional pathways. Speciﬁcally, we show that
renal cell cancer (RCC) associated polymorphisms co-
localize and are statistically enriched at binding sites for the
transcriptional enhancer, hypoxia-inducible factor (HIF).
HIF is constitutive activated in kidney cancer through loss
of the von Hippel-Lindau (VHL) tumor suppressor. Deter-
mining HIF-target genes linked to RCC-associated poly-
morphisms helps identifying HIF-target genes that are
driving kidney cancer from those that are simply co-
acquired as a result of pathway activation. We show func-
tional effects of RCC-associated polymorphisms, by
demonstrating allele-speciﬁc HIF binding in heterozygous
cells lines and link the polymorphic binding sites to their
target genes by examining chromatin looping. Finally, we
use eQTL analysis to show the effect of the RCC-associated
polymorphism on expression of the target gene and
demonstrate the dependence of genotype-expression corre-
lations on HIF. Although focused on the HIF pathway in
kidney cancer, this work forms a paradigm for studying the
effect of non-coding variants linked to other diseases.
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Introduction: Colorectal cancer (CRC) presents sometimes
familial aggregation with an autosomal dominant pattern of
inheritance but no alterations are found in the known her-
editary genes. The purpose of this study was the identiﬁ-
cation of novel variants in candidate genes potentially
involved in the germline predisposition to familial CRC
with an unknown basis. The possible tumor suppressor gene
(TSG) role of the selected candidates was evaluated based
on the Knudson’s two-hit hypothesis.
Materials and Methods: Integrated analysis of germline
and tumor whole exome sequencing data was performed in
ﬁve unrelated familial CRC patients. Deleterious single
nucleotide (SNV) and copy number variants (CNV) were
assessed as candidates for ﬁrst germline or second somatic
hits. A ﬁltering process considering sequencing quality,
frequency, family segregation and pathogenicity was used.
Somatic mutational proﬁling was also performed for all
samples.
Results: A series of germline-somatic variant pairs
affecting proteins and miRNAs functionally related with
CRC were prioritized. Among them, ADCY8, MUC16 and
HEXIM1 were ﬁnally selected as the most promising can-
didates for a putative role as TSGs related to CRC germline
predisposition. A hypermutator phenotype was suggested in
one of the analyzed tumors, due to the elevated number of
variants detected in the somatic proﬁle analysis.
Conclusions: The identiﬁcation of new potential pre-
disposition genes to familial CRC was achieved by our
integrated analysis. Integrative Genomics Viewer and San-
ger sequencing validations were performed for SNV,
whereas somatic CNV were veriﬁed by OncoScan. Further
functional studies will be required to conﬁrm the selected
candidates.
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Introduction. In Spain the population-based CRC screening
program offered by the public health system does not
achieve the expected participation due to the low acceptance
of the common stool blood tests. Today, there are other
screening options available, like the “Septin9” test, that
consists in detecting the methylation status of SEPT9 gene
in plasma. Sensitivity and speciﬁcity are 80.6% and 99.3%
respectively, and the positive predictive value is 45.7%
(data from manufacturer), whilst stool blood test shows a
sensitivity and speciﬁcity of 61–69% and 91–98%,
respectively (1, 2). The objective of this work has been to
review the 2272 Septin9 samples studied since 2012.
Samples are from asyntomatic and mixed (high and low
risk) population.
Materials and Methods. 2272 plasma samples from
Spanish population from low and high risk patients, col-
lected from 2012–2016. EpiproColon2.0 test has been car-
ried out following manufacturer protocol, both for
technique and analysis (Roche LightCycler480).
Results. From the 2272 samples, 154 (6.8%) have been
rejected prior to the study mainly because of a bad sample
quality. Of the 2118 studied samples, positivity rate was
7.0% (148), so that 1970 samples were informed as negative
for Septin 9 test (93%).
Conclusions. Positivity rate in our mixed cohort (7.0%)
was higher than the one described in literature (3,4%) in
general population (3); we assume that a 3,6% of samples
with CRC and advanced adenomas were detected.
The compliance to CRC screening programs using a
blood test is considerably higher, allowing a better perfor-
mance of the screening (4).
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INTRODUCTION: Colorectal cancer (CRC) represents the
third most common cancer worldwide. Next generation
sequencing (NGS) has permitted to identify germline pre-
disposition genes for this disease. Copy number variants
(CNV) can be the mutational event involved in this pre-
disposition, and they can be inferred from NGS data.
METHODOLOGY: We analyzed germline DNA whole-
exome sequencing (WES) data from 38 families with strong
CRC and 16 families with serrated polyposis syndrome
(SPS) aggregation without alterations in known hereditary
genes. To infer rare candidate CNVs involved in this pre-
disposition, we used ExomeDepth and CoNIFER. Variants
shared between family members were compared to Data-
base of Genomic Variants catalog and our in-house data-
base. Selected CNVs were validated and segregation
analysis was performed using Comparative Genome
Hybridization. In some cases, gene expression arrays, qRT-
PCR and immunohistochemistry (IHC) were conducted to
check for gene and protein expression alterations.
RESULTS: Sixteen candidate CNVs were detected in CRC
families. After multiple ﬁltering steps, a duplication in
chromosome 1 stood out including TTF2, TRIM45, VTCN1
and miR942. Expression studies pointed out TTF2 and
miR942 overexpression in carriers, and tumor IHC showed
high levels of TTF2 protein and low levels of the
TMEM158 protein, a predicted miR942 target. Six candi-
date CNV were inferred in SPS families and one duplication
in chromosome 3 including GOLGA3, C3orf35 and ITGA9
was further selected and validated. CONCLUSIONS: WES
data can be used as a ﬁrst approach to identify CNVs.
Conﬁrmed duplications may correspond to the initial
germline mutational event involved in CRC and SPS
predisposition.
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Introduction: Colorectal cancer is the third most common
cancer worldwide. It is a multifactorial disease, with etiol-
ogy encompassing environmental exposures, inﬂammatory
conditions and genetic factors. TP53 is the most common
mutated gene in human cancers. This gene is involved in
cell cycle control and apoptosis induction response to DNA
damage. The sequence polymorphism at codon 72 of this
gene results in either a proline or an arginine. It is hypo-
thesized that two codon 72 variants may induce different
functional activities. Cyclin D1 is encoded by CCND1 gene
and regulates the cellular proliferation by controlling cell
cycle transition from G1 phase to S phase. A common
polymorphism (G870A) at codon 242 in CCND1 may
inﬂuence an individual's susceptibility to the development
of certain cancers.
Materials and Methods: in this study, we investigated
TP53 codon 72 and CCND1 G870A polymorphisms in 80
colorectal cancer cases and 120 healthy individual in
Northwestern Iran. TP53 codon 72 and CCND1 G870A
were genotyped by ARMS-PCR and RFLP-PCR
respectively.
Results: There was a signiﬁcant difference between
frequencies for TP53 Proline variant in patients with col-
orectal cancer (41.6%) and healthy controls (13.2%; P=
0.0001). There was also a signiﬁcant difference between
frequencies for CCND1 AA genotype in patients and
healthy groups (30.12% and 10.25%, respectively; P=
0.01).
Conclusions: In conclusion, our ﬁndings suggest that
genetic polymorphisms in TP53 codon 72 and CCND1
G870A are associated with the risk of colorectal cancer in
an Iranian population.
S. Darvishi: None. M. Faraji Saravani: None. M.
Eskandari: None. D. Rahimiyan: None. M. Jahani
Sayyad Noveiri: None.
P12.079C
Search for rare variants in unexplained adenomatous poly-
posis: Relevance of DNA repair pathways
M. Alvarez-Barona1, X. Bello1, J. Amigo1, F. Valentin2, C.
Fernandez-Rozadilla1, S. Franch-Exposito3, T. Ocaña3,
F. Balaguer3, L. Garcia-Nimo4, J. Cubiella2, M. Pujals5,
F. Fernandez-Bañares5, M. Juarez6, L. Bujanda7,
EPIPOLIP Consortium, S. Castellvi-Bel3, R. Jover6, A.
Carracedo1, C. Ruiz-Ponte1
1Fundacion Publica Galega de Medicina Xenomica-SER-
GAS, Grupo de Medicina Xenomica-USC, IDIS, Santiago
de Compostela, Spain, 2Gastroenterology Department,
Complexo Hospitalario Universitario de Ourense, Instituto
de Investigacion Biomedica Ourense, Ourense, Spain,
3Gastroenterology Department Hospital Clinic, IDIBAPS,
CIBEREHD, Barcelona, Spain, 4Clinical Analysis Depart-
ment, Complexo Hospitalario Universitario de Ourense,
Ourense, Spain, 5Gastroenterology Department, Hospital
Universitari Mutua de Terrassa, CIBEREHD, Terrassa,
Spain, 6Gastroenterology Department, Hospital General
Universitario de Alicante, Instituto de Investigación
Biomedica ISABIAL, Alicante, Spain, 7Gastroenterology
Department, Hospital Donostia/Instituto Biodonostia,
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Introduction: Patients with colorectal adenomatous poly-
posis are at high risk of colorectal cancer (CRC). However,
the genetic basis underlying the development of multiple
adenomas has not yet been fully explained, since approxi-
mately 30% of the patients tested negative for germline
mutations in APC or MUTYH.
Materials and Methods: Whole-exome sequencing was
performed in 27 patients with unexplained colonic poly-
posis (>10 adenomas, onset <60 years) from 19 unrelated
families. Common variants with MAFExAC>0.001 (hetero-
zygous variants) or >0.01 (homozygous variants) were
excluded. To identify rare causative variants, we focused on
all truncating variants and missense of high functional
impact. Subsequently, we prioritised genes exhibiting
recurrent rare variants, and genes implicated in cancer-
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related KEGG pathways or identiﬁed through CRC GWAS.
Further gene prioritization included cosegregation analysis
in families and sequencing in an external validation cohort
of 300 unexplained polyposis patients and healthy controls.
Results: Rare potentially pathogenic variants were
especially found in genes involved in DNA repair such as
Nucleotide Excision Repair, Mismatch Repair and Homo-
logous Recombination pathways. Moreover, genes of the
Fanconi Anemia pathway were also enriched with CRC risk
variants.
Conclusions: According to previous studies in which the
DNA repair genes NTHL1 and MSH3 have been proposed
as susceptibility genes to multiple colonic adenomas and
CRC, these results might suggest the importance of DNA
repair pathways in polyposis etiology.
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CCCTC-binding factor (CTCF) is a highly conserved ubi-
quitously expressed protein that have 11 Zinc Finger DNA
binding domain (DBD). CTCF is able to use combinations
of the ZFs to bind different DNA target sequences and
proteins. It is directly implicated in cancer development and
frequently altered by hemizygous deletion or mutation in
cancers. NGS recently led to sequencing of cancer exomes
and genomes. 10 CTCF missense mutations were selected
from COSMIC database and studied in vitro to identify their
functionality in primary cancers. CTCF mutations were
generated by site-directed mutagenesis with CTCF cDNA
cloned into pET7.1. 10 mutant plasmids were synthesized
together with WT-human CTCF. Mutants were used for
coupled in vitro transcription/translation to synthesize pro-
teins. These proteins were tested in Electro Mobility Shift
Assay (EMSA) to compare with the WT protein. 8 DNA-
probes were used for EMSA including cancer related genes,
promoters etc. The binding of CTCF mutants was reduced
to the probes that were important for the expression of
tumor suppressor genes but was not affected to globin
insulator. ZF1 mutants showed no reduction of binding to
Probe4 (Mus musculus selenoproteinT) compared to WT-
CTCF, whereas in linkers’ and ZF11 mutants binding is
signiﬁcantly reduced. However, the binding afﬁnity of
mutant ZF6 Q418R is markedly increased to Probe4 (~50–
100 folds). To further test the functionality of ZF6 Q418R,
to deﬁne its binding behaviour, in vivo experiments will be
performed. Expected results might have translational sig-
niﬁcance, as they could lead to development of novel
diagnostics and treatment of cancers.
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markers in Cutaneous Squamous Cell Carcinoma
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Introduction: Cutaneous squamous cell carcinoma (CSCC)
accounts for approximately 20% of skin cancer. Mortality
arises secondary to the development of metastases and
angiolymphatic invasion (ALI) seems to play a role. ALI is
considered a poor prognosis sign by different authors
regarding several neoplasias Aim: To asses if expression of
angiogenic and lymphangiogenic proteins in primary CSCC
correlates to disease relapse or progression. Methods: A
preliminary study was designed. We measured VEGFA,
VEGFR2 and VEGFC gene expression by RT-qPCR using
TaqMan probes in FFPE samples corresponding to 29
patients (11 females; 20 males) showing CSCC without ALI
by routine techniques. Eleven of them developed disease
relapse or progression (to lymph nodes or to viscera) and 18
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did not suffer disease progression after at least 60 months of
follow-up. ACTB, 18S, HPRT1, TFRC were analyzed as
internal reference control genes. Results: No signiﬁcant
differences were evidenced for sex, age or tumour location
between groups. Consistent results were obtained when
using ACTB and 18S as internal control genes in CSCC
tissue. VEGFC gene expression was signiﬁcantly higher for
patients with disease progression (p=0.027) compared to
those without it. Nor VEGFA neither VEGFR2 gene
expression did differ between the analyzed groups (p>0.05).
Conclusions: Current results suggest that the expression of
the angiogenic and lymphangiogenic protein VEGFC in
primary CSCC may be related to disease progression in
patients without diagnosis of IAL by routine methods. A
larger cohort is needed to conﬁrm its role as a marker of
poor prognosis in patients with CSCC.
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Background. DICER1 syndrome is an autosomal dominant
inherited disorder associated with a large spectrum of
malignant and benign tumours including pleuropulmonary
blastoma (PPB), cystic nephroma (CN), ovarian Sertoli-
Leydig cell tumours (OSLCT) and thyroid multinodular
goiter or cancer. The genetic diagnosis relies on the iden-
tiﬁcation of a germline DICER1 inactivating pathogenic
variant. To improve the knowledge of clinical and genetic
aspects of this syndrome, we performed a retrospective
study of DICER1 gene analysis on patients diagnosed with
lesions suggesting the DICER1 syndrome.
Methods. This study was conducted on 204 subjects:
101 probands and 103 relatives, from 2012 to 2016.
DICER1 gene analysis was carried out at the Institut Curie,
Paris, by Sanger sequencing or Next Generation Sequen-
cing. Genetic counselling was performed in various family
cancer clinics and hospitals.
Results. Germline DICER1 inactivating pathogenic
variants were identiﬁed in 43 probands (n= 43/101) and 45
relatives (n= 45/103). Most pathogenic variants were
identiﬁed in patients diagnosed with PPB (n= 27/35), CN
(n= 7/12) and OSLCT (n= 10/19). Germline pathogenic
variants were inactivating point mutations in DICER1
coding sequence or exon/intron junctions except two large
rearrangements and one deep intronic substitution. Seven
pathogenic variants were de novo, including a mosaic
variant.
Conclusion. This large cohort study conﬁrms that 77%
of PPB and 53% of OSLCT are associated with germline
DICER1 pathogenic variants. DICER1 gene analysis should
therefore be proposed to all patients diagnosed with any of
these lesions. Tumor-speciﬁc DICER1 variants could
explain some sporadic cases. Further studies are needed to
identify other genes involved in this syndrome.
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Acute myeloid leukemia in a case with Tatton-Brown-
Rahman syndrome: the peculiar DNMT3A R882-mutation
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Recently a novel syndromic form of overgrowth with
intellectual disability and distinct facial features was iden-
tiﬁed caused by constitutional mutations in the epigenetic
regulator DNA-methyltransferase 3A (DNMT3A), referred
to as Tatton-Brown-Rahman syndrome (TBRS). Somati-
cally acquired mutations in DNMT3A occur in hematolo-
gical malignancies and are frequently present in acute
myeloid leukemia (AML) affecting in the vast majority the
arginine residue at position 882 (R882). To date, none of
the reported cases with TBRS developed AML.
Here we present the ﬁrst case of a TBRS patient who
developed AML at the age of 15 years. Whole exome
sequencing identiﬁed a constitutional heterozygous
DNMT3A R882C-mutation. The patient exhibits macro-
cephaly, intellectual disability, distinct facial dysmorphisms
and other features ﬁtting with the TBRS phenotype. The
AML of the myelomonocytic subtype harbored only few
additional somatically acquired mutations, i.e. an aberrant
karyotype and a recurrent PTPN11-mutation. After rela-
tively uncomplicated AML treatment, he has persistent high
hemoglobin and thrombocytopenia without enough evi-
dence for polycythemia or myelodysplastic syndrome.
Interestingly, among the constitutional DNMT3A-muta-
tions in TBRS, residue R882 is only affected in a minority
of patients (4 out of 29, including our case described here),
which clearly differs from the somatic mutational spectrum
in AML. We speculate that the R882-mutation gives a more
potent predisposition for AML in contrast to the other
DNMT3A mutations.
In conclusion, our case represents the ﬁrst evidence that
TBRS patients might be at increased risk for the develop-
ment of hematological malignancies in particular AML.
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Introduction: This report compares the life factors, tumor
phenotype, family history and BRCA1/BRCA2 genotype of
early onset breast cancer (EOBC) between France and
North Africa (NA).
Methods: 455 women with invasive EOBC (≤40 years)
were prospectively included from 4 centers in France (n=
270) and 4 centers in NA (Algeria, Egypt, Morocco,
Tunisia; n= 185).
Results: We found an older age at menarche, a higher
number of childbearing, a longer duration of breastfeeding,
a higher body mass index, a lower use of oral contraceptives
in North African as compared to French women. TNM
stage at diagnosis was higher in North African women.
Incidence of triple negative and proliferative (Ki 67 index)
tumors was lower in NA. There was a lower rate of BRCA1
mutation in NA (7% vs 15%, P=0.02) but no difference for
BRCA2 mutation (8% vs 7%, P=0.583). The rate of
mutations in BRCA1/2 was higher for sporadic EOBC in
NA (BRCA1: 8% vs 1%, p<0.03 ; BRCA2: 7% vs 1%,
p<0.05). Three putative BRCA1/2 founder mutations were
identiﬁed in NA.
Conclusions: In EOBC, we found higher incidences of
triple negative and proliferative tumors in France as com-
pared to NA. This difference is not fully explained by the
higher incidence of BRCA1 mutations observed in French
women. It could be hypothesized that major differences
observed in life factors could inﬂuence the phenotype of
EOBC. The worst prognosis previously reported for EOBC
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in NA is more likely due to a higher stage at diagnosis than
to a more aggressive phenotype.
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Carcinoma of the uterus is one of the most common inva-
sive malignancy in women worldwide. Most endometrial
cancers are adenocarcinomas. The occurence of the endo-
metrial cancers may be connected with the genetic factors in
about 1% of cases. Hereditary endometrial cancer is a
genetic predisposition to cancer with an autosomal domi-
nant pattern of inheritance caused by mutations in the
MSH6 gene in the most of the cases. Herein, we describe a
family diagnosed with endometrial cancer in ﬁve women in
two generations caused by a novel mutation in the MSH6
gene. In immunohistochemistry performed on probands
endometrial cancer parafﬁn tissue block is the lack of
MSH6 protein expression. This mutation is a p. Thr767Ile
(c. 2300C>T) substitution. The novelty of this substitution
have been veriﬁed in a number of mutation databases as
well as large-scale genome sequencing databases. Func-
tional consequences of MSH6 T767I were predicted by
several algoritms using sequence and structural information.
MSH6 T767I was predicted deleterious that likely decreases
afﬁnity of MSH6 to MSH2 and decreases afﬁnity of MSH2/
MSH6 complex to DNA. Furthermore the mutations cose-
gregated with the disorder in family. To the best of our
knowledge, this is the ﬁrst description of MSH6 T767I
mutation in the literature that could be coupled with a
hereditary endometrial cancer.
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Introduction: Laryngeal cancers which constituting 2% of
adult tumors are one of the most common malignant tumors
of the head and neck region. The mortality rate of larynx
cancers which is responsible for around 7% of male deaths
in Turkey is quite high. In our study, it was aimed to detect
altered gene expression between primary laryngeal squa-
mous cell carcinoma and adjacent normal tissue.
Materials Methods: During surgery, tumor and normal
tissue samples were taken from the 12 patients who diag-
nosed larynx cancer as clinical and histopathological. Izo-
lated RNA was studied by whole genome expression
microarray method (Illumina iScan) and gene were identi-
ﬁed which expression signiﬁcantly increasing and decreas-
ing tumor tissue than in normal tissue.
Results: In study using 47,323 probe, expression dif-
ferences revealed at 14.294 mRNA. When the FC value is
considered to be 2 for the signiﬁcance of the expression
differences, increased expression of 22 genes and decreased
expression of two genes were observed. While the cell cycle
pathway and extracellular matrix degradation pathway are
the most active pathway, electron transport chain pathway is
one of the most repressed pathways according to the path-
way analysis of affected genes.
Conclusions: 11 new genes have been identiﬁed which
is differentially expressed in cancerous tissue compared to
normal tissue in addition to 13 genes known to be involved
in the etiology of laryngeal tumors. These genes which
identiﬁed for the ﬁrst time in our study, are thought to be
biomarker for early diagnosis, prognosis and targeted ther-
apy on larynx cancer patients.
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Introduction: Duodenal polyposis and cancer are important
but poorly understood causes of morbidity and mortality in
familial adenomatous polyposis (FAP) and MUTYH-
associated polyposis (MAP). This study aimed to char-
acterise somatic genetic changes in duodenal adenomas
from patients with FAP and MAP to better understand
duodenal tumorigenesis in these disorders.
Materials and methods: Sixty-nine duodenal adenomas
were biopsied during upper GI endoscopy in 16 FAP
patients and 10 MAP patients. Ten FAP, 10 MAP adenomas
and matched blood DNA samples were subjected to whole
exome sequencing; 42 further adenomas underwent targeted
sequencing and 47 were studied by array comparative
genomic hybridisation. Findings in duodenal adenomas
were compared to each other and to the reported mutational
landscape in FAP and MAP colorectal adenomas.
Results: MAP duodenal adenomas had signiﬁcantly
more protein-changing somatic mutations (p = 0.018),
truncating mutations (p = 0.006) and copy number variants
(p = 0.005) than FAP adenomas, even though MAP
patients had lower Spigelman stage duodenal polyposis.
Fifteen genes were mutated signiﬁcantly more than expec-
ted from the background mutation rate. Targeted sequen-
cing of APC, KRAS, PTCHD2 and PLCL1 identiﬁed further
mutations in each of these genes. In contrast to MAP and
FAP colorectal adenomas, neither exome nor targeted
sequencing identiﬁed any WTX mutations (P=0.0017).
Conclusions: The mutational landscapes in FAP and
MAP duodenal adenomas overlap with, but have signiﬁcant
differences to those reported in colorectal adenomas. The
signiﬁcantly higher burden of somatic mutations in MAP
than FAP duodenal adenomas could increase cancer risk in
lower Spigelman grade disease.
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Introduction: Ten percent of all gastric cancers show
familial aggregation. Whilst germline defects were found
for “hereditary diffuse gastric cancer” and “gastric adeno-
carcinoma and proximal polyposis of the stomach”,
“familial intestinal gastric cancer” (FIGC) remains geneti-
cally unexplained. We hypothesised that the rare FIGC
syndrome is caused by germline co-occurrence of moderate-
risk alleles and represent a polygenic, rather than a classical
monogenic disease. Therefore, we dissected the germline
and somatic landscapes of the largest FIGC cohort ever
studied.
Materials and Methods: Constitutional and tumour DNA
from 53 families, fulﬁlling clinical criteria of FIGC, were
screened for 55 candidate gastrointestinal cancer-associated
genes with Illumina’s MiSeq-platform, and classiﬁed
according to ACMG. Somatic loss of heterozygosity and
promoter methylation at potentially causative genes were
also searched for in FIGC tumours.
Results: 25/53 (47%) families carried germline variants,
and co-occurrence of germline moderate-risk alleles was
found in ten families. 7/10 families harboured one patho-
genic/likely pathogenic variant combined with one or more
unclassiﬁed novel variants. Three families carried clusters
of novel unclassiﬁed variants. Moderate-risk alleles of
BRCA2, MAP3K6, MSH6, MSR1, SDHB and SDHD were
the most frequently found in this cohort. Tumours arising in
these 10 families were enriched in somatic variants within
DNA repair genes and often display microsatellite
instability phenotype.
Conclusions: The clinical homogeneity and relatively
high number of FIGC families herein studied allowed
supporting the hypothesis that FIGC may be a polygenic
syndrome caused by moderate-risk alleles in gastrointestinal
cancer-associated genes. Grants; Fellowships: NORTE-07-
0162-FEDER-000118 and -000067; NSFC Foundation;
SFRH/BPD/89764/2012; /86543/2012; /79499/2011.
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P12.090B
Direct evidence for a polygenic etiology in familial multiple
myeloma
B. Halvarsson1, A. Wihlborg1, M. Ali1, K. Lemonakis1,2,
E. Johnsson1, A. Niroula1, C. Cibulskis3, N. Weinhold4, A.
Försti5,6, E. Alici7, C. Langer8, M. Pfreundschuh9, H.
Goldschmidt4,10, U. Mellqvist11, I. Turesson1, A. Waage12,
K. Hemminki5, T. Golub3, H. Nahi7, U. Gullberg1, M.
Hansson1,2, B. Nilsson1,3
1Hematology and Transfusion Medicine, Dept. of Labora-
tory Medicine, Lund University, Lund, Sweden, 2Hematol-
ogy Clinic, Skåne University Hospital, Lund, Sweden,
3Broad Institute, Cambridge, MA, United States, 4Depart-
ment of Internal Medicine V, University of Heidelberg,
Heidelberg, Germany, 5German Cancer Research Center,
Heidelberg, Germany, 6Center for Primary Health Care
Research, Lund University, Malmö, Sweden, 7Center for
Hematology and Regenerative Medicine, Karolinska Insti-
tutet, Stockholm, Sweden, 8Department of Internal Medicine
III, University of Ulm, Ulm, Germany, 9José-Carreras-
Center for Immuno- and Gene Therapy, Department of
Internal Medicine I, Saarland University Medical School,
Homburg (Saar), Germany, 10Germany and National
Center for Tumor Diseases, Heidelberg, Germany, 11Sec-
tion of Hematology, Sahlgrenska University Hospital,
Gothenburg, Sweden, 12Department of Cancer Research
and Molecular Medicine, Norwegian University of Science
and Technology, Trondheim, Norway
While common risk alleles for multiple myeloma (MM)
were recently identiﬁed, their contribution to familial MM is
unknown. Analyzing 38 familial cases identiﬁed primarily
by linking Swedish nation-wide registries, we demonstrate
an enrichment of common MM risk alleles in familial
compared to 1,530 sporadic cases (P=4.8×10−2 and 6.0×10
−2 respectively for two different polygenic risk scores) and
10,171 population-based controls (P=1.5×10−4 and 1.3×10
−4 respectively). Using mixture modeling, we estimate that
about one third of familial cases result from such enrich-
ments. Our results provide the ﬁrst direct evidence for a
polygenic etiology in a familial hematologic malignancy.
This work was supported by research grants from the
Swedish Foundation for Strategic Research (KF10-0009),
the Marianne and Marcus Wallenberg Foundation
(2010.0112), the Knut and Alice Wallenberg Foundation
(2012.0193), the Swedish Research Council (2012-1753),
the Royal Swedish Academy of Science, ALF grants to the
University and Regional Laboratories (Labmedicin Skåne),
the Medical Faculty at Lund University, the Swedish
Society of Medicine, the International Myeloma Founda-
tion, Multiple Myeloma Research Foundation, the German
Ministry of Education and Science (01ZX1309B), the
Harald Huppert Foundation and Deutsche Krebshilfe.
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Pfreundschuh: None. H. Goldschmidt: None. U. Mellq-
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P12.091C
Improving Appropriateness of Referrals for Familial Breast
Cancer in Primary Care
N. Qureshi, B. Dutton, C. Sheehan, S. Weng, J. Kai;
niversity of Nottingham, Nottingham, United Kingdom
Abstract Body
Introduction Breast cancer is the commonest cancer in
women, with up to 20% signiﬁcant inherited component.
Taking a family history in primary care can help identify
those at increased risk requiring specialist assessment.
However, this typically occurs in an opportunistic and
variable way, and it is unclear whether women are referred
appropriately, with implications for best care and use of
resources. This study aimed to explore whether an inter-
vention to proactively identify women at risk, and support
assessment, in primary care improves appropriateness of
referrals.
Methods and Materials Women, aged 30 - 60 years, in
four family practices were invited to complete a validated
family history questionnaire, providing information for
primary care practitioners to use in a familial breast cancer
risk assessment tool (FaHRAS), based on English NICE
guidelines for risk stratiﬁcation and specialist referral.
Women were followed-up for 16 months to determine
referral outcomes.
Results 1137 (16.22%) of 7012 eligible women partici-
pated. Among the 1337 women, 122 (10.73%) were
assessed at higher than average population risk with referral
to secondary care recommended. At 16 months, 69 women
had taken up offer of referral, and 59 (85.5%) of these were
conﬁrmed appropriate by specialist review, and offered
increased cancer surveillance.
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Conclusions This observational study suggests system-
atically identifying familial breast cancer risk in primary
care has potential to optimise referral for specialist assess-
ment and reduce breast cancer morbidity through increased
targeted surveillance. Further assessment of effectiveness in
a randomised trial is now needed.
Grant Reference: Project 206
N. Qureshi: None. B. Dutton: None. C. Sheehan:
None. S. Weng: None. J. Kai: None.
P12.092D
Male breast cancer susceptibility due to FANCM mutation:
a case report
R. Janavicius1,2
1Vilnius university Hospital Santariskiu Clinics, Hematol-
ogy, oncology and transfusion medicine center, Vilnius,
Lithuania, 2State Research Institute, Innovative Medicine
Center, Vilnius, Lithuania
Male breast cancer (MBC) is a rare, poorly understood
disease. Germline susceptibility to MBC is substantial and
mostly is conﬁned to BRCA2/BRCA1 genes mutations,
however majority familial MBC has no known genetic
basis. Recently, with the broader application of NGS, newer
female breast cancer (FBC) susceptibility genes were
established. Interestingly, a vast majority of FBC suscept-
ibility genes are related to Fanconi anemia pathway.
FANCM was recently identiﬁed as a moderate FBC pre-
disposition gene, with the preponderance to triple negative
BC. However, the contribution of these genes to MBC is
still understudied. Case report. 66 yrs old male patient was
referred to VULSK Oncogenetic Unit due to MBC diag-
nosed at the age of 65 (pT1cN0M0, ductal carcinoma G2,
ER-98%, PR-90%, HER2(FISH)(-)). Family history
showed prostate cancer in paternal uncle (dx 87). As part of
routine comprehensive genetic testing, the patient under-
went 96 cancer genes TruSight Cancer NGS testing panel
on MiSeq (Illumina). Truncating FANCM (NM_020937)
gene mutation c.5101C>T (p.Gln1701*) was identiﬁed; no
other pathogenic/likely pathogenic genes mutations were
revealed. During predictive testing, healthy daughter carrier
(age 29) was identiﬁed. Discussion: From the newly iden-
tiﬁed FBC genes to date, only PALB2 was associated with
possible MBC risk. No clear FANCM involvement in MBC
susceptibility was demonstrated in published studies; only
one MBC case (untested) was noted in a family with
FANCM c.5791C>T mutation from Spain. Conclusion:
FANCM c.5101C>T in MBC patient is reported for the ﬁrst
time, highlighting potential contribution of FANCM to
MBC susceptibility. Funding: Lithuanian Research Coun-
cil, SEN18/2015.
R. Janavicius: None.
P12.093A
Hereditary leiomyomatosis and renal cell cancer: Descrip-
tion of the families identiﬁed at the Catalan Institute of
Oncology
A. Teule1, J. del Valle2, E. Grau1, M. Pineda2, M.
Navarro1, A. Stradella1, A. Izquierdo3, M. Salinas1, S.
Iglesias1, S. Gonzalez2, A. Solanes4, E. Darder3, A.
Velasco3, G. Capellá2, L. Feliubadaló2, M. Menendez2, E.
Tornero2, C. Lazaro2, J. Brunet3
* Genetic Counseling Unit. Hereditary Cancer Program-
CIBERONC, Institut Català d’Oncologia, L'Hospitalet,
Spain, 2Molecular Diagnostics Unit. Hereditary Cancer
Program-CIBERONC. Institut Català d'Oncologia, L'Hos-
pitalet, Spain, 3* Genetic Counseling Unit. Hereditary
Cancer Program-CIBERONC, Institut Català d’Oncologia,
Girona, Spain, 4* Genetic Counseling Unit. Hereditary
Cancer Program-CIBERONC, Institut Català d’Oncologia,
Badalona, Spain
Introduction: Hereditary leiomyomatosis and renal cell
cancer (HLCCR) is an autosomal dominant genodermatosis
with a very low incidence predisposing to cutaneous and
uterine leiomyomas and renal cancer. It's caused by germ-
line mutations in the Fumarate Hydratase (FH) gene.
Material and methods: We have reviewed the families
visited in our institution from 1998 to the present, identi-
fying in our database 6 families with a FH germline test
because of their clinical characteristics. 4 were studied with
direct sequencing, 2with techniques of massive sequencing.
Results: 5 familes with FH mutations (80%) have been
identiﬁed, these mutations are all distinct. In these families,
a total of 11 individuals were studied, with mutations
detected in 10 (91%). Among the carriers the average age at
time of study was 53 years. 70% women, 30% men. Three
cases of renal cancer (30%) have been detected, one of them
bilateral, with a mean age at diagnosis of 48 years (histol-
ogies: 2 hypernefromas (1 bilateral) and 1 papillary. Cuta-
neous leiomyomas have been detected in 70% of cases and
6/7 (85%) women have uterine ﬁbroids, with 3 with hys-
terectomies (42%) at a mean age of 31 years. Only 1/5
families (20%) had no individuals with suspected skin
lesions. Among other neoplasms in carriers, metastatic
colon cancer stands out at 57 years.
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Conclusions: Families with HLCCR are infrequent.
Although cutaneous and uterine leiomyomatosis is the most
frequent manifestation, about 30% of cases are associated
with renal cancer, generally aggressive. Not all families
have cutaneous manifestations, which could make diagnosis
difﬁcult.
A. Teule: None. J. del Valle: None. E. Grau: None. M.
Pineda: None. M. Navarro: None. A. Stradella: None. A.
Izquierdo: None. M. Salinas: None. S. Iglesias: None. S.
Gonzalez: None. A. Solanes: None. E. Darder: None. A.
Velasco: None. G. Capellá: None. L. Feliubadaló: None.
M. Menendez: None. E. Tornero: None. C. Lazaro:
None. J. Brunet: None.
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Deep excavation of gallbladder carcinoma genomes using
targeted sequencing
S. Yadav1, N. Sarkar2, A. Kumar1, N. Kumari1, B. Mittal3
1SGPGIMS Lucknow, Lucknow, India, 2Fred Hutchinson
Cancer Research Centre, Seattle, WA, United States,
3Babasaheb Bhimrao Ambedkar University, Lucknow, India
Gallbladder carcinoma is common carcinoma of the hepa-
tobiliary tract, its late diagnosis makes it fatal type of cancer
with very poor prognosis. Unlike other common cancers,
GBC remains under-studied as only a few small-scale
mutational investigations have been reported yet. This study
is the ﬁrst ever effort to perform ultra-deep sequencing
across 409 AmpliSeq comprehensive cancer panel genes, on
11 GBC patients from North-Indian descent. We have
identiﬁed nonsynonymous somatic and rare germline dele-
terious and likely deleterious mutations. We detected
highest number of somatic mutations in the exonic regions
of SYNE1 and NBPF9 genes. Bona-ﬁde cancer associated
genes like TP53, SMAD4, APC were also observed to be
frequently mutated. In addition, we detected high impact
somatic mutations in novel genes (table) in GBC, these
genes are known to play a role in carcinogenesis in common
cancers. All the early onset cases or hyper-mutated cases
harbour mutation(s) in critical DNA repair genes. Our
results indicate signiﬁcance of inherited germline mutations
in DNA repair pathway genes in addition to acquired
somatic mutations in GB tumorigenesis. Additionally, by
considering the entire pool of germline and somatic muta-
tions, possible clinical strategies for each tumour could be
assessed. This study highlights importance of comprehen-
sively studying mutation proﬁles in rare tumour types such
as GBC to realistically achieve the goals of precision
medicine.
Table: Detected novel genes mutations in GBC.
CASE
NUMBER
CHR:
COORDINATE
NOVEL GENE
WITH
MUTATIONS
MUTATIONS IN
COSMIC (GB
ADENOCARCINOMA
S1 chr14:99641509 BCL11B 0
S8 chr15:99434685 IGF1R 0
S1 chr8:145739015 RECQL4 0
S1 chr7:13978764 ETV1 0
S4 chr3:12475559 PPARG 0
S5 chr17:17127274 FLCN 0
S5 chr4:123374914 IL2 0
S5 chr9:120475302 TLR4 0
S5 chr9:120475602 TLR4 0
S8 chr1:147092612 BCL9 0
S8 chr10:96540292 CYP2C19 0
S10 chr1:147095804 BCL9 0
S. Yadav: None. N. Sarkar: None. A. Kumar: None.
N. Kumari: None. B. Mittal: None.
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CDH1 missense variant disrupts N-glycosylation and pro-
motes gastric cancer
L. Pena1, S. Melo2,3,4, J. Perea5, F. Mercadillo1, J.
Figueiredo2,3, J. Sanches6, A. Sánchez7, L. Robles8, R.
Seruca2,3,4, M. Urioste1,9
Spanish National Cancer Research Centre (CNIO), Madrid,
Spain, 2Instituto de Investigação e Inovação em Saúde
(i3S), University of Porto, Porto, Portugal, 3Institute of
Molecular Pathology and Immunology of the University of
Porto (IPATIMUP), Porto, Portugal, 4Medical Faculty of
the University of Porto, Porto, Portugal, 5Surgery Depart-
ment and Digestive Cancer Research Group, University
Hospital 12 de Octubre, Madrid, Spain, 6Institute for
Systems and Robotics, Instituto Superior Técnico, Lisboa,
Portugal, 7Medical Oncology Service, University Hospital
Puerta de Hierro, Madrid, Spain, 8Medical Oncology
Service, University Hospital 12 de Octubre, Madrid, Spain,
9Centre for Biomedical Network Research on Rare Diseases
(CIBERER), Madrid, Spain
Introduction: Germline mutations in the CDH1 tumor
suppressor gene are associated to Hereditary Diffuse Gastric
Cancer (HDGC), which predisposes to a higher risk to
develop diffuse gastric cancer and lobular breast cancer.
Prophylactic gastrectomy is usually considered in carriers of
CDH1 pathogenic mutations, but management of patients
carrying missense variants is complicated and there is a
need to assess the functional impact in the E-cadherin
protein.
Material and Methods: Genetic screening of CDH1
identiﬁed three unrelated Spanish families with HDGC that
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harbored the same missense variant of uncertain clinical
signiﬁcance. In order to determine the outcome of this
variant, we performed genetic studies, together with in
silico and in vitro functional analyses.
Results: The consequent amino acid shift disrupts a
consensus NST sequence required for N-glycosylation, a
relevant modiﬁcation for proper E-cadherin status. Con-
sistent with this, every tool used supported a pathogenic
effect of the variant. The variant segregated with the disease
and was not found in a control cohort, in silico analyses
predicted the variant as deleterious and in vitro approaches
revealed an impairment in the protein’s ability for cell
aggregation, an irregular pattern of E-cadherin expression
and an increased invasive ability of mutant cells.
Conclusions: Our work demonstrates the pathogenic
effect of the variant found and hence allows us to accom-
plish an accurate genetic counseling in the three families.
Work supported by MINECO and FEDER (PI14/00459).
First author holds a FPI fellowship funded by MINECO and
FSE.
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Exome sequencing method applied for molecular genetics
study of gastric cancer
A. Nurgalieva1, L. Yusupova1, O. Antonova1, M.
Yankina2, F. Munasipov3, D. Sakaeva3, E.
Khusnutdinova1,4
1Bashkir State University, Ufa, Russian Federation, 22Insti-
tute of Biochemistry and Genetics, Ufa Scientiﬁc Center,
Russian Academy of Sciences, Ufa, Russian Federation,
3State Institution of Health Republican Clinical Oncology
Center of the Ministry of Health of the Republic of
Bashkortostan, Ufa, Russian Federation, 4Institute of
Biochemistry and Genetics, Ufa Scientiﬁc Center, Russian
Academy of Sciences, Ufa, Ufa, Russian Federation
Gastric cancer (GC) - one of the most common cancers in
the world. The aim of this study was to ﬁnd new candidate
genes associated with the risk of gastric cancer. This study
enrolled 16 samples of DNA isolated from the tumor and
adjacent to it a normal stomach tissue of patients with
gastric cancer (GC) with the adenocarcinoma of the sto-
mach. The DNA fragmentation, preparation of libraries and
capture exome were performed in accordance with the
manufacturer's instructions. Select speciﬁc DNA fragments
was performed using the SureSelect system with subsequent
parallel sequencing on Illumina received library technology
on the device HiSeq 2000. Discovered annotated using
ANNOVAR program. The analysis has revealed an average
33134 nucleotide sequence changes in normal tissue
(including 3.3% have mutations that lead to frame shift
reading, 40.0% - nonsynonymous substitutions, 0.3% -
mutations that lead to the formation of stop codons) and
38960 - in the tumor tissue (including 3.3% have mutations
resulting in a frame shift, 37.1% - nonsynonymous sub-
stitutions, 0.4% - mutations that lead to the formation of a
stop codon). Each sample showed an average of
7516 somatic mutations. With the highest frequency of
mutations identiﬁed in genes TP53AIP1, ARID1A,
PDGFRA, SEPT9, CACNA1G, PCDH17, NDRG2,
SUPT16H, MLLT10. Also found pathogenic changes in
genes whose role in gastric cancer has not been described
previously. To determine the functional signiﬁcance of the
identiﬁed options and the involvement of the genes found in
the pathogenesis of the disease requires further in-depth
analysis of the results.
A. Nurgalieva: None. L. Yusupova: None. O. Anto-
nova: None. M. Yankina: None. F. Munasipov: None. D.
Sakaeva: None. E. Khusnutdinova: None.
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Genetic and clinical heterogeneity in families with gastric
neuroendocrine tumors
O. Calvete1, M. Herraiz2, J. Reyes3, A. Patiño4, J. Benitez1
Centro Nacional de Investigaciones Oncologicas (CNIO),
Madrid, Spain, 2Department of Gastroenterology. Univer-
sity Clinic of Navarra, Pamplona, Spain, 3Department of
Gastroenterology, Hospital INCA, Majorca, Spain,
4Department of Pediatrics and Clinical Genetics Unit,
University Clinic of Navarra, Pamplona, Spain
Type I gastric neuroendocrine tumors (gNETs) classically
arise from hypergastrinemia. gNETs cause parietal cells
(PC) destruction that are responsible of gastric acid secre-
tion through ATP4A proton pump and correlates with
achlorhydria. However, we have described different gNET
familial cases with mutations in genes that affect the func-
tion and viability of PCs that affect gastric acidiﬁcation. By
NGS, we recently identiﬁed a homozygous deleterious
mutation in the ATP4A gene that explained an aggressive
familial form of gNETs. The achlorhydria was described as
the causative parameter of the hypergastrinemia that
develops gNET. A second family with eleven siblings and
three affected members with classic clinic of gNETs plus
hypothyroidism and rheumatoid arthritis was also studied
and a missense mutation in heterozygosis in ATP4A was
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identiﬁed. Carriers of this variant had low ferritin levels but
without gNETs development. By WES, a second hetero-
zygous mutation in a novel gene, PTH1R p.E546K, was also
uncovered. Gastrin also activates PTHLH/PTH1R regula-
tion factor, which is involved in PC development. Activa-
tion of PTH/PTH1R, which is upregulated by thyrotropin in
thyroid, is also involved in RANKL expression to regulate
bone homeostasis. Thyrotropin and RANKL expression
were found deregulated in those members carrying PTH1R
mutation plus hypothyroidism and rheumatoid arthritis
suggesting a link between PTH1R gene and these pathol-
ogies and gastric disease. Both mutations in ATP4A and
PTH1R genes suggest a digenic model for this family and
contribute to the function and viability of PC and lead to the
achlorhydria that drives hypergastrinemia and gNETs
instead of classic assumption.
O. Calvete: None. M. Herraiz: None. J. Reyes: None.
A. Patiño: None. J. Benitez: None.
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Use of a custom-designed NGS-hereditary cancer panel
increases the diagnostic yield in the clinical setting
J. del Valle1, L. Feliubadaló1, A. Stradella1,2, E. Grau1, E.
Tornero1, M. Menéndez1, M. Pineda1, E. Montes1, C.
Gómez1, R. Cuesta1, O. Campos1, M. Salinas1, S.
González1, E. Castellanos3, B. Gel3, S. Iglesias1, À.
Velasco4, E. Darder4, A. Solanes5, M. Navarro1,5, À.
Izquierdo4, J. Sanz6,7, I. Guasch7, J. Balmaña8, À.
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d’Oncologia (ICO), L'Hospitalet de Llobregat, Spain,
3Hereditary Cancer Program-CIBERONC, IGTP-PMPPC,
Badalona, Spain, 4Hereditary Cancer Program-CIBER-
ONC, Institut Català d’Oncologia ICO-IDIBGI, Girona,
Spain, 5Hereditary Cancer Program-CIBERONC, Institut
Català d’Oncologia ICO-IGTP, Badalona, Spain, 6Familial
Cancer Risk Evaluation Unit, Oncology Service, H.
General de Vic, Vic, Spain, 7Familial and Hereditary
Cancer Unit, Hospital de Sant Joan de Déu- Althaia,
Manresa, Spain, 8High Risk and Cancer Prevention Unit,
Medical Oncology Department, University Hospital Vall
d’Hebron, Universitat Autònoma de Barcelona, and Vall
d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Objectives: Mutation analysis of 122 genes in a cohort of
432 patients with clinical suspicion of hereditary cancer.
Evaluation of the diagnostic yield.
Materials and Methods: NGS using a custom panel (1,2)
analysed in a two-tiered mode. In a ﬁrst “diagnostics stage”
a speciﬁc subset of genes is analyzed depending on the
clinical categorization of the patients; in a second “research
stage”, the whole panel is investigated.
Results: The table below summarizes the number of
patients with putative pathogenic mutations. It can be
observed that the second stage analysis identiﬁed mutations
in an additional 10% of the patients.
Clinical
Suspicion
n +ve
Diagnostics
Additional +ve
Research
HBOC 215 31 27
HNPPC 129 41 13
FAP/AFAP 18 3 3
Others 70 14 2
432 89 (21%) 45 (10%)
Currently a panoramic view of the variation spectrum
landscape is under evaluation in order to investigate the role
of genetic modiﬁers.
In addition, in 10 patients more than one pathogenic
mutation was detected (2.3%), consistent with the existence
of the so-called MINAS syndrome (Multilocus Inherited
Neoplasia Alleles) (see abstract of Stradella et al.).
Conclusions: Our developed NGS-strategy led to an
increase of the diagnostics yield in our clinical setting,
improving clinical management of our patients as well as
providing a better knowledge of the genetic bases of her-
editary cancer.
(1,2) Castellanos et al., and Feliubadaló et al., Scientiﬁc
Reports, 2017-Jan.
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Genetic alterations in benign prostatic hyperplasia patients
by FISH
M. S. Aly1, H. M. Mohamed1, T. H. Dardeer2; Faculty of
Science, Beni-Suef University, Beni-Suef, Egypt, 2Faculty
of Science, Cairo University, Cairo, Egypt
Introduction: Benign prostate hyperplasia [BPH] is the
classical age related disease of prostate, present in 20% of
men at the age of 40 years with progression to 70 % by the
age of 60 years. BPH is associated with various lower
urinary tract symptoms, which affect their day to day life.
Materials and Methods: Our objective was to evaluate
the association between HER-2/neu, c-myc, p53, and clin-
icopathologic variables in 47 patients diagnosed with
benign prostatic hyperplasia patients using ﬂuorescence
in situ hybridization (FISH). The patients underwent
transurethral prostate resection to address their primary
urological problem. All patients were evaluated by use of a
comprehensive medical history and rectal digital examina-
tion. The preoperative evaluation also includes serum
prostate-speciﬁc antigen (PSA) measurement and ultra-
sonographic measurement of prostate volume. Prostate
cancer was detected in two patients, who were then exclu-
ded from the study. The mean age of the 45 patients was
66.8±7.2 years. The mean PSA value of patients was 6.7
±7.0 ng/mL. The mean prostate volume was 56.6±24.9 mL.
Results: Ampliﬁcation of HER-2/neu was seen in 4/45
(8.8%) cases and ampliﬁcation of c-myc was seen in 7 of 45
(15.5%) cases; neither was associated with adverse clin-
icopathologic variables. Deletion of p53 was seen in 31/45
(68.8%) cases. This study found that p53 deletion is a
common genetic alteration in BPH.
Conclusions: In this study, we discuss genetic markers
in benign prostatic hyperplasia patients which may, in the
future, be used as markers for diagnosis and prognosis, as
well as targets for therapeutic intervention.
M.S. Aly: None. H.M. Mohamed: None. T.H. Dar-
deer: None.
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MiRNA proﬁling of gastrointestinal stromal tumors by next
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Introduction: Deregulation of miRNAs has been observed
virtually in all major types of cancer, whereas the miRNA
signature in GIST is not well characterized yet. In this study
the ﬁrst high-throughput miRNA proﬁling of GIST was
performed and differentially expressed miRNAs, as well as
isomiRNAs, were deﬁned. Materials and Methods: miRNA
proﬁle of 15 paired GIST and adjacent normal tissue sam-
ples was determined using small RNA-seq approach.
Highly signiﬁcantly deregulated miRNAs were selected for
validation by Taq-Man low-density array in replication
group of 40 paired samples. Validated miRNAs were fur-
ther subjected to the miRNA set enrichment analysis. Fur-
ther, we used an integrated analysis of miRNA-mRNA
correlations for KIT and PDGFRA target genes. All statis-
tical analyses were performed using the in-house bioinfor-
matics pipelines and statistical computing environment R.
Results: 110 miRNAs were identiﬁed to be differentially
expressed in GIST by small RNA-seq approach and 19 were
veriﬁed to be associated with GIST after validation (13
novel associations). Enrichment analysis revealed sig-
niﬁcantly enriched KEGG pathways in the main GIST
associated pathways and a signiﬁcant correlation was found
between all of the enriched miRNAs and their target gene
KIT. Results of the phenotype analysis showed miR-509-3p
to be up-regulated in epithelioid and mixed cell types
compared to spindle type, whereas miR-215-5p showed
negative correlation with risk grade of GIST. Conclusions:
Our data reveal a detailed miRNA proﬁle of GIST and
highlight new candidates that may be important in the
development of malignant disease. Supported by the
Research Council of Lithuania (Grant No: MIP-006/2014).
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Genotype-phenotype correlations in Gorlin syndrome
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Introduction: Gorlin syndrome (GS) is an autosomal
dominant syndrome leading to multiple basal cell carcino-
mas and an increased risk of jaw cysts and brain tumours.
Individuals with GS can manifest a wide range of pheno-
typic abnormalities, with about 5% of affected individuals
developing a medulloblastoma in early life. Gorlin syn-
drome is associated with germline mutations in components
of the Sonic Hedgehog pathway (SHH) including Patch1
(PTCH1) and SUFU.
Methods: We analysed 182 patients with clinical features
of GS and correlated their phenotype with their germline
mutation status. A total of 126 patients had a heterozygous
pathogenic PTCH1 variant, 9 had SUFU pathogenic var-
iants and 46 had no identiﬁed mutation.
Results: Patients with PTCH1 variants were more likely
to be diagnosed earlier (p=0.02), have jaw cysts (p=0.002)
and have biﬁd ribs (p=0.003) or any skeletal abnormality
(p=0.003) than patients with no identiﬁed mutation.
Patients with a missense variant in PTCH1 were diagnosed
later (p=0.03) and were less likely to develop at least 10
BCCs and jaw cysts than those with other pathogenic
PTCH1 variants (p=0.03). Patients with SUFU pathogenic
variants were signiﬁcantly more likely than those with
PTCH1 pathogenic variants to develop a medulloblastoma
(p=0.009), a meningioma (p=0.02) or an ovarian ﬁbroma
(p=0.015), but were less likely to develop a jaw cyst
(p=0.0004).
Conclusions: We have identiﬁed a number of features
that predict the presence of a PTCH1 or SUFU mutation as
well as showing that missense mutations in PTCH1 may be
associated with a milder phenotype.
G. Evans: None. D. Oudit: None. M.J. Smith: None.
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Germline mutational spectrum of Armenian HBOC patients
analyzed with multigene panel
D. Babikyan1,2, M. Moradian1
1Center of Medical Genetics and Primary Health Care,
Yerevan, Armenia, 2Yerevan State Medical Univesity after
Mkhitar Heratsi, Yerevan, Armenia
Background: Genetic counselling and testing of hereditary
breast and ovarian cancer (HBOC) are not appropriately
provided in Armenia, and no data was available on the
genetic background of HBOC in this homogeneous popu-
lation. Given NGS allows cost-effective testing of a panel of
genes with high and intermediate/low risk of HBOC, we
studied the spectrum of genetic variations among 39
patients selected according HBOC clinical criteria.
Methods: 14 genes with known hereditary risk on HBOC
were screened by NGS analysis with minimum coverage of
100x depth), including BRCA1, BRCA2, CDH1, PALB2,
PTEN, STK11, TP53, ATM, BARD1, BRIP1, CHEK2,
MRE11, NBN, and RAD50.
Results: 22 patients had only BC at young age of
diagnosis (56%, mean age at diagnosis 36 years) and 17
patients had also a family history of the disease (mean age
at diagnosis 40 years). 5 and 4 pathogenic variants were
identiﬁed in high risk genes BRCA1 and BRCA2, respec-
tively. 12 variants of uncertain signiﬁcance were detected in
5 genes (BRIP1, BRCA1, BRCA2, BARD1, CHEK2), and 18
other benign/likely benign variants were identiﬁed in six
genes.
Conclusions: A multigene panel testing revealed
pathogenic mutations only in high susceptibility genes and
contributes in the diagnosis of HBOC patients to beneﬁt of
surveillance strategies. However, a proportion of patients
with clinical criteria for HBOC had no known germ-line
mutations, and another proportion of patients were found
with novel and/or variants of uncertain signiﬁcance in high,
moderate and low penetrance genes for which no genetic
counselling or management guidelines are available yet.
D. Babikyan: None. M. Moradian: None.
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The results of BRCA1 and BRCA2 testing in a cohort of
patients in the Department of medical genetics in the
Teaching hospital of Olomouc
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V. Curtisova1, M. ídková2, R. Kratochvílová1
Department of Human Genetics, Fakultní nemocnice
Olomouc, Olomouc, Czech Republic, 2Slezská nemocnice
v Opavě, Opava, Czech Republic
BRCA1- and BRCA2-associated hereditary breast and
ovarian cancer syndrome (HBOC) is the cause of 5–10%
breast cancers. Mutation testing should be undertaken fol-
lowing a genetic consultation in eligible patients, either as a
diagnostic or predictive test.
We set out to determine if in the 146 patients tested in the
lab of the Department of Clinical Genetics of the Teaching
Hospital of Olomouc during 2013 the indication criteria
were fulﬁlled, what was the detection rate, which mutations
were found, what percentage of mutations would be
detected by DTC testing offered in Czechia and what was
the sex ratio of predictively tested patients.
The indication criteria were not fulﬁlled in 14 (9.5%)
patients, in none of them was a mutation found. 88 (60%)
patients were tested because of a disease occurrence - a
mutation was found in 15(17%, 9 in BRCA1, 6 in BRCA2).
18 (12%) patients were tested because of a positive family
history and an impossibility of testing the index case - a
mutation was found in 1 (5%, BRCA2).
All mutations were unique. DTC kit would detect 3/9
(33%) BRCA1 mutations and 1/7 (14%) BRCA2 mutations.
12/16 (75%) mutations would not be detected.
Out of the 40 predictively tested patients 26(65%) were
female and 14(32%) were male.
Our results conﬁrmed good adherence to indication cri-
teria, good sensitivity of indication criteria, increased
interest in predictive testing in women compared to men
and poor detection rate of the DTC kit.
V. Curtisova: None. M. ídková: None. R. Kra-
tochvílová: None.
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Next-Generation Sequencing in uniformly treated Head and
Neck Squamous Cell Carcinoma within Spanish population,
preliminary results
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Rubio Casadevall4, C. García Girón5, L. Iglesias6, S.
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Introduction: Head and neck squamous cell carcinoma
(HNSCC) is the sixth most common neoplasia in the
developed world. Tobacco smoking and alcohol consump-
tion are the most classical risk factors although viral etiol-
ogy is an established factor too. However, both ways
represents a distinct clinical and epidemiological entity.
Next-generation sequencing (NGS) technologies have
identiﬁed genetic alterations, transforming illness diag-
nostics and therapeutics. Targeted sequencing has become
an easier and cheaper tool in the analysis of those genes
previously correlated with HNSCC.
Materials and methods: 162 head and neck squamous
cell carcinoma formalin-ﬁxed parafﬁn-embedded blocks
were included in this study. All of them belong to the
clinical trial TTCC-2007-01. After deparafﬁnization and
DNA extraction, we performed the TruSight Tumour 26
panel technology. VCF ﬁles were read in the Variant Studio
Software.
Results: 134 (82.7%) patients carry one or more patho-
genic mutations in the 26 genes amplicon-based panel,
while 28 (17.3%) do not have any mutations. Although not
signiﬁcant, we found a tendency between 27 (16.7) HPV+
tumours and a lower mutation percentage than mutated
ones, p=0.063. Furthermore this distribution seems to be
related with sex, where HNSCC in women have less
mutations than men, p=0.056. However we do not ﬁnd any
association between mutation status and other clin-
icopathologic features or response to treatment.
Conclusion: Female sex and HPV+ infection are asso-
ciated to lower mutations in HNSCC in classical driver
genes. This result corroborates different HPV etiology in
HNSCC. Studies in larger groups should be done to reply
these results.
J. Fernández Mateos: None. J. Pérez García: None. R.
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Fusion chimeras between HBV and humans in HCC
development
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gapore, 6Genome Institutue of Singapore, Singapore,
Singapore
Hepatocellular carcinoma (HCC) is a deadly cancer of the
liver due to late detection and the limited interventional
methods. Chronic infection by Hepatitis B virus (HBV) is
associated with this cancer and it is known that the genome
of the virus can integrate into the genome of the host cell
during a chronic HBV infection leading to a series of events
that can potentially alter host cells leading to tumorigenesis.
Transcriptome proﬁling of the tumors and adjacent non-
tumorous tissues of 25 HBV-HCC patients using Next-
Generation Sequencing Technology reveals that differen-
tially expressed transcripts are mainly involved in cell-cycle
regulation and several are associated with clinical char-
acteristics. An average of 230 somatic mutations was
identiﬁed in in each patient. Greater than 90% of the
somatic mutations are genic. Greater than one type of HBx-
Human chimeric transcripts was observed in each patient
with tumor tissue harboring less variety of chimeric tran-
scripts than the adjacent non-tumorous tissues.
A few chimeric HBx-Human transcripts were recapitu-
lated in the non-transformed LO2 liver cell-line. Interest-
ingly, one chimeric transcript exhibited faster cell
proliferation, higher resistance to induced apoptois and was
able to transform the non-transformed LO2 cell-line.
Expression proﬁle of this chimeric transcript compared to
the wild-type revealed 151 genes to be deregulated. Char-
acterization of these deregulated genes is in progress.
We would like to acknowledge the National Medical
Research Council (NMRC), Singapore for funding this
project (CBRG14nov034 and NMRC/CBRG/0095/2015).
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Introduction: Cancer genetics services for the population
of British Columbia, Canada are provided solely by the BC
Cancer Agency’s Hereditary Cancer Program (HCP). In
October 2014, the HCP introduced a multi-gene panel for
affected adults meeting speciﬁc phenotypic-based testing
criteria for at least one syndrome on the panel. Testing
criteria for Hereditary Breast and Ovarian Cancer Syndrome
(BRCA1, BRCA2) have shown variable mutation detection
rates. Based on preliminary data, the criterion of 3 breast
cancer (BrCa) cases in a family with one diagnosed at age
50 years or younger has a mutation detection rate of only
4%.
Materials and Methods: 179 patients met the criterion of
3 BrCa cases with one diagnosed at age 50 or younger, 8 of
which tested positive for presumed pathogenic variants in
BRCA1 or BRCA2. We calculated BOADICEA and Man-
chester scores for all mutation positive pedigrees and 10%
of uninformative pedigrees.
Results: The mean BOADICEA scores for unin-
formative versus positive pedigrees were 13.8% and 23.1%,
respectively (p= 0.41), and the mean Manchester scores
were 18 and 24, respectively (p= 0.21).
Conclusion: While risk prediction methods BOADICEA
and Manchester have higher mean scores for positive versus
uninformative pedigrees, the range in scores was large. Our
preliminary ﬁndings reveal the variability within families
that meet this criterion. Further analysis of families with
uninformative testing may help clarify the subset of cases
for which targeted enrichment within the current criterion
could improve mutation detection rates.
V.K. Beard: None. A.C. Bedard: None. J.E.J. Bedard:
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Case-control analysis of truncating mutations in DNA
damage response genes connects TEX15 and FANCD2 with
hereditary breast cancer susceptibility
A. Tervasmäki1, T. Mantere1, A. Nurmi2, K. Rapakko3,4, S.
Kauppila5, J. Tang6, J. Schleutker7, A. Kallioniemi8, J. M.
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Background Several known hereditary breast cancer sus-
ceptibility genes encode proteins involved in DNA damage
response (DDR) and are characterized by rare loss-of-
function mutations. However, these explain less than half of
the familial cases. To identify novel susceptibility factors,
39 rare truncating mutations, identiﬁed in 189 Northern
Finnish hereditary breast cancer patients in parallel
sequencing of 796 DDR genes, were studied for disease
association.
Methods Mutation screening was performed for North-
ern Finnish breast cancer cases (n= 578–1565) and controls
(n= 337–1228). Four mutations showing potential cancer
association were analyzed in additional Finnish cohorts.
Results A duplication leading to premature stop codon in
TEX15, a gene encoding a DDR factor important in meiosis,
associated with hereditary breast cancer (p=0.018,
OR=14.6) and likely represents a Northern Finnish founder
mutation. The duplication was stable at mRNA level,
whereas another studied TEX15 nonsense mutation pro-
duced a null allele and did not show association. A dele-
terious splice site mutation in the Fanconi anemia gene,
FANCD2, was over two times more frequent in the com-
bined Finnish hereditary breast cancer cohort compared to
controls. A deletion in RNF168, involved in BRCA1-
mediated DDR and causative for recessive RIDDLE syn-
drome, had high prevalence in majority of the analyzed
cohorts, but did not associate with breast cancer.
Conclusions Protein truncating variants in TEX15 and
FANCD2 are potential breast cancer risk factors, warranting
further investigations in other populations. Furthermore,
high frequency of the identiﬁed RNF168 deletion indicates
the need for its testing in Finnish patients with RIDDLE
syndrome symptoms.
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Novel candidate alleles for hereditary breast cancer identi-
ﬁed in Greek families via whole exome sequencing
S. Glentis1, A. C. Dimopoulos1, K. Rouskas1, F. Fostira2,
I. Konstantopoulou2, A. S. Dimas1, D. Yannoukakos2, J.
Ragoussis3,1
1BSRC Alexandrer Fleming, Athens, Greece, 2NCSR
Demokritos, Athens, Greece, 3McGill University and
Genome Quebec Innovation Centre, Montreal, QC, Canada
Introduction: Approximately ~10% of breast cancer (BC)
cases are hereditary (HBC) and are caused by loss-of-
function (LoF) mutations in known genes. HBC is
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suspected when familial clustering of BC is observed, or
when BC is diagnosed at a young age. To date, LoF alleles
in over 20 genes have been associated to HBC suscept-
ibility. However, the genetic aetiology for a large fraction of
cases remains unexplained and additional causal variants
are expected to be found. The aim of this project was to
identify novel genetic variants linked to HBC in Greek
patients who were negative for mutations in known HBC
genes.
Subjects and Methods: Whole exome sequencing (WES)
was performed on 52 individuals (33 patients and 19 rela-
tives). Following variant calling, we applied three prior-
itization strategies to shortlist HBC candidate variants.
Variants were ﬁltered further by interrogating BC patient
data of The Cancer Genome Atlas (TCGA).
Results:We identiﬁed twelve variants (ten missense, one
stop gain and one splice variant), as the most likely can-
didates for HBC susceptibility. Of these, three variants were
found in unrelated patients and nine were also present in BC
TCGA patients.
Conclusion: Candidate variants detected in Greek
families map in genes involved in distinct biological pro-
cesses. Variants in genes involved in DNA repair (PARP9,
ERCC4) and cell proliferation (DIS3L2) are interesting
candidates to take forward to functional studies to explore
their possible role in cancer pathogenicity. Funding was
provided by NSRF 2007–2013 (SYN11_10_19) and the
Stavros Niarchos Foundation.
S. Glentis: None. A.C. Dimopoulos: None. K. Rous-
kas: None. F. Fostira: None. I. Konstantopoulou: None.
A.S. Dimas: None. D. Yannoukakos: None. J. Ragoussis:
None.
P12.109A
Hereditary breast/ovarian cancer families: beyond BRCA1
and BRCA2
S. Fragoso1, S. Santos1, B. Mira2, P. Machado1, A. Luís3,
A. Clara3, A. Opinião3, S. Bento3, I. Miguel3, P.
Rodrigues3, J. Parreira3, C. Simões3, F. Vaz3
Molecular Biology Department - Portuguese Institute of
Oncology Francisco Gentil, Lisbon, Portugal, 2Medical
Oncology Department - Portuguese Institute of Oncology
Francisco Gentil, Lisbon, Portugal, 3Breast/ Ovarian
Cancer Risk Evaluation Clinic - Portuguese Institute of
Oncology Francisco Gentil, Lisbon, Portugal
Introduction: Many breast/ovarian high risk cancer famil-
ies have a BRCA-like phenotype in the absence of BRCA
mutations (BRCAness). Other genes also implicated in
DNA repair may be related to the genetic risk in these
families. Objective: to understand the contribution of genes
besides BRCA1/2 in high-risk BRCA wildtype families.
Patients and Methods: All patients selected for this study
were BRCA1/2 wildtype and consented on multigene testing
after counseling. Mutation screening was performed by
NGS for point mutations and sequencing was carried out in
the MiSeq platform (Illumina). Results: Since September
2016 multigene testing allowed the identiﬁcation of 6
pathogenic mutations in 57 BRCA wildtype index probands:
2 in RAD50 gene (3.5%), 2 in RAD51C gene (3.5%), 1 in
RAD51D gene (1.7%), 1 in CHEK2 gene (1.7%). Pre-
viously we had tested 93 patients with a different panel of
genes and found 7 pathogenic mutations: 1 in RAD51C
gene (2%), 2 in PALB2 gene (2%), 2 in CHEK2 gene (2%),
1 in TP53 gene (1%) and 1 in ATM gene (1%). The ATM
mutation segregated with one PALB2 mutation in the same
patient. All carriers of mutations in these genes belong to
families with history of breast and ovarian cancer except for
the carrier of the RAD51D mutation (only ovarian cancer)
and the TP53 mutation carrier who belongs to a family with
only breast cancer in 3 consecutive generations. Conclu-
sion: Taken together, these preliminary results suggest the
contribution of RAD51C, RAD50 and CHEK2 genes in our
BRCA wildtype families.
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Machado: None. A. Luís: None. A. Clara: None. A.
Opinião: None. S. Bento: None. I. Miguel: None. P.
Rodrigues: None. J. Parreira: None. C. Simões: None. F.
Vaz: None.
P12.110B
Absence of large genomic rearrangements of cancer pre-
disposition genes in Romanian patients
L. Negura1, A. Chicos1, A. Negura2
1Gr. T. Popa Medicine and Pharmacy University, IASI,
Romania, 2Alexandru Ioan Cuza University, IASI, Romania
Germline mutations in BRCA1/2 genes confers up to 90%
lifetime risk to familial breast and ovarian cancer (HBOC),
while carriers of mutations in MMR genes (MSH2, MLH1,
MSH6, PMS2) are mainly predisposed to familial colorectal
cancer (Lynch syndrome). Although the majority of germ-
line defects represent point substitutions or short frameshift
alterations, deletions and duplications of complete exons
were also observed in HBOC or Lynch families, with pro-
portions variating from 3% to 40% in different populations.
Common oncogenetic diagnostic, mainly focusing on entire
gene sequencing, is missing such alterations, which can be
detected by Multiplex Ligation-dependent Probe Ampliﬁ-
cation (MLPA). Oncogenetic diagnostic in Romania was
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implemented 10 years ago, and up to date no large genomic
rearrangement has been reported. In order to obtain a wider
overview of Romanian population, we performed an
extended investigation by MLPA in familial and non-
familial cancer patients, using MRC-Holland kits P002,
P077, P045, P003, P008, P072 and P248. We screened
overall 50 familial HBOC and 20 familial Lynch cases, as
well as sporadic young cases of breast(50), ovarian(50) and
colorectal(50) cancer patients. After investigating all
220 samples, no large genomic rearrangement was observed
in BRCA or MMR genes. Although previous results
showed a more important proportion of hereditary altera-
tions comparing to other populations, this striking result is
questioning the opportunity to implement MLPA proce-
dures in local oncogenetic diagnostic. This report is the ﬁrst
extensive investigation of large genomic rearrangements in
cancer predisposition genes in Romanian patients.
Acknowledgement: Research Grant PN-II-RU-TE-2014-4-
2257, UEFISCSDI.
L. Negura: None. A. Chicos: None. A. Negura: None.
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Panel gene analysis allows the identiﬁcation of multiple
mutations in hereditary cancer patients
A. Stradella1,2, E. Grau1, L. Feliubadaló1, J. del Valle1, E.
Tornero1, M. Menéndez1, M. Pineda1, E. Montes1, C.
Gómez1, R. Cuesta1, O. Campos1, M. Salinas1, S.
Gonzalez1, E. Castellanos3, B. Gel3, S. Iglesias1, A.
Velasco4, E. Dader4, A. Solanes5, M. Navarro5, A.
Izquierdo4, J. Sanz6,7, J. Balmaña8, A. Teulé1,2, E. Serra3,
G. Capellà1, C. Lázaro1, J. Brunet1,4
Hereditary Cancer Program-CIBERONC, Institut Català
d’Oncologia (ICO-IDIBELL), L'Hospitalet de Llobregat,
Spain, 2Medical Oncology Department, Institut Català
d’Oncologia (ICO), L'Hospitalet de Llobregat, Spain,
3Hereditary Cancer Program-CIBERONC, IGTP-PMPPC,
Badalona, Spain, 4Hereditary Cancer Program-CIBER-
ONC, Institut Català d’Oncologia ICO-IDIBGI, Girona,
Spain, 5Hereditary Cancer Program-CIBERONC, Institut
Català d’Oncologia ICO-IGTP, Badalona, Spain, 6Familial
Cancer Risk Evaluation Unit, Oncology Service, H.
General de Vic, Barcelona, Spain, 7Familial and Heredi-
tary Cancer Unit, Hospital de Sant Joan de Déu- Althaia,
Barcelona, Spain, 8High Risk and Cancer Prevention Unit,
Medical Oncology Department, University Hospital Vall
d’Hebron, Universitat Autònoma de Barcelona, and Vall
d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
The analysis of 432 patients with clinical suspicion of
hereditary cancer using our custom 122-gene panel I2HCP
(1,2) (see abstract of del Valle et al.) identiﬁed 10 patients
carrying more than one putative pathogenic mutation (see
Table).
Patient/Family
Criteria
First
Mutation
Additional
Pathogenic Mutations
(Dominant genes)
Hereditary Breast
and Ovarian Cancer
BRCA1 EXO1; XPA
Hereditary Breast
and Ovarian Cancer
BRCA2 LZTR1
Reed''s syndrome FH BARD1
HNPCC-Bethesda MSH2 KLLN
HNPCC-Amsterdam,
Multiple Endocrine
Neoplasia-1
MEN1 MLH1
HNPCC-Bethesda MSH6 PRSS1
Familial
Adenomatous
Polyposis
APC BRCA1
Tuberous Sclerosis TSC2 RAD51D
Additional
Pathogenic
Mutations
(Recessive Genes)
Hereditary Breast
and Ovarian Cancer
CDH1 MUTYH
HNPCC-Bethesda MSH6 MSH3
Although we are still working in collecting clinical and
genotype data of patients and relatives of each family, our
ﬁrst glance analysis was unable to identify a clear correla-
tion between the molecular results and the clinical pheno-
type. In most of the cases the patient has clinical criteria
associated with the ﬁrst identiﬁed mutation but not for the
other. However, in a few families, clinical characteristics of
the two mutated genes are observed (such as MEN1-MLH1;
MSH6-PRSS1). Several considerations have to be taken into
account when analyzing these results: incomplete pene-
trance, possible de novo mutations, etc. Note the importance
of identiﬁed unexpected pathogenic mutations in high risk
genes for predictive testing and clinical surveillance of other
carriers in the family.
(1,2) Castellanos et al. and Feliubadaló et al., Scientiﬁc
Reports, 2017-Jan 4;7. Grants: Instituto Salud Carlos III-
FEDER (PI13/00285, PI16/00563, PIE13/00022, RD12/
0036/0031), Govern Catalunya (2014SGR338), Asociación
Española Contra el Cáncer.
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P12.112D
Spectrum of mutations in hereditary cancer syndromes
associated genes in patients at high risk of breast and
ovarian cancer
R. Michalovska, M. Hrabikova, M. Rímska, M. Blaskova,
Z. Vlckova, M. Konecny
GHC Genetics, Praha 1, Czech Republic
Introduction: Breast cancer is among the most common
cancers in women and in the Czech Republic. Carcinomas
of the ovaries and fallopian tubes represent approximately
15% of all malignant tumors in women. Hereditary breast
and ovarian cancer syndrome (HBOC) concerns 5 - 10% of
all breast cancer cases and in majority is caused by con-
genital mutations in the BRCA1 and BRCA2 genes. How-
ever, actually there is also PALB2 gene recommended for
HBOC testing in the Czech population, because mutations
in this gene seem to be the third most frequent DNA pre-
disposition events in our population.
Materials and Methods: For HBOC patients we per-
formed massive parallel sequencing on MiSeq (Illumina)
using sequence capture approach on the gene panel
(ROCHE, own design including 48 genes), followed by
Sanger sequencing and MLPA analysis.
Results: Altogether, we have tested 720 patients using
own-designed Oncogene panel and detected germline
deleterious alterations within BRCA1 and BRCA2, and
PALB2 gene. We have also identiﬁed pathogenic or
potential pathogenic variations in other genes included in
the Oncogene panel. These results demonstrate the efﬁ-
ciency of gene panel approach in performing molecular
diagnosis of HBOC. Detection of several mutations within
other genes than BRCA1/2, PALB2 highlights the genetic
heterogeneity of HBOC.
Conclusions: We have tested patients for presence of
pathogenic mutations in BRCA1/2 and PALB2 gene. Using
own-designed panel of associated HBOC genes we were
able to identify several pathogenic mutations in genes
related also to other malignancies (e.g. colorectal, gastric,
pancreatic, gallbladder, bile duct cancer and malignant
melanoma).
R. Michalovska: None. M. Hrabikova: None. M.
Rímska: None. M. Blaskova: None. Z. Vlckova: None.
M. Konecny: None.
P12.113A
Exploring germline variation in known cancer predisposing
genes amongst CDH1-negative hereditary diffuse gastric
cancer families
E. R. Fewings1, A. Larionov1, J. Redman1, M.
Goldgraben1, R. Hardwick2, M. Di Pietro3, M.
O'Donovan4, S. Richardson5, P. Pharoah6, C. Caldas7, R.
Fitzgerald3, M. Tischkowitz1
Department of Medical Genetics, University of Cambridge,
Cambridge, United Kingdom, 2Department of Oesophago-
Gastric Surgery, Cambridge University Hospitals NHS
Trust, Cambridge, United Kingdom, 3MRC Cancer Cell
Unit, Hutchison/MRC Research Centre, University of
Cambridge, Cambridge, United Kingdom, 4Department of
Histopathology, Cambridge University Hospitals NHS
Trust, Cambridge, United Kingdom, 5Familial Gastric
Cancer Registry, University Department of Oncology,
Cambridge, United Kingdom, 6Centre for Cancer Genetic
Epidemiology, University of Cambridge, Strangeway's
Research Laboratory, Wort's Causeway, Cambridge, Uni-
ted Kingdom, 7Cancer Research UK Cambridge Institute,
Cambridge, United Kingdom
Introduction: Gastric cancer is the fourth most common
cancer globally. Between 1–3% of these cases, of which the
majority are of the diffuse type, arise from predisposition
syndromes. Within hereditary diffuse gastric cancer
(HDGC) families, 25%-30% of cases can be attributed to a
germline mutation in CDH1, of which over 100 have been
described.
Materials and Methods: Whole exome sequencing
(WES) was performed on DNA extracted from blood
obtained as part of the Familial Gastric Cancer Study.
Analysis was performed over 37 individuals, both affected
and unaffected, from 21 CDH1-negative families with a
strong family history of HDGC. Genes with loss-of-
function variants were prioritised using prior biological
knowledge to identify those that could be involved in
HDGC predisposition.
Results: High quality sequencing data was generated
from 11 unaffected and 26 diffuse gastric cancer cases.
Germline protein affecting variants were identiﬁed in
known cancer predisposition genes in 4 HDGC families. A
frameshift deletion within PALB2 was found in a family
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with a history of gastric and breast cancer. Two MSH2
variants were identiﬁed, one frameshift insertion and one
previously described start loss, in unrelated affected indi-
viduals. The BRCA2 polymorphic stop codon variant
(c.9976A>T) was identiﬁed in an individual with DGC and
Lobular breast cancer.
Conclusions: PALB2, MSH2 and BRCA2 variants have
been previously described in diffuse gastric cancer families
however they are more commonly associated with other
cancers. This study suggests that more work should be done
to understand their role in HDGC predisposition.
E.R. Fewings: None. A. Larionov: None. J. Redman:
None. M. Goldgraben: None. R. Hardwick: None. M. Di
Pietro: None. M. O'Donovan: None. S. Richardson:
None. P. Pharoah: None. C. Caldas: None. R. Fitzgerald:
None. M. Tischkowitz: None.
P12.114B
1st Slovak germline deletion in CDH1 gene concurrently
with BRCA2 mutation in patient with hereditary diffuse
gastric cancer
T. Slamka1, L. Vavrova1, J. Markus1, L. Dolesova1, I.
Mlkva2, R. Lohajova Behulova1
1Department of Clinical Genetics, St. Elisabeth Cancer
Institute, Bratislava, Slovakia, 2Institute of Medical Biology,
Genetics and Clinical Genetics, Faculty of Medicine and
UNB, Bratislava, Slovakia
Introduction: Hereditary diffuse gastric cancer (HDGC) is
an inherited condition associated with an increased risk of
diffuse gastric and lobular breast cancer (LBC). CDH1
genomic rearrangements are not frequent but present in
HDGC. We screened germline DNA from mutation nega-
tive probands for large genomic rearrangements. Materials
and Methods: We performed Sanger sequencing analysis of
CDH1 gene in 82 samples with HDGC or LBC families
fulﬁlled revised International Gastric Cancer Linkage
Consortium criteria. Subsequently, we selected 43 mutation
negative probands for MLPA analysis. Results: We iden-
tiﬁed 2 truncating mutations out of 82 samples (2.5%) in
CDH1 gene. Series of 43 probands, negative for CDH1
germline point mutations, were tested for the presence of
large genomic alterations at the CDH1 locus using MLPA.
We found that 1 out of 43 samples (2.3%) showed signal
reduction of exons 15–16. Meanwhile, clinical genetics
identiﬁed distant kindred with truncating BRCA2 mutation
carrier. Our proband share this BRCA2 mutation with her
cousin. Conversely, cousin of our proband carried only
BRCA2 mutation without CDH1 deletion. Young daughter
of our proband displayed the same deletion exons 15–16
without BRCA2 mutation, so far in age 37 is asymptomatic.
Conclusions: In our study we identiﬁed two germline
mutations, and one CDH1 genomic rearrangement in patient
who harbors germline BRCA2 truncating mutation simul-
taneously. This publication is the result of the project
implementation: ‘Establishment of competence centre for
research and development in the ﬁeld of molecular medi-
cine’. Supported by the Research & Development Opera-
tional Programme funded by the ERDF (ITMS
26240220071).
T. Slamka: None. L. Vavrova: None. J. Markus:
None. L. Dolesova: None. I. Mlkva: None. R. Lohajova
Behulova: None.
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Diagnostic yield of a comprehensive gene panel for her-
editary tumor syndromes
J. Henn1, I. Spier1,2, R. Adam1,3, K. Kayser1, S. Peters1, S.
Uhlhaas1, S. Holzapfel1,2, G. Plotz4, S. Aretz1,2
Institute of Human Genetics, University of Bonn, Bonn,
Germany, 2Center for Hereditary Tumor Syndromes,
University of Bonn, Bonn, Germany, 3Center for Experi-
mental and Molecular Medicine, Academic Medical Center
Amsterdam, Amsterdam, Netherlands, 4Medizinische Klinik
1, Biomedical Research Laboratory, University of Frank-
furt, Frankfurt, Germany
Background: In several patients with suspected hereditary
tumour syndromes (HTS), no germline mutation can be
identiﬁed in the most likely affected genes. Here, we ana-
lysed the diagnostic yield and clinical utility of an extensive
gene panel including all known genes relevant for solid
HTS.
Methods: The Illumina TruSight™Cancer Sequencing
Panel of 94 known genes for HTS was extended by 54
genes. For validation, 64 HTS patients with various known
germline mutations were included. Additionally, 173
patients with suspected but unexplained HTS were
analysed.
Results: In addition to the known mutations, 192 rare,
potentially pathogenic variants were identiﬁed. The pro-
portion of rare variants was similar in both patient groups
including variants in the moderate penetrant genes CHEK2
and ATM. After further ﬁltering, potential causative muta-
tions were identiﬁed in 22% of patients with known muta-
tion (eight truncating, six missense and one stoploss). The
most interesting ﬁnding was a NF1 nonsense mutation in a
case with known TP53 frameshift mutation. In 17% of
patients without known mutation, we identiﬁed 20 trun-
cating mutations, one startloss and 15 missense variants. In
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three patients (2%), the mutations are very likely causative
(PMS2, PTEN, POLD1). In both groups, presumptive pre-
dictive information could be revealed (truncating mutations
in SDHA, EXT1, RAD51C).
Conclusions: We demonstrate that a comprehensive
gene panel can identify the etiology in some prescreened
patients and provide predictive incidental ﬁndings. How-
ever, our ﬁndings also show that some patients harbour
predicted pathogenic mutations in more than one estab-
lished cancer gene which makes the interpretation even
more challenging.
J. Henn: None. I. Spier: None. R. Adam: None. K.
Kayser: None. S. Peters: None. S. Uhlhaas: None. S.
Holzapfel: None. G. Plotz: None. S. Aretz: None.
P12.116D
Down regulation of human telomerase reverse transcriptase
(hTERT) expression by BIBR1532 in human glioblastoma
LN18 cells
C. K. Ghati, L. Ch, S. MK, S. M.M, M. M. Venkataswamy
National Institute of Mental Health and Neuroscinces,
Bangalore, India
Introduction: Increased telomerase activity can be blocked
by targeting the hTERT activity at both RNA and catalytic
subunits. Various inhibitors have been used to regulate
hTERT activity in glioblastoma cell lines and showed
conﬂicting results. The present study shows that the
BIBR1532 effectively down-regulate the telomerase activity
in LN18 glioblastoma cell line.
Methods: LN18 glioblastoma cell line was treated with
different concentrations of BIBR1532 at different time
intervals. MTT assay was performed to determine cell
viability after BIBR1532 treatment. hTERT mRNA and
protein expressions were quantiﬁed using qRT-PCR and
western blotting. Flow cytometry assay and TRAP assay
was performed to detect the rate of apoptosis and telomerase
activity in treated and control.
Results: LN18 cells showed a signiﬁcant dose dependent
cytotoxic effect after treatment with BIBR1532. The level
of hTERT mRNA expression in cells treated with 25 μM,
100 μM and 200 μM BIBR1532 treated groups was
decreased ~ 21% and ~ 61.2% and ~ 77% respectively with
a p<0.05. We also observed that, BIBR1532 treatment
reduce the expression levels of hTERT protein in LN18
cells in a dose dependent manner. The Flow cytometry data
showed that, the drug induce signiﬁcant increase in the total
percentage of apoptotic cells with 200 μM concentration of
BIBR1532 in all time points.BIBR1532 exhibited potent
inhibition of telomerase activity in a dose-dependent man-
ner in LN18cells.
Conclusion: BIBR1532 could induce apoptosis in LN18
glioblastoma cells through the down-regulation of telo-
merase activity at transcriptional and translational level.
Grant: UGC RGNF, New Delhi, India
C.K. Ghati: None. L. Ch: None. S. Mk: None. S. M.m:
None. M.M. Venkataswamy: None.
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Juvenile polyposis syndrome in a family suspected of
familial adenomatous polyposis - a case report
S. E. Boonen1, A. Skytte2
Clinical Genetic Unit, Department of Pediatrics, Zealand
University Hospital, Roskilde, Denmark, 2Department of
Clinical Genetics, Aarhus University Hospital, Aarhus,
Denmark
Introduction: Juvenile Polyposis Syndrome (JPS) and
Familial Adenomatous Polyposis (FAP) are histologically
characterized by distinct polyps with different ability of
malignant transformation. JPS: a few to more than a hun-
dred hamartomatous polyps, mainly benign but malignant
transformation might occur. FAP: hundreds to thousands
precancerous adenomatous polyps, malignancy is almost
inevitable. Autosomal dominant inheritance of both
syndromes.
Patients and Methods: We report a family that for a
quarter of a century was clinically suspected of having FAP.
The proband is a 50-year-old female who had a total
colectomy with ileorectal anastomosis performed by the age
of 24 years due to suspicion of FAP, because her father was
diagnosed with polyposis and she was beginning to develop
polyps. Her paternal grandmother was diagnosed with sig-
moid colon cancer at the age of 50 and died shortly after.
Results: Using a predesigned cancer gene panel targeted
next generation sequencing was performed. Due to the
clinical diagnosis of FAP, ﬁrst the APC data was analyzed,
the result was normal. Then the subpanel of the polyposis
genes were analyzed and a paternally inherited known
pathogenic, BMPR1A variant, (c.1328G>A; p.Arg443His)
was identiﬁed, conﬁrming the diagnosis of JPS. We present
the detailed clinical data of the three family members in
comparison with cases reported in medical literature.
Conclusions: Colectomy is advised for FAP but not
necessarily for JPS. This case illustrates the importance of
molecular genetic screening, as management and surveil-
lance of at-risk family members and affected individuals is
very different depending on the syndrome.
S.E. Boonen: None. A. Skytte: None.
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Examination of effects of daylight on melatonin hormone,
kisspeptin protein, skin cancer formation and metastasis in
mice
P. Pazarci1, H. M. Kaplan2, D. Alptekin1, M. B. Yilmaz1,
Ü. Lüleyap1, H. Öksüz1
1Cukurova University, Medical Faculty, Medical Biology,
Adana, Turkey, 2Cukurova University, Medical Faculty,
Pharmacology, Adana, Turkey
Introduction: Relationship of skin cancer with constant
redundancy of melatonin is known. Kisspeptin’s cellular
level is inversely proportional with melatonin level in blood
and it is mostly synthesized in hypothalamus. Kisspeptin
functions as a metastasis suppressor in melanomas. This
study aimed to determine the relationship between daylight,
melatonin levels in blood and kisspeptin levels in hypo-
thalamus. In addition, skin cancer is formed on mice to
examine relationship between cancer formation, metastasis,
daylight, melatonin levels and kisspeptin levels. Materials
and Methods: New born mice are raised for 17 weeks as
blind group (24 hours dark, n= 45) and daylight group
(12 hours light/12 hours dark, n= 42). At the end of 11th
week, melanoma cell lines are inoculated and tumor growth
is observed for 6 weeks. At the end of the experiment,
melatonin levels are measured from blood serum, kisspeptin
levels and KISS1 gene expressions are measured from
hypothalamus tissue. Results: Blind group is found to have
higher melatonin levels and lower KISS1 levels with respect
to daylight group. Melatonin levels are found to be inver-
sely proportional and KISS1 levels are found to be directly
proportional with tumor volumes. Tumor growth speed is
found to be lower in blind group than in daylight group.
Conclusions: Melatonin and kisspeptin are shown to be
important tumor suppressors who are highly affected by
daylight. Levels of these suppressors are found to be
affected by each other, however, this relationship is
speculated to be complicated and affected by other factors
too instead of being simple and direct.
P. Pazarci: None. H.M. Kaplan: None. D. Alptekin:
None. M.B. Yilmaz: None. Ü. Lüleyap: None. H. Öksüz:
None.
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Detection of KRAS mutations in metastatic colorectal
cancers
B. Durak Aras, 264801, M. Özdemir1, M. Dinçer2, O.
Çilingir1, Ö. Kutlay1, S. Aslan1, S. Artan1
Eskisehir Osmangazi University Medical Faculty Depart-
ment of Medical Genetics, Eskisehir, Turkey, 2Eskisehir
Osmangazi University Department of Medical Oncology,
Eskisehir, Turkey
The KRAS oncogene that encodes p21 protein, regulates
critical cellular processes. The most frequent mutations of
KRAS gene occur in codons 12 and 13. Activating point
mutations in codons 12 and 13 of KRAS gene are predictive
biomarker for resistance to anti-EGFR therapies in mCRC.
The present study showed the frequencies and types of
KRAS mutations in the tumor samples of 63 patients with
mCRC.
Genomic DNAs were extracted from FFPE sections that
included at least 60% tumor cells of the samples. The
pyrosequencing technique was used in determining the
KRAS mutational status. The gDNAs were ampliﬁed by
TheraScreen KRAS assays and evaluated by using Pyro-
Mark software.
Of 63 mCRC samples, KRAS codon 12 mutations were
detected in 38% and codon 13 mutations were in 15%. The
most common mutations were G-A transitions (61 %) fol-
lowed by a G-T transversions (32%) (Table). The relations
between the mutation types and clinical features of the cases
were compared.
Our results showed that the frequency and type of
mutations were in accordance with other studies. In agree-
ment with previous data of the literature, the highest fre-
quency of KRAS mutation was detected in codon 12. We
concluded that pyrosequencing is highly speciﬁc and can
productively be used in the detection of hot spot KRAS
mutations in mCRC samples for the establishment of the
effective therapy.
Table1. KRAS mutation results
Codon Mutations Frequence (n / %)
12 c.35G>A
p.G12D
10 /22%
12 c.35G>T
p.G12V
9 /20%
12 c.34G>T
p.G12C
2 /4%
12 c.34G>A
p.G12S
1 / 2%
12 c.35G>C
p.G12A
2 / 4%
12 c.34G>C
p.G12R
–
13 p.G13D
c.38G>A
10 / 22%
Abstracts from the 50th European Society of Human Genetics Conference:. . . 573
B. Durak Aras: None. M. Özdemir: None. M. Dinçer:
None. O. Çilingir: None. Ö. Kutlay: None. S. Aslan:
None. S. Artan: None.
P12.120D
Mutational screening of KRAS, NRAS and BRAF genes in
Romanian colorectal patients
P. Apostol1, F. Iordache1, S. Dinu1, V. Valeanu2, G.
Cardos1, C. Marias3
1Personal Genetics, Bucharest, Romania, 2County Clinical
Emergency Hospital, Sibiu, Romania, 3Top Diagnostics,
Bucharest, Romania
Colorectal cancer (CRC) is a heterogeneous disease, exhi-
biting multiple genetic alterations. Screening for KRAS,
NRAS and BRAF mutations becomes increasingly impor-
tant for clinical assessment, activating mutations in these
genes being strong predictors of resistance to EGFR-
targeted agents.
Aim: screening of KRAS, NRAS and BRAF genes in
CRC patients for tailoring their speciﬁc therapeutic strategy.
Our on-going study has included 60 unrelated Cauca-
sians patients, between 38–85 years old, with histologically-
proven diagnosis of CRC in advanced stages. Genomic
DNA was isolated from FFPE primary (34) or secondary
(26) tumors samples, with 2–96% tumor cells content.
Mutational status of KRAS, NRAS and BRAF genes was
analyzed by Real-Time PCR and capillary sequencing.
Mutations in KRAS, NRAS and BRAF genes are
mutually exclusive and confer resistance to anti-EGFR
therapy in CRC patients. In our study, KRAS activating
mutations were detected in 27 samples (45%), distributed in
exon 2 (codon 12- 70.37%; codon 13- 22.23%), exon 3
(3.7%) and exon 4 (p.Ala146Thr- 3.7%). NRAS activating
mutations were identiﬁed in 3 samples (5%), distributed in
exon 2 (p.Gly12Ser- 66.7%) and exon 3 (p.Gln61Leu-
33.3%). Five K-/NRAS wild-type CRC patients underwent
screening of BRAF V600 locus without any mutation
identiﬁed.
Nowadays, screening for activating mutations in the
KRAS, NRAS and BRAF genes has became a routine
analysis for CRC Romanian patients, contributing in this
way to their effective selection prior to anti-EGFR targeted-
therapy initiation. Also, our results, in accordance with
international data, have shown that mutational screening is
essential for tailoring of speciﬁc therapeutic strategy in
CRC patients.
P. Apostol: None. F. Iordache: None. S. Dinu: None.
V. Valeanu: None. G. Cardos: None. C. Marias: None.
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The silenced potassium channels Kv1.3 and Kv10.1 affects
miR-126 in breast cancer cells
D. Turgut Cosan1, A. Soyocak2, C. Oner1
Eskisehir Osmangazi University, Eskisehir, Turkey, 2Istan-
bul Aydın University, Eskisehir, Turkey
Introduction: It has been shown that non-coding regulatory
RNAs, especially play a role in formation and progression
of cancer. miR-126 is markedly downregulated in human
breast cancer tissues. Various studies indicate that some
voltage gated potassium channels are also overexpressed in
the tumor. Kv1.3, a member of the voltage-gated potassium
channel family is overexpressed in cancerous breast tissues
than in normal breast tissues. Another protein, Kv10.1 is
overexpressed in many human tumors, including breast
cancer and it has oncogenic properties. Ether à go-go 1
(Eag1) channel is overexpressed in a variety of cancers and
plays important roles in cancer progression. However, the
association between with voltage gated potassium channels
and miR-126 is unclear. In our study, we aimed to show
whether there is association between miR-126/miR-126*
and Kv1.3 or Kv10.1 in non-invasive estrogen positive
MCF-7 and invasive estrogen negative MDA-MB-231
human BC cells. Materials and Methods: MCF-7 and
MDA-MB-231 cells were transfected with Kv1.3 and
Kv10.1 speciﬁc siRNA. miR-126 and miR-126* expression
was determined in total RNA isolated from the cells. All
samples were normalized to the internal controls, and fold
changes were calculated through relative quantiﬁcation (2
−ΔΔCt). Results: The results of our research indicate that
there is a strong inverse relationship with the expression
levels of miR-126 and potassium channels. Conclusions:
The miR-126/126* expressions increased in the MDA-MB-
231 cells and decreased in the MCF-7 cells by using siRNA
against potassium channels Kv1.3 and Kv10.1.
D. Turgut Cosan: None. A. Soyocak: None. C. Oner:
None.
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Germline TP53 Mutations Result into a Constitutive Defect
of p53 DNA Binding and Transcriptional Response to DNA
Damage
574
Y. Zerdoumi, R. Lanos, S. Raad, J. Flaman, G. Bougeard,
I. Tournier, T. Frebourg
Inserm U1245 and Rouen University Hospital, Normandy
Centre for Genomic and Personalized Medicine, Rouen,
France
Introduction: Li-Fraumeni Syndrome (LFS) results from
heterozygous germline mutations of TP53, encoding a key
transcriptional factor activated in response to DNA damage.
Materials and Methods: We performed the p53 func-
tional assay, based on the p53 transcriptional response to
DNA damage, in lymphocytes from 56 TP53 mutation
carriers harboring 35 distinct alterations, then chromatin
immunoprecipitation-sequencing (ChIP-Seq) in lympho-
cytes exposed to doxorubicin in order to compare the
impact of the different types of germline TP53 mutations on
DNA binding.
Results: The p53 functional assay shows that germline
dominant-negative missense mutations alter the transcrip-
tional response to DNA damage more drastically than null
mutations, indicating that this defect constitutes an endo-
phenotype of germline TP53 mutation severity. ChIP-Seq
performed in wild-type TP53 control lymphocytes accu-
rately mapped 1287 p53-binding sites. New p53-binding
sites were validated using a functional assay in yeast. ChIP-
Seq analysis of LFS lymphocytes carrying the TP53
dominant-negative missense mutations p.R273H or p.
R248W revealed only 310 and 143 p53-binding sites,
respectively, and the depths of the corresponding ChIP-Seq
peaks were drastically reduced. In contrast, analysis of LFS
lymphocytes with TP53 null mutations (p.P152Rfs*18 or
complete deletion) or with the low penetrant “Brazilian” p.
R337H mutation revealed a moderate decrease of p53-
binding sites (949, 580 and 620, respectively) and of peak
depths.
Conclusions: Altogether, our results show that TP53
mutation carriers exhibit a constitutive defect of the tran-
scriptional response to DNA damage and that the clinical
severity of TP53 dominant-negative missense mutations is
explained by a massive and global alteration of p53 DNA
binding.
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Highly reliable single cell whole exome sequencing of
circulating tumor cells (CTCs)
U. Lahrmann, J. Kunze, B. Polzer, Z. Czyz, C. Klein, S.
Kirsch
raunhofer ITEM-R, Regensburg, Germany
Whole exome sequencing (WXS) allows to determine the
mutational landscape in cancer at the single-nucleotide-
level. Together with whole genome ampliﬁcation the full
potential of the method is applicable down to the single cell
level to investigate individual heterogeneity. For several
reasons we combined the single cell genome ampliﬁcation
method Ampli1TM WGA with the whole exome enrichment
technology SureSelect XT for WXS of circulating tumor
cells (CTCs) in liquid biopsy samples from metastatic
cancer patients: (1) Ampli1TM WGA excludes random
priming thereby eliminating introduction of priming-
derived sequence alterations; (2) the deterministic nature
of this technology ensures that the genomic amplicon
population is ampliﬁed equally in all single cells of all
patients thus facilitating sample quality control (QC)
implementation; and (3) Agilent SureSelect XT has shown
the best performance in coverage of clinically interesting
mutations. The assessment of the combination of both
technologies on WGA samples derived from single per-
ipheral blood lymphocytes (PBLs) isolated from a healthy
human donor revealed a high reproducibility and reliability
of the optimized workﬂow, almost equivalent to routine
diagnostic pathology. In applying the established approach
on single CTCs of metastatic breast cancer patients from
DETECT III, a multicentric phase III study, the newly
developed sample QC permits to identify high-quality
ampliﬁed CTC samples. The comparison of the identiﬁed
mutation proﬁles with matched PBLs allowed to eliminate
vastly ampliﬁcation-induced sequence alterations. By
developing a bioinformatics tool ﬁne-tuned for Ampli1TM
WGA, single cell WXS data sets can be additionally used
for reliable CNV analysis in CTCs.
U. Lahrmann: None. J. Kunze: None. B. Polzer: None.
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Dysregulation of the long non-coding RNA, PRNCR1, in
breast cancer
E. Soleimanpour, M. Hosseinpour feizi, E. Babaei
Tabriz University, Tabriz, Iran, Islamic Republic of
Breast cancer (BC) is one of the most common cancers
worldwide. Long non-coding RNAs (lncRNAs) have been
approved to play a critical regulatory role in various cellular
activities such as carcinogenesis, which indicates that
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lncRNAs are therapeutic targets and potential biomarkers
for cancer detection. Prostate cancer associated non-coding
RNA1 (PRNCR1) that is located in 8q24.21 is a long non-
coding RNA that deregulate in some cancers. In our study,
we investigated the expression level and clinical sig-
niﬁcance of PRNCR1 in BC.
Quantitative real-time polymerase chain reaction (qRT-
PCR) was used to assess the expression level of PRNCR1 in
BC tissues. In a cohort of 25 patients, PRNCR1 was sig-
niﬁcantly overexpressed in BC tissues compared with the
expression in adjacent tissues, with an average fold increase
of 6.26 (P=0.004). Additionally, a high level of PRNCR1
was associated with large tumor size and lymph node
metastasis (P<0.05). Based on receiver operating char-
acteristic curve (ROC), we found that the area under the
curve (AUC) of PRNCR1 was 0.76 indicating that
PRNCR1 could be a sensitive diagnostic biomarker of BC.
In conclusion, our study demonstrated that PRNCR1 is
an oncogene of breast cancer and dysregulation of PRNCR1
could be a potential target for gene therapy in breast cancer.
(No grant)
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Clinical and biological signiﬁcance of Y chromosome loss
in a series of 2,423 male patients with Myelodysplastic
syndromes and Chronic Myelomonocytic Leukemia
D. Costa1, M. Nomdedeu2, A. Pereira1, X. Calvo3, J.
Colomer1, F. Soler4, E. Luño5, J. Cervera6, A. Arias1, C.
Gómez1, M. Ortega7, R. Collado8, I. Granada9, G. Sanz6,
J. Esteve1, E. Campo1
Hospital Clinic, Barcelona, Spain, 2Hospital Plató, Barce-
lona, Spain, 3Hospital del Mar, Barcelona, Spain, 4Josep
Carreras Leukemia Research Institute, Badalona, Spain,
5Hospital Central de Asturias, Oviedo, Spain, 6Hospital
Universitari i Politècnic La Fe, CIBERONC, Valencia,
Spain, 7Hospital Universitari Vall d'Hebron, Barcelona,
Spain, 8Hospital General Universitario de Valencia,
Valencia, Spain, 9ICO-Hospital Universitari Germans Trias
i Pujol, Badalona, Spain
Isolate loss of chromosome Y (-Y) in myelodysplastic
syndromes (MDS) is associated to a better outcome but it is
also well described as an age-related phenomenon. In this
study we aimed to analyze the prognostic impact of -Y in
the context of the IPSS-R cytogenetic classiﬁcation, eval-
uate the clinical signiﬁcance of the percentage of meta-
phases with isolated -Y, and test whether ﬁnding -Y may
predispose to over-diagnose MDS in patients with
borderline morphological features. We evaluated 3,581
male patients from the Spanish MDS Registry with a
diagnosis of MDS or chronic myelomonocytic leukemia
(CMML). -Y was identiﬁed in 177 patients (4.9%). Com-
pared with the 2,246 male patients with normal karyotype,
-Y group showed a reduced risk of leukemic transformation
that did not translate into a survival advantage. The overall
survival and the risk of leukemic transformation were not
inﬂuenced by the percentage of metaphases with -Y. The -Y
group was not enriched in patients with minor morphologic
traits of dysplasia, suggesting that the better outcome in the
-Y group cannot be explained by enrichment in cases mis-
diagnosed as MDS. In conclusion, our results support the
current recommendation of classifying patients with -Y
within the very good risk category of the IPSS-R for MDS
and rule out a selection bias as a possible explanation of this
better outcome. An analysis of the molecular basis of MDS
with isolated -Y would be of interest as it may provide a
biological basis of protection against progression to acute
leukemia.
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The Use of Molecular Identiﬁers (MIDs) for Improved Low
Frequency Mutation Detection in Ovarian Cancer
C. Brown1, S. Sandhu1, M. Dashkoff2, T. Harkins1, O.
Camacho-Vanegas2, P. Dottino2, L. Kurihara1, J.
Martignetti2, V. Makarov1
1Swift Biosciences, Inc., Ann Arbor, MI, United States,
2Ichan School of Medicine at Mount Sinai, Departments of
Genetics and Genomic Sciences and Obstetrics/Gynecology
& Reproductive Sciences, New York, NY, United States
Improving the sensitivity of next generation sequencing
(NGS) technologies to detect low frequency variants
involves removal of PCR duplicates to achieve accurate
coverage. By uniquely labeling every DNA molecule within
an NGS library, more conﬁdent detection of low frequency
mutations and other genetic variants is possible. Molecular
ID (MID) labeling of unique library molecules enables
detection and removal of PCR duplicates while preserving
fragmentation and complementary strand duplicates. Prior
to removal, the MID can also be used to generate a con-
sensus sequence from PCR duplicates, reducing sequencing
and PCR-induced errors. Here MID technology was com-
bined with Swift Biosciences’ Accel-NGS® 2S Hyb DNA
Library Kit to evaluate the effect on data analysis. Libraries
were prepared with DNA from a series of tumors from a
stage 3B ovarian carcinosarcoma patient and circulating
cfDNA from blood plasma collected at the time of surgery.
We determined data retention after de-duplication using
either standard Picard tools without using MIDs or UMI-
tools (Fulcrum Genomics) that utilize MIDs. We observed
an increase in data retention for both Covaris-sheared
gDNA and cfDNA libraries that lead to a 1.7 to 2.9 fold
increase in coverage using UMI-tools over Picard de-
duplication under the conditions tested and found this effect
was maximized by lower DNA input quantities and higher
depth of sequencing. These libraries were further evaluated
for variant calling using oncology-related gene panels. We
identiﬁed low frequency variants (as low as 0.5%) present
across all tumor samples and within cfDNA, as well as
variants unique to each tumor sample.
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Integrated DNA methylation and copy-number proﬁling in
adults with lower-grade brain gliomas
Z. Zemanova1, H. Lhotska1, K. Svobodova1, H. Cechova2,
S. Ransdorfova2, L. Lizcova1, F. Kramar3, Z. Krejcik2, L.
Pavlistova1, S. Izakova1, A. Berkova1, K. Skipalova1, K.
Michalova1
Center of Oncocytogenetics, Institute of Medical Biochem-
istry and Laboratory Diagnostics, General University
Hospital and First Faculty of Medicine, Charles University,
Prague, Czech Republic, 2Institute of Hematology and
Blood Transfusion, Prague, Czech Republic, 3Department
of Neurosurgery, Central Military Hospital and First
Faculty of Medicine, Charles University, Prague, Czech
Republic
Lower-grade gliomas (LGG, grade II-III) represent hetero-
geneous group of brain tumors that comprise astrocytomas
(A), oligodendrogliomas (O) and oligoastrocytomas (OA).
Patients with LGG have highly variable clinical behavior
not adequately predicted on the basis of histological clas-
siﬁcation. Assessment of the genome aberrations by inte-
grated molecular-cytogenetic techniques allows robust and
prognostically relevant classiﬁcation of these tumors.
To investigate the genetic and epigenetic proﬁle of tumor
cells, genome-wide analyses of 111 samples of LGG (76xA,
28xO, 7xOA) was performed. The tissues taken from pri-
mary tumors were analyzed to detect recurrent chromoso-
mal aberrations, copy number variations, IDH mutations
and hypermethylation of MGMT and MMR genes pro-
moters using I-FISH (Abbott), SNP array (Illumina), and
MLPA (MRC-Holland).
Mutation of IDH genes was detected in 75.7% LGG. A
total of 30.6% patients with mutated IDH had simultaneous
co-deletion 1p/19q, which is considered the predictive
marker of better response to radio-chemotherapy. In 35.3%
astrocytomas, shattering of different chromosomes (chro-
mothripsis) always in combination with complex changes
was observed by SNP array. Copy-neutral LOH17p, often
associated with TP53 mutation, was proved in 56.6% of
astrocytomas. In 37.8% LGG hypermethylation of MLH3
gene promoter was detected. Patients with hypermethylated
MLH3 had signiﬁcantly better overall survival (p=0.001).
At present, sub-classiﬁcation of highly heterogeneous
diffuse LGG based on genetic and epigenetic proﬁle of
tumor cells and its continuous monitoring provides better
genetically deﬁned patient’s sets with narrowed variability
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of clinical outcomes. In the future it will facilitate more
personalized treatment.
Supported by research grants RVO-VFN64165, GACR
P302/12/G157 and ProgresQ28.
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Famale NSCLC genes' mutation screening with Ion
AmpliSeqTM colon and lung cancer research panel
I. Mirskyte1,2, A. Laurinavicius1,3, A. Krasauskas1,4, S.
Cicenas1,4, D. Schveigert4, J. Kasnauskiene1,2
1Vilnius University, Vilnius, Lithuania, 2Klaipeda Univer-
sity Hospital, Klaipeda, Lithuania, 3Vilnius University
Hospital Santariskiu Klinikos, Vilnius, Lithuania, 4Institute
of Oncology, Vilnius, Lithuania
Objectives: Molecular testing of cancer is increasingly
critical to medicine. Next-generation sequencing (NGS)
provides comprehensive, unbiased, and inexpensive muta-
tion analysis of multiple genes with a single test. The aim of
our study was to assess the clinical usefulness of the Ion
AmpliSeqTM colon and lung cancer’s research panel on Ion
Torrent™ PGM, which allows sequencing 22 genes and
detects mutations of lung cancer DNA.
Methods: NGS was performed with DNA from frozen
and formalin-ﬁxed, parafﬁn-embedded NSCLC tumor
samples obtained from 16 non-smoking women using Ion
AmpliSeq colon and lung cancer research panel, Thermo-
Fisher. Twenty-two oncogenes: KRAS, EGFR, BRAF,
PIK3CA, AKT1, ERBB2, PTEN, NRAS, STK11, MAP2K1,
ALK, DDR2, CTNNB1, MET, TP53, SMAD4, FBX7,
FGFR3, NOTCH1, ERBB4, EGFR1 and FGFR2 have been
sequenced with this panel.
Results: 16 DNA samples from NSCLC female tumors
were sequenced and mutations were detected in 12 onco-
genes. Mutations in KRAS gene were found for 4 patients,
BRAF – 1 patient, PIK3CA – 2 patients, TP53 – 8 patients,
EGFR – 2 patients and ERBB2 – 1 patient. Furthermore, for
4 cases mutations were detected in two different genes, for 7
cases mutations were detected in one gene and in one case
gene with two different mutations was identiﬁed.
Conclusion: The the Ion AmpliSeqTM colon and lung
cancer’s research panel exhibited good clinical perfor-
mance, strongly supporting the implementation of the NGS
assay in routine clinical use to facilitate therapeutic
decision-making for lung cancer patients.
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Monitoring lung cancer therapy via liquid biopsy
M. Chatzidaki1, G. Thodi2, Y. Loukas1, E. Molou2, O.
Triantafylli2, K. Schulpis3
Department of Pharmacy, National and Kapodistrian
University of Athens, Athens, Greece, 2Neoscreen, Ltd.,
Voreiou Hpeirou 1–3, Athens, Greece, Athens, Greece,
3Department of Mental Health and Social Welfare, Hospital
Paidon “Agia Soﬁa”, Thivon & Papadiamantopoulou,
Athens, Greece, Athens, Greece
Introduction: Liquid biopsy is a non-invasive sample
source that can be utilized to assess cancer response to drug
therapy by measuring the tumor- derived fraction of circu-
lating cell-free DNA (cfDNA) in plasma. The purpose of
this study was to evaluate the clinical signiﬁcance of liquid
biopsy by monitoring the treatment outcome of a patient
with lung cancer (NSCLC).
Materials/Methods: Both FFPE and cfDNA samples of
this patient were subjected to Accel-Amplicon 56G
Oncology Panel which offers comprehensive and hotspot
coverage of 56 clinically-relevant oncology-related genes.
The runs were conducted on MiSeq platform (Illumina)
with MiSeq- 300V2 kit. Liquid biopsy was performed after
one week and then after a month of the beginning of a third
generation EGFR-TKI treatment (with rociletinib).
Results: The mutation T790M of the EGFR gene was
detected in both FFPE and in ﬁrst cfDNA samples. The
T790M mutation levels were slightly decreased after one
week and much further after one month of therapy. There-
fore, therapy seems to be effective.
Conclusion: Tissue biopsy still represents the gold
standard for characterizing the initial tumor sample, but
liquid biopsy seems to be a valuable tool for monitoring
patients subjected to therapy.
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“Omic” approach in non-smokers with adenocarcinoma
pinpoints to germline susceptibility and personalized
medicine
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Ghisalberti3, C. Bellan4, F. Cetta5, S. Furini6, P.
Paladini3, G. Gotti3, F. Ariani1,2, A. Renieri1,2
1Medical Genetics, University of Siena, Siena, Italy,
2Genetica Medica, Azienda Ospedaliera Universitaria
Senese, Siena, Italy, 3Thoracic Surgery Unit, Azienda
Ospedaliera Universitaria Senese, Siena, Italy, 4Depart-
ment of Medical Biotechnology, Section of Pathology,
University of Siena, Siena, Italy, 5IRCCS MultiMedica,
Milan, Italy, 6Department of Medical Biotechnology,
University of Siena, Siena, Italy
A cohort of four never-smoker patients with primary EGFR/
KRAS/ALK-negative lung adenocarcinoma and their normal
sibs were subjected to a novel integrative “omic” approach
using a pedigree-based model for discovering genetic fac-
tors leading to cancer in the absence of well-known envir-
onmental trigger. A ﬁrst-step whole-exome sequencing on
tumor and normal tissue did not identify mutations in
known/candidate driver genes. Building on the idea of a
germline oligogenic origin of lung cancer, we performed
whole-exome sequencing of DNA from patients’ peripheral
blood and their unaffected sibs. Filtering for rare variants
with CADD>25 and potentially damaging effect, we iden-
tiﬁed a mean of 100 potentially deleterious variants per
patient, 20% of which mapping in genes previously asso-
ciated with cancer. The majority of the variants were
exclusively identiﬁed in patients with few exceptions being
present also in the healthy sib. Transcriptome proﬁling on
both tumor and normal lung tissues revealed that among the
selected mutated genes, a mean of 10 genes per patient were
either down- or up-regulated in cancer specimens. Among
the down-regulated genes, 80–90% of reads carried the
mutated allele suggesting a loss of heterozygosity. Notably,
the group of mutated genes was unique for each patient
pinpointing to a “private” oligogenic germline signature.
Noteworthy, at least 2 mutated genes per patient turned to
be druggable because related to known drivers, such as
NOTCH1 and YAP1. In the era of precision medicine, this
report emphasizes the importance of an “omic” approach to
uncover oligogenic germline signature underlying cancer
development and identify suitable therapeutic targets.
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Histological and molecular hallmarks of PMS2 associated
CRC
S. ten Broeke1, T. van Bavel1, A. Janssen2, E. Gomez
Garcia3, L. P. van Hest4, T. G. W. Letteboer5, J. W.
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Tromp1, L. Spruijt8, J. T. Wijnen1, H. Morreau2, T. van
Wezel2, M. Nielsen1
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ical Centre, Leiden, Netherlands, 2Department of Pathol-
ogy, Leiden University Medical Centre, Leiden,
Netherlands, 3Department of Clinical Genetics, Maastricht
University Medical Centre, Maastricht, Netherlands,
4Department of Clinical Genetics, VU Amsterdam, Amster-
dam, Netherlands, 5Department of Clinical Genetics,
University Medical Centre Utrecht, Utrecht, Netherlands,
6Department of Clinical Genetics, University Medical
Centre Groningen, Groningen, Netherlands, 7Department
of Clinical Genetics, Academic Medical Centre, Amster-
dam, Amsterdam, Netherlands, 8Department of Clinical
Genetics, Radboud University Medical Centre, Nijmegen,
Netherlands
Background Lynch syndrome is caused by germline
mutations in one of the mismatch repair genes, including
PMS2. This study aims to unravel for the ﬁrst time the
histological and molecular hallmarks of PMS2 associated
CRC.
Methods Histological hallmarks in 20 PMS2 deﬁcient
tumours were scored by an experienced pathologist. The
Ampliseq Cancer Hotspot panel was used to analyse the
somatic tumour spectrum, which covers 50 genes (~2800
COSMIC mutations), including KRAS, APC and TP53.
Results were compared with (hypermethylated and mutated)
MLH1 deﬁcient and sporadic CRCs.
Results PMS2 associated CRCs showed a number of LS
associated hallmarks: 81% were right-sided, 43% had
Crohn’s like inﬁltrate and 81% showed microsatellite
instability. However, a majority (63%) hardly had any
tumour inﬁltrating lymphocytes, a well-known character-
istic of Lynch associated tumours. We identiﬁed a high
percentage of a speciﬁc FBXW7 mutation (c.1393C>T, p.
Arg465Cys). Notably, 5/20 CRCs had this transition, where
the sporadic controls had none. We also found a relatively
rare KRAS mutation in exon 4 (c.436G>A, p.Ala146Thr)
occurring three times in the PMS2 cohort but not in the
control cohort and once in MLH1 associated CRCs. Strik-
ingly we found CTNNB1 mutations in 14/25 (60%) of
MLH1 associated CRCs, but none in the PMS2 cohort.
Discussion Results from this study indicate the possibi-
lity of a speciﬁc route to tumorigenesis in PMS2 carriers,
which may have consequences for detection and treatment.
Moreover, these observations might also contribute to
tailor-made surveillance guidelines for PMS2 mutation
carriers. Supported by the Dutch Cancer Society
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Introduction After colorectal cancer, endometrial cancer
(EC) is the second most prevalent cancer in Lynch syn-
drome, and EC is the ﬁrst cancer in approximately 50% of
women with Lynch syndrome. We present a study with
consecutive screening for Lynch syndrome using immu-
nohistochemistry (IHC) of the mismatch-repair (MMR)
proteins in patients diagnosed with EC.
Material and Methods All incident EC cases in the
Northern Region of Denmark diagnosed between 2013 and
2016 were screened with IHC of the four MMR proteins
pMLH1, pMSH2, pMSH6, and pPMS2 and methylation
analysis of the MLH1 promotor in tumors with loss of
pMLH1/pPMS2. Patients with loss of pMLH1/pPMS2 and
no MLH1 promotor methylation, loss of pMSH2/pMSH6,
or isolated loss of one MMR protein were offered screening
with Sanger sequencing of the MMR genes.
Results Out of 246 EC patients, IHC revealed 65 patients
with loss of MMR proteins. 46 patients had loss of pMLH1/
pPMS2 and MLH1 promotor methylation. Nineteen patients
were offered genetic counselling. Sequencing of the MMR
genes in 11 of these patients revealed six patients with a
pathogenic variant (one MSH2 and ﬁve MSH6) and one
patient with a variant of unknown signiﬁcance in PMS2.
Conclusion Lynch syndrome was identiﬁed in 2.4% of
the EC patients. None of the ﬁve patients with MSH6
mutations would have been diagnosed with Lynch
syndrome if only family based criteria had been used.
Universal screening with IHC of the MMR proteins seems
as relevant in patients diagnosed with EC as it is in color-
ectal cancer cases.
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Routine molecular analysis for Lynch syndrome in
patients with advanced adenoma or colorectal cancer
within a national screening program for colorectal
cancer
A. Goverde, W. N. M. Dinjens, M. J. Bruno, R. M. W.
Hofstra, M. Doukas, M. M. van der Weiden, H. J.
Dubbink, A. Wagner, M. C. W. Spaander
Erasmus MC University Medical Center, Rotterdam,
Netherlands
Aim To assess the diagnostic yield of immunohistochem-
istry (IHC) for Lynch syndrome (LS) in patients with
advanced adenomas or CRC within a national colorectal
cancer (CRC) screening program.
Methods We included participants of the national CRC
screening program, referred for colonoscopy from Decem-
ber 2013 onwards. IHC was performed on advanced ade-
nomas (adenomas with villous component, high-grade
dysplasia or ≥ 10mm in size) and CRCs. Also, in cases with
≥4 non-advanced adenomas, IHC was performed on the
largest adenoma. MLH1 hypermethylation analysis was
performed if indicated. Patients suspect for LS were offered
germline mutation analysis. If no pathogenic mutation was
found, we performed somatic mutation analysis.
Results We included 913 patients (53% male; mean age
66 years (±6 years)). At colonoscopy, 345 (38%) patients
(63% male; mean age 67 years (±6 years) were eligible for
IHC. In total, 316 adenoma patients were analyzed. None
had aberrant IHC. Of these adenomas, 148 (47%) had vil-
lous component and/or high-grade dysplasia. Out of 44
CRC patients, 6 (15%) showed loss of MLH1 and PMS2
protein expression. Four cases had MLH1 promoter hyper-
methylation. In the remaining two patients no germline
MLH1 mutation was found and somatic mutation analysis
showed that both had a likely sporadic tumor. Conclusion
Our results indicate that routine LS screening by IHC in
patients with advanced and multiple adenoma within a
national CRC screening program is not an effective strat-
egy. The diagnostic yield of LS screening in younger ade-
noma patients should be assessed.
A. Goverde: None. W.N.M. Dinjens: None. M.J.
Bruno: None. R.M.W. Hofstra: None. M. Doukas: None.
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FANCM germline mutations in BRCA1/2-negative male
breast cancer cases from Italy
V. Silvestri1, P. Rizzolo1, V. Zelli1, V. Valentini1, A. S.
Navazio1, M. G. Tibiletti2, L. Varesco3, A. Russo4, S.
Tommasi5, G. Giannini1, D. Calistri6, A. Viel7, L. Cortesi8,
M. Montagna9, D. Palli10, P. Radice11, P. Peterlongo12, L.
Ottini1
1Department of Molecular Medicine, Sapienza University of
Rome, Rome, Italy, 2Unit of Pathology, Ospedale di
Circolo, Varese, Italy, 3Unit of Hereditary Cancers, IRCCS
AOU San Martino – IST, Genoa, Italy, 4Section of Medical
Oncology, Department of Surgical and Oncological
Sciences, University of Palermo, Palermo, Italy, 5Molecu-
lar Genetics Laboratory, Istituto Tumori “Giovanni Paolo
II”, Bari, Italy, 6Istituto Scientiﬁco Romagnolo per lo
Studio e la Cura dei Tumori, Forlì, Italy, 7Unit of
Functional onco-genomics and genetics, CRO Aviano,
National Cancer Institute, Aviano (PN), Italy, 8Department
of Oncology and Haematology, University of Modena and
Reggio Emilia, Modena, Italy, 9Immunology and Molecular
Oncology Unit, Veneto Institute of Oncology IOV - IRCCS,
Padua, Italy, 10Molecular and Nutritional Epidemiology
Unit, Cancer Research and Prevention Institute (ISPO),
Florence, Italy, 11Unit of Molecular Bases of Genetic Risk
and Genetic Testing, Department of Preventive and
Predictive Medicine, Fondazione IRCCS Istituto Nazionale
Tumori (INT), Milan, Italy, 12IFOM, The FIRC (Italian
Foundation for Cancer Research) Institute of Molecular
Oncology, Milan, Italy
Introduction: Male breast cancer (MBC) is a rare disease.
Inherited mutations in BRCA1, BRCA2 and PALB2 accounts
for 10–15% of all cases. Thus, a fraction of MBCs is
expected to be caused by genetic risk factors yet to be
identiﬁed.
FANCM has been suggested as a novel breast cancer
(BC) susceptibility gene. Particularly, two FANCM muta-
tions, c.5101C>T (rs147021911) and c.5791C>T
(rs144567652) have been associated with female BC risk.
Materials and methods: Aimed at investigating the
genetic component of MBC, FANCM c.5101C>T and
c.5791C>T mutations were genotyped in 506 BRCA1/2
mutation negative MBCs and 854 male controls from the
Italian Multicenter Study on MBC using TaqMan assays.
Furthermore, the entire coding region of FANCM was
screened in 286 MBCs, by a custom gene panel using NGS
technologies.
Results: Case-control study showed that FANCM
c.5101C>T was not present in any of the samples analyzed,
and FANCM c.5791C>T was found in two controls
(0.23%). Screening of the whole gene revealed two FANCM
truncating mutations, c.1432C>T (p.Arg478Ter) and
c.1972C>T (p.Arg658Ter) in two (0.7%) young MBC
patients (42 and 55 years old, respectively).
Conclusions: FANCM c.5101C>T and c.5791C>T
mutations may not have a major role in MBC susceptibility.
Nevertheless, other rare FANCM truncating mutations may
be associated with MBC risk. We suggest the inclusion of
FANCM in gene panel testing for MBC cases, so that the
identiﬁcation of a higher number of mutation carriers will
help estimate MBC risk associated with FANCM mutations.
Study supported by Italian Association for Cancer
Research (AIRC IG16933) to LO.
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P12.135C
Characterisation of myelodysplastic syndromes in an
Asian population by conventional cytogenetics
G. Y. Lee1, A. S. T. Lim1, G. Y. M. Cheah2, S. L. Tien1
Singapore General Hospital, Singapore, Singapore,
2Nanyang Technological University, Singapore, Singapore
Introduction: Myelodysplastic syndromes (MDS) is a
neoplastic bone marrow disorder characterised by dyspoi-
esis of the hematopoietic cells of all lineages. Hence, MDS
patients are often cytopenic. The aim of this study was to
corroborate and charaterise the karyotypic aberrations of
MDS among our Singapore General Hospital (SGH)
patients by conventional cytogenetics (CC).
Materials and Methods: A review was done on patients
in our laboratory with MDS between January 2010 and
December 2014.
Results: A total of 340 patients with MDS was identi-
ﬁed, comprising 140 females and 200 males, with a ratio of
1 female:1.4 male. The ages of the patients ranged between
15 and 92 years, with a median age of 67 years. CC was
performed on 332 patients, with 166 patients presenting
chromosomal abnormalities.The detection rate of MDS by
CC was therefore 50.5%. Eighty-three patients presented
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with a single aberration, with trisomy 8 (+8) being the most
common sole abnormality, followed by a loss the Y (-Y)
chromosome, deletion of the q-arms of chromosome 20
(del20q) and chromosome 5 (del5q). Twenty-eight patients
had 2 aberrations, with trisomy 1 (+1) as the most common
additional aberration, followed by a loss/partial loss of the
q-arm of chromosome 7 (-7/del7q) and+ 8 as the second
most common additional aberration. Ten and 50 patients
had 3 and >3 chromosomal aberrations, respectively.
Conclusions: MDS more often presents with a sole
abnormality and more often affects the elderly. The aber-
rations commonly but not exclusively include +8, -Y,
del20q, del5q, +1 and -7/del7q, in decreasing order.
G.Y. Lee: None. A.S.T. Lim: None. G.Y.M. Cheah:
None. S.L. Tien: None.
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Detecting EGFR exon 19 deletions and L858R in
patients with non small cell lung cancer
Z. A. Hammoudeh1, V. Koleva2, Y. Kyuchukov2, P.
Dakova2, A. Penev2, T. Minchev2, D. Toncheva1
1Department of Medical Genetics, Medical University -
Soﬁa, Bulgaria, Soﬁa, Bulgaria, 2Tokuda Hospital Soﬁa,
Bulgaria, Soﬁa, Bulgaria
Background: Non-small-cell lung cancer (NSCLC) is the
leading cause of death in Bulgaria for both men and women.
NSCLC patients usually have activating EGFR mutations
which leads to a very good response when is treated with
EGFR-tyrosine kinase inhibitors (TKIs). We evaluate the
presence of active EGFR mutations in a large sample of
NSCLCs. Methods: DNA was extracted from formalin-
ﬁxed parafﬁn-embedded NSCLC tumor samples and was
performed by QIAamp DNA FFPE Tissue Kit. The samples
were analysed by real-time PCR, using therascreen EGFR
assay. We determined the types and frequency of EGFR
mutations and their association with smoking status, sex and
histology. Results: We tested 600 lung cancer samples for
the presence of EGFR exon 19 deletions, L858R in exon 21
and another 9 somatic mutations. EGFR sensitive mutations
were found in 57 NSCLC samples (9.5%). The frequency of
EGFR mutations was greater for females versus males
(6.6% versus 3%, P < .001). The frequency of EGFR
mutations is greater in never smokers (5.5%) after that is the
frequency of ever smokers (3.83%) at the last is the smokers
(0.16%) with P < .001, and the frequency for adenocarci-
nomas versus other histological types (squamous cell car-
cinoma and other) are 7% versus 2.5%; P < .001.
Conclusion: Oure results show that activating EGFR
mutations are more frequent in females than in males, in
adenocarcinoma than squamous cell carcinoma and large
cell carcinoma. EGFR mutations are more frequent in non-
smokers than smokers. Acknowledgements: Astra Zeneca
Z.A. Hammoudeh: None. V. Koleva: None. Y. Kyu-
chukov: None. P. Dakova: None. A. Penev: None. T.
Minchev: None. D. Toncheva: None.
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Novel germline variants in melanoma families
N. K. Hayward1, A. Pritchard1, P. Johansson1, L. Aoude1,
G. Jonsson2, V. Höiöm3, K. Wadt4, D. Adams5
QIMR Berghofer Medical Research Institute, Brisbane,
Australia, 2Lund University, Lund, Sweden, 3Karolinska
Institute, Stockholm, Sweden, 4Rigshospitalet, Copenhagen,
Denmark, 5Wellcome Trust Sanger Institute, Cambridge,
United Kingdom
Germline mutations in CDKN2A account for susceptibility
in ~40% of cutaneous melanoma (CM) families, while
mutations in the CDK4, MITF, TERT, POT1, ACD and
TERF2IP genes each occur in <1–2% of CM families.
Mutations in BAP1 have been associated with susceptibility
to both CM and uveal melanoma (UM), as well as meso-
thelioma and a range of other cancers. BAP1 is the only
known high penetrance UM gene, responsible for suscept-
ibility in ~5% of CM families with single cases of UM.
Thus the genetic mutations underlying predisposition in the
majority of CM and UM families is unknown. To identify
new familial melanoma genes we have used whole genome
sequencing (WGS) or whole exome sequencing (WES) of
multiple affected members of >176 CM and/or UM famil-
ies. Each family was prescreened and shown to be wildtype
for all of the known melanoma predisposition genes. WGS/
WES was performed by the Wellcome Trust Sanger Insti-
tute (UK) or Macrogen (Korea) on the Illumina Hiseq 2000
or X Ten platforms. Variants were ﬁltered for stringency
using quality score of >70 and alternate read counts of >2
and >20% of all reads at a given position. Novel or rare
(frequency < 0.001 in the ExAC Consortium population of
60,706 individuals) protein-changing variants that lead to
premature truncation of the protein were prioritized as likely
pathogenic variants. Based on known biology several of
these genes are plausible candidates for novel familial
melanoma genes. Follow-up studies are underway to accrue
additional support.
Funded by NHMRC grant 633004.
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Analysis of mutations in melanocytic nevus and mela-
noma samples by next-generation sequencing
I. S. Abramov1,2, M. Emelyanova1,2, O. Ryabaya2, L.
Ghukasyan1, E. Stepanova2, N. Petrochenko2, T.
Belysheva2, L. Lyubchenko1, A. Zasedatelev1,2, T.
Nasedkina1,2
1Engelhardt Institute of Molecular Biology RAS, Moscow,
Russian Federation, 2N.N. Blokhin Russian Cancer
Research Center, Ministry of Health of Russia, Moscow,
Russian Federation
Melanoma remains one of the most aggressive types of
cancer despite advancements in our understanding of the
molecular mechanisms underlying malignization, disease
progression, and therapeutic response. Identiﬁcation of
mutations predicts the progression of disease and deter-
mines the choice of therapy, providing a personalized
approach to treating melanoma. In addition, the search for
new mutations that can cause tumor response to target
inhibitors is of great interest. In present study we used
targeted next-generation sequencing (NGS) for the analysis
of mutations in 6 melanocytic nevus and 29 melanoma
samples. Sequencing was performed using a platform GS
Junior (454/Roche). The Nimblegen technology (Roche)
was used for target regions enrichment including NRAS,
PDGFRA, KIT, RASA1, RAC1, MET, BRAF, PTEN, AKT1,
MAP2K1, MAP2K2, TP53 and TERT genes. In melanocytic
nevus somatic mutations in BRAF (p.Val600Glu) (16%),
and germline mutations in CDKN2A (p.Ala148Thr, p.
Gly63Arg) (33%), PDGFRA (p.Ser478Pro) (33%) were
found. In melanoma samples different types of somatic
mutations in NRAS (p.Gly13Arg, p.Gln61His) (10%),
BRAF (p.Val600Glu, p.Val600Lys) (45%), MAP2K1 (p.
Pro124Ser) (3%), TP53 (p.Gln331Ter, p.Glu224Lys) (7%),
PDGFRA (p.Glu571Lys) (3%) and germline mutations in
PDGFRA (p.Leu221Phe) (3%), KIT (p.Met541Leu, p.
Val50Leu) (20%), RASA1 (p.Ala99Val) (14%) were dis-
covered. The somatic/germline nature of the mutations was
determined by Sanger sequencing of normal tissue from the
same patients. Further investigations using NGS may help
in searching of new pathogenic mutations on different
stages of tumor development. This work was supported by
the Russian Science Foundation (grant # 14−35-00107).
I.S. Abramov: None. M. Emelyanova: None. O.
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The molecular differences between tumor and its liver
metastases in colorectal cancer
V. P. Shubin, A. S. Tsukanov, A. A. Ponomаrenko, O. A.
Maynovskaya, S. A. Frolov, V. N. Kashnikov, Y. A.
Shelygin
Ministry of Health / State Scientiﬁc Centre of Coloproctol-
ogy, Moscow, Russian Federation
Presence of malignant cells with different biological char-
acteristics in one tumor is an intratumoral heterogeneity.
Formation and development of tumor metastases of color-
ectal cancer in distant organs are observe in 50% cases. It is
known there are tumors and metastases cells with different
aggressive grade. The aim of our study was to analyze
genes expression (ZEB1, ZEB2, VIM, CDH1, SFRP2,
FOXQ1, TNC, MACC1, PLS3, CFTR, FLNA, MUC2, TFF3
и RARRES3) and genes somatic mutations (KRAS, NRAS,
BRAF, PIK3CA) in the primary tumor and liver metastasis.
In this study, using PCR real time and sequencing, were
investigated samples of synchronic metastatic CRC from 40
patients. In 120 cases, tissue, tumor and nodes of the liver
metastases were available. Data expression genes of tumors
and its liver metastases have been concurred for 55%
samples. Epithelial-mesenchymal transition was found in
one tumor and 7 liver metastases from 8 patients. NRAS and
BRAF mutations were not found. Overall frequency of
KRAS, PIK3CA mutations of tumors was 18/40 (45%), 9/40
(23%), respectively and had been correspond to with
metastases. Our study revealed that gene expression proﬁle
in the primary tumor and metastasis is different for half
cases, whereas there are full concordance between tumor
and metastasis for somatic mutations.
V.P. Shubin: None. A.S. Tsukanov: None. A.A.
Ponomаrenko: None. O.A. Maynovskaya: None. S.A.
Frolov: None. V.N. Kashnikov: None. Y.A. Shelygin:
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Themurine miR-302 host gene structure and its potential
use as cancer stem cellmarker
K. Rahimi1,2, E. Füchtbauer3, A. Füchtbauer3
1Department of Molecular Biology and Genetics - Gene
Expression and Gene Medicine, Aarhus University, Aarhus
C, Denmark, 2Interdisciplinary Nanoscience Center -
INANO-MBG, iNANO-huset, Aarhus University, Aarhus
C, Denmark, 3Department of Molecular Biology and
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Stem cells have unique properties including self-renewal
and multipotency that are shared with cancer stem cells.
MicroRNAs are important regulators of stemness state of
the cells. MiR-302s/367 is a polycistronic miRNA cluster
including miR-302b/c/a/d and miR-367 which is located in
the intron of a non-coding host gene. MiR-302s have been
shown to repress mRNAs required for differentiation to
induce pluripotency in somatic cells. The stem cell speciﬁc
transcription factors Oct4, Sox2 and Nanog drive miR-302s
expression. We found mmiR-302 expression in CJ7 murine
ES cells, teratomas, and PymT induced mammary gland
tumors. Of these, teratomas showed the highest miR302
expression. 'Rapid Ampliﬁcation of cDNA Ends' (RACE)
for the 5′ and 3′ ends of the miR-302 host gene showed that
this RNA is capped and polyadenylated. Sequencing of ES
cell and teratoma derived cDNAs showed alternative spli-
cing and polyadenylation which differs in ES and teratoma
derived cells. Cell fractionation and qPCR showed that the
host RNA of mmiR-302 is exported to the cytoplasm.
Utilizing luciferase-based reporter vectors we found the
regulatory sequences to extend at least 2 kb upstream of the
transcription start site. This regulatory region contains
several conserved binding sites for both transcriptional
activators and suppressors. Reporter constructs with dif-
ferent upstream regions result in differential expression in
ES and teratomas and might therefore explain the differ-
ential expression of miR-302 in different types of stem
cells. Moreover, as a proof of principle, cancer stem-like
cells were selected from teratomas utilizing the NEO
resistance gene driven by the mmiR-302 promoter.
K. Rahimi: None. E. Füchtbauer: None. A.
Füchtbauer: None.
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The microRNA 221: Biogenesis, Function and signatures in
Human Cancers
A. Abak, E. Sakhinia, A. Abhari, S. Amini
abriz university of medical sciences, Tabriz, Iran, Islamic
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MicroRNAs (miRNAs) are small non-coding RNAs of (18–
25 nucleotides) that control gene expression in post tran-
scriptional level through binding to the 3´-UTR of mRNAs
and block mRNA transcription and/or adversely regulate its
resistance. Much research indicates that dysregulation of
miRNA is a sign of cancer. The expression of miRNA are
frequently abberant and their function is relevant to the
regulation of oncogenes and/or tumor suppressor genes
involved in cell signaling pathway. MiR-221 and miR-222
are two extremely homologous microRNAs, which high
expression has been commonly indicated in various types of
human cancers. The function of miR-221/miR-222 have
been investigated as oncogenes or tumor suppressors,
related to tumor system. Here we review the role of miR-
221/miR-222 in various types of cancer progression and
development: controling proliferative signaling pathways,
avoiding cell death from tumor suppressors, monitoring
angiogenesis and even supporting epithelial-mesenchymal
transition. We discuss that miR-221/miR-222 act as pro-
mising biomarkers for prognosis in various types of cancer
and they would suggest a new pathway in molecular tar-
geting cancer treatment.
A. Abak: None. E. Sakhinia: None. A. Abhari: None.
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microRNA-31 explicitly down-regulated in PTEN low
gastric cancers
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Altinay2, D. Ece4, P. Engin Zerk2, A. Aydin5
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bul Medeniyet University, Goztepe Research and Training
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3Istanbul Medeniyet University, Faculty of Medicine,
Istanbul, Turkey, 4Istanbul Dr. Lutﬁ Kırdar Kartal
Research and Training Hospital, Department of Pathology,
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Medicine, Department of Pathology, Istanbul, Turkey
Introduction: Gastric cancer is one of the most common
world-wide cancers where early diagnosis is essential due to
its poor prognosis. MicroRNAs (miRNAs) are small (~22
nucleotide) non-coding RNAs that gained great impact in
the last decade owing to their critical roles in regulating
gene expressions through post-transcriptional suppression
or translational repression. Recent studies have linked
deregulation of miR-31 to gastric cancer; however its pre-
cise mechanism remains to be elucidated.
Materials/Methods: We immunohistochemically eval-
uated SMAD4, PTEN and microsatellite instability bio-
markers of MLH1, MSH2, MSH6 and PMS2 expressions
within 115 Gastric adenocarcinoma (GA) and 20 control
gastric tissue samples with prognostic signiﬁcance of clin-
icopathological factors. Moreover, 15 miRNA expressions
were investigated within subgroups of GA according to
SMAD4 and PTEN expressions. miRNAs were isolated
584
from parafﬁn-embedded tissue specimens and expressions
were carried out by Real Time PCR using miScript miRNA
Primer Assays (Qiagen, USA) and analysed by online
analysis tool (www.qiagen.com). Results: miR-31 expres-
sions were signiﬁcantly 6.87 (p<0,001), 4.25 (p= 0,048)
and 4.28 (p=0,012) fold down-regulated in PTEN low GA
subgroups as all low (SMAD4, PTEN, MLH1, MSH2,
MSH6 and PMS2), only PTEN low and both PTEN and
SMAD4 low, respectively. Conclusion: Not only miR-21
by up-regulation, but also miR-31 by down-regulation
might have role on apoptosis pathway through PTEN and
p53 in gastric cancer. Hence, miR-31 might be served as
tumor suppressor biomarker for gastric cancer. Grant:
Research Fund of Istanbul Medeniyet University; Project #
TSA-2013-401 and TSG-2013-333 Reference: Wang H
et al. 2016. PMID: 27174918
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HTG EdgeSeq miRNA Platform Performance Metrics Uti-
lizing The MicroRNA (miRQC) Study Specimens
B. LaFleur, S. Aissaoui; TG Molecular Diagnostics, Inc.,
Tucson, AZ, United States
Introduction: miRNAs are short, ~22nt RNA sequences
that modulate gene transcription and downstream cell
behavior. There are several platforms used for quantitation
of low abundance miRNAs found in circulating human
bodily ﬂuids, the miRQC manuscript included 12 such
platforms from quantitative PCR (PCR), hybridization
(HYB), and sequencing (SEQ) based technologies. The
HTG EdgeSeq miRNA Whole Transcriptome Assay
(WTA) is a technology that enables users to measure the
expression of human miRNA transcripts using NGS.
Methods: We obtained control samples used in the
miRQC study (Mastdagh, et. al., Nature, 2014) to measure
performance of our miRNA assay using the methods
described in the Nature publication. Sixteen mandatory and
4 optional human serum RNA control samples were inclu-
ded in the miRQC study. These were prepared using HTG
protocols; including RNA at 25ng. These control samples
were constructed to evaluate a series of metrics measuring
platform performance: reproducibility, detection rate sensi-
tivity, accuracy, speciﬁcity, and differential expression.
Results: The HTG assay demonstrated excellent repro-
ducibility with an area to the left of the cumulative dis-
tribution curve (ALC) of 0.108, ranking 2nd across
platforms. Accuracy, measured by the median deviation
from the expected ratio, was 22% (ranking 5th). Speciﬁcity
(cross-reactivity) was moderate at 29.2%. The 14% false
positive rate was equivalent to that seen in two other plat-
forms PCR and SEQ based technologies with only 4 plat-
forms performing better.
Conclusions: With the lowest RNA input of all 12
comparator platforms the HTG EdgeSeq miRNA WTA
produced reproducible, accurate, and sensitive results using
the miRQC study samples.
B. LaFleur: None. S. Aissaoui: None.
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MiRNAs and MAPK signaling pathway in pediatric acute
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Andoin2, A. Navajas3, A. Sastre4, A. Carboné Bañeres5, I.
Astigarraga6,3, A. García-Orad1,3
1University of the Basque Country, Leioa, Spain, 2Univer-
sity Hospital Donostia, Donostia, Spain, 3BioCruces Health
Research Institute, Barakaldo, Spain, 4University Hospital
La Paz, Madrid, Spain, 5University Hospital Miguel Servet,
Zaragoza, Spain, 6University Hospital Cruces, Leioa, Spain
Background
Recently, several Genome wide associations studies
(GWAS) have found genetic variants associated with
pediatric acute lymphoblastic leukemia (ALL) risk. These
studies were mainly focused in coding regions. Nowadays,
it is known that more than 40% of signiﬁcant variants
associated with cancer risk are situated in non-coding
regions, where non-coding RNAs are located. MicroRNAs
(miRNAs) are non-coding RNA molecules dysregulated in
ALL, suggesting a role in ALL risk. Despite miRNA SNPs
interfere with miRNA levels or function, only 3 studies in
ALL susceptibility were done, showing signiﬁcant results.
Therefore, variants in miRNAs could contribute to child-
hood B-ALL predisposition. Nowadays, a large number of
new miRNAS were annotated. Therefore, the aim of this
study was to determine if any of SNPs in these new miR-
NAs are involved in B-ALL susceptibility.
Material and Methods
Blood samples of 217 pediatric patients with B-cell ALL
in complete remission and 330 healthy controls of Spanish
origin were analyzed. We selected all the SNPs described in
pre-miRNAs with a MAF > 1% (213 SNPs in 206 miR-
NAs). VeraCode GoldenGate platform was used. MirWalk,
RNAFold web server and Consensus Path Databases were
used to performed bioinformatic analysis.
Results
The SNPs rs12402181 in mir3117 and rs62571442 in
mir3689d2 were associated with B-ALL risk possibly
through its effect on MAPK signaling pathway.
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Conclusion
Therefore, in this study we found rs12402181 in mir3117
and rs62571442 in mir3689 associated with B-ALL risk.
These SNPs could be novel markers for B-ALL
susceptibility.
This project was supported by UPV/EHU (UFI 11/35)
and Basque Government (IT989-16).
A. Gutierrez-Camino: None. I. Martín-Guerrero:
None. N. García de Andoin: None. A. Navajas: None. A.
Sastre: None. A. Carboné Bañeres: None. I. Astigarraga:
None. A. García-Orad: None.
P12.146B
Frequency of germline mutations in MMR genes among
Russian patients with Lynch syndrome
A. S. Tsukanov, V. P. Shubin, A. V. Vardanyan, D. A.
Semenov, S. I. Achkasov, V. N. Kashnikov, Y. A.
Shelygin; inistry of Health / State Scientiﬁc Center of
Coloproctology, Moscow, Russian Federation
Introduction: Lynch syndrome is one of the most frequent
hereditary colorectal cancer syndromes. The syndrome is
caused by mutation in one of the mismatch repair (MMR)
genes: mainly MLH1, MSH2, MSH6, PMS2 and PMS1. The
aim of this investigation was to study frequency and spec-
trum of germline mutations of MMR genes among Russian
patients. Materials and Methods: Microsatellite instability
was studied in tumor samples of probands who corre-
sponded to next criteria: age ≤ 45 and/or family history of
colorectal cancer. Germline mutations in MMR genes of
patients with MSI-H (high level) tumors were detected by
PCR, conformation-sensitive electrophoresis, Sanger
sequencing and NGS. Results: Microsatellite instability of
high level was found in 88 tumor samples. Thirty nine out
of 88 patients had germline mutations in MMR genes.
Seventeen mutations were found in MLH1, 17 mutations -
in MSH2, 3 mutations - in MSH6, 1 mutation - in PMS2 and
1 - in PMS1. Eighteen of these mutations were frameshift,
10 - nonsense, 5 - splice sites and 6 pathogenic missense
mutations. Conclusion: Frequency of germline mutations in
MLH1, MSH2, MSH6, PMS2 and PMS1 genes among
Russian patients with Lynch syndrome was 43,6%, 43,6%,
7,6%, 2,6% and 2,6% respectively.
A.S. Tsukanov: None. V.P. Shubin: None. A.V. Var-
danyan: None. D.A. Semenov: None. S.I. Achkasov:
None. V.N. Kashnikov: None. Y.A. Shelygin: None.
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Cowden syndrome caused by low level mosaicism of PTEN
Y. GOLDBERG1, Z. Levi2, D. Berkovich3, A. Jacobson4,
C. C. Pritchard4, T. Walsh4, I. B. Kedar1
1Raphael Recanati Genetics Institute, Rabin Medical
Center, Petah Tikva, Israel, 2Department. of Gastroenter-
ology, Rabin Medical Center, Petah Tikva, Israel, 3GGA
Galil Genetic analysis, Kazrin, Kazrin, Israel, 4Department
of Laboratory Medicine, University of Washington,, Seattle,
WA, United States
Introduction: Cowden syndrome (CS) is part of the PTEN
cancer predisposition syndrome, characterized by an
increased risk for benign or malignant thyroid tumors,
breast, endometrial and renal cancer. Individuals with CS
may have macrocephaly, trichilemmomas and papilloma-
tous papules. The main gene known to cause CS is PTEN.
Description: A 47 years old woman was referred to our
Onco-genetics clinic by oral surgery clinic for mucosal
papillomatosis and the possibility of CS. A tongue biopsy
revealed multiple fragments of epithelial hyperplasia.
Recently she was diagnosed with a follicular variant of
papillary thyroid carcinoma. An endometrial polyp was
diagnosed as complex hyperplasia with moderate atypia.
Colonoscopy detected several polyps, one of them adenoma
with low grade dysplasia and gastroscopy revealed glyco-
genic acanthosis. Head circumference measured 59 cm (>
98th percentile). Her family history included her mother
with breast cancer at age 68, not a carrier of the 3 Ashkenazi
mutations in the BRCA1/2 genes. Her father had CLL at age
78.
Methods: A cascade genetic testing approach was
applied on DNA extracted from blood; Sanger sequencing
and MLPA analysis for duplication/deletion mutations in
the PTEN gene and promotor sequencing were followed by
deep next generation sequencing.
Results: Only deep next generation sequencing revealed
a pathogenic mutation. The pathogenic variant p.Q149X;
c.445C>T in the PTEN gene was detected in 22/646 (3%)
reads - indicating mosaicism.
Conclusion: We report low level mosaicism causing
classic CS. Mosaicism should be evaluated by deep
sequencing when the phenotype ﬁts clinical criteria, even
with normal Sanger sequencing.
Y. Goldberg: None. Z. Levi: None. D. Berkovich:
None. A. Jacobson: None. C.C. Pritchard: None. T.
Walsh: None. I.B. Kedar: None.
P12.148D
Prevalence of multilocus inherited neoplasia alleles syn-
drome among lynch syndrome patients
R. Ferrer-Avargues1, M. I. Castillejo1, T. Molina2, V.
Díez-Obrero1, A. Codoñer Alejos1, M. García-Bautista2,
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N. Garrigos2, A. Castillejo1, J. L. Soto1; Hospital General
Universitario Elche, Elche, Spain, 2Centro Inmunológico
de Alicante, Alicante, Spain
Introduction: Multilocus Inherited Neoplasia Alleles Syn-
drome (MINAS) has been recently described as the pre-
sence of two or more inherited cancer predisposition alleles
in the same individual. This condition could explain a part
of the large phenotypic variability in Lynch syndrome (LS).
We aimed to study the prevalence of MINAS in genetically
diagnosed LS patients.
Materials and Methods: Eighty-four LS probands with
characterized pathogenic variants in MMR genes were
included in this study. All patients were treated through the
Hereditary Cancer Program, Comunidad Valenciana
(Spain). DNA from PBL was sequenced by NGS for 94
hereditary cancer related genes (MiSeq and TrueSight
Cancer Panel, Illumina). Standard pipeline for genetic var-
iant analysis and recommended international guidelines for
clinical variant classiﬁcation were applied. All pathogenic
(class 5) and probably pathogenic (class 4) variants were
conﬁrmed by Sanger sequencing.
Results: The average coverage at 20X of the 255Kb
target sequence was 96.2%. Besides the known mutations in
LS genes, we found 6 pathogenic/probably pathogenic
variants in 6 patients associated to 3 hereditary cancer
syndromes: hereditary breast cancer (ATM, NBN, FANCA,
FANCI), neuroﬁbromatosis type 1 (NF1) and hereditary
leiomyomatosis (FH). These results show that the pre-
valence of MINAS is about 7% (6/84).
Conclusions: The prevalence of MINAS among LS
patients is relevant. The underlying genetic landscape in LS
becomes more complex than expected. Further analyses are
needed to clarify the clinical impact of these ﬁndings.
Supported by FISABIO UGP-14-192 and UGP-15-159
grants. RF-A is recipient of a Fellowship from the Con-
sellería Educación of the Comunidad Valenciana.
R. Ferrer-Avargues: None. M.I. Castillejo: None. T.
Molina: None. V. Díez-Obrero: None. A. Codoñer Ale-
jos: None.M. García-Bautista: None. N. Garrigos: None.
A. Castillejo: None. J.L. Soto: None.
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Proﬁling cancer-related gene alterations in Japanese multi-
ple myeloma patients by targeted amplicon sequencing
H. Fukushima1,2, Y. Sasaki2, M. Tamura2, H. Ikeda3, K.
Ishiguro4, T. Tokino2, A. Sakurai1
1Department of Medical Genetics, Sapporo Medical Uni-
versity, Sapporo, Japan, 2Department of Medical Genome
Sciences, Research institute for Frontier Medicine, Sapporo
Medical University, Sapporo, Japan, 3Department of
Hematology, Sapporo Medical University, Sapporo, Japan,
4Department of Gastroenterology, Sapporo Medical Uni-
versity, Sapporo, Japan
Introduction: Multiple myeloma (MM) is an incurable and
refractory hematological malignancy even after introduction
of the novel treatments. The comprehensive analysis of
genetic alterations in tumor by next generation sequencing
can allow for the prediction of drug resistance and facilitate
improvements in the treatment of MM. We tried to deﬁne
genetic changes speciﬁc for each MM sample using targeted
semiconductor sequencing technology. Materials and
Methods: DNA was extracted from ﬁve MM cell lines and
magnetic bead-enriched bone marrow CD138-positive
malignant plasma cells from 11 cases of MM, and
CD138-negative cells were used as matched non-tumor
cells. 40ng of DNA were used for multiplex PCR ampliﬁ-
cation with an Ion Ampliseq Comprehensive Cancer Panel
that offers targeted coverage of all exons in 409 tumor
supressor genes and oncogenes frequently cited and muta-
ted in human cancers. Results: The average numbers of
non-synonymous mutations and copy number variations
(CNVs) detected were 6.1 (range 3-11) and 15.2 (3–27) per
patient, and 16.8 (13–26) and 59.8 (18–154) per cell lines.
Somatic mutations and CNVs were found in known MM-
associated genes, including TP53, NRAS and CCND1. We
also identiﬁed numbers of novel recurrent alterations.
Pathway assessment has shown that somatic aberrations
within MM genomes are mainly involved in several
important pathways, including cell cycle regulation, RTK-
MAPK-PI3K and NF-kB. Conclusions: We performed
targeted next-generation sequencing for rapid (2 days),
standardized, and cost-effective gene analysis of MM
patients. This targeted next generation sequencing may
allow clinically oriented variant screening in MM.
H. Fukushima: None. Y. Sasaki: None. M. Tamura:
None. H. Ikeda: None. K. Ishiguro: None. T. Tokino:
None. A. Sakurai: None.
P12.150B
Whole genome sequencing in patients with multiple pri-
mary tumors
K. Wallander, D. Nilsson, E. Tham; arolinska Institute,
Stockholm, Sweden
Introduction
The risk of developing three or more different primary
tumors is very low in the population, but not uncommon in
hereditary cancer syndromes e.g. Lynch syndrome. It is thus
reasonable to believe that there is a genetic predisposition to
cancer in individuals with multiple tumors.
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Materials and Methods
DNA from peripheral blood from twelve patients with
three or more primary tumors was analyzed with exome/
genome sequencing on the Illumina platform. Variant triage
was performed in two steps. Variants fulﬁlling initial cri-
teria (in a gene associated with cancer, minor allele fre-
quency <2%, previously reported in mutation databases or
affecting the RNA/protein structure) were classiﬁed
according to the ACMG criteria.
Results
So far, six patients have been analyzed. The age-range of
ﬁrst cancer diagnosis was 27–60 years. Five patients had
one or more variants classiﬁed as either pathogenic or
probably pathogenic. All patients also had three or more
variants of unknown signiﬁcance. Two patients had a
CHEK2-variant. One had 1100delC, pathogenic in heredi-
tary breast cancer, and she had tumors in the ovaries,
endometrium, colon and lymphoma. The other, with tumors
in the ovaries, breast and rectum, had a missense variant (p.
Arg224Cys), previously described in prostate cancer
syndrome.
Conclusion
Whole genome sequencing may identify predisposing
pathogenic variants in individuals with more than three
primary tumors. More research is needed to evaluate the
complex interplay between these different genetic variants
in order to determine if genetic testing can improve the
follow-up and clinical care of these patients.
K. Wallander: None. D. Nilsson: None. E. Tham:
None.
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Complex chromosome translocations as a driving event of
MYC upregulation in multiple myeloma
A. Mikulasova, C. T. Ashby, R. G. Tytarenko, O. W.
Stephens, E. Tian, P. H. Patel, C. K. Stein, C. P. Wardell,
S. Roy Choudhury, F. E. Davies, G. J. Morgan, B. A.
Walker; Myeloma Institute, University of Arkansas for
Medical Sciences, Little Rock, AR, United States
Introduction: Activation of MYC is a late progressional
event in multiple myeloma (MM), which negatively affects
patients’ survival. Here, we focused on the characterization
of MYC rearrangements and their association with MYC
upregulation.
Materials and Methods: In total, 48 MM patients were
analyzed using a custom targeted-capture of a 4.5Mb region
surrounding MYC. Copy-number abnormalities were ana-
lyzed by normalized tumor/germline depth ratio. Manta and
Strelka were used for structural and single nucleotide
variants, respectively. MYC expression level was deter-
mined by gene expression arrays.
Results: MYC rearrangements including translocations,
gains/tandem duplications, deletions and/or inversions were
detected in 52% (25/48) of samples. 92% (23/25) of
abnormal cases had a gain and/or translocation which
associated with higher MYC expression (P<0.0001),
hyperdiploidy (P<0.001) and NRAS mutation (P<0.01). We
considered translocations as drivers of MYC activation as 1)
they were detected in 88% (22/25) of abnormal cases; 2)
they deﬁned a subgroup of MM with signiﬁcantly higher
MYC expression compared to cases with other MYC rear-
rangements (P<0.01); and 3) most (68%, 15/22) involved
known super-enhancers near IGH, IGK, IGL, FAM46C and
TXNDC5 loci. A minimally gained region of 59kb was
present in 44% (11/25) of abnormal cases and included the
MYC locus. Translocations co-occurred with gain of MYC
in 10 cases identifying a group with highest MYC expres-
sion. Complex rearrangements were identiﬁed which will be
resolved by phased-read whole-genome sequencing.
Conclusions: 8q24.21 is a hotspot for heterogeneous
rearrangements in MM, however, MYC translocations are
the most important events as they result in signiﬁcant MYC
upregulation.
A. Mikulasova: None. C.T. Ashby: None. R.G.
Tytarenko: None. O.W. Stephens: None. E. Tian: None.
P.H. Patel: None. C.K. Stein: None. C.P. Wardell: None.
S. Roy Choudhury: None. F.E. Davies: None. G.J.
Morgan: None. B.A. Walker: None.
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Evaluation of antifolate drug in head and neck carcinoma
and preneoplastic lesions
G. M. M. Fernandes1, A. L. S. Galbiatti-Dias1, C. H. V.
Nascimento Filho1, L. A. M. Ferreira1, A. P. G. Campos2,
J. V. Maniglia2, J. A. Padovani Junior2, R. S. Kawasaki-
Oyama1, P. M. Biselli-Chicote1, É. C. Pavarino1, E. M.
Goloni-Bertollo1; Genetics and Molecular Biology
Research Unit (UPGEM), São José do Rio Preto Medical
School (FAMERP), São José do Rio Preto-SP, Brazil,
2Department of Otolaryngology and Head and Neck
Surgery, São José do Rio Preto Medical School
(FAMERP), São José do Rio Preto-SP, Brazil
Introduction: There are subpopulations of tumor cells
identiﬁed by biomarkers such as CD44, which have been
considered as cancer stem cells (CSCs). These cells are
responsible for sustaining tumor growth, resistance to con-
ventional therapies and disease recurrence. The aim of this
study was evaluated the treatment response of 5-
Fluorouracil in a subpopulation CD44+ cells of head and
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neck carcinoma and preneoplastic lesions (dysplastic and
hyperplastic epithelium). Material and Methods: HEP-2
(laryngeal carcinoma) and HN13 (oral cavity carcinoma)
cell lines, primary oral tumor and preneoplastic lesions were
incubated at 37°C in 5% CO2. CD44+ phenotype cells were
isolated by ﬂuorescence-activated cell sorting (FACS)
equipment (BD Becton Dickinson). CD44+ subpopulation
was considered as CSCs and it was cultured and exposed to
chemotherapeutic treatment with 0.37 mg/ml of 5-
Fluorouracil for 24 hours. CD44+ cells untreated were
used as control. Trypan blue staining was performed to
identify viable cells. Student t test was used for statistical
analyzes and the signiﬁcance level was 0.05. Results: The
percentages of viable tumor cells after 5-ﬂuorouracil treat-
ment compared to non-treated cells were 45.05%. The
treatment of preneoplastic lesions resulted in 54.31% of
viable cells. No signiﬁcant difference was shown between
the number of viable cells after the treatment and without
treatment (p>0.05). Conclusion: The 5-ﬂuorouracil treat-
ment appears to have no effect on elimination of CD44+
subpopulation in head and neck carcinoma and pre-
neoplastic lesions. The evaluation of CSCs-targeting agents
is essential for the development of therapies that can avoid
cancer eradication. Grants: FAPESP (2015/04403-8) and
CAPES.
G.M.M. Fernandes: None. A.L.S. Galbiatti-Dias:
None. C.H.V. Nascimento Filho: None. L.A.M. Ferreira:
None. A.P.G. Campos: None. J.V. Maniglia: None. J.A.
Padovani Junior: None. R.S. Kawasaki-Oyama: None.
P.M. Biselli-Chicote: None. É.C. Pavarino: None. E.M.
Goloni-Bertollo: None.
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Treatment response with Docetaxel and Paclitaxel in head
and neck cancer stem cells
A. L. S. Galbiatti-Dias1, G. M. M. Fernandes1, C. H. V.
Nascimento Filho1, R. S. Kawasaki-Oyama1, L. A. M.
Ferreira1, J. V. Maniglia2, L. S. Raposo2, P. M. Biselli-
Chicote1, E. C. Pavarino1, E. M. Goloni-Bertollo1
1Genetics and Molecular Biology Research Unit (UPGEM),
São José do Rio Preto Medical School (FAMERP), São
José do Rio Preto, Brazil, 2Department of Otolaryngology
and Head and Neck Surgery, São José do Rio Preto
Medical School (FAMERP), São José do Rio Preto, Brazil
Introduction: Docetaxel and Paclitaxel chemotherapies
treatment in head and neck cancer has presented failure. The
fact may be explained due to presence of cancer stem cells
(CSC) that have high capacity of tumorigenic potential,
self-renewal properties and slow growth cycle. CSC can be
detected with speciﬁc biomarkers such as CD44 associated
with cell aggregation, proliferation, invasion. This study
evaluated the treatment response with Docetaxel and
Paclitaxel drugs in CD44+ stem cells of head and neck
cancer.
Material and Methods: Primary oral tumor, HEP-2
(laryngeal carcinoma) and HN13 (oral cavity carcinoma)
cell lines were cultured and maintained in a 5% CO2
humidiﬁed incubator. CSC were identiﬁed by cell sorting
with anti-CD44-PE-conjugated using FACSAria Fusion
Citometry (BD Biosciences). CD44+ subpopulation were
cultured and treated with 3.7 mg/ml of Docetaxel and 0.05
mg/ml of Paclitaxel during 24 hours, separately. CD44+
cells without treatment were used as control group. Living
cells was identiﬁed by trypan blue staining. Test t Student
was utilized for statistical analysis. P<0.05 was considered
signiﬁcant.
Results: The number of living CD44+ cells in primary
tumor and cell lines was lower after the treatment with
Docetaxel (p=0.03) and Paclitaxel (p=0.009) when com-
pared with non-treated living CD44+ cells.
Conclusion: The treatment with Docetaxel and Paclitaxel
reduced the number of living CSC of head and neck. The
use of drugs targeting CSC is a promising therapeutic
strategy in cancer eradication so further studies are required
before their clinical application in the future.
Grants: São Paulo Research Foudation (FAPESP 2014/
15009-6 and 2015/04403-8)
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a novel risk SNP in the colorectal-cancer risk locus on
chromosome 9q22
J. Thutkawkorapin, H. Mahdessian, S. Picelli, S. Von
Holst, J. Lundin, V. Kontham, T. Liu, D. Nilsson, X. Jiao,
A. Lindblom; arolinska Institute, Solna, Sweden
Introduction: Heritable factors are well known to increase
the risk of cancer in families. Our linkage analysis in
2006 suggested a region on chromosome 9q22. to be linked
to an increased risk of adenomas and cancer in one large
study and the same region was also published by others. A
few years later we performed another linkage study in
familial colorectal cancer and again could replicate the
region on chromosome 9q22.
Aims: We set up to identify the genetic mutation within
this locus.
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Materials and Methods: We used a combination of
exome sequencing, targeted sequencing and association
study. The cases are Swedish familial and consecutive
colorectal cancer samples. 500 genotypes in the 9q region
were selected from an ongoing genome-wide association
study in Swedish colorectal cancer to search for a founder
effect in the 9q.
Results: In the exome sequencing study, there was no
mutations suggested to be disease causing in the coding
region. In the association study using 2709 colorectal cancer
cases and 4782 controls, one SNP, rs6477733, suggested a
risk with odds ratio 1.53 and p-value 0.000192.
Conclusions: We proposed a novel SNP, rs6477733, as
a moderate risk factor to colorectal cancer. Further studies
will show how the risk SNP inﬂuence the risk of colorectal
cancer.
Grant references: Swedish Cancer Society 160458
J. Thutkawkorapin: None. H. Mahdessian: None. S.
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NGS analysis of BRCA negative hereditary ovarian cancer
patients: aimed on repair genes
E. Machackova1, J. Hazova1, P. Vasickova1, E. Stahlova
Hrabincova1, P. Zemankova2, M. Svoboda1, M.
Navratilova1, L. Foretova1
1Masaryk Memorial Cancer Institute, Brno, Czech Repub-
lic, 2Institute of Biochemistry and Experimental Oncology,
Prague, Czech Republic
Ovarian cancer represents the leading cause of cancer
deaths among gynecological malignancies. The lack of
effective early detection strategies is associated with the
advanced stage at diagnosis and poor prognosis. As a ret-
rospective study, NGS panel (enrichment/hybridization
approach) targeting main cancer predisposition genes,
double-strand breaks repair as well as other repair pathway
genes (MMR, BER, NER) was used to analyze genomic
DNA of 100 high risk ovarian cancer patients with sig-
niﬁcant personal and family history of ovarian/breast can-
cers without previously identiﬁed mutation in BRCA genes.
All deleterious mutations detected by NGS technology have
been conﬁrmed by Sanger sequencing. In about 1/3 of
tested individuals at least one deleterious mutation was
detected. Several mutations were detected in known ovarian
cancer predisposing genes in DSBs repair genes as
RAD51C, BRIP1, RAD51D. NGS analysis revealed also
cancer syndromes including Cowden (PTEN), Von Hippel-
Lindau (VHL) and Lynch syndrome (MSH2) in relation to
ovarian cancer. Majority of deleterious mutations were
detected in genes where association with ovarian cancer
remains unclear: ATM, CHEK2, BARD1, NBS1,
FANCD2, RAD52, MUTYH, MSH5, EXO1, ERCC3,
ERCC5, TELO2, RECQL, BUB1B, GRB7 and others.
Panel genetic testing in high risk individuals may provide
valuable information for potential personalized therapy and
extend the possibilities of predictive testing in families and
specialized management. Supported by Czech Ministry of
Health: grant NV15-27695A and DRO: MMCI 00209805
E. Machackova: None. J. Hazova: None. P. Vasick-
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High resolution copy number variant and mutation analysis
identify novel candidate genes in optic nerve hypoplasia
S. Dahl1, M. Pettersson2, R. Wickström1, K. Teär
Fahnehjelm3,4,5, B. Anderlid2,6, A. Lindstrand2,6;
Department of Women's and Children's Health,
Neuropediatric Unit, Karolinska Institutet, Stockholm,
Sweden, 2Department of Molecular Medicine and
Surgery, Centre of Molecular Medicine, Karolinska
Institutet, Stockholm, Sweden, 3Department of Paediatric
Ophthalmology, St. Erik Eye Hospital, Stockholm,
Sweden, 4Department of Clinical Neuroscience,
Karolinska Institutet, Stockholm, Sweden, 5Department of
Neuroscience and Rehabilitation, University of
Gothenburg, Gothenburg, Sweden, 6Department of
Clinical Genetics, Karolinska University Hospital,
Stockholm, Sweden
Introduction: Optic nerve hypoplasia (ONH) is a con-
genital ocular malformation and a common cause of visual
impairment in children. Patients with ONH often have
coexisting pituitary hormone deﬁciencies, intellectual dis-
ability, autism, and neurological impairments. In the
majority of cases the etiology is unknown, but both envir-
onmental factors (e.g. prenatal alcohol exposure, congenital
infections) and genetic causes have been described. This
study was performed to establish the genetic contribution to
ONH and to identify novel candidate genes.
Materials and Methods: We have performed a systematic
investigation of genetic variants in a population-based
cross-sectional cohort of children and adolescents with
ONH. DNA from 37 patients was available for genetic
analysis. To identify both single nucleotide changes as well
as gene dose alterations we used a combination of massive
parallel sequencing of 56 candidate genes and a custom
design array-comparative genomic hybridization able to
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detect both large copy number variants (CNVs) and small
intragenic variants in 2000 target genes.
Results: The CNV analysis revealed 5 deletions and 6
duplications in 10 ONH cases, affecting 11 genes. The
sequencing of candidate genes in 17 cases identiﬁed can-
didate variants in one third, of which three individuals had a
pathogenic variant in COL4A1.
Conclusions: COL4A1 is a major genetic contributor to
ONH with mutations found in 3/17 (18%) cases studied
here. Our data also highlights several novel candidate genes
involved in different developmental pathways.
Grant references: The Swedish Brain Foundation, Sci-
LifeLab National projects, Linnea och Josef Carlsson
Foundation, and Sunnerdahl’s Handicap Foundation.
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Role of 14q32 miRNA cluster in Osteosarcoma
susceptibility
N. Bilbao-Aldaiturriaga1,2, I. Martín-Guerrero1, A.
Gutierrez-Camino1, J. Uriz3, A. García-Orad1,4
1University of the Basque Country, Leioa, Spain, 2Instituto
Ginecológico y Reproducción Asistida iGin S.L., Bilabo,
Spain, 3University Hospital Donostia, Donostia, Spain,
4BioCruces Health Research Institute, Barakaldo, Spain
Background
Recent genome wide association study (GWAS) in
osteosarcoma risk showed that several signiﬁcant results
were located in intergenic positions. These results suggest
that non-coding regions could play an important role in the
risk of osteosarcoma. One of the most studied non-coding
molecules are microRNAs (miRNAs), whose deregulation
has been associated with osteosarcoma evolution. There-
fore, genetic variants affecting miRNA function could
contribute to the risk of the disease. To date, only three
polymorphisms in miRNAs have been analyzed in relation
to the risk of osteosarcoma, and two of them showed sig-
niﬁcant association. In this context, this study aimed to
evaluate the involvement of all genetic variants in pre-
miRNAs in the risk of osteosarcoma.
Material and methods
We selected all SNPs described in miRNAs with a
MAF>0.1. A total of 213 SNPs in 206 pre-miRNAs were
analyzed in a cohort of patients (n= 74) and their corre-
sponding controls (n= 160) using Goldengate Veracode
technology. χ2 or Fisher and FDR were used.
Results
The most remarkably ﬁnding was the association detec-
ted between 4 SNPs located at 14q32 miRNA cluster.
Interestingly, miRNAs in this cluster have been associated
with MYC deregulation. Therefore, genetic variations in
these miRNAs could lead to their downregulation, which in
turn would lead to the overexpression of MYC. These
results suggest that this region is a hotspot for the devel-
opment of the disease.
Conclusion
In conclusion, different variants in 14q32 miRNA cluster
could be implicated in osteosarcoma susceptibility.
This project was supported by UPV/EHU (UFI 11/35)
and Basque Government (IT-989-16).
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BRCA1 and BRCA2 tumoral mutation detection in Nantes's
molecular genetics laboratory
J. LE GALL1, V. Guibert1, D. Dansette2, F. Airaud1, C.
Delnatte1, S. Bézieau1, V. Amarger3, D. Loussouarn2, C.
Garrec1; Laboratoire de Génétique Moléculaire, Service
de Génétique Médicale, CHU Nantes, Nantes, France,
2Service d'anatomie et cytologie pathologiques, CHU de
Nantes, Nantes, France, 3UMR PHAN, INRA, &
Université de Nantes, IMAD, CRNH-Ouest, Nantes,
France
Ovarian cancer has an estimated incidence of 225.000
women per year worldwide and remains a signiﬁcant cause
of mortality (140.000 deaths per year). The mean prob-
ability of ﬁnding a germline BRCA1 or BRCA2 mutation in
epithelial ovarian cancer is 12.7%. Somatic mutations of the
BRCA genes have been identiﬁed in approximately 6% of
serous ovarian carcinomas. It has been shown that tumors
with BRCA1 or BRCA2 pathogenic mutations respond to
drugs which inhibit PARP. It’s becoming increasingly
apparent that knowledge of BRCA status has prognostic
utility that can affect treatment decisions and may improve
survival.
In the molecular genetics laboratory of Nantes, we ana-
lyzed formalin-ﬁxed parafﬁn-embedded ovarian carcinoma
of 160 patients, from April 2016 to January 2017. Tumoral
mutations of BRCA1 and BRCA2 were screened by high-
throughput sequencing. Pathogenic mutations were found in
18/160 (11.25%) tumors ; 11/160 (6.8%) were only
somatic.
Recent studies have suggested that homologous recom-
bination deﬁciency in epithelial ovarian cancer can be due
to BRCA1 and BRCA2 mutations (included large
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rearrangements), epigenetic silencing of BRCA1, and loss of
function of other genes involved in homologous recombi-
nation. Reduced BRCA1 expression as a result of promoter
methylation has been reported in 11.5% high-grade serous
ovarian adenocarcinomas.
We therefore assessed complete BRCA status of some of
these ovarian cancer specimens by analyzing tumoral
BRCA1 and BRCA2 loss of heterozygosity, BRCA1 pro-
moter hypermethylation and BRCA1 protein expression.
Here, we present the results of these analyses.
J. Le gall: None. V. Guibert: None. D. Dansette: None.
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Single nucleotide polymorphisms of genes immune
response and ovarian cancer pathogenesis
E. Mingazheva1, D. Prokofyeva1, D. Sakaeva2, E.
Khusnutdinova1,3
1Bashkir State University, Ufa, Russian Federation,
2Republic Clinical Oncology Center, Ufa, Russian Federa-
tion, 3Institute of Biochemistry and Genetics, Ufa Scientiﬁc
Center, Ufa, Russian Federation
Ovarian cancer (OC) is the third most common gynecolo-
gical malignancy following uterine corpus cancer and cer-
vix cancer. Annually in the world registered more than 238
000 new cases of the disease, half of which are fatal. The
situation is similar in Russia. The immune system is thought
to be an important mediator of ovarian cancer.
We analyzed the associations of the 2 single nucleotide
polymorphisms (c.C1438T in ITIH2 gene and c.G481A in
gene AGBL2) with the risk of ovarian cancer in cases (n=
286) and controls (n= 223) from Bashkortostan. Poly-
merase chain reaction - restriction fragment length poly-
morphism was used for genotyping.
We identiﬁed an association of allele T for the c.C1438T
polymorphism in ITIH2 gene and decreased ovarian cancer
risk, OR=0,04, 95% CI:(0,01–0,15), p=0,0005. ITIH2
involved in inﬂammation and immune response, also inhi-
bits tumor metastasis and interacts with proteins such as the
EGFR and FN1. According to some studies, breast cancer
observed expression loss ITIH2 gene.
Also we identiﬁed an association polymorphism c.
G481A in AGBL2 gene with the risk of OC in Russian,
OR=0.11, 95% CI:(0.04–0.3), p=0,0005. AGBL2 partici-
pates in the regulation of proliferation of tumor cells,
epithelial-mesenchymal transition and resistance to
chemotherapy.
Our data indicate that c.C1438T and c.G481A poly-
morphisms are associated with ovarian cancer risk in
Bashkortostan.
E. Mingazheva: None. D. Prokofyeva: None. D.
Sakaeva: None. E. Khusnutdinova: None.
P12.160D
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Background: Ovarian cancer is the ﬁfth leading cause of
cancer mortality among women. There is no early diag-
nostic tool for the detection of this type of aggressive
malignancy. Cell-free microRNAs seem to be a promising
possible biomarker in the diagnosis.
Materials and methods: We involved 11 ovarian cancer
patients and 11 controls in the study. 15–16 ml EDTA
blood was drawn; the microRNA was isolated with miR-
Neasy Mini kit (Qiagen, Germany). cDNA was synthesised
and miR-103; miR-125, miR-193b and miR-200b expres-
sion were determined by using miRCURY Universal RT
microRNA PCR Starter kit (Exiqon, USA). miRNA-93 was
used as reference gene. Student t-test was applied for the
statistical calculations of the results.
Results: The isolated microRNA was suitable for cDNA
synthesis. We found signiﬁcant difference in the expression
of miR-103 (p=0.001), miR-193b (p=0.0236), miR-125
(p=0.029) and miR-200b (p=0.0273) among the cancer
patients and controls.
Conclusion: We determined the concentration of four
cell-free microRNAs from the plasma of healthy controls
and ovarian cancer patients. There was signiﬁcant differ-
ence in the expression of the studied microRNAs. We
extend our study on higher number of cases as these
microRNAs seem to be promising biomarkers for the
diagnosis of ovarian cancer.
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Polymorphisms associated with breast cancer susceptibility
in patients with ovarian cancer
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Ovarian cancer is the third most frequent gynecological
tumor and the ﬁfth cause of women cancer deaths in Spain.
Only 5–10% of the cases of ovarian cancer have an inher-
ited genetic condition. Therefore, a diagnosis of hereditary
Ovarian Cancer Syndrome should be considered in families
with multiples cases of breast cancer. Two genes have been
associated with familiar breast and ovarian cancer: BRCA1
and BRCA2. For this reasons, the aim of our study was to
characterize whether polymorphisms in genes associated
with breast cancer susceptibility would modify the risk of
developing ovarian cancer. We have studied BRCA1
rs799917, BRCA1 rs16941, BRCA1 rs16942, TP53
rs1042522, miR146 rs2910164, FGFR2 rs2981582, 8q24
region rs13281615 polymorphisms in a cohort of 117
Spanish patients and 116 healthy subjects.
Our results show that being a carrier of the allele C of
TP53 rs1042522 polymorphism is associated with reduced
risk of developing ovarian cancer. Non-signiﬁcantly dif-
ferences were found in the analysis of the BRCA1, miR146,
FGFR2 and 8q24 region polymorphisms in our cohort of
patients.
In conclusion, there seems to be no relation between
studied polymorphisms associated with breast cancer and
susceptibility to ovarian cancer, with the exception of the
allele C of TP53 rs1042522.
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Introduction: The main objective of precision medicine is
ﬁnding the right therapy for the right patient. In oncology,
this goal is particularly challenging also due to poor tissue
biopsies and low-tumor content, precluding in most cases
the study of tumor complexity. Here we describe a multi-
level approach that allows an accurate tumor characteriza-
tion in FFPE samples with low tumor-cellularity.
Methods: FFPE sections from pancreas ductal adeno-
carcinoma, with <20% tumor content, were processed by
DEPArray™ sorting protocol. Pools with different number
of cells (range=1–142) from 100%-pure stromal and tumor
populations were recovered and lysed. Single-cell DNA was
ampliﬁed using Ampli1™ WGA kit. DNA libraries were
prepared for low-pass Whole Genome Sequencing on
MiSeq. At the same time, two libraries from a stromal (n=
142) and tumor (n= 129) pool of cells were enriched with
Agilent SureSelectXT capture kit for Whole Exome
Sequencing (WES) on HiSeq. Moreover, cell pools were
used as input for the DEPArray™ OncoSeek amplicon-
based panel.
Results: Paired analysis of low-pass copy-number pro-
ﬁles and WES data identiﬁed several Loss-of-
Heterozigosity (LOH) as well as absolute copy-number
alterations in sorted pure-tumor populations, both unde-
tectable in bulk DNA from unsorted cells. Moreover, this
paired approach allowed to unambiguously detect a
homozygous loss of PTPRD onco-suppressor gene. Inter-
cell heterogeneity was observed through the analysis of
single-cell copy-number proﬁles. Finally, most non-
synonymous somatic variants detected, all conﬁrmed by
panel results, are relevant in pancreatic cancer.
Conclusions: Our results demonstrate the value of
DEPArray™ technology for the characterization of cancer
genomes in low-cellularity FFPE tumor samples.
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BRAF V600E mutation, the most potent activator of the
mitogen-activated protein kinase pathway, plays a central
role in the regulation of cell growth, division, and pro-
liferation. To date, BRAF V600E analysis has been widely
adopted in the management of papillary thyroid carcinoma
(PTC) patients. Here, we explore the correlation and the
clinical value of B-RAF V600E mutation detection in PTC
and regional lymph node metastasis (LNM). Two Tunisian
female patients P1 and P2 (aged 22 and 32 years respec-
tively), suffering from PTC, underwent total thyroidectomy
to remove the primary tumor as well as a routine cervical
lymphadenectomy. Real Time Polymerase Chain Reaction
was used to detect BRAF V600E mutation using ﬁxed
parafﬁn-embedded tumor samples from both, primary
tumor and LNM detected at histological evaluation. The
BRAF mutation was present in the two primary tumors.
However, only LNM of P2 was positive for the V600E
mutation. These two patients were followed up for
47 months with no disease recurrence, no lymph or distant
metastasis, no radioactive iodine resistance and no death.
Growing number of evidence has shown that BRAF
mutation is associated with a higher risk of recurrence and
mortality in PTC, but the correlations with parameters for
aggressiveness such as tumor size, multifocality and
metastasis remains controversial. A more controversial
topic is whether routine central lymph node dissection
should be performed in PT microcarcinoma (PTMC)
patients without evident LNM. However, limited data are
available on the analysis of somatic mutations in lymph
nodes in adult patients with PTC and PTMC.
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Background: Pheochromocytomas and paragangliomas
(PPGLs) are rare neuroendocrine tumours of the adrenal
glands and the sympathetic and parasympathetic para-
ganglia. They can occur sporadically or as a part of different
hereditary tumour syndromes. About 30% of PCCs and
PGLs are currently believed to be caused by germline
mutations and several novel susceptibility genes have
recently been discovered. The clinical presentation,
including localization, malignant potential, and age of
onset, varies depending on the genetic background of the
tumours. Genetic testing for PPGLs is not well studied in
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Asia. We review our clinical management of PPGLs in
Singapore and highlight current gaps in clinical practice.
Methods. Medical records of patients with PPGLs
between 2005 - 2016 were reviewed. Diagnosis was con-
ﬁrmed histologically. Patients were stratiﬁed into; familial/
syndromic (FS), those with positive family history and/or
syndromic presentation, or sporadic.
Results. Twenty-seven (21.8%) patients were referred to
the Cancer Genetics Service (CGS). Incidence of FS PPGLs
(18.5%) and extra-adrenal PPGLs (58.1%) were higher than
previous studies. Genetic referrals were much lower for
sporadic PPGLs patients compared to FS PPGLs patients
(3.7% vs 100%). Genetic referrals were highest at age of
diagnosis <20years old (80%) and decreases with increasing
age; ≥20-<40years old (32.1%), ≥40-<60years old (10.6%).
Genetic testing uptake was 12/27 (44.4%) patients of which
7/12 (58.3%, 3 SDHB, 2 SDHD, 2 VHL) had germline
mutations.
Conclusion. Missed opportunities for genetic testing due
to low referral rates in patients with SPR PPGLs and those
presenting at age ≥20-<40years old and ≥40-<60years.
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Introduction: Lynch syndrome (LS), the most common
inherited colon cancer syndrome, is associated with DNA
mismatch repair (MMR) malfunction. While ~50%
expression decrease (mutation carrier level) of the main LS
susceptibility genes MLH1, MSH2 and MSH6 has been
shown to affect MMR capability, the inﬂuence of reduced
PMS2 expression is not known. Here, the repair efﬁciency
of knockdown (KD) cell lines retaining varying levels of
PMS2 mRNA expression is assessed in a functional MMR
assay.
Materials and Methods: Four different PMS2-speciﬁc
shRNA targets were used for stable transfection in human
ﬁbroblasts. RNA was reverse transcribed into cDNA for
quantitative PCR carried out using Taqman® assays and
GAPDH, HPRT1 and ACTB as reference genes. Nuclear
proteins were extracted from selected KD cell lines and the
repair efﬁciencies were studied in the in vitro MMR assay.
Results: KD clones retaining 18.5%, 33% and 52.5% of
PMS2 expression were selected for functional analysis. A
prerequisite for clone selection was that the KD cell line
would retain 50% of PMS2 expression or less. All selected
clones were shown to be MMR proﬁcient, although clones
retaining 18.5% or 33% of normal expression repaired less
efﬁciently than their respective controls. Further tests are
ongoing.
Conclusions: PMS2 mutations have been difﬁcult to
detect and interpret due to several pseudogenes in the
human genome, low mutation penetrance, and/or complex
disease phenotype. Our preliminary ﬁndings suggest that
already reduced level of PMS2 mRNA expression results in
decreased MMR efﬁciency, which may help to elucidate the
variant pathogenicity.
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Germline mutations of POLE are responsible for poly-
merase proofreading-associated polyposis syndrome
(PPAP). These mutations were hypothesized to predispose
to extra-digestive tumors (ovarian, endometrial, brain) but
this association was not conﬁrmed so far. We report a
family with an autosomal dominant inheritance of PPAP
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due to a mutation of POLE c.1089C>A; p.(Asn363Lys) in
the proofreading exonuclease domain. 11 patients with
colorectal tumor onset and three patients with polyposis are
indexed in this family. Two carriers (siblings) developed
glioblastoma (at 55 and 42 respectively) and another
member (not tested) presented glioblastoma at 37 years old.
This is the second family reported with such a mutation. In
the ﬁrst described, one patient among 12 mutation carriers
displayed a glioblastoma at 28 years old and his grandfather
(not tested) developed a glioblastoma at 68 years old. All
mutations of POLE seem not to be equally associated with
extra-digestive tumors. These cases suggest that POLE
germline mutation c.1089C>A could be involved in an
increased risk of brain cancer (incidence: 15 % (3/20) in
mutation carriers combining the two families). More cases
are needed to support this hypothesis. Although carriers of a
mutation responsible for PPAP syndrome should beneﬁt
from screening for colorectal and uterine cancer, due to the
rapid evolution of glioblastoma, neurological and brain
imaging screening remains questionable. Nevertheless,
taking into account the limited standard therapy for glio-
blastoma, mutation status could be useful for targeting
therapy and to adapt radiotherapy procedures. The biolo-
gical mechanism linking POLE mutation to glioblastoma is
still to be demonstrated.
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Mutations in ion and transporter genes in aldosterone
producing adenoma.
Introduction: Primary aldosteronism is the most com-
mon form of secondary hypertension and affects 8–13% of
patients with hypertension. Genes encoding for either cell
membrane ion channels or ion exchanger have been found
to be mutated in about 60% of patients with aldosterone
producing adenomas (APAs). The aim of this study was to
identify the mutation rates of KCNJ5, CACNA1D, ATP2B3,
ATP1A1 and CTNNB1 in our cohort. We also compared the
genome wide expression of tumors with either KCNJ5 or
CACNA1D mutation.
Material and Method: 35 APAs were analyzed by
Sanger sequencing for mutations in the hot spot regions of
the genes. Genome wide expression analysis was performed
on KCNJ5 and CACNA1D mutant adenomas.
Result: We identiﬁed 11 (31%) mutations in KCNJ5, 2
(6%) in ATP1A1, 3 (9%) in ATP2B3, 3 (9%) in CACNA1D
and 1 (3%) in CTNNB2. CACNA1D mutations were
exclusively found in males, patients with younger in age,
smaller tumors and patients with higher aldosterone levels.
In contrast, KCNJ5 mutations were more prevalent in
females, larger tumors, older patients and patients with
lower aldosterone levels.
The top pathways found to be enriched were Wnt/β-
Catenin pathway, GNRHR pathway, angiogenesis, cadherin
and integrin signaling pathways. CACNA1D mutant tumors
had higher expressions of CYP11B2, GNRHR, PRKCQ,
NPNT and lower expressions of CYP17A1, CYP11B1,
KLHL4 compared to KCNJ5 mutant tumors.
Conclusion: In our cohort, we found mutations in almost
60% of APAs. Patient with CACNA1D mutations had a
more aggressive phenotype.
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Prostate cancer (PCa) is non-cutaneus malignancy diag-
nosed in men, especially in the elderly. The development,
growth and function of the prostate gland depend on the
Androgen signalling. Mutations or polymorphisms on
Androgen Receptor (AR) gene had been known to play a
role in the carcinogenesis of the prostate tissue. The aim of
this study was to performed AR mutations/polymorphism
analysis in PCa patients in Indonesian population.
Thirty eight PCa patients from Javanese ethnic in Indo-
nesia group enrolled in this study. The diagnosis of PCa was
based on histopathology of prostate tissue using Gleason
Score criteria. All exons and exon-intron boundaries of AR
gene was ampliﬁed using Polymerase Chain Reaction and
followed by Sanger sequencing.
The age of PCa patients who were enrolled in this study
were between 54 to 89 years old. Two types of
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polymorphism were identiﬁed in the exon 1, those are p.
P214E and CAG repeat sequences (CAGn) with the length
of the repeats between 13 to 34. Two rare variants in exon 1
were identiﬁed in one patient. Those are novel missense
mutation (p. P146Q) and deletion of GCA sequence (p.
Q91del). Hence, the frequency of AR mutations in PCa
patients from Javanese population is 2.6% (2/76 alleles).
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Introduction: PTEN hamartoma tumour syndrome (PHTS)
is a severe genetic tumour risk syndrome predisposing to
multiple types of malignancies and non-malignant syn-
dromic signs. Timely detection mutation carriers is impor-
tant for optimal cancer risk management. We aimed to
evaluate the trends in detection and clinical presentation of
PTHS patients.
Materials and Methods: A consecutive cohort study
including nationally referred probands (N= 2.384) and
their relatives (N= 504) undergoing PTEN germline testing
at our centre over the last 20 years (1997–2016). The
mutation detection rates and demographics of probands
only and of all mutation carriers were assessed using
descriptive statistics and logistic regression analyses.
Results: In total 202(8.5%) probands and 138(27.4%)
relatives were tested positive for a pathogenic PTEN
mutation. The median annual detection rates were 10.5%
(range 3.5–50%) and 30% (range 0–80%), respectively.
Summarized per 5 years (1997–2001,2002–2006,2007–
2016), the number of mutation positive probands were 19
(21%), 35 (11%), 89 (8%) and 57 (6%), and the median age
of the probands 41, 23, 31 and 44 years. The annual
detection rates showed a decreasing trend (p<0.001), and
the age genetic testing an increasing trend (p<0.001). The
median age of female and male probands was 46 (range 0–
95) and 9 (range 0–82, p<0.001), and detection rates 7% (N
= 103) and 11% (N= 98, p=0.006), respectively.
Conclusions: Annual PTEN mutation detection rates
decrease, but number of detected mutation carriers increase.
The effect of year, age and gender on detection rates likely
reﬂect less stringent referral e.g. female malignancies.
Though, further research should address optimization of
testing criteria.
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3MUHC-RI, Montreal, QC, Canada, 4Lady Davis
Institute, Montreal, QC, Canada, 5University of Ottawa,
Ottawa, ON, Canada, 6Jewish General Hospital,
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Canada, 8Centre de recherche du CHUM, Montreal, QC,
Canada, 9CHU Saint Justine Hospital, Montreal, QC,
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Introduction: RAD51D is a key player in DNA repair by
homologous recombination (HR) and RAD51D truncating
mutation carriers have an increased risk for ovarian cancer
(OC). The contribution of non-truncating RAD51D variants
to cancer predisposition remains uncertain.
Methods and Results: A panel screening identiﬁed the
RAD51D -c.620C>T;p.S207L variant in two French Cana-
dian (FC) kindred affected with familial High Grade Serous
Cancer (HGSC) of the ovary. Through a case-control gen-
otyping study, we showed that the missense RAD51D var-
iant c.620C>T;p.S207L is over-represented in the French
Canadian population affected by HGSC of the ovary (3.8%
cases vs 0.002% controls; p < 0.0001).The frequency of the
p.S207L variant did not differ from that of controls in
breast, endometrial, pancreas and colorectal adenocarcino-
mas. A common haplotype shared by all the carriers sug-
gested a founder origin for c.620C>T;p.S207L mutation.
Whole exome sequencing (WES) analysis of RAD51D
associated tumor proﬁles revealed the presence of signature
3, known to be associated with HR defects. RAD51 foci
formation, CRISPR-Cas9-stimulated gene targeting assay
and a DR-GFP assay conﬁrmed HR impairment activity of
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RAD51D-c.620C>T;p.S207L mutated cells. By co-
immunoprecipitation and in-vivo single cell colocalization
assays we show that this mutation impairs HR by disrupting
the RAD51D-XRCC2 interaction. Sensitivity to PARP
inhibitors (PARPi) was conﬁrmed in RAD51D-c.620C>T;
p.S207L mutant cells .
Conclusions: This work identiﬁes RAD51D-c.620C>Tp.
S207L as the ﬁrst bona ﬁde pathogenic missense suscept-
ibility allele for HGSC of the ovary and supports the use of
targeted PARPi therapies in OC patients carrying missense
RAD51D mutations.
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Extended RAS minor variant detection by Sanger sequen-
cing from FFPE samples to a 5% Limit of Detection
A. Gerstner, E. Schreiber, S. Schneider, S. Jackson, V.
Kamini; Thermo Fisher Scientiﬁc, South San Francisco,
CA, United States
RAS mutational testing is frequently performed by clinical
researchers because of a demonstrated strong correlation
between RAS mutational proﬁles of colorectal cancers and
their anti-EGFR response. Sanger sequencing is an ideal
choice for detection of RAS mutations due to its high
accuracy, fast turnaround time, simple workﬂow and cost-
effectiveness. When combined with Minor Variant Finder
software, Sanger sequencing enables high sensitivity with
variant detection down to a 5% Limit of Detection.
We have developed an extended RAS Sanger sequencing
panel targeting eight hot-spot regions of KRAS and NRAS
genes (codons 12–13, 59–61, 117 and 146). Besides these
hotspot codons, the panel is capable of detecting any var-
iants along the entire amplicons. The panel was optimized
for low amount of FFPE DNA input, down to 1 ng/reaction.
To further streamline the workﬂow for the user, we
designed and developed 96-well plates pre-loaded with the
eight hot-spot primer pairs so only the PCR mix and tem-
plates need to be added. The same plate migrates through
the entire workﬂow, minimizing risk of sample mix-up or
contamination.
The 96-well plates were tested using hot-spot positive
FFPE control DNAs, and Minor Variant Finder successfully
identiﬁed the expected 5% variant allele frequency. Addi-
tionally, variants from numerous FFPE DNAs derived from
colon cancer biopsies with variant allele frequencies ran-
ging from approximately 5% to 80% were also successfully
identiﬁed.
These extended RAS plates performed well on all models
of Applied Biosystems capillary electrophoresis instruments
that were tested.
For Research Use only. Not for use in diagnostic
procedures.
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Expression proﬁles of miRNA genes in clear cell renal cell
carcinoma patients
E. Klimentova1, I. Gilyazova1, G. Gimalova1, A. Izmailov2,
I. Sultanov2, V. Pavlov2, E. Khusnutdinova1; Institute of
Biochemistry and Genetics, Ufa, Russian Federation,
2Bashkir State Medical University, Ufa, Russian
Federation
Introduction: Renal cell carcinoma (RCC) constitutes
about 3% of all human cancers. Clear cell renal cell carci-
noma (ccRCC) is the most common subtype at diagnosis
and accounts for 75–88% of RCCs. MicroRNAs (miRNAs)
are small noncoding RNAs that play a key role in cancer
pathogenesis and are involved in several human cancers,
including ccRCC.
Materials and Methods: A global miRNA proﬁling study
to identify a speciﬁc miRNA signature characterizing
ccRCC was performed at 18 samples of tumor and 6 sam-
ples of normal kidney tissue of ccRCC patients using
OpenArray technology at QuantStudio 12K Flex Real-Time
PCR System. In total, 758 miRNA genes were analyzed
using TaqMan OpenArray MicroRNA Panel. Validation
study was performed using TaqMan qRT-PCR assays at 48
ccRCC samples.
Results: Microarray analysis identiﬁed two over-
expressed microRNA genes in tumor kidney tissue - miR-
210 (FDR p-value=0.033) and miR-642 (FDR p-
value=0.021). After validation only miR-210 showed sta-
tistically signiﬁcant expression levels between normal and
tumor kidney tissue (p-value=0.0134). There is a large
amount of data that miR-210 is the most ubiquitously
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upregulated miRNA in different cancers including renal
cancer. Recently a few studies showed that changing of the
microRNA-210 expression levels is directly related to
hypoxia and HIF1α activity, key components of
tumorigenesis.
Conclusions: Our results suggest that microRNA gene
expression alteration may contribute to the genetic predis-
position for kidney cancer and may serve a diagnostic
marker of the disease. The work was supported by RFBR
grant №14-04-97083.
E. Klimentova: None. I. Gilyazova: None. G. Gima-
lova: None. A. Izmailov: None. I. Sultanov: None. V.
Pavlov: None. E. Khusnutdinova: None.
P12.174B
Germline nonsense mutations of the SMARCB1 gene in
Russian patients with rhabdoid renal tumors
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The malignant rhabdoid tumor (RT) is one of the most
aggressive childhood neoplasms. RTs are characterized by
the presence of inactivating mutations in the SMARCB1
(hSNF5/INI1/BAF47) gene - a tumor suppressor localized in
22q11.2. The SMARCB1 gene is involved in chromatin
remodeling. Up to 30% of RTs are caused by germline
mutations of this gene, to date those cases are considered as
a manifestation of the rhabdoid tumor predisposition syn-
drome type 1 (RTPS1). We have analyzed the SMARCB1
mutations for improving of genetic laboratory diagnostics of
the RTPS1, as well as searching of genotype-phenotype
correlations in this disease. Genomic DNA was isolated
from blood samples of 18 patients with RT in different
localizations. Then SMARCB1 exons 2–9 were ampliﬁed by
PCR and subsequent Sanger sequencing with the 3500xl
ABI capillary genetic analyzer was performed. Three
patients had de novo nonsense mutations c.157C→T (p.
R53*), c.669_670del (p.C223*) and c.843G→A (p.
W281*), conﬁrming RTPS1, which were associated with
RT in the kidney, early age at diagnosis (median
2.6 months) and poor prognosis. High frequency of the
nonsense mutations corresponds to data obtained by other
authors in the studies of renal RTs, but not of RTs in other
localizations. This study is a ﬁrst experience of SMARCB1
mutation testing in Russian population to our knowledge.
Identiﬁcation of germline SMARCB1 mutations in the
patients with RTs is essential to assess the risk of meta-
chronous tumors and for genetic counseling of other family
members.
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RET-gene rearrangements in papillary thyroid carcinoma
subtypes
O. Popa1, S. Schipor1,2, D. Ioachim1, I. Nedelcu1, A.
Caragheorgheopol1, D. Manda1, C. Badiu1,2; “C. I.
Parhon” National Institute of Endocrinology, Bucharest,
Romania, 2“Carol Davila” University of Medicine and
Pharmacy, Bucharest, Romania
RET gene rearrangement is considered the second most
important mutational event involved in the occurrence of
papillary thyroid carcinoma (PTC). Aim of the study was to
investigate the occurrence of RET gene rearrangements in
tumor cells from different PTC subtypes: classic PTC
(cPTC), follicular variant (fvPTC) and aggressive forms
(AGR). Patients and methods: Parafﬁn-embedded tumor
tissues from 57 PTC patients were examined for RET
rearrangements using ﬂuorescence in situ hybridization
(FISH) technique: 12 cPTC cases, 31 fvPTC cases and 14
aggressive PTC cases. FISH was performed with the
ZytoLight SPEC RET Dual Color break-apart probe
(ZytoVision GmbH, Germany). At least 100 non-
overlapping nuclei were taken into account and were ana-
lyzed with Leica CW4000 CytoFISH program to indicate
the percent of positive RET-split cells. Results: The percent
of positive RET-split cells ranged from 5% to 95%. We
established 10% RET-split positive cells as the cutoff level
to consider this event as a clonally one. In cPTC cases the
positivity was registered in 8 cases (66.67%), in 13 fvPTC
cases (41.94 %), and in 6 AGR cases (42.86%). Overall,
RET gene rearrangements was encountered in 47.37% of
cases, with 52.63% of tumors having positive RET-split
cells below 10%. Split level over 20% is correlated with the
invasiveness of tumor. Conclusion: The frequency of RET
gene rearrangements in this study is similar with those
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reported in other European populations without important
differences between PTC subtypes. This study was funded
by UEFISCDI grant no.135/2012
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Incidence of second primary cancers in heritable and non-
heritable retinoblastoma: Results from a Danish population
based study with more than 70 years follow-up
P. A. Gregersen1,2, M. H. Olsen3, S. O. Dalton3, M.
Funding4, S. F. Urbak4, J. Overgaard1, J. Alsner1
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Copenhagen, Denmark, 4Department of Ophthalmology,
Aarhus University Hospital, Aarhus, Denmark
Purpose
To determine the incidence of second primary cancer in
the 323 patients diagnosed with retinoblastoma in Denmark
from 1943–2013.
Methods
Data was retrieved from the Danish Retinoblastoma
Database, a national population database complete since
1943. Heritable retinoblastoma is deﬁned by bilateral or
multifocal disease, familial presentation, and/or identiﬁca-
tion of an RB1 mutation. Data on second primary cancers
and standardized incidence rates (SIR) were extracted from
the Danish Cancer Registry.
Results
For the 323 retinoblastoma patients diagnosed from
1943–2013 in Denmark, data on secondary primary cancers
was divided in 133 heritable retinoblastoma (her-RB, 41%)
and 190 non-heritable retinoblastoma (non-her-RB, 59%).
25 patients with her-RB (19%) and 13 patients with non-
her-RB (7%) were diagnosed with a second primary cancer
(p=0.001). In her-RB the most common second cancer
diagnosis were sarcoma (56%) and malignant melanoma
(24%). The overall SIR for her-RB is 11.4 (95% CI: 7.4–
16.8) and 1.5 (0.8–2.6) for non-her. The cumulative inci-
dence rate of a second primary cancer at 60 years of age is
51% for her-RB and 13% for non-her-RB (p<0.001). The
hazard ratio is 5.0 (2.5–10.2). There is no indication of an
association between risk of second primary cancer and the
use of external radiotherapy in the treatment of her-RB.
Conclusion
The incidence of second primary cancer is signiﬁcantly
higher in heritable retinoblastoma versus non-heritable
retinoblastoma. The most common types in heritable reti-
noblastoma are sarcoma and malignant melanoma. Unique
for this study are the completeness of our nationwide col-
lected data and the extent of long-term follow-up.
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Correlation between RB1germline mutation and second
primary malignancies in hereditary retinoblastoma patients
treated with external beam radiotherapy
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Retinoblastoma (Rb) results from biallelic inactivation of
the RB1 gene. Hereditary Rb patients i.e germline carriers of
a RB1 mutation also have a risk of developing subsequent
malignant neoplasms (SMN) such as osteosarcomas. This
SMN risk is maximized by external beam radiotherapy
treatments (EBRT) which is why these treatments are now
avoided. Nevertheless, EBRT is still a matter of great
concern, as EBRT-treated patients are in their adulthood
and SMNs remain the major cause of death for patients. To
decipher the relationship between RB1 genotype and SMN
development in EBRT treated patients, we conducted a
retrospective study in a cohort of 160 irradiated hereditary
Rbs with fully resolved RB1 mutational status. Among these
160 Rb patients, 120 did not develop any SMN (75%) and
40 developed SMNs (25%). We didn’t ﬁnd any difference
in RB1 mutation type between patients with or without
SMN, neither could we detect any linkage between muta-
tion type and SMN location, SMN type and age at diag-
nosis. Fisher’s test for RB1 mutation type and SMN showed
that they are not independent variables (p=0.016) but the
series is too small to point out a speciﬁc mutation type.
Interestingly, among 8 carriers of a RB1 low penetrance
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mutation, 3 of them developed sarcomas, a rare tumor that
cannot be attributed to the general population. Our study
cannot explain why a RB1 mutation leads or not to a SMN
but demonstrated that EBRT patients with a low penetrance
mutation remain at risk of SMN and should be cautiously
monitored.
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Identiﬁcation of a SMAD4 retroduplication event using
NGS targeted gene panel
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Flament4, T. Lovecchio4, S. Fourneaux5, J. Bou5, M.
Vezain1, S. Coutant1, R. Lanos1, I. Tournier1, T.
Frebourg1, M. Buisine2, S. Baert-Desurmont1
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Introduction: We report a 69 y/o male patient, who pre-
sented at the age of 53 with 9 adenoma treated by total
colectomy.
Materials and methods: We performed molecular analy-
sis of genes involved in hereditary colorectal cancer and
polyposis using Next Generation Sequencing (NGS) and
copy number assessment by Multiplex Ligation Probe
Annealing (MLPA).
Results: MLPA and NGS revealed the duplication of the
whole coding region of the SMAD4 gene, while the introns
and other non coding regions were present in two copies.
NGS depth proﬁle was unusual and several aberrant exon-
exon sequences were identiﬁed. These ﬁndings, together
with consistent Quantitative Multiplex PCR of Short
Fluorescent Fragments (QMPSF) brought the hypothesis of
the insertion within the genome of a retrotranscribed copy
of SMAD4 mRNA. Successful ampliﬁcation of the full
length cDNA sequence from genomic DNA validated this
hypothesis. NGS capture data allowed the identiﬁcation of
the insertion breakpoints, located in a deep intronic region
of the SCAI gene, on chromosome 9.
Discussion: This so-called retroduplication variant
(RDV) with no obvious biological or clinical signiﬁcance is
unlikely to be responsible for this patient’s polyposis. But
the identiﬁcation of this particular event highlights the
beneﬁt of our NGS targeted panel which includes not only
coding regions of genes but also introns, and thus allows
detection of genomic structural variants.
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detection of genetic alterations in haematological
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Introduction: Recurrent chromosome aberrations resulting
in gene fusions or altered expression are of particular
prognostic signiﬁcance in patients diagnosed with acute
lymphoblastic leukaemia, acute myeloid leukaemia and
multiple myeloma. Interrogation of mRNA has the capacity
to detect altered transcripts and expression, in addition to
gene mutations. Retrospective analyses of patients with
these neoplasms were carried out using RNAseq next gen-
eration sequencing and compared with results from tradi-
tional cytogenetic methods (karyotyping and FISH).
Materials and Methods: RNA from 20 diagnostic patient
samples and 2 normal controls extracted from blood, mar-
row or CD138+ separated cells were obtained from an
ethically approved biobank. The patient samples selected
had chromosome rearrangements, complex karyotypes or
other aberrations of signiﬁcance. All samples were enriched
using the 1,385 gene Illumina TruSight® RNA Pan-Cancer
panel and sequenced using the Illumina MiSeq. Bioinfor-
matics tools used included TopHat-Bowtie, Star and Cuf-
ﬂinks. Results: Fusion transcripts were detected in all 9
patients with known gene fusions. Of the 4 patients with
rearrangements known to cause altered expression, only 1
had statistically signiﬁcant differential expression. In total
13 patients had signiﬁcantly altered expression of a number
of clinically relevant genes associated with haematological
neoplasms including MECOM, FLT3 and PAX5. Discussion
Our results have shown that RNAseq panels have the ability
to detect gene fusions and altered expression. However,
further work is needed to improve expression analysis to
enable implementation into diagnostic service. This tech-
nology represents one of the ﬁrst signiﬁcant steps away
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from karyotyping and FISH analysis for haematological
malignancies.
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Introduction: Pheochromocytoma and paraganglioma
(PPGL) carry the highest degree of heritability among
human neoplasms. Germline mutations in ﬁve succinate
dehydrogenase (SDH) genes, predispose heterozygous car-
riers for the development of PPGL. So far, clinical infor-
mation of germline SDHA mutation carriers is limited to
case reports and small series.
Subjects and Methods: This retrospective nationwide
study included 393 genetically unexplained PPGL-patients
referred for germline SDH mutation analysis. Relatives of
SDHA mutation carriers were tested through cascade
screening.
Results: Germline SDHA mutations were identiﬁed in 30
of the 393 index-patients (7.6%), exerting head and neck
PGL (n= 22), pheochromocytoma (n= 4) and sympathetic
PGL (n= 4). The mean age ( ± SD) at diagnosis in index
SDHA mutation carriers was 43 ± 16 years compared to 52
± 15 years in non-mutation carriers (p=0.002). Three index-
patients had malignant PPGL, and one had furthermore a
SDHA-related pituitary adenoma. Two index-patients had
each one relative with a SDHA-associated tumour, one with
head and neck PGL and one with gastrointestinal stromal
tumor. The SDHA-associated disease penetrance was 6% in
51 identiﬁed non-index SDHA mutation carriers, with a
mean age ( ± SD) of 56±20 years.
Conclusion: Germline SDHA mutations can be fre-
quently found in genetically unexplained PPGL patients.
The majority of identiﬁed index-patients presented with an
apparently sporadic solitary PPGL. In the largest SDHA
series assembled so far, we found the lowest penetrance of
all major PPGL predisposition genes. This suggests that
recommendations for genetic counselling of at risk relatives
and stringency of surveillance for SDHA mutation carriers
might need to be reassessed.
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Exome sequencing identiﬁed potential candidate genes for
serrated polyposis syndrome
S. Peters1, C. Trueck1, J. Altmueller2,3, K. Kayser1, E.
Mangold1, S. Holzapfel1,4, R. Adam1,5, H. Thiele2, I.
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University of Cologne, Cologne, Germany, 4Center for
Hereditary Tumor Syndromes, University of Bonn, Bonn,
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Background: Serrated polyposis syndrome (SPS) is a still
poorly deﬁned colorectal cancer predisposition syndrome
characterized by the occurrence of multiple and/or large
serrated lesions throughout the colon. To date, only few
molecular signatures have been described and the etiology
of the syndrome has not been identiﬁed in the vast majority
of patients.
Methods: To uncover causative mutations, the exomes
of 31 SPS patients have been sequenced (Illumina HiSeq)
using leukocyte DNA. The germline variants were ﬁltered
for rare (MAF: biallelic ≤ 1%, heterozygous 0.1% according
to dbSNP, EVS, and ExAC), truncating, and missense
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variants (predicted to be pathogenic by ≥ 2/3 prediction
tools). For data analysis and ﬁltering, the GATK software
and the Cartagenia Bench Lab NGS Software were applied.
Results: After stringent ﬁltering steps, potentially bial-
lelic variants were found in 60 genes, some of which are
recurrently mutated or functioning in tumorigenesis-
associated pathways. Most interesting, seven genes were
affected by biallelic truncating mutations with two patients
carrying a homozygous nonsense mutation in one speciﬁc
gene. Heterozygous variants in at least two patients were
found in 334 genes. These encompass 40 cancer genes or
genes of cancer-associated pathways. Here, the most inter-
esting ﬁnding was a heterozygous RNF43 splice-site
mutation identiﬁed in an index patient and his affected
daughter.
Conclusions: The data indicate that exome sequencing
might identify causative variants for SPS. The current work-
up includes testing of relatives to determine the zygosity of
assumed biallelic variants, analyzing the segregation with
the phenotype, and functional analyses of the most inter-
esting variants.
S. Peters: None. C. Trueck: None. J. Altmueller:
None. K. Kayser: None. E. Mangold: None. S. Holzapfel:
None. R. Adam: None. H. Thiele: None. I. Spier: None. S.
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Improved differential diagnostic information on soft tissue
tumors by genomic array analysis of pre-operative core
needle biopsies
L. Olsson, M. Bidgoli, T. Jonson, F. Mertens; Department
of Clinical Genetics, Division of Laboratory Medicine,
Lund University Hospital, Lund, Sweden
Introduction: The most important pre-operative informa-
tion in the management of patients with bone and soft tissue
tumors (BSTT) concerns histologic subtype and malignancy
grade; increasingly, such tumor classiﬁcation is based on
cells obtained through core needle biopsies (CNB). Several
BSTTs have characteristic genetic changes and chromo-
some banding analysis was often used as a diagnostic
adjunct, but turned out have a low success rate in CNB.
Therefore, the aim of this study was to evaluate the use of
genomic array analysis as a diagnostic tool for CNB from
BSTT.
Materials and methods: All CNB obtained for diagnostic
purposes from 47 patients with suspected BSTT from
March 2016 to January 2017 were included. QIAamp Fast
DNA Tissue Kit (Qiagen) was used to extract DNA and
CytoScan HD genomic array (ThermoFisher/Affymetrix),
including ChAS 3.1 software, was applied for detecting
aberrations. When applicable, these ﬁndings were compared
with genetic aberrations detected in the surgically removed
tumor.
Results: DNA could be extracted from all 47 samples,
28 (60%) of which showed an abnormal array proﬁle. All
10 samples that turned out to be non-neoplastic and 6/7
benign lesions had normal proﬁles. Only 3/30 (10%) sam-
ples from BSTT that typically show imbalances lacked
aberrations. A speciﬁc diagnosis could be suggested in 4
cases. Abnormal array proﬁles in CNB were largely iden-
tical to those in post-operative samples in all 8 evaluable
cases.
Conclusions: By replacing chromosome banding ana-
lysis with genomic array as the gold standard for CNBs
from BSTTs the success rate increased from <50% to 90%.
L. Olsson: None. M. Bidgoli: None. T. Jonson: None.
F. Mertens: None.
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Application of subtractive hybridization approach for
somatic retroelement insertions detection in human cancer
cells
A. Y. Komkov1,2, A. A. Minervina1, G. A. Nugmanov1, Y.
V. Olshanskaya2, Y. B. Lebedev1, I. Z. Mamedov1;
Shemyakin-Ovchinnikov Institute of Bioorganic
Chemistry of the Russian Academy of Sciences, Moscow,
Russian Federation, 2Dmitry Rogachev National
Research Center of Pediatric Hematology, Oncology and
Immunology, Moscow, Russian Federation
Introduction: Retroelement (RE) transpositional activity is
one of the important cause of the human genome instability.
Previous studies revealed that new somatic RE insertions
occur in different type of tumor cells especially in tumors of
epithelial origin. Modern approaches for somatic RE
detection are based on high-throughput sequencing of
amplicons containing DNA fragments adjacent to RE
insertions in target and reference samples. However, exist-
ing methods have a relatively low level of enrichment by
target molecules. This fact signiﬁcantly limits the depth of
somatic RE detection and the number of analyzed samples.
Here we describe a new cost-effective approach allowing to
perform speciﬁc enrichment for somatic RE insertions.
Materials and Methods: Libraries for high-throughput
sequencing were generated from DNA of 1000 acute
myeloid leukemia cells (target) and 1000 normal white
blood cells (control) from the same patient. Target and
control amplicons for subtractive hybridization were pre-
pared by selective ampliﬁcation with AluYa5-speciﬁc pri-
mers and than were mixed in a ration 1:2000. Duplex-
Abstracts from the 50th European Society of Human Genetics Conference:. . . 603
speciﬁc nuclease from Kamchatka Crab was used for homo-
and hetero-duplex DNA elimination.
Results: The utilization of subtractive hybridization
reduce amount of sequences ﬂanking ﬁxed (not somatic) RE
insertions by 5-fold in average and thus increase a portion
of somatic RE insertion ﬂanking molecules in the sequen-
cing library by 40-fold.
Conclusions: The advantages of developed method
signiﬁcantly increase the efﬁciency of somatic RE inser-
tions detection in different type of tumor cells.
This work was supported by RFBR grants №16-04-
00779-a,№16-34-01100-mol_a,№17-04-01280-a, Russian
Science Foundation grant №17-14-01197 and Russian
President’s Fellowship №SP-4059.2016.4
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Detection of KRAS oncogene mutations (codon 12 and 13)
in stool DNA of patients with sporadic colorectal cancer
S. Khadem Rad1, M. Khalaj-Kondori1, H. Samadi Kaﬁl2,
A. Eftekharsadat3, M. Shirmohamadi4, E. Sakhinia5
1Department of Biology, Faculty of Natural Sciences,
University of Tabriz, Tabriz, Iran, Islamic Republic of,
2Drug Applied Research Center, Faculty of Medicine,
Tabriz University of Medical Sciences, Tabriz, Iran, Islamic
Republic of, 3Department of Pathology, Imam Reza
Hospital, Faculty of Medicine, Tabriz University of Medical
Sciences, Tabriz, Iran, Islamic Republic of, 4Liver and
Gastrointestinal Disease Research Center, Faculty of
Medicine, Tabriz University of Medical Sciences, Tabriz,
Iran, Islamic Republic of, 55Department of Biochemistry
and Clinical Laboratory, Division of Medical Genetics,
Faculty of Medicine,Tabriz University of Medical Sciences,
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Introduction: colorectal cancer is one of the most common
cancer types and leading causes of cancer death worldwide
and it is curable if diagnosed at an early stage. Since KRAS
mutations occur early in colorectal cancer tumorigenesis
and happen in 30–50% of all CRC cases, the aim of this
study was to detect KRAS mutations in stool samples as a
non-invasive screening method among patients with color-
ectal cancer. Materials and Methods: DNA was extracted
from stool samples of 50 individuals with colorectal cancer
using a Qiagene kit. KRAS mutations were identiﬁed using
polymerase chain reaction method and direct sequence
analysis. Results: sequencing of all PCR products showed
no mutations in KRAS codons 12 and 13 of the cases.
Conclusion: our results revealed no mutations in common
KRAS mutated codons. These observations may reveal the
association of different etiological factors in the occurrence
of colorectal cancer of which KRAS mutation might not
appear in all populations.
S. Khadem Rad: None. M. Khalaj-Kondori: None. H.
Samadi Kaﬁl: None. A. Eftekharsadat: None. M. Shir-
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Telomere length, ATM mutation status and cancer risk in
Ataxia-Telangiectasia families
A. Renault1,2,3, N. Mebirouk1,2,3, E. Cavaciuti1,2,3, D. Le
Gal1,2,3, J. Lecarpentier4, C. Dubois d'Enghien5, A.
Laugé5, M. Dondon1,2,3, M. Labbé1,2,3, G. Lesca6, D.
Leroux7, L. Gladieff8, C. Adenis9, L. Faivre10, B. Gilbert-
Dussardier11, A. Lortholary12, J. Fricker13, K. Dahan14, J.
Bay15, M. Longy16, B. Buecher5, N. Janin14, H. Zattara17,
P. Berthet18, A. Combès19, I. Coupier20,21, CoF-AT study
collaborators, J. Hall22,23,24, D. Stoppa-Lyonnet5,25,26, N.
Andrieu1,2,3, F. Lesueur1,2,3; INSERM U900, Paris,
France, 2PSL Research University, Paris, France,
3Institut Curie, Paris, France, 4Centre for Cancer Genetic
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Care, University of Cambridge, Cambridge, United
Kingdom, 5Service de Génétique, Institut Curie, Paris,
France, 6CHU de Lyon, Groupement Hospitalier Est,
Service de Génétique Médicale, Lyon, France, 7CHU de
Grenoble, Hôpital Couple-Enfant, Département de
Génétique, Grenoble, France, 8Institut Claudius Regaud-
IUCT-Oncopole, Service d’Oncologie Médicale, Toulouse,
France, 9Centre Oscar Lambret, Lille, France, 10Hôpital
d’Enfants, Service de Génétique Médicale, Dijon, France,
11CHU de Poitiers, Service de Génétique Médicale,
Poitiers, France, 12Centre Catherine de Sienne, Service
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Strauss, Unité d’Oncologie, Strasbourg, France,
14Clinique Universitaire Saint-Luc, Génétique, Brussels,
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Clermont-Ferrand, France, 16Institut Bergonié,
Bordeaux, France, 17Hôpital Saint-Joseph, Marseille,
France, 18Centre François Baclesse, Caen, France,
19Centre Hospitalier Universitaire de Nîmes, Unité de
Génétique Médicale et Cytogénétique, Nîmes, France,
20Hôpital Arnaud de Villeneuve, CHU Montpellier,
Service de Génétique Médicale et Oncogénétique,
Montpellier, France, 21ICM Val d'Aurel, Unité
d'Oncogénétique, Montpellier, France, 22Centre de
Recherche en Cancérologie de Lyon, Lyon, France,
23UMR Inserm 1052, Lyon, France, 24CNRS 5286, Lyon,
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France, 25Inserm U830, Paris, France, 26Université Paris
Descartes, Paris, France
Recent studies have linked constitutive telomere length
(TL) to aging-related diseases including cancer at different
sites. ATM participates in the signaling of telomere erosion,
and inherited mutations in ATM have been associated with
increased risk of cancer, particularly breast cancer. The goal
of this study was to investigate whether carriage of an ATM
mutation and TL interplay to modify cancer risk in ataxia-
telangiectasia (A-T) families. The study population con-
sisted of 284 heterozygous ATM mutation carriers (HetAT)
and 174 non-carriers (non-HetAT) from 103 A-T families.
Forty-eight HetAT and 14 non-HetAT individuals had
cancer, among them 25 HetAT and 6 non-HetAT were
diagnosed after blood sample collection. We measured
mean TL using a quantitative PCR assay and genotyped 7
single-nucleotide polymorphisms (SNPs) recurrently asso-
ciated with TL in large population-based studies. HetAT
individuals were at increased risk of cancer (OR=2.3, 95%
CI=1.2–4.4, P=0.01), and particularly of breast cancer for
women (OR=2.9, 95%CI=1.2–7.1, P=0.02), in compar-
ison to their non-HetAT relatives. HetAT individuals had
longer telomeres than non-HetAT individuals (P=0.0008)
but TL was not associated with cancer risk, and no sig-
niﬁcant interaction was observed between ATM mutation
status and TL. Furthermore, rs9257445 (ZNF311) was
associated with TL in HetAT subjects and rs6060627
(BCL2L1) modiﬁed cancer risk in HetAT and non-HetAT
women. Our ﬁndings suggest that carriage of an ATM
mutation impacts on the age-related TL shortening and that
TL per se is not related to cancer risk in ATM carriers. TL
measurement alone is not a good marker for predicting
cancer risk in A-T families.
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TaqMan Rare Mutation Assays targeting the TERT pro-
moter region<!--EndFragment-->
M. Laig1, D. Dewolf2, K. Varma1, V. Venkatesh1
1Thermo Fisher Scientiﬁc, South San Francisco, CA, United
States, 2Thermo Fisher Scientiﬁc, Courtaboeuf Cedex,
France
The enzyme Telomerase maintains telomeres at the ends of
chromosomes. The Telomerase Reverse Transcriptase
(TERT) gene codes for the enzyme’s catalytic domain and
is not expressed in normal somatic cells. As a consequence,
normal cells acquire senescence by shortening of their tel-
omeres during cell division and eventually undergo apop-
tosis. In contrast to normal somatic cells, expression of
TERT is reinstated in cancer cells causing escape from
senescence and apoptosis by maintaining the telomeres. It
has recently been shown that mutations in the TERT pro-
moter region play a key role in regulating and reinstating
TERT expression. 90% of cancers carry a mutation in the
TERT promoter region. Mutations like C228T and C250T
create a new binding site for the E26 transformation-speciﬁc
(ETS) transcription factor that regulates TERT expression.
Experimental evidence showed that the ETS factor GA-
binding protein, alpha subunit (GABPA) binds to the de
novo ETS motif and activates TERT transcription in cancer
cells.
We undertook a project designing TaqMan Rare Muta-
tion assays addressing mutations in the TERT promoter.
These assays are TaqMan SNP Genotyping assays opti-
mized for use in digital PCR with the Applied Biosystems
QuantStudio 3D. Digital PCR facilitates detection and
quantiﬁcation of rare mutant alleles. TaqMan SNP Geno-
typing Assays ensure reliable discrimination of mutant and
wild-type allele. This will enable easy and sensitive detec-
tion of TERT promoter mutations in cancer research sam-
ples. These assays are suitable for detection in liquid biopsy
applications with cell free DNA (cfDNA).
For Research Use Only. Not for use in diagnostic
procedures.
M. Laig: A. Employment (full or part-time); Signiﬁcant;
Thermo Fisher Scientiﬁc. D. Dewolf: A. Employment (full
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Varma: A. Employment (full or part-time); Signiﬁcant;
Thermo Fisher Scientiﬁc. V. Venkatesh: A. Employment
(full or part-time); Signiﬁcant; Thermo Fisher Scientiﬁc.
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Genetic risk factors for sporadic testicular germ cell tumors
I. S. Dantsev1, E. V. Ivkin1, A. A. Tryakin2, V. V.
Rudenko3, S. A. Tulandin2, O. B. Loran1, M. V.
Nemtsova4; Russian Medical Academy of Continuous
Professional Education, Moscow, Russian Federation,
2Blokhin Russian Research Center for Oncology,
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4Sechenov First Moscow State Medical University,
Moscow, Russian Federation
Testicular germ cell tumors (TGCTs) derive from embryo-
nic stem cells and directly related to the formation of male
gametes. Genes KITLG, SPRY4, BAK1 have an effect on
testis development, their change results in a signiﬁcant
increase in the risk TGCTs. We have developed the system
for detecting and investigated the frequency of the alleles
and genotypes of KITLG (rs995030, rs1508595), SPRY4
(rs4624820, rs6897876) and BAK1 (rs210138) in 90 fertile
men and 73 patients with TGCTs (34 seminomas and 39
non-seminomas).
Signiﬁcant association with the development of TGCTs
was identiﬁed in KITLG (rs1508595: p = 0.0003 for G, p =
0.0014 for GG), rs995030: p = 0.003 for GG). When
comparing patients with seminomas and fertile men we
revealed signiﬁcant differences in SPRY4 (rs4624820: p =
0.0226 for A), in KITLG (rs995030: p = 0.037 for G and p
= 0.028 for GG), rs1508595: p = 0.03 for G) in BAK1
(rs210138: p = 0.032 for G and p = 0.02 for GG). When
comparing patients with non-seminomas and fertile men we
revealed signiﬁcant differences only in KITLG (rs1508595:
p = 0.0005 for G and p = 0.002 for GG).
We have shown that the combination of three genes
genotypes increases the risk of TGCTs in 6.5 times (p =
0.0005; OR: 6.526 [2.078–20.5]), and the risk of seminoma
in 12 times (p <0.0001; OR: 12.68 [3.73–43.11]).
The study of genotypes associated with TGCTs can be
used to identify of the individuals with an increased risk of
TGCTs.
I.S. Dantsev: None. E.V. Ivkin: None. A.A. Tryakin:
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A novel homozygous germline mutation in TP53 presenting
with aggressive synchronous tumours in infancy
N. J. Brown1,2,3, K. Bhatia4, J. Teague5, S. M. White2,3,6,
P. Lo7, J. Challis2, V. Beshay8, M. Sullivan4, D. Malkin9,
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Australia, 7The Royal Children’s Hospital, Department of
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Introduction: Li-Fraumeni Syndrome (LFS) is a rare
autosomal dominant cancer predisposition syndrome. Het-
erozygous germline mutations in the TP53 tumour sup-
pressor gene are causative in ~80% of cases; furthermore,
somatic TP53 mutations are frequent in human cancers.
Intact p53 function is fundamental to maintenance of
genomic integrity, cell cycle regulation, DNA repair and
apoptosis. Homozygous germline TP53 mutations are rare,
only previously described in individuals with a low pene-
trance founder mutation (Arg337His).
Materials and Methods: We describe a consanguineous
family in which the infant proband presented with two
synchronous tumours; family history includes several rela-
tives with cancer. SNP microarray was performed on DNA
derived from lymphocytes, and both tumours. Sanger
sequencing of the TP53 gene was performed.
Results: Tumour histopathology conﬁrmed two distinct
malignancies, a periorbital embryonal rhabdomyosarcoma
and choroid plexus carcinoma; in addition, the proband’s
pregnancy was complicated by metastatic choriocarcinoma.
The family meet revised Chompret criteria. SNP microarray
identiﬁed several long continuous stretches of homo-
zygosity, encompassing ~5% of the genome, including the
TP53 locus. We identiﬁed a novel homozygous germline
TP53 mutation in exon 2 (c.[52delA]+[52delA]: p.
Thr18Hisfs*26), This mutation is predicted cause protein
truncation and a null product. Predictive testing conﬁrmed
parents and younger sibling are heterozygous for this
mutation.
Conclusions: We report a consanguineous family in
which the proband is homozygous for a novel TP53
mutation, predicted to produce loss of p53 function. This
case demonstrates that bi-allelic loss of TP53 is compatible
with human development, but appears associated with an
aggressive, early onset cancer phenotype.
N.J. Brown: None. K. Bhatia: None. J. Teague: None.
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Beshay: None. M. Sullivan: None. D. Malkin: None. J.R.
Hansford: None.
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Introduction: Germline TP53 mutations predispose to a
wide range of early onset cancers most commonly breast
cancer, soft tissue sarcoma, osteosarcoma, brain tumors and
adrenocortical carcinoma. p53 is a transcription factor that
binds to DNA after tetramerization and regulates several
pro-apoptotic and cell cycle regulating proteins like Mdm-2,
p21, Bax, and PUMA. Materials and Methods: We have
generated cDNA expression constructs for all novel germ-
line TP53 mutants in the Swedish cohort and investigated
the activity and molecular effects of these mutations on
downstream target proteins by immunoblotting, immuno-
ﬂuorescent and ﬂowcytometry. Results: In this cohort of 32
families, we found 25 different mutations in the TP53 gene.
Nine have not been reported previously as germline muta-
tions according to the IARC databases. Five of these have
not even been reported as somatic mutations in the IARC or
cosmic databases and are thus truly novel. We showed that
some mutations have activities close to wildtype while
others have undetectable activities. We also reported that
some mutations can increase expression of PUMA and Bax
in p53-null cell lines which lead to caspase 3 cleavage and
apoptosis. Cellular localizations of the mutated p53 proteins
were also investigated and varied among the mutants.
Conclusions: We showed that all novel mutations were
stably express in p53-null cell lines and reduced sponta-
neous apoptosis as a result of less expression of pro-
apoptotic proteins. The nuclear translocation ability of the
different mutants varied. These data indicate that affected
individuals are susceptible to development of neoplasia.
Grant: BRECT
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TRIM8 in the pathogenesis of glioma: a possible role in the
mitotic spindle regulation
S. Venuto1,2, L. Monteonofrio3, M. Monti4, T. Mazza5, I.
Appolloni6, P. Pucci4, P. Malatesta6,7, S. Soddu3, G.
Merla1, L. Micale1
1Medical Genetics Unit, IRCCS Casa Sollievo della
Sofferenza Hospital, San Giovanni Rotondo, Foggia, Italy,
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Networks and Molecular Therapeutic Targets, IRCCS
Regina Elena National Cancer Institute, Roma, Italy,
4CEINGE Advanced Biotechnology and Department of
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IRCCS-AOU San Martino-IST, Genova, Italy, 7IRCCS AOU
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Introduction: Our data showed a down regulation of the E3
ubiquitin ligase TRIM8 in glioma, a lethal brain tumor, and
its role in controlling tumor cell growth. We hypothesized
that TRIM8 activity impairment might alter the glioma-
related proteome, perturbing speciﬁc normal pathways and
favoring tumorigenesis. This study explored TRIM8 role in
gliomagenesis by identifying TRIM8-associated proteins
and biological pathways in embryonic neural stem cells
(ENSC), the healthy counterpart of glioma
Materials and methods: We proﬁled transcriptome and
proteome of ENSC overexpressing Trim8 by using RNAseq
and LC-MS/MS, respectively
Results: Gene-set enrichment analysis of RNAseq data
highlighted pathways related to neurological functions, cell
death, and inﬂammation. Proteomic analysis followed by
co-immunoprecipitation assays identiﬁed as TRIM8 inter-
actors four members of the kinesin-like protein family,
including KIF11 and KIFC1, known to be involved in
mitotic spindle dynamic. Based on our data, we explored
the effect of TRIM8 expression on mitotic spindle organi-
zation by performing immunoﬂuorescence assays in glioma
cells depleted for TRIM8. The absence of binucleated cells,
chromosomal bridges, and micronuclei in TRIM8 interfered
cells excludes cytokinesis defects. However, an accumula-
tion of monopolar spindles in TRIM8 depleted metaphase
cells suggested its role in centrosome maturation and
separation, a phenotype also observed in cells with a per-
turbed expression of KIF11 or KIFC1
Conclusions: TRIM8 might play a crucial role in con-
trolling the mitotic process and contribute to the glioma
development through an aberrant regulation of key mitotic
factors. Further studies will elucidate a possible role of
TRIM8 in the organization of the microtubule dynamic
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Four novel pathogenic variants in TSC2 gene of Turkish
patients with tuberous sclerosis complex
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Introduction: Tuberous sclerosis complex (TSC) involves
multiple abnormalities in different tissue and organ systems
of effected patients like skin, brain, kidney, heart and lungs.
Heterozygous pathogenic variations of TSC2(OMIM *
191092) gene are responsible from �73% of Tuberous
Sclerosis Complex (TSC, OMIM # 613254) patients. The
aim of this study to summarize novel pathogenic TSC2
variants found in Turkish patients who were directed to
Trakya University Genetic Diagnosis Center with a suspi-
cion of TSC. Materials and Methods: Genomic DNA
samples isolated from peripheral blood of patients were
used. Two different Next Generation Sequencing (NGS)
platforms [Ion Torrent PGM (Thermo Fisher) and MiSeq
(Illumina)] were used to investigate the genetic basis of
TSC in four patients (4 female aged between 5–30). TSC2
gene coding regions were ampliﬁed using Ion AmpliSeq™
Library Kit 2.0 before enrichement by OT2 200 Kit and
sequenced on the Ion Personal Genome Machine. TruSight
Cancer Kit (Illumina) was used to determine the variations
on the MiSeq System (Illumina). Ion Reporter v4 (Thermo
Fisher) and Base Space (Illumina) softwares and IGV 2.3.36
(Broad Institute) were used to deﬁne the variations of TSC2
gene. Results: Pathogenic variants deﬁned with Ion Torrent
were mosaic c.996_998delGGT(p.Val333del) and hetero-
zygous c.5192_5193insA(N1731Kfs*44). Other pathogenic
variants found with MiSeq system were mosaic c.4006-
4_4010deletionCTAGTCGTC (S1336Lfs*76) and hetero-
zygous c.4252_4253insC(p.Gln1419fs). Conclusions: NGS
is a powerfull tool for determining pathogenic variants in
TSC2 gene and allows to determine low mosaic variations
even in DNA samples extracted from peripheral blood of
patients.
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Increased TSPY copy number represents a risk factor for
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The human TSPY is a multi copy gene family (20–40
copies) located on the Y chromosome and expressed in
spermatogonia and early spermatocytes, where it is
involved in sperm differentiation and proliferation. It is
abundantly expressed in germ cell cancers and gonado-
blastoma. Ectopic expression of TSPY has been demon-
strated in some somatic cancers such as melanoma, prostate
and liver cancer. The aim of our study was to investigate the
possible association of TSPY gene copy number with the
occurrence of male speciﬁc cancers. To overcome possible
population stratiﬁcation bias the distribution of TSPY copy
numbers in different Y chromosome haplogroups was also
analyzed. We have analyzed a total of 125 cancer patients:
92 prostate cancer (mean age 68.7±7.47) and 33 testicular
cancer patients (33.6±13.43) as well as 79 healthy controls
(64.4±14.85). TSPY gene copy number measurement was
based on real-time qPCR (ddCt method) using a sample
with known TSPY copy number as a reference. Single copy
SRY gene was used for data normalization. Y chromosome
haplogroups were predicted using 17 Y-STR markers. Our
results showed statistically signiﬁcant higher mean TSPY
copy number among cancer patients (38.75±16.14,
p=0.0006, Student’s t-test) than controls (30.87±15.24).
The mean values were higher in cancer patients than con-
trols in all haplogroups except J1, thus favoring unbiased
statistical signiﬁcance. In conclusion, TSPY copy number
represents a risk factor for prostate and testicular cancers.
Further studies are needed to clarify the association of TSPY
copy number variation with TSPY mRNA expression levels.
P. Noveski: None. M. Kuzmanovska: None. K.
Kubelka-Sabit: None. V. Filipovski: None. S. Lazar-
evski: None. N. Matevska Geshkovska: None. A.
Dimovski: None. D. Plaseska-Karanﬁlska: None.
P12.193A
PCR Recombinants, Off-target Alignments and their Effect
on the Genetic Diagnosis of Tumour Tissue
G. R. Taylor, Guillermina Nickless, Kezia Brown, Nahid
Kamal, Nicola Foot, Michael Neat, Michael Yau; iapath,
London, United Kingdom
We describe an effective diagnostic tool for the analysis of
low mass tumour DNA samples by NGS with a limit of
detection of 1%.
Routine genetic analysis of tumours is becoming a
standard of care required for the effective delivery of tar-
geted therapy, for example the use of EGFR TKIs, such as
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afatinib, geﬁtinib or erlotinib
in non-small cell lung carcinoma (NSCLC). The majority of
NSCLC patients present with advanced disease, cytology
and small biopsy specimens can pose challenges due to low
tumor content. Multiple usage of the same sample for single
amplicon tests soon depletes the tissue, yet typical NGS
sequencing libraries require 100ng to 1ug of tissue.
Here we report on the use of a multiplex PCR amplicon
panel that can produce sequencing libraries from as little as
10ng DNA. We observed a success rate of >95% with an
unselected series of clinical samples. Our analytical path-
way, AmpliVar (https://github.com/LordGenome/amplivar)
permits robust identiﬁcation of variants down to a selectable
sensitivity, typically 1%. Since sequence reads are hashed at
an early stage in the analysis, it is possible to see output
prior to alignment and ﬁltering. Especially at low DNA
mass, we saw an increasing percentage of PCR recombi-
nants and off-target products were generated in the course
of ampliﬁcation.
As well as genome-wide alignment of the sequence
reads, AmpliVar includes an orthogonal genotyping method
matches known variants to a look-up table, obviating the
necessity for conﬁrmatory Sanger sequencing.
G.R. Taylor: None.
P12.194B
A novel RHBDF2 mutation in a Black African family with
tylosis and squamous cell carcinoma of the oesophagus
E. J. van Rensburg1, C. M. Dorﬂing1, M. Smit2, T.
Mokoena2
1Department of Genetics, University of Pretoria, Pretoria,
South Africa, 2Department of Surgery, University of
Pretoria, Pretoria, South Africa
Introduction: Tylosis with squamous cell carcinoma of the
esophagus (TOC; OMIM 148500) is a rare autosomal
dominant disorder. The condition is characterized by focal
non-epidermolytic palmoplantar keratoderma and a high
risk for squamous cell carcinoma of the oesophagus. Three
pathogenic missense mutations in the RHBDF2-gene (p.
Ile186Thr, p.Asp188Asn and p.Pro189Leu) were recently
described to be associated with TOC in four families (one
each from the UK, USA, Germany and Finland). To the best
of our knowledge TOC has not been reported in patients of
African descent. We here describe the ﬁrst African family,
with tylosis and oesophageal cancer.
Patients and methods: This four generation African
family had a total of six members presenting with palmo-
plantar keratosis. None exhibited the extreme ﬁssuring of
the palmoplantar skin or oral leukokeratosis that is usually
associated with TOC. Two of the family members also
developed oesophageal cancer. After written informed
consent was obtained from the family members, blood
samples were taken for RHBDF2-gene analysis. Genomic
DNA was extracted and the RHBDF2-gene
(NC_000017.10), was ampliﬁed and subjected to Sanger
sequencing using Life Technologies BigDyeV3.1
chemistry.
Results: A novel missense mutation (c.562 G>T, p.
Asp188Tyr) of RHBDF2 (NM_024599.5) was detected in
all affected members of the African family and was absent
in unaffected family members. Interestingly, this mutation
alters the same codon as that in the family from Finland (p.
Asp188Asn).
Conclusions: These results further validate RHBDF2
mutations as the cause of TOC. In addition, this family can
now proactively manage their cancer risks through regular
clinical screening.
E.J. van Rensburg: None. C.M. Dorﬂing: None. M.
Smit: None. T. Mokoena: None.
P12.195C
Von Hippel Lindau Syndrome - Multidisciplinary Clinics in
Western Denmark
M. Smerdel1, A. Skytte1, K. Stochholm2,3, H. Møller4, T.
Hansen5, L. Sunde1; Aarhus University Hospital,
Department of Clinical Genetics, Aarhus, Denmark,
2Aarhus University Hospital, Department of Internal
Medicine and Medical Endocrinology, Aarhus, Denmark,
3Aarhus University Hospital, Department of Pediatrics,
Aarhus, Denmark, 4Aarhus University Hospital,
Department of Pediatric Ophtalmology, Aarhus,
Denmark, 5Aarhus University Hospital, Department of
Neurosurgery, Aarhus, Denmark
Background: Von Hippel Lindau syndrome (vHL) is a
genetic condition with an increased risk of especially renal
cell cancer and abnormal growth of blood vessels in many
organs. Surveillance programs are crucial for early detec-
tion. Until recently, these patients spent several days a year
attending various surveillance programs at the departments
of neurosurgery, ophthalmology, urology, endocrinology,
audiology, and radiology, respectively, potentially limiting
self-esteem, causing stress as well as causing lost earnings.
By establishing multidisciplinary clinics, patients may
substantially reduce time spent on transport and hospital
visits. Compliance may increase and in addition, the spe-
cialists will gain easy access to multidisciplinary discus-
sions, optimizing patient treatment and care.
Methods: In 2015, a multidisciplinary team was set with
representatives from the involved medical departments.
Surveillance is scheduled for two days starting with all
Abstracts from the 50th European Society of Human Genetics Conference:. . . 609
diagnostic imaging, blood and audiometric tests on day 1.
Day 2 is initiated by a one-hour conference with specialists
in neurosurgery, ophthalmology, urology, endocrinology,
audiology, radiology, hepatology, pediatrics, and genetics.
Each patient is discussed. Next, each patient is seen by
specialists in neurosurgery, opthalmology, endocrinology,
and genetics. If tumors needing treatment are identiﬁed, the
treatment is planned instantaneously.
Results: In 2015, 12 patients underwent surveillance in
the multidisciplinary vHL clinic and in 2016 the total
number of patients was 22.
Conclusion: The increasing number of patients choosing
the multidisciplinary clinic indicates that process optimi-
zation is beneﬁcial for the patient as well as for the
healthcare system.
M. Smerdel: None. A. Skytte: None. K. Stochholm:
None. H. Møller: None. T. Hansen: None. L. Sunde:
None.
P12.196D
Lower penetrance of von Hippel-Lindau disease (vHL)
inﬂuences risk assessment in predisposed families
M. M. Binderup, M. Galanakis, E. Budtz-Jørgensen, M.
Bisgaard; University of Copenhagen, Department of
Cellular and Molecular Medicine, København N,
Denmark
von Hippel-Lindau disease (vHL) is a multisystemic tumor
syndrome; carriers of germline VHL mutations should
undergo prophylactic surveillance due to risk of multiple
tumors. Before genetic testing was available, vHL was
estimated to be fully penetrant at age 60.
In a national cohort of all Danish VHL mutation-carriers,
we evaluated how and when families were diagnosed and
assessed vHL penetrance.
Through interviews and hospital records, we evaluated
34 families with VHL mutations (97 mutation-carriers and
262 ﬁrst-degree relatives). In the majority of familial cases
(74%, 58 of 78), the vHL diagnosis was made pre-
symptomatically or at the time of their ﬁrst manifestation.
In the remaining 31 patients diagnosed while alive, there
was a median delay of 10 years (range: 2–34 years) from
their ﬁrst manifestation to vHL diagnosis.
Remarkably, 35% (46 of 131) of the living ﬁrst-degree
relatives were not genetically tested (median age when their
family’s VHL mutation was found: 52.5 years (range: 0 - 85
years)). Especially siblings (61%) and parents (20%) were
not tested, and relatives over 40 years at the time the
familial VHL mutation was found, were signiﬁcantly less
likely to be genetically tested (p<0.0001).
vHL penetrance was 87% at age 60. When considering
only patients without pre-symptomatic surveillance, 20%
were asymptomatic at age 60. This is important in relation
to genetic counselling when assessing vHL risk in asymp-
tomatic adult ﬁrst-degree relatives, who not often geneti-
cally tested. Funding: the Lundbeck Foundation, the Danish
Cancer Society, and the Danish Association for vHL asso-
ciation and their relatives.
M.M. Binderup: None. M. Galanakis: None. E.
Budtz-Jørgensen: None. M. Bisgaard: None.
P12.197A
von Hippel-Lindau development in children and
adolescents
K. Launbjerg, I. Bache, M. Galanakis, M. Bisgaard, M.
M. Binderup; niversity of Copenhagen, Department of
Cellular and Molecular Medicine, København N,
Denmark
The autosomal dominant von Hippel-Lindau disease (vHL)
is associated with a high risk of tumour development
throughout life, especially retinal and CNS hemangio-
blastomas, pheochromocytoma, and renal cell carcinoma.
Knowledge of paediatric vHL development is limited, and
current Danish surveillance guidelines are based on best
clinical judgement. We aimed to describe the course of vHL
manifestation development in children and adolescents,
focusing on age at ﬁrst manifestation, manifestation fre-
quencies, and types.
The prevalence of the vHL diagnosis, as well as mani-
festations in childhood, were evaluated based on 99 vHL
patients, who had started surveillance before 18 years: 37
Danish patients from the national vHL research database
and 62 international patients reported in 15 scientiﬁc
articles.
Overall, 70% (69 of 99) developed manifestations before
18 years (median age at ﬁrst manifestation: 12 years (range:
6–17 years)). Thirty per cent (30 of 99) had developed more
than one manifestation type; the most frequent were retinal
(34%) and CNS (30%) hemangioblastomas. Among the 37
Danish patients, 25 (68%) had manifestations and 85% (97
of 116) of their tumours were asymptomatic.
We found that childhood manifestations of vHL were
more frequent than previously reported. We recommend
surveillance ophthalmoscopies from early childhood to
detect retinal hemangioblastomas. Further, we suggest that
surveillance MRIs of the CNS should be initiated around
the age of eight years, which contrasts most international
guidelines that recommend MRI initiation between 15–16
years.
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Funding: the Lundbeck Foundation, the Danish Cancer
Society, and the Danish Association for von Hippel-Lindau
Association and their relatives.
K. Launbjerg: None. I. Bache: None. M. Galanakis:
None. M. Bisgaard: None. M.M. Binderup: None.
P12.198B
No inﬂuence of XPC gene polymorphisms on FLT3 or
DNMT3Amutations in acute myeloidleukemiapatients
C. Banescu1, A. Crauciuc2, V. Moldovan1, A. Boglis2, F.
Tripon2, E. Lazar Benedek2, C. Duicu2
1Genetics Laboratory, Center for Advanced Medical and
Pharmaceutical Research, University of Medicine and
Pharmacy TirguMures, Romania, Tg. Mures, Romania,
2University of Medicine and Pharmacy TirguMures,
Romania, Tg. Mures, Romania
Background: Recently, it was reported thatXPC gene,
involved in the nucleotide excisions repair system, con-
fersusceptibility to developingacute myeloid leukemia
(AML). We aimed to assess the impact of XPC C499Tgene
polymorphism on developing AML and to investigate the
correlation between XPC C499T and FLT3 and DNMT3A
mutations. Material and methods: This study included
253 subjects divided in two groups: AML group with 123
patients and the control group with 130 heathy individuals.
XPC C499T polymorphism was investigated in all subjects
by RFLP-PCR technique byusing Cfr42I digestion enzyme.
FLT3 (ITD, D835) and DNMT3A mutations were investi-
gated in AML patients. Results: For XPC C499T poly-
morphism wild type genotype (CC) was identiﬁed in 26
patients and 59 controls; heterozygous genotype (CT) in 91
cases and 59 controls,while thevariant homozygous geno-
type in 6 patients and 17 controls.FLT3 (ITD, D835) was
found in 28 patients, DNMT3A mutation in 16 cases, while
both genes mutation was observed in 7 AML patients
Variant genotype CT+TT XPC C499T was associated with
the risk of developing AML (p=0.0001, OR=2.89 and 95%
CI:1.67–5.02) but no withthe presence of FLT3/DNMT3A
mutations. Conclusion: The XPC C499Tgene polymorph-
ism is a risk factor for AML in this population. The pre-
sence of variant genotype was not a predisposing factor for
the presence of FLT3 or DNMT3A mutations. Acknowl-
edgement: This work was supported by a grant of the
Romanian National Authority for Scientiﬁc Research and
Innovation, CNCS/CCCDI-UEFISCDI, project number PN-
III-P2-2.1-PED-2016-1076 WITHIN PNCDI III, contract
no 147 PED/2017.
C. Banescu: None. A. Crauciuc: None. V. Moldovan:
None. A. Boglis: None. F. Tripon: None. E. Lazar Ben-
edek: None. C. Duicu: None.
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P13.01A
Molecular genetic and functional analysis indicate novel
genes involvement in retinopathy of prematurity
S. Rathi1, S. Jalali1, S. Chakrabarti1, S. Shahulhameed1,
S. Patnaik1, G. R. Musada1, D. Balakrishnan1, R.
Kekunaya1, P. P. Chabblani1, T. Ramakrishna2, M. Rao2,
I. Kaur1; L V Prasad Eye Institute, Hyderabad, India,
2Centre for Cellular and Molecular Biology, Hyderabad,
India
Retinopathy of prematurity (ROP) is one of the major
complications of premature birth which causes abnormal
retinal vascular development leading to severe visual
impairment. The underlying molecular mechanisms behind
ROP pathogenesis is still unclear. The present study is
focused on unravelling the factors responsible for the pro-
gression of ROP to severe stage among only 10–15% of
preterm infants with initial symptoms despite of similar and
timely antenatal care. A comprehensive analysis of candi-
date genes in premature infants with (n= 200) and without
ROP (n= 200) was undertaken to identify genetic variants
conferring disease susceptibility. Subsequently, the func-
tional analysis of identiﬁed genetic associations were
undertaken at vitreous and cellular levels. Of 384 variants
evaluated, signiﬁcant associations of few variants in CFH,
C2/BF, ANGPT2, FBLN5, CETP, CXCR4 and MMP9 were
observed with ROP. At protein level, also, MMP9, CFH,
C3, C4, APOA1, APOC3, VEGF and proinﬂammatory
cytokines exhibited signiﬁcant elevations in ROP vitreous
as compared to the controls. Western blotting and zymo-
graphy further provided interesting insights on the activa-
tion of complement components and matrix
metalloproteinases in ROP pathogenesis. LC-MS/MS ana-
lysis after in-gel digestion of proteins in vitreous further
validated the complement activation in the patients. Paral-
lelly, we also found that macrophages/microglia might have
a major contribution in the progression of ROP. Summarily,
the present study demonstrated that along with genetic pre-
disposition, hypoxia driven complement activation medi-
ated by retinal macrophage/ microglia could eventually
cause neovascularization and lead to the progression of
disease in premature infants. Grant Support from Depart-
ment of Biotechnology to IK
S. Rathi: None. S. Jalali: None. S. Chakrabarti: None.
S. Shahulhameed: None. S. Patnaik: None. G.R.
Musada: None. D. Balakrishnan: None. R. Kekunaya:
None. P.P. Chabblani: None. T. Ramakrishna: None. M.
Rao: None. I. Kaur: None.
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P13.02B
Cryptic complexity and disease candidate genes identiﬁed
in de novo apparently balanced translocations using whole-
genome mate-pair sequencing
C. Aristidou1,2, M. M. Mehrjouy3, M. Bak3, A.
Theodosiou1, V. Christophidou-Anastasiadou4, N.
Skordis5,6, N. Tommerup3, C. Sismani1,2
1Department of Cytogenetics and Genomics, The Cyprus
Institute of Neurology and Genetics, Nicosia, Cyprus, 2The
Cyprus School of Molecular Medicine, The Cyprus Institute
of Neurology and Genetics, Nicosia, Cyprus, 3Wilhelm
Johannsen Centre for Functional Genome Research,
Department of Cellular and Molecular Medicine, Univer-
sity of Copenhagen, Copenhagen, Denmark, 4Department
of Clinical Genetics, The Cyprus Institute of Neurology and
Genetics and Archbishop Makarios III Medical Centre,
Nicosia, Cyprus, 5Division of Pediatric Endocrinology,
Paedi Center for Specialized Pediatrics, Nicosia, Cyprus,
6St George's University of London Medical School at the
University of Nicosia, Nicosia, Cyprus
The majority of apparently balanced translocation (ABT)
carriers are phenotypically normal; however phenotype
association is present in 6–10% de novo cases. Detailed
ABT characterization is crucial for precisely reconstructing
derivative chromosomes, as well as identifying disease
candidate genes in affected individuals and making accurate
pregnancy risk estimations in non-affected individuals,
especially in those with complex translocations.
In the current study, whole-genome mate-pair sequen-
cing (WG-MPS) was applied to characterize ﬁve de novo
ABT carriers with neurodevelopmental or other abnormal-
ities and three non-affected individuals with recurrent mis-
carriages. All ﬁndings were validated with Sanger
sequencing and real-time PCR.
WG-MPS precisely mapped all ABT breakpoints. Based
on their molecular characterization, microhomology-
mediated or non-homologous end-joining mechanisms are
suggestive for ABT generation. Gene disruption occurred in
4/8 cases while cryptic complexity and imbalances were
detected in 2/8 cases. Speciﬁcally, an additional breakpoint
was detected in a phenotypically normal t(6;7;10) carrier
thus increasing the percentage of unbalanced gametes and
future pregnancy risk. In a t(6;7;8;12) carrier with intel-
lectual disability, a chromothripsis rearrangement was
detected with thirty-eight translocation breakpoints and a
heterozygous deletion disrupting SOX5, a dominant nervous
system development gene previously reported in similar
patients. Finally, in a t(1;X) carrier with hearing loss, the
chrX breakpoint mapped ~90kb upstream POU3F4, an X-
linked non-syndromic deafness gene, indicative of an
underlying position effect mechanism.
In conclusion, we demonstrated that WG-MPS can
accurately characterize de novo translocation breakpoints,
reveal ABTs’ full complexity, and suggest underlying
mechanisms for phenotype association, thus supporting its
potential introduction in the clinical investigation of ABTs.
C. Aristidou: None. M.M. Mehrjouy: None. M. Bak:
None. A. Theodosiou: None. V. Christophidou-Anasta-
siadou: None. N. Skordis: None. N. Tommerup: None. C.
Sismani: None.
P13.03C
Nested inversion polymorphisms predispose for chromo-
some 22q11.2 rearrangements
W. Demaerel1, M. S. Hestand1, E. Vergaelen1, A. Swillen1,
M. López-Sánchez2, L. A. Pérez-Jurado3, D. M.
McDonald-McGinn4, E. H. Zackai4, B. S. Emanuel5, B. E.
Morrow6, J. Breckpot1, K. Devriendt1, J. R. Vermeesch1;
KU Leuven, Leuven, Belgium, 2Universitat Pompeu
Fabra, Barcelona, Spain, 3Institut Hospital del Mar
d'Investigacions Mèdiques, Barcelona, Spain, 4Children’s
Hospital of Philadelphia, Philadelphia, PA, United States,
5Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA, United States, 6Albert
Einstein College of Medicine, Bronx, NY, United States
Inversion polymorphisms between low copy repeats (LCRs)
often predispose to meiotic non-allelic homologous
recombination (NAHR) events causing genomic disorders.
However, for the 22q11.2 deletion syndrome (22q11.2DS),
the most common genomic disorder, no such inversions
have been uncovered as of yet. Using ﬁber-FISH, we
demonstrate that parents transmitting the de novo 3 Mb
LCR22A-D 22q11.2 deletion, the reciprocal duplication,
and the smaller 1.5 Mb LCR22A-B 22q11.2 deletion, carry
inversions between LCR22B or LCR22C and LCR22D.
Hence, the inversions predispose to meiotic 22q11.2 rear-
rangements and increase the individual risk over two-fold
for transmitting rearrangements when compared to the
population. Interestingly, the inversions are nested or
ﬂanking rather than coinciding with the deletion/duplication
sizes. This ﬁnding raises the possibility that inversions are a
prerequisite not only for 22q11.2 rearrangements but for all
NAHR mediated genomic disorders. Additionally, the lack
of normal individuals homozygous or patients hemizygous
for the inversion suggests negative selection.
Funding: W.D. is a fellow at KU Leuven supported by
IWT (131625). This work was made possible by grants
from the KUL PFV/10/016 SymBioSys to J.R.V. and GOA/
12/015 to J.R.V. and K.D, by the National Institute of
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ence Policy Ofﬁce Interuniversity Attraction Poles (BEL-
SPO-IAP) program through the project IAP P7/43-BeMGI.
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Zackai: None. B.S. Emanuel: None. B.E. Morrow: None.
J. Breckpot: None. K. Devriendt: None. J.R. Vermeesch:
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P13.04D
Alpha-1 antitrypsin gene expression in liver organoids
G. Gomez1, C. Epifano1, N. Matamala1, S. Martinez1, M.
Martínez2, M. Huch3, I. Perez de Castro1, B. Martinez
Delgado1
1Institute of Health Carlos III (ISCIII), Madrid, Spain,
2Hospital 12 de Octubre, Madrid, Spain, 3University of
Cambridge, Cambridge, United Kingdom
Introduction: In vitro organoids are three dimensional (3D)
cell culture systems, in which adult stem cells can self-
organize and differentiate into structures that show realistic
micro-anatomy. This new cell culture tool facilitates mod-
eling of diseases, study of biological processes and testing
of new therapies. Alpha-1 antitrypsin (AAT) is largely
secreted by the liver, and its accumulation into hepatocytes
causes AAT deﬁciency in individuals with Z mutation
(Glu342Lys) in SERPINA1 gene. Nevertheless, since liver
biopsies are difﬁcult to obtain, organoids might be a good
alternative to study molecular processes associated with
AAT deﬁciency.
Materials and methods: We have determined optimal
culture conditions for generation of liver organoids from
healthy donors and patients with AAT deﬁciency. We have
evaluated AAT gene and protein expression in organoids
and its secretion into the medium. To characterize the
expression of SERPINA1 gene in liver cells, expression of
the alternative transcripts of SERPINA1 has been investi-
gated by RT-PCR and QT-PCR.
Results: We have analyzed the expression of transcripts
1A, 1B and 1C in liver organoids and obtained the speciﬁc
proﬁle of the alternative transcripts of SERPINA1 in liver
cells. We are evaluating the ability of organoids to repro-
duce AAT deﬁciency in vitro, by detection of AAT protein
aggregates.
Conclusions: Generation of liver organoids might be a
useful tool to investigate the factors contributing to hepatic
disease in AAT deﬁciency.
G. Gomez: None. C. Epifano: None. N. Matamala:
None. S. Martinez: None. M. Martínez: None. M. Huch:
None. I. Perez de Castro: None. B. Martinez Delgado:
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P13.05A
Alpha-thalassemia due to novel deletions and complex
rearrangements in the subtelomeric region of chromosome
16p
J. Ferrão1, M. Silva1, L. Gonçalves1, S. Gomes1, P.
Loureiro1, A. Coelho1, A. Miranda2, F. Seuanes2, A.
Batalha Reis3, C. Valtonen-André4, A. Sonesson4, F.
Pina5, R. Maia6, P. Kjöllerström6, E. Monteiro7,8, J. F.
Lacerda7,9, J. Lavinha1,10, J. Gonçalves1,11, P.
Faustino1,12; Departamento de Genética Humana,
Instituto Nacional de Saúde Doutor Ricardo Jorge
(INSA), Lisboa, Portugal, 2Departamento de Promoção da
Saúde e Doenças não Transmissíveis, Instituto Nacional
de Saúde Doutor Ricardo Jorge (INSA), Lisboa, Portugal,
3Serviço de Patologia Clínica, Hospital São Francisco
Xavier, Centro Hospitalar Lisboa Ocidental, Lisboa,
Portugal, 4Department of Clinical Chemistry, University
and Regional Laboratories Region Skåne, Malmö,
Sweden, 5Serviço de Hemato-Oncologia, Hospital do
Espírito Santo de Évora, Évora, Portugal, 6Unidade de
Hematologia, Hospital de D. Estefânia, Centro Hospitalar
de Lisboa Central, Lisboa, Portugal, 7Faculdade de
Medicina, Universidade de Lisboa, Lisboa, Portugal,
8Serviço de Gastroenterologia, Hospital de Santa Maria,
Centro Hospitalar de Lisboa Central, Lisboa, Portugal,
9Serviço de Hematologia, Hospital de Santa Maria,
Centro Hospitalar de Lisboa Central, Lisboa, Portugal,
10BioISI, Faculdade de Ciências, Universidade de Lisboa,
Lisboa, Portugal, 11Centro de Toxicogenómica e Saúde
Humana (ToxOmics), Faculdade de Ciências Médicas,
Universidade Nova de Lisboa, Lisboa, Portugal,
12ISAMB, Faculdade de Medicina, Universidade de
Lisboa, Lisboa, Portugal
Introduction: Inherited deletions removing the α-globin
genes and/or their upstream regulatory elements (MCSs)
give rise to alpha-thalassemia, one of the most common
genetic recessive disorders worldwide. The pathology is
characterized by microcytic hypochromic anemia due to
reduction of the α-globin chain synthesis, which are
essential for hemoglobin tetramerization.
Material and Methods: In order to clarify the sugges-
tive α-thalassemia phenotype in eleven patients, we per-
formed Multiplex Ligation-dependent Probe Ampliﬁcation
with commercial and synthetic probes, gap-PCR, and
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Sanger sequencing to search for deletions in the sub-
telomeric region of chromosome 16p.
Results: We have identiﬁed six distinct large deletions,
three of them novel, and one indel. The deletions range
from approximately 3.3 to 323 kb, and i) remove the whole
α-globin cluster; or ii) remove exclusively the upstream
regulatory elements leaving the α-globin genes structurally
intact. The indel consists in the loss of MCS-R2 (HS-40),
which is the most important distal regulatory element for the
α-globin gene expression, and the insertion of 39 nt, see-
mingly resulting from a complex rearrangement involving
two DNA segments (probably from chromosome 3q),
bridging the deletion breakpoints with a CC-bp orphan
sequence in between. Finally, in one patient no α-globin
deletion or point mutation were found. This patient revealed
to have acquired alpha-thalassemia associated with a mye-
lodysplastic syndrome.
Conclusions: Our study widens the spectrum of mole-
cular lesions by which α-thalassemia may occur and
emphasizes the importance of diagnosing large α0-deletions
to provide patients with appropriate genetic counseling.
J. Ferrão: None. M. Silva: None. L. Gonçalves: None.
S. Gomes: None. P. Loureiro: None. A. Coelho: None. A.
Miranda: None. F. Seuanes: None. A. Batalha Reis:
None. C. Valtonen-André: None. A. Sonesson: None. F.
Pina: None. R. Maia: None. P. Kjöllerström: None. E.
Monteiro: None. J.F. Lacerda: None. J. Lavinha: None.
J. Gonçalves: None. P. Faustino: None.
P13.06B
Splice-site variant validation by NGS based amplicon
sequencing of rtPCR products in short stature
N. N. Hauer1, B. Popp1, E. Schoeller1, A. Ekici1, H. Dörr2,
A. Reis1, C. Thiel1
1Institute of Human Genetics, Friedrich-Alexander-Univer-
sität Erlangen-Nürnberg, Erlangen, Germany, 2Department
of Pediatrics and Adolescent Medicine, Friedrich-Alexan-
der-Universität Erlangen-Nürnberg, Erlangen, Germany
The application of next generation sequencing technologies
has been successful in unraveling the causes of genetic
disorders, but simultaneously increased the number of var-
iants potentially affecting the splice-sites. To identify the
genetic origins of idiopathic short stature by exome
sequencing in more than 200 patients, we observed 44
variants possibly affecting splicing. Computational methods
to calculate their potential effect were partly inconclusive.
Therefore we performed standard rtPCR analyses compris-
ing Sanger sequencing. In case of suspected alternative
splicing the evaluation of the distinct resulting isoform,
though, was often hampered by the overlap of sequences.
This was especially severe when multiple alternative tran-
scripts were present. To circumvent these issues, we
established a deep sequencing approach (targeted rtPCR-
Seq) to identify all present isoforms in patients and controls.
For this method the 44 rtPCR fragments were normalized to
generate an equimolar mixture. We generated libraries by
ligation of distinct index adaptors for both amplicon pools
and subsequently sequenced on an Illumina MiSeq plat-
form. The resulting reads were aligned and visualized as
sashimi plots. Observed splice-junctions in patients were
compared to the controls and public databases. Whereas the
computational approach was able to imply potential effects
on splicing only rtPCR results gave conclusive information.
The speciﬁc effect was more obviously ascertained by the
NGS based approach. rtPCR-Seq was able to unambigu-
ously separate multiple co-occurring isoforms. Thus, we
established a simple amplicon based deep sequencing
approach for standard rtPCR fragments enabling a fast,
comfortable and precise interpretation of the effect of a
speciﬁc variant.
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Sequencing analysis of the ISL1 gene in human bladder
exstrophy
S. Arkani1, J. Cao1, J. Lundin1,2,3, D. Nilsson3,4, T.
Källman5, G. Barker6, G. Holmdahl7, C. Clementsson
Kockum8, H. Matsson1, A. Nordenskjöld1,9
1Department of Women's and Children's Health, Karolinska
Institutet, Stockholm, Sweden, 2Department of Clinical
Genetics, Stockholm, Sweden, 3Department of Molecular
Medicine and Surgery and Center for Molecular Medicine,
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Laboratory, Karolinska Institutet Science Park, Stockholm,
Sweden, 5Science for Life Laboratory, Department of
Medical Biochemistry and Microbiology, Uppsala Univer-
sity, Uppsala, Sweden, 6Department of Women’s and
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Bladder exstrophy is a rare congenital closure defect of the
urinary bladder with profound impact on morbidity. A
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genetic background of the malformation is supported by an
increased recurrence risk in offspring and siblings,
higher concordance rates in monozygotic twins and asso-
ciated chromosomal aberrations including chromosome
22q11 duplications. Recently, ISL1 was presented as a
candidate gene in a genome wide association study for
bladder exstrophy. Here, we assessed the frequency of
single nucleotide variations in exons of ISL1 using DNA
from 125 Swedish bladder exstrophy patients. In addition,
we assessed ISL1 expression levels in human foetal bladder
tissue during the critical time period of bladder
development.
In total 17 genetic variants in ISL1 were identiﬁed
including one splice variant, c.479-4G>A, and one novel
missense variant, c.137C>G p.(Ala46Gly). The c.137C>G
variant is predicted to be possible pathogenic/possible
damaging by M-CAP and PANTHER, respectively, how-
ever the pathogenicity is currently uncertain. Both variants
were inherited from a healthy mother. The existence of
these variants in healthy parents may not exclude causation
in accordance with the previously reported 22q11 duplica-
tion carriers. Furthermore, we detected ISL1 mRNA
expression during week 5–10 of foetal bladder
development.
Our results suggest that mutations in ISL1 may be a rare
mechanism behind bladder exstrophy. Further, functional
studies of ISL1 mutations and gene expression proﬁles
during bladder development could identify key genes
important for bladder development.
We acknowledge funding from the Swedish Research
Council, Stiftelsen Frimurare Barnhuset i Stockholm,
Stockholm County Council and Karolinska Institutet.
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Sequencing of synthetic long reads to elucidate structure
and mechanisms for formation in patients with genomic
structural alterations
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Zanardo1, A. T. Dias1, A. M. Nascimento1, J. G.
Damasceno1, F. A. R. Madia1, T. V. M. M. Costa1, Y. G.
Oliveira1, C. Kaminski2, J. Garifallou2, M. V. Gonzales2,
L. Tian2, C. Kao2, C. A. Kim3, R. Pellegrino2, H.
Hakonarson2, L. D. Kulikowski1
1Department of Pathology, Cytogenomics Laboratory/ LIM
03 - Faculdade de Medicina da Universidade de São Paulo,
São Paulo, Brazil, 2Center for Applied Genomics –
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Introduction: Genomic rearrangements are structural
alterations in the DNA molecule. For identiﬁcation of its
mechanisms, a base-pair level analysis is necessary. Next
Generation Sequencing (NGS) is an option, but it generally
uses short reads, which make it difﬁcult to identify the
actual position of a determined fragment in a chromosome.
Recently, techniques have been developed that synthesize
long reads by adding barcodes in long fragments before
performing the fragmentation. Materials and Methods:In
this sense, we used the new 10x Chromium protocol, fol-
lowed by exome sequencing by Illumina HiSeq, in order to
understand the structure of rearranged chromosomes and
propose, in an unprecedented way, mechanisms for forma-
tion. We performed Chromium analysis in samples of two
patients previously identiﬁed with structural alterations by
karyotype.
Results: The analysis was successful in detecting the
translocations revealed by karyotype and, furthermore,
delineated breakpoints more accurately. Patient 1 presented
a karyotype 46,XY,t(7;14)(q34;q21.2) which was redeﬁned
as 46,XY,t(7;14)(7pter->q34::14q21.2->qter) with break-
points precisely at chr7:138.399.664 and chr14:46.624.191.
Patient 2 presented a karyotype 46,XY,der(9)t(9;18)(p22;
q12.2) which was redeﬁned as 46,XY,der(9)t(9;18)(9qter-
>p24.1::18q12.3->qter) with breakpoints precisely at
chr9:4.368.704 and chr18:39.163.156. Since there are no
other alterations in each patient, nor LCRs (Low-Copy
Repeat) nearby, we could infer that NHEJ (Non- Homo-
logous End Joining) was the mechanism that generated both
rearrangements.
Conclusions:These results show the efﬁciency of the
10x Chromium method for identifying structural rearran-
gements and its importance in the investigation of break-
point mechanisms. Grant reference: CNPq
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A tale of two anomalies. A paternal duplication and a
maternal deletion of 15q13
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CHU Liège, Liège, Belgium, 2CHR Liège, Liège, Belgium
A male newborn presented with an antenatally detected
cardiac malformation. Postnatal examinations revealed a
double chambered left ventricle as single malformation.
Array-CGH molecular karyotyping identiﬁed a chromo-
somal anomaly of the 15q13.2q13.3 region (hg19,
30,954,726–31,972,705;1018kb) including 21 genes,
among others TRPM1, MTMR10, OTUD7A, KLF13,
ARHGAP11B and FAN1.
Familial analyses revealed that his mother carried a
deletion overlapping the same region (30,954,726–
32,509,926; 1555 kb) while his father carried a duplication
of the same chromosomal region (32,065,000–35,509,926;
445kb). His father presented with a congenital cataract and
a congenital deafness, both attributed to neonatal asphyxia.
His mother presented with a hypophysary microadenoma.
Both parents have a normal intelligence. A healthy sister
with a normal development at the age of 3 presented the
same heterozygous anomaly as his brother.
A double chambered left ventricle has never been
described previously in patients with 15q13 deletion.
However, other congenital cardiac anomalies have been
described possibly associated with haploinsufﬁciency of
KLF13. In our case, we postulate that the co-occurrence of
two chromosomal anomalies of the same 15q13 region has
contributed to the occurrence of this malformation. Chro-
mosomal anomalies are risk factors for malformations with
a wide variability of phenotype, even including the absence
of symptoms, thereby explaining the sister normal
phenotype.
The possibility of a co-occurrence of a parentally
inherited duplication on one allele with a complementary
deletion of the allele inherited from the other parent has
been postulated in the literature, but according to our
knowledge has never been described yet.
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Introduction: Next-generation sequencing (NGS) has
revolutionised the mapping of balanced chromosomal
rearrangements (BCRs), linking truncated genes to speciﬁc
diseases, and pinpointing the functional importance of the
genomic organisation into topologically associating
domains (TADs). However, we lack data from healthy
BCR-carriers.
Methods and Materials: We present the ﬁrst data from
the International Breakpoint Mapping Consortium (IBMC),
a world-wide effort which includes mapping of normal
carriers. We compared breakpoints from simple two-way
BCRs in affected vs. controls using truncation of genes,
including known autosomal recessive (AR) and dominant
(AD) disease genes and loss-of-function (LOF)-constrained
genes. Breakpoints potentially associated with long range
position effects (LRPE) are reported separately.
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Results: We increased the number of NGS-mapped
healthy BCR carriers manyfold, and expanded the number
of affected carriers (Table).
Conclusion: The proportion of truncated genes are
similar in unaffected and affected carriers, with a signiﬁcant
excess of truncated AD disease and LOF-constrained genes
in the latter. Truncation of known AD genes in apparently
healthy carriers does occur, e.g. ABCC9, DCC, CACNB4
and TGFB2. Strikingly, 23% of the truncated genes in
healthy carriers are LOF-constrained, at odds with exome
sequencing data. Our study illustrates the importance of
NGS-based mapping of BCRs irrespective of phenotype,
and the potential of IBMC to conﬁrm known disease genes
and identify novel candidate disease genes and LRPE-
regions.
Supported by the Danish Council for Independent
Research [4183-00482B]
Number of mapped BCRs and breakpoints truncating genes
Phenotype Total number of BPs truncating Novel candidate
disease genes in
IBMC
BCR carriers
(published)
#BPsgenes
(%)
2 genes
(%)
AD genesAR genesLOF-genes
(%)
Affected 87 (198) 570 231 (40)44 (15)39 20 95 (41) 57
Healthy 117 (8) 250 110 (44)27 (22)4 13 26 (23)
204 (206) 830 p=0.0024 p=0.0016
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Introduction: Genomic/chromosomal instability (GIN/
CIN) can be a consequence of alterations to DNA repair,
cell cycle and/or apoptosis pathways and GIN/CIN can be
associated with debilitating cancerous and neurodegenera-
tive conditions. Here, we have evaluated CNVs of genes
implicated in DNA repair machinery, cell cycle and apop-
tosis pathways in individuals with GIN/CIN manifested as
chromothripsis.
Materials and methods: We have evaluated the pre-
sence of copy number variations (CNV) in genes involved
in cell cycle pathway (according to KEGG database) in 433
children with intellectual disability, autism, epilepsy, and/or
congenital malformations addressed by SNP-array mole-
cular karyotyping. Among them, children exhibiting GIN/
CIN manifested as chromothripsis were further addressed
bioinformatically.
Results: We found a full loss of the distal half of N-
terminal exon of the EP300 in 4 patients with GIN/CIN
manifested as chromothripsis. In addition to chromothripsis,
these patients also exhibited dramatically increased CNV
burden (50–100 times more than an average number of
CNV per genome). This gene encodes an acetyltransferase
p300 involved in transcriptional regulation by both chro-
matin remodeling and activation of various transcription
factors.
Conclusions: Terminal exon of EP300 encodes zinc
ﬁnger domain is essential for protein activity and a reg-
ulatory binding site. EP300 terminal exon loss is likely to
alter cell cycle pathways and contribute to GIN/CIN in these
patients. Our study allows speculations that genetic defects
in EP300 is involved in generation of GIN/CIN manifested
as chromothripsis. Supported by the Russian Science
Foundation (project #14-35-00060).
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Analysing the expression proﬁles of human DES
orthologous desma and desmb by using knockout zeb-
raﬁsh models
C. Koyunlar1, G. Kayman-Kurekci1, E. Kural1, B. Talim2,
N. Purali3, P. Dincer1
1Hacettepe University, Dept. of Medical Biology, Ankara,
Turkey, 2Hacettepe University, Dept. of Pathology, Ankara,
Turkey, 3Hacettepe University, Dept. of Biophysics, Ankara,
Turkey
Desmin, a basic intermediate ﬁlament protein speciﬁc to
muscle tissue, facilitates the transmission of force during
muscle contraction and relaxation by forming a large net-
work structure. In zebraﬁsh, there are two DES orthologous
gene (desma and desmb) and for modeling of DES-related
diseases, the tissues in which these genes are expressed
need to be analysed.
In this study, mRNA and protein expressions of desma
and desmb was compared among wild type AB, desma KO
(-/-) and desmb KO (-/-) zebraﬁsh. mRNA expression was
determined by qRT-PCR and whole mount in situ hybri-
dization. Protein expression was observed by whole mount
immunoﬂuorescence staining technique.
In qRT-PCR study, 99% of desma mRNA expression in
desma KO (-/-) zebraﬁsh and 98% of desmb mRNA
expression in desmb KO (-/-) zebraﬁsh were found to
decrease relative to the wild type AB zebraﬁsh. In situ
hybridization and immunoﬂuorescence staining studies
have shown that, in wild-type AB zebraﬁsh, desma and
desmb have similar somite and heart expression proﬁle until
70 hpf; but after 70 hpf, it was observed that the desma was
expressed predominantly in somites and heart, while desmb
was expressed mainly in the gut. In desmb KO (-/-) zebra-
ﬁsh desma is also expressed in the gut. However, in desma
KO (-/-) zebraﬁsh, no expression occurs in somites or heart.
In conclusion, the DES ortologous genes’ expression has
been analysed in zebraﬁsh and in the future it will remove
the barriers of modeling DES-related diseases in zebraﬁsh.
Funded by TUBITAK, Project number 214S174 to P.
Dincer.
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High diagnostic yield through a gene-agnostic trio
exome sequencing strategy that identiﬁes mutations in
new and old rare disease genes
J. Baptista1,2, K. L. Stals1, M. Wakeling2, G. Jones1, A.
Parrish1, A. Bussell1, R. Caswell2, C. Tysoe1, E. Baple1,2,
S. Ellard1,2
1Royal Devon and Exeter, Exeter, United Kingdom, 2Uni-
versity of Exeter Medical School, Exeter, United Kingdom
Exome sequencing has accelerated novel disease gene dis-
covery from ~2700 in 2010 to ~6000 today. Over the past
year ~85 OMIM phenotypes with a newly discovered
molecular basis were discovered per month but most tar-
geted exome captures (“clinical exomes”) were designed at
least 3 years ago. We developed a bioinformatics pipeline to
identify SNV, indel and CNVs in unaffected parent-affected
child trios using the Agilent (v5/6) whole exome capture.
Patients with a high prior probability of a monogenic dis-
order were selected for testing through multi-disciplinary
assessment. Most had already undergone extensive genetic
testing. In 21 of the ﬁrst 50 consecutive trios we identiﬁed
the likely cause of the patient’s presenting phenotype .
Variants were classiﬁed as pathogenic or likely pathogenic
according to the ACMG guidelines and after assessment by
a multi-disciplinary team. De novo, AR and X-L variants
accounted for 9, 10 and 2 of the cases respectively. A
deﬁnitive genetic diagnosis was obtained for 6 of 13 cases
during an on-going pregnancy. In 5 of these the result was
communicated within 3 weeks from sample submission and
facilitated prenatal testing decisions. In one family the gene-
agnostic approach identiﬁed an incidental genetic diagnosis
that changed the family’s clinical management. For 3 of the
21 cases, the disease gene was discovered in the past 3
years. We conclude that a combination of case selection and
whole exome trio-based approach enables a high diagnostic
yield (42%) in the clinical setting through a gene-agnostic,
hypothesis-free approach that includes all new disease
genes.
J. Baptista: None. K.L. Stals: None. M. Wakeling:
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Investigation of role of some glaucoma risk factors in the
disease pathogenesis
F. Suri1,2, E. Elahi1, S. Yazdani2
1School of Biology, University College of Sciences,
University of Tehran, Tehran, Iran, Islamic Republic of,
2Ophthalmic Research Center, Shahid Beheshti University
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Introduction: Glaucoma is an optic neuropathy frequently
associated with elevated intraocular pressure (IOP) and
extracellular matrix (ECM) remodeling in the trabecular
meshwork (TM). The pathogenesis is multifactorial and
complex, but role of transforming growth factor-β (TGF-β)
has been shown in the process. Patients with glaucoma have
elevated levels of TGF-β2 in their aqueous humor, and
TGF-β has been shown to increase TM ECM production.
The bone morphogenetic proteins (BMPs) are other mem-
bers of TGF-β superfamily that antagonize TGF-β signaling
in TM. Gremlin, a BMPs antagonist, is increased in glau-
comatous aqueous humor. Mutations in LTBP2 that encodes
latent TGF-β binding protein 2 cause primary congenial
glaucoma. On the other hand, many studies have conﬁrmed
oxidative stress biomarkers in glaucomatous tissues. Mate-
rials and Methods: Cultured human TM cells were treated
with TGF-β2, gremlin, LTBP2 siRNA, H2O2 and N-Acetyl-
L-cysteine (NAC) + H2O2. NAC is an antioxidant that
serves as negative control for oxidative stress events.
Effects of all treatments on activation of TGF-β and BMP
pathways and expression of several ECM related genes
were evaluated by Western blot and real time PCR,
respectively. Results: LTBP2 knock down and oxidative
stress signiﬁcantly increased activation of TGF-β signaling
pathway, concomitant with decreased activation of BMP
pathway. TGF-β2 and gremlin serve as positive controls of
these events. All treatments also increased expression of
some ECM genes. Conclusions: These ﬁnding in cultured
TM cells may exert the same effects on the TM of glaucoma
patients, and these may contribute to decreased aqueous
humor outﬂow and increased IOP.
F. Suri: None. E. Elahi: None. S. Yazdani: None.
P13.15C
Difﬁculties obtaining iPSCs from scratch
A. J. Duarte1, J. Braganca2, O. Amaral1
1INSA, Porto, Portugal, 2University of Algarve, Faro,
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Lysosomal storage disorders (LSDs) are a group of genetic
diseases characterised by lysosomal dysfunction. Some of
the commonest LSDs are currently treated by enzyme
replacement therapy. However, particularly in cases of
advanced disease or late onset, results are discouraging. The
lack of good ex vivo models hinders R&D and delays the
understanding of the human pathophysiologic mechanisms.
Thus, using iPSCs methods to generate the cell-targets to
reproduce the disease, might help create ideal models for
studying pathogenic mechanisms and to ﬁnd new or more
effective therapeutic strategies. iPSCs generated from
somatic cells from patients are a necessary source for
patient-speciﬁc studies since they maintain the patient’s
genetic background.
Material and Methods: Using commercially obtained
skin ﬁbroblasts, as a control, guarantees better consistency
in technical conditions. In this study we used two different
methods to achieve forced expression of Oct4, Sox2, Klf4
and c-Myc: a non-integrative polycistronic plasmid vector
and the Sendai virus method Transformation conditions
with different vehicles of delivery were tested: different
reagents, concentration ratios and timings were compared.
Posterior validation of cells pluripotent state is currently
underway.
Results: Fibroblasts are very difﬁcult to transform but
colonies were observed at around three weeks post-
transfection using plasmid DNA. The Sendai virus
method proved to be easier and faster.
Aims: Currently we are generating iPSCs from human
skin ﬁbroblasts and intend to obtain a good cellular model
for LSDs.
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Chromosomes) by array methods
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Introduction: sSMC (small supernumerary marker chro-
mosome) is a structurally abnormal chromosome that can-
not be exactly identiﬁed or characterized by classical
cytogenetics (karyotyping, FISH) alone. According to
deﬁnition is equal or smaller in size than a chromosome 20
of the same metaphase spread. It may be formed by non-
coding heterochromatine only, but also can contain coding
euchromatine and could have a deleterious effect for car-
riers. With respect to this fact, identiﬁcation of sSMC is an
important task for molecular cytogenetics.
Material and Methods: Identiﬁcation of sSMCs was
performed by SNP array HumanCytoSNP 12v2.1, Illumina
or SurePrint G3 CGH ISCAv2, 8×6K, Agilent (GRCh37/
hg19). The majority of sSMCs were originally detected by
karyotyping, but two sSMCs were detected by the „ﬁrst
choice regime“ of oligoarray examination. We present
results of 10 prenatal and 11 postnatal cases.
Results: Out of 21 cases, 10 sSMCs were in mosaic form
(48%). One third (33%) of all cases came from acrocentric
chromosomes. For 12 (8 post- and 4 prenatal) carriers
(57%) the presence of sSMC in genome were clinically
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relevant. One sSMC detected in karyotype was not identi-
ﬁed either by FISH or array. In one case an inconclusive
array result was amended by FISH (chromosome Y origin).
Conclusion: It was conﬁrmed that not only SNP array,
but also oligoCGH technology is suitable for mosaic sSMC
identiﬁcation in case of higher percentage of aberrant cells.
In the average the lowest number of genes for phenotypical
abnormities was 3, the size of a duplicated region was about
3 Mb.
V. Becvarova: None. N. Jencikova: None. H. Pekova:
None. E. Svobodova: None. R. Mansfeldova: None. K.
Markova: None. V. Nedomova: None. J. Sehnalova:
None.M. Koudova: None. D. Stejskal: None. J. Horacek:
None. M. Trkova: None.
P13.17A
Impaired balance of mitochondrial ﬁssion and fusion in
an in-vitro model of mitochondrial unfolded protein
response
E. Aksu1, B. Talim2, B. B. Hayta1
1Hacettepe University Faculty of Medicine, Department of
Medical Biology, Ankara, Turkey, 2Hacettepe University
Faculty of Medicine, Department of Pediatrics, Pathology
Unit, Ankara, Turkey
Introduction: Mitochondrial function is vital for cellular
health and mitochondrial dysfunction/dysmorphology has
been recognized as a key pathological hallmark of several
neuromuscular disorders. In order to maintain mitochondrial
quality, several control pathways that act on the molecular,
organelle and cellular level have evolved. Mitochondrial
fusion and ﬁssion are recognized to be an important con-
stituent of quality control mechanisms at the organelle level.
The counterbalance of these two mechanisms regulates and
maintains function and distribution of organelle, as well as
cellular homeostasis. However, the relationship between
these mechanisms and mitochondrial unfolded protein
response (UPRmt), which is activated in response to dif-
ferent types and levels of stress, especially in conditions
where unfolded/misfolded mitochondrial proteins accumu-
late and aggregate, has not been investigated yet.
Materials and Methods: Key proteins involved in
mitochondrial fusion (Mfn1, Mfn2, OPA1) and ﬁssion
(Drp1, Fis1, Mff) were analyzed by western blot and
immunoﬂuorescence staining in C2C12 myogenic cells in
which UPRmt is activated by treating cells with an appro-
priate non-toxic conditions of antimycin A. Results:
UPRmt activation in myogenic cells results in a reduction in
the fusion GTPase Mitofusins (Mfn1 and Mfn2) in outer
membrane and long form of OPA1 (L-OPA1) in inner
membrane and affects mitochondrial morphology, cellular
respiratory and bioenergetic functions due to the impair-
ment of the mitochondrial dynamics.
Conclusion: Identiﬁcation of the relationship between
mitochondrial quality control pathways has opened new
directions for exploring mitochondrial biology and novel
therapeutic targets for neuromuscular diseases related to
mitochondrial failure. This study was supported by TÜBİ-
TAK (Project no:114S876).
E. Aksu: None. B. Talim: None. B.B. Hayta: None.
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Unexpected mosaicism for two unbalanced derivative
chromosomes without normal cell line
A. Guichet, E. Colin, M. Barth, D. Bonneau
service de genetique, angers, France
Mosaicism is the presence of genetically different cell lines
in one individual derived from a single zygote. We well
known mosaicism for a full aneuploidy or for a structural
rearrangement like a marker or ring but rarely with unba-
lanced reciprocal translocation. In this latter case, the
mosaicism involves both normal cells and cells carrying
an unbalanced reciprocal translocation (Pater et al 2003,
Gijsbers 2011Robberecht 2012).
We report an unique case of mosaicism of two unba-
lanced cell lines from a probable malsegregation from a
reciprocal translocation without normal cell.
A young child was referred at 1 year of age to our
hospital for isolated developmental delay. She was the third
child born to healthy unrelated parents. SNPa analysis
detected a terminal duplication of 34Mb of 5p13.2pter and a
90% mosaic deletion of 2.2Mb of 8p23.2pter. Chromosome
analysis on cultured peripheral lymphocyte revealed a 46
chromosomes number with two cell lines: a major one with
a derivative of chromosome 5 and a very smaller one with
one mitosis out of 26 with a derivative of chromosome 8.
FISH analysis conﬁrmed the mosaicism state with 5% of
der(8).The karyotype of our patient is :46,XX,der(5)t(5;8)
(p13.2;p23.2)[47],der(8) t(5;8)(p13.2;p23.2)[3]. The par-
ents’ karyotypes were normal.
We discuss the possible mechanisms for obtaining such
an unusual karyotype and review the literature.
Our case appears to be unique in showing reciprocity for
two derivatives products from malsegregation of a likely
(5;8) translocation.
A. Guichet: None. E. Colin: None. M. Barth: None. D.
Bonneau: None.
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Development of harmatomas is associated with con-
stitutive activated mTORC1 in Tuberous Sclerosis
complex
L. B. Moeller1, B. Schönewolf-Greulich1, T. Rosengren1,
L. Larsen1, J. Ostergaard2, M. Sommerlund2, C.
Ostenfeldt1, B. Stausbøl-Grøn2, K. Markussen Linnet2, P.
Axél Gregersen2, U. Jensen2
1Kennedy Center, Rigshospitalet, Glostrup, Denmark,
2Aarhus University Hospital, Aarhus, Denmark
Introduction: TSC1 and TSC2 are genes mutated in the
syndrome TSC (tuberous sclerosis complex). The gene
products of TSC1/2 form a complex which at energy lim-
iting states, down-regulates the activity of the regulator of
protein synthesis, the mammalian target of rapamycin
complex1 (mTORC1).
Materials and Methods: We describe a 3-generation
family with 17 affected members, all presenting classic TSC
features except renal manifestations. The index was
screened for mutations in TSC1 and TSC2. The effect of the
identiﬁed mutation was investigated by RT-PCR on RNA
isolated from ﬁbroblasts. Activity of mTOR was investi-
gated in cultured ﬁbroblast.
Results: The disease segregates with a silent substitution
in TSC2, c.4149C>T, p.(Ser1838Ser), which leads to the
formation of an active donor splice site, resulting in three
shorter alternatively spliced transcripts with premature stop
codons. A small amount of normal spliced transcript is
apparently produced from the mutated allele, which might
explain the milder phenotype. Interestingly, in contrast to
cultured control ﬁbroblasts, starvation of cultured patient
ﬁbroblasts obtained from lesional skin (harmatoma) did not
lead to repression of mTORC1, whereas partial repression
was observed in patient ﬁbroblasts obtained from non-
lesional skin.
Conclusion: The ﬁndings indicate that the development
of harmatomas is associated with constitutive activated
mTORC1, whereas mild deregulation of mTORC1 allows
the maintenance of normal skin. Furthermore, the ﬁnding
emphasizes the need for awareness when interpreting silent
substitutions in general.
Grants: the Danish council for independent research
(#12-127196) and Aase and Ejnar Danielsens Fond (#10-
000748).
L.B. Moeller: None. B. Schönewolf-Greulich: None. T.
Rosengren: None. L. Larsen: None. J. Ostergaard: None.
M. Sommerlund: None. C. Ostenfeldt: None. B.
Stausbøl-Grøn: None. K. Markussen Linnet: None. P.
Axél Gregersen: None. U. Jensen: None.
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The mechanism through which nonsense mutations are
recognized as premature translation-termination codons
L. Romão1,2, Claudia Onofre1,2, Juliane Menezes1,2, Isabel
Peixeiro1,2, Cristina Barbosa1,2
1Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa,
Portugal, 2Biosystems & Integrative Sciences Institute
(BioISI), Faculdade de Ciências, Universidade de Lisboa,
Lisboa, Portugal
About one third of the gene mutations found in human
genetic disorders, including cancer, result in premature
termination codons (PTCs) and the rapid degradation of
their mRNAs by nonsense-mediated decay (NMD). NMD
controls the quality of eukaryotic gene expression. The
strength of the NMD response appears to reﬂect multiple
determinants on a target mRNA. We have reported that
human mRNAs with a PTC in close proximity to the
translation initiation codon (AUG-proximal PTC), and thus,
with a short open reading frame, can substantially escape
NMD. Our data support a model in which cytoplasmic poly
(A)-binding protein 1 (PABPC1) is brought into close
proximity with an AUG-proximal PTC via interactions with
the translation initiation complexes. This proximity of
PABPC1 to the AUG-proximal PTC allows PABPC1 to
interact with eRF3 with a consequent enhancement of the
release reaction and repression of the NMD response. Here,
we provide strong evidence that the eIF3 is involved in
delivering eIF4G-associated PABPC1 into the vicinity of
the AUG-proximal PTC. In addition, we dissect the bio-
chemical interactions of the eIF3 subunits in bridging
PABPC1/eIF4G complex to the 40S ribosomal subunit.
Together, our data provide a framework for understanding
the mechanistic details of PTC deﬁnition and mRNA
translation initiation.
L. Romão: None.
P13.22B
Intronic PAH gene mutations cause a splicing defect by
a novel mechanism involving U1snRNP binding
A. Martínez Pizarro1, M. Dembic2, B. Perez1, B. S.
Andresen2, L. R. Desviat1; Centro de Biologia Molecular
Severo Ochoa, Madrid, Spain, 2University of Southern
Denmark, Odense M, Denmark
In the phenylalanine hydroxylase (PAH) gene, responsible
for phenylketonuria (PKU), one of the most common
inherited diseases of amino acid metabolism, exon 11 was
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recently identiﬁed as a vulnerable exon due to a weak 3′
splice site. Different exonic mutations affected exon
11 splicing by altering exonic splicing regulatory elements.
In this work, we report novel intron 11 regulatory elements
that are involved in exon 11 splicing, as revealed by the
investigated pathogenic effect of variants c.1199+17g>a
and c.1199+20g>c, identiﬁed in PKU patients. Both
mutations cause exon 11 skipping in a minigene system and
RNA binding assays indicate that binding of U1snRNP70 to
this region is disrupted, concomitant with a slightly
increased binding of inhibitors hnRNPA1/H. We have
performed deletion and point mutagenesis and over-
expression of adapted U1snRNP to identify critical motifs
involved in the regulation of correct splicing at the natural
5′ splice site. The results indicate that U1snRNP binding at
the intronic region is determinant for efﬁcient exon
11 splicing. In this work we expand the role of intronic
U1 snRNP binding as a splicing enhancer for PAH exon 11,
describing a novel mechanism by which intronic mutations
cause exon skipping. Notably, our results provide a ratio-
nale to explain the reported therapeutic effect of exon spe-
ciﬁc U1 snRNP (ExSpeU1) for splicing mutations in
different diseases. Supported by grants from Fundación
Ramón Areces (to L.R.D).
A. Martínez Pizarro: None. M. Dembic: None. B.
Perez: None. B. S. Andresen: None. L. R. Desviat: None.
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Altered Expression of Perineuronal Net Elements in
SMN Knockdown Cells
D. Dayangac-Erden1, N. Eskici1, S. Erdem-Ozdamar2
1Hacettepe University Faculty of Medicine Department of
Medical Biology, Ankara, Turkey, 2Hacettepe University
Faculty of Medicine Department of Neurology, Ankara,
Turkey
Introduction: The extracellular matrix surronding the ner-
vous system, which is called as perineuronal nets, play roles
in the control of neuronal plasticity, development and
function. It also has a neuroprotective property. The major
components of the perineuronal net are chondroitin sulfate
proteoglycans (aggrecan), hyaluronan, link proteins
(HAPLN1) and tenascin-R. In some neurodegenerative
disorders like Alzheimer’s disease, multiple sclerosis,
stroke, amyotrophic lateral sclerosis loss of perineuronal net
elements and also degradation in perineuronal net mor-
phology is detected. However there is no data available
about the role of perineuronal net elements in spinal mus-
cular atrophy, one of the most common childhood onset
neurodegenerative genetic disorders.Materials and
Methods: In this study we investigated the expression of
perineuronal net components in an in-vitro model estab-
lished by survival motor neuron (SMN) gene down-
regulation by RNA interference. PC12 rat
pheochromocytoma cell line was differentiated into neurons
and was transfected with 50 pmol SMN siRNA (Ambion).
Aggrecan, HAPLN1, tenascin-R mRNA and protein levels
were analyzed by qPCR and Western blot.
Results: PC12 cell lines was differentiated and at day 3,
HAPLN1 mRNA levels increased 2 fold whereas HAPLN1
protein levels showed 50% decrease in SMN depleted cells.
TNR and ACAN mRNA/ protein levels did not change
compared to negative control siRNA.
Conclusions: Detecting perineuronal net loss and
degradation also in SMA mouse models, will clarify novel
candidate proteins and pathways. Identiﬁcation of mole-
cules that target perineuronal net will help to discover novel
therapeutic approaches. (TUBITAK 114S914)
D. Dayangac-Erden: None. N. Eskici: None. S.
Erdem-Ozdamar: None.
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Identiﬁcation of NIN missense mutations in a boy with
Seckel syndrome
E. Nishi1,2, A. L. Ritter3, K. Masuda4, K. Fujiki5, M.
Arakawa1, Y. Katoh5, K. Shirahige5,6, K. Izumi5,3,7
1Division of Medical Genetics,Nagano children's hospital,
Azunimo city, Japan, 2Life Science Research Center,
Nagano Children's Hospital,, Azumino city, Japan, 3Divi-
sion of Human Genetics, Department of Pediatrics, The
Children’s Hospital of Philadelphia, Philadelphia, PA,
United States, 4Research Center for Epigenetic Disease,
Institute for Molecular and Cellular Biosciences, The
University of Tokyo, Tokjyo, Japan, 5Research Center for
Epigenetic Disease, Institute for Molecular and Cellular
Biosciences, The University of Tokyo, Tokyo, Japan,
6CREST, Japan Science and Technology Agency, Kawa-
guchi, Japan, 7Division of Genomic Diagnostics, Depart-
ment of Pathology and Laboratory Medicine, The
Children’s Hospital of Philadelphia, Philadelphia, PA,
United States
Microcephalic primordial dwarﬁsm (MPD), a group of
disorders characterized by prenatal growth retardation with
microcephaly, includes Seckel syndrome, microcephalic
osetodysplastic primordial dwarﬁsm, and Meier-Gorlin
syndrome. Seckel syndrome is clinically unique from
other MPDs due to the presence of developmental delays
and intellectual disability. MPDs are known to be associated
with mutations in genes important for DNA replication and
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cell cycle regulation. Here we report a boy with MPD,
consistent with Seckel syndrome, who was found to have
compound heterozygous NIN mutations by whole exome
sequencing, the second case with a MPD phenotype.The
patient was the ﬁrst child of a healthy 26-year-old non-
consanguineous parents without relevant family history of
genetic disorders or birth defects. Severe intrauterine
growth retardation was ﬁrst noted around 25 weeks of
gestation. He was born at 39 weeks, 4 days of gestation. His
birth weight was 1444 g (−4.9 SD), length was 35.0cm
(−7.6 SD), and occipital-frontal circumference (OFC) was
26.5 cm (−5.2SD). At birth, severe microcephaly, severe
growth retardation, micrognathia and facial dysmorphisms
(narrow forehead, hypertelorism, down-slanting palpebral
ﬁssures, epicanthus, and prominent nose) were noted. We
performed whole exome sequencing for the patient with
MPD, phenotypically resembling Seckel syndrome, and
found compound heterozygous NIN mutations, the second
reported case of MPD due to mutations in this gene. NIN
encodes the protein ninein, which is involved in micro-
tubule anchoring and centrosomal structure, and was
recently proposed as a novel gene related to MPD. Our
report further supports the notion that NIN mutations cause
MPD phenotype.
E. Nishi: None. A.L. Ritter: None. K. Masuda: None.
K. Fujiki: None. M. Arakawa: None. Y. Katoh: None. K.
Shirahige: None. K. Izumi: None.
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Differences in the BMPR2 gene expression in B Lym-
phocytes inherent to Epstein-Barr virus immortalization
G. Pousada1, M. Lago-Docampo1, S. Prado-López1, A.
Baloira2, R. Varela-Calviño3, B. Mantiñán4, D. Valverde1
1Universidad de Vigo, Vigo, Spain, 2Complejo Hospitalario
de Pontevedra, Pontevedra, Spain, 3Universidad de San-
tiago de Compostela, Santiago de Compostela, Spain,
4Complejo Hospitalario Universitario de Vigo, Vigo, Spain
BMPR2, whose expression is describes as ubiquitous, is the
main gene implied in Pulmonary Arterial Hypertension
(PAH), a rare disease characterized by the increase of vas-
cular resistance. The aim was to functionally characterize
the c.419-43delT mutation in BMPR2, present in 18% of the
patients analyzed.
Minigene assay for mutant sequence and wild type was
performed using the pSPL3 vector in order to detect
alterations in the splicing process. Peripheral blood samples
were drawn from patients (with deletion, without it and
controls) and B lymphocytes were subsequently isolated
and cultured. Later, immortalization using Epstein-Barr
Virus was performed on them. The immortalization process
was conﬁrmed by ﬂow cytometry. Lymphoblastoids were
then separated according to their cell cycle phase by cell
sorting. BMPR2 gene expression was analyzed by qPCR
using commercial Taqman® assays.
No splicing alterations were detected. BMPR2 expression
was not detected in B lymphocytes from peripheral blood,
neither after its culture, even though control genes (GADPH
and ACTB) were detected. After immortalization, BMPR2
and control genes expression were detected. Normalized
expression showed increased expression in phase S between
patients and controls, and a decrease in phase G2/M.
Patients without deletion showed intermediate values.
BMPR2 expression in lymphoblastoids may be triggered
by the immortalization process. Expression differences in
BMPR2 between patients with deletion, without it and
controls, suggest that this mutation may inﬂuence in its
expression regulation. Although, further studies will be
needed to corroborate this hypothesis.
G. Pousada: None. M. Lago-Docampo: None. S.
Prado-López: None. A. Baloira: None. R. Varela-Cal-
viño: None. B. Mantiñán: None. D. Valverde: None.
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Recurrent 10q11.2 deletions unmasking CHAT or
SLC18A3 recessive mutations can lead to congenital
myasthenic syndrome
S. Whalen1, M. Schwartz2, A. Benzarti2, A. Afenjar1, A.
Isapof3, B. Chabrol4, M. Portnoï2, S. Nicole5, D.
Sternberg6, S. Heide2, S. Chantot-Bastaraud2, J. Siffroi2
1Unité Fonctionnelle de génétique clinique, Hôpital
Armand-Trousseau, APHP, Paris, France, 2Département
de génétique médicale, Hôpital Armand-Trousseau, APHP,
UPMC, Paris, France, 3Unité de Neuropédiatrie et
pathologie du développement, Hôpital Armand-Trousseau,
APHP, Paris, France, 4Service de Neurologie pédiatrique,
Hôpital de la Timone, CHU de Marseille, Marseille,
France, 5Inserm U 1127, CNRS UMR 7225, UPMC, Institut
du Cerveau et de la Moëlle épinière, Paris, France, 6Unité
de Génétique Cardiaque et Musculaire, Service de
Biochimie, Centre de génétique moléculaire et chromoso-
mique, Groupe Hospitalier Pitié Salpêtrière, APHP, Paris,
France
Recurrent deletions localized in 10q11.21-q21.1 have been
associated with variable phenotypes, and can be found in
asymptomatic individuals as well as in patients showing
intellectual disability, sometimes associated with various
symptoms (hypotonia, sleep apnea, chronic constipation,
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epilepsy, cerebellar syndrome, dysphagia or ptosis), thus
suggesting the role of modifying genetic factors.
Several genes are contained in this chromosomal region,
such as the Choline Acetyltransferase gene (CHAT; MIM#
118490), which catalyzes pre-synaptic synthesis of acetyl-
choline (ACh). Interestingly, CHATs ﬁrst intron contains a
small gene, SLC18A3, which encodes the highly conserved
vesicular ACh transporter (VAChT). Compound hetero-
zygous or homozygous CHAT mutations have been identi-
ﬁed in patients suffering from congenital myasthenic
syndrome (CMS) with episodic apnea. These patients are at
risk of lethal episodes of acute respiratory distress and
bulbar weakness. These life-threatening events can be
reduced with a speciﬁc treatment.
Recently, recessive mutations of SLC18A3 have been
involved in a similar congenital myasthenic syndrome.
Here, we report cases of two unrelated children carrying
a 10q11.2 deletion and who displayed signs of CMS with
episodic apnea. In both cases, the 10q11.2 deletion
unmasked a recessive mutation, in CHAT gene for patient 1
and in SLC18A3 gene for patient 2.
S. Whalen: None. M. Schwartz: None. A. Benzarti:
None. A. Afenjar: None. A. Isapof: None. B. Chabrol:
None. M. Portnoï: None. S. Nicole: None. D. Sternberg:
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Somatic reversion assists in identiﬁcation of RPL4 as a
novel disease gene for a condition resembling Diamond
Blackfan Anemia
M. Jongmans1,2,3, R. Kuiper3,1, R. Pfundt1
1Radboud University Medical Center, Nijmegen, Nether-
lands, 2University Medical Center Utrecht, Utrecht, Nether-
lands, 3Princess Máxima Center for Pediatric Oncology,
Utrecht, Netherlands
Revertant mosaicism is caused by the spontaneous correc-
tion of a mutation followed by clonal expansion of the
revertant cell, resulting in diminished or altered disease
symptoms. A cause of reversion in dominant disorders is
mitotic recombination, recognized by aquired uniparental
disomy (UPD). We report about a girl with intellectual
disability, short stature, a cleft lip, hearing loss and toe
anomalies. SNP array analysis on blood DNA revealed
mosaic 15q22-tel UPD. We hypothesized that this clonal
UPD resulted from selective advantage of the homozygous
15q cells. Indeed analysis on DNA taken on earlier and later
timepoints revealed a shift from normal heterozygosity
patterns towards complete 15q homozygosity. We con-
ﬁrmed that this UPD is conﬁned to blood by testing muscle
DNA. The fact that UPD of 15q provoked a selective
advantage to blood cells suggests the presence of a hae-
matological condition, caused by a mutation distal from the
most telomeric recombination breakpoint. Indeed the girl
had transient anemia early in life. We performed whole
exome sequencing on muscle DNA and identiﬁed a de novo
c.176-7A>G mutation in RPL4 on 15q22.31
(r.175_176insUUUUAG; p.(Ala58_Gly59insValLeu)).
RPL4 ﬁts in the list of ribosomal protein genes causative for
Diamond Blackfan anemia, and the features of this condi-
tion indeed overlap with the phenotype in our patient.
Remarkably, in 20% of patients with DBA anemia goes in
remission. In conclusion, we report mitotic recombination-
based somatic reversion in a girl with a Diamond Blackfan
anemia-like phenotype, which directed us to the identifation
of RPL4 as a novel DBA-like disease gene.
M. Jongmans: None. R. Kuiper: None. R. Pfundt:
None.
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Single-cell RNA-seq reveals distinct dynamic behavior
of sex chromosomes during human early embryogenesis
Q. Zhou1,2,3, T. F. Wang2,3, J. R. Huang2,3, L. Yang2,3, F.
P. Xu1,2,3
1Department of Biology, University of Copenhagen,
Copenhagen, Denmark, 2BGI-Shenzhen, Shenzhen
518083, China, 3China National GeneBank-Shenzhen,
BGI-Shenzhen, Shenzhen 518083, China
Introduction: In mammals, various studies have been
focused on the differences in sex-chromosome constitution
between males (XY) and females (XX). However, limited
data exists to investigate whether sex differences are already
present during human early embryogenesis.
Methods: We performed global expression analysis
between males and females using RNA-sequencing data of
1644 individual cells from 117 human preimplantation
embryos, covering development stages from zygote to late
blastocyst.
Results: Consistent chromosome-wide transcriptomic
level of autosomes was observed in all stages, while sex
chromosomes showed signiﬁcant differences after
embryonic genome activation (EGA). The distinction of Y
chromosome was due to speciﬁc genes, RPS4Y1 and
DDX3Y, with abundant expression in all male cells. For X
chromosomes in female, over one hundred signiﬁcantly
higher expressed genes were deﬁned in 8-cell stage and
both alleles of most heterozygous sites could be detected in
our allelic analysis. Contrary to constant pattern of Y, their
expression distinctly dropped at late blastocyst stage,
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especially in trophectoderm cells, revealing the exact time
point and details of dosage compensation.
Conclusion: We conclude that sex chromosomes are
activated immediately after EGA, for speciﬁc genes and
broad region of Y and X chromosome, respectively, with a
following dosage compensation ﬁrstly occurring in female
trophectoderm cells. The two Y-linked genes we ﬁnd might
be novel expression markers to distinguish gender of early
embryos for clinical trial. We predict broad utility of such
dynamic behavior of sex chromosomes in future studies on
human development and sex-speciﬁc disease.
Grant: The Shenzhen Municipal Government of China
(NO.CXZZ20150330171838997)
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Deep phenotyping and exome sequencing in patients
with short stature
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In short stature the underlying cause often remains elusive
due its heterogeneity. We deep phenotyped 565 patients and
randomly selected 200 for whole exome sequencing. Using
WES we identiﬁed mutations in 27 known short stature
associated genes in 17% of patients with only part of the
symptomatology precluding an early clinical diagnosis.
Heterozygous carriers of recessive skeletal dysplasia alleles
(ACAN, NPR2) were a frequent cause of idiopathic short
stature (3.5%). 54 % of the affected proteins are involved in
the main functional categories cartilage formation, chro-
matin modiﬁcation and Ras-MAPK signaling. We identiﬁed
37 further strong candidate genes, of which seven had
deleterious mutations in at least two families. 48% of these
candidate genes are involved in the 10 main functional
categories already identiﬁed for the known short stature
associated genes further supporting their pathogenicity.
Finally, in 16% of the 200 sequenced individuals our
ﬁndings were of signiﬁcant clinical relevance regarding
preventive measures, symptomatic or even targeted treat-
ment. Besides evaluation for orthopedic or developmental
issues especially screening for neoplasias (TRIM37,
PTPN11, NF1), symptomatic treatment for chronic kidney
disease (CLCN5) and targeted treatment for severe hyper-
tension (PDE3A) were of clinical relevance for the affected
individuals. These results demonstrated that deep pheno-
typing combined with targeted genetic testing and whole
exome sequencing is able to increase the diagnostic yield in
short stature up to 31% with concomitant improvement in
treatment and prevention. Rigorous variant analysis con-
sidering phenotypic data further led us to the identiﬁcation
of further 37 probable novel candidate genes.
C.T. Thiel: None. N. Hauer: None. B. Popp: None. E.
Schöller: None. S. Schuhmann: None. K.E. Heath: None.
A. Hisado-Oliva: None. P. Klinger: None. C. Kraus:
None. U. Trautmann: None. M. Zenker: None. C. Zwe-
ier: None. A. Wiesener: None. R. Abou Jamra: None. E.
Kunstmann: None. D. Wieczorek: None. S. Uebe: None.
F. Ferrazzi: None. C. Büttner: None. A.B. Ekici: None.
A. Rauch: None. H. Sticht: None. H. Dörr: None. A.
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Genomic and biochemical characterization of sialic acid
acetyl esterase (siae) in zebraﬁsh
V. Ravasio, E. Damiati, D. Zizioli, F. Orizio, E.
Giacopuzzi, M. Manzoni, R. Bresciani, G. Borsani, E.
Monti
ep. of Molecular and Translaional Medicine, University of
Brescia, Brescia, Italy
Sialic acid acetyl esterase (SIAE) removes acetyl moieties
from the carbon 9 and 4 hydroxyl groups of sialic acid and
recently a debate has been opened on its association to
autoimmunity. Trying to get new insights on this intriguing
enzyme we have studied siae in zebraﬁsh (Danio rerio). In
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this teleost siae encodes for a polypeptide with a high
degree of sequence identity to human and mouse counter-
parts. Zebraﬁsh siae behaviour upon transient expression in
COS7 cells is comparable to human enzyme concerning pH
optimum of enzyme activity, subcellular localization and
glycosylation. In addition, and as already observed in case
of human SIAE, the glycosylated form of the enzyme from
zebraﬁsh is released into the culture media. During
embryogenesis, in situ hybridization experiments demon-
strate that siae transcript is always detectable during
development, with a more speciﬁc expression in the central
nervous system, in pronephric ducts and liver in the more
advanced stages of the embryo development. In adult ﬁsh
siae mRNA is mainly detectable in muscle, ovary and brain.
These results provide novel information about siae and
point out zebraﬁsh as animal model to better understand the
biological role of this rather puzzling enzyme in vertebrates,
regarding immune system function and the development of
central nervous system.
V. Ravasio: None. E. Damiati: None. D. Zizioli: None.
F. Orizio: None. E. Giacopuzzi: None. M. Manzoni:
None. R. Bresciani: None. G. Borsani: None. E. Monti:
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Enhancer swapping: dual loss and gains of enhancers by
balanced translocations and inversions between highly
conserved regulatory domains
M. M Mehrjouy1, M. Bak1, D. G. Lupiáñez2, V. Heinrich2,
I. Bache1, S. Mundlos2, N. Tommerup1
1Copenhagen University, Copenhagen, Denmark, 2Max
Planck Institute for Molecular Genetics, Berlin, Germany
Introduction: Balanced chromosomal translocations/
inversions (BCR) may cause disease by long range position
effects (LRPE) due to rearrangements of regulatory land-
scapes. One consequence of this may be enhancer adoption,
where the ectopic action of an enhancer dysregulates
another gene. We have deﬁned >400 Topological Domains
(TAD) and TAD clusters enriched for evolutionary con-
served non-genic elements (CNEs) as high-risk candidates
for LRPE. These CNE-TADs might also be high-risk
regions for enhancer adoption and even more complex
regulatory disturbances.
Materials and Methods: We compared published cases
of enhancer adoption with CNE-TADs, and looked for
double involvement of CNE-TADs in published and
unpublished affected and healthy carriers of two-way
BCRs. We exemplify the deleterious nature of this by a
46,XX,t(2;13)(p25;q32)dn associated with severe
intellectual disability/microcephaly, analysed by mate-pair
sequencing and 4C-Seq analysis.
Results: Ten/eleven cases with proven enhancer adop-
tion involved one or two CNE-TADs. Furthermore, 13/283
affected BCR carriers (4.6%) had breakpoints involving two
CNE-TADs, vs. 0/125 healthy BCR carriers (p=0.012). The
t(2;13)-breakpoints were located within the regulatory
domains of SOX11 on chr2, and SOX21 on chr13. 4C-seq
analysis of t(2;13)-ﬁbroblasts showed ectopic interactions
between the SOX11 promoter and the translocated SOX21-
domain segment, and between the SOX21 promoter and the
translocated SOX11-domain segment.
Conclusion: CNE-TADs are high-risk domains for
enhancer adoption events, and dual exchanges between
CNE-TADs are high-risk mutations. We term this enhancer
swapping, due to the simultaneous removal of CNEs and
gain of ectopic CNEs in both domains, with potentially
unpredictable phenotypic consequences.
Supported by the Danish Council for Independent
Research [4183-00482B]
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Interruption of the AG-exclusion zone is the major
mechanisms of 90 non-canonical NF1 3′ splice-site
mutations: lessons to learn for intronic unclassiﬁed
variants
K. Wimmer1, E. Schamschula1, A. Wernstedt1, P. Kroisel2,
P. Traunfellner1, A. Amberger1, T. Callens3, L. Messiaen3
1Division Human Genetics, Medical University Innsbruck,
Innsbruck, Austria, 2Institute of Human Genetics, Medical
University of Graz, Graz, Austria, 3Medical Genomics
Laboratory, Department of Genetics, University of Ala-
bama at Birmingham, Birmingham, AL, United States
Introduction: Two thirds of the NF1 splice mutations do
not involve the canonical dinucleotides GT-AG of the splice
sites. Hence, this gene is highly suited to elucidate
mechanisms of action of non-canonical splice mutations.
Methods and Results: Through a series of mini-gene
experiments we studied the mode of action of NF1:c.1722-
11T>G, and found that this pyrimidine (Y) to purine (R)
transversion, although expected to weaken the poly-
pyrimidine tract (PPT), caused exon skipping primarily by
introducing a novel AG between the natural 3′-splice site
and the branch point, interrupting the AG-exclusion zone
(AGEZ). Evaluating 90 non-canonical intronic NF1 3′-
splice-site mutations, with known effect on splicing through
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RNA analysis, showed that 49/55 single-nucleotide variants
located between positions -35 and -4 created a novel AG
dinucleotide in the AGEZ. Two further motifs identiﬁed in
this cohort were: Y>R transversion at position -3 and
removal of ≥2 Ys in the AGEZ. 90% (81/90) of the non-
canonical NF1 3′-splice-site mutations follow one of these
three motifs. To test whether the three identiﬁed motifs can
distinguish spliceogenic from splice-neutral variants also in
different genes, we analyzed a cohort of 49 BRCA1/2
variants, with already known splicing outcome. The pre-
dictions in this cohort reached 85.7% accuracy with 78%
positive and 97.5% negative predictive values.
Conclusions: Comparing this three-motifs strategy to a
previously suggested strategy using splice-site prediction
tools indicated a comparable sensitivity with the three-
motifs strategy however offering the advantage of being
applicable also to variants located at further distance from
the natural 3′ splice site.
K. Wimmer: None. E. Schamschula: None. A.
Wernstedt: None. P. Kroisel: None. P. Traunfellner:
None. A. Amberger: None. T. Callens: None. L. Mes-
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Correction of IKBKAP exon 20 splicing by splice
switching oligonucleotides
G. H. Bruun, T. K. Doktor, J. S. Andersen, A. G. B.
Grønning, B. S. Andresen
University of Southern Denmark, Odense M, Denmark
Introduction: Familial dysautonomia (FD) is a severe
recessive disease affecting the sensory and autonomic ner-
vous system. FD is frequent in Ashkenazi Jews with an
estimated carrier frequency of 1/30. Almost all patients with
FD are homozygous for an IVS20+6T>C mutation in
IKBKAP, which decreases the 5′ splice site strength of exon
20 thereby causing exon 20 skipping and an NMD-sensitive
transcript. Correct splicing of exons with weak splice sites
depends on a tight balance between positive and negative
splicing regulatory elements (SREs), which are bound by
various splicing regulatory proteins (SRPs). Results: Pre-
viously we identiﬁed in vivo binding sites for the major
negative SRP hnRNP A1 by iCLIP. An hnRNP A1 binding
site in IKBKAP intron 20 close to the 5′ splice site of exon
20 was identiﬁed, and the binding of hnRNP A1 to this site
was validated by in vitro studies. Furthermore, knockdown
of hnRNP A1 in FD patient ﬁbroblasts suggested that
hnRNP A1 represses the inclusion of IKBKAP exon 20.
Therefore, we designed a splice switching oligonucleotide
(SSO) blocking the hnRNP A1 binding site in intron 20.
Transfection of this SSO into FD patient ﬁbroblasts fully
restores IKBKAP exon 20 splicing and increases the amount
of full-length IKBKAP transcript. Conclusion: SSO-based
blocking of hnRNP A1 binding may thus be a promising
approach for future treatment of FD. Funding: The Novo
Nordisk Foundation and Natur og Univers, Det Frie
Forskningsråd
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Functional analysis of splicing-affecting genomic var-
iants in hereditary diseases
M. Y. Skoblov1,2,3, A. Y. Filatova1, Y. V. Vyahireva1, T. A.
Vasilyeva1, A. V. Marakhonov1,2, R. A. Zinchenko1,3, Y. A.
Rogozhina4, M. &. Polyak4, E. V. Zaklyazminskaya4, A.
Orlova5, E. Pomerantseva5
1Research Center for Medical Genetics, Moscow, Russian
Federation, 2Moscow Institute of Physics and Technology,
Moscow, Russian Federation, 3Pirogov Russian National
Research Medical University, Moscow, Russian Federation,
4Petrovsky Russian Research Center of Surgery, Moscow,
Russian Federation, 5Center of Genetics and Reproductive
Medicine Genetico LLC, Moscow, Russian Federation
Introduction: NGS technology greatly promoted the efﬁ-
ciency of DNA diagnostics of hereditary diseases and
understanding their pathogenesis. However, the functional
interpretation of the pathogenicity of genomic variants is a
very difﬁcult task. Splicing-affecting genomic variants are
one of the interesting cases that require functional analysis.
Materials and methods: Functional analysis of splicing
mutations was performed by two approaches. If gene of
interest is expressed in blood, we used RT-PCR from
patient’s blood samples. If gene of interest is not expressed
in blood, we used expression system in model cell line
HEK293N. For this aim we constructed expression vectors
containing the studied genome region with or without
analyzed genomic variant. The obtained plasmids were
transfected into HEK293N cell line. After RNA isolation
and cDNA synthesis, we carried out expression analysis of
target gene isoforms.
Results: For intron variant (c.732+4A>G) in B4GALT7
gene in patient with Ehlers-Danlos syndrome we used RT-
PCR from blood sample and showed isoform with exon
skipping. For dozen of genome variants in SPTB, PAX6
and MYH7 genes in patients with spherocytosis, congenital
aniridia, early-onset myopathy respectively we used
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expression system and showed their pathogenicity which
leads to different splicing scenario.
Conclusions: Splicing-affecting genomic variants may
occur in exonic or intronic splicing regulatory elements.
Prediction of pathogenicity of these mutations is difﬁcult
due to an incomplete understanding of the multiple factors
that may be responsible. Functional analysis allows us not
only to establish their pathogenicity, but also helps to
understand the mechanisms of splicing of investigated
genes.
M.Y. Skoblov: None. A.Y. Filatova: None. Y.V.
Vyahireva: None. T.A. Vasilyeva: None. A.V. Mar-
akhonov: None. R.A. Zinchenko: None. Y.A. Rogozhina:
None.M.&. Polyak: None. E.V. Zaklyazminskaya: None.
A. Orlova: None. E. Pomerantseva: None.
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SRSF10 effects splicing of SMN2 exon 7
S. Brøner1, T. Doktor1, Y. Hua2, M. Larsen1, A. Krainer2,
B. Andresen1
1Department of Biochemistry and Molecular Biology, the
Villum Center for Bioanalytical Sciences, University of
Southern Denmark, Odense, Denmark, 2Cold Spring
Harbor Laboratory, Cold Spring Harbor, NY, United States
Introduction: Isoform speciﬁcity within the SR protein
family is poorly understood. The unusual splicing reg-
ulatory factor SRSF10 is highly expressed in neuronal tis-
sue. However, there are two isoforms of SRSF10, which
could potentially have different targets or different effects.
Results: Using iTRAQ MS/MS, we found that both
isoforms of SRSF10 bind to the ISS-N1 splicing regulatory
motif in SMN. ISS-N1 has previously been shown to bind
the ubiquitously expressed splicing repressor hnRNPA1.
Protein binding to ISS-N1 is currently being blocked by an
antisense oligonucleotide in the recently approved and very
successful treatment of Spinal Muscular Atrophy (SMA).
We show that only the long isoform of SRSF10 is able to
repress splicing of SMN2 exon 7. We hypothesize that
SRSF10 could contribute to SMA pathogenesis by repres-
sing the inclusion of SMN2 exon 7 in neuronal tissue.
Furthermore, we demonstrate that splice shifting oligonu-
cleotides can be used to switch the ratio between the long
and the short isoform of SRSF10 making it possible to
investigate the role of each isoform independently. We have
performed RNA-seq analysis to investigate isoform speciﬁc
regulation of alternative splicing. This showed that the long
SRSF10 isoform regulates the largest number of events, but
that there are both common and unique targets for the two
SRSF10 isoforms.
Conclusions: We conclude that alternative splicing of
SRSF10 produces functionally different isoforms and that
this is important to consider when investigating its role in
alternative splicing.
Supported by the Lundbeck Foundation.
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Unravelling structural chromosomal rearrangements by
whole genome sequencing: results of the ANI project, a
French collaborative study including 55 patients with
intellectual disability and/or congenital malformations
C. Schluth-Bolard1,2, F. Diguet1,2, P. A. Rollat-Farnier1,
J. Amiel3, M. A. Belaud-Rotureau4, B. Benzacken5, P.
Callier6, N. Chatron1,2, P. Collignon7, B. Demeer8, M.
Doco-Fenzy9, L. Faivre6, B. Gilbert-Dussardier10, A. M.
Guerrot11, S. Jaillard4, B. Keren12, V. Kremer13, D.
Lacombe14, A. Lebbar15, C. Le Caignec16, J. Lespinasse17,
V. Malan18, M. Mathieu-Dramard8, C. Missirian19, A.
Moncla19, S. Odent20, C. Pebrel-Richard21, V. Paquis22,
M. F. Portnoï23, J. Puechberty24, C. Rooryck-Thambo14,
V. Satre25, A. C. Tabet26, R. Touraine27, A. Toutain28, M.
Vekemans18, A. Verloes26, P. Edery1,2, D. Sanlaville1,2
1Service de Génétique, Hospices Civils, Lyon, France,
2Centre de Recherche en Neurosciences, Lyon, France,
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France, 4Laboratoire de Cytogénétique, CHU, Rennes,
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Bondy, France, 6Service de Génétique, CHU, Dijon,
France, 7Service de Génétique Médicale, CHI, Toulon,
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France, 9Service de Génétique, CHU, Reims, France,
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13Laboratoire de Cytogénétique, CHU, Strasbourg, France,
14Service de Génétique Médicale, CHU, Bordeaux, France,
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Général, Chambéry, France, 18Service de Cytogénétique,
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Montpellier, France, 25Laboratoire de Génétique
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Introduction: Apparently balanced chromosomal rearran-
gements (ABCR) associated with abnormal phenotype are
rare events, but may be challenging for genetic counseling.
Abnormal phenotype may be explained either by cryptic
genomic imbalances detectable by array-CGH or by gene
disruption or position effect. However, breakpoint cloning
using conventional methods is laborious and not performed
routinely. Recently, Whole Genome Sequencing (WGS)
proved to be a powerful and rapid technique to characterize
ABCR breakpoints at the molecular level.
Material and methods: The ANI project is a French
collaborative study that aims at characterizing ABCR in
patients presenting with intellectual disability and/or con-
genital anomalies. We included 55 patients (41 reciprocal
translocations, 4 inversions, 2 insertions, 8 complex chro-
mosomal rearrangements). Array-CGH showed no patho-
genic imbalance. Breakpoints were characterized by paired-
end WGS and conﬁrmed by Sanger sequencing. Expression
studies of disrupted and neighboring genes were performed
on blood cells.
Results: At this time, 45 patients were analyzed by
WGS. Breakpoints were characterized for 39 patients
(86%). The rearrangements showed unexpected complexity,
since 186 breakpoints were identiﬁed against 97 break-
points according to karyotype and included 6 cases of
chromoanagenesis. Sixty-seven breakpoints disrupted a
gene (36%). In 14/39 patients, WGS allowed a diagnosis,
either by gene disruption (11) or by position effect (3), thus
a diagnostic rate of 35%.
Conclusion: These preliminary results showed the
diagnostic relevance of this approach. We will present the
complete results of this study, including molecular char-
acteristics of the breakpoints and expression studies.
This work is supported by ANR and DGOS (PRTS 2013
grants).
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Peptide drug Semax affects neurotransmitter systems in
the rat brain in conditions of transient focal ischemia
S. A. Limborska1,2, V. V. Stavchansky1, A. E. Denisova2,
E. V. Medvedeva1, I. B. Filippenkov1, V. G. Dmitrieva1, K.
A. Ivanova1, N. F. Myasoedov1, L. V. Dergunova1,2
1Institute of Molecular Genetics, Russian Academy of
Sciences, Moscow, Russian Federation, 2Pirogov Russian
National Research Medical University, Moscow, Russian
Federation
Introduction: Synthetic peptide Semax, consisting of a
fragment ACTH(4–7) (Met-Glu-His-Phe) and C-terminal
tripeptide Pro-Gly-Pro, has established itself as an effective
drug for the treatment of patients with severe disorders of
cerebral circulation. Nevertheless, many aspects of its
neuroprotective effect remain unclear. To elucidate the
molecular mechanisms of peptide action we used the ana-
lysis of the brain cells' transcriptome in the experimental
ischemia model.
Materials and Methods: The model of transient focal
ischemia in rats, high-throughput RNA sequencing (RNA-
Seq), real-time RT-PCR, bioinformatics.
Results: Using RNA-Seq, the genes with statistically
signiﬁcant change of mRNA level were identiﬁed in the
subcortical brain structures of ischemic rats treated with
Semax 24 h after occlusion. The functional annotation of
these differentially expressed genes using DAVID bioin-
formatic resource has allowed to identify groups of genes,
proteins of which participate in the work of GABAergic,
Cholinergic, Dopaminergic, Glutamatergic, Serotoninergic
synapses, and in Retrograde endocannabinoid signaling. A
group of Neuroactive ligand-receptor interaction was made
up by the genes, most of which encode membrane receptors,
including cholinergic (Chrm1; Chrm4; Chrna3), dopamine
(Drd1; Drd2), GABA type A (Gabrb1, Gabra2; Gabra5),
and glutamate ionotropic and metabotropic (Gria3; Grin2b;
Grik5; Grm3 and Grm5).
Conclusions: In the subcortical structures of rat brains
damaged by ischemia, Semax has effects on the regulation
of neurotransmitter systems that agrees with nootropic
properties of peptide and efﬁcient recovery of cognitive
functions in patients with stroke.
This work was supported by grants from the Russian
Science Foundation 16-14-00077.
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Segmental uniparental disomy of chromosome 1 causing
Leber congenital amaurosis and hereditary non-
spherocytic hemolytic anemia
M. Bertelsen1, E. Østergaard1, M. Dunø1, T. Rosenberg2,3,
J. Ek1
1Department of Clinical Genetics, Rigshospitalet, Copenha-
gen, Denmark, 2Faculty of Health and Medical Sciences,
University of Copenhagen, Copenhagen, Denmark,
3Department of Ophthalmology, Rigshospitalet, Copenha-
gen, Denmark
Introduction: The severe generalized retinal dystrophy,
Leber congenital amaurosis (LCA) and the hereditary
nonspherocytic hemolytic anemia (HNSHA) caused by
pyruvate kinase deﬁciency are two autosomal recessive
disorders caused by mutations in the RPE65 and PKLR
gene both located on chromosome 1.
Methods: Here we used Whole exome sequencing
(WES) to unravel the underlying genetic cause in a 17 year
old boy suffering from both LCA and HNSHA. The retinal
dystrophy was clinically characterized by ophthalmological
examinations, fundus imaging, Goldmann perimetry and
electroretinogram (ERG). The clinical diagnosis of HNSHA
was established by a broad spectrum of metabolic and
hematologic laboratory tests.
Results: Clinically the boy had suffered from severe
haemolytic anemia from birth and received a bone-marrow
transplant from his father at the age of 4 years. His gen-
eralized retinal dystrophy was characterized by a pro-
gressive loss of rod and cone photoreceptors leading to
night blindness, reduced visual acuity and a progressive
visual ﬁeld loss. The boy was born to consanguineous
parents. Using WES, we identiﬁed known homozygous
pathogenic variants in the RPE65 and PKLR genes, shown
to be caused by paternal segmental uniparental disomy of
chromosome 1 (UPD1).
Conclusions: In a young boy with both LCA and
HNSHA we found segmental UPD1 that resulted in
homozygosity of two recessive mutations. The detection of
RPE65 mutations might have a therapeutic consequence,
since this gene is the subject of several promising clinical
treatment trials.
M. Bertelsen: None. E. Østergaard: None. M. Dunø:
None. T. Rosenberg: None. J. Ek: None.
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A next-generation sequencing approach targeting the
highly repetitive ORF15 region of RPGR improves
molecular diagnostics of X-linked retinitis pigmentosa
A. De Jaegher1, S. De Jaegere1, T. Rosseel2, S. Lefever3,
F. Coppieters3, K. De Leeneer1, E. De Baere2
1Ghent University Hospital, Ghent, Belgium, 2Ghent
University and Ghent University Hospital, Ghent, Belgium,
3Ghent University, Ghent, Belgium
Purpose: Retinitis Pigmentosa (RP) represents the most
frequent inherited retinal dystrophy, with a prevalence of ~1
in 4000. The most severe form of RP, X-linked RP, can be
explained by mutations in the RPGR and RP2 genes,
accounting for 75–80% and 20% of XLRP cases, respec-
tively. RPGR contains a large exon, RPGR open reading
frame 15 (ORF15), harboring 60% of the RPGR mutations.
Because of its highly repetitive and purine-rich regions,
conventional Sanger and next-generation sequencing (NGS)
of ORF15 is challenging and difﬁcult to implement in a
clinical context. Here, it was our goal to develop a NGS-
based test targeting the XLRP genes, including the highly
repetitive and purine-rich regions of ORF15. Methods and
results: To improve the coverage depth of ORF15, we used
a customized targeted resequencing workﬂow, based on an
optimized singleplex PCR for enrichment of ORF15 with in
house designed primers, followed by a modiﬁed Nextera
XT protocol for the library preparation, and NGS on a
MiSeq instrument, as described by De Leeneer et al. (2015).
This allowed us to identify novel sequence variations in
ORF15, which could be validated by Sanger sequencing.
Conclusions: We propose an optimized test targeting
low-depth regions such as ORF15, without the need for
complementary approaches such as Sanger sequencing. As
ORF15 represents a mutational hotspot, this will improve
molecular diagnostics of XLRP. Finally, our approach can
likely be extrapolated to other repeat-rich regions of Men-
delian disease genes.
A. De Jaegher: None. S. De Jaegere: None. T. Rosseel:
None. S. Lefever: None. F. Coppieters: None. K. De
Leeneer: None. E. De Baere: None.
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Tracing the dark matter: investigating the prevalence of
exonic copy number and structural variants in Mende-
lian disorders
S. Aradhya, R. Truty, J. Paul, M. Kennemer, E. Gafni, S.
Fay, S. Lincoln, R. Nussbaum
Invitae, San Francisco, CA, United States
Exonic copy number variants and large structural variants
(CNVs/SVs) contribute to disease but their prevalence is not
well understood. We applied a next-generation sequencing
method to simultaneously detect single nucleotide variants
or small indels (SNVs) as well as intragenic CNVs/SVs in a
large population undergoing clinical testing for hereditary
cancer, cardiac, neurological, or pediatric disorders. From
testing subsets of 981 genes in over 58,000 unrelated
individuals (equivalent of 1.6 million single gene tests), we
identiﬁed 1050 CNVs/SVs, or large indels in 386 genes.
These included 606 deletions, 373 duplications, and 71
other large variants, representing 591 unique variants.
While CNVs/SVs were observed in 1.3% of all patients and
accounted for 2.6% of all types of reported events, they
represented 7.8% of variants in patients with any clinically
signiﬁcant ﬁnding. 95% of deletions were pathogenic
whereas only 43% of duplications were. Nearly a quarter of
unique CNVs encompassed an entire gene and some were
likely larger cytogenetic variants. CNVs/SVs accounted for
6.8% of pathogenic ﬁndings in pediatric and rare disorders,
26% in neurological disorders, 4.6% in cardiac disorders,
and 8.1% in cancer disorders. CNVs/SVs variants were
frequently (71.8%) pathogenic, at a rate far greater than
SNVs. In 67 individuals a CNV was compound hetero-
zygous with an SNV, and in 26 individuals the two variants
constituted a molecular diagnosis for a recessive disorder.
Our data suggest that universal exon-level CNV testing is
valuable in genetic testing, and provides clinicians a better
view into CNV/SV prevalence and their disproportionate
frequency among pathogenic variants.
S. Aradhya: A. Employment (full or part-time); Sig-
niﬁcant; Invitae. R. Truty: A. Employment (full or part-
time); Signiﬁcant; Invitae. J. Paul: A. Employment (full or
part-time); Signiﬁcant; Invitae. M. Kennemer: A.
Employment (full or part-time); Signiﬁcant; Invitae. E.
Gafni: A. Employment (full or part-time); Signiﬁcant;
Invitae. S. Fay: A. Employment (full or part-time); Sig-
niﬁcant; Invitae. S. Lincoln: A. Employment (full or part-
time); Signiﬁcant; Invitae. R. Nussbaum: A. Employment
(full or part-time); Signiﬁcant; Invitae.
P14.003C
Next generation phenotyping in Emanuel and Pallister
Killian syndrome using computer-aided facial dysmor-
phology analysis of 2D photos
T. Liehr1, N. Acquarola2, K. Pyle1, S. St-Pierre3, M.
Rinholm4, I. Schreyer1
1Jena University Hospital, Friedrich Schiller University,
Institute of Human Genetics, Jena, Germany, 2Pallister-
Killian Syndrome Foundation of Australia, Myaree, Aus-
tralia, 3Chromosome 22 Central, Fuquay-Varina, NC,
United States, 4Chromosome 22 Central, Timmins, OH,
Canada
Forms of Next-Generation-Phenotyping (NGP) are needed
to increase further the value of traditional and high
throughput genetic diagnostics. As NGP we used in this
study the Facial-Dysmorphology-Novel-Analysis (FDNA)
technology to automatically identify facial phenotypes
associated with Emanuel (ES) and Pallister-Killian Syn-
drome (PKS) from 2D facial photographs. ES and PKS
have in common that they are characterized both cytogen-
etically by a small supernumerary marker chromosome
(sSMC). 81 frontal images of children with molecularly
diagnosed ES and 92 images from PKS were analyzed and
compared to 2 control groups: facial images of unaffected
children (n= 1,000) and of children affected with one of
100 other syndromes characterized by dysmorphic facial
phenotypes (n= 1,000) collected from public image col-
lections and medical publications. A comparison between
ES or PKS and normal individuals expressed a full
separation between these cohorts. A slightly lower dis-
crimination was possible when comparing between ES or
PKS and individuals affected with other syndromes.
Applying the FDNA technology we were able to choose the
correct syndrome with a mean accuracy of 89.6%. This
result is more than 3 times higher than the random chance of
25%. Our results show that computer aided facial recogni-
tion is able to help in the clinic and could possibly reduce
the time patients spent in the diagnostic odyssey. It may
also help differentiate ES or PKS from other patients with
sSMC, especially in countries with no access to more
sophisticated genetic approaches apart from banding cyto-
genetics. The continuous support of Nicole Fleischer
(FDNA) is kindly acknowledged.
T. Liehr: None. N. Acquarola: None. K. Pyle: None. S.
St-Pierre: None. M. Rinholm: None. I. Schreyer: None.
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P14.004D
A rapid genotyping research assay for ABO RhD blood
types
E. Schreiber1, S. Higdon1, T. Nong2, J. Lee2
1Thermo Fisher Scientiﬁc, South San Francisco, CA, United
States, 2Thermo Fisher Scientiﬁc, Canoga Park, CA, United
States
Bone marrow registries require high resolution HLA gen-
otyping data to match donor specimens with their recipients.
For optimal outcome, it is also preferable to use bone
marrow of identical or compatible blood types between
donor and recipient. To aid research in this area, we have
developed an assay that utilizes buccal swab DNA from
potential donors to determine the ABO and Rh-antigen
genotypes. The assay also detects a 32 bp deletion in the
CCR5 gene. Homozygous carriers of the deletion are
resistant to HIV-1 infection, and thus could be valuable
stem cell donors for HIV-infected recipients. This research
assay is based on a multiplex-PCR reaction with 5
ﬂuorescently-labeled and 12 allele-speciﬁc primers fol-
lowed by capillary electrophoresis on an Applied Biosytems
Genetic Analyzer. The primers for the human ABO gene
target 4 SNPs allowing the determination of the basic A,
A2, B, O1,2 and O3 alleles. Rh-antigen genotyping is
determined by targeting a small deletion that differs
between the RhD and RhCE genes. The peak pattern is
analyzed by GeneMapper® software, and the resulting peak/
genotype table is translated into a genotype/phenotype
report using a standard spreadsheet. The assay was veriﬁed
by analyzing a panel of DNA samples with known blood
group antigens and CCR5 gene types, and found to be
100% accurate. This easy to use, rapid research assay may
prove useful for future development of bone marrow donor
identiﬁcation assays, and other areas of public health stu-
dies. For research use only. Not for use in diagnostic
procedures.
E. Schreiber: A. Employment (full or part-time); Sig-
niﬁcant; Thermo Fisher Scientiﬁc. S. Higdon: A.
Employment (full or part-time); Signiﬁcant; Thermo Fisher
Scientiﬁc. T. Nong: A. Employment (full or part-time);
Signiﬁcant; Thermo Fisher Scientiﬁc. J. Lee: A. Employ-
ment (full or part-time); Signiﬁcant; Thermo Fisher
Scientiﬁc.
P14.005A
Easy diagnosis of Farber disease in dried blood spots
using a speciﬁc biomarker conﬁrmed by ASAH1 gene
sequencing
M. Iurascu1, C. Cozma1, S. Zielke2, J. Lukas2, A. Rolfs2,1
1Centogene AG, Rostock, Germany, 2Albrecht-Kossel-
Institute, University of Rostock, Rostock, Germany
Farber disease is an autosomal recessive, extremely rare
disease caused and characterized by a deﬁcient acid cer-
amidase activity encoded by ASAH1 gene. Low ceramidase
activity is resulting in accumulation of fatty substances,
mainly ceramides. At clinical level, Farber disease is man-
ifesting through hallmark symptoms such as: periarticular
nodules, lipogranulomas, swollen and painful joints and a
hoarse voice or a weak cry; in addition to these, also
hepatosplenomegaly, rapid neurological deterioration or
developmental delay are reported. Seven different Farber
types were described, with phenotypes varying from mild
cases with a longer life expectancy to very severe cases,
where the patients do not survive past their ﬁrst year of life.
We present here a new method of diagnosis of Farber dis-
ease by determining the concentration of C26 ceramide
isoforms using LC/MRM-MS and C25 ceramide as internal
standard followed by ASAH1 gene sequencing. We can
demonstrate that cis-isomer of the C26 ceramide is a spe-
ciﬁc biomarker for Farber disease, with pathological values
in a range of 39.2–150.0 nmol/L blood (normal range 13.6–
23.4 nmol/L blood, N= 192, healthy individuals). The new
biomarker can be determined directly in the dried blood
spot extract with low sample consumption, easy sample
preparation, high reproducibility and it presents the possi-
bility of being used in high throughput screenings.
M. Iurascu: A. Employment (full or part-time); Sig-
niﬁcant; Centogene AG. C. Cozma: A. Employment (full
or part-time); Signiﬁcant; Centogene AG. S. Zielke: None.
J. Lukas: None. A. Rolfs: A. Employment (full or part-
time); Signiﬁcant; Centogene AG.
P14.006B
Comparison of blood microbiome using 16S rRNA
amplicon and unmapped reads from WGS
H. Kim, Y. Yun, S. Kim, H. Kim
wha Womans University, Seoul, Korea, Republic of
Introduction: Blood has been generally considered a sterile
environment, however, microbiome has been consistently
detected in blood in healthy individuals. Identifying the
microbiome composition from blood affords opportunity to
study the causative relationships between the host micro-
biome and disease. However, this is challenging due the low
abundance of microbial DNA relative to the host. Materials
and Methods: The study was conducted with blood DNA of
632
200 healthy individuals. We performed a whole genome
sequencing (WGS) of 30x coverage as well as a 16S rRNA
gene sequencing (16S) and quantitative polymerase chain
reaction (qPCR) assay to analyze the blood microbiome.
About 99% of whole genome sequencing were mapped to
the human reference genome. The remaining unmapped
reads are then assigned to taxonomic labels.
Results: We observed differences in the relative abun-
dances of blood microbiome in between 16S and WGS. The
Proteobacteria was the most abundant phylum in 16S and
WGS, but the abundance was <50% and >95% in 16S and
WGS, respectively. After the Proteobacteria, the Actino-
bacteria phylum showed relative abundance of >2.5% in
WGS, while it was rare in 16S. The quantiﬁcation by qPCR
assay did not prove the relative abundance of 16S nor WGS.
Conclusions: The blood microbiome, even when
present in very low abundance, may have important phy-
siologic role. Proving existence of microbiome in
healthy blood could be implicated in non-infectious dis-
eases. Grants: NRF-2016R1A6A3A11932719, NRF-
2014R1A2A2A04006291, HI14C1234, and intramural
research support program of Ewha Womans University
School of Medicine. It was also supported by GSDC and
KREONET in KISTI.
H. Kim: None. Y. Yun: None. S. Kim: None. H. Kim:
None.
P14.008D
Integrated diagnostic solution for routine testing of
mutations in BRCA1 and BRCA2 with the BRCA
MASTR plus Dx assay
K. Bettens, B. Slabbinck, M. Vyverman, L. Standaert, C.
Marqués, A. Rotthier, P. Vauterin, J. Del Favero
Multiplicom N.V., Niel, Belgium
Targeted NGS has tremendous potential in clinical diag-
nostics. Tumor tissue oncogenetic proﬁling allows to steer
targeted therapy. In addition, NGS has been implemented in
routine testing for germline mutations causing hereditary
cancers. To address this dual intended use within clinical
setting, Multiplicom’s BRCA MASTR Plus Dx assay has
been validated for the identiﬁcation of germline mutations
in blood derived DNA and of somatic mutations in formalin
ﬁxed parafﬁn embedded (FFPE)-derived tumor DNA.
Despite many beneﬁts, NGS poses challenges such as the
proper, assay speciﬁc bioinformatics analysis of raw NGS
data. Multiplicom now offers an integrated diagnostic
solution by adding its proprietary MASTR Reporter soft-
ware as data analysis to the diagnostic workﬂow. Next to
SNVs, the software permits reliable CNV identiﬁcation.
MASTR Reporter not only provides high standard data
analysis, but also a unique Quality Control dashboard,
allowing customers to monitor their sequencing workﬂow
in real time. BRCA MASTR Plus Dx on blood derived
DNA in combination with Illumina sequencing (MiSeq,
MiniSeq, NextSeq) and MASTR Reporter software showed
uniformity of ampliﬁcation of 100% and target speciﬁcity of
97.7%. Diagnostic accuracy was 100% [95% CI ≥99.99%]
(100% sensitivity [95% CI ≥99.12%], 100% speciﬁcity
[95% CI ≥99.99%]). Both repeatability and reproducibility
were 100% [95% CI ≥99.99%]. Summarized, the BRCA
MASTR Plus Dx solution, including the integrated MASTR
Reporter software, can be routinely applied in identifying
germline mutations in BRCA1/2 causative for hereditary
breast and ovarian cancer.
Products described above are CE-IVD and are not
available for sale in the US and other geographies.
K. Bettens: None. B. Slabbinck: None. M. Vyverman:
None. L. Standaert: None. C. Marqués: None. A. Rot-
thier: None. P. Vauterin: None. J. Del Favero: None.
P14.009A
Evaluation of methods for BRCA1 and BRCA2 muta-
tion screening of FFPE-DNA
T. Törngren, S. Aradottir, K. Haraldsson, L. Tellhed, S.
Malander, A. Kvist, Å. Borg
Division of Oncology and Pathology, Department of
Clinical Sciences, Skåne University Hospital, Lund Uni-
versity, Lund, Sweden
Background: Mutation screening of BRCA1 and BRCA2
has recently gained importance as germline and somatic
BRCA mutations are now treatment predictive for PARP-
inhibitors in patients suffering from recurrent ovarian can-
cer. DNA from formalin-ﬁxed, parafﬁn-embedded (FFPE)
is often the only material available for screening. This
brings additional challenges as lower DNA quantity and
quality can introduce artifacts and allelic drop-outs, besides
the general difﬁculties of detecting somatic low frequency
variants.
Methods: We evaluated two methods and three designs,
all including BRCA1 and BRCA2 as targets, on DNA from
FFPE. Illumina TruSeq Amplicon (TSA) is a strand-speciﬁc
amplicon based method. Both TSA designs were dual-
stranded (separate assays targeting each strand). The ﬁrst
included only BRCA1 and BRCA2 (design optimized by
Illumina). The other was a custom 6-gene design. Qiagen
Generead DNAseq Targeted Panel v2 is based on
multiplex-PCR. The design included only BRCA1 and
BRCA2. All kits include a qPCR to evaluate the DNA
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quality and identify potential failing samples. Libraries from
10 FFPE-DNA samples were prepared using each kit and
sequenced on the Illumina Miseq. Evaluated parameters
include design (theoretical coverage and amplicon size),
coverage (% on target, uniformity and drop-outs) and var-
iant sensitivity and speciﬁcity.
Results and conclusion: All kits perform well in terms
of coverage and uniformity. The dual-stranded design of the
TSA kits reduces the number of FFPE artifacts. The
Generead kit targets complete coding region and splice sites
of BRCA1 and BRCA2.
T. Törngren: None. S. Aradottir: None. K. Har-
aldsson: None. L. Tellhed: None. S. Malander: None. A.
Kvist: None. Å. Borg: D. Speakers Bureau/Honoraria
(speakers bureau, symposia, and expert witness); Modest;
Astra Zeneca.
P14.010B
Comparison of buccal specimens collected with
FLOQSwabs™ to saliva and blood for genetic
investigations
A. Squassina, S. Castriciano
Copan Italia, Brescia, Italy
Introduction: Buccal swab collection is not invasive, easy
to use, less expensive and better accepted by donors with
respect to blood and saliva sample collection. Copan is
producing human DNA free FLOQSwabs™(FS), certiﬁed
human DNA, DNase and RNase free. The objective of this
study was to compare quantity and quality of human DNA
(hDNA) obtained FS to saliva in Oragene (OR), ORA-
collect (OC) by DNA Genotek, and blood.Materials and
Methods: FS, OR and OC from 20 volunteers were col-
lected. FS were stored in dry tubes, while saliva was col-
lected in OR and OC collection devices+medium. Blood
samples were collected from 2 donors. DNA was extracted
from 200 ul of each sample type using QIAamp® DNA
Mini Kit. hDNA was quantiﬁed by PCR (Quantiﬁler® Trio
kit), Quality was measure by agarose gel electrophoresis
and by NanoDrop. (Thermo Fisher). Results: FS gave an
average of 5000 ng hDNA/swab (lowest/ highest con-
centration: 1200ng/ 13000ng), OR gave an average of 4700
ng/200ul (lowest/ highest concentration: 780ng/14600ng) of
liquid medium, OC gave an average of 3500ng /sponge
(lowest /highest concentration: 1900ng/5900ng), while
blood gave an average of 2800 ng/200ul. Absorbance’s
values at 260/280 and at 260/230 were within acceptability
limits for all the samples analyzed (that means good purity
of extracted hDNA), and no DNA degradation was detected
on agarose gel with all samples. Conclusions: Data
obtained demonstrated that Copan hDNA free FLOQS-
wabs™ provide good quantity and quality of hDNA com-
pared to saliva and blood and are less expensive and easy to
use.
A. Squassina: A. Employment (full or part-time); Sig-
niﬁcant; Copan Italia. S. Castriciano: A. Employment (full
or part-time); Signiﬁcant; Copan Italia.
P14.011C
C9orf72 testing in a diagnostic laboratory using the
Asuragen AmplideX® PCR/CE C9orf72 kit
R. van Minkelen1, P. Reichgelt1, S. Theunise2, K. Culp3, J.
M. Papma1, L. Donker Kaat1,4, J. C. van Swieten1,5, R. de
Graaf1, L. H. Hoefsloot1, M. Wilke1
1Erasmus MC, Rotterdam, Netherlands, 2Sanbio B.V.,
Uden, Netherlands, 3Asuragen, Inc., Austin, TX, United
States, 4LUMC, Leiden, Netherlands, 5VUMC, Amsterdam,
Netherlands
Introduction: The pathogenic expanded hexanucleotide
repeat element (G4C2) in intron 1 of the Chromosome 9
open reading frame 72 gene (C9orf72) is the most prevalent
genetic cause of the neurodegenerative disorders fronto-
temporal dementia (FTD) and amyotrophic lateral sclerosis
(ALS). Here we describe our experiences in using the newly
introduced Asuragen AmplideX® PCR/CE C9orf72 assay
compared to our home-made long range and repeat-primed
PCR tests for the detection of C9orf72 repeats. Our home-
made tests are limited to detection of up to ~60 C9orf72
repeats.
Materials and Methods: DNA samples isolated from
EDTA blood (n= 23) were tested for C9orf72 using the
Asuragen AmplideX® PCR/CE C9orf72 kit. Amplicons
were sized on an ABI 3730xl Genetic Analyzer and ana-
lyzed using GeneMarker software. All samples were pre-
viously tested using long range and repeat-primed PCR
tests. For purposes of this study, normal repeats were
categorized as <30 repeats and pathogenic repeats >30
repeats.
Results: All samples previously scored as pathogenic
using the home-made tests also showed a pathogenic repeat
expansion of at least 145 repeats using the new Asuragen
test. No repeats were sized in the range 60–145. Repeats in
the normal range were sized exactly the same. DNA con-
centrations of 50ng/μl (our standard lab dilution) and 25ng/
μl showed similar results. A dilution (including a second
30s injection on the ABI) of the PCR products was needed
to overcome the saturated normal allele peaks in the undi-
luted PCR products.
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Conclusions: The Asuragen AmplideX® PCR/CE
C9orf72 kit is an effective method for the detection of
C9orf72 repeats.
R. van Minkelen: None. P. Reichgelt: None. S.
Theunise: None. K. Culp: None. J.M. Papma: None. L.
Donker Kaat: None. J.C. van Swieten: None. R. de
Graaf: None. L.H. Hoefsloot: None. M. Wilke: None.
P14.012D
Implementation of a laboratory workﬂow for the par-
allel analysis of somatic and germline samples in the
routine diagnostic
M. Locher, A. Baumgartner, A. M. Nissen, A. Laner, A.
Benet-Pagès, E. Holinski-Feder
Medical Genetics Center Munich, Munich, Germany
Molecular proﬁling of tumor and blood specimens can help
to identify somatic mutations that arise in cancer cells and
are relevant for patient treatment. Next-generation sequen-
cing (NGS) offers high sensitivity and accurate data quality
for identifying somatic variants in cancer. However,
laboratory protocols for analysis of parafﬁn-embedded
(FFPE) tumor tissue are still challenging and often blood
and tumor specimens cannot be processed with the same
protocol. Here we present a single sample preparation and
sequencing protocol for the parallel analysis of blood and
FFPE based on targeted exon capture. This approach
comprises parafﬁn removal and tissue rehydration using the
Covaris AFA method. Sample preparation combines Tru-
Seq Exome Illumina protocol and TruSight Cancer Panel
enrichment followed by sequencing in a NextSeq500.
Adapted non-equimolar pooling of blood vs. tumor libraries
allowed sequencing all samples in the same run. Evaluation
of quality criteria with FASTQC showed similar results for
blood and tumor samples: DNA OD260/280 >1.8 in all
samples, sequencing quality Q30>90% (150-cycle, paired-
end), error rate <1%, but tumor samples produced more
duplicates (20–50%) compared to blood (17–28%) and
mapped ﬁltered reads were also lower in tumor samples.
However, sequencing depth of the coding region of
BRCA1, BRCA2, MLH1, MSH2, MSH6 and PMS2 genes
ranged from 30-fold to 2500-fold for tumor samples which
resulted in sufﬁcient coverage for the detection of variant
mosaicism down to 10%. Overall, around 90% of the
evaluated samples resulted in successful libraries and pas-
sed sequencing and mapping quality criteria.
M. Locher: None. A. Baumgartner: None. A.M. Nis-
sen: None. A. Laner: None. A. Benet-Pagès: None. E.
Holinski-Feder: None.
P14.013A
Optimising efﬁciency and cost-effectiveness in a clinical
genetics laboratory
A. Strydom, S. Seal, S. Mahamdallie, E. J. Ramsay, I. M.
S. Uddin, H. Wylie, A. Elliott, E. Ruark, N. Rahman
Institute of Cancer Research, London, London, United
Kingdom
Most clinical testing laboratories are facing increasing
pressures to expand testing volume whilst reducing costs
and turnaround times. TGLclinical is a medical genetic
testing laboratory, accredited to ISO15189, that delivers
cancer predisposition gene tests to cancer and genetic ser-
vices. Over the last 4 years we have changed from using
Sanger+MLPA to NGS testing with the TruSight Cancer
Panel (Illumina). Through strategic restructuring of activ-
ities and development of automated pipelines and bespoke
databases this change has allowed us to double the number
of tests we perform, within the same testing budget. The key
difference in cost was the ratio of personnel to consumables
which is 80:20 for Sanger+MLPA, and 50:50 for NGS. The
cost of NGS analyses is much more volume-dependent than
Sanger+MLPA; the affordability of our tests is dependent
on performing 96 TruSight Cancer tests every week. Our
highly automated data analysis and interpretation pipelines
allow a fast turnaround time, median 18 days, whilst
requiring only a modest workforce. Although we have been
able to achieve efﬁciency savings and cost-effectiveness in
many areas, there are factors that impact on effectiveness
that are currently beyond our control. For example, 20% of
all test requests received in TGLclinical require some detail
to be queried with the referring clinician. This is time-
consuming and has to be done manually. We are currently
monitoring and evaluating these residual inefﬁciencies and
devising strategies to try to reduce them.
A. Strydom: None. S. Seal: None. S. Mahamdallie:
None. E.J. Ramsay: None. I.M.S. Uddin: None. H.
Wylie: None. A. Elliott: None. E. Ruark: None. N.
Rahman: None.
P14.014B
A direct from plasma approach to non-invasive prenatal
fetal sex determination and RhesusD genotyping by
quantitative PCR
M. Parks
Nonacus Ltd, Birmingham, United Kingdom
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Introduction: cell free fetal DNA (cffDNA) analysis by
quantitative PCR (qPCR) is commonly used to perform
non-invasive prenatal fetal sex determination in pregnancies
where the fetus is at risk of inheriting a sex-linked disorder;
and fetal RhesusD (RhD) genotyping in pregnant women at
risk of developing Hemolytic Disease of the Fetus and
Newborn. Currently, cffDNA extraction is required prior to
qPCR testing. In this study we demonstrate the perfor-
mance, time and cost advantages of performing qPCR
directly from plasma.
Materials & Methods: plasma from 100 RhD(-) and 50
normal pregnant women was prepared for qPCR using
Cell3TMDirect technology (Nonacus Ltd). Testing for fetal
RhD status was conducted by targeting exons 5, 7 and 10 of
the RhD gene; while fetal sex determination was performed
by detecting the SRY, TSPY and DAZ genes located on
chromosome Y.
Results: initial testing on genomic DNA proved that the
multi-target qPCR approach could detect down to 3 geno-
mic equivalents of the RhD and chromosome Y-located
genes. Validation on plasma samples yielded highly accu-
rate and consistent results for both assays. Sensitivity and
speciﬁcity for fetal RhD genotyping was 100%, with repeat
and inconclusive rates of 4% and 2% respectively. For fetal
sex determination, sensitivity and speciﬁcity were also
100%, with repeat and inconclusive rates of 2% and 0%
respectively.
Conclusions: use of a multi-target qPCR approach
coupled with direct from plasma testing delivers highly
accurate non-invasive diagnosis of fetal RhD status and
fetal sex determination, whilst providing a streamlined and
more cost effective service.
M. Parks: A. Employment (full or part-time); Sig-
niﬁcant; Nonacus Ltd.
P14.015C
Creation of a novel site-speciﬁc CHO-K1 platform cell
line using Jump-In™TI™ Technology and genetic
analyzing by QF-PCR and ST-PCR
n. Damavandi1, S. Zeinali2,1, F. Davami2, A. Joudaki3
1Tehran university, Tehran, Iran, Islamic Republic of,
2Pasteur Institute, Tehran, Iran, Islamic Republic of,
3Kawsar Biotech Co., Tehran, Iran, Islamic Republic of
Introduction: Chinese Hamster Ovary cell lines, due to
their ability in post-translational modiﬁcation, are preferred
systems for biopharmaceutical protein production, but
selection of stable cell lines remains a challenge due to
random location of integration, since it is a very laborious
and time consuming approach. Also, due to positional
effects, it results in low and unpredictable yields of
expression in the genome.Methods: The CHO-K1 adherent
cell line was maintained in DMEM-F12 medium and 10%
FBS. Then, pJTITM/ZEO plasmid (Invitrogen) and PhiC31/
Int plasmids were co-transfected to cells, using Lipofecta-
mine 2000. After 48 h, cells were selected with 600 μg/mL
of hygromycin B for 3 weeks. Single cells were isolated
from the resistant pool. Individual clones were expanded
and their genomic DNA was isolated. Using 5 markers,
Quantitive Florescent PCR was done to ﬁnd vector copy
number integrated in each clone. Semi-ransom Two-step
PCR was done to determine site of integration.Results:
28single clones were isolated. QF-PCR results showed that
13 clones have obtained a single copy of vector and 15 have
2 copies of integrated vector. Using ST-PCR, genomic site
of integration was determined, which was chromosome 1,
contig2404 for 3 clones. Conclusion: Using Jump-In™
TI™ technology, we successfully generated platform CHO-
K1 cell lines containing R4 attP site and analyzed it with
QF-PCR and ST-PCR, which is a novel strategy tobe
employed in cell line development. These platform cell
lines are stable and because of single copy, site-speciﬁc R4
attP site, they can be used for recombinant protein pro-
duction and drug discovery.
N. Damavandi: None. S. Zeinali: None. F. Davami:
None. A. Joudaki: None.
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Circulating free DNA digestion in microﬂuidic devices
based on lab-on-a-chip in Non-invasive prenatal testing
A. Rodriguez-Martinez1, E. Sarasola-Diez1, M.
Agirregabiria2, J. M. Ruano-Lopez2, T. Codd3, K. R.
Ward4, J. Bekacz5, M. Gaboyard6, M. Garcia-Barcina1
1Basurto University Hospital, Bilbao, Spain, 2IK4-Ikerlan,
Mondragon, Spain, 3Biopharma Technology, Winchester,
United Kingdom, 4Biopharma Technologies, Winchester,
United Kingdom, 5EV Group, St.Florian am Inn, Austria,
6Ademtech, Pessac, France
Introduction: Circulating free DNA (cfDNA) digestion
with methylation-sensitive restriction enzymes constitutes
an important diagnostic tool for differentiating methylated
from non-methylated DNA sequences. In the context of
prenatal analysis, this is used to differentiate fetal from
maternal DNA. RASSF1A gene is one the most reliable
fetal markers detected in maternal plasma because it is
methylated in fetal DNA and unmethylated in maternal
DNA. In a previous work, we optimized a short digestion
protocol of 3.5 hours with multiple enzymes(1). In this
work, we present the implementation of this 3.5-hour
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digestion protocol in miniaturized device based on lab-on-a-
chip technology with freeze-dried enzymes.
Materials and methods: Plasma samples from pregnant
and non-pregnant controls were collected after informed
consent. The cfDNA extraction and digestion process was
performed in lab-on-a-chip as previously reported(2). For
digestion, BstUI, HhaI and BstYI enzymes were freeze-
dried, and transferred to the digestion chamber in the chip.
Digestion products were collected from the chip and
RASSF1A, ACTB and GAPDH genes were further analysed
by qPCR.
Results: GAPDH was detected in all samples as cfDNA
extraction control. RASSF1A gene was detected in samples
from pregnant women and not detected in non-pregnant
control samples. No detection of ACTB gene was observed
in digested samples.
Conclusions:To the best of our knowledge, this is the
ﬁrst report of cfDNA extraction and digestion process in a
microﬂuidic device based on lab-on-a-chip technology.
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High diagnostic yield using Whole Exome Sequencing
and a multidisciplinary team approach
M. Jansson1, S. Lillis1, J. Hoyle1, Y. Patel1, L. Hollis1, A.
Jones1, K. Ryan1, C. Walsh1, J. Campbell1, A. Bond1, A.
Slater1, A. Beleza2, E. Thomas2, M. Irving2, F. Flinter2, L.
Izatt2, D. Josifova2, L. Robert2, T. Beuser2, C.
Deshpande2, M. Holder-Espinasse2, A. Shaw2, D. Ruddy2,
G. Taylor1, J. W. Ahn1, S. Mohammed2, S. Yau1
1Viapath, London, United Kingdom, 2Clinical Genetics,
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We have implemented a Clincial WES Service at Guy’s
Genetic Centre that uses virtual panels to interrogate exome
data, restricting the investigations to clinically relevant
genes and reducing incidental ﬁndings, whilst providing
ﬂexibility to add new disease genes to panels. Using WES
rather than ﬁxed gene panels allows the use of alternative
virtual panels if new phenotypic information becomes
available. Virtual panels are designed by scientists and
clinical geneticists, while 100K Genomes "PanelApp"
panels are also available for selection during the ﬂexible
user-driven ordering process. Additionally, clinicians can
add genes to virtual panel(s) allowing for patients with
heterogenous clinical presentation to have custom built
panels. We have developed an integrated laboratory and
bioinformatics platform in which Agilent CRE libraries are
sequenced on a NextSeq with automatic data transfer to
DNAnexus for alignment and variant calling using BWA
and GATK. The generated VCF ﬁles are uploaded into
QIAGEN IVA for variant assessment. This cloud-based
data processing is efﬁcient and fast and provides for future
prooﬁng. Collaborative efforts between scientists and clin-
icians involving MDT meetings where putative pathogenic
variants are discussed before actions are determined have
provided a high diagnostic yield. We have issued reports for
189 cases with variants identiﬁed in 82 (43%). Using
ACMG guidelines ~35% were class 4/5 variants, while ~8%
were novel variants that were consistent with the patient’s
clinical phenotype but require further investigation. Our
results demonstrate that this WES service is an effective
diagnostic approach for uncovering genetic defects in
patients who may otherwise remain undiagnosed.
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Lessons from the clinical exome: description of three
cases
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Moya, I. Maeso, L. Izquierdo, J. Lopez García-Asenjo,
A. Belinchon
Synlab, Madrid, Spain
Introduction: The molecular diagnosis of complex genetic
diseases with clinical exome is an increasingly frequent
approach in diagnostic laboratories. We present three cases,
from which we can extract a lesson to apply in future cases.
Materials and Methods: Samples were sequenced using
TruSight One kit (Illumina), in Illumina platform. Results
were ﬁltered using Variant Studio, GeneGrid and
phenotype.
Results: Female patient, 17 years of age. Started with
difﬁculty to achieve a standing position at 16 months old,
and progressed with cognitive delay, loss of speech, spastic
paraparesia and basal ganglia calciﬁcation. We identiﬁed p.
Gly1007Arg in ADAR, in heterozygous state. This is the
fourth described case of autosomal dominant Aicardi-
Goutières syndrome due to mutations in ADAR. Our patient
also presents pubertal delay and delayed bone age, non-
previously reported clinical features.
Female patient, 2 years of age. Clinically diagnosed as
malignant infantile osteopetrosis. We identiﬁed p.
Thr360Pro and p.Arg444His in TCIRG1. Based in the
molecular diagnosis, hematopoietic stem cell transplanta-
tion was performed.
Male patient, 52 years of age with albinism, pulmonary
ﬁbrosis, Crohn-disease, and bleeding tendency, and 49-
year-old brother with albinism. We identiﬁed p.Asn16Ilef-
sTer in HPS4, in homozygous state in both siblings. They
were diagnosed with Hermansky-Pudlak syndrome, illus-
trating the intra-familial variability of clinical expression of
the disease.
Conclusions: In these cases, clinical exome analysis has
allowed us to: (a)deﬁne an infrequent molecular diagnosis
and expand the phenotypic characteristics; (b)impact ther-
apeutic decisions in a prompt way; (c)diagnose two siblings
with a disease with a high degree of genetic heterogeneity
and variable expressivity.
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Data from Leipzig recommends exome sequencing based
on trio analysis and detailed clinical information as an
early diagnostic step
S. Martin1, C. Bianchini2, T. Bartholomeus1, E. Coci3, A.
Rolfs4,5, J. Lemke1, B. Liesfeld6, R. Abou Jamra1
1Institute of Human Genetics, University Medical Center
Leipzig, 04103 Leipzig, Germany, 2Pediatric Neurology,
Neurogenetics and Neurobiology Unit and Laboratories,
Neuroscience Department, A Meyer Children’s Hospital,
University of Florence, Florence, Italy, 3Center of Social
Pediatrics and Pediatric Neurology, General Hospital of
Celle, 29221 Celle, Germany, 4Centogene AG, 18057
Rostock, Germany, 5Albrecht-Kossel-Institute for Neuror-
egeneration, Medical University Rostock, 18057 Rostock,
Germany, 6Limbus Medical Technologies GmbH, 18055
Rostock, Germany
Introduction: We present our experience in exome
sequencing in diagnostic setting to review its reported need
at an early diagnostic stage.
Materials and methods: Whole exome sequencing was
performed by Centogene. We used the annotation software
VarvisTM. We studied 83 cases, 93% were trios. Of all
cases, 89% had a neurodevelopmental disorder.
Results and Discussion: A reliable clinical genetic
diagnosis was made in 40% of the cases. In further 7% we
found a variant of an unknown signiﬁcance that indicated
further investigations. Moreover, in additional 7% we
identiﬁed convincing de novo variants in candidate genes
for neurodevelopmental disorders (GRIA4, GABRB2,
ACTL6B, TOB1, TUBA1B, and CUX1). In the 31 solved
trio-exomes with non-consanguineous parents, we surpris-
ingly found 8 compound-heterozygous variants and one
homozygous variant. In total, we reported the ﬁnding of a
variant in 52% of the cases. Reducing the available clinical
information to solely the indication allowed the identiﬁca-
tion of the correct variant in only 43% of the cases, and led
to a wrong diagnosis in additional 38%. As we have
reported a variant in 53% of the trio cases, excluding the
exome data of the parents allowed identifying the correct
variant in only 43% of the cases and led to wrong diagnosis
in 27%.
Conclusion: The high diagnostic yield strongly indicates
exome sequencing as an early diagnostic step. Also, our
data emphasizes the importance of running the analysis in a
trio constellation based on as much clinical information as
possible to avoid signiﬁcant loss of sensitivity and
speciﬁcity.
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Semi-automated generation of custom clinical genomic
reports for rare disease
L. Matalonga1,2, R. Tonda1,2, D. Piscia1,2, S. Laurie1,2, J.
Whalley1,2, R. Thompson3, H. Lochmüller3, I. Gut1,2, S.
Beltran1,2
1Centro Nacional de Análisis Genómico (CNAG-CRG),
Center for Genomic Regulation, Barcelona Institute of
Science and Technology (BIST), Barcelona, Spain, 2Uni-
versitat Pompeu Fabra (UPF), Barcelona, Spain, 3Institute
of Genetic Medicine, MRC Centre for Neuromuscular
Diseases, Newcastle University, Newcastle, United
Kingdom
Next-generation sequencing provides a higher molecular
diagnostic yield than traditional molecular diagnostic
methods. In fact, whole genome/exome sequencing is being
increasingly applied to the molecular diagnosis of indivi-
duals with rare genetic disorders. However, this new tech-
nology also brings challenges in terms of data management,
analysis, quality metrics, interpretation of results and the
generation of comprehensive, and human readable, clinical
reports. As part of a collaboration between the ELIXIR-
EXCELERATE Rare Disease Use Case (www.elixir-
europe.org) and RD-Connect (www.rd-connect.eu), we are
developing a software module to overcome these challenges
and facilitate the generation of reports by the clinical
geneticists themselves. The module enables the generation
of custom clinical reports following current regulations and
recommendations made by European projects and profes-
sional societies such as EuroGentest and ACMG. These
reports can be generated from data analysed using platforms
such as RD-Connect and may include several sections,
including scope and design of the test (applicability, type of
sample, technology, reference genome and annotation, tar-
geted genes, etc.), quality metrics (amount of data gener-
ated, sequencing coverage, non-tested regions, etc.),
relevant variants associated to a clinical condition, inci-
dental ﬁndings in actionable genes and pharmacogenomics
associations. The baseline of these reports is written in a
style that is clear and informative to the clinician and does
not require in-depth knowledge of molecular genetics.
Therefore, the semi-automated generation of reports
through already existing rare genetic data analysis platforms
will facilitate the clinical interpretation of genomic data for
the whole scientiﬁc/medical community.
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Detection of copy number variations with next genera-
tion sequencing: laboratory validation
G. Klancar, V. Setrajcic Dragos, S. Novakovic
Institute of Oncology, Division of Diagnostics, Department
of Molecular Diagnostics, SI-1000 Ljubljana, Slovenia
Introduction: Copy number variations (CNVs) have been
recognized as pathogenic alterations for many years, where
single or multiple exons are deleted or duplicated, respec-
tively. CNVs are a common feature in pathogenicity of
sporadic or hereditary cancer syndromes. MLPA is golden
standard for detection of large deletions and/or insertions.
However, NGS technology offers detection of single
nucleotide variants as well as CNV analysis in one
workﬂow.
Materials and Methods 131 whole intravenous blood
samples were sequenced using Illumina TruSight Cancer
Panel kit, in order to detect copy number variations. Study
included 7 MLPA-positive samples, 6 samples harboring a
large deletion and 1 sample harboring a large duplication.
The in silico CNV analysis was performed using SeqPilot
software (CNV module) (JSI Medical Systems, Germany).
All samples were also validated by MLPA. Results: All
known MLPA-positive samples were successfully detected
using in silico CNV analysis. In silico CNV analysis was
consistent with MLPA in 97 % cases, false positive samples
were detected in 3% cases. Importantly, no false negative
samples were detected.
Conclusions: To conclude, in silico CNV analysis using
SeqPilot software (CNV detection module) could be used
for detection of CNVs. However, due to false positive
results all samples must be conﬁrmed by MLPA.Abel, H.J.,
Duncavage, E.J. (2013). Cancer Genet. 206, 432–440.
Stuppia, L., Antonucci, I., Palka, G., and Gatta, V. (2012).
Int. J. Mol. Sci. 13, 3245–3276.
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Extra diagnostic yield gained by CNV detection in WES,
clinical exome sequencing and targeted NGS panels
F. A. Konovalov, I. V. Kanivets, E. R. Tolmacheva, D. N.
Khmelkova, M. A. Ampleeva, E. I. Surkova, A. O.
Shumarina, A. V. Antonets, D. V. Pyankov, S. A.
Korostelev
Genomed Ltd., Moscow, Russian Federation
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Chromosome abnormalities and copy number variations
(CNVs) are a well-studied and important type of genetic
variation that is missed by traditional NGS data analysis.
Algorithms have been developed that are able to detect
CNVs in exome-level data by comparing relative coverage
between samples; however, their routine clinical use is
mostly reported on whole-exome level only.
In 2015–2016 we performed 2376 NGS-based tests for
patients with suspected monogenic disorders using Illumina
NextSeq 500 and in-house analysis software. 1710 samples
were sequenced using Illumina TruSightOne enrichment
("clinical exome", ~4800 genes); 447 samples using our
custom 2000-gene platform focused on neuromuscular
disorders and epilepsy; 68 samples using smaller panels;
151 samples by whole-exome sequencing. A deﬁnitive
molecular diagnosis could be established in 837 cases
(35.2%), with another 387 (16.3%) having a possible
diagnosis based on variants of unknown signiﬁcance with a
need for additional evidence. In addition to standard variant
analysis, CNV detection was performed in all the samples.
This allowed us to report CNVs that we believe to be
causative or signiﬁcant in 80 cases, ranging from 1-exon
homozygous deletions to a whole-chromosome duplication,
with many microdeletions identiﬁed including Wolf-
Hirschhorn, Angelman and Miller-Dieker syndromes; the
diagnostic yield increase was 3.4% of all cases, or 9.6% of
the ones with an established cause. CNVs were detected in
all enrichment panel types. In all cases where CMA was
available and its resolution was enough, the alterations were
conﬁrmed. A major challenge remains in conﬁrming
medium-sized CNVs that require MLPA as a method of
choice.
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The ICR96 exon CNV validation series: a resource for
orthogonal assessment of exon CNV calling
E. Ruark, S. Mahamdallie, S. Yost, E. J. Ramsay, I. M.
Uddin, H. Wylie, A. Elliott, S. Seal, A. Strydom, N.
Rahman
Institute of Cancer Research, London, London, United
Kingdom
Detection of deletions and duplications of whole exons
(exon CNVs) is a key requirement of genetic testing.
Calling this class of variation, particularly those involving
only a single exon, is especially challenging in targeted
next-generation sequencing (NGS) data which typically
does not provide sequence information at the breakpoints.
Exon CNV calling methods are often validated based on
simulated or in-house data due to a lack of publicly-
available datasets with orthogonally generated results. This
hinders comparisons of different tools, transparency and
reproducibility. To provide a vital community resource for
assessment of exon CNV calling methods in targeted NGS
data, we present the ICR96 exon CNV validation series.
The dataset includes high-quality sequencing data from the
TruSight Cancer Panel together with MLPA and digital
MLPA results for 96 independent samples; 66 samples with
at least one validated exon CNV and 30 samples with
validated negative results for 26 genes. The validated exon
CNVs include 22 single exon CNVs with excellent repre-
sentation of the cancer predisposition genes most frequently
tested in clinical practice. The series includes 45 exon
CNVs in BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2,
EPCAM, PTEN, and TP53. The ICR96 exon CNV valida-
tion series dataset will be available from the European
Genome-phenome archive (EGA), further empowering
development, validation and comparison of exon CNV
detection tools for the genetic community.
Funder, Wellcome:200990/Z/16/Z
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Identiﬁcation of mismatch repair deﬁcient tumours
using a molecular inversion probe based sequencing
assay of short homopolymer repeats
H. Sheth1, R. Gallon1, L. Redford1, G. Alhilal1, A. M.
Alonso2, S. M. Laguna3, M. Arends4, A. Oniscu4, O.
O'Brien2, S. Needham2, M. S. Jackson1, M. Santibanez-
Koref1, J. Burn1
1Institute of Genetic Medicine, Newcastle University, New-
castle upon Tyne, United Kingdom, 2Northern Genetics
Service, Newcastle Hospitals NHS Foundation Trust,
Newcastle upon Tyne, United Kingdom, 3Servicio de
Genética Médica, Complejo Hospitalario de Navarra,
Hospital Virgen del Camino, C/ Irunlarrea 4, E-31008,
Pamplona, Spain, 4Western General Hospital, Edinburgh,
United Kingdom
Introduction: Recent draft guidelines from the UK’s NICE
recommends that microsatellite instability (MSI) testing
should be performed in all patients with colorectal cancer to
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identify Lynch syndrome patients. Current techniques for
mismatch repair (MMR) status evaluation- immunohis-
tochemistry and fragment analysis, require trained staff for
result interpretation and are not amenable to high through-
put diagnostics. We aim to develop an automatable, robust
and high throughput MSI assay based on next generation
sequencing.
Methods and Results: We have developed a sequencing
based assay using 17 short intragenic homopolymer repeats
(7–12 bp), which are selected from the CGAP database.
These are less prone to technical artefact than the longer
repeats used in fragment analysis. The repeats used are
linked to an informative SNP; to facilitate separation of
genuine mutations which display allelic imbalance from
PCR artefacts generated from both alleles. Using fragment
analysis as the reference technique, we have demonstrated
>97% sensitivity and speciﬁcity using over 100 residual
samples from diagnostic laboratories in Newcastle, Edin-
burgh and Pamplona. Further enhancement of laboratory
procedure involved implementation of a two-step multi-
plexed target capture and library preparation method which
utilised molecular inversion probes (MIPs). We demonstrate
that MIPs allow multiplexing of the 17 markers plus
inclusion of BRAF mutation testing for minimal additional
cost. We will present results of assay sensitivity, robustness
and reproducibility against fragment analysis, using DNA
from fresh and FFPE tissues.
Conclusion: Our novel assay has the potential to
streamline diagnostic pathology services by providing a
quick and automatable assay for MMR-deﬁcient tumour
diagnosis.
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Introducing genetics training and competency assess-
ment into day to day working practice
Z. Deans1, F. Khawaja1, I. Bamsey2, B. Lings2, A. Seller3,
S. Abbs4
1UK NEQAS for Molecular Genetics, Edinburgh, United
Kingdom, 2Certus Technology, Exeter, United Kingdom,
3Health Education England, Birmingham, United Kingdom,
4Cambridge University Hospitals NHS Foundation Trust,
Cambridge, United Kingdom
The requirement for laboratories to work to ISO 15189 has
introduced the need to evidence the training and compe-
tency of staff for all tasks performed. The demonstration of
staff following testing protocols has been widely adopted,
however providing evidence for training and competency of
routine genetic laboratory duties is problematic.UK
National External Quality Assessment Service (NEQAS)
for Molecular Genetics has developed an online Genetics
Training Assessment and Competency Tool (G-TACT) in
conjunction with Certus Technology, to provide assessment
of the ability of individuals to perform both routine and
non-routine tasks. These currently include tasks that are
undertaken by Sample Receptionists, Duty Scientists, Data
Analysts, and Report Authorisers e.g. logging samples into
a Laboratory Information Management System, activating/
prioritising requests from service users, analysing and
interpreting genomic data and authorising clinical reports.
Participants enter a virtual genetic laboratory and navigate
between workstations to complete randomly generated
tasks. Errors/problems are introduced to expose the parti-
cipant to more challenging scenarios, e.g. handling inap-
propriate samples, analysing and reporting sub-optimal
results. The system assesses the participant’s handling of
the scenario. A manager is assigned locally so the outcomes
can be integrated into the appraisal system and training
needs identiﬁed. The modular format enables new work-
stations, tasks and roles to be introduced as the laboratory
environment changes. G-TACT offers, for the ﬁrst time, a
consistent approach to ensure individuals at all levels across
genetic laboratories are appropriately trained and competent
to perform their assigned tasks to a high quality standard.
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Comprehensive next-generation sequencing panel for
detection of mutations and large deletions in congenital
disorders of glycosylation
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N. Vidal-Folch, A. McDonald, C. Wang, E. Klee, D.
Matern, D. Oglesbee, P. Rinaldo, S. Tortorelli, K.
Raymond, D. Gavrilov
Mayo Clinic, Rochester, MN, United States
Introduction: Congenital disorders of glycosylation (CDG)
comprise a group of >100 conditions affecting glycosyla-
tion. CDG can present at any age with a broad spectrum of
clinical symptoms, affecting multiple organ systems.
Recently, many new genes have been identiﬁed by whole
exome sequencing testing (WES), utilizing next generation
sequencing (NGS) technology. Materials/Methods: We
developed targeted NGS panel which includes 116 genes
associated with CDG utilizing custom probe mix (Sur-
eSelectXT, Agilent). CLC Bio Genomics Server was used
for read alignment and variant calling. PatternCNV (in
house developed algorithm) was used for copy number
variant (CNV) detection. Accuracy was assessed by testing
19 patient samples, 21 samples with large deletions or
duplications, 3 controls from Coriell and 2 samples with
WES data.
Results: On average, 78.9% of the reads were mapped to
target with depth of coverage of 2427. We observed 100%
concordance in the 19 samples with previously identiﬁed
CDG mutations and 21 samples with previously identiﬁed
large deletions or duplications; and >99.4% concordance
with the control set. In addition to all variants reported in
samples with WES data, we detected additional 169 variants
of unknown signiﬁcance (43% exonic), demonstrating the
higher sensitivity of targeted panels.
Conclusions: An approach, combining biochemical
screening and targeted analysis of genes known to be
associated with different CDG can facilitate the diagnosis in
a signiﬁcant fraction of patients with suggestive clinical
presentation. Bioinformatics analysis of NGS data allows
reliable screening for large genomic rearrangements and is a
viable alternative to methods such as aCGH and MLPA.
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Validation of low-coverage whole genome sequencing
assay for detection of copy number aberrations in
inherited disorders
J. Koskenvuo1, P. Salmenperä1, M. Valori1, I.
Scheinin1,2,3, M. Gentile1, S. Myllykangas1
1Blueprint Genetics, Helsinki, Finland, 2VU University
Medical Center, Amsterdam, Netherlands, 3University of
Helsinki, Helsinki, Finland
Detection of copy number aberrations in clinical diagnostics
has been limited to few genes in MLPA and low resolution
in microarrays. We have developed and validated a low-
coverage whole genome sequencing assay for genome-wide
and high-resolution detection of copy number aberrations
(CNAs) from inherited disorders. We used Illumina
NextSeq500 sequencing system to generate paired-end 40
base reads. 28 reference samples with 34 conﬁrmed chro-
mosomal aberrations and the golden standard reference
sample (NA12878) were applied in the validation. Reads
were divided into 5 kb bins and difﬁcult to sequence regions
(bins representing 5.8% of the genome) were ﬁltered out.
Read counts were corrected for GC content and average
mappability of each bin. Segmentation and calling algo-
rithms (ODNAseq, DNAcopy and CGHcall) were applied
to detect CNAs. The CNA calls from the reference samples
were compared to Affymetrix Genome-Wide Human SNP
Array 6.0, G-banded karyotyping analysis and ﬂuorescence
in situ hybridization (FISH) results. The assay's sensitivity
to detect >100kb deletions and duplications was 0.97. We
utilized a golden standard reference sample containing high-
quality copy number variation (CNV) calls of variable sizes
to demonstrate the assay’s sensitivity to detect smaller
changes. The analytical sensitivity was 0.765 for detecting
CNVs of 25–50kb in size and 0.990 for detecting CNVs of
over 50kb in size. The smallest detected deletion was 10kb.
Our results show the validity of the low-coverage whole
genome sequencing assay for diagnostic analysis of CNAs
in inherited disorders.
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time); Signiﬁcant; Blueprint Genetics. E. Ownership Inter-
est (stock, stock options, patent or other intellectual prop-
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Monitoring Guide RNA Synthesis for CRISPR-Cas9
Genome Editing Workﬂow
M. Liu1, J. Molitor2, A. Padmanaban3, D. Marjenberg4
1Agilent Technologies, Inc., La Jolla, CA, United States,
2Agilent Technologies, Inc., Waldbronn, Germany, 3Agilent
Technologies, Inc., Bangalore, India, 4Agilent Technolo-
gies, Inc., Manchester, United Kingdom
Bacterial clustered regularly interspaced short palindromic
repeats (CRISPR) - associated protein 9 (Cas9) system has
increased in popularity as a genome editing tool for targeted
mutations, insertions, deletions and gene knock-out studies.
CRISPR genome editing has also proved superior to Zinc-
ﬁnger nucleases (ZFN) and transcription activator- like
effector nucleases (TALENs) due to its simplicity and easy
programmability. In CRISPR, a guide RNA (gRNA) is used
to recognize and introduce a double standard break (DSB)
in a target DNA. The DNA repair mechanism triggered after
the break is then exploited to introduce an insertion-deletion
(indel) in the case of non-homologous end joining (NHEJ),
or precise genetic modiﬁcation if a homology-directed
repair (HDR) pathway is triggered.
A critical part of the CRISPR-Cas9 tool is the design and
synthesis of the gRNA that comprises T7 promoter
sequence, target sequence, and protospacer adjacent motifs
(PAM). Monitoring the transcription of the gRNA is critical
to the workﬂow to ensure successful gene editing. Here we
present an automated electrophoresis approach for mon-
itoring the synthesis, integrity, and functional activity of
gRNAs created for a CRISPR-Cas workﬂow.
M. Liu: A. Employment (full or part-time); Signiﬁcant;
Agilent Technologies. J. Molitor: A. Employment (full or
part-time); Signiﬁcant; Agilent Technologies. A. Padma-
naban: A. Employment (full or part-time); Signiﬁcant;
Agilent Technologies. D. Marjenberg: None.
P14.031C
RNaseH2-dependent PCR (rhPCR) and universal
reporter system enables quantitative and multiplex
genotyping
D. Tsang1, K. Datta1, K. Beltz2, Y. Wang1, S. Rose2, A.
Menezes2, C. Chen1, Y. Bao1
1Integrated DNA Technologies, Redwood City, CA, United
States, 2Integrated DNA Technologies, Coralville, IA,
United States
Introduction: rhPCR genotyping assays combine a unique
two enzyme system with DNA-RNA hybrid primers to
detect genetic variations including SNPs and InDels. Allele
speciﬁc primers (ASPs) contain a 5′ universal tail, a single
RNA base targeting the SNP, and a terminal blocking
group. The thermostable RNase H2 cleaves the primer at the
RNA base, releases the blocking group only upon hybri-
dization to its perfectly matched target, and hence activates
the primer which can be then extended by DNA poly-
merase. This enables rhPCR genotyping assays to detect
different ratios of allele input or quantitative genotyping. A
universal reporter system provides cost-effective genotyp-
ing, and enables multiple ﬂuorophore detection of multi-
allelic variants in a single reaction.
Materials and Methods: Assays were designed to target
SNPs on human CYP2D6 genes known to have copy
number variation. Assays were tested with synthetic tem-
plates at various ratios of allele input and >90 Coriell gDNA
samples from three populations. Multiplex genotyping was
performed by combining two assays together in the same
reaction and using four ﬂuorescence dyes, one for each
allele, for detection.
Results: Genotyping results on mixed synthetic tem-
plates showed the assays can detect 10% alternative allele in
end-point analysis output. Human gDNA data showed the
assays are speciﬁc and quantitative to measure allelic copy
number ratio. Multiplex genotyping was successful with
high ﬂuorescent signal and good cluster separation.
Conclusion: New rhPCR genotyping technology pro-
vides highly speciﬁc genotyping for quantitative and mul-
tiplex allelic detection. This technology is applicable for
genomics research and molecular diagnostics.
D. Tsang: A. Employment (full or part-time); Sig-
niﬁcant; Integrated DNA Technologies. K. Datta: A.
Employment (full or part-time); Signiﬁcant; Integrated
DNA Technologies. K. Beltz: A. Employment (full or part-
time); Signiﬁcant; Integrated DNA Technologies. Y.
Wang: A. Employment (full or part-time); Signiﬁcant;
Integrated DNA Technologies. S. Rose: A. Employment
(full or part-time); Signiﬁcant; Integrated DNA Technolo-
gies. A. Menezes: A. Employment (full or part-time);
Signiﬁcant; Integrated DNA Technologies. C. Chen: A.
Employment (full or part-time); Signiﬁcant; Integrated
DNA Technologies. Y. Bao: A. Employment (full or part-
time); Signiﬁcant; Integrated DNA Technologies.
P14.032D
Novel droplet digital PCR for Non-invasive prenatal
testing rhesus genotyping
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A. Rodriguez-Martinez1, N. Borst2, E. Sarasola-Diez1, M.
Agirregabiria3, J. Ruano-Lopez3, T. Codd4, K. R. Ward4,
J. Bekacz5, M. Gaboyard6, M. Garcia-Barcina1
1Basurto University Hospital, Bilbao, Spain, 2Hahn-Schick-
ard, Freiburg, Germany, 3IK4-Ikerlan, Mondragon, Spain,
4Biopharma Technology, Winchester, United Kingdom, 5EV
Group, St.Florian am Inn, Austria, 6Ademtech, Pessac,
France
Introduction: The development of new more sensitive and
easy handling technologies with affordable equipment is a
challenge. In the frame of EU 7th Framework ANGELAB
project a digital droplet PCR on disk was developed (1). In
this work, we present the application of this novel approach
in the context of NIPT rhesus genotyping.
Materials and methods: Plasma samples from RhD
positive and RhD negative pregnant women were collected
after informed consent. cfDNA extraction and digestion was
performed in lab-on-a-chip as previously reported (2) with
modiﬁcations in digestion protocol and enzymes composi-
tion. Digestion products were collected from the chip and
subsequently analyzed by ddPCR. Droplets generation was
performed as previously reported (1) adapted to slide for-
mat. Detection of RASSF1A, RHD exon 5, and RHD exon
7 was performed using a microarray scanner and a ﬂuor-
escence microscope. Samples were also analyzed by qPCR.
Results: Positive detection of the three targets analysed
was achieved in samples from Rh positive pregnant women.
Fetal rhesus genotyping in Rh negative pregnant women
was a challenge due to low gene copy numbers and
adjustments in the methodology were needed. A correlation
with qPCR was also established.
Conclusions: This novel ddPCR approach was proved to
be suitable for rhesus genotyping. Its use for fetal rhesus
genotyping will constitute a sensitive and easy handling
technology.
References
(1) Schuler F, et al., Digital droplet PCR on disk. Lab
Chip. 2016 Jan 7;16(1):208–16. doi: 10.1039/c5lc01068c.
(2) M. Agirregabiria, et al., μTAS 2015. KOREA.
EU Framework 7 project-“ANGELab”-Grant#317635
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P14.033A
Diagnostic yield of whole exome sequencing in a highly
consanguineous population
A. Alsaegh
ultan Qaboos University, Muscat, Oman
Whole exome sequencing (WES) is increasingly used and is
fast becoming the tool of choice in establishing an accurate
diagnosis in patients with a suspicion of inherited Mende-
lian diseases.
In this study, the results of 105 consecutive patients with
undiagnosed complex disorders at the Genetics and
Developmental Clinic of Sultan Qaboos University Hospital
from September 2013 to September 2015 are presented.
Whole exome sequencing was performed on all patients.
The most common referral indication was intellectual dis-
ability (47%). Analysis of the WES generated data was ﬁrst
limited to a predetermined disease gene panel whose
selection was based on the patient’s clinical presentation. In
the absence of a pathogenic or likely pathogenic mutation,
sequence data analysis was then extended to the entire
exome.
A pathogenic or likely pathogenic mutation was identi-
ﬁed in 33 patients. Consistent with the relatively high rate of
consanguinity in our population, the mutations observed
were inherited in autosomal recessive manner (28/33). A
total of 6 patients had a combination of 2 single gene dis-
orders. Variants of unknown signiﬁcance (VUS) were fre-
quently observed, in about 23% of our cases.
The overall detection rate of pathogenic / likely patho-
genic mutations achieved in this cohort is consistent with
the expected yield in the context of proband-only WES
analysis. Challenges remain with the identiﬁcation of VUS
and highlights the importance of further studies, segregation
and/or functional.
A. Alsaegh: None.
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Back-tracing of leukemia clones in childhood B-cell
progenitor acute lymphocytic leukemia using digital
PCR
F. Taylan1, V. Zachariadis1, B. Bang1, I. Öfverholm1, A.
Harila-Saari2, M. Heyman2, A. Tran1,3, G. Barbany1,3, A.
Nordgren1,3
1Department of Molecular Medicine and Surgery, Center
for Molecular Medicine, Karolinska Institutet, Stockholm,
Sweden, 2Department of Women’s and Children’s Health,
Karolinska Institutet, Karolinska University Hospital Solna,
Stockholm, Sweden, 3Department of Clinical Genetics,
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Introduction: The time of onset of childhood leukemia,
especially t(12;21)(p13;q22)[ETV6-RUNX1]-positive
ALL, has been explored using nested and real-time PCR in
dried blood spots (DBSs) and cord bloods, and contra-
dictory results have been reported. Our main goal is to
develop a sensitive and quantitative method to trace leu-
kemic clones at DNA level in DBSs. We used digital PCR
(dPCR) to ﬁve patients with different aberrations.
Materials and Methods: We collected ﬁve 3-mm DBS
from 5 BCP-ALL patients (1 MLL, 2 t(12;21) and 2 dic
(9;20)). We designed patient speciﬁc in-house assays tar-
geting the breakpoints. Following DNA isolation, dPCR
mixes were run in 4–8 chips, each containing ~50 ng DNA.
Chips were scanned in QuantStudio 3D Digital PCR System
and analysed in QuantStudio 3D AnalysisSuite Cloud
Software v3.1.
Results: Among DBSs, we detected leukemic clone,
3,44%, in one KMT2A/MLL-positive patient. We were not
able to detect any leukemic clone in the rest of the DNA
samples isolated from the DBSs (Table 1).
Table 1. Summary of dPCR results of ﬁve ALL patients
SampleChromosomal
aberrration
Age of
leukemia
onset
Ratio of
target to
total at
diagnosis
Amount of
DNA
obtained
from DBS
(ng)
Ratio of
target to
total at
birth
Calculated
sensitivity
of the test
Lowest
detectable
level
achieved
Average
number of
false
positives in
the assay
P1 MLL
rearrangement
1 mo 25,3% 290 3,44% 0,0946% 0,25% 3,47(±2,87)
P2 t(12;21) 1 y 8 mo 28,4% 250 0% 0,048% 0,09% 1,25(±1,88)
P3 t(12;21) 3 y 29,9% 312 0% 0,033% 0,2% 0,9(±1,1)
P4 dic(9;20) 1 y 1 mo 29,5% 312 0% 0,06% 0,17% 1,5(±1,17)
P5 dic(9;20) 3 y 3 mo 16,2% 183 0% 0,049% 0,15% 1,4(±1,91)
Conclusion: dPCR enables accurate and sensitive
detection and absolute quantiﬁcation of low-prevalence
target sequences. Our study conﬁrms the presence of the
MLL rearrangement at birth but not
t(12;21) and dic(9;20). This could be explained by levels
of preleukemic clones below the detection level.
This study has been supported by The Swedish Child-
hood Cancer Foundation.
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Detection of oxidative base damage in DNA with Fpg
treatment and Northern Lights Analysis
H. I. Ragnarsson1, B. Gudmundsson1,2, H. G. Thormar1,3,
J. J. Jonsson1,2
1University of Iceland, Reykjavik, Iceland, 2Landspitali -
National University Hospital of Iceland, Reykjavik, Iceland,
3Lifeind ehf. (BioCule), Reykjavik, Iceland
Introduction: Northern Lights Assay (NLA) is a versatile
technique for comprehensive detection of DNA damage
based on changes in conformation or structure of DNA
molecules. We tested if oxidised base lesions could also be
detected by pretreatment of samples with Fpg, an N-
glycosylase and AP-lyase acting with a broad substrate
speciﬁcity for oxidized bases.
Materials and Methods: NLA is based on Two-
Dimensional Strandness-Dependent Electrophoresis (2D-
SDE), a technique of nucleic acid separation based on size,
strandness, and conformation changes. NLA was done in
microgels to improve sensitivity and speed of analysis. Each
DNA specimen was analyzed in sample pairs of non-
digested DNA to detect single- and double-stranded breaks
and MboI-digested DNA to detect other lesions. In addition,
isolated DNA samples were treated for different incubation
times with the Fenton reaction and digested with different
amounts of Fpg enzyme.
Results: NLA detected single-stranded breaks, double-
stranded breaks, interstrand and intrastrand DNA crosslinks,
single-stranded DNA and bulky lesions. Conditions were
established were NLA with Fpg pretreatment detected
oxidized bases in a speciﬁc and semiquantitative manner as
increased single-stranded breaks. In addition, we detected
interstrand crosslinks in samples treated with the Fenton
reaction.
Conclusions: We extend the application of NLA to
detection of oxidised bases in DNA as increased single-
stranded breaks after Fpg enzyme treatment. Important
potential application of NLA-Fpg is analysis of cfDNA, an
advantage over the Comet assay, which can only be used on
whole cells. We also demonstrated conclusively that he
Fenton reaction can induce formation of interstrand
crosslinks.
H.I. Ragnarsson: None. B. Gudmundsson: B.
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An approach to detect chromosomal aberrations,
absence of heterozigosity and single nucleotide variants
from exome sequencing in clinical setting
D. Villela, S. Da Costa, A. Vianna-Morgante, A.
Krepischi, C. Rosenberg
University of São Paulo, São Paulo, Brazil
The aim of the present study was to evaluate the perfor-
mance of a new exome sequencing kit that consists of
backbones probes for detection and mapping of DNA copy
number variations (CNVs), and, ultimately, substitute the
use of chromosomal microarray testing and exome
sequencing for a single test. A total of 14 DNA samples
with known alterations ranging from Megabase-scale CNVs
to single base modiﬁcations were used as positive controls
for exome sequencing data analysis. In the DNA panel were
included copy number changes (n= 11) of variable sizes
(25 kb to 27 Mb), uniparental disomy (UPD) (n= 1), and
single point mutations (n= 2). Our results show that all
DNA mutations were correctly identiﬁed by exome
sequencing, except for two CNVs, which had no coverage
in the current platform, showing that CNVs of at least 25 kb
can be properly detected. Also, the calculated size of the
genomics imbalances detected by microarrays and exome
sequencing are virtually the same, suggesting that this
approach presents a resolution and sensitivity similar at
least to DNA microarrays. Accordingly, our data show that
the combination of a sequencing platform comprising
exome and whole genome backbone, with the right algo-
rithm is very promising for simultaneous detection of CNVs
and single nucleotide variants (SNVs), and should enable a
cost-effective and efﬁcient solution for detecting genomic
aberrations and SNVs detection simultaneously.
Financial Support: FAPESP
D. Villela: None. S. Da Costa: None. A. Vianna-
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Utility of exome sequencing in elucidating molecular
etiology of monogenic disorders in consanguineous and
non-consanguineous Indian families
S. R. Phadke1, A. Rai1, A. Moirangthem1, D. Narayanan1,
V. Giri1, P. S. Gambhir1, N. Gupta2, S. J. Patil3, A. Dutta4,
D. Agarwal5, B. Singh1, P. Srivastava1, S. Danda6, D.
Saxena1, K. Mandal1
1Sanjay Gandhi Postgraduate Institute of Medical Sciences,
Lucknow, India, 2All India Institute of Medical Sciences,
New Delhi, India, 3Narayana Hrudayalaya Hospitals,
Banglore, India, 4West Bengal Medical College, Darjeel-
ing, India, 5Sir Ganga Ram Hospital, New Delhi, India,
6Christian Medical College, Vellore, India
Introduction: Consanguinity which is observed in upto
40% of some Indian groups helps in analysis of exome data.
The experience of our centre in identifying causative var-
iations in cases with monogenic or possibly monogenic
phenotypes is presented.
Materials and Methods: Patients with monogenic dis-
orders like osteogenesis imperfecta, Sotos syndrome,
intellectual disability, limb malformations and other mal-
formation syndromes, etc. have been included. Exome
sequencing was outsourced (Illumina Nextera Rapid Cap-
ture Exome). The annotated data was analysed for identi-
ﬁcation of disease causing sequence variations.
Results: In total, the data of 66 cases has been analysed,
out of which causative sequence variations in known genes
were identiﬁed in 49% of cases. These included 14 het-
erozygous pathogenic variations in genes causing auto-
somal dominant disorders and 17 homozygous or
compound heterozygous mutations in genes for autosomal
recessive disorders. Out of the total sequence variations
labelled as causative, 14 were known pathogenic and 19
were novel. In addition, in a case from consanguineous
family, possibly pathogenic mutations in novel genes have
been identiﬁed and needs further work up. Out of the rest 12
cases from consanguineous families, causative homozygous
mutations were identiﬁed in 11 cases. In 4 out of the 6 cases
from non-consanguineous families with autosomal reces-
sive disorder, the identiﬁed sequence variations were
homozygous. Conclusions: The mutation detection yield
increases to more than 90% in cases with consanguinity. In
signiﬁcant proportion of non-consanguineous families with
rare autosomal recessive disorders, the mutations occur in
homozygous form suggesting hidden consanguinity or
inbreeding.
Funding: ICMR (63/8/2010-BMS), DBT (BT/PR9635/
MED/97/198/2013)
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The added value of rapid exome sequencing in critical
clinical situations
K. Neveling, S. van den Heuvel, D. Zafeiropoulou, S.
Castelein, F. van de Veerdonk, D. Koolen, A. Simons, R.
Rodenburg, A. Mensenkamp, R. Matthijsse, R. Pfundt, J.
Hehir-Kwa, E. Kamsteeg, M. Nelen
1Radboud University Medical Centre, Nijmegen,
Netherlands
For critical clinical situations, turnaround times (TATs) of
exome sequencing need to be fast in order to have an impact
on clinical decision making. We therefore set out to develop
a fast exome sequencing approach (max 14 days). Urgent
exomes are preferably sequenced as trios to enable de novo
analysis and assist data interpretation. A total of hundred
samples (37 families, mostly trios) have been sequenced
until now: Six trios were used for experimental setup, in 14
families (possible) pathogenic SNVs were identiﬁed, some
of which still need follow up, and 17 families remained
negative after inspection of SNVs and small indels. A trio-
based reference-free CNV approach is still under develop-
ment, but preliminary data show that all control CNVs
(53kb-6Mb) are detected correctly. Shorter TATs were
already beneﬁcial for some patients, i.e. an adult male
suffering from myeloﬁbrosis and autoinﬂammatory symp-
toms. A STING-like phenotype was suspected, with pos-
sible involvement of the JAK/STAT pathway. Urgent
exome sequencing was performed and results were avail-
able within 9 days. Interestingly, both a somatic variant in
MPL (=trombopoetine receptor > myeloﬁbrose) and a het-
erozygous variant in ACP5 (TRAP, known immune dysre-
gulation disorder) were identiﬁed, both ﬁtting to the patients
phenotype. Based on these results the medication of the
patient was changed, resulting in a substantial improvement
of the patients constitution. In conclusion, we have imple-
mented a rapid exome sequencing workﬂow for urgent
cases. The rapid identiﬁcation of pathogenic variants
already had implications on patient treatment, underlying
the added value of a fast genetic diagnosis.
K. Neveling: None. S. van den Heuvel: None. D.
Zafeiropoulou: None. S. Castelein: None. F. van de
Veerdonk: None. D. Koolen: None. A. Simons: None. R.
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Comprehensive use of extended exome analysis
improves diagnostic yield in heterogeneous rare disease -
a retrospective survey in 1.087 cases
A. Maver, G. Bergant, B. Peterlin
Clinical Institute of Medical Genetics, Ljubljana, Slovenia
Background Next-generation sequencing, especially with
exome sequencing, has become a cornerstone of diagnostics
in rare genetic disorders. Because exome sequencing is
primarily aimed at detection of single nucleotide and indel
variants in coding regions of genes, it may fail to detect a
considerable proportion of causative genetic variation.
Recently, several studies have shown that information
content of exome sequencing data allows for the expansion
of the scope of detectable variation, which may be inter-
rogated with extended bioinformatic analyses.MethodsWe
retrospectively analysed the results of genetic testing in
1.087 distinct cases referred for exome sequencing to our
institution. In these, we routinely employed extended
exome analysis approaches in addition to basic variant
analysis, including (1) copy number variation (CNV)
detection, (2) genomic breakpoint detection, (3) non-
consensus splice defect detection, (4) homozygosity map-
ping and (5) mitochondrial variant analysis. Results Com-
bined use of selected extended exome analysis approaches
assisted in identiﬁcation of causative genetic variant in 47
cases. This represented an 4.3% increase in diagnosed
cases, raising the overall diagnostic yield from 35.6% to
39.9%. The greatest increase of diagnostic yield was asso-
ciated with CNV detection (1.7%) and splice variant pre-
diction (1.5%), whereas the remaining approaches
contributed an additional 1.1% to the diagnostic yield.
Conclusions In conclusion, we show that routine use of
extended exome analysis approaches improves genetic
diagnosis of heterogeneous genetic disorders and results in
considerable increase of diagnostic yield of exome
sequencing.
A. Maver: None. G. Bergant: None. B. Peterlin: None.
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Simultaneous extraction of DNA, RNA and protein for
genomic and proteomic applications from fat tissue
E. C. Lawrence1, S. L. Rosenthal1, M. A. Schustermann
II2, L. E. Kokai2, J. P. Rubin2, E. E. Kershaw3, Z. Urban1
1Department of Human Genetics, University of Pittsburgh
Graduate School of Public Health, Pittsburgh, PA, United
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Pittsburgh School of Medicine, Pittsburgh, PA, United
States, 3Department of Medicine, Division of Endocrinology
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Medicine, Pittsburgh, PA, United States
Parallel sets of genome, transcriptome and proteome data
offer powerful means to deﬁne the molecular basis of
common diseases, such as obesity. However, adipose tissue
poses a particular problem for biomolecule extraction given
its high lipid and low protein content. The goal of this study
was to compare 11 current simultaneous extraction methods
for comprehensive downstream omics analyses of adipose
tissue. We used adipose tissue collected from pannicu-
lectomy (n= 5) in triplicates with 20–100 mg of input tis-
sue according to the manufacturer’s protocol (kits) or
established published protocols (Trizol). DNA and RNA
concentrations and quality was assessed using UV spec-
trophotometry. Protein concentration was measured using
the Bradford assay. The Trizol-based method yielded highly
variable amounts of nucleic acids (0.5–90 μg DNA, 1–40 μg
RNA) and protein (4–120 μg). The quality of DNA was
poor (OD260/280<1.0), but RNA was good (OD260/280=1.6–
2.0). The Allprep protocol provided very low yields and
quality of nucleic acids, and variable yield of protein (6–
140 μg). The Zymo protocol, which extracts nucleic acids
but not proteins, yielded variable amounts (0.4–7 μg) but
good quality (OD260/280=1.5–2.0) of DNA and low amounts
(0.3–3 μg) and quality (OD260/280=1.8–2.8) of RNA.
Similar to previous studies, our results suggest variability in
both quantity and quality among the different methods, as
well as considerable within-subject variability, likely due to
difﬁculty in obtaining precise amounts tissue and the het-
erogeneous nature of the tissue samples. Existing protocols
will need to be modiﬁed to optimize the consistency, purity
and yield of biomolecules from adipose tissue. Grant
HL093093
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the utility of computer-assisted facial recognition in the
etiologic diagnosis of patients with global developmental
delay & intellectual disability
L. Morlan, M. Garcia jimenez, J. Lopez pison, J. Peña
Segura, L. Monge Galindo, A. Lopez Lafuente, M.
Lafuente, S. Izquierdo, A. Rodriguez, M. Miramar, S.
Feo, G. Miguel, M. Tirado, L. Lahilla; ragon Institute for
Health Research, ZARAGOZA, Spain
Introduction: global developmental delay (GDD) and
intellectual disability (ID) are the most frequent reason for
consultation in the neuro-pediatrics outpatients, with a
prevalence of 1–10% of cases. Of these, 50–80% of patients
do not have a set etiologic diagnosis. The aim of this study
is to evaluate the efﬁciency of the computer program
Face2Gene (FDNA Inc, USA) as a diagnostic aid in clinical
practice, for cases of GDD and ID followed in a tertiary
hospital.
Material and Methods: Double blinded prospective
observational study. Face2Gene is a search and reference
tool designed for the exclusive use of medical staff.
Through the analysis of clinical ﬁndings and automated
recognition of facial traits, the program suggests 30 possible
diagnosis per patient. Our study correlates these proposed
syndrome matches with genomic data of the patients
attending our clinic, after adding the frontal photo and the
clinical features of the patient.
Results: 91 patients, ages 6 month to 20 years, have been
uploaded to Face2Gene, of which 21 have a molecular
diagnosis. Face2Gene recognized 7 of these. For 70 patients
we are waiting for molecular results. We will consider
Face2Gene a useful tool if in at least 10% of the patients,
one of the suggested syndrome matches does coincide with
the molecular diagnosis of the patient.
Conclusion: If the results are positive at the end of this
study, this could be considered a shortening of the diag-
nostic odyssey of the patient as well as an increase in the
rate of etiologic diagnostics.
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pison: None. J. Peña Segura: None. L. Monge Galindo:
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Clinical Application of a Facial Dysmorphology Tool: a
performance analysis
D. Lopergolo1, A. Currò1, A. M. Pinto1, C. Lo Rizzo1, M.
Baldassarri1, G. Cevenini2, M. A. Mencarelli1, F. Mari1,
A. Renieri1
1Medical Genetics, Department of Medical Biotechnologies,
University of Siena, Siena, Italy, 2Department of Medical
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Diagnosis of genetic syndromes associated with facial
dysmorphology in children is a real challenge. The rarer the
syndrome, the hardest reaching the diagnose. Computer-
aided dysmorphology analysis enables to beneﬁt from the
cumulative knowledge of geneticists worldwide. Face2-
Gene (FDNA Inc. Boston, MA) is an analytic tool that
utilizes the Facial Dysmorphology Novel Analysis tech-
nology to identify facial patterns associated with genetic
syndromes analyzing two-dimensional facial photos. For
each case, Face2Gene provides a ranked list of up to 30
possible syndrome matches based on anthropometric mea-
surements, phenotypic features and frontal facial photos
submitted. In this study, we aimed to measure the tools
performance with patients followed at Clinical Genetics in
the University of Siena. Frontal and often lateral pictures of
444 cases were uploaded, among which sixty cases with
clinical and/or molecular diagnosis (syndromes diagnosed
were 6% Nicolaides-Baraitser, 16% Rett, 10% Pitt-Hopkins,
6% Cofﬁn-Siris, 6% Cohen, 6% Kabuki, 16% other). F2G
matched correct diagnosis as ﬁrst hypothesis in 33,3%; as
ﬁrst 5 hypotheses in 41,6%;as ﬁrst 10 hypotheses in 46,6%
of cases. Although these results do not prove the systematic
efﬁcacy of F2G tools usage in the clinical practice, it should
be taken into account that in some cases, pictures quality
and the lack of anthropometric measurements due to F2G
continue updates could have affected the results of dys-
morphology analysis. Therefore, although F2G database
still lacks some syndromes, we envision that in the future it
can be improved to help the clinicians reaching a diagnose
validating his idea about a clinical case.
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An approach for determination of copy number varia-
tion using short-read next-generation sequencing
K. Reeves1, M. Bourbon2,3, D. Hurd1, J. Reid1, D. Molha1,
D. Houniet1, J. Cousin1
1Oxford Gene Technology, Oxford, United Kingdom, 2Uni-
dade de I&D, Grupo de Investigação Cardiovascular,
Departamento de Promoção da Saúde e Prevenção de
Doenças Não Transmissíveis, Instituto Nacional de Saúde
Doutor Ricardo Jorge, Lisboa, Portugal, 3BioISI –
Biosystems & Integrative Sciences Institute, Faculdade de
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Introduction: The ability to determine Copy Number
Variation (CNV) from short-read Next Generation
Sequencing (NGS) data would enable labs to determine
both CNV and Single Nucleotide Variations (SNVs)
simultaneously in one assay. We show here an approach to
detecting intragenic CNVs using Next-Generation Sequen-
cing and Bioinformatics. This is demonstrated with exam-
ples including LDLR, involved in Familial
Hypercholesterolaemia; and DMD on the X chromosome,
involved in Muscular Dystrophy.
Material and Methods: The NGS libraries were pre-
pared by fragmentation of DNA, followed by end-repair and
ligation of adaptors. The genes of interest were enriched
using a bait-capture hybridisation process and following
PCR the libraries were loaded onto an Illumina MiSeq
instrument. Array CGH was carried out using high resolu-
tion microarrays speciﬁcally designed with a high density of
probes within the genes of interest.
Results: Intragenic CNVs were detected using the NGS
assay and conﬁrmed with Array CGH. The concordance
was 100%.
Conclusions: A combined Next Generation Sequencing
and bioinformatics approach can be reliably used to deter-
mine CNVs in DMD and LDLR with potential for use in
other applications.
K. Reeves: A. Employment (full or part-time); Sig-
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part-time); Signiﬁcant; Oxford Gene Technology. D.
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Archival tissue use in NGS applications- Evaluation of
DNA extraction methods
S. McDonough, Z. Sun, M. Zschunke, J. Gorman, W. E.
Highsmith, K. Kopp, J. M. Cunningham; Mayo Clinic,
Rochester, MN, United States
Archival tissues represent a rich resource for clinical
genomic studies, particularly when coupled with a com-
prehensive medical record. The Mayo Clinic has tissues
from many decades of clinical trials, and use of these with
NGS applications is a priority. Nine FFPE DNA extraction
methods were evaluated using twelve FFPE samples of
varying tissue types. Quality assessment included the total
yield, percent ds DNA, fragment analysis and multiplex
PCR. After assessment, three tissue types from four FFPE
DNA methods were selected for NGS downstream
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evaluation. All samples were prepared using two different
low input library protocols, and enriched with Agilent’s
SureSelect XT Target Enrichment System V5 + UTR. For
additional examination, breast tumor samples extracted
using the same four methods were prepared using QIA-
GEN’s QIAseq™ Targeted DNA Human Breast Cancer
panel. All samples were sequenced on an Illumina HiSeq
4000, PEln 150 bp. Bioinformatics analysis revealed the
average coverage across the target regions for the Agilent
SureSelect Target Enrichment was approximately 130X for
all four FFPE DNA methods. For the targeted panel, the
highest molecular tag coverage of ~1600X was obtained
with the Kingﬁsher FFPE extraction method, while three
other methods yielded coverage of ~700–800×. Variant
comparison between the whole exome and the targeted
panel reveals a higher number of called variants with the
targeted panel as the result of its higher depths of coverage.
The genotype concordance was 99% for the commonly
called variant positions between all 4 extraction methods
with the targeted PCR NGS panel and 96% with WES.
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Oligoprobes as personalised tools for transformative
medicine in FISH
A. E. Rushton, R. K. Neely
University of Brimingham, Birmingham, United Kingdom
Introduction: Fluorescence in situ hybridisation (FISH) is
a widely-used technique in cytogenetic diagnostics. Whilst
typical hybridisation for commercial probes occurs in
16 hours, using short oligoprobes (~100 bp), results in faster
hybridisation kinetics which could allow much quicker
diagnosis. These probes are designed synthetically,
increasing ﬂexibility and personalisation.
Methods: Our probes were labelled using methyl-
transferases. These enzymes recognise speciﬁc DNA
sequences and facilitate the transfer of a methyl group from
their cofactor to the target. This technology utilises syn-
thetic cofactors that allow transfer of ﬂuorophores, as
opposed to methyl groups, to the speciﬁc DNA sequence.
By incorporating methyltransferase recognition sites into
the probe design, we can direct ﬂuorophore labelling to the
probe.
Results: As proof-of-concept we have explored the use
of oligoprobes in cases of acute lymphocytic leukaemia
(ALL). Hypodiploidy of chromosome 1, 7 or 17 can be
indicative of ALL, a faster hybridisation could result in
rapid diagnosis for patients. We have successfully designed
oligoprobes for the centromere of chromosome 17 which
have proven to hybridise to the complementary target in just
15 minutes, signiﬁcantly quicker than the traditionally used
methods.
Conclusion: Using methyltransferase directed labelling
of FISH probes will allow more control over the labelling
density and therefore sensitivity of probes, as well as
increased speciﬁcity, and at a fraction of the cost compared
to commercial probes. This is conducive to a range of
potential applications including rapid detection of rare or
private mutations.
Funding: The European Union’s Horizon 2020 research
programme (Grant 634890)
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Pitfall in molecular diagnosis of Friedreich Ataxia
J. Steffann1, M. Magen1, Z. Assouline1, M. Koenig2, B.
Funalot1, A. Rotig1, A. Munnich1, J. Bonnefont1, G.
Barcia1, J. Bengoa1
1Necker-Enfants Malades, Paris, France, 2CHU Montpel-
lier, Montpellier, France
Freidreich ataxia (FRDA) is the most common hereditary
ataxia, nearly 98% of patients presenting homozygous GAA
expansions in intron 1 of the FXN gene. The remaining
patients are compound heterozygotes for an expansion and a
point mutation, or an exonic deletion. Molecular screening
for FXN expansion is therefore focused on (GAA)n
expansion analysis, commonly performed by triplet repeat
primed PCR (PT-PCR).
We report on an initial pitfall in the molecular char-
acterization of a 15 year-old girl with FRDA who carried a
rare deletion in intron 1 of the FXN gene, resulting in a TP-
PCR failure of the expanded allele. This exceptional con-
ﬁguration induced misinterpretation of the molecular defect
in this patient, who was ﬁrst reported as having no FXN
expansion. NGS analysis of a panel of 215 genes involved
in nuclear mitochondrial disorders further revealed an
intragenic deletion encompassing exons 4–5 of the FXN
gene. Modiﬁed TP-PCR analysis conﬁrmed the presence of
a classical (GAA)n expansion located in trans. This case
points out the possible pitfalls in molecular diagnosis of
FRDA in affected patients and their relatives: detection of
the FXN expansion may be impaired by several non-
pathological or pathological variants around the FXN
(GAA)n repeat. We propose a new molecular strategy to
accurately detect expansion by TP-PCR in FRDA patients.
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Use of epilepsy gene panels for early diagnosis of epi-
lepsy in children 2–4 years of age: expert considerations
on current and future practices in Europe
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tory, Pitié-Salpêtrière Hospital, Pierre and Marie Curie
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ment of Neurology and Epileptology, University of Tubin-
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Introduction: The epilepsy gene panel is a molecular test
increasingly used in clinical practice for the genetic diag-
nosis of epilepsy. A delay from clinical onset to molecular
diagnosis may occur due to variability in referral criteria,
regional variability in gene panel content, test availability/
awareness and cost. Methods: In December 2016, eight
European experts in the genetic diagnosis of epilepsy
completed a survey and met to discuss current and future
application of epilepsy gene panels in the diagnosis of
children aged 2–4 years. The meeting was sponsored by
BioMarin Pharmaceutical Inc.
Results: Upon ﬁrst presentation of unprovoked seizures
in children aged 2–4 years, molecular testing is usually
ordered only after several clinical examinations (e.g.
metabolic investigations, EEG, MRI), seizure worsening,
manifestation of additional symptoms, and/or resistance to
anti-epileptic drugs (AEDs). Key considerations offered: i)
To shorten the time to genetic diagnosis of epilepsy, a gene
panel test performed during initiation of AEDs may be
warranted before worsening of symptoms, when an addi-
tional symptom is present; ii) all epilepsy gene panels
should include a core set of genes linked to epilepsy syn-
dromes/diseases presenting with epilepsy and with clini-
cally actionable potential; iii) a gene panel is the ﬁrst-tier
choice in contrast to whole-exome/genome, due to higher
gene coverage and lower cost.
Conclusions: Early use of an epilepsy gene panel pro-
vides a cost-effective diagnostic approach for timely iden-
tiﬁcation of genetic causes of pediatric epilepsy which
informs: clinical management, genetic counseling, prog-
nosis and, when available, targeted therapy.
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Usefulness of the genetic risk score to identify pheno-
copies in families with Autosomal Dominant
Hypercholesterolemia?
Y. Ghaleb1,2,3, S. El Bitar1,2,3, P. El Khoury1,2, J.
Rabès1,4,5, C. Boileau1,3,6, M. Abifadel1,2, M. Varret1,3
1INSERM U1148, PARIS, France, 2Université Saint Joseph,
Beyrouth, Lebanon, 3Université Denis Diderot, Paris,
France, 4Université Versailles Saint Quentin, Saint Quentin
en Yvelines, France, 5AP-HP, Ambroise Paré, Département
de Biochimie, Biologie génétique et moléculaire, Boulogne
Billancourt, France, 6AP-HP, CHU Xavier Bichat, Dépar-
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Autosomal Dominant Hypercholesterolemia (ADH) is
caused by mutations in LDLR, APOB, APOE or PCSK9
gene in 80% cases. It has been supposed that polygenic
forms of hypercholesterolemia may be present among ADH
patients with no identiﬁed mutation. Such phenocopies
within ADH-families are obstacles in linkage analyses
which are not identiﬁable by clinico-biological criteria.
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To address whether polygenic forms may explain phe-
nocopies reported in ADH-families with an identiﬁed
mutation, we calculated the genetic risk score (GRS), cor-
responding to the weighted sum of six LDL-C raising SNPs,
in affected members from six French ADH families.
In the family with the APOE-p.Leu167del, the two
affected members with no mutation present a high GRS
suggesting a polygenic form for these two phenocopies.
In the family with the large LDLR rearrangement, the
eight affected carriers present a low GRS consistent with the
monogenic form of the disease.
In the family with the LDLR-p.Glu228Lys, the two
affected members with no mutation present a high GRS
revealing the possible polygenic origin for their hypercho-
lesterolemia. However, the three affected carrier also all
present a high GRS which can increase the disease severity.
Indeed, two of them present higher LDL-C levels than the
other affected relatives.
In the three remaining families (APOB or PCSK9
mutations) all fourteen affected member are mutation car-
riers, but eight of them present a high GRS which is not
systematically associated with higher LDLC-levels.
To conclude, this six families study is not in favor of the
use of the GRS to identify phenocopies within ADH-
families.
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Prioritizing causal variants for rare, inherited syn-
dromes, using patient phenotypes
S. Shah, S. S. Kramer, S. S. Rebres, S. S. Richards, S. S.
Tang
1IAGEN, Redwood City, CA, United States
A key challenge in using genome and exome sequencing, to
identify disease causing variants in patients with multiple
congenital abnormalities and rare, undiagnosed genetic
disorders, is ﬁnding the true causal variant among the
hundreds of rare, functional (coding and regulatory) var-
iants. Here we present a patient phenotype driven sorting
algorithm that ranks variants using phenotype-disease
associations to facilitate improved diagnosis and causal
variant discovery. To enable the phenotype-driven ranking,
users enter phenotype terms or HPO identiﬁers that are
mapped to the Ingenuity Knowledge Base (IKB). The
syndrome prioritization algorithm connect genes and asso-
ciated diseases with patients' phenotypes, using a directed
network built from gene/disease relationships, disease/
phenotype relationships, as well as the process hierarchy
(ontology) that relates more speciﬁc terms of diseases and
phenotypes to more general terms in a hierarchical manner.
For each gene/disease combination a score that measures
how many disease phenotypes can be explained by the
disease, while also taking into account phenotype pre-
valence among all diseases represented in the IKB, along
with the conﬁdence of connecting phenotypes to diseases,
when traversing the process hierarchy (path weight), is
calculated. The speciﬁcity is the likelihood of the phenotype
being speciﬁc to the disease it characterizes and path weight
of a shortest path from a phenotype to a disease in the
network. The total score for a given gene/disease combi-
nation is then computed as the sum over all phenotypes
connected to the disease through at least one path. Pre-
liminary benchmarking shows successful prioritization and
causal variant discovery in 75% cases.
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Genetic and viral characterization by high throughput
mass spectrometry in kidney transplant recipients
C. P. Cristalli1,2,3, V. Mucciacciaro1, S. De Carolis1,3, A.
Mattiaccio1,3, R. Minardi1,2,3, M. Ruggeri2, G. Comai2, M.
Cricca3, M. Bonafè1,3, V. Mantovani1,4, G. La Manna2
1Center for Applied Biomedical Research (CRBA), S.
Orsola-Malpighi University Hospital, Bologna, Italy,
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Alma Mater Studiorum, University of Bologna, Bologna,
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Introduction: The infections are one of the most important
risk factors for renal allograft survival. Polyomaviruses
(PyVs), a group of small and circular dsDNA viruses,
mediate a broad spectrum of diseases in immunocompro-
mised patients. The NF-κB is a key regulator of immune
and inﬂammatory processes and the -94ins/delATTG
(rs28362491) polymorphism in the gene promoter has been
widely investigated for clinical associations. To date, it has
been associated with systemic lupus erythematosus,
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rheumatoid arthritis, inﬂammatory bowel disease and
recently renal rejection.
Materials and Methods: We developed a high-throughput
mass spectrometry (MS)-based method to detect the
rs28362491 and 18 PyVs types. Primer pairs of MS assay
were designed within the speciﬁc large T antigen genes.
Viral and human DNA were extracted from blood samples
of 43 kidney transplant recipients, before and after
transplantation.
Results: We analysed the correlation among PyVs
infections, rs28362491 genotype and post transplant follow
up. 5 out of the 18 viral types tested were found in the
specimens analysed: BKV, JCV, Merkel cell PyV, Human
PyV6 and SV12. In our cohort, 14 patients showed SV12
infection: 10 cases were -94ins/-94ins, 4 were -94ins/-94del.
All the patients with the NF-kB -94del/-94del genotype
were characterized by the absence of SV12 strain. No cor-
relation between genotype and viral infection was observed
for the other viral types.
Conclusions: Our MS assay improved the PyVs typing
and allowed to drive towards the identiﬁcation of novel
biomarkers for the infective management of transplanted
patients. The genetic background might modulate the viral
infection susceptibility.
C.P. Cristalli: None. V. Mucciacciaro: None. S. De
Carolis: None. A. Mattiaccio: None. R. Minardi: None.
M. Ruggeri: None. G. Comai: None. M. Cricca: None.
M. Bonafè: None. V. Mantovani: None. G. La Manna:
None.
P14.051C
A cloud-based high-resolution melting analysis applica-
tion capable of processing genotyping and copy number
variation data from different thermocyclers
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Introduction: PCR followed by high-resolution melting
(HRM) is a fast, reliable, and cost-effective method for
DNA genotyping and copy number variation (CNV)
assessment. Each thermocycler has speciﬁc accompanying
software, which hinders users from uniformly analyzing
their data across thermocyclers. We developed a cloud-
based HRM analysis application with comprehensive
algorithms capable of analyzing data from different ther-
mocyclers and well plate formats. A cloud-based applica-
tion does not require installation, and updates for improved
functionality and performance are automatically available.
Methods: Relevant, successive steps of curve processing
are displayed to provide fast and accurate genotyping and
CNV assessment. These steps include performing curve
normalization based on nucleic acid thermodynamics and
reaction model theory, calculating the negative derivatives,
and performing curve comparison through differencing with
a baseline curve and data clustering. We collected HRM
data from three different, commercially available thermo-
cyclers to assess the application’s reliability in curve
processing.
Results: For 20 small-amplicon, 20 unlabeled-probe, and
4 CNV assays, the sample melt curves were imported into
our software. The data were reviewed by an expert in HRM
analysis. Regardless of the source data or assay type, the
result determined by the expert was in congruence with the
original result.
Conclusion: Our cloud-based software application can
reliably process HRM data from different thermocyclers,
allowing users to make accurate genotyping and copy
number variation calls.
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Using Human Phenotype Ontology (HPO) to direct
diagnostic testing
Abstracts from the 50th European Society of Human Genetics Conference:. . . 653
N. Y. Roberts1, E. Shaham2, T. Taylor1, J. Clayton-Smith1,
S. C. Ramsden1, A. Brass3, the DDD study4
1Central Manchester University Hospitals NHS Foundation
Trust, Manchester, United Kingdom, 2Department of
Computer Science, Bar-Ilan University, Ramat Gan, Israel,
3School of Computer Sciences, University of Manchester,
Manchester, United Kingdom, 4Wellcome Trust Sanger
Institute, Wellcome Genome Campus, Cambridge, United
Kingdom
Diagnostic next-generation sequencing for genetically het-
erogeneous disorders is now widespread in clinical practice.
Clinically curated ﬁxed gene-panels have a clear and
demonstrable clinical utility. However, for indications such
as learning disability (LD), where genotype/phenotype
relationships are still emerging, the ﬂexibility of this
approach may be limiting. Exome sequencing overcomes
this, however it identiﬁes large numbers of variants in sin-
gletons, which is costly in analysis time and can reveal
unsolicited ﬁndings. We therefore wanted to investigate the
potential of using human phenotype ontology (HPO) to
improve gene-prioritisation, in an attempt to maximise
diagnostic sensitivity in this clinical group through the
development of virtual gene-panels.
Using 100 patients who have received a conﬁrmed
molecular diagnosis from whole exome sequencing through
the Deciphering Developmental Disorders study, we carried
out a blinded retrospective comparison of gene-
prioritisation methods using HPO terms submitted at the
time of patient recruitment by means of the following:
(1) A clique-based tool using HPO-gene relationships.
(2) A simple Phenotype-to-Gene-List tool, selecting
genes output that matched 60% of HPO terms.
(3) A manually curated LD diagnostic panel (currently
used in practice).
The curated LD gene-panel offered the highest sensitiv-
ity (78%) versus Phenotype-To-Gene-List (33%) and
clique-based analysis (24%). Precision-recall analysis
showed that clique-based analysis had the highest precision
over Phenotype-to-Gene-List or the curated LD gene-panel.
We suggest that whilst gene-panels are currently the most
effective method for detecting disease-associated genes, that
clique-based analysis using HPO-gene relationships may
provide a useful ﬁrst approach, reducing costly analysis
time.
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11p15-associated imprinting disorders - experiences
from three rounds of External Quality Assessment
(EQA) organised by EMQN
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The chromosome 11p15-associated imprinting disorders
(IDs), Silver-Russell and Beckwith-Wiedemann syndrome
(SRS, BWS), are characterized by heterogeneous molecular
alterations affecting the imprinting control regions 1 and 2
(ICR1, 2), including aberrant methylation, copy number
variations (CNVs), uniparental disomies (UPD) and point
mutations). In SRS, ICR1 hypomethylation is the pre-
dominant ﬁnding, whereas most BWS patients show ICR2
hypomethylation or paternal UPD. Methylation testing of
these loci is recommended for ﬁrst-line diagnosis (see
EMQN best practice guidelines for SRS and BWS). In case
of exclusion, other genomic loci should be considered in the
diagnostic workup. The European Molcular Genetics
Quality Network (EMQN) has developed an external
quality assessment (EQA) scheme for 11p15-associated
IDs. Here we discuss the results of three rounds of this
scheme. So far, 38 laboratories from 24 countries have
participated in the scheme. Methylation-sensitive (MS)-
MLPA is used by almost all laboratories to detect aberrant
methylation and copy number variants, however, data
interpretation is often challenging. Unrequested testing was
an occasional problem but most reports were satisfactory.
The quality of diagnostic testing improved over three years
of EQA scheme provision, especially in interpretation and
reporting of test results. We present a detailed summary of
our ﬁndings, including comments on appropriate testing and
genetic counselling in affected families, and reﬂect on dif-
ferential diagnoses.
K. Eggermann: None. K. Groenskov: None. D.
Mackay: None. F. Brioude: None. T. Eggermann: None.
M. Begemann: None. S. Patton: None.
P14.054B
Global diagnosis of 270 Morquio A patients based on a
dry blood spot assay: a two years study
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C. Cozma1, S. Oppermann1, L. Demuth1, S. Eichler1, A.
Rolfs2,1
1Centogene AG, Rostock, Germany, 2University of Rostock,
Rostock, Germany
Mucopolysaccharidosis 4a (MPS IVA; Morquio A disease)
is an autosomal recessive disease caused and characterized
by an impaired activity of galactosamine-(N-acetyl)-6-sul-
fate-sulfatase (GALNS), resulting in keratan sulfate and
chondroitin-6-sulfate accumulation in tissues and secondary
organ damage. Enzyme replacement therapy, currently in
clinical trials, renders the identiﬁcation of MPS IVa patients
in a rapid and facile manner of out-most importance. We
developed for the early and easy diagnosis of suspected
patients an enzymatic assay in dry blood spots (DBS) for
the stabile and reproducible detection of GALNS deﬁciency
(Cozma et al, 2015). The material extracted from DBS was
incubated with a 4-methylumbelliferyl-β-D-galactopyrano-
side-6-sulfate as a speciﬁc synthetic substrate. Final enzy-
matic product, 4-methylumbelliferone, obtained after
adding exogenous beta-galactosidase, was quantiﬁed by
LC/MRM-MS (liquid-chromatography/multiple-reaction-
monitoring mass-spectrometry). 4-propyl-5-hydroxy-7-
methyl-2H-chromen-2-one was used as internal standard, a
compound with similar molecular structure and fragmenta-
tion pattern in negative ion mode as 4-methylumbelliferone.
The assay yielded a positive and negative predictive value
of 1.0 for genetically conﬁrmed MPS IVa patients (with a
GALNS activity of 0.35 ± 0.21 μmol/L/h) compared with
controls (normal GALNS activity 23.1 ± 5.3 μmol/L /h).
We present here the results of a global screening study of
over 2 years. The samples with low GALNS activity were
subjected further to GALNS gene sequencing to conﬁrm
MPS 4a. The study so far lead to the identiﬁcation of 270
Morquio A individuals, from which are 186 MPS 4a
patients and 85 carriers. In total 121 unique mutations have
been found where 44% were not been described before.
C. Cozma: A. Employment (full or part-time); Sig-
niﬁcant; Centogene AG. S. Oppermann: A. Employment
(full or part-time); Signiﬁcant; Centogene AG. L. Demuth:
A. Employment (full or part-time); Signiﬁcant; Centogene
AG. S. Eichler: A. Employment (full or part-time); Sig-
niﬁcant; Centogene AG. A. Rolfs: A. Employment (full or
part-time); Signiﬁcant; Centogene AG.
P14.055C
ACMG classiﬁcation of variants in LDLR gene found in
patients with a clinical diagnosis of Familial
Hypercholesterolaemia
J. R. Chora, A. Alves, A. M. Medeiros, M. Bourbon
Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa,
Portugal
Familial Hypercholesterolaemia (FH) is an autosomal dis-
order of lipid metabolism presenting with increased cardi-
ovascular risk due to life long exposure to high LDL values.
LDLR mutations are the cause of disease in 90% of the
cases but proof of pathogenicity has only been obtained for
about 10%. The aim of this study was to classify all LDLR
variants found in patients with a clinical diagnosis of FH. A
database with all variants reported in public databases and
in literature review (2005–2016) was constructed. All var-
iants were classiﬁed using the recent American College of
Medical Genetics and Genomics (ACMG) guidelines. A
total of 1924 LDLR variants have been identiﬁed. The
majority were classiﬁed as variants of unknown signiﬁcance
(VUS, 804), followed by pathogenic (709), likely patho-
genic (398), benign (7) and likely benign (6). The majority
of VUS are classiﬁed as such due to lack of evidence on its
functional effect, but some variants with functional studies
are still wrongly classiﬁed as VUS or Likely Pathogenic.
Additionally, 99 null variants are classiﬁed as VUS.
Although the ACMG algorithm is a valid toll for variant
interpretation it must be adapted to FH to overcome the
gaps encountered. For now we recommend that a positive
FH molecular diagnosis should only be reported to the
clinician if (1) solid functional evidence exists towards the
pathogenicity of a variant, (2) ACMG algorithm classiﬁes
the variant as pathogenic or likely pathogenic or (3) the
variant found produces a null protein. This will avoid
misdiagnosis.
J.R. Chora: None. A. Alves: None. A.M. Medeiros:
None. M. Bourbon: None.
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Lyso-SM-509 is an easy-measurable and highly sensitive
biomarker for Niemann-Pick disease: a two year study
A. Giese1,2, C. Cozma3, S. Eichler3, G. Kramp3
1Albrecht-Kossel-Institute, University of Rostock, Rostock,
Germany, 2Massachusetts General Hospital, Boston, MA,
United States, 3Centogene AG, Rostock, Germany
Niemann Pick Type C (NPC) disease is an autosomal
recessive disease caused by mutations in NPC1 or NPC2
genes translated in defects of the lysosomes cholesterol
transport system leading to abnormal accumulation of
cholesterol and glycolipids in the lysosome. We present
data from a 2 year global cohort of Niemann Pick patients
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using lyso-SM-509 biomarker determination, followed by
sequencing of NPC1/2 genes. The levels of lyso-SM-509 in
blood reﬂect the burden of the NP disease and it can be used
for the easy diagnosis of NPC patients and for the mon-
itoring of the disease progression. Determination of lyso-
SM-509 is performed by LC/MRM-MS in plasma, serum,
EDTA blood and dried blood spots (DBS). We identiﬁed in
a world-wide study using lyso-SM-509 as primary screen-
ing in DBS samples 268 NPC and 147 SMPD1 affected
patients .The diagnosis was conﬁrmed by sequencing of the
NPC1/NPC2 genes. In NPC1/2 sequencing negative
patients with increased lyso-SM-509 concentrations the
sequencing of sphingomyelinase (SMPD1) gene was done.
Lyso-SM-509 has a sensitivity of 100 % and speciﬁcity of
99.15 % for NPC1/2. Most of the NPC cases were diag-
nosed in the age of3 to 10 years (30.65 %). We could
identify over 700 pathological alleles in 425 different NPC
cases. Only 42% of the unique variants identiﬁed in this
study were previously published. Most NPC cases were
linked with detailed clinical information; the most common
symptoms were: hepatomegaly (63.6%), splenomegaly
(55.8%), neurodevelopment delay (53%), ataxia (35.6%),
psychopathology (34.6%), brain atrophy (30.4%), ophthal-
moplegia (30.4%), spasticity (30%)Dystonia (24.4%), sei-
zures (20.7%).
A. Giese: None. C. Cozma: A. Employment (full or
part-time); Signiﬁcant; Centogene AG. S. Eichler: A.
Employment (full or part-time); Signiﬁcant; Centogene AG.
G. Kramp: A. Employment (full or part-time); Signiﬁcant;
Centogene AG.
P14.058B
Targeted next-generation sequencing for clinical of
genomic proﬁles of idiopathic infertile men and a com-
parison of variant calling pipelines
F. Raicu1,2, R. Coco1,3
1"Carol Davila" University of Medicine and Pharmacy,
Bucharest, Romania, 2Francisc I. Rainer Anthropological
Research Institute, Romanian Academy, Bucharest, Roma-
nia, 3Genome Life Research Centre, Bucharest, Romania
The improvement of the knowledge on the molecular basis
of spermatogenesis failure allows gaining insights into the
interplay of causative disease-associated genes and genetic
variants changes of the genome in male infertility.
We redesigned the previous AmpliSeq panel to capture
the exons and introns of 135 genes to identify the genetic
variants that could be associated with male infertility based
on a targeted sequencing protocol onto Ion Torrent PGM
platform
Here, we analyzed 42 out of 120 patients with idiopathic
infertility that presented no Y chromosome microdeletions.
In addition, for a systematic comparison we assessed the
impact of different variant calling pipelines comparing the
same read aligner, BWA-MEM, and four variant callers
GATK HaplotypeCaller, SAMtools (the vcfutils.pl script),
Platypus and FreeBayes. Veen diagrams using the R
package were constructed to illustrate the concordance
among all variant-calling pipelines.
We identiﬁed 63 possible causative variants in 42 dif-
ferent genes, excluding common polymorphisms, and a
higher concordance among the GATK, SAMtools and
Platypus (72%) variant calling pipelines compared to a
lower concordance with the FreeBayes variant caller.
Our data found an essential variation between the ana-
lyzed variant-calling pipelines and suggests the standardi-
zation of the available bioinformatics pipelines to reduce the
implication on analyzing the next-generation sequencing
data (ﬁnancial support CNCS-UEFISCDI grant PN-II-RU-
TE-2014-4-0527).
F. Raicu: None. R. Cocoş: None.
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Whole exome sequencing or small panels for develop-
mental disorders? Read between
V. DAVID1,2, E. Cherot3,2, C. Mignot4,5, C. Dubourg2,1, W.
Carré2,1, A. Lavillaureix4, D. Héron4,5, F. Demurger3, M.
Fradin3, C. Quélin3, C. Depienne4,6, S. Odent3,1, C.
Nava4,6, L. Pasquier3,7, B. Keren4,6
1UMR 6290 CNRS, IGDR, Rennes, France, 2Laboratoire de
Génétique Moléculaire, CHU Pontchaillou, Rennes,
France, 3Service de Génétique Médicale, CHU Hopital
Sud, CLAD Ouest, Rennes, France, 4AP-HP Hôpital de la
Salpétrière, Département de Génétique, Paris, France,
5Groupe de recherche Clinique (GRC) Déﬁciences intel-
lectuelles de causes rares, Paris, France, 6INSERM, U
1127, CNRS UMR 7225, Sorbonne Universités, UPMC
Univ, Paris, France, 7INSERM CIC pédiatrique 1414, CHU
Pontchaillou, Rennes, France
Second generation of sequencing technologies is now
widely used for genetic diagnosis. Nevertheless, whole
genome or exome sequencing are still challenging, mainly
because of their expensive cost and the broad amount of
data they provide. In this study, we present another diag-
nostic tool: the medical exome. Its analysis is restricted to
OMIM genes of clinical interest.
219 patients with developmental disorders were recruited
from two French genetic centers, the Groupe Hospitalier
Pitié-Salpêtrière and the Centre Hospitalier Universitaire of
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Rennes. Their clinical features correspond to our day-to-day
practice i) patients with developmental disorders but no
precise diagnoses, ii) patients with well-deﬁned clinical
hypotheses implying Sanger sequencing with high expen-
ditures. Each case was screened for fragile X syndrome
when appropriate and for chromosomal microarray before
inclusion. Samples were prepared with the Illumina Tru-
Sight One kit. After sequencing, every pathogenic variation
was conﬁrmed by Sanger Sequencing.
We had a global diagnosis yield of 26%. Clinical exome
was particularly efﬁcient to identify a pathogenic mutation
in patients with neurological disorders including epilepsy,
intellectual disability, micro or macrocephaly and neuro-
degenerative disorders. In contrast, only few mutations were
identiﬁed in patients with autism.
Medical exome thus appears as a good compromise
because of its moderate cost and its capacity to diagnose
efﬁciently genetically heterogeneous conditions in a medi-
cal purpose. It provides a way to reduce the probability of
subsequent sequencing and may thus limit diagnostic
odyssey.
V. David: A. Employment (full or part-time); Sig-
niﬁcant; Employment. E. Cherot: A. Employment (full or
part-time); Signiﬁcant; Employment. C. Mignot: A.
Employment (full or part-time); Signiﬁcant; Employment.
C. Dubourg: A. Employment (full or part-time); Sig-
niﬁcant; Employment. W. Carré: A. Employment (full or
part-time); Signiﬁcant; Employment. A. Lavillaureix: A.
Employment (full or part-time); Signiﬁcant; Employment.
D. Héron: A. Employment (full or part-time); Signiﬁcant;
Employment. F. Demurger: A. Employment (full or part-
time); Signiﬁcant; Employment. M. Fradin: A. Employ-
ment (full or part-time); Signiﬁcant; Employment. C.
Quélin: A. Employment (full or part-time); Signiﬁcant;
Employment. C. Depienne: A. Employment (full or part-
time); Signiﬁcant; Employment. S. Odent: A. Employment
(full or part-time); Signiﬁcant; Employment. B. Research
Grant (principal investigator, collaborator or consultant and
pending grants as well as grants already received); Sig-
niﬁcant; Groupama. C. Nava: A. Employment (full or part-
time); Signiﬁcant; Employment. L. Pasquier: A. Employ-
ment (full or part-time); Signiﬁcant; Employment. B.
Keren: A. Employment (full or part-time); Signiﬁcant;
Employment.
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A novel high-multiplex homogeneous PCR assay format
S. M. Echwald
napa Biotech A/S, Hoersholm, Denmark
Background: Multiplex PCR has become an increasingly
popular method to provide more, clinically relevant answers
from the same sample. In many clinical settings, achieving
multiplex answers from the same sample provide beneﬁts
both in terms of cost, speed, added clinical value as well as
preservation of limited samples. In cases such as sepsis,
RSV-testing, gastrointestinal testing and many others, a
broad spectrum of agents are relevant for testing to assess
possible infections. However, PCR readout is commonly
limited to the current maximum of 4–5 ﬂuorophores on
most instruments. We have developed MeltPlex - a homo-
genous assay method to allow read-out of more than 20
answers from a single PCR reaction.
Material/methods: MeltPlex utilizes a system of label-
led probes allowing each to be read out by subsequent
melting curve analysis by more than 5 probes per ﬂuor-
ophore. By utilizing meltcurve readout of modiﬁed probes -
one for each target - rather than the only amplicons, the
system adds an extra level of speciﬁcity to meltcurve ana-
lysis. Reaction and melting analysis is performed without
the need to re-open PCR reaction tubes.
Results: We will present proof-of-principle of the
method and demonstrate its relevance in routine clinical
infectious agent testing.
Conclusions: MeltPlex comprise a robust, high-multi-
plex, homogeneous system to provide 20+ readouts per
PCR reaction.
S.M. Echwald: A. Employment (full or part-time);
Signiﬁcant; Anapa Biotech A/S.
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A highly ﬂexible and fast approach for high-throughput
genetic testing using next-generation amplicon
sequencing
F. Vogel, K. Brüsehafer, T. Koledachkina, R. Löwe, O.
Paknia, K. K. Kandaswamy, M. Weiss, S. Kishore, A.
Rolfs, P. Bauer
Centogene AG, Rostock, Germany
Introduction: Parallel sequencing of hundreds of patients
for a small number of genes has become very cost-efﬁcient
using next-generation amplicon sequencing. We have
established amplicon-based assays to screen patient samples
for disease-associated mutations in a broad variety of trea-
table rare diseases in parallel. This approach utilizes mul-
tiplexing that allows large numbers of libraries to be pooled
and sequenced simultaneously during a single sequencing
run using the Illumina MiSeq system.
Material and Methods: Our assay design consists of
two subsequent PCR ampliﬁcation reactions. The ﬁrst
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multiplex PCR of ~150bp amplicons is designed to cover all
coding exons, part of the promoter region and deep intronic
regions previously reported to harbor disease-associated
variants. A second PCR ampliﬁcation is performed with the
puriﬁed amplicons. This reaction adds Illumina-compatible
and patient-speciﬁc barcoded index primers to each ampli-
con. After second puriﬁcation, samples are pooled and
prepared for sequencing. After sequencing on the MiSeq
(2×150bp paired-end), de-multiplexing, alignment of
sequence reads and variant calling is performed with an in-
house bioinformatics pipeline.
Results: This setup allows multiple combinations, eg.
complete sequencing of 250 patients for the GLA gene
AND 10 BRCA1/BRCA2 gene assays AND CFTR gene
sequencing for 20 patients (10.000 amplicons total). To
enable high-throughput analysis, the whole workﬂow is
automated including order entry, variant interpretation with
CentoMD®, batch report writing and portal-based report-
transmission.
Conclusions: This automated amplicon-based NGS
approach using the MiSeq System allows high-throughput
genetic testing of multiple genes and a high number of
patient samples in parallel by a single sequencing run.
F. Vogel: A. Employment (full or part-time); Signiﬁcant;
Centogene AG. K. Brüsehafer: A. Employment (full or
part-time); Signiﬁcant; Centogene AG. T. Koledachkina:
A. Employment (full or part-time); Signiﬁcant; Centogene
AG. R. Löwe: A. Employment (full or part-time); Sig-
niﬁcant; Centogene AG. O. Paknia: A. Employment (full
or part-time); Signiﬁcant; Centogene AG. K.K. Kandas-
wamy: A. Employment (full or part-time); Signiﬁcant;
Centogene AG. M. Weiss: A. Employment (full or part-
time); Signiﬁcant; Centogene AG. S. Kishore: A.
Employment (full or part-time); Signiﬁcant; Centogene AG.
A. Rolfs: A. Employment (full or part-time); Signiﬁcant;
Centogene AG. P. Bauer: A. Employment (full or part-
time); Signiﬁcant; Centogene AG.
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A new methodology for controlling mutagens using
cancer cell line SKOV3
A. Chousmekeridou1, E. T. Lialiaris1, B. Asimakopoulos2,
R. Sandaltzopoulos3, T. S. Lialiaris1
1Demokritus University of Thrace, Medical School, Dept of
Genetics, Alexandroupolis, Greece, 2Demokritus University
of Thrace, Medical School, Dept of Pgysiology, Alexan-
droupolis, Greece, 3Demokritus University of Thrace, Dept
of Molecular Biology and Genetics, Alexandroupolis,
Greece
Sister Chromatid Exchanges (SCEs) is a known mutageni-
city test and its frequency enhances as a consequence of
exposure to various mutagenic agents. It is appeared also to
indicate DNA damaging effects and/or subsequent repair by
homologous recombination. The purpose of this study was
to test the applicability of cancer SKOV3 cells, as a muta-
genic and genotoxic screening test for various environ-
mental agents using SCEs alone or in comparison with
normal human peripheral lymphocytes (NHPL). SKOV3
cells are human ovarian cancer cells and our results are
compared using the mitotic index (MI), the proliferation rate
index (PRI) and the frequency of SCEs. By this way, we
managed to determine qualitatively and quantitatively the
damage caused by camptothecin (CPT), a known anticancer
agent, used as a positive control. SCEs methodology
resolves problems concerning the structure and function of
chromosomes and DNA replication and it detects muta-
genicity and/or genotoxicity, even at low concentrations and
it can be applied to normal or cancer cells, both in vivo and
in vitro experiments. The results of our study showed that
cancer SKOV3 cells are more sensitive in CPT, in very low
concentrations, in comparison to lymphocytes. Addition-
ally, they showed that cancer SKOV3 cells need much less
quantity of BrdU and any possible mutagen to display high
levels of SCEs. We also approved, that cancer SKOV3 cells
appear concurrency which makes easier the calculation of
MI, PRI and SCEs.
A. Chousmekeridou: None. E.T. Lialiaris: None. B.
Asimakopoulos: None. R. Sandaltzopoulos: None. T.S.
Lialiaris: None.
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Diagnosing unsolved patients by combining DNA
sequencing with bloodtranscriptomics
S. van Dam, P. Deelen, J. M. Karjalainen, J. C. Herkert1,
P. A. van der Zwaag, B. Sikkema- Raddatz, W. S.
Kerstjens-Frederikse, K. Abbott, N. de Klein, F. van Dijk,
R. J. Sinke, C. C. van Diemen, M. Swertz, L. Franke
UMCG, Groningen, Netherlands
Introduction: The University Medical Center Groningen
has a rapid whole genome sequencing project for newborns
and young children admitted to the intensive care that are
suspected to have a genetic disorder. Unfortunately, thus far
only about 30% of these patients can be successfully
diagnosed. We aim to provide a diagnosis for additional
patients by using gene expression data (RNA-seq) obtained
from blood.
Material and Methods: Using RNA-seq data, we
identiﬁed genes with aberrant gene expression levels and
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alternative splice junction/exon usage. We compared the
patients’ RNA-seq data to a reference panel of blood RNA-
seq data from 4,000 population based Dutch samples, while
correcting for metabolic and physiological variation that has
been deﬁned by a re-analysis of 32,000 public RNA-seq
samples.
Results: We show that severe aberrant expression/spli-
cing events can indeed be observed in the causal gene 3 out
of 9 patients in whom a genetic diagnosis has already been
made. Interestingly, although these disorders do not man-
ifest themselves in blood, these effects are detected in this
easily accessible tissue. Subsequently, we have identiﬁed
aberrantly expressed genes in the unresolved patients and
compared this with variants of unknown signiﬁcance, which
have been found through whole genome sequencing of
these patients. This resulted in the identiﬁcation of a small
number of aberrantly expressed genes with mutations that
we are currently following up.
This work is supported by a grant from the European
Research Council (ERC Starting Grant agreement number
637640 ImmRisk) to Lude Franke, two VIDI grants
(917.14.374 and 917.16.455) from the Netherlands Orga-
nization for Scientiﬁc Research (NWO) and a grant from
the Gratama Stichting (2015–06) to Patrick Deelen.
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None. B. Sikkema- Raddatz: None. W.S. Kerstjens-
Frederikse: None. K. Abbott: None. N. de Klein: None.
F. van Dijk: None. R.J. Sinke: None. C.C. van Diemen:
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Copy number variation detection using small, targeted
panels and the NEBNext Direct enrichment method
C. L. Hendrickson1, N. Henig1, K. M. Patel1, A. B.
Emerman1, S. K. Bowman1, S. M. Adams1, C. Elfe1, A.
Barry2, B. Textor3
1Directed Genomics, Ipswich, MA, United States, 2New
England Biolabs, Ipswich, MA, United States, 3New
England Biolabs, Frankfurt, Germany
Variations in copy number are the most common type of
DNA structural variations. These alterations are often
associated with disease or indicate disease susceptibility.
Clinical next-generation sequencing applications require
fast and cost effective methods such as targeted resequen-
cing, but copy number variations (CNVs) can be difﬁcult to
detect with these methods.
Here we describe the use of the NEBNext Direct®
hybridization-based target enrichment method to identify
somatic CNVs with high sensitivity. This approach captures
gDNA fragments prior to library preparation and PCR
ampliﬁcation then converts the targeted fragments into an
Illumina-compatible library that has deﬁned 3′ ends and
contains unique molecular identiﬁers (UMIs). The UMIs
both enhance the identiﬁcation of duplicate reads to ensure
conﬁdent allelic frequency calls and allow for duplicate
consensus-based error correction to increase sensitivity.
To validate this approach, we used two control systems.
First, we titrated DNA from a cell line known to contain a
deletion in the CDKN2A gene into a HapMap DNA sample
that contains full diploid copies of CDKN2A. Second, we
used a primary ductal carcinoma cell line containing several
copy number variations sites combined with a matched
control. In each case, we were able to detect the gene
deletions and duplications as a somatic CNV in a dose
dependent manner with high sensitivity and accuracy. Thus,
we demonstrate that the NEBNext Direct approach is an
efﬁcient technique to detect somatic CNVs of high and low
frequencies.
C.L. Hendrickson: None. N. Henig: None. K.M. Patel:
None. A.B. Emerman: None. S.K. Bowman: None. S.M.
Adams: None. C. Elfe: None. A. Barry: None. B. Textor:
None.
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Implementation of an automated sample quality control
tool in a whole exome sequencing workﬂow
E. Viering1, J. Petersen2, M. Beckhaus2, J. Molitor1, S.
Wolf2
1Agilent Technologies, Waldbronn, Germany, 2DKFZ
Genomics and Proteomics Core Facility, High Throughput
Sequencing Unit, Heidelberg, Germany
Sample quality control is of major importance in the Next
Generation Sequencing (NGS) workﬂow as it avoids time-
and cost-intensive repetition of experiments. Here the
German Cancer Research Center (DKFZ) demonstrates how
an automated electrophoresis system can be used to control
an exome sequencing workﬂow to assure the generation of
high quality sequencing data.
88 genomic DNA samples from formalin-ﬁxed parafﬁn-
embedded (FFPE) tumor tissues were analyzed. Samples
that passed the initial quality assessment, with respect to
sample quantity and integrity, were submitted to the library
preparation workﬂow. Depending on the DNA integrity, a
suitable DNA fragmentation protocol was used to enable
library preparation from degraded DNA. Implementation of
quality control steps at various steps throughout the proto-
col allowed the monitoring of the workﬂow by checking for
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library preparation artifacts, as well as controlling sample
concentrations and average fragment sizes to increase read
number during sequencing.
The stringent quality control criteria used by the DKFZ
allow for an increase in efﬁciency during library preparation
and ensure reliable sequencing results in high throughput
sample analysis.
E. Viering: None. J. Petersen: None. M. Beckhaus:
None. J. Molitor: None. S. Wolf: None.
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The evaluation of a new NGS system (GeneReader NGS
System) in clinical use of cancer diagnostics: The ﬁrst
report
A. Bisgin1,2, O. Sonmezler2, I. Boga2
1Cukurova University Faculty of Medicine, Medical Genet-
ics Department of Balcali Hospital and Clinics, Adana,
Turkey, 2Cukurova University AGENTEM, Adana, Turkey
Introduction: As a result of technological and practical
advances, next-generation-sequencing(NGS) becomes a
standard molecular diagnostic tool. However, the inter-
pretation of NGS data is still the critical step by allowing
clinicians to act on genomic information for new therapies
that target somatically mutated genes. Thus, we evaluated
new NGS system(GeneReader-NGS-System) that is the
most recent one in the market for the diagnosis of somatic
mutations in various cancer types.
Materials and Methods: KRAS, NRAS, KIT, BRAF,
PDGFRA, ALK, EGFR, ERBB2, PIK3CA, ERBB3, ESR1
and RAF1 genes were sequenced in FFPE tumor samples by
a new NGS system (GeneReader-NGS-System) according
to the manufacturer’s manuals but with modiﬁcations.
Results: 127 tumor samples were analyzed which; 15 of
127 were malign-melanoma(11.8%), 89 were lung(70.1%),
19 were colorectal(14.9%) and 4 were ovarian cancer
(3.2%). 66.7%(n= 11) malign-melanoma patients had
pathogenic variations in BRAF, NRAS, KIT and PIK3CA
genes. 50.6%(n= 45) lung-cancer patients had mutations in
EGFR, ALK, PIK3CA, BRAF, ERBB2, ERBB3, KIT, NRAS
and KRAS genes while 4 (4.5%) patients had uncertain
signiﬁcant variants in PDGFRA and KRAS genes. 36.8%(n
= 7) colorectal patients had clinically signiﬁcant variations
in KRAS, NRAS, BRAF and EGFR genes while 1 patient
(5.3%) had an uncertain signiﬁcant variant in EGFR gene.
One ovarian-cancer patient(25%) had pathogenic variations
in PIK3CA and RAF1 genes.
Conclusion: NGS systems became most successful
diagnostic tool, only in hands of experienced medical
geneticists for detection of clinically relevant variants. This
is the ﬁrst report of this new NGS system as a useful
diagnostics in clinical practice across wide range cancers.
A. Bisgin: None. O. Sonmezler: None. I. Boga: None.
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Validation of OS-Seq panels for clinical diagnostics of
inherited disorders
S. Myllykangas, P. Salmenperä, M. Gentile, S. Bruce, M.
Valori, M. Muona, A. Sarin, J. Koskenvuo
Blueprint Genetics, Helsinki, Finland
We have developed a comprehensive set of next-generation
sequencing tests for detecting single-nucleotide variants
(SNVs), insertions and deletions (INDELs) and deletions
and duplications (Del/Dups) in all inherited diseases. The
214 panels contain 2053 clinically actionable genes that
span 2243 conditions in 14 medical specialities. We adop-
ted Oligonucleotide-Selective Sequencing (OS-Seq) method
for targeted sequencing and implemented the ﬂow-cell
capture using the Illumina NextSeq500 sequencing system.
We generated six OS-Seq assays that targeted 374 to 585
genes’ coding exons, 15 adjacent bases of the splice regions
and pathogenic intronic variants. Analytic validity of the
NGS assays was demonstrated for SNVs, INDELs and Del/
Dups using cohorts of reference samples with high-quality
variant calls. Analytic validation results showed that the
NGS assays achieve, on average, 0.993 sensitivity,
0.999 speciﬁcity, 0.993 positive predictive value for
detecting SNVs and 0.961, 0.885 and 0.668 sensitivity for
detecting INDELs of 1–10, 11–20, and 21–30 bases,
respectively. Longest detected INDEL was 46 bases.
Repeatability and reproducibility of the OS-Seq assays were
0.994 and 0.998, respectively. 99.6% of the target regions
were covered with over 15x sequencing depth and mean
sequencing depth at nucleotide level was 234×. We
demonstrated the assays' sensitivity to detect different size
(1–4 exons) Del/dups: 0.715, 0.952, 0.990 and 0.999. Del/
dup detection was demonstrated to detect >316bp deletions
and >544bp duplication and clinical sensitivity of the del/
dup detection was 92.42%. Our results demonstrate the
analytic validity of the Blueprint Genetics’ sequencing
panels and show that the technology is well-suited for
clinical diagnostics of inherited disorders.
S. Myllykangas: A. Employment (full or part-time);
Signiﬁcant; Blueprint Genetics. E. Ownership Interest
(stock, stock options, patent or other intellectual property);
Signiﬁcant; Blueprint Genetics. P. Salmenperä: A.
Employment (full or part-time); Signiﬁcant; Blueprint
Genetics. E. Ownership Interest (stock, stock options, patent
or other intellectual property); Signiﬁcant; Blueprint
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(stock, stock options, patent or other intellectual property);
Signiﬁcant; Blueprint Genetics. S. Bruce: A. Employment
(full or part-time); Signiﬁcant; Blueprint Genetics. M.
Valori: A. Employment (full or part-time); Signiﬁcant;
Blueprint Genetics. M. Muona: A. Employment (full or
part-time); Signiﬁcant; Blueprint Genetics. A. Sarin: A.
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erty); Signiﬁcant; Blueprint Genetics.
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Diagnosis of mendelian disorder using a comprehensive
4813 genes next-generation sequencing panel - review of
111 cases
A. L. Carvalho1,2, J. Rosmaninho-Salgado1,3,4, M.
Venâncio1,2, S. B. Sousa1,5, M. L. Almeida1, T. Carminho-
Rodrigues1, J. Pereira6, F. Melo7, L. Almeida7, J. Pinto-
Basto7, P. Louro1, A. Garabal1, S. Maia1,2, F. Ramos1, J.
Sá1, L. Ramos1,5, J. M. Saraiva1,8
1Medical Genetics Unit, Hospital Pediátrico, Centro
Hospitalar e Universitário de Coimbra, Coimbra, Portugal,
2University Clinic of Genetics, Faculty of Medicine,
University of Coimbra, Coimbra, Portugal, 3CNC – Center
for Neuroscience and Cell Biology, University of Coimbra,
Coimbra, Portugal, 4Institute for Interdisciplinary Research
(IIIUC), University of Coimbra, Coimbra, Portugal,
5Faculty of Health Sciences, University of Beira Interior,
Covilhã, Portugal, 6Department of Haematology, Centro
Hospitalar e Universitário de Coimbra, Coimbra, Portugal,
7CGC Genetics, Porto, Portugal, 8University Clinic of
Pediatrics, Faculty of Medicine, University of Coimbra,
Coimbra, Portugal
Introduction: The accurate choice in each patient between
a (broad vs focused) gene-targeted panel or whole-exome
sequencing (WES) and their respective interpretation con-
stitute crucial challenges for the clinical geneticist. In this
study, we sought to review our experience analysing one-
hundred-eleven consecutive cases using a broad multi-gene
panel. Methods: A predesigned next generation sequencing
(NGS) panel for 4813 genes with known associated clinical
phenotypes (Illumina Trusight One) was performed in
selected patients with unknown genetic or with a diagnosis
with genetic heterogeneity. We analysed the laboratory
reports which complied with the ACMG 2015 guidelines,
clinically re-evaluated each patient and their medical
records, performed family studies when appropriate and
conﬁrmed or reclassiﬁed the variants. These variants were
categorized in four groups: pathogenic or likely pathogenic
variants in disease genes associated with the reported phe-
notype (Group 1), variants of uncertain signiﬁcance in
disease genes associated with the reported phenotype
(Group 2), secondary ﬁndings according to the ACMG
2013 recommendations (Group 3) and other variants not
associated with the reported phenotype (Group 4). Results:
One-hundred-eleven index unrelated patients were tested.
The laboratory reported a total of 150 variants. After our
classiﬁcation, we concluded that 30 variants should be
included in Group 1, 6 in Group 2, 3 in Group 3 and 111 in
Group 4. A diagnosis was achieved in 31 patients which
represents an overall diagnosis yield of 28%. Discussion:
We will present a comparison with the few other studies in
the literature which used a broad multi-gene NGS panel and
also WES.
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A novel method for building custom AmpliSeq™ panels
using optimized PCR primers
S. J. Roman1, A. Kothandaraman2, C. Van Loy1, A.
Broomer1, T. Biorac1, X. Duan1, J. Kilzer1, M. Allen1, J.
Chang1, D. Mandelman1, F. Hyland2, M. Manivannan2,
Y. Fu1, Y. Zhu1, E. Williams1, A. Hatch1, Y. Tian1, S.
Sovan3, M. Andersen1
1Thermo Fisher Scientiﬁc, Carlsbad, CA, United States,
2Thermo Fisher Scientiﬁc, South San Francisco, CA, United
States, 3Thermo Fisher Scientiﬁc, Pleasanton, CA, United
States
AmpliSeq™ is a next generation sequencing library pre-
paration method for targeted re-sequencing that utilizes
highly multiplexed PCR to amplify regions of interest. A
key to successful AmpliSeq libraries is the primer panel
used for target ampliﬁcation. Until now primers have been
available as pre-assembled ready-to-use panels, or as cus-
tom “made-to-order” panels. We describe a new process for
creating customized panels consisting of optimized and
veriﬁed PCR primers. The primer sets are available as
whole genes (i.e., all of the primers needed to create
libraries that cover the entire coding regions of genes) and
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are selectable on the ampliseq.com website by either
uploading gene lists or choosing genes from disease
research areas.
We show NGS sequencing data from 10 disease
research-oriented panels, including newborn screening
research and inherited cancer research, assembled from
individual pre-veriﬁed gene sets. Panel performance data
include coverage uniformity, reproducibility, and sensitivity
and speciﬁcity of variant calling. To demonstrate ﬂexibility
of panel content and performance, the coverage uniformity
of the 59 genes recommended by the American College of
Medical Genetics and Genomics for reporting of incidental
ﬁndings (ACMG59) was evaluated in various panels with
50–250 additional genes and shown to be ≥ 97% in all
contexts. We also demonstrate the robustness of this method
using a variety of sample types (fresh and dried blood,
saliva, cheek swabs) with both manual and fully automated
library preparation methods. For Research use only. Not for
use in diagnostic procedures.
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Employment (full or part-time); Signiﬁcant; Thermo Fisher
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Employment (full or part-time); Signiﬁcant; Thermo Fisher
Scientiﬁc. Y. Fu: A. Employment (full or part-time); Sig-
niﬁcant; Thermo Fisher Scientiﬁc. Y. Zhu: A. Employment
(full or part-time); Signiﬁcant; Thermo Fisher Scientiﬁc. E.
Williams: A. Employment (full or part-time); Signiﬁcant;
Thermo Fisher Scientiﬁc. A. Hatch: A. Employment (full
or part-time); Signiﬁcant; Thermo Fisher Scientiﬁc. Y.
Tian: A. Employment (full or part-time); Signiﬁcant;
Thermo Fisher Scientiﬁc. S. Sovan: A. Employment (full or
part-time); Signiﬁcant; Thermo Fisher Scientiﬁc. M.
Andersen: A. Employment (full or part-time); Signiﬁcant;
Thermo Fisher Scientiﬁc.
P14.070B
Multiplexed next generation sequencing reference
materials for testing of inherited disorders
R. Santhanam1, F. L. Tomson1, C. Huang1, J. Dickens1,
R. Truty2, S. Lincoln2, R. Garlick1, B. Anekella1
1SeraCare Life Sciences, Gaithersburg, MD, United States,
2Invitae, San Francisco, CA, United States
Introduction: Next Generation Sequencing (NGS) has
rapidly advanced genetic testing for inherited disorders.
However, these assays present challenges for test develop-
ment, validation, and quality control. Reference materials
are essential for validating and monitoring NGS assays
during wet-lab procedures and subsequent software analy-
sis. We developed a reference material technology that can
be used to assess the detection of variants, including those
that are rare and challenging, such as large indels (>20 bp).
Materials and Methods: GM24385 human gDNA was
blended with biosynthetic constructs containing variants
introduced into the endogenous sequence. The construct
was titrated to 50% allele frequency, conﬁrmed using digital
PCR (dPCR). A pilot reference material for hypertrophic
cardiomyopathy was developed and tested using multiple
capture-based NGS assays. The same concept was then
extended to select mutations in seven inherited cancer
genes.
Results: NGS testing showed that variants in the con-
struct were detected as heterozygous sites and these data
mimic that of the same variant when seen in a patient. SNVs
were detected with allele balances between 47–52%. A 25
bp deletion was detected at ~30%, similar to the bias
observed in patient samples for this variant even though the
frequency was 50% by dPCR.
Conclusions: The SeraseqTM Inherited Disease Refer-
ence Materials are designed to challenge NGS assays and
fulﬁll needs for accurate, multiplexed quality controls.
These materials can be used to challenge variant detection
pipelines, aid in assay optimization, and provide assurance
when detecting complex mutations.
R. Santhanam: A. Employment (full or part-time);
Signiﬁcant; SeraCare Life Sciences. F.L. Tomson: A.
Employment (full or part-time); Signiﬁcant; SeraCare Life
Sciences. C. Huang: A. Employment (full or part-time);
Signiﬁcant; SeraCare Life Sciences. J. Dickens: A.
Employment (full or part-time); Signiﬁcant; SeraCare Life
Sciences. R. Truty: A. Employment (full or part-time);
Signiﬁcant; Invitae. S. Lincoln: A. Employment (full or
part-time); Signiﬁcant; Invitae. R. Garlick: A. Employment
(full or part-time); Signiﬁcant; SeraCare Life Sciences. B.
Anekella: A. Employment (full or part-time); Signiﬁcant;
SeraCare Life Sciences.
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SALSA: a fast, accurate, validated software package for
clinical NGS panel data analysis
S. Yost, E. Ruark, M. Munz, S. Mahamdallie, E. J.
Ramsay, I. M. Uddin, H. Wylie, A. Elliott, S. Seal, A.
Strydom, N. Rahman
Institute of Cancer Research, London, London, United
Kingdom
The demand and volume of clinical NGS panel testing is
increasing rapidly. However, the speed, accuracy and con-
sistency of clinical NGS analytical pipelines would beneﬁt
from improvement in many labs. We have developed a
Standardized Automated Large-scale Sequencing Analysis
pipeline (SALSA), to quickly and accurately analyze NGS
panel data to clinical standards. Importantly, SALSA
accurately identiﬁes both small variants (base substitutions,
small indels) and exon CNVs (including single exon dele-
tions/duplications). SALSA provides comprehensive qual-
ity metrics, allowing identiﬁcation of exons that do not meet
user-speciﬁed quality and coverage thresholds. Additional,
customisable interpretation information can also be inte-
grated. SALSA returns easily readable outputs, to clinical
standards. We used SALSA to analyse >8.000 samples
tested in batches of 96 with the TruSight Cancer panel,
which targets 100 genes. The average SALSA runtime for
96 samples is eight hours. We evaluated SALSA perfor-
mance with orthogonally generated data of 995 results in 52
genes; 234 negative results, 303 base substitutions, 383
indels and 75 exon CNVs. Sensitivity was 100% for all
variant classes. Speciﬁcity was 229/233 (98%). All four
false positives were ﬂagged as poor quality by SALSA.
SALSA also correctly ﬂagged four results as failing pre-
deﬁned quality thresholds, avoiding false negative results.
SALSA does not require bioinformatic expertise to run and
it easily, accurately and quickly processes clinical NGS
panel data. SALSA is now in use in TGLclinical, a clinical
genetic testing laboratory accredited to ISO15189, and a
freely-available version is being released for other labs to
use. Funder, Wellcome:098518/Z/12/Z
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Incidental ﬁndings related to sex determinism in a NIPT
workﬂow
B. Grisart, V. Benoit, A. Destrée, D. Lederer, I. Maystadt,
D. Roland, S. Rombout, N. Simonis, P. Hilbert, K. Dahan
entre de Génétique Humaine, Institut de Pathologie et de
Génétique, Charleroi (Gosselies), Belgium
Non-invasive Prenatal Testing (NIPT) has been imple-
mented in many genetic labs for the screening of trisomies
of chromosomes 13, 18 and 21. More than 6000 samples
have been tested in our facility. Our workﬂow was not
validated to detect sex chromosome aneuploïdies but it can
reliably identify fetal sex. This experience lead to the
detection of 4 interesting clinical situations.
1. A male 46, XY fetus with an ambiguous female
phenotype by ultrasound. Because of this sexual ambiguity
and in utero growth retardation sequencing of DHRC7 was
performed. Two pathogenic mutations responsible for
Smith-Lemli Opitz syndrome were observed : c.452G>A (p.
Trp151*) and c.1190C>T (p.Ser397Leu) .
2. A suspicion of monosomy X (Turner) was reported
given negative Z-score values for X chromosome. At birth
baby’s karyotype was 100% 46, XX but mother’s karyotype
showed a mosaïcism 45×(28%) /46,XX (72%).
3. Another suspicion of monosomy X in a male fetus by
ultrasound. FISH analysis demonstrated the presence of
mosaicism in amniocytes with a mixture of 45,X cells
(20%) and male cells with an iso-chromosome Yp (80%).
4. A male 46, XY fetus with a non ambiguous female
phenotype by ultrasound. Further analysis showed that the
mother is carrier of a pathogenic mutation in exon 1 of the
androgen receptor gene (c.1421_1425dupAGGCG, p.
Gly476Argfs*5) transmitted to the fetus as well as to her 2
year old 46,XY daughter.
These results illustrate some of the incidental ﬁndings
which can be identiﬁed in the context of NIPT with an
adequate genetic follow-up.
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Optical mapping of enriched, megabase-sized DNA
molecules in nanodevices
J. Lopacinska-Jørgensen1, J. N. Pedersen2, M. Bak1, M.
Mehrjouy1, P. Østergaard2, A. Kristensen2, R. Taboryski2,
H. Flyvbjerg2, R. Marie2, N. Tommerup1, A. Silahtaroglu1
1University of Copenhagen, Copenhagen, Denmark, 2Tech-
nical University of Denmark, Kongens Lyngby, Denmark
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Despite the enormous progress in next-generation sequen-
cing (NGS), de novo assembly of genome sequence and the
detection of genomic structural variations (SVs) remain a
challenge. Single DNA molecule optical mapping, con-
sidered as a complementary technique to NGS, enables the
analysis of megabase-sized DNA molecules and is useful
for the detection of large-scale SVs. Sequencing and optical
mapping of a whole human genome is time consuming and
costly, and frequently only a speciﬁc genomic region is of
interest. Here, we present a method for selection and
enrichment of megabase-sized DNA molecules for single-
molecule optical mapping in nanodevices based on NotI
rare-cutting enzyme digestion and size-selection by pulsed-
ﬁeld gel electrophoresis. More than 600 sub-megabase to
megabase sized DNA molecules were recovered from the
gel and analysed by optical mapping in a nanodevice. Size-
selected DNA from the same gel were sequenced by NGS.
Both the molecules analysed by optical mapping and the
reads from NGS showed enrichment for long molecules
from regions deﬁned by the NotI recognition sites. The
method provides a low-cost option for investigation of SVs
in enriched human genomic regions, including SVs in
human diseases. We can identify molecules that ﬂank and
reach into the unannotated part of the genome, and thus
allow the visualization of these regions that are extremely
difﬁcult to analyse with other DNA sequencing methods.
Moreover, the method could be adapted to work with any
other genome or target other regions by applying multiple
restriction enzymes or other genomic editing tools, such as
the CRISPR/Cas9 system.
J. Lopacinska-Jørgensen: None. J.N. Pedersen: None.
M. Bak: None. M. Mehrjouy: None. P. Østergaard:
None. A. Kristensen: None. R. Taboryski: None. H.
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Off the street phasing (OTSP): Free no hassle haplotype
phasing for molecular PGD applications
G. Altarescu1, F. Zahdeh1, Y. Kling1, P. Renbaum1, E.
Levy-Lahad1, S. Carmi2, D. A. Zeevi1
1Medical Genetics Institute, Shaare Zedek Medical Center
(SZMC), Jerusalem, Israel, 2Braun School of Public Health
and Community Medicine, The Hebrew University of
Jerusalem, Jerusalem, Israel
Introduction: Parental phasing of mutation-ﬂanking hap-
lotypes is an essential, yet time-consuming, laborious, and
costly pre-requisite for preimplantation genetic diagnosis
(PGD) of monogenic disorders. Accordingly, the aim of this
study was to validate rapid, low cost, population-assisted
haplotype derivation in a pre-clinical setting.
Materials and Methods: Targeted sequencing of CFTR
variants and gene-ﬂanking polymorphic SNPs in 38 Jewish
individuals from 9 different PGD families was performed at
the SZMC PGD lab. Heterozygous genotype calls were
both trio-phased to obtain ground-truth haplotypes, and also
population-phased using Shapeit software. Reference panels
for population phasing were derived from either ‘1000
Genomes’ or from 128 or 574 sample Ashkenazi Jewish
whole genome sequences (kindly provided by The Ashke-
nazi Genome Consortium). Accuracy of resulting haplo-
types was benchmarked against trio-phased haplotypes. The
study population consisted of 4 subgroups as shown in
Table 1.
Results: Haplotype phase benchmarking results are
summarized in Table 1. In general, the 574 sample Ash-
kenazi genome reference was the most accurate and
appropriate for population-based phasing. Importantly, vir-
tually all phase errors in the FA group (and the PAWM
group, along a subregion of 3Mb) were traceable to low-
coverage sequencing errors in the ground-truth.
Discussion: These striking results indicate that it may
soon be possible to replace experimental haplotype phasing
with clinical “OTSP,” population-based phasing, provided
that one has access to an appropriate population-matched
reference dataset of sufﬁcient size.
Table 1
Study subgroup
(Abbreviation;
No. individuals)
1000 Genomes
Avg. No.
Heterozygous
SNPs per
individual
(+/-SEM)
1000
Genomes
Phasing
Accuracy
(+/-SEM)
128 Ashkenazi
Ref. Avg. No.
Heterozygous
SNPs per
individual
(+/-SEM)
128
Ashkenazi
Ref.
Phasing
Accuracy
(+/-SEM)
574 Ashkenazi
Ref. Avg. No.
Heterozygous
SNPs per
individual
(+/-SEM)
574
Ashkenazi
Ref.
Phasing
Accuracy
(+/-SEM)
Non-Ashkenazi
(NA;10)
589.4+/-66.2 71.0%
+/-4.2%
519.9+/-57.3 72.7%
+/-4.2%
579.4+/-62.3 84.9%
+/-3.3%
Partial
Ashkenazi no
CFTR
mutation
carriage
(PANM; 13)
544.5+/-35.9 73.1%
+/-4.3%
484.9+/-32.8 78.9%
+/-4.9%
547.8+/-34.7 86.7%
+/-5.2%
Partial
Ashkenazi
W1282X
Ashkenazi
mutation
carriage
(PAWM; 5)
741.2+/-48.7 70.9%
+/-4.0%
665.6+/-40.3 94.3%
+/-2.2%
732.8+/-47.0 91.4%
+/-5.3%
Full Ashkenazi
(FA; 10)
626.5+/-48.5 65.2%
+/-6.4%
559.4+/-42.0 88.4%
+/-5.5%
621.4+/-47.4 98.2%
+/-1.1%
G. Altarescu: None. F. Zahdeh: None. Y. Kling: None.
P. Renbaum: None. E. Levy-Lahad: None. S. Carmi:
None. D.A. Zeevi: None.
664
P14.075C
Automated patient matching from facial photos - initial
feasibility study Automated patient matching from facial
photos - initial feasibility study
N. Ekhilevitch1,2, T. Hershkovitz1, A. Kurolap2, M.
Steinberg1, H. N.Baris1,2, N. Fleischer3
1The Genetics Institute,Rambam Health Care Campus,
Haifa, Israel, 2The Ruth and Bruce Rappaport Faculty of
Medicine,Technion-Israel Institute of Technology, Haifa,
Israel, 3FDNA Inc., Boston, MA, United States
Introduction: The importance of matching patients for
diagnosis and gene discovery necessitates connecting clin-
icians and researchers from around the world. This is an
initial feasibility study to assess if the automated facial
recognition technology is able to provide connections
between undiagnosed patients with similar facial
phenotype.
Methods: We composed a survey of 53 pairs of possibly
matching facial photos of diagnosed, undiagnosed and
control patients, asked four geneticists to rate the similarity
between each pair and compared their results to the Patient
Matching technology of the Facial Dysmorphology Novel
Analysis (FDNA) algorithm. We used Pearson Correlation
coefﬁcient and the area under the curve (AUC) of the ROC
curve to assess correlations.
Results: Of the diagnosed pairs, the phenotype com-
parison performance of the FDNA technology (3.6 on
similar pairs, 3.25 on different pairs) and the geneticists (2.5
on similar pairs, 2.25 on different pairs) was comparable,
with a slight advantage to the technology. This trend is also
seen by AUC: 0.65 for the technology vs. AUC 0.51 for the
mean of the clinician’s answers. The overall agreement
level between the four geneticists is relatively low (mean
correlation 0.52).
Conclusions: The importance of the task and the com-
parable results is a strong motivator to continue with a
second stage of a feasibility study, with more photos, more
clinicians and without the intrinsic biases - familiarity of
geneticists with the patients. Future applications of this
technology could complement next generation sequencing
in undiagnosed patients and lead to the discovery of rare
novel syndromes
N. Ekhilevitch: None. T. Hershkovitz: None. A.
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Proteomic Peptide Screening of Dried Blood Spots: A
Potential Clinical Application
S. Hahn1,2, S. Jung2, R. Daiyuha2, J. Whiteaker3, L.
Zhao3, T. Torgerson1,2, W. A. Gahl4, A. Paulovich3
1University of Washington/Seattle Children's Hospital,
Seattle, WA, United States, 2Seattle Children's Hospital
Research Institute, Seattle, WA, United States, 3Fred
Hutchinson Cancer Research Center, Seattle, WA, United
States, 4National Human Genome Research Institute/NIH,
Bethesda, MD, United States
Background: Many proteins of great interest for NBS are
often in the low ng/mL range existing only inside the cells.
Recently, peptide immunoafﬁnity enrichment coupled to
SRM (immuno-SRM) has emerged as a promising techni-
que for the quantiﬁcation of low abundance proteins in
complex matrices such as dried blood spots (DBS). We
investigated the immuno-SRM methodology to determine
the concentrations of ATP7B protein in DBS from unaf-
fected and 13 Wilson disease (WD) patients and demon-
strated a possible screening for WD in newborns. Methods:
Several candidate peptides of each targeted protein for 11
primary immunodeﬁciencies, Wilson disease and Cystinosis
were screened by In Silico, BLAST search, then selected
based on detectability and response in LC-MS/MS analyses
followed by polyclonal/monoclonal antibody generation for
enrichment. We then analyzed these target peptides in DBS
using SRM mode with 6500 QTRAP (ABSCIEX) to
develop a high-throughput, multiplex assay. Results:
Cystinosin and three SHPK target peptides were absent in
two Cystinosis patients (57-kb del homozygotes). A mul-
tiplexed immuno-SRM assay was conﬁgured using
polyclonal-based antibodies targeting two to three peptides
from the three-targeted proteins (BTK, CD3e, and WASP).
Two BTK targeted peptides were absent or markedly
reduced in two XLA patients, while the other target peptides
designed to detect SCID, WAS in the XLA patients were
normal. Conclusions: We have demonstrated that extre-
mely low abundant proteins can be detected by immuno-
SRM analysis in complex samples such as DBS. When
multiplexed, there is a signiﬁcant potential to increase our
capacity to screen various congenital disorders lacking
speciﬁc protein markers.
S. Hahn: None. S. Jung: None. R. Daiyuha: None. J.
Whiteaker: None. L. Zhao: None. T. Torgerson: None.
W.A. Gahl: None. A. Paulovich: None.
Abstracts from the 50th European Society of Human Genetics Conference:. . . 665
P14.077A
New deep intronic mutation c.1029+384 A to G in
SERPING1 gene creates de novo donor splice site and
causes aberrant splicing
P. Hujová1, H. Grombiříková1, P. Souček1,2, L.
Grodecká1, B. Ravčuková1, P. Kuklínek3, R. Hakl3, T.
Freiberger1,2
1Molecular Genetics Laboratory, CKTCH, Brno, Czech
Republic, 2Medical Genomics, Central European Institute
of Technology, Masaryk university, Brno, Czech Republic,
3St. Anne's University Hospital, Brno, Czech Republic
Traditionally, the diagnostics of hereditary diseases is pri-
marily focused on detection of mutation in exons or
immediately ﬂanking regions of introns. However, the
occurrence of the cases with no detected mutations is not
unusual. The diagnostic process in these cases is very
variable and may include analyses at mRNA level and/or
applying next generation sequencing approach. In this
work, we have investigated a family diagnosed with her-
editary angioedema with no detected exonic or ﬂanking
intronic mutation in SERPING1 gene encoding C1 inhibitor
protein. Nevertheless, subsequent capillary analysis of the
blood-derived mRNA revealed a low abundant variant
prolonged by approximately 89 bp, which had not been
detected using standard gel electrophoresis. After intron
sequencing, mutation c.1029+384 A to G was found 384
bp downstream of the exon 6, which co-segregated with
HAE phenotype in all available family members. According
to in silico splicing analysis the mutation results in strong
donor splice site creation with possible subsequent pseu-
doexon activation. This hypothesis was conﬁrmed by
sequencing of the patient's cDNA using a speciﬁc primer
hybridizing to the predicted pseudoexon and independently
by a minigene analysis. The low amount of the aberrant
transcript variant may be explained by its degradation by a
natural mechanism called nonsense mediated decay. In
conclusion, these ﬁndings highlight the importance of
mRNA analysis and minigene assay as useful approaches in
diagnostics.
The study was supported by internal grant of the Centre
for Cardiovascular Surgery and Transplantation, number
201606.
P. Hujová: None. H. Grombiříková: None. P. Souček:
None. L. Grodecká: None. B. Ravčuková: None. P.
Kuklínek: None. R. Hakl: None. T. Freiberger: None.
P14.078B
Optimising next generation sequencing data analysis to
tackle pseudogene sequences in the PMS2 and PKD1
loci
K. De Leeneer1,2, T. Rosseel1, M. De Bleeckere1, X.
Leroy1, K. Claes1,2
1CMGG Ghent University Hospital, Ghent, Belgium, 2Can-
cer Research Institute Ghent (CRIG), Ghent, Belgium
Introduction: Pseudogenes are segments of DNA related to
real genes that have lost their ability to encode proteins. As
sequence homology between the pseudogenes and the par-
ental gene can be very high, such regions complicate
molecular diagnostics. Famous examples are the pseudo-
genes of PKD1 (involved in autosomal dominant polycystic
kidney disease) and PMS2 (associated with Lynch syn-
drome). For these genes several pseudogenes are described
with a sequence homology up to 98% for certain regions.
Materials and Methods: We optimized long range PCRs
with primers located in unique regions. All coding exons of
PKD1 and PMS2 are ampliﬁed in respectively 9 (ranging 2–
4kb) and 3 (9kb, 9kb and 18kb) reactions. The fragments
underwent Nextera XT library preparation and were
sequenced on a Miseq. Data for 80 PKD1 and 20
PMS2 samples were used to set up a reliable data analysis
workﬂow in CLCbio v7, detected variants are validated in
an independent NGS run. Results and conclusion: Applying
standard settings true sequence variants (n= 108) could be
easily distinguished from false positives (n= 22) in
PMS2 sequences. The PKD1 locus showed more variation
and it seems that in certain patients some co-ampliﬁcation
of pseudogene sequences occurs despite the use of gene-
speciﬁc primers. Literature suggests to retain variants with
VAFs of 20–30%. However, we found that in mosaic
mutations may be missed applying these cutoffs. Careful
visual inspection in combination with masking reads with
putative mutations may distinguish mosaicism from pseu-
dogene interferences.
K. De Leeneer: None. T. Rosseel: None. M. De
Bleeckere: None. X. Leroy: None. K. Claes: None.
P14.079C
DName barcodes allow absolute quality control of
genetic test processes based on NGS
H. Cuppens1, S. Dillen1, M. Jaspers2
1DName-iT, Leuven, Belgium, 2KULeuven, Experimental
Oto-rhino-laryngology Group, Leuven, Belgium
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Genetic tests based on next generation sequencing (NGS)
are complex and consist of many handling steps from
patient sampling to result, which can lead to errors (e.g.
sample switching and/or contamination). Genetic testing
labs take extreme measures to overcome errors and will
often process patient samples in duplicate to validate the
obtained results, amongst many other QC procedures.
However, this still does not guarantee 100% quality assur-
ance and comes with a considerable extra cost. We have
developed a powerful technology that provides quality
assurance throughout the entire genetic testing process. The
technology allows to economically produce over millions of
unique spiking DNA molecules (DName barcodes), which
are used only once. Proof of principle experiments illustrate
that these barcodes can be universally applied with respect
to the used DNA extraction method, NGS template pre-
paration method and NGS platform, and detect sample
switching and allows detection of contaminations. Different
unique barcodes can be added at different time points in a
genetic test process, such as at the time of blood collection,
after DNA extraction before NGS sequencing, so that
quality assurance problems can be traced to different sub
processes in a genetic test process. NGS testing can thus be
outsourced, while retaining full control of the process. The
unique quality assurance properties of these barcodes will
boost the reliability of genetic tests while maintaining
patient conﬁdentiality. Furthermore, it will help to unleash
the unprecedented informative power of NGS by improving
accuracy, ﬁdelity and automation of genetic test processes
at a reduced cost.
H. Cuppens: A. Employment (full or part-time); Sig-
niﬁcant; DName-iT. E. Ownership Interest (stock, stock
options, patent or other intellectual property); Signiﬁcant;
DName-iT. S. Dillen: A. Employment (full or part-time);
Signiﬁcant; DName-iT. M. Jaspers: None.
P14.080D
Check your cultures! Identiﬁcation of genetic instability
through karyotyping
U. A. Mau-Holzmann1, B. Schmid2, J. Osorio3, N.
Schwarz4, O. Riess1; University of Tuebingen, Institute for
Medical Genetics and Applied Genomics, Tuebingen,
Germany, 2Danish Technological University, Bioneer A/S,
Hoersholm, Denmark, 3University of Copenhagen -
Center for Basic and Translational Neuroscience -
Division of Cell and Gene Therapy, Copenhagen,
Denmark, 4University of Tuebingen, Hertie Institute for
Clinical Brain Research, Dpt. of Neurology and
Epileptology, Tuebingen, Germany
Many useful guides and guidelines exist for those working
with cell cultures to be aware of contamination with
microorganisms, phenotypic and genetic instability or even
cell-line misidentiﬁcation. A lot of these problems are
avoidable with the nescessary foresight. Though, simple
rules are frequently ignored. With depressing regularity
retraction or modiﬁcation of these data is seen.
Among the problems that continue to affect cell culture,
genetic instability is an important mosaic stone. Depending
on the cell type (senescent or immortal cell lines, human or
not human, iPSC, cancer cell lines) the chromosomal con-
tent can be euploid, aneuploid (abnormal chromosome
content) and heteroploid / mosaic (variable chromosome
content within the population). Aneuploidy, heteroploidy or
even special structural aberrations can be typical for speciﬁc
cell lines. The latter can be very useful for authentication.
Descendents of normal lines or iPSC lines usually are
euploid. Anyway, pluripotent stem cell lines (i.e. iPSCs),
which are usually clonal in origin, are well known to be
susceptible to developing chromosomal changes. Therefore,
they need to be periodically karyotyped.
The primary purpose of this poster is to increase
awareness for genetic instability to those new in the ﬁeld
and those engaged in teaching and instruction. Results of
conventional karyotyping (which has the advantage to
detect balanced structural aberrations compared to array
technologies) of different cell types and cell lines will be
presented.
U.A. Mau-Holzmann: None. B. Schmid: None. J.
Osorio: None. N. Schwarz: None. O. Riess: None.
P14.081A
The importance of External Quality Assessment for a
molecular diagnostic center: the experience of a Brazi-
lian Cancer Reference Center
G. C. Fernandes, A. E. de Paula, C. S. Sabato, R. M. Reis,
E. I. Palmero; Barretos Cancer Hospital, Barretos, Brazil
Introduction: The Barretos Cancer Hospital (BCH) is a
Brazilian reference cancer center, offering genetic testing to
patients and relatives at-risk for hereditary cancer predis-
position syndromes (HCPS).
Methodology: Genetic tests are performed using labora-
tory developed and validated methodologies (Sanger/NGS
sequencing and MLPA). Since 2011, the Molecular Diag-
nostics Center (MDC) of BCH has participated annually in
the EMQN External Quality Assessment (EQA) schemes
(BRCA, FAP, HNPPC, VHL schemes).
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Results: Hitherto, over 3,200 individuals from 1,600
families with criteria for HCPS have been referred for
genetic testing, including 742 families tested for BRCA1/2
genes (25% mutated), 125 for APC/MUTYH (50% muta-
ted), 478 for TP53 (15% mutated). 344 HNPCC families
have received MSI/IHC screening, and 99 of them went on
to have genetic testing (61% mutated). Furthermore, CDH1/
PTEN/CHEK2/RET tests are also offered. Since participat-
ing in the EMQN-EQA schemes, we have observed a ﬁve-
fold increase in the number of tests performed, not only
from BCH patients, but also from other Brazilian hospitals
and private laboratories. In addition, we have been able to
raise awareness of the importance of verifying/certifying the
quality of tests offered nationally, and making participation
in EQA schemes a mandatory requirement for all Brazilian
genetic laboratories/centers.
Conclusions: Participation in EQA programs has resul-
ted in a signiﬁcant improvement in the quality of our
genetic test results and reporting. In addition, it brought
national visibility to the center and enabled other Brazilian
centers to see the importance of participating in EQA as a
tool for benchmarking performance and improving test
quality.
G.C. Fernandes: None. A.E. de Paula: None. C.S.
Sabato: None. R.M. Reis: None. E.I. Palmero: None.
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Quality Sequencing Metric (QSM) a concise, transpar-
ent, description of NGS data quality
S. Mahamdallie, E. Ruark, S. Yost, M. Munz, E. J.
Ramsay, I. M. Uddin, H. Wylie, A. Elliott, S. Seal, A.
Strydom, N. Rahman; nstitute of Cancer Research,
London, London, United Kingdom
Consistent, transparent NGS data analysis is essential for
research and clinical applications. Conventional descrip-
tions typically give basic summary information, e.g. the
average coverage across the target. This is inadequate for
clinical requirements and many research settings. More
comprehensive quality information, available per base, is
typically required. However, it is also essential that the
information can be compared across platforms, which
requires common standards and a transparent, easy-to-use,
easy-to-understand notation. Here we describe the QSM, a
quality sequencing metric that aims to achieve these
objectives. The QSM includes information about coverage
(C), Base Quality (B) and Mapping Quality (M). This is
given per base, but can also be provided per target, or per
exon, as appropriate. For example, the QSM for small
variant detection in a pipeline will be given per base
whereas the QSM for exon CNV detection will be given per
exon. Importantly, fulﬁllment of the QSM can be assessed
directly from BAM ﬁles, allowing seamless integration in
NGS pipelines. As an example, the QSM for TruSight
Cancer Panel analysis in TGLclinical is C50B10M20. This
means that every base has minimum Coverage of ≥50 reads
with Base quality of ≥10 (in at least 85% of reads) and
Mapping quality of ≥20 (in at least 95% of reads). A fuller
description would be C50B1085M2095, to encompass the
proportion of reads that are required to meet the base and
mapping quality standards. The QSM allows comprehen-
sive, transparent information about quality thresholds of
NGS data, and could have broad utility.
S. Mahamdallie: None. E. Ruark: None. S. Yost:
None. M. Munz: None. E.J. Ramsay: None. I.M. Uddin:
None. H. Wylie: None. A. Elliott: None. S. Seal: None. A.
Strydom: None. N. Rahman: None.
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From Face to Gene - Identifying the Genotype of
RASopathies with FDNA
S. B. Kamphausen, M. Zenker; Institute of Human
Genetics, Magdeburg, Germany
Introduction: RASopathies comprise a group of disorders
caused by germline mutations in RAS-MAPK pathway
genes. Characteristic features are growth retardation, heart
defects and craniofacial dysmorphism. Facial Dysmor-
phology Novel Analysis technology (FDNA) was used to
deeply phenotype and objectively evaluate the craniofacial
features of RASopathy patients. We aimed to analyze the
ability of the technology to discriminate between the facial
phenotype associated with mutations in different genes.
Method: 256 images of 211 patients with mutations in
either one of the genes PTPN11, SOS1, BRAF, RAF1 and
RIT1 were analyzed by FDNA and grouped according to
the pathogenic gene. The mean area under the curve (AUC)
was used as a means of comparison between the samples
together with ROC curve plotting the true positive rate as
function of false positive rates. Binary as well as multiclass
analysis was conducted.
Results: Mean AUC results yielded high values with
relatively low STD, showing the best result for RIT1 and
the lowest for SOS1. The multiclass challenge is able to
assign the case to the correct gene out of ﬁve with a mean
accuracy result of 61% with low STD (5.9), which is
roughly three times bigger than the random chance accuracy
of 20%.
Discussion: Facial recognition technology that detects
dysmorphic features from 2D photographs holds the pro-
mise to assist in deep phenotyping of syndromic patients
and automatically associating these clinical ﬁndings with
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disease-causing genes. However, perfect recall is naturally
limited by the signiﬁcant overlap within a clinically and
pathogenetically related group of genetic entities.
S.B. Kamphausen: None. M. Zenker: None.
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Analysis of 477 systematic Sanger sequencing valida-
tions of NGS identiﬁed variants
R. Sanchez-Alcudia, M. Martinez-Garcia, N. Sanchez-
Bolivar, C. Rodriguez, D. Rodriguez, I. Diez, M. Peña-
Vilabelda, G. Benito, M. Carcajona, P. Maietta, J. C.
Cigudosa, J. Botet, S. Alvarez; IMGenetics S.L., Madrid,
Spain
Introduction: The NGS technologies that have revolutio-
nized genetic diagnostic are expecting to be generally
implemented in clinical practice. The role of routine Sanger
validation of NGS variants is actually under consideration.
A proposal, speciﬁc for each technology, about which
variants should be systematically evaluated, is necessary.
Material and Methods: We have analysed by Sanger
sequencing a total of 477 variants (48 indels and 429 mis-
sense), with 302 unique changes, identiﬁed in exome ana-
lysis (Ion AmpliSeqTM Exome RDY, Ion ProtonTM/Ion
S5TM) of patients with a variety of genetic disorders.
Sanger sequencing was used to validate all variants classi-
ﬁed as pathogenic or probably pathogenic. Additionally,
variants located in homoplymeric, repetitive regions and/or
variants located in low coverage regions were also analysed.
Results: Sanger sequencing results conﬁrmed 462 out of
477 variants (97%) identiﬁed on the exome analysis. All
SNVs not located in homoplymeric or repetitive regions
with a coverage >20x and an heterozygous ratio >40%,
were validated. Non-validated variants presented: (i) low
coverage (<20×) (n= 8), (ii) heterozygous ratio < 20% (n
= 3), and/or (iii) they were mainly located in homo-
polymeric or repetitive regions (n= 4).
Conclusions: Reported results show that Sanger con-
ﬁrmation should be considerer in all variants with low
coverage (<20×), heterozygous ratio <20% and/or variants
located in homopolymeric or repetitive regions. According
to these results and in concordance with previous studies,
systematic evaluation of Sanger validation in clinical prac-
tice should be restricted to variants with speciﬁc features.
Validation criteria should be established based on the NGS
selected approach.
R. Sanchez-Alcudia: None. M. Martinez-Garcia:
None. N. Sanchez-Bolivar: None. C. Rodriguez: None. D.
Rodriguez: None. I. Diez: None. M. Peña-Vilabelda:
None. G. Benito: None. M. Carcajona: None. P. Maietta:
None. J.C. Cigudosa: None. J. Botet: None. S. Alvarez:
None.
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Elucidating of novel genetic causes: Exome sequencing
at the Center of Rare Diseases Lübeck, Germany
K. Lohmann, S. Tunc, N. Brüggemann, G. Gillessen-
Kaesbach, C. Klein, A. Münchau; University of Luebeck,
Luebeck, Germany
Background: Rare diseases are deﬁned by a prevalence of
<5/10,000 persons. However, a large number of different
rare diseases affects millions of people. Notably, ~80% of
rare diseases are thought to have a genetic origin. We here
present data from an exome-sequencing project conducted
in 2015–2016 which included ~100 patients. Methods:
After careful clinical phenotyping and exclusion of 1–5
candidate genes, patients and, if available, their parents
were exome-sequenced. We analyzed 20 parent-offspring
trios, 12 quadros (two affected siblings and unaffected
parents), 3 duos (affected offspring, one parent), and
54 single samples. Results: Most of the patients had a
movement disorder with features of dystonia, parkinsonism,
ataxia, or spasticity, possibly combined with intellectual
disability. We identiﬁed novel mutations in 14 established
disease genes including ANK3, ATCAY, CACNA1A,
ECEL1, MCOLN1, MT-TK, PANK2, PLA2G6, PNPLA6,
PNPT1, POLG, SACS, SPG11, SYNGAP1, often with an
extension of previously described phenotypic features. In
addition, we detected novel mutations in recently described
disease genes such as CAPN1, GNB1, KMT2B, TMEM230,
and VAC14. For some of the mutations, functional investi-
gations were performed and demonstrated altered func-
tionality for many but not all variants. The diagnostic yield
in our study was 40–50% for trios and quadros but <10% in
exomes of single patients. Conclusions: Exome sequencing
is a useful tool to dissect the likely genetic cause in rare
diseases and should be established in standard diagnostics.
Currently, interpretation of the data poses the greatest
challenge, particularly for variants of unknown signiﬁcance
requiring functional characterization. Funding: Dys-
TRACT, DFG, UKSH foundation
K. Lohmann: None. S. Tunc: None. N. Brüggemann:
None. G. Gillessen-Kaesbach: None. C. Klein: F. Con-
sultant/Advisory Board; Modest; Centogene AG. A.
Münchau: None.
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AUTOMATED APPROACH FOR RAPID AND
ACCURATE SNP GENOTYPING
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S. Bauer1, L. Linz2, A. Kolb2; LGC, Hoddesdon, United
Kingdom, 2LGC, Alexandria, MN, United States
Improvements to next-generation sequencing technologies
have enabled extensive discovery of single nucleotide
polymorphisms (SNPs) in numerous organisms. Due to
their large numbers and genome-wide distribution, SNPs
are the molecular marker of choice in plant, animal, and
human genetic research. As the discovery of SNP markers
continues to expand, there is a need for a more efﬁcient
method for routine genetic analysis. The IntelliQube® real-
time qPCR instrument in conjunction with BHQplus®
probe-based SNP genotyping assays provides an effective
solution to address this need. BHQplus probes incorporate
duplex-stabilizers allowing enhanced binding stability,
enabling compact probe sequences with excellent mismatch
discrimination. Utilizing Array Tape® technology, the
IntelliQube integrates liquid handling with qPCR analysis
in miniaturized reaction volumes. In this study, we assess
the performance of custom BHQplus genotyping assays run
in a duplex fashion using fast thermal cycling protocols.
Accuracy and reproducibility of this platform was assessed
using puriﬁed gDNA samples from cell lines obtained from
the NIGMS Human Genetic Cell Repository at the Coriell
Institute for Medical Research. Genotype results were
compared to previously published literature. The results
demonstrate that the IntelliQube, when used in conjunction
with BHQplus assays, provides an accurate and streamlined
real-time PCR-based method for genetic analysis.
S. Bauer: None. L. Linz: None. A. Kolb: None.
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Impact of probe density in single nucleotide poly-
morphism arrays (SNP-Array) tests for the detection of
genomic alterations
C. L. Clozato, E. D. R. P. Velloso, R. M. Minillo, C. L. P.
Mangueira, R. Sitnik; Sociedade Beneﬁcente Israelita
Brasileira Albert Einstein, São Paulo, Brazil
Background: SNP-Array is a molecular cytogenetics assay
that genotypes DNA at thousands of SNPs across the gen-
ome simultaneously and detects copy number variation
(CNVs), loss of heterozygosity (LOH) and low level
mosaicism. Commercial SNP-array platforms vary in probe
density, which impacts costs, but alters test sensitivity. We
compared the results of two Affymetrix assays, Cytoscan
HD (2.6 million probes) and Cytoscan 750k (750,000
probes) in selected patients. Methods: 13 patients presenting
developmental delay and dysmorphisms with known pre-
vious results from KT/MLPA, FISH or CGH-Array were
analyzed. Genomic alterations tested are shown in Table 1.
Cytoscan HD was performed for all patients. Raw data from
Cytoscan HD was used to simulate Cytoscan 750k data.
Results between platforms were compared. Results:
Cytoscan HD reproduced previous results, regardless the
alteration size. Cytoscan 750k reproduced most results,
except from patient T_4 (7.6%), with the smallest alteration
tested: arr[hg19]9q34.3(140,651,785–140,659,056)x1 (7
kbp). Cytoscan HD contained 17 markers in this region,
while 750k contained none. Two RefSeq genes (EHMT1,
FLJ40292) were deleted. Region 9q34.3 encompasses gene
EHMT1, associated with Kleefstra syndrome (OMIM
#610253), a recognizable mental retardation syndrome
among other phenotypical features, which matched the
patient’s clinical indication. Conclusion: Lower probe
density may hinder identiﬁcation of small genomic altera-
tions, despite being a rare event. Overall, Cytoscan 750k is
able to identify correctly most alterations with comparable
results to that of Cytoscan HD.
Table 1 Genomic alterations for each sample used in this
study.
SampleGenomic Alteration Size
(kbp)
N°
Markers
in HD
N°
Markers
in 750k
T_1 arr5p15.33p15.1
(113,576–15,525,664)
x1
15412 18836 3844
T_2_a arr18q21.32q23
(56,315,322–
78,014,123)x1
21699 18756 5555
T_2_b arr15q11.2
(22,770,421–
23,286,507)x3
516 784 281
T_3 arr4p16.1(9,501,60–
9,953,835)x3
452 400 119
T_4 arr9q34.3
(140,651,785–
140,659,056)x1
7 17 N/A
T_5 arr14q11.2
(22,855,144–
22,940,138)x1
85 100 15
T_6_a arr21q22.12
(35,944,343–
37292,915)x1
1349 2876 860
T_6_b arr16p11.2p11.1
(34,449,594–
34,755,816)x3
306 176 64
T_7_a arr8p23.3q24.3
(158,048–146,295,771)
x3(0.7)
146138125254 35590
670
T_7_b arr5p12p11
(45,365,046–
46,365,391)x3
1000 712 235
T_8 arr5p14.2p14.1
(23,909,889–
24,990,295)x1
1098 712 194
T_9_a arr7p22.3q36.3
(43,360–159,119,707)
x1
159076153640 42417
T_9_b arr1q21.3q22
(154,567,653–
155,322,846)X1
755 664 224
T_9_c arr2p25.3p16.2
(12,770–54,147,279)x3
54135 50004 14343
T_9_d arr2q24.1q24.2
(159,644,037–
159,947,059)x3
303 258 65
T_10 arrXp22.33q28
(168,546–155,230,271)
x1
155062189800 43954
T_11 arr16p11.2
(29,628,661–
30,177,807)x1
549 393 393
T_12 arr16p11.2
(29,421,694–
30,240,227)x3
819 452 188
T_13 arr21q11.2q21.3
(15,381,880–
30,421,277)x1
15039 12605 3542
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Screening for causative structural variants in neurolo-
gical disorders using long-read sequencing
J. Ekholm1, S. Kujawa1, Y. Tsai1, D. Greenberg1, T. Hon1,
K. Eng1, A. Wenger1, E. Tseng1, J. Wang2, M. Jarosz2, K.
Giorda2, T. Clark1; Paciﬁc Biosciences, Menlo Park, CA,
United States, 2Integrated DNA technologies, Coralville,
IA, United States
Over the past decades neurological disorders have been
extensively studied producing a large number of candidate
genomic regions and candidate genes. The SNPs identiﬁed
in these studies rarely represent the true disease-related
functional variants. However, more recently a shift in focus
from SNPs to larger structural variants has yielded break-
throughs in our understanding of neurological disorders.
Here we have developed candidate gene screening
methods that combine enrichment of long DNA fragments
with long-read sequencing that is optimized for structural
variation discovery. We have also developed a novel,
ampliﬁcation-free enrichment technique using the CRISPR/
Cas9 system to target genomic regions.
We sequenced gDNA and full-length cDNA extracted
from the temporal lobe for two Alzheimer's patients for 35
GWAS candidate genes. The multi-kilobase long reads
allowed for phasing across the genes and detection of a
broad range of genomic variants including SNPs to multi-
kilobase insertions, deletions and inversions. In the full-
length cDNA data we detected differential allelic isoform
complexity, novel exons as well as transcript isoforms. By
combining the gDNA data with full-length isoform char-
acterization allows to build a more comprehensive view of
the underlying biological disease mechanisms in Alzhei-
mer’s disease. Using the novel PCR-free CRISPR-Cas9
enrichment method we screened several genes including the
hexanucleotide repeat expansion C9ORF72 that is asso-
ciated with 40% of familiar ALS cases. This method
excludes any PCR bias or errors from an otherwise hard to
amplify region as well as preserves the basemodication in a
single molecule fashion which allows you to capture
mosaicism present in the sample.
J. Ekholm: A. Employment (full or part-time); Sig-
niﬁcant; Paciﬁc Biosciences. E. Ownership Interest (stock,
stock options, patent or other intellectual property); Sig-
niﬁcant; Paciﬁc Biosciences. S. Kujawa: A. Employment
(full or part-time); Signiﬁcant; Paciﬁc Biosciences. E.
Ownership Interest (stock, stock options, patent or other
intellectual property); Signiﬁcant; Paciﬁc Biosciences. Y.
Tsai: A. Employment (full or part-time); Signiﬁcant; Paciﬁc
Biosciences. E. Ownership Interest (stock, stock options,
patent or other intellectual property); Signiﬁcant; Paciﬁc
Biosciences. D. Greenberg: A. Employment (full or part-
time); Signiﬁcant; Paciﬁc Biosciences. E. Ownership
Interest (stock, stock options, patent or other intellectual
property); Signiﬁcant; Paciﬁc Biosciences. T. Hon: A.
Employment (full or part-time); Signiﬁcant; Paciﬁc Bios-
ciences. E. Ownership Interest (stock, stock options, patent
or other intellectual property); Signiﬁcant; Paciﬁc Bios-
ciences. K. Eng: A. Employment (full or part-time); Sig-
niﬁcant; Paciﬁc Biosciences. E. Ownership Interest (stock,
stock options, patent or other intellectual property); Sig-
niﬁcant; Paciﬁc Biosciences. A. Wenger: A. Employment
(full or part-time); Signiﬁcant; Paciﬁc Biosciences. E.
Ownership Interest (stock, stock options, patent or other
intellectual property); Signiﬁcant; Paciﬁc Biosciences. E.
Tseng: A. Employment (full or part-time); Signiﬁcant;
Paciﬁc Biosciences. E. Ownership Interest (stock, stock
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grated DNA technologies. K. Giorda: A. Employment (full
or part-time); Signiﬁcant; Integrated DNA technologies. T.
Clark: A. Employment (full or part-time); Signiﬁcant;
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When solo diagnostic exomes fail: parent's sequencing
added-value
F. Tran Mau Them1,2, A. Vitobello1, A. Bruel1, J.
Thevenon1,2, E. Tisserant1, D. Lehalle1,2, N. Jean2, M.
Assoum1, V. Carmignac1, C. Poe1, T. Jouan1, M.
Chevarin1, S. Moutton2, N. Houcinat2, A. Mosca-
Boidron3, P. Callier3, C. Philippe1,3, Y. Duffourd1, L.
Faivre2,1, C. Thauvin-Robinet1,2
1INSERM UMR 1231, équipe de génétique des anomalies
du dévelopement (GAD), CHRU Dijon, Dijon, France,
2Centre de référence Anomalies du Développement et
Syndromes Malformatifs, CHU Dijon, Dijon, France,
3Laboratoire de génétique, Plateau Technique de Biologie,
CHU Dijon, Dijon, France
Background: Advent of next generation sequencing and in
particular whole-exome sequencing (WES) has helped
resolving many Mendelian diseases.However, clinical WES
does not identify the disease cause in approximately 70% of
patients. WES pitfalls have emerged namely that candidate
variations might not be in exons or that copy number var-
iations and structural variations are poorly detected.
Accordingly, whole-genome sequencing might increase
diagnostic yield. However, the presence of disease causing
variant(s) in exon of genes not yet involved in human dis-
eases remains the most likely hypothesis.
Methods: To evaluate this hypothesis, we secondarily
sequenced the parents after negative clinical solo-WES
strategy in 8 selected individuals with syndromic develop-
ment disorders and diagnostic odyssey. Bioinformatics
analyses following a trio strategy allowed to efﬁciently ﬁlter
de novo variants and candidate variations were intensively
shared with the Matchmaker Exchange system.
Results: Trio-WES strategy allowed identiﬁcation of de
novo likely pathogenic variants in a new candidate gene in
at least 2/8 patients. Gene matching permitted to gather
enough additional affected individuals with a similar phe-
notype to conclude towards a new disease-causing gene. In
one patient, a de novo variant of unknown signiﬁcance has
been identiﬁed in a new candidate gene and gene matching
is in progress.
Conclusion: Trio-WES combined with intense data
sharing seems to be a valuable strategy as a second step
after negative diagnostic solo-WES in patients with diag-
nostic odyssey, before WGS would be routinely available in
clinical practice. This strategy allowed identiﬁcation of new
causing genes in at least 25% of this small series.
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Improvement of the molecular diagnostics in tuberous
sclerosis complex (TSC) by NGS deep sequencing of the
entire TSC genes and inclusion of mTOR pathway genes
K. Mayer, M. Scholz, V. Hasselbacher, T. Tolj, J. Schulz,
D. Becker, M. Ziegler, Y. Dincer, I. Rost; enter for Human
Genetics and Laboratory Diagnostics (AHC), Martinsried,
Germany
Conventional molecular genetic testing consisting of Sanger
sequencing and deletion/duplication analysis of theTSC1
and TSC2 coding regions during the past 20 years detected
pathogenic variants in about 85% of patients with a deﬁnite
clinical diagnosis TSC. In the remaining “no mutation
identiﬁed (NMI)” cases the presence of low level mosaicism
and regulatory variants in both TSC genes or variants in
other genes leading to TSC-like phenotypes may have
escaped mutation detection.
We reanalysed TSC NMI patients by resequencing the
entire genomic regions of TSC1 and TSC2 applying deep
Next Generation Sequencing (NGS). A custom designed
target enrichment applying the Agilent SureSelect technol-
ogy covered 65.000 bp TSC1 and 46.000 bp TSC2 genomic
sequence and the coding regions of 13 additional genes of
the mTOR signalling pathway. Furthermore, routine diag-
nostics was converted to hybridization based enrichment
and Illumina NGS technology for the coding regions of
both TSC genes.
In a series of 25 NMI patients, deep resequencing iden-
tiﬁed pathogenic TSC2 variants in 11 cases (44%). These
included 4 mosaic variants in the coding region/canonical
splice sites, 4 heterozygous deep intronic variants, 2 mosaic
deep intronic variants and one mosaic genomic deletion.
Additionally, revised routine NGS diagnostics of TSC
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genes in 29 patients detected 3 additional mosaic coding/
splice site variants (10%). Interestingly, two patients with
uncovered pathogenic variants in mTOR pathway genes
(mTOR and DEPDC5) presented with additional clinical
features like complex focal epilepsy, cataract and hemi-
megalencephaly therefore supporting that mutations in these
genes are not a cause of “classic” TSC phenotypes.
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UDPICS, a laboratory-medical informatics system for
translational research in the NIH Undiagnosed Diseases
Program
Z. M. Valivullah, S. Sadozai, G. Yu, D. D. Draper, D. M.
Davis, D. R. Adams, W. A. Gahl; NIH Undiagnosed
Diseases Program, National Human Genome Research
Institute, Bethesda, MD, United States
Introduction:
The Undiagnosed Diseases Program (UDP) is a transla-
tional medicine initiative based in the NIH Clinical Center
which aims to diagnose patients with mysterious conditions
and study unique and rare genetic disorders. The program
has received over 10,000 inquiries, reviewed 3,500 appli-
cations, and seen almost 900 patients. Patient presentation is
heterogeneous and our evaluation process initially treats
each patient as independent. Therefore, managing patient
and research data became increasingly difﬁcult after the ﬁrst
years of the UDP.
Materials and Methods:
To allow clinicians and researchers to seamlessly colla-
borate on UDP cases, we built a web-based workﬂow
management system called the Undiagnosed Diseases Pro-
gram Integrated Collaboration System (UDPICS). The
system is based on a commercial Ruby on Rails platform,
which we expanded and customized for translational
research. UDPICS integrates external biobanking, model
organism, and genome analysis systems for easy access.
Furthermore, we incorporated the open source tool Pheno-
Tips for ontological patient phenotyping and Phenogrid for
phenotype-genotype comparisons in humans and model
organisms.
Results:
UDPICS has allowed us to track patients and associated
research from application to followup. Beneﬁts of the sys-
tem include rapid transit of records and tasks, reduced error
in workﬂows, and ease of collaboration.
Conclusions:
By implementing complex process management, geno-
mic analysis, biospecimen management, ontological phe-
notyping, and electronic laboratory notebooks, UDPICS has
become a scalable collaborative workspace for research,
clinical, and bioinformatics staff. The system is a mechan-
ism for efﬁcient, transparent, and scalable translational
research and addresses many of the scientiﬁc and logistical
problems of the NIH UDP.
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Diagnostic exome sequencing of Danish families with
rare genetic diseases
J. Ek, L. Risom, E. Østergaard, M. Dunø; niversity
Hospital Copenhagen, Copenhagen, Denmark
Introduction: The advancement in DNA sequencing has in
recent years highly increased the likelihood of identifying
causative variants among patients with various disorders.
Whole Exome Sequencing (WES) facilitates an unbiased
screening for genetic defects. We have implemented WES
for the genetic work-up of patients primarily under suspi-
cion for neurological and mitochondrial disorders, or com-
plex syndromes involving intellectual disability.
Materials and methods: This is a retrospective study of
in-house whole exome sequencing conducted at the
Department of Clinical Genetics at Copenhagen University
and includes more than 100 probands and their families. All
the patients/families were prior to analysis thoroughly
assessed by medical specialists and counselled by a clinical
geneticist, in order to provide detailed and complete clinical
information, aiding variant classiﬁcation.
Results: Causative mutations were identiﬁed in approx.
35% of the patients. One ﬁfth of the mutations had arisen de
novo or was found in mosaic form in one parent. Approx.
75% of the identiﬁed mutations were absent from the lit-
erature and common mutation databases, i.e. novel
mutations.
Conclusion: In this study, WES facilitated a genetic
diagnosis in approx. 35% of patient with complex aetiolo-
gies. The tight collaboration and discussions between clin-
icians and laboratory scientists is instrumental in reaching a
conclusive diagnosis. WES will move to the forefront of
genetic work-up and become the ﬁrst tier analysis for dis-
orders of complex aetiology. Most likely, this will result in
an even higher diagnostic yield of WES, when it is used in
the initial screening in patients with suspected genetic
disorders.
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Clinical exome sequencing as a powerful tool for the
diagnosis of complex phenotypes
E. Yucel1, S. Eraslan1, U. Altunoglu2, A. Bertoli-Avella3,
A. Rolfs3, H. Kayserili4
1Koc University Hospital, Istanbul, Turkey, 2Istanbul
Faculty of Medicine, Istanbul, Turkey, 3Centogene AG,
Rostock, Germany, 4Koc University, Istanbul, Turkey
Introduction: Complex phenotypes, manifested by a col-
lection of clinical ﬁndings pertaining to complex multi-
system disorders, constitute one of the most challenging
cases in the diagnostic ﬁeld. Clinical whole exome
sequencing (WES), which has now been increasingly
adopted to diagnose single-gene disorders, is also a pow-
erful tool for complex phenotypes lacking a deﬁnitive
diagnosis. Materials and Methods: Samples were prepared
using the Nextera Capture System (Illumina, San Diego,
CA) and the enriched exome libraries were sequenced using
paired-end, 300-cycle chemistry on the Illumina NextSeq or
HiSeq (Illumina, San Diego, CA). Results: Three trio-WES
were performed for three probands with their families. One
case was diagnosed with Sanﬂippo syndrome along with
ichthyosis vulgaris, with a new mutation in FLG gene. In
the second case, new likely pathogenic mutations were
detected in PIGO and TGFB2 genes, with the diagnoses of
hyperphosphatasia with mental retardation and Loeys-Dietz
syndromes for the proband. For the ﬁnal case, two muta-
tions which had already been deﬁned as pathogenic were
co-located in the proband, in SLC5A2 and MMAB genes,
rendering the diagnoses of renal glucosuria and methyl-
malonic aciduria, type cbIB possible for her. Conclusions:
This study demonstrates the utility of diagnostic exome
sequencing in the context of complex phenotypes resulting
from two underlying pathogenic genetic alterations, which
would otherwise elude discovery (i.e. with traditional
single-gene testing methods) and offers hope to those
patients who do not exhibit a classic disease phenotype.
This study is founded by TUBITAK-112S398 (ERA-Net
consortium, CRANIRARE2). Acknowledgement: Cen-
togene AG, Germany
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Clinical WES quality assessment scheme shows oppor-
tunities for improvement and harmonization: a national
collaborative study of the Dutch Society for Clinical
Genetic Laboratory Diagnostics (VKGL)
M. G. Elferink1, I. Nijman1, M. A. Haagmans2, A. H. B.
Bollen3, R. W. W. Brouwer4, B. de Koning5, L. F.
Johansson6, D. van Beek7, O. R. Mook2, M. van
Slegtenhorst8, S. Stegmann5, B. Sikkema-Raddatz6, M.
Nelen9, Q. Waisﬁsz7, M. M. Weiss7, J. D. H. Jongbloed6,
N. van der Stoep3, K. L. I. van Gassen1; Department of
Genetics, University Medical Centre Utrecht, Utrecht,
Netherlands, 2Department of Clinical Genetics, Academic
Medical Centre, Amsterdam, Netherlands, 3Department of
Clinical Genetics, Leiden University Medical Centre,
Leiden, Netherlands, 4Center for Biomics, Erasmus
Medical Centre, Rotterdam, Netherlands, 5Department of
Clinical Genetics, University Medical Centre Maastricht,
Maastricht, Netherlands, 6Department of Genetics,
University Medical Centre Groningen, Groningen,
Netherlands, 7Department of Clinical Genetics, VU
University Medical Centre, Amsterdam, Netherlands,
8Department of Clinical Genetics, Erasmus Medical
Centre, Rotterdam, Netherlands, 9Department of Human
Genetics, Radboud University Medical Center, Nijmegen,
Netherlands
Clinical whole exome sequencing (WES) has proven to be
very effective for diagnosing heterogeneous genetic dis-
eases, and has therefore been adopted in standard Dutch
genetic diagnostic services. Quality standards have been
published for gene panel based Next Generation Sequen-
cing, but for WES these have not been determined yet. Goal
of this study is to deﬁne quality standards for WES and to
enable laboratories to improve and harmonize quality. The
exome of Genome in a Bottle (GIAB) sample NA12878
was sequenced and processed by all Dutch genetic diag-
nostic centers according to their standard diagnostic proto-
cols. Anonymized VCF and BAM ﬁles were collected and
used for comparisons. VCF ﬁles were used to calculate
variant detection sensitivity using the GIAB high con-
ﬁdence call set. BAM ﬁles were used to calculate infor-
mative exome coverage statistics based upon a standardized
target deﬁned by all coding exons of UCSC and Ensembl
+/- 20bp intron ﬂanks. Results showed that single nucleo-
tide variant (SNV) detection sensitivity varied between 93%
and 99% (average 97%) and that INDEL detection sensi-
tivity varied between 73% and 96% (average 88%). Exome
coverage at ≥15x varied between 80% and 96% (average
92%). Precision of SNV detection was not substantially
different, but varied between 75% and 97% (average 91%)
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for INDEL detection. These results show a relatively vari-
able variant detection sensitivity and exome coverage
between Dutch genetic diagnostic centers. We will present
quality standards and guidelines to harmonize WES quality
between laboratories. These efforts will enable optimal and
standardized patient care within the Netherlands.
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Whole exome sequencing in rare syndromes using
family trios - Clinical experience and outcome
K. Lagerstedt-Robinson, B. Anderlid, A. Nordgren, M.
Kvarnung, A. Lindstrand, G. Grigelioniene, E. Tham, P.
Gustavsson, D. Nilsson, M. Nordenskjöld, H. Malmgren;
Department of Molecular Medicine and Surgery,
Karolinska Institutet and Department of Clinical Genetics,
Karolinska Univ Hospital, Stockholm, Sweden
Exome sequencing in trios is becoming a common mole-
cular diagnostic tool for rare genetic disorders.
At Clinical Genetics, Karolinska University Hospital,
clinical trio exome sequencing has increased tenfold from
2012 - 2016. In total, trio exome sequencing and analysis
has been ﬁnalized for 254 patients with undiagnosed, sus-
pected rare genetic conditions. Data was analyzed for
sequence variants consistent with Mendelian traits. In gen-
eral CGH-array and, when indicated, FRAXA analyses had
been performed on the patients prior to exome analysis.
Of the 254 cases, the molecular diagnosis rate was 36%.
De novo heterozygote sequence variants were the most
prevalent causes of genetic disorder, 54%. Sequence var-
iants consistent with autosomal recessive inheritance were
detected in 30% and X-linked recessive inheritance in 11%
of the cases. In ﬁve cases, an autosomal dominant inherited
sequence variant was identiﬁed - this can be explained by a
known dominant trait or variable expressivity. Most patients
were referred regarding intellectual disability and/or a
syndromic phenotype. The spectrum of affected genes
varied. The only genes affected in three or more of our
patients were GRIN2B and ANKRD11. The different
detected genetic diagnoses are rare, and for most cases the
genetic outcome could not be predicted.
In conclusion, trio exome analysis in families with an
unknown rare disorder has proven to be a valuable tool to
obtain a genetic diagnosis. The identiﬁcation of the genetic
aberration in these patients is crucial for estimation of
recurrence risk. It is also a pre-requisite for carrier testing,
prenatal- or preimplantation diagnostics.
K. Lagerstedt-Robinson: None. B. Anderlid: None. A.
Nordgren: None. M. Kvarnung: None. A. Lindstrand:
None. G. Grigelioniene: None. E. Tham: None. P. Gus-
tavsson: None. D. Nilsson: None. M. Nordenskjöld:
None. H. Malmgren: None.
P14.097A
Utility of whole-genome sequencing in the clinical diag-
nostic of rare inherited anaemias
C. Camps1,2, N. B. A. Roy3,4, H. Dreau3, S. Henderson3, S.
J. L. Knight1,2, E. M. Kvikstad1,2, M. M. Pentony1,2, M.
Proven3, A. Schuh3, J. C. Taylor1,2; Wellcome Trust
Centre for Human Genetics, Oxford university, Oxford,
United Kingdom, 2Comprehensive Biomedical Research
Centre, National Institute for Health Research (NIHR),
Oxford, United Kingdom, 3BRC Blood Theme and BRC/
NHS Translational Molecular Diagnostics Centre, John
Radcliffe Hospital, Oxford, United Kingdom, 4Molecular
Haematology Unit, Weatherall Institute of Molecular
Medicine, Oxford, United Kingdom
Whole-genome sequencing (WGS) has clear advantages
over other next-generation sequencing and genomic
approaches, making it an attractive tool for the genetic
diagnostic of rare diseases. It is unbiased compared to
whole-exome sequencing and gene panels, allowing to
explore non-coding regions and to detect copy number and
loss of heterozygosity events with good resolution and
sensitivity. We are evaluating the clinical utility of WGS in
healthcare, taking rare haematological diseases as case
studies, and discuss here the lessons learnt from the ﬁrst
cases analysed.
We performed WGS of 7 trios (30X coverage), where all
probands have a rare anaemia of suspected genetic origin
and were pre-screened with a targeted panel containing ~50
genes, none of which had yielded causative variants. The
analysis involved Stampy for read alignment, Platypus for
variant calling and Ingenuity Variant Analysis (Qiagen) for
variant annotation and ﬁltering.
Known causative variants in genes not included in the
targeted panel were detected in two patients (28%), whereas
candidate variants in novel genes not previously associated
with these diseases were identiﬁed across the other ﬁve
cases. Familial segregation and functional studies are
underway to provide further evidence of causality for these
novel variants.
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The results illustrate the phenotypic overlap existing
among these conditions and the importance of identifying
the genetic defect for the correct diagnostic and clinical
management of the patients. We also demonstrate the ben-
eﬁt of using WGS over gene panels given the difﬁculty of
having comprehensive gene panels and keeping them up-to-
date as new candidate genes are identiﬁed.
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Investigation of simplex patients born to consanguineous
parents: Whole exome sequencing has a high yield, with
signiﬁcant contribution of de novo mutations
A. Eaton1, T. Hartley2, C. Beaulieu2, D. Dyment2, F.
Bernier1, R. Lamont1, J. Parboosingh1, J. Majewski3, E.
Bareke3, Care4Rare Canada2, K. Boycott2, A. M. Innes1
1Department of Medical Genetics and Alberta Children’s
Hospital Research Institute, Cumming School of Medicine,
University of Calgary, Calgary, AB, Canada, 2Children's
Hospital of Eastern Ontario Research Institute, University
of Ottawa, Ottawa, ON, Canada, 3Department of Human
Genetics, McGill University, Montreal, QC, Canada
Whole exome sequencing (WES) is an effective diagnostic
and research tool. It is recommended as a frontline inves-
tigation in undiagnosed consanguineous rare disease
patients. Here we review the results from two research
initiatives, the FORGE Canada and Care4Rare consortia,
which leveraged consanguinity for gene discovery. We
analyzed the yield in isolated (simplex) subjects with con-
ﬁrmed or suspected (including founder populations) con-
sanguinity and contrasted to projects with multiple affected
individuals.
In simplex cases (n = 48), 73% were solved (known or
novel genes). Of these, 71% were autosomal recessive (57%
homozygous, 14% compound heterozygous) while 29%
were de novo. When we deﬁned two groups within this
cohort based on degree of relatedness, in individuals born to
second cousins or closer (n = 28), 75% were solved (90%
homozygous and 10 % de novo). However, with more
distant relatedness or presumed consanguinity (n = 20),
70% were solved, but strikingly, the variant was de novo in
57%. In consanguineous families with multiple affected
individuals (n = 54) 78% were solved, with 97.5% of
solved cases being inherited (90% homozygous) and
apparent de novo variants accounting for only 2.5%.
Our data underscores the high yield of WES in the
context of consanguinity. These results are inﬂuenced by
the selected and highly studied nature of these research
patients, and hence are higher than other unselected or non-
consanguineous cohorts. Nevertheless, in simplex cases,
particularly in the absence of close consanguinity, trio WES
remains essential due to the higher proportion of de novo
mutations.
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Analytic validation of whole exome sequencing for
clinical diagnostics of inherited disorders
M. Muona, M. Gentile, J. Koskenvuo, S. Myllykangas;
lueprint Genetics, Helsinki, Finland
Utility of Whole Exome Sequencing (WES) in clinical
diagnostics has been limited by the non-uniform sequencing
coverage across exons, leaving typically 5–10% of the
regions with shallow coverage that prevents accurate variant
detection. We have implemented a WES assay that enables
wide breadth of coverage resembling high-coverage gene-
panel based assays and provides high sensitivity in variant
detection. We have performed analytic validation of the
WES assay, which utilizes Agilent SureSelect Human All
Exon V6 hybrid capture selection to capture 60 Mb of
exonic targets in high coverage. Sequencing was performed
using an Illumina HiSeq sequencing system. Analytic
validity of the WES assay was demonstrated for single
nucleotide variants (SNVs) and insertions and deletions
(INDELs) using reference samples from The Genome In a
Bottle Consortium with high-quality variant calls obtained.
In the analytic validation, the WES assay achieved 99.5%
sensitivity, 99.9% speciﬁcity and 99.4% positive predictive
value for detecting SNVs and 97.2%, 95.7% and 97.0%
sensitivity for detecting INDELs of 1–10, 11–20, and 21–30
bases, respectively. Longest detected INDEL was 35 bases.
Repeatability of the WES assay was 99.4%. Of the target
regions, 98.86% were covered with over 15x sequencing
depth and the mean sequencing depth at nucleotide level
was 149×. The results demonstrate that comprehensive
sequencing coverage allowing high variant calling sensi-
tivity makes this WES assay well-suited for clinical diag-
nostics of inherited disorders.
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A feasibility study for rapid Whole-Exome Sequencing
for paediatric genetic disorders in Hong Kong
B. Chung, G. Leung, C. Mak, K. Yeung, S. Lee, Y. L. Lau,
G. Chan; Department of Paediatrics, The University of
Hong Kong, Hong Kong, Hong Kong
Traditionally genetic tests have long turn-around-time
(TAT) and are unhelpful in acute patient care. Our objec-
tive is to test the feasibility of rapid WES in Hong Kong.
Methods
We recruit patients suspected to have a genetic disorder
and (i) are critically ill; or (ii) a timely diagnosis may affect
decision in management. We use a trio-based WES
approach. First, we analyse genetic variants within one of
the 13 gene panels based on clinical information, then the
Mendeliome (4,278 OMIM genes) if negative. We aim to
complete this stage of analysis within 14 working days. We
will proceed to the exome-wide analysis with no time
constraints if the ﬁrst-tier testing is negative.
Results and Conclusion
This is an on-going study. So far, we have made 2
molecular diagnoses out of 10 cases. The ﬁrst patient (M/
4y) presented with Juvenile Myelomonocytic Leukemia
(JMML). A de-novo mutation in NF1, p.R1947X, was
identiﬁed as heterozygote in buccal mucosa and as homo-
zygote in blood. This resulted in a diagnosis of NF1 and the
“2nd hit” mutation leading to JMML. The second patient
(F/9d) had prenatally detected bilateral echogenic kidneys.
We identiﬁed 2 disease-causing mutation in PKHD1 (p.
D703N and p.A3057fs), and substantiated the diagnosis of
AR polycystic kidney disease. In both, the TAT was 5 days.
Our preliminary results support the feasibility of a timely
and accurate genetic diagnosis by WES.
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Experiences from whole genome sequencing in diag-
nostics - broad in silico panels and introducing struc-
tural variant detection
D. Nilsson, K. Lagerstedt Robinson, H. Malmgren, M.
Karlsson, P. Gustavsson, A. Hammarsjö, G.
Grigelioniene, M. Paucar Arce, E. Tham, M. Hellström
Pigg, B. Anderlid, A. Nordgren, J. Jörholt, M. Kvarnung,
T. Sejersen, A. Lieden, J. Lundin, J. Eisfeldt, A.
Lindstrand, V. Wirta, M. Nordenskjöld; arolinska
institutet, Solna, Sweden
We employ whole genome sequencing (WGS) and analysis
by in silico gene panels for patients (N= 330) with a range
of suspected genetic disorders since 2015 (e.g. neuromus-
cular disorder, ataxia, skeletal dysplasia, connective tissue
disorder, neutropenia). Panels achieve a high diagnostic
yield by including a large number of genes with established
causation, each rare contributors to total disease burden.
Indication driven panels enables us to triage variants in a
limited number of genes. Even without parent samples, to
ascertain inheritance model already at the variant triage
stage, gene panels of hundreds of genes can be analysed
conﬁdently and in a timely fashion.Our diagnostic rate
varies by group of disorder, ranging from 35% to 67%,
averaging 43% overall. Coverage increases in panels from a
typical 92% bases at minimum 15x using exome capture
data to > 99% for whole genome data.
We have previously developed bioinformatic tools for
detecting chromosomal structural aberrations from WGS
data (e.g. Hofmeister 2014; Nilsson 2017). These allow
study of not only imbalances, but also balanced transloca-
tions and inversions. In the gene panels studied, several
genes have structural variation as a common mechanism of
variation. When these tools were applied in the clinical
setting, a discovery rate of 10% was seen (3 out of N= 30).
Using this approach, we detected a SATB2 duplication
exons 5–7 (Lieden, 2015), GNAS inversion (Grigelioniene,
2017), and a LAMA2 duplication exon 30.
In summary WGS can succesfully be applied in a clincal
setting using in silico gene panels in combination with
structural aberration detection.
D. Nilsson: None. K. Lagerstedt Robinson: None. H.
Malmgren: None. M. Karlsson: None. P. Gustavsson:
None. A. Hammarsjö: None. G. Grigelioniene: None. M.
Paucar Arce: None. E. Tham: None. M. Hellström Pigg:
None. B. Anderlid: None. A. Nordgren: None. J. Jörholt:
None. M. Kvarnung: None. T. Sejersen: None. A. Lie-
den: None. J. Lundin: None. J. Eisfeldt: None. A.
Lindstrand: None. V. Wirta: None. M. Nordenskjöld:
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Clinical beneﬁt of Whole Genome Sequencing: report on
226 families
A. M. Bertoli-Avella1, Z. Yüksel1, O. Brandau1, J. Balázs1,
J. Garcia-Aznar1, C. Baldi1, A. Marais1, O. Paknia1, M.
Weber1, M. E. R. Weiss1, H. Yavuz1, S. Franzenburg1, C.
Voigt1, K. Kumar Kandaswamy1, D. Trujillano1, A. Saeed
Al Shamisi2, M. Alfadhel3, M. A. Albalwi4, N. Abbas Al-
Sannaa5, S. Kishore1, P. Bauer1,6, A. Rolfs1,7
1CENTOGENE GA, Rostock, Germany, 2Department of
Pediatrics, Tawam Hospital, Al-Ain, United Arab Emirates,
3Division of Genetics, Department of Pediatrics, King Saud
bin Abdulaziz University for Health Sciences, King
Abdullah Specialized Children’s Hospital, King Abdulaziz
Medical City, Riyadh, Saudi Arabia, 4Pathology and
Laboratory Medicine, King Abdulaziz Medical City,
Riyadh, Saudi Arabia, 5John Hopkins Aramco Health Care,
Pediatric Services, Dhahran, Saudi Arabia, 6Institute of
Medical Genetics and Applied Genomics, University of
Tübingen, Tübingen, Germany, 7Albrecht-Kossel-Institute,
Rostock, Germany
Introduction: Clinical practice in medical genetics has
dramatically changed in the last decade with the introduc-
tion of next generation sequencing. Today, whole genome
sequencing (WGS) is holding the potential to stirring
human genetics to a higher level.
Patients and Methods: Samples from 226 families
underwent WGS analysis in Centogene, using Illumina’s
technology. Diagnostic yield was calculated for the total
group and subgroups with (n= 172) or without (n= 54)
prior whole exome sequencing (WES). Most of the families
had undergone WES previously (76%).
Results: Overall pathogenic or at least likely pathogenic
variants were identiﬁed in 41 index cases from the 226
families (18%). Additionally, in 15% of the cases (n= 34)
a variant of uncertain signiﬁcance (VUS) was reported, for a
total diagnostic yield of 33%. Importantly, in 27 of the 172
cases with prior negative WES analysis, a genetic diagnosis
was achieved by WGS (16%). In 23 additional cases (13%)
a VUS was identiﬁed (total 29%). Positive WGS diagnosis
following a negative WES was among others, due to deep
intronic variants known to be causative, exon deletions or
previously uncovered regions. For the group without prior
WES (n= 54) the diagnostic yield was lower than expected
with 26%. Additionally, in 20% a VUS was reported.
Conclusion: These results highlight the strength of WGS
and should direct the decision for WGS as the ﬁrst line test
in clinically undiagnosed complex cases. WGS is providing
genetic diagnosis for many patients for whom all previous
genetic testing including WES failed to identify the sus-
pected genetic cause.
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Modest; Centogene. Z. Yüksel: A. Employment (full or
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Classiﬁcation of LMNA-variants by means of zebraﬁsh
phenotyping
J. M. Vanoevelen1,2, F. van Tienen1,2, E. Lambrichs1, J.
A. C. Grashorn1, I. P. Krapels1, J. A. J. Verdonschot3, J.
L. Broers4,2, H. G. Brunner1,5, A. van den Wijngaard1,6;
Maastricht University Medical Centre+, Clinical Genetics,
Maastricht, Netherlands, 2GROW - School for Oncology
and Developmental Biology, Maastricht, Netherlands,
3Maastricht University Medical Centre+, Cardiology,
Maastricht, Netherlands, 4Maastricht University Medical
Centre+, Cell Biology, Maastricht, Netherlands, 5Radboud
UMC, Human genetics, Nijmegen, Netherlands, 6CARIM
- School for Cardiovascular Diseases, Maastricht,
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Implementation of next-generation sequencing (NGS)
techniques in human genetics improved the diagnostic
yield, but also resulted in an increase of many genetic
variants with unknown clinical signiﬁcance (VUS). Despite
the presence of in silico prediction programs and databases
to predict the functional consequences of a variant, the
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effect of the majority of variants still remains unknown.
Functional follow up is therefore crucial to enable further
classiﬁcation of a variant as pathogenic or not.
In this proof-of-concept project we are currently char-
acterizing 20 variants in LMNA by means of phenotypic
evaluation in zebraﬁsh embryos. To this end, we have set up
a phenotyping pipeline to evaluate cardiomyopathy in
zebraﬁsh. The parameters that we evaluate are: heart mor-
phology, pericardial edema, heart rate and fractional
shortening.
The cardiac read-out parameters were ﬁrst validated
using another known genetic cardiomyopathy model
(tnnt2a-loss-of-function) in zebraﬁsh. In the next step we
characterized the phenotype of a morpholino-mediated lmna
model. We observed a concentration-dependent increase of
the lmna-knockdown embryos displaying cardiac edema
and a signiﬁcantly reduced heart rate. Additionally, sig-
niﬁcant cardiac arrhythmia was observed in the knockdown
condition. We now are evaluating 20 genetic variants in our
model; 5 known (pathogenic and non-pathogenic) controls
from the literature and 15 VUS, found in our cardiomyo-
pathy patient cohort. We intend to use this diagnostic
phenotyping pipeline as a routine functional evaluation of
LMNA-variants, detected in cardiomyopathy patients, lead-
ing to improved diagnostics. If desired, this pipeline can be
extended to include other genes or phenotypes.
J.M. Vanoevelen: None. F. van Tienen: None. E.
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A GGPS1 mutation found by WES in three sisters with
bisphosphonate-associated atypical femoral fractures
N. Roca-Ayats1, N. Garcia-Giralt2, M. Falcó-Mascaró3, N.
Martínez-Gil3, J. F. Abril3, R. Urreizti1, J. Dopazo4, J. M.
Quesada Gómez5, X. Nogués2, L. Mellibovsky2, D. Prieto-
Alhambra2,6, J. E. Dunford6, M. K. Javaid6, R. G.
Russell6,7, D. Grinberg1, S. Balcells1, A. Díez-Pérez2
1Universitat de Barcelona, IBUB, CIBERER, Barcelona,
Spain, 2URFOA, RETICEF, IMIM, Parc de Salut Mar,
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Introduction: Atypical femoral fractures (AFFs) are a rare
but devastating type of fracture often associated with long-
term bisphosphonate (BP) therapy, the main treatment for
osteoporosis and cancer-related bone disease. The
mechanisms underlying the pathogenesis of AFFs are
unclear. Given its low incidence, there may be underlying
genetic causes that might interact with BPs to give rise to
AFF.
Materials and methods: We identiﬁed three sisters and
three additional unrelated patients, all presenting with AFF
and treated with BPs for more than 5 years. Their genetic
background was explored by whole exome sequencing.
Rare non-synonymous mutations shared among the three
sisters were selected, considering either a dominant or a
recessive inheritance model.
Results: We detected 37 rare heterozygous mutations in
34 genes. Among them, a novel mutation was found in the
gene encoding geranylgeranyl diphosphate synthase
(GGPPS), an enzyme crucial for osteoclast function, which
can be inhibited by BPs. Other identiﬁed variants, such as
those found in the CYP1A1 and in the mevalonate pyr-
ophosphate decarboxylase (MVD) genes, may also con-
tribute to susceptibility to AFF. Pathway analysis among the
mutated genes showed enrichment of the isoprenoid bio-
synthetic pathway (GO:0008299), containing these three
genes (p-value 0.0006).
Conclusions: Our results are compatible with a model in
which an accumulation of susceptibility variants (including
some in relevant genes, notably GGPS1) constitutes a
possible genetic component of AFF causality and may lead
to novel risk assessment tools to personalize osteoporosis
therapy.
Funding: Catalan Government (2014SGR 932), Spanish
Government (SAF2014-56562-R), and FPU13/02066 fel-
lowship to NRA.
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Characterization of two novel non-synonymous genomic
variations altering drug response of the DNA topoi-
somerase II alpha in the Iranian population
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Top2-α is an important target for many anti-cancer drugs.
Variations in this enzyme may inﬂuence drug responses in
different populations. A variety of mutations and non-
synonymous genomic variations in the gene coding Top2-α
have been found associated with the development of drug
resistance. The aim of the study was to characterize two
novel non-synonymous genomic variations in TOP2A gene,
which could affect its response to Amsacrine and Mitox-
antrone as important inhibitors of the enzyme. The docking
studies of Amsacrine and Mitoxantrone with structures of
Top2-α and two linked variations including rs762022284
(c.1585A>G, p.Lys529Glu) and rs764177670 (c.1589C>T,
p.Thr530Met) were performed using Autodock 4.2.6.
AutoDock tools, LigPlot 4.5.3 and Chimera 1.5.3 were used
for analysis of Top2-α/drug complexes. Furthermore, the
genomic variations were genotyped in the Iranian popula-
tion and the data were analyzed using PLINK and PICcalc
programs. Docking and simulation data showed that the
presence of rs762022284 and rs764177670 could sig-
niﬁcantly change the protein-drug interactions in a syner-
gistic manner. Genotyping data indicated the allele
frequency of 0.30 (PIC=0.42) and 0.05 (PIC=0.09) for
rs762022284 and rs764177670, respectively. Together, the
data suggested that the presence of rs762022284 and
rs764177670 could affect Top2-α response to Amsacrine
and Mitoxantrone, suggesting the necessity of consideration
of population dependent genotypes in cancer chemotherapy
using these drugs.
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Cross disease pharmacogenetic analysis predicting anti-
TNF response identiﬁes SNPs predicting adalimumab
response in Crohn’s disease patients
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Slovenia, 3University Medical Centre Maribor, Maribor,
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Introduction: Crohn’s disease (CD), rheumatoid arthritis,
psoriatic arthritis and other inﬂammatory diseases comprise
a group of chronic diseases with immune-mediated patho-
genesis which share common pathological pathways as well
as treatment strategies including anti-TNF biologic therapy.
However, response rate to anti-TNF therapy among those
diseases varies and approximately one third of patients do
not response. Since pharmacogenetic studies for anti-TNF
therapy have been more frequent for other related diseases
and are rare in CD, the aim of our study was to further
explore markers, associated with anti-TNF response in other
inﬂammatory diseases, in Slovenian CD patients treated
with adalimumab. Materials and Methods: We enrolled 102
CD patients on adalimumab for which response has been
deﬁned after 4, 12, 20 and 30 weeks of treatment, using
IBDQ questionnaire score and blood CRP value. 45 SNPs,
signiﬁcantly associated with response to anti-TNF treatment
in other diseases, were genotyped using PCR-RFLP, PCR-
HRM or TaqMan technique. Results: Out of 45 SNPs, 13
SNPs showed at least one statistically signiﬁcant association
with either IBDQ and/or CRP response. Out of 13 SNPs,
two loci (rs755622 in gene MIF and rs767455 and
rs1800693 in gene TNFRSF1A) were associated with anti-
TNF response in CD patients for the ﬁrst time. For SNP
rs755622 (MIF) consistent association during all 30 weeks
of treatment has been observed (p=0,004). In addition,
strong and consistent association has been replicated for
SNP rs2275913 (IL17A) and response to adalimumab
(p=0,006). Conclusions: These results suggest common
mechanism of response/nonresponse to anti-TNF treatment
in related diseases.
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Tumour heterogeneity and FGFR3 mutation detected in
urinary sediment by digital PCR in bladder cancer
patients
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Introduction: Genomic alterations in the ﬁbroblast growth
factor receptor 3 (FGFR3) are frequently observed in urin-
ary bladder cancer. The aim of the study was detection of
FGFR3 mutation (Y373C) in urinary sediment by droplet
digital PCR technique as a highly sensitive and speciﬁc
method. Materials and methods: Urinary DNA was ana-
lysed from 150 primary bladder cancer patients (87 cases
G1 and 63 cases G2-G3). There were 33 females in that
study group and the average age of patients was 68 (range
680
41–88). DNA was also isolated from tumor tissue and we
sequenced FGFR3 gene. Results: We identiﬁed FGFR3
mutation (Y373C) in urinary sediment using droplet digital
PCR in 27% cases (28/150:23 G1;5 G2). Both methods
(sequencing and digital PCR) detect mutation in 40/150
(27%) bladder cancer patients. Only in 8/40 (20%) cases the
mutation was observed both in urine and tissue. In 12/40
(30%) cases (5G1 and 7 G2-G3) we did not detect FGFR3
mutation in urine although it was conﬁrmed by sequencing.
In 20/40 (50%) cases (15 G1, 5 G2-G3) we found mutation
only in urine. We analysed overall survival of patients and
we found correlation with presence of FGFR3 mutation in
urinary sediment and higher grade of the disease (G2-G3).
Conclusion: In our opinion two factors plays a crucial role
in explanation such results: tumour hetrogeneity and ran-
domly taken urine sample. Further study are needed to
prove clinical usefulness of genetic markers in routine
practice.
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Introduction: Integration of mammographic density (MD)
measurements improves the accuracy of breast cancer risk
prediction models necessary to stratify screening and
improve disease prevention. Many single nucleotide poly-
morphisms (SNPs) have been associated with breast cancer
susceptibility. However, current breast cancer risk predic-
tion models do not routinely include SNP data. This study
investigates the predictive ability of 18 SNPs (SNP18)
associated with breast cancer risk adjusting for classical risk
factors and MD.
Methods: 462 individuals with breast cancer and 8899
controls prospectively ascertained through the Predicting
Risk Of Cancer At Screening study were genotyped.
Logistic regression was applied to assess the calibration and
inter-quartile range odds ratio (IQR-OR) of SNP18 alone
and after adjustment for MD and Tyrer-Cuzick.
Results: SNP18 was predictive of breast cancer risk;
IQR-OR=1.56 (95%CI 1.38–1.77), with increasing dis-
criminative power when adjusting for MD and Tyrer-
Cuzick IQR-OR=1.70 (95%CI 1.51–1.91).
SNP18 substantially improved the ability to identify high-
risk women from classical risk factors alone. SNP18, MD
adjusted Tyrer-Cuzick 10-year risk of ≥5% identiﬁed 17.7%
of the population, 31.3% of breast-, 33.3% of interval- and
40% of stage 2+ cancers. In contrast, at < 2% risk, 29.9%
of the population developed only 17.2%, 14.8% and 11.7%
of the total-, interval- and stage 2+ breast cancers,
respectively.
Conclusion: SNP18 is an independent predictor of breast
cancer risk. Incorporation of SNP18 and MD into Tyrer-
Cuzick gives a better discrimination between risk groups
and therefore can be used for risk stratiﬁcation and perso-
nalized treatment.
This study is funded by prevent breast cancer.
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Multi institutional evaluation of a new NGS assay for
mutation detection from cfDNA
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Introduction: The circulating cell-free tumor DNA
(ctDNA) isolated from plasma of cancer patients is an
alternative, minimally invasive source of tumor DNA that
also allows rapid determination of the mutational status of
the tumor. Here we report a multi-institutional validation of
the Oncomine cfDNA Lung Cancer assay for the analyses
of ctDNA in molecular pathology laboratories. Methods:
The Oncomine cfDNA Lung assays is a multiplexed
sequencing assay for liquid biopsy that generates reads
containing targeted ctDNA regions along with a molecular
tag. In order to allow an initial evaluation, the Multiplex I
cfDNA Reference Standard (Horizon Dx) was used. The
same lot of control sample was distributed to all partici-
pating laboratories within OncoNetwork Consortium.
Samples were sequenced twice in each laboratory either
using the Ion PGM or Ion S5 system. A bioinformatics
pipeline within Torrent Server software allowed for auto-
mated variant calling. Results: Laboratories involved in the
study were able to detect the 8 hotspot base changes and
indels present in the control samples with an average
94.81% sensitivity and 99.82% speciﬁcity. When only
considering variants at the 0.1% allelic frequency, the
average sensitivity was 83.93% and the average speciﬁcity
was 99.88%. Notably, at the 0.1% allelic frequency, the
participating laboratories were able to detect the challenging
EGFR p.T790M variant that is a marker of sensitivity to
EGFR tyrosine kinase inhibitors. Conclusions: These pre-
liminary data conﬁrm the potential of Oncomine cfDNA
lung assay for plasma genotyping to allow noninvasive,
multiplexed detection of targetable genomic alterations in
lung cancer.
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Introduction: In 2013 a Pharmacogenetics (PhGx) Unit
was created willing to ease the implementation of PhGx in
the clinical practice. This unit was based on a Clinical PhGx
consultation and a SNP-microarray which allowed testing of
180 SNPs associated to drug response (PharmArray®). In
this study we report our experience over the past 3 years
with the aim of evaluating the beneﬁts of implementing a
PhGx strategy in the clinical practice of a third care level
hospital.
Material and Methods: The PhGx Unit evaluates all
inquiries in order to determine if a genetic test is indicated
for the selection of a pharmacological treatment, dose
adjustment or the identiﬁcation of therapeutic failures or
adverse reactions. Our PhGx test consists on the simulta-
neous screening of 180 SNPs in genes coding drug meta-
bolizing and transporter enzymes with a custom platform
(PharmArray®). HLA-B*57:01 determinations before Aba-
cavir prescription are performed by classic sequencing and
INNOLIPA®. Taking into account both the clinical and
genetic information the clinical pharmacologist develops a
ﬁnal clinical report.
Results: Over the past 3 years we have performed 1687
HLA-B*57:01 determinations for Abacavir prescription and
600 PharmArray® studies before the administration of dif-
ferent pharmacological treatments: Thioguanines (60%),
Methotrexate (20%), Immunosuppressants (6%), Vor-
iconazol (2%), Anticoagulant drugs (3%) and Antineoplasic
agents (3%) mainly.
Conclusions: 32% of our patients showed molecular
proﬁles related to alterations in any of the included meta-
bolism and transporter enzymes and therefore treatment
revision and adjustment was recommended in the Clinical
Pharmacogenetics Implementation Consortium (CPIC)
guidelines and EMA or FDA recommendations.
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Haplotype analyses of CYP2C19*2 and CYP2C19*17
genetic polymorphisms in clopidogrel non-
responsiveness after percutaneous coronary interven-
tion with stent implantation
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Dual antiplatelet medication with aspirin and clopidogrel is
currently recommended strategy for patients undergoing
percutaneous coronary intervention (PCI) with stent
implantation. However, emerging non-responsiveness to
clopidogrel often results in fatal stent thrombosis. Previous
ﬁndings suggest that the CYP2C19*2 polymorphism is
associated with non-responsiveness to clopidogrel and the
CYP2C19*17 polymorphism enhances antiplatelet activity
of clopidogrel. We therefore aimed to analyze the haplo-
types of these polymorphisms in clopidogrel non-
responsiveness. Antiplatelet activity of clopidogrel activity
was measured by the VerifyNow P2Y12 assay in blood
samples collected from patients that took a standard dose of
clopidogrel (75 mg/day) for at least 7 days. 243 responder
and 104 non-responder patients underwent PCI with stent
implantation are included in our study. The CYP2C19*2
(c.681G>A) and CYP2C19*17 (c.-806C>T) polymorph-
isms are genotyped using the Sequenom MassARRAY
system. The genotype frequencies for each polymorphism
were in good agreement with the predicted Hardy-Weinberg
equilibrium values. Haplotypes with a frequency of <0.03
were excluded. Only frequencies of the A-T haplotype were
<0.03 in our study group. The comparison of the G-T
haplotype frequencies between the responder and non-
responder group did not reveal any signiﬁcant difference.
The A-C haplotype was signiﬁcantly associated with non-
responsiveness to clopidogrel (OR= 2.855, 95%CI: 1.868–
4.364, P<0.001). Conversely, the G-C haplotype was
associated with responsiveness to clopidogrel (P= 0.002).
Our ﬁndings suggest that the A-C haplotype has a 2.8-fold
increased risk and the G-C haplotype enhances antiplatelet
activity of clopidogrel. Checking the A-C haplotype as a
pharmacogenetics test for risk patients will make treatment
effective.
F. Saydam: None. I. Değirmenci: None. A. Birdane:
None. M. Özdemir: None. C. Özbayer: None. N. Ata:
None. H.V. Güneş: None.
P15.09A
Cross-validation of next-generation sequencing and
digital PCR technologies for tumor proﬁling of
colorectal cancer patients
E. Melucci1, G. Cottone2, B. Casini1, M. Allegretti3, F.
Carboni4, A. Garofalo4, S. Buglioni1, E. Pescarmona1, A.
Nuccitelli5, S. Bono5, E. Cotroneo6, F. Fiorentino5, P.
Giacomini3, F. Spinella5
1Pathology, National Cancer Institute Regina Elena, Rome,
Italy, 2Genoma Group, Oncogenomic Unit Genoma Group,
Rome, Italy, 3Oncogenomics and Epigenetics, National
Cancer Institute Regina Elena, Rome, Italy, 4Digestive
Surgery, National Cancer Institute Regina Elena, Rome,
Italy, 5Genoma Group, Oncogenomic Unit, Rome, Italy,
6Genoma Group, Molecular Oncology Laboratory, Rome,
Italy
Introduction: Success of precision oncology relies on
accurate tumor proﬁling. Use of next-generation sequencing
(NGS) to detect somatic variants in FFPE tissue DNAs
(tDNAs) is challenging for clinical diagnostic laboratories
due to low quality of these analytes, frequently impairing
the possibility to assign patient to targeted treatments. Here
we compare the performance of two different NGS plat-
forms, further validating our results with digital PCR
(dPCR) technology. Materials and Methods: Performance
of MiSeq and Ion PGM sequencers with TruSight® Tumor
15 and Ion AmpliSeq® Colon/Lung Cancer Research Panel
v2 were evaluated on 32 tDNAs from non-metastatic col-
orectal carcinoma (CRC) patients. dPCR assays were cus-
tomized to screen point mutations detected by both NGS
platforms. Results: A total of 28 point mutations were
identiﬁed in 32 CRC patients. Somatic variants were con-
cordantly detected by both MiSeq and Ion PGM in 21/21
(100%) tDNAs, even when samples presented low allele
frequencies (<15%). Negligible differences were found
between platforms (2.5%±2.4%, range 0.0–9.5%). MiSeq
and Ion PGM revealed potentially actionable targets in 14/
32 patients (43.7%). dPCR analysis validated all NGS data,
conﬁrming the previously identiﬁed somatic mutations in
21/21 (100%) of cases. A mean difference in allele fre-
quencies of 1.0%±0.9% (range 0.0–2.4%) was found
between NGS and dPCR analysis. Conclusions: Our results
demonstrate that a combined workﬂow including different
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NGS platforms and dPCR enables to successfully proﬁle
tumor aberrations from tDNAs, even when mutational
burden is low, thus providing a useful approach for the
assignment of personalized therapies to CRC patients.
E. Melucci: None. G. Cottone: None. B. Casini: None.
M. Allegretti: None. F. Carboni: None. A. Garofalo:
None. S. Buglioni: None. E. Pescarmona: None. A.
Nuccitelli: None. S. Bono: None. E. Cotroneo: None. F.
Fiorentino: None. P. Giacomini: None. F. Spinella: None.
P15.10B
Screening for CYP2B6 polymorphisms in the Roma
(Gypsy) population
A. Kuhanec1, Z. Tomas2, T. Skaric Juric2, N. Smolej
Narancic2, B. Janićijević2, M. Zajc Petranovic2, M.
Pericic Salihovic2; Faculty of Science, University of
Zagreb, Zagreb, Croatia, 2Institute for Anthropological
Research, Zagreb, Croatia
Introduction: ADME genes exhibit signiﬁcant variation
among the human populations due to the past demographic
and evolutionary events. Generally, the knowledge on dis-
tribution of ADME genes in isolated populations is limited,
particularly in the Roma, transnational minority population
of Indian origin. The aim of this study is to determine the
variation of CYP2B6 among Croatian Roma. It is one of the
most polymorphic ADME genes in humans and plays role
in several drug metabolizing pathways (e.g. efavirenz and
nevirapine, bupropion).
Methods: Within the broadly designed project, we
investigated the variation of a large panel of ADME genes
among the Roma minority populations of Croatia. Geno-
typing was done using KASP method. Here we present
CYP2B6 gene variation, which was detected by genotyping
seven SNP loci (rs12721655, rs2279343, rs28399499,
rs34097093, rs3745274, rs7260329, rs8192709) in 440
DNA samples belonging to the three socio-culturally and
geographically distinct Croatian Roma groups.
Results: Three of the investigated loci (rs12721655,
rs28399499, rs34097093) were monomorphic in all sam-
ples. MAFs of polymorphic loci (rs2279343, rs3745274,
rs7260329, rs8192709) ranged 17–30%, 12–26%, 24–45%,
5–17%, respectively, with signiﬁcant differences among the
investigated groups. Moreover, MAF of locus rs8192709 is
in two of the three Roma populations four times higher than
the average global frequency. Signiﬁcant LD values
between different pairs of loci were detected in all three
investigated populations indicating recent founder effect.
Conclusion: Our results suggest that each investigated
Roma population has unique CYP2B6 genetic proﬁle which
should be considered in the modulation of pharmacotherapy
due to its possible clinical importance.
A. Kuhanec: None. Z. Tomas: None. T. Skaric Juric:
None. N. Smolej Narancic: None. B. Janićijević: None.
M. Zajc Petranovic: None. M. Pericic Salihovic: None.
P15.11C
Impact of pharmacogenetic on voriconazole plasma
concentration in patients with invasive fungal disease
S. Allegra1, G. Fatiguso1, S. De Francia2, A. Arduino1, F.
Favata1, G. Di Perri1, A. D'Avolio1
1Department of Medical Sciences; Univeristy of Turin - asl
Città di Torino, Laboratory of Clinical Pharmacology and
Pharmacogenetics (uni en iso 9001:2008 and 13485:2016
(ce-ivd) certiﬁed laboratory), Amedeo di Savoia Hospital,
Turin, Italy, 2Department of Biological and Clinical
Sciences, University of Turin, S. Luigi Gonzaga Hospital,
Orbassano, Turin, Italy
Introduction: Voriconazole is a second-generation triazole
antifungal agent with a broad spectrum of activity. It
exhibits a nonlinear pharmacokinetic and its interindividual
variability has been reported to be inﬂuenced by cyto-
chrome (mainly CYP2C19) polymorphisms. Voriconazole
therapeutic drug monitoring is suggested in major guide-
lines to improve treatment outcomes. Our study aimed to
investigate the relationship between voriconazole exposure
and single nucleotide polymorphisms (SNPs), to guide the
adjustment of drug individual dosage regimen. Materials
and methods: Adult patients with invasive fungal disease
and without HIV-infection, severe malnutrition, liver or
kidney failure, treated with voriconazole (oral or intrave-
nous route), were enrolled. MDR1 3435C>T (rs1045642),
1236C>T (rs1128503), 2677G>T (rs2032582) and
1199G>A (rs2229109), OATP1B1521 T>C (rs4149056),
PXR 63396C>T (rs2472677), BSEP T>C (rs228762),
MRP2 1249G<A (rs2273697), BCRP1 T>C (rs13120400),
MRP2 24G>A (rs717620), CYP2C19*2G>A (rs4244285)
and SLCO3A1 T>G (rs8027174) SNPs was performed by
real-time PCR. Plasma concentrations at the end of dosing
interval (Ctrough) was measured using HPLC-MS validated
methods. Results: Three hundred ﬁfty-one adult patients
(249 males, 338 Caucasians, median age 57 years and
median BMI 23.32 Kg/m2) were included in the study.
Median voriconazole Ctrough was 2150.00 ng/mL (inter-
quartile range, 1122–3927 ng/mL). We found signiﬁcantly
higher voriconazole Ctrough in patients with OATP1B1
521TCC (p<0.001), MRP2 24GA/AA (p= 0.006),
CYP2C19*2GA/AA (p= 0.001) and SLCO3A1 GG
(p=0.004) genotypes. Conclusions: We here reported the
inﬂuence of single nucleotide polymorphisms in OAT1B1,
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MRP2 and SLCO3A1 thus conﬁrming the role of CYP2C19
on voriconazole exposure. This study suggests the useful-
ness of genetic-based antifungal therapy and highlights the
needed of therapy personalization.
S. Allegra: None. G. Fatiguso: None. S. De Francia:
None. A. Arduino: None. F. Favata: None. G. Di Perri:
None. A. D'Avolio: None.
P15.12D
Comprehensive analysis of CYP2D6 variants and copy
numbers using reverse-hybridization and real-time PCR
based assays
A. Berndt, C. Oberkanins, H. Puehringer; iennaLab
Diagnostics, Vienna, Austria
Introduction: The cytochrome P450 2D6 (CYP2D6) is an
important liver enzyme involved in the metabolism of up to
25% of clinically used drugs. The CYP2D6 gene is highly
polymorphic, with numerous (sub)variants described in the
Human Cytochrome P450 Database (www.cypalleles.ki.se).
While the most frequent allelic variations are caused by
single nucleotide polymorphisms and small insertions/
deletions, highly homologous regions in the CYP2D6 gene
locus facilitate unequal cross-over leading to large dele-
tions, duplications and gene conversions.
Material and Methods: We developed a reverse-
hybridization assay (PGX-CYP2D6 XL StripAssay) for
the simultaneous detection of 19 sequence variations in the
CYP2D6 gene, which deﬁne the most prevalent alleles
impacting enzyme activity in Caucasians. For the detection
of copy number variations a real-time PCR based assay
(CYP2D6 RealFast CNV Assay) was established. The
StripAssay and real-time PCR assay were validated on 118
and 98 samples, respectively.
Results: The PGX-CYP2D6 XL StripAssay correctly
identiﬁes allelic variants with normal (*1, *2, *35, *39),
reduced (*9, *10, *17, *29, *41) and no (*3 to *8, *11,
*12, *14, *15, *40, *58) enzyme activity, and hence allows
the classiﬁcation of individuals into extensive (EM), inter-
mediate (IM) and poor (PM) metabolizers. In addition,
ultrarapid (UM) metabolizers and CYP2D6*5 carriers can
be identiﬁed by quantiﬁying their abnormal copy number
status using the CYP2D6 RealFast CNV Assay. Both assays
demonstrate a test accuracy of > 0.99.
Conclusions: The metabolizer phenotype of patients
treated with CYP2D6 substrates can be accurately deter-
mined by the combined use of both assays.
A. Berndt: A. Employment (full or part-time); Sig-
niﬁcant; ViennaLab Diagnostics. C. Oberkanins: A.
Employment (full or part-time); Signiﬁcant; ViennaLab
Diagnostics. H. Puehringer: A. Employment (full or part-
time); Signiﬁcant; ViennaLab Diagnostics.
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Small molecules for the recovery of wild-type CFTR
splicing
L. Straniero1, V. Rimoldi1,2, G. Soldà1,2, V. Giannone3, F.
Ferrari3, M. Seia3, C. Orrenius4, C. Colombo5, R.
Asselta1,2, S. Duga1,2
1Department of Biomedical Sciences, Humanitas Univer-
sity, Rozzano, Milan, Italy, 2Humanitas Clinical and
Research Center, Rozzano, Milan, Italy, 3Medical Genetics
Laboratory, Fondazione IRCCS Ca' Granda Ospedale
Maggiore Policlinico, Milan, Italy, 4Nerviano Medical
Sciences, Nerviano, Italy, 55Cystic Fibrosis Center of
Milan, Fondazione IRCCS Cà Granda Ospedale Maggiore
Policlinico, Milan, Italy
Introduction: Cystic ﬁbrosis is a recessive disorder caused
by > 1900 mutations in the CFTR gene. About 13% of
CFTR mutations are classiﬁed as splicing defects. Among
them, the polymorphic locus TG(9–13)T(5,7,9) is known to
inﬂuence exon-10 inclusion and has been associated with
monosymptomatic forms of the disease.
Recent advances in therapy demonstrated the efﬁcacy of
drugs targeting speciﬁc molecular defects (potentiators,
correctors). However, no personalized treatments are
available for splicing mutations. For this reason, we
explored the possibility to improve exon-10 inclusion in
CFTR mRNA using small molecules.
Methods: We started with kinetin and its analogue
RECTAS, previously found to correct speciﬁc aberrant
splicing events in other genetic disorders. We then selected
other kinetin derivatives, prioritized by in-silico structural-
based screening, to identify molecules with a better efﬁcacy.
We treated Caco-2 cells with different concentrations of the
selected drugs for 24h and we measured the wild-type
CFTR mRNA levels by competitive-ﬂuorescent RT-PCR.
Results: These experiments showed a dose-response
increase of exon-10 inclusion conﬁrming a remarkable
impact on splicing ﬁdelity by all the tested molecules.
Among them, RECTAS seems to have the best efﬁcacy at
the lowest dose (25% increase in exon-10 inclusion; P <
0.022). The effect of kinetin and RECTAS on CFTR spli-
cing have also been conﬁrmed in a more disease-relevant
cell system, i.e. primary cultures of epithelial cells isolated
from patients’ nasal brushings. We are also planning to
validate new compounds by cell-based screening using a
dual-color ﬂuorescent reporter vector.
This study is supported by the Italian Cystic Fibrosis
Foundation FFC#5/2015.
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Novel endometrial receptivity markers detected in large-
scale RNA-sequencing study combining samples from
different populations
T. Laisk1,2, M. Suhorutshenko2, V. Kukushkina3, A.
Velthut-Meikas2, R. Mägi3, M. Peters1,2, S. Altmäe2, K.
Krjutshkov2, J. F. Martinez-Blanch4, F. M. Codoñer4, F.
Vilella5,6, C. Simon5,6, A. Salumets1,2; Department of
Obstetrics and Gynecology, University of Tartu, Tartu,
Estonia, 2Competence Centre on Health Technologies,
Tartu, Estonia, 3Estonian Genome Center, Tartu, Estonia,
4Lifesequencing SL, Valencia, Spain, 5Instituto
Universitario IVI/INCLIVA, Valencia, Spain, 6Igenomix
SL, Valencia, Spain
Introduction: Numerous genes regulate the endometrial
transition from pre-receptive to receptive state. Addition-
ally, transcriptome dysregulation and problems with endo-
metrial receptivity have been proposed as a potential
mechanism behind repeated IVF failure. Due to small
between-study overlap, there is only a handful of clinical
biomarkers for diagnosing endometrial receptivity problems
or selecting the optimal receptivity window for embryo
transfer in IVF. Material and methods: Paired samples
from pre-receptive (n= 35) and receptive (n= 35) endo-
metrium in healthy fertile women (aged 23–36) and
receptive phase samples (n= 39) from women with repe-
ated IVF failure (aged 26–49) were collected in Estonia and
Spain. Biopsies were analysed using Illumina paired-end
RNA-sequencing. For cohort-level differential expression
analyses, edgeR was used, while meta-analysis was per-
formed using METAL. Results were selectively validated
using qPCR. Main results: After multiple testing correc-
tion, 3,591 differentially expressed transcripts (DETs) were
identiﬁed in the pre-receptive vs receptive endometrium
analysis of healthy women. Up-regulated DETs were enri-
ched for immune system and cellular adhesion terms, while
cell-cycle and DNA repair-related processes were down-
regulated. Comparison of receptive phase samples from
healthy women and repeated IVF failure patients resulted in
338 DETs. These transcripts were enriched for cellular
adhesion and immune response. Conclusion: Differentially
expressed transcripts identiﬁed in our study have consistent
effects in different populations and therefore have the
potential for being evaluated as robust and efﬁcient markers
for endometrial receptivity in the clinical setting. Compar-
ison between healthy women and IVF patients provides
novel information on potential causes of repeated IVF
failure. Funding: EU41564 (NOTED), EU48695,
EU692065 (WIDENLIFE)
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Electrophysiological modeling of Hnrnpu-related epi-
leptic encephalopathy in mice for purpose of targeted
therapy identiﬁcation
S. A. Dugger, V. Letts, M. Boland, W. N. Frankel, D. B.
Goldstein; Columbia University Med Center, New York,
NY, United States
Introduction: Despite the availability of over twenty anti-
epileptic drugs, nearly one third of epilepsy patients remain
refractory to treatment. Fortunately, with recent advance-
ments in genomic technologies, genetic causes of epilepsy
are increasingly recognized, thereby offering a window into
the underlying disease biology and the opportunity to
identify targeted therapies. Here we model Hnrnpu-related
epileptic encephalopathy using both in vitro and in vivo
electrophysiology screening methods performed on a
knockout mouse line. Phenotypes that emerge from these
studies will serve as the basis for future drug screening.
Materials & Methods: A heterozygous Hnrnpu knockout
mouse line was established using CRISPR/Cas9 genome
editing technology. Spontaneous seizures and seizure
thresholds of 6–8-week-old mutant and wildtype mice were
subsequently assessed using electroencephalography (EEG)
and electroconvulsive threshold studies (ECT). Neuronal
network activity was further evaluated using a multi-
electrode array (MEA) performed on primary cortical neu-
ron cultures derived from postnatal day 0 pups.
Results: Although EEGs performed on three mutant
mice thus far have not revealed any evidence of sponta-
neous seizures, preliminary data from ECT studies reveal a
10–20% reduction in seizure threshold compared to wild-
type littermates (N= 3 mutants, 5 wildtypes). MEA studies
have yet to demonstrate any signiﬁcant differences in the
spontaneous ﬁring patterns of mutant neuronal networks.
Conclusion:While preliminary electrophysiological data
thus far do not reveal abnormalities in spontaneous neuronal
ﬁring, Hnrnpu knockout mice show an overall lower
threshold to seizure induction. This ECT phenotype can
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thereby serve as a reliable and quantiﬁable trait for future
drug screening efforts.
S.A. Dugger: None. V. Letts: None. M. Boland: None.
W.N. Frankel: None. D.B. Goldstein: None.
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The Challenge of Whole Genome Sequencing in a clin-
ical setting
E. V. Davison1, Z. C. Deans1, C. Turnbull2, S.
Henderson2, E. Baple2, E. Thomas2, R. Scott2, S. L. Hill1;
NHS England, London, United Kingdom, 2Genomics
England, London, United Kingdom
The creation of a national network of NHS Genomic
Medicine Centres (GMCs) is integrating genomics into
mainstream medicine in England. The 100,000 Genomes
Project is an initiative to sequence 100,000 genomes from
patients with rare disease and cancer, has driven the
implementation of a framework to enable the acquisition of
samples and clinical data of sufﬁcient quality to enable
whole genome sequencing (WGS). For patients with rare
diseases, pathways have been developed to collect appro-
priate family samples and extract high quality DNA for
WGS to enable a diagnosis previously unobtainable, and the
family with reproductive options. The cancer programme
pilot phase identiﬁed difﬁculties with genomic testing of
tumour samples and led to the embedding of formalin-free
tissue handling pathways from theatres to laboratories to
ensure samples were WGS conducive. The ability to
simultaneously detect small variants, copy number variants
and structural variants for cancer patients provides oppor-
tunities e.g. new treatment options and clinical trials. The
standardisation of processes from sample handling, DNA
extraction, quality control, validation and reporting has
enabled the delivery of WGS and evidences the provision of
genomic services within a national healthcare system is
beneﬁcial and deliverable. An external quality assessment
has been integrated into all pathways from the outset to
monitor and measure the quality of the service and has
driven the improvement of patient care.
This approach has adopted innovative approaches to
design the GMC genomics services, created genomics
multi-disciplinary teams spanning a multitude of special-
isms, driven creative workforce training and forward-
thinking approaches to informatics.
E.V. Davison: None. Z.C. Deans: None. C. Turnbull:
None. S. Henderson: None. E. Baple: None. E. Thomas:
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Association of IL28B and CCL5 polymorphisms with
chronic hepatitis C treatment outcome
M. Rodzkin, A. Liaudanski, V. Pankratov, O. Davydenko;
Institute of Genetics and Cytology of the NAS of Belarus,
Minsk, Belarus
Chronic infection with hepatitis C virus (HCV) affects
approximately 3% of people worldwide and can cause
serious liver damage. Although the recommended treatment
involves pegylated interferon (PegIFN) combined with
ribavirin (RBV), it is well-known that for many patients the
mentioned therapy is not effective. This makes the search of
factors that affect the treatment outcome extremely impor-
tant. We aimed to analyze the role of rs12979860 (IL28B)
and rs2107538 (CCL5) in the outcome of the HCV infection
treatment with PegIFN and ribavirin. 130 Belarusians with
HCV after full course of PegIFN/RBV therapy were stu-
died. They were divided into two groups on the basis of
treatment outcome. The ﬁrst group included 49 patients
with sustained virological response (SVR), the second - 81
individuals with non-response (NR). Signiﬁcant differences
in the genotype distribution of IL28B were revealed
between the two groups (p=2.04*10−7). Among CC gen-
otype carriers the SVR rate was much higher (81.5%) than
among CT and TT groups (31.1% and 13.8%, respectively)
(p=2.29*10−7). The frequencies of CCL5 genotypes were
alike in two cohorts (p>0.05). But when combined with
IL28B, it turned out that carriers of CT/GA and CT/AA
combinations (IL28B/CCL5, respectively) had signiﬁcantly
higher probability to achieve SVR than patients with CT/
GG (p=6.61*10−3). Thus, SNP rs12979860 (IL28B) can be
considered as an independent predictor of the treatment
outcome in the Belarusian population. On top of that, SNP
rs2107538 (CCL5) can deﬁnitely enhance the predictor
properties of IL28B.
M. Rodzkin: None. A. Liaudanski: None. V. Pank-
ratov: None. O. Davydenko: None.
P15.18B
Actions, roles, and responsibilities in implementation of
pharmacogenomics in primary care
M. E. Jansen1,2, T. Rigter1,2, S. Janssen2, W. Rodenburg2,
M. C. Cornel1; Department of Clinical Genetics, Section
Community Genetics and Amsterdam Public Health
Research Institute, VU University Medical Center,
Amsterdam, Netherlands, 2Centre for Health Protection,
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Introduction: Barriers and facilitators of pharmacoge-
nomics have been widely studied. Nonetheless, limited
implementation of pharmacogenomics is observed in rou-
tine health care, especially in primary care. To study how to
overcome barriers and to draw on facilitators, we deﬁned
actions, roles, and responsibilities in consultation with sta-
keholder groups.
Materials and methods: Interviews were conducted with
general practitioners (n= 8), patients (n= 21), and phar-
macists (n= 24) to elicit perceived barriers and facilitators
for pharmacogenomics. Main outcomes were grouped into
themes, which were used to organize an expert meeting to
further deﬁne needed actions, roles and responsibilities.
Results: From interviews it appeared that existing
pharmacogenomic dosing advices are not included in rou-
tine health care guidelines for general practitioners, only for
pharmacists. Lack of evidence on clinical utility was men-
tioned as a general barrier to include pharmacogenomic
dosing advices in guidelines for general practitioners.
Besides lack of evidence other main structural prerequisites
were mentioned, such as reimbursement of the test and
subsequent therapy, user-friendly software systems, and
data sharing infrastructures. Furthermore, protocols when to
test a patient are considered essential to implement phar-
macogenomics successfully. However, disagreement exists
about the best division of responsibilities between general
practitioners and pharmacists, and the patient’s role.
Based on the interview data, four themes were deﬁned
and discussed in an expert meeting: generating evidence for
guideline development, reimbursement, division of
responsibilities, and data registration and sharing.
Conclusions: Prioritization of the distilled actions with
actionable stakeholder groups is needed as a roadmap to
progress implementation of relevant pharmacogenomic
applications in primary care.
M.E. Jansen: None. T. Rigter: None. S. Janssen:
None. W. Rodenburg: None. M.C. Cornel: None.
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Dynamics of changes in the genome of hepatitis B virus
for chronic HBsAg-carrier after Lamivudine treatment
M. V. Konopleva1, M. S. Belenikin1,2, M. V. Sokolova1, A.
I. Bajenov3, S. A. Kiryanov1, A. V. Shanko1, T. A.
Semenenko1, V. G. Nesterenko1, A. P. Suslov1
1Gamaleya Research Institute of Epidemiology and Micro-
biology, Moscow, Russian Federation, 2Moscow Institute of
Physics and Technology (State University), Dolgoprudny,
Russian Federation, 3Sklifosovsky Research Institute of
Emergency Care, Moscow, Russian Federation
Background: targeted therapy is the main goal of persona-
lized medicine. High-throughput molecular genetic studies
are particularly important in antiviral therapy and oncology
to overcome drug resistance, to save time, and to predict the
effectiveness of medical treatment. The aims of study:
analysis of the dynamic effect of Lamivudine to HBV iso-
late with escape-mutation Gly145Arg under treatment of
chronic HBsAg-carrier.
Methods: serum samples in time 2004–2007 were stu-
died for patient 53 y/o with a combination of chronic
hepatitis B and chronic Hodgkin's disease. Initial HBV
isolate got Gly145Arg mutation, affecting changes in ser-
ological properties of the HBV samples. Medical treatment
by Lamivudine since 2006 was started. High-throughput
sequencing was performed by Ion Torrent PGM (2150×-
2700x coverages). Informed consent was obtained from
patient according local ethical approval. Results: ser-
ological markers in the time series of sample were stable the
entire period of observation (+ /+ /+/+/- proﬁle for
HBsAg/HBeAg/anti-HBe IgG/anti-HBс IgM+IgG/anti-
HBsAg, respectively; HCV and HDV markers were nega-
tive). HBV isolate samples from 2004 and 2005 were
identical. After Lamivudine therapy was started the HBV
genome was mutated. HBV isolate acquired the resistance
to Lamivudine by Y(M/V)DD, as well as codon of escape-
mutation Gly145Arg got the second mutation resulting
heterogeneity Gly145(Arg/Lys). The other important fea-
ture was the appearance of heterogeneous Gly10Lys
mutation. Sequencing of HBV isolates from 2006 and 2007
proved their identity. Conclusion: in chronic HBsAg-
carrier with Gly145Arg mutation in HBsAg region Lami-
vudine treatment resulting to the emergence of a drug-
resistance mutation. This case illustrate importance of HBV
isolate features for personalized therapy.
M.V. Konopleva: None. M.S. Belenikin: None. M.V.
Sokolova: None. A.I. Bajenov: None. S.A. Kiryanov:
None. A.V. Shanko: None. T.A. Semenenko: None. V.G.
Nesterenko: None. A.P. Suslov: None.
P15.20D
Variants in CD5 and IRF4 impact into melanoma
survival
J. A. Puig-Butillé1,2, M. Potrony3, P. Giménez-Xavier3,2,
G. Tell-Marti3,2, A. Rebollo-Morell3, L. Zimmer4, E.
Carreras5, F. Aranda5, A. Sucker4, N. Armiger5, M.
Martínez-Florensa5, C. Badenas1,2, P. Aguilera3,2, C.
Carrera3,2, J. Malvehy3,2, F. Lozano5,6,7, D. Schadendorf4,
S. Puig3,2; Biochemical and Molecular Genetics Service,
Hospital Clinic of Barcelona and Institut d’Investigacions
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Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona,
Spain, 2Centro de Investigación Biomédica en Red de
Enfermedades Raras (CIBERER), Barcelona, Spain,
3Dermatology Department, Melanoma Unit, Hospital
Clinic of Barcelona and Institut d’Investigacions
Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona,
Spain, 4Department of Dermatology, University Hospital
Essen, Essen, Germany & German Cancer Consortium,
Heidelberg, Germany, 5Grup d'Immunoreceptors del
Sistema Innat i Adaptatiu, Institut d'Investigacions
Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona,
Spain, 6Department of Immunology, Hospital Clínic,
Barcelona, Spain, 7Department of Cell Biology,
Immunology and Neurosciences, School of Medicine,
University of Barcelona, Barcelona, Spain
Introduction: The CD5 gene is a negative T-cell regulator,
and p.Pro224Leu (rs2241002) and p.Ala471Val
(rs2229177) variants constitute a more immunoreactive
haplotype that worsens clinical autoimmune outcome. The
IRF4 gene is transcription factor associated with immune
system development and response. The rs12203592 IRF4
modulates an enhancer element that controls the IRF4
expression and is associated with high nevi count. The
study asses the role of these variants in melanoma survival.
Material and Methods: The CD5 variants (p.Pro224Leu
and p.Ala471Val) and IRF4 rs12203592 variant were gen-
otyped in two independent sets of melanoma patients from
Barcelona (N= 500 cases) and Essen (CD5 variants and
IRF4 variant were genotyped in 215 cases and 432 cases,
respectively). Results: The p.Ala471 CD5 variant corre-
lated with better melanoma outcome in both datasets. In
contrast, increased melanoma-speciﬁc mortality was asso-
ciated with p.Leu224 CD5 variant and IRF4 rs12203592 T
allele in both datasets (Table1).Survival analyses showed
that CD5 Pro224-Ala471 haplotype in homozygosis
improved melanoma survival in the entire set of patients
(hazard ratio [HR]=0.27 [0.11–0.67], Adj. p=0.005).
While, IRF4 survival analyses only showed signiﬁcance for
the Barcelona set (HR=4.58 [1.11–18.92], Adj. p=0.03).
Conclusions: CD5 immunoreactive haplotype associates
with better melanoma outcome and IRF4 rs12203592 T
allele with worse melanoma prognosis. These results high-
light the relevance of immune-related genes for clinical
outcome in melanoma. Funding: This work was funded by
Instituto de Salud Carlos III, Spain, grant 12/00840, co-
ﬁnanced by European Development Regional Fund “A way
to achieve Europe”
J.A. Puig-Butillé: None. M. Potrony: None. P. Gimé-
nez-Xavier: None. G. Tell-Marti: None. A. Rebollo-
Morell: None. L. Zimmer: None. E. Carreras: None. F.
Aranda: None. A. Sucker: None. N. Armiger: None. M.
Martínez-Florensa: None. C. Badenas: None. P.
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SNPs in microRNAs associated with vincristine periph-
eral neurotoxicity in Spanish children with acute lym-
phoblastic leukemia
M. Umerez1, A. Gutierrez-Camino1, I. Martin-Guerrero1,
N. García de Andoin2, A. Sastre3, A. Echebarria-Barona4,
A. Navajas5, I. Astigarraga4,5, A. García-Orad1,5
1University of the Basque Country, Leioa, Spain, 2Univer-
sity Hospital Donostia, Donostia, Spain, 3University
Hospital La Paz, Madrid, Spain, 4University Hospital
Cruces, Barakaldo, Spain, 5BioCruces Health Research
Institute, Barakaldo, Spain
13/02/2017 17:00
Background
Vincristine (VCR), an important drug in childhood Acute
Lymphoblastic Leukemia (ALL) treatment protocols, often
causes peripheral neurotoxicity in early phases of the ther-
apy. Association between genetic variants in VCR phar-
macokinetic (PK) genes and neurotoxicity has been
reported. It is known that these PK genes are regulated by
microRNAs (miRNAs). Polymorphisms affecting the levels
or function of miRNAS targeting those genes could affect
their expression having in turn a role in the VCR-related
neurotoxicity. Nowadays, a large amount of new miRNAs
have been annotated. Therefore, the aim of this study was to
determine if variants in miRNAs are associated with VCR
neurotoxicity during induction.
Methods
Blood samples of 175 Spanish pediatric B-ALL patients
treated with LAL/SHOP protocol were analyzed. We
selected all the SNPs described in pre-miRNAs with a
MAF>1% (213 SNPs in 206 miRNAs) that could regulate
VCR PK/PD genes. Genotyping was performed with Ver-
aCode GoldenGate platform.
Results
Statistically signiﬁcant association was found between 8
miRNA SNPs and neurotoxicity during induction phase.
The most signiﬁcant result was found for rs12402181 in
mir-3117 seed region. This miRNA was predicted to reg-
ulate ABCC1 and RALBP1, genes involved in VCR
transport.
Conclusion
In this study we detected a SNP in miR-3117 that might
alter ABCC1 and RALBP1 VCR transport genes regulation
and could affect VCR-induced neurotoxicity in patients
with pediatric B-ALL.
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P15.22B
Ensemble Random Forest Classiﬁer for predicting
myeloproliferative neoplasms subtype using patient's
genomic proﬁle
M. R. Jabalameli, S. Ennis, A. Collins, N. C. P. Cross, W.
J. Tapper; uman Genetics & Genomic Medicine, Faculty
of Medicine, University of Southampton, Southampton,
United Kingdom
Introduction: Myeloproliferative neoplasms (MPN) are a
group of related hematological disorders identiﬁed by clonal
expansion of one or more myeloid cell lineages. Six dif-
ferent types of MPN are distinguished; the most prominent
of these are polycythemia vera (PV) and essential throm-
bocythemia (ET), respectively characterized by ery-
throcytosis and thrombocytosis. Acquired somatic mutation
of JAK2V617F underlies more than 96% of PV and 50–60%
ET. We applied machine learning models to germline
genetic variants and constructed a robust prediction model
for alternative classiﬁcation of ET and PV patients.
Materials and methods: A cohort of 499 JAK2+ve ET-
cases and 505 JAK2+ve PV-cases were genotyped using the
Illumina Human OmniExpressExome-v1.2. Quality control
involved removal of SNPs with MAF < 0.01, SNPs and
samples with > 10% missing genotypes and SNPs deviation
from HWE proportions. In order to account for multi-
colinearity and avoid overﬁtting SNPs with r2>0.2 within
50kb window were excluded. PCA was used as an unsu-
pervised approach for data visualization and classiﬁcation.
7144 SNPs with signiﬁcant alternative allele association (p-
value> 0.05) between ET and PV were used to construct
classiﬁer model.
Result: Our MPN ensemble classiﬁer model was highly
predictive of MPN subtypes. Using 5 fold cross-validation;
Random Forest model achieved superior accuracy (AUC:
0.9) compared to Decision Tree model (AUC: 0.87).
Discussion: The results demonstrate that the germline
variant information is useful for prediction of MPN type
with machine learning modelling. To our knowledge, this
study is the ﬁrst investigation of the MPN classiﬁcation
using machine learning and germline mutation data.
M.R. Jabalameli: None. S. Ennis: None. A. Collins:
None. N.C.P. Cross: None. W.J. Tapper: None.
P15.23C
Study of correlation between the NAT2 phenotype and
genotype status among Greenlandic Inuit
F. Geller1, E. Birch1, V. Yakimov1, K. Bjorn-Mortensen1,
B. Soborg1, A. Koch1, M. Andersson1, K. B. Kristensen1,
S. W. Michelsen1, L. Skotte1, A. A. Bjerregaard1, M.
Blaszkewicz2, K. Golka2, J. Hengstler2, B. Feenstra1, M.
Melbye1
1Statens Serum Institut, Copenhagen, Denmark, 2IfADo,
Dortmund, Germany
Introduction: Greenland has one of the highest tubercu-
losis incidences in the world and the standard treatment
includes isoniazid. N-acetyltransferase 2 (NAT2) is the
main enzyme metabolizing isoniazid and genotype-based
treatment has been studied for years without becoming
common practice yet.
Material and Methods: We sequenced the coding
sequence of NAT2 and determined the NAT2 enzyme-
activity by caffeine test in 260 Greenlanders.
Results: No additional genetic variants were identiﬁed in
the coding sequence of NAT2, so that genotype status could
be assessed by the well-established 7-SNP panel. Studying
the enzyme activity by the ratio of the two caffeine meta-
bolites AFMU and 1X showed that all 42 individuals with
two haplotypes associated with slow metabolism had slow
metabolism. The remaining individuals with intermediate or
rapid genotype status displayed some phenotypical varia-
tion, with 79 out of 218 (36%) misclassiﬁed with slow
metabolism. Further investigation revealed that drinking
coffee and not tea or cola was important for high levels of
both metabolites, resulting in fewer misclassiﬁcations.
Furthermore, taking a second urine sample of 15 partici-
pants on another day indicated individual variation between
two measurements in our study group.
Conclusion: The concordance between phenotype and
genotype status with regard to slow metabolism supported
the recommendation of lower isoniazid doses in individuals
with slow genotype status in order to avoid liver-injury, a
frequent side effect.
Grant support: Danish Council for Independent Research
(DFF), Sundhedspuljen (Grønlands Sundhedsvidenskabe-
lige Forskningsråd), Torben og Alice Frimodts Fond,
Augustinusfondet, Fonden til Lægevidenskabens Fremme
(Maersk Foundation), NunaFonden, Højmosegård grant and
Frimodt-Heinike Fonden.
F. Geller: None. E. Birch: None. V. Yakimov: None.
K. Bjorn-Mortensen: None. B. Soborg: None. A. Koch:
None.M. Andersson: None. K.B. Kristensen: None. S.W.
Michelsen: None. L. Skotte: None. A.A. Bjerregaard:
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P15.24D
Association between genetic variants of the nicotinic
receptor genes and smoking cessation: a pharmacoge-
netic study
C. Wu1, W. Wu1, C. Li1, W. Chien1, Y. Chang1, H. Leu2,
C. Lai3, K. Hsuch4, L. Chen5, I. Tsai6, K. Liang1, M. Lin1;
Institute of Public Health, National Yang-Ming
University, Taipei, Taiwan, 2Healthcare Center, Taipei
Veterans General Hospital, Taipei, Taiwan, 3Department
of Family Medicine, Taipei Veterans General Hospital,
Taipei, Taiwan, 4Department of Family Medicine,
Kaohsiung Veterans General Hospital, Kaohsiung,
Taiwan, 5Department of Psychiatry, Washington
University, St. Louis, MO, United States, 6Institute of
Health Policy and Welfare, National Yang-Ming
University, Taipei, Taiwan
Introduction: Many smoking cessation methods have been
developed that may help quit smoking, however, no single
method is effective for all smokers. Previous studies iden-
tiﬁed genetic variants on nicotinic acetylcholine receptors
(nAChRs) for nicotine dependence. However, their rela-
tionship with pharmacotherapy remains inconclusive. This
study aims to examine whether nicotinic receptors gene
variants could predict short/long-term effect of smoking
cessation and their interaction with medication on smoking
cessation. Methods: A total of 697 ever-smokers receiving
nicotine replacement therapy or Varenicline treatment were
recruited from medical centers. Fifty-ﬁve SNPs on ten
nAChRs subunit genes were selected for genotyping. The
short/long-term effect of smoking abstinence were eval-
uated at 3-month and 12-month. Multiple logistic regression
was used to assess the effects of genetic variants and ces-
sation methods on smoking cessation using gPLINK and
SAS 9.3v. software. Results: Our results showed that ﬁve
variants on CHRNA5-A3-B4, CHRNA2, and CHRNA7 are
associated with short/long-term smoking cessation. Subjects
carrying one additional minor allele of CHRNA7
rs35114543 and rs11637923 would signiﬁcantly increase
the odds of short/long-term abstinence if receiving Vareni-
cline treatment (OR=5.04, 95% C.I.: 1.32–19.3; OR=3.22,
95% C.I.: 1.36–7.66, respectively). However, subjects car-
rying one additional minor allele of CHRNA5 rs680244 and
CHRNA3 rs6495308 would signiﬁcantly decrease short/
long-term abstinence odds (OR=0.38, 95% C.I.: 0.15–0.98;
OR=0.36, 95% C.I.: 0.15–0.90, respectively) despite
receiving Varenicline. Conclusion: Our study demonstrated
that variants on CHRNA5-A3-B4, CHRNA2, and CHRNA7
genes are signiﬁcantly associated with short/long-term
smoking cessation among subjects receiving Varenicline
treatment. Further studies are warranted to replicate our
ﬁndings. Grant No: NHRI-EX105-10304PI & NHRI-
EX106-10304PI
C. Wu: None. W. Wu: None. C. Li: None. W. Chien:
None. Y. Chang: None. H. Leu: None. C. Lai: None. K.
Hsuch: None. L. Chen: None. I. Tsai: None. K. Liang:
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P15.25A
Clinical cancer diagnostics and treatment using next
generation technologies
K. Huminska, M. Kuś-Słowińska, A. Młodzińska, A.
Brylak, J. Wojciechowicz; DNA Research Center, Poznan,
Poland
Introduction: Cancer is a very variable disease and mole-
cular links between cancer susceptibility and progression
alteration levels remain mostly unknown. That’s why our
cancer patients were screened towards germline and somatic
mutations, looking for the potential of integrating genomic
data for a comprehensive and personalized cancer medicine.
Materials and Methods: Using NGS technology, our
cancer patients were screened towards 170 genes, suspected
to play a role in predisposing to cancer. We also screened
those patients towards a wide range of “hot spot” mutations
in 56 tumor suppressor genes and oncogenes annotated in
the COSMIC database. In order to conﬁrm the occurrence
of somatic mutation we additionally did a comparison of 3
techniques: Sanger sequencing, qPCR and ddPCR.
Results: NGS technology speeds up the identiﬁcation of
causative alterations, proper diagnostics and treatment of
patients. Comparison of 3 techniques highlighted the sen-
sitivity of ddPCR, which can precisely quantify mutant
allele frequency of a rare tumorigenic mutations in a high
background of “normal” cells, routinely down to 0.01%,
much deeper than the standard real-time PCR (1–5% limit
detection) and Sanger sequencing (often over 30%).
Conclusions: There is a great potential for integration of
new generation technologies looking for germline-somatic
links in terms of development, usage of individualized
biomarkers and monitoring response to chemotherapy.
Targeted cancer therapies may give medical oncologists a
better way to customize cancer prevention and treatment.
“Project co-ﬁnanced by the European Union from the
European Regional Development Fund.”
K. Huminska: None. M. Kuś-Słowińska: None. A.
Młodzińska: None. A. Brylak: None. J. Wojciechowicz:
None.
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Personalized medicine via Pharmacogenetics: Investi-
gating critical success factors for clinical implementation
M. Plantinga1, I. van Langen1, A. Ranchor2, P. Lanting1,
B. Wilffert3,4, R. Sijmons1; Department of Genetics,
University Medical Center Groningen, University of
Groningen, Groningen, Netherlands, 2Department of
Health Psychology, University Medical Center Groningen,
University of Groningen, Groningen, Netherlands,
3Department of Clinical Pharmacy and Pharmacology,
University Medical Center Groningen, University of
Groningen, Groningen, Netherlands, 4Groningen
Research Institute of Pharmacy, Unit of
PharmacoTherapy, Epidemiology & Economics, Dept. of
Pharmacy, University of Groningen, Groningen,
Netherlands
Background and aim: Pharmacogenetics (PGx) has the
potential to improve drug efﬁcacy and safety by identifying
patients likely to respond well to a certain drug or who
could be at risk. Although substantial evidence has been
published to support the clinical use of PGx, clinical
implementation is limited. The University Medical Center
Groningen (UMCG) is developing a PGx implementation
pilot. As a ﬁrst step, we assessed impeding and facilitating
factors as well as needs of pharmacists, prescribers and
patients in applying PGx. Materials and Methods: Qua-
litative interview and focus group studies were conducted
with 7 pharmacists, 13 prescribers and 19 patients. Results:
Both professionals and patients were positive towards PGx.
A lack in PGx knowledge among pharmacists and pre-
scribers was, however, considered a barrier. For PGx
implementation, clinical decision support was considered a
prerequisite for prescribers. The distribution of responsi-
bilities also needs addressing. Prescribers and pharmacists
differed in views, both holding the other responsible. For
patients the offer of an animation in addition to an infor-
mation brochure aided in understanding PGx. Since the
term PGx was found to be difﬁcult, it was suggested to
speak of personalized medication in the implementation
process. Conclusions: A positive attitude towards clinical
implementation of PGx was found. The availability of
clinical decision support is regarded as a critical success
factor. In the UMCG implementation pilot, PGx will be
implemented within three departments of the UMCG
(psychiatry, internal medicine, geriatrics) and clinical
decision support software based on the GASTON® frame-
work will be used and evaluated.
M. Plantinga: None. I. van Langen: None. A. Ran-
chor: None. P. Lanting: None. B. Wilffert: None. R.
Sijmons: None.
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Genome-wide association study of angioedema induced
by ACE inhibitors or ARBs in Sweden
M. Wadelius1, N. Eriksson1,2, C. Johansson3, M. Persson1,
M. Karawajczyk1, L. Nordang1, G. Islander4, S.
Hugosson5, T. Axelsson1, Q. Y. Yue6, P. K. E.
Magnusson7, P. Hallberg1, PREDICTION-ADR
consortium; 1Uppsala University, Uppsala, Sweden,
2Uppsala Clinical Research Center, Uppsala, Sweden, 3Q-
Linea AB, Uppsala, Sweden, 4Skåne University Hospital,
Lund, Sweden, 5Örebro University, Örebro, Sweden,
6Medical Products Agency, Uppsala, Sweden, 7Karolinska
Institutet, Stockholm, Sweden
Introduction: Angioedema is a rare and potentially serious
adverse reaction to angiotensin-converting enzyme (ACE)
inhibitor and angiotensin receptor blocker (ARB) treatment.
It is characterized by a sudden swelling that can be fatal if
the upper airways are involved. Associations between
angioedema and candidate genes in the bradykinin pathway
have been inconsistent. A previous genome-wide associa-
tion study (GWAS) found no genome-wide signiﬁcant
association with a single-nucleotide polymorphism (SNP).
Materials and Methods: We performed a GWAS on
173 patients with angioedema induced by ACE inhibitor or
ARB treatment from Swedegene (http://www.swedegene.
se) and 4890 population controls from TwinGene (http://ki.
se/en/meb/twingene-and-genomeeutwin). Cases and con-
trols were genotyped using the Illumina arrays Huma-
nOmni2.5 and HumanOmniExpress 700K. After quality
control, the merged genotyped set contained 600K SNPs.
The genotyped data was adjusted for gender and principal
components 1–4. After phasing and imputation, the dataset
contained 7.6 million SNPs. The genome-wide signiﬁcance
p-value threshold was set to p<5×10−8 to correct for mul-
tiple testing.
Results: Angioedema was signiﬁcantly associated with
SNPs on chromosome 10 with minor allele frequencies of
0.14 in cases and 0.06 in controls. The strongest associa-
tions were with rs2253201 and rs2253202 located in an
intron of the KCNMA1 gene (odds ratio 2.47 [95% con-
ﬁdence interval 1.79, 3.42], p = 4.31×10−8).
Conclusions: Our GWAS detected a novel association
between angioedema induced by ACE inhibitor or ARB
treatment and the calcium-activated potassium channel gene
KCNMA1.
Funding: The European Union FP7 grant no. 602108 for
PREDICTION-ADR, the Swedish Research Council
(Medicine 521-2011-2440 and 521-2014-3370), and Heart-
Lung Foundation (20120557 and 20140291).
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Inﬂuence of CYPA4*1B, CYP3A5*3, GSTT1 and
GSTM1 polymorphism with treatment-related Chronic
Myeloid Leukemia
E. P. SILVEIRA-LACERDA, K. DELMOND, R. M.
GOVEIA, D. C. ABREU, T. M. TEIXEIRA, R. H.
ROCHA; EDERAL UNIVERSITY OF GOIAS, GOIAS,
Brazil
Imatinib Mesylate (IM) (Gleevec™ [STI571]; is used in
Brazil as a ﬁrst- line drug inhibitor of bcr-abl for Chronic
Myeloid Leukemia treatment. However, cases of treatment
failure or of suboptimal response are sometimes seen. This
study aimed to investigate if variations in polymorphic
genes CYP3A4, CYP3A5 (involved in IM metabolism) and
GSTs (xenobiotics metabolism in general) inﬂuence the IM
treatment response. A total of 107 CML patients in use of
IM from Hospital das Clínicas-UFG, Goiânia, Goiás, Brazil,
were recruited. Response criteria were based on European
Leukemia Net recommendations. Genotyping was carried
out for CYP3A4*1B (-392A>G (rs2740574)), CYP3A5*3
(6986A>G (rs776746)), GSTT1*0 (null allele) and
GSTM1*0 (null allele) polymorphisms by q-PCR. Statistical
analysis was carried out using GraphPad Prism5® software.
The Kaplan-Meier survival analyses method was used to
estimate if there are difference at the time for achieve and
lost response for each genotype. No statistical signiﬁcance
was observed for none genotypes and time for achieve and
lost response. Despite this, a tendency to achieve faster
cytogenetic response in patients with GST1 presence,
GSTM1 deletion and CYP3A5*3 polymorphism together
with functional CYPA3A4 gene was observed. Unlike
CYP3A4 and CYP3A5, GSTT1 and GSTM1 are not spe-
ciﬁc imatinib metabolizers. This study highlights the
importance of population studies to investigate metaboliz-
ing genes inﬂuence in imatinib treatment response.
E.P. Silveira-lacerda: None. K. Delmond: None. R.M.
Goveia: None. D.C. Abreu: None. T.M. Teixeira: None.
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Identiﬁcation of a novel locus associated with asthma
treatment response with inhaled corticosteroids in
African-admixed children
N. Hernandez-Pacheco1, N. Farzan2,3, S. Vijverberg2,3, B.
Francis4, M. Schieck5,6, M. Pirmohamed7, V. Berce8,9, K.
Repnik9,10, U. Potočnik9,10, D. Hawcutt4, M. Kabesch5,11,
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Amsterdam, Amsterdam, Netherlands, 3Division of
Pharmacoepidemiology and Clinical Pharmacology,
Faculty of Science, Utrecht University, Utrecht,
Netherlands, 4Department of Women's and Children's
Health, University of Liverpool, Liverpool, United
Kingdom, 5Department of Pediatric Pneumology and
Allergy, University Children's Hospital Regensburg
(KUNO), Regensburg, Germany, 6Department of Human
Genetics, Hannover Medical School, Hannover,
Germany, 7Department of Molecular and Clinical
Pharmacology, Institute of Translational Medicine,
University of Liverpool, Liverpool, United Kingdom,
8Department of Pediatrics, University Medical Centre
Maribor, Ljubljanska ulica 5, Maribor, Slovenia, 9Centre
for Human Molecular Genetics and Pharmacogenomics,
Faculty of Medicine, University of Maribor, Taborska
ulica 8, Maribor, Slovenia, 10Laboratory for Biochemistry,
Molecular Biology and Genomics, Faculty for Chemistry
and Chemical Engineering, University of Maribor,
Smetanova ulica 17, Maribor, Slovenia, 11Member of the
German Lung Research Center (DZL), Gießen, Germany,
12Population Pharmacogenetics Group, Biomedical
Research Institute, Ninewells Hospital and Medical
School, University of Dundee, Dundee, United Kingdom,
13CIBER de Enfermedades Respiratorias, Instituto de
Salud Carlos III, Madrid, Spain, 14Department of
Medicine, University of California, San Francisco, CA,
United States, 15Department of Bioengineering and
Therapeutic Sciences, University of California, San
Francisco, CA, United States
Introduction: Inhaled corticosteroids (ICS) are the most
widely prescribed asthma controller medication. High
variability in response to ICS has been described among
individuals and populations, with African-Americans hav-
ing a lower response. In fact, ICS treatment can be inef-
fective and patients can suffer severe exacerbations despite
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the use of them. This can be partially attributed to genetic
factors, since a large heritability has been estimated for ICS
response (40–60%). Here, we aimed to identify loci asso-
ciated with asthma exacerbations in children taking ICS.
Methods: We performed a meta-analysis of two genome-
wide association studies (GWAS) of asthma exacerbations
including 1,401 African-admixed individuals from the
GALA II and SAGE II studies. Imputation of genetic var-
iants was carried out using the Haplotype Reference Con-
sortium as reference panel and association testing was
performed with logistic regression models. A total of 8.6
million variants with minor allele frequency ≥1% were
meta-analyzed. Variants with p≤5×10−6 were followed up
in 1,204 participants from three European studies (PAC-
MAN, followMAGICS, and PASS).
Results: Suggestive association was found for 27 poly-
morphisms (p≤5×10−6) in African-admixed individuals, 3
of them showing evidence of replication in the European
populations (p≤5.4×10−3). The most signiﬁcant variant was
located in the intergenic region of the APOBEC3B and
APOBEC3C genes.
Conclusions: We identiﬁed the association of a novel
locus with asthma exacerbations in children despite the use
of ICS.
Supported by Instituto de Salud Carlos III (AC15/00015)
within the ERACoSysMed 1st Joint Transnational Call
(SysPharmPedia), European Union Horizon 2020.
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Management of secondary ﬁndings from whole exome/
genome sequencing: a ﬁrst step into genomic medicine
J. Delanne1,2, O. Putois3,4, A. Chassagne3,5, E. Cretin3,5,
A. Pelissier3,6, C. Peyron3,6, E. Gauthier1, J. Thevenon7,3,2,
S. Nambot1,2, P. Kuentz3,2,8, A. Bruel2, J. Skrzypski9, F.
Ghiringhelli9, R. Boidot9, D. Lehalle1,2, N. Jean-Marçais1,
P. Callier3,2,10, A. Mosca-Boidron2,10, P. Vabres3,2, L.
Demougeot11, C. Poé2, T. Jouan2, M. Chevarin2, M.
Lefebvre1,2, M. Bardou12, E. Tisserant2, M. Luu13, C.
Philippe2,3,10, F. Tran Mau Them2,10,3, C. Binquet12, Y.
Duffourd1,2,3, C. Thauvin-Robinet1,3,2, L. Faivre1,3,11;
Centre de Génétique et Centre de Référence Maladies
Rares ‘Anomalies du Développement de l’Interrégi, Dijon,
France, 2EA 4271 GAD « Génétique des Anomalies du
Développement », IFR 100 - Santé STIC, Université de
Bourgogne, Dijon, France, 3FHU TRANSLAD, Centre
Hospitalier Universitaire et Université de Bourgogne-
Franche Comté, Dijon, France, 4EA 3071 SuLiSoM,
Université de Strasbourg, Strasbourg, France, 5CIC-IT
Inserm 808, CHU de Besançon et Université de
Bourgogne-Franche Comté, Besançon, France, 6EES-
LEDI, Université de Bourgogne – UMR CNRS INSERM,
Dijon, France, 7CHU de Grenoble, département de
génétique et procréation, Grenoble, France, 8EA 3922,
E2SNC, Université de Franche-Comté, UFR Sciences et
Techniques, Laboratoire de Biochimie et de Biologie
moléculaire, Besançon, France, 9Oncogénétique, Centre
Georges François Leclerc, Dijon, France, 10Laboratoire
de génétique moléculaire et de Cytogénétique, Plateau
Technique de Biologie, CHU Dijon, Dijon, France,
11Filière AnDDI-Rares, Centre Hospitalier Universitaire
et Université de Bourgogne-Franche Comté, Dijon,
France, 12CIC, Centre Hospitalier Universitaire et
Université de Bourgogne-Franche Comté, Dijon, France,
13CIC-IT Inserm 808, CHU de Besançon et Université de
Bourgogne-Franche Comté, Dijon, France
Introduction: Genomic medicine is deﬁned by the NHGRI
as “an emerging medical discipline that involves using
genomic information about an individual as part of their
clinical care and the health outcomes and policy implica-
tions of that clinical use”. With next generation sequencing
(NGS), beyond identifying the cause of manifestations that
justiﬁed prescription of the test, other information with
potential interest for patients and their families, deﬁned as
secondary ﬁndings, can be provided to patients once they
have given informed consent, in particular when therapeutic
and preventive options are available. The disclosure of such
ﬁndings has caused much debate amongst ethicists and
healthcare professionals.Materials and Methods: A review
of the literature was performed, focusing on all PubMed
articles reporting qualitative, quantitative or mixed studies
that interviewed healthcare providers, patients, or society
regarding this subject. The methodology was carefully
analysed, in particular whether or not studies distinguished
between actionable and non-actionable secondary ﬁndings.
Results: From 2010 to 2016, 35 articles were compiled
including 29 from North America, three from Australia and
three from Europe. A total of 11,827 people were inter-
viewed in these studies (1,098 patients, 3,224 healthcare
providers, 7,505 representatives of society at large). When
actionable and non-actionable secondary ﬁndings were
analysed separately (76%), about 93% of respondents were
keen to have results regarding actionable secondary ﬁnd-
ings, against 71% for non-actionable secondary ﬁndings.
Conclusions: This review shows the need to consider this
option among diagnostic labs. An effort should be made to
develop educative tools to facilitate decision-making.
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Using genome editing to identify and characterize
functional variants that determine response to
metformin
M. Keller1, J. Dalla-Riva1, N. Wierup1, C. Ling1, E.
Renström1, H. Mulder1, P. Franks1,2,3
1Lund University, Malmö, Sweden, 2Umeå University,
Umeå, Sweden, 3Harvard T. H. Chan School of Public
Health, Boston, MA, United States
Introduction: Several pharmacogenetics studies have
identiﬁed that the minor allele at rs2289669 in intron 10 of
the SLC47A1, which codes for the metformin transporter
multidrug and toxin extrusion 1 (MATE1), is associated
with a greater reduction in HbA1c levels. However, it is
currently not known if rs2289669 is itself causal or how this
functional variant operates at the molecular level. To
address these questions, we combined in silico analysis with
in vitro genome engineering using the CRISPR-Cas9 sys-
tem in human Huh-7 hepatocytes. Materials/Methods:
Functional annotation using ANNOVAR for all SNPs in
tight LD with rs2289669 revealed rs8065082 as the top
ranking functional candidate. Two gRNAs per SNP target
were designed, cloned into a Cas9 plasmid vector and
optimized for high transfection efﬁciency in Huh-7 cells.
Further, to generate SLC47A1/MATE1 KO cells, prede-
signed gRNAs were used to excise a ~2kb region for
functional downstream analysis using metformin treatment.
Finally, the same gRNAs will be used to perform CRISPR-
Cas9 individual SNP editing experiments. Results:
SLC47A1/MATE1 KO cells show ~60% reduction in
SLC47A1/MATE1 mRNA expression as well as ~88%
lowered MATE1 protein level in a heterogeneous cell
population. Functional downstream experiments, comparing
clonal cell populations of SLC47A1/MATE1 KO and
WT cells, and testing metformin-dependent inhibition of
gluconeogenesis as well as the effect of lifestyle mimetics
(e.g. AICAR) on potential gene x environment interactions,
are ongoing. Conclusion: This study will contribute to
illuminate the underlying functional effect of metformin in
hepatocytes as well as the identiﬁcation of the functional
polymorphism.
Funding: European Research Council
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New susceptibility loci for cold medicine-related Ste-
vens-Johnson syndrome with severe ocular complica-
tions identiﬁed by GWAS using an ethnicity-speciﬁc
SNP array
K. Tokunaga1, M. Ueta2, H. Sawai1, Y. Kawai3, C.
Sotozono2, K. Kojima3, M. Nagasaki3, S. Kinoshita2;
Graduate School of Medicine, University of Tokyo, Tokyo,
Japan, 2Kyoto Prefectural University of Medicine, Kyoto,
Japan, 3Tohoku Medical Megabank Organization,
Tohoku University, Sendai, Japan
A genome-wide association study (GWAS) for cold
medicine-related Stevens-Johnson syndrome (CM-SJS)
with severe ocular complications (SOC) was performed in a
Japanese population with 117 patient and 691 control
samples. A recently developed ethnicity-speciﬁc array
(Japonica Array) with genome-wide imputation that was
based on the whole-genome sequences of 1,070 unrelated
Japanese individuals was used. Validation analysis with
additional samples from Japanese individuals and replica-
tion analysis using samples from Korean individuals iden-
tiﬁed two new susceptibility loci on chromosomes 15 and
16. Moreover, combination of variants' effects between the
previously identiﬁed risk allele, HLA-A*02:06, and the
newly detected risk variants were observed. This study
conﬁrmed the usefulness of GWAS using the ethnicity-
speciﬁc array and genome-wide imputation based on large-
scale whole-genome sequences. These ﬁndings contribute
to the understanding of genetic predisposition to CM-SJS
with SOC.
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Tacrolimus troughs in Caucasians with two CYP3A5
loss-of-function alleles: Evidence for additional genetic
inﬂuences using a genome wide association study
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W. S. Oetting1, B. Wu1, D. P. Schladt2, W. Guan1, R. P.
Remmel1, R. B. Mannon3, A. J. Matas1, A. K. Israni4, P.
A. Jacobson1
1University of Minnesota, Minneapolis, MN, United States,
2Minneapolis Medical Research Foundation, Minneapolis,
MN, United States, 3University of Alabama, Birmingham,
MN, United States, 4Hennepin County Medical Center,
Minneapolis, MN, United States
Background. The commonly used immunosuppressant
tacrolimus (TAC) is metabolized by cytochrome P450
(CYP) 3A4 and CYP3A5 enzymes. The presence of the
CYP3A5*1 allele is well-known to increase TAC metabo-
lism. However, it is common for Caucasian recipients to
carry two CYP3A5 loss-of-function (LoF) variants which
profoundly reduces TAC metabolism. We observed that
individuals who carry two LoF alleles have considerable
variability in TAC trough blood concentrations, even in the
absence of CYP3A5 enzyme activity. We hypothesize that
variants in genes outside of CYP3A5 will provide insight
into this variability.
Methods. We analyzed TAC trough levels in 1,446 adult
Caucasian kidney allograft recipients having two CYP3A5
LoF alleles (*3, rs776746; *6, rs10264272; or *7,
rs41303343) resulting in reduced or absent CYP3A5 func-
tion. We used a genome wide association study (GWAS) to
identify additional genetic variants associated with dose
normalized TAC trough variation.
Results. The GWAS of Caucasian recipients identiﬁed
several variants within CYP3A4, including CYP3A4*22
(rs35599367, p=2.21e−17), previously associated with TAC
trough variation. After adjusting for this variant, no other
common variants were genome wide signiﬁcant. However,
we identiﬁed several less frequent variants showing pro-
mising evidence of association including rs34104306 in
EPHB2 (p=1.98e−9, MAF=0.015) rs147025569 in POLQ
(p=4.22e−7, MAF=0.011) and an Alu ins/del in NEBL
(p=3.97e−7, MAF=0.06).
Conclusion. Additional high allele frequency genetic
variants associated with TAC trough variability are unlikely
to be present in Caucasian recipients. These data suggest
that low allele frequency variants identiﬁed by DNA
sequencing should be evaluated and may contribute to
pharmacokinetic variability of TAC metabolism.
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Utilization of genetic data can improve the prediction of
type 2 diabetes incidence in a Swedish cohort
H. Fakhrai-Rad; aseHealth Inc., Sunnyvale, CA, United
States
The aim of this study was to measure the impact of genetic
data in improving the prediction of type 2 diabetes (T2D) in
a Swedish cohort. The current study was performed in 3,835
Swedish individuals and utilizes a set of genetic and
environmental risk data. We ﬁrst veriﬁed that the genetic
data has a statistically signiﬁcant positive correlation with
incidence of T2D in the studied population. We also ver-
iﬁed that adding genetic data slightly but statistically
increased the Area Under Curve (AUC) of a model based
only on environmental risk factors (AUC shift + 1.0%, p-
value = 0.0194). We veriﬁed that the improved AUC will
result in 2% improvement in sensitivity or speciﬁcity of
T2D predictions. To study the dependence of the results on
the environmental risk factors, we divided the population
into two equally sized risk groups based only on their
environmental risk and repeated the same analysis within
each subpopulation. While there is a statistically signiﬁcant
positive correlation between the genetic data and incidence
of T2D in both environmental risk categories, the positive
shift in the AUC remains statistically signiﬁcant only in the
category with the lower environmental risk (p-value =
0.0189). These results demonstrate that genetic data can be
used to increase the accuracy of T2D prediction. Also, the
data suggests that genetic data is more valuable in
improving T2D prediction in populations with lower
environmental risk. Finally, it suggests that genetic asso-
ciation studies should be performed in light of the under-
lying environmental risk of the population.
H. Fakhrai-Rad: A. Employment (full or part-time);
Signiﬁcant; BaseHealth Inc.. E. Ownership Interest (stock,
stock options, patent or other intellectual property); Sig-
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The pharmacogenetics of metformin and its effect on
plasma metformin concentration and glycated
hemoglobin
B. Bankura1, A. Roy2, S. Chowdhury2, K. V. Desai3, M.
Das1
1University of Calcutta, Kolkata, India, 2Institute of Post-
Graduate Medical Education and Research, Kolkata, India,
3National Institute of Biomedical Genomics, Kalyani, India
Introduction: Metformin is the most often used ﬁrst line
pharmacotherapy for Type 2 Diabetes (T2D) treatment;
however considerable interindividual variability in clinical
efﬁcacy of metformin is recognized. The goal of this study
was to investigate variability in genes coding for metformin
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transporters (OCT1, OCT2, OCT3, MATE1, MATE2, and
PMAT) and metformin molecular targets (LKB1, ATM) to
identify the speciﬁc genetic variants associated with intol-
erance and efﬁcacy of metformin therapy.
Materials and Methods: A total of 206 treatment naïve
newly diagnosed T2D patients were included in this study.
To identify the genetic alterations, Ion PGM next-
generation sequencing method was used. Patients received
500 mg dose of metformin followed by collection of blood
and urine samples for pharmacokinetics study of metformin.
Results: In this study, 121 variants were identiﬁed in
metformin responders and non-responders. Three functional
variants: R287G, G401S and 420del identiﬁed in OCT1
gene and correlate with metformin non-responsiveness. The
rs2457574, rs4724524, rs587781368, rs7225817,
rs139394521 and rs7223097 are signiﬁcantly associated
with metformin non-responder, whereas rs3218681 is
associated with metformin response. Pharmacokinetic
properties of metformin, including AUC, V/F, and Cmax
were signiﬁcantly different between the individuals who
carried one of the reduced function alleles, R287G, G401S
or 420del and those who carried only OCT1- reference
alleles.
Conclusions: Genetic alteration in OCT1, is the most
important aspect for the metformin glycemic response in
West Bengal, India. OCT1 activity affects metformin
steady-state pharmacokinetics, and OCT1 genotype has a
bearing on HbA1C during metformin treatment.
Grant: DBT, India [BT/PR5917/MED/12/568/2012-20/
2007].
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GeneHancer: Genome-wide integration and scoring of
enhancers and target genes in GeneCards
R. Nudel, S. Fishilevich, N. Rappaport, N. Rosen, R.
Hadar, T. Iny Stein, M. Twik, M. Safran, D. Cohen, D.
Lancet; eizmann Institute of Science, Rehovot, Israel
A major challenge in the ﬁeld of transcription regulation is
identifying the connections between enhancers and genes,
key to the understanding of developmental and disease
mechanisms. We present GeneHancer, a novel database of
human enhancers and their inferred target genes, in the
framework of GeneCards (www.genecards.org). First, we
integrated data from four databases that reported enhancers
in the human genome: a) ENCODE, with ~176,000 pre-
dicted enhancer-like regions; b) Ensembl, with ~213,000
regulatory build-predicted enhancers; c) FANTOM, with
~43,000 enhancer RNA (eRNA) enhancers; d) VISTA, with
~1,700 enhancers validated by transgenic mouse assays.
Subsequently, we generated gene-enhancer maps and
combinatorial scores using information that helped link
enhancers to genes: 1) GTEx expression quantitative trait
loci (eQTLs), whereby a signiﬁcant genetic association
occurs between variants in enhancers and the expression of
candidate target genes; 2) Capture Hi-C promoter-enhancer
long range interactions; 3) FANTOM expression correla-
tions between eRNAs and candidate target genes; 4) Cross-
tissue expression correlations between transcription factors
interacting with enhancers and candidate target genes; 5)
Enhancer-gene physical distance. GeneHancer presents
~285,000 integrated enhancers connected to ~101,000
genes. Deﬁning “elite” as supported by ≥2 data sources, we
highlight ~40,000 double-elite gene-enhancer pairs as most
relevant to whole genome sequence analyses. To this end
we are also upgrading our VarElect/TGex WGS analysis
and interpretation tools so as to map variants to uniﬁed
enhancers, identify their high-scoring target genes, and
interpret the results in terms of gene-phenotype/disease
keywords. Supported by LifeMap Sciences Inc.
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Comorbidity landscape of the Danish patient population
affected by chromosomal abnormalities
F. Russo1, I. Friis Jørgensen1, D. Westergaard1, A. Boeck
Jensen2, J. Xin Hu1, K. Belling1, S. Brunak1
1Novo Nordisk Foundation Center for Protein Research,
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Introduction: In this work we present a systematic and
comparative analysis of comorbidities in the Danish popu-
lation for patients affected by the chromosomal abnormal-
ities such as Klinefelter (47,XXY), Turner (45,X) and
Down syndromes (47,XX/XY+ 21).
Material and Methods: We analysed data from elec-
tronic patient records in the Danish National Patient Reg-
istry. The registry includes 6.9 million patients hospitalized
between 1994 and 2015 and comprises more than 108
million hospital encounters. We quantiﬁed the association
between chromosomal abnormalities and diseases by cal-
culating the age and sex corrected relative risk, using a
matched background population.
Results: We identiﬁed 9,803 patients with a chromoso-
mal abnormality in this dataset (ICD-10 codes Q90-Q99).
This epidemiological and data driven approach pointed out
a speciﬁc signature of comorbidities for each chromosomal
instability considered. However, there was also interesting
overlaps between co-occurring diseases including diabetes,
hearing loss and infectious diseases.
Conclusions: Patients with chromosomal abnormalities
are predisposed for a wide range of diseases. By studying
comorbid diseases we can shed light on the genetic
mechanisms that drive these diseases. In this study we
presented a population wide comparative analysis of
comorbidities in patients affected by chromosomal
abnormalities. We found that even though each chromoso-
mal disease had a unique comorbidity signature, there are
still overlaps pointing towards shared genetic mechanisms
or pleiotropic effects. Taken together, these results high-
lighted a deeper understanding of chromosomal disorders
that can be exploited in prospective studies. Future direc-
tions will consider the integration of more data types
including genomic, proteomic or even socioeconomic data.
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panelcn.MOPS: CNV detection in targeted NGS panel
data for clinical diagnostics
G. Povysil1, A. Tzika2, J. Vogt2, V. Haunschmid1, L.
Messiaen3, J. Zschocke2, G. Klambauer1, S. Hochreiter1,
K. Wimmer2; Institute of Bioinformatics, Johannes Kepler
University Linz, Linz, Austria, 2Division of Human
Genetics, Medical University Innsbruck, Innsbruck,
Austria, 3Medical Genomics Laboratory, Department of
Genetics, University of Alabama at Birmingham,
Birmingham, AL, United States
Targeted next-generation-sequencing (NGS) panels have
largely replaced Sanger sequencing in clinical diagnostics.
Enrichment-based targeted NGS panels allow for the
detection of copy-number-variations (CNVs) in addition to
single-nucleotide-variants and small insertions/deletions.
However, existing computational CNV detection methods
have shortcomings regarding accuracy, quality control,
incidental ﬁndings, and user-friendliness.
To solve these problems we developed panelcn.MOPS, a
novel pipeline for detecting CNVs in targeted NGS panel
data. Using NGS panel data from 170 samples, we com-
pared panelcn.MOPS with 5 state-of-the-art methods.
We present the ﬁrst thorough comparison of CNV
detection methods for targeted NGS panel data. Most
methods achieved comparably high sensitivity and/or spe-
ciﬁcity, but panelcn.MOPS led the ﬁeld with a sensitivity
and speciﬁcity of 100%. panelcn.MOPS reliably detected
CNVs ranging in size from 20 nucleotides (only part of a
region-of-interest - ROI), to whole genes, which may
comprise all ROIs investigated in a given sample. The latter
is enabled by analyzing reads from all ROIs of the panel,
but presenting results exclusively for user-selected genes,
thus, avoiding incidental ﬁndings. Additionally, panelcn.
MOPS offers quality control criteria not only for samples
but also for individual ROIs within a sample which
increases the conﬁdence in called CNVs.
panelcn.MOPS is freely available both as an R package
and as standalone software with an intuitive graphical user
interface. It can therefore readily be used by clinical
geneticists without any programming experience or inte-
grated into existing analysis pipelines. Taken together,
panelcn.MOPS combines high sensitivity and speciﬁcity
with user-friendliness rendering it highly suitable for rou-
tine clinical diagnostics.
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High-throughput clonal analysis of tumors with droplet
microﬂuidics
D. Eastburn, M. Pellegrino, S. Treusch, A. Sciambi;
Mission Bio, Inc., South San Francisco, CA, United States
Single cell analysis tools are crucial to understand the role
that rare or heterogeneous cancer cells play in the evolution
of tumor progression. To enable the characterization of
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genetic diversity within cancer cell populations, we devel-
oped a novel approach that barcodes ampliﬁed genomic
DNA of individual cells conﬁned to microﬂuidic droplets.
The barcodes are used to reassemble the genetic proﬁles of
individual cells from next-generation sequencing data. A
key feature of our approach is the “two-step” microﬂuidic
workﬂow. The microﬂuidic workﬂow ﬁrst encapsulates
individual cells in droplets, lyses the cells and prepares the
genomic DNA for ampliﬁcation with proteases. Following
this lysate preparation step, the proteases are inactivated and
droplets containing the genomes of individual cells are then
paired with molecular barcodes and PCR reagents. We
demonstrate that the two-step microﬂuidic approach is
superior to workﬂows without the two-step process for
efﬁcient DNA ampliﬁcation on tens of thousands of indi-
vidual cells per run with high coverage uniformity and low
allelic dropout of targeted genomic loci. To apply our
single-cell sequencing technology to human tumor samples,
we developed a targeted panel to sequence genes frequently
mutated in acute myeloid leukemia (AML) including TP53,
DNMT3A, FLT3, NPM1, NRAS, IDH1 and IDH2. Using
this panel, we were able to sensitively identify clonal
populations from AML research samples; moreover, the
single-cell nature of our approach enabled the correlation of
multiple mutations within subclones. Collectively, our
results show a greater degree of heterogeneity in AML
tumor samples than is commonly appreciated with bulk
sequencing methods.
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Myeloid gene expression in acute lymphoblastic leuke-
mia with very early relapse
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Núñez-Enríquez3, J. M. Mejía-Aranguré3, G. B. Martínez-
Morales3, M. L. Pérez-Saldívar3, J. Flores-Lujano3, V. C.
Bekker-Méndez4, J. G. Peñaloza-González5, L. E. Merino-
Pasaye6, K. A. Solis-Labastida3, J. R. Torres-Nava7, F. O.
Beltrán-Anaya8, A. Hidalgo-Miranda2; Programa de
Posgrado en Ciencias Biológicas, UNAM, Mexico City,
Mexico, 2Instituto Nacional de Medicina Genómica,
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XXI, IMSS, Mexico City, Mexico, 4Centro Médico
Nacional La Raza, IMSS, Mexico City, Mexico, 5Hospital
Juárez de México, Mexico City, Mexico, 6Centro Médico
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7Hospital Pediátrico de Moctezuma, Mexico City, Mexico,
8Programa de Doctorado en Ciencias Biomédicas UNAM,
Mexico City, Mexico
Introduction: Acute lymphoblastic leukemia (ALL) is the
most common childhood cancer in Mexico, where a high
mortality rate from this disease has been reported. ALL very
early relapse (VER: within 18 months from diagnosis) in
one of the main causes of death in this country. To identify
genes involved in VER as well as potential prognostic
biomarkers we performed a whole gene expression analysis
in Mexican pediatric patients.
Materials and methods: We obtained 57 total bone
marrow samples (49 at diagnosis and 8 at VER) from
patients under 18 years old with pre-B ALL. Gene
expression analysis was carried out using oligonucleotide
microarrays HTA 2.0 (Affymetrix). To identify differen-
tially expressed genes in VER samples we used TAC
software (Affymetrix). Genes with a FC of 1.5 and FDR
<0.05 were considered statistically signiﬁcant. Pathway
enrichment analysis and biological processes were per-
formed with IPA (QIAGEN) and Gene Ontology.
Results: We found 288 differentially expressed genes in
the VER group, of which, genes (EBF1, BLNK, PAX5 and
DNTT) involved in B-cell differentiation were down regu-
lated. Meanwhile, myeloid lineage genes such as CEBPA,
S100A9, RAB31 and MPO (p < 0.02, 0.004, 0.0007, 0.001,
respectively) were up regulated. Other differential expres-
sed genes were associated with infectious and respiratory
diseases.
Conclusion: Our analysis support previous evidences
suggesting that low expression of PAX5 and EBF1 switch
from B-cell to myeloid lineage gene expression during ALL
relapse and exhibited those genes as potential biomarkers in
VER in ALL. More studies are needed to validate these
ﬁndings.
D.A. Bárcenas-López: None. S. Jiménez-Morales:
None. J.C. Núñez-Enríquez: None. J.M. Mejía-Ara-
nguré: None. G.B. Martínez-Morales: None.M.L. Pérez-
Saldívar: None. J. Flores-Lujano: None. V.C. Bekker-
Méndez: None. J.G. Peñaloza-González: None. L.E.
Merino-Pasaye: None. K.A. Solis-Labastida: None. J.R.
Torres-Nava: None. F.O. Beltrán-Anaya: None. A.
Hidalgo-Miranda: None.
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P16.06B
Allele balance based variant callability score for whole
exome sequencing
F. Muyas, M. Bosio, L. Zapata, H. Susak, R. Rabionet, A.
Puig, S. Ossowski; Center for Genomic Regulation
(CRG), Barcelona, Spain
Introduction: Next generation sequencing (NGS) sig-
niﬁcantly changed biomedical research in the last years.
Nonetheless, the use of high-throughput DNA sequencing
for identiﬁcation of causal/associated variants is highly
sensitive to technical –random and systematic- errors, which
can lead to false associations. Therefore, understanding and
identifying systematic errors is needed to avoid misleading
results in NGS analysis.
Methods: We present a callability score based on allele
balance (AB) (proportion of reads supporting alternative
alleles in a speciﬁc genomic position) to detect systematic
errors. Speciﬁcally, the relation between the recurrent AB
bias (ABB) and false positive (FP) calls. In a cohort of 987
exome samples, we obtained AB distribution models for all
possible DNA genotypes and measured the recurrence of
ABB across all positions. Using these measures, we
developed a logistic regression model able to predict
recurrent ABB in independent samples (benchmarked in
200 independent samples).
Results: Our callability score (ABB-score) showed high
precision and recall for detecting ABB (positively corre-
lated with FP rates) in germline variant calling pipelines
(~4% of the GATK variants calls), ~50% of which were
found to be FP with Sanger validation. Additionally, it
labeled ~8% of the conﬁdent somatic calls reported by
MuTect for 450 cancer exomes (Chronic lymphocytic leu-
kemia) as likely FP calls.
Conclusion: We have developed a variant callability
score (ABB-score) able to identify FP calls caused by
systematic sequencing or alignment errors in the human
exome. This model can be integrated in disease variant
prioritization-association pipelines to remove spurious
results and reﬁne true positive variants.
F. Muyas: None.M. Bosio: None. L. Zapata: None. H.
Susak: None. R. Rabionet: None. A. Puig: None. S.
Ossowski: None.
P16.07C
Improving gene annotation to identify missing variants
of clinical signiﬁcance
C. A. Steward1, M. M. Suner2, D. Pervouchine3, B.
Uszczynska-Ratajczak3, J. M. Gonzalez2, S. Fitzgerald2, D.
Grozeva4, K. Carss5, P. Cossette6, F. Hamdan7, R.
Petryszak8, E. Tapanari8, M. Diekhans9, B. A.
Minassian10, F. L. Raymond4, R. Guigó3, A. Frankish2;
Congenica, Cambridge, United Kingdom, 2Wellcome
Trust Sanger Institute, Cambridge, United Kingdom,
3Centre for Genomic Regulation, Barcelona, Spain,
4Cambridge Institute for Medical Research, Cambridge,
United Kingdom, 5University of Cambridge, Cambridge,
United Kingdom, 6Centre Hospitalier de l'Universite de
Montreal, Montreal, QC, Canada, 7Hopital Ste Justine,
Montreal, QC, Canada, 8European Bioinformatics
Institute, Cambridge, United Kingdom, 9UCSC, Santa
Cruz, CA, United States, 10The Hospital for Sick Children,
Toronto, ON, Canada
High quality gene models provide a foundation for the
annotation of sequence variation in clinical samples. Com-
plete and accurate annotation of gene structure and function
is essential to reduce both false negative (from missing
annotation) and false positive (from incorrect annotation)
errors in identiﬁcation of disease-associated variants. As
part of the GENCODE project, we produce detailed refer-
ence annotation of all human and mouse protein-coding
genes. We will describe the re-annotation of 70 genes on
reference diagnostic panels for Early Infantile Epileptic
Encephalopathies (EIEE), a group of disorders character-
ized by early onset seizures and developmental delay.The
re-annotation utilised public transcriptional evidence,
focussing on next-generation sequence data from human
brain. We used RNAseq, SLRseq and PacBio reads to ﬁnd
new alternative splicing (AS) events; novel exon inclusion
and skipping, and shifted splice sites. Although these genes
had been annotated previously by GENCODE, with 685 AS
transcripts compared to 193 in the RefSeq geneset, our re-
annotation added a further 1092 AS transcripts, 706 novel
exons, 224 shifted splice sites and more than 141kb addi-
tional genomic coverage of which approximately 15.2kb
represented novel CDS. More than 80% of these novel
splice features were expressed in foetal brain and ~30% of
those in the CDS show high cross-species sequence con-
servation, suggesting functionality. Variants in the SCN1A
gene are responsible for the majority of cases of the EIEE
Dravet syndrome. We will describe a study using updated
SCN1A annotation to identify variants missed using pre-
existing annotation and discuss the novel pathogenic var-
iants found.
C.A. Steward: A. Employment (full or part-time); Sig-
niﬁcant; Congenica. M.M. Suner: None. D. Pervouchine:
None. B. Uszczynska-Ratajczak: None. J.M. Gonzalez:
None. S. Fitzgerald: None. D. Grozeva: None. K. Carss:
None. P. Cossette: None. F. Hamdan: None. R. Pet-
ryszak: None. E. Tapanari: None.M. Diekhans: None. B.
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P16.08D
Efﬁcient de novo structural variation analysis and
annotation using Bionano's Next-Generation Mapping
(NGM) technique
A. Pang1, K. Sugerman1, J. Lee1, M. Austin1, M.
Saghbini1, A. Hastie1, H. Cao1, M. Borodkin1, G.
Papoutsoglou2
1Bionano Genomics, San Diego, CA, United States, 2Bio-
Nano Genomics, San Diego, CA, United States
De novo mutations are known to cause genetic diseases.
With the advent of family-based whole genome techniques,
de novo mutations can now be detected. De novo structural
variation (SV), beyond large deletions and duplications,
remains elusive by sequencing. Short reads can miss com-
plex SVs, and makes false calls due to high error rates and
misalignments.
The Bionano Saphyr™ system captures long DNA to
delineate SV structures. DNA molecules measuring greater
than 100 kbp are extracted from 2 mL of whole blood,
labelled at speciﬁc motifs, and linearized through Nano-
Channels arrays for subsequent visualization. Digitized
images of those molecules are then assembled de novo,
creating megabases long assembled optical maps. While our
calling algorithm can sensitively detect homozygous and
heterozygous SVs in these long maps, we also use a variant-
annotation workﬂow to speciﬁcally uncover de novo SVs, a
key feature for family studies.
We ran a quintet family with three autistic children. For
each sample, we collected 100x coverage depth across the
genome, generated de novo assemblies, detected and
annotated heredity for SVs. This process, from sample
collection to SV-discovery took only one week on one
Saphyr system. In each sample, we detected >3,500 inser-
tions and deletions >500 bp. We found 3–4 de novo SVs in
each child, one of which was shared, suggesting that this
was a mosaic in a parent. This workﬂow enables efﬁcient
selection of candidates for curation. With one comprehen-
sive platform, Saphyr may replace conventional approaches
for discovery of functionally-relevant variants, and
improves our understanding of genomes.
A. Pang: A. Employment (full or part-time); Signiﬁcant;
Bionano Genomics. K. Sugerman: A. Employment (full or
part-time); Signiﬁcant; Bionano Genomics. J. Lee: A.
Employment (full or part-time); Signiﬁcant; Bionano
Genomics. M. Austin: A. Employment (full or part-time);
Signiﬁcant; Bionano Genomics. M. Saghbini: A.
Employment (full or part-time); Signiﬁcant; Bionano
Genomics. A. Hastie: A. Employment (full or part-time);
Signiﬁcant; Bionano Genomics. H. Cao: A. Employment
(full or part-time); Signiﬁcant; Bionano Genomics. M.
Borodkin: A. Employment (full or part-time); Signiﬁcant;
Bionano Genomics. G. Papoutsoglou: None.
P16.09A
Cross-Species Genomics Explorer™ for disease
mutation identiﬁcation through cross-species analysis
S. C. Wong, S. Häkkinen, M. Kuisma, K. Ojala, H.
Edgren; edisapiens Ltd, Helsinki, Finland
Recent developments in ngs technologies have made them
widely used in the diagnosis of inherited diseases and
developmental conditions. However, in a sizable fraction of
cases, no causative mutation can be pinpointed with high
certainty. This is likely to be the case especially when only a
single member of a family is affected, or the presentation of
a condition is atypical. In these cases, the use of phenotypic
data on animals with targeted genetic alterations is an
intriguing possibility to narrow down on a speciﬁc mutation
as likely causative. However, effective cross-species use of
genotype-phenotype data is hampered by the difﬁculty in
effectively accessing this data and using it together with the
sequencing data itself.
To solve this problem, we have developed Cross-Species
Genomics Explorer™, a browser based system that enables
efﬁcient and ﬂexible analysis of (human) genomics data in a
cross-species context. It incorporates a variant storage and
analytic system for big variant data together with efﬁcient
exploration of human genetic variants. This exploration is
done in the context of the variants’ orthologous positions in
the genomes of model organisms, through multi-species
genome tracks and on the ﬂy cross-species genome build
conversion. Together with an extensive database of the
known phenotypic consequences of genetic alterations in
model organisms, this allows researchers to quickly test
human hypotheses against data on organisms such as
mouse, zebraﬁsh or fruitﬂy and, conversely, starting from
model organism data and speciﬁc genotype-phenotype
observations, generate hypotheses about human gene
function in health and disease.
S.C. Wong: A. Employment (full or part-time); Sig-
niﬁcant; Medisapiens Ltd. S. Häkkinen: A. Employment
(full or part-time); Signiﬁcant; MediSapiens Ltd. M.
Kuisma: A. Employment (full or part-time); Signiﬁcant;
MediSapiens Ltd. K. Ojala: A. Employment (full or part-
time); Signiﬁcant; MediSapiens Ltd. E. Ownership Interest
(stock, stock options, patent or other intellectual property);
Signiﬁcant; MediSapiens Ltd. H. Edgren: A. Employment
(full or part-time); Signiﬁcant; MediSapiens Ltd. E.
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P16.10B
CAW - Cancer Analysis Workﬂow to process normal/
tumor WGS data
M. Garcia1, S. Juhos2, M. Larsson3, T. Diaz de Ståhl4, J.
Eisfeldt5, S. DiLorenzo6, P. Olason7, B. Nystedt7, M.
Nistér4, M. Käller8
1BarnTumörBanken, Department of Oncology Pathology,
Science for Life Laboratory, Karolinska Institutet, Solna,
Sweden, 2Department of Biochemistry and Biophysics,
Science for Life Laboratory, Stockholm University, Solna,
Sweden, 3Science for Life laboratory, Department of
Physics, Chemistry and Biology, Linköping University,
Linköping, Sweden, 4BarnTumörBanken, Department of
Oncology Pathology, Karolinska Institutet, Solna, Sweden,
5Clinical Genetics, Department of Molecular Medicine and
Surgery, Karolinska Institutet, Solna, Sweden, 6Department
of Medical Sciences, National Bioinformatics Infrastructure
Sweden, Science for Life Laboratory, Uppsala University,
Uppsala, Sweden, 7Science for Life Laboratory, Depart-
ment of Cell and Molecular Biology, Uppsala University,
Uppsala, Sweden, 8Science for Life Laboratory, School of
Biotechnology, Division of Gene Technology, Royal
Institute of Technology, Solna, Sweden
As whole genome sequencing is getting cheaper, it is viable
to compare NGS data from normal and tumor samples of
numerous patients. There are still many challenges, mostly
regarding bioinformatics: datasets are huge, workﬂows are
complex, and there are multiple tools to choose from for
somatic and structural variants and quality control.
We are presenting CAW (Cancer Analysis Workﬂow) a
complete open source pipeline to resolve somatic variants
from WGS data: it is written in Nextﬂow, a domain speciﬁc
language for workﬂow building. We are utilizing GATK
best practices to align, realign and recalibrate short-read
data in parallel for both tumor and normal sample. After
these preprocessing steps several somatic variant callers
scan the resulting BAM ﬁles; MuTect1, MuTect2 and
Strelka are used to ﬁnd somatic SNVs and small indels.For
structural variants we use Manta. Furthermore, we are
applying ASCAT to estimate sample heterogeneity, ploidy
and CNVs.
The software can start the analysis from raw FASTQ
ﬁles, from the realignment step, or directly with any subset
of variant callers. At the end of the analysis the resulting
VCF ﬁles are merged to facilitate further downstream pro-
cessing, though the individual results are also retained. The
ﬂow is capable of accommodating further variant calling
software or CNV callers. It is also prepared to process
normal - tumor - and several relapse samples.
Besides variant calls, the workﬂow provides quality
controls presented by MultiQC. A docker image is also
available, the open source software can be downloaded
from https://github.com/SciLifeLab/CAW .
M. Garcia: None. S. Juhos: None. M. Larsson: None.
T. Diaz de Ståhl: None. J. Eisfeldt: None. S. DiLorenzo:
None. P. Olason: None. B. Nystedt: None. M. Nistér:
None. M. Käller: None.
P16.11C
MR-Base: a platform for systematic causal inference
across the phenome using billions of genetic associations
G. Hemani1, J. Zheng1, K. H. Wade1, C. Laurin1, B.
Elsworth1, S. Burgess2, J. Bowden1, R. Langdon1, V.
Tan1, J. Yarmolinsky1, H. A. Shihab1, N. Timpson1, D. M.
Evans1,3, C. Relton1, R. M. Martin1, G. Davey Smith1, T.
R. Gaunt1, P. C. Haycock1; University of Bristol, Bristol,
United Kingdom, 2University of Cambridge, Cambridge,
United Kingdom, 3University of Queensland Diamantina
Institute, Brisbane, Australia
Published genetic associations can be used to infer causal
relationships between phenotypes, bypassing the need for
individual-level genotype or phenotype data. We have
curated complete summary data from 1094 genome-wide
association studies (GWAS) on diseases and other complex
traits into a centralised database, and developed an analy-
tical platform that uses these data to perform Mendelian
randomization (MR) tests and sensitivity analyses (MR-
Base, http://www.mrbase.org). Combined with curated data
of published GWAS hits for phenomic measures, the MR-
Base platform enables millions of potential causal rela-
tionships to be evaluated. We use the platform to predict the
impact of lipid lowering on human health. While our ana-
lysis provides evidence that reducing LDL-cholesterol,
lipoprotein(a) or triglyceride levels reduce coronary disease
risk, it also suggests causal effects on a number of other
non-vascular outcomes, indicating potential for adverse-
effects or drug repositioning of lipid-lowering therapies.
Supported by Cancer Research UK grants C18281/
A19169 (the Integrative Cancer Epidemiology Programme)
and C52724/A20138 (PCH), the Roy Castle Lung Cancer
Foundation 2013/18/Relton, Medical Research Council
grants MC_UU_12013/1, MC_UU_12013/2,
MC_UU_12013/8 (MRC Integrative Epidemiology Unit)
and MR/N501906/1 (JB), the Australian Research Council
Future Fellowship FT130101709 (DME).
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Patient Archive: A platform for clinical deep
phenotyping
T. Groza1,2, T. Roscioli3, G. Baynam4, H. Dawkins5, M.
Haendel6, C. Mungall7, D. Smedley8, P. Robinson9, M.
Dinger1, A. Zankl10
1Kinghorn Centre for Clinical Genomics, Darlinghurst,
Australia, 2St Vincent's Clinical School, Faculty of
Medicine, UNSW Australia, Sydney, Australia, 3Kinghorn
Centre for Clinical Genomics, Sydney, Australia, 4Genetic
Services of Western Australia, Perth, Australia, 5Ofﬁce of
Population Health Genomics, Perth, Australia, 6Oregon
Health & Science University, Portland, OR, United States,
7Lawrence Berkeley National Laboratory, Berkeley, CA,
United States, 8Queen Mary University of London, London,
United Kingdom, 9The Jackson Laboratory for Genomic
Medicine, Farmington, CT, United States, 10The University
of Sydney, Sydney, Australia
Phenotype has long been used to substantially reduce the
search-space for genomic variation and to determine
underlying genetic etiologies. The incomplete linking of
detailed phenotypic terms to genomic variants is now the
major factor limiting rapid diagnostics. The Monarch
Initiative develops data models, algorithms and platforms to
enable translational deep phenotyping. Patient Archive
(PA), a platform part of the Monarch suite, focuses on
accurate clinical phenotyping to facilitate disease stratiﬁ-
cation and exploration of the candidate gene space. PA uses
the widely adopted Human Phenotype Ontology to create
structured patient phenotype proﬁles and supports both
bottom-up, as well as top-down phenotyping. The former
emulates the standard clinical workﬂow and is driven by the
automatic extraction of HPO concepts from free text. The
latter, starts from a provided disease model and enables
clinicians to create a structured proﬁle by externalizing the
alignment between this model and the phenotypes exhibited
by the patient. Additional analytical capabilities are pro-
vided via HPO-driven semantic similarity matching algo-
rithms. These can be used for a variety of tasks, ranging
from patient matchmaking or disorder exploration to per-
sonalized gene list generation to power the variant ﬁltering
process. A second aim of the platform is to create a
seamless data exchange channel for the clinicians. Conse-
quently, it supports ﬁne-grained access control in both
individual and group contexts, and full integration into the
Global Alliance for Genetic Health MatchMaker Exchange
Program. PA provides a seamless solution for the harmo-
nization of phenomic information to enable the acceleration
of translational and clinical applications.
T. Groza: A. Employment (full or part-time); Sig-
niﬁcant; Genome.One. T. Roscioli: None. G. Baynam:
None. H. Dawkins: None. M. Haendel: None. C. Mun-
gall: None. D. Smedley: None. P. Robinson: None. M.
Dinger: A. Employment (full or part-time); Signiﬁcant;
Genome.One. A. Zankl: None.
P16.13A
Interactome mapping of copy number variations for
candidate process prioritization in intellectual disability
and autism
M. A. Zelenova1,2,3, S. G. Vorsanova1,2,3, Y. B. Yurov1,2,3,
I. Y. Iourov1,2,4; Mental Health Research Center, Moscow,
Russian Federation, 2Academician Yu.E. Veltishchev
Research Clinical Institute of Pediatrics, N.I. Pirogov
Russian National Research Medical University, Ministry
of Health of the Russian Federation, Moscow, Russian
Federation, 3Moscow State University of Psychology and
Education, Moscow, Russian Federation, 4Russian
Medical Academy of Postgraduate Education, Moscow,
Russian Federation
Introduction The interpretation of CNVs represents a
major challenge. Various methodologies are used to estab-
lish consequences of genetic variants. In this light, bioin-
formatic methods play a crucial role. Here, we describe an
original approach towards revealing the effects of CNVs
through walking the interactome (interactome mapping) and
candidate process prioritization. Materials and methods
Eleven children with resembling phenotypic manifestations
of intellectual disability, congenital malformations and
autism were analyzed using molecular karyotyping (SNP
array) and an original bioinformatic technology for prior-
itizing genetic changes (Iourov et al., 2014) including
interactome analysis. Results In all the patients, likely
pathogenic CNVs involving 43 genes were revealed. Using
STRING Database, BioGRID and NCBI Gene, we walked
their complete interactome encompassing 813 genes.
Employing bioinformatic algorithms, we found an inter-
connected net of 544 elements (genes). According to
KEGG, these genes are involved in 240 pathways. Among
the pathways which scored the highest according to our
algorithm, we selected following candidate processes: viral
carcinogenesis pathway (44 genes), cell cycle pathway (38
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genes), PI3K-Akt signaling pathway (33 genes) and MAPK
signaling pathway (33 genes). Conclusions Although dys-
regulations of these pathways are not unique for intellectual
disability and autism, data mining and original bioinfor-
matic methodologies have conﬁrmed the associations.
Consequently, we concluded that interactome mapping can
be an effective bioinformatics tool for uncovering molecular
and cellular mechanisms of genomic pathology. Supported
by the Russian Science Foundation (project #14-35-00060).
M.A. Zelenova: None. S.G. Vorsanova: None. Y.B.
Yurov: None. I.Y. Iourov: None.
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WISEexome: Detection of copy number variations in
clinical exome sequencing data based on a within-sample
comparison scheme
M. M. Weiss1, R. Straver1, D. van Beek1, E. Sistermans1,
M. Reinders1,2
1VU University Medical Center, Amsterdam, Netherlands,
2Delft Bioinformatics Lab, Delft University of Technology,
Delft, Netherlands
Clinical exome sequencing (CES) can provide a molecular
diagnosis in families with an unexplained genetic disease.
Both SNPs and CNVs can be pathogenic and are searched
for in diagnostic settings. At the moment most clinical labs
perform both CES and array to be able to detect SNPs and
CNVs (resolution ~20 kb). To be able to replace array with
CES we developed a method, based on a combination of
our previous work (WISECONDOR; https://github.com/
rstraver/)) and a segmentation algorithm. Our method fully
depends on an internal comparison of DNA fragments per
probe, rather than comparisons with a reference set of
samples. All 18 known CNVs in our dataset of 24 samples
were correctly identiﬁed. Size ranges from 4 kb to 5,2 Mb.
The smallest CNV contained a deletion of 3 exons. Results
can be sorted by a score that indicates the reliability of a
call, usually providing the true positives in the top 5. We are
now in the process of retrospectively analyzing our diag-
nostic exome cohort (~500 trio analysis) and expect to
detect small pathogenic CNVs that may have been missed
by the routinely used array analysis (resolution of 20 kb).
Our work provides an alternative method to ﬁnd CNVs in
exome data. We do not require that reference samples are
resequenced in the same run, and we are able to detect
variable-sized CNVs. Consequently, WISEexome has the
potential to replace array analysis and maybe even MLPA
tests in a diagnostic setting in a cost-effective way.
M.M. Weiss: None. R. Straver: None. D. van Beek:
None. E. Sistermans: None. M. Reinders: None.
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Systematical identiﬁcation of essential genes in Acute
Lymphoblastic Leukemia (ALL)
A. Palm*1, M. Pertesi*1, L. Ekdahl1, L. Järvstråt1, E.
Johnsson1, A. Kvist2, T. Törngren2, Å. Borg2, U.
Gullberg1, A. Wihlborg1, B. Nilsson1; Division of
Hematology and Transfusion Medicine, Institute of
Laboratory Medicine, Lund University, Lund, Sweden,
2Division of Oncology and Pathology, Lund University,
Lund, Sweden
Deletion of chromosomal material is a hallmark of cancer
genomes. Genomic deletion of tumor suppressor genes
frequently encompasses essential neighboring genes, ren-
dering cancer cells with hemizygous deletions vulnerable to
further suppression of such genes. Identifying these vul-
nerabilities is one of the current challenges in cancer
genomics.
We developed a computational method to identify
genomic regions harboring frequently deleted, yet essential
genes, by applying pattern recognition techniques to large
sets of DNA copy-number proﬁles. In total, we identiﬁed
four regions, located on chromosomes 9, 13 and 17, that
fulﬁlled the criteria of our pattern recognition framework
and harbored multiple candidate essential genes. The
strongest signals were located in the hemizygously deleted
regions ﬂanking the commonly deleted region containing
CDKN2A, a well-known tumor suppressor gene that is
frequently homozygously deleted in several tumor types,
including Acute Lymphoblastic Leukemia (ALL). To vali-
date the essentiality of the genes in this region, we used
pooled CRISPR/Cas9 editing in ALL cells with and without
a CDKN2A deletion. This provided further evidence for the
essentiality of several genes in the identiﬁed regions,
including one gene that was essential only in CDKN2A-
deleted cells.
Haploinsufﬁciency for the identiﬁed genes could be
further exploited as a therapeutic advantage for ALL
treatment.
Funded by: BCF project grant PR2015-0028
A. Palm*: None. M. Pertesi*: None. L. Ekdahl: None.
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CnvHunter: a new tool for highly accurate detection of
single exon copy number variants in next generation
sequencing data, validated in 994 samples from a tar-
geted hereditary breast cancer panel
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B. Auber1, G. Schmidt1, W. Hofmann1, M. Sturm2
1Hannover Medical School, Hannover, Germany, 2Univer-
sity of Tübingen, Tübingen, Germany
Introduction: Copy number variants (CNVs) represent an
important proportion of all detectable pathogenic variants in
certain genes. Due to an ever increasing amount of genes in
next generation sequencing (NGS) panels, the use of addi-
tional methods like multiplex ligation-dependent probe
ampliﬁcation (MLPA) for CNV detection becomes
impractical. Using NGS data for the detection of CNVs
would greatly reduce costs and yield important data of
diagnostic value. However, high resolution single exon
CNV detection is challenging, especially in data sets with
variable sample sizes or different sequencing platforms
used.
Methods: CnvHunter was validated with a data set of
994 samples from a targeted panel (TruSight Cancer panel;
12 to 24 samples per run on MiSeq or NextSeq platforms,
Illumina,). CNVs were independently validated with MLPA
in up to ﬁve genes (BRCA1, BRCA2, CHEK2, RAD51C,
RAD51D). CnvHunter takes depth of coverage (DOC)
proﬁles from several targeted NGS samples as input that
were processed with the same enrichment kit. It detects
CNVs for each sample individually, based on reference data
from the most similar samples in the input dataset.
Results: In this highly heterogeneous validation data set,
using MLPA 27 CNVs were detected in 119 exons.
CnvHunter detected CNVs in 116 exons, including 5 single
exon CNVs. CnvHunter achieved 98% sensitivity and 99%
speciﬁcity and a positive predictive value of 78%.
Conclusions: CnvHunter is a robust high resolution tool
for CNV detection in heterogeneous NGS data with a very
high sensitivity and speciﬁcity rate.
B. Auber: None. G. Schmidt: None. W. Hofmann:
None. M. Sturm: None.
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Whole genome copy number variation analysis using a
SNP-focused targeted sequencing panel for tumor
analysis
J. Wang, J. W. Giorda, J. W. Mudivarti, C. Walworth, J.
W. Kupec, J. W. Jarosz, M. Jarosz; ntegrated DNA
Technologies, Redwood City, CA, United States
Introduction: Accurate detection of somatic copy number
variation (CNV) is crucial but presents challenges due to
tumor purity, heterogeneity, and ploidy. While there’s been
a shift towards new Next Generation Sequencing (NGS) for
other mutation types, somatic copy number detection often
still relies on ﬂuorescence in situ hybridization, array
comparative genomic hybridization, or SNP arrays. There
are signiﬁcant throughput, coverage, cost, and sample input
advantages to broadening NGS-based targeted sequencing
to include accurate somatic CNV detection.
Material and Methods: An xGen® Lockdown® CNV
panel targeting evenly spaced SNPs across the genome was
developed. For additional resolution, probe density was
increased 3-to-10-fold for chromosome 7 and ten additional
genes known to commonly exhibit somatic. Coverage and
allele fraction at the SNP sites were used to determine tumor
purity and ploidy, thus enabling higher accuracy somatic
CNV detection.
Results: We demonstrate use of the panel as an addition
to the xGen® Exome Research Panel. SNPs present in
NA12878 were used to validate the panel’s ability to detect
heterozygous germline SNPs with >95% sensitivity and
speciﬁcity. In addition, mixtures of cell lines from the
Cancer Cell Line Encyclopedia were tested with varying
levels of background copy-neutral genomic DNA. Sensi-
tivity and speciﬁcity of the panel to detect CNV and loss of
heterozygosity events were compared to expectations given
pure cell line sequencing and SNP array data.
Conclusion: The xGen® Lockdown® CNV panel enables
the detection of somatic copy number alterations with high
resolution and accuracy, which will be a valuable resource
for cancer research.
J. Wang: A. Employment (full or part-time); Signiﬁcant;
Integrated DNA Technologies. J.W. Giorda: A. Employ-
ment (full or part-time); Signiﬁcant; Integrated DNA
Technologies. J.W. Mudivarti: A. Employment (full or
part-time); Signiﬁcant; Integrated DNA Technologies. C.
Walworth: None. J.W. Kupec: A. Employment (full or
part-time); Signiﬁcant; Integrated DNA Technologies. J.W.
Jarosz: A. Employment (full or part-time); Signiﬁcant;
Integrated DNA Technologies. M. Jarosz: None.
P16.18B
RBV: Allele-speciﬁc copy-number validation of whole
genome sequence and whole exome sequence data
W. Whitford1,2, K. Lehnert1,2, R. G. Snell1,2, J. C.
Jacobsen1,2
1School of Biological Sciences, University of Auckland,
Auckland, New Zealand, 2Centre for Brain Research, The
University of Auckland, Auckland, New Zealand
The increased use of genome resequencing has led to the
development over 80 software tools created to identify copy
number variants (CNVs) from sequence data. These gen-
erally utilise characteristics of the sequence data including:
read depth, split reads, read pairs, and assembly-based
techniques.
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The assessment of the relative number and read coverage
of heterozygous loci has not been extensively used for NGS
CNV investigations. We sought to develop a bioinformatic
tool to validate CNVs using the relative number of het-
erozygous alleles and the distribution of reads for hetero-
zygous alleles within putative CNVs.
The number of heterozygous single nucleotide poly-
morphisms (SNPs) in a given length of the genome follows
a Poisson distribution. Therefore, the probability of a spe-
ciﬁc region being deleted can be calculated using a Poisson
distribution centred on the average number of heterozygous
SNPs in a sample of genomic regions of the same length.
The relative proportion of reads at each heterozygous
position of the aligned genome, reﬂects the relative copy
number at that position. Hence, the distribution of the ratio
of reads for the allele with higher coverage at heterozygous
loci in the putative CNV region can be compared to the
distribution of those in a sample of diploid regions.
RBV is currently applied to validate CNVs in a cohort of
New Zealand cases with undiagnosed neurodevelopmental
disorders (Minds for Minds cohort) using the relevant
aligned genome and a list of coordinates for the predicted
CNVs. Potential further uses include ploidy estimation, and
calculating degree of mosaicism.
W. Whitford: None. K. Lehnert: None. R.G. Snell:
None. J.C. Jacobsen: None.
P16.19C
An integrated analysis tool for analyzing hybridization
intensities and genotypes using new-generation popula-
tion-optimized human arrays
M. Huang1,2,3, T. Chuang4,5, C. Chen6, J. Wu6, Y. Chen6,
L. Li6, H. Yang2,3; Institute of Biomedical Informatics,
National Yang-Ming University, Taipei, Taiwan,
2Bioinformatics Program, Taiwan International Graduate
Program, Institute of Information Science, Academia
Sinica, Taipei, Taiwan, 3Institute of Statistical Science,
Academia Sinica, Taipei, Taiwan, 4Taiwan International
Graduate Program in Molecular Medicine, National
Yang-Ming University and Academia Sinica, Taipei,
Taiwan, 5Institute of Biochemistry and Molecular
Biology, National Yang-Ming University, Taipei, Taiwan,
6Institute of Biomedical Sciences, Academia Sinica,
Taipei, Taiwan
Background: Affymetrix Axiom single nucleotide poly-
morphism (SNP) arrays provide a cost-effective, high-den-
sity, and high-throughput genotyping solution for
population-optimized analyses. However, no public soft-
ware is available for the integrated genomic analysis of
hybridization intensities and genotypes for this new-
generation population-optimized genotyping platform.
Results: A set of statistical methods was developed for
an integrated analysis of allele frequency (AF), allelic
imbalance (AI), loss of heterozygosity (LOH), long con-
tiguous stretch of homozygosity (LCSH), and copy number
variation or alteration (CNV/CNA) on the basis of SNP
probe hybridization intensities and genotypes. This study
analyzed 3,236 samples that were genotyped using different
SNP platforms. The proposed AF adjustment method con-
siderably increased the accuracy of AF estimation. Th e
proposed quick circular binary segmentation algorithm for
segmenting copy number reduced the computation time of
the original segmentation method by 30%–67%. The pro-
posed CNV/CNA detection, which integrates AI and LOH/
LCSH detection, had a promising true positive rate and
well-controlled false positive rate in simulation studies.
Moreover, our real-time quantitative polymerase chain
reaction experiments successfully validated the CNVs/
CNAs that were identiﬁed in the Axiom data analyses using
the proposed methods; some of the validated CNVs/CNAs
were not detected in the Affymetrix Array 6.0 data analysis
using the Affymetrix Genotyping Console. All the analysis
functions are packaged into the ALICE (AF/LOH/LCSH/
AI/CNV/CNA Enterprise) software.
Conclusions: ALICE and the used genomic reference
databases, which can be downloaded from http://hcyang.sta
t.sinica.edu.tw/software/ALICE.html, are useful resources
for analyzing genomic data from the Axiom and other SNP
arrays.
Grant references: AS-100-CDA-M03 and MOST 103-
2314-B-001-008-MY3.
M. Huang: None. T. Chuang: None. C. Chen: None. J.
Wu: None. Y. Chen: None. L. Li: None. H. Yang: None.
P16.20D
Turning big data into small data through crowdsourced
curation: integrating all types of medical and scientiﬁc
knowledge
T. D. Taylor, M. Hebrard, N. Kumar; RIKEN, Yokohama,
Japan
Big data in the form of scientiﬁc media comes in many
languages and formats: journal articles, books, images,
videos, etc. Text media often includes additional embedded
or associated information such as tables, ﬁgures and sup-
plementary data. While there are many resources for
browsing, searching and annotating some of this media,
there is no single place to search them all at once, and
generalized search engines do not allow for the compre-
hensive and precise searches researchers require. One could
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argue that any scientiﬁc media that is on the web is there-
fore connected, but much of it is inaccessible and is neither
discoverable nor connected. To this end, we created
iCLiKVAL, a web-based tool that uses the power of
crowdsourcing to accumulate annotation information for all
scientiﬁc media found online. Annotations in the form of
key-relationship-value tuples (any language) added by
users through various means can make vast amounts of
unstructured data easier to comprehend and visualize by
turning it into small structured data. This allows for richer
data searches and discovery of novel connections by inte-
grating all forms of scientiﬁc knowledge through common
terminology. It currently supports PubMed, YouTube,
Flickr, SoundCloud and anything with a DOI name,
allowing for the inclusion of hundreds of millions of
media objects. We also created a Chrome Browser exten-
sion that allows any non-password protected online media
to be annotated, even while the user is ofﬂine. The
iCLiKVAL database is completely searchable, and all of the
data is freely available to registered users via our API.
T.D. Taylor: None. M. Hebrard: None. N. Kumar:
None.
P16.21A
Optimizing data compression technique determined by
decoding HIV-1 HXB2 DNA genome assists in deci-
phering the means the human genome is transcribed
and translated
L. B. Scheiber, II, L. B. Scheiber; steoporosis & Arthritis
Center, Grosse Ile, MI, United States
An optimizing data compression technique involving mul-
tiple genes is revealed in analyzing HIV-1 HXB2 genome
K03455.1. Understanding HIV’s data compression assists
in an expanded understanding of the human genome. The
data compression technique ingeniously utilizes features of
the codon code and nucleotide code to generate overlapping
genetic information, which facilitates 8 segments of HIV’s
pre-mRNA code to be read twice producing differing
mRNA sequences each time the pre-mRNA code is
deciphered.
The HIV-1 HXB2 genome k03455.1, 9719 nucleotides,
which produce 9 genes/master proteins designated as gag
PRO_0000261216, gag-pol PRO_0000223620, vif
PRO_0000042759, vpr PRO_0000085451, tat
PRO_0000085364, rev PRO_0000085279, vpu
PRO_0000085433, env PRO_0000239240, and nef
PRO_0000038365.
Demonstrated in Table 1, is evidence of a frameshift
involving each gene. There are 8 segments where the codon
code overlaps, which facilitate the HIV genome to be 825
nucleotides shorter than if such a data compression tech-
nique were not utilized. Env, tat-2, rev-2 all share a 45
nucleotide sequence. This data compression technique
represents a higher order complexity in the construct of the
genome, beyond a simple linear read, facilitating the HIV
genome to ﬁt inside HIV virion.
HIV genome utilizes the same genetic cellular machinery
as human genes; recognizing the microcosm of data com-
pression present in HIV genome broadens the analysis
regarding how the spliceosome and ribosome complexes
interact with human DNA, which will inspire innovative
human genetic therapies.
Table 1: Data compression frameshift present in 8 genes
Gene 1
Protein 1
------------
Gene 2
Protein 2
Start-Stop
Positions
Point of
Frameshift
-----------------
# Nucleotides
Which
Overlap
Nucleotide Code
at Point of
Frameshift
Codon Code at
Point of
Frameshift
gag
261216
--------
gag-pol
223620
790-2292
-------------
2091-
5096
2091
------
202
…ttt tta ggg aag…
…………….agg
gaa gat
--------I
--------2091
…NFLGK…
…………RED…
------^
------2091
gag-pol
223620
---------
vif
042759
2091-
5096
------------
5041-
5619
5041
------
56
…tat gga aaa
cag…
…….atg gaa
aac…
----I
----5041
…DYGKQ…
………MENR…
-----^
-----5041
vif
042759
---------
vpr
085451
5041-
5619
------------
5559-
5850
5559
------
61
…aga aga tgg
aac…
……………….atg
gaa..
----------I
----------5559
…DRWNK…
……….
MEQA…
-----^
-----5559
vpr
085451
---------
tat-1
085364
5559-
5850
-------------
5831-
6049
5831
------
20
…aga aat gga gcc..
…………….atg
gag…
--------I
--------5831
…ARNGA…
…………
MEPV…
------^
------5831
tat-1
085364
---------
rev-1
085279
5831-
6049
------------
5970-
6045
5970
------
80
…tcc tat ggc
agg…
………….atg gca
gga
-------I
-------5970
…GISYGR…
……….MAG…
-----^
-----5970
vpu
085433
---------
env
239240
*33-856
6062-
6310
-------------
6225-
8795
6225
------
86
…ggc aat gag agt..
…………..atg aga
gtg..
--------I
--------6225
…SGNES…
…………
MRV…
------^
------6225
env
239240
---------
rev-2
085279
6225-
8795
-------------
8379-
8653
8379
------
275
..cag acc cac..
…………((a)ac)
cca*
--------I
--------8379
*combine 'a' from
…SFQTH…
…..(N)PP*…
----^
----8379
*combined 'aac'
codon for 'N'
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rev-1, 'ac' from
rev-2
env
239240
---------
tat-2
085364
6225-
8795
-------------
8380-
8424
8380
------
45
…cag acc cac ctc..
……………ccc
acc tcc
--------I
--------8380
….FQTHL…
…………PTS…
------^
------8380
env
239240
---------
nef
038365
6225-
8795
------------
8797-
9417
8797
------
0
…cta taa…
…………………..
atg ggt ggc…
------------I
------------8797
ILL(stop)…
…………………
MGG
-----------^
-----------8797
L.B. Scheiber: None. L.B. Scheiber: None.
P16.22B
Boosting genotype-phenotype and translational research
on rare diseases by establishing Findable, Accessible,
Interoperable and Reusable (FAIR) data resources
through data linking technologies
D. van Enckevort1, C. Carta2, R. Thompson3, M.
Thompson4, F. Ehrhart5,6, R. Kaliyaperumal4, R. Reihs7,
P. Sernadela8, A. Jacobsen4,9, L. O. Bonino da Silva
Santos10,9, M. D. Wilkinson11, H. Müller7, C. T. A. Evelo5,
J. L. Oliveira8, P. A. C. 't Hoen4, D. Taruscio12, M. Roos4
1University Medical Center Groningen, Groningen, Nether-
lands, 2Istituto Superiore di Sanità, Rome, Italy, 3Newcastle
University, Newcastle upon Tyne, United Kingdom, 4Leiden
University Medical Center, Leiden, Netherlands, 5Maas-
tricht University, Maastricht, Netherlands, 6Maastricht
University Medical Center, Maastricht, Netherlands, 7Med-
ical University of Graz, Graz, Austria, 8Universidade de
Aveiro, Aveiro, Portugal, 9Vrije Universiteit Amsterdam,
Amsterdam, Netherlands, 10Dutch Techcentre for Life
Sciences, Utrecht, Netherlands, 11Universidad Politécnica
de Madrid, Madrid, Spain, 12Istituto Superiore di Sanità,
Rome, Netherlands
Genotype-phenotype and translational research on rare
diseases (RDs) depends on combining data from biobanks,
knowledge-bases, patient registries, and ‘omics’ sources.
RD data are sparse, often sensitive, and distributed across
countries and institutes. Infrastructure that boosts RD
research allows researchers to avoid spending too much
time reconciling data ambiguities for every analysis, but
with 5000–7000 RDs, the scale and ethical and legal bot-
tlenecks make a central data warehouse impossible to
maintain. We present a ‘rare disease data linkage service
plan’ that applies the principles of Findable, Accessible,
Interoperable, and Reusable data for humans and computers
(FAIR) at the source to create a decentralised infrastructure.
It follows ‘Bring Your Own Data’ workshops and an
ELIXIR-supported pilot that demonstrated the concept for
answering cross-resource questions. RD stakeholders,
infrastructure experts, programs such as ELIXIR and
BBMRI, and patient organisations support the plan. The
plan brings together an international collaboration of FAIR
data engineers and RD software engineers. They support
RD data managers in incorporating FAIR data elements and
services that reduce the effort to combine data for compu-
tational analysis (using globally unique identiﬁers, ontolo-
gies, Linked Data, and an application programming
interface to provide controlled access to data). Speciﬁc
ontology choices include the Human Phenotype Ontology
and the Orphanet Rare Disease Ontology. Software and
ontological models that are used for each resource are
shared with the community to be reused for similar cases,
thus stimulating convergence within the RD domain. We
acknowledge the generous support from RD-stakeholders,
RD-Connect, ELIXIR, ELIXIR-EXCELERATE, BBMRI-
NL, ODEX4All and FAIR-dICT.
D. van Enckevort: None. C. Carta: None. R.
Thompson: None. M. Thompson: None. F. Ehrhart:
None. R. Kaliyaperumal: None. R. Reihs: None. P. Ser-
nadela: None. A. Jacobsen: None. L.O. Bonino da Silva
Santos: None. M.D. Wilkinson: None. H. Müller: None.
C.T.A. Evelo: None. J.L. Oliveira: None. P.A.C. 't Hoen:
None. D. Taruscio: None. M. Roos: None.
P16.23C
Trusted Friend Computing: data mining federated
OMICS knowledge source
B. Wolf1,2, P. Kuonen1, D. Atlan3, M. Lourenço1, J.
Stoppani1, T. Dandekar2; University of applied sciences
and arts western switzerland, Villars-sur-Glâne,
Switzerland, 2University Würzburg, Würzburg, Germany,
3Phenosystems SA, Wallonia, Belgium
Introduction: Interpretation of OMICs data requires com-
parison and thus access to a large number of previously
analysed samples, but sharing of human OMICs data has
many complex legal and ethical constraints. Because of this,
many laboratories restrict their comparison to internal
OMICs knowledge bases. To solve this problem, we pro-
pose a new approach called TFC (Trusted Friend Comput-
ing), which lets laboratories transparently and securely
share their internal knowledge bases, as well as other
resources, especially computing resources. Methods: We
are extending POP-Java, a Java language extension for
distributed computing, with the features to implement the
sharing of both data and computing power through a net-
work of friends. A network of friends is created through a
process similar to social networks, allowing for detailed
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control with whom to share resources. The open-source
implementation of TFC is used to implement those features
inside GensearchNGS, a graphical NGS data analysis
pipeline developed by Phenosystems SA. Results: We
implemented a prototype that demonstrates the functionality
of TFC. We also show the feasibility to integrate this
functionality into an existing application like Gen-
searchNGS. We also present the larger concept of Trusted
Friend Computing and how it can be used to securely share
and datamine OMICs knowledge across laboratories.
Conclusion: We propose a new method to share securely
OMICs knowledge sources as well as computing resource.
We demonstrate this through a prototype of the technology
and show how the integration into an existing software, like
GensearchNGS, is possible. Grants: CTI no. 18781.1 PFES-
ES
B. Wolf: None. P. Kuonen: F. Consultant/Advisory
Board; Modest; Phenosystems SA. D. Atlan: A. Employ-
ment (full or part-time); Signiﬁcant; Phenosystems SA. M.
Lourenço: None. J. Stoppani: None. T. Dandekar: None.
P16.24D
Towards automated sharing of genetic variants between
genome diagnostics laboratories and beyond: an initia-
tive of the Dutch diagnostic data sharing consortium
C. A. L. Ruivenkamp1, M. E. van Gijn2, M. A. Swertz3
1Leiden University Medical Center, Leiden, Netherlands,
2University Medical Center Utrecht, Utrecht, Netherlands,
3University Medical Center Groningen, Groningen,
Netherlands
The use of genomic information in both research and clinic
has expanded enormously in the last decade. Exome ana-
lyses have become part of routine diagnostics. Yet, the
interpretation of the obtained data is a huge challenge,
because information on individual DNA variants is often
absent in public databases. In order to improve patient care
the Dutch genome diagnostic laboratories decided to share
their data, most importantly the individual variant patho-
genicity classiﬁcations and observed variant frequencies.
When a variant has been previously carefully classiﬁed by
one or more expert centers, there is less need to (re-)
evaluate this variant when encountered for the ﬁrst time by
another center. Towards this goal we created a central
national database with connections to each of the labora-
tories for automated bi-directional sharing. Data are stored
separately for variant classiﬁcations and variant frequencies,
using open source MOLGENIS and VARDA systems so
that this procedure can be reused by other countries.
Through this national node data will be shared with inter-
national databases. Currently the database contains 46.500
classiﬁed DNA variants in 4.500 genes, of which 40.000
variants have been classiﬁed by only one laboratory and
6.500 were classiﬁed by multiple laboratories. For 650
variants (10%) classiﬁcations differ, but only 2 variants
have an opposite classiﬁcation. First data has already been
shared with the LOVD3 and CafeVariome; variant sharing
is the most effective way forward to annotate WES and
WGS data.
C.A.L. Ruivenkamp: None. M.E. van Gijn: None. M.
A. Swertz: None.
P16.25A
LOVD: variant annotation software and a public
database
M. Kroon1, J. T. den Dunnen2, I. F. A. C. Fokkema1;
Human Genetics, Leiden University Medical Center,
Leiden, Netherlands, 2Human Genetics and Clinical
Genetics, Leiden University Medical Center, Leiden,
Netherlands
As genotyping becomes cheap and widespread in both
research and diagnostics, new genetic variants are dis-
covered at an ever increasing rate. Recording, storing and
sharing this information, including any consequences of the
variants (their classiﬁcation), is critical to allow efﬁcient
evaluation of the sequencing data. We have developed the
LOVD software to facilitate these processes.
LOVD is a freely available open source database system
for recording, storing, curating and annotating genetic var-
iants, running on any platform. LOVD processes informa-
tion on individuals, their phenotype, screenings performed
and variants detected. LOVD offers great ﬂexibility to store
information via custom deﬁned columns, aids automatic
validation and translation of HGVS variant descriptions and
directly links to external resources like PubMed, OMIM,
UCSC, Ensembl, etc. Recent improvements include an API
to submit new data automatically and the possibility to
share access to data submissions with other users.
Besides providing software we host public LOVD data-
bases where >2000 users (submitters) share data and >250
gene experts curate the incoming information. Data is stored
per allele at the DNA, RNA and protein level and variant
classiﬁcations are shown separately based on the opinion of
the submitter and the expert curator. Locally installed
databases have an option to share information with a central
LOVD server where the data are shared via a web service.
Currently 71 databases are sharing nearly 1 million variants.
LOVD and its services are maintained by the Leiden Uni-
versity Medical Center and is available through http://www.
lovd.nl.
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M. Kroon: None. J.T. den Dunnen: None. I.F.A.C.
Fokkema: None.
P16.26B
Locus Reference Genomic (LRG): reference resource
for the accurate reporting of clinically relevant variants
J. Morales1, A. McMahon1, L. Gil1, R. Tully2, A.
Astashyn2, T. Murphy2, K. Pruitt2, D. Maglott2, F.
Cunningham1
1European Molecular Biology Laboratory, European
Bioinformatics Institute, Hinxton, United Kingdom,
2National Center for Biotechnology Information, Bethesda,
MD, United States
Accurate and unambiguous annotation is essential for the
correct interpretation of clinically relevant sequence var-
iants. Central to this is the reference sequence against which
a variant is reported. Ongoing changes to the reference
assembly, the existence of numerous versioned reference
sequences and the use of legacy reporting systems present
challenges in the clinic. The Locus Reference Genomic
(LRG), a manually curated resource designed speciﬁcally
for the reporting of clinically relevant variants, addresses
these challenges. Each LRG record provides a stable and
non-versioned genomic DNA sequence for a human locus,
establishing a coordinate system that is independent from
upgrades to the reference assembly. The record also con-
tains a minimal set of transcripts to be used as reference
standards and deﬁnes the relationship between these and
existing RefSeq and GENCODE models. Only transcripts
required for reporting of disease-causing variants, and for
which there is currently good biological understanding, are
included. LRGs are based on RefSeqGenes, a sibling pro-
ject at the NCBI, and are created in consultation with locus-
speciﬁc experts. Over 1100 LRGs have been requested, of
which almost 700 are public. LRGs have been recom-
mended by HGVS and other key organisations. Their
widespread use will ensure consistent variant reporting over
time. LRGs are created jointly by the NCBI and EMBL-EBI
(http://www.ebi.ac.uk), are available on the LRG website
(http://www.lrg-sequence.org/) and can be visualised in all
genome browsers. This work is supported by the Wellcome
Trust [WT200990/Z/16/Z], the European Molecular Biol-
ogy Laboratory, and the Intramural Research Program of
the NIH, National Library of Medicine.
J. Morales: None. A. McMahon: None. L. Gil: None.
R. Tully: None. A. Astashyn: None. T. Murphy: None.
K. Pruitt: None. D. Maglott: None. F. Cunningham:
None.
P16.27C
Tissue-speciﬁc expression and co-expression analyses of
gene families in human brain regions to prioritize genes
potentially implicated into brain diseases
S. Brohard-Julien1,2,3, S. Chalabi1, J. Deleuze1, V.
Frouin2, C. Battail1, E. Le Floch1; Centre National de
Génotypage, Institut de Génomique, CEA, EVRY, France,
2UNATI, Neurospin, I²BM, CEA, Gif-sur-Yvette, France,
3Université Paris-Sud, Université Paris-Saclay, Orsay,
France
A gene family is a set of genes formed by duplication of a
common ancestor originated from Whole Genome or Small-
Scale (SSD) duplications. The retention of duplicates in the
genome may favor gain of functions and tissue-speciﬁc
expression contributing to organism evolution. Moreover,
duplicates are enriched in brain disease genes compared to
singletons. Our objective is to better understand contribu-
tions of gene families to tissue differentiation and brain
diseases.
We carried out expression and tissue differentiation
analyses of 13 brain sub-regions using RNA-Seq data from
GTEx consortium. Tissue-speciﬁcity was assessed by a
score computed per gene and co-expression of gene families
across brain regions was explored by weighted gene co-
expression network analysis.
We determined that duplicates better differentiate brain
sub-regions than singletons based on their expression pro-
ﬁles. Therefore, we developed a comprehensive resource on
gene family expression in brain regions by integrating
evolutionary, co-expression network, tissue-speciﬁcity and
disease information. First, from our integrated data, we
found that brain disease genes are enriched in tissue-speciﬁc
genes and in SSD duplicates. Then, we pointed out that co-
expressed families are enriched in SSDs. This result is
consistent with previous studies, indeed it has been shown
that tissue-speciﬁc SSD families tend to be expressed in the
same tissue.
We generated a unique resource on gene families to
facilitate associations between evolutionary, tissue-speciﬁ-
city, co-expression and brain disease characteristics. Inter-
rogation of these integrated data may highlight new genes
potentially implicated in brain pathologies.
Funding from “Université Paris-Sud” and “Centre
National de Génotypage / CEA”.
S. Brohard-Julien: None. S. Chalabi: None. J.
Deleuze: None. V. Frouin: None. C. Battail: None. E. Le
Floch: None.
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GARFIELD: Genomic vARiants FIltering by dEep
Learning moDels
E. Giacopuzzi, V. Ravasio; Department of Molecular and
Translational Medicine, University of Brescia, Brescia,
Italy
Exome sequencing approach is extensively used in research
and diagnostic laboratories to discover pathological variants
and study genetic architecture of human diseases. Even if
present platforms produce high quality sequencing data,
false positives variants remain an issue, particularly for
indel detection, and can confound subsequent analysis and
result interpretation. Advanced ﬁltering methods have been
developed for large datasets, while strategies for single
samples or trio analysis are usually limited to hard ﬁltering
of variants based on quality parameters. Here, we propose a
new tool named GARFIELD (Genomic vARiants FIltering
by dEep Learning moDels), which uses deep learning
algorithm to predict false and true variants assigning a
prediction value from 0 to 1 (P true). GARFIELD consists
of 4 distinct models speciﬁcally trained for INDELs or
SNPs variants and applies to both Illumina and ION data. In
our tests using the gold-standard exome variants dataset
NA12878 (NIST v.3.3.2), GARFIELD outperformed pre-
viously proposed hard ﬁlters. AUC values: (i) ION SNPs
0.96; (ii) ION INDELs 0.98; (iii) Illumina SNPs 0.71; (iv)
Illumina INDELs 0.90. The method is robust also at low
coverages down to 30X and performs well also for the
recently introduced Illumina two-colour data. GARFIELD
is implemented as Perl and R scripts and it can be easily
applied to regular VCF ﬁles to add P true annotation for
variants. Different thresholds on P-true value can be applied
based on the desired level of sensitivity and speciﬁcity.
E. Giacopuzzi: None. V. Ravasio: None.
P16.29A
eDiVA: Exome sequencing pipeline to identify clinically
relevant mutations in disease studies
M. Bosio1, O. Drechsel2, R. Rahman3, S. Ossowski1,4;
Centre for Genomic Regulation CRG, Barcelona, Spain,
2Core Unit Bioinformatics, Berlin Institute of Health,
Berlin, Germany, 3Netherlands Cancer Institute NKI,
Amsterdam, Netherlands, 4Universitat Pompeu Fabra
(UPF), Barcelona, Spain
Introduction: Next generation sequencing boosted causal
variant identiﬁcation in people affected by Mendelian dis-
eases, helping to link genetic variation to phenotype.
Multiple tools exist to call, annotate, and prioritize genetic
variants, but with currently 25–30% success rate, identify-
ing the causal mutations is still an issue.
Materials: We developed eDiVA to identify coding
mutations causing rare diseases in small families using
exome-seq data, focusing on optimizing functional anno-
tation and prioritization.
eDiVA calls variants using best practices to reduce false
positives. Thereafter, variants are annotated with functional,
OMICs and clinical information from many sources like
CADD, SFIT, PhyloP, dbSNP, 1000genomes, EVS, ExAC,
Clinvar, or OMIM to provide contextual information.
eDiVA integrates annotation into a machine-learning
based variant pathogenicity classiﬁer (eDiVA-score).
eDiVA-score is integrated with domain-knowledge ﬁltering
to correctly prioritize variants following speciﬁc disease
models, (autosomal dominant, recessive, de novo, X-linked,
and compound heterozygous) in small families and parent-
child trios.
Results: We compared eDiVA-score with M-Cap,
CADD, Eigen-score and Revel in thousands of semi-
synthetic cases, as well as the full prioritization pipeline
against PhenoDB and Phen-Gen. eDiVA consistently out-
performed existing methods in terms of ROC, precision and
recall of pathogenic variants.
We also validated eDiVA studying 35 families affected
by rare diseases like ataxia, myasthenia, and immunodeﬁ-
ciency. On average eDiVA reported less than 30 candidate
variants per family, which included the (subsequently
validated) causal variant in about 50% of the cases.
Conclusion: eDiVA, available at www.ediva.crg.eu,
provides a clinically tested prioritization method to identify
causal variants for genetic diseases with remarkable success
rate.
M. Bosio: None. O. Drechsel: None. R. Rahman:
None. S. Ossowski: None.
P16.30B
Automating clinical interpretation of NGS data in
oncopathology using by an expert system xGenCloud
I. Ugarov1,2, O. Novoselova3,2, V. Chernykh4,2, I.
Sharkova4,2, A. Sharkov2,5, N. Ivanov2
1Moscow State Medical Stomatological University
(MGMSU), Moscow, Russian Federation, 2xGen Cyber-
netics, Moscow, Russian Federation, 3Filatov Children's
clinical hospital, Moscow, Russian Federation, 4Federal
state scientiﬁc budgetary Institution «Research Centre for
Medical Genetics», Moscow, Russian Federation, 5Ministry
of Health of Russian Federation, Separated Structural Unit
“Clinical Research Institute of Pediatrics” at Pirogov
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Russian National Research Medical University, Moscow,
Russian Federation
Introduction: The interpretation of the results of NGS
sequencing associated with the problems of processing large
quantities of genetic and biomedical information, especially
in cases of genetically heterogeneity pathologies presented
in oncology. This requires the development and use of
specialized computer software.Materials and methods:
Publicly available online sources of Internet used for ﬁlling
the knowledge base «xGenCloud» expert system. Infor-
mation from Database OMIM used to form the catalog of
monogenic diseases. Information about the pathogenicity of
mutations was taken from ClinVar database. TruSight
Cancer by Illumina used to generate test cases. Sequencing
was carried out on MiniSeq system. Genome assembly and
alignment was carried out using Illumina software, with
GRCh37 as the standard reference assembly sequence used.
Results: Expert biomedical xGenCloud computer program
was created. Report on the diagnostics results includes the
following sections: an introduction to the methodology of
interpretation, the description of the genetic panel, the
ranking criteria based on pathogenicity, the list of the
identiﬁed pathogenic mutations and associated monogenic
and multifactorial diseases, the total risk assessment,
recommendations for additional laboratory tests and
instrumental investigations, the literature, list of detected
variants. Automation of the process of data analysis and
report generation can reduce expended time from 3–5 hours,
required previously, up to 5–10 minutes, depending on the
number of pathogenic variants detected.Conclusion: The
using of specialized software service for interpreting of the
NGS data can signiﬁcantly optimize work of the clinician
and thus enhance the effectiveness of the genetic counsel-
ling in the oncopathology.
I. Ugarov: None. O. Novoselova: None. V. Chernykh:
None. I. Sharkova: None. A. Sharkov: None. N. Ivanov:
None.
P16.31C
eQTLs affecting annotated and un-annotated alternative
splicing events in human basal ganglia are enriched for
risk variants for adult neurological disorders
M. S. Guelﬁ1, K. D'Sa2, J. A. Botía2, J. Vandrocova2, The
UK Brain Expression Consortium (UKBEC), J. A.
Hardy2, M. E. Weale3, M. Ryten2; Intitute of Neurology
(UCL), London, United Kingdom, 2Department of
Molecular Neuroscience, UCL Institute of Neurology,
London, United Kingdom, 3Department of Medical &
Molecular Genetics, King's College London, London,
United Kingdom
Alternative splicing (AS) is a form of post-transcriptional
RNA processing whereby a single gene encodes for multi-
ple distinct transcripts. With the widespread use of RNA
sequencing, it has become clear that alternative splicing is
more prevalent than previously recognised particularly in
human brain. Given that AS can modify the properties of
encoded proteins, it has the potential to contribute to adult
neurological disease. As part of the UKBEC project, we
performed eQTL analyses on whole transcriptome RNA
sequencing (RNA-seq) data originating from 134 neuro-
pathologically normal post-mortem human brains and
including 180 samples dissected from the putamen and
substantia nigra. We performed conventional gene-level
quantiﬁcation together with quantiﬁcation of AS events.
This was done using: i) the software Altrans, which detects
both annotated and novel AS events present within gene
boundaries, ii) inferring AS using exon-level quantiﬁcations
tested for beta heterogeneity across a given gene, and iii) an
in-house pipeline to identify and quantify novel exons and
the associated AS events outside gene boundaries (addi-
tional 5′ and 3′ novel exons). The results of cis-eQTL
mapping performed using MatrixEQTL were integrated
with information on risk loci identiﬁed through genome-
wide association studies (GWAS). A signiﬁcant enrichment
of risk SNPs for adult neurological diseases was seen
amongst eQTLs affecting AS events. This was particularly
evident amongst diseases, characterised by dysfunction of
the basal ganglia, such as Parkinson’s disease. Thus, we
demonstrate that the identiﬁcation of eQTLs regulating AS
events, both annotated and novel, provides insights that
would be hidden by conventional analyses.
M.S. Guelﬁ: None. K. D'Sa: None. J.A. Botía: None. J.
Vandrocova: None. J.A. Hardy: None. M.E. Weale:
None. M. Ryten: None.
P16.32D
Integrated high-throughput biomolecular analyses of
FRA10AC1 altered expression in a human cell model
M. Papadimitropoulos1,2,3, S. Anastasopoulou1,2, E.
Galliopoulou1,4, A. Manousopoulou5,6, S. Bicciato7, S.
Garbis5,8, T. Saraﬁdou4, M. I. Klapa2, N. K. Moschonas1,2
1Laboratory of General Biology, School of Medicine,
University of Patras, Rio-Patras, Greece, 2Metabolic
Engineering & Systems Biology Laboratory, Institute of
Chemical Engineering Sciences, Foundation for Research
& Technology-Hellas (FORTH/ICE-HT), Rio-Patras,
Greece, 3Division of Genetics, Cell and Developmental
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Biology, Department of Biology, University of Patras, Rio-
Patras, Greece, 4Laboratory of Genetics, Comparative &
Evolutionary Biology, Department of Biochemistry &
Biotechnology, University of Thessaly, Larissa, Greece,
5Centre for Proteomic Research, Institute for Life Sciences,
University of Southampton, Southampton, United Kingdom,
6Clinical and Experimental Sciences Unit, Faculty of
Medicine, University of Southampton, Southampton, United
Kingdom, 7Center for Genome Research, Department of
Life Sciences, University of Modena and Reggio Emilia,
Modena, Italy, 8Division for Cancer Sciences, Southampton
General Hospital, University of Southampton, Southamp-
ton, United Kingdom
Introduction: The FRA10A fragile site causative gene,
FRA10AC1, encodes a well-conserved nuclear protein with
yet, uncharacterized function (Saraﬁdou et al., Genomics,
84:69,2004). The FRA10AC1 position in the human protein
interactome (Klapa et al., BMC Syst. Biol. 7:96,2013; www.
pickle.gr) suggests its involvement in pre-mRNA processes
(Galliopoulou et al, in prep.). To elucidate the biological
role of FRA10AC1, we developed HeLa cells with impaired
FRA10AC1 expression and performed integrated tran-
scriptomic, proteomic and metabolomic analyses.
Materials and Methods: The respective proﬁles were
acquired using GeneChip® U133 Plus2.0 arrays, LC-MS
with iTRAQ-labeling and GC-MS, capturing information
for ~24000 transcripts, ~6400 proteins, and ~130 metabolite
derivatives, respectively. After normalization and ﬁltering,
5153 proteins and 69 metabolites were further considered.
Results: Multivariate statistical analysis indicated that
FRA10AC1 downregulation strongly affected the abundance
of ~2000 transcripts with unique UniProt_IDs, 560 proteins
and 32 metabolites. Its overexpression had a strong impact
on ~1540 transcripts with unique UniProt_IDs, 215 proteins
and 16 metabolites. Ontological analysis of the differen-
tially expressed transcripts and proteins indicated that most
are implicated in mRNA splicing and metabolism, alter-
native splicing, transcription and translation, strongly sup-
porting a role for FRA10AC1 in pre-mRNA processing.
Discussion: The educated integration of all three omic
proﬁles indicated that the aberrant FRA10AC1 expression
affects the cytoskeleton and cell membrane organization,
the endoplasmic reticulum and Golgi apparatus function,
the cell signaling through protein phosphorylation and
response to glucocorticoids, the glucose and cholesterol
homeostasis, the oxidative phosphorylation and the anti-
inﬂammatory response activity. Interestingly, the observed
alterations can be associated with certain neurological
disorders.
M. Papadimitropoulos: None. S. Anastasopoulou:
None. E. Galliopoulou: None. A. Manousopoulou: None.
S. Bicciato: None. S. Garbis: None. T. Saraﬁdou: None.
M.I. Klapa: None. N.K. Moschonas: None.
P16.33A
Gene prioritization tools facilitate identiﬁcation of novel
variants in neuromuscular disorders
S. Tomar, R. Sethi, P. Lai; National University of
Singapore, Singapore, Singapore
Neuromuscular disorders (NMDs) are a phenotypically and
genetically heterogeneous group of diseases whose accurate
diagnosis continues to be a challenge for clinicians. Next
Generation Sequencing (NGS) technology is gaining wide
acceptance in routine diagnostics with targeted sequencing
of the exome being increasingly adopted for clinical diag-
nosis of NMD patients. However, a current challenge in
variant analysis is the efﬁcient ranking of potential disease
associated variants based on genotype-phenotype correla-
tions. In this study, we reviewed 42 web-based gene
prioritization tools and developed an in-house variant ana-
lysis pipeline incorporating three platforms - VarElect,
Phenolyzer and Manteia, for candidate gene ranking. Our
variant analysis pipeline was used to resolve four undiag-
nosed cases of NMD. Genomic DNA isolated from per-
ipheral blood of patients was sequenced on Agilent
SureSelect Targeted capture platform for a custom panel of
110 genes which are known to be associated with NMD.
We identiﬁed and validated four single nucleotide variants
likely to be causative for given patient phenotypes, viz., a
novel truncating DMD mutation (p.Leu268X); a novel
protein coding BICD2 variant (p.Arg141Cys); and lastly,
compound heterozygous mutations in TRAPPC11 gene
comprising a rare nonsense (p.Arg48X) and a known
pathogenic mutation (p.Gly980Arg). Our study highlights
the signiﬁcance of variant analysis pipeline based on gene
prioritization tools for more efﬁcient and faster clinical
dignosis of rare genetic disorders like NMDs. In addition,
this pipeline can be applied to data from any sequencing
platform besides that described in this study.
S. Tomar: None. R. Sethi: None. P. Lai: None.
P16.34B
Sharing dog exome/genome variant and phenotype data in
Varda and LOVD3
The BPSDA Dog Project team, W. Suring, P. Taschner;
Generade Center of Expertise Genomics, Leiden, Nether-
lands.Finding sufﬁcient evidence to prove causality is the
main hurdle in current whole exome (WES) and whole
genome sequencing (WGS) studies aimed at cracking rare
disease. Roughly, studies give a yield of 1/3 proven caus-
ality, 1/3 likely causality and 1/3 unresolved cases. Other
resources providing additional positive or negative evidence
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for candidate variants might improve overall yield. Impor-
tant obstacles: other resources often not easy to ﬁnd and
access; lack of standards and metadata may interfere with
reuse of data. We hypothesize that efﬁcient sharing of
genetic variants and phenotype data from other species may
help overcoming these problems
Reference protein sequences from other organisms are
already used to predict amino acid conservation scores [1,
2]. These might be improved if protein variants from indi-
vidual breeds could be included in the calculations. Variants
causing disease in animals are currently stored in Online
Mendelian Inheritance in Animals (OMIA, http://omia.
angis.org.au/), which partially follows standards resembling
HGNC and HGVS nomenclature. We demonstrate that
variants from VCF ﬁles can be stored and annotated with
their frequency in the variant frequency database Varda
(Dog Varda, http://varda.generade.nl). Information about
functional effects of variants and the resulting phenotypes in
individual animals can be stored in the LOVD3 gene variant
database platform [3] (Dog LOVD, http://databases.genera
de.nl/dog/). We hope that this example will be followed by
research and diagnostic centers world-wide for other
species.
[1] PolyPhen-2, PMID:20354512, http://genetics.bwh.ha
rvard.edu/pph2/
[2] SIFT, PMID:11337480, http://sift.bii.a-star.edu.sg/
[3] LOVD, Leiden Open-source Variation Database,
PMID: 21520333, http://www.LOVD.nl
The BPSDA Dog Project team: None. W. Suring:
None. P. Taschner: None.
P16.35C
Simplifying access to human genomic data: community
platform Repositive.io
N. V. Kovalevskaya, C. Whicher, M. Corpas, R. Shaw, F.
Nielsen
epositive Ltd, Cambridge, United Kingdom
Introduction: Common practice suggests that human
genomic data should be deposited in public repositories for
further reuse. Finding and accessing deposited genomic
datasets, however, is often cumbersome, with data and
metadata being scattered throughout the Internet, annotated
inconsistently and often machine unreadable. This makes it
difﬁcult for researchers to ﬁnd existing genomic datasets of
interest.
Materials and Methods: Genomic data sources were
identiﬁed from our interactions with the genomics com-
munity, by monitoring announcements and by targeted
searching of the Internet. State-of-the-art interfaces have
been deployed on top of our database to facilitate the dis-
covery of existing human genomic datasets through a
variety of ﬁlters and querying options such as assay type or
keyword.
Results: More than 300 data sources are identiﬁed, more
than 1,1 million datasets from 38 sources are currently
indexed. We created the Repositive platform (https://
repositive.io/?ESHG17) as a free online portal and com-
munity of users that facilitate ﬁnding, accessing, and shar-
ing of published genomic data. Indexed datasets cover
population studies, microbiomes, methylomes and other
types of NGS data. Many of these datasets are further
classiﬁed into curated collections.
Conclusions: Repositive.io is a free community platform
that allows users to ﬁnd, annotate, curate and share datasets,
and form data collaborations. It facilitates data access and
re-use in the genomics community and is a “one-stop shop”
to discover and explore the most relevant human genomic
datasets published to date.
N.V. Kovalevskaya: A. Employment (full or part-time);
Signiﬁcant; Repositive Ltd. C. Whicher: A. Employment
(full or part-time); Signiﬁcant; Repositive Ltd. M. Corpas:
A. Employment (full or part-time); Signiﬁcant; Repositive
Ltd. R. Shaw: A. Employment (full or part-time); Sig-
niﬁcant; Repositive Ltd. F. Nielsen: A. Employment (full or
part-time); Signiﬁcant; Repositive Ltd.
P16.36D
Increasing the utility of the NHGRI-EBI genome-wide
association study (GWAS) Catalog for users
J. A. L. MacArthur1, M. R. Amode1, T. Burdett1, M.
Cerezo1, F. Cunningham1, P. Flicek1, J. A. Guillen1, P.
Hall2, L. Harris1, E. Hastings1, L. Hindorff2, H. Junkins2,
C. Malangone1, A. McMahon1, A. Milano1, J. Morales1,
H. S. Riat1, A. Thormann1, S. Trevanion1, D. Welter1, H.
Parkinson1
1European Bioinformatics Institute, Hinxton, Cambridge,
United Kingdom, 2Division of Genomic Medicine, NHGRI,
NIH, Bethesda, MD, United States
The GWAS Catalog (www.ebi.ac.uk/gwas) is a manually
curated summary resource of human genotype-phenotype
associations from GWAS publications. The Catalog con-
tains a vast amount of data, encompassing over 35,000
SNP-trait associations from 2,700 publications as of Feb-
ruary 2017. This data is used by a growing community of
biologists and bioinformaticians to identify causal variants,
understand disease mechanisms and establish targets for
treatment. We have made several recent improvements,
with the aim of improving the utility of GWAS Catalog data
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in these analyses. A prototype GWAS Catalog variant-
speciﬁc page is now available (http://wwwdev.ebi.ac.uk/
gwas/beta/variants) that integrates additional variant infor-
mation from Ensembl, along with links to co-located genes
and regulatory elements, population genetics and phenotype
information. It includes an interactive visualisation, allow-
ing users to identify and explore variants in linkage dis-
equilibrium with the Catalog variant. Updates have also
been made to support hosting of full p-value data sets for
GWAS Catalog studies, vastly increasing the potential of
downstream analyses. Published summary statistics are now
available for download via the search interface and will be
added for additional studies when curated. We encourage
authors of GWAS Catalog publications to contact us if
summary statistics are available so we can add these. We
welcome feedback from the user community on these
improvements and any other changes they would like to see.
Funding: NHGRI, NHLBI, the NIH Common Fund (U41-
HG006104, U41-HG007823) and the European Molecular
Biology Laboratory.
J.A.L. MacArthur: None. M.R. Amode: None. T.
Burdett: None.M. Cerezo: None. F. Cunningham: None.
P. Flicek: F. Consultant/Advisory Board; Modest; Omicia,
Inc.. J.A. Guillen: None. P. Hall: None. L. Harris: None.
E. Hastings: None. L. Hindorff: None. H. Junkins: None.
C. Malangone: None. A. McMahon: None. A. Milano:
None. J. Morales: None. H.S. Riat: None. A. Thormann:
None. S. Trevanion: None. D. Welter: None. H. Par-
kinson: None.
P16.37A
Ampliﬁcation-free targeted SMRT sequencing using
CRISPR/Cas9 for studying repeat expansions in Hun-
tington’s disease
I. Höijer1, Y. Tsai2, A. Ameur1, T. Clark2, M. Bondeson1,
D. Greenberg2, P. Kotturi2, I. Jonasson1, U. Gyllensten1
1Uppsala University, Uppsala, Sweden, 2Paciﬁc Bios-
ciences, Menlo Park, CA, United States
Targeted enrichment of speciﬁc loci is a widely used
approach in next generation sequencing. Most available
methods for targeted enrichment require ampliﬁcation dur-
ing library preparation, which can be challenging for
example when targeting low complexity regions or long
repeat expansions. Here, we present a novel ampliﬁcation-
free method for targeted enrichment utilizing the CRISPR/
Cas9 system for long-read Single Molecule Real-Time
(SMRT) sequencing. Guide RNA (gRNA) was designed in
proximity to the region of interest and was used to target
and digest whole genome libraries. Capture adapters were
subsequently ligated to the digestion site and magnetic
beads used to enrich for libraries containing the target
sequence. We used this approach to target the Huntingtin
(HTT) gene, the causative gene for Huntington's disease by
a CAG repeat expansion. Twelve individuals with Hun-
tington's disease were sequenced and analyzed. In all cases
the CAG repeat count from our data agreed with previous
results from fragment analysis. The alleles for all samples
were resolved. Furthermore, novel trinucleotide repeats in
the ﬂanking regions of the CAG repeats were found. With
this ampliﬁcation-free technique and the long reads of
SMRT sequencing, we demonstrate that we accurately can
sequence through repeat expansions that are difﬁcult or
impossible to investigate using PCR based methods. We are
currently optimizing this method to allow for multiplexing
of several samples/targets in the same run. Also, since this
method captures native DNA it is also possible to detect
epigenetic modiﬁcations in the data.
I. Höijer: None. Y. Tsai: A. Employment (full or part-
time); Signiﬁcant; Paciﬁc Biosciences. A. Ameur: None. T.
Clark: A. Employment (full or part-time); Signiﬁcant;
Paciﬁc Biosciences. M. Bondeson: None. D. Greenberg:
A. Employment (full or part-time); Signiﬁcant; Paciﬁc
Biosciences. P. Kotturi: A. Employment (full or part-time);
Signiﬁcant; Paciﬁc Biosciences. I. Jonasson: None. U.
Gyllensten: None.
P16.39C
Machine learning-based gene prioritization identiﬁes
novel candidate risk genes for inﬂammatory bowel
disease
O. Isakov1, I. Dotan2, S. Ben-shachar2
1Tel Aviv University, Tel-Aviv, Israel, 2Tel Aviv Medical
Center, afﬁliated to Tel Aviv University, Tel-Aviv, Israel
Background: The inﬂammatory bowel diseases (IBD) are
chronic inﬂammatory disorders, associated with genetic,
immunologic and environmental factors. While hundreds of
genes are implicated in IBD etiology, it is likely that
additional genes play a role in the disease process. We
developed a machine learning-based gene prioritization
method to identify novel IBD risk genes. Methods: Known
IBD genes were collected from genome wide association
studies and annotated with expression and pathway infor-
mation. Using these genes, a model was trained to identify
IBD risk genes. A comprehensive list of 16,390 genes was
then scored and classiﬁed. Results: Immune and inﬂam-
matory responses, as well as pathways such as cell adhe-
sion, cytokine-cytokine receptor interaction, and sulfur
metabolism were identiﬁed to be related to IBD. Scores
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predicted for IBD genes were signiﬁcantly higher than for
non-IBD genes (P<10−20). There was a signiﬁcant asso-
ciation between the score and having an IBD publication
(P<10−20). Overall 347 genes had a high prediction score
(>0.8). A literature review of the genes, excluding those
used to train the model, identiﬁed 67 genes without any
publication concerning IBD. Those genes represent novel
candidate IBD risk genes which can be targeted in future
studies. Conclusions: Our method successfully differ-
entiated IBD risk genes from non-IBD genes by utilizing
information from expression data and a multitude of gene
annotations. Crucial features were deﬁned and we were able
to detect novel potential risk genes for IBD. These ﬁndings
may help detect new IBD risk genes and improve the
understanding of IBD pathogenesis.
O. Isakov: None. I. Dotan: None. S. Ben-shachar:
None.
P16.40D
DOMINO: a bioinformatic tool for the identiﬁcation of
dominant disease genes
M. Quinodoz1, B. Royer-Bertrand1,2, K. Cisarova1, S. A.
Di Gioia1,3, A. Superti-Furga2, C. Rivolta1
1Department of Computational Biology, Unit of Medical
Genetics, University of Lausanne (UNIL), Lausanne,
Switzerland, 2Division of Genetic Medicine, Lausanne
University Hospital (CHUV) and University of Lausanne,
Lausanne, Switzerland, 3Department of Neurology, F.M
Kirby Neurobiology Center, Boston Children’s Hospital,
Harvard Medical School, Boston, MA, United States
Introduction: In a typical exome or genome sequencing
analysis, ~400 heterozygous, rare and nonsynonymous or
splicing DNA variants are found per individual. In patients
with dominant conditions, these variants include a single
pathogenic mutation. To help ascertaining the causative
mutation among these many variants, we developed
DOMINO, a bioinformatic tool able to identify genes sus-
ceptible to be associated with dominant conditions. No such
tool seems to be currently available.Methods: DOMINO
utilizes linear discriminant analysis to compute the prob-
ability of a gene to harbor mutations that are pathogenic at
the heterozygous state. It is based on a broad array of fea-
tures including genomic, expression, interaction, structural,
and functional data. We instructed this analytical framework
with a set of >500 genes extracted from OMIM and
manually curated for well-established inheritance patterns
(the “training set”). We used 10-fold cross-validation to
determine the essential features.Results: In the training set,
a small number of features was sufﬁcient to provide an
AUC higher than 0.85. We validated the model on different
sets of genes associated with Mendelian conditions,
including skeletal nosology, retinal degeneration, and genes
published in AJHG in 2016. In these validation sets, AUCs
were even higher than in the training set.Conclusion:
DOMINO displays high sensitivity and speciﬁcity for genes
associated with dominant disorders. It may ﬁll the need for a
method to prioritize the numerous heterozygous variants
identiﬁed in highly parallel sequencing. Its precision may
increase as novel annotations and features become avail-
able.PhD Fellowship of FBM, UNIL; Grant #156260,
SNSF
M. Quinodoz: None. B. Royer-Bertrand: None. K.
Cisarova: None. S.A. Di Gioia: None. A. Superti-Furga:
None. C. Rivolta: None.
P16.42B
Primary and metastatic melanoma reveal speciﬁc
lncRNAs expression signatures
A. D. D. Siena1,2, J. R. Plaça2,3, L. F. Araújo1,2,3, I. I.
Barros1,2, A. F. Aristizabal-Pachon1,2,3, K. P. Zueli2, R.
Torrieri3,4, J. F. Sousa2,3, E. M. Espreaﬁco5, W. A. Silva
Jr1,2,3,4
1Department of Genetics at Ribeirão Preto Medical School,
University of São Paulo, Ribeirão Preto, Brazil, 2Center for
Cell-Based Therapy (CEPID/FAPESP); National institute
of Science and Technology in Stem Cell and Cell Therapy
(INCTC/CNPq), Regional Blood Center of Ribeiraõ Preto,
Ribeirão Preto, Brazil, 3Center for Integrative Systems
Biology (CISBi) – NAP/USP, Ribeirão Preto, Brazil, 4Cen-
ter for Medical Genomics, HCFMRP/USP, Ribeirão Preto,
Brazil, 5Department of Cellular and Molecular Biology at
Ribeirão Preto Medical School, University of São Paulo,
Ribeirão Preto, Brazil
Introduction: Melanoma is the deadliest form of skin
cancer with known aggressiveness. Cutaneous melanoma
accounts for only 2% of skin cancers, but melanoma death
rate is approximately 80%. Previous studies demonstrated
an association of many noncoding RNAs with melanoma
development. Nevertheless, the long noncoding RNAs
(lncRNAs) and their role on melanomagenesis just have
emerged and remained poorly understood. The recent
identiﬁcation of melanoma-associated lncRNAs BANCR,
SPRY4-IT1 and others opened a research ﬁeld with many
challenges and questions to elucidate. Until now, others
studies has not entirely focused on lncRNAs involvement in
every step of melanoma progression. Materials and Meth-
ods: We performed RNA-Seq in melanocyte, primary
melanoma, and metastatic melanoma cell lines to detect
716
lncRNAs associated with melanoma progression. To iden-
tify lncRNA differentially expressed (adjusted P-value <
0.01 and -1>fold change>1) we used a public dataset of
RNA-Seq from melanocyte and melanoma. Results: mela-
nocyte, primary and metastatic melanoma showed lncRNA
speciﬁc expression. Comparison between melanocyte ver-
sus all melanoma samples revealed 110 upregulated and 52
downregulated lncRNAs. Principal Component Analysis
(PCA) presented primary melanoma with some discrepancy
from the melanocyte and metastatic melanoma. Some dif-
ferentially expressed lncRNAs were predicted to interact
with proteins, suggesting their participation in a range of
biological processes associated with cancer progression.
Conclusions: We identiﬁed potential lncRNAs candidates
with involvement in melanoma progression, as the recently
described lncRNA SAMMSON, that have a fundamental
role in melanoma survival, and which we also identiﬁed in
our study. Grants and fellowships: FAPESP, CNPq,
CAPES, FUNDERP and FAEPA.
A.D.D. Siena: None. J.R. Plaça: None. L.F. Araújo:
None. I.I. Barros: None. A.F. Aristizabal-Pachon: None.
K.P. Zueli: None. R. Torrieri: None. J.F. Sousa: None. E.
M. Espreaﬁco: None. W.A. Silva Jr: None.
P16.43C
Salivary microbiome changes associated with asthma in
African American children
A. Espuela-Ortiz1, F. Lorenzo-Diaz1,2, A. Baez-Ortega3, C.
Eng4, E. G. Burchard*4,5, C. Flores*1,6, M. Pino-
Yanes*1,2,6, (*equal contribution)
1Hospital Universitario N.S. de Candelaria, Santa Cruz,
Spain, 2Section of Genetics, Department of Biochemistry,
Microbiology, Cell Biology and Genetics, Universidad de
La Laguna, San Cristobal de La Laguna, Spain, 3Depart-
ment of Veterinary Medicine, University of Cambridge,
Cambridge, United Kingdom, 4Department of Medicine,
University of California, San Francisco, CA, United States,
5Department of Bioengineering and Therapeutic Sciences,
University of California, San Francisco, CA, United States,
6CIBER de Enfermedades Respiratorias, Instituto de Salud
Carlos III, Madrid, Spain
Introduction: Several studies have shown that the airways
of asthma patients contain higher diversity of bacteria and
are enriched in certain pathogenic species. However, sam-
pling the airways in children is challenging. Here aimed to
identify differences in the salivary bacterial composition
between children with and without asthma.
Methods: Saliva samples from 147 Latinos from the
GALA II study (33 asthma cases and 114 controls) and 113
African Americans from SAGE II (56 asthma cases and 57
controls) were analysed. The V4 16S rRNA gene was
sequenced in a MiSeq sequencer (Illumina) with 250 bp
paired-end reads. Data processing was performed using a
custom QIIME-based pipeline. Differences in bacterial
abundance between cases and controls were assessed with
Explicet, using the non-parametric Wilcoxon test and
adjusting for multiple comparisons.
Results: A total of 5 Phylum and 19 genera were iden-
tiﬁed as core microbiome (>1% abundance), being Pre-
votella, Streptococcus and Veillonella the most abundant
genus. In African Americans, differences were observed for
the genera Veillonella (14.0% in cases vs 9.7% in controls,
p=3.1×10–4) and Streptococcus (16.9% in cases vs 23.9%
in controls, p=2×10-3). Conversely, no differences were
found at the taxonomic levels assessed among cases and
controls in Latinos.
Conclusions: We identiﬁed changes in the salivary
microbiome composition associated with asthma suscept-
ibility in African American children.
Funding: Supported by Instituto de Salud Carlos III
(AC15/00015, PI14/00844), co-ﬁnanced by the European
Regional Development Funds, “A way of making Europe”,
and the ERACoSysMed 1st Joint Transnational Call
(SysPharmPedia) from the European Union (Horizon 2020).
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Baez-Ortega: None. C. Eng: None. E.G. Burchard*:
None. C. Flores*: None. M. Pino-Yanes*: None.
P16.44D
The methylome of duodenal cell populations reveals
epigenetic effects of the HLA region in celiac disease
N. Fernandez-Jimenez1,2, K. Garcia-Etxebarria1, L.
Plaza-Izurieta1, A. Jauregi-Miguel1, I. Romero-
Garmendia1, M. Legarda3, S. Ecsedi2, A. Castellanos-
Rubio1, V. Cahais2, C. Cuenin2, D. Degli Esposti2, I.
Irastorza3, H. Hernandez-Vargas2, Z. Herceg2, J. Bilbao1
1University of the Basque Country (UPV/EHU), Leioa,
Spain, 2International Agency for Research on Cancer
(IARC), Lyon, France, 3Cruces University Hospital,
Barakaldo, Spain
Introduction: The Human Leucocyte Antigen (HLA) locus
and other DNA variants identiﬁed in GWA (Genome-Wide
Association) studies explain around 50% of the heritability
of celiac disease (CD). However, the pathogenesis of CD
could be driven by other layers of genomic information
independent from inherited sequence variation, like DNA
methylation. It could also be that allele-speciﬁc DNA
methylation explains a fraction of SNP associations.
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Methods: To answer these questions, knowing that the
DNA methylation landscape may vary across cell types, we
analyzed the methylome of cellular fractions enriched for
epithelial and immune populations from duodenal biopsies
in CD patients and controls. We also obtained Immunochip
SNP genotypes and cell-type speciﬁc transcriptomes from a
subset of the samples.
Results: We ﬁnd a cell type-speciﬁc methylation sig-
nature that includes the HLA region and is characterized by
a loss of CpG island boundaries, often resulting in altered
gene expression, and by increased variability in the epi-
thelial fraction. The overlap between differentially methy-
lated positions and those SNPs that are associated with the
disease or correlated with methylation levels is minimal.
There is a remarkable enrichment for immune-related genes
(including several previously unrelated to CD) around dif-
ferentially methylated regions.
Conclusions: These results support the idea of methy-
lation as a genotype-independent, disease-related event and
conﬁrm its role in the HLA region (apart from the well-
known DQ allele-speciﬁc effect). Additionally, differential
methylation does not explain a signiﬁcant fraction of the
GWAS-SNP associations. Interestingly, the methylation
proﬁle of the celiac epithelial fraction resembles early stages
of solid tumors.
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The Human-Mouse: Disease Connection: facilitating the
quest for translational mouse models
S. M. Bello, A. V. Anagnostopoulos, J. T. Eppig, C. L.
Smith, The MGI Software Team; ouse Genome
Informatics (MGI), The Jackson Laboratory, Bar Harbor,
ME, United States
The mouse is a pivotal model system for investigating
etiopathogenesis and therapeutic targets for human heredi-
tary disease. The Human-Mouse: Disease Connection
(HMDC, www.diseasemodel.org), developed by MGI
(www.informatics.jax.org), is a translational tool providing
integrated access to human-mouse genomic, phenotypic,
and disease information. Researchers can dynamically
explore phenotypes and disease correlations, identify can-
didate genes, and assess experimentally deﬁned mouse
genotypes modeling clinically relevant proﬁles. The latest
HMDC release features a redesigned search form, and
parallel integration of human phenotype terms and known
disease-to-phenotype associations from the Human Pheno-
type Ontology (HPO) along with human disease terms from
the Disease Ontology (DO). Users can initiate searches from
a human or mouse viewpoint using gene names, symbols or
IDs, human or mouse phenotype terms or IDs, disease
(OMIM or DO) terms or IDs, or genomic locations. Mul-
tiple search criteria may be combined or used individually
via Booleans (e.g., “Charcot-Marie-Tooth” AND PMP22);
or users can select speciﬁc disease/phenotype terms of
interest (e.g., “Charcot-Marie-Tooth Disease, Type 4B2”)
using the optional autocomplete feature. Initial results
appear in a visual, color-coded grid juxtaposing phenotypes
and diseases associated with human and mouse orthologs,
and may be further reﬁned by ﬁlters. Importantly, grid cells
link to underlying MGI and HPO data, including pheno-
typic detail, disease information, available mouse model
resources, and supporting references. Alternate views pre-
sent gene- and disease-centric data in tabular format. We
highlight HMDC content and enhanced ﬂexibility to
visually compare human-mouse phenotypes, prioritize
candidate disease genes, and identify mouse models of
translational value. Supported by NIH grant HG000330.
S.M. Bello: None. A.V. Anagnostopoulos: None. J.T.
Eppig: None. C.L. Smith: None.
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DNA methylation differences in CD4+ and CD8+
T cells of multiple sclerosis patients and healthy controls
I. S. Brorson1, B. Rhead2, H. Quach2, P. Berg-Hansen1,3,
T. Berge1,3,4, H. F. Harbo1,3, S. D. Bos1,3, L. F. Barcellos2
1Institute of Clinical Medicine, University of Oslo, Oslo,
Norway, 2Genetic Epidemiology and Genomics Laboratory,
Division of Epidemiology, School of Public Health,
University of California, Berkeley, CA, United States,
3Department of Neurology, Oslo University Hospital, Oslo,
Norway, 4Faculty of Technology, Art and Design, Oslo and
Akershus University College of Applied Science, Oslo,
Norway
Introduction: Multiple sclerosis (MS) is a chronic inﬂam-
matory, demyelinating disorder of the central nervous sys-
tem and one of the most common neurological conditions
among young adults. The cause of MS is largely unknown,
however the best-supported hypothesis is that MS onset is
triggered by common environmental and genetic factors and
interactions between these. Epigenetics has emerged as a
critical factor of gene regulation that may link genetic
makeup and environmental exposures in complex diseases
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such as MS. Here we investigate the role of DNA methy-
lation in immune cells relevant for MS.
Materials and Methods: CD4+ and CD8+ T cells were
collected from a highly homogeneous group of 30 newly
diagnosed, treatment-naive Norwegian female MS patients
and 29 age-matched healthy controls. We measured DNA
methylation at ~450,000 sites using a chip-based assay.
Since DNA methylation often occurs on groups of CpG
sites, we looked for differently methylated regions (DMR)
using the Bumphunter R package.
Results: We identiﬁed ﬁve DMRs between MS patients
and controls in our sample. Interestingly, some of these
DMRs were identiﬁed in both CD4+ and CD8+ T cells,
suggesting that these regions are more global DNA
methylation patterns associated to MS.
Conclusions: DNA methylation may play a role in the
risk of getting MS. We replicate the previously identiﬁed
DNA hypermethylation in CD8+ T cells from MS patients
compared to healthy controls. In addition, we identiﬁed ﬁve
DMRs that may mark processes involved in MS risk.
I.S. Brorson: None. B. Rhead: None. H. Quach: None.
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Using neural networks to predict effects of mutations on
protein binding
A. G. B. Grønning1,2, T. K. Doktor1,2, S. J. Larsen3, G. H.
Bruun1,2, J. Baumbach3, B. S. Andresen1,2
1Department of Biochemistry and Molecular Biology,
University of Southern Denmark, Odense M, Denmark,
2Villum Center for Bioanalytical Sciences, University of
Southern Denmark, Odense M, Denmark, 3Department of
Mathematics and Computer Science, University of Southern
Denmark, Odense M, Denmark
Introduction: Modern sequencing technologies has made
sequencing affordable in the clinical setting at a scale pre-
viously unheard of. With the wealth of data comes the
problem of understanding variations and assessing their
effect on the phenotype. In particular, the potential patho-
genic effect of intronic and silent sequence variations are
challenging, since they can have strong effects by disturbing
the splicing process and cause insufﬁcient protein produc-
tion. Moreover, it is often overlooked that also missense
mutations can disrupt splicing. Mutations that affect spli-
cing often do so by disrupting binding of regulatory splicing
proteins (SRPs), such as SR and hnRNP proteins. SRPs
bind short degenerate motifs within splicing enhancers (SE)
or splicing silencers (SS), but their exact binding
preferences in vivo are often insufﬁciently characterized and
the effect of a mutation on SRP protein binding to an SE or
SS does not always correlate with in silico predictions.
Results: To address this problem we have developed
DeepCLIP, a neural network than can be trained on protein
bound sequences, such as those from in vivo cross-linking
studies and can predict binding of a protein to a given
sequence. We show here that it can efﬁciently discriminate
between bound and un-bound sequences and that the
binding of protein to mutants correlates with the computed
score and splicing pattern.
Conclusions: We suggest that DeepCLIP can be used to
predict the effect of mutations on protein binding and in
larger contexts be used to correlate genotype with
phenotype.
Funding: Grant to BSA from FNU (DFF–4181-00515).
A.G.B. Grønning: None. T.K. Doktor: None. S.J.
Larsen: None. G.H. Bruun: None. J. Baumbach: None.
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Methods for low and ultra-low variant detection using
molecular tagging, targeted sequencing and error cor-
rection algorithms
M. Light, W. Lee, K. Lai, P. Mudivarti, J. Wang, C.
Walworth, D. Kupec, M. Jarosz
Integrated DNA Technologies, Redwood City, CA, United
States
Introduction: Low frequency variant detection is crucial
for clinical sequencing, particularly with the advancement
of testing “liquid biopsy” samples with very low tumor
fraction. Accurate calling of these rare mutations is further
hindered by artifacts introduced during sample preparation,
target enrichment, and sequencing. Here, we report error
rates for canonical base substitutions and show how con-
sensus building from molecular tags enables in silico cor-
rection of false positives, greatly improving accuracy for
sub-1% variants.
Materials and Methods: Low frequency variants were
modeled using mixtures of well-characterized normal cell
line DNA, resulting in 1% and 0.5% alternative allele fre-
quencies. Libraries were constructed using adaptors con-
taining Unique Molecular Identiﬁers (UMIs) and captured
with custom IDT xGen® Lockdown® probes targeting a
35kb region of highly polymorphic SNPs. Positive and
negative variant calls were assessed for accuracy using high
conﬁdence regions annotated in the Genome in a Bottle
database.
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Results: The most prevalent artifactual mutations were
G > A/C > T substitutions likely introduced via oxidative
damage during sample preparation. Consensus building
using a minimum family size of 20 improved positive
predictive value (PPV) from 45% to 85%. PPV was further
increased to 98% by increasing the minimum alternate-
allele consensus read count for variant calls symptomatic of
oxidation damage.
Conclusions: Building consensus sequences enables in
silico error correction, dramatically increasing variant call-
ing speciﬁcity. Due to the prevalence of artifacts arising
from oxidative damage, mutation-speciﬁc thresholding is
necessary to accurately detect variants present below 1%.
M. Light: A. Employment (full or part-time); Sig-
niﬁcant; Integrated DNA Technologies. W. Lee: A.
Employment (full or part-time); Signiﬁcant; Integrated
DNA Technologies. K. Lai: A. Employment (full or part-
time); Signiﬁcant; Integrated DNA Technologies. P.
Mudivarti: A. Employment (full or part-time); Signiﬁcant;
Integrated DNA Technologies. J. Wang: A. Employment
(full or part-time); Signiﬁcant; Integrated DNA Technolo-
gies. C. Walworth: A. Employment (full or part-time);
Signiﬁcant; Integrated DNA Technologies. D. Kupec: A.
Employment (full or part-time); Signiﬁcant; Integrated
DNA Technologies. M. Jarosz: A. Employment (full or
part-time); Signiﬁcant; Integrated DNA Technologies.
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Optimal workﬂow for next generation sequencing data
processing using existing technology
J. Martin1, A. Larionov1,2, G. Clark1,3, E. R. Maher1,3
1University of Cambridge, Cambridge, United Kingdom,
2Cancer Research UK, Cambridge, United Kingdom,
3Cambridge NIHR Biomedical Research Centre, Cam-
bridge, United Kingdom
Introduction Next Generation Sequence (NGS) instru-
ments are becoming the standard tool in genetics, however,
this process has not been accompanied by the development
of a “gold standard” pipeline for germline NGS data pro-
cessing. Our goal in the present study is to determine the
optimal workﬂow in the speciﬁc case of whole exome
sequencing (WES) to maximize the cost-efﬁciency of the
process.
Material and Methods For our analysis, we selected a
cohort of 200 individuals sequenced for WES. All the
samples considered were processed using sixteen different
workﬂows composed of the different algorithms and soft-
ware available. We selected up to ten quality parameters
and indices to discern the best possible workﬂow.
Results Using bwa mem for the alignment compared to
using bwa sampe improved the number of aligned reads by
roughly a 10%. When performing and not performing
BQSR and indel realignment, there were no signiﬁcant
differences in the number of variants called or the quality of
those, but there was an increase of computing time (4:32
versus 2:24). Regarding the variant calling, there were no
signiﬁcant differences in the number of variants called or
their quality between algorithms, while the depth of read
was signiﬁcantly higher in uniﬁed genotyper (73.63 versus
53.83). Also, the computational time was signiﬁcantly
lower for uniﬁed genotyper (2:24 versus 11:13).
Conclusions Our results indicate an optimal workﬂow
for the processing of NGS WES germline data which can
cut the time per sample down to a tenth while maintaining
the quality of the results produced.
J. Martin: None. A. Larionov: None. G. Clark: None.
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P16.50B
Innovative technologies for high performance Next
Generation Sequencing data processing delivering fast-
est turn arounds
B. Tolhuis, L. Baarspul, H. Karten
GENALICE BV, Harderwijk, Netherlands
Next Generation Sequencing (NGS) is rapidly being adop-
ted and implemented in clinical settings to improve patient
diagnostics, prognosis and therapy. Simultaneously new
platforms produce more sequencing data at a higher pace.
Consequently, NGS data analysis is becoming the bottle-
neck. It takes more resources to process sequence data into
clinically interpretable variants. Both time and costs are
crucially important for clinical diagnostics. As a solution to
this growing pain we present GENALICE MAP, a high
performance NGS data analysis software solution. It maps
sequence reads, calls variants, detects somatic mutations
and discovers copy number variations (CNV), all at sig-
niﬁcantly reduced processing times. GENALICE MAP can
do read mapping and variant calling of a human 30x whole
genome sequencing data set in approximately 30 minutes.
Daunting tasks, such as migration of large data sets to
reference build 38 of the human genome can be performed
in a few days. Because of its unexceeded processing speed,
trio- and large cohort size analysis becomes easy and
affordable. Its unique methods ensure high quality results.
For example, Consensus Based Call Enhancement enables
high accuracy and low Mendelian error rates in trio analy-
sis, facilitating de novo variant discovery. Likewise, proﬁles
give higher sensitivity for detecting pathogenic variants. We
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conclude that GENALICE MAP is an accurate and high
performance software solution to accelerate NGS data
processing, consuming little resources. As such, it is an
excellent solution to process an ever-increasing NGS data
stream supporting relevant diagnostic improvements such as
faster clinical outcome enabling more cost-effective
decisions.
B. Tolhuis: A. Employment (full or part-time); Sig-
niﬁcant; GENALICE B.V. L. Baarspul: A. Employment
(full or part-time); Signiﬁcant; GENALICE B.V. H. Kar-
ten: A. Employment (full or part-time); Signiﬁcant; GEN-
ALICE B.V..
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Methodical comparison of variant calling pipelines for
next generation sequencing data
D. R. Bobbili1, M. Sturm2, P. May1, M. Sharma3
1Luxembourg Centre for Systems Biomedicine, Esch-sur-
Alzette, Luxembourg, 2Institute for Medical Genetics and
Applied Genomics, Tubingen, Germany, 3Institute for
Clinical Epidemiology and Applied Biometry, Tubingen,
Germany
Several variant calling pipelines have been developed to
identify the genome variants from next generation sequen-
cing (NGS) data. Still, the concordance rate between dif-
ferent pipelines is poor and the reliability of identiﬁed
variants is often questionable. We aim to address this pro-
blem by systematically evaluating the performance of pre-
processing to variant caller algorithms, using combination
of different tools. In the pre-processing steps – mark
duplicates (tools: Picard and samblaster), indel realignment
(tools: Genome Analysis Tool Kit (GATK) indel realigner
and ABRA), adapter trimming by SeqPurge and quality
score recalibration by GATK base quality score recalibra-
tion along with three different freely available variant
callers - GATK HaplotypeCaller, Freebayes, Platypus will
be compared. Furthermore, we compare the performance of
previously mentioned variant callers with a commercial
platform known as Dynamic Read Analysis for Genomics
(DRAGEN) from Edico genome. As a gold standard variant
list we use a set of high-conﬁdent variant calls for one
individual (NA12878) from the Genome in a Bottle (GIAB)
consortium to bench mark different variant calling pipe-
lines. After bench marking the pipelines, we will validate
the efﬁcacy of our pipeline by using publically available
exome data from the Parkinson's Progression Markers
Initiative (PPMI) study, which is an effort to identify the
biomarkers of PD progression, and our in-house data
comprising of whole-exome and whole-genome sequencing
data. The results of this study will not only help to
streamline the variant calling pipeline strategies, but also
provide appropriate ground rules for dependable variant
detection for future NGS based studies.
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Need for speed in high-throughput sequencing data
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M. Plüss1,2, S. M. Caspar1, J. Meienberg1, A. M. Kopps1,
I. Keller3, R. Bruggmann4, M. Vogel2, G. Matyas1
1Center for Cardiovascular Genetics and Gene Diagnos-
tics, Foundation for People with Rare Diseases, Schlieren-
Zurich, Switzerland, 2Institute of 4D Technologies, Uni-
versity of Applied Sciences and Arts Northwestern Switzer-
land, Windisch, Switzerland, 3Department of Clinical
Research, University of Berne, Berne, Switzerland, 4Inter-
faculty Bioinformatics Unit and Swiss Institute of Bioinfor-
matics, University of Berne, Berne, Switzerland
Introduction: Rapidly evolving high-throughput sequen-
cing (HTS) technologies produce huge amounts of data,
requiring high-throughput data analyses with appropriate
sensitivity/recall. However, widely-used alignment and
variant calling tools are either too slow (e.g., BWA
+GATK) or have insufﬁcient sensitivity/recall (e.g., Isaac).
In this study, we compared speed, disk footprint, and sen-
sitivity/recall of the current gold standards BWA+GATK
and Isaac with GENALICE MAP (genalice.com), a recently
introduced ultra-fast HTS data analysis software solution.
Materials and Methods: We performed alignment and var-
iant calling on short-read (2×150bp) 60x PCR-free WGS
data of NA12878 using BWA+GATK, Isaac, and GENA-
LICE MAP. While measuring analysis time and disk foot-
print, we assessed the sensitivity/recall of the three pipelines
according to GIAB v3.3 using RTG Tools. Results: Our
data demonstrate more than 95 and 15 times higher speed as
well as more than 45 and 20 times decreased disk footprint
of GENALICE MAP compared to BWA+GATK and Isaac,
respectively. The sensitivity/recall of GENALICE MAP
was considerably higher than that of Isaac and close to
BWA+GATK. Conclusion: The GENALICE MAP soft-
ware offers hitherto unprecedented high speed and low disk
footprint in alignment and variant calling with reasonable
sensitivity/recall. Thus, it is a promising new tool in HTS
data analysis either as a stand-alone/primary or a secondary
solution, enabling realignments and reanalyses in ever-
growing patient cohorts (e.g., due to updates of the refer-
ence genome such as hg19 to hg38).
Abstracts from the 50th European Society of Human Genetics Conference:. . . 721
M. Plüss: None. S.M. Caspar: None. J. Meienberg:
None. A.M. Kopps: None. I. Keller: None. R. Brugg-
mann: None. M. Vogel: None. G. Matyas: None.
P16.53A
Genomics England PanelApp: A Key Open Source
Genetic Resource for the Rare Disease Community
E. M. McDonagh, A. Rueda, S. E. A. Leigh, R. E.
Foulger, L. C. Daugherty, O. Niblock, M.
Athanasopoulou, A. Gardham, A. Tucci, E. Baple, A.
Devereau, T. Fowler, T. Hubbard, D. Smedley, K. R.
Smith, E. R. A. Thomas, C. Turnbull, M. J. Caulﬁeld, R.
H. Scott, A. Rendon; enomics England, London, United
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The Genomics England 100,000 Genomes Project is
sequencing, analysing and interpreting genomes from NHS
rare disease patients, their relatives, and cancer patients in
order to provide diagnoses and consequently deliver better
clinical care for NHS patients. Curation and community
engagement are fundamental to the interpretation of gen-
omes within the project. Gene panels are used in the
interpretation of sequencing data and aid identiﬁcation of
candidate pathogenic variants for rare disease diagnoses.
Historically, gene panels for the same disease differed
across diagnostic labs, thus, Genomics England curators
aim to establish consensus lists. Within the open-source
PanelApp database (https://panelapp.extge.co.uk/crow
dsourcing/PanelApp), virtual gene panels are constructed,
expert reviews are crowd-sourced, and panels are revised to
establish diagnostic-grade lists for each disease category. A
range of biological databases are used in this process and
knowledge is sourced from experts in clinical and scientiﬁc
communities. Using a trafﬁc-light system genes are classi-
ﬁed: “green” (diagnostic level) these genes are used for
genome interpretation and “red” candidates for further
investigation if additional data becomes available, thereby,
providing a useful resource for both clinical and research
communities. PanelApp has > 500 registered reviewers
from >20 countries. To date, it contains 3696 genes and 127
revised gene panels (publicly available to view and down-
load via the user interface, or query via web services) and
currently ≈160 rare disease categories can be analysed.
PanelApp is a publicly available, dynamic resource for the
rare disease community and demonstrates how a coordi-
nated curation effort combined with community involve-
ment can be key to genome interpretation.
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Population variation improves genetic variant inter-
pretation within protein domains
L. Wiel1,2, H. Venselaar1, G. Vriend1, J. Veltman3,4, C.
Gilissen3
1Centre for Molecular and Biomolecular Informatics,
Radboud Institute for Molecular Life Sciences, Radboud
University Medical Center, Nijmegen, Netherlands,
2Department of Human Genetics, Radboud Institute for
Molecular Life Sciences, Radboud University Medical
Center, Nijmegen, Netherlands, 3Department of Human
Genetics, Donders Institute for Brain, Cognition and
Behaviour, Radboud University Medical Center, Nijmegen,
Netherlands, 4Institute of Genetic Medicine, International
Centre for Life, Newcastle upon Tyne, United Kingdom
Large datasets of population variation resulting from exome
sequencing studies have made it feasible to identify differ-
ences in variation patterns among genes. Many protein
domains have homologues in multiple human genes, and we
hypothesize that genetic variation in each protein domain
can be extrapolated to its homologues, which subsequently
can improve variant interpretation.
We built a novel framework that enables mapping of the
longest translations for all 20,345 human protein-coding
genes to protein sequences in Swiss-Prot. This resulted in
16,684 genes with 100% sequence identity and similarity to
a Swiss-Prot canonical or isoform sequence. Of these genes
90% has at least one Pfam domain of which for 2,699
unique Pfam domains there are multiple homologues among
these human genes. We used the high quality (PASS) ﬁl-
tered variants from the Exome Aggregation Consortium
(ExAC), to compute genetic intolerance scores for all Pfam
domains based on Dn/Ds.
First, we investigated whether tolerance to normal
genetic variation is preserved for each unique domain with
respect to its homologues and this is indeed the case (p-
value < e-30). Next, we tested if unique ExAC variants in
one domain predicts the same variation in its homologues
and this is signiﬁcant for 83% of the homologous Pfam
domains (Bonferroni p-value < 0.05). These results show
that aggregation of variant information across homologues
can potentially be used to improve variant effect predictions
within protein domains.
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Predicting disease genes from cancer somatic mutations
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Genomic sequence mutations in both the germline and
somatic cells can be pathogenic. Several authors have
observed that often the same genes are involved in cancer
when mutated in somatic cells and in genetic diseases when
mutated in the germline. Recent advances in high-
throughput sequencing techniques have provided us with
large databases of both types of mutations, allowing us to
investigate this issue in a systematic way. Here we show
that high-throughput data about the frequency of somatic
mutations in the most common cancers can be used to
predict the genes involved in inheritable phenotypes and
diseases. The predictive power of somatic mutation fre-
quencies is largely independent of that of prioritization
methods based on germline mutation frequency, so that the
two can be successfully integrated into a powerful disease
gene predictor. These results conﬁrm the deep relationship
between pathogenic mutations in somatic and germline
cells, provide new insight into the common origin of cancer
and genetic diseases and can be used to improve the iden-
tiﬁcation of new disease genes.
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Database of protein features mapped to the human
genome
D. Stanek1, D. Bis2, C. Saghira2, A. Rebelo2, A. J.
Abrams2, P. Seeman1, S. Zuchner2
1DNA lab, Department of Paediatric Neurology, 2nd
Faculty of Medicine, Charles University in Prague a,
Prague 5, Czech Republic, 2Department of Human Genetics
and John P. Hussman Institute for Human Genomics,
Miller School of Medicine, University of Miami, Miami, FL,
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Introduction: Nowadays there are many tools for NGS
variants evaluation, none of them provides information if a
speciﬁc variant is translated into an annotated domain or
feature of protein. NCBI database provides information
about domains and features but without connection to
genomic coordinates. The availability of such mapped
information will be advantageous in characterizing and
annotating DNA variants detected in exome and genome
studies.
Materials and methods: For gathering all of the necessary
data were used Entrez Programming Utilities. This tool
helps to access all desired information about proteins. After
processing protein features, they were reverse translated and
mapped to the reference genome hg19 and stored in a
MySQL database.
Results: The resulting database provides information
about 760,487 features, from 42,371 proteins. There are
522,660 protein Regions (19,375 unique types) with an
average length 647.37 bp and 237,827 protein Sites (19
unique types) with average length 14.78 bp.
After entering genomic coordinates (e.g. chr2:15229777)
into our website a user will retrieve a list of protein features,
which covers the entered coordinates. Each record is
structured into Gene name, Refseq IDs (NM_xxxx and
NP_xxxx), type (Region/Site), all NCBI content and chro-
mosomal location of start and end of feature (divided to
cover only exons).
Conclusion: We have created the most comprehensive
mapping of protein features of chromosomal coordinates to
enhance DNA variant annotation.
The information in this database will help identify novel
functional variation and further assists in sifting through the
large number of coding variants produced by NGS.
Supported by: AZV-16-30206
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PLATELET PROTEOMICS PROFILING IN
TRANSFUSION ADVERSE EVENTS
C. ALOUI1, C. Barlier2, S. Claverol3, J. Fagan2, H.
Benamara2, E. Tavernier4, F. Cognasse2, O. Garraud5, S.
Laradi2
1GIMAP-EA3064, University of Lyon, Saint Etienne,
France, 2French Blood Establishment (EFS) Auvergne-
Rhône-Alpes, Saint Etienne, France, 3Proteome Plateform,
CGFB, University of Bordeaux, Bordeaux, France, 4Can-
cerology institute L. Neuwirth, Saint Priest en Jarez,
France, 5National Institute of Blood transfusion (INTS),
Paris, France
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Introduction: Blood platelets destined for transfusion
release panoply of molecules during preparation and sto-
rage. The leukoreduction process made the transfusion safer
but did not completely abolish the adverse events. The
rationale of this study is to identify potential proteins in
Platelet Components (PCs) involved in serious adverse
events (SAEs). Methods: Pellets from leukodepleted PCs
were sampled from 5 PCs implicated in adverse events and
5 PC matched controls. We performed a Label-Free quan-
titative analysis using an LC-MS/MS method: LC system
coupled to an Electrospray Q-Exactive quadrupole Orbitrap
benchtop mass spectrometer. Subsequently, data were
searched by SEQUEST through Proteome Discoverer 1.4.
Raw LC-MS/MS data were imported in Progenesis QI 2.0
for peptide quantiﬁcation and statistical comparison.Func-
tionnal analysis was performed using Ingenuity Pathway
Analysis software.Results: 1000 proteins were identiﬁed in
our samples of which 423 were differentially expressed
(p<0.05, Fold Change>2) between the two studied groups.
These 423 proteins revealed increased activation of platelets
with degranulation and an intense modiﬁcation of the
structure of their cytoskeleton as well as an increase in their
inﬂammatory functions in the event of an SAE. The most
enriched signaling pathways are: actin cytoskeleton sig-
naling, the intrinsic pathway of mitochondrial apoptosis,
integrin signaling, remodeling of epithelial adherens junc-
tions, RhoA signaling, oxidative phosphorylation, signaling
of the acute phase inﬂammatory response, and protein
ubiquitination pathways.
Conclusion: The proteomic study of PC pellets induced
by SAE may help to better understand the physiopatholo-
gical aspect of SAE and thus may help to better prevent EIR
in platelet-transfused patients.
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Share and solve rare diseases with RD-Connect's ana-
lysis platform
S. Laurie1,2, D. Piscia1,2, J. Protasio1,2, A.
Papakonstantinou1,2, I. Martinez1,2, J. Fernández3,4, A.
Cañada3,4, R. Kaliyaperumal5, S. Lair6, P. Sernadela7, T.
Katsila8, G. P. Patrinos8, O. J. Buske9, M. Girdea9, M.
Brudno9, A. Blavier6, R. Thompson10, J. Dawson10, H.
Lochmüller10, M. Bellgard11, D. Spalding12, M. Roos5, P.
t'Hoen5, A. Valencia3,4, D. Salgado13,14, C. Béroud13,14, I.
Gut1,2, S. Beltran1,2
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active Biosoftware, Rouen, France, 7DETI/IEETA, Uni-
versity of Aveiro, Aveiro, Portugal, 8Department of
Pharmacy, University of Patra, Patras, Greece, 9Centre
for Computational Medicine, University of Toronto,
Toronto, ON, Canada, 10Institute of Genetic Medicine,
University of Newcastle, Newcastle, United Kingdom,
11Centre for Comparative Genomics, Murdoch University,
Perth, Australia, 12European Molecular Biology Labora-
tory, European Bioinformatics Institute (EMBL-EBI),
Hinxton, United Kingdom, 13Aix-Marseille Université,
Marseille, France, 14INSERM, UMR_S 910, Marseille,
France
RD-Connect is a platform for facilitating rare disease
research through the integration of sequencing and pheno-
typic data while incorporating associated biosample and
patient registry information. It is open to any rare disease
researchers willing to share their sequencing and phenotypic
data. RD-Connect provides both a centralised data reposi-
tory and a user-friendly online analysis system to registered
users. Whole-genome, exome and gene panel data are freely
shared within the platform, and transferred to the EGA for
archival. Raw genomic data is fully reprocessed through a
standardised analysis pipeline, while associated clinical
information is recorded in PhenoTips using HPO, OMIM
and ORDO, allowing machine-readable querying. Results
are made available through the genomics analysis interface,
which enables ﬁltering and prioritisation of variants by
location/gene(s) of interest, impact, pathogenicity, control
population frequencies, and phenotype-gene associations
using Exomiser/OMIM. This allows users to perform entire
primary genomic analyses of their own patients online, and
compare ﬁndings with other submitted cohorts. Future
developments include tools to study non-coding regions,
obtain pharmacogenomic proﬁles, and incorporate other
-omics data types (e.g. transcriptomics, metabolomics). The
platform facilitates external data sharing at various levels,
including through the GA4GH beacon network (www.bea
con-network.org), and Matchmaker Exchange (MME,
www.matchmakerexchange.org). MME allows users of
different systems to exchange non-reidentiﬁable informa-
tion to ﬁnd similar cases, which is particularly useful for
complex phenotypes and/or cases proving refractory to
resolution. The platform already includes several thousand
cases from partner projects such as NeurOmics (www.rd-
neuromics.eu) and BBMRI-LPC (www.bbmri-lpc.org). RD-
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Connect is free and open for contributions: https://platform.
rd-connect.eu/.
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mRNA Half-Life in Single T Cells
E. Y. Shum, J. C. Tsai, H. G. Shah, C. Chang, H. Fan
BD Genomics, Menlo Park, CA, United States
Introduction: Gene expression proﬁle is dictated by the
delicate equilibrium of RNA synthesis and turnover.
Accurate regulation of mRNA turnover - whether by
microRNAs or other post-transcriptional mechanisms - is
crucial for immune system development and disease.
However, there is still lack of methods to accurately mea-
sure this dynamic aspect of gene regulation in a high
throughput manner to understand post-transcriptional
mechanisms that affect the immune system.
Materials and Methods: We sorted single T cells into
96 well plates at different time points after transcription
inhibition to proﬁle the RNA decay rates of over 300 T cell
marker genes in hundreds of cells with molecular barcod-
ing. Unlike other traditional assays, molecular barcoding
allows accurate counting of originally tagged mRNA tran-
scripts by eliminating PCR bias.
Results and Conclusions: From our single cell
sequencing data, we calculated the half-lives of T cells
marker mRNAs based on molecular barcode counts. First,
we identiﬁed a class of steady transcripts that are likely
important for T cell maintenance. On the other hand, we
identiﬁed a class of transcripts with extremely rapid RNA
turnover, suggesting that they are important in dynamic
cellular responses such as cell cycle or T cell activation.
Unlike traditional RNA-seq assays that measure the steady
state expression of genes, RNA half life proﬁling in single
cells uncovers the underappreciated dynamics of gene reg-
ulation in development and disease.
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Developing custom next-generation sequencing panels
using pre-optimized assays: an integrated approach
from disease research area to functionally annotated
variants
F. Hyland, M. Manivannan, B. Krishnaswami, C. Van
Loy, A. Broomer, T. Biorac, D. DeWolf, Y. Fu, E.
Williams, Y. Zhu, Y. Tian, F. Hernandez Guzman, A.
Kothandaraman, S. Roman
Thermo Fisher, South San Francisco, CA, United States
Targeted next-generation sequencing panels enable inter-
rogation of multiple genes across many samples to more
deeply understand human genetic disease. However, ﬁnding
all relevant genes, developing robust, high performing,
multiplex panels, and implementing scalable, reproducible
and accurate analysis pipelines is challenging. We present a
coordinated suite of tools to facilitate genetic disease
research. First we developed the Disease Research Database
which organizes human diseases hierarchically, and links all
diseases to a set of associated genes; and the Gene Scoring
Algorithm which ranks genes by clinical relevance. We
developed optimized assays for the most studied 1000
disease research genes. An interactive web interface allows
scientists to select any disease of interest, display all asso-
ciated genes, select any genes and add additional genes, for
any number of diseases. Empirical coverage for each gene
can be visualized in IGV. A custom Ion Ampliseq gene
panel can be built using the optimized assays from all the
selected genes. Optimized gene panels can be developed
narrowly targeted to speciﬁc diseases, or larger gene panels
can be developed for broader phenotypes. Disease cate-
gories include early onset neonatal phenotypes such as
metabolic disorders, Severe Combined Immunodeﬁciency,
heme disorders; cancer predisposition; and late onset phe-
notypes such as cardiovascular disorders. The panel infor-
mation is integrated into a seamless end to end analysis.
Single sample, Trio, and Tumor-Normal pipelines are
available. Pipelines include mapping and variant calling,
followed by functional annotation, protein prediction, and
detailed annotation of variants and genes based on their
presence in public databases.
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Background: Clinical utilities of Next Generation Sequen-
cing (NGS) are continuously expanding. Here, we aimed to
examine the performance, accuracy, sensitivity and speci-
ﬁcity of NGS vs Sanger-sequencing, and to estimate the
possibility of replacing targeted gene sequencing, or gene-
panel sequencing with standard, commonly available,
whole exome sequencing (WES) kits.
Methods: Genomic DNA was extracted from peripheral
leukocytes and buccal swabs. Sanger-sequencing was per-
formed for 258 genes. NGS data was obtained in duplicates
from the Illumina HiSeq2500 platform using the Nextera
(FC-140-1006) and Agilent (SureSelectQXT) capture kits for
both DNA sources. Standard NGS analytic pipelines with
predeﬁned quality thresholds followed.
Results: The Nextera and the SureSelect assays yielded
>20x coverage for >91% and >98% of the expected geno-
mic regions, respectively. The average coverages were 103x
for Nextera and 253x for SureSelect. A total of 449 variants
were identiﬁed by at least one of the experiments, of which
407 (90.6%) were detected by all experiments. We deter-
mined that 23 of the 42 discordant variants were true calls,
summing-up to a truth set of 430 variants. The calculated
sensitivities ranged between 97%-100%.
Conclusions: The overall concordance between Sanger-
sequencing and NGS assays was satisfactory. Despite clear
differences in the obtained sequencing coverage for the two
capture kits, the detection rates of the true calls were not
signiﬁcantly different. We concluded that neither Sanger
nor NGS can be regarded as a “gold-standard” method, as
both had false calls. Accordingly, high suspicion of a given
diagnosis should override negative molecular results of
either Sanger-sequencing or NGS.
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Single-cell sequencing is a powerful tool to investigate the
biology of cellular heterogeneity and is revolutionizing
different ﬁelds of life sciences. To sequence a single cell,
whole-genome ampliﬁcation (WGA) and subsequent library
preparation is currently still the standard. While there are
many approaches to achieve this, the methods for single-cell
library preparation are time consuming and very expensive,
often far exceeding the actual sequencing cost per cell.
Indeed, we and others have previously shown that the
detection of DNA copy number aberrations (CNAs) can be
performed by sparse sequencing of single-cell sequencing
libraries. To enable studies that require sequencing of
hundreds to thousands of single cells, we developed an
accessible method that is cost and time effective, called SC-
NxtSeq. In SC-NxtSeq we omit the upfront whole-genome
ampliﬁcation step and immediately prepare sequencing
libraries from single-cell lysates. We evaluated the robust-
ness of our method by comparing SC-NxtSeq to conven-
tional single-cell sequencing approaches using 7 different
WGA technologies. The accuracy of single-cell DNA copy
number proﬁles following SC-NxtSeq was at least as good
as the other methods and often even better, while the cost is
more than an order of magnitude lower. Finally, to
demonstrate that SC-NxtSeq can be used for primary tissue,
we applied it on single cells biopsied from a human breast
tumor. In conclusion, SC-NxtSeq is a readily available, low-
cost and highly accurate method for CNA proﬁling of
single-cell genomes.
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Faster Workﬂow, Lower Inputs and Longer Read
Lengths for SMRT Sequencing of the Human Genome
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L. Kurihara1, V. Makarov1, M. Smith2, R. Sebra2, T.
Harkins1
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Single Molecule Real-Time (SMRT) sequencing platforms
offered by Paciﬁc Biosciences (PacBio) provide continuous,
low bias DNA reads. This long-read technology facilitates
sequencing of regions beset by low complexity, repetitive
elements, or large structural variants. These capabilities
enable enhanced coverage and assembly metrics for appli-
cations like de novo assembly, whole-genome sequencing,
and full-length RNA isoform detection. Despite these ben-
eﬁts of long-read SMRT sequencing, the current limits of
read length and input requirements could be improved to
complete genome assemblies with less difﬁculty and lower
inputs.
Here, we push the boundaries of long-read sequencing
with a novel library preparation optimized for long-read
SMRT sequencing. The Accel-NGS Long Insert Library Kit
combines Swift’s enhanced repair and ligation chemistries
to produce high library conversion rates while simulta-
neously eliminating adapter dimers and chimeric inserts. In
addition to enhanced performance, this method offers a
single-tube library prep workﬂow that can be completed in
as little as 4 hours.
To validate performance, large insert libraries were pre-
pared from human gDNA, enriched for large inserts using
the Sage BluePippen, and run on the PacBio platform. Swift
libraries resulted in mean and N50 subread lengths that
were 2 kb larger than SMRTBell libraries. Additionally, the
Swift Long Insert library yields generally exceeded that of
traditional SMRTBell libraries, allowing for reduced large
shear DNA inputs as low as 2μg, opening up SMRT
sequencing to difﬁcult-to-acquire DNA samples. Overall,
the Accel-NGS Long Insert Library kit provides both a
convenient workﬂow and enhanced performance optimized
for the needs of long-read SMRT sequencing.
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Breaking the curse of dimensionality for machine
learning on genomic data
A. O'Brien1, P. Szul2, R. Dunne1, D. C. Bauer1
1CSIRO, North Ryde, Australia, 2CSIRO, Brisbane,
Australia
Introduction: Genomic research is performed on ever lar-
ger cohorts with insights jointly drawn over the full dataset.
However, traditional approaches are unable to cater for this
task, with especially the ﬁnite resource of computer mem-
ory becoming the bottleneck. Systems like Apache Hadoop
and Spark aim to overcome these obstacles.
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Materials and Methods: Leveraging the power of Spark
and its machine learning libraries (Spark ML), we built
VariantSpark: A ﬂexible framework for analysing genomic
data. We previously demonstrated VariantSpark’s ability to
cluster 2,500 individuals with 80 million genomic variants
each (1000 Genomes Project, phase 3) into their super-
population groups achieving an ARI=0.82 (1 perfect and -1
random clustering). However, when aiming to improve this
performance and distinguish between the American and
European populations, Spark ML’s supervised machine
learning methods suffer from “the curse of dimensionality”.
That is, they scale well with samples (n) but not with fea-
tures (p, variants), quickly exceeding memory limits.
Results: We hence extended VariantSpark to include
CursedForest, a bespoke random forests implementation
able to scale to whole genome approaches. We successfully
trained a random forest on the same data achieving a cross-
validated accuracy of ARI=0.96. Our tailored random for-
est implementation is 80% faster than comparable imple-
mentations on subsets of the data and the only method
coping with the full dataset; classifying all individuals in
just 30 minutes.
Conclusions: VariantSpark allows real-time classiﬁca-
tion of population-scale patient cohorts enabling advanced
machine learning applications like ﬁnding “patients like
mine” from whole genome sequencing proﬁles.
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SNP2TFBS - a database of regulatory SNPs affecting
predicted transcription factor binding site afﬁnity
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Introduction: Transcription factor (TF)-target site interac-
tions are the elementary molecular events of gene regula-
tion. Knowing the potential effects of regulatory genetic
variants on TF-target site interactions is thus essential to
understand their molecular mode of action.
Methodology: We present SNP2TFBS, an automatically
generated resource aimed at annotating genetic variants
with predicted effects on transcription factor binding afﬁ-
nities. The database consists of a collection of text ﬁles
providing speciﬁc annotations for human SNPs, namely
whether they are predicted to abolish, create or change the
afﬁnity to one or several TFs. A SNP’s effect on TF binding
is estimated based on a position weight matrix (PWM)
model. SNP2TFBS is regenerated at regular intervals by an
automatic procedure that takes as input a reference genome,
a comprehensive SNP catalogue, and a collection of PWMs.
SNP2TFBS is also accessible over a web interface, enabling
users to view the information provided for an individual
SNP, to extract SNPs based on various search criteria, to
annotate uploaded sets of SNPs, or to display statistics
about the frequencies of binding events affected by selected
SNPs. All scripts and binary programs that were used to
generate SNP2TFBS are available from our FTP site and
can potentially be used to generate similar resources for
other organisms from analogous inputs.
Conclusions: SNP2TFBS is a useful resource for any
type of research that aims at understanding the phenotypes
of regulatory genetic variants at the level of TF-target site
interactions. SNP2TFBS Home page: http://ccg.vital-it.ch/
snp2tfbs/.
Grant reference: Swiss National Science Foundation
CRSII3_154500.
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Next-Generation Mapping: Application to Clinically
Relevant Structural Variation Analysis
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Next-generation mapping (NGM) from Bionano Genomics
allows researchers to interrogate genomic structural varia-
tions (SVs) in the range of one kilobase pairs and above. It
uses extremely long range information to span interspersed
and long tandem repeats making it suitable for elucidating
the structure and copy number of complex regions of the
human genome, such as loci with complex pseudogene and
paralogous gene families. Because NGM is a de novo
process and because molecules analyzed are longer than
almost all genomic repeats, NGM is able to detect a wide
range of SVs including insertions of novel sequence, tan-
dem duplications, interspersed duplications, deletions,
inversions and translocations, a range of SV types detect-
able by NGM alone. Because of the high speed and com-
prehensiveness of the SV types detected, NGM is
increasingly being applied to the analysis of clinical gen-
omes for the detection of SVs potentially involved in dis-
ease pathogenesis. We present several in silico and
biological validation experiments to demonstrate the
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sensitivity and speciﬁcity of NGM for insertion, deletion
and translocation SVs and compare it to benchmark studies
using short read and long read sequencing. We also show
the application of NGM to studying somatic variation in a
breast cancer cell line, ﬁnding hundreds of somatic struc-
tural variations. Finally, we applied NGM to several leu-
kemia patient samples to ﬁnd more than 50 cancer related
SVs in each patient. NGM is a fast and cost effective
method for detection of a broad range of traditionally
refractory SVs across the genome.
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niﬁcant; Bionano Genomics. A.W.C. Pang: A. Employ-
ment (full or part-time); Signiﬁcant; Bionano Genomics. J.
Lee: A. Employment (full or part-time); Signiﬁcant; Bio-
nano Genomics. E.T. Lam: A. Employment (full or part-
time); Signiﬁcant; Bionano Genomics. W. Andrews: A.
Employment (full or part-time); Signiﬁcant; Bionano
Genomics. T. Anantharaman: A. Employment (full or
part-time); Signiﬁcant; Bionano Genomics. M. Saghbini:
A. Employment (full or part-time); Signiﬁcant; Bionano
Genomics. H. Cao: A. Employment (full or part-time);
Signiﬁcant; Bionano Genomics.
P16.67C
Detecting Pathogenic Structural Variants with Low-
Coverage PacBio Sequencing
L. Hickey, A. M. Wenger, P. Baybayan, P. Peluso, J.
Korlach
Paciﬁc Biosciences, Menlo Park, CA, United States
Though a role for structural variants in human disease has
long been recognized, it has remained difﬁcult to identify
intermediate-sized variants (50 bp to 5 kb), which are too
small to detect with array comparative genomic hybridiza-
tion, but too large to reliably discover with short-read DNA
sequencing. Recent studies have demonstrated that PacBio
Single Molecule, Real-Time (SMRT) sequencing ﬁlls this
technology gap. SMRT sequencing detects tens of thou-
sands of structural variants in the human genome,
approximately ﬁve times the sensitivity of short-read DNA
sequencing.
As the application of PacBio SMRT sequencing to detect
structural variants moves from initial studies to broad
adoption, it is important to produce consistent results at
reasonable costs. Towards this end, we have developed a
workﬂow and implemented supporting software for low-
coverage (about 10-fold), whole genome sequencing on the
PacBio Sequel System and a reference-based, re-sequencing
approach to variant calling.
To benchmark performance, we applied the workﬂow to
NA12878, a genome that has been deeply characterized by
NIST Genome in a Bottle. With 10-fold coverage sequen-
cing, we identify over 85% of known structural variants in
NA12878. We also applied the workﬂow to an individual
with Carney complex for whom short-read whole genome
sequencing was non-diagnostic. Filtering for rare, genic
structural variants left six candidates, one of which was
determined to be likely causative. These applications
demonstrate the ability of low-coverage PacBio sequencing
to detect structural variants and suggest the potential to
increase diagnostic yield for individuals with undiagnosed
genetic disorders.
L. Hickey: A. Employment (full or part-time); Sig-
niﬁcant; Paciﬁc Biosciences. E. Ownership Interest (stock,
stock options, patent or other intellectual property); Sig-
niﬁcant; Paciﬁc Biosciences. A.M. Wenger: A. Employ-
ment (full or part-time); Signiﬁcant; Paciﬁc Biosciences. E.
Ownership Interest (stock, stock options, patent or other
intellectual property); Signiﬁcant; Paciﬁc Biosciences. P.
Baybayan: A. Employment (full or part-time); Signiﬁcant;
Paciﬁc Biosciences. E. Ownership Interest (stock, stock
options, patent or other intellectual property); Signiﬁcant;
Paciﬁc Biosciences. P. Peluso: A. Employment (full or
part-time); Signiﬁcant; Paciﬁc Biosciences. E. Ownership
Interest (stock, stock options, patent or other intellectual
property); Signiﬁcant; Paciﬁc Biosciences. J. Korlach: A.
Employment (full or part-time); Signiﬁcant; Paciﬁc Bios-
ciences. E. Ownership Interest (stock, stock options, patent
or other intellectual property); Signiﬁcant; Paciﬁc
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Seeing the whole picture: an integrated view of CNVs,
AOH, and sequence variants leads to improved results
S. Shams, A. Venier, A. O'Hara, Z. Che
BioDiscovery, El Segundo, CA, United States
Introduction: Given the separate technologies used to
detect CNVs, AOH, and Sequence Variants (SNP Micro-
arrays for CNVs and AOH, and NGS for Sequence Var-
iants), this data commonly has been reviewed in isolated
silos. This segregation has also been exaggerated by the
separate expertise in Cytogenomics and Molecular Genet-
ics. Materials and Methods: As the ﬁelds are now coming
together, the importance of an integrated view of the data
has become even more apparent. Here we present a new
system that can integrate data from any array as well as
NGS platforms to create a single genomic view of structural
changes in a sample.
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Results: The data is presented in a view familiar to
cytogenomicists with aberrations displayed across an ideo-
gram with supporting evidence for each call (e.g. probes
from arrays and reads from NGS). Historical data and
outside database knowledge is integrated into this view
allowing the analyst access to all information needed to
make assessments of the results. We will demonstrate the
utility of this system using a few samples with compound
heterozygous aberrations that are detected using different
technologies. This includes a case with a microdeletion
detected by custom exon array and SNV detected with a
custom targeted NGS panel. Another case includes a variant
in a large region of homozygosity.
Conclusion: An integrated view of CNVs, AOH and
sequence variants leads to improved results.
S. Shams: None. A. Venier: None. A. O'Hara: None.
Z. Che: None.
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Improving the interpretation of exonic changes by
combining in silico predictions, RNA splicing assays and
protein functional data
O. Soukarieh1, L. Grodecka2, N. Köger3, T. Fréboug4, G.
Plotz5, A. Martins1
1Inserm U1245, UNIROUEN, Normandie Univ, Normandy
Centre for Genomic and Personalized Medicine, Rouen,
France, Rouen, France, 2Department of Molecular Immu-
nology and Microbiology, Central European Institute of
Technology, Masaryk University, Brno, Czech Republic;
Molecular Genetics Laboratory, Centre for Cardiovascular
Surgery and Transplantation, Brno, Czech Republic, Brno,
Czech Republic, 3Biomedical Research Laboratory, Depart-
ment of Internal Medicine 1 and Department of Human
Genetics, Universitätsklinikum Frankfurt, Frankfurt D-
60590, Germany, Institute of Human Genetics, University
of Bonn, Bonn D-53127, Germany, Frankfurt, Germany,
4Inserm U1245, UNIROUEN, Normandie Univ, Normandy
Centre for Genomic and Personalized Medicine, Rouen,
France; Department of Genetics, Rouen University Hospi-
tal, Normandy Centre for Genomic and Personalized
Medicine, Rouen, France, Rouen, France, 5Medizinische
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Frankfurt, Frankfurt, Germany, Frankfurt, Germany
Introduction: Even if next-generation sequencing has
improved the detection of nucleotide changes, the biological
interpretation of most exonic variants remains challenging.
Recently, we found that exonic splicing mutations are more
prevalent than currently estimated and can be predicted by
using new algorithms. Here again, we used the exon 10 of
MLH1, a gene implicated in hereditary cancer, as a model
system for evaluating variant interpretation methods.
Materials and Methods: First, newly described MLH1-
exon 10 variants (n= 6) were analyzed for their impact on
exonic splicing regulatory elements (ESR) both by using the
new algorithms and by performing minigene assays. Then,
all currently known, but not-yet-fully-characterized, MLH1-
exon 10 missense variants (n= 11) were analyzed at the
protein level by resorting to bioinformatics predictions and
experimental analyses focused on protein expression and
mismatch repair activity levels. Bioinformatics predictions
were compared with experimental results both from this
study and from published reports for the 9 remaining
MLH1-exon 10 missense variants.
Results: We found that the ESR-dedicated algorithms
could predict the impact on splicing of the new variants:
either increased exon inclusion or skipping. In contrast,
protein-dedicated algorithms showed poor performance in
discriminating non-damaging (n= 15) from damaging
missense variants (n= 5) as assessed in protein functional
assays. We identiﬁed 2 new mutations with a negative
impact on splicing and 4 new loss-of-function missense
variants.
Conclusions: This study conﬁrms the pertinence of
using ESR-dedicated algorithms for prioritizing variants for
functional RNA splicing analyses, and pinpoints the
importance of combining RNA and protein experimental
data to interpret missense variants.
O. Soukarieh: None. L. Grodecka: None. N. Köger:
None. T. Fréboug: None. G. Plotz: None. A. Martins:
None.
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Comparison of multiple hybrid capture technologies:
high quality oligonucleotide capture baits improve
performance
K. Giorda1, S. Groenewold2, K. Lai1, C. Walworth1, D.
Kupec1, L. Lewis2, Y. Bao1, M. Jarosz1
1Integrated DNA Technologies, Redwood City, CA, United
States, 2Integrated DNA Technologies, Coralville, IA,
United States
Introduction: NGS target enrichment is cost effective and
efﬁcient but is historically less uniform than whole genome
sequencing. Some studies show that coverage of coding
exons is better in whole genome data than in targeted
sequencing, particularly for GC-rich regions like ﬁrst exons.
Materials and Methods: We compared the performance
of 4 different exome capture sequencing technologies of
similar size (~40–50 Mb). Prepared libraries were pooled
730
into a 12-plex and split into each capture. Each 12-plex
capture was sequenced on a single lane of an Illumina
HiSeq 2500 in high output mode. We compared the uni-
formity of coverage, coverage of RefSeq and sequencing
requirements for each technology.
Results: Per base coverage histograms indicate that the
xGen® exome had the tightest coverage distribution and the
lowest fraction of uncovered bases. For RefSeq genes, 93%
of bases had ≥20x coverage for the IDT exome, whereas the
other three technologies ranged from 57–71%. When con-
sidering only ﬁrst exons, the disparity increased sig-
niﬁcantly. 94% of ﬁrst exon bases were covered at ≥20x
with IDT’s exome, whereas poor coverage of GC-rich tar-
gets in the other exome captures resulted in only 49–60% of
ﬁrst base exons being covered at ≥20×. This led to better
end-to-end gene coverage with every position in a gene
covered at ≥20x for 92% of genes with the IDT panel verses
58–73% for other methods.
Conclusions: Here we present how individually syn-
thesized and QC’ed capture baits dramatically improve the
performance of target enrichment, changing the targeted vs.
whole genome calculation.
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P17 Epigenetics and Gene Regulation
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Characterization of the expression of the imprinted
Kcnk9-gene in speciﬁc brain regions and the phenotypic
analysis of Kcnk9-knockout mice
A. Cooper1, M. Linke1, F. Lesage2, S. Schweiger1, U.
Zechner1
1Institute of Human Genetics, Mainz, Germany, 2Institut de
Pharmacologie Moléculaire et Cellulaire, Valbonne,
France
Kcnk9/KCNK9 is a maternally expressed imprinted gene
whose mutations are responsible for the maternally inher-
ited Birk-Barel mental retardation syndrome. It encodes a
member of the superfamily of K+ -channel and is involved
in the modulation of the resting membrane potential and
excitability of neurons.
In this study, we set out to characterize the allele-speciﬁc
expression of Kcnk9 in various regions of the mouse brain
and to analyze several parameters of brain function in
homozygous (Kcnk9KOhom) and heterozygous Kcnk9 KO
mice with inactivation of the maternal Kcnk9 allele
(Kcnk9KOmat).
Quantiﬁcation of Allele-Speciﬁc Expression by Pyr-
osequencing (QUASEP) method was performed for differ-
ent brain areas of (C57BL/6xCast/Ei) F1-hybrid mice.
Exclusive expression from the maternal Kcnk9 allele was
detected in the hippocampus, mesencephalon, brainstem
and thalamus. Biallelic expression was observed in the
olfactory bulbs, cortex, cerebellum and striatum.
The Phenotype of WT, Kcnk9KOmat and Kcnk9KOhom
mice were examined in a behavioral test battery. Results
show a clearly impaired working memory of the
Kcnk9KOmat and Kcnk9KOhom mice in comparison to WT
mice. The spontaneous alternation in the Y-Maze was sig-
niﬁcantly reduced by approx. 10–20%. In acoustic startle
response and prepulse inhibition tests Kcnk9KOhom mice
showed signiﬁcantly reduced acoustic startle response
(ASR), Kcnk9KOmat and Kcnk9KOhom mice also showed
reduced pre-pulse inhibition compared to B6-WT. Investi-
gations of the circadian rhythm reveal an increased loco-
motor activity during the dark phase in Kcnk9KOhom and
Kcnk9KOmat mice. Our ﬁndings shall further elucidate the
role of Kcnk9/KCNK9 in pathophysiology and open new
avenues for treatment of cognitive dysfunctions in Birk-
Barel syndrome.
A. Cooper: None.M. Linke: None. F. Lesage: None. S.
Schweiger: None. U. Zechner: None.
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Functional dissection of the enhancer network in human
embryonic stem cells by ChIP-STARR-seq
S. Barakat1,2, F. Halbritter3, I. Chambers2
1Erasmus MC-University Medical Center, Rotterdam,
Netherlands, 2MRC Centre For Regenerative Medicine,
University of Edinburgh, Edinburgh, United Kingdom,
3CeMM Research Center for Molecular Medicine of the
Austrian Academy of Sciences, Vienna, Austria
Enhancers are genetic elements that direct correct spatio-
temporal regulation of gene expression and are often pre-
dicted by co-localization of transcription factors (TFs) and
enhancer-associated histone-modiﬁcations (e.g. H3K27ac,
H3K4me1/3). Only a limited number of putative enhancers
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identiﬁed can be experimentally validated, indicating that
current-state-of-the-art methods to identify functional
enhancers have limitations. To identify functional enhancers
quantitatively in a genome-wide manner, we have devel-
oped a new high-throughput screen, which combines
chromatin-immunoprecipitation for TFs or histone mod-
iﬁcations, with a massively-parallel-reporter-assay. Non-
coding DNA sequences bound by TFs or marked by
histone-modiﬁcations are cloned en masse in reporter
plasmid libraries, which can be used in cell-transfection
experiments, where enhancer-activity of cloned sequences
can be quantiﬁed by RNA-seq. Using this ChIP-STARR-
seq approach, we can directly functionally assess enhancer-
activity of non-coding sequences at an unprecedented scale.
We have applied this approach to stem cell biology,
focusing on the TFs NANOG, OCT4 and the histone
modiﬁcations H3K4me1 and H3K27ac in human primed
and naive embryonic stem cells. We found that from 270K
regions marked by these factors, spanning > 320Mb of
sequence, only approximately 20K regions display enhan-
cer-activity, allowing distinction of functional from non-
functional sites, and dissection of super enhancers into
smaller active elements. Active ChIP-STARR-seq enhan-
cers are associated with highly expressed genes displaying
cell-type speciﬁc gene ontology, and a group of house-
keeping genes. Commonly, they are marked by a unique
activator signature of related TFs and chromatin-modiﬁers,
thereby providing new biological insights in enhancer
biology and further clarifying the functionality of the non-
coding genome
S. Barakat: None. F. Halbritter: None. I. Chambers:
None.
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Unveiling the regulatory landscapes of genes involved in
pancreatic cancer using a zebraﬁsh model
R. Bordeira-Carriço1, J. Teixeira1, T. Freitas1, J. Tena2, J.
Goméz-Skarmeta2, J. Bessa1
1I3S, Porto, Portugal, 2CABD, Sevilla, Spain
Pancreatic carcinoma (PC) is a highly aggressive disease
with very poor prognosis. Mutations in non-coding regions,
particularly cis-regulatory elements (CREs), have been
associated with cancer, but their role is yet to be uncovered.
Enhancers are CREs controling the transcriptional output of
target genes in speciﬁc tissues and developmental times,
being crucial for gene expression and when mutated may
cause loss-of-expression. The aim of this work is to unveil
the effect of mutations in CREs of tumor-suppressor genes
(TSGs) involved in PC. By using a zebraﬁsh we can
identify and validate the impact of those non-coding
mutations in an in vivo model. Zebraﬁsh has been used as
a model of PC and genetic regulators of zebraﬁsh pancreatic
development can be translated into potential clinical bio-
markers and therapeutic targets in human PC. Currently we
are exploring the transcriptional regulatory genome (reg-
ulome) of zebraﬁsh pancreas, using genome-wide techni-
ques combined with next-generation sequencing, such as
Assay for Transposase-Accessible Chromatin (ATAC-seq),
Chromatin-Immunoprecipitation (ChIP-seq) and Circular-
ized Chromosome Conformation Capture (4C-seq). Ana-
lyzing these data, we have identiﬁed putative enhancers of
pancreas TSGs and we are now validating their activity by
transgenic assays. The demonstration of regulatory regions
determining the expression of TSGs in pancreatic tissue will
have a major impact on understanding pancreatic cancer
genetics. These results may further be translated to human
genetics and the same strategy be applied to identify human
CREs involved in PC, which will broaden the perspectives
of new therapeutic approaches and clinical management of
PC patients.
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DNMT inhibitor 5-Azacitidine modulates immune
responses in CD4+T cells from patients with Cystic
Fibrosis
E. Kvaratskhelia1,2, N. Dabrundashvili1, M. Gagua1,3, E.
Maisuradze1, M. Kamkamidze1, E. Abzianidze2
1Tbilisi State Medical University, Institute of Medical
Biotechnology, Tbilisi, Georgia, 2Tbilisi State Medical
University, Dept. of Molecular and Medical Genetics,
Tbilisi, Georgia, 3Tbilisi State Medical University, Dept. of
Histology, Cytology and Embriology, Tbilisi, Georgia
Introduction: Cystic ﬁbrosis (CF) characterized by the
overproduction of the pro-inﬂammatory cytokines and
reduced expression of anti-inﬂammatory cytokines. Epige-
netic factors such as altered DNA methylation in T cells
might play a role in cytokine dysregulation during CF. In
the present study we examined expression of IFN-γ and IL-
4 by T cells prior to and following the DNA methyltran-
spherase inhibitor 5-Azacytidine (5-azaC) treatment. Mate-
rials and Methods: Eight CF patients (age: 5–12 years) were
included in the study and compared to six age-matched
healthy subjects. The Ethical Committee of the TSMU
(Tbilisi, Georgia) had approved the protocol and the parents
of each CF patient and healthy subject provided informed
732
consent. CD4+T cells were isolated from PBMC using CD4
MicroBead kit (Miltenyi Biotec GmbH) and were cultured
in RPMI 1640 medium at 37°C with 5% CO2, in presence
or absence of 5-Azacytidine (Sigma Aldrich, Germany) at a
dose of 2μM. Cells were activated with PMA (20ng/ml)/
Ionomycin (250 ng/ml). Concentrations of IL-4 and INF-γ
in CD4+ T Cell were measured by ELISA (eBoiscience, san
Diego, CA, USA). Results: In our study we showed that 5-
Azacytidine modulates cytokine exspression in CD4
+T cells derived from CF patients. After 5-azaC treatment
secretion of IFN-γ was signiﬁcantly decreased in CF T cells,
while amount of IL-4 was elevated by ~2.8 times compared
to controls. Conclusions: Our data demonstrates that epi-
genetic mechanisms such as DNA methylation may be
considered as a one of the potential therapeutic target in a
treatment of Cystic Fibrosis.
E. Kvaratskhelia: None. N. Dabrundashvili: None. M.
Gagua: None. E. Maisuradze: None. M. Kamkamidze:
None. E. Abzianidze: None.
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5-Azacitidine and NSAIDs alter levels of DNA
methyltransferases in nucleus raphe magnus in
formalin induced inﬂammatory pain
T. Gorgiladze1, E. Kvaratskhelia1, T. Tkemaladze1, L.
Nozadze2, M. Tsagareli2, E. Abzianidze1,2
1Tbilisi State Medical University, Dept. of Molecular and
Medical Genetics, Tbilisi, Georgia, 2Ivane Beritashvili
Centre of Experimental Biomedicine, Dept of Pain and
Analgesia, Tbilisi, Georgia
Introduction: It has been established that nucleus raphe
magnus (NRM) is one of the important parts of anti-
nociceptive system of CNS. Epigenetic mechanisms, mainly
DNA methylation, may play a major role in regulating
nociception.The aim of the present study was to evaluate the
changes of a subset of DNA methyltransferases level in
NRM neurons in inﬂammatory pain and prior intraper-
iotonal injection of 5-AzaC and NSAID. Materials and
Methods: All animal studies conformed to the Guidelines
of International Association for the study of Pain regarding
investigations. Adult rats were divided into seven groups. In
ﬁrst group 50 ml of 10% v/v formalin solution (Sigma-
Aldrich) unilateral intraplantar injection was made. Second
group was injected with saline as vehicle. 3rd-7th groups
were administrated with different doses and combinations
of various drugs (Xefocam, Diclofenac, ketorolac, 5-AzaC,
Naloxone - Sigma-Aldrich) 30- 45 min. prior to pain
induction with formalin. Mechanical pressure paw with-
drawal thresholds were used to assess pain. The levels of
DNMT1, DNMT3a and DNMT3b were measured in
nuclear extracts of NRM neurons using DNMTs assay kits
(Abcam). Results: Received data demonstrated increased
levels of DNMT3a/b in NRM neurons of rats after formalin
induced pain compared with controls. NSAIDs diminished
levels of DNMT3a/b in NRM, as well as 5-AzaC dose-
dependantly. Prior preinjection of naloxone, 5-AzaC and
Xefocam didn’t cause decrease of DNMT3a/b. Conclu-
sions: Our results suggest that reduction of DNMTs with 5-
AzaC and NSAIDs may be mediated via DNA methylation-
dependent antinociceptive mechanisms in the NRM and
also these alterations may be opioid dependent.
T. Gorgiladze: None. E. Kvaratskhelia: None. T.
Tkemaladze: None. L. Nozadze: None. M. Tsagareli:
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Long-term prenatal exposure to paracetamol is asso-
ciated with DNA methylation changes and ADHD:
identiﬁcation of dysregulated pathways involved in oxi-
dative stress and the olfactory system
R. Lyle1,2, H. Nordeng2, E. Ystrom3,2, T. Reichborn-
Kjennerud3,2, K. Gervin2
1Oslo University Hospital, Oslo, Norway, 2University of
Oslo, Oslo, Norway, 3Norwegian Institute of Public Health,
Oslo, Norway
Epidemiological studies have shown that long-term expo-
sure to paracetamol during pregnancy is associated with
attention-deﬁcit/hyperactivity disorder (ADHD). The
mechanism by which paracetamol modulates the increased
risk of developing ADHD is currently unknown. We have
conducted an epigenome-wide association study to inves-
tigate whether prenatal exposure to paracetamol is asso-
ciated with DNA methylation changes and ADHD.
Participants (n= 384) were selected from a large pro-
spective birth cohort (Norwegian Mother and Child Cohort
Study), which contains information about medication use
during pregnancy. The ADHD diagnoses were obtained
from the Norwegian Patient Registry. Case-control analysis
of paracetamol or ADHD alone did not reveal any differ-
ential DNA methylation. However, comparison of samples
with ADHD exposed to paracetamol for more than 20 days
to healthy controls identiﬁed differentially methylated CpGs
(n= 6 211). In addition, these samples were differentially
methylated compared to samples with ADHD exposed to
paracetamol for less than 20 days (n= 2 089 CpGs) and not
exposed to paracetamol (n= 193 CpGs). Interestingly,
several of the top genes ranked according to signiﬁcance
and effect size have been linked to ADHD, neural
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development and neurotransmission. Gene ontology analy-
sis revealed enrichment of pathways involved in oxidative
stress, neurological processes and the olfactory sensory
system, which have previously been implicated in the
etiology of ADHD. These results lend novel insights into
the epigenetic aspect of ADHD and provide a possible
pharmaco-epigenetic link between the prenatal exposure to
paracetamol and ADHD development.
Norwegian Research Council (32251), Southern and
Eastern Norway Regional Health Authority (39671), ERC
Starting Grant (678033)
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A mediating role for F2RL3 methylation in the rela-
tionship between smoking and cardiovascular disease:
evidence from population and laboratory studies
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Introduction: Smoking is robustly associated with hypo-
methylation of F2RL3 (coagulation factor II receptor-like 3)
which encodes protease-activated receptor 4 (PAR4), a
thrombin receptor involved in platelet activation. Epigenetic
control of PAR4 could be important in mediating cardio-
vascular risk from smoking.
Materials and Methods: We performed epidemiological
analyses of the association of F2RL3 methylation at four
CpG sites (CpG_1–4) with smoking and acute myocardial
infarction (AMI) in 853/2,352 nested cases/controls from
the Copenhagen City Heart Study (CCHS). We investigated
platelet activity in 41 never smokers from the Avon
Longitudinal Study of Parents and Children (ALSPAC)
recruited on methylation at F2RL3. In in vitro studies we: 1)
exposed primary human coronary artery endothelial cells
(HCAEC) to cigarette smoke extract (CSE) and measured
methylation at F2RL3 and PAR4 expression; and 2) trans-
fected HEK-293 cells with reporter constructs containing
different fragments of F2RL3 and assessed gene expression.
Results: In CCHS, hypomethylation of F2RL3 was
associated with smoking and higher odds of AMI (smoking-
adjusted OR:1.12 per 10% decrease in methylation, 95%
CI:1.05,1.20). In ALSPAC participants, lower methylation
was associated with increased PAR4 speciﬁc platelet
activity. CSE exposure reduced F2RL3 methylation and
increased F2RL3 expression in HCAEC. Transfection of
HEK-293 cells conﬁrmed that exon 2 (containing CpG_1–
4) has enhancer activity that is partially enabled by a
CCAAT recognition site located 2 bp 3′ of CpG_1.
Conclusions: These ﬁndings strengthen support for
methylation-dependent platelet activation as a mediator
between smoking and AMI, highlighting this pathway for
clinical intervention to reduce harmful consequences of
smoking.
Grants: MRC:MC_UU_12013/3
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Pathogenic SNPs with allelic imbalance show higher
expression in the major allele
F. van Dijk1, N. de Klein1, A. Claringbould1, P. Deelen1,
U. Vosa1, J. Verlouw2, K. Gagalova3, R. Monajemi3, S.
Kielbasa3, R. Sinke1, M. Swertz1, P. A. C. 't Hoen3, L.
Franke1
1University Medical Center Groningen, Groningen, Nether-
lands, 2Erasmus Medical Center, Rotterdam, Netherlands,
3Leiden University Medical Center, Leiden, Netherlands
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In recent years eQTL studies have been conducted on a
large scale. However, due to limited sample-sizes most
studies have been statistically powered to identify effects of
common genetic variants. To overcome this, we investi-
gated RNA-seq data from 3,685 unrelated population-based
blood samples from BIOS, a large Dutch biobank con-
sortium, and performed allele speciﬁc expression (ASE)
analysis to identify effects of proven pathogenic variants on
gene expression.
To identify these pathogenic variants, we called geno-
types from the RNA-seq directly. We observed that the
quality of this genotype calling and subsequent imputation
was very high, as determined by comparing genotypes of
446,096 called SNPs with DNA array and whole genome
sequencing (WGS) genotype data of 155 samples (average
concordance with WGS data was 99%). We subsequently
calculated allelic ratios, and observed that 48,207 SNPs
showed at least one sample with an allelic imbalance. Out of
2,661 pathogenic SNPs from Clinvar, we identiﬁed 15
SNPs where at least one individual was heterozygous and
also showed an allelic imbalance. This was signiﬁcantly
more as compared to a null-distribution of coding SNPs,
matched for minor allele frequency. This suggests that it is
possible to use whole blood RNA-seq reference datasets to
make inferences on the molecular consequences of rare
pathogenic variants. As such this provides avenues for
prioritizing likely pathogenic variants that cause disease by
ascertaining their effects on gene expression levels.
F. van Dijk: None. N. de Klein: None. A. Clar-
ingbould: None. P. Deelen: None. U. Vosa: None. J.
Verlouw: None. K. Gagalova: None. R. Monajemi: None.
S. Kielbasa: None. R. Sinke: None. M. Swertz: None. P.
A.C. 't Hoen: None. L. Franke: None.
P17.09A
Decreased mitochondrial DNA methylation in periph-
eral blood cells of Alzheimer’s disease patients
A. Stoccoro1,2, F. Coppedè1, G. Siciliano3, L. Migliore1
1Department of Translational Research and New Technol-
ogies in Medicine and Surgery, University of Pisa, Pisa,
Italy, 2Doctoral School in Genetics, Oncology, and Clinical
Medicine, Department of Medical Biotechnologies, Uni-
versity of Siena, Siena, Italy, 3Unit of Neurology, Depart-
ment of Neuroscience, Pisa University Hospital, Pisa, Italy
Several evidences suggest that mitochondrial dysfunction
occurs early in Alzheimer’s disease (AD), both in affected
brain regions and in peripheral blood cells, likely promoting
neurodegeneration through increased oxidative stress. Oxi-
dative stress induces cell death through several cellular
pathways, including epigenetic mechanisms. In recent years
several investigations highlighted an impairment of nuclear
DNA methylation in AD pathogenesis but little attention
was given to the mitochondrial epigenome itself. In the
current study we developed a protocol for the study of
mtDNA methylation by means of the cost effective tech-
nique Methylation Sensitive-High Resolution Melting. We
investigated the presence of DNA methylation modiﬁca-
tions in the mitochondrial displacement loop (D-loop)
region, which regulates mitochondrial DNA replication and
transcription, in peripheral blood cells of 133 AD patients
and 130 healthy matched controls. D-loop methylation
analyses showed the existence of an interindividual varia-
bility with methylation levels ranging from 0 to 9 %. D-loop
methylation levels were lower in AD patients respect to
control subjects in a statistically signiﬁcant manner (P =
0.04). No signiﬁcant correlation between D-loop methyla-
tion levels and age was observed (r = -0.09, P = 0.14), and
no differences in methylation levels between males and
females were detected (P = 0.55). Present data indicate that
the D-loop region is hypomethylated in peripheral blood
DNA of AD patients, suggesting that mtDNA epimutations
deserve further investigations in AD pathogenesis.
A. Stoccoro: None. F. Coppedè: None. G. Siciliano:
None. L. Migliore: None.
P17.10B
DNA methylation levels in blood of amyotrophic lateral
sclerosis patients carrying not fully penetrant SOD1
mutations
F. Coppedè1, A. Stoccoro1,2, A. Marocchi3, S. Penco3, L.
Migliore1
1Department of Translational Research and New Technol-
ogies in Medicine and Surgery, University of Pisa, Pisa,
Italy, 2Doctoral School in Genetics, Oncology, and Clinical
Medicine, Department of Medical Biotechnologies, Uni-
versity of Siena, Siena, Italy, 3Department of Laboratory
Medicine, Medical Genetics, Niguarda Ca’ Granda Hospi-
tal, Milan, Italy
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease resulting from the degeneration of motor neurons in
the motor cortex, brainstem and spinal cord. Superoxide
dismutase 1 (SOD1) has been the ﬁrst identiﬁed causative
gene for ALS and more than 180 different mutations have
been described so far in ALS patients, including not com-
pletely penetrant ones, leading to a phenotypic hetero-
geneity ranging from asymptomatic or paucisymptomatic
individuals to slowly progressive or even very aggressive
ALS forms, suggesting that the severity of the phenotype
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may be modulated by other genetic variants and/or envir-
onmental factors that could act by means of epigenetic
mechanisms. In the present study we collected DNA sam-
ples from ﬁve ALS families with not fully penetrant SOD1
mutations (p.Asn65Ser, p.Gly72Ser, p.Gly93Asp, and p.
Gly130_Glu133del) and searched for the presence of
additional mutations in the major genes of ALS, namely
FUS, TARDBP and C9orf72 as well as for epigenetic dif-
ferences between ALS patients, asymptomatic/pauci-
symptomatic carriers and non-carriers of SOD1 mutations.
No additional mutations were found in the analyzed sub-
jects. Global DNA methylation levels were signiﬁcantly
higher in blood DNA of ALS patients than in asympto-
matic/paucisymptomatic carriers or in familial non-carriers
of SOD1 mutations. However the promoters of SOD1, FUS,
TARDBP and C9orf72 were completely demethylated in all
the analysed samples. The present study suggests that global
changes in DNA methylation might contribute to the ALS
phenotype in carriers of not fully penetrant SOD1 muta-
tions, but those changes do not occur at the promoter of
major ALS genes.
F. Coppedè: None. A. Stoccoro: None. A. Marocchi:
None. S. Penco: None. L. Migliore: None.
P17.12D
Role of natural antisense transcripts in human gene
expression regulation
A. Filatova1, I. Krivosheeva1, J. Vyakhireva1, A.
Marakhonov1,2, M. Skoblov1,2
1Research Centre for Medical Genetics, Moscow, Russian
Federation, 2Moscow Institute of Physics and Technology
(State University), Moscow, Russian Federation
Introduction Antisense transcription is a frequent but
insufﬁciently studied phenomenon. It was shown that anti-
sense RNAs play role in the development of some genetic
diseases. Natural antisense transcripts (NATs) transcribe
from opposite DNA strands of the same genome locus (cis-
NATs) or different genome loci (trans-NATs). One of the
mechanisms of antisense regulation is realized by formation
of complementary RNA-RNA duplex.Materials and
methods We used qPCR to measure expression of cis-
NATs in different samples. Knockdown was performed
using siRNAs. Overexpression was performed using
expression vector pEYFP-C1. Besides, we made RNA-
RNA pull-down control experiments to identify the most
appropriate conditions for detection of RNA-RNA interac-
tions. Results Based on bioinformatic analysis, we chose
four pairs of cis-NATs to study their antisense regulation
(AFAP1 - AFAP1-AS1, SIRT3 - RIC8A, HSPE1 - HSPD1,
S100A13 - CHTOP). For each pair we selected suitable cell
line for further experiments using two criteria: expression of
both antisense transcripts and their overlapping regions.
Next, knockdown of one gene from each pair was per-
formed in the selected cell line. We showed that knockdown
of HSPE1 and S100A13 do not affect expression level of
their cis-NATs HSPD1 and CHTOP, respectively. Whereas
AFAP1-AS1 and RIC8A knockdown and overexpression
showed the possible positive antisense regulation of their
corresponding cis-partner. Conclusions We have shown
possible positive antisense regulation for cis-NATs pairs
AFAP1-AFAP-AS1 and SIRT3-RIC8A. We hypothesize
that this regulation could be realized through formation of
RNA-RNA duplexes. Our further study will be aimed at
performing RNA-RNA pull-down to test this hypothesis.
A. Filatova: None. I. Krivosheeva: None. J. Vya-
khireva: None. A. Marakhonov: None. M. Skoblov:
None.
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Overgrowth and Undergrowth/ID: Two faces of a
unique CDKN1C-mutation
S. Berland1, B. I. Haukanes1, P. B. Júlíusson2, G. Houge1
1Center for Medical Genetics and Molecular Medicine,
Haukeland University Hospital, Bergen, Norway, 2Depart-
ment of Paediatrics, Haukeland University Hospital,
Bergen, Norway
LoF mutations in the maternal CDKN1C gene may cause
Beckwith-Wiedemann syndrome (BWS) and overgrowth,
while missensemutations in the gene’s PCNA-binding motif
are associated with IMAGe syndrome (Intrauterine Growth
retardation, Metaphyseal Dysplasia, Adrenal Insufﬁciency,
Genital abnormalities) and Silver-Russel-syndrome (SRS).
We present a male patient with elements of both BWS
(large omphalocele, macroglossia, facial nevus ﬂammeus
and ear creases) and IMAGe (IUGR, genital abnormalities,
prolonged neonatal hypoglycemia, small kidneys, feeding
difﬁculties, no adrenal insufﬁciency). Examination of
CDKN1C revealed a frameshift change (c.822_826delins-
GAGCTG p.Asp274GlufsTer12) in the same region where
the IMAGe mutations have been found. CDKN1C RNA-
analysis suggested that nonsense mediated RNA-decay
(NMD) occurred in blood leukocytes but not skin ﬁbro-
blasts. This was supported by Western blots, showing a
stronger band of right size in patient ﬁbroblasts than in
control ﬁbroblasts. In theory, the mutated allele will give
rise to a shortened protein with substitution of IMAGe-
related amino acids (in pos. 276–281) and loss of a likely
nuclear localization signal.
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Interestingly, the CDKN1C-mutation was inherited from
an asymptomatic mother and a mildly affected mosaic
grandfather. Haplotype analysis showed that the mutation
was de novo on the grandfather’s maternal allele.
To the best of our knowledge, this is the ﬁrst time the
same mutation leads to both LoF (in blood) and GoF (in
ﬁbroblasts) and therefore the presence of elements of two
mirror-image syndromes in the same patient. The patient is
also microcephalic with delayed development, without any
other ﬁndings on WES and methylation analysis. Further
functional analysis is planned.
S. Berland: None. B.I. Haukanes: None. P.B. Júlíus-
son: None. G. Houge: None.
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A novel 11p15.5 microduplication upstream IGF2
associated with Beckwith-Wiedmann syndrome
J. Lévy1, D. Haye1, C. Dupont1, A. Verloes1, A. Fauret1,
M. Thaly1, E. Pipiras2, B. Benzacken3, S. Chantot-
Bastaraud4, F. Brioude5, A. Tabet1
1APHP, Hôpital universitaire Robert - Debré, Département
de Génétique, Paris, France, 2APHP, Hôpital Jean-Verdier,
Département de Cytogénétique, Embryologie et Histologie,
Bondy, France, 3APHP, Hôpital Jean-Verdier, Départe-
ment de Cytogénétique, Embryologie et Histologie, Paris,
France, 4APHP, Hôpital Armand Trousseau, Service de
Génétique et d'Embryologie Médicales Paris, France,
Paris, France, 5APHP, Hôpital Armand Trousseau, Service
de Biologie Moléculaire endocrinienne, Paris, France,
Paris, France
Beckwith-Wiedemann syndrome (BWS, MIM 130650) is
an overgrowth disorder characterized by variable clinical
manifestations and may include omphalocele, macroglossia,
hemihyperplasia, ear pits, umbilical hernia, hypoglycemia
and high risk of tumor development. Several molecular
mechanisms have been involved in the dysregulation of
imprinted growth regulatory genes on chromosome 11p15.
This genomic region contains two imprinted domains
regulated by two independent imprinting control regions
(ICR), ICR1 and ICR2. We report on a 1 year-old patient
with high clinical suspicion of BWS. Evaluation of ICR1
and ICR2 methylation and CDKN1C sequencing were
normal. SNP array analysis revealed a 102 kb micro-
duplication at 11p15.5 which encompassed the non-
imprinted genes LSP1, TNN3, MRPL23 but not H19 and
IGF2 nor the ICR2 region. Duplications or deletions of the
chromosome 11p15.5 region are rares and can be inherited
or de novo. All microdeletions reported were maternally
inherited while duplications were maternally or paternally
inherited, sometimes spanning both domains in the chro-
mosome 11p15.5 region. In the present case, the micro-
duplication has occurred de novo on the maternal
chromosome 11 and only covered the regulatory elements
located upstream IGF2. We hypothesized that this dupli-
cation could interfere with the structure of topologically
associating domains (TAD), a structural unit shared
between the different cell types and conserved between
species. The structural modiﬁcation of the TAD generated
by 11p15.5 duplication could lead to an overexpression of
IGF2. Since genomic structural variants that disrupt TAD
boundaries have been reported to cause developmental
disorders, this observation suggests a new mechanism
behind the BWS.
J. Lévy: None. D. Haye: None. C. Dupont: None. A.
Verloes: None. A. Fauret: None. M. Thaly: None. E.
Pipiras: None. B. Benzacken: None. S. Chantot-Bastar-
aud: None. F. Brioude: None. A. Tabet: None.
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C9orf72 epigenetic modiﬁcations in patients with
amyotrophic lateral sclerosis and fronto-temporal
dementia
C. Tiloca1, D. Calini1, F. Verde1,2, C. Colombrita1, C.
Volpe1,3, D. Gentilini4, N. Ticozzi1,2, V. Silani1,2, A. Ratti1,2
1Department of Neurology and Laboratory of Neu-
roscience, IRCCS Istituto Auxologico Italiano, Milan, Italy,
2Department of Pathophysiology and Transplantation,
Università degli Studi di Milano, Milan, Italy, 3MD/PhD
Program, Faculty of Medicine and Surgery, Università
degli Studi di Milano, Milan, Italy, 4Centro di Ricerche e
Tecnologie Biomediche, IRCCS Istituto Auxologico Ita-
liano, Milan, Italy
A non-coding GGGGCC repeat expansion (RE) in C9orf72
represents the main genetic cause of amyotrophic lateral
sclerosis (ALS) and fronto-temporal dementia (FTD). Pre-
vious ﬁndings strongly suggest that methylation of mutant
C9orf72, resulting into decreased pathological RNA foci/
dipeptide repeat protein aggregates in brain tissues, may
have a neuroprotective role and act as a modifying factor in
disease presentation. To consolidate these ﬁndings, we
investigated C9orf72 promoter and RE methylation in a
cohort of 60 Italian ALS and FTD mutation carriers. By
using bisulﬁte conversion of blood genomic DNA and
methylation-speciﬁc repeat-primed PCR, we conﬁrmed that
methylation of RE is present in all mutation carriers. By
bisulﬁte Sanger sequencing, we assessed methylation status
of 33 CpG sites within the promoter CpG island and
observed a signiﬁcant hypermethylation (methylated CpG
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sites > 3) in about 60% of carriers, but not in C9orf72-
negative patients. NGS approach was used, for the ﬁrst
time, to accurately estimate methylation at individual CpG
sites, revealing higher levels of methylation at the 5′ of the
island. We found that promoter methylation levels were
inversely correlated with C9orf72 expression of both total
mRNA and the three different isoforms in blood. In our
cohort, C9orf72 promoter methylation was associated with
disease duration in ALS, but not with age at onset, and was
inversely associated with RE size. This study conﬁrms that
assessment of C9orf72 RE and promoter methylation, fre-
quent in both ALS and FTD mutation carriers, is important
when considering genotype-phenotype correlations.
C. Tiloca: None. D. Calini: None. F. Verde: None. C.
Colombrita: None. C. Volpe: None. D. Gentilini: None.
N. Ticozzi: None. V. Silani: None. A. Ratti: None.
P17.16D
Integrating Capture Hi-C with RNAseq timecourse data
to uncover the regulatory interactions modulated by
genetic variation in disease
A. J. McGovern1, J. Yang1, P. Martin1, P. Fraser2, M.
Rattray1, S. Eyre1
1University of Manchester, Manchester, United Kingdom,
2The Babraham Institute, Cambridge, United Kingdom
Introduction: There is compelling and growing genetic
evidence as to the importance of T-cells in rheumatoid
arthritis (RA). Overlaying RA GWAS hits with cell speciﬁc
expression data and epigenetic marks of gene activity
(histone marks, DNaseHS), suggests T-cells, and speciﬁ-
cally CD4 T-cells, play the driving role in RA genetic
susceptibility. A large number of likely RA genes are dif-
ferentially expressed in primary CD4 T-cells under stimu-
latory conditions suggesting it will be most informative to
initiate studies under stimulatory conditions, to deﬁne the
key genetic pathways for RA. Here, we incorporate Capture
Hi-C and nuclear RNAseq data from a CD4 T-cell stimu-
lation timecourse to link chromatin modelling and gene
expression over time. Materials and Methods: Primary
human CD4 T-cells were isolated from PBMCs using an
EasySep T-cell isolation kit then stimulated with CD3/
CD28 Dynabeads over a period of 24-hours. Pooled cells
from multiple samples were used to make libraries for
Capture Hi-C and RNAseq. Capture Hi-C enriched for
promoters and disease-associated enhancers was used to
identify physical interactions and how these change through
time. Nuclear RNAseq was used to quantify nascent tran-
scription. Results: Here we show that interactions between
GWAS SNPs and genes associated with RA, can be
correlated with gene expression. IRF8 gene expression
occurs only after four hours of stimulation and at this point
interactions with GWAS SNPs can also be detected. Con-
clusions: These data suggest that dynamic chromatin
remodelling takes place post-stimulation allowing interac-
tions with the target gene to take place. Funded by MRC
project no MR/N00017X/1
A.J. McGovern: None. J. Yang: None. P. Martin:
None. P. Fraser: None.M. Rattray: None. S. Eyre: None.
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Epigenetic changes mediated by UHRF1 (ubiquitin-like
with PHD and ring ﬁnger domains 1) are associated with
silencing of MIR137HG, a tumor suppressor gene fre-
quently downregulated in multiple solid tumors
M. LE TERTRE1,2, C. KA1,3, M. LECOURT1, L.
CORCOS1,2, C. FEREC1,2,3, G. LE GAC1,2,3
1Inserm UMR1078, Brest, France, 2Université Bretagne
Loire-Université de Bretagne Occidentale, IBSAM, Brest,
France, 3CHRU de Brest, Laboratoire de Génétique
Moléculaire et d'Histocompatibilité, Brest, France
Introduction: The miR-137 encoding gene (MIR137HG) is
epigenetically silenced in colorectal adenomatous tissues to
the same extent as in colorectal cancer and in diverse solid
tumors. Restoration of miR-137 expression decreases pro-
liferation and promotes cell cycle arrest at the G0/G1 stage
in different human cancer cell lines. These observations
suggest that miR-137 down-regulation is an early event in
carcinogenesis and that it may act as a tumor suppressor.
MIR137HG is embedded in a CpG island, but the
mechanism through which it is repressed is unknown.
Results: Chromatin immunoprecipitation of HCT116
human colon carcinoma cells nuclear extracts showed the
presence of UHRF1, DNMT3b and the transcriptional
repressors HDAC1 and G9a on the MIR137HG promoter.
Identical epigenetic marks were found at the PPARG locus,
a well-known tumor suppressor gene. SiRNA-mediated
UHRF1 silencing relieved repression of endogenous miR-
137. Using bisulﬁte-treated DNA pyrosequencing and
western blotting in a panel of colorectal tumors, we
observed a correlation between UHRF1 expression and
MIR137HG hypermethylation. An opposite result was
obtained from paired adjacent normal colon mucosa speci-
mens. We further showed that miR-137 negatively regu-
lated Cdk6 (cyclin dependent kinase 6) and Cdc42 (cell
division cycle 42), two enzymes that play a critical roles in
regulating cell cycle progression. Consistently, ectopic
miR-137 expression inhibited proliferation and promoted
senescence of HCT116 cells. Conclusion: We provide
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evidence that UHRF1 coordinates MIR137HG epigenetic
silencing. We propose that UHRF1 overexpression is a
mechanism underlying DNA hypermethylation at diverse
microRNA-related tumor suppressor gene loci, a mechan-
ism that could constitute an early event in carcinogenesis.
M. Le tertre: None. C. Ka: None. M. Lecourt: None.
L. Corcos: None. C. Ferec: None. G. Le gac: None.
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Epigenetic and gene expression changes in patients with
Crohn's disease, and responsiveness to adalimumab
therapy
H. Celesnik1, S. Koder2, U. Potočnik1
1Center for Human Molecular Genetics & Pharmacoge-
nomics, Faculty of Medicine, University of Maribor,
Maribor, Slovenia, 2University Medical Center Maribor,
Maribor, Slovenia
Introduction: Inﬂammatory bowel disease (IBD) is a
chronic autoimmune intestinal inﬂammation with two sub-
types, ulcerative colitis and Crohn's disease. Treatment with
TNF inhibitors presents an important therapy advancement.
However, it is only successful in a subset of patients, with
about 20–40% failing to respond. Due to anti-TNF ther-
apy’s side effects and high cost, ability to determine which
patients are likely to respond would be beneﬁcial. Although
some biomarkers predictive of anti-TNF treatment response
have already been identiﬁed in IBD, epigenetic alterations
correlated with anti-TNF responsiveness (e.g. DNA
methylation changes) have not yet been explored. Addi-
tionally, epigenetic modiﬁcations that indicate or contribute
to the pathophysiology of IBD have not been well
characterized.
Materials and methods: Pre-treatment whole blood
samples from Crohn's patients receiving anti-TNF drug
adalimumab (responders and nonresponders), together with
blood from healthy subjects, were used to correlate Crohn-
speciﬁc DNA methylation/expression proﬁles. These pat-
terns were compared in responsive and non-responsive
patients. Methylation proﬁling was carried out by HRM
analyses and bisulﬁte sequencing, and integrated with gene
expression levels (RT-qPCR).
Results: Several genes previously implicated in IBD
through genome-wide studies were analyzed, as well as
genes that had previously been implicated in anti-TNF
responsiveness in other autoimmune diseases, including
inﬂammatory cytokines from the CXC chemokine family,
S100 family of calcium-binding proteins, WNT-signaling
pathway and Low Density Lipoprotein Receptor-Related
Protein (LRPAP1). Discussion: Our preliminary expression
results identify two Crohn’s-associated candidates
(LRPAP1, Axin1), and studies aimed at identiﬁcation of
biomarkers that will facilitate prediction of Crohn patients’
responsiveness to adalimumab are under way.
H. Celesnik: None. S. Koder: None. U. Potočnik:
None.
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Dies1/VISTA expression loss is a recurrent event in
gastric cancer due to epigenetic regulation
P. Oliveira1,2, J. Carvalho1,2, S. Rocha1,2, M. Azevedo1, I.
Reis1, V. Camilo1, B. Sousa1,2, S. Valente1, J. Paredes1,2,3,
R. Almeida1,3,2, D. Huntsman4, C. Oliveira1,2,3
1IPATIMUP, Porto, Portugal, 2i3S, Porto, Portugal,
3Faculty of Medicine, University of Porto, Porto, Portugal,
4BCCA, Vancouver, BC, Canada
Introduction: Dies1/VISTA induces embryonic stem-cell
differentiation, via BMP-pathway, but also acts as inﬂam-
mation regulator and immune-response modulator. Dies1
inhibition in a melanoma-mouse model led to increased
tumour-inﬁltrating T-cells and decreased tumour growth,
emphasizing Dies1 relevance in tumour-microenvironment.
Dies1 is involved in cell de/differentiation, inﬂammation
and cancer processes, which mimic those associated with
Epithelial-to-Mesenchymal-Transition (EMT). Despite this
axis linking Dies1 with EMT and cancer, its expression,
modulation and relevance in these contexts is unknown.
Materials and Methods: We analysed Dies1 expression,
its regulation by promoter-methylation and miR-125a-5p
overexpression, and its association with BMP-pathway
downstream-effectors, in a TGFβ1-induced EMT-model,
cancer cell-lines and primary samples.
Results: We detected promoter-methylation as a
mechanism controlling Dies1 expression in our EMT-model
and in several cancer cell-lines. We showed that the rela-
tionship between Dies1 expression and BMP-pathway
effectors observed in the EMT-model, was not present in
all cell-lines, suggesting that Dies1 has other cell-speciﬁc
effectors, beyond the BMP-pathway. We further demon-
strated that: Dies1 expression loss is a recurrent event in
GC, caused by promoter methylation and/or miR-125a-5p
overexpression and; GC-microenvironment myoﬁbroblasts
overexpress Dies1.
Conclusions: Our ﬁndings highlight Dies1 as a novel
player in GC, with distinct roles within tumour cells and in
the tumour-microenvironment. Grants and Fellowships:
POCI-01-0145-FEDER-007274; SFRH/BPD/89764/2012;
SFRH/BPD/86543/2012; SFRH/BD/63300/2009; SFRH/
BPD/104208/2014.
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Integrated analysis of DNA methylation and gene
expression ﬁngerprints of human atherosclerotic
plaques
M. S. Nazarenko1,2, A. V. Markov1, A. A. Sleptsov1, V. P.
Puzyrev1,2
1Research Institute of Medical Genetics, Tomsk National
Research Medical Center, Russian Academy of Sciences,
Tomsk, Russian Federation, 2Siberian State Medical
University, Tomsk, Russian Federation
Aberrant DNA methylation and gene expression have been
reported in human atherosclerotic plaques of patients with
carotid atherosclerosis. In the present study, the DNA
methylation and gene expression ﬁngerprints of arterial
tissue were investigated together. The Illumina Human-
Methylation27 BeadChip and Illumina HumanHT-12 ver-
sion 4 Expression BeadChip microarrays were used for
analysis of advanced carotid atherosclerotic plaques and
healthy internal mammary arteries of ﬁve statin-treated
patients with atherosclerosis. The advanced atherosclerotic
plaques in comparison with the healthy arteries were char-
acterized by the predominant DNA hypermethylation
changes. There were no biological processes in Gene
Ontology terms associated with the hypermethylated genes.
In contrast, hypomethylated genes encode molecules
belonging to different biological processes such as devel-
opment, lipid storage, programmed cell death, immune and
inﬂammatory responses. The majority of differentially
expressed genes were down-regulated in advanced athero-
sclerotic plaques. “Cellular response to metal ion” and
“extracellular matrix organization” were the most sig-
niﬁcant Gene Ontology terms among the down- and up-
regulated genes, respectively. Unexpectedly, genes
involved in immune and inﬂammatory responses were
down-regulated in advanced atherosclerotic plaques com-
pared to the healthy arteries. Statins are likely to attenuate
the expression of inﬂammatory genes in blood vessels.
After integration of the DNA methylation and gene
expression data, we identiﬁed four hypermethylated-
downregulated genes (LIPE, CIDEC, TMEM88, GATA2)
and one hypomethylated-upregulated gene (S100A4). In
conclusion, we identiﬁed the atherosclerosis-speciﬁc DNA
methylation and gene expression ﬁngerprints that provide
new insights into the pathogenesis of atherosclerosis. The
study was supported by the Russian Science Foundation
(No. 16-15-10150).
M.S. Nazarenko: None. A.V. Markov: None. A.A.
Sleptsov: None. V.P. Puzyrev: None.
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Genome-wide miRNA proﬁling in plasma of pregnant
women with Down syndrome fetuses
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M. Brestak2, M. Krkavcova3, O. Seda1, A. Horinek1
1Institute of Biology and Medical Genetics, First Faculty of
Medicine, Charles University and General University
Hospital in Prague, Prague 2, Czech Republic, 2Depart-
ment of Obstetrics and Gynecology of the First Faculty of
Medicine, Charles University and General University
Hospital, Prague, Czech Republic, Prague 2, Czech
Republic, 3GENVIA genetic laboratories, Prague, Czech
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Introduction: Down syndrome (DS) is the most common
aneuploidy. Impact of epigenetic mechanisms is currently
often discussed in the context of DS. We follow up on a
previous study comparing miRNA expressions in normal
and trisomic placentas, where seven miRNAs were found as
being signiﬁcantly upregulated in DS placentas. To further
investigate biological functions of miRNA, in the present
study we focused on plasma samples. Methods: Genome-
wide miRNA expressions were proﬁled using Affymetrix
miRNA 4.1 array strips. A total of 26 plasma samples from
pregnant women - 13 bearing DS fetuses and 13 normal
karyotype fetuses, were included. Results were evaluated
using Partek Genomics Suite. The one-way ANOVA with a
cut-off p-value < 0.05 and Benjamini-Hochberg correction
for multiple testing was used for detection of differentially
expressed miRNAs. Results: We identiﬁed 61 human
miRNAs as being signiﬁcantly dysregulated between com-
pared groups of samples. Unlike the placenta, most of these
miRNAs (44) were down-regulated in plasma of women
bearing the DS fetus. Many biological pathways were
identiﬁed as being potentially inﬂuenced by altered miRNA
levels. Cell communication and signalling pathways were
between the most enriched ones. Seven miRNAs, pre-
viously determined as upregulated in DS placentas, did not
differ on the level of plasma. Conclusion: Our study shows
that differences of miRNA proﬁles between normal and DS
fetuses are detectable even on the level of maternal plasma.
Such differences could mirror alterations in placental
development and they deserve further study. Supported by
the Ministry of Health of the Czech Republic RVO
VFN64165.
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Effects of genetic variation on promoter usage (pmQTL)
and enhancer activity (enQTL)
M. Garieri1,2,3, O. Delaneau1,2,3, F. Santoni1,4, D. Mull1, P.
Carninci5, E. T. Dermitzakis1,2,3, S. E. Antonarakis1,2,4, A.
Fort1
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Switzerland, 4Service of Genetic Medicine, University
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Identiﬁcation of genetic variants affecting gene expression,
splicing, and chromatin states have increased our under-
standing of mechanisms underlying human traits. We
hypothesized that some eQTLs (expression_quantitative_-
trait_loci) act on differential promoter-usage and enhancer-
activity. Transcriptomes of 154 unrelated individuals were
proﬁled using CAGE on total-nuclear-RNAs extracted from
LCLs. Sequences were mapped to promoters of the FAN-
TOM atlas, yielding to the quantiﬁcation of 38,759 pro-
moters/transcripts that we tested for association against
7,508,202 genetic variants; we discovered 5,491 cis-pro-
moter-QTL (pmQTL,FDR<0.05). As eQTLs, pmQTLs
localize preferentially near to TSSs and are marked with
active transcriptional marks. Approximately 90% of
pmQTLs are found to also affect mRNA-levels (π1=0.904)
as quantiﬁed with RNA-seq, half of them are not associated
with main but with alternative promoters and 26.3% of the
associated genes have more than one promoter linked with a
pmQTL. Opposite regulatory effects of pmQTLs were
detected on ≥2 promoters for 139 genes. The integration of
pmQTL with eQTL allows the evaluation of the relative
participation of alternative promoters to mRNA abundance
and the detection of variants associated with promoter-
usage and not with mRNA-levels. Together this gives
insights into eQTL mechanisms involving differential
promoter-usage. Furthermore, using the FANTOM enhan-
cers and the quantiﬁcation of enhancer-RNAs (eRNAs) as a
proxy for enhancer-activity, we mapped 108 cis-enhancer-
QTL (enQTL,FDR<0.05). For each enQTL-enhancer pair,
we tested causal inference of eRNAs as molecular-
mediators for the expression of enhancer-target-genes,
using causal inference testing. Causality was detected for 48
triplets (p-value<0.05). This approach provides insights into
eQTL mechanisms delineating effects on both distant-
enhancers and proximal-promoters.
M. Garieri: None. O. Delaneau: None. F. Santoni:
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Is the FADS1-FADS2-FADS3 gene cluster enriched with
variants that interact with dietary fats in cardiometa-
bolic traits?
Y. Chen1, A. Estampador1, M. Keller1,2, J. Dalla-Riva1, F.
Renström1,3, A. Kurbasic1, T. V. Varga1, P. W. Franks1,4,5
1Department of Clinical Sciences, Genetic and Molecular
Epidemiology Unit, Lund University, Skåne University
Hospital Malmö, Malmö, Sweden, 2Medical Faculty, IFB
Adiposity Diseases, University of Leipzig, Leipzig, Ger-
many, 3Department of Biobank Research, Umeå University,
Umeå, Sweden, 4Department of Nutrition, Harvard T.H.
Chan School of Public Health,, Boston, MA, Austria,
5Department of Nutrition, Harvard T.H. Chan School of
Public Health, Boston, MA, United States
Introduction: Recent analyses in in Greenlandic Inuit
identiﬁed novel genetic variants in the fatty acid desaturase
gene cluster (FADS1-FADS2-FADS3) that are associated
with with multiple metabolic and anthropometric traits.
Objective: We extended this work by testing whether
these associations are driven by high polyunsaturated fat
intake using a Swedish cohort.
Material and Methods: Adults from the GLACIER
cohort (max N= 5,160) were genotyped with the Meta-
bochip array. Height, body weight, fasting and 2hr-glu-
coses, triglycerides, and HDL- and LDL-cholesterol, total
cholesterol were assessed. Dietary intakes of poly-
unsaturated fat acids (PUFA), n-3 fatty acids, and n-6 fatty
acids were calculated from food-frequency questionnaires.
We tested: 1) interactions between FADS genetic variants
and dietary fat intake using linear regression models; 2)
centric joint analyses to detect overall interaction signals
in FADS region; 3) haplotype blocks joint analyses to
pinpoint the causing region.
Results: 1) The strongest interactions were observed
between rs174570 and n-6 fatty acid intake on fasting
glucose (Pinteraction= 0.007); 2) Borderline signiﬁcant joint
and random interaction effect was emerged for FADS and n-
3 PUFA on triglycerides (PJOINT = 0.014, PINT_RAN =
0.005); 3) With n-3 PUFA intake, haplotype block analyses
showed that haplotype 12 (PINT_RAN = 0.011), haplotype 16
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(PINT_RAN = 0.010), and haplotype 21 (PINT_RAN = 0.011)
are the driving force of random effect interaction on
triglycerides.
Conclusion: These ﬁndings support that the association
between fat intake and triglycerides can be modiﬁed by
genetic variants in the FADS cluster.Funding: Swedish
Research Council, Swedish Heart-Lung Foundation, and the
Novo Nordisk Foundation
Y. Chen: None. A. Estampador: None. M. Keller:
None. J. Dalla-Riva: None. F. Renström: None. A.
Kurbasic: None. T. V. Varga: None. P.W. Franks: None.
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Epigenetic silencing of FBXW7 through promotor
hypermethylation in ovarian cancer
Y. Tamimi1,2, M. Al Hinai11, I. Gupta1, R. Lakhtakia1, M.
Al Kalbani1, I. Burney1, A. Okamoto3, M. Al Mounthri1
1SQU, Muscat, Oman, 2College of Medicine and Health
Sciences, Sultan Qaboos University, PO Box 35, PC 123,,
Muscat, Oman, 3Jikei University, Tokyo, Japan
FBXW7, is a tumor suppressor gene with a critical role in
cell cycle progression regulated by E2F5. While FBXW7 is
silenced in several cancers; its role in ovarian cancer
pathogenesis is still unclear. This study explored FBXW7
methylation status in ovarian cancer and its functional sig-
niﬁcance. FBXW7 mRNA and protein expression were
assessed in OV2008, OVSAHO and MCAS cells by qRT-
PCR and western blotting. Expression of FBXW7 was high
in MCAS and low in OV2008 and OVSAHO cells. FBXW7
gene methylation status was analyzed in OVSAHO and in 8
EOC patients by methylation-speciﬁc PCR. Five out of
eight (62.5%) patients analyzed as well as OVSAHO
showed methylation. To evaluate its functional importance,
FBXW7 expression was restored in OVSAHO cells by
treatment with the demethylating agent, 5′-aza-2′deox-
ycitidine. Western blotting in FBXW7-restored OVSAHO
cells and FBXW7-positive cell line (MCAS) showed an
upregulation in caspases-2, 3, 7, BAX, P53, BAD, Cyclin
D1, pNFkB and pGSK3-beta, whereas Bcl-2, Bcl-x, pBad,
STAT3, GSK3-beta and NFkB were downregulated; indi-
cating cells to undergo apoptosis via the STAT3 pathway.
Response of OV2008 and OVSAHO cells to platinum and
5-azacitidine drugs were investigated. While OVSAHO was
sensitive to platinum-drugs, OV2008 was highly resistant.
Interestingly, resistant OV2008 cells treated with 5-azaci-
tidine, showed an enhanced sensitivity to platinum. This
study described an alternative mechanism for FBXW7
inactivation, namely promoter speciﬁc methylation in
ovarian cancer and identiﬁed FBXW7 as a potential target
for guiding the development of therapeutic strategies
against ovarian cancer.
Y. Tamimi: B. Research Grant (principal investigator,
collaborator or consultant and pending grants as well as
grants already received); Modest; SR/MED/BIOC/14/01.
M. Al Hinai1: None. I. Gupta: None. R. Lakhtakia:
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Chromosome 18p deletion is a risk factor for FSHD
J. Balog1, R. Goossens1, R. J. F. L. Lemmers1, M. M. L.
van den Boogaard1, P. J. van der Vliet1, S. P. Nations2, M.
Kriek3, C. L. A. Ruivenkamp3, P. Heard4, B. Bakker3, S.
Tapscott5, J. D. Cody4, R. Tawil6, S. M. van der Maarel1
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Facioscapulohumeral muscular dystrophy (FSHD) is a
progressive muscle disorder with a prevalence of 1:8500.
FSHD is associated with somatic expression of DUX4, a
germline transcription factor normally repressed in somatic
tissue. A copy of DUX4 is located within each unit of the
D4Z4 repeat array, which adopts a repressive chromatin
structure in somatic tissue. Repeat array contraction in
FSHD1, or mutations in D4Z4 chromatin repressors such as
SMCHD1 (FSHD2) lead to partial D4Z4 chromatin
relaxation and derepression of DUX4 in skeletal muscle
when occurring on FSHD-permissive chromosomes that
contain a DUX4 polyadenylation signal. The SMCHD1
gene maps to chromosome 18p and is often deleted in 18p
deletion (18p-) individuals together with other genes. We
hypothesized that 18p- individuals harbouring a FSHD
permissive 4q35 allele are at risk of FSHD because of
SMCHD1 haploinsufﬁciency.
We studied a cohort of 18p- and control primary ﬁbro-
blast cell cultures and quantiﬁed SMCHD1 mRNA and
protein levels. We found that 18p- samples have sig-
niﬁcantly lower levels of SMCHD1, which is associated
with decreased amounts of SMCHD1 associates and
increased levels of H3K27me3 at the D4Z4 repeat, similar
to FSHD2. Transdifferentiation of 18p- ﬁbroblasts with a
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permissive and moderately sized D4Z4 repeat into myo-
tubes resulted in DUX4 and DUX4 target expression in 6
out of 8 cell cultures.
Our results show that SMCHD1 haploinsufﬁciency can
lead to DUX4 expression through a similar mechanism as in
FSHD2 and that some 18p- individuals are at risk of
developing FSHD.
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The methylome of the inner ear: implications for reg-
ulation and pathogenesis of the auditory system
O. YIzhar-Barnea1, C. Valensisi2, Y. Noy1, K. Kishore3, T.
Kofﬂer-Brill1, K. Ushakov1, M. Pellizola3, D. R. Hawkins2,
K. B. Avraham1
1Department of Human Molecular Genetics & Biochem-
istry, Sackler Faculty of Medicine, Tel Aviv University, Tel
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3Center for Genomic Science of IIT@SEMM, Fondazione
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Mechanisms of epigenetic regulation have been studied
vigorously, gaining a major boost by coupling traditional
molecular biology methods with high-throughput Next
Generation Sequencing (NGS). The mammalian inner ear is
a complex morphological structure responsible for hearing
and balance, and its pathology is associated with deafness
and balance disorders. To evaluate the role of epigenomic
dynamics for mouse inner ear sensory epithelium develop-
ment and maturation and its implications in deafness, we
performed whole-genome bisulﬁte sequencing (WGBS) on
inner ear tissue for three key time points. We identiﬁed both
unmethylated (UMR) and low methylated (LMR) regions
across all datasets. UMRs and LMRs have been shown to
predict promoters and enhancers, respectively, allowing us
to generate the ﬁrst regulatory maps in the mouse inner ear
sensory epithelium. We also determined differentially
methylated regions (DMRs) among these three time points.
Approximately 75% of the identiﬁed DMR sequences were
conserved between the mouse and the human genome.
These regions may include regulatory mutations associated
with deafness in the human genome. Finally, we also
assessed nonCG context and observed that between 5% and
12% of CHH/CHG were methylated. Our DNA methylation
study is part of an integrated analysis to build a hierarchical
regulatory scheme of auditory pathways including non-
coding RNAs, nucleosome occupancy and histone post-
translational modiﬁcations. The breakthroughs enabled by
epigenomic analysis may help guide the development of
therapeutics for hearing loss, by providing multiple inter-
vention points for manipulation of the auditory system.
O. YIzhar-Barnea: None. C. Valensisi: None. Y. Noy:
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Induction of fetal hemoglobin by modulation of epige-
netic and genetic factors in beta thalassemia major
patients
I. Keser1, Y. Arikan1, A. Kupesiz2, T. Bilgen3, E. Kurtoglu4
1Akdeniz University, Medical Faculty, Dept. of Medical
Biology and Genetics, Antalya, Turkey, 2Akdeniz Univer-
sity, Med Fac, Dept. of Pediatric Hematology, Antalya,
Turkey, 3Namik Kemal University, Central Research
Laboratory, NABILTAM, Tekirdag, Turkey, 4University of
Health Sciences, Antalya State Hospital, Dept. of Hematol-
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Objective: Our aim is to reveal relationship between
genetic variations of KLF1 and BCL11A genes which are
implied on HbF induction pathways, and modifying prop-
erties of epigenetic mechanisms of resveratrol and sodium
butyrate on both K562 cells and primary erythroid cells in
patiens with beta thalassemia major.
Method: RNA proﬁles of globin genes, p38, ERK1/2
and NRF2 signalling pathways are evaluated in both K562
cells and primary erythroid cells in 30 well-characterized
BTM patients in which were induced with resveratrol and/or
sodium butyrate. Among the factors which regulates the
amount of HbF, KLF1whole gene, BCL11A rs11886868
variation and XmnI polymorphisms were investigated using
both RFLP and Sanger Sequencing.
Results: Resveratrol and sodium butyrate caused dose-
dependent hemoglobinization pattern in K562 cells. No
synergistic effect was found between these two agents.
Apoptotic effect was observedat high dose resveratrol in
K562 cells. The potential of gamma globin induction of
both resveratrol and sodium butyrate were elucidated.
NRF2, ERK1/2 and p38 activation were screened in K562
cells while there was activation of p38 and inactivation of
ERK1/2 pathways in primary erythroid cells of patients.
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BCL11A rs11886868, XmnI polimorphisms and KLF1var-
iations were found to be compatible with the literature.
Conclusion: Guidance on selection of pharmacological
molecules in HbF induction studies, individual genetic and
epigenetic factors should be taken account in patients with
beta thalassemia major
I. Keser: None. Y. Arikan: None. A. Kupesiz: None. T.
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Targets of DNMT3b identiﬁed in Enteric Precursor
Cells as candidate genes for Hirschsprung disease
L. Villalba-Benito1,2, A. Torroglosa1,2, B. Luzón-Toro1,2,
R. Fernández1,2, M. Ruíz-Ferrer1,2, G. Antiñolo1,2, S.
Borrego1,2
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Hirschsprung disease (HSCR) is attributed to a failure of
neural crest cells (NCCs) to migrate, proliferate, differ-
entiate and/or survive in the bowel wall during embryonic
Enteric Nervous System (ENS) development. ENS forma-
tion is the result from a speciﬁc gene expression pattern
regulated by epigenetic events, such DNA methylation by
the DNA methyltransferases (DNMTs), among other
mechanisms. Speciﬁcally, DNMT3b de novo methyl-
transferase is associated with NCCs development and has
been shown to be implicated in ENS formation and in
HSCR. Aiming to deep into the speciﬁc gene expression
pattern established by epigenetic mechanisms during these
processes, we have performed a study based on the identi-
ﬁcation of DNMT3B target genes in enteric precursor cells
(EPCs) from mice, through a chromatin immunoprecipita-
tion coupled with massively parallel sequencing analysis
(ChIP-seq). In addition we have applied several bioinfor-
matic tools to determine the potential target genes. This
approach led us to ﬁnd 20 genes whose expression could be
maintained at basal levels by DNMT3b in EPCs. These
target genes may be part of the signaling pathways required
for the proper ENS formation. Therefore this ﬁnding leads
us to propose that a failure in their expression might con-
tribute to the onset of HSCR.
This work was supported by Instituto de Salud Carlos III
and co-funded by European Union (ERDF/ESF, “Investing
in your future”) [PI16/0142]; and the Regional Ministry of
Innovation, Science and Enterprise of the Autonomous
Government of Andalucia [CTS-7447]. L V-B is supported
by a fellowship associated whit the CTS-7447 project.
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DNA methyltransferases and MBD genes expression
levels in HPV-induced cervical lesions
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Human papilloma virus (HPV) is considered the aetiologic
agent of cervical neoplasia and infection with high risk
types HPVs was associated with cervical dysplasia and
carcinogenesis. DNA methylation and histone modiﬁcations
are the main mechanisms of epigenetic regulation. MBD
proteins exhibit methyl-CpG-binding domains that mediate
the interaction with methylated DNA. The aim of this study
was to establish the inﬂuence of hrHPVs infection on
MBDs, DNMTs expression pattern and 5-mC percentage in
cervical oncogenesis. In this purpose DNA and RNA were
isolated (TriZol) from cervical samples (159 patients and 40
control samples). Gene expression levels (MBD1,3,4 and
DNMT1,3a) were investigated using qRT-PCR. 2−ΔΔCt
method was used to establish n-fold gene expression. 5-mC
percentage was estimated with 5-mC DNA ELISA (Zymo
Research). Signiﬁcant differences were found in DNMT1
gene expression especially between CIN2+ and SCC
samples (p=0.0013), whereas for DNMT3B gene the
expression level was increased in tumor samples (mean=
2.406 ± 1.088) as compared to the precursor lesions
(p=0.0027). A signiﬁcant increase was observed for MBD1
gene between CIN2+ and SCC (p=0.046) samples, while
MBD3 gene found a signiﬁcant difference in expression
levels between CIN1 and CIN2+ (p=0.0229). MBD4 gene
showed a signiﬁcantly high level of expression in tumors
(mean= 2.824 ± 0.9320) (p=0.004). The correlation
between the MBDs level of expression, and the percentage
of 5-mC, showed a good connection with MBD1 levels
(r2=0.3551, p=0.0056). These results illustrate the invol-
vement of epigenetic alterations in cervical oncogenesis and
could serve as a starting point for diagnosis and prognosis.
PNIIRU-TE-2014-4-2502
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Widespread recovery of methylation at gametic imprints
in hypomethylated mouse stem cells following rescue
with DNMT3A2
A. Thakur1,2, S. J. Mackin2, R. E. Irwin2, K. M. O'Neill3,2,
G. Pollin2, C. P. Walsh2
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Belfast, United Kingdom
Introduction: Imprinted loci are paradigms of epigenetic
regulation and are associated with many genetic disorders in
human. A key characteristic of the imprints is the presence
of a gametic differentially methylated region (gDMR)
which must be passaged through the germline to be
reprogrammed.
Materials and Methods: We examined the most complete
current set of imprinted gDMRs that could be assessed
using quantitative pyrosequencing assays in ESCs that
lacked DNMT1 (1KO) and those cells lacking a combina-
tion of DNMT3A and DNMT3B (3abKO). We further
veriﬁed results using clonal analysis and combined bisulﬁte
and restriction analysis.
Results: Our results showed that loss of methylation was
approximately equivalent in both cell types. 1KO cells
rescued with a cDNA-expressing DNMT1 could not restore
methylation at the imprinted gDMRs, conﬁrming some
previous observations. However, nearly all gDMRs were
remethylated in 3abKO cells rescued with a DNMT3A2
expression construct (3abKO + 3a2). Transcriptional
activity at the H19/Igf2 locus also tracked with the methy-
lation pattern, conﬁrming functional reprogramming in the
latter.
Conclusions: These results suggested (1) a vital role for
DNMT3A/B in methylation maintenance at imprints, (2)
that loss of DNMT1 and DNMT3A/B had equivalent
effects, (3) that rescue with DNMT3A2 can restore imprints
in these cells. This may provide a useful system in which to
explore factors inﬂuencing imprint reprogramming.
Grants: Work was supported by a Medical Research
Council Grant (MR/J007773/1). Attendance at the ESHG
supported by a Travel Grant from The Genetics Society and
funding from Northern Ireland Department of Education
and Learning (DEL).
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Detection of imprinted genes by single-cell allele speciﬁc
gene expression
C. Borel, F. A. Santoni, G. Stamoulis, M. Garieri, E.
Falconnet, P. Ribaux, S. E. Antonarakis
University of Geneva Medical School, Geneva, Switzerland
Genomic imprinting results in parental-speciﬁc gene
expression. Imprinted genes are involved in the etiology of
rare syndromes and have been associated with common
diseases such as diabetes and cancer. Standard RNA bulk
cell sequencing applied to whole tissue samples has been
used to detect imprinted genes in human and mouse models.
However, lowly expressed genes cannot be detected by
using RNA bulk approaches. Here, we report an original
and robust method that combines single-cell RNAseq and
whole genome sequencing into an optimized statistical
framework to analyze genomic imprinting in speciﬁc cell-
types and in different individuals. Using samples from the
probands of 2 family trios and 3 unrelated individuals, 1084
individual primary ﬁbroblasts were RNA sequenced, and
more than 700000 informative heterozygous single
nucleotide variations (SNVs) were genotyped. The allele
speciﬁc coverage per gene of each SNV in each single cell
was used to ﬁt a beta-binomial distribution to model the
likelihood of a gene being expressed from one and the same
allele. Genes presenting a signiﬁcant aggregate allelic ratio
(between 0.9–1) were retained to identify of the allelic
parent of origin. Our approach allowed us to validate the
imprinting status of all of the known imprinted genes
expressed in ﬁbroblasts and the discovery of 9 putative
imprinted genes, thus demonstrating the advantages of
single-cell over bulk RNAseq to identify imprinted genes.
The proposed single-cell methodology is a powerful tool for
establishing a cell type-speciﬁc map of genomic imprinting.
C.B. and F.S. contributed equally to this work.
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IRS1 DNA promoter methylation in human adipose
tissue mediates the relationship of rs2943650 near IRS1
to fat distribution and metabolic traits
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Aims/Hypothesis: Body Fat composition measures fat
distribution more precise than BMI. A SNP near the IRS1
locus was reported that associates with decreased body fat,
IRS1 gene expression and an adverse metabolic proﬁle in
humans. We hypothesized that these effects may be medi-
ated by epigenetics.
Methods: We measured DNA methylation within the
IRS1 promoter and mRNA expression in paired human
adipose tissue samples (SAT and OVAT) from 146 and 43
individuals, respectively. Genotyping of the body fat asso-
ciated variant rs2943650 near IRS1 was performed (N=
146).
Results: The total cohort shows signiﬁcantly higher IRS1
promoter DNA methylation in OVAT compared to SAT
(P=8.0×10−6), while expression levels show the opposite
effect direction (P=0.011). OVAT and SAT methylation is
correlated to gene expression in obese subjects (P=0.007
and P=0.010). The major T-allele is related to increased
DNA methylation in OVAT (P=0.019). Finally, DNA
methylation and gene expression in OVAT correlates with
clinical variables such as waist-circumference, waist-to-hip
ratio (WHR) and glucose metabolism in obese individuals.
Conclusions/Interpretation: Anthropometric and
metabolic variables may be inﬂuenced, in addition to and in
concert with genetic factors, by changes in DNA methyla-
tion that translates into altered gene expression. Larger
studies are warranted to further dissect the interplay
between rs2943650, DNA methylation and gene expression
of IRS1 and its inﬂuence on metabolism.
Grants: IFB AdiposityDiseases: ADI-K50D, ADI-K6e-
96, ADI-K7-39, K7-45 (supported by BMBF, Germany,
FKZ: 01EO1501). Kompetenznetz Adipositas funded by
the Federal Ministry of Education and Research (German
Obesity Biomaterial Bank; FKZ 01GI1128). Deutsche
Forschungsgemeinschaft for CRC 1052/1: “Obesity
mechanisms”.
K. Rohde: None. M. Keller: None. X. Liu: None. M.
Klös: None. M. Stumvoll: None. A. Dietrich: None. M.R.
Schön: None. D. Gärtner: None. T. Lohmann: None. M.
Dreßler: None. P. Kovacs: None. M. Blüher: None. Y.
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Identifying distal interactions between RUNX1 and a
Juvenile Idiopathic Arthritis associated SNP by Chro-
mosome Conformation Capture
C. J. Taylor1, A. Hinks1, A. McGovern1, H. Ray-Jones1, A.
Yarwood1, P. Martin1, K. Duffus1, W. Thomson1,2, S.
Eyre1
1University of Manchester, Manchetser, United Kingdom,
2NIHR Manchester Musculoskeletal Biomedical Research
Unit, Manchester, United Kingdom
Background: 17 genetic loci have been identiﬁed which
confer susceptibility to juvenile idiopathic arthritis (JIA).
Several of these loci harbour genes involved in the
Interleukin-2 (IL2) pathway: an important signalling cas-
cade involved in many autoimmune diseases including JIA.
Capture Hi-C data has shown several interactions occur
between the non-coding, JIA susceptibility SNP rs9979383
and the haematopoiesis master regulator gene Runt-Related
Transcription Factor (RUNX1), a crucial transcription factor
involved in the regulation of IL2. Methods: To prioritise
the most likely functional candidate SNPs and select
appropriate cell types, several bioinformatics databases
were interrogated. Chromosome conformation capture (3C)
experiments were designed to try to validate these interac-
tions using T-cell lines and genotype speciﬁc B-cell lines.
Results: The highest prioritised SNP in the RUNX1 gene
region was identiﬁed as rs9979383 Stebased on transcrip-
tion factors, Hi-C data and histone marks. 3C data showed
signiﬁcantly increased interactions between the anchor
fragment containing rs9979383 and several fragments near
the RUNX1 promoter in B-cells when compared to controls,
with some evidence of genotype speciﬁc interaction fre-
quencies. In contrast no interactions could be detected at
this locus in the T-cell line. Conclusion: The bioinformatics
approach proved to be highly informative and aided the
design of 3C experiments. rs9979383 may be regulating
RUNX1 expression in B-cells, with one interaction in par-
ticular revealing a long-range, 400kb interaction between
the SNP fragment and the RUNX1 promoter region frag-
ment. Expression analysis, chromatin immunoprecipitation
and CRISPR-Cas9 are now being employed to further
investigate the regulatory mechanisms driving this
interaction.
C.J. Taylor: None. A. Hinks: None. A. McGovern:
None. H. Ray-Jones: None. A. Yarwood: None. P.
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Effects of Kaiso (binding) to the differentially methy-
lated ICR1
F. Bohne1, D. Langer1, U. Martine1, C. S. Eider1, T.
Enklaar1, U. Zechner2, T. Eggermann3, R. Cencic4, J.
Pelletier4, D. Prawitt1
1Center for Pediatrics and Adolescent Medicine, University
Medical Center, Mainz, Germany, Mainz, Germany, 2Insti-
tute of Human Genetics, University Medical Center, Mainz,
Germany, Mainz, Germany, 3Institute of Human Genetics,
RWTH, Aachen, Aachen, Germany, 4Department of Bio-
chemistry and The Rosalind and Morris Goodman Cancer
Research Centre, McGill University, Montreal, Montreal,
QC, Canada
Introduction: The correct dosage of imprinted genes is
important for normal development and anomalies of geno-
mic imprinting often manifest as developmental disorders or
are causative for cancer. The expression of imprinted genes
is generally regulated by differentially methylated imprint-
ing control regions (ICRs). The methylation of many ICRs
is maintained by the ZFP57/KAP1/SETDB1-complex, with
the exception of the ICR1 that controls the uniparental
expression of IGF2 and H19.
Methods: Using EMSA and ChIP we identiﬁed ZBTB33
(Kaiso) as a factor binding to the ICR1. Lentiviral Kaiso
knock-down experiments and CRISPR/Cas9 mediated
deletion of the ICR1-Kaiso-bindingsite were used in com-
bination with bisulﬁte-conversion and pyrosequencing to
address the relevant function of Kaiso for the ICR1
methylation.
Results: We show that Kaiso binds to methylated CpGs
and to an unmethylated consensus sequence in the ICR1.
Reduction of the Kaiso transcript as well as the deletion of
the unmethylated binding-site both show reduced methyla-
tion within the ICR1 and also effect transcription of IGF2
and H19. Other ICRs, e.g. the KvDMR on the same chro-
mosome, showed no difference in the methylation after
manipulation of Kaiso.
Conclusion: We show the binding of Kaiso to the ICR1
and proof its essential role for the methylation maintenance
in the ICR1. Kaiso binding to the ICR1 also effects the
expression levels of IGF2 and H19. Our work thus estab-
lishes Kaiso as a previously unrecognized indispensable
factor for a speciﬁc ICR1 function in imprinted gene
regulation.
This work was funded by BMBF (01GM11513B and
01GM1513C) and the Studienstiftung des deutschen
Volkes.
F. Bohne: None. D. Langer: None. U. Martine: None.
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Mutations in the DNA-binding Domain of KLF1 lead to
Autosomal Dominant Anemia via altered sequence spe-
ciﬁcity and ectopic gene expression
K. R. Gillinder, M. D. Ilsley, G. W. Magor, A. C. Perkins;
Mater Research - University of Queensland, Brisbane,
Australia
The average human genome contains nearly 100 missense
mutations within the DNA-binding domain (DBD) of var-
ious sequence-speciﬁc transcription factors (TFs). Despite
their potential medical importance, the consequence of these
mutations remains largely unknown. Missense mutations in
the DBD of TFs can alter both the afﬁnity and the speciﬁ-
city of DNA-binding leading to disruption of gene regula-
tion. Here, we demonstrate how a missense mutation in the
second zinc ﬁnger of Krüppel-like factor-1 (KLF1) leads to
an altered DNA-binding speciﬁcity in vivo, resulting in
ectopic transcription in a murine model of Congenital
Dyserythropoietic Anaemia (CDA). To investigate how this
mutation might cause disease, we introduced tamoxifen-
inducible versions of wildtype and mutant KLF1, an
essential TF required for nearly every aspect of red blood
cell formation, into a Klf1−/− erythroid cell line. We
employed ChIP-seq and 4sU-RNA-seq to identify aberrant
DNA-binding events genome wide and the ectopic tran-
scriptional consequences of this binding. We conﬁrmed
novel sequence speciﬁcity of the mutant recombinant zinc
ﬁnger domain by performing biophysical measurements of
in vitro DNA-binding afﬁnity. Together, these results shed
new light on the mechanisms by which missense mutations
in DNA-binding domains of transcription factors can lead to
autosomal dominant diseases.
This work was funded by the National Health and
Medical Research Council (Australia).
K.R. Gillinder: None. M.D. Ilsley: None. G.W.
Magor: None. A.C. Perkins: None.
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Long noncoding RNAs abnormally expressed in
relapsed acute lymphoblastic leukemia
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S. Jimenez-Morales1, D. A. Bárcenas-López2, J. M. Mejía-
Aranguré3, J. C. Nuñez-Enriquez3, M. Ramírez-
Florencio4, E. Jiménez-Hernández5, C. A. Pérez-Amado4,
A. Medina-Sanson6, A. Cedro-Tanda7, L. A. Alfaro-Ruíz1,
A. Hidalgo-Miranda1
1Instituto Nacional de Medicina Genómica, Mexico City,
Mexico, 2Programa de Maestría en Ciencias Biológicas,
UNAM, Mexico City, Mexico, 3Centro Médico Nacional
Siglo XXI, IMSS., Mexico City, Mexico, 4Programa de
Maestría en Ciencias Bioquímicas, UNAM, Mexico City,
Mexico, 5Centro Médico Nacional La Raza, IMSS., Mexico
City, Mexico, 6Hospital Infantil de Mexico, Mexico City,
Mexico, 7Programa de Doctorado en Ciencias Biomédicas,
UNAM, Mexico City, Mexico
Introduction: Long noncoding RNAs (lncRNAs) are
emerging as important players in normal biological pro-
cesses as well as pathological conditions, including cancer.
In fact, several of them have been proposed as potential
prognostic, poor survival, and cancer metastasis bio-
markers. Acute lymphoblastic leukemia (ALL) is the most
common childhood cancer worldwide, which displays a
differential incidence rate between ethnic groups. Mexican
population exhibits one of the highest incidence and rate
mortality due to early relapse (within the ﬁrst 18 months
after diagnosis). We performed a comparative transcriptome
analysis to identify lncRNAs differentially expressed in
ALL with relapse.
Materials and Methods: We included 60 bone marrow
samples from pediatric ALL patients, of which 11 were
relapsed samples. Expression analysis was performed using
the Affymetrix Human Transcriptome Array 2.0 platform
following the manufacturer's protocol. Annotation was
carried out using Transcriptome Analysis Console software
(Affymetrix). P-values <0.05 were considered as statisti-
cally signiﬁcant.
Results: Regarding gender, age at diagnosis, leukocyte
count, immunophenotype, risk classiﬁcation and frequency
of gene rearrangements (ETV6-RUNX1, TCF3-PBX1, BCR-
ABL1 and MLL rearrangements), no statistically signiﬁcant
differences between no-relapsed and relapsed groups were
observed. On overage, relapse occurred 10.6 months after
diagnosis and survival of this group was three months
(range 0–8 months). Expression analysis showed ﬁve dif-
ferentially expressed lncRNAs (fold-change > 1.2 and p
value <0.01) between both studied groups, being Linc00341
one of the highest abnormally expressed (p= 0.004).
Conclusions: Our data provide evidence that lncRNAs
could play a relevant role in the relapse of this hematolo-
gical malignancy.
S. Jimenez-Morales: None. D.A. Bárcenas-López:
None. J.M. Mejía-Aranguré: None. J.C. Nuñez-
Enriquez: None. M. Ramírez-Florencio: None. E. Jimé-
nez-Hernández: None. C.A. Pérez-Amado: None. A.
Medina-Sanson: None. A. Cedro-Tanda: None. L.A.
Alfaro-Ruíz: None. A. Hidalgo-Miranda: None.
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Computational mapping of regulatory domains of
human genes
I. Patarcic, V. Franke, A. Akalin; MDC BIMSB, Berlin,
Germany
As a result of recent IHEC efforts, a large number of epi-
genome proﬁles became publicly-available. However, a
systematic, integrative and accessible approach for dis-
covery and documentation of genome-wide cis-regulatory
relationships is still missing. In this research, we performed
the most detailed data-integration analysis to associate
enhancers to the genes they regulate across the human
genome.
Cross-cell-types proﬁles of H3K27ac, H3K4me1, DNA
methylation, DNase I hypersensitivity and RNA-Seq were
selected from four different IHEC data-sets to quantify
enhancer activity and gene expression. Long-range inter-
actions were identiﬁed by successfully running linear
regressions of gene expression and enhancer activity. Indi-
vidual gene-enhancer models were meta-analyzed across
consortia datasets. To conﬁrm associations, a benchmark
dataset was built based on: 1) GTEx database, 2) published
chromatin interactions, and 3) massively parallel reporter
assays results.
We quantiﬁed cross-cell-types enhancer activities and
gene expressions based on up to 179 epigenome proﬁles.
More than 32,000 genes we modelled successfully; whereas
we meta-analyzed 21,000 genes across all consortia. We
tested more than 3.7 million gene-enhancer pairs, and
approximately 17,000 genes and 80,000 enhancer regions
passed ﬁltering procedure (q-value 10−8). Our results con-
ﬁrm previously reported examples of long-range interac-
tions, including the famous FTO-IRX3-IRX5 long-range
interactions. This indicates that we should extract many
novel long-range interactions from this database in the
future.
This database represents the most detailed regulatory
catalog in existence so far. It should empower the future
functional interpretations of disease-associated variants by
facilitating the precise identiﬁcation of genes which are
affected by variants of interest.
I. Patarcic: None. V. Franke: None. A. Akalin: None.
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Genetic variants associated with inﬂammatory disease
can alter m6A RNA methylation and inﬂuence immune
response
A. Castellanos-Rubio1, A. Jauregi-Miguel1, K. Garcia-
Etxebarria1, C. Tutau2, J. Bilbao1
1University of the Basque Country, Leioa, Spain, 2Cruces
University Hospital, Barakaldo, Spain
m6A modiﬁcations are a novel RNA-based regulatory layer
known to regulate the gene expression programme at a post-
transcriptional level. It has been speculated that the m6A
methylome can be related to immune tolerance. However,
the inﬂuence of disease associated regions in the variability
of the so called epitranscriptome has not been studied to
date. In order to ﬁnd m6A candidate regions that could be
altered by the presence of genetic association of immune-
mediated diseases, Immunochip regions were scrutinized
for described m6A marks. One of these regions, which is
associated to multiple immune diseases (i.e celiac disease,
Crohn’s disease or psoriasis) harbors a functionally
uncharacterized lncRNA. m6A immunoprecipitacion con-
ﬁrmed the presence of mRNA methylation in this lncRNA
in different intestinal cell lines. Moreover, when using
intestinal biopsies of heterozygous individuals the methy-
lation was preferentially found in the allele that confers risk
to intestinal inﬂammatory diseases. Further characterization
of the risk-conferring lncRNA form showed that the m6A
mark containing transcript is present at lower levels in
intestinal biopsies, correlating with higher expression of a
closeby gene, which regulates Hsp90 function, and
increased levels of the inﬂammatory cytokine TNFa. In the
same way, induced overexpression of the risk lncRNA in
intestinal cells, leads to higher expression of Hsp90 reg-
ulator, together with increased NFKB1 levels. In conclu-
sion, we found an uncharacterized lncRNA whose levels are
regulated by a genotype/tissue dependent RNA methylation
and which seems to induce inﬂammatory gene expression
by an Hsp90 linked pathway.
A. Castellanos-Rubio: None. A. Jauregi-Miguel:
None. K. Garcia-Etxebarria: None. C. Tutau: None. J.
Bilbao: None.
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miR-125b, miR-182 and miR-200c as prognostic bio-
markers in primary cutaneous malignant melanoma
and their association with clinicopathological para-
meters and clinical outcome
B. Sánchez Sendra1, J. González Muñoz1, C.
Monteagudo2
1INCLIVA, Valencia, Spain, 2Pathology Department, Med-
icine Faculty, University of Valencia, Valencia, Spain
Introduction: Metastatic dissemination causes 15–25% of
melanoma deaths. It has been observed that miRNAs
mediate melanoma invasion and metastasis. Here, we
inquired into the association of miR-125b, miR-182 and
miR-200c with clinicopathological parameters and their
ability to determine patient clinical outcome at the time of
primary tumor as a way to differentiate patients with higher
risk to develop metastasis.
Materials and Methods: 65 fresh frozen primary human
melanoma samples were analyzed. We determined miR-
125b, miR-182 and miR-200c expression of these primary
tumors by miRNA RT-qPCR and the results were correlated
with clinicopathological parameters and the clinical out-
come of patients. Correlation and contrast statistic tests
were performed.
Results: In all samples, satisfactory RT-qPCR ampliﬁ-
cation curves were obtained for miR-125b, miR-182 and
miR-200c. Clinicopathological parameters such as Breslow
thickness and number of mitoses per mm2 were negatively
correlated with the three miRNAs expression, and there was
also a relation between these miRNAs and ulceration and
growth phase (radial or vertical). Clinical follow up was
prolonged to 134 months. Only 16 cases (24,6%) developed
distant metastasis. All three miRNAs were down-regulated
in metastatic versus non-metastatic primary melanomas
(p≤0,001) and were capable to distinguish patients with
different metastatic risk.
Conclusions: miR-125b, miR-182 and miR-200c could
be used as determinants of prognosis at the time of primary
diagnosis due to their ability to classify patients regarding
their invasive potential.
This work was supported by PI13/02786 co-ﬁnanced by
FEDER funds, ISCIII, and PROMETEOII/2015/009
(INCLIVA).
We want to acknowledge the INCLIVA BioBank for its
collaboration.
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Development of a robust method to study epigenetic
changes in highly degraded FFPE DNA
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Wezel4, M. van Iterson5, N. Pedersen2, S. Hägg2, B.
Janssen1
1GenomeScan B.V., Leiden, Netherlands, 2Karolinska
Institutet, Department for Medical Epidemiology and
Biostatistics, Stockholm, Sweden, 3Karolinska Institutet,
Center for Alzheimer Research, division of Neurogeriatrics,
Stockholm, Sweden, 4Leiden University Medical Center,
Department of Pathology, Leiden, Netherlands, 5Leiden
University Medical Center, Department of Medical Statis-
tics and Bioinformatics, Leiden, Netherlands
Biomarkers for age-related disorders such as Alzheimer´s,
dementia and Parkinson’s disease can be discovered by
assessment of epigenetic markers in the brain. This research
is hampered by the massive DNA shredding and partial
nucleotide breakdown. For the ﬁrst time, the methylation
status of brain coupes from the Swedish Twin Registry
(STR) could successfully be assessed using a novel
approach.
Three cutting-edge procedures for DNA restoration prior
to methylation assessment were benchmarked. The superior
technique was then validated using highly deteriorated
DNA from Formalin-Fixed Parafﬁn-Embedded (FFPE) tis-
sue dating from 1988(3). In all samples ≥98% of the epi-
genetic loci were detected (R2≥0.98 for duplicates). The
concordance of FFPE DNA with their 30-year old fresh
frozen counterparts was excellent (R2≥0.9), showing that
the biological relevance remains intact after restoration. The
most degraded samples showed the most signiﬁcant
improvements (R2 increased from 0.4 to 0.9). The observed
call rates could be predicted by qPCR before proceeding to
array hybridization.
Epigenetic measurements were performed on frontal
cortex and cerebellum of the STR cohort (49 individuals;
99 samples) using Illumina’s MethylationEPIC-array.
Despite the apparent deterioration of the samples (average
fragment length: ~300 bp), 79 samples showed sufﬁcient
quality. Overall, sample quality was consistent within
individuals. Principal component analysis showed tissue
type as the main inducer of variation. The analysis now
focuses on detecting epigenetic differences in the progres-
sion of dementia and Alzheimer’s disease.
We here show a robust and powerful method to study
epigenetic changes in previously unattainable cohorts.
K. Hertoghs: A. Employment (full or part-time); Sig-
niﬁcant; GenomeScan B.V.. Y. Wang: None. F. Behrouz:
A. Employment (full or part-time); Signiﬁcant; Geno-
meScan B.V.. C. Graff: None. T. van Wezel: None. M.
van Iterson: None. N. Pedersen: None. S. Hägg: None. B.
Janssen: A. Employment (full or part-time); Signiﬁcant;
GenomeScan B.V..
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genome-wide DNA methylation variation in maternal
and cord blood of gestational diabetes population
J. Kang1, C. N. Lee1, H. Y. Li2, K. H. Hsu3, S. Y. Lin1
1Department of Obstetrics and Gynecology, National
Taiwan University Hospital, Taipei, Taiwan, 2Department
of internal medicine, National Taiwan University Hospital,
Taipei, Taiwan, 3Institute of Molecular Medicine, College
of Medicine, National Taiwan University, Taipei, Taiwan
Introduction: Gestational diabetes mellitus (GDM) has
been a concerning issue for pregnant women. It will cause
various complications such as shoulder dystocia and neo-
natal hypoglycemia. In recent studies, gestational diabetes
was found to be related to epigenetics modiﬁcation, leading
to high probability of developing metabolic syndrome and
diabetes later in life. This study was aimed to analyze the
genome-wide DNA methylation status of patients and
offspring.
Materials and methods: Maternal and cord blood were
collected from 16 pregnant women and their newborns,
including 8 exposed to GDM. DNA methylation was
measured at > 841,573 CpG sites (Inﬁnium Human-
MethylationEPIC BeadChip). Ingenuity Pathway Analysis
was conducted to identify genes and pathways epigeneti-
cally affected by GDM.
Results: We identiﬁed the top 200 loci and their corre-
sponding genes in maternal blood group (n= 151) and cord
blood group (n= 167), which were differently methylated
in GDM and the unexposed group. Metabolic diseases
related genes and pathways were also identiﬁed in both
groups. Suggesting that GDM has epigenetic effects on both
mother and their offspring, which may cause future meta-
bolic syndrome or diabetes.
Conclusions: This high throughput platform enabled us
to analyze through methylation status and identify and the
most promising genes and pathways associated to gesta-
tional diabetes, which are worthy for future studies in epi-
genetics and its effect on GDM offspring.
This work was supported by grants from Taiwan Min-
istry of Science and Technology (NSC 105-2628-B-002
-032 -MY2 and 104-2314-B-002-100) and grant from
National Taiwan University Hospital (105-003223 and 106-
003682).
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750
P17.43C
Investigation of methylation patterns of SFRP1, SFRP2,
SHP1, SOCS3, EBF2 genes before and after treatment
in acute myeloid leukemia and chronic myeloid
leukemia
E. Tunçez1, A. U. Bilgin2, A. Acar3
1Medical Genetics Section, Sanliurfa Training and
Research Hospital, Sanliurfa, Turkey, 2Department of
Hematology, Koru Hospital, Ankara, Turkey, 3Department
of Molecular Biology and Genetics, Faculty of Arts and
Sciences, Istanbul Bilim University, İstanbul, Turkey
Introduction: Dysregulated epigenetic mechanisms have
important roles in the pathogenesis of cancer. This study
designed to investigate methylation levels of SFRP1,
SFRP2, SHP1, SOCS3 and EBF2 genes possible con-
tributions to the pathogenesis of myeloid leukemia.
Methods: Methylation levels of SFRP1, SFRP2, SHP1,
SOCS3 and EBF2 genes of 25 AML and 25 CML patients
at initial diagnosis compared with methylation levels of the
same genes after treatment and 25 healthy volunteers.
Pyrosequencing method was preferred due to its advantages
as giving accurate, rapid and quantitative results.
Results: In our study, mean methylation values of
SFRP1, SFRP2, SHP1 and EBF2 genes in AML group at
initial diagnosis have been identiﬁed signiﬁcantly higher
compared to healthy controls. SFRP1, SFRP2 genes
methylation values were found signiﬁcantly low after
treatment. Mean methylation values of SHP1 and EBF2
genes in CML group at initial diagnosis was observed
signiﬁcantly different compared to healthy controls and
only EBF2 gene methylation was changed with treatment.
No statistically signiﬁcantly difference was observed
between AML, CML and healthy control group for mean
methylation values of SOCS3 gene and no change in
methylation value was determined with treatment.
Conclusion: These results may suggest that SHP1 and
EBF2 genes play a role in the pathogenesis of myeloid
leukemia and methylation of SFRP1, SFRP2 genes con-
tribute the pathogenesis of AML. SHP1 gene methylation
do not seen to be affected by treatment in both AML and
CML, this brought to mind the idea that using demethyla-
tion agent could be useful.
E. Tunçez: None. A.U. Bilgin: None. A. Acar: C. Other
Research Support (supplies, equipment, receipt of drugs or
other in-kind support); Modest; Selcuk University's Ofﬁce
of Scientiﬁc Research Projects.
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Trastuzumab treatment response prediction by micro-
RNAs proﬁle in HER2 positive breast cancer tumors
E. Beristain1, B. Calvo2, N. Ancizar3, A. Lahuerta4, L.
Larburu4, I. Ruiz3, R. Rezola4, M. A. Viguri1, I. Guerra1,
M. Martinez de Pancorbo5, N. G. Bediaga5
1OSI Araba University Hospital, Vitoria-Gasteiz, Spain,
2Intelligent Systems Group, University of the Basque
Country (UPV/EHU), Donostia, Spain, 3Donostia Univer-
sity Hospital, Donostia, Spain, 4Onkologikoa, Donostia,
Spain, 5BIOMICs Research Group, Lascaray Research
Center, University of the Basque Country (UPV/EHU).,
Vitoria-Gasteiz, Spain
Introduction: Breast cancer is the most common cancer in
women worldwide, showing Her2 oncogene overexpression
in 25–30% of them. Current therapies, as the humanized
monoclonal antibody trastuzumab, lead to the silence of its
activity. However, most of women with metastatic Her2+
breast cancer get resistance to trastuzumab within a year
(acquired resistance), and even 40% of Her2+ tumors are
resistant or low sensitive since the beginning of the treat-
ment (primary resistance). Thus, the identiﬁcation of tras-
tuzumab resistance mechanisms would be of huge
importance to identify those patients really sensible to
trastuzumab.
Taking in account the role of miRNAs regulating several
gene expressions and its implication in several cancer
pathways, the objective of this work is the identiﬁcation of a
miRNA predictive model which determines the response to
trastuzumab therapy in women with Her2+ breast cancer.
Material and Methods: The expresion of 768 miRNA
by TLDA cards (Applied Biosystems) was analyzed in 37
Her2+ breast cancer core biopsies, 21 with a complete
pathologic response after anthracyclines + taxanes + tras-
tuzumab neoadyuvant treatment.
Results: Nine miRNAs with a good predictive value
(AUC 0.8–0.75) were obtained. Samples without complete
pathologic response behaved more homogeneously than
with a complete response, showing in general over-
expression of these miRNAs.
Conclusions: The great number of miRNAs analyzed
and our sample size, validation studies are needed to con-
ﬁrm the clinical utility of this predictive model for trastu-
zumab treatment response.
This work is been supported by a grant from The Basque
Country Government Health Department: project
GV2012111091.
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Single Cell Gene Proﬁling of Cell Migration
E. Y. Shum, N. Bansal, R. Lam, H. Fan
BD Genomics, Menlo Park, CA, United States
Introduction: RNA-Seq has been a powerful method to
understand sample-to-sample differences in gene expression
from basic biology studies to translational biomedical
research. Recently, single cell RNA-seq (scRNA-seq) is
also getting increasingly adopted as a standard procedure to
tease out cell-to-cell heterogeneity within biological sam-
ples, which is crucial for understanding health and disease.
In this study, we ﬁrst explore why scRNA-seq is important
in even in simple biological samples that conventional
‘bulk’ RNA-seq cannot decipher.
Materials and Methods: Migration assay is initiated
after multiple scratch wound is applied in adherent cells.
After 12 hours, ~10,000 cells were collected from the same
treatment dish to perform either bulk RNA-seq or single cell
RNA-seq with molecular barcoding. Gene expression pro-
ﬁles obtained using different gene expression assays were
compared.
Results and Conclusions: We explored the gene
expression pattern as seen by bulk RNA-seq compared to
scRNA-seq studies from 10,000 cell resolution. Bulk RNA-
seq revealed average gene expression changes during cell
migration; however, using scRNA-seq, we were able to map
the dynamic gene expression patterns exhibited during cell
migration. For example, we have identiﬁed genes that have
similar transcripts per million (TPM) value as assessed by
bulk RNA-seq, but their unique expression pattern across
single cells are different. This heterogeneity in gene
expression across single may reveal differences in cellular
regulatory mechanisms for these mRNAs in during cell
migration or other dynamic cellular phenomenon.
E.Y. Shum: A. Employment (full or part-time); Sig-
niﬁcant; BD Genomics. N. Bansal: A. Employment (full or
part-time); Signiﬁcant; BD Genomics. R. Lam: A.
Employment (full or part-time); Signiﬁcant; BD Genomics.
H. Fan: A. Employment (full or part-time); Signiﬁcant; BD
Genomics.
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Micro RNA 196a-5p serum levels show reverse asso-
ciation with severity of coronary artey disease
Ö. F. Karaçorlu1, H. Bağış1,2, M. Çetin3, Ö. Yumrutaş4,
I. Bozgeyik4
1Adiyaman University Medical Faculty, Department of
Medical Genetics, Adıyaman, Turkey, 2Adiyaman Univer-
sity Medical Faculty, Head of Department of Medical
Genetics, Adıyaman, Turkey, 3Adiyaman University Medi-
cal Faculty, Departmet of Cardiology, Adıyaman, Turkey,
4Adiyaman University Medical Faculty, Department of
Medical Biology, Adıyaman, Turkey
Introduction: MicroRNAs (miRNAs) are relatively
recently discovered cardiovascular diseases(CVD) bio-
markers which have important implications for CVD early
diagnosis, treatment and estimation of prognosis. It shown
that miRNAs have role in macrovascular/microvascular
(dys)function. We aimed to test whether miR-196a-5p has
different expression levels according to severity of coronary
arter disease(CAD) patients. Methods: In this study, 135
patients with angina or acute myocardial infarction(MI)
who underwent coronary angiography were recruited and
divided into 3 groups:45 normal coronary arteries(coronary
lesion<50% stenosis), 45 critical stenotic(≥50%) and 45 MI
(complete stenosis or thrombosis). Serum obtained from
blood samples which drawn before coronary angiography.
After RNA isolation and cDNA synthesis, expression of
miR-196a-5p were analyzed by using Qiagen’s miScript
SYBR Green PCR kit and quantitative real-time PCR
method performed. Statistical analysis of real-time PCR
results was achieved using the 2−ΔCt formula. Results: 2
−ΔCt results indicate that miR-196a-5p was signiﬁcantly
down-regulated in patients with MI compared to non-CAD
group (fold change 0.3,p <0.05). Critical CAD group fold
change was0.6 but not statistically signiﬁcant compare to
non-CAD group. Using miRDB target prediction tool, we
identifed HOXA5 is a strong candidate (target score=92)for
miR-196a-5p. Conclusions: It is known that HOXA5 gene
and HoxA5 transcription factor is effective in the endothelial
cell shear stress response and atherosclerosis by epigenetic
mechanisms and also play crucial role in antiangiogenesis.
These results suggest Hox-related miR-196a-5p have
reverse association with severity of CAD and further eva-
luation by functional gene expression study recommended.
This study was funded by the Adiyaman University Sci-
entiﬁc Research Projects Unit
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Involvement of miR424-5p and miR-221-3p in tumour
metastasis in laryngeal squamous cell carcinoma
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S. Giragosyan1, G. Stancheva1, T. Popov2, D. Konov2, J.
Rangachev2, V. Mitev1, R. Kaneva1
1Molecular Medicine Center, Department of Medical
Chemistry and Biochemistry, Medical University-Soﬁa,
Soﬁa, Bulgaria, 2University Hospital Tsaritsa Yoanna –
ISUL; ENT Clinic, Medical University-Soﬁa, Soﬁa,
Bulgaria
Introduction: miRNAs are one of the most studied biolo-
gical regulators of gene expression. The aim of our study is
to evaluate miR-424-5p and miR-221-3p expressions, and
to analyze both miRNAs as potential markers for metastasis
in laryngeal squamous cell carcinoma (LSCC). Materials
and Methods: The expression of miR-424-5p and miR-221-
3p was evaluated in 26 freshly-frozen LSCC tumour and 12
metastatic samples by RT-qPCR technique. Statistical ana-
lysis was performed using SPSS17.0 software program. A
p-value less than 0.05 was considered statistically sig-
niﬁcant. Results: We observed upregulation of miR-424-5p
and miR-221-3p in 69.23% and 26.92% in tumour tissue.
MannWhithey Utest showed signiﬁcant higher expression
levels of miR-424-5p (RQ=6.35±6.65; p=0.018) in tumour
samples from patients with metastasis in comparison with
those without metastasis (RQ=2.52±1.77). Wilcoxon Test
showed that elevated expression levels of miR-424-5p are
statistically higher (RQ=6.35±6.65; p=0.028) in tumour
tissue than metastatic tissue (RQ=3.22±4.00). The ROC
curve analysis of miR-424-5p showed discriminative
accuracy with AUC=0.736 (p=0.05) (95%CI: 0.530–
0.942) with 83.3% sensitivity and 58.3% speciﬁcity. In
combination both miRNAs reach stronger discriminative
accuracy with AUC=0.750 (p=0.03) (95%CI: 0.548–
0.952) with 91.7% sensitivity and 58.3% speciﬁcity. miR-
221-3p did not show signiﬁcant data for all statistical ana-
lysis. Conclusion: These ﬁndings suggest that miR-424-5p
may plays distinct roles in tumor progression and metas-
tasis. The combination of miR-424-5p and miR-221-3p
could be potential discriminative biomarker in biomedicine.
These results may contribute to future studies on elucidating
the metastatic mechanisms of contribution miRNAs to
LSCC. Grant: The study was supported by the Science
Fund, Medical University - Soﬁa (12-D/2016).
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Bovine miRNA Mir154-c can survive human digestion
and affect human genes in epithelial cells
K. N. Felekkis
University of Nicosia, Nicosia, Cyprus
Colorectal cancer (CRC) is the second most frequent human
cancer with over 1.3 million new cases globally and over
half a million deaths per year. The global burden of CRC is
expected to increase by 60% by 2030 despite the increased
preventing screening efforts. CRC is a complex disease
caused by the interaction of both genetic and environmental
factors with diet and in particular the high consumption of
red meat (especially beef) being a risk factor for CRC
initiation. The current research focused on a novel
hypothesis regarding the molecular mechanisms behind the
initiation and progression of CRC while also addressing a
new, emerging and highly controversial scientiﬁc ﬁeld
entitled: “The Dietary XenomiR hypothesis” which, if
proven, could have imperative biomedical impact, challen-
ging our current knowledge on the nutrition-disease inter-
connection. In this proof-of-principle study we tested
whether a selected ingested beef miRNA (namely bovine
Mir154-c) has the potential to regulate human genes initi-
ating or adding to the progression of colorectal cancer.
Speciﬁcally, Mir154-c was selected after bioinformatic ﬁl-
tering and further studied for its “survival” through cooking
as well as through human digestion. Mir154-c was also
tested for its effect on human intestinal epithelial cells after
transfection. Identiﬁcation of beef miRNAs as the link
between diet and CRC will have implications for preven-
tion, risk-assessment and therapy of an increasingly fre-
quent human cancer while add to the growing and
controversial ﬁeld of “cross-species regulation by dietary
miRNA”; a phenomenon that could revolutionize our
understanding of the effect of diet on human disease.
K.N. Felekkis: None.
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Characterization of genetic variation in transcription
binding sites nearby human genes associated with Bru-
gada syndrome
M. Pinsach-Abuin1,2,3, B. del Olmo1,2, J. Mates1,2, J.
Zhang3, D. Merkurjev3, C. Allegue1,2, S. Konovalov3, F.
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Girona, Spain, 2Biomedical Research Institute of Girona
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States, 4Institute of Computational Chemistry and Catalysis,
University of Girona, Girona, Spain
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The genomic sequence of each human individual contains
thousands of genetic variations. When underlying noncod-
ing regions, genetic variations may disrupt transcription
factor (TF) binding and alter gene expression of nearby
genes, contributing to phenotypic disparity within the
human population. Here, we aimed to characterize genetic
variation at noncoding regions that may host TF binding
events nearby genes associated with Brugada syndrome
(BrS). BrS is a human cardiac disease often associated with
genetic mutations in coding regions of cardiac ion channels
(25–30%), but the contribution of non-coding variation
remains largely unknown. We have integrated data of
topological organization, chromatin accessibility, histone
marks, and TF maps in human cardiac cells, and identiﬁed
1,300 genomic regions that may host binding events of
cardiac TFs. We have selectively captured and extensively
sequenced (x100) these regions in a cohort of n= 89 BrS
patients, and using a very stringent combination of sequence
mappers and variant callers, we have identiﬁed 5,388 single
nucleotide variants (SNVs) and 1,196 insertions and dele-
tions (INDELs). To investigate their potential effects on TF
binding, we have generated TF binding proﬁles in iPSC-
derived cardiomyocytes to identify the exact location of
cardiac TF binding. Using a machine-learning algorithm,
we have predicted the potential effects of personal combi-
nations of variants (haplotypes) on cardiac TF binding,
further supported by experimental validation in luciferase
reporter assays. Together, we have identiﬁed a rich variation
in noncoding variants within BrS-associated TF binding
sites that may explain some cases of this cardiac disease.
Funding: Agaur-fellowship (MP-A), SAF2015-70823-R
(MINECO/FEDER-UE), IRG07-GA-2010-268395 (FP7-
PEOPLE)
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Epigenetic studies of ovarian cells: understanding the
aetiology and management of Polycystic Ovary
Syndrome
E. Makrinou1, A. Drong2, N. Masrour1, G.
Christopoulos3, A. Lerner1, T. Caraderi2, K. Hardy1, C.
Lindgren2, S. Franks1
1Imperial College London, Institute of Developmental and
Reproductive Biology, London, United Kingdom, 2The
Wellcome Trust Centre for Human Genetics, Oxford,
United Kingdom, 3Imperial College Healthcare NHS Trust,
London, United Kingdom
Polycystic Ovary syndrome (PCOS) is a common hetero-
geneous endocrine disorder of unknown aetiology, with
more than 5% prevalence amongst women of reproductive
age. Its main characteristic is the hypersecretion of andro-
gens, predominantly of ovarian origin that in turn can cause
infertility, hirsutism, psychological distress and metabolic
defects, with PCOS women having an increased risk of
developing type 2 diabetes and cardiovascular disease later
in life. Our hypothesis is that PCOS pathogenesis may be
explained by an integrated epigenetic model that in relation
with environmental factors, modiﬁes the effect of suscept-
ibility genes and results in disease during adult life. We
have conducted a genome wide epigenetic (EWAS) case-
control microarray study, using the EPIC BeadChip array
from Illumina, with DNA from granulosa cells (GCs) that
were obtained during IVF treatment. In total, > 861K CpG
sites were interrogated. Data from 32 samples (16 PCOS
cases and 16 controls), were analysed with linear regression
using as variables age, BMI, ovarian morphology (PCOS vs
non-PCOS), cumulative dose of FSH during ovarian sti-
mulation, number of eggs collected and type of egg
maturation trigger. Ovarian morphology as linear predictor
indicated 106 hits with p values less than the genome wide
threshold set to p<5×10−8. Amongst those hits were several
genes related to the PCOS phenotype, or had ovarian
function or localisation. A number of these targets have
been selected for further validation using Pyrosequencing.
Preliminary data indicate a trend in differential methylated
patterns following the EWAS analysis predictions.Funder
by the Genesis Research Trust
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Rapid Identiﬁcation of Small Molecules Affecting Stem
Cell Pluripotency
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Introduction: The advancement of stem cell research
has lead to a promising future for regenerative medicine.
High throughput screening (HTS) of small compounds
allows identiﬁcation of drug treatments that affect cellular
maintenance and function. However, conventional HTS
methods for identifying compounds of could be a laborious
procedure. In this study, we have applied a high throughput
96 well RNA-seq assay as a rapid yet thorough phenotyping
screen for a small compound library to identify molecules
that may affect stem cell maintenance and differentiation.
Materials and Methods: The small molecule library is
applied on a 96-well plate of human mesenchymal stem
cells (hMSCs) grown on media that promotes pluripotency.
Drug-induced hMSCs are harvested over different time
points after treatment and immediately stamped onto the BD
Precise Targeted 96-plates for rapid RNA-seq screening
studies. Libraries from 96 treatments are completed in one
day without the aid of automation.
Results and Conclusions: We were able to perform
accurate gene expression proﬁling using Molecular Index-
ing on 96 drug treatments with minimal technical errors and
PCR bias. We have identiﬁed compounds that affects
hMSC pluripotency, which can be useful for potential
protocols to drive stem cell differentiation. Moreover, this
scalable screening procedure can be used to facilitate other
HTS studies by reducing screening time and cost.
<!--EndFragment-->
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Human sphingomyelin synthase genes: from structure to
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I. B. Filippenkov, L. V. Dergunova, S. A. Limborska;
Institute of Molecular Genetics, Russian Academy of
Sciences, Moscow, Russian Federation
Introduction: Sphingomyelin synthase activity is provided
by two enzymes in cell – sphingomyelin synthase 1 (SMS1)
and sphingomyelin synthase 2 (SMS2). Sphingomyelin
synthases are essential enzymes that are involved in the
functioning of lipid metabolism in norma and pathology.
They are highly conserved in mammals and encoded by
paralogous genes (SGMS1 and SGMS2). Previously, we
have shown that the SGMS1 human gene encodes several
isoforms of mRNA as well as transcripts, which don’t
provide the synthesis of SMS1. Particularly, it has been
found the circular RNAs (circRNAs) with brain-speciﬁc
expression.
Materials and Methods: High-throughput RNA sequen-
cing “RNA-CaptureSeq”, Sanger sequencing, real-time RT-
PCR, bioinformatics.
Results: Detailed analysis of transcripts of SGMS1 gene
in the human frontal cortex and blood was carried out using
RNA-CaptureSeq. The recursive exons which are located in
the 5'-untranslated region (5'-UTR) of SGMS1 gene were
identiﬁed. Some of them are part of the circRNAs that have
predominant cytoplasmic localization and can be considered
as potential cis-regulatory molecules. In contrast to SGMS1,
SGMS2 gene doesn’t contain the multi-exons 5'-UTR, it
encodes circRNAs composed of the coding exons of the
gene. SGMS2 gene has a low level of expression, and
recursive exons are not found in their structure.
Conclusions: Sphingomyelin synthase genes have dif-
ferent structure and expression pattern that is important for
understanding the mechanisms of physiological processes
regulation in cells in norma and pathologies associated with
lipid disorders.
I.B. Filippenkov: None. L.V. Dergunova: None. S.A.
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The osteogenic differentiation via conditioned medium
of human dental pulp mesenchymal stem cell: an
experimental study
E. Ergen1, Z. Gonen1, H. Salkin2, Y. Ozkul3,4
1Stem Cell Unit Genome and Stem Cell Center (GENKOK),
Erciyes University, Kayseri, Turkey, 2Department of
Pathology Laboratory Techniques Vocational School,
Beykent University, İstanbul, Turkey, 3Department of
Medical Genetics Faculty of Medicine, Erciyes University,
Kayseri, Turkey, 4Genome Unit, Genome and Stem Cell
Center, Erciyes University, Kayseri, Turkey
Aim: The aim of study was to investigate the effect of
conditioned media of osteogenic differentiated cells on
undifferentiated mesenchymal stem cells (MSC). Materials
and Methods: hDPSCs were characterized with ﬂow cyto-
metry, immunostaining, differentiation assays. In study,
hDPSCs were differentiated with osteogenic differentiation
medium. At the end of 14 days, differentiation was assessed
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by alizarin red staining, mineralization assay, and RUNX2,
Osteopontin, Osteonectin gene expression level. Condi-
tional media were collected from differentiatied cells. Col-
lected conditional media were applied on undifferentiated
hDPSCs. On days 7 and 14, β-Gal staining and mitocondrial
activity were performed, The differentiation in the condi-
tioned medium group was assessed alizarin red staining,
mineralization assay and gene expression.Results: hDPSCs
were CD90 +, CD44 +, CD105 + and CD45-, CD34- by
ﬂow cytometry and immunoﬂuorescence staining. The
CFU-F assay showed that the cells were clonogenic. In
addition, these cells were identiﬁed by adipogenic, osteo-
genic and chondrogenically differentiated with adipo red,
alizarin red, safranin O, toluidine blue-positive stains. After
14 days, in group to treatment of conditional media,
minerals deposited on cells were positively stained with
alizarin red and mineralization assay. Real-time PCR ana-
lysis showed that expression levels of RUNX2, Osteopontin
and Osteocalcin genes were increased in cells collected at
the end of 14 days after induction but not in the control
group. There was statistically signiﬁcant difference between
the groups (p <0,05). Conclusion: The conditioned medium
obtained from osteogenic differentiated hDPSCs can create
an alternative medium for inducing osteogenic differentia-
tion of cells.
E. Ergen: None. Z. Gonen: None. H. Salkin: None. Y.
Ozkul: None.
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Telomerase inhibiton in glioma cells: Epigenetic reﬂec-
tions to therapy
G. Biray Avci, F. Dogan, Z. Abbaszadeh, B. Goker, C.
Caliskan Kurt, N. Ozateş, Z. Mutlu, O. Ozalp, C. Gunduz
Ege University Medical Faculty, İzmir, Turkey
The telomerase enzyme is low expressed or undetectable in
normal cells, but is overexpressed in human cancer cells.
Upregulation or reactivation of telomerase enzyme regulates
several cellular mechanisms such as gene expression, pro-
liferation, apoptosis, cellular metabolism and therapy
resistance. It’s emphasized that TERT regulates expression
of several gene but interaction mechanism between target
genes and TERT is still unknown. Telomerase can be
inhibited by several mechanisms. BIBR1532 is the most
studied telomerase inhibitor. It targets telomerase compo-
nents hTR and hTERT, and inhibits cancer cell growth by
shortening and decreasing functions of telomeres. We
observed that BIBR1532 treatment increased apoptosis by
2.41 fold in U87MG cells compared to control. Histone
deacetylases (HDACs) regulate chromosome structure and
are linked to the loss of genomic integrity in cancer cells.
Recent studies have demonstrated a negative correlation
between HDAC gene expression and glioma grade, sug-
gesting that HDAC4, HDAC11 might play important roles
in glioma malignancy. We found that BIBR1532 treatment
increased HDAC4 and HDAC11 gene expression levels
2,4975 and 3,0008, respectively. HDAC4 and HDAC11
gene expressions are downregulated in gliomas and might
play pivotal roles in glioma malignancy. Lysine acetyl-
transferases (KATs) family member KAT6B has tumor-
suppressor properties with histone H3 Lys23 acetyl-
transferase activity. We observed that BIBR1532 inhibitor
has increased KAT6B gene expression levels by 3,3108
fold. Consequently, we thought that inhibition of telomerase
enzyme by BIBR1532 regulates epigenetic pathways and it
is crucial to target it for glioma treatment.
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Temple syndrome: comprehensive molecular and clin-
ical ﬁndings in 32 Japanese patients
M. Kagami1, K. Nagasaki2, R. Kosaki1, R. Horikawa1, Y.
Naiki1, S. Saitoh3, T. Tajima4, T. Yorifuji5, C. Numakura6,
S. Mizuno7, A. Nakamura1, K. Matsubara1, M. Fukami1,
T. Ogata8
1National Research Institute for Child Health and Devel-
opment, Tokyo, Japan, 2Niigata University Graduate
School of Medical and Dental Sciences,, Niigata, Japan,
3Nagoya City University Graduate School of Medical
Sciences, Nagoya, Japan, 4Jichi Children's Medical Center,
Shimotsuke, Japan, 5Children's Medical Center, Osaka City
General Hospital, Osaka, Japan, 6Yamagata University
School of Medicine, Yamagata, Japan, 7Central Hospital,
Aichi Human Service Center, Aichi, Japan, 8Hamamatsu
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Purpose: Temple syndrome (TS14) is a rare imprinting
disorder caused by aberrations at the 14q32.2 imprinted
region. Here, we report comprehensive molecular and
clinical ﬁndings in 32 Japanese patients with TS14.
Methods: We performed molecular studies for TS14 in
356 Japanese patients with variable phenotypes, and clinical
studies in all the TS14 patients including previously
reported 13 Japanese patients.
Results: We identiﬁed 19 new patients with TS14, and
the total of 32 patients consisted of 23 patients with UPD
(14)mat, six patients with epimutations, and three patients
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with microdeletions. Clinical studies in infancy revealed
both Prader-Willi syndrome (PWS)-like marked hypotonia
and Silver-Russell syndrome (SRS)-compatible phenotype
in 50% of patients, PWS-like hypotonia alone in 20% of
patients, SRS-compatible phenotype alone in 20% of
patients, and non-syndromic growth failure in the remaining
10% of patients, and those in puberty showed gonadotropin-
dependent precocious puberty in 76% of patients.
Conclusion: These results suggest that TS14 is not only
a genetically diagnosed entity but also a clinically recog-
nizable disorder. Genetic testing for TS14 should be con-
sidered in patients with growth failure (and placental
hypoplasia) plus both PWS-like hypotonia and SRS-
compatible phenotypes in infancy, and/or precocious pub-
erty, as well as familial history of deletion-type Kagami-
Ogata syndrome.
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miRNA expressions of HEK-293 cell lines after Galpha
(s) protein related RIC8B transfection
U. Telli1, S. Yildirim2, E. Akbas2, E. Aslan1, S. Yilmaz1, S.
S. Oner3, I. Akalin4
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Introduction:MicroRNAs (miRNAs) are small non-coding
RNAs that regulate various cellular processes such as pro-
liferation, differentiation, apoptosis and development.
RIC8B (RIC8 Guanine Nucleotide Exchange Factor B) is a
protein coding gene that plays speciﬁc role in G alpha(s)
protein levels by positively regulates G(s) signalling. The
aim of this study is to determine the expressions of miRNAs
after RIC8B transfection.
Material and Method:We examined 16 miRNAs in cell
cultures of untransfected, transfected with ﬂuorescent pro-
tein (GFP) and GFP + RIC8B in duplicate using 1×10E6
HEK293 cells per well in 2ml of DMEM +5% FBS + 1%
Pen/Strep. miRNAs expressions were analysed by real time
PCR (RotorGene Q, Qiagen) using miScript miRNA primer
assays and SYBR Green PCR Kits (Qiagen) according to
manufacturer’s instructions.
Results: mir375 and mir146a were selectively expressed
after Galpha(s) protein related RIC8B transfection. mir125b
and mir218 were expressed by any transfected cells with
any vector (Table).
miRNA expression of HEK293 cells before and after
transfection
Control GFP GFP + RIC8B
mir-106b-3p mir-106b-3p mir-106b-3p
mir-155-5p mir-125b-3p mir-125b-3p
mir-331-3p mir-218-3p mir-218-3p
mir-331-3p mir-155-5p
mir-146a-3p*
mir-375-5p*
Discussion/Conclusions: mir375, mir146a and RIC8B
has solely been related to increased inﬂammatory
responses. Hence, mir375 and mir146a might be novel
potential targets for inﬂammation through RIC8B
related cAMP signalling.
Reference: Lu etal. 2013. PMID: 23735656,
Grant# TSG-2013-333.Research Fund of Istanbul
Medeniyet University.
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Republic of
Gonadal mosaicism in grandfather leading to the transmis-
sion of severe hemophilia A in the grandson
Khosravipour K1, Zafarghandi motlagh F1, Abiri M*3, 2,
Zeinali S*2,1
This study reports a patient affected with severe hemo-
philia A in which the germline mosaicism in the maternal
grandfather complicate the X-linked inheritance of Hemo-
philia A. Pedigree analysis suggested that the proband
would be a new and sporadic case. Genetic testing of the
proband showed the common mutation of inversionI. There
for, mother would be the obligate carrier of the mutation
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which conﬁrmed by linkage analysis and also direct
investigation of the gene. Linkage analysis was performed
using STR markers linked to the VIII gene. Testing four
uncles revealed normal results with direct methods and also
linkage analysis conﬁrmed the obtained results. On the
other hand, one of the aunts were carrier by haplotype
analysis but were negative for the familial mutation.
Maternal grandmother also was investigated. The analysis
showed no mutation and also haplotype analyses were
consistent with a normal haplotype pattern. According to
the results, the only mechanism which could justify the
scenario would be differential somatic or germline mosai-
cism of the grandfather. DNA testing may help carrier
detection but negative results will not rule out the possibi-
lity of mosaicism. Gonadal mosaicism of the male indivi-
dual is a rare event which usually occurs in female. This
observation suggests the importance of conﬁrming the
carrier status of the family members with different
approaches. The results have important implication in
pedigree analysis and genetic counseling.
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Gagalova2,4, H. H. M. Draisma2,3, S. J. White2, G.
Santen5, S. M. Kielbasa3, J. T. den Dunnen2,5, P. A. C. 't
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ical Center, Leiden, Netherlands, 3Department of Medical
Statistics and Bioinformatics, Leiden University Medical
Center, Leiden, Netherlands, 4GenomeScan B.V., Leiden,
Netherlands, 5Department of Clinical Genetics, Leiden
University Medical Center, Leiden, Netherlands
X-inactivation is a well-established dosage compensation
mechanism ensuring similar X-chromosomal gene expres-
sion in both sexes. In female carriers of alleles causing X-
linked recessive disorders, inactivation of the X-
chromosomal copy carrying the healthy allele may cause
symptoms. Predominant inactivation of either the maternal
or the paternal copy of the X-chromosome in a given
individual is usually considered to be driven either by
chance or by the presence of a selective allele. We used
blood-derived RNA-sequencing data from female offspring
of trios in the Genome-of-the-Netherlands (GoNL) project
to establish: 1) the parental origin for all X-linked
heterozygous SNP alleles and 2) the median ratios of
paternal over total read counts in an individual, at all het-
erozygous SNPs covered by more than ten reads. We
observed that median ratios away from 0.5, indicative of
skewing, are common in the population. Random X-
inactivation in the 8-cell germinal stage is sufﬁcient to
explain the observed range. Our observations are consistent
with those obtained with assays measuring the methylation
status of the AR locus, but now extend these to the entire X-
chromosome. Strikingly, many of the genes known to
escape X-inactivation demonstrate a similar skewing as
non-escapee genes, indicating that their escape from X-
inactivation is not common in the blood. Collectively, our
data suggest that skewed X-inactivation is common in the
female population, and affects the far majority of genes.
This may contribute to manifestation of symptoms in car-
riers of alleles causing recessive X-linked disorders. This
research was ﬁnancially supported by BBMRI-NL, NWO
grant 184021007, 184033111.
E. Shvetsova: None. A. Sofronova: None. R. Mon-
ajemi: None. K. Gagalova: A. Employment (full or part-
time); Signiﬁcant; Genome Scan B.V.. H.H.M. Draisma:
None. S.J. White: None. G. Santen: None. S.M. Kielbasa:
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De novo truncating mutations in ZNF148, a transcrip-
tional regulator with possible involvement in the epige-
netic machinery cause global developmental delay,
absent or hypoplastic corpus callosum, and dysmorphic
facies (GDACCF) syndrome (OMIM # 617260)
A. F. Elias1, S. J. C. Stevens2, A. J. van Essen3, C. M. A.
van Ravenswaaij3, J. A. Haven1, S. H. Lelieveld4, R.
Pfundt4, W. M. Nillesen4, H. G. Yntema4, K. van
Roozendaal2, A. P. Stegmann2, C. Gilissen4, H. G.
Brunner2
1Department of Medical Genetics, Shodair Children's
Hospital, Helena, MT, United States, 2Department of
Clinical Genetics, Maastricht University Medical Center,
Maastricht, Netherlands, 3Department of Genetics, Uni-
versity Medical Center Groningen, Groningen, Nether-
lands, 4Department of Genetics, Radboud University
Medical Center, Nijmegen, Netherlands
Introduction Mutations in components of epigenetic reg-
ulatory networks cause diverse disorders and syndromes of
which some are linked to the emerging group of Mendelian
disorders of the epigenetic machinery (MDEM). Krüppel-
type zinc ﬁnger genes (ZNF) constitute a large gene family
encoding proteins that recognize speciﬁc DNA motifs in
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gene promoters. They act as transcriptional co-activators or
-repressors via interaction with chromatin remodeling pro-
teins and other transcription factors.
Methods Routine diagnostic exome sequencing data
were obtained from 2,172 patients with intellectual dis-
ability and/or multiple congenital anomalies.
Results Truncating de novo mutations in the last exon of
ZNF148 were identiﬁed in four individuals with a newly
recognized syndrome characterized by global develop-
mental delay, absent or hypoplastic corpus callosum (ACC),
and dysmorphic facies (GDACCF, OMIM #617260). Other
features include short stature, micro-/macrocephaly, cardiac
and renal malformations. Among the target genes hypo-
thetically linked to the phenotype are GHR, PKD1, PKD2,
and CTNNB1, the latter associated with ACC. ZNF184 also
interacts with histone deacetylases (HDAC) and histone
acetyltransferase EP300 suggesting a possible link to the
epigenetic machinery. One patient presented with features
reminiscent of Floating Harbor syndrome and Rubinstein-
Taybi syndrome. Pathways regulated by EP300-ZNF148
interactions may be involved in chromatin remodeling by
histone deacetylation via complexing with HDAC.
Conclusion Some phenotypic features observed in indi-
viduals with ZNF184 mutations might be related to epige-
netic effects. Characteristics shared with MDEM include
neurodevelopmental dysfunction, abnormal growth, and
variable organ involvement. Identiﬁcation of a distinct
phenotype in individuals with mutations in ZNF184 will
help elucidating its role in neurodevelopment.
A.F. Elias: None. S.J.C. Stevens: None. A.J. van
Essen: None. C.M.A. van Ravenswaaij: None. J.A.
Haven: None. S.H. Lelieveld: None. R. Pfundt: None. W.
M. Nillesen: None. H.G. Yntema: None. K. van Roo-
zendaal: None. A.P. Stegmann: None. C. Gilissen: None.
H.G. Brunner: None.
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P18.01A
A genetic overview of Atlantic coastal populations from
Europe and North-West Africa based on a 17 ×-STR
panel
E. Prieto-Fernández1, A. Díaz-de Usera1, M. Baeta1, C.
Núñez1, F. Chbel2, S. Nadiﬁ3, K. Rouault4, C. Férec4, O.
Hardiman5,6, F. Pinheiro7, M. M. de Pancorbo1
1BIOMICs Research Group, Lascaray Research Center,
University of the Basque Country UPV/EHU. Avda. Miguel
de Unamuno, 3, 01006, Vitoria-Gasteiz, Spain, 2Labora-
toire National De Référence, Université Mohammed IV des
Sciences de la Santé, Boulevard Mohamed Taieb Naciri,
Hay El Hassani, BP 82403, Casa Oumrabii, Casablanca,
Morocco, 3Laboratoire de Génétique Humaine, Faculté de
Médecine et de Pharmacie, Université Hassan II, Casa-
blanca, Morocco, 4Inserm, UMR 1078, France, Université
de Bretagne Occidentale, Brest, France, Etablissement
Français du Sang, Bretagne, CHRU Brest, Hôpital Morvan,
Laboratoire de Génétique Moléculaire et d’Histocompati-
bilité, Brest, France, 5Academic Unit of Neurology, Trinity
Biomedical Sciences Institute, Dublin, 2, Ireland, 6Depart-
ment of Neurology, Beaumont Hospital, Dublin, 9, Ireland,
7Delegação do Norte do Instituto Nacional de Medicina
Legal, Jardim Carrilho Videira, 4050-167, Porto, Portugal
Introduction: The forensic use of X-STRs requires allele
and haplotype frequency databases for the populations
where they are going to be used. Recently, a new 17 ×-STR
panel has been developed and an updated Spanish allele and
haplotype frequency database has been performed. Being
the only database available up to now for this new multi-
plex, the objective of this work was to broaden the forensic
applicability of this panel to other Atlantic coastal popula-
tions since they have experienced genetic exchanges
throughout history.
Materials and Methods: 513 individuals from four
different populations located on the Atlantic Coast of Eur-
ope and North-West Africa, i.e. Brittany (France), Ireland,
northern Portugal, and Casablanca (Morocco) were studied,
and pairwise FST genetic distances between the analyzed
populations and others from the Atlantic Coast were
calculated.
Results: Allele and haplotype frequency databases, as
well as parameters of forensic interest are presented. Our
results suggest that certain nearby populations located on
the European Atlantic coast could have undergone episodes
of genetic interchange as they have not shown statistically
signiﬁcant differentiation between them. However, the
autochthonous Basque Country and Brittany populations
have shown distinctive allele frequency distributions
between them. In contrast, the population of Casablanca
showed signiﬁcant differentiation with the majority of the
European populations.
Conclusions: These ﬁndings seem to support that the use
of independent allele and haplotype frequency databases for
each population instead of a global database would be more
appropriate for forensic purposes.
Funds were provided by the Basque Government (Grupo
Consolidado IT833-13).
E. Prieto-Fernández: None. A. Díaz-de Usera: None.
M. Baeta: None. C. Núñez: None. F. Chbel: None. S.
Nadiﬁ: None. K. Rouault: None. C. Férec: None. O.
Hardiman: None. F. Pinheiro: None. M. M. de Pan-
corbo: None.
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How migration and sociopolitical institutions have
shaped the genetic structure of present-day Democratic
Republic of Congo
L. van Dorp1, N. Ansari-Pour2, S. Lowes3, J. Weigel4, J.
Robinson5, J. Henrich6, M. G. Thomas1, N. Nunn3, G.
Hellenthal1
1Department of Genetics, Evolution and Environment,
University College London, London, United Kingdom,
2Faculty of New Sciences and Technology, University of
Tehran, Tehran, Iran, Islamic Republic of, 3Department of
Economics, University of Havard, Boston, MA, United
States, 4Department of Government, University of Havard,
Boston, MA, United States, 5Harris School of Public Policy,
University of Chicago, Chicago, IL, United States,
6Department of Human Evolutionary Biology, University
of Havard, Boston, MA, United States
The Democratic Republic of Congo (DRC) has been largely
uncharacterised from a genetics perspective. This is despite
its pivotal location in West-Central Africa; a region
important for understanding the migrations of Bantu-
speaking peoples and sub-Saharan African genetic diver-
sity in general. Here we provide the ﬁrst genome-wide
assessment of population structure in the Kasai region of the
DRC by analysing novel genotype data from 693 indivi-
duals from 27 ethnic groups. We demonstrate that popula-
tion structure in the region is extremely subtle and
haplotype based approaches such as chromosome painting
offer greater resolution when inferring ﬁne-scale differences
between ethnic groups. Using GLOBETROTTER we
detected admixture in the ancestry of multiple DRC groups
at the time of a late Bantu expansion associated with
metallurgy. In addition, we explored the genetic legacy of
the pre-colonial political dynasty of the Kuba Kingdom
which existed in Kasai from the early 17th century until the
DRC became a Belgian colony in the early 1900s. By
comparing patterns of haplotype sharing we demonstrate
that the existence of this Kingdom seems to have acted to
promote genetic diversity relative to surrounding regions
outside the Kingdom. In this way, we provide a character-
isation of the genetic structure of the DRC as well as a
compelling example of where a socio-political system
appears to have directly impacted patterns of human genetic
diversity.
LvD is supported by CoMPLEX via EPSRC (grant
number EP/F500351/1).
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The genetic basis of lactase persistence in ethnically
diverse african populations
A. Ranciaro1, E. Eyermann1, S. Thompson1,2, D.
Woldemeskel3, S. Fagbemi1, W. Beggs1, G. Belay4, T.
Nyambo5, S. W. Mpoloka6, S. Tishkoff1,7
1university of pennsylvania, philadelphia, PA, United
States, 2Queen Mary University of London, London, United
Kingdom, 3Addis Ababa University, Biology Department,
Addis Ababa, Ethiopia, 4Addis Ababa University, Biology
Department, addis ababa, Ethiopia, 5Department of
Biochemistry, Muhimbili University of Health and Allied
Sciences, Dar es-Salaam, Tanzania, United Republic of,
6Department of Biological Sciences, University of Bots-
wana, Gaborone, Botswana, 7Department of Biology,
University of Pennsylvania, Philadelphia, PA, United States
In most humans, levels of lactase, an enzyme encoded by
LCT, decrease after weaning leading to a reduced ability to
digest lactose, the primary sugar found in milk, referred to
as “lactase non-persistence” (LNP). However, some indi-
viduals maintain high expression of lactase and are able to
digest lactose into adulthood, “lactase persistence” (LP). LP
is a recent adaptive trait and has evolved in populations that
practice milk production and consumption. We sequenced
555 bp in intron 13 of MCM6 gene, a candidate enhancer
region for LCT where LP-associated variants have been
identiﬁed in European and African populations. Our sample
consists of 641 individuals from 4 Tanzanian populations,
641 individuals from 18 Ethiopian populations and 650
individuals from 8 Botswana populations that practice
diverse subsistence methods. In addition to genetic data,
phenotypic data from a lactose tolerance test were collected
in a subset of 209 Tanzanian individuals, 151 Ethiopian
individuals and 50 Botswana individuals. We conducted a
genotype-phenotype association analysis, tests of neutrality
and we reconstructed the haplotypes network. We con-
ﬁrmed an association between LP and the C-14010 variant
in Tanzania and for the ﬁrst time we identiﬁed the C-14010
and G-13915 variants in the Hadza of Tanzania, tradition-
ally hunter-gatherers. The G-13915 variant had not been
identiﬁed in Tanzanian populations previously studied. The
G-13907 variant was not found in the Tanzanians but was
identiﬁed in the Ethiopians. Tests of neutrality based on
EHH and iHS statistics indicated evidence for strong recent
selection of these genetic variants.
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P18.04D
Immunochip meta analysis and follow up study in alo-
pecia areata
A. Tafazzoli1, T. Vaitsiakhovich2, L. Pethukova3, S.
Heilmann-Heimbach1, S. Redler4, R. Kruse5, B.
Blaumeiser6, M. Böhm7, G. Lutz8, H. Wolff9, U. Blume-
Peytavi10, A. Christiano11, P. Kokordelis1, M. Nöthen1, R.
Betz1
1Human genetics, bonn, Germany, 2Institute for Medical
Biometry, Informatics and Epidemiology, bonn, Germany,
3Department of Dermatology and Epidemiology, NY, NY,
United States, 4Human Genetics, Düsseldorf, Germany,
5Dermatological Practice, Paderborn, Germany, 6Depart-
ment of Medical Genetics, Antwerp, Belgium, 7Department
of Dermatology, Münster, Germany, 8Hair & Nail,
Dermatological Practice, Wesseling, Germany, 9Depart-
ment of Dermatology, Münich, Germany, 10Clinical
Research Center for Hair and Skin Science, Berlin,
Germany, 11Department of Epidemiology, NY, NY, United
States
Background: Alopecia areata (AA) is a common hair loss
disorder that affects both sexes and all age groups. AA is
thought to be an autoimmune disease directed against the
hair follicle. Genome-wide association studies have identi-
ﬁed more than 10 susceptibility loci for AA; however, a
large percentage of the heritable risk still awaits identiﬁ-
cation. To provide further insight into immune nature of
AA, we performed an immunochip meta-analysis and are
now following up the best results using a Sequenom assay
to identify novel susceptibility loci.
Method: We conducted the meta-analysis combining
data from our US calibrators and own sample studies on
Illumina BeadChip arrays including 1,096 cases and 3,176
controls of CEU origin. Synthesis of regression slopes
(MSRS) was used for the analyses which are implemented
in METAINER package. We chose the most 25-promising
candidate SNPs for the follow-up step. These are examined
with the Sequenom MassARRAY iPLEX Platform in an
independent AA sample (CEU) comprising 1,459 cases and
970 controls.
Results: The Meta-analysis identiﬁed 49 novel loci with
a suggestive p-value of PBecker-Wu ≤ 10
−3 (PHet ≥ 0.01).
Among them, NFKB is the most signiﬁcant locus (PBecker-Wu
=1.5 ×10
−07). We considered the 19 most signiﬁcant loci
(lower P-Becke-Wu value) for the follow-up step. The experi-
ments are ongoing and results will be presented at the
meeting.
Conclusion: Despite the recent identiﬁcation of sus-
ceptibility loci for AA, our understanding of the genetics of
AA is incomplete. Identiﬁcation of new loci may lead to a
better elucidation of disease pathophysiology.
A. Tafazzoli: None. T. Vaitsiakhovich: None. L.
Pethukova: None. S. Heilmann-Heimbach: None. S.
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GWAS meta-analysis yields novel insights into the
biology of male-pattern baldness
S. Heilmann-Heimbach1,2, C. Herold3, L. M. Hochfeld1,2,
A. M. Hillmer4,5, D. R. Nyholt6, J. Hecker7, A. Javed4, E.
G. Y. Chew4, S. Pechlivanis8, D. Drichel9, X. Heng4, R. C.
H. del Rosario10, H. L. Fier7,11, R. Paus12, R. Ruedi13,14, T.
E. Galesloot15, S. Moebus8, T. Anhalt1,2, S. Prabhakar10,
R. Li16, S. Kanoni17, G. Papanikolaou18, G.
Papanikolaou18, Z. Kutalik14,19, P. Deloukas17,20, M. P.
Philpott21, G. Waeber22, T. D. Spector23, P.
Vollenweider22, L. A. L. M. Kiemeney15, G. Dedoussis18, J.
B. Richards23,16, M. Nothnagel9, N. G. Martin24, T.
Becker25, D. A. Hinds26, M. M. Nöthen1,2
1Department of Genomics, Life & Brain Center, University
of Bonn, Bonn, Germany, 2Institute of Human Genetics,
University of Bonn, Bonn, Germany, 3German Center for
Neurodegenerative Disorders (DZNE), Bonn, Germany,
4Cancer Therapeutics and Stratiﬁed Oncology, Genome
Institute of Singapore, Singapore, Singapore, 5TRON-
Translational Oncology at the University Medical Center
of Johannes Gutenberg University, TRON gGmbH, Mainz,
Germany, 6Institute of Health and Biomedical Innovation,
Queensland University of Technology, Brisbane, Australia,
7Institute of Genomic Mathematics, University of Bonn,
Bonn, Germany, 8Institute of Medical Informatics, Biometry
and Epidemiology, Medical Faculty, University of Duis-
burg-Essen, Essen, Germany, 9Cologne Center for Geno-
mics, Cologne, Germany, 10Computational and Systems
Biology, Genome Institute of Singapore, Singapore, Singa-
pore, 11Department of Biostatistics, Havard School T.H.
Chan pf Public Health, Boston, MA, United States, 12Der-
matology Research Center, Institute of Inﬂammation and
Repair, University of Manchester, Manchester, United
Kingdom, 13Department of Computational Biology, Uni-
versity Lausanne, Lausanne, Switzerland, 14Swiss Institute
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of Bioinformatics, Lausanne, Switzerland, 15Radboud
Institute for Health Sciences, Radboud University Medical
Center, Nijmegen, Netherlands, 16Center for Clinical
Epidemiology, Departments of Medicine, Genetics and
Epidemiology, Lady Davis Instiute of Medical Research,
Jewish General Hospital, McGill University, Montreal, QC,
Canada, 17William Harvey Research Institute, Barts and
The London School of Medicine and Dentistry, Queen Mary
University of London, London, United Kingdom, <su
Male-pattern baldness (MPB) is a highly heritable trait and
the most common form of hair loss among men. It is
characterized by androgen-dependent, progressive loss of
hair from the scalp. So far, genetic MPB research has
identiﬁed 12 risk loci and has already implicated several
plausible candidate genes. However, a signiﬁcant fraction of
the overall heritable risk still awaits identiﬁcation and no
conclusive data exist on how these genetic risk factors
contribute to the key pathophysiological signs of MPB.
Here, we carried out a large GWAS meta-analysis of MPB,
comprising 10,846 early-onset cases and 11,672 controls
from eight independent European cohorts. We identify 63
MPB-associated loci (P<5×10−8) of which 23 have not been
reported previously. The 63 loci explain ~39% of the phe-
notypic variance in MPB and highlight novel candidate
genes and pathways that are likely to be implicated in the
key-pathophysiological features of MPB such as deregula-
tion of the hair growth cycle (FGF5,EBF1,DKK2,adipo-
genesis); increased androgen sensitivity (SRD5A2,
melatonin signalling); and transformation of pigmented
terminal hair into unpigmented vellus hair (IRF4). In
addition to conﬁrming the involvement of well-established
pathways that control hormonal status (androgen metabo-
lism, oestrogen signalling) and hair follicle cycling (WNT-
signalling, EGF-signalling), our data support the importance
of less-well studied biological contexts, such as the invol-
vement of perifollicular macrophages and adipocytes in
MPB development. Moreover, our data provide molecular
evidence that rather than being an isolated trait, MPB shares
a biological basis with numerous other human phenotypes
such as body height, skin-/hair-pigmentation, prostate can-
cer and cardiovascular traits.
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Genetic structure of the Armenian population based on
genome-wide data
A. Hovhannisyan, Z. Khachatryan, L. Yepiskoposyan
Institute of Molecular Biology NAS RA, Yerevan, Armenia
Located at the crossroads of Europe and the Middle East,
the Armenian Highland played a crucial role in the ancient
migrations of Anatomically Modern Human (AMH). The
region was a migratory pathway for the Neolithic farmers
from the Near East and, relatively recently, for different
tribes and ethnic groups. This may have had an impact on
the genetic structure of the Armenians, who have inhabited
the region over several millennia.
We applied the genome-wide SNP proﬁles for 31
Armenian samples and compared these with previously
published data sets from the populations of Europe, the
Near East, Central Asia and the North Caucasus. Further-
more, we analyzed genome-wide data of 202 ancient indi-
viduals from across Eurasia, including 17 Chalcolithic and
Bronze Age samples from the eastern regions of the
Armenian Highland.
The genetic makeup of Armenians mainly consists of the
Near Eastern and Caucasus components, of which the for-
mer has relatively higher contribution in respect to that of
the populations of the North Caucasus. On the genetic
landscape, Armenians occupy an intermediate position
between the Near Eastern populations, on one side, and
European and Caucasian clusters, on the another side.
Moreover, we detected the presence of genetic continuity
between modern Armenians and ancient inhabitants of the
Armenian Highland.
On the whole, the modern Armenian gene pool preserves
main features of the ancestral population of the Armenian
Highland, the origin of which should be attributed to at least
the Chalcolithic.
The work was supported by Armenian National Science
and Education Fund (ANSEF-2017 Hubio-4562).
A. Hovhannisyan: None. Z. Khachatryan: None. L.
Yepiskoposyan: None.
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GENEVARASSOC and SCOREASSOC - programs to
facilitate gene-based analyses of next generation
sequence data
D. Curtis
UCL Genetics Institute, London, United Kingdom
Introduction: Whole exome or genome sequence (WES,
WGS) data provides information on very large numbers of
variants. We have previously described a weighted burden
method of gene-based analysis which is implemented in the
SCOREASSOC program. Variants which are rare and/or
predicted to have a functional effect are weighted more
highly than others.
Method: A program called GENEVARASSOC has been
written in C++ to conveniently produce input ﬁles for
SCOREASSOC from standard VCF ﬁles such as would be
produced in a case-control WES or WGS study. The pro-
gram automatically extracts all variants for a particular
gene. It annotates them according to either inbuilt functions
or using Variant Effect Predictor (VEP). User-deﬁned
expressions allow for arbitrarily complex weighting
schemes and exclusion criteria to be speciﬁed according to a
variety of variant features: inbuilt or VEP annotations;
annotations stored externally such as SIFT and POLY-
PHEN results; allele frequencies in ExAC or 1KG; geno-
type quality scores; other characteristics of the variant. The
programs were applied to a WES sample of over
11,000 schizophrenia cases and controls.
Results: All genes can be analysed within a few hours.
The weighting schemes and exclusion criteria can be altered
and analyses repeated so that the gene-wise p values
obtained using different weighting schemes and exclusion
criteria can be compared. Discussion: GENEVARASSOC
provides a convenient means of setting up analyses for
SCOREASSOC and provides the user with a great deal of
power and ﬂexibility. The source code, documentation and
example ﬁles can be downloaded at: https://github.com/da
venomiddlenamecurtis/geneVarAssoc
D. Curtis: None.
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The causal effect of BMI on the metabolome proﬁle in
childhood
M. Ward, T. Gaunt, C. Relton
University of Bristol, Bristol, United Kingdom
Introduction: Numerous studies have observed strong
associations between adiposity and the metabolome, how-
ever few of these studies investigated the direction of the
causal pathway in these relationships. We used Mendelian
randomization (MR) to investigate whether BMI has a
causal effect on the metabolome in childhood.
Methods: We investigated the relationship between BMI
and 160 metabolite measures in children age 7 years in the
Avon Longitudinal Study of Parents and Children (n=
~5400 children). Having observed associations between
BMI and several of the metabolite measures, we used a BMI
allele score to perform MR analysis to assess whether our
observed associations between BMI and metabolites
represent a causal effect of BMI on the metabolome.
Results: We observed associations between BMI and
106 metabolite measures (using Bonferroni correction p <
0.05/160 ≈ 0.0003). We observed associations for almost all
of the VLDL concentration measures, the majority of the
HDL concentration measures, and several other measures
including diacylglycerol, cholines, apolipoproteins, fatty
acids and amino acids. The causal effect estimates from MR
analyses were mostly directionally consistent with the
observational estimates, however the conﬁdence intervals of
the causal effect estimates were wide and the majority of
them spanned zero.
Conclusions: We observed strong evidence of associa-
tions between BMI and several metabolite measures in 7-
year-old children. The results of our MR analyses suggest
that BMI may have a causal effect on some components of
the metabolome, however the evidence is not conclusive.
MW is supported by Wellcome Trust 099873/Z/12/Z.
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XPAT: A toolkit to conduct cross-platform association
studies with heterogeneous sequencing datasets
Y. Yu1, H. Hu1, R. J. Bohlender1, F. Hu1, J. Chen1, C.
Holt2, J. Fowler1, P. Scheet1, M. Hildebrandt1, M.
Yandell2, C. D. Huff1
1The University of Texas MD Anderson Cancer Center,
Houston, TX, United States, 2University of Utah, Salt Lake
City, UT, United States
High-throughput sequencing data is increasingly being
made available to the research community for secondary
analyses, providing new opportunities for large-scale asso-
ciation studies. However, heterogeneity in target captures
and sequencing technologies often introduce strong tech-
nological stratiﬁcation biases that overwhelm subtle signals
of association in studies of complex traits. Here, we
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introduce the Cross-Platform Association Toolkit, XPAT,
which provides a suite of tools designed to support large-
scale association studies with heterogeneous sequencing
datasets. XPAT includes tools to support cross-platform
aware variant calling, quality control ﬁltering, gene-based
association testing, and rare variant effect size estimation.
To evaluate the performance of XPAT, we conducted
whole-exome case-control association studies with 783
breast cancer cases, 272 ovarian cancer cases, and
1,722 shared controls using sequencing data from multiple
sources. XPAT greatly reduced Type I error inﬂation in the
case-control analyses, while replicating many previously
identiﬁed cancer-gene associations. We also show that
association tests conducted with XPAT using cross-
platform data have comparable performance to tests using
matched platform data. XPAT enables new association
studies which combine existing sequencing datasets to
identify novel genetic loci associated with common diseases
and other complex traits.
This work was supported by US National Institutes of
Health grants R01 CA195614, R01 GM104390, and R01
HG005859.
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Association of VEGF Polymorphisms with Breast Can-
cer Risk in North Indians
K. Guleria1, R. Kapahi1, V. Sambyal1, M. Manjari2, M.
Sudan3, M. S. Uppal4, N. R. Singh4
1Human Cytogenetics Laboratory, Department of Human
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India, Amritsar, India, 2Department of Pathology, Sri Guru
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Amritsar, Punjab, India, Amritsar, India, 3Department of
Radiotherapy, Sri Guru Ram Das Institute of Medical
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India, 4Department of Surgery, Sri Guru Ram Das Institute
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Objectives: To investigate the potential association of ten
promoter (-2578C/A, -2549I/D, -460T/C, -417T/C, -172C/
A, -165C/T, -160C/T, -152G/A, -141A/C and -116G/A),
two 5′-UTR (+405C/G, -7C/T) and one 3′-UTR (+936C/T)
polymorphisms of VEGF with breast cancer risk in patients
from Punjab, North-West India. Methods: The DNA
samples of 250 breast cancer patients and 250 age and
gender matched controls were screened for thirteen selected
VEGF using direct PCR, PCR-RFLP and Sanger sequen-
cing. Results: Of 250 breast cancer patients, 7 were males
and 243 were females. About 73.6% of patients developed
breast cancer after 40 years of age. There was a signiﬁcant
association of VEGF -2578AA, -2549II, -460CC, +405GG,
-152AAand -116AA genotypes with increased breast cancer
risk. VEGF -165CT and -141AC genotypes were associated
with decreased risk for breast cancer. Linkage dis-
equilibrium analysis revealed that VEGF -2578C/A and
-2549I/D, -2578C/A and -460T/C, -2549I/D and -460T/C
and -165C/T and -141A/C polymorphisms were in strong
linkage disequilibrium. Haplotype analyses revealed that
VEGF -2578A/-2549I/-460C/+405G/-7C/+936C and
-417T/-172C/-165C/-160C/-152A/-141A/-116A combina-
tion was associated with increased risk while combination
-2578C/-2549D/-460T/+405G/-7C/+936C was associated
with decreased risk for breast cancer. Analysis using
TFSEARCH software revealed that VEGF -2578C/A,
-417T/C, -172C/A and +405C/G polymorphisms altered
the binding site of speciﬁc transcription factors. Conclu-
sion: In this case-control study, VEGF -2578C/A, -2549I/D,
-460T/C, +405C/G, -165C/T, -152G/A, -141A/C and
-116G/A polymorphisms were associated with suscept-
ibility to breast cancer in patients from Punjab, North-West
India.
K. Guleria: None. R. Kapahi: None. V. Sambyal:
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The heritable basis of gene-environment interactions in
cardiometabolic traits
A. Poveda1,2, Y. Chen1, A. Brändström3, E. Engberg3, G.
Hallmans3, I. Johansson3, F. Renström1,3, A. Kurbasic1,
P. W. Franks1,3,4
1Lund University, Malmö, Sweden, 2University of the
Basque Country (UPV/EHU), Bilbao, Spain, 3Umeå Uni-
versity, Umeå, Sweden, 4Harvard T.H. Chan School of
Public Health, Boston, MA, United States
Introduction: Little is known about the heritable basis of
gene–environment interactions in humans. Therefore, mul-
tiple cardiometabolic traits were screened to assess the
probability that they are inﬂuenced by genotype–environ-
ment interactions.
Materials and Methods: 14 established environmental
risk exposures and 11 cardiometabolic traits were analysed
in the VIKING study, a cohort of 16,430 Swedish adults
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from 1682 extended pedigrees, using a maximum likelihood
variance decomposition method in SOLAR software.
Results: All cardiometabolic traits had statistically sig-
niﬁcant heritability estimates (range: 24%-47%). Genotype–
environment interactions were detected for age and sex (for
the majority of traits), physical activity (for triacylglycerols,
2h glucose and DBP), smoking (for weight), alcohol intake
(for weight, BMI and 2h glucose) and diet pattern (for
weight, BMI, glycaemic traits and SBP). Genotype–age
interactions for weight and SBP, genotype–sex interactions
for BMI and triacylglycerols and genotype–alcohol intake
interactions for weight remained signiﬁcant after multiple
test correction.
Conclusions: Statistically signiﬁcant evidence for
genotype-environment interaction was found for several
cardiometabolic traits. Age, sex and alcohol intake are
likely to be major modiﬁers of genetic effects for a range of
cardiometabolic traits. This information may prove valuable
for studies that seek to identify speciﬁc loci that modify the
effects of lifestyle in cardiometabolic disease.
Funding: The study was funded by the Swedish Heart–
Lung Foundation, Novo Nordisk, the Swedish Research
Council, and the European Research Council. AP was
funded in part by a postdoctoral grant from the Basque
Government and a research grant from the Swedish
Research Council.
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Repeated expansion of human amylase genes create
multiple independent CNV series
N. A. A. Shwan1, S. Louzada2, F. Yang2, J. A. L. Armour1
1University of Nottingham, Nottingham, United Kingdom,
2Wellcome Trust Sanger Institute, Cambridge, United
Kingdom
Introduction: The human amylase gene family is highly
copy number variable, and the salivary (AMY1) and pan-
creatic (AMY2A and AMY2B) amylase genes encode the
starch-digesting enzyme expressed in the salivary gland and
pancreas, respectively. High AMY1 copy number (CN) has
been shown to be correlated with adaptation to human
dietary starch intake, and low AMY1 CN reported to be a
predisposition factor to obesity. Reliable measurement
methods and accurate structural characterisation of the
region are important to address such ﬁndings.
Methods: We used high-resolution measurement meth-
ods and segregation analysis in trios to show independent
allelic series of amylase CN variants (CNV) in sub-Saharan
Africans. To conﬁrm the haplotype compositions we used
ﬁbre-FISH (Fluorescence in situ hybridization), which
revealed some structural complexity difﬁcult to observe
using conventional methods.
Results: Our work showed rearrangements including
multiple expansion of a unit containing one copy each of
AMY1, AMY2A and AMY2B. Overall, our data demonstrated
at least ﬁve independent rearrangements of pancreatic
amylase genes, in which the region has undergone homo-
logous and non-homologous rearrangements to create new
haplotypes, some of which contain ﬁve copies each of the
AMY2A and AMY2B genes.
Conclusions: Structural features shared by fundamen-
tally distinct lineages strongly suggest that the common
ancestral state for the human amylase cluster contained
more than one, and probably three, copies of AMY1. The
additional rearrangements we have discovered in the pan-
creatic amylase genes suggest that the pancreatic amylase
genes should be taken into account when evaluating the
adaptive signiﬁcance of variation in this gene cluster.
N.A.A. Shwan: None. S. Louzada: None. F. Yang:
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EUROlinkCAT - a HORIZON2020 study 2017–2021
I. Barisic1, J. K. Morris2, M. Loane3, E. Garne4, J.
Rankin5, J. Densem6, A. J. Neville7, A. Pierini8, H. E. K.
de Walle9, EUROlinkCAT Consortium
1Children's Hospital Zagreb, Medical School University of
Zagreb, Zagreb, Croatia, 2Queen Mary University of
London, London, United Kingdom, 3Ulster University,
Belfast, United Kingdom, 4Hospital Lillebaelt, Kolding,
Denmark, 5Newcastle University, Newcastle upon Tyne,
United Kingdom, 6BioMedical Computing Limited, St
Leonards on Sea, United Kingdom, 7University of Ferrara,
Ferrara, Italy, 8CNR Institute of Clinical Physiology, Pisa,
Italy, 9Department of Genetics, Groningen, Netherlands
Introduction: Congenital anomalies (CA) are the leading
cause of stillbirth and infant mortality and an important
contributor to childhood morbidity. Over 130,000 children
with CA are born in Europe each year. Their physical,
mental and social handicaps are a signiﬁcant burden on the
health care, social and educational services. Still, compre-
hensive epidemiological and clinical data on morbidity,
treatment, and education of these patients are lacking.
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Methods: The Horizon2020 funded EUROlinkCAT
project will support 21 EUROCAT registries from 13
European countries to link their data on children with CA to
mortality, hospital discharge, prescription and educational
databases. Each registry will send standard aggregate tables
and analysis results to a Central Results Repository (CRR).
Registries will use a novel sustainable e-forum, “Con-
nectEpeople”, to link families with local/national and
international registries and information resources allowing a
meaningful dissemination of project outcomes.
Results: The CRR will contain standardised data and
analyses on an estimated 200,000 children with a CA born
1995–2014 up to age 10, enabling hypotheses on their
treatment, health and education to be investigated at the EU
level. This will provide evidence to inform national treat-
ment guidelines and screening programs, and to optimise
management. The geographical differences in morbidity
and mortality and an economic evaluation of the hospitali-
sation costs associated with CA will be presented.
Conclusion: This enhanced information on prognosis,
outcome, geographical differences in morbidity and mor-
tality at the European level will allow optimisation of per-
sonalised care and treatment decisions for children with
CAs, hopefully reducing health inequalities in Europe.
(H2020-SC1-2016-RTD:733001)
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Common and rare copy number variants at chromo-
somes 3q13, 12p12 and 14q11 are associated with
sporadic colorectal cancer risk
P. Cheah1,2, L. Thean1, Y. Low1, M. Lo1, Y. Teo2, W.
Koh2, J. Yuan3, M. Chew1, C. Tang1
1Singapore General Hospital, Singapore, Singapore,
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Introduction: Multiple single nucleotide polymorphisms
have been associated with colorectal cancer (CRC) risk. The
role of structural or copy number variants (CNV) in CRC,
however, remained unclear. Methods: We performed a
genome-wide association study on 1,000 Singapore Chinese
patients aged 50 or more with no family history of CRC and
1,000 ethnicity-, age-, and gender-matched healthy controls
using the Affymetrix SNP 6 platform. After 16 principal
component corrections, univariate and multivariate seg-
mentations followed by association testing were performed
on 1830 samples that passed quality assurance tests.
Results: A rare copy number variant region (CNVR) at
chromosome 14q11 (Odds Ratio (OR) =1.92 {95% CI
1.59–2.32}, p=2.7e-12) encompassing CHD8, and com-
mon CNVR at chromosomes 3q13.12 (OR=1.54 {95% CI
1.33–1.77}, p=2.9e-9) and 12p12.3 (OR=1.69 {95% CI
1.41- 2.01}, p=2.8e-9) encompassing CD47 and RERG/
ARHGDIB respectively were signiﬁcantly associated with
CRC risk. CNV loci were validated in an independent
replication panel using an optimized copy number assay.
Genome-wide expression data in matched tumors of a
subset of cases demonstrated that copy number loss at
CHD8 was signiﬁcantly associated with dysregulation of
several genes in the Wnt, TP53 and inﬂammatory pathways.
Copy number loss at RERG and ARHGDIB were associated
with up-regulation of MUC15 and ST8SIA1. Conclusions:
Rare CNV has greater effect size than common CNVs and
copy number loss rather than copy number gain sig-
niﬁcantly altered expressions of genes implicated in color-
ectal tumorigenesis. This study was funded by National
Medical Research Council Singapore.
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CYP2C19 is associated with platelet reactivity, but not
with 1-Year major adverse cardiac and cerebrovascular
events in Chinese people undergoing percutaneous cor-
onary intervention with stenting
Z. Wang1, Z. Liu1, W. Wang2, W. Chen1, Y. Tang2, Z.
Zhou1
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Introduction: Dual antiplatelet therapy, clopidogrel com-
bined with aspirin, is recommended for patients undergoing
percutaneous coronary intervention (PCI). But, therapeutic
effects affected by CYP2C19*2 and *3 remain con-
troversial. We evaluated the association of CYP2C19 with
platelet reactivity (PR) and 1-Year major adverse cardiac
and cerebrovascular events (MACCE) in Chinese people.
Materials and Methods: 3410 unrelated patients under-
going PCI with stenting were recruited from March 25,
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2010 to June 29, 2015, who were followed up to 1 year.
Association studies were analysis by a logistic regression
model, and the Cox proportional hazards model is used to
analyze the survival data. PR is grouped by an ADP-
maximum amplitude, a platelet aggregation rate and a
combination criteria. CYP2C19 *2 and *3 are genotyped by
sequencing.
Results: The PR is associated signiﬁcantly with
CYP2C19 *2, *3 and metabolic type (P<0.01). Patients
with risk allele A in CYP2C19*3 is susceptibility to high
PR (OR=1.29, 95% CI=1.14–1.47, P=0.0001). As the
number of risk allele A increase in both CYP2C19 *2 and
*3, PR also gradually increase which maybe cause clots
(OR=1.29, 95% CI =1.14–1.46, P=0.0001). The results
are replicated by the low PR grouping. No signiﬁcant
associations are observed between MACCE and
CYP2C19*2 and *3.
Conclusions: Our researches suggest that allele A in
CYP2C19*2 and *3 is a risk factor for HPR. Patients with
more allele A have a higher risk of clot. But, the two SNPs
are not related to the MACCE.
This work was supported by Starting Fund for 1000
Youth Talents (No.2013-RSQ02).
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Analysis of CFTR by next-generation sequencing in
patients with cystic ﬁbrosis from West Siberia
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Cystic ﬁbrosis (CF) is a common autosomal recessive dis-
order caused by CFTR mutations. CFTR encodes cystic
ﬁbrosis transmembrane conductance regulator protein. We
carried out the NGS analysis by "MiSeq" ("Illumina", USA)
in 27 patients from West Siberia. Bioinformatic ﬁltering of
the DNA sequencing results was performed using "Gene-
Talk" (https://www.gene-talk.de/), "UGENE" (http://ugene.
unipro.ru/), "Reporter Ion" (https://ionreporter.
lifetechnologies.com/ir/), "SIFT" (http://sift.jcvi.org/) and
"PolyPhen2" (genetics.bwh.harvard.edu/pph2/). Final
results were veriﬁed by direct Sanger sequencing using ABI
3130 genetic analyzer ("Applied Biosystems", USA).
The most frequent mutation, delF508, was identiﬁed in
26% of CF chromosomes. In two patients, we detected three
mutations (instead of commonly presented two mutations):
delF508/S466X/R1070Q. According to the literature, this
variant S466X/R1070Q is a complex allele carrying a severe
disease. Five novel mutations were found: c.T3983A (p.
I1328K), c.43delC (p.L15fs), c.1580dupA (p.E527fs), c.
T698G (p.L233R), c.T252A (p.Y84X). However, the efﬁ-
ciency of the CF allele detection after NGS was 76%. One
of the most important NGS disadvantages is an inability to
identify large deletions and insertions. For example, large
mutation CFTR21kbdel was detected in one patient only by
PCR analysis. The low efﬁciency of the CF allele detection
may suggest the presence of the large CFTR deletions or
insertions in patients with unknown genotype. Also, we
identiﬁed polymorphic variant V470M with quite high fre-
quency 55% in this group.
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A simulation study on power of epigenome-wide asso-
ciation analysis using disease-discordant twin design
W. Li1, J. Baumbach1,2, L. Christiansen1, Q. Tan1
1University of Southern Denmark, Odense, Denmark, 2Max
Planck Institute for Informatics, Saarbrücken, Germany
Background: Identical twin pairs discordant for a disease
have been widely used in epigenome-wide association stu-
dies (EWAS) of complex diseases because the underlying
genetic background is cancelled out. Although the twin
design is deemed to have enriched power as compared with
ordinary case-control design, its statistical power has not
been well investigated.
Methods: We perform a computer simulation study on
the power of the disease discordant twin design assuming
that both genetic and environmental factors contribute to the
liability of a disease phenotype. Power is assessed under
different levels of genetic contribution or heritability for
various effect sizes of environmental exposure that induce
change in the level and variance of the normal-distributed
M value of DNA methylation.
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Results: In general, the discordant twin design outper-
forms ordinary case-control design especially for CpG sites
with moderate effect and for diseases with heritability>0.3.
The power advantage in discordant twin design becomes
more obvious with increasing heritability. For diseases with
no genetic background, the twin design is slightly under-
powered, while for high heritability (0.5), high intrapair
methylation correlation (0.5) and small effect CpG sites (R2
= 0.1), sample size required for power over 0.8 is 215 for
ordinary case-control design, and only 59 for discordant
twin design, which is an over three folds reduction.
Conclusion: The twin design is powerful in detecting
epigenetic alterations induced by environmental exposure
especially for complex diseases with a strong genetic
background. The use of twin design should be encouraged
in EWAS using microarray and high-cost bisulﬁte sequen-
cing techniques.
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Introduction: Expanded carrier screening for an ever-
increasing number of disorders with pan-ethnic applicability
has become available. However, clinical utility, cost effec-
tiveness, and ethical standards for this practice have yet to
be fully established. We describe a simple model for pre-
dicting carrier detection rates, and some of its implications.
Materials and Methods: We developed a simple mathe-
matical model based on binomial distribution for predicting
carrier detection rates. We validated this model using the
ﬁve most prevalent recessive disorders in the Ashkenazi
Jewish population, then incrementally extrapolated the
model to include up to ~1300 recessive diseases in a pan-
ethnic population.
Results: An increase in the number of tested disorders
results in a logarithmic increase in predicted carrier rates. In
the Ashkenazi Jewish population, testing for only ﬁve dis-
orders results in a carrier detection rate of 13%, but exceeds
50% when a dozen conditions are included. In an
exogamous population, the rate of rise in carrier detection is
slower, but continues to climb and may exceed 60% when
testing for larger numbers of disorders.
Conclusions: This model is concordant with empirical
carrier rates observed in both Ashkenazi Jewish and pan-
ethnic populations. The carrier detection rate continues
rising with increasing size of the panel. The implications for
downstream demand on clinical genetics services warrants
novel approaches, such as considering the couple as the
testing unit, rather than the individual.
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Familial amyloid polyneuropathy (FAP) ATTRV30M in
Portugal: APOE gene as a genetic modiﬁer of age-at-
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TTR Val30Met related familial amyloid polyneuropathy
(FAP) is an autosomal dominant systemic amyloidosis, with
a wide variation in age-at-onset (AO). An increasing num-
ber of late-onset cases has been identiﬁed; anticipation has
been found to be a true biological phenomenon, as has the
difference in AO according to sex. Hence, AO must be
studied in the view of genetic modiﬁers. Several studies
described APOE ε4 to be associated with early- and late-
onset forms of Alzheimer disease, whereas ε2 allele seems
to have a protective effect.
We analysed 10 coding-sequence polymorphisms in
APOE in 299 patients (113 families), to evaluate whether
functionally-signiﬁcant variants have a modiﬁer effect in
AO in Portuguese families with TTR-related FAP. In sta-
tistical analysis, generalized estimating equations were used
to account for non-independency of AO among relatives.
Mean AO was ≈39y, but higher in females (40.71y vs.
37.35y in men), as previously described. The TT genotype
of rs7412 and CG genotype of rs267606661 were
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signiﬁcantly associated with earlier onset (p<0.001), cor-
responding to a decrease of ≈9 and 12 years in mean AO,
respectively. No signiﬁcant results were found regarding the
CT genotype of rs7412 and rs429358.
The rs7412 may act as a potential genetic modiﬁer of AO
variation in TTR-related FAP, as seen in other neurological
diseases. The G allele of rs267606661 is rare in European
populations, in accordance to our results. Further investi-
gation of AO variation in FAP is crucial to provide further
insight into the mechanisms underlying anticipation, as the
potential loss of a protective factor.
J. Abreu-Silva: None. D. Santos: None. T. Coelho:
None. M. Alves-Ferreira: None. J. Sequeiros: None. I.
Alonso: None. A. Sousa: None. C. Lemos: None.
P18.21A
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Introduction: What ones eat matters for health and dis-
eases, still little is known about the food preferences, and
most ﬁndings had been based on young children. Adults
have more autonomy in food selection together with more
sociocultural inﬂuences than children. We attempted to
understand components of food preference and its genetic/
environmental architecture.
Materials and Methods: Open questionnaires about
fondness/distaste for food were taken for 1029 adults (154
identical twin pairs, MZ), with genome-wide SNP infor-
mation; asking them to name particular food (up to 3 items
each). All items were categorized by a committee. For
ﬁnalized food categories, food frequency information (~
3,500 individuals) was combined where appropriate, to
estimate heritability and identify associated genetic variants
(family-based GWAS GEMMA-GMMAT).
Results: Food preferences were categorized into fol-
lowing: 1) olfaction/ﬂavor, 2) consistency/texture, 3) psy-
cho-emotional/revolting, 4) particular food groups
(vegetable, seafood and offal). For above categories, both
preferences (liking/disliking) were found.
Food distastes that showed genetic inﬂuences were
olfaction/ﬂavors (h2=0.27), consistency/texture (0.45),
vegetable (0.46), and seafood (0.38). Interestingly, antipa-
thy for psycho-emotional/revolting categories showed
environmental inﬂuences (no MZ correlation versus strong
spouse similarity), whereas fondness was heritable (0.36).
GWAS study showed that CFTR on 7q31.2 was association
with fondness of offal (OR: 1.985, P= 2.89E-08).
Conclusion: Our ﬁndings suggest food preferences
consist of composite sensory traits as well as perceptional
and emotional components. Some components are heritable
and probably oligogenic, while some are formulated by
cultural/environmental inﬂuences, and subject to change
gradually.
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Weighted functional linear regression models for gene-
based association analysis
N. M. Belonogova, G. R. Svishcheva, T. I. Axenovich
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Russian Federation
The essence of all gene-based methods is to merge the
information about association between the trait and geno-
types of every genetic variant in a single value of statistical
test for whole region. This can be achieved by either mer-
ging genotypes in collapsing-based methods, or summation
of score-tests in the kernel-based methods, or construction
of continuous smoothing functions in the methods based on
functional data analysis (FDA). Differential weighting of
genetic variants is a common practice for both collapsing-
and kernel-based methods. However, until now, the weights
were not incorporated into FDA models, one of the most
powerful tools for gene-based association analysis.
Here we present an FDA mixed model with assigned
differential weights of genetic variants. We estimate the
statistical properties of the new method using independent
and family data sets released by Genetic Analysis Work-
shop 17 in a wide range of simulation scenarios. The weight
of each variant was deﬁned in a standard way using beta
distribution density function on its minor allele frequency.
We show that all type I errors correspond to declared levels,
while increasing the weights of causal variants improves
power of weighted models. The model is included in
FREGAT R-package (https://cran.r-project.org/web/packa
ges/FREGAT/index.html) and can be used for testing the
association on both independent and structured samples.
Weights can be prespeciﬁed using minor allele frequencies,
biological functional annotations and any other a priori
information available.
N.M. Belonogova: None. G.R. Svishcheva: None. T.I.
Axenovich: None.
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P18.23C
Gene-environment interaction test in generalized linear
mixed models with family data
M. d. Andrade1, M. L. Mazo2
1Mayo Clinic, Rochester, MN, United States, 2National
University of Colombia, Mendellin, Colombia
Introduction: Detection of gene-environment (GE) inter-
actions has important implications for explaining the etiol-
ogy of complex diseases that are caused by a combination
of genetic factors and environment. Several methods have
been proposed using linear mixed models (LMM) and
generalized linear mixed models (GLMM) to detect the
interaction effects assuming independent observations.
However, in family data, the correlation between relatives
cannot be ignored. Thus, we propose a test for GE inter-
action in a GLMM with family data.
Materials and Methods: We used semiparametric
additive mixed models to develop the GE test. The link
function is expressed as the linear combination of ﬁxed (a
set of covariates, genetic markers and an interest environ-
mental variable) and random (family and shared household)
effects assuming the GE variable as a ﬁxed and as a random
effect in the GLMM. We also model this interaction by
means of a non-parametrical functional relationship with the
link function and by rewriting the generalized additive
mixed model (GAMM) model as a GLMM to test if this
functional relationship is signiﬁcant. We compare this latter
method with the two former ones, using simulated data
assuming the environmental variable is either correlated or
uncorrelated with the genetic variants (SNPs).
Results & Conclusions: Our preliminary results using
simulated data demonstrate that the random variance com-
ponents are very similar to the simulated values. We are in
the process of analysing complete clinical and genetic
information from the Baependi Heart Study which consists
of 80 families with 1207 subjects.
M.D. Andrade: None. M.L. Mazo: None.
P18.24D
Estimating the correlation between the accuracy of
simulation-based genetic risk modelling and its principal
prediction parameters interrelationship
O. Borisov1, K. Babalyan1, N. Kulemin2, E. Generozov2
1Moscow Institute of Physics and Technology, Research
Institute of Physical-Chemical Medicine, Moscow, Russian
Federation, 2Research Institute of Physical-Chemical
Medicine, Moscow, Russian Federation
Introduction: Genetic risk modelling using simulated
datasets demonstrated to be a useful method having pre-
dictive ability comparable with empirical data. The outcome
of such modelling is measured as area under the receiver-
operating characteristic curve (AUC) and is ultimately
deﬁned by simulation and prediction parameters. We aimed
to check whether there is correlation between modelling
outcome and its principal parameters interrelationship to
estimate the workability of the method.
Materials and Methods: Genotype modelling and risk
prediction was based on Bayes’ theorem and depended on
prevalence of disorders, allele frequencies, and odds ratios
(OR). These empirical parameters were retrieved from
GWAS Catalog. Subsequent risk prediction was performed
using c-statistics. Calculations were performed in R version
3.2.3 (the code is available at https://github.com/Olegbor/
Statgen).
Results: A total of 3492 entries (associations) related to
32 disorders from GWAS Catalog were selected to be
analyzed. Simulated sample consisted of 100.000 indivi-
duals. Obtained AUC values demonstrated high dis-
criminative accuracy of genetic risk prediction: median
AUC was 0.94 [interquartile range: 0.91, 0.98]. We found
no correlation between prediction accuracy and principal
prediction parameters interrelationship (allele frequencies
and OR): Pearson's product-moment correlation coefﬁcient
was -0.06 (p-value 0.74).
Conclusions: Being based on various extrinsic para-
meters, genotype datasets simulation followed by genetic
risk modelling present an autonomous and self-sufﬁcient
method that shows high accuracy in genetic risk prediction.
This work was supported by the Russian Science Founda-
tion (grant No. 17-15-01436)
O. Borisov: None. K. Babalyan: None. N. Kulemin:
None. E. Generozov: None.
P18.26B
Use of a Bayesian Mixture Model (BayesR) to investi-
gate the genetic control of complex traits
R. F. Oppong1, O. Devuyst2, C. Hayward3, P. Navarro3, C.
S. Haley3,4, S. Knott1
1IEB, SBS, University of Edinburgh, Edinburgh, United
Kingdom, 2ZIHP, University of Zurich, Zurich, Switzerland,
3MRC IGMM, University of Edinburgh, Edinburgh, United
Kingdom, 4The Roslin Institute and Royal (Dick) School of
Veterinary Studies, University of Edinburgh, Edinburgh,
United Kingdom
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In this study, we implemented a Bayesian mixture model to
perform a Genome-wide Association analysis for nine urine
phenotypes. These traits were measured on 2934 individuals
from the Generation Scotland: Scottish Family Health Study
genotyped at genome-wide ~700K SNPs. The Bayesian
model assumes SNP effects are from a mixture of four
normal distributions with different variances and was used
to investigate the underlying genetic architectures and
genome-wide SNP heritabilities for the urinary traits. We
also assessed the performance of the BayesR model on
simulated phenotypes. We report that more than 99% of the
SNPs were sampled to have no effect in the analysis of the
urine traits. The number of SNPs sampled to have effect
varied from 620 to more than 4000 in some traits. All the
traits were estimated to have a polygenic architecture with
the small and moderate effects components of the mixture
distribution explaining between 70% and 83% of the
additive genetic variance. Estimated heritabilities were
generally very low, ranging from 3.5% to 12.5%, with only
urine glucose having a moderate heritability (44%). These
heritability estimates were similar to estimates previously
obtained from these data by a variance component analysis
which ranged from 0 to 13.07%.Results from the simulation
study showed that the Bayesian mixture model provided
good estimates of the model parameters (genetic and error
variance, overall mean and mixing proportions of SNPs) for
traits with moderate to high heritability whilst it under-
estimated parameters of low heritability traits.
R.F. Oppong: None. O. Devuyst: None. C. Hayward:
None. P. Navarro: None. C.S. Haley: None. S. Knott:
None.
P18.27C
The position of Bulgarian uniparental diversity in the
Slavic genetic landscape
S. Karachanak-Yankova1, D. Nesheva1, A. Galabov2, D.
Toncheva1
1Department of Medical Genetics, Medical Faculty, Med-
ical University-Soﬁa, Soﬁa, Bulgaria, 2The Stephan Angel-
off Institute of Microbiology, Bulgarian Academy of
Sciences, Soﬁa, Bulgaria
Introduction: To date, the Bulgarian gene pool has been
analyzed from many aspects, but the impact of certain
ancestral populations in its formation is unknown. In order
to contribute to the understanding of the Slavic component
in the Bulgarian genetic make-up, we have performed an
analysis of the Bulgarian uniparental genetic diversity in the
Slavic context. Materials and methods: The mtDNA phy-
logenetic analysis was performed on 855 Bulgarian males
by sequencing of the control region followed by RFLP
analysis of coding markers, whereas the Y-chromosome
haplogroup classiﬁcation was performed on a sample
comprising 808 Bulgarian males using DHPLC and RFLP
analysis. The obtained frequencies of Y-chromosome and
mtDNA haplogroups were analyzed in the context of Slavic
speaking populations in order to determine their genetic
proximity with Bulgarians. The determination of the
matrilineal and patrilineal relationships was performed by
Principal Component Analysis (PCA) on 23 and 33 (sub-)
populations, respectively. Results: In the PCA of Y-
chromosome haplogroup proﬁles, the distribution of the
populations is mainly determined by the south-north cline
of the ﬁrst principal component. It positions Bulgarians at
the one extreme close to other South Slavic speaking
populations; East Slavic speaking populations on the other
extreme and West Slavic speaking populations in-between.
The Y-chromosome haplogroup PCA proﬁle follows simi-
lar pattern separating South and East by West Slavic
speaking populations. Conclusion: Similarly to previous
uniparental and genomic studies, our analysis shows that
Bulgarians are genetically most close with Serbs, Croats
and Herzegovians and are particularly distant from East
Slavic speaking populations.
S. Karachanak-Yankova: None. D. Nesheva: None. A.
Galabov: None. D. Toncheva: None.
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The migrations and barriers that shaped the Central
AsianY-chromosomal pool
O. Balanovsky1,2, M. Zhabagin3, V. Zaporozhchenko1, I.
Alborova4, O. Balaganskaya1, A. Agdzhoyan1,2, K.
Dibirova2, Y. Yusupov5, Z. Sabitov6, M. Lavryashina7, P.
Nymadawa8, Z. Isakova9, K. Mustaﬁn4, C. Tyler-Smith10,
E. Balanovska2
1Vavilov Institute for General Genetics, Russian Academy
of Sciences, Moscow, Russian Federation, 2Research
Centre for Medical Genetics, Moscow, Russian Federation,
3National Laboratory Astana, Nazarbayev University,
Astana, Kazakhstan, 4Moscow Institute of Physics and
Technology, Dolgoprudnyi, Russian Federation, 5Institute
of Humanitarian Research of the Republic of Bashkorto-
stan, Ufa, Russian Federation, 6L.N.Gumilyov Eurasian
National University, Astana, Kazakhstan, 7Kemerovo State
University, Kemerovo, Russian Federation, 8Mongolian
Academy of Sciences, Ulaanbaatar, Mongolia, 9Institute of
Molecular Biology and Medicine, Bishkek, Kyrgyzstan,
10The Wellcome Trust Sanger Institute, Wellcome Trust
Genome Campus, Hinxton, United Kingdom
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Central Asia is a contact region in between all other parts of
Eurasia, but its Y-chromosomal landscape is very under-
studied. To compensate for this bias, we ﬁrst genotyped
5,295 Y-chromosomes from 64 populations representing
Mongolia, Russia, Kazakhstan, Uzbekistan, Tajikistan, and
Kirgizia. Analysis at the common level of phylogenetic
resolution (50 Y-SNPs and 17 Y-STRs) revealed Mongol-
Kazakh, Altaian-Uralic, and Persian clusters of populations.
Cartographic analysis revealed that a core Central Asian Y-
chromosomal pool (centered in Mongolia) spread westward
as a narrow stream between the Tian-Shan and Altay
mountains, and became much more pronounced in nomads
from the lowlands than from the mountains. Thus mountain
chains served as one important factor structuring the
paternal lineage pool in Central Asia. In phase two of our
study, we focused on the major Central Asian haplogroup
C2 (formerly C3)-M217. We sequenced 62 Y-chromosomes
(~11 Mb each) and constructed a detailed phylogenetic tree.
Remarkably, six independent branches expanded simulta-
neously around 1,000 years ago, indicatingrapid male
demographic growth on the eve of the Mongol expansion.
We genotyped 1,490 M217-positive samples using 23
branch-deﬁning SNPs discovered in our study, and recon-
structed the complex picture of haplogroup C2 branch
spread across Central Asia and Siberia. Finally, we
observed that barriers between clans were more important
for structuring the Central Asian Y-chromosomal pool than
geographic barriers. This study was supported by the RSF
grant 14-14-00827 (Y-chromosomal sequencing) and the
Vavilov Institute for General Genetics theme 0112-2016-
0006 (gene pool structure analysis).
O. Balanovsky: None. M. Zhabagin: None. V.
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ganskaya: None. A. Agdzhoyan: None. K. Dibirova:
None. Y. Yusupov: None. Z. Sabitov: None. M. Lav-
ryashina: None. P. Nymadawa: None. Z. Isakova: None.
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Genetic determinants of healthy ageing
M. Kuokkanen1,2, F. Stilling3, T. Haller4, A. Wolk3, A.
Metspalu4, M. Perola1,2,4
1National Institute for Health and Welfare, Helsinki,
Finland, 2Institute for Molecular Medicine Finland, Hel-
sinki, Finland, 3Karolinska Institute, Stockholm, Sweden,
4Estonian Genome Center, University of Tartu, Tartu,
Estonia
A long and healthy lifespan has a signiﬁcant genetic com-
ponent. It is yet unclear, whether this is due to lack of
predisposing genetic variants for various diseases in healthy
elderly people or whether there would be speciﬁc genetic
variants that make the effect of ageing less detrimental for
the carriers. We performed a genome-wide association
study and a meta-analysis in participants of Finrisk (Fin-
land), the Cohort of Swedish Men and the Estonian Genome
Center of the University of Tartu (total N of 11913). We
compared individuals with a long (>75 years) healthspan
(N= 1323) to persons deceased under 75 years of age or to
those being over 75 years old unhealthy survivors diag-
nosed with (at least one of following condition) CVD,
diabetes, dementia, cancer, COPD, asthma, rheuma,
Crohn’s disease, malabsorption, kidney failure.
We found that a locus including the TRRAP gene,
having histone acetyltransferase activity, in chromosome 7
was genome-wide signiﬁcantly associated with healthy
ageing (p=3.8×10-08). TRRAP may affect in the devel-
opment of several types of cancer. Another locus close to a
genome-wide signiﬁcant level was found to be in close
vicinity of SREK1 in chromosome 5 (p=1.1×10-07).
SREK1 modulates alternative splicing by modulating the
activity of other splicing factors.
Our goal is to further conﬁrm these ﬁndings in other
available cohorts with European descent. These results offer
a good starting point to model and understand longevity and
healthy life.
The work was supported by EU from H2020 grants
633589, 692145 and the Swedish Cancer Foundation.
M. Kuokkanen: None. F. Stilling: None. T. Haller:
None. A. Wolk: None. A. Metspalu: None. M. Perola:
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Inuit in Greenland have signiﬁcantly higher heritability
for anthropometric traits
E. R. Appel1, I. Moltke2, M. E. Jørgensen3, P.
Bjerregaard4,5, A. Linneberg6,7,8, T. Hansen1, N. Grarup1,
A. Albrechtsen2
1Novo Nordisk Foundation Center for Basic Metabolic
Research, Section for Metabolic Genetics, Copenhagen Oe,
Denmark, 2The Bioinformatics Centre, Department of
Biology, University of Copenhagen, Copenhagen, Den-
mark, 3Steno Diabetes Center, Gentofte, Denmark,
4National Institute of Public Health, University of Southern
Denmark, Copenhagen, Denmark, 5Greenland Centre for
Health Research, University of Greenland, Nuussuaq,
Greenland, 6Research Centre for Prevention and Health,
Copenhagen, Denmark, 7Department of Clinical
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Experimental Research, Copenhagen, Denmark, 8Depart-
ment of Clinical Medicine, Faculty of Health and Medical
Sciences, University of Copenhagen, Copenhagen,
Denmark
Introduction: Heritability is the amount of variation that
can be explained by genetic variation. Different models for
estimating heritability are applied to different types of
datasets, ranging from populations samples to families and
twin cohorts. The resulting estimates previously published
differ considerably between models, but not between ethnic
populations.
Aims: In this study we ﬁrstly aim to investigate the
heritability of metabolic traits in the Greenlandic popula-
tion, which is an admixed, highly interrelated and small
population. Secondly, we aim to compare these estimates to
those of cohorts from the outbred European population.
Results: Using the GCTA-REML unadjusted model, we
ﬁnd systematically higher estimates of heritability in
Greenlanders (N= 4724) for anthropometric traits, such as
BMI (h2=0.25, SE=0.016), but not glycemic traits, such as
fasting glucose levels, when comparing with the Danish
Inter99 cohort (N= 6127) (BMIInter99: h2=0.11,
SE=0.021). The difference does not seem to be explained
by admixture, since the heritability estimate for Green-
landers with little or no European admixture (<5%) are
similar to estimates for Greenlanders with a range of
admixture proportions (BMIGreenlanders with <5% European admix-
ture: h
2=0.33, SE=0.070). The shared environment in
families does not explain the higher heritability either, since
we observe comparable estimates when only including one
member for each family (BMIGreenlanders with <5% European
admixture and no families: h
2=0.46, SE=0.16)
Conclusion: These results suggest that the heritability of
some anthropometric traits is markedly higher in Green-
landers than that found in Europeans, and that the difference
cannot be explained by admixture or shared family
environment.
E.R. Appel: None. I. Moltke: None. M.E. Jørgensen:
None. P. Bjerregaard: None. A. Linneberg: None. T.
Hansen: None. N. Grarup: None. A. Albrechtsen: None.
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A molecular genetic anatomy of Hirschsprung disease
and its risk proﬁle
J. M. Tilghman1, A. Y. Ling1, T. Turner1, M. X. Sosa1, N.
Krumm2, S. Chatterjee1, A. Kapoor1, B. Coe2, K. Nguyen1,
N. Gupta3, S. Gabriel3, E. Eichler2, C. Berrios1, A.
Chakravarti1
1Johns Hopkins School of Medicine, Baltimore, MD, United
States, 2University of Washington, Seattle, WA, United
States, 3Broad Institute of Harvard and MIT, Boston, MA,
United States
Introduction: Hirschsprung disease (HSCR), a frequent
cause of functional intestinal obstruction in neonates, is a
multifactorial disorder with > 80% heritability, harboring
associations with rare and common sequence variants in
enteric nervous system (ENS) genes, together with mono-
genic and chromosomal syndromes. We quantiﬁed the total
genetic burden in individual patients and their population
risk proﬁles.
Methods: We genotyped and exome sequenced 190
European ancestry HSCR probands to identify genetic
variants contributing to HSCR. We deﬁned pathogenic
alleles (PA) as common functional enhancer variants; rare
nonsense, conserved missense (PhyloP>4) and canonical
splice-altering single nucleotide (SNV) and INDEL coding
variants; or large (>500kilobase) copy number variants
(CNV). PAs, genes and loci were identiﬁed through a sta-
tistically signiﬁcant excess in cases versus appropriate
controls.
Results: 72% of all patients have at least one identiﬁable
genetic risk factor with an estimated population attributable
risk of ~69%; of these, 48.4% (92 cases) have a structural or
regulatory deﬁciency in the RET gene that regulates an early
step in ENS differentiation.
Conclusions: HSCR has major identiﬁable genetic
components with a diversity of molecular lesions, coding
and non-coding, SNV and CNV, rare and common,
affecting ENS development. Individual patients have com-
binations of risk variants such that ~2%, 22%, 50% and
26% of probands have all 3, any 2, any 1 or none of these
variant types with total risk varying ~130-fold across these
classes. We demonstrate that individual patients can arise
from multiple diverse common and rare risk factors, chal-
lenging assumptions about the etiology of complex
disorders.
NIH-HD28088
J.M. Tilghman: None. A.Y. Ling: None. T. Turner:
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Whole genome sequencing of two indigenous high alti-
tude populations identiﬁes adaptive genetic variants for
survival in a hypobaric hypoxic environment
A. M. Cole1, R. Bohlender2, H. Hu2, E. Heinrich3, C.
Ramirez4, Y. Yu2, F. Powell3, E. Gaio5, F. Villafuerte4, C.
Taylor6, C. Huff2, T. Simonson3, G. L. Cavalleri1
1Royal College of Surgeons in Ireland, Dublin 2, Ireland,
2Department of Epidemiology, Division of OVP, Cancer
Prevention and Population Sciences, The University of
Texas MD Anderson Cancer Center, Houston, TX, United
States, 3Division of Physiology, School of Medicine,
University of California, San Diego, CA, United States,
4Laboratorio de Fisiología Comparada-LID, Unidad de
Transporte de Oxígeno-IIA, Universidad Peruana Cayetano
Heredia, Lima, Peru, 5Pulmonary Division, University of
Brasília, Brazil, Brazil, 6School Of Medicine, Conway
Institute, University College Dublin,, Dublin 8, Ireland
Introduction: There are approximately 140 million people
living at altitudes ≥ 2500 m above sea level. These indivi-
duals are exposed to a reduced atmospheric pressure. They
have between 11% - 14% effective oxygen availability,
instead of the 21% available at sea level. We set out to
identify signals of selection in the genome that facilitate the
adaptation of these populations to their hypobaric hypoxic
environment. We also present an insight to the molecular
mechanisms involved in the response to hypoxia.
Methods: We performed whole genome sequencing on
two populations; the Quechua from the Andes and the
Sherpa from the Himalaya. We modelled the demographic
history of these populations and performed ﬁve tests of
selection, iHS, XPEHH, Fst, diHH and DAFF. These ﬁve
tests will be combined to give a composite of multiple
signals score, which will identify regions of the genome that
are under the selective force of hypoxia.
Discussion and Conclusion: We identify a list of can-
didate genes under selection in each of our cohorts. Given
the molecular pathways these genes are involved in, they
are likely to play a direct biological role in adaptation to
high altitude. On-going work will involve the functional
characterisation of these genetic adaptive variants in-vitro.
This research was supported by an Investigators Pro-
gramme grant from Science Foundation Ireland (12/IP/
1727).
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Towards development of an Irish Traveller Genetic
database
S. Lynch1,2, N. Byrne1, E. Crushell3,2, K. Gorman4, M.
King4,2, V. McConnell5, J. Turner1, A. Green6,2, D.
Lambert1, J. Casey2
1National Rare Disease Ofﬁce, Dublin 7, Ireland, 2Aca-
demic Centre for Rare Disease, University College Dublin,
Dublin 4, Ireland, 3National Centre for Inherited Metabolic
disease, Dublin 1, Ireland, 4Neurology, Temple Street
hospital, Dublin 1, Ireland, 5Genetics, Belfast City
Hospital, Belfast, United Kingdom, 6Genetics, Temple
Street Hospital, Dublin 1, Ireland
Irish Travellers are an endogamous, ethnically Irish popu-
lation of ~40,000. Consanguinity is common. Whilst, there
is knowledge of Traveller disorders in specialised centres,
knowledge gaps exist elsewhere. Most Traveller disorders
are published but ethnicity is often not explicit, hampering
diagnoses.
Aims: To catalogue inherited Irish Traveller disorders,
publications and mutations and develop a database to
facilitate diagnoses.
Methods
A literature review was undertaken. Key national and
international Clinician/scientists were contacted to identify
relevant disorders and publications. Laboratory and clinical
databases were searched to retrieve disorders & mutations.
Annotations were updated. An Excel database was estab-
lished listing each disorder, its associated mutation and
linked to a relevant publication.
Results
76 distinct rare genetic disorders resulting in 65 pheno-
types were identiﬁed; 69/76 were autosomal recessive; 4 of
these were dominant disorders but presented only in the
recessive state. Six dominant disorders with no recessive
phenotype were included as > one affected individual
existed. One common 17q12 duplication was included,
presenting in two unrelated families. Homozygous muta-
tions were found in all recessive disorders bar one. The
genetic basis of 72/76 was established. A further 2/76 have
common haplotypes; the genetic basis of two disorders
remains unclear.
Genetic heterogeneity was observed for eight disorders.
We observed disorders in linkage disequilibrium; 4 families
with McArdles disease had co-existing microcephaly, 9
individuals have co-existing Friedreich’s ataxia &
galactosemia.
Conclusion Our work is the ﬁrst step towards catalo-
guing inherited Irish Traveller disorders. Future challenges
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include development of an NGS panel and moving towards
a population screening service.
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Genomic characterization of three Italian isolated
populations through low-coverage whole genome
sequencing
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The contribution of rare and low frequency genetic variants,
as opposite to the contribution of common variants, is still
largely incomplete and it has become fundamental in order
to search causative variants for mendelian and complex
traits.
Here we present a genomic characterization of three
South European populations from the Italian Network of
Genetic Isolates (INGI). Through the use of low-coverage
Whole Genome Sequencing of 926 samples, we were able
to identify more than 26 million variants. A fraction of them
(between the 11% and the 29%) could be considered rare
variants (MAF <1% and AC>1) both shared with outbred
populations and private of our cohorts.
Our genomic characterization ranges from the analyses
of ROH to the distribution of putatively deleterious variants,
in the latter focusing on variants with CADD score over
than 20 and signiﬁcantly enriched in our population respect
to European reference (Pvalue Fisher<0.05). As an exam-
ple, we discovered that in one isolated South Italian popu-
lation the TYR gene rs1126809-A allele reached the
frequency of 0.37, this allele is associated with increased
risk of cutaneous malignant melanoma.
Considering the geographical localization of our three
isolates we argue that our data could be representative of the
genetic variation of a good portion of the Italian population.
We also generated a reference panel for imputation in order
to improve the coverage of Southern European populations.
We add ~6.9M of INGI private sites in comparison to the
already available resources, providing a new resource for
future GWAS studies on Southern Europeans.
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Investigating the Italian exome: population-speciﬁc dif-
ferences in the coding genome
G. Birolo1,2, C. Di Gaetano2,1, S. Aneli1,2, A. Allione1,2, E.
Paraboschi3,4, D. Ardissino5, S. Duga3,4, R. Asselta3,4, G.
Matullo2,1
1HuGeF, Turin, Italy, 2Dept. of Medical Sciences, Uni-
versity of Turin, Turin, Italy, 3Dept. of Biomedical Sciences,
Humanitas University, Rozzano, Milan, Italy, 4Humanitas
Clinical and Research Center, Rozzano, Milan, Italy, 5Div.
of cardiology, Azienda Ospedaliero-Universitaria di
Parma, Parma, Italy
Just a small portion of the human genomic variability has
been explored so far, especially for rare and population-
speciﬁc variants. Even within the relatively homogeneous
European population, there are variants whose frequencies
vary widely across different areas. This is of special interest
concerning exome variants, since they allow for better
interpretation of phenotypic differences between popula-
tions, especially in a clinical context. Although many var-
iant databases exist, population-speciﬁc frequencies of
exome variants are needed to distinguish real disease
associations from population-speciﬁc polymorphisms.
In this study, whole-exome sequencing data of around
1700 healthy Italian individuals from almost all Italian
regions were analyzed. This sample size provides enough
power to detect 90% of variants with an allelic frequency of
0.01% and virtually all the variants with a frequency greater
than 0.02%.
Signiﬁcant differences in allele frequencies of exome
variants were found between Italy and Europe and between
Northern and Southern Italy as well, focusing on variants
with a functional role in diseases and drug response. Several
thousands of identiﬁed variants were not listed in dbSNP.
As expected, most of these novel variants were rare.
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However, a few high-quality variants had a frequency
greater than 1%, mostly indels in non-coding regions, and
were thus polymorphisms private to the Italian population.
Comparing allele frequency within Italy, signiﬁcant differ-
ences were found: for instance, in the HERC2 (hair and eye
color), LCT (lactose intolerance) and ADH1B (ethanol
metabolism) genes and in variants associated with hyper-
tension and with methotrexate-induced toxicity.
G. Birolo: None. C. Di Gaetano: None. S. Aneli: None.
A. Allione: None. E. Paraboschi: None. D. Ardissino:
None. S. Duga: None. R. Asselta: None. G. Matullo:
None.
P18.36D
Genetic signature of ancient humans in Lakshadweep
Island: A complex scenario as mainland India
M. Naveen1, N. Rai2, G. Chaubey3, S. Prakash2, K.
Thangaraj2, M. S. Mustak1
1Department of Applied Zoology, Mangalore University,
Mangalore, Karnataka, India, 2CSIR-Centre for Cellular
and Molecular Biology, Hyderabad, Telangana, India,
3Department of Evolutionary Biology, Estonian Biocentre,
Riia23b, Tartu, Estonia
Introduction: The heritage of contemporary Indian popu-
lation is well studied for the aspects of diverse ethnic, lin-
guistic, genetic and geographical architecture. Although,
many questions remain contested and unresolved for Indian
ancestral population such as proximal ancestral sources,
possible ways of inﬂux and degree of admixture of the
ancestral component. To address these aspects many
attempts have been made by reconstructing Indian mainland
and Island population history, but Lakshadweep Island (LD)
population are least studied for their ancestral sources.
However, with its distinct geography in the Arabian Sea
(western Indian Ocean), obscure history and rigid popula-
tion structure of LD drawn our interest. The knowledge of
ancient ancestry of this population would be desirable to re-
evaluate Indian ancestral component.
Material and Method: We determine Mitochondrial
DNA (mtDNA) haplogroup (Hg) pattern in 1359 indivi-
duals from LD by employing Sanger sequencing and
compared with other South Asian (SA) data set.
Results: We observed major mtDNA Hgs (R30, M30
and M35), with signiﬁcantly less haplotype diversity. These
clades are nested within previously reported Indian-speciﬁc
mtDNA macro Hgs. Our Hg frequency-based analyses
reveal that LD shared greater ancestry with Indian mainland
population irrespective of geography and language.
Conclusion: Thus, inconsistent mainland afﬁnity in LD
population resemblance that LD was a central hub for
ancient human admixture. Our result also indicates that
Lakshadweep Islands were an important destination during
ancient trading practices and it could have been served as a
junction between India and other SA countries.
This research work was funded by SERB-DST, New
Delhi, India.
M. Naveen: None. N. Rai: None. G. Chaubey: None. S.
Prakash: None. K. Thangaraj: None. M.S. Mustak:
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P18.37A
Genetic Architecture of the longevous Amish population
S. Smieszek, J. Haines
Case Western Reserve Univeristy, Cleveland, OH, United
States
Numerous research efforts have focused on searching for
‘longevity genes’. However, attempting to decipher the
genetic component of the longevous phenotype have
resulted in limited success. We conducted a genome-wide
homozygosity analysis of the founder population of the
Amish community in central Ohio. The Amish provide a
large cohort of extended kinships allowing for in depth
analysis via family-based approach. The present analysis
integrated both phenotypic and genotypic data and led to
discovery of a series of variants, distinct for stratiﬁed
populations across ages and distinct for paternal and
maternal cohorts. Speciﬁcally 5437 subjects were analyzed
and a subset of 893 successfully genotyped individuals was
used to assess CHIP heritability. We examined if homo-
zygosity is associated with increased risk of living beyond
90. We delineated 10 signiﬁcant regions of homozygosity
(ROH) speciﬁc for the age group of interest (>90). Of
particular interest was ROH on chromosome 13, P <
0.0001. Furthermore we built a classiﬁer using the obtained
SNPs from the signiﬁcant ROH region with 0.945 AUC
giving ability to discriminate between those living beyond
to 90 years of age and beyond. The identiﬁed regions of
interest via ROH analysis could be of profound importance
for the understanding of genetic underpinnings of longevity.
We will validate all the candidate variants in independent
cohorts of centenarians, to test whether they are robustly
associated with human longevity. In conclusion our results
suggest that a history of longevity does indeed contribute to
increasing the odds of individual longevity.
S. Smieszek: None. J. Haines: None.
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Identiﬁcation of likely non-pathogenic loss-of-function-
variants in consanguineous families
P. Makrythanasis1,2, M. Ansar2, N. Batool3, H. Shaikh4,
M. T. Sarwar3, A. A. Khan4, S. A. Paracha3, J. Khan3, Y.
M. Waryah4, S. Temtamy5, M. Guipponi2, A. Megarbané6,
A. Masri7, M. S. Aglan5, N. Al-Allawi8, S. Kitsiou-Tzeli9,
A. Seﬁani10, S. Al-Hait11, L. Al-Gazali12, N. Jalkh13, H.
Frysira9, M. S. Zaki5, H. Hamamy2, E. Frengen14,15, A. M.
Waryah4, J. Ahmed3, S. E. Antonarakis1,2,16
1University Hospitals of Geneva, Geneva, Switzerland,
2University of Geneva, Geneva, Switzerland, 3Khyber
Medical University, Peshawar, Pakistan, 4Liaquat Univer-
sity of Medical and Health Sciences, Jamshoro, Pakistan,
5National Research Center, Cairo, Egypt, 6Institut Jerome
Lejeune, Paris, France, 7The University of Jordan, Amman,
Jordan, 8University of Dohuk, Dohuk, Iraq, 9University of
Athens, Athens, Greece, 10Institut National d'Hygiène,
Rabar, Morocco, 11The Farah Hospital, Amman, Jordan,
12University Arab Emirates University, Al-Ain, United Arab
Emirates, 13Saint Joseph University, Beirut, Lebanon,
14Oslo University Hospital, Oslo, Norway, 15University of
Oslo, Oslo, Norway, 16iGE3 Institute of Genetics and
Genomics of Geneva, Geneva, Switzerland
Consanguineous marriages could expose autosomal reces-
sive disorders. Consanguinity not only helps to discover
causative homozygous variants in families affected from
autosomal recessive genetic disorders but also to identify
homozygous nonsense and stop-loss variants that are likely
benign. Here, we have ascertained 118 consanguineous
families with several phenotypes mainly intellectual dis-
ability/developmental delay or visual impairment, originat-
ing from Arab countries and Pakistan. In the current study,
we looked for (likely) non-pathogenic homozygous loss-of-
function variants in order to contribute to the improvement
of the diagnostic algorithms and reduce the false positive
calls for pathogenicity. To identify the non-disease causing
homozygous nonsense and stop-loss variants, we used a
combination of homozygosity mapping and exome
sequencing. At least ﬁve individuals per nuclear family
were genotyped and one individual per family was
sequenced (exome sequencing). We have identiﬁed 48
homozygous non-sense that did not segregate correctly with
the recessive phenotype and therefore are likely tolerated.
We conclude that the discovery of novel non-pathogenic
homozygous loss-of-function mutations can be accelerated
by analyzing large cohorts of consanguineous families,
which in-turn will be beneﬁcial for correct molecular
diagnosis, and counselling of the affected families. An
international, open-access database of these variants would
accelerate the functional analysis of protein-coding genes,
and the diagnostic capabilities of (near) Mendelian
disorders.
P. Makrythanasis: None. M. Ansar: None. N. Batool:
None. H. Shaikh: None. M.T. Sarwar: None. A.A. Khan:
None. S.A. Paracha: None. J. Khan: None. Y.M. War-
yah: None. S. Temtamy: None. M. Guipponi: None. A.
Megarbané: None. A. Masri: None. M.S. Aglan: None.
N. Al-Allawi: None. S. Kitsiou-Tzeli: None. A. Seﬁani:
None. S. Al-Hait: None. L. Al-Gazali: None. N. Jalkh:
None. H. Frysira: None. M.S. Zaki: None. H. Hamamy:
None. E. Frengen: None. A.M. Waryah: None. J.
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P18.40D
Genomic and epigenetic signatures of mosaic Y chro-
mosome loss highlight cell cycle genes and overlap with
cancer susceptibility
D. J. Wright1, F. R. Day1, N. D. Kerrison1, F. Zink2, A.
Cardona1, P. Sulem2, D. J. Thompson3, S.
Sigurjonsdottir2, D. F. Gudbjartsson2, A. Helgason2, J. R.
Chapman4, S. P. Jackson5,6, C. Langenberg1, N. J.
Wareham1, R. A. Scott1, U. Thorsteindottir2,7, K. K.
Ong1,8, K. Stefansson2,7, J. R. B. Perry1
1MRC Epidemiology Unit, University of Cambridge School
of Clinical Medicine, Cambridge, United Kingdom,
2deCODE Genetics/Amgen Inc., Reykjavik, Iceland, 3Cen-
tre for Cancer Genetic Epidemiology, University of Cam-
bridge, Cambridge, United Kingdom, 4Wellcome Trust
Centre for Human Genetics, University of Oxford, Oxford,
United Kingdom, 5Wellcome Trust and Cancer Research
UK Gurdon Institute, University of Cambridge, Cambridge,
United Kingdom, 6Department of Biochemistry, University
of Cambridge, Cambridge, United Kingdom, 7Faculty of
Medicine, University of Iceland, Reykjavik, Iceland,
8Department of Paediatrics, University of Cambridge,
Cambridge, United Kingdom
The Y chromosome is frequently lost in hematopoietic cells,
representing the most common somatic mutation in men.
However, the mechanisms that regulate mosaic loss of
chromosome Y (mLOY), and its clinical relevance, are
unknown. Using both genotype array intensity data and
sequence reads in up to 85,542 men, we identify 19 geno-
mic regions (P<5×10-8) and 36 differentially-methylated
regions associated with mLOY. Cumulatively, these loci
also predict X chromosome loss in women (N= 96,123,
P=4×10-6). Identiﬁed genes functionally converge on
aspects of cell proliferation and cell-cycle regulation,
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including DNA synthesis (NPAT), DNA damage response
(ATM), mitosis (PMF1, CENPN, MAD1L1) and apoptosis
(TP53). We highlight a shared genetic architecture between
mLOY and cancer
susceptibility, in addition to inferring a causal effect of
smoking on mLOY. Collectively, our results demonstrate
that genotype array intensity data enable a measure of cell
cycle efﬁciency at population scale, identifying genes
implicated in aneuploidy, genome instability and cancer
susceptibility.
D.J. Wright: None. F.R. Day: None. N.D. Kerrison:
None. F. Zink: A. Employment (full or part-time); Sig-
niﬁcant; deCODE Genetics/Amgen Inc.. A. Cardona:
None. P. Sulem: A. Employment (full or part-time); Sig-
niﬁcant; deCODE Genetics/Amgen Inc.. D.J. Thompson:
None. S. Sigurjonsdottir: A. Employment (full or part-
time); Signiﬁcant; deCODE Genetics/Amgen Inc. D.F.
Gudbjartsson: A. Employment (full or part-time); Sig-
niﬁcant; deCODE Genetics/Amgen Inc. A. Helgason: A.
Employment (full or part-time); Signiﬁcant; deCODE
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son: None. C. Langenberg: None. N.J. Wareham: None.
R.A. Scott: None. U. Thorsteindottir: A. Employment
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P18.41A
Molecular characterization and haplotype analysis in a
large group of Mucopolysaccharidosis type IIIC (MPS
IIIC) patients reveal the evolutionary history of the
disease
C. Martins1, P. Frassinetti de Medeiros2, S. Leistner-
Segal3, N. Elcioglu4, M. Behnam5, L. Lacerda6, J. F.
Lefèbvre1, R. Giugliani3, A. V. Pshezhetsky7
1Research Center, CHU Sainte Justine, Montreal, QC,
Canada, 2Federal University of Campina Grande, Campina
Grande, Brazil, 3Medical Genetics Service, HCPA/UFRGS,
Porto Alegre, Brazil, 4Department of Pediatric Genetics,
Marmara University Hospital, Istanbul, Turkey, 5Medical
Genetics Center of Genome, Isfahan, Iran, Islamic Republic
of, 6Institute of Medical Genetics Jacinto Magalhães/Centro
Hospitalar do Porto, Porto, Portugal, 7Division of Medical
Genetics, Sainte-Justine University Hospital Research
Center, Montreal, QC, Canada
MPS IIIC is an autosomal recessive disorder caused by
mutations in the HGSNAT gene. So far 64 mutations have
been described altering production and/or activity of the
HGSNAT enzyme and leading to accumulation of heparan
sulfate in lysosomes. In order to identify the origin and
evolution of MPS IIIC in human populations we analyzed
all exons of HGSNAT as well its ﬂanking sequences, a 3′
UTR and two extragenic sequences in 69 MPS IIIC index
cases from 20 countries, the largest group studied so far.
The haplotypes, deﬁned by polymorphic SNPs, were
inferred by PHASE. Amongst all patients, 20 were new
cases without previous molecular characterization. Six
novel mutations (one deletion, one insertion, one nonsense
and three missense) were detected in these patients. Func-
tional studies conﬁrmed that HGSNAT-p.G173D, p.N258I
and p.G423W mutant proteins had no enzymatic activity.
HGSNAT-p.N258I also lacked lysosomal proteolytic pro-
cessing suggesting that the mutation interferes with its
folding and targeting. Of a total of 44 mutations identiﬁed,
19 were shared by more than two populations. Haplotype
analysis allowed to suggest the same origin for mutations
observed in different populations, and those with potential
founder effect such as the novel mutations c.773A>T (p.
N258I) and c.164T>T (p.L55X) that represent 58.3% and
25%, respectively, of the mutant alleles in the Paraiba state
of Brazil. In conclusion, haplotype results combined with
geographic and historical data allowed to get insight into the
migration roots and founder effects for a number of
HGSNAT mutations and helped to reveal the history of MPS
IIIC.
C. Martins: None. P. Frassinetti de Medeiros: None.
S. Leistner-Segal: None. N. Elcioglu: None. M. Behnam:
None. L. Lacerda: None. J.F. Lefèbvre: None. R. Giu-
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Association between mitochondrial DNA copy-number
in leukocytes with plasma lactate levels after glucose
loads in non-diabetic women
J. L. Santos1, L. R. Cataldo1, C. Cortés1, C. Bravo1, L.
Díaz-Casanova1, F. Milagro2,3, A. Martínez2,3, J. Galgani1
1Department of Nutrition, Diabetes and Metabolism, School
of Medicine. Pontiﬁcia Universidad Católica de Chile,
Santiago, Chile, 2Centre of Nutrition Research, University
of Navarra, Pamplona, Spain, 3CIBERobn. Institute of
Health Carlos III, Madrid, Spain
Introduction: Increased lactatemia occurs after glucose
loads, in a magnitude that is possibly linked to reduced
mitochondrial respiratory capacity. Additionally, both
plasma lactate and mitochondrial DNA (mtDNA) copy-
number have been proposed as biomarkers of aerobic oxi-
dative capacity and insulin resistance. The aim of this study
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was to evaluate the association between mtDNA copy-
number, measured in DNA from leukocytes, with circulat-
ing plasma lactate levels after oral or intravenous glucose
loads in non-diabetic women.
Subjects and Methods: 69 Chilean non-diabetic women
(age: 26.8 ± 6.3 years; BMI: 23.9 ± 3.5 kg/m2) were
recruited. mtDNA copy-number was determined by quan-
titative PCR (qPCR) and digital-droplet PCR (ddPCR)
techniques in DNA from leukocytes, using the same set of
primers. Serial measurements of plasma lactate, glucose and
insulin were obtained during a 2-hour Oral Glucose Toler-
ance Test (OGTT) (75 g. glucose) and from 50-minute
Abbreviated Minimal-Model Intravenous Glucose Toler-
ance Test (MM-IVGTT) (0.3 g/kg). We calculated the Area
Under the Curve for lactatemia during OGTT (AUCL) and
the difference in plasma lactate levels at 50 versus 10 min-
utes during the MM-IVGTT (IVL50-10).
Results: mtDNA copy-number measured with qPCR and
ddPCR showed strong association (rho=0.52; p<0.0001)
with moderate concordance. We found a signiﬁcant direct
association between the mtDNA copy number and plas-
matic lactate levels both for AUCL (rho=0.33; p=0.02) and
IVL50-10 (rho=0.32; p=0.03).
Conclusion: This research support the hypothesis that
increased mtDNA copy-number in leukocytes may repre-
sent a biomarker of reduced systemic aerobic oxidative
capacity given its direct association with plasma lactate
levels after glucose loads. FONDECYT 1150416.
J.L. Santos: B. Research Grant (principal investigator,
collaborator or consultant and pending grants as well as
grants already received); Signiﬁcant; FONDECYT. L.R.
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Ancient Out-of-Africa mitochondrial DNA variants
associate with distinct mitochondrial gene expression
patterns
T. Cohen, L. Levin, D. Mishmar
Ben Gurion University of the Negev, Beer Sheva, Israel
Mitochondrial DNA (mtDNA) variants have been tradi-
tionally used as markers to trace ancient population
migrations. Although experiments relying on model
organisms and cytoplasmic hybrids, as well as disease
association studies, have served to underline the function-
ality of certain mtDNA SNPs, only little is known of the
regulatory impact of ancient mtDNA variants, especially in
terms of gene expression. By analyzing RNA-seq data of
454 lymphoblast cell lines from the 1000 Genomes Project,
we found that mtDNA variants deﬁning the most common
African genetic background, the L haplogroup, exhibit a
distinct overall mtDNA gene expression pattern, which was
independent of mtDNA copy numbers. Secondly, intra-
population analysis revealed subtle, yet signiﬁcant,
expression differences in four tRNA genes. Strikingly, the
more prominent African mtDNA gene expression pattern
best correlated with the expression of nuclear DNA-
encoded RNA-binding proteins, and with SNPs within the
mitochondrial RNA-binding proteins PTCD1 and MRPS7.
Our results thus support the concept of an ancient regulatory
transition of mtDNA-encoded genes as humans left Africa
to populate the rest of the world.
This study was funded by research grants from the Israeli
Science Foundation (ISF 610/12), from the Binational
Science Foundation (BSF) 2013060, and from the US Army
Life Science division grant 67993LS awarded to DM.
T. Cohen: None. L. Levin: None. D. Mishmar: None.
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Prediction of pleiotropic genes using a multilocus
approach
B. Karacaören
Akdeniz University, Antalya, Turkey
Introduction: Genome wide association studies (GWASs)
used to search for genetic variants associated with quanti-
tative traits. Pleiotropic effect of genes may cause the
observed correlations among different phenotypes. The
main aims were 1) investigate if the multilocus model was
useful for detecting pleiotropic genes using a simulated data
set and to investigate pleiotropic genes for testis weight and
testis gene expression levels in house mouse. Material and
Methods: The pedigree included 4100 individuals for
3 simulated quantitative traits (Usai et al., 2014). The
genome consisted of 10000 Single Nucleotide Polymorph-
isms (SNPs) distributed over 5 chromosomes. The mice
data consists of 179 males from house mouse (Turner and
Harr, 2014). Results: We assumed different genetic archi-
tectures for the QTLMAS phenotypes. The posterior mean
number of major SNPs were 51, 73 and 200 for 3 traits
respectively. To identify fertility related pleiotropic geno-
mic regions in 179 male mice: we analyzed relative testis
weight and genome wide testis gene expression patterns
using multilocus model. The ﬁrst principal component (PC)
account for highest explanatory proportion (14 %) of the
data. And each succeeding PCs predicted very small sizes of
SNPs effects. Multilocus model detected 50 and 53 major
SNP effects using ﬁrst and the second PCs. Conclusion:
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We presented a multilocus model to detect pleiotropic
SNPs. These ﬁndings show that assumption for different
pleiotropic SNPs effects sizes lead to better genomic pre-
dictions compared with the single SNP approach. The study
was supported by Akdeniz University Scientiﬁc Research
Projects Unit, project number: FBA-2015-1117.
B. Karacaören: None.
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Reconstructing the origin of Csango people on a
genome-wide basis
Z. Bánfai1,2, V. Ádám1, K. Sümegi1,2, A. Szabó1,2, A.
Miseta3, B. Melegh1,2
1Department of Medical Genetics, Clinical Centre, Uni-
versity of Pécs, Pécs, Hungary, 2Szentágothai Research
Centre, University of Pécs, Pécs, Hungary, 3Department of
Laboratory Medicine, Medical School, University of Pécs,
Pécs, Hungary
Csangos are a closed ethnic group living mostly in Mol-
davia, Romania, counting approximately 230,000 indivi-
duals. Their traditional language is Csango, an old
Hungarian dialect, which recently became severely endan-
gered. Their culture has remarkable connections to Hun-
garian culture, yet their origins are still heavily disputed by
Hungarian and Romanian sources. Theories regarding their
origin were established since the 19th century. This study
concentrates on relationship of Csangos, Romanians and
Hungarians to investigate the origin of Csango people.
Here we analyzed genome-wide SNP array data from
Csango individuals (n= 30), genotyped on Affymetrix 1M
chip. We used datasets at our disposal to represent distinct
Eurasian populations. Ancestry estimating and clustering
software based on statistical (ADMIXTURE1.22, FineS-
TRUCTURE2) and algorithmic (EIGENSTRAT6.01)
methods were applied. IBD analyses were carried out using
BEAGLE4.1 for supporting purposes and to attempt spe-
cifying the sources of Csango ancestry.
Results show that investigated populations have strong
relationship with East European populations. Csangos are
closer to Hungarians, since average pairwise IBD sharings
were 3.36Mb with Hungarians and 2.63Mb with Roma-
nians. Latter is close to sharing between Hungarians and
Romanians (2.59Mb). East-Central European populations
have strong relationship with Turkic people, which is more
signiﬁcant in case of Hungarians. However, Csangos show
even higher relationship with Turkic people from the Rus-
sian area, which distinguishes them also from the major
populations of the region.
Our ancestry analyses of Csangos indicates their highest
relationship to Hungarians. They show also a signiﬁcant
common history with nomadic Turkic people who are
nowadays settled in the territory of Russia.
Z. Bánfai: None. V. Ádám: None. K. Sümegi: None. A.
Szabó: None. A. Miseta: None. B. Melegh: None.
P18.48D
Sequence variants associating with serum protein levels
in icelanders
R. P. Kristjansson, O. B. Davidsson, S. Benonisdottir, G.
Halldorsson, G. Norddahl, F. Zink, S. Gudjonsson, B. O.
Jensson, A. Oddsson, G. A. Arnadottir, S.
Gudmundsdottir, G. Masson, P. Nioi, U. Thorsteinsdottir,
P. Sulem, K. Stefansson
deCode genetics / Amgen Inc, Reykjavík, Iceland
Introduction: Genome-wide association studies have
focused largely on the effect of sequence variants on clinical
phenotypes. It remains necessary to bridge the gap between
diversity of genotypes and normal phenotypes in order to
shed light on pathogenesis of diseases. We attempt this by
studying the effects of sequence variants on serum protein
levels.
Materials and Methods: We performed a genome-wide
association study searching for sequence variants associat-
ing with serum protein levels (pQTL). A total of 1,310
proteins were assayed using the SOMAmer proteomics
platform (SomaLogic Inc.) in 294 Icelanders. We performed
conditional analysis on sequence variants in a systematic
manner in order to separate distinct signals from each other.
Results: The study yielded 228 independent associations
with a total of 204 proteins. Of these signals, 138 are
located within 1Mb of the gene encoding the protein in
question (cis signals) and 90 are located more than 1Mb
away from the encoding gene, or on another chromosome
(trans). Of note, the missense Thr400Met in VTN (MAF =
49.3%) associates signiﬁcantly with levels of 24 proteins
(including vitronectin itself). The allele associating with
decreased levels for 20 of these proteins is also reported to
associate with a decreased risk of age-related macular
degeneration. In addition, using our own and public data we
assessed the relationship of pQTL with expression (eQTL).
Conclusion: We detect a large number of highly sig-
niﬁcant distinct signals, shedding light on the genetics of
the human proteome. These data have the potential to
provide insight into human pathophysiology.
R.P. Kristjansson: A. Employment (full or part-time);
Signiﬁcant; deCode genetics / Amgen Inc. O.B. Davidsson:
A. Employment (full or part-time); Signiﬁcant; deCODE
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Polygenic analysis of genome-wide SNP data identiﬁes
common variants on allergic rhinitis
A. Mohammadnejad1, C. Brasch-Andersen1, A.
Haagerup2, J. Vestbo3, J. Baumbach1, Q. Tan1
1University Of Southern Denmark, Odense, Denmark,
2Aarhus University, Herning, Denmark, 3University Of
Manchester, Manchester, United Kingdom
Background: Allergic Rhinitis (AR) is a complex disorder
that affects many people around the world. There is a high
genetic contribution to the development of the AR, as twins
and family studies have estimated heritability of more than
33%. Due to the complex nature of the disease, single SNP
analysis has limited power in identifying the genetic var-
iations for AR. We combined genome-wide association
analysis (GWAS) with polygenic risk score (PRS) in
exploring the genetic basis underlying the disease.
Methods: We collected clinical data on 631 Danish
subjects with AR cases consisting of 434 sibling pairs and
unrelated individuals and control subjects of 197 unrelated
individuals. SNP genotyping was done by Affymetrix
Genome-Wide Human SNP Array 5.0. SNP imputation was
performed using "IMPUTE2". Using additive effect model,
GWAS was conducted in discovery sample, the genotypes
and their effect sizes were used to calculate PRS in the
testing sample. Gene-based test and biological pathway
analysis were performed using "VEGAS2" software.
Results: We found 56 suggestive signiﬁcant SNPs from
GWAS (p < 10−5). A signiﬁcant PRS (p=0.0016) was
deﬁned by 745 SNPs (P-value cut-off <0.0005) which
explains 3% of the variation in AR. Furthermore, we found
1195 signiﬁcant genes (p<0.05) enriched by their relevant
SNPs. Biological pathway analysis identiﬁed multiple sig-
niﬁcant gene-sets with the top-most of them implicated in
signaling pathways.
Conclusion: Our polygenic analysis identiﬁed sig-
niﬁcant common SNPs underlying AR. Gene-based and
biological pathway analysis revealed signiﬁcant and
meaningful pathways implicated in AR.
A. Mohammadnejad: None. C. Brasch-Andersen:
None. A. Haagerup: None. J. Vestbo: None. J. Baum-
bach: None. Q. Tan: None.
P18.50B
Estimating the number of patients with a paediatric
onset Rare Disease seen by a single National Genetics
centre born in a single year
E. Gunne1, A. Ward1, L. Bradley1, D. Lambert2, S.
Lynch1,2
1National Centre for Medical Genetics, Dublin 12, Ireland,
2National Rare Disease Ofﬁce, Dublin 7, Ireland
Objective: To derive a proxy estimate the number of
childhood onset rare diseases through referrals to the
country’s only Genetics centre, as the Republic of Ireland
does not have a centralized rare disease registry.
Methods: A retrospective review of referrals to cytoge-
netics and clinical genetics for the years 2000–2016, for
patients born in the year 2000, was undertaken. Anon-
ymized data was catalogued into rare, common, normal,
likely rare & unclassiﬁable diagnoses by review of records,
and assigned Orphacodes based on diagnosis. Census
livebirth data was used as the denominator.
Results: 54,789 livebirths were recorded by the census in
2000. 1872 referrals to Genetics (representing 1749 indi-
viduals) were retrieved for review. 1006 had cytogenetics
testing only, of which 51 had rare chromosomal anomalies.
Review of 743 referrals to clinical genetics identiﬁed 541
with a rare disease (73%), and 9 with a likely rare disease.
Of the 53/1749 who had died (3%), 51 had a rare disease,
with congenital malformations (24) the most common
cause. A further 89 had trisomy 21, which is not rare in
Ireland.
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Conclusion: A total of at least 592 rare disease patients
presented by age 16 in this cohort, giving a minimum
incidence of 1.1% for paediatric rare diseases. Including the
Trisomy 21 and likely rare cases, the incidence of 1.3% is
still less than international estimates, but represents a ﬁrst
attempt to estimate numbers of Irish rare disease patients.
Clearly, extending the study to include other rare disease
sources (metabolics, molecular genetics) would improve
ascertainment.
E. Gunne: None. A. Ward: None. L. Bradley: None.
D. Lambert: None. S. Lynch: None.
P18.52D
Rare variant association tests for pleiotropy in long-
itudinal family studies
J. Yu, Y. Chiu
National Health Research Institutes, Zhunan, Taiwan
Abundant pleiotropy has been observed in many complex
traits or disease. When pleiotropy exists, testing rare var-
iants for multiple phenotypes simultaneously is often more
powerful than for single phenotype through borrowing
additional information from cross-phenotype correlation.
Likewise, identifying rare variants associated with repeated
phenotypic measurements in longitudinal studies can also
have greater statistical power than that in a cross-sectional
study. On the other hand, functional rare variants are often
enriched in family-based designs. Longitudinal family-
based designs therefore provide valuable opportunities to
increase statistical power on identifying pleiotropic rare
variants associated with multiple phenotypes. In addition,
identiﬁcation of pleiotropic variants is helpful for elucidat-
ing shared pathogenesis of multiple phenotypes. However,
statistical tests for pleiotropic rare variants detection in
longitudinal family studies remain fairly limited. We
extended pedigree-based burden and kernel association tests
to longitudinal studies with multiple phenotypes. General-
ized estimating equation (GEE) approaches were used to
account for the correlations from multiple phenotypes at
individual time points as well as the complex correlations
between repeated measures of the same phenotype (serial
correlations) and between individuals within the same
family (familial correlations). Extensive simulation studies
were conducted to evaluate performance of the proposed
tests under various conﬁgurations. The proposed tests were
illustrated by a real data example. Both simulation study
and data example suggested that incorporating multiple
phenotypes can increase statistical power of the proposed
tests on rare variant detection. (This study has been sup-
ported by grants from Ministry of Science and Technology
(MOST105-2314-B-400-017) and National Health
Research Institutes in Taiwan (PH-104~106-PP-04).)
J. Yu: None. Y. Chiu: None.
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A correction for sample overlap in GWAS in a polygenic
pleiotropy-informed framework
M. LeBlanc1,2, V. Zuber3,4,5, W. K. Thompson6, O. A.
Andreassen3,4, the Schizophrenia and Bipolar Disorder
Working Groups of the Psychiatric Genomics Consortium,
A. Frigessi1, B. Kulle Andreassen1,7
1Oslo Centre for Biostatistics and Epidemiology, Oslo,
Norway, 2Department of Clinical Molecular Biology,
Institute of Clinical Medicine, University of Oslo, Oslo,
Norway, 3NORMENT-KG Jebsen Centre for Psychosis
Research, Institute of Clinical Medicine, University of
Oslo,, Oslo, Norway, 4Division of Mental Health and
Addiction, Oslo University Hospital, Oslo, Norway, 5Eur-
opean Bioinformatics Institute (EMBL-EBI), Cambridge,
United Kingdom, 6Department of Psychiatry, University of
California, San Diego, La Jolla, CA, United States,
77Department of Research, Cancer Registry of Norway,
Oslo, Norway
Backgroud: There is considerable evidence that many
complex traits have a partially shared genetic basis, termed
pleiotropy. It is therefore useful to consider integrating
genome-wide association study (GWAS) data across several
traits, usually at the summary statistic level. A major
practical challenge arises when these GWAS have over-
lapping subjects. This is particularly an issue when esti-
mating pleiotropy using methods that condition the
signiﬁcance of one trait on the
signﬁcance of a second, such as the covariate-modulated
false discovery rate (cmfdr).
Methods and Principle Findings: We propose a method
for correcting for sample overlap at the summary statistic
level. We quantify the expected amount of spurious corre-
lation between the summary statistics from two GWAS due
to sample overlap, and use this estimated correlation in a
simple linear correction that adjusts the joint distribution of
test statistics from the two GWAS. The correction is
appropriate for GWAS with case-control or quantitative
outcomes. Our simulations and data example show that
without correcting for sample overlap, the cmfdr is not
properly controlled, leading to an excessive number of false
discoveries and an excessive false discovery proportion.
Our correction for sample overlap is effective in that it
restores proper control of the false discovery rate, at very
little loss in power.
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Conclusion: With our proposed correction, it is possible
to integrate GWAS summary statistics with overlapping
samples in a statistical framework that is dependent on the
joint distribution of the two GWAS.
M. LeBlanc: None. V. Zuber: None.W.K. Thompson:
None. O.A. Andreassen: None. A. Frigessi: None. B.
Kulle Andreassen: None.
P18.54B
Signiﬁcance of secondary genetic ﬁndings in a large
prospective population sample
K. Kristiansson1,2, P. Salo1,2, V. Salomaa1, P. Jousilahti1,
H. Kääriäinen1, M. Perola1,2,3
1National Institute for Health and Welfare, Helsinki,
Finland, 2Institute for Molecular Medicine Finland, Uni-
versity of Helsinki, Helsinki, Finland, 3University of Tartu,
Estonian Genome Centre, Tartu, Estonia
Introduction: Genetic studies are encouraged to return
secondary ﬁndings from clinically important genes to the
study participants. The rare but highly penetrant mutations
in these genes typically lead to serious consequences, such
as cancer or serious heart dysrhythmia, but there are known
medical interventions with potential life-saving value.
Although classiﬁed as pathogenic in web-based databases,
the impact of most risk variants at a population level
remains unclear.
Material and Methods: We studied variation in the 59
genes of the American College of Medical Genetics and
Genomics (ACMG) secondary ﬁndings recommendation.
Impact of the risk variants on clinical outcomes was eval-
uated in 25–74 year old FINRISK study participants (N~23
000) using up to 23 years of follow-up. The variants, gen-
otyped with genome-wide microarrays and imputed using
population speciﬁc reference panel, were analyzed in time-
to-event and logistic regression models.
Results: The expected number of risk allele carriers for
75 ACMG risk variants varied between 4 and 300 based on
publicly known allele frequencies and similar numbers were
seen in FINRISK. Although some variants associated with
increased risk of an event during follow up (e.g. carriers of a
risk variant in a cardiomyopathy associated gene had a 3.7
times higher risk of heart failure compared to non-carriers in
Cox survival analysis (p=0.0014)), for a large majority we
observed no clinical signiﬁcance.
Conclusions: Before secondary ﬁndings from clinically
important genes are returned to study participants, the sig-
niﬁcance of the variants needs to be carefully evaluated at a
population level.
Funding information: Academy of Finland.
K. Kristiansson: None. P. Salo: None. V. Salomaa:
None. P. Jousilahti: None. H. Kääriäinen: None. M.
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Genetic signals of selection in Native and admixed
populations of Latin America
J. Mendoza-Revilla1, K. Adhikari1, M. Fumagalli2, V.
Acuña-Alonzo1, S. Canizales-Quinteros3, C. Gallo4, G.
Poletti4, F. Rothhammer5, M. Bortolini6, G. Bedoya7, R.
Gonzalez-José8, F. Balloux1, D. Balding1, A. Ruiz-
Linares1
1University College London, London, United Kingdom,
2Imperial College London, London, United Kingdom,
3Facultad de Medicina and Facultad de Química, UNAM;
Instituto Nacional de Ciencias Médicas y Nutrición
Salvador Zubirán, Mexico City, Mexico, 4Laboratorios de
Investigación y Desarrollo, Facultad de Ciencias y
Filosofía, Universidad Peruana Cayetano Heredia, Lima,
Peru, 5Instituto de Alta Investigación Universidad de
Tarapacá, Tarapacá, Chile, 66 Departamento de Genética,
Universidade Federal do Rio Grande do Sul, Porto Alegre,
Brazil, 7Laboratorio de Genética Molecular, Facultad de
Ciencias Exactas y Naturales, Universidad de Antioquia,
Medellín, Colombia, 8Centro Nacional Patagónico, CON-
ICET, Puerto Madryn, Argentina
The peopling of the Americas represents the last major
expansion of human populations worldwide. As the ﬁrst
humans moved into the continent they were exposed to
multiple new environments requiring them to adapt. The
subsequent colonization of the continent by Europeans,
along with the African slave trade, involved a major
admixture process that was accompanied by new selective
pressures, most notably exposure to new pathogens and
disease.
In this study we examine how these major events have
shaped the genetic landscape of present day inhabitants of
the Americas. Using genome-wide data from over 200
Native Americans genotyped at over 700,000 autosomal
SNPs, we test for signatures of positive selection using a
suite of haplotype and population differentiation-based
methods. Our top candidate regions of selection include
genes associated with metabolic traits, highlighting a pos-
sible adaptation to dietary changes.
Taking advantage of the complex admixture history of
Latin America, we also explore the distribution of Native
American, European and African ancestry across the gen-
ome of 5 different admixed populations in Latin America.
We test for regions of the genome with inferred ancestry
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signiﬁcantly different from the genome-wide average, to
identify regions under post-colonial selection. Using this
method, we demonstrate that the HLA region, largely
involved in the immune response, shows the highest
deviation towards African ancestry across all populations
tested. This result suggests a major widespread selective
pressure throughout the continent likely in response to
infectious diseases introduced by the arrival of Europeans.
J. Mendoza-Revilla: None. K. Adhikari: None. M.
Fumagalli: None. V. Acuña-Alonzo: None. S. Canizales-
Quinteros: None. C. Gallo: None. G. Poletti: None. F.
Rothhammer: None. M. Bortolini: None. G. Bedoya:
None. R. Gonzalez-José: None. F. Balloux: None. D.
Balding: None. A. Ruiz-Linares: None.
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The Human Variome Project Global Globin 2020
Challenge and the ITHANET Portal: pioneering global
epidemiological data collection and removing the diag-
nostic divide
C. W. Lederer1, P. Kountouris1, C. Stephanou1, J. Elion2,
R. Ramesar3, Z. bin Alwi4, H. M. Robinson5, M.
Kleanthous1, HVP Global Globin 2020 Challenge
1The Cyprus Institute of Neurology and Genetics, Nicosia,
Cyprus, 2Paris Diderot University Medical School, Paris,
France, 3University of Cape Town, Cape town, South
Africa, 4Universiti Sains Malaysia, Kelantan, Malaysia,
5Human Variome Project International Coordinating
Ofﬁce, Melbourne, Australia
Haemoglobinopathies are severe monogenic diseases with
growing worldwide distribution and signiﬁcant health-
economic impact. Their prevalence in low- and middle-
income countries (LMICs) poses an apparently insur-
mountable challenge to many affected communities through
the frequent absence or inadequacy of three key factors: a)
an infrastructure for safe and universal treatment of hae-
moglobinopathy patients, b) a system for carrier screening
and disease prevention and c) molecular epidemiological
information. Even approximate provision of the latter
allows data-guided policies to address all three factors and
has thus historically proven to contribute to tremendous
savings in health expenditure, disease control and preven-
tion of suffering.
The Global Globin 2020 Challenge (www.humanva
riomeproject.org/gg2020), initiated by the Human Variome
Project, has set as its goal to achieve the comprehensive
collection and sharing of variant data in LMICs and to use
this information towards more effective disease prevention
and management in LMICs. Shared database development
and strategic support of screening technology in partner
countries will serve as key instruments in achieving these
objectives. GG2020 already comprises clinicians, geneti-
cists and bioinformaticians from over 40 countries and in
close partnership with the ITHANET Portal (www.ithanet.
eu) has helped compile an unprecedented resource of
national and regional etymological and health care infor-
mation on IthaMaps (www.ithanet.eu/db/ithamaps). The
critical mass of expertise, liaison with ClinGen and envi-
saged screening activities of GG2020 will further add to
variants and their classiﬁcation in IthaGenes (www.ithanet.
eu/db/ithagenes), which with 2590 fully annotated muta-
tions in over 200 genes, regulatory sequences and intergenic
regions is already the largest disease-speciﬁc mutation
database for haemoglobinopathies.
C.W. Lederer: None. P. Kountouris: None. C. Ste-
phanou: None. J. Elion: None. R. Ramesar: None. Z. bin
Alwi: None. H.M. Robinson: None. M. Kleanthous:
None.
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Circadian genes and differentiated thyroid cancer risk
T. Truong1, T. Berrandou1, E. Cordina-Duverger1, M.
Sanchez1, A. Guizard2,3, C. Schvartz4, C. Mulot5, P.
Laurent-Puig5, F. de Vathaire6, P. Guénel1
1CESP - Cancer and Environment team, INSERM U1018,
Université Paris-Sud, Université Paris-Saclay, Villejuif,
France, 2Registre Général des tumeurs du Calvados,
Centre François Baclesse, Caen, France, 3U1086
INSERM-UCNB, Cancers and Prevention, Caen, France,
4Centre de Lutte Contre le Cancer Jean Godinot, Reims,
France, 5Center for Biological Resources EPIGENETEC,
Université Paris Descartes, INSERM UMR 5775, Paris,
France, 6CESP - Cancer and Radiations team, INSERM
U1018, Université Paris-Sud, Université Paris-Saclay,
Villejuif, France
Differentiated thyroid carcinoma (DTC) is the most com-
mon malignancy of the human endocrine system and its
incidence is 3–4 times higher in women than in men. DTC
has a familial relative risk higher than others cancers, sug-
gesting a contribution of inherited factors to the disease.
However, the susceptibility variants identiﬁed to date only
account for a small part of genetic predisposition in DTC
risk. It has been hypothesized that clock genes may affect
cancer susceptibility by impacting on the biological path-
ways that regulate DNA damage and repair, carcinogen
metabolism and/or detoxiﬁcation and cell-cycle.
We investigated the role of circadian clock gene poly-
morphisms in DTC risk in women from a population-based
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case-control study conducted in France including 463 DTC
cases and 482 controls. We estimated thyroid cancer risk
associated with each of the 570 SNPs in 23 circadian clock
genes. We also used a gene- and pathway-based approach to
investigate the overall effect on DTC of circadian clock
gene variants that might not be detected in analyses based
on individual SNPs. Interactions with suspected risk factors
of DTC such as BMI, reproductive factors, alcohol drinking
and smoking status were tested at the SNP, gene, and
pathway levels.
Overall, we reported no main genetic association at the
SNP, gene or pathway level with DTC risk. There was some
evidence of an interaction between PER3 or RORC and
smoking status in DTC. Our results suggest that circadian
clock gene variants may modulate the association between
smoking status and DTC risk.
T. Truong: None. T. Berrandou: None. E. Cordina-
Duverger: None. M. Sanchez: None. A. Guizard: None.
C. Schvartz: None. C. Mulot: None. P. Laurent-Puig:
None. F. de Vathaire: None. P. Guénel: None.
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Annotation of genetic variation within Genome Russia
project
D. V. Zhernakova1,2, S. Kliver1, N. Cherkasov1, I.
Evsukov1, A. Gorbunova1, S. Kolchanova1, A.
Shevchenko1, M. Rotkevich1, A. Yurchenko1, S. Sidorov1,
G. Tamazian1, P. Dobrynin1, A. Komissarov1, K.
Krasheninnikova1, S. V. Malov1, D. E. Polev3, T. K.
Davydova4, T. Sivtseva4, A. Glotov3, V. Osakovsky4, A.
Novozhilov5, V. Brukhin1, S. J. O'Brien1
1Theodosius Dobzhansky Center for Genome Bioinfor-
matics, St. Petersburg State University, St. Petersburg,
Russian Federation, 2University of Groningen, University
Medical Center Groningen, Department of Genetics,
Groningen, Netherlands, 3Research Resource Center for
Molecular and Cell Technologies, Research Park, St.
Petersburg, Russian Federation, 4Institute of Health,
North-Eastern Federal University, Yakutsk, Russian Fed-
eration, 5Department of Ethnography and Anthropology, St.
Petersburg State University, St. Petersburg, Russian
Federation
Recent years have seen a large number of national genomic
projects highlighting the diversity and similarity of world
populations, providing insight into population history and
aiding in medical genomics applications. In spite of being
the largest country in the world, until recently Russia has
not participated in large sequencing projects. To overcome
this, Genome Russia project was initiated aiming to
generate whole genome sequences of more than
2,000 samples coming from diverse populations throughout
Russia. General objectives of Genome Russia include
characterization of known and novel genetic variation of
different Russian population groups and ethnic minorities;
creating a reference database of genetic variation within
Russia that can be further used for medical studies; inves-
tigating population history and admixture; identifying
genetic variants that may affect the frequency of known
diseases in Russian populations. Here we present the results
obtained on the ﬁrst batch of 32 samples representing three
population groups coming from Novgorod region, Pskov
region and Yakutia. We identiﬁed more than 4 million
SNPs and more than 120,000 short indels in our data. We
combined our SNV results with the same mined from 206
recently released Russian genomes samples (Pagani et al.
2016; Mallick et al. 2016) in order to increase the sample
size. We annotated the identiﬁed variants and investigated
the predicted effect of known and novel variants and
compared minor allele frequencies with those of popula-
tions represented in 1000G data.
D.V. Zhernakova: None. S. Kliver: None. N. Cher-
kasov: None. I. Evsukov: None. A. Gorbunova: None. S.
Kolchanova: None. A. Shevchenko: None.M. Rotkevich:
None. A. Yurchenko: None. S. Sidorov: None. G.
Tamazian: None. P. Dobrynin: None. A. Komissarov:
None. K. Krasheninnikova: None. S.V. Malov: None. D.
E. Polev: None. T.K. Davydova: None. T. Sivtseva:
None. A. Glotov: None. V. Osakovsky: None. A.
Novozhilov: None. V. Brukhin: None. S.J. O'Brien:
None.
P18.59C
The SweGen project: building a whole-genome refer-
ence dataset for the Swedish population
A. Ameur1, H. Che1, I. Buniks1, P. Olason1, R. Karlsson2,
I. Höijer1, I. Jonasson1, P. Magnusson2, U. Gyllensten1
1Uppsala University, Uppsala, Sweden, 2Karolinska Insti-
tutet, Stockholm, Sweden
We are undertaking the largest human whole-genome
sequencing (WGS) project in Sweden to date; the genera-
tion of a reference database that reﬂects the genetic structure
of the population. 1000 individuals were selected for this
project, sampled to cover the genetic variation within
Sweden based on results from PCA analysis of available
SNP array data. All of these 1000 individuals have been
subjected to short-read WGS using Illumina technology at
30X coverage. Two individuals were used to generate high-
quality de novo reference genomes for the population.
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Assembly of 75X coverage of PacBio data for each of the
samples resulted in N50 values of 8.3 and 8.9 Mb, and
BioNano optical genome maps increased the N50 to over 50
Mb. Our two Swedish de novo genomes are now being used
to study population-speciﬁc structural variation in some of
the regions in the human genome that are difﬁcult to resolve
using Illumina technology.
A principal aim of this project is to establish a reference
dataset of genetic variants in the Swedish population for use
in disease association studies and as a look-up resource for
the evaluation genetic variants identiﬁed in sequencing of
patients. It will also provide a unique dataset for research on
the structure of genetic variation within Sweden, as well as
for international collaborative projects. The SweGen variant
frequency data is made available from the following web-
site: swefreq.nbis.se
A. Ameur: None. H. Che: None. I. Buniks: None. P.
Olason: None. R. Karlsson: None. I. Höijer: None. I.
Jonasson: None. P. Magnusson: None. U. Gyllensten:
None.
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P19.01A
Reconciling non-directivity and the counselors' pre-
ference in prenatal counseling
S. L. van der Steen1, I. M. Bakkeren1, R. J. H. Galjaard1,
M. G. Polak2, J. J. Busschbach1, S. R. Riedijk1, A. Tibben3
1Erasmus Medical Center, Rotterdam, Netherlands, 2Eras-
mus University Rotterdam, Rotterdam, Netherlands, 3Lei-
den University Medical Center, Rotterdam, Netherlands
Background: In the Netherlands, non-invasive prenatal
testing (NIPT) is offered next to prenatal diagnosis (PND)
to pregnant women at increased risk of common aneu-
ploidies. Although non-directivity is the guiding principle in
prenatal counseling, counselors might inadvertently prefer
one option over the other, which may impact reproductive
autonomy and/or lead to unequal access to care. This study
explored to which extent counselor preference for NIPT/
PND affected patients’ choice, whether patients were aware
of counselor preference and whether there were differences
in knowledge scores.
Materials and Methods: 327 women were eligible of
whom 158 women were included in the study; 82% opted
for NIPT and 18% chose PND. We assessed patients’
knowledge scores and perception of counselor test pre-
ference. Counselors were either senior obstetricians (SO;1–
3) or a senior nurse (SN) (SO1:57; SO2:71; SO3: 23; and
SN:23 patients). Counselors participated in a semi-
structured interview about the content of their counseling
and their own NIPT/PND preferences.
Results: Signiﬁcant differences in NIPT/PND ratios
were observed between counselors, with the largest differ-
ence between patients from SO2 and SO3 (38% PND versus
7% respectively). Patients were aware of counselors’ pre-
ference, and patients’ choices were consistent with these
preferences, as established through interview analysis.
Knowledge scores were equal, however, chi-square tests
revealed that counselor preference was associated with
more patient knowledge of NIPT or PND.
Conclusion: Patients displayed a tendency to choose in
accordance with the personal preference of their counselor.
These results are more in line with the paradigm of shared
decision-making, than the paradigm of non-directivity.
S.L. van der Steen: None. I.M. Bakkeren: None. R.J.
H. Galjaard: None. M.G. Polak: None. J.J. Busschbach:
None. S.R. Riedijk: None. A. Tibben: None.
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Pregnant genetic counselors in the era of advanced
genomic tests: What do the experts test prenatally?
S. Shkedi-Raﬁd1, Y. Hashiloni-Dolev2
1Hadassah Hebrew University Medical Center, Jerusalem,
Israel, 2The Academic College of Tel Aviv-Yaffo, Tel Aviv,
Israel
Purpose: Advanced genomic tests in pregnancy, such as
chromosomal-microarray-analysis (CMA), provide higher
detection rates, yet often produce probabilistic and uncertain
information.
This study aimed to understand how knowledgeable
patients, i.e., pregnant genetic counsellors, act during their
own pregnancies, and by so doing to gain insight into the
contribution of patient's knowledge to the diagnostic
experience.
Methods: In-depth interviews were conducted with
seventeen Israeli genetic counsellors, either pregnant or up
to two-years post-pregnancy.
Findings: One third of the participants chose not to have
CMA, and two-thirds underwent CMA, even though they
had no abnormal-ﬁndings during pregnancy. Although
knowledge was the main motivation for genomic testing,
counsellors varied in the desired degree of knowledge.
Two-thirds of those opting for CMA wished to be informed
of all ﬁndings identiﬁed via CMA. About a third asked for a
targeted-platform, whereby only large deletions/duplica-
tions and those associated with known syndromes are dis-
closed, wishing to avoid uncertain results.
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Being knowledgeable was described as mostly empow-
ering and desired both by counselors opting for CMA, and
those avoiding it. Nevertheless, counsellors acknowledged
the disadvantages of unlimited information, including a
sense of distress and moral confusion.
Conclusion: Our ﬁndings suggest that being knowl-
edgeable promotes a sense of control on the one hand, but
stress and moral-dilemmas on the other hand. We therefore
argue that while the basic premise for informed-consent is
crucial, it does not ubiquitously make things easier for
educated patients. Consequently, raising levels of patient
knowledge is a limited step forward in the strive for best
practice.
S. Shkedi-Raﬁd: None. Y. Hashiloni-Dolev: None.
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Reproductive experiences, medical concerns and moral
attitudes among preimplantation genetic diagnosis
(PGD) users: Synthesis of qualitative and quantitative
analysis
S. Zuckerman1, S. Gooldin2, G. Altarescu1
1Hebrew University; Shaare Zedek Medical Center, Jer-
usalem, Israel, 2Hebrew University, Jerusalem, Israel
PGD may eliminate some of the obstacles related to con-
servative options of prenatal diagnosis, but can raise per-
sonal, social and moral questions. Scant empirical data
focused on PGD users’ experiences. A combined metho-
dology was used to investigate PGD’s implications on its
users: Qualitative analysis of semi-structured in-depth face-
to-face interviews with 43 PGD users, representing variety
of population’s sub-groups. On the basis of the interviews, a
detailed closed web-based questionnaire was developed.
Univariate and multivariate adjustment was performed on
data obtained from 155 subjects. PGD is considered a
preferable diagnostic procedure for 139 (95%) subjects.
Nevertheless, 71 (47 %) reported a complex decision-
making process. Perceived advantages are: assurance of the
embryo's unaffected status from the beginning of the
pregnancy, thus avoiding the need for pregnancy termina-
tion and invasive prenatal tests. Perceived disadvantages
focused on the medical actions involved, and the delay in
time between the ﬁrst counseling and the PGD procedure
itself. Other future needs included improving the commu-
nication with medical staff and implementing emotional
support. The study indicates special needs of respondents
from groups with distinct genetic and socioeconomic
backgrounds. Subjects introduce permissive moral stand
regarding different PGD uses but made a clear distinction
between medically justiﬁed applications to unjustiﬁed social
and aesthetic uses. This interdisciplinary qualitative and
quantitative analysis of a large sample of PGD users can
form a basis for development of counseling and guidance
programs of future PGD users and will also help foster a
public debate concerning medical, ethical, sociological and
economic aspects of the technology.
S. Zuckerman: None. S. Gooldin: None. G. Altarescu:
None.
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Pooling genomic data into a "national data lake": the
ﬁrst steps towards establishing a UK learning healthcare
system
S. Dheensa1, S. Sterckx2, J. Cockbain2, A. Fenwick1, A.
Lucassen1
1Clinical Ethics and Law, Faculty of Medicine, University
of Southampton, Southampton, United Kingdom, 2Bioethics
Institute Ghent, Ghent, Belgium
Introduction: The National Health Service (NHS) recently
proposed integrating genomic and other omic data, and data
from digitised health records, wearables, and apps, from the
general UK population, into a “national data lake”. Pseu-
donymised and identiﬁable data would be made available
for research and analytics by pharma and tech companies
(e.g., Google’s Deep-Mind). These are the ﬁrst steps
towards establishing a learning healthcare system, a model
that hybridises research and clinical care, in the UK. A
principle that is professed to underlie the proposed approach
is for information-sharing to be based on the local trusted
relationship between citizens and healthcare professionals.
In light of this, we investigated the acceptability of this
proposal to patients and the public.
Method: We analysed online public opinion; surveys
with 300+ patients with rare diseases from the UK
100,000 genomes project, and interviews with 25 of these
participants.
Results: We will present key themes, furnished with
survey results. (1) patients/the public do not know, so
cannot be assumed to trust, the commercial actors and
government departments with access to their data; (2) broad
consent for data-usage is not as acceptable as the genomics
literature suggests; (3) patients/the public emphasise the
importance of beneﬁt-sharing and equality of access to
healthcare; (4) but a discourse of altruism surrounds data
sharing practices, which masks this importance.
Conclusions: Meaningful, non-tokenistic, public and
patient involvement is needed for any learning healthcare
system to be of beneﬁt. We make recommendations to
policy and practice on how this should be achieved.
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Educating a community of practice in clinical
bioinformatics
A. C. Davies, D. Harris, A. Banks-Gatenby, A. Brass
The University of Manchester, Manchester, United
Kingdom
Introduction: At the University of Manchester we are
training a masters-level cohort of clinical bioinformaticians,
training in the NHS, using a ‘ﬂipped teaching’ approach
focussed on group-centred problem-based learning groun-
ded in clinical case studies. . A new profession to the NHS,
many clinical bioinformaticians are geographically isolated
preventing rapid sharing of best practices. Therefore,
building a strong network or community of practice (CoP)
to support this important and innovative profession is
critical.
Methodology: In a research study involving Manchester
Institute of Education (MIE) students were interviewed
using a semi-structured approach regarding their experi-
ences of the new teaching strategy. In order to ascertain
whether one or more CoPs were formed, we evaluated
against Wenger’s key themes characterising CoPs were
investigated in the data: (i) mutual engagement of partici-
pants; (ii) concepts of the joint enterprise and (iii) shared
repertoire.
Results: The results of the interviews aligned to the
following main themes:
• Shared best practice in bioinformatics.
• Integration and accountability of a new profession into
the NHS.
• Isolation in practice
• Novel teaching approaches
• Continuous course development based upon student
feedback
• Cohort maintaining strong ties and ownership of the
ﬁeld.
Conclusions This research showed that via a ‘ﬂipped
teaching’ approach the bioinformatics students were able to
develop the three distinct elements of a CoP, i.e. mutual
engagement, joint enterprise and shared repertoire, and this
CoP extended into their workplace supporting otherwise
isolated students.
Wenger, E. (1998). Communities of Practice: Learning,
meaning and identity. Cambridge UK, Cambridge Uni-
versity Press.
A.C. Davies: None. D. Harris: None. A. Banks-Gate-
nby: None. A. Brass: None.
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BRCA1/BRCA2 mutations in a Mediterranean popula-
tion with breast or ovarian cancer. A single center
experience
M. Caloro1, L. Orlando1, E. S. Lutrino1, A. Quaranta1, C.
Caliolo1, P. Schiavone1, G. Aprile2, M. C. Chetrì1, M.
D'amico1, P. Rizzo1, P. Fedele1, D. Loparco1, E. Mazzoni1,
A. Marino1, N. Calvani1, F. Sponziello1, A. Nacci1, M.
Cinefra1, P. Ferrara1, S. Cinieri1
1Ospedale Antonio Perrino-Brindisi, Brindisi, Italy, 2Ospe-
dale San Bortolo, Vicenza, Italy
Introduction: Mutation of BRCA1/2 genes are present in
30% of hereditary breast (BC) and ovarian cancers (OC).
BRCA1/2 mutations substantially increase the lifetime risk
of developing BC and OC. The purpose of our study is to
investigate the percentage of BRCA mutations in patients
(pts) with BC or OC treated in our institution.Materials and
Methods: Three hundred twenty-three pts (319 women and
4 men) with BC (82%), OC (16.7%) or BC plus OC (1.2%)
were included. We used multiplex ligation-dependent probe
ampliﬁcation (MLPA) to screen mutations in BRCA.
Results: Of the 323 pts analyzed, 58 (18%) were
BRCA1/BRCA2 mutated, 34 (10.5%) at BRCA1 gene and
25 (7.8%) at BRCA2; only one subject had both BRCA1
and BRCA2 mutations. Among BC pts, 47 (17.6%) had
triple negative (TN) disease and BRCA1/2 mutations were
present in 16 (34%) of these: 13 TNBC pts had BRCA1
(81.2%) and 3 (18.7%) BRCA2 mutation. Among BRCA1
mutations, the most frequent was c.5266dupC (67.6%). In
TNBC pts, c.5266dupC constitutes about 92% of the
BRCA1 mutations (one pt had c.5503C > T).
Conclusions: Different ethnic and geographical Coun-
tries have different BRCA1/2 mutation spectrum. The
BRCA1 mutation c.5266dupC was originally described as a
founder mutation in the Ashkenazi Jewish (AJ) population,
but is also present in other Counties. The high incidence of
this alteration in our pts may be linked to international
migration ﬂows. Understanding genetic predisposition to
develop BC and OC may contribute to reﬁne more cost-
effective screening measures in a high-risk population.
M. Caloro: None. L. Orlando: None. E.S. Lutrino:
None. A. Quaranta: None. C. Caliolo: None. P. Schia-
vone: None. G. Aprile: None. M.C. Chetrì: None. M.
D'amico: None. P. Rizzo: None. P. Fedele: None. D.
Loparco: None. E. Mazzoni: None. A. Marino: None. N.
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P19.07C
Development of cancer risk prediction models into tools
for use in clinical settings
C. L. Babb de Villiers, A. C. Antoniou, D. Easton, M.
Tischowitz, F. M. Walter
University of Cambridge, Cambridge, United Kingdom
Aim Advances in cancer research have allowed cancer risk
prediction models to start incorporating genetic, epidemio-
logical and clinical data. We aim to develop a user-friendly
electronic tool to utilise these models in various clinical
settings. Method We held a workshop on cancer risk pre-
diction, model and tool development, and risk commu-
nication. All plenary sessions and smaller group work were
facilitated, audio-recorded, and transcribed. Data were the-
matically analysed, and themes compared between clinical
settings. Results 38 (UK and international) experts in Pri-
mary(GPs, public health and social scientists), Secondary
(oncology, surgery and radiology) and Tertiary(clinical
geneticists and counsellors) healthcare participated. There
was general consensus that patients pre-completing parts of
the tool prior to their appointment would be valuable. Other
themes included challenges of data storage, conﬁdentiality
and consent(family and individual) and data transfer across
the clinical care levels. Discussions about risk factors were
focused on deﬁnitions, evidence-base for inclusion and
impact on the assessment, and potential impact of behaviour
change. There was broad agreement across clinical groups
that the risk score should be presented in several formats
(graphical, pictogram, expected frequency trees, national
guidelines). Most also agreed that such a tool could aid
patient-centred risk assessment, communication and man-
agement in all clinical settings. Conclusions These ﬁndings
have contributed to the development of the tool prototypes;
these will be assessed among clinicians and patients for
usability and face validity using mixed methods approaches.
Subsequent versions will then be assessed for accuracy and
reliable function in the various healthcare settings. Funding
from Cancer Research UK(CRUK)-C12292/A20861
C.L. Babb de Villiers: None. A.C. Antoniou: None. D.
Easton: None. M. Tischowitz: None. F.M. Walter: None.
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Optimal size of pedigrees for risk assessement in cancer
genetic counselling using electronic mega-pedigrees
O. T. Johansson1, V. Stefansdottir2,3, H. Skirton4, H.
Olafsdóttir1, L. Tryggvadottir5,6, G. Olafsdottir5, J. J.
Jonsson2,3,7
1Landspitali, Reykjavik, Iceland, 2Dept. of Genetics and
Molecular Medicine, Landspitali, Reykjavik, Iceland, 3Dept.
of Biochemistry and Molecular Biology, Univ. of Iceland,
Reykjavik, Iceland, 4Faculty of Health and Human
Sciences, Plymouth University, Plymouth, United Kingdom,
5Icelandic Cancer Registry, Reykjavik, Iceland, 6University
of Iceland, Reykjavik, Iceland, 7Genetical committee of the
University of Iceland and Landspitali, Reykjavik, Iceland
Introduction: Family history, usually provided by the
counsellee and veriﬁed by medical records and cancer
registry data, is an essential tool to assess risk and guide
surveillance in cancer genetic counselling. Guidelines on
pedigree size exist, although more data about the correlation
of size and informational value is needed. Circumstances in
Iceland allow for such evaluation using electronic mega
pedigrees constructed from both a population-based gen-
ealogy database and cancer registry.
Methods: The Study group comprised 179 women, ran-
domly chosen from the genetics clinic at Landspitali: 89
were positive and 90 were negative for the founder mutation
BRCA2:999del5),. Boadicea was used to calculate like-
lihood of being a BRCA2 carrier using Icelandic allele fre-
quency 0.3 for the founder mutation BRCA2:999del5,
mutation search sensitivity of 0.8 and cancer incidence rates
for Iceland. Receiver Operating Curves were used to assess
the optimal pedigree size for risk assessment.
Results: Average no. of individuals in pedigrees with 1°
relatedness was 8.8, range 3–22, 2° 25.6, range 6–92, 3°
53.8, range 9–220, 4° 102.4, range 15–257, 5° 146.1, range
15–498 and 6° 164, range 15–565. The lowest risk score
was 0.1% and highest 92.6%. The optimal pedigree size
included three degree of relatedness or up to ﬁve genera-
tions (AUC 0.801). Larger pedigrees made possible to
connect counsellees to known BRCA families.
Conclusions: This study demonstrates the usefulness of
basing risk cancer assessment on large pedigrees. Many
countries already have the electronic information avail-
ability to use genealogy cancer registry data to construct
electronic mega-pedigrees, with better risk assessment.
O.T. Johansson: None. V. Stefansdottir: None. H.
Skirton: None. H. Olafsdóttir: None. L. Tryggvadottir:
None. G. Olafsdottir: None. J.J. Jonsson: None.
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The impact of cancer genetics on the management of
patients with hereditary cancer syndromes
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X. W. Chin1, E. Courtney2, J. Yuen2, S. Li2, Y. Chen2,3, J.
C. Allen4, J. Ngeow2,5,6
1Faculty of Medicine, University of Malaya, Petaling Jaya,
Malaysia, 2Cancer Genetics Service, National Cancer
Centre Singapore, Singapore, Singapore, 3Department of
Psychology Oncology, National Cancer Centre Singapore,
Singapore, Singapore, 4Centre for Quantitative Medicine,
Duke-NUS Medical School, Singapore, Singapore, 5Oncol-
ogy Academic Clinical Program, Duke-NUS Medical
School, Singapore, Singapore, 6Lee Kong Chian School of
Medicine, Nanyang Technological University, Singapore,
Singapore
Introduction: Hereditary cancer syndromes account for at
least 5–10% of all cancers. Early detection and/or preven-
tion resulting from appropriate risk management behaviour
improve survival rates. This study aimed to: (1)assess the
adherence to risk management guidelines among mutation
carriers seen by the Cancer Genetics Service(CGS), Sin-
gapore; (2)compare the risk management behaviour
between affected and unaffected carriers; and (3)describe
the cancers subsequently detected among the risk manage-
ment adherent group.
Method: A retrospective study was conducted to review
70 mutation carriers seen at the CGS. Subjects deemed
appropriate for cancer surveillance and/or risk-reducing
surgery were identiﬁed and their risk management beha-
viour was recorded. Findings of each procedure were traced,
speciﬁed with the stage of cancer.
Results: Of the 70 mutation carriers, 38 subjects were
appropriate for cancer surveillance and/or risk-reducing
surgery(54%). Of the 38 subjects, 27(71%) were fully or
partially adherent to risk management recommendations,
with unaffected carriers being more likely to exhibit this
behaviour. Of 17 BRCA1/2 carriers, 3 underwent risk-
reducing mastectomy(18%). Among 7 BRCA1/2 carriers
whom risk-reducing bilateral salpingo-oophorectomy
(RRBSO) recommendation were appropriate, 4 underwent
the surgery(57%). There was 100% adherence to risk-
reducing surgery for APC or CDH1 mutation carriers(2/2
and 1/1, respectively). Of 27 risk management adherent
individuals, 5 cancers have subsequently been detected.
Conclusion: The risk management adherence rate
among mutation carriers is high and the vast majority of
cancers were subsequently detected at early stage. Despite
small numbers, this study demonstrates the impact of CGS
on the management of patients with hereditary cancer
syndromes in Singapore.
X.W. Chin: None. E. Courtney: None. J. Yuen: None.
S. Li: None. Y. Chen: None. J.C. Allen: None. J. Ngeow:
None.
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It’s only one extra sample of blood: Offering prenatal
carrier screening for sickle cell disease and thalassemia
in a high-risk population
K. C. A. Holtkamp1, P. Lakeman2, H. Hader1, S. M. J. P.
Jans3, M. Hoenderdos4, M. C. Cornel1, M. Peters2, L.
Henneman1
1VU University Medical Center, Amsterdam, Netherlands,
2Academic Medical Center, Amsterdam, Netherlands, 3TNO
Quality of Life, Leiden, Netherlands, 4Vida, Amsterdam,
Netherlands
Background: Carrier screening for hemoglobinopathies
(HbPs; sickle cell disease and thalassemia) aims to facilitate
autonomous reproductive decision-making. In the Nether-
lands, in the absence of a national HbP carrier screening
program, some primary care midwives offer screening on an
ad hoc basis. This study explores how pregnant women
perceive an offer of carrier screening for HbP by their
midwife.
Methods: Semi-structured interviews (n= 26) were
conducted with pregnant women at risk of being a HbP
carrier, and whom were offered screening at their booking
appointment in one of two midwifery practices in
Amsterdam.
Results: Half of the respondents were familiar with
HbPs. Generally, women perceived the offer of HbP carrier
screening as positive, and most women (n= 19) accepted
screening. Seven declined, of whom two already knew their
carrier status. Important reasons to accept screening were
obtaining knowledge about their own carrier status and/or
health of their unborn child, and the ease of the procedure
(It’s only one extra sample of blood). A multistep process of
decision-making was observed, as many women, while
deciding on accepting or declining HbP carrier screening,
did not give follow-up testing (e.g. partner, invasive diag-
nostics) much consideration yet.
Conclusion: Women experienced information overload,
and preferred receiving the information at a different
moment (e.g. before the intake, or even preconceptionally).
While prenatal HbP carrier screening is perceived as posi-
tive, informed decision-making seems to be suboptimal, and
both the content and timing of the information provided
needs improvement.
Funding: Netherlands Organization for Health Research
and Development (ZonMw grant no.: 209040001)
K.C.A. Holtkamp: None. P. Lakeman: None. H.
Hader: None. S.M.J.P. Jans: None. M. Hoenderdos:
None. M.C. Cornel: None. M. Peters: None. L. Henne-
man: B. Research Grant (principal investigator,
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We are pretty sure we can never say never: risk and
uncertainty communication within complex South Afri-
can paediatric cases
M. Scott1, C. Penn1, J. Watermeyer1, T. Wessels2
1University of the Witwatersrand, Johannesburg, South
Africa, 2University of Cape Town, Cape Town, South Africa
Introduction: Risk and uncertainty play a fundamental role
in medical genetics. Genetic risk communication is affected
by personal perception, formats used to explain risk, and
contextual inﬂuences. Few studies have focused on the
process of genetic risk communication in non-western set-
tings, particularly for paediatric consultations. It is unclear
how this is negotiated in South African genetic specialist-
patient healthcare interactions. This study aimed to explore
how genetic risk and uncertainty is communicated within
South African paediatric healthcare interactions between
genetic specialists and patients.
Methods: This research is part of an ongoing study
which is being conducted at genetic clinics based at three
South African tertiary hospitals. Preliminary ﬁndings of
four video-recorded paediatric genetic consultations will be
highlighted. Video-recordings were transcribed and ana-
lyzed using principles of conversation analysis and dis-
course analysis.
Results: Analysis of interactions suggests that South
African paediatric genetic consultations present a complex
entanglement of micro and macro phenomena. These are
created through the presence of multiple individuals, var-
ious participant characteristics, the challenges of providing
risk explanations and prediction, as well as the social, cul-
tural and clinical setting. Collectively these inﬂuence the
effectiveness of risk communication.
Conclusion: Results suggest that risk and uncertainty are
marked features of South African paediatric genetic con-
sultations. Qualitative interactional methods provide
opportunities for reﬂection of practice and recommenda-
tions for more ﬂexible approaches to healthcare provision.
This is particularly important for services functioning
within diverse and dynamic linguistic and cultural settings.
Grants: DST-NRF Centre of Excellence in Human
Development; PV Tobias Scholarship, University of the
Witwatersrand
M. Scott: B. Research Grant (principal investigator,
collaborator or consultant and pending grants as well as
grants already received); Modest; DST-NRF Centre of
Excellence in Human Development, University of the
Witwatersrand, PV Tobias Scholarship, University of the
Witwatersrand. C. Penn: None. J. Watermeyer: None. T.
Wessels: None.
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The continuous professional medical education for
geneticists in Russia: the ﬁrst experience of the short
educational course
E. Baranova1, E. Ginter1,2, V. Izhevskaya2
1Russian Medical Academy of Continuous Professional
Education (RMACPE), Moscow, Russian Federation,
2Research Centre for Medical Genetics, Moscow, Russian
Federation
<META NAME="author" CONTENT="Елена" >
Introduction: The postgraduate education programmes
in speciality "genetics" in Russia were created in 1988.
Today, after 29 years, we number about 500 certiﬁcated
geneticists who can work in a variety of settings in multiple
specialty areas of human gene. Previously professional
certiﬁcate "genetics" should be conﬁrmed every 5 years by
training 144 hours. But it's hard to keep up with the growth
of knowledge, especially in the ﬁeld of genetics. Since 2016
came into force a law continuing professional medical
education according to which every medical specialist must
obtain at least 50 credits (hours) per year, as cycles in the
department and participation in scientiﬁc and practical
activities. Our aim was to evaluate the effectiveness of short
courses on a number of parameters, including the satisfac-
tion of the trainees. Materials and Methods: We have
developed a two-day conference, including the short edu-
cational course "New technologies of diagnosis of heredi-
tary diseases". 217 geneticists were interviewed after the
course.
Results: We found that the respondents had a high level
of satisfaction with the short program of the education: 96%
of respondents consider it useful, 89% said that it was
available, 98% reported that they were satisﬁed with the
program. At the same time, 76% of respondents correctly
answered all test questions.
Conclusions:We conclude that the development of short
educational programs for geneticists are effective and
deserve special attention when medical knowledge is
rapidly changing.
E. Baranova: None. E. Ginter: None. V. Izhevskaya:
None.
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Danish Cytogenetic Central Register
L. Al-Zehhawi1, J. Hansen1, S. Kjærgaard2, L. Ousager3,
C. Fagerberg3, L. Sunde1, M. Rasmussen1
1Department of Clinical Genetics, Aarhus University
Hospital, Aarhus, Denmark, 2Department of Clinical
Genetics, Rigshospitalet, Copenhagen, Denmark, 3Depart-
ment of Clinical Genetics, Odense University Hospital,
Odense, Denmark
Background: The Danish Cytogenetic Central Register
(DCCR) is a nationwide Danish register. Since 1968, the
results of all prenatal and postnatal chromosome analyses,
and results of all prenatal molecular analyses conducted in
Denmark are registered in the DCCR. No previous study
has measured the quality of these data. We aimed to validate
the registration of analyses results in the DCCR. Also, we
aimed to describe the number of analyses registered over
time.
Method: The quality of the data registration in the
DCCR was examined by estimating the positive predictive
value (PPV) of the registration of analyses results in the
DCCR. We retrieved 300 analysis results from the DCCR
registered from 2010 to 2014 and compared them with the
analysis results recorded in the local laboratory systems.
Results: The estimated PPV was 98.6% (95% CI 96.6%-
99.6%). In four cases, the registration of the sex-
chromosomes was missing. The number of chromosomal
microarray analyses (CMA) is increasing while traditional
karyotyping is decreasing.
Number of analyses in the period 2001–
2015
Period Prenatal Karyotyping Prenatal
CMA
Postnatal
Karyotyping
Postnatal
CMA
2001–
2005
29,596 4 17,048 953
2006–
2010
18,541 20 17,305 2,792
2011–
2015
15,530 2,716 14,707 6,858
Conclusion: The data in the DCCR are reliable and
illustrate the shift in diagnostic methods that have occurred
over time. Because all analyses are registered with the
unique identiﬁer of the person analyzed, data from the
DCCR can be accurately matched with data from other
Danish national registers. Overall, The DCCR has great
potential as a data source for research.
L. Al-Zehhawi: None. J. Hansen: None. S.
Kjærgaard: None. L. Ousager: None. C. Fagerberg:
None. L. Sunde: None. M. Rasmussen: None.
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Finding yourself in front of the mirror: development of a
theory regarding presymptomatic genetic testing in
young adults
L. Godino1,2, D. Turchetti1, L. Jackson2, C. Hennessy3, H.
Skirton2
1Center for Studies on Hereditary Cancer, Department of
Medical and Surgical Sciences, University of Bologna, and
Unit of Medical Genetics, Bologna, Italy, 2Faculty of
Health and Human Sciences, School of Nursing and
Midwifery, Plymouth University, Plymouth, United King-
dom, 3Visiting Professor, Faculty of Health and Social
Sciences, School of Health and Social Care, Bournemouth
University, Bournemouth, United Kingdom
Introduction: Genetic counselling is a specialist health
service provided to those affected by or at risk of a genetic
condition. Presymptomatic genetic testing should always
involve a considered choice. Young adults are at a key life
stage as they may be developing a career, forming part-
nerships and potentially becoming parents. The aim of this
study was to develop a theoretical model regarding the
factors involved when young adults undergo genetic
counselling for hereditary cancer risk. Material and
Methods: A mixed-methods sequential explanatory design
was used. Results: Participants surround themselves with
other people who inﬂuence their knowledge and awareness.
The decision-making process started as a result of the
inﬂuence of these people and only those young adults who
decided to be tested presented for genetic counselling.
During genetic counselling they viewed themselves as in
front of the mirror. They took distance from themselves and
spoke about themselves not in ﬁrst but in second person,
especially when they talked about sensitive situations.
Finally, they achieved some autonomy and recognised how
integrate the test result into their everyday life. Conclu-
sions: Counselling approaches to this population may
require modiﬁcation both for young adults and their parents.
Health professionals could have a role in both supporting
parents and young adults. It is important to publicise the
supportive and educational role of genetic services. The
traditional ‘wait until they come to us’ approach by health
services may be failing to meet the educational and emo-
tional needs of this population.
L. Godino: None. D. Turchetti: None. L. Jackson:
None. C. Hennessy: None. H. Skirton: None.
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Couples' experiences of terminating pregnancy follow-
ing prenatal diagnosis of Down’s syndrome. A qualita-
tive study
S. Lou1,2, O. B. Petersen1,3, L. Hvidman3, C. P. Nielsen2, I.
Vogel1,4
1Center for Prenatal Diagnostics, Aarhus University
Hospital, Aarhus, Denmark, 2DEFACTUM - Public Health
and Health Services Research, Aarhus, Denmark, 3Depart-
ment of Obstetrics and Gynecology, Aarhus University
Hospital, Aarhus, Denmark, 4Department of Clinical
Genetics, Aarhus University Hospital, Aarhus, Denmark
Introduction: In Denmark, 95% of pregnant women
choose to have combined ﬁrst trimester screening (cFTS).
When diagnostic results show Down's syndrome, the
majority choose to terminate the pregnancy. However, little
is known about these women’s and their partners' experi-
ences following diagnosis and termination. Materials and
Methods: Qualitative interviews with 14 women and 9 male
partners, 5–8 weeks after termination. All interviews were
recorded and transcribed ad verbatim. The material was
analyzed using thematic analysis.
Results: Twelve couples had decided to terminate in
case of a Downs syndrome diagnosis. Two couples decided
in face of the actual diagnosis. All couples reported feeling
intense grief and sadness. Uncertainty about severity of
cognitive and physical disability was central to the decision
to terminate. All couples reported termination to be the
‘right’ decision, even if it was painful. They grieved not
only the loss of a healthy child but also loss of a desired
future as family and parents. None felt pressure to termi-
nate, however some felt rushed by the time-limit for sur-
gical abortion. Upon deciding to terminate, some women
immediately disconnected from the fetus, while others spent
time saying goodbye and/or asking the fetus for forgiveness.
All couples felt sensitive to potential negative comments
from social networks.
Conclusions: Couples reported that termination was the
right decision, but still experienced prenatal diagnosis and
termination of pregnancy as painful and difﬁcult. The
research was supported by the Health Research Fund of
Central Denmark Region.
S. Lou: None. O.B. Petersen: None. L. Hvidman:
None. C.P. Nielsen: None. I. Vogel: None.
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An adaptable practitioner and patient visual aid for
prenatal aneuploidy screening and testing options
C. Cameron1, M. Hunter1,2, K. Rose1, N. Gelfand1, H.
Curd1, A. Springer1,3, A. Feigin1, F. Cunningham1
1Monash Medical Centre, Clayton, Australia, 2Department
of Paediatrics, Monash University, Clayton, Australia,
3Monash IVF, Clayton, Australia
<The introduction of prenatal chromosomal microarray and
Non-invasive prenatal testing (NIPT) as options for patients
at increased risk of fetal aneuploidy (on ﬁrst or second tri-
mester maternal screening) has signiﬁcantly increased the
volume and complexity of prenatal consultations. Increased
risk prenatal counselling is particularly challenging, because
it is emotionally driven and time restricted. In response to
the added volume and complexity and to ensure consistency
of information offered across multiple genetic counsellors,
we designed a visual aid with dual purpose. Its primary
purpose is to assist the genetic counsellors to standardise the
application of new technologies and options offered during
increased risk prenatal counselling. A secondary purpose is
to provide patients with a visual aid to assist their under-
standing during consultation and enhance informed
decision-making. We present this unique, adaptable visual
aid, designed to assist both practitioner and patient. The aid
is easily adaptable as new technologies become available,
for different prenatal scenarios, and for use by different
practitioners (e.g. midwives, obstetricians, family practi-
tioners). We have subsequently adapted the “increased risk
aid” and developed a “routine prenatal aneuploidy screen-
ing aid” and an “advanced maternal age aid”. Genetic
counsellors at a major Australian maternity hospital have
been using the three aids for approximately two years, and
we have recently implemented the two latter visual aids for
use by midwives at the hospital. We have surveyed the
genetic counsellors and midwives using the aid. We present
ﬁndings from the surveys and a proposal for implementa-
tion of these aids into routine prenatal care.>
C. Cameron: None. M. Hunter: None. K. Rose: None.
N. Gelfand: None. H. Curd: None. A. Springer: None. A.
Feigin: None. F. Cunningham: None.
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Financing regulation for registered genetic counsellors
in the United Kingdom & Eire
C. M. Watt1, C. A. Barnes2, C. Benjamin2, W. Heywood2,
C. King2, C. Kirwan2, A. Kulkarni2, M. McAllister2, N.
Meade3, D. Stirling2, V. Tripathi2, M. Watson2, J.
Wiggins2, S. Whyte2
1West of Scotland Regional Genetics Service, Glasgow,
United Kingdom, 2Genetic Counsellor Registration Board,
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In the United Kingdom (UK) the Genetic Counsellor
Registration Board (GCRB) was formed in 2001. The
purpose of the GCRB is to establish, maintain and improve
standards of practice in genetic and genomic counselling to
assure public safety.
This elected board is responsible monitoring the conduct
and practice of Registered of Genetic Counsellors (RGCs)
in the UK which in May 2016 became an Accredited
Register veriﬁed by the Professional Standards Authority
(PSA).
PSA Accredited Registers show that an organisation has
met speciﬁc standards in key areas including education,
training, governance and complaints handling.
As part of the PSA accreditation process the GCRB had
to demonstrate ﬁnancial viability and accountability. The
GCRB is a limited not for proﬁt company submitting
accounts to Companies House each year. Currently there are
201 registered genetic counsellors each paying Euros 119
annually. Other income sources include registration and
course accreditation.
The PSA charged Euros 14 200 for the initial application
which included recommendations to the GCRB to meet the
criteria for an Accredited Register. These recommendations
included revising the GCRB website and setting up a
Patient and Public Group to feedback to the board. The
GCRB approached regional genetic centres for ﬁnancial
donations to support accreditation.
The PSA reviews Accredited Registers annually and the
GCRB will require its registrants to meet and maintain high
standards. This annual review will cost Euros 10 638.
Financing and maintaining the GCRB Accredited Register
will be challenging including handling complaints and
hearings.
C.M. Watt: None. C.A. Barnes: None. C. Benjamin:
None. W. Heywood: None. C. King: None. C. Kirwan:
None. A. Kulkarni: None. M. McAllister: None. N.
Meade: None. D. Stirling: None. V. Tripathi: None. M.
Watson: None. J. Wiggins: None. S. Whyte: None.
P19.18B
The reasons for not choosing prenatal aneuploidy
screening in pregnant women receiving genetic coun-
seling for advanced maternal ages
E. Kise1, M. Ishikawa1, K. Takano1,2, S. Ohira1,3, N.
Kikuchi1,3, M. Kanai1,3,4, Y. Fukushima1,2, T. Kosho1,2
1Center for Medical Genetics, Shinshu University Hospital,
Matsumoto, Nagano, Japan, 2Department of Medical
Genetics, Shinshu University School of Medicine, Matsu-
moto, Nagano, Japan, 3Department of Obstetrics and
Gynecology, Shinshu University Hospital, Matsumoto,
Nagano, Japan, 4Department of Family and Child Nursing,
and Midwifery, Shinshu University School of Health
Sciences, Matsumoto, Nagano, Japan
In Japan, non-invasive prenatal testing (NIPT) has been
available as a clinical research since the introduction in
2013. Shinshu University Hospital does not participate in
this clinical research, and offers careful genetic counseling
solely for the decision whether or not to have amniocentesis
in cases of advanced maternal ages (AMA). Our prenatal
genetic counseling (GC) for AMA includes (1) pre-
counseling by certiﬁed genetic counselors (CGC), where
reservations are made and family trees are described; (2)
main GC by CGC collecting more information and fol-
lowing narratives, and by clinical geneticists specializing in
chromosomal or genetic disorders, adding comprehensive
medical and social information and discussing freely what
the testing truly mean for the women and their husbands; (3)
post-counseling by CGC by phone or after prenatal
checkups. In total, 151 pregnant women received such GC
from April 2013 to December 2016: 70 (46%) had testing
(amniocentesis in most) and the rest 79 did not. Among the
two groups, mean ages, the percentages of having histories
of infertility treatment and delivery were not different.
Reasons for not choosing testing are “refusal to terminate
their fetuses” and “information that any pregnant women
could be mothers of babies with congenital disorders or
handicaps and that there is sufﬁcient medical and social
support system in Japan”. These observations implicate the
fundamental value of prenatal GC, both for invasive testing
and for NIPT, that appropriate information and fruitful
discussion could empower pregnant women to imagine
which decision would ﬁt them truly in their lifelong point of
view.
E. Kise: None. M. Ishikawa: None. K. Takano: None.
S. Ohira: None. N. Kikuchi: None. M. Kanai: None. Y.
Fukushima: None. T. Kosho: None.
P19.19C
Distance from genetic counseling services as a system-
based resource for Young Breast Cancer Survivors
C. Nikolaidis1, K. Mendelsohn-Victor2, N. K. Janz3, S. D.
Merajver4, M. C. Katapodi1
1Nursing Science, School of Medicine, University of Basel,
Basel, Switzerland, 2University of Michigan School of
Nursing, Ann Arbor, MI, United States, 3University of
Michigan School of Public Health, Ann Arbor, MI, United
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Introduction: Distance from the closest genetic counseling
center can be an important barrier for utilization of genetic
services for women diagnosed with breast cancer less than
45 years old (Young Breast Cancer Survivors - YBCS). We
calculated the minimum distance between residential loca-
tion and the closest genetic counseling service in a popu-
lation of YBCS randomly selected from the Michigan
cancer registry and recruited in an efﬁcacy trial, which was
initiated in 2012 and concluded in 2014. Materials and
Methods: ZIP codes were available for N= 608 YBCS.
Residential and genetic counseling center ZIP codes were
geocoded in latitude/longitude coordinates using the R
package ‘zipcode’. Minimum distance (in miles) from
YBCS place of residence to the closest board-certiﬁed
genetic counseling service was calculated using the Great
Circle Distance Formula, D=3963.0(arccos[sin(T1)*sin(T2)
+ cos(T1)*cos(T2)*cos(G2-G1)], where Ti is the latitude and
Gi is the longitude of locations 1 and 2 in radians. Results:
In 2012 there were 21 certiﬁed genetic counseling services/
centers in the state of Michigan. Since then, approximately
11 additional services began operating. By 2014, N= 194
YBCS had genetic testing (31.9%). Median distance from
the closest genetic counseling center in 2012 was 8.3 miles
(min= 0, max=147.6, IQR=18.4 miles). There was no
statistically signiﬁcant change in the mean distance avail-
ability to genetic counseling services between 2012 and
2017 (t=0.308, p=0.758). Conclusions: Given the avail-
ability of genetic counseling services, other factors related
to accessibility of genetic services (e.g., provider recom-
mendation, barriers accessing care related to cost, etc.) are
currently being explored.
C. Nikolaidis: None. K. Mendelsohn-Victor: None. N.
K. Janz: None. S.D. Merajver: None. M.C. Katapodi:
None.
P19.20D
Responding to patient's anxiety: Overall structure of
conversation in genetic counselling in Japan
A. Kondo1,2, H. Maeda3, Y. Onuki2, C. Fukano1, D.
Nakaoku1, M. Yamasaki1, M. Morine1, K. Hinokio1, S.
Izumi4, A. Clarke5, K. Maeda1
1Shikoku Medical Center, Zentsuji, Japan, 2Tokai Univer-
sity School of Medicine, Isehara, Japan, 3Tokai University
Center for Liberal Arts, Isehara, Japan, 4Tokai Univeristy
School of Medicine, Isehara, Japan, 5Clinical Genetics,
Cardiff University, Cardiff, United Kingdom
Introduction: Genetic counselling was introduced to Japan
quite recently, about 20 years ago, and is still considered
rather ‘unfamiliar’. Previously, outpatient services had often
been paternalistic in their approach. We have conducted
qualitative analyses of genetic consultations focusing on the
structural aspects of communication.
Materials and Methods: The data for this pilot study
consists of transcripts of the ﬁrst consultations of three
children referred for clinical genetic assessments to one
centre in Japan. The sessions were delivered by an experi-
enced clinical geneticist. Our approach is rooted in ethno-
methodology and conversation analysis.
Results: In paediatric genetic consultations in Japan, the
phases of each session are relatively distinct. The overall
structure of each session consists of three phases: (1)
Opening and setting the agenda, (2) Assessment/Examina-
tion/Explanation, (3) Additional issues and closing. It
appeared that the clients often delayed expression of his/her
anxieties to the ﬁnal part, after the main explanation by the
clinician. While the basic manner of the geneticist met the
expected standards of good genetic counselling, the parents
did not express their principal concerns until the closing.
Conclusion: In these three consultations, the structure of
the consultation consists of three parts. This is related to the
teaching of communication for genetic specialists in Japan.
Visiting the genetics clinic and meeting new doctors might
impact on a client, inhibiting expression of their concerns.
We aim to analyse additional genetic counselling con-
sultations to see if this ﬁnding applies more generally.
This study is supported by Pﬁzer Health Research
Foundation
A. Kondo: None. H. Maeda: None. Y. Onuki: None. C.
Fukano: None. D. Nakaoku: None. M. Yamasaki: None.
M. Morine: None. K. Hinokio: None. S. Izumi: None. A.
Clarke: None. K. Maeda: None.
P19.21A
Genetic counselling in the EB Centre at University
Hospital in Brno, Czech Republic - Changes due to new
possibilities in DNA analysis
R. Gaillyová1,2, H. Bučková3, J. Němečková1, L.
Fajkusová4, L. Kopečková4
1University Hospital, Dept. of Medical Genetics, Brno,
Czech Republic, 2Masaryk University, Dept. of Biology,
Brno, Czech Republic, 3University Hospital, Pediatric
Clinic, Brno, Czech Republic, 4University Hospital, Center
of Molecular Biology and Gene Therapy, Clinic of Internal
Medicine – Hematology and Oncology, Brno, Czech
Republic
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Centre for patients with Epidermolysis bullosa congenita
(EB) works at the University Hospital in Brno, Czech
Republic since 2001 and since 2012 as a highly specialized
medical care centre and member of the international net-
work of EB centres and clinical experts. In 2016 our EB
Centre was conﬁrmed as a part of European Reference
Network-Skin. The Centre cooperates with DEBRA Czech
Republic (member of the Czech Association for rare dis-
eases) that workes since 2004 and supports people with EB
and their families to engage people with EB to a full life.
The centre offers care for all EB patients in Czech Republic
(about 300). Previously, we performed the DNA analysis of
KRT5 and KRT14 genes for EB simplex and the DNA
analysis of the COL7A1 gene for dystrophic EB. We found
causal pathological sequence variations in all patients with
the recessive dystrophic EB but only in a part of patients
with the simplex or dominant dystroﬁc forms (about 60%).
The junctional EB we diagnosed in cooperation with "EB
Haus Salzburg - Austria". Since 2014, we have used the
NGS analysis for 18 genes associated with EB and we
conﬁrmed the diagnosis in next 40 EB patients. In 13
families, we changed the supposed diagnosis EB simplex
with AD inheritance to suprabasal form EB (Acral peeling
skin syndrome) with AR inheritance. We also changed the
prognosis for the recurrence of the disease in these families.
R. Gaillyová: None. H. Bučková: None. J. Němeč-
ková: None. L. Fajkusová: None. L. Kopečková: None.
P19.22B
Genetic counselling in the era of genomics: what's all the
fuss about?
G. R. Brett1,2, E. Wilkins1,2, E. Creed3,2, E. Lynch2,
Melbourne Genomics Health Alliance, C. Gaff2, I.
Macciocca1,2
1Victorian Clinical Genetics Services, Murdoch Childrens
Research Institute, Melbourne, Australia, 2Melbourne
Genomics Health Alliance, Melbourne, Australia, 3Mel-
bourne Health, Melbourne, Australia
Background: As genomic sequencing becomes more widely
available in clinical settings, new counselling issues are
arising, raising the question whether genetic counsellors
currently possess the necessary skills to support clients
through the testing process. The ability to adapt to and
manage these new issues will be paramount as genetic and
non-genetic healthcare providers navigate the complexities
of using genomic technologies to improve diagnosis and
patient management. However, care must be taken not to
overstate differences between counselling issues in
genomics and issues previously established in genetic
counselling.
Methods: Counselling issues different to those estab-
lished in genetic counselling literature prior to the advent of
clinical genomics were identiﬁed by four genetic counsel-
lors with ten years collective experience providing genetic
counselling to individuals undergoing genomic sequencing.
These themes were further discussed and reﬁned at a
meeting of genetic counsellors working in genomics in
Melbourne, Australia. Illustrative cases were selected where
pre- and post-test genetic counselling was provided to
individuals undergoing singleton or trio whole exome
sequencing with targeted analysis through a Melbourne
Genomics Health Alliance study. The Alliance is a colla-
boration between ten research and clinical organisations,
conducting research into the integration of genomic
sequencing into clinical care.
Outcomes: Identiﬁed counselling issues and illustrative
cases will be presented, including; managing expectations
of genomic sequencing, counselling for secondary use and
reanalysis of data, secondary ﬁndings and trio sequencing.
Considerations discussed contribute to expanding under-
standing of these issues and highlight the applicability of
existing genetic counselling theories and techniques to
managing new counselling issues.
G.R. Brett: None. E. Wilkins: None. E. Creed: None.
E. Lynch: None. C. Gaff: None. I. Macciocca: None.
P19.23C
Genetic Counselling the integration of novel educational
program
w. S. M. Mulah Abed, M. S. M. Al-Araimi, Nishath
Hamza, Manal Al-Kharusi; National Genetic Centre,
Muscat, Oman
Genetic Counselling is deﬁned as the procedure applied for
helping people and families to understand and adapt to the
medical, psychological and familial implications of genetic
contributions to the disease of concern. In the National
Genetic Centre, the Department of Genetic Counselling and
Education has operated a on the job training in genetic
Counselling through clinically exposure course work. This
course is considered to be the ﬁrst academic and profes-
sional course in genetic counselling to be operated in the
region. It has been designed to broaden all candidates with
the knowledge about Medical Genetics and the gain insight
into the theory that supports the process of genetic coun-
selling. The curriculum consists of nine modules in three
days every 2 months, and includes theory, clinical rotations,
and laboratory rotation. The total period of the course is
16 months. The course strives to train candidates to be able
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to interface between patients, clinicians and medical
geneticists. The candidates of the course will gain the skills
of genetic counsellors, including technical, ethical and
social awareness. There is a need for the graduates of the
course in many different areas in the medical profession
such as paediatric genetic clinics, cancer medicine, prenatal
diagnosis clinics, as well as in laboratory genetics. The aims
and objectives of the course together with other related
details will be presented in the conference.
W.S.M. Mulah Abed: None.M.S.M. Al-Araimi: None.
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High value genetic services through outcomes-based
systems speciﬁcations
A. Puggina1, D. Vojinovic2, A. Demirkan2, R. Pastorino1,
O. Damman3, P. Parente1, T. Lagerberg4, C. G. van El3,
H. Meijers-Heijboer3, M. Cornel3, A. Jani5, M. Gray5
1Università Cattolica del Sacro Cuore, Rome, Italy, 2Eras-
mus Medical Center, Rotterdam, Netherlands, 3VU Uni-
versity Medical Center, Amsterdam, Netherlands, 4Better
Value Healthcare Ltd, Oxford, United Kingdom, 5Univer-
sity of Oxford, Oxford, United Kingdom
Introduction: In 2015 the Personalized pREvention of
Chronic DIseases consortium (PRECeDI) obtained funding
from the European Commission [1]. The consortium aims to
generate multidisciplinary knowledge through exchange of
staff involved in training and research on the prevention of
chronic diseases. In WP 6, partner institutions collaborated
on drafting outcomes-based systems speciﬁcations to deli-
ver value-based healthcare for cardiovascular disorders
(Familial Hypercholesterolaemia, Long QT), Lynch syn-
drome, and BRCA-related breast cancer.
Methods: The speciﬁcations are based on a format
developed by Better Value Healthcare Ltd in Oxford, UK.
After a literature search on genetic testing, treatment, and
patient pathways for the selected disorders, key perfor-
mance indicators were selected. These were expected to be
relevant to FH, LQT, LS and BRCA-related breast cancer
services. The speciﬁcations were discussed with clinicians
to check appropriateness.
Results: Indicators include: the numbers of patients
identiﬁed in a speciﬁc population, the number of family
members informed, the number of patients under surveil-
lance or receiving treatment, and the extent to which
patients are involved in decision-making. Criteria for mea-
suring performance and standards are speciﬁed, which
allow clinical networks to make annual reports to monitor
their services.
Conclusion: Clinical networks will be able to improve
their services by monitoring their results, taking the popu-
lation served into account. Interventions that have high
technical value (such as cascade screening) should be
delivered in ways that optimize personal value. Identifying
high value performance allows for reallocating budgets and
(human) resources.
[1] EC Horizon 2020 research and innovation pro-
gramme MSCA-RISE-2014: grant agreement N°645740.
http://www.precedi.eu/site/index.php.
A. Puggina: None. D. Vojinovic: None. A. Demirkan:
None. R. Pastorino: None. O. Damman: None. P. Par-
ente: None. T. Lagerberg: A. Employment (full or part-
time); Signiﬁcant; Better Value Healthcare Ltd. C.G. van
El: None. H. Meijers-Heijboer: None. M. Cornel: None.
A. Jani: A. Employment (full or part-time); Signiﬁcant;
Better Value Healthcare Ltd. M. Gray: E. Ownership
Interest (stock, stock options, patent or other intellectual
property); Signiﬁcant; Better Value Healthcare Ltd.
P19.25A
comparison between public and private health care in
the state of Rio Grande do Norte, Brazil
J. I. C. F. Neri1,2
1Medicina, Universidade Potiguar, Laureate International
Universities, Natal, Brazil, 2Child Rehabilitation Center,
SESAP, State of Rio Grande do Norte, Natal, Brazil
Introduction: Brazil is a country with huge discrepancies,
especially in health care. This situation is most pronounced
for genetic diseases. While the Ministry of Health, through
the National Agency for Supplementary Health, has deter-
mined that private health-care providers provide clinical and
laboratory care, it is not determined in public attention, even
though it has been a constitutional guarantee to the popu-
lation since 1988. Materials and Methods: The medical
records of 1,097 patients from the public health system and
986 private patients, all of whom were attended by the only
medical geneticist in the State of Rio Grande do Norte,
Northeast Brazil, were reviewed. The study considered the
difﬁculty of access to the professional and the exams
requested by him to conclude the case. Results: The access
to the professional in the private regime was always simple
and direct, having occurred even spontaneously in 8%. In
the public system, access was only possible by means of
referral and prior evaluation of the staff of the service to
which the professional is linked. While the patients of the
private health sector had quick and easy access to any
examination, including exoma, in the public system,
patients with Down syndrome had to wait until four years
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for a karyotype. Conclusion: The results clearly show that
an archaic and bureaucratic-based political system becomes
the biggest obstacle in access to health, and that situation is
more serious how much differentiated the specialty is,
especially if an academic background is not common sense
in the country.
J.I.C.F. Neri: None.
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Impact of early genomic testing on health and repro-
ductive outcomes: a follow up study
Z. Stark1,2, M. Martyn2, D. Schoﬁeld1,3,4, L. Rynehart1, R.
Shrestha3, K. Alam1,5, S. Lunke1, T. Y. Tan1,5, Melbourne
Genomics Health Alliance, S. M. White1,5, C. Gaff2,5
1Murdoch Childrens Research Institute, Melbourne, Aus-
tralia, 2Melbourne Genomics Health Alliance, Melbourne,
Australia, 3Faculty of Pharmacy, University of Sydney,
Sydney, Australia, 4Garvan Institute of Medical Research,
Sydney, Australia, 5Department of Paediatrics, University
of Melbourne, Melbourne, Australia
Background Clinical genomic testing is increasingly used
in the diagnosis of rare genetic disease but the longer-term
impact on patient management, family decision-making,
and service provision has not been investigated.
Methods and results We collected follow-up data in a
cohort of 80 infants with suspected monogenic disorders
who underwent singleton whole exome sequencing (WES)
as a ﬁrst-tier sequencing test. The median duration of
follow-up post result was 473 days (interquartile range 411–
650). There was no statistical difference in tertiary hospital
use between those receiving a diagnosis and those without,
although a small number of diagnosed patients (n= 4) had a
substantial change in health outcomes such as cessation of
hospital admissions. Continued standard-of-care investiga-
tions in the undiagnosed group (N= 29) at a cost of AUD
$16,975(€12,250) did not result in any additional diagnoses,
whereas WES data re-analysis at a cost of AUD$11,350
(€8,191) yielded four additional diagnoses. The parents of
14 diagnosed children and two undiagnosed children
accessed reproductive genetic services at a cost of AUD
$39,517(€28,519). All couples at high risk of recurrence
and achieving a pregnancy utilized either pre-implantation
or prenatal genetic diagnosis. One termination of pregnancy
occurred in the undiagnosed group, based on uncertainty
regarding recurrence risk. Overall, parents of diagnosed
children had 8 more ongoing pregnancies compared to those
without a diagnosis.
Conclusions These data provide further support for the
early use of genomic testing in the diagnostic trajectory,
highlighting the value of storage and re-analysis of genomic
data, beneﬁts in improved patient management, and
restoration of reproductive conﬁdence in families.
Z. Stark: None.M. Martyn: None. D. Schoﬁeld: None.
L. Rynehart: None. R. Shrestha: None. K. Alam: None.
S. Lunke: None. T.Y. Tan: None. S.M. White: None. C.
Gaff: None.
P19.27C
Developing, establishing and supporting specialist roles
in genomics across a National Health Service
A. Seller1, M. Bishop1, J. Bell1, S. L. Hill2
1Health Education England, Birmingham, United Kingdom,
2NHS England, London, United Kingdom
The integration of genomics into mainstream healthcare is
fast moving and needs a workforce with the right skills and
abilities to provide appropriate, high quality and regulated
practice at all points in the patient pathway. This requires
the development of new specialist roles and care models
within existing healthcare professions, together with the
establishment of new disciplines. Health Education Eng-
land’s Genomics Education Programme (GEP) is leading
the co-ordinated approach to workforce transformation in
Genomics in the National Health Service (NHS) across all
professional groups. By working with key stakeholders to
address educational needs, the GEP is ensuring genomics is
represented at appropriate levels throughout training pro-
grammes for the NHS workforce. In collaboration with the
National School of Healthcare Science, the GEP has
facilitated development of accredited training pathways for
emergent ﬁelds in genomics (bioinformatics) and re-shaped
training pathways for established professions (genetic
counselling) under the Modernising Scientiﬁc Careers fra-
mework, a UK-wide education and training strategy for the
healthcare science workforce. The GEP has also formed key
partnerships with regulators and professional bodies repre-
senting the wider clinical workforce and advised on new
curricula developments, with a key achievement the inclu-
sion of genomics in the training framework for the newly
established Nursing Associate role. In addition, the GEP has
supported the development of a Specialist Genetic Nurse
network in diabetes, with the aim of developing a trans-
ferable model. We will present exemplars of our work,
highlighting the impact these roles have played in the
development of patient pathways for genomic conditions.
A. Seller: None. M. Bishop: None. J. Bell: None. S.L.
Hill: None.
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Evolving Careers in Genetics: Attitudes of Healthcare
Scientists
A. J. Clarkson1,2
1Genetics Laboratory, Cambridge University Hospitals
NHS Trust, Cambridge, United Kingdom, 2School of
Management and Business, King's College London, Lon-
don, United Kingdom
Genomics has the potential to revolutionise healthcare and
as such the science service in the NHS is changing.
Studying the specialist workforce in the Genomics Service,
particularly in Cytogenetics and Molecular Genetics, offers
potential insights into the nature and impact of the changes
on their occupational boundaries. Both disciplines have
evolved as separate occupations with their own professional
bodies in the UK. Recently, the distinction between them
has become increasingly ‘blurred’ through the advancement
of shared technology; the need to decrease service costs and
ﬁnd efﬁciencies; and the Modernising Scientiﬁc Careers
policy programme which merges two previously separate
scientist education and training programmes. As a result, the
two specialities are being merged and the services rationa-
lised. This is leading to changes in healthcare science
careers and scientists’ future working roles and relation-
ships in this clinical domain.
Research into how these changes have affected the two
disciplines has been conducted and the recently analysed
data based on a national survey of scientists working in
NHS Genetics Laboratories will be presented. A response
rate of 47% was achieved with the respondent demographic
being representative of the workforce population. Statistical
analysis showed that there were signiﬁcant differences,
when analysing the scientist responses by occupation, over
a number of variables including their intention to remain in
the profession. The ﬁndings shed light on the nature and
potential impact of inter-professional change, and contribute
to further policy making in education and training and
specialist workforce development.
A.J. Clarkson: C. Other Research Support (supplies,
equipment, receipt of drugs or other in-kind support);
Modest; Doctoral study supported by the Chief Scientiﬁc
Ofﬁcer's workforce research programme.
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An exploratory study among hereditary breast and
ovarian cancer patients: the relationship between cli-
ents’ psychosocial situations and their solo/group visit to
genetic counseling
M. Matsukawa1, M. Torishima2, C. Sato1, S. Honda1, H.
Miyake1,2, S. Kosugi1,2
1Genetic Counselor Course, Kyoto University School of
Public Health, Kyoto, Japan, 2Clinical Genetics Unit,
Kyoto University Hospital, Kyoto, Japan
Background: It is important for genetic counselors to
understand the psychosocial background of each client in
order to ensure that initial genetic counseling (GC) sessions
are successful. In order to help genetic counselors under-
stand clients’ backgrounds at the beginning of the session,
we attempted to elucidate the relationship between clients’
visiting style, whether they visited by solo or group, and
their psychosocial situations. Object: The object is to
explore factors that determine hereditary breast and ovarian
cancer (HBOC) clients’ solo or group visit before the ﬁrst
session of genetic counseling. Method: Semi-structured
telephone interviews were conducted. The interviews were
analyzed inductively from the viewpoint of “visiting solo
factors” and “visiting with companion(s) factors.” Result:
The updated interview data for 17 subjects were analyzed.
Most of the subjects were women from, the Clavis Arcus,
the HBOC advocacy group in Japan, giving positive reac-
tions to their treatment. In addition to their personalities,
behavior patterns, and education levels, considerations and/
or conﬂicts toward their families affected their decisions as
“visiting solo factors.” Demands of sharing medical infor-
mation and/or their daily medical practices visit style
affected their decisions as “visiting with companion(s)
factors.” Conclusion: This is the ﬁrst qualitative study
focusing on clients’ solo visit determination factors
(CCDF). From the interview, various CCDF which relate to
the clients’ psychosocial situations were discovered. These
factors could be a sign to understand cancer risk perception
levels and/or coping strategy styles of each client, which
could help genetic counselors to plan customized sessions
and follow-ups.
M. Matsukawa: None. M. Torishima: None. C. Sato:
None. S. Honda: None. H. Miyake: None. S. Kosugi:
None.
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Improving follow-up after predictive testing in Hun-
tington’s disease: evaluating a narrative group session in
a genetic counselling clinic
C. L. Stopford1, M. Ferrer-Duch2, R. M. MacLeod3
1University of Manchester, Division of Evolution and
Genomic Sciences, School of Biological Sciences, Manche-
ster, United Kingdom, 2University of Leeds, Faculty of
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Centre for Genomic Medicine, St Mary’s Hospital, Central
Manchester University Hospitals NHS Foundation Trust,
Manchester Academic Health Sciences Centre, Manchester,
United Kingdom
Introduction: Recently updated Huntington’s disease (HD)
predictive testing guidelines emphasise clinicians’ respon-
sibility to facilitate emotional support following testing,
regardless of the result. Yet there has been little investiga-
tion of models of post-test counselling support.
Materials and Methods: In this pilot project, a genetic
counsellor (RM) and clinical psychologist (MFD) devel-
oped a one-off group session using collective narrative
practices for individuals post testing. Four group sessions
have been run to date. This evaluation focuses on one group
of six people known to the North West family register
service, who have tested mutation positive for HD and
remain pre-symptomatic. Two partners also attended the
session. The aim was to appraise the integration of collec-
tive narrative practices within genetic counselling, by
inductively exploring experiences of participation. Obser-
vations, evaluation forms, and telephone interviews were
used in data collection. Qualitative data were analysed using
a thematic framework approach.
Results: Participant responses were overwhelmingly
positive, emphasising the importance of a speciﬁcally
arranged time and space to share their experiences with
others in a structured way. Typically, this was the ﬁrst time
participants had spoken openly with someone in their
situation. Facilitation of group discussion, using the narra-
tive approach, encouraged participants to re-discover their
strengths and resilience in the face of dealing with HD, with
similar experiences being discovered through connections
with others.
Conclusions: The pilot was successful in implementing
group narrative interventions as part of the predictive test
counselling support for Huntington’s disease. Participants
suggested that the approach could be adopted for other
genetic conditions.
C.L. Stopford: None. M. Ferrer-Duch: None. R.M.
MacLeod: None.
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Attitudes toward informed assent for genomic research
Z. Yamagata1, K. Muto2, T. Oooka1
1University of Yamanashi, Chuo, Japan, 2The University of
Tokyo, Tokyo, Japan
Introduction: The purpose of this study is to determine the
attitudes of the general Japanese public toward genetic
research on children and informed based on nationwide
surveys conducted in 2013 and 2016. Methods: 2,000
people (age = 20–69) from the general Japanese population,
were selected using a stratiﬁed two-phase sampling method.
In a mail survey administered in 2013 and 2016, the par-
ticipants were surveyed regarding the following topics: (1)
their attitudes toward genetic testing; (2) their perspective
regarding informed assent; (3) their level of scientiﬁc lit-
eracy regarding genomics; and (4) their demographic
information and socioeconomic status. Results: The
response rate was 51.2% in 2013 and 50.8% in 2016.
Conducting genetic testing on children for disease sus-
ceptibilities was favored by 57.2% of participants.
Regarding obtaining blood donations from children, 55.2%
approved, 11.3% disapproved, and 34.8% were undecided.
A higher proportion of participants with high genomic lit-
eracy levels approved of obtaining blood donations from
children. The multiple logistic analysis odds ratio regarding
genomic literacy was 1.40 (95% conﬁdence interval =
1.08–1.52). Regarding whether seeking consent from chil-
dren is appropriate, 52.0% of people answered that seeking
consent from a child is acceptable if the child understands
the details of the research. These responses were associated
with participants with high genomic literacy. Conclusions:
The results of this study suggest that people’s genomic
literacy is related to people’s perspective on genomic
research on children.
Z. Yamagata: None. K. Muto: None. T. Oooka: None.
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Karyotyping Optimised Online Learning
I. Perva1, C. Perva2, D. Rusu2, S. Farcas1, A. Chirita-
Emandi1, N. Andreescu1, A. Mihailescu1, C. Zimbru3, N.
Morar1, M. Puiu1
1Genomic Medicine Centre, Victor Babe University of
Medicine and Pharmacy, Timisoara, Romania, 2Automa-
tion and Applied Informatics department, Politehnica
University, Timisoara, Romania, 3Genomic Medicine Cen-
tre, Victor Babe University of Medicine and Pharmacy,
Automation and Applied Informatics department, Politeh-
nica University, Timisoara, Romania
Introduction: Karyotyping is one of the skill geneticists
should master in their formation. The current form of
developing this ability is time consuming for both the fel-
low and the coordinator. We created an application to fasten
the process. Materials and Methods: Using images cap-
tured by Zeiss Axio Imager.N1 and sorted in karyograms
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with the Ikaros v5.2.8 software, with the help of HTML,
CSS, JavaScript, SQL, MySQL, PHP scripting language we
developed an education software for medical genetics fel-
lows. Results: The internet based application aids in the
karyotyping learning of new geneticists. It has a theory
section, MCQ tests based on it and hands on learning how
to recognise the chromosomes and set them into pairs.
Using a simple drag and drop system the program stops you
from misplacing the chromosomes. It counts the number of
false positioning attempts and the time you spend on each
test, giving you a progress evaluation feedback. At the end
of each test a pop up message appears containing the par-
ticularity of the arranged chromosome set(eg: deletion,
inversions, duplications etc.). The application can be found
at http://optimx.ro/ool/. Conclusions: This tool will help the
future generation of geneticist develop their skills faster and
give them more schedule ﬂexibility. Acknowledgements:
Some of the research was done at the Center of Genomic
Medicine of the “Victor Babeș” University of Medicine and
Pharmacy of Timișoara, POSCCE 185/48749, contract 677/
09.04.2015.
I. Perva: None. C. Perva: None. D. Rusu: None. S.
Farcas: None. A. Chirita-Emandi: None. N. Andreescu:
None. A. Mihailescu: None. C. Zimbru: None. N. Morar:
None. M. Puiu: None.
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The "Monte Santo" experience: a population-based
public health care programme to screen, diagnose and
manage genetic diseases in Brazil
A. X. Acosta1,2,3, D. S. D. da Silva3,4, P. C. Oliveira3,5, P.
B. Corrêa2,6, A. M. M. Fontes2, J. Fernandes7, K. Abé-
Sandes3,8
1Departamento de Pediatria, Faculdade de Medicina,
Universidade Federal da Bahia (UFBA), Salvador, Brazil,
2Serviço de Genética Médica, Hospital Universitário
Professor Edgard Santos (HUPES/UFBA), Salvador, Bra-
zil, 3Instituto Gonçalo Moniz, Fundação Oswaldo Cruz,
Salvador, Brazil, 4Maternidade Climério de Oliveira
(UFBA), Salvador, Brazil, 5Departamento de Ciências da
Vida, Universidade do Estado da Bahia, Salvador, Brazil,
6nstituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salva-
dor, Brazil, 7Pós Graduação em Medicina em Saúde
(UFBA), Salvador, Brazil, 8Laboratório de Imunologia e
Biologia Molecular (UFBA), Salvador, Brazil
Introduction: Monte Santo is a rural area in NE Brazil
where several studies have shown high frequencies of dif-
ferent genetic disorders, implicating endogamy and con-
sanguinity as risk factors. In 2014 a public health
programme was established to deliver care and education
for the detection of genetic diseases, to organize diagnostic
facilities, and train local health professionals to offer pri-
mary health care linked and coordinated by a reference
centre.
Subjects and Methods: Across the population a ques-
tionnaire with suitable parameters to detect individuals with
suspected hearing impairment (HI), intellectual disability
(ID), mental disorder (MD), or congenital disease (CD) is
completed by community health staff. Positive cases are
evaluated by a multidisciplinary team with conﬁrmed dis-
orders investigated according the most probable genetic
cause. Local health professionals have been trained to fol-
low and maintain this systematic routine.
Results: Sensitivity and speciﬁcity levels of 59% and
68% were achieved with HI; 78% and 53% with ID; 90%
and 95% with MD; and 77% and 70% respectively with
CD. Data on 8,445 individuals (16% of the population)
were collected, with 1,505 persons evaluated by the multi-
disciplinary team and 3,150 tests performed to investigate
possible genetic diseases. The consanguinity rate of the
1,505 positive cases was 31%, indicating potential vulner-
ability to recessive genetic diseases besides multifactorial
conditions.
Conclusion: The “Monte Santo” experience can provide
a feasible and efﬁcient model in the development of public
health strategies for the detection and diagnosis of rare
diseases via primary care, helping the current Public
National Policy of Rare Diseases.
A.X. Acosta: None. D.S.D. da Silva: None. P.C. Oli-
veira: None. P.B. Corrêa: None. A.M.M. Fontes: None.
J. Fernandes: None. K. Abé-Sandes: None.
P19.35C
Too low risk to test?
J. Imrie
NPUK, Washington, United Kingdom
Niemann-Pick Type C(NPC) is a rare neurodegenerative,
autosomal recessively inherited, lysosomal storage disorder
with an incidence of about 1:100,000. There are about 100
known cases in the UK. Genetic Counsellors may see sib-
lings and extended family requesting carrier testing but as
the risk of meeting another carrier and having an affected
child is so low they may not agree to the test being carried
out. The author will examine the reasons why close family
may request carrier testing from known family cases. This
presentation will look at 2 case studies with very similar
family backgrounds and scenarios with very different out-
comes. The professionals seem to view only the probability
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whilst affected family members see only the impact. Whilst
the risk factor may be numerically resolved the issue is one
of perception. The main point is that it might bring relief to
wider family members knowing that they are not carriers of
the disease causing mutation, or, if they are, then fore-
warned is forearmed. This presentation looks at the psy-
chosocial impact of testing or not testing against the cost to
the NHS of familial screening. In looking for a cost effec-
tive solution the author will discuss the option of a Genetic
Counsellor with good knowledge of the disease working
closely with all affected families with a view to initiating
testing if it was felt appropriate despite low risk.
J. Imrie: F. Consultant/Advisory Board; Modest;
Orphazyme.
P19.36D
European collaborative work to establish standards for
Orphanet quality assessment of genetic counsellors
D. Lambert1,2, V. Corrochano3, F. Palau3,4, M.
Paneque2,5, R. Moldovan2,6, C. Cordier2,7, C. Serra-
Juhé2,8, I. Feroce2,9, S. Pasalodos2,10, E. Haquet2,11, I.
Bjørnevoll2,12, H. Skirton2,13, B. McInnes14, A. Rath15
1National Rare Diseases Ofﬁce, Dublin, Ireland, 2Genetic
Nurse and Counsellor Professional Branch Board, Eur-
opean Board of Medical Genetics, Vienna, Austria, 3Center
for Biomedical Network Research on Rare Diseases
(CIBERER), Valencia, Spain, 4Sant Joan de Déu Children’s
Hospital, Barcelona, Spain, 5Institute for Molecular and
Cell Biology; UnIGENe and Centre for Predictive and
Preventive Genetics (CGPP), Universidade do Porto,
Porto, Portugal, 6Department of Psychology, Babe-Bolyai
University, Cluj-Napoca, Romania, 7Synlab Genetics,
Department of Genetics, Lausanne, Switzerland, 8Genetics
Unit, Universitat Pompeu Fabra - Hospital del Mar
Research Institute, Barcelona, Spain, 9Division of Cancer
Prevention and Genetics, European Institute of Oncology,
Milan, Italy, 10Navarrabiomed - Biomedical Research
Centre, Genomic Medicine Unit, Pamplona, Spain,
11Département de Génétique Médicale, CHRU de Mon-
tpellier - Hôpital Arnaud de Villeneuve, Montpellier,
France, 12Department of Medical Genetics, St. Olavs
University Hospital, Trondheim, Norway, 13School of
Nursing and Midwifery, Plymouth University, Plymouth,
United Kingdom, 14Department of Genetics, Alberta
Children's Hospital, Calgary, AB, Canada, 15Orphanet,
INSERM, Paris, France
Introduction: Orphanet, recognized as the largest interna-
tional rare disease online portal, contains information about
709 expert centres that provide genetic counselling for rare
diseases. Unlike medical management centres for rare dis-
eases, which are assessed by criteria established by the
European Union Committee of Experts on Rare Diseases,
there was no quality assessment of self-declared genetic
counselling activity.
Methods: A pilot quality questionnaire was developed by
Orphanet Spain regarding patient population, pathways,
quality management and teaching. A collaborative work
was undertaken with the Genetics Nurses and Counsellors
Professional Brach of the European Board of Medical
Genetics in order to integrate European Board of Medical
Genetics published standards: core competencies for genetic
counselling; professional and educational standards; and
code of professional practice for genetic counsellors. To
ensure cross-country generalizability the questionnaire was
also reviewed by two Orphanet Information Scientists who
are certiﬁed by the Canadian Association of Genetic
Counsellors.
Results: The ﬁnal questionnaire is available for use in all
40 Orphanet countries. Domains queried include: patient
population, qualiﬁcations and professional registration sta-
tus of staff providing genetic counselling, multidisciplinary
input and access to psychological support, the scope of
genetic counselling activities, quality management, com-
mitment to continuing education and teaching.
Conclusion: Existing and newly registered genetic
counselling centres on the Orphanet database will undergo
national assessment via the new quality standard. Orphanet
has once again demonstrated its commitment to quality data
for rare diseases, and has made a commitment towards the
recognition of quality genetic counselling as a valued
resource for rare disease patients.
D. Lambert: None. V. Corrochano: None. F. Palau:
None. M. Paneque: None. R. Moldovan: None. C. Cor-
dier: None. C. Serra-Juhé: None. I. Feroce: None. S.
Pasalodos: None. E. Haquet: None. I. Bjørnevoll: None.
H. Skirton: None. B. McInnes: None. A. Rath: None.
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Australian public’s awareness, use and interest in
health-related and recreational personal genomic testing
S. A. Metcalfe1, R. Tytherleigh1, C. Hickerton1, J. Savard2,
B. Terrill3, E. Turbitt1, E. Stackpoole1, C. Gaff4, K. Gray5,
A. Middleton6, B. Wilson7, A. Newson2
1Murdoch Childrens Research Institute and Dept Paedia-
trics, University of Melbourne, Parkville, Vic, Australia,
2University of Sydney, Camperdown (Sydney), NSW,
Australia, 3Garvan Institute of Medical Research and
Genome.One, Darlinghurst (Sydney), NSW, Australia,
4The Walter and Eliza Hall Institute and Dept Paediatrics,
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University of Melbourne, Parkville, Vic, Australia, 5Health
and Biomedical Informatics Centre, University of Mel-
bourne, Parkville, Vic, Australia, 6Wellcome Trust Sanger
Institute, Hinxton, Cambridge, United Kingdom, 7Univer-
sity of Ottawa, Ottawa, ON, Canada
Background Individuals can access genetic information
relating to their health, as well as ‘recreational’ personal
genomic information such as ancestry and sporting ability,
either online or through a health professional. This has
predominantly been marketed within the USA, and is
accessible to everyone, including Australians. Aim To
investigate Australians’ awareness, interest, and experiences
of personal genomics.Methods An online survey was made
available and advertised through social media, community
and professional groups, and researchers’ networks. The
survey is open until April 2017. Results To date, 1,636
Australians have attempted the survey: 75.7% female,
74.1% undertaking/had university education and 22.2%
working/had worked in genomics/life sciences. The major-
ity (75.3%) were aware of ‘personal genomics’, mostly
having heard about it through formal studies and media. 283
reported having some type of genetic testing, and testing
was greater in females (χ2=9.8. p=0.007) and those
working in genomics/life sciences (χ2=14.8, p=0.001). Of
respondents who had testing, 80 had ordered the test online
only, often for multiple purposes, with ancestry most
common. 591 had considered but not had testing, while of
418 who had not considered testing, 74.6% had never
thought about it. Conclusion In this highly educated
population, the level of online personal genomic testing was
low, with recreational (especially ancestry) testing of
greatest interest. While the current cohort of respondents
presents a select sampling, efforts are being made to expand
recruitment to provide a more representative sample of the
Australian population. Findings will contribute to guide-
lines for policy and education in genomics in Australia.
S.A. Metcalfe: None. R. Tytherleigh: None. C. Hick-
erton: None. J. Savard: None. B. Terrill: A. Employment
(full or part-time); Signiﬁcant; Genome.One. E. Turbitt:
None. E. Stackpoole: None. C. Gaff: None. K. Gray:
None. A. Middleton: None. B. Wilson: None. A. Newson:
None.
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Young adults' experiences with risk and with pre-
symptomatic testing for late-onset neurological dis-
orders: ﬁndings from a Portuguese qualitative study
J. Pereira1, C. Costa2, M. Paneque1, J. Sequeiros1,3, Á.
Mendes1
1i3S, UnIGENe and CGPP, University of Porto, Porto,
Portugal, 2Faculdade de Psicologia e de Ciências da
Educação, University of Porto, Porto, Portugal, 3ICBAS -
Instituto de Ciências Biomédicas Abel Salazar, Universi-
dade do Porto, Porto, Portugal
Young adulthood is typically a challenging development
transition. Literature recognizes the additional challenges
presymptomatic testing may pose at this age, both for young
adults and for genetics health professionals. Although
young adult’s requests of presymptomatic testing for late-
onset disorders are increasing, research in this area is scarce.
This qualitative exploratory study aimed at exploring
experiences of young adults (aged 18–26) with their
increased genetic risk for late-onset neurological disorders.
We sought to identify key motivators for testing uptake, to
understand its anticipated psychosocial impacts, and parti-
cipants’ perspectives on the nature of the information about
genetic risks. Psychosocial needs were also explored. After
written consent, a semi-structured interview was conducted
with twelve participants in our presymptomatic testing
protocol, before its results were known. Interviews were
recorded, transcribed verbatim and analyzed thematically.
Preliminary ﬁndings have shown that most participants
recognize the psychosocial impact of their increased genetic
risk, including feeling more anxious and an augmented
sense of vulnerability regarding a potential carrier result.
Participants perceive PST as a means to reduce uncertainty
about their genetic status, leading to important life-planning
decisions (e.g., reproductive choices). Presymptomatic
testing has allowed participants to feel more empowered
and ‘responsible’ for the management of their own health
status. They also acknowledged genetic information as
being of a complex nature, both with a personal and a
familial dimension. All participants declared to be willing to
share their test results with family members. This has
important implications for genetic counselling and potential
psycho-educational interventions in this age group. (SFRH/
BPD/88647/2012)
J. Pereira: None. C. Costa: None. M. Paneque: None.
J. Sequeiros: None. Á. Mendes: B. Research Grant
(principal investigator, collaborator or consultant and
pending grants as well as grants already received); Sig-
niﬁcant; Postdoctoral grant by the Portuguese Foundation
for Science and Technology, Refª (BPD/88647/2012).
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15 years of public engagement: from launch of the bio-
bank to personalised medicine initiative in Estonia
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A. Allik1, L. Leitsalu1, A. Metspalu1,2
1Estonian Genome Center, University of Tartu, Tartu,
Estonia, 2Institute of Molecular and Cell Biology, Uni-
versity of Tartu, Tartu, Estonia
Introduction: The Estonian Genome Center of the Uni-
versity of Tartu (EGCUT) is a research institute with a
population-based, longitudinal biobank representing about
5% of Estonia’s adult population. The EGCUT has strongly
focused on public engagement in order to explain the
potential of biobanks and the ﬁeld of human genetics,
introduce research conducted using biobank’s data, and the
potential of personalized medicine. By the summer of 2017,
the entire EGCUT cohort will be genotyped and we plan to
start with return of individual genomic results to biobank’s
participants.
Methods: Various approaches have been used to inform
and engage stakeholders (the public, physicians and deci-
sion-makers) as the main goals of the biobank have shifted
from recruitment to research, and translation of research to
clinical practice. For monitoring public’s perspectives,
annual surveys on awareness of and attitude towards the
biobank have been conducted (2001 - 2014) and perspec-
tives regarding the use of genomic information in healthcare
have been surveyed in 2011, 2013, and 2014.
Results: According to the last poll conducted in 2014,
73% of responders were aware of the biobank and 70% of
them supported the project while 1% were against it.
Reportedly, 77% would be interested in personalized
genetic risk predictions.
Conclusions: Stakeholders engagement is of particular
importance as the up-coming plans of the EGCUT involve
offering return of individual research results and imple-
mentation of genomic data in national personalized medi-
cine initiative.
A. Allik: None. L. Leitsalu: None. A. Metspalu: None.
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The Orphanet Knowledge Base - a community-driven
knowledge curation platform for rare disorders
A. Olry1, V. Lanneau1, M. Hanauer1, C. Gueydan1, C.
McNamara2, E. Zhang2, T. Groza2,3,4, G. Baynam5,6, H. J.
S. Dawkins7, A. Rath1
1Orphanet, INSERM, US14, Paris, France, 2Kinghorn
Centre for Clinical Genomics, Garvan Institute of Medical
Research, Darlinghurst, Australia, 3St Vincent's Clinical
School, Faculty of Medicine, UNSW Sydney, Sydney,
Australia, 4Genome.One, Darlinghurst, Australia, 5Western
Australian Register of Developmental Anomalies and
Genetic Services of Western Australia, King Edward
Memorial Hospital Department of Health, Government of
Western Australia, Perth, Australia, 6School of Paediatrics
and Child Health, University of Western Australia, Perth,
Australia, 7Ofﬁce of Population Health Genomics, Public
Health Division, Health Department of Western Australia,
Perth, Australia
Since 1997, Orphanet maintains a multilingual database of
rare disorders (RD), based on literature and on expert
advice. Orphanet’s scientiﬁc data is comprised of a nosol-
ogy (classiﬁcation of RD), textual information, epidemio-
logical data, information on natural history, relationships
between RD and genes, phenotypes and disabilities. Data
are manually curated.
The Orphanet Knowledge Base (OKB), jointly devel-
oped by the INSERM and the Garvan Institute, is an expert
community-driven knowledge curation platform for RD
based on Orphanet scientiﬁc content. It is a pilot project that
allows users to explore the Orphanet scientiﬁc data through
an user-friendly web interface.
Each RD is represented as a single web page including
the ORPHA number, names and synonyms of the disorder,
its semantic typology, a textual description organized into
sections, the associated genes (including the type of asso-
ciation) and phenotypes (including frequency of occur-
rence), and data on natural history and epidemiology, as
well as the alignments with other terminological resources.
The platform allows users - the expert community at
large – to propose corrections or modiﬁcations to the sci-
entiﬁc content. Suggestions can be discussed virtually with
other experts and with the Orphanet curators. Decisions on
changes can therefore be done in a participative, expert-
corwd-sourced manner. Changes validated in the OKB are
then incorporated to the Orphanet database. The OKB
creates an interactive knowledge curation process that
enables for input from the RD expert community, sig-
niﬁcantly reducing the time for curation while maintaining
the high quality standard of the Orphanet data in a trans-
parent, traceable way.
A. Olry: None. V. Lanneau: None.M. Hanauer: None.
C. Gueydan: None. C. McNamara: None. E. Zhang:
None. T. Groza: None. G. Baynam: None. H.J.S. Daw-
kins: None. A. Rath: None.
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ERN-EYE: the European Reference Network dedicated
to European patients with Rare Eye Diseases
D. Leroux1, H. Dollfus2, J. Ashworth3, G. Black3, D.
Böhringer4, C. J. Boon5, F. Cremers6, A. Daly7, C.
Fasser8, D. Fischer9, D. Keegan10, K. Khan11, F. Larkin12,
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Martinho17, S. Mohand-Saïd18, A. Petzold12, M.
Preising16, T. Reinhart4, T. Wheeler-Schilling9,19, S.
Wong12, E. Zrenner9, all the ERN-EYE Members
1SENSGENE Coordination Team, Hôpitaux Universitaires
de Strasbourg, Strasbourg, France, 2CARGO, Hôpitaux
Universitaires de Strasbourg, Strasbourg, France, 3Central
Manchester University Hospitals NHS Foundation Trust,
Manchester, United Kingdom, 4Eye Centre, University
Hospital Freiburg, Freiburg, Germany, 5Leiden University
Medical Center/Academic Medical Center Amsterdam,
Leiden, Netherlands, 6Radboud University Medical Center,
Nijmegen, Netherlands, 7Retina International, Dublin, Ire-
land, 8Retina International, Zürich, Switzerland, 9Univer-
sity Eye Hospital, Centre for Ophthalmology, Tübingen,
Germany, 10Mater Misericordiae University Hospital,
Dublin, Ireland, 11St. James's University Hospital, Leeds,
United Kingdom, 12Moorﬁelds Eye Hospital, London,
United Kingdom, 13Rigshospitalet, Glostrup, Denmark,
14Ghent University Hospital, Ghent, Belgium, 15General
University Hospital in Prague, Prague, Czech Republic,
16Universitätsklinikum Giessen, Giessen, Germany,
17EVICRnet, AIBILI, Coimbra, Portugal, 18REFERET,
CHNO des Quinze-Vingt, Paris, France, 19European Vision
Institute EEIG, Bruxelles, Belgium
Introduction: Rare Eye Diseases (RED) are a diverse
group of orphan diseases that display major genetic and
phenotypic heterogeneity and represent the leading cause of
visual impairment/visual loss in children and young adults
in Europe. Signiﬁcant barriers remain for early diagnosis
and patient management. Speciﬁc treatments for this highly
heterogeneous group of diseases remain challenging reason
why RED represent a major socio-economic burden. As for
other rare diseases, a multidisciplinary consortium of spe-
cialists across the EU has decided to join forces in a Eur-
opean Reference Network (ERN): ERN-EYE.
Methods: ERN-EYE currently consists of 29 healthcare
providers from 13 Member States, with important interac-
tions with patients and patient groups (European Patient
Advocacy Groups noticeably), and will cover pre-
dominantly genetic RED. The general organisation of the
ERN as well as mapping of all collaborators across the EU
will be presented.
Results: ERN-EYE will address the following genetic
ﬁelds: retinal diseases, paediatric syndromic and non-
syndromic ophthalmic diseases, optic neuropathies, eye
movement disorders, anterior segment diseases, and cover
domains such as improving genetic counselling, improving
genetic diagnosis including organisation of molecular
diagnosis on an EU basis, clinical research including
boosting of clinical trials and registries.
Conclusion: We anticipate that ERN-EYE network will
improve upon existing resources dedicated to patients with
RED across the EU and create new facilities to better
diagnose, understand and treat patients and families with
RED.
*ERNs are co-funded by the EU Healthcare program.
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Reporting genomic research results to population bio-
bank participants - participant preferences and
response
L. Leitsalu1, M. Alver1,2, M. Palover1,2, A. Reigo1, T.
Nikopensius1, H. Alavere1, A. Metspalu1,2, N. Tõnisson1,3,
T. Esko1,4
1Estonian Genome Center, University of Tartu, Tartu,
Estonia, 2Institute of Molecular and Cell Biology, Uni-
versity of Tartu, Tartu, Estonia, 3Dept. of Genetics, Tartu
University Hospital, Tartu, Estonia, 4Broad Institute,
Cambridge, MA, United States
Introduction: Returning research results to biobank parti-
cipants is a topic of ongoing debate. Procedural guidelines
are limited, largely due to a dearth of studies on the clinical
and psychological impacts of such disclosure. The Estonian
biobank legislation gives participants the right to be
informed about the data collected and generated and also
the corresponding right not to know. Methods: A genotype-
ﬁrst project involving population biobank participants car-
rying pathogenic variants in three genes associated with
familial hypercholesterolemia was initiated. The procedural
framework used to offer return of clinically signiﬁcant
genetic ﬁndings to participants includes contacting without
ﬁrst disclosing genetic status, project speciﬁc consent,
independent validation of the ﬁnding, disclosure accom-
panied with genetic counseling, collaboration with cardiol-
ogists, and immediate and long-term feedback surveys.
Results: Of 42 carriers identiﬁed, 21 have visited the bio-
bank and expressed interest towards return of results. The
12 participants who have received the results, so far, have
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perceived this information valuable and eight have had
relatives attend the cascade screening. Although three par-
ticipants report feeling worry, all appreciate being con-
tacted. Conclusions: The choices of participants contacted
indicate that there is preference towards disclosure and as
per the survey results the information disclosed is perceived
valuable. The long-term effect and the impact of the cascade
screening are still to be determined. The surveys and
follow-up allow us to generate much needed empirical data
on the effect of communicating genetic risk information to
biobank participants and inform procedural guidelines for
future projects involving return of medically actionable
ﬁndings.
L. Leitsalu: None. M. Alver: None. M. Palover: None.
A. Reigo: None. T. Nikopensius: None. H. Alavere:
None. A. Metspalu: None. N. Tõnisson: None. T. Esko:
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A randomized controlled trial of return of genomic
results shows non-inferiority of web-based compared to
counselor return of carrier results
L. G. Biesecker, K. Lewis, K. Umstead, J. Johnston, B.
Biesecker
National Human Genome Research Institute, Bethesda,
MD, United States
A critical bottleneck in genomics is the mismatch of large
volumes of results to the capacity of the current standard of
returning results in-person by a healthcare professional. To
test a web-based alternative to in-person results return, we
designed a web platform that integrated education regarding
carrier results with individualized test results and compared
return of results through this platform to the same infor-
mation returned via a counselor in a randomized controlled
non-inferiority trial. Our outcomes included knowledge,
test-speciﬁc distress, risk worry, decisional conﬂict, and
communication of results to family members and healthcare
providers. We randomized 462 participants into web or
counselor arms. One to seven carrier results were returned
to each participant. The web was non-inferior to the coun-
selor on outcomes assessed six months after return of results
including: knowledge (d=0.18; upper limit of 97.5%
CI=0.63; non-inferiority margin= 1), distress (d=−0.54;
lower limit of 97.5%CI=−1.00; NFM=−1), risk worry
(d=−0.10; lower limit of 97.5%CI=−0.32; NFM=−0.5),
and decisional conﬂict (d=−1.18; lower limit of 97.5%CI=
−2.66; NFM=−6). There were no signiﬁcant differences
between education arms in disclosure rates to children,
siblings, or providers. Participants with children
experienced signiﬁcantly more decisional conﬂict when
educated by the web, but the lower limit did not cross the
non-inferiority margin. No other differences in outcomes
were found between parents and non-parents. This well-
powered trial demonstrates non-inferiority of web-based
communication of carrier results and should spur efforts to
shift the communication of information about genomic test
results from the clinic to the internet to improve efﬁciency
and reduce healthcare costs.
L.G. Biesecker: F. Consultant/Advisory Board; Modest;
Unpaid Consultant Illumina Corp. K. Lewis: None. K.
Umstead: None. J. Johnston: None. B. Biesecker: None.
P19.44D
EGA - future plans
G. Kerry1, P. Flicek1, T. Keane1, H. Parkinson1, D.
Spalding1, J. Almeida-King1, M. Courtot1, P. Acre-
Garcia1, J. Kandasamy1, A. Senf1, S. Ur-Rehman1, R.
Guigó Serra2, A. Navarro Cuartiellas2, J. Rambla2, M.
Alberich2, A. Carreño2, A. Gill2, A. lloret2, Ó. Martínez2,
M. Moldes2, S. de la Torre2, M. Cabili3
1EMBL-EBI, Cambridge, United Kingdom, 2CRG, Barce-
lona, Spain, 3BROAD, Cambridge, MA, United States
As of February 2017, the EGA holds 3.5 petabytes of data
and has handled some 2,500 help-desk tickets in the last
year alone.
Genomic data analysis is no longer for a small number of
highly expert scientists but is increasingly a staple of bio-
medical research. Users from across the world and scientiﬁc
spectrum wish to access the data held by the EGA and it is
important that the services provided by the EGA are
accessible and user-friendly so that all researchers, regard-
less of prior experience, can beneﬁt from the resource.
In the Autumn of 2016 the EGA embarked on its ﬁrst
ever user survey, contacting over 1,000 individuals in order
to seek feedback on, and suggestions to, how we might look
to improve on and increase our existing services.
In addition to this, the EGA has been involved with the
work of Global Alliance for Genomics and Health
(GA4GH).In particular, the EGA, in partnership with the
Sanger Institute, has set up a small proof-of-concept project
to implement “Consent Codes” (SOM Dyke, et al PLoS
Genetics. 12(1): e1005772), which provide users with an
easily understood view of the conditions under which the
data may be accessed and used.
Here we present the ﬁndings of the EGA survey com-
bined with the Consent Code work in order to provide
insight into how the EGA of the future might look.
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The EGA is maintained by European Bioinformatics
Institute (EMBL-EBI) and the Center for Genomic regula-
tion (CRG) and is available at http://www.ega-archive.org.
G. Kerry: None. P. Flicek: None. T. Keane: None. H.
Parkinson: None. D. Spalding: None. J. Almeida-King:
None. M. Courtot: None. P. Acre-Garcia: None. J.
Kandasamy: None. A. Senf: None. S. Ur-Rehman: None.
R. Guigó Serra: None. A. Navarro Cuartiellas: None. J.
Rambla: None.M. Alberich: None. A. Carreño: None. A.
Gill: None. A. lloret: None. Ó. Martínez: None. M.
Moldes: None. S. de la Torre: None. M. Cabili: None.
P19.45A
A pilot study of a support group in the follow-up of
oncogenetic counseling services for women with BRCA
mutation
N. Taris1, S. Laurent2
1Centre Paul Strauss, Strasbourg, France, 2Hôpital Civil de
Strasbourg, Strasbourg, France
Introduction: Patients who learn from oncogenetic services
that they carry harmful constitutional BRCA1 or 2 gene
mutations experience high levels of psychological distress.
In France, additional psychological assistance for these
patients has been recommended; however, the optimal
conditions for and duration of such assistance need to be
clearly deﬁned. To begin addressing these parameters, we
proposed a pilot study in which women with BRCA muta-
tions would participate in a support group as a follow-up to
oncogenetic counseling services at the Centre Paul Strauss,
located in Strasbourg, France.
Materials and Methods: In June 2014, we sent by mail a
one-page questionnaire to one hundred women, with or
without personal history of cancer, and who had been
identiﬁed within the past two years as carrying a BRCA
mutation. The questionnaire was designed to survey the
potential interest for these women to take part to the support
group.
Results: Four month later, 44% answered the ques-
tionnaire, and of those responding, 64% expressed interest
in participation. Two groups, led by a psychologist and
involving jointly a genetic counselor, were established in
November 2014. An average of 3 women and 7 women
participated in a Wednesday evening group and a Saturday
morning group, respectively. Group meetings took place
every two months and lasted approximately 2 hours.
Conclusion: After two years in operation, we present our
preliminary ﬁndings and discuss the effectiveness of post-
counselling group support for patients with BRCA
mutations.
N. Taris: None. S. Laurent: None.
P19.46B
A new instrument for quality assessment of genetic
counselling practice: the contribution of Portuguese
genetics healthcare services
M. Paneque1, C. Costa2, J. Sequeiros1, M. S. Lemos2
1IBMC-CGPP, Porto, Portugal, 2Faculdade de Psicologia
e de Ciências da Educação da Universidade do Porto,
Porto, Portugal
The importance of appropriate genetic counselling when
offering genetic testing has been consensual. Although there
are guidelines for practice of genetic counselling, the tools
and measures for quality assessment are still insufﬁcient.
Recent Portuguese’s studies on consultands’ and profes-
sionals’ views highlighted the need for instruments and
quality indicators that support them. We present the meth-
odological design, preliminary validation, results and chal-
lenges faced along the process of construction of a new
instrument for assessing the quality of Portuguese genetic
counselling practice. The Reciprocal-Engagement Model of
Genetic Counselling Practice served as a theoretical basis
for this tool. Five main dimensions were outlined and
related to: (1) provision of information; (2) emotional issues
as part of the counselling process; (3) counsellor-consultand
relationship; (4) effects of genetic counselling on con-
sultands; and (5) standards of care. A ﬁrst pool of 130 items,
resulting from previous national studies and the literature,
underwent pre-test validation, through cognitive interview-
ing with ﬁve national experts who assessed clarity, format
and content, appropriateness, usefulness and relevance.
Currently, the instrument underwent validation through
statistical analysis of the items testing accuracy and value of
the information collected, which will allow the selection of
the best ones. Portuguese professionals of national genetics
services are involved in an undergoing process of psycho-
metric validation that should be completed by March. It is
expected that this instrument may be useful both in asses-
sing the quality and effectiveness of the genetic counselling
practice, and in monitoring improvement of national
genetics healthcare services.
M. Paneque: None. C. Costa: None. J. Sequeiros:
None. M.S. Lemos: None.
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Uncertainty in consultations about genetic testing for
cancer. An explorative observational study
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N. M. Medendorp1, M. A. Hillen1, L. Murugesu1, C. M.
Aalfs1, A. M. Stiggelbout2, E. M. A. Smets1
1Academic Medical Center, Amsterdam, Netherlands, 2Lei-
den University Medical Center, Leiden, Netherlands
Abstract
Introduction: People seek cancer genetic counseling
(CGC) to obtain certainty about their medical situation.
Unfortunately, the information provided during CGC
involves many uncertainties, e.g., the risk of developing
cancer. Communicating about uncertainties is important to
maintain patients’ wellbeing, enhance patient autonomy and
enable shared decision making. Yet, the optimal way of
managing and communicating uncertainties remains
unknown. To address this problem, we explored whether,
how and what types of uncertainty are expressed and dis-
cussed during CGC.
Materials and methods: Initial cancer genetic con-
sultations (N= 25) were audiotaped, transcribed and qua-
litatively analyzed using MAXQDA. A coding scheme
identifying all types of uncertainty was developed induc-
tively, in parallel with coding the transcripts. Next, codes
were thematically categorized using the literature. All
transcripts were double-coded independently and dis-
crepancies were discussed until consensus was reached.
Results: Uncertainty is highly prevalent during CGC in
communication by both counselors and counselees.
Uncertainties discussed most by counselors relate to sci-
entiﬁc issues such as risks and scientiﬁc limitations. In
contrast, counselees mainly express uncertainty related to
personal and practical issues, e.g., their family history, their
own and their relatives’ health and their knowledge of
genetics.
Conclusions:Many types and causes of uncertainty were
found. Moreover, a prominent discrepancy appears between
uncertainty expressed by counselors compared to counse-
lees. This implies that counselees may lack awareness of
uncertainty related to scientiﬁc issues. These ﬁndings will
be used to inform future studies addressing optimal ways of
managing and communicating uncertainty in CGC.
N.M. Medendorp: None. M.A. Hillen: None. L.
Murugesu: None. C.M. Aalfs: None. A.M. Stiggelbout:
None. E.M.A. Smets: None.
P19.48D
Whole exome sequencing becomes a must in daily
practice due to the changing demographic pattern; 100
patients and beyond
A. Bisgin1,2, S. Tug Bozdogan1
1Cukurova University Faculty of Medicine, Adana, Turkey,
2Cukurova University AGENTEM, Adana, Turkey
Introduction: Whole-exome-sequencing has rapidly
become one of the most successful methods for diagnosis.
The main reason for its increasing clinical use is the wide
range of clinical phenotypes. This obstacle becomes more
obvious than ever, since the great demographic movement
occurs in the last decade. Our institute serves as the ﬁrst-
thier, tertiary referral hospital to a very large scale habitat
from Mediterranean coast to Middle East borders that are
the richest pools of rare disorders with more than 5000
patients per year with most recently established Medical
Genetics Department.
Materials and Methods: We set up clinical genetics
policlinics for outpatient inclusion and counseling, and a
diagnostic laboratory. Our analysis in this report comprises
an experience of the changing demographic pattern effect
with whole exome sequencing results of 100 patients.
Results: We identiﬁed 74 mutated alleles achieving a
74% diagnostic rate. Twentythree of 74(31%) were novel
mutations that were likely to be causative and all were
conﬁrmed in the parents. 11 of 74(15%) were proved to be
de-novo mutations. Among the 74 patients, 27%(n= 20)
had autosomal-dominant disease, 70%(n= 52) had
autosomal-recessive disease and most interestingly 2
patients(3%) had two different diseases while one of them
had both autosomal-recessive, the other had one autosomal-
dominant and one autosomal-recessive disease. A total of
10%(n= 2) of the autosomal-dominant mutant alleles
occured de-novo.
Conclusion: The standard of clinical practice involves
the recognition of speciﬁc phenotypic features. However,
demographic changes effects the clinical evaluation quality
due to the clinical variables. Thus, whole-exome-
sequencing becomes the most important diagnostic tool.
A. Bisgin: None. S. Tug Bozdogan: None.
P19.49A
Feasibility of couple-based expanded preconception
carrier screening offered by the general practitioner
J. Schuurmans1,2, L. M. van den Heuvel1, M. Plantinga1,
E. Birnie1, A. M. Lucassen2, A. V. Ranchor3, A. D.
Diemers4, I. M. van Langen1
1Department of Genetics, University Medical Center
Groningen, University of Groningen, Groningen, Nether-
lands, 2Clinical Ethics and Law, Faculty of Medicine,
University of Southampton, Southampton, United Kingdom,
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3Department of Health Psychology, University Medical
Center Groningen, University of Groningen, Groningen,
Netherlands, 4Department of General Practice and Elderly
Care, University Medical Center Groningen, University of
Groningen, Groningen, Netherlands
Introduction Our previous research showed that Dutch
professionals and target population consider the general
practitioner (GP) most suitable to provide expanded pre-
conception carrier screening (ECS). As part of an imple-
mentation study on couple-based ECS offered by GPs, we
evaluated feasibility using predeﬁned criteria, explored
GPs’ experiences and measured patient satisfaction.
Beforehand, GPs received training, knowledge-evaluation
and supervision (twice).
Methods and materials: Feasibility was deﬁned as (1)
< 20% of GPs require additional training or supervision
(2) ≥ 80% of consultations occur within 20 minutes (regular
double-consultation time) and (3) GPs refer < 20% of
average-risk couples to clinical genetics for additional
counseling. GPs recorded consultation time. Patient satis-
faction with GPs’ counselling was measured using a survey.
Semi-structured interviews with 10/13 participating GPs
were qualitatively analysed to explore test-counseling
experiences and views on future implementation.
Results: 130 consultations took place. 1: 0/13 partici-
pating GPs required additional training or supervision. 2:63/
108 (58%) consultations took place within 20 minutes
(median 20, IQR 18–28). 3: No average-risk couples were
referred. All GPs felt competent to provide counseling after
preparation and with supportive materials provided. GP-
training was considered essential for future implementation.
Couples’ prior knowledge-level and administrative practi-
calities affected consultation time. 91% of patients were
(very) satisﬁed with GPs’ counselling.
Conclusions: During our pilot it was feasible for moti-
vated and trained GPs to provide couple-based ECS. Asking
couples to review information about ECS prior to coun-
seling might improve efﬁcient use of GP time. We expect
adequately trained GPs will be able to offer couple-based
ECS.
J. Schuurmans: None. L.M. van den Heuvel: None.
M. Plantinga: None. E. Birnie: None. A.M. Lucassen:
None. A.V. Ranchor: None. A.D. Diemers: None. I.M.
van Langen: None.
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P20.01A
Regulation of direct-to-consumer genetic testing in
Europe: a fragmented landscape
L. Kalokairinou1, H. C. Howard2, S. Slokenberga2, C. M.
Romeo-Casabona3, E. Fisher4, M. Flatscher-Thöni5, M.
Hartlev6, R. van Hellemondt7, J. Juškevičius8, J.
Kapelenska-Pregowska9, P. Kovac10,11, L. Lovrečić12, H.
Nys1, de Paor13, A. Phillips14, L. Prudil15, E. Rial-
Sebbag16, J. Sandor17, A. Schuster18, S. Soini19, K. H.
Søvig20, D. Stoffel21, T. Titma22, T. Trokanas23, P. Borry1
1KU Leuven, Leuven, Belgium, 2Uppsala University,
Uppsala, Sweden, 3University of the Basque Country,
Leioa, Spain, 4Commission on Genetic Testing, Robert
Koch-Institute, Berlin, Germany, 5UMIT, Hall in Tirol,
Austria, 6University of Copenhagen, Copenhagen, Den-
mark, 7Leiden University Medical Centre, Leiden, Nether-
lands, 8Mykolas Romeris University, Vilnius, Lithuania,
9Nicolaus Copernicus University, Toruń, Poland, 10Foren-
sic.sk Intitút forenzných medicínskych expertíz s.r.o.,
Bratislava, Slovakia, 11Trnava University, Trnava, Slova-
kia, 12University Medical Centre Ljubljana, Ljubljana,
Slovenia, 13Dublin City University, Dublin, Ireland, 14Uni-
versity of Dublin, Dublin, Ireland, 15AK PRUDIL a spol,
Prague, Czech Republic, 16Institut national de la santé et de
la recherche médicale, Paris, France, 17Central European
University, Budapest, Hungary, 18University of Trento,
Trento, Italy, 19Helsinki University Central Hospital,
Helsinki, Finland, 20University of Bergen, Bergen, Norway,
21University Paris-Est Créteil, Créteil, France, 22Tallinn
University, Tallinn, Estonia, 23European University of
Cyprus, Egkomi, Cyprus
Introduction: Despite the increasing availability of direct-
to-consumer (DTC) genetic testing (GT), the way such
services are regulated in Europe remains unclear. While EU
laws largely cover genetic tests as products, aspects of GT
akin to services (e.g. medical supervision, genetic coun-
selling and informed consent) have been regulated mostly
on the national level. This has resulted in a potentially
heterogeneous and still unmapped European regulatory
landscape. Materials and Methods: In order to explore the
different ways DTGT may be regulated across Europe,
experts in health law and/or regulation of GT from EU and
European Free Trade Association countries were contacted
and asked a total of eight questions, regarding their national
laws pertinent to DTCGT. Each collaborator’s answers were
analyzed, summarized and grouped into categories.
Results: Information on the legislation of 26 European
countries was collected. These countries are: Austria, Bel-
gium, Cyprus, Czech Republic, Denmark, Estonia, Finland,
France, Germany, Greece, Hungary, Ireland, Italy, Latvia,
Lithuania, Luxembourg, Norway, Poland, Portugal, Roma-
nia, Slovakia, Slovenia, Spain, Sweden, the Netherlands
and the UK. Our results indicate that of these countries, 9
prescribe mandatory medical supervision for GT, 16 require
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mandatory genetic counselling for some types of GT and 14
provide speciﬁc requirements for informed consent in this
context. Conclusion: Currently there is a wide spectrum of
laws regulating GT in Europe. There are countries (e.g.
France and Germany) which essentially ban DTCGT, while
in others (e.g. Luxembourg and Poland) DTCGT may only
be restricted by general laws, usually regarding healthcare
services and patients’ rights.
L. Kalokairinou: None. H.C. Howard: None. S. Slo-
kenberga: None. C.M. Romeo-Casabona: None. E.
Fisher: None. M. Flatscher-Thöni: None. M. Hartlev:
None. R. van Hellemondt: None. J. Juškevičius: None. J.
Kapelenska-Pregowska: None. P. Kovac: None. L. Lov-
rečić: None. H. Nys: None. H. Nys de Paor: None. A.
Phillips: None. L. Prudil: None. E. Rial-Sebbag: None. J.
Sandor: None. A. Schuster: None. S. Soini: None. K.H.
Søvig: None. D. Stoffel: None. T. Titma: None. T. Tro-
kanas: None. P. Borry: None.
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A duty to hunt for pathogenic mutations? Ethical con-
siderations regarding routine screening of genomic data
R. H. P. Wouters1, R. M. Bijlsma1, J. J. M. van Delden1,
M. G. E. M. Ausems1, E. E. Voest2, A. L. Bredenoord1
1UMC Utrecht, Utrecht, Netherlands, 2NKI, Amsterdam,
Netherlands
Introduction: next-generation sequencing allows for an
unprecedented generation of genomic data. This collection
of data raises questions regarding the responsibilities of
professionals who are dealing with these data. A highly
controversial possibility is to routinely check sequencing
data for a list of pathogenic mutations (also referred to as
routine or opportunistic screening), as has been proposed by
the American College of Medical Genetics and Genomics.
Materials and methods: this presentation provides an
ethical analysis of arguments pro and contra routine
screening. Special attention will be given to the ethically
relevant differences between disclosure of unsolicited
ﬁndings and actively searching for these ﬁndings (some-
times called a ‘duty to hunt’).
Results: reasons for and against routine screening are
reviewed. Amongst others, beneﬁcence, iatrogenic harm,
costs and fairness are given due consideration. We establish
that both sides of the debate have put forward strong
arguments. Experts have very different views on the
acceptability and desirability of routine screening. Like-
wise, patients may have different preferences regarding
routine screening that should be taken into account.
Therefore, patient engagement will be a necessary step to
determine whether routine screening should be adopted.
Conclusion: A decent healthcare policy should
acknowledge the diversity of judgements regarding routine
screening by striving for a stronger engagement of patients,
both individually and on a group level. This engagement is
needed to make personalized medicine truly personal. The
introduction of electronic health records and other IT
applications offers unprecedented opportunities for incor-
porating personal preferences into healthcare policies.
R.H.P. Wouters: None. R.M. Bijlsma: None. J.J.M.
van Delden: None.M.G.E.M. Ausems: None. E.E. Voest:
None. A.L. Bredenoord: None.
P20.03C
Which policies work?: Comparative approaches to
regulating life insurer use of genetic information from
the UK, Canada, and Australia
A. Prince
UNC-Chapel Hill, Chapel Hill, NC, United States
Introduction: For over two decades, debates have arisen in
many countries over whether life insurers should access and
use genetic test results. These debates are sometimes emo-
tionally charged, evoking dire consequences, such as
genetic discrimination on the one hand and ﬁnancial inse-
curity and industry demise on the other. In response,
countries have adopted a variety of policy approaches, from
prohibitive bans to maintenance of the status quo to the
establishment of an independent body that approves tests
available for insurer consideration.Materials and Methods:
This presentation examines the effectiveness of the policies
of three countries. It reports on a comparative analysis of
case-studies in Canada, the United Kingdom, and Australia.
Qualitative analysis employs transcribed data from semi-
structured interviews with key stakeholders, including pol-
icy experts, government ofﬁcials, advocacy group members,
and insurance representatives. The analysis explores whe-
ther stakeholders believed their country’s policy was
effective and how they conceptualized effectiveness.
Results: This presentation will report on the effectiveness
of the chosen policy at addressing public fear of genetic
discrimination and industry concerns. Predominately, sta-
keholders measured effectiveness of the policy by whether
it had addressed either fears of discrimination, industry
ﬁnancial concerns, or dually addressed both concerns.
Conclusion: As additional countries consider and debate
policies in this area, measuring the potential effectiveness of
options is a necessary element of any debate.Research
reported in this presentation is supported by the National
Human Genome Research Institute of the National Institutes
of Health under Award Number K99HG008819.
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as well as grants already received); Signiﬁcant; National
Institutes of Health (NIH).
P20.04D
Adolescent attitudes towards genetic testing for adult-
onset conditions
A. K. Rahm1, L. Bailey1, O. D'Accordo2, Y. Munishor2, C.
Miller2, E. Davidson2, K. Pulliam3, H. Zhang3, L.
Hercher2, M. Williams1, M. J. Dougherty3,4
1Genomic Medicine Institute, Geisinger Health System,
Danville, PA, United States, 2Joan H. Marks Graduate
Program in Human Genetics, Sarah Lawrence College,
Bronxville, NY, United States, 3American Society of Human
Genetics, Bethesda, MD, United States, 4Department of
Pediatrics, University of Colorado School of Medicine,
Aurora, CO, United States
Introduction: When to test children for adult-onset con-
ditions is an ongoing issue in genetics, and information is
lacking on the attitudes and opinions of adolescents
themselves.
Materials and Methods: Essays submitted by 9th–12th
grade students to the American Society of Human Genetics’
2016 national DNA Day Essay Contest underwent thematic
analysis. All submitted student essays were analyzed for
adult condition discussed and why testing should be
deferred to adulthood or not. Demographic information
including gender, grade, school type, and location were
analyzed.
Results: 1241 student essays were submitted from 44 U.
S. states (87%) and other countries (13%). Over 100 adult-
onset conditions were discussed by students; most com-
monly discussed conditions were Huntington’s disease
(38%), BRCA-related breast or ovarian cancer (17%), and
Alzheimer’s disease (10%). Overall, students were evenly
split whether they believed testing should be delayed until
adulthood or not; however, more agreed to defer testing for
Alzheimer’s (59%) or Huntington’s (57%) than BRCA
(42%). Reasons for deferring testing included potential
psychological harm and anxiety, while reasons for wanting
testing included prevention and life planning. Factors such
as family history and personal anxiety were given as rea-
sons for the need for choice. Additional analyses are
ongoing and will be presented comparing attitudes towards
actionable and non-actionable conditions and perceived
psychological risk.
Conclusions: The DNA Day essays provide valuable
insights into the attitudes of adolescents regarding genetic
testing for adult-onset conditions. This research contributes
to understanding the potential psychosocial impact of
learning genetic information for adult onset-conditions in
healthy adolescents. Funding: 3U01HG8679-02S1
A.K. Rahm: None. L. Bailey: None. O. D'Accordo:
None. Y. Munishor: None. C. Miller: None. E. Davidson:
None. K. Pulliam: None. H. Zhang: None. L. Hercher:
None. M. Williams: None. M.J. Dougherty: None.
P20.06B
The use of an electronic health record to facilitate
communication ofadditional ﬁndings in families
L. Ballard, D. Sandi, A. Fenwick, A. Lucassen, A.
Lucassen
University of Southampton, Southampton, United Kingdom
Introduction: An estimated 20–40% of at-risk relatives are
not told about a risk relevant to them. ‘Additional ﬁndings’
(AFs), such as those the UK 100,000 genomes project
offers, will likely make this more common: there may be no
known family history of, or knowledge about, the risks.
How clinicians can best report AFs is debated, and even
with primary ﬁndings, they perceive several barriers to
facilitating communication in the family, such as resource-
constraints. Patients also face barriers to communication,
such as poor comprehension of risk.
Methods: We are exploring (1) how an electronic health
record called My Medical Record (MyMR) might help
patients/families understand AFs and (2) whether
communication-based web-apps (that MyMR can integrate)
could facilitate communication. We hypothesise that the
interactivity of web-apps could mitigate some of patients’
perceived barriers to communication by providing an efﬁ-
cient and focused view of the content to be communicated
and by being more engaging and conducive to identifying
and contacting relatives than (what is sometimes) a one-off
clinical consultation. As a ﬁrst step, we are determining
patients/families’ (n= 25) needs and views using mixed-
methods research.
Results: Findings so far show that MyMR is under-used.
But it has potential to improve understanding of, and
increase perceived support for telling relatives about, risk.
Crucially, participants underscored the importance of priv-
acy, and transparency around, and control over, who has
access to the record.
Conclusion: Based on our ﬁndings, we will design and
develop web-tools; and pilot and rigorously evaluate them
for functionality, usability, perceived impact, and utility.
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ELSI concerning underage subjects in human genome/
gene analysis research: the situation in Japan and the
issues we face
N. Ohashi
Osaka University, Suita, Japan
Background: Recently it has become possible to perform
increasingly rapid and low-cost comprehensive genome
sequencing. In Japan, these new technologies have given
rise to a variety of clinical research. Purpose: Some of the
subjects involved in these studies are minors. Using subjects
who lack the ability to consent raises the issue of consent by
proxy, as well as other issues that concern the speciﬁc
nature of genetic information. In this presentation, I would
like to consider the issues. Methods: Investigation and
analysis of various research papers, guidelines, and legal
regulations at home and abroad.
Results: In contrast to western countries, there has been
little debate in Japan on the ELSI of minors used in medical
research and the legislation concerning these issues has not
been fully developed. In the case of human genome/gene
analysis research, at present there are only guidelines that
have no legal force. Considering the situation in Japan, it is
clear that deliberate and binding regulations are needed in
the areas of genetic research to protect the rights and
interests of underage subjects. On the other hand, we should
not ignore the beneﬁts of the research.
Conclusions: Is the subject a healthy minor or one with a
condition related to the research? Will the research be
beneﬁcial to the subject? How developed is the subjects’
ability to give consent?—these kinds of questions should be
used to help categorize cases, so that we can better create
regulations. This work was supported by KAKENHI Grant
Number JP15K08550.
N. Ohashi: None.
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Legal and ethical issues for pharmacogenomics: the
Ubiquitous Pharmacogenomics state of the art
A. Constantin, M. Dupui, E. Rial-Sebbag
UMR 1027, INSERM - University of Toulouse, Toulouse,
France
The Ubiquitous Pharmacogenomics (U-PGx) project aims
at implementing pharmacogenomics testing in European
patient care. Beyond scientiﬁc challenges, U-PGx must
respond to ethical issues and comply with European
requirements.
On the regulatory side, U-PGx will be challenged by the
implementation of several EU instruments. By 2018, the
Clinical Trial Regulation will implement the EU Portal and
database, point of entry to submit all information (including
genetic information) on clinical trials, which will be stored
in the database and made public. At the same time, the
General Data Protection Regulation will introduce new
legal procedures implying then for U-PGx and all devel-
opers of pharmacogenetics drugs to modify data storage and
management of the clinical trial. Finally, the in vitro diag-
nostic medical devices (IVD) Regulation (expected for
2017) will impact on U-PGx activities as it will include
genetic testing as IVD in its scope.
From an ethical angle, the return of results in a clinical
application project represents a major ethical and legal issue
for patients’ rights. Genetic data are intrinsically personal,
familial and possibly identifying, which raises the issue of
communicating results to patients and their families, and
particularly of incidental ﬁndings. The European Society of
Human Genetics recommends communicating unsolicited
results in cases where a serious disease is discovered and if
this disease can be treated or prevented; but there is no
consensus in Europe. In order to achieve European har-
monization, guidelines for informed consent need to be
developed as a goal of all projects in pharmacogenomics.
A. Constantin: None. M. Dupui: None. E. Rial-Seb-
bag: None.
P20.09A
Paternity testing in minors under the cloak of recrea-
tional genetics
N. Moray, K. E. Pink, P. Borry
M. H. D. Larmuseau, 1983; KU Leuven, Leuven, Belgium
Direct-to-Consumer (DTC) internet companies are selling
widely advertised and highly popular genetic ancestry tests
to the broad public. These tests are often classiﬁed as falling
within the scope of so-called ‘recreational genetics’ but little
is known about the impact of using these services. In this
talk, a particular focus is whether minors (and under what
conditions) should be able to participate in the use of these
DTC tests. Current ancestry tests are easily able to reveal
whether participants are related and can therefore also
reveal misattributed paternity, with implications for the
minors and adults involved in the testing. We analysed the
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publicly available privacy policies and terms of services of
43 DTC genetic ancestry companies to assess whether
minors are able to participate in testing DTC genetic
ancestry and also if and how companies ethically account
for the potential of paternity inference. Our results indicated
that the majority of DTC genetic ancestry testing companies
do not speciﬁcally address whether minors are able to
participate in testing. Furthermore, the majority of the
policies and terms of services fail to mention the vulner-
ability of minors and family members in receiving unex-
pected information, in particular in relation to
(misattributed) paternity. Therefore, recreational genetics
carries both the risk of unintentionally revealing mis-
identiﬁed paternity, and also the risk that fathers will
deliberately use these services to test their children’s
paternity without revealing their intentions to the mother or
any other third party.
N. Moray: None. K.E. Pink: None. P. Borry: None.M.
H.D. Larmuseau: None.
P20.10B
Communicating information about genetic risks within
the family: putting the family at the heart of it
Á. Mendes1, A. Metcalfe2, M. Paneque1, L. Sousa3, A. J.
Clarke4, J. Sequeiros1,5
1i3S, UnIGENe and CGPP, University of Porto, Porto,
Portugal, 2Florence Nightingale Faculty of Nursing and
Midwifery, King’s College London, London, United King-
dom, 3Department of Education and Psychology, University
of Aveiro; CINTESIS.ua – Center for Health Technology
and Services Research, University of Aveiro, Aveiro,
Portugal, 4School of Medicine, Institute of Medical
Genetics, Cardiff University, Cardiff, United Kingdom,
5ICBAS – Instituto de Ciências Biomédicas Abel Salazar,
Universidade do Porto, Porto, Portugal
With the application of genome sequencing technologies,
more and increasingly complex information is generated
and so the need for genetic counselling and intrafamilial
circulation of information on genetic risks grow accord-
ingly. This is a great challenge, as families may feel unsure
about how, when and whom to tell what. Ethical constraints
generally prevent professionals from contacting relatives
directly. Drawing on literature on the psychosocial and
ethical aspects of disclosing genetic risk information to
family members, and on a systematic review we undertook
on how genetics professionals address such communication
within families, we reﬂected on sharing information on
genetic risks with relatives. Here we present several clinical
cases, and our perspective on the main issues raised.
Genetics and genomics are indeed “a family affair”, because
of the distinctive familial character of genetic information.
Current ethical perspectives may not be completely appro-
priate for genomic testing. The framing and “effectiveness”
of family communication about inherited conditions often
fails to acknowledge the relational and communicative
processes that operate within the family. Consultands often
feel unsupported in this process and would welcome more
support from health care professionals. Help offered by
health care professionals is usually information-based and
focuses predominantly on the individual, rather than the
family unit. Strict adherence to a narrow concept of “non-
directiveness” may be an additional obstacle. We propose
that family-oriented interventions, such as multifamily dis-
cussion-groups, may help professionals to engage with
families in this process, and should be included in training
programmes for genetic counsellors.
(SFRH/BPD/88647/2012).
Á. Mendes: B. Research Grant (principal investigator,
collaborator or consultant and pending grants as well as
grants already received); Signiﬁcant; from FCT - Fundação
para a Ciência e a Tecnologia (SFRH/BPD/88647/2012). A.
Metcalfe: None.M. Paneque: None. L. Sousa: None. A.J.
Clarke: None. J. Sequeiros: None.
P20.11C
Diagnostic whole exome sequencing in pediatrics and
developmental delay: a model for informed consent and
return of incidental ﬁndings
C. Cornelis1, W. Dondorp2, I. Bolt3, G. de Wert2, M. van
Summeren4, E. Brilstra4, N. Knoers4, M. Düwell3
1University Medical Center Utrecht; Ethics Institute,
Utrecht University, Utrecht, Netherlands, 2Maastricht
University, Maastricht, Netherlands, 3Ethics Institute,
Utrecht University, Utrecht, Netherlands, 4University
Medical Center Utrecht, Utrecht, Netherlands
Introduction: Current models for informed consent and
return of incidental ﬁndings (IFs) are not well-equipped to
address the situations of children undergoing whole exome
sequencing (WES) for clarifying a developmental delay
(DD). We present a model that is tailored to these cases.
Method: An ethical framework was developed aimed at
protecting both children’s best interests and the interests of
parents/relatives. Data from qualitative semi-structured
interviews with parents of twenty children with a DD,
aged <1–17, undergoing WES (trio-analyses) regarding
views about WES and IFs were used to translate the ethical
framework into guidelines in the model.
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Results: Uncertainty about young children's/infants
future cognitive development complicated choices for IFs,
prompting some parents to ask whether they should decline
certain IFs due to considerations surrounding a child's
future autonomy. In contrast, parents of older children had
clearer prognoses that their child would remain incompe-
tent; their reasoning for/against receiving IFs was often-
times related to their child's special needs. Interpreting a
child's best interests requires acknowledging future auton-
omy considerations as a precautionary measure in cases
with high uncertainty regarding the child's autonomous
development. In cases with low uncertainty, i.e., future
autonomy is highly unlikely/impossible, safeguarding the
child's welfare should be a central aim.
Conclusion: The model has different disclosure guide-
lines for IFs (always/never disclose at present, opt-in/-out)
based on the degree of certainty regarding the child's future
autonomy. Parents should generally have more discretion
over IFs when children's future autonomy is unlikely.
Funding: ZonMw (grant 70-73000-98-047), The Neth-
erlands Organization for Health Research and
Development.
C. Cornelis: None. W. Dondorp: None. I. Bolt: None.
G. de Wert: None.M. van Summeren: None. E. Brilstra:
None. N. Knoers: None. M. Düwell: None.
P20.12D
Numberacy, risk information and ethical requirements
of informed decision making
J. Inthorn
Institut for History, Philosophy and Ethics of Medicine,
University Medical Center Mainz, Mainz, Germany
Introduction: With a growing demand in many ﬁelds of
medicine genetic counselling will become a part of physi-
cian patient communication also outside specialized con-
texts. Especially in such contexts of genetic counselling
with physicians who’s ﬁeld of expertise is not genetics (eg
physicians with a special 72hours training for genetic
counselling according to German law GenDG and GEKO
regulations), there is an ongoing controversy on the impli-
cations of this for dealing with risk information.
Method: While some experts believe that dealing with
uncertainty and probability is something that can be
improved by training and by providing information in a way
that is not misleading, other experts are not as optimistic
and vote for a new type of paternalism (libertarian patern-
alism). This controversy will be analyzed on two levels.
First, based on the results of a review of studies on num-
beracy in the context of medical information it is discussed
what type of professional expertise is needed to enable
informed decision making. Second, if counselling is sup-
ported by standardized tools to support decision making the
question arises if patients should have a choice about dif-
ferent types of information.
Results and conclusion: The paper will argue for a third
way of assessing needs for information. It starts with the
perspective of patients and their need to transform prob-
abilistic knowledge on risk factors into options for agency,
informing family members or life style changes. The
knowledge difference between experts and patients can be
bridged by better understanding how information gains
relevance for patients.
J. Inthorn: None.
P20.13A
Readability of informed consent forms for whole exome/
genome sequencing
E. Niemiec1,2,3, D. Vears4, P. Borry4, H. C. Howard5
1Eramus Plus PhD Programme in Law, Science and
Technology, University of Bologna, Bologna, Italy,
2Department of Law, University of Turin, Turin, Italy,
3Centre for Ethics and Law in the Life Sciences, Leibniz
University Hannover, Hannover, Germany, 4Centre for
Biomedical Ethics and Law, Department of Public Health
and Primary Care, KU Leuven, Leuven, Belgium, 5Centre
for Research Ethics and Bioethics, Uppsala University,
Uppsala, Sweden
Whole genome sequencing (WGS) can generate an unpre-
cedented amount of complex information making the
informed consent (IC) process challenging. While the ele-
ments of information necessary for IC for WGS and pre-test
counselling have been discussed and studied, research has
not focused speciﬁcally on the way information is presented
or worded in IC forms. The aim of our study was to assess
the readability of IC forms of English language for clinical
whole- exome or genome sequencing. Readability of forms
was assessed using SMOG test (based on the number of
complex words in sentences). The presence of additional
elements such as requisition forms combined with consent
forms, sections dedicated to healthcare professionals, and
the length of documents were also analysed. We analysed
35 forms, most of which were from US providers. The
largest readability grade group was 16 forms with a grade
level of 13, indicating that the forms would be completely
understandable for a person who completed 13 years of
education (ﬁrst year(s) university in the US system). The
lowest and the highest grade levels were 12.7 and 18.4
respectively. All the forms studied seem to fail to meet the
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recommended readability grade level of 8 (e.g. by US
medical schools) for IC forms. The aspects of effective
communication in consent forms are crucial given that in
the future, WGS is likely to increasingly be offered by
clinicians who are not experts in genomics and who may
therefore be more reliant on the consent forms themselves to
obtain informed consent.
E. Niemiec: None. D. Vears: None. P. Borry: None. H.
C. Howard: None.
P20.14B
Australian Life Insurers use of genetic test results in
underwriting decisions
M. Liepins1, M. Otlowski2, A. Doble3, K. K. Barlow-
Stewart1
1University of Sydney, Sydney, Australia, 2University of
Tasmania, Hobart, Australia, 3Retired Actuary, Sydney,
Australia
Since 1999, the Financial Services Council (FSC) has
requested its Australian life insurance member companies
provide data on applications where a genetic test is dis-
closed. The FSC provided data collected 2010–2013 to
enable repetition of an independent analysis undertaken of
applications 1999–2003 (Otlowski et al 2007 Aust J Law
and Medicine).
Materials and methods: Data included de-identiﬁed
insurer; age; gender; genetic condition; reason for testing
and result; underwriting decision-maker; and insurance
cover. Data was classiﬁed as to type of result or other
factors relevant to risk, underwriting decisions and, where
necessary, FSC-facilitated clariﬁcation by insurers.
Results: 340/547 applications were for adult-onset con-
ditions: hereditary haemochromatosis (HH-200); cancer
(51); thrombophilia (31); cardiovascular (17), neurodegen-
erative (13), neuromuscular (9); and other (19). The genetic
test result solely inﬂuenced the underwriting decision in
170/340 applications: 24 positive, 139 negative, 2 unin-
formative, 3 pending and 2 unknown. Policies were pro-
vided at standard rate for all negative test results and 20/24
positive (HH-14, thrombophilia-5, breast cancer-1) with
recognition of screening and risk reduction. Non-standard
polices with a broad exclusion of all cancers were provided
for positive BRCA2 (2) and Lynch syndrome results; for the
two BRCA1/2 uninformative results, breast cancer exclu-
sion and 50% loading were applied respectively. All
applications with results pending (cancer-2, Huntington
disease-1) were denied outright. There was evidence of
reassessment of previous non-standard decisions when a
negative result was declared.
Conclusion: No widespread systemic issues regarding
genetic discrimination were identiﬁed though analysis is
limited by the few positive test results disclosed.
M. Liepins: None. M. Otlowski: None. A. Doble:
None. K.K. Barlow-Stewart: None.
P20.15C
Genetic testing and life insurance in Canada
A. C. Bedard1, G. St-Martin2,3, J. E. J. Bedard3
1BC Cancer Agency, Abbotsford, BC, Canada, 2California
State University, Stanislaus, Turlock, CA, United States,
3University of the Fraser Valley, Abbotsford, BC, Canada
Introduction: Compared with many European jurisdic-
tions, Canada has had no legal protection addressing the use
of genetic test results by insurance companies; at present, a
potential law regulating this issue is in the ﬁnal stages of
consideration by Canadian parliament. This study is a
baseline assessment of Canadian insurance company
applications and genetic testing. Materials and Methods:
We reviewed primary applications for voluntary life insur-
ance and critical illness insurance from Canadian compa-
nies. Applications were assessed for questions related to the
applicant’s medical history pertaining to genetic testing and
counselling, and analyzed for their depth of family medical
history assessment.
Results: None of the companies speciﬁcally asked about
genetic testing, however all assessed if applicants pursued
medical testing in the past. The majority assessed whether
the applicant had sought consultation from a health pro-
fessional, including advisement about testing. All applica-
tions asked about family medical history, with the majority
limiting assessment to the parents and siblings. An average
of 11 conditions were assessed for the family medical his-
tory. None of the applications asked if family members had
sought genetic testing.
Conclusion: This study provides a baseline assessment
of Canadian life insurance applications, and may serve as a
benchmark for comparison after the probable passage of
Canadian legislation. It is imperative that genetics profes-
sionals are educated on this topic, as it is a signiﬁcant
concern to many of our patients and their family members.
A.C. Bedard: None. G. St-Martin: None. J.E.J.
Bedard: None.
P20.16D
Is there a legal duty to warn a patient’s family about
genetic diseases?
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N. L. Hawkins, T. Hughes-Davies
University of Exeter, EXETER, United Kingdom
Conﬁdentiality is a cornerstone of medical practice, and is a
key legal duty owed by healthcare practitioners (HCPs) to
patients. However, because of the familial nature of genetic
information, situations arise where HCPs may feel that
conﬁdential information about a patient should be disclosed
to family members. In such cases, HCPs may ﬁnd their
ethical and legal duties are conﬂicting.
This paper analyses the English law of the duty of con-
ﬁdentiality and the duty to warn. We argue that the blunt
exclusion of any duty to warn a family member in all cir-
cumstances in the recent case of ABC v St George’s has
pushed the balance of rights too far in the direction of the
maintenance of conﬁdentiality. As a result, a HCP will
never be liable for failure to disclose to a third party, but
could be liable for breach of conﬁdence. A prudent HCP
will therefore be likely to maintain conﬁdentiality, in spite
of ethical arguments in favour of disclosure. This is
problematic.
We conclude that, while in most cases there will be no
duty owed to family members, in certain limited circum-
stances, a duty of care should arise. The legal duties of
conﬁdence and tort are likely to increasingly compete as
genetics becomes part of mainstream clinical practice and it
is therefore important that the distinct legal tests for con-
ﬁdentiality and duty to warn result in legally and ethically
congruent outcomes.
Funder: Economic and Social Research Council UK
N.L. Hawkins: None. T. Hughes-Davies: None.
P20.17A
'I would like to discuss it further with an expert': a focus
group study of Finnish adults' perspectives on genetic
incidental ﬁndings
M. Vornanen1, K. Aktan-Collan1, N. Hallowell2, H.
Konttinen1, H. Kääriäinen3, A. Haukkala1
1University of Helsinki, Helsinki, Finland, 2University of
Oxford, Oxford, United Kingdom, 3National Institute for
Health and Welfare, Helsinki, Finland
Introduction: Lowered costs of genomic sequencing
facilitate analysing large segments of genetic data and
generating many types of incidental ﬁndings (IFs). Intense
ethical debate has focused on whether and what kind of IFs
to report, and how to obtain valid informed consent,
whereas what support or resources people need after
receiving IFs has received less attention. The aim of this
study was to explore Finnish adults’ perspectives on the
reporting of genetic IFs.
Materials and methods: We performed a qualitative study
with four focus group discussions (N= 23). Four vignette
letters were used, each reporting an IF predisposing to a
different disease that varied in terms of treatability: familial
hypercholesterolemia, long QT syndrome, Lynch syndrome
and Li–Fraumeni syndrome. Transcribed focus group dis-
cussions were analysed through inductive thematic analysis.
Results: Despite a general positive attitude towards
receiving IFs, concern of being left alone to deal with them
was widely expressed. Empathetic expert support and
access to preventive care were seen as essential to coping
with the immediate shock and potential prolonged worry,
and to being able to appropriately disclose the IF to family.
Conclusions: Professional discussion should focus not
only on which IFs to report but also on how to do it in
practice, and how to ensure access to relevant support and
preventive care for the patient/participant and their family.
Distrust towards research and health care may arise if
practices of reporting IFs and referral for treatment are
perceived as disrespectful, unorganized, or unequal.
Funding: Academy of Finland (grant 275033).
M. Vornanen: None. K. Aktan-Collan: None. N.
Hallowell: None. H. Konttinen: None. H. Kääriäinen:
None. A. Haukkala: None.
P20.18B
Assessing Next Generation Sequencing Recommenda-
tions in Oncogenetics: legal and ethical issues for
patients' rights
E. Rial-Sebbag, M. Maheu
INSERM UMR 1027, Toulouse, France
Since the discovery of DNA, technologies for sequencing
have tremendously grown.leading to an increase of means
for explaining physiopathology of diseases, elaborating
diagnosis and proposing adequate treatment in particular for
cancer. Hence, last generation sequencing permits to gen-
erate massive data to be applied for diagnosis to improve
preventive measures or the treatment of small groups of
patients in the context of the so-called personalised medi-
cine. Several recommendations and initiatives are on-going
in France (e.i. Plan France Génomique) and at the interna-
tional level (International Cancer Genome Consortium,
Global alliance for Genomics and Health, European Society
of Human Genetics) trying to address the technical and
Ethical, legal, social issues (ELSI) of these technological
developments from research to their implementation in
practice. However, these initiatives are wild and address the
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challenges for society at a broad level. Thus, very few has
been speciﬁcally developed in the area of oncogenetics
whereas we hypothesis that there is a need to test and to
adapt these recommendations for their implementation
oncology services. The change of scale from “traditional”
genetic tests to Next Generation Sequencing (NGS) in
therapeutic or genetic counseling has raised speciﬁc issues
for patients in oncology. To this end we surveyed the
existing recommendations at the French, European and
international level for supporting the use of NGS in onco-
genetics. The analysis shows that despite several recom-
mendations adopted from European and French institutions
there is a need to reassess them in the speciﬁc context of
oncogenetics notably regarding patients’ rights and for their
relatives.
E. Rial-Sebbag: None. M. Maheu: None.
P20.20D
Bioethical issues in personalized medicine and phar-
macogenomics: Students' awareness and attitudes
S. Semiz1, L. Halilovic1, B. Akcesme1, C. Durakovic1, F.
B. Akcesme1, M. Adilovic1, N. Hamad1, A. Maric1, F.
Serdarevic2
1Faculty of Engineering and Natural Sciences, Interna-
tional University of Sarajevo, Sarajevo, Bosnia and
Herzegovina, 2Faculty of Medicine, University of Sarajevo,
Sarajevo, Bosnia and Herzegovina
Introduction: Personalized medicine offers the detection of
a disease at its earliest stage, the prevention of disease
progression, and the optimization of disease treatment.
However, there are many challenges in broader clinical
implementation of pharmacogenomics. Speciﬁc concerns
regarding pharmacogenomics are related to potential health
disparities, stigma, use of direct-to-consumer genetic tests,
genetic data handling, and patient’s privacy. Materials and
Methods: Here we performed a descriptive, cross-sectional
study based on the survey of 559 students from several
universities in Bosnia and Herzegovina (BH), including
students of the Faculty of Pharmacy, Faculty of Medicine,
Genetics and Bioengineering, and Faculty of Health Stu-
dies. The statistical analysis was performed by IBM
SPSS®23.
Results: A majority of students participating in this
survey showed an interest to perform a genetic test (70%)
and agreed that personalized medicine represents a pro-
mising healthcare model (57%). Interestingly, 44% of the
students were worried about the possibility that the results
of pharmacogenomic test might be passed to unauthorized
persons. Furthermore, the ﬁeld of study appears to
signiﬁcantly inﬂuence the students’ wish to continue their
postgraduate education in the area of personalized medi-
cine, prior (1.73 CI: 0.99–3.02), p= 0.056) and upon
adjustment to age and gender (1.79 CI:1.01–3.19, p=
0.045) with the level of education particularly affecting the
students’ opinion (2.4 CI:1.28–4.48, p= 0.006).
Conclusions: The results of our survey indicate a posi-
tive attitude of biomedical students in BH towards phar-
macogenomics and emphasizes its importance in the
education of future healthcare professionals.
S. Semiz: None. L. Halilovic: None. B. Akcesme:
None. C. Durakovic: None. F.B. Akcesme: None. M.
Adilovic: None. N. Hamad: None. A. Maric: None. F.
Serdarevic: None.
P20.21A
Amended Act on the Protection of Personal Information
of Japan and its impact to research and direct-to-
consumer testing
K. Muto1, Z. Yamagata2, A. Nagai1
1The University of Tokyo, Tokyo, Japan, 2Yamanashi
University, Chuo, Japan
In Japan, the Personal Information Protection Act (the
‘PIPA’) was amended in 2015 and will fully come into
force on May 30, 2017. The PIPA includes several impor-
tant amendments to harmonize with the regulation on per-
sonal information in the EU, with respect to issues such as
sensitive personal information, traceability and cross-border
transfer of personal information. The Personal Information
Protection Committee (the ‘PPC’) was established as an
independent supervising authority to protect personal
information instead of each Ministry. The new PIPA further
clariﬁes what "personal information’ is, in order to protect
privacy with certainty. ‘Base sequence constituting DNA
taken from a cell’ is newly included in the scope of personal
information. Moreover, the New PIPA classiﬁes personal
information into two grades of protection with a new
category of ‘sensitive information.’ This includes race,
religion, medical history, and other personal information
that could potentially lead to unjustiﬁable discrimination or
prejudice. A prior consent is required to transfer sensitive
information to a third party. An opt-out procedure for
transferring personal information to third parties is not
available for sensitive information. Regarding genomic
research, researchers have to comply with Ethical Guide-
lines for Human Genome/Gene Analysis Research (2001,
latest revision in 2013). The Cabinet Order was also
amended to enforce the PIPA. We review the impact of its
revision to research and direct-to-consumer genetics.
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K. Muto: None. Z. Yamagata: None. A. Nagai: None.
P20.22B
Non-Invasive Prenatal Test (NIPT): a national study on
receiving incidental ﬁndings
I. M. Bakkeren1, S. L. van der Steen1, L. C. P. Govaerts1,
H. van Hall1, I. Feenstra2, M. C. van Maarle3, N. S. den
Hollander4, K. D. Lichtenbelt5, S. R. Riedijk1, R. J. H.
Galjaard1
1Erasmus Medical Center, Rotterdam, Netherlands, 2Rad-
boud University Medical Center, Nijmegen, Netherlands,
3Academic Medical Center, University of Amsterdam,
Amsterdam, Netherlands, 4Leiden University Medical
Center, Leiden, Netherlands, 5University Medical Center
Utrecht, Utrecht, Netherlands
Introduction: In the Netherlands NIPT is offered to preg-
nant women at increased risk for aneuploidy in a national
trial. NIPT has a small chance to detect other chromosomal
abnormalities than trisomies 13, 18 or 21. Often the inci-
dental ﬁnding (IF) is merely present in the placenta, but
sometimes also in the fetus. This study examined couples’
attitude towards being informed of an IF and its psycholo-
gical impact. Furthermore, reproductive choices were
assessed.
Methods: Women who received an IF from NIPT
between 2014 and 2016 were invited for a semi-structured
interview ( ± 30–60 minutes). Seventeen women and 12
partners participated and provided written consent.
Results: Twelve women and ten partners were unaware
that NIPT could yield IFs. All participants initially experi-
enced receiving the IF as a shock. In three cases the IF was
conﬁrmed with amniocentesis, these couples subsequently
chose to end their pregnancy. The other 14 pregnancies
were monitored to make sure the fetus’ growth was normal
and all resulted in the birth of unaffected children. Although
in those pregnancies the implications of the IF were not
always clear, all couples insisted upon receiving this
information to exert their reproductive autonomy. Couples
counselled by a clinical geneticist experienced less uncer-
tainty regarding their IF than couples counselled by any
other specialist. Sixteen out of 17 women would opt for
NIPT again in future pregnancies.
Conclusion: All participants expressed that IFs should
be disclosed to enable reproductive autonomy. In preg-
nancies where NIPT yielded an IF, counselling by a genetic
counsellor was psychologically favorable.
I.M. Bakkeren: None. S.L. van der Steen: None. L.C.
P. Govaerts: None. H. van Hall: None. I. Feenstra: None.
M.C. van Maarle: None. N.S. den Hollander: None. K.D.
Lichtenbelt: None. S.R. Riedijk: None. R.J.H. Galjaard:
None.
P20.23C
Patient values and perceived utility of incidental genome
sequencing results
Y. Bombard1,2, M. Clausen1, C. Mighton1, L. Carlsson3, S.
Casalino1, E. Glogowski4, K. Schrader5,6, A. Scheer1,2, M.
Evans1,2, J. Hamilton7, K. Ofﬁt7, M. Robson7, N.
Baxter1,2, K. Thorpe1,2, J. Lerner-Ellis8, A. Laupacis1,2
1St. Michael's Hospital, Toronto, ON, Canada, 2University
of Toronto, Toronto, ON, Canada, 3University Health
Network, Toronto, ON, Canada, 4GeneDx, Gaithersburg,
MD, United States, 5BC Cancer Agency, Vancouver, BC,
Canada, 6University of British Columbia, Vancouver, BC,
Canada, 7Memorial Sloan Kettering Cancer Center, New
York, NY, United States, 8Mount Sinai Hospital, Toronto,
ON, Canada
Introduction: Genome sequencing (GS) can reﬁne diag-
noses and treatments, but may incidentally reveal inherited
risks for thousands of other diseases. Guidelines recom-
mend clinicians inform individuals of their incidental GS
results (IR). Previous research explores patient preferences
using abstract concepts for IR, yet little is known about
patient informed and deliberated values towards IR. We
describe patient considered values and perceived utility of
learning their IR following a deliberative, educational
intervention.
Methods: Semi-structured interviews were conducted
with 15 cancer patients participating in usability testing of a
decision aid (DA) designed to facilitate informed, value-
based selection of IR. Patients selected IR from ﬁve cate-
gories deﬁned as being medically actionable or not. Content
analysis was used to analyse the data.
Results: Participants were enthusiastic towards GS itself,
and expressed an inherent value for its use in their own
healthcare. All participants chose to receive some IR; 9
participants selected all IR. Participants’ primary motivation
for receiving IR was to inform disease prevention or treat-
ment. When considering IR about non-medically actionable
diseases, participants believed this information would
encourage actions that could slow or delay onset. Partici-
pants also valued learning IR to beneﬁt their relatives’
health and to inform their families’ future ﬁnancial or
reproductive planning.
Conclusion: Despite this small sample size, results
reveal patients’ enthusiasm for receiving IR. Patients apply
broader deﬁnitions of actionability than medical experts,
reﬂecting a key divergence in valuing this incidental
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information. Findings can inform service delivery and pol-
icy guiding the expected return and anticipated use of IR
from GS.
Y. Bombard: None. M. Clausen: None. C. Mighton:
None. L. Carlsson: None. S. Casalino: None. E.
Glogowski: None. K. Schrader: None. A. Scheer: None.
M. Evans: None. J. Hamilton: None. K. Ofﬁt: None. M.
Robson: None. N. Baxter: None. K. Thorpe: None. J.
Lerner-Ellis: None. A. Laupacis: None.
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